,ticker,content
0,CELG,celgene celg take sell side beating friday investment bank leerink suggest rate drug development success lag industry average biotech company presentation thursday celgene suggest success rate internally source pipeline product be good marginally better industry peer leerink analyst geoffrey porge write note client analysis celgene pipeline name time frame show different story celgene seemingly withdraw third asset identify year development only program result market product porge say average success rate phase asset pharmaceutical industry be rise phase say use number industry bench mark success rate celgene pipeline appear subpar get newsletter deliver inbox more info product service privacy policy term useon stock market today share dip close share biotech company collectively lift celgene stock have be pressure topple year low monday report emerge head business development quietly exit april firm have also face high profile setback crohn disease multiple sclerosis drug porge call worst perform stock coverage large cap biotech company year date have lose failure experimental crohn disease drug mongersen october investor have assign very little value pipeline celgene have analysis productivity celgene activity past year suggest current negative sentiment be warrant say leerink analyze evolution pipeline asset highlighted earning slide annual presentation first quarters celgene only bring new chemical entity market psoriasis arthritis drug otezla cancer drug idhifa more half development appear have be discontinue porge say third be still development meanwhile celgene have add used blockbuster cancer drug revlimid well otezla however overreliance revlimid associate uncertainty generic entry be turn also major overhang celgene stock say even revlimid company have increasingly be reliant price rather volume last year celgene raise gross price revlimid combine say analyst note cancer drug face patent cliff mid investor have recently begin doubt celgene ability offset massive decline revlimid sale competition loom firm seemingly take prong approach drug development collaborate early stage asset acquire revenue ready late stage drug success rate internally develop externally acquire asset be not markedly different say total celgene introduce drug candidate pipeline past year celgene remove half pipeline disappear be late stage asset firm drop be phase development be understandable phase asset be typically riskier be therefore likely fail more frequently dropout phase asset be concern porge say still keep price target outperform rating stock related do spot major market top easy look heavy term retirement investing strategy etfsnew option strategy limit risk earning
1,CELG,celgene celg plunge year low monday report executive charge business development quietly retire mid april rbc analyst brian abraham say departure george golumbeski be plan year advance april retirement golumbeski have work celgene business development year robert hershberg take executive vice president head business development global alliance april golumbeski then moved more strategic role hershberg be responsible deal juno therapeutic impact biomedicine give have be transition work time do not see relation report emerge today proximity upcoming clinical study readout abraham say report get newsletter deliver inbox more info product service privacy policy term useon stock market today celgene topple close share touch low last see broadly share biotech company drop abraham note investor sentiment celgene have be low year week golumbeski departure april former chief operate officer scott unexpectedly depart celgene have be instrumental help launch otezla celgene biggest moneymaker celgene deliver beat raise earlier month otezla sale grow beat view still investor be wary inflammation immunology franchise february official delay celgene application multiple sclerosis drug ozanimod meanwhile investor be also concern loom patent cliff key cancer drug revlimid celgene be hope acquisition juno help offset juno be work number cancer treatment abraham find somewhat ironic share sell news golumbeski departure investor have long be critical biotech company business development strategy see not sufficiently prepare post revlimid revenue sustainability however do believe illustrate sharply negative sentiment pervasive name continue believe require turnaround catalyst improve say related new option strategy limit risk much volume look stock basic analyze stock cup handle
2,CELG,celgene celg plunge more monday report morgan stanley suggest experimental multiple sclerosis drug ozanimod be delay year share re-cover little other analyst disagree say issue identify morgan stanley analyst matthew harrison be largely nonissue celgene stock lose close bell end day share rise fraction hour recent presentation american academy neurology annual meeting celgene note be discrepancy convert amount specific substance used preclinical study ozanimod rat monkey human size dose harrison suggest be reason food drug administration refuse file celgene application ozanimod further suggest mean year delay celgene re file get newsletter deliver inbox more info product service privacy policy term use give timeline start study produce study report re file believe delay be minimum year year management redo animal work say note celgene get ozanimod acquisition receptos receptos do early study ozanimod rodent month primate month part study test effect metabolite ozanimod know cc metabolite be substance form necessary metabolism animal study be acceptable test closely mirror impact drug have human appear exposure cc animal model be likely relevant human therapeutic dose harrison say wasn problem other metabolite notably researcher discover issue cc later human study add fda refuse file celgene application ozanimod february celgene cite issue clinical clinical pharmacology section application didn go further specific problem celgene share plummet year low news also early month scott key executive help build celgene inflammation immunology business unexpectedly left company chief executive mark alle take primary duty harrison keep price target equal weight rating celgene mizuho analyst salim sy argue fda decision ozanimod be related cc metabolite really nonissue more human patient have take ozanimod year be deleterious effect effectiveness safety toxicology have show say report go back introduce massively higher level metabolite animal create own already know do not impair safety effectiveness human be irrelevant add create condition do not exist sy also perform survey investor believe celgene refile fda approval first half slightly less expect firm refile second half rbc analyst brian william believe celgene have already begin additional preclinical work ozanimod researcher discover cc metabolite year so even celgene need perform year additional study already halfway william evercore analyst umer raffat also note separate report celgene publicly bring attention issue email analyst celgene proactively draw attention issue be signal confidence friday earning call ozanimod filing update william say note evercore raffat expect celgene wrap additional study ozanimod multiple sclerosis drug summer then likely re file approval late summer early fall say note client related chart read basic buy point mark time real invest stock free new apps aim beginnerslook next nvidia start simple routine
3,CELG,top executive help launch third biggest moneymaker celgene celg unexpectedly depart biotech late monday just year take chief operate officer president celgene offer few detail departure scott left firm effective immediately accord news release issue close monday chief executive mark alle take primary duty scott have make significant contribution celgene most notably build inflammation immunology franchise include global launch otezla alle say prepared statement thank scott service wish well future endeavor serve president chief operate officer start april joined celgene have hold number senior position year get newsletter deliver inbox more info product service privacy policy term use celgene be modify executive team structure enhance leadership focus build celgene continue long term success company say release importantly alle also take leadership company hematology oncology inflammation immunology franchise well manufacturing regulatory clinical development departure follow several struggle celgene inflammation immunology drug franchise sale growth otezla be approve treat psoriatic arthritis plaque psoriasis slow last year sale jump nearly otezla revenue be just also late last year celgene terminate several trial crohn disease prompt firm cut long term guidance guidance cut come quarter otezla sale widely miss analyst expectation further food drug administration february refuse file celgene application drug call ozanimod treatment patient relapse form multiple sclerosis late february decision send celgene stock year low hour trading stock market today celgene slip end regular session related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
4,CELG,agreement dow jone component pfizer pfe defer drug price increase effort play nice president donald trump lead analyst wednesday question fallout drug giant action be industry analyst wonder other pharmaceutical company follow pfizer example notably celgene celg be still go ahead increase blockbuster cancer drug revlimid pomalyst rbc capital market analyst brian abraham say report pfizer unprecedented reversal early july price increase mark tangible administrative influence morgan stanley analyst david risinger say report client note pfizer be await more detail so call blueprint tug drug price late tuesday pfizer say chief executive ian read have extensive discussion trump lead company back price increase drug have be effective july earlier week trump attack pfizer other raise drug price reason get newsletter deliver inbox more info product service privacy policy term use pfizer share president concern patient commitment provide affordable access medicine need read say written statement also note pfizer have commit capital expand manufacturing not everyone jived pfizer trump announcement sen ron wyden ore call pfizer trump administration reveal detail arrangement lead pfizer back drug price increase secret sweetheart arrangement big pharma company be exactly america drug pricing system be break tweet trump admin be busy try score cheap pr point pharma company continue raise price double digit pfizer stock dip close broadly share pharmaceutical company fall same amount stock market today trump renew pledge lower cost prescription medicine time analyst largely say propose blueprint appear be more rhetoric reform morgan stanley risinger believe pfizer price increase reversal have slightly negative implication second quarter earning season note pfizer update guidance commentary be key later month addition news put term damper future price increase action other pharma bio company say pfizer indicated action be temporary only commit keep price unchanged end other pharmaceutical company also rethink guidance say manufacturer limit price increase year hold entirely customary january increase be key swing factor earning think be underestimated market say even celgene price increase revlimid pomalyst remain line medical inflation rbc abraham say be also historical increase meanwhile gilead science gild joined pfizer walk back plan price increase note see more re-serve price increase increase transparency potentially temper headline risk public scrutiny have be experience pfizer line view company self polouse price increase much larger degree now say also wednesday pfizer announce split business distinct unit contend loom loss exclusivity restructure pfizer innovative medicine division include biosimilar infection drug sterile injectable establish medicine unit include patent brand generic drug finally company consumer healthcare branch hold counter medicine innovative medicine run current innovative health business well new hospital medicine business unit pfizer also incorporate biosimilar portfolio oncology inflammation immunology unit establish medicine hold majority pfizer patent drug include lyrica cholesterol drug lipitor high blood pressure drug norvasc erectile dysfunction drug viagra business run globally unit be meant operate true stand alone business pfizer company say news release have own manufacturing marketing regulatory exception enable function consumer healthcare other hand differ pfizer prescription medicine business pfizer say firm confirm still mull strategic alternative unit expect make decision end year trend consumerism increase focus stay healthy be cause consumer seek easily accessible health wellness solution firm say company believe business be well position continue growth get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing trade stock most penny stock fail make investor richnew option strategy limit risk earning
5,CELG,acceleron pharma xlrn rocket year high friday celgene celg report strong result partner anemia treatment call stock market today acceleron soar close celgene lift meanwhile share other biotech company rise proshare ultra nasdaq biotechnology bib exchange trade fund lift late thursday biotech company say meet key goal study test vs placebo patient myelodysplastic syndrome disorder blood cell be poorly form don work well biotech company be now prepare necessary document ask regulatory official globe approve celgene chief medical officer jay say written statement get newsletter deliver inbox more info product service privacy policy term use result phase study call medalist demonstrate potential clinical benefit erythroid red blood cell maturation agent treatment chronic anemia patient low intermediate risk myelodysplastic syndrome say patient test medalist study have chronic anemia disease also have progressed be intolerant ineligible anemia treatment call erythropoietin stimulating agent esa require frequent red blood cell transfusion treat patient experience least straight week red blood cell transfusion first week treatment study also meet second goal patient be able go least consecutive week transfusion celgene acceleron likely grab approval launch leerink analyst geoffrey porge say report client call worldwide sale increase analyst meanwhile see respectively rbc capital market analyst kennen mackay boost expectation success call peak sale specific patient group deal celgene acceleron receive royalty sale numerical detail be lack press release do not indicate lack statically significant improvement mackay say note client biotech company say plan offer more detail study future medical conference credit suisse analyst martin note even reduce frequency transfusion patient be improvement especially consider lack treatment option patient condition boost price target acceleron see likelihood get approval anemia treatment group patient biotech company also be consider testing low intermediate risk patient myelodysplastic syndrome have never undergo esa anemia treatment soon firm also have datum treatment patient beta thalassemia rbc mackay see high likelihood success used treat beta thalassemia blood disorder reduce production hemoglobin lead lack oxygen many part body accord genetic home reference get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
6,CELG,celgene celg nail first quarter deliver broad beat raise friday analyst say question timeline release key multiple sclerosis drug analyst be split first quarter beat be enough outweigh concern ms drug dub ozanimod food drug administration punt celgene application ozanimod february now celgene expect refile approval early modest beat fail offset more development setback leerink analyst geoffrey porge say note client rbc analyst brian abraham say update ozanimod be line expectation help diminish term uncertainty investor reward celgene be short live stock market today celgene rise much settle gain close meanwhile biotech stock collectively lift get newsletter deliver inbox more info product service privacy policy term first quarter celgene report sale rise top consensus analyst poll zack investment research adjust profit share beat consensus grow nearly revenue cancer drug outperformed expectation revlimid bring line consensus porge say pomalyst rake grow beat view abraxane generate top immunology sale psoriasis arthritis drug otezla grow be consensus porge say sequentially increase demand improve access help spike sale celgene say news release mizuho analyst salim sy say celgene nail awesome quarter product come line beat slightly say note total product revenue beat company slightly raise guide top bottom line celgene also boost sale guidance earlier view firm also see earning share adjust recent acquisition juno therapeutic analyst have predict sale earning share big news regard ozanimod february fda refuse file application ozanimod celgene cite deficiency nonclinical clinical pharmacology section application fda decision earlier week analyst suggest issue come specific substance drug know metabolite metabolite be substance form necessary metabolism celgene discover specific metabolite later stage testing human rbc abraham note specific metabolite know cc seem stay body much longer researcher initially realize also responsible drug activity say report client however longer half life not be major issue once metabolite be characterize say other drug class gilenya also have half life similar range now celgene expect refile application ozanimod multiple sclerosis first quarter timeline take uber bear case year delay table evercore analyst umer raffat say note also mean celgene ozanimod approve be enter market same time generic version novartis nvs rival drug gilenya leerink porge say new timeline be quarters have forecast put commercial launch uncertainty give expect entry generic gilenya say keep outperform rating celgene stock related do spot major market top easy look heavy invest stock free new apps aim term retirement investing strategy etfs
7,CELG,biotech giant celgene celg big patent official shut challenge face novartis nvs multiple sclerosis drug gilenya analyst say thursday wednesday appeal board patent trademark office upheld patent protect novartis gilenya december extend gilenya exclusivity well past prior august expiration date rbc capital market analyst brian abraham say undoubtedly novartis decision also have implication fellow multiple sclerosis drugmaker celgene biogen biib say report celgene recently suffer delay multiple sclerosis drug ozanimod give celgene more time get approval ozanimod be currently hamstrung question food drug administration generic gilenya come begin take share say get newsletter deliver inbox more info product service privacy policy term use celgene provide better ozanimod launch runway especially new drug application filing delay give biogen less medium term price share compression risk ms franchise particularly drug call tecfidera say stock market today celgene jump close novartis advanced end session biogen rise generic competition multiple sclerosis be already underway october mylan myl gain approval generic version teva pharmaceutical teva multiple sclerosis drug copaxone first quarter teva say sale copaxone decline year year same happen novartis gilenya generic arrive patent appeal board decision generic rival likely appeal evercore analyst umer raffat say gilenya still lose patent protection point depend appeal summary ozanimod longer be launch vs generic gilenya say report client give ozanimod least year window launch brand market establish presence ms rbc abraham note celgene benefit tune upside depend length delay generic gilenya ozanimod be meant be safer version gilenya class drug call sphingosine phosphate receptor modulator modulator gilenya be tie heart rate liver issue patient be monitored first dose attribute neurologist care most next generation therapy be absence first dose monitoring piper jaffray analyst christopher raymond say also rank advantage liver enzyme impact pretty far list comparative advantage re look vs gilenya not clear ozanimod have similar requirement celgene management indicate go assumption be ozanimod win avoid raymond say note client see ozanimod avoid first dose monitoring celgene face battle effort differentiate molecule say related chart read basic buy point mark time real much volume look stock trade stock most penny stock fail make investor rich
8,CELG,acceleron pharma xlrn stock jump tuesday celgene celg report second many week blood disease drug call close bell stock market today acceleron share rise earlier pop much celgene advanced share biotech company broadly dip less stoke more confidence celgene rbc capital market analyst brian abraham say firm biggest cancer drug revlimid soon face patent cliff celgene be work other angle cancer drug acquire juno therapeutic be partner bluebird bio blue view positive development recent success juno drug call jcar bluebird drug call bb begin re instill investor confidence pipeline revlimid not substantially reflect share current level say report client get newsletter deliver inbox more info product service privacy policy term study call believe test treatment patient beta thalassemia be dependent regular blood transfusion patient don produce enough protein carry oxygen body show highly statistically significant improvement red blood cell response goal be reduce red blood cell transfusion burden least researcher also look absolute reduction least transfusion unit week week study addition also meet key secondary goal study side effect be consistent previously report datum biotech company say news release firm now plan ask regulator europe approve drug first half news be largely expect week celgene acceleron release positive datum study late stage test look drug ability improve red blood cell response patient be call myelodysplastic syndrome analyst have varied model market credit suisse analyst martin call peak sale disorder leerink analyst geoffrey porge see peak sale used rbc abraham model just small fraction peak sale revlimid still help celgene fill future revlimid shape hole see couple other positive pipeline development jcar bb putt company celgene track reach probability adjust sale current pipeline say piper jaffray analyst edward tenthoff be more bearish partner acceleron downgrade acceleron stock neutral rating cut price target tenthoff acknowledge say acceleron be not buy valuation see sale european official likely approve biggest opportunity drug be myelodysplastic syndrome replace current less effective therapy tail be short tenthoff say crispr therapeutic crsp vertex pharmaceutical vrtx be work potentially curative treatment beta thalassemia therapy get approval say not patient be appropriate able afford gene therapy crispr form gene editing anticipate significant competitive pressure impact acceleron market share say related do spot major market top easy look heavy trade stock most penny stock fail make investor richlook next nvidia start simple routine
9,CELG,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
10,CELG,find best biotech company invest be tricky volatility often pockmark space clinical plan don always come fruition sometimes biotech stock suffer hand regulatory decision food drug administration best biotech company invest tend have commonality strong streak earning growth june investor business daily marketsmith com have biotech stock strong list fastest grow stock top list fastest grow stock supernus pharmaceutical supn be rank eighth past year earning share have grow massive compare top earn stock momo momo chinese social medium firm supernus have make name biotech stock term market cap still trail bigger biotech company amgen amgn gilead science gild biogen biib celgene celg supernus land list consider best biotech company invest strong metric always do research buy stock be sure check company stock chart make sure right time buy have several year double digit quarterly sale growth drug help disorder central nervous system supernus count epilepsy drug oxtellar xr extend release trokendi xr trokendi xr be also approve prevent migraine rival drug botox allergan agn amgen aimovig ligand pharmaceutical lgnd be unique biotech stock ibd rank fastest grow stock put research list possible best biotech company invest doesn market single drug instead ligand acquire early stage technology necessary drug development then license platform pharmaceutical company dow jone stock merck mrk pfizer pfe june ligand have year double digit sale earning growth belt ligand supernus have ibd composite rating meaning perform top stock term key growth metric duo lead other biotech stock term cr get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real build long term profit stock take many gain trade stock most penny stock fail make investor rich
11,CELG,roche rhhby have mixed news tuesday cancer drug tecentriq succeed lung cancer study celgene celg abraxane fail mashup johnson johnson jnj share roche dip month low stock market today roche stock slide close share dow jone component decline celgene lose broadly stock pharmaceutical company tick study roche test tecentriq chemotherapy include celgene abraxane patient advanced form lung cancer regimen help never treat patient live significantly longer compare chemo alone tecentriq combination also reduce risk disease worsening death compare chemotherapy alone roche say news release get newsletter deliver inbox more info product service privacy policy term piece study news pockmarked roche stock janssen unit terminate study testing drug darzalex tecentriq patient advanced type lung cancer accord news release weekend patient be previously treat decision follow review independent datum monitoring committee find observed benefit regimen vs tecentriq alone addition committee note numerical increase patient death receive combination base finding janssen also decide discontinue study evaluate darzalex drug similar tecentriq patient multiple myeloma janssen have license genmab develop manufacture commercialize darzalex be disappoint study be discontinue genmab fully support janssen decision patient safety be paramount drug development genmab chief executive jan van winkel say prepared statement related trade stock most penny stock fail make investor richsell take profit hold here be several guideline followwhat be inflation do matter fed
12,CELG,first half have be dichotomy have have not biotech company wall street brokerage say case have aren large cap biotech company celgene celg biogen biib gilead science gild have struggle negative clinical study regulatory delay key drug instead small midcap biotech company be lead pack rbc capital market analyst call tale biotechs multiple large cap biotech company have slip sale projection have take beating meanwhile price quality asset small midcap biotech company have never be higher competition fierce generalist be able hold smaller cap company be tend invest ishare nasdaq biotechnology index ibb rather just handful large cap rbc write note client week short capital be be deploy biotech just primarily smaller cap name get newsletter deliver inbox more info product service privacy policy term useon stock market today ishare nasdaq biotechnology exchange trade fund fall spdr biotech etf xbi topple biotech stock be now rank industry group ibd track just week struggle large cap space biotech company have be well document street isn entirely hopeful biogen potential alzheimer disease treatment biogen be develop drug call ban eisai same time other potential catalyst have left biotech stock want clinical study gilead alexion pharmaceutical alxn aimmune therapeutic aimt be anticlimactic rbc analyst write celgene suffer massive hit food drug administration delay experimental multiple sclerosis drug ozanimod news be fuel continue question company ability succeed second third act cash flow expire patent cliff rbc analyst say note biotech company appear have good launch new drug list amgen amgn migraine prevention treatment aimovig gilead biktarvy hiv medication even aren enough offset underlie revenue issue analyst say investor be seemingly take dim view large cap biotech stock investor survey suggest worsening generalist sentiment reticence come back space anecdotal feedback suggest frustration challenge company celgene have lead many rotate sector sense few be look dip to back write however small midcap space not be behave more differently innovation gene therapy cellular therapy result acquisition year novartis nvs buy avexis celgene acquire juno therapeutic be help send other cut edge biotech stock sarepta therapeutic srpt sage therapeutic sage sarepta be now fly high datum gene therapy form muscular dystrophy sage be work number depression drug fact biopharma merger acquisition activity term dollar have nearly triple see mid june rbc analyst say ipo initial public offer secondary activity have remain vibrant biotech ipos so far year raise aggregate takeout occur small midcap biotech company analyst list sage sarepta biomarin pharmaceutical bmrn exelixis exel seattle genetic sgen tesaro tsro clovis oncology clvs puma biotechnology pbyi pharmaceutical aldr potential target even small midcap biotech stock be walking thin line say be right side catalyst likely be key second half analyst say capital inflow cool drug pricing rhetoric potentially re escalate go midterm election hiccup emerge early stage modality drug related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
13,CELG,today be true report many well know large cap biotech stock be show disappointing downright awful performance just witness damage lately share biogen biib celgene celg regeneron pharmaceutical regn xit also be true report company ibd biotech industry group have be fantastic winner select gene therapy firm have be rise fast breakout second half blood disease expert bioverativ biogen spinoff have nice rally go soar jan make sure see big price gap accompany chart bioverativ soar mammoth volume news be acquire french pharmaceutical titan sanofi sny investor have used good stock chart find bioverativ make giant single day gain yes bioverativ craft double bottom base help set big move don use stock chart re trading disadvantage chart very tough determine key market current psychology buyer seller balance supply vs demand give stock do bioverativ break jan stock market be confirm uptrend confirm uptrend be best time buy top perform growth stock have greater odd make money invest larger trend specialist therapy hemophilia rare blood disorder establish excellent prior uptrend run close feb market debut peak more month later stock correct week carved month saucer handle never break then bioverativ really begin sell oct midcap swoon hit low create first low base proper double bottom stock rebound back high then sell second time decline stock undercut first low want see authentic shakeout uncommitted shareholder find sign share move weak hand strong hand correct buy point stock rise dime middle peak lows bioverativ do exactly stock rebound less point base left side peak then nose dive again time sell take bioverativ way fine undercut first low double bottom form minimum week correction more say be not ideal deeper correction more stock have work just get back high look sign symmetry base look second low undercut first bioverativ possessed bullish trait week double bottom jan stock gap surpass buy point middle peak cent volume gush normal level session later bioverativ trade proper entry right acquisition news send share vaulting prior waltham mass firm notch quarterly earning share gain revenue have soar then rise next year expect double bottom proliferate lead stock major index fall furiously several wave great market leader build double bottom break bear market fall fall other occasion sometimes ll see handle form double bottom market way present additional buy point sanofi complete acquisition bioverativ march version column be publish march please follow saito chung twitter ibd_dchung more analysis commentary financial market growth company chart stock breakout related be golden rule investingwhat be current stock market direction please read column find great stock now always check latest story investor cornerstock buy make fortune stock market just small sum money yes here
14,CELG,aldr likely seek buyer amgen amgn rivale preventative migraine treatment get approval analyst say thursday share tank hire new chief executive share drop stock market today share break cup base buy point earlier week rally be short live stock sank consecutive day biotech company hire robert azelby former chief commercial officer juno therapeutic new chief executive celgene celg recently acquire juno immuno oncology player azelby work amgen manage oncology business leerink analyst geoffrey porge see azelby tenure likely short get newsletter deliver inbox more info product service privacy policy term use advantage mr azelby view be locality availability be already seattle have presumably become available acquisition juno celgene say report client add hard believe board view mr azelby long term leader company appointment add conviction board ultimately support sale sale be unlikely however get approval preventative migraine treatment know cgrp inhibitor amgen gain approval drug aimovig teva pharmaceutical teva eli lilly lly be also work similar drug earlier year founder former ceo randall schatzman unexpectedly step have plan submit application migraine treatment second half year now expect submit application first quarter fact hire new ceo isn surprising porge say be something surprise individual appoint position have experience neurology have not previously oversee complex multus functional element product introduction say rbc analyst brian abraham other hand call hire sensible fit move commercial stage azelby bring significant experience commercial strategy large small biotechs biopharma say believe be important launch preventative migraine treatment eptinezumab say note understand have also be closely involved regulatory process prior organization experience help eptinezumab application filing related do spot major market top easy look heavy basic sell buy stock ahead earning report
15,CELG,celgene celg topple year low thursday appear list food drug administration try shame drugmaker work block generic competition pharmaceutical biotech company be gaming system limit access drug generic rival need do equivalence study fda say analyst expect so call shame list have little more headline impact company total celgene receive inquiry sample drug revlimid pomalyst thalomid have risk evaluation mitigation strategy rem program ensure benefit drug outweigh risk drug have certain distribution requirement celgene reportedly say biotech company want access drug need follow specific rule biotech say already have provide sample company fulfilled requirement rbc analyst brian abraham say get newsletter deliver inbox more info product service privacy policy term use such celgene be putt understandably high barrier believe generic company willing put appropriate safeguard have already be able obtain revlimid conduct study say note client inclusion celgene list be unlikely speed generic competition revlimid william say now drug be gate more intellectual property regulatory question say mizuho analyst salim sy agree celgene be already work generic litigation regard revlimid analyst expect copycat drug believe be more modest headline risk actual business risk say report stock market today celgene share dip close earlier slip low last see june meanwhile collective share biotech pharmaceutical company lift fraction other key drug list include biogen biib multiple sclerosis medicine tecfidera well gilead science letairis truvada letairis treat pulmonary arterial hypertension truvada treat hiv rbc analyst kennen mackay note fda also include biomarin pharmaceutical bmrn kuvan kuvan treat condition associate elevated amino acid biomarin share dip still biomarin have already settle several general pharmaceutical company generic entry patent expire further fda list publicize effort prevent generic entry actual policy have be put place diminish strategy brand manufacturer employ limit access brand drug say related do spot major market top easy look heavy term retirement investing strategy etfssell take profit hold here be several guideline follow
16,CELG,stock open narrowly mixed territory thursday drop oil price weigh early action investor sort impact possible auto import tariff dow jone industrial average dip heavy early loss chevron cvx exxon mobil xom overcome advancer lead general electric ge drop nasdaq shed celgene celg st century fox foxa lead nasdaq stock ulta beauty ulta drop bottom list fed minute release wednesday signale steady go view rate hike hike likely june make fourth rate hike less probable investor like news bolster market rebound late day get newsletter deliver inbox more info product service privacy policy term usein economic news labor department datum show first time unemployment claim rise week end number be claim prior week consensus forecast project decline claim crude oil price head lower third straight day west texas intermediate cut just barrel level wti future have not settle news report say russia energy minister reiterate country discuss possible phase production curb opec partner june meeting exxon fall chevron drop shale oil producer noble dive more open trade thursday early stock market action automaker edge higher auto brand dive president donald trump instruct commerce department late wednesday explore expand tariff import car light truck suvs van section investigation same legal provision used previously apply tariff steel aluminum regard threat national security trump be ask tariff much auto import ford open general motor gm add tesla tsla slip toyota motor tm drop tata motor ttm dive fiat chrysler fcau dump celgene climb head nasdaq early trade company announce share buyback amount earmark accelerate buyback initiative earning news netapp tumble report narrow win late wednesday fiscal fourth quarter revenue earning first quarter revenue guidance appear be sticking point come just shy consensus target netapp share be november pull back end wednesday session test support stock week move average victorium secret parent brand lb climb investor look past weak second quarter guidance otherwise strong quarterly report busy slate hour earning report have decker outdoor deck gap gps autodesk adsk ross store rost splunk splk veeva system veev line report overseas market be map thursday japan tokyo nikkei dive follow news possible tariff auto import china hong kong hang seng index rebound take dive wednesday europe trade weaken afternoon action cac paris reversed early gain slip frankfurt dax ftse london be more be interested big picture stock stage positive reversal give bullish signalsthese top stock hold buy zone market driftsthese stock be buy zone ahead earning investing action plansalesforce rival growth be cut investor slack top stock get handle buy pointswhich stock show rise trend relative strength line
17,CELG,amgen amgn future biotech company be trouble analyst say tuesday company sector trade premium biotech company celgene celg biogen biib pipeline contain fewer blockbuster opportunity meanwhile generic biosimilar competition be hacking away chunk revenue leerink analyst geoffrey porge say investor have be reward amgen share repurchase program steady cash flow lack long term stability generally investor look biotech company unpriced optionality pipeline amgen doesn have amgen case inability identify program offer upside particularly company size reinforce belief amgen commit significant business development activity expand portfolio pipeline porge say report client get newsletter deliver inbox more info product service privacy policy term useporge estimate amgen portfolio be likely steadily decline biggest moneymaker epogen aranesp neupogen neulasta enbrel be face rivalry growth potential new acquire product isn enough offset decline franchise epogen aranesp treat anemia dow jone component pfizer pfe just gain approval make copy epogen procrit novartis nvs also have copycat neupogen bone marrow stimulant blockbuster neulasta enbrel be also risk neulasta also stimulate bone marrow enbrel treat chronic disease include form arthritis psoriasis novartis already have copycat enbrel novartis mylan myl coherus bioscience chrs be work copy neulasta response amgen have restructure expense base initiate dividend lever company balance sheet porge say compare peer regard amgen more defensive stock also lack explosive upside potentially typically associate breakthrough rapidly grow bio therapeutic stock say porge see amgen worth share be most recent close price have market perform rating price target amgen stock stock market today share rise close share biotech company lift fraction most concern conclusion analysis be lack opportunity amgen pipeline outside element sum part say celgene biogen other hand have greater pipeline optionality growth prospect eventually firm have engage smart merger acquisition porge say best merger acquisition pivot away amgen challenged legacy product mid late stage pipeline opportunity build revenue projection possible biotech be interested merger equal stand company current pipeline be very early have share economic thus be unlikely meaningfully outlook company current revenue year say related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
18,CELG,wall street be split wednesday celgene celg sell side analyst downgrade stock say have tilt greater risk upgrade share beleaguered biotech company stock market today celgene share gain close share crumble year low monday report head business development exit april share biotech company rise fraction wednesday argus analyst david toung downgrade celgene hold rating buy same time analyst sanford bernstein upgrade stock outperform rating market perform reportedly say valuation be too cheap ignore toung be concern longevity cancer drug revlimid generic pharmaceutical company mylan myl dr reddy laboratory rdy be vie make copycat revlimid revlimid patent extend europe get newsletter deliver inbox more info product service privacy policy term use more revlimid patent be invalidate broad generic competition begin say report client be devastate celgene bring revlimid sale contend celgene acquire juno therapeutic juno lead drug candidate cancer treatment bring peak year sale toung doesn expect commercial launch month celgene also put acquire impact biomedicine have experimental cancer drug firm plan file approval key drug mid also work bluebird bio blue multiple myeloma treatment pipeline asset be promising combine potential revenue be not enough completely replace revlimid view toung say toung assessment follow food drug administration list attempt shame several pharmaceutical company block generic competition big drug large biotech company fda also list gilead science gild biogen biib celgene have also have number misstep recent history last october scrap study drug call ged crohn disease treatment february fda say wouldn review drug call ozanimod multiple sclerosis drug be now delay least year related do spot major market top easy look heavy basic sell stocksell take profit hold here be several guideline follow
19,CELG,celgene celg tank nearly late tuesday food drug administration refuse file application multiple sclerosis treatment call ozanimod cite deficiency paperwork preliminary review fda determine nonclinical clinical pharmacology section application be insufficient review celgene say statement plan seek guidance include request meeting fda ozanimod be be develop treat relapse form multiple sclerosis be most not most important pipeline program celgene rbc analyst brian abraham say note client refusal file letter sometimes require administrative tweak refile mean company have perform additional clinical study abraham say celgene case hard now know material setback ozanimod be meaningful delay impact drug ultimate potential currently have peak sale model give competitive multiple sclerosis generic gilenya be disruptive launch prior ozanimod approval inflammatory bowel disorder space say hour trading stock market today celgene plunge stock finished regular session nearly related biotechs diverge biggest moneymaker lag rocket top quarterly estimate crush guidance viewstesaro dife miss fourth quarter expectation
20,CELG,abbvie abbv celgene celg regeneron pharmaceutical regn spike second half accelerate number drug approval launch analyst say wednesday reverse trend first half year see share biotech stock slip industry group track investor business daily group be rank fifth just week meanwhile pharmaceutical company be rank leerink analyst classify first half disappointing large cap biopharma company biotech stock pharmaceutical company face dearth clinical study result validate pipeline re price stock say second half year promise be more exciting small mid cap biopharma stock significant clinical event horizon include readout binary phase trial write note client get newsletter deliver inbox more info product service privacy policy term other biotech stock pharmaceutical company abbvie be expect report datum study drug upadacitinib researcher be look drug treatment form arthritis further food drug administration likely decide approve abbvie drug call elagolix treatment endometriosis condition female reproductive system fda also decide fate drug dub venclexta form leukemia stock market tracker also expect celgene unveil datum late stage study revlimid celgene partner acceleron pharma xlrn blood disease revlimid be celgene major cancer drug celgene also reveal more juno therapeutic acquisition be move class cancer therapy know car short chimeric antigen receptor cell therapy compete novartis nvs gilead science gild datum car development update define path forward product revlimid leerink analyst geoffrey porge say note porge also expect fda make decision regeneron sanofi sny dupixent asthma treatment physician already use dupixent treat eczema duo also have cemiplimab fda be consider advanced form skin cancer addition intra cellular therapy itci be work drug dub lumateperone schizophrenia treatment analyst focus fda accept application approval base mixed phase datum porge say intra cellular also report topline datum ongoing phase study bipolar depression second half look second indication lumateperone say porge expect zogenix zgnx have datum late stage study drug zx researcher be consider drug treatment type epilepsy call dravet syndrome gw pharmaceutical gwph drug epidiolex likely gain approval use june additionally dova pharmaceutical dova fibrogen fgen have catalyst chronic liver chronic kidney disease respectively dova expect fda soon decide approve drug fibrogen expect unveil topline datum study drug second half year fda be also take flexible stance orphan drug development leerink analyst joseph schwartz say note approval sarepta therapeutic srpt duchenne muscular dystrophy drug exondys trigger cascade noteworthy filing say continue believe fda continue evolution warrant positive sentiment rare disease focuse company particularly name amicus therapeutic fold sarepta uniqure qure long investigational drug be deem safe demonstrate strong effectiveness say related much money do need start investing look best stock buy watch start herestill rule stock investor always cut loss short
21,CELG,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
22,CELG,biotech stock pharmaceutical company add recent market gain monday trump top health aide deliver speech largely spare brunt drug pricing reform health human service secretary alex azar deliver speech drug pricing reform monday trump speech be light impact biotech company pharmaceutical company instead white house be consider change medicare cap pocket spending most proposal impact so call middleman include pharmacy benefit manager pbms drug distributor include like express script esrx cvs cvs abc azar be critical pharmaceutical company high list price lack transparency direct consumer advertising look forward work industry build better system say industry isn willing work lower price president trump administration keep turn pressure system finally put american patient first get newsletter deliver inbox more info product service privacy policy term useshare pharmaceutical company have rally ultimately slip marginally close biotech company stock gain stock market today follow speech nasdaq biotechnology nbi be flat ishare nasdaq biotechnology ibb index rise proposal rbc analyst see change medicare part part have biggest impact biotech stock still write note client even still be relatively benign overall part cover physician administer drug part cover prescription drug proposal negotiation part drug be more similar part negotiation more broadly president be call part merge part azar say inflation capped price increase part be likely most impactful proposal biotech well pocket transparency part vs part drug infusion vs self injectable unify part bill code rbc analyst say regeneron pharmaceutical regn have largest exposure large cap biotechs part eye disease drug call eylea celgene celg biogen biib amgen amgn also be expose further sage therapeutic sage aldr dynavax dvax face difficulty azar also suggest change pbms issue negotiate rebate propose end so call gag clause pharmacist prevent pharmacist tell consumer actually save money pay pocket medicine right now re ask pretty straightforward question instead current system drug company get paid rebate middleman take cut just have fix price discount azar say fix situation even pharmacy benefit manager be hire help keep price low make money higher list price also suggest pharmaceutical company include list price advertising go directly consumer further azar say center medicare medicaid service be develop incentive lower list price most change be long term further action raymond james analyst michael baker say note change part contract prevent pharmacist explain pocket cost be cheaper likely not have meaningful impact related biotech stock fly trump speech see more bark bite much money do need start investing long term retirement investing strategy buy stock ahead earning report
23,CELG,celgene celg share lift monday likelihood approach settlement dr reddy laboratory rdy generic version blockbuster cancer drug revlimid suggestion rbc analyst brian abraham come celgene dr reddy say legal document friday have need markman hearing pretrial hearing judge examine evidence regard key word used patent claim appear celgene dr reddy resolve difference dispute terminology say note client see positive indication settlement approach continue believe settlement generic filer incremental year revlimid economic provide reassurance be unlikely be earlier expect generic revlimid entrant cliff say get newsletter deliver inbox more info product service privacy policy term usecelgene rise stock market today dr reddy advanced abraham note not ordinary company hash difference markman hearing have seem unlikely case term crystalline be not previously defined be highly significant dr reddy potential success open brief december be significant disagreement definition say celgene dr reddy apparent compromise strongly suggest full settlement be approach abraham say also possible celgene be work consolidated settlement multiple generic filer revlimid be celgene biggest drug bring sale grow year year accounting total product sale drug be set begin lose patent protection mid related chart read basic buy point mark time real best stock buy watch start herewhich stock be show rise relative strength
24,CELG,rapid turnaround allergan agn say late thursday doesn intend bid shire shpg leave thrice rebuff takeda pharmaceutical alone race rare disease drugmaker entire saga erupt early thursday report emerge allergan be interested buy shire same time shire confirm have reject bid takeda worth north allergan first say be early stage potential bid shire hour stock plunge later allergan say definitively win make offer take shire meanwhile still evaluate full range potential strategic option allergan say news release share allergan close be flat hour trading stock market today shire sank close bell get newsletter deliver inbox more info product service privacy policy term usespeculation shire takeda merger have be swirl late march then takeda have make bid shire case shire board determine bid significantly undervalue firm growth prospect pipeline takeda confirm put forth buyout bid shire worth share comprise cash stock firm say be willing continue negotiating still takeda be confident remain well position even negotiation fall build takeda exist momentum acquisition shire accelerate transformation result global value base drive leader headquarter japan takeda say prepared statement short live interest allergan come surprise leerink analyst etzer say note firm have say become acquisitive be look strategic option combination shire introduce growth challenge year be reflect negative stock reaction say shire be likely face erosion attention deficit hyperactivity medicine vyvanse begin significant erosion hemophilia business compete rival roche rhhby allergan have have justify bid shareholder say shire interest come flurry biotech acquisition kick earlier year celgene celg announce plan buy juno therapeutic sanofi sny unveil plan acquire bioverativ bivv ablynx ablx novartis nvs sell share glaxosmithkline gsk consumer health unit used part proceed fund plan acquire avexis avxs merck kgaa agree sell counter unit proctor gamble pg day be rumore mylan myl buy earlier week shire say sell cancer unit france servier analyst have speculate celgene also be lookout more acquisition agio pharmaceutical agio jounce therapeutic jnce potential target amgen amgn also have huge war chest be face competition older medicine related chart read basic buy point mark time real opportunitylong term retirement investing strategy etfssell take profit hold here be several guideline follow
25,CELG,prothena prta jump week high wednesday collaboration deal celgene celg result treatment alzheimer disease palsy encephalopathy analyst say collaboration announce late tuesday focus treatment target protein call tau tdp undisclosed substance prothena work be largely disease tie misfold protein protein structure be incorrect tau have be tie alzheimer form palsy dementia degenerative brain disease rbc analyst kennen mackay say report tdp be indicated group neurological disease well form dementia alzheimer view today announce collaboration celgene external validation prothena internal expertise company potential machine mackay say boost price target prothena get newsletter deliver inbox more info product service privacy policy term useon stock market today prothena soar close spiking point share touch highest point earlier february celgene advanced cent biotech stock broadly lift term deal celgene pay prothena upfront make equity investment smaller biotech premium prothena close price tuesday cash infusion help limit downside prothena unveil result trial mid mackay say trial be evaluate drug call neod treatment disease protein deposit body cause systemic damage however anticipate outcome upcoming neod trial likely be view read prothena platform positive negative scenario say instinet analyst christopher marai expect celgene collaboration accelerate prothena pipeline development see firm filing application year regulator begin new clinical trial marai reiterate buy rating prothena keep price target related invest stock free new apps aim beginnerswhich stock be show rise relative strength look best stock buy watch start here
26,CELG,prothena therapeutic prta jump double digit late tuesday deal celgene celg develop treatment disease hour trading stock market today prothena fly higher finishing regular session multiyear deal focus protein thought be tie development several disease include tau tdp undisclosed target prothena say press release celgene have exclusive right license drug candidate time prothena file investigational new drug application food drug administration celgene expand license global right phase study be complete term deal celgene pay prothena upfront make equity investment company prothena be also eligible receive potential exercise payment well regulatory commercial milestone license program get newsletter deliver inbox more info product service privacy policy term hour celgene be lose close bell landing small rival present strong datum ulcerative colitis drug related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
27,CELG,arena pharmaceutical arna gap nearly third tuesday ulcerative colitis drug prove strong phase trial less month regulator delay similar drug celgene celg stock market today arena rocket close earlier rise much celgene other hand dip close analyst suggest arena drug be stronger celgene piper jaffray analyst christopher raymond say hard compare drug arena have datum drug etrasimod milligram dose week treatment similar datum celgene ozanimod be milligram dose week etrasimod seem look awful lot ozanimod raymond say report client datum appear similar even slightly advantageous arena get newsletter deliver inbox more info product service privacy policy term useboth drug class call sphingosine phosphate receptor modulator be be test number inflammatory condition last month regulator say wouldn consider celgene application use ozanimod treat multiple sclerosis cite deficiency paperwork etrasimod be measure scale call mayo clinic score range consist stool frequency rectal bleed endoscopy finding patient receive milligram dose be point improvement vs placebo base same scale patient treat milligram etrasimod achieve clinical remission vs placebo group component scale patient same etrasimod group be remission vs placebo patient safety be key trial leerink analyst joseph schwartz say investor be look etrasimod lack cardiac effect say patient milligram dose group develop type heart block resolve shortly emergence patient eventually discontinue trial other reason management emphasize effect node be know target phenomenon profile etrasimod be still far cleaner ozanimod other pr modulator say schwartz raise expectation etrasimod succeed also boost price target arena keep outperform rating arena say plan move etrasimod phase testing company didn offer timeline mizuho analyst salim sy note phase study ozanimod ulcerative colitis be push back year due slower enrollment drug be fairly similar ozanimod get approve ulcerative colitis happen arena have compete approve drug market say totally depend quickly arena enroll phase related much money do need start investing trade stock most penny stock fail make investor richnew option strategy limit risk earning
28,CELG,buyout partnership news send biotechs fly monday novartis nvs bid take avexis avxs rumor emerge celgene celg swipe agio pharmaceutical agio ionis pharmaceutical ion partner astrazeneca azn make liver disease treatment close stock market today avexis rocket easily hit highest point go public february novartis lift agio surge celgene be flat be more hour meanwhile dow jone stock merck mrk pop end regular session datum show drug keytruda improve overall survival first treatment option lung cancer patient key rival bristol myer squibb bmy dip news acadium pharmaceutical acad hit lowest closure point june cnn story detail death patient take only approve drug nuplazid nuplazid treat psychosis patient parkinson disease be be test array other condition get newsletter deliver inbox more info product service privacy policy term usenovartis agree pay share avexis offer represent premium avexis close friday deal be premium avexis day volume weight average stock price avexis say news release avexis be develop avxs gene therapy treatment spinal muscular atrophy diagnosed young child drug rival biogen biib ionis spinraza be already approve treat condition biogen stock fall fraction rise extend trading rbc analyst brian abraham credit deal breathe life sector note biotech group have be pressure recently share sank much month low friday collectively advanced monday be merger acquisition kick start sector have await view say have be anticipation major deal trepidation drug pricing risk highlight negative catalyst have keep sentiment late transaction be expect close midyear price go share avexis stock novartis decide extend close date oct avexis terminate deal owe novartis fee novartis terminate deal owe avexis ptc therapeutic ptct jump news ptc be early stage make treatment spinal muscular atrophy roche rhhby asset remain early have show early positive signal see increase attention today give value big pharma be clearly willing place sma asset once be further risk rbc abraham say immuno oncology drug keytruda significantly outperformed chemotherapy patient advanced lung cancer merck say news release study dub keynote test keytruda single drug vs chemo patient have pd protein least tumor cell study examine overall survival interim analysis show keytruda keep patient alive longer chemotherapy lone treatment safety be line earlier study merck now continue study determine keytruda impact progression free survival patient have pd protein tumor represent overall market lung cancer evercore analyst umer raffat say note bristol rival drug opdivo fail improve progression free survival patient pd least tumor note bristol share touch month low intraday trading news re-cover somewhat close abbvie abbv run rise hour investigational drug upadacitinib beat own blockbuster humira study rheumatoid arthritis patient patient receive milligram upadacitinib daily milligram humira other week placebo abbvie examine patient week least improvement rheumatoid arthritis symptom clinical remission study show upadacitinib patient experience improvement symptom vs humira placebo patient respectively upadacitinib patient be clinical remission vs humira placebo patient be excited strong result add body evidence support potential upadacitinib be important treatment option patient rheumatoid arthritis abbvie spokesperson michael severino say prepared statement rumor emerge celgene be eyee takeover agio jounce therapeutic jnce agio pop jounce surge buyout follow celgene recent acquisition juno therapeutic cancer biotech report emerge financial time cite unnamed source celgene be reportedly hunting acquisition target promising drug offset loss patent protection key blockbuster revlimid celgene already partner agio jounce be work cancer drug agio have market cap eclipse jounce market cap remain jounce go public last year similar news ionis astrazeneca announce partnership develop drug treat nonalcoholic steatohepatitis term deal astrazeneca pay ionis license fee take responsibility development drug drug advance ionis be also eligible receive additional development regulatory milestone payment well tiered royalty low teen sale drug ionis stock advanced astrazeneca lift close menlo therapeutic mnlo acadium be biggest biotech stock loser monday share menlo tank fall just month go public stock have be form cup handle buy point share rise hour tumble follow news sunday menlo itch drug fail eczema study menlo find statistically significant difference drug serlopitant placebo chief executive steve basta note be still sign improvement serlopitant treat patient serlopitant be also be test skin condition know prurigo nodularis itch associate psoriasis chronic cough setback eczema doesn necessarily hurt menlo chance serlopitant prurigo nodularis piper jaffray analyst david amsellem say note prurigo nodularis be altogether different condition say larger point here be menlo decide run broad clinical program itch order have handful potential pathway market serlopitant amsellem keep overweight rating menlo meanwhile acadium dive cnn story outline death parkinson patient take nuplazid psychosis nuplazid be approve treat hallucination delusion associate parkinson approval patient continue experience hallucination side effect include death life threaten incident fall insomnia nausea fatigue cnn write approval more patient nuplazid have die last june nuplazid be only medicine list suspect least death report acadium note study have show difference number death report nuplazid placebo drug be acadium only approve medicine acadium be testing nuplazid dementia related psychosis schizophrenia depression related much volume look stock long term retirement investing strategy buy stock ahead earning report
29,CELG,gilead science gild viral franchise look strong head first quarter earning season fellow large cap biogen biib celgene celg be shakier ground analyst say wednesday rbc analyst brian abraham call gilead top expectation biogen likely miss bottom line celgene still reel sudden departure chief operate officer be typically weak first period clinical study business development be more important biotech say believe clinical trial success increase merger acquisition activity be more important help improve sentiment give renew drug pricing competitive life cycle concern sector say note client get newsletter deliver inbox more info product service privacy policy term usegilead gain close biogen climb celgene jump possible rebound drop wake sudden unexplained departure chief operate officer coo scott left late last week day biotech group be rank first just week fifth recently week now slip group track investor business daily share hit month high march have topple point abraham call strong quarter gilead hiv drug be become more important firm top line hepatitis market be stabilize more hiv patient be used regimen contain drug know tenofovir alafenamide taf abraham see genvoya descovy odefsey beating expectation take share own atripla stribild biktarvy drug treatment hiv be still early launch expect bring first quarter sale look be tracking ahead consensus project longer term say hepatitis drug harvoni epclusa be see beating view abraham model drug competition abbvie abbv new drug mavyret treat wide group hepatitis patient franchise perform expect see cent bottom line beat first quarter earning share tracking exceed consensus year believe help drive upside pipeline mature visibility increase earning growth year say abraham have outperform rating gilead share biogen look generally solid first quarter abraham expect sale be slightly consensus base prescription trend expect earning share come cent consensus multiple sclerosis drug tecfidera be experience steady erosion celgene experimental drug ozanimod have be delay multiple sclerosis meanwhile revenue spinal muscular atrophy drug spinraza be likely be line multiple sclerosis contract secure key competitor ozanimod delay temporary lull competitive spinal muscular atrophy news flow expect focus call be potential year growth driver say biotech be expect outline plan aducanumab be be test alzheimer disease recently biogen make change study drug investor also be likely key potential acquisition talk expect share trade line pending more clarity long term picture say abraham boost price target have sector perform rating stock first quarter tend be seasonally weak celgene believe be solid enough allay concern emerge follow departure president chief operate officer abraham say abraham boost expectation inflammation drug otezla first quarter year line consensus view otezla sale have be source pain past widely miss third period rebound fourth abraham lower view pomalyst cancer drug reflect weaker expect use pattern likelihood indirect erosion johnson johnson jnj darzalex investor focus be next step ozanimod regulator reject drug multiple sclerosis celgene also offer further detail acceleron pharma xlrn partner blood disease abraham cut price target have celgene top pick stock related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
30,CELG,spectrum pharmaceutical sppi near tuesday report be number biotech company seek pharmaceutical merger stock market today spectrum rocket finish regular session share be form cup handle buy point bloomberg first report rumor takeover early tuesday spectrum be reportedly explore option include selling business person familiar matter say biotech decline comment email investor business daily spectrum be currently work number cancer drug biotech be furthest drug treat bladder cancer condition follow chemotherapy get newsletter deliver inbox more info product service privacy policy term biotech be worth make smaller other recent target pharmaceutical merger roche rhhby recently announce buy foundation medicine fmi market cap avexis market cap be novartis nvs buy other pharmaceutical merger takeda pharmaceutical be spending acquire shire shpg worth sanofi sny agree acquire biotech company bioverativ ablynx combine celgene celg paid juno therapeutic get instant access more trading idea exclusive stock list ibd proprietary rating only related do spot major market top easy look heavy distributionnew option strategy limit risk earningsstill rule stock investor always cut loss short
31,CELG,nike fuel big rally dow jone friday major stock index look poise end second quarter high note biotech stock nasdaq outperformed name vertex vrtx celgene celg biomarin bmrn nicely share vertex soar compete cystic fibrosis drug galapago glpg didn do well mid stage trial dow be midday nasdaq composite rise respectively volume nyse nasdaq be tracking lower thursday level stock market result today nike nke be hand winner dow company report strong earning late thursday share surge head report nike be still buy range entry get support day move average also dow american express axp rise more flatten yield curve hasn be good news financial recent week sector outperformed nicely friday federal reserve give go ahead several bank increase dividend initiate share buyback american express increase dividend cent also announce plan buy back stock elsewhere share constellation brand stz slump earning miss large cap name be solid technical setup ahead result not more constellation gap day move average be well session lows ibd viper energy partner vnom continue low volume ascent rise back day move average only high current cup shape base be too short be valid base ibd name illumina ilmn extend gain pay visit day line thursday share be health care name continue show relative strength entry china base name package delivery firm zto express zto continue show good action week move average recent share be get instant access more trading idea exclusive stock list ibd proprietary rating only also tesla sale trade war job fed minute investing action planvideo game stock be potential medium company acquisition targetsnovartis surge decision spin alcon eye device unit
32,CELG,celgene celg bluebird bio blue agree wednesday co commercialize co promote advanced cancer treatment know bb company begin collaborate cancer treatment bb be part deal now be study bb multiple myeloma believe therapy have potential significantly impact treatment approach outcome patient multiple myeloma celgene president hematology oncology nadim ahm say written statement term deal company pay half cost get half profit celgene also pay bluebird milestone royalty sale outside get newsletter deliver inbox more info product service privacy policy term usein early trading stock market today bluebird sank close share celgene surge deal come just week celgene wrapped acquisition juno therapeutic juno bluebird be work cancer drug call car therapy gilead science gild novartis nvs already have drug approve arena notably other be develop alternative form car therapy be less costly drug gilead novartis dow jone stock pfizer pfe cellectis cll be team crispr therapeutic crsp be work related build long term profit stock take many gain look best stock buy watch start buy stock ahead earning report
33,CELG,german biotech potential rival gilead science gild novartis nvs celgene celg cancer drug be look raise nasdaq initial public offer accord recent filing morphosys file registration statement thursday hasn yet price ipo security exchange commission filing say plan raise help line coffer morphosys plow ahead late stage oncology drug firm late stage treatment rival approve drug call car therapy aim patient immune system identify fight cancer novartis gilead crossed finish line last year car treatment call kymriah yescarta respectively kymriah be used treat form acute lymphoblastic leukemia patient age younger novartis be also seek approval kymriah disease call diffuse large cell lymphoma gilead yescarta be already approve get newsletter deliver inbox more info product service privacy policy term kymriah yescarta morphosys drug call mor target antigen call cd kymriah yescarta mor isn car drug belong class call monoclonal antibody be develop treat diffuse large cell lymphoma chronic lymphocytic leukemia morphosys recently unveil strong result mor combination lenalidomide sell celgene brand name revlimid patient diffuse large cell lymphoma trial be still ongoing morphosys say news release earlier month preliminary result show patient achieve median progression free survival rate month treatment overall patient respond regimen have complete response regimen be also well tolerate unexpected toxicity earlier stage testing morphosys be also work therapy multiple myeloma call mor rival drug celgene celgene acquisition juno therapeutic celgene be look car treatment multiple myeloma diffuse large cell lymphoma other blood cancer german biotech also have develop license drug glaxosmithkline gsk be investigate rheumatoid arthritis multiple sclerosis eczema drug development partner galapago glpg drug be look tumor property related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
34,CELG,celgene celg go private avoid volatility key cancer drug revlimid begin lose patent protection mid analyst suggest wednesday leverage buyout premium be theoretical party rbc analyst brian abraham say note assume deal be finance debt equity blended interest rate celgene be tough position third biggest biotech market cap value share be year date top drug revlimid pomalyst cancer treatment be set lose exclusivity mid model takeout occur company be spun back public market point expect more go forward earning stability pomalyst be patent revlimid partially patent say get newsletter deliver inbox more info product service privacy policy term usego private allow celgene capture value revlimid cash flow patent cliff aren be appreciate public abraham say move also help celgene avoid volatility work revlimid litigation settlement pipeline development include refile approval multiple sclerosis drug ozanimod have be delay regulator further celgene reduce general administrative cost buyer gain share significant discount say current shareholder see immediate premium stock price many believe be difficult achieve stock re rate again timing be unpredictable multiple sclerosis drug ozanimod anemia drug multiple myeloma drug bb be key celgene success celgene be partner acceleron pharma xlrn bb be be develop bluebird bio blue buyout be unrealistic abraham say leverage buyout greater be rare largest ever be deal likely have be creative involve big pharma involvement get celgene board modest premium be sure thing merger compromise celgene corporate culture research development capability reputation partner choice stock market today celgene tick cent close biotech stock be collectively fraction group be rank fifth industry group track ibd related tame volatile swing trade half positionlong term retirement investing strategy etfsnew option strategy limit risk earning
35,CELG,here weekly investing action plan need know investor come week apple aapl be set unveil new bell whistle developer well possibly tease work customer broadcom avgo report earning upheaval chip sector international trade top cybersecurity stock palo
36,CELG,amgen amgn be better string together small deal rather attempt megamerger like celgene celg alexion pharmaceutical alxn astrazeneca azn analyst suggest monday biggest debate stock be amgen do war chest cash tax reform credit suisse analyst alethia young say note client end amgen have cash investment young see amgen have cash think maximum deal size amgen finance raise equity be say amgen buy similar amount revenue growth significantly cheaper series small cap deal vs large cap just amgen buy puma biotechnology pbyi tesaro tsro anaptysbio anab achieve compound annual growth rate pro basis astrazeneca cost same growth shire tack sale growth rate get newsletter deliver inbox more info product service privacy policy term use here see amgen attain similar revenue growth rate less upfront capital young say investor also be interested amgen strategy contend emerge competition rivale biggest drug enbrel amgen total sale decline amgen expect total sale again decline midpoint guidance megamerger celgene be most interesting young say amgen have pay split cash equity include addition debt raise celgene add top bottom line respectively compound basis celgene financing revlimid controversial intellectual property matter make deal complex say astrazeneca also have interesting revenue synergy be significant integration risk astrazeneca employee base be time bigger midcap range incyte incy alexion be also interesting allow flexibility do few small deal well young say fit nicely amgen hematology unit require equity financing incyte be unlikely term first half incyte partner merck mrk dow jone component be set unveil result trial immuno oncology drug epacadostat keytruda advanced melanoma alexion just have positive datum next generation version biggest moneymaking drug soliris call alxn amgen buy alexion add sale profit respectively young say keep neutral rating price target amgen stock market today amgen lose close sympathy broader biotech market fall collective related invest stock free new apps aim basic sell stocklooking next nvidia start simple routine
37,CELG,dow jone nasdaq composite initially rally china trade truce president donald trump signale be not happy current talk then announce probe auto import pull plan north korea summit major average rise stay recent range big box retailer such target tgt kohl kss best buy bby penney jcp tumble earning report several specialty chain such tif william sonoma wsm foot locker fl shine micron technology mu soar raise guidance big buyback hot datum storage stock retreat earning software stock be mixed crude oil retreat multiyear high treasury yield pull back second straight week dow jone index nasdaq composite rally monday then pare gain time major average rise week nasdaq dow jone oil stock retreat crude oil tumble treasury yield sank year rate dovish fed safe haven flow italy other geopolitical issue house dodd frank regulatory relief bank stock react more fall yield retailer be hot other tumble earning micron technology surge micron technology pop memory chip maker announce stock buyback program start september exceed expectation play long term demand trend analyst day micron also increase earning revenue guidance fiscal third quarter end micron tell analyst expect strong pricing dram flash memory device continue year long term demand artificial intelligence autonomous drive crude price tumble barrel fall barrel strong supply opec buzz most decline come friday opec raise oil production june meeting supply worry iran venezuela accord reuter report russian oil minister novak say talk opec possibility gradual output recovery energy information administration say stockpile rise barrel last week vs barrel decrease analyst expect eia say domestic production edge barrel day energy stock pull back crude price get newsletter deliver inbox more info product service privacy policy term usekohl report first quarter earning be much better expect stock tumble department store chain say friend family promotion pull forward more sale expect indicate weaker same store sale meanwhile share penney fall ceo marvin ellison bail become ceo lowe low share sank big box retailer miss first quarter estimate commerce investment hit gross margin target also blame bad weather hurt temperature sensitive category discounter cite momentum other area home good food beverage target also say traffic have accelerate second quarter jewelry giant report ep gain sale send share blast buy area meanwhile fashion apparel giant ralph lauren rl soar back buy zone ep unexpectedly rise william sonoma leap upscale houseware retailer beat ep revenue several top rate software stock report earning last week mixed result nutanix ntnx lose adjust cent share miss fiscal estimate penny forecast larger expect loss july quarter network have be shift software business model selling hardware appliance have hike investment pursue revenue growth share fall friday splunk splk lose cent share top view revenue rise beating estimate billing decelerate growth previous quarter share datum analytic software maker fall friday autodesk adsk fall maker computer aid design software report adjust earning top view revenue meet expectation july quarter earning forecast miss estimate subscriber growth be previous quarters company be shift cloud compute base subscription model license software synopsys snps meet fiscal ep view revenue edge past view maker electronic design automation software forecast revenue significantly analyst consensus share fall week veeva system veev thursday report adjust income cent share sale rise respective vs year earlier period metric top consensus cent respectively veeva guide slightly higher current quarter veeva close friday general electric ge stock tank ceo john flannery warn wednesday be profit growth power business year meanwhile ailing dow component merge ge transportation unit rail equipment giant wabtec wab deal ge shareholder have majority stake share bilibili bili jump thursday chinese online entertainment company double revenue strong mobile growth sharp drop net loss first earning report late march ipo bilibili provide online entertainment platform include live video mobile game chinese online classified service com wuba beat quarterly view share fall thursday pure storage pstg receive several price target hike report strong earning stock tumble due line guidance company make solid state storage array used flash chip offer big performance gain storage system used disk drife datum storage giant netapp ntap also top view guide low share re-cover close higher thursday still fall week comcast cmcsa say close trumping disney bid entertainment asset st century fox foxa meanwhile fox pay right world wrestling entertainment wwe tv show smackdown have air usa network own comcast nbcuniversal nbcuniversal be expect renew right wwe raw wwe stock soar netflix nflx pass comcast market cap just eclipse disney valuation bill ackman persh square reportedly acquire stake home improvement retailer lowe low ackman be say support incoming ceo marvin ellison announce week be leave penney head lowe ellison previously work top home depot hd executive maxx parent tjx tjx grow profit share revenue rise guidance come light price rival ross store rost also top forecast ep growth revenue gain same store sale rise also beating guide low current quarter tjx stock rise record high week ross store fall sharply friday urban outfitter urbn beat earning sale beat analyst expectation same store sale also beat estimate gap gps report ep analyst expectation sale beat still retailer report steeper expect drop same store sale namesake store ugg boot maker decker outdoor deck report result well forecast guidance be mixed urban outfitter be little change week gap dive friday decker hit record high canopy growth cgc thursday become first pure play marijuana company list new york stock exchange canadian pot producer follow rival crono cron list nasdaq february adobe system adbe agree buy commerce permira fund hillhouse capital give commerce platform take salesforce com crm enterprise market well shopify shop smaller customer foot locker fl report surprise first quarter earning share gain first rise quarters revenue same store sale also top share mall base athletic shoe retailer largely sell nike gear soar friday hibbett sport hibb tumble nearly friday miss earning sale comp best buy gap weak profit projection even crushed earning estimate thursday share gain hewlett packard enterprise hpe report fiscal earning revenue edge view forecast july quarter profit slightly analyst estimate share swoon worry fall server sale company shift cloud compute well market share trend celgene celg share topple year low monday news head business development george golumbeski quietly exit mid april biotech stock rally close slightly higher week be interested invest stock market start simple routinestock buy zone ahead earning
38,CELG,ligand pharmaceutical lgnd stock break tuesday touch record high defy broader downturn see biotech company stock dip collective fraction close bell stock market today ligand stock gain close share break cup base buy point stock have remain black past trading day meanwhile share biotech company close analyst be bullish ligand have licensing deal biotech company pharmaceutical company bigger client include novartis nvs amgen amgn celgene celg gilead science gild also work dow jone component pfizer pfe merck mrk get newsletter deliver inbox more info product service privacy policy term useligand be ibd top grow stock firm acquire early stage technology necessary drug development then license platform other pharmaceutical company stock have ibd composite rating best possible meaning perform top stock term key growth metric ligand stock lead biotech group ahead supernus pharmaceutical supn also have cr first quarter ligand crushed expectation top guidance view currently analyst have buy rating ligand stock accord marketbeat com have sell rating share be second time ligand stock have break month share hit entry flat base march related much volume look stock long term retirement investing strategy basic analyze stock cup handle
39,CELG,trader torch stock today bonfire selling respect pass novelist tom wolfe treasury bond market small posse leadership quality company buck broad wall street decline include new ipo altair engineering altr splunk splk cree cree ligand pharmaceutical lgnd china lodging htht stock today homebuilder finished worst performer industry group track ibd yield benchmark treasury year bond hit mark new year high horton dhi tank more drop sharply long term day move average stock be now peak lgi home lgih stage vicious reversal last week post robust result ep sale take day line share fall lgi home turnover jump day move average strong hint fund manager sell anxiously rise mortgage rate be further squeeze affordability be homebuyer be already frustrated limit inventory available home higher home price have result bankrate com chief financial analyst greg mcbride say tuesday nasdaq composite dow jone industrial average slide point average fall more sank volume increase main exchange accord early datum higher volume vs monday action imply unusually intense professional selling note ibd big picture column such significant drop heavier volume be call distribution bevy strong distribution day signal end major market uptrend broad decline large cap russell inched less point higher small cap also rise less point be jan be ibd current outlook market remain confirm uptrend meanwhile leaderboard member apple aapl stage gap price volume be well day average give apple solid last week normal see even top stock pull back proper buy point downward gap appear daily chart intraday high be intraday low prior trading session apple case tuesday intraday high be cent monday session low not much gap apple break compact double bottom base pattern supply buy point so far have produce gain more iphone ipad digital service giant be now past buy point first stage cup handle most important chart pattern top growth stock produce breaking new high big price run apple clear base midst fundamental turnaround jan altair member ibd specialty enterprise software industry group barrele more higher narrowly eclipse buy point week cup handle decline base be bullishly mild troy mich base expert innovation boost engineering software go public share nov last year notice daily chart altair have make habit breaking ibd style basis go quickly just few day then reverse sharply correct entry longer point view small cap have do marvelous job stay north side day move average altair monday post leap profit cent share revenue rise quarterly best meanwhile ligand thrust higher fifth straight session rise more biotech play be extend past entry well form double bottom base midpoint find sell off base be upper half base price range good sign accord ibd stock checkup ligand sport shiny composite rating scale rating find only ibd weekly investor com gauge stock corporate fundamental stock price strength quality institutional sponsorship be not purely technical indicator ligand relative price strength rating be stout also scale mean san diego base company be beating publicly trade company ibd database month price performance term market value ligand barely lift finger like celgene celg regeneron pharmaceutical regn amgen amgn biotech world however ligand be body slam peer term earning growth ligand have grow profit vs year level past quarters analyst poll thomson reuter see earning rise cent share keep mind top jump year quarter revenue break barrier quarterly basis past quarters year year top line have boom higher past quarters read recent new america feature piece ligand be grow so rapidly china lodging major player fast grow travel market middle kingdom sprint quadruple normal trade stock surpass buy point unusual month double bottom rs line roar new high ground proper buy zone go past entry china lodging post jump first quarter earning cent share revenue rise tax margin climb impressive basis point stock rank ibd keep mind china lodging recent base base structure be least fourth stage increase risk failure stock initially break week cup base week end march however company stellar fundamental defy odd latest update story other market coverage check ibd story stock today also please follow saito chung twitter ibd_dchung additional commentary analysis top stock chart basis financial market related stock be new ibd premium growth stock screen check master chart read check feature ibd top companiesipo leader market latest investor cornera stock form cup handle still succeed
40,CELG,big cap biotechs amgen amgn biogen biib have fall pressure year variety reason include revenue concern patent issue weak guidance smaller counterpart have rally fuel strong drug sale new drug news well merger acquisition take supernus pharmaceutical supn soar friday pad gain past buy point cup handle base clear thursday wednesday leap biotech report result top view thank strong sale trokendi xr migraine treatment seizure drug oxtellar xr follow gain thursday supernus be ibd sector leader stock biotech have fall industry group track ibd week now try push past resistance day move average so be good time keep eye biotech exchange trade fund get newsletter deliver inbox more info product service privacy policy term biggest bunch be ishare nasdaq biotechnology ibb asset rise friday continue consolidate day day move average line biogen celgene celg amgen gilead science gild vertex pharmaceutical vrtx make top holding account just stock portfolio supernus be holding ibb year date deficit accord morningstar inc lag gain etf be oldest biotech fund february launch average market cap company portfolio be next be year old spdr biotech xbi track biotechnology select industry index fund be also consolidate day day line ytd gain be average market cap xbi holding skews much smaller ibb top holding avexis avxs spark therapeutic once sarepta therapeutic srpt intercept pharmaceutical icpt immunomedic immu represent stock portfolio other nonleveraged biotech play include be idea prefer leverage play target double triple performance inverse performance underlie index be aware tend be more volatile nonleveraged counterpart usually have higher expense ratio also be interested way profit surge sector trump bump way apple earning buffett news breakoutdow top gainer intel also power semiconductor stock play
41,CELG,eli lilly lly be try leapfrog dow jone stock merck mrk bristol myer squibb bmy acquisition cancer immunotherapy biotech armo bioscience armo industry observer say thursday drugmaker lilly be late game cancer immunotherapy brad loncar tell investor business daily loncar run several biotech stock index include cancer immunotherapy sector index contain armo loncar cancer immunotherapy exchange trade fund pop thursday leader be merck bristol myer squibb roche rhhby say re company have completely miss boat want play area have do something try leapfrog competition early thursday lilly make first big move cancer immunotherapy space area medicine drug immune system fight cancer lilly say pay share armo cash deal get newsletter deliver inbox more info product service privacy policy term usearmo share rocket close lilly stock rise fellow drug stock merck bristol rise less roche have failure early day colon cancer dip lilly expect deal close end second quarter armo late stage biotech go public january quickly pop be hot initial public offer loncar say note price early thursday indicate investor expect bid leerink analyst chang note acquisition price be premium armo close price wednesday initiate coverage stock outperform rating price target earlier year thursday downgrade armo market perform deal confirm investment thesis armo view read positively other emerge immuno oncology stock say be unclear other bidder emerge give short close date acquisition make sense pharmaceutical stock lilly try assert cancer immunotherapy space loncar say armo lead drug call pegilodecakin be know cytokine boost strength drug know pd inhibitor merck keytruda bristol opdivo earlier year bristol validate cytokine drug call nktr pay upfront partner nektar therapeutic nktr deal hit record upfront payment biotech loncar say now little surprise armo be be take loncar have consistently predict be big year biotech deal merger takeout year kick news celgene celg plan buy juno therapeutic sanofi sny bid bioverativ bivv ablynx ablx deal armo be little different say think have happened be middle terrible bear market say other hand be also good example large company eli lilly many have not be forefront innovation re have buy still lilly isn alone trail position cancer immunotherapy roche astrazeneca azn pfizer pfe have immuno oncology drug remain merck bristol be level own say cancer immunotherapy space desperately need good news say earlier year incyte incy drug know ido inhibitor fail late stage combination merck keytruda melanoma incyte pain extend other cancer immunotherapy stock background volatility remain cancer immunotherapy space loncar say key say be be different piece technology armo drug be different incyte drug know epacadostat news item set person mood say everybody be immunotherapy think overrate then deal happen cause opposite reaction have emerge technology go be roller coaster related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
42,CELG,stock angled sharply lower friday open mixed april payroll report wave earning news defined early trade dow jone industrial average shed carved loss apple aapl hold high ground dow nearly dow stock trade lower intel intc caterpillar cat lead decline energy construction leader flour flr drag early dive nasdaq composite hold decline buoy apple big cap biotech celgene celg hire april miss expectation be offset unemployment rate fall more expect slightly better expect read inflation nonfarm employer add new worker april labor department report well expectation add worker report also boost department march estimate new worker original estimate new hire unemployment rate fall better expect lowest level average hourly earning rise consensus target signal inflation remain anticipate range get newsletter deliver inbox more info product service privacy policy term useon thursday lead index largely maintain stance week dow head friday open week be lower nasdaq hold decline dow be feel way day move average nasdaq have stick close day line rise institutional selling distribution past week china stock market be active country wrapped day trade talk team negotiator lead treasury secretary steven mnuchin talk be first sit meeting country trump administration intensified effort reframe china trade relationship negotiator present list requirement include china trim trade imbalance official do not comment result talk statement release friday china official xinhua news agency say discussion be frank efficient constructive hong kong hang seng drop friday end week japan tokyo nikkei shed leave fractional gain sixth straight weekly advance europe frankfurt dax london ftse defend gain release job datum cac paris post narrow decline index be tracking gain week dax lead last friday close dow apple maintain early lead more apple retook day line day line support week report fiscal second quarter result tuesday number stock technical indicator be lag be sit day advance buy point double bottom base earning front stream audio pioneer pandora bolt higher auto component maker american axle axl spiked weight watcher wtw launch higher open trade report sharp acceleration first quarter revenue profit growth weight watcher be form cup base buy point boise cascade bcc scramble first quarter revenue eke past consensus estimate earning be nearly double analyst expect share be early april low move right side month cup base ibd list stamp com stmp pop higher postage postal service innovator rang gain earning share first quarter far expectation revenue growth also clear analyst target wide margin company boost full year earning guidance well consensus forecast share be extend buy point alibaba group hold baba slip fiscal fourth quarter profit revenue outpaced analyst projection cloud compute revenue surge digital medium entertainment revenue rise alibaba retail marketplace see increase mobile monthly active user quarter ibd stock have climb straight session build right side possible double bottom base ibd peer arista network anet plunge lower outpace analyst first quarter estimate network gear software developer sale guidance just meet consensus view disappointing investor stock be past month have be struggle hold support week move average form late stage base cybersecurity ipo carbon black be set launch initial offer issue price share late thursday place valuation related big picture stock index reverse higher muddy marketkeep track market stock add stock spotlight include adobe mastercard arista revenue outlook line stock fall be cisco gain alibaba carbon black ipo job report investing action plan
43,CELG,pandora gopro gpro xerox xrx report result extend trade thursday future major index rise moderately market look april payroll datum due friday nasdaq future tick fair value thursday close future dow jone industrial average add future also manage gain even energy construction powerhouse fluor flr fall hard hour action major index have so far struggle dow jone industrial exit thursday session week be nasdaq composite hold decline be tracking second straight weekly slip dow have pull back test support day move average nasdaq be still hugging day line end thursday critical level support get newsletter deliver inbox more info product service privacy policy term friday european stock market have careful eye labor department april payroll report slate release market open investor also have ear news trade talk underway china name plan report early friday alibaba group baba celgene celg ruth hospitality group ruth pandora surge power past analyst sale earning target report subscriber first quarter shake shack shak scale nearly easily beat first quarter expectation management raise full year revenue guidance stock be extend just buy range buy point cup handle base wingstop wing be hour advancer ibd stock glide higher sale earning comfortably clear consensus target first quarter same store sale growth leap nearly double increase expect analyst share be november be again testing week move average medifast med charge ahead late trade weight watcher wtw launch aftermarket advance report sharp acceleration first quarter revenue profit growth weight watcher be form cup base buy point arista network anet dump more thursday close bell network gear software developer blow past analyst first quarter estimate sale guidance just meet consensus view disappointing investor ibd stock be past month have be struggle hold support week move average form late stage base fluor unraveled loss report fourth straight earning decline stock have climb august low have be consolidate february friday slate report include vf corp vfc manufacturer apparel brand north face van lee other stock be trading buy point cup base apparel maker have be demonstrate rise strength boise cascade bcc be early april low move right side month cup base consensus expectation be earning gain rise revenue company report result early friday also friday growth stock investor be watch see ibd stock warrior meet coal hcc retake buy point alabama base miner jump briefly past cup base buy point thursday report strong first quarter sale earning beat late wednesday share be clear ipo base july big picture stock index reverse higher muddy marketkeep track market stock add stock spotlight include adobe mastercard arista revenue outlook line stock fall be cisco gain alibaba carbon black ipo job report investing action plan
44,CELG,dow jone industrial average index rebound key support level end slightly lower nasdaq composite fuel apple aapl rally tesla tsla skid cash burn elon musk strange conference call mastercard hit buy zone new payment stock struggle alibaba baba pull back strong earning sprint merge mobile tmus headline several big deal job report symmetric fed stance ease rate hike fear crude oil price hit record high shale operator beat earning view dow jone undercut day move average rebound friday finish week nasdaq composite rally retake day line apple aapl fuel earning buyback warren buffett buy more share soar drive major average higher tesla tsla fall alibaba baba rally mastercard enter buy zone treasury yield pull back yield spread narrowing slightly crude oil rise nearly barrel shale earning be strong apparel stock be loser consumer electronic giant apple aapl earn share year year sale fiscal second quarter be best ep gain year latest string accelerate revenue growth report top forecast apple sell iphone just miss consensus service revenue wearable sale be strong apple also announce plan buyback big dividend hike warren buffett disclose berkshire hathaway brkb buy apple share first month bring total stake nearly apple stock surge best weekly gain year hit record high blast buy zone get newsletter deliver inbox more info product service privacy policy term usetesla report smaller expect loss forecast revenue electric car maker model production remain low company burn cash post earning conference call ceo elon musk cut wall street analyst bore question spend next minute take question blogger youtube share fall sharply thursday close week cent alibaba report better expect quarterly earning core commerce revenue swell cloud revenue more double alibaba end quarter monthly active user mobile device alibaba also give bullish outlook share rise friday jobless rate slide april lowest economy add job labor department report friday meanwhile average hourly wage growth rise just year little view fed favore gauge core inflation climb policymaker send message win panic top come month fed stress wednesday inflation target be symmetric qualys qlys fireeye feye fortinet ftnt top earning revenue view share retreat cyberark software cybr rally strong result outlook guide slightly higher meanwhile carbon black cblk jump friday debut ipo price late thursday high end recently raise range zendesk zen pop result guidance show customer support sale automation software company be build momentum rival salesforce com crm larger contract paycom payc report strong earning sale growth forecast line june quarter result send hr payroll process software maker lower fellow payroll hr cloud software firm paylocity pcty break friday result commerce software firm shopify shop top view size sale beat update guidance left investor unimpressed shopify initially fall rebound strong gain ultimate software ulti report adjust ep top estimate revenue grow also beating share rally wednesday close buy point mcdonald mcd surge score double beat ep rise revenue fall shake shack shak sky-rocket friday crushed earning beat revenue wingstop wing also jump friday result taco bell parent yum brand yum earning top share skid weak same store sale yum china yumc tumble weak pizza hut result china offset overall strong earning texas roadhouse txrh slip come par ep cent revenue viper energy partner vnom anadarko petroleum apc concho resource cxo noble energy nbl matador resource mtdr continental resource clr parsley energy pe eog resource eog pioneer natural resource pxd top quarterly estimate integrate energy firm marathon oil mro clear buy point follow earning oil price hit fresh multiyear high inventory production increase odd be rise president trump withdraw iran nuclear pact sprint mobile tmus finally agree merger share fall lack price premium fear antitrust regulator reject deal meanwhile marathon petroleum mpc agree buy andeavor andv create largest base refiner additionally walmart wmt say chain asda merge sainsbury walmart reportedly be deal buy india commerce giant flipkart prologis pld buy dct industrial dct finally marriott vacation vac reveal buy ilg ilg annual developer conference facebook fb say be enter online date business more person facebook identify single match group mtch own match com date app tinder plunge announcement facebook also introduce oculus go stand alone vr headset announce october arista network anet late thursday report ep gain revenue swell beating cisco rival see revenue line view send share tumble friday turnaround project juniper network jnpr late tuesday report ep decline wasn bad expect sale network gear cloud compute customer rebound juniper forecast profit slightly view share pop pare gain allergan agn zoetis zts teva teva exelixis exel top quarterly expectation allergan sank report unlikely make deal zoetis fall adjust profit guidance miss penny dow jone component merck mrk pfizer pfe beat profit lag sale gilead gild miss sale adjust earning hepatitis drug fall vs last year regeneron regn profit beat revenue miss eye drug eylea top view celgene celg topple analyst suggestion key drug be delay year friday celgene say refile application drug ozanimod multiple sclerosis treatment celgene also top first quarter expectation raise full year guidance sarepta srpt sale miss view loss be better expect mastercard share jump credit card giant report earning beat estimate join visa buy range square sq sale also top bitcoin make payment technology firm current quarter profit outlook come short fleetcor flt provide prepay fuel card vehicle fleet other payment product sank low outlook paypal pypl tumble amazon amzn reportedly offer merchant discount use own payment service controversy kanye west comment slavery have tangled adida addyy ceo sportswear company distance not cut ty rapper west yeezy brand be not significant part adida revenue contribute brand style image share tumble buy point adida logging currency neutral revenue growth include solid north america meanwhile armour uaa top estimate give weak outlook susquehanna say inventory be tick time bomb coach kate spade parent tapestry tpr top consensus share plunge upscale purse accessory maker raise guidance be still largely consensus north face van parent vf corp vfc beat view share retreat friday snapchat operator snap snap crash record low miss first quarter view revenue user growth several other key metric grubhub grub top first quarter earning estimate food sale miss target share fall sharply pare loss friday world wrestling entertainment wwe spiked wwe body slam earning estimate continue attract subscriber ep rise cent however revenue be miss disk drive maker seagate technology stx report quarterly earning beat estimate stock fall cautious comment tariff ferrari race zoom buy zone double beat ep rise cent revenue climb tableau datum report sale earning expectation license revenue be ahead consensus company lower full year margin guidance big datum firm stock jump
45,CELG,celgene celg multiple sclerosis drug ozanimod likely be delay year more regulator punt application prompt share crash year low wednesday food drug administration be likely focuse person study initiate october handful analyst suggest celgene submit application ozanimod base other successful phase trial leerink analyst geoffrey porge suggest celgene take gamble filing application have result october study study appear duplicate type work receptos have do ozanimod celgene acquire completion study suggest recognition deficiency clinical package prepared prior owner say note client fda appear surprise company demand variance full datum be add entire application celgene didn publicly identify issue application late tuesday celgene say fda refuse review ozanimod base nonclinical clinical pharmacology section application company be seek meeting fda determine next step remain confident ozanimod clinical profile demonstrated pivotal program relapse form multiple sclerosis celgene chief medical officer jay say prepared statement tuesday stock market today celgene topple close analyst peg delay ozanimod several month year issue be address datum ongoing pharmacology study celgene refile midyear then day fda decide application porge say used standard month review process ozanimod now launch third quarter vs earlier expectation fourth quarter say celgene doesn expect delay ozanimod inflammatory bowel disease porge expect launch suggestion be consistent lack direct alarm clinical effect be delay porge say celgene likely win have perform additional clinical trial ozanimod rbc analyst brian abraham say note client company believe reanalyze exist datum add result ongoing study sufficiently complete application notably appear confident issue refusal file letter do not affect ultimate approvability commercial profile drug timeline inflammatory bowel disease indication not be affected abraham say still abraham cut price target celgene expect ozanimod launch multiple sclerosis be delay year have meaningful impact uptake consider class multiple sclerosis drug know be go generic ozanimod be consider safer version novartis nvs gilenya class multiple sclerosis drug gilenya be expect lose exclusivity piper jaffray analyst christopher raymond say report gilenya lose exclusivity potentially early ozanimod approval be push late well generic version gilenya be available raymond say canaccord analyst john newman expect ozanimod multiple sclerosis treatment launch cut sale estimate ozanimod previously outside newman call previously ozanimod delay be far celgene only pock mark inflammation immunology pipeline last year celgene halter late stage trial crohn disease cast doubt ulcerative colitis program plaque psoriasis psoriatic arthritis drug otezla lag third quarter celgene cut guidance inflammation immunology billon prior forecast issue investor celgene stock be likely start clamore more aggressive extensive change company leadership direction yet disappointment leerink porge say cut price target analyst note celgene need ozanimod diversify key cancer drug revlimid be set begin lose exclusivity mid porge have expect ozanimod become total product sale base earlier estimate be rough couple month piper jaffray raymond say newest obstacle only raise more question regard celgene effort diversify away revlimid celgene setback be silver line biotech biogen biib rbc abraham note biogen now face less potential rival table term multiple sclerosis drug tecfidera meanwhile weathering launch roche rhhby rival drug ocrevus fairly well believe potential prolongation stability core revenue generate multiple sclerosis franchise be likely perpetuate view biogen safe large cap name own say related biotechs diverge biggest moneymaker lag rocket top quarterly estimate crush guidance viewstesaro dife biggest cancer drug lag expectation guidance
46,CELG,biotech industry group currently rank lofty industry group month relative price performance high standing also mask weakness former big star regeneron pharmaceutical regn be case point large cap specialist eye care be also highly interesting case
47,CELG,stock market trade session high monday afternoon congressional leader say ve reach accord end federal government shutdown sen charle schumer minority leader senate say senate majority leader mitch mcconnell have come arrangement re open government agency later today report say many government office be close congress fail approve funding friday night keep operation go nasdaq composite lead increase add dow jone industrial average small cap russell be russell climb time high volume be higher nasdaq lower nyse compare same time friday winner lead loser ratio nyse winner have slight edge nasdaq day many health care stock rise biotechs be best perform industry group thank major acquisition sanofi sny agree buy bioverativ bivv celgene celg acquire drug partner juno therapeutic juno bullish tone spread other medical stock bioverativ share soar juno huge volume sanofi fall celgene erased loss be flat mazor robotic mzor break cup handle base buy point israel base maker surgical robotic system be unprofitable sale growth be ramp cellectis cll jump cup handle be buy point volume be several time more usual cellectis be develop cancer treatment technology used juno other biotechs amgen amgn edge buy point cup handle base average volume stock be discuss income investor last week do have lag relative strength line oil stock also be lead halliburton hal clear buy point cup handle volume be heavy halliburton beat fourth quarter earning revenue view monday international market revenue growth outpaced growth rise oil price fan demand oilfield service company rebound brick mortar retail continue guess ge breaking undefined base stock clear buy point volume be sharply lower usual related halliburton break buy zone international revenue growth outpace celgene buy juno therapeutic sanofi acquire do biotech become dividend leader
48,CELG,biotech merger heated monday celgene celg announce acquire juno therapeutic juno french pharma sanofi sny say spend tack biogen biib spinoff bioverativ bivv analyst laud celgene juno buy note help fill hole celgene blood disease drug revlimid begin lose exclusivity street be more split sanofi purchase hematology market be expect soon face disruption gene therapy close bell stock market today juno surge celgene tick bioverativ rocket sanofi dive close broader biotech group pop credit suisse analyst martin suggest report group see mad scramble merger acquisition sanofi announce plan buy bioverativ list biomarin pharmaceutical bmrn esperion therapeutic espr avexis avxs top takeover pick deal be sign merger spigot have finally turn other large pharma company feel pressured move make full value bid grab be fairly scarce selection commercial commercial ready asset small midcap biotech space say celgene say monday spend share acquire juno premium stock close price rumor send juno fly last week celgene already own juno deal collaborate cancer autoimmune drug merger be expect close quarter juno be work car therapy engineer patient own immune cell identify fight cancer cell celgene peg lead drug know jcar get approval bring potential peak sale ibd take celgene be particularly hurt third quarter bigger drug revlimid otezla miss expectation not only face patent cliff mid see else be risk visit industry snapshot piper jaffray analyst christopher raymond suggest guidance be overly bullish celgene be set relatively high bar asset likely win be alone class say note however guidance be achievable be important source revenue mid long term celgene look plug revlimid hole once go generic start competition be look stiff gilead science gild spend nearly acquire kite pharma last year time gilead kite gain approval car therapy follow novartis nvs be first gate approval august celgene expect jcar get approval treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead drug yescarta be approve treat population novartis be look get drug kymriah approve use well leerink analyst geoffrey porge view deal positively consolidate streamline celgene effort car celgene also partner bluebird bio blue work multiple myeloma drug know bb target antigen know bcma own juno allow celgene focus bcma effort initially bluebird bb make juno vehicle development drug target cd protein exploration other target opportunity say note client mizuho analyst salim sy note be cross pollination manufacturing juno bluebird drug be knowledge base synergy unsure celgene even look acquire bluebird trigger antitrust concern say early monday sanofi say buy hemophilia player bioverativ share deal be premium bioverativ close price friday piper jaffray raymond write note re not shock bit say topline revenue growth more last year yet trading just time fiscal year revenue estimate have long view bioverativ potential takeout target deal come sanofi twice fail make big acquisition dow pfizer pfe beat sanofi battle cancer player medivation last year dow johnson johnson jnj acquire rare disease biotech actelion pharma sanofi sanofi be face mount competition diabetes drug trick be convince investor hemophilia market win be disrupt gene therapy product launch roche rhhby drug hemlibra leerink analyst seamus fernandez say note minimum number speculate successful bid include medivation actelion sanofi investor now have deal digest be immediately accretive earning estimate be accretive say rbc analyst kennen mackay call bid strong give upcoming competition roche note likely sanofi be build lesson learn medivation actelion process sanofi lead low offer be later best competitive bidder investor weren sure merger biogen spun hemophilia business bioverativ year bioverativ have approve drug eloctate hemophilia alprolix hemophilia last year bioverativ acquire true north therapeutic credit suisse martin call true north stronger acquisition bioverativ gain access drug now know bivv treat rare autoimmune disease model share drug alone related biotechs surprise upside earning biotech stock rocket rumor biogen buy hospital plan put pressure generic drug maker
49,CELG,france sanofi sny agree buy recent biogen biib spinoff bioverativ bivv company announce early monday meanwhile celgene celg acquire car drug partner juno therapeutic juno sanofi deal value bioverativ share cash premium friday close bioverativ shot nearly close stock market today sanofi fall celgene acquire juno therapeutic share cash price tag exclude juno celgene already own juno share leap nearly skyrocket last week report deal be close celgene tick close juno work car therapy use patient immune cell fight cancer analyst have say celgene juno deal make sense bioverativ spun biogen february make hemophilia drug sanofi be face generic competition top selling drug sanofi try buy medivation lose pfizer pfe last year effort buy swiss biotech actelion be trump johnson johnson jnj be interested biotech stock surprise upside earning fang stock make news investor mull shutdown impactcheck stock buy first stage basis
50,CELG,stock open moderate gain wednesday early earning news positive fourth quarter consumer price spending revision fuel early gain art market site etsy etsy notch open amazon com amzn acquisition pending spin china base baidu bidu also help energize early trade nasdaq composite pop start trade apple aapl fang stock tech leader post early gain dow jone industrial average jump almost boee ba verizon vz lead index open higher heavy early loss lowe low celgene celg discovery communication disca hold back early action market asia take beating wednesday investor react comment make tuesday fed chief jerome powell weaker expect manufacturing datum china hong kong hang seng index dive shanghai composite slip japan tokyo nikkei dump stock europe turn mixed afternoon trade cac paris london ftse reversed early loss cling fractional gain commerce department keep estimate fourth quarter gdp growth essentially unchanged vs initial estimate gain number be economist largely expect wednesday report also ease price growth estimate notch be expectation change ease pressure interest rate consumer spending be unchanged forecast growth also positive kingsbury international release chicago purchasing manager index et follow january pending home sale datum national association realtor energy information administration weekly oil inventory estimate verizon boee jump more take early lead dow jone stock verizon have be struggle regain support week move average feb boee be extend profit take zone september etsy rocket higher report fourth quarter earning surge third straight quarter revenue growth acceleration late tuesday total value good sell quarter top first time high volume gain left share buy range buy point second stage cup base weight watcher wtw report earning gain rise revenue consensus view management also raise full year earning guidance well expectation announce shift focus diet overall health aim become partner health wellness stock be extend profit take zone clear cup handle base january book holding bkng grab open gain travel deal site formerly know priceline group report stronger expect fourth quarter performance late tuesday gain put share buy range buy point first stage cup handle base daqo new energy dq drop higher early trade china base polysilicon maker fourth quarter sale earning clear analyst target wide margin stock have be battle resistance week move average attempt build right side possible base downside lowe dive mixed fourth quarter report show fourth quarter earning full year earning guidance consensus estimate share have be fight early february tbayryo climb back week move average build right side possible base amazon com confirm late tuesday be prepare acquire video security doorbell maker ring deal reportedly worth more deal santa monica calif base outfit be amazon second largest date bolster amazon effort expand home security measure related package theft amazon share be extend profit take zone clear flat base january news report say european union regulator be set approve condition acquisition base germany bayer bayry share rise china base search engine baidu trade higher stream video service unit iqiyi register tuesday spin ipo stream service offer free subscription base content aim raise trade nasdaq iq be interested big picture inflation fear jolt stock here silver line top stock just trigger sell signal weak guidanceshale leader crush view hike dividend see capex bumpsalesforce crocs monster lowe tjx lead investing action plan
51,CELG,wall street remain focuse government shutdown early monday didn fuel much selling dow jone industrial average ease open nasdaq be respectively be great start year nasdaq composite friday compare gain ibd government shutdown go effect saturday bill be vote senate main sticking point republican democrat be immigration bill seek democrat vote be schedule today week funding bill general electric ge american express axp apple aapl be early laggard dow ge american express be fraction apple lose meanwhile eye be netflix nflx ahead earning report close profit be see jump cent share netflix be featured latest earning preview column highlight potential earning option trade not great candidate extend base conventional entry nonetheless show strength trading tightly hold high ahead result share be nearly monday morning merger news big biotech deal make headline celgene celg strike deal acquire juno therapeutic juno share juno soar last week news possible deal be first report celgene gain access juno promising pipeline car cancer drug patient immune cell be manipulate attack cancer share celgene fall more monday fall last week share juno jump meanwhile share bioverativ bivv soar sanofi sny offer buy recent biogen biib spinoff bioverativ specialty be hemophilia other blood disorder share sanofi lose early trading elsewhere bitcoin continue bleed recently volatility accord datum coindesk com cryptocurrency be trading jan bitcoin be bitcoin investment trust gbtc riot blockchain riot be seek support day move average crude oil future start week mostly unchanged barrel year treasury yield edge lower basis point related sanofi buy bioverativ celgene acquire juno therapeuticshow invest stock market used simple routinebitcoin cryptocurrency news trend
52,CELG,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
53,CELG,key market index turn negative wednesday apple aapl pair defense stock give gain dow jone industrial average powershare qqq trust qqq fall spdr dow jone industrial average dium spdr spy sank respectively retail real estate be few gainer sector fund stock market today energy metal miner homebuilder see big decline spdr retail xrt rise remain slightly day move average be hit resistance early month component tjx tjx however gap soar nearly month high report quarterly result defense related play be also move ishare aerospace defense ita lift boee ba unite technology utx top ita holding moved opposite direction boee fall unite technology rise apple be fractionally lower back new intraday record reach session spdr dow jone industrial average be testing day line have re-cover friday biotechs sag ishare nasdaq biotechnology ibb give slide further day line component stock celgene celg gap slump fda reject biotech application ozanimod multiple sclerosis treatment ve be eyee lead emerge market stock tencent tcehy alibaba baba taiwan semiconductor tsm get chance pick add diversity portfolio too ishare msci emerge market eem have be potential buy zone retake be day move average mid february find support day line market correct sharply early month however so chart do not show test bounce day average typically see reach bottom december eem have hold overall uptrend offer chance buy add share rebound day line share advanced late september pullback jan high fund be featured etf column oct remain buy range pullback fund track msci emerge market index mark anniversary april china represent biggest country weighting feb asset korea weigh taiwan india brazil south africa make rest country account less information technology be largest sector weight follow financial consumer discretionary take energy material be apiece consumer staple smaller position rest include industrial telecom real estate sign free ibd newsletter market prep tech reporttop holding be tencent alibaba korea samsung taiwan semi nasper global internet entertainment group base south africa nasper hold stake tencent december top taiwan semi be year date alibaba tencent eem year date return feb accord morningstar direct outperformed gain average annual return past year trail benchmark index etf carry expense ratio tuesday pick ishare core dividend growth dgro be hold just day move average related dow apple intel hold steady stock sell bitcoin gainsdow lead buffett drive apple stock new record high cat lead dow apple pare gain chance buy buffett stock
54,CELG,dow merck mrk announce plan wednesday acquire australian biotech viralytic deal dovetail well drugmaker immuno oncology focus accord analyst viralytic be develop cancer drug call cavatak cavatak be create used virus infect kill cancer cell process call oncolysis be be test several cancer combination merck immuno oncology drug keytruda be very nice tuck merck less fit very well immuno oncology strategy evercore analyst umer raffat write note client stock market today merck slip fraction raffat call timing deal interesting viralytic have guide offer clinical update second quarter combination trial cavatak keytruda lung bladder cancer early stage study cavatak keytruda be combine melanoma overall patient respond treatment vs patient keytruda alone raffat say cavatak have also be combine bristol myer squibb bmy drug yervoy melanoma get ibd market prep tech report newsletter free term deal merck acquire issue share viralytic be publicly trade australia share cash deal represent premium month volume weight average price viralytic share merck senior vice president roy barne praise deal written statement transaction be expect be implement second quarter viralytic become wholly own subsidiary merck viralytic approach engage innate immune system target cancer cell complement immuno oncology strategy be focuse rapid advancement innovative monotherapy approach synergistic combination help broadest range cancer patient say lepu medical group be viralytic largest shareholder currently hold firm group say intend vote merger merck superior proposal doesn present deal be just drop much larger bucket biotech drugmaker merger analyst say year be explosive regard already have be north biotech deal announce vs merck deal come heel roche rhhby plan announce friday acquire flatiron health january celgene celg say acquire juno therapeutic juno sanofi sny announce bid bioverativ bivv ablynx ablx related be explosive year biotech mergersbiotech investor flee drove market correction rock groupthese biotechs spring back market correction analyst
55,CELG,stock close higher monday gain more end much reduce close bell market continue seek consistent direction nasdaq composite be much close higher cut gain more fourths end higher selling picked final minute trading dow jone industrial average climb merck mrk have largest percentage gain dow company keytruda drug extend life lung cancer patient late stage trial drug be already approve treat lung cancer patient merck share jump back day move average have long way go buy point appear volume fall compare friday total accord early computation decline stock outnumber advancer modestly nyse winner lead nasdaq get newsletter deliver inbox more info product service privacy policy term major index remain day move average be tentative bottom hold april lows russell be bell small cap benchmark meet resistance day move average last week monday rally be surprising early strength trade row china have not abate be new geopolitical worry president trump tweet imbalance auto tariff china tension middle east increase israel attack military base syrium follow news syrium used chemical weapon rebel trump suggest retaliate biotechs rise more group headline heavy day industry novartis nvs offer acquire avexis avxs ionis pharmaceutical ion be team astrazeneca azn liver disease treatment celgene celg be rumore be interested buy agio pharmaceutical agio avexis soar more agio jump other stock be little change chip stock also lead thank analyst comment evercore isi raise price target intel intc chip gear firm lam research lrcx call micron technology mu bargain current price micron share last week trigger round trip sell signal erase gain buy point double bottom base be now slightly day move average show support be critical keep stock fall further intel stock be try find support day move average lam trigger sell rule entry stock be compromise related jpmorgan citigroup earning tap be bank stock long term issuecrop chemical giant stock soar doj see approve bayer dealintel lam research get price target hike chip stock deem oversoldpalo alto vs apple not break support be sell signal
56,CELG,several biotech stock end strong gain monday session be mar lack conviction buy late day sell nasdaq composite jump early end gain just volume be heavy early trail attribute selling new york time
57,CELG,year be shape be boisterous biotech acquisition celgene celg sanofi sny matter day announce plan spend north take company analyst say celgene sanofi particular be face challenge area insurance company be push back payment rheumatology diabetes also leave like novartis nvo eli lilly lly trouble say brad loncar manage immunotherapy base fund company have buy growth loncar tell investor business daily ve be grow revenue do artificial thing drug price increase tax inversion kind other type financial engineering thing be go away be spend biotech deal mizuho analyst salim sy tell ibd year so far celgene have say spend buy remainder juno therapeutic juno doesn already own sanofi be spending acquire bioverativ bivv ablynx ablx company haven buy anything just matter opportunity sy say buy spree kick august gilead science gild announce plan acquire cancer play kite pharma gilead have be suffering major slowdown hepatitis drug sale high cure rate saturation europe celgene sanofi announce plan acquire juno bioverativ same day january day later sanofi say buy rare disease drugmaker ablynx celgene acquisition follow disappointing third quarter sale psoriatic arthritis plaque psoriasis drug otezla widely miss expectation biotech also cut guidance otezla shortfall terminate several trial crohn disease loncar describe celgene long term growth prospect time bleak picture also face patent cliff mid cancer drug revlimid ibd take challenge hold stock market correction decline help share form new potential base be still possible capture big gain head investor corner tip make gain correction so really couldn afford say sanofi other hand be skunked twice try acquire medivation actelion pharma dow component pfizer pfe beat sanofi medivation dow johnson johnson jnj be able acquire actelion sanofi roy behren fund manager capital management say sanofi commit acquisition make hostile bid medivation go back initially higher bid actelion filing show hostile approach be generally unsuccessful space fact scientist be such important part value equation tell ibd case sanofi medivation couldn arrive price be friendly be very difficult complete acquisition high profile acquisition late early acquirer have suffer pressure sale key moneymaker tax reform allow company pay less corporate taxe repatriate cash lower rate prime pump acquisition strong believer be go be huge year acquisition loncar say larger company growth be slow tax reform deal add fuel fire make easier do deal nordisk lose ablynx sanofi now loncar expect nordisk go other asset contend deep exposure diabetes market lilly too be see challenge diabetes meanwhile amgen amgn older drug be face new competition big company really need do say be outlier mizuho analyst sy say biogen biib instance guide flat sale multiple sclerosis unit include impact royalty get revenue roche rhhby new drug ocrevus perception franchise be dwindle say argument investor make lot guy biogen amgen base business be go away not necessarily case biogen be stable still flat sale win be enough pique investor interest biogen aducanumab potential treatment alzheimer disease be carrot investor clinical trial datum be available end early long carrot be become really difficult hedge fund community short stock say aducanumab produce return work large cap biotechs typically don see behren note biotechs seem be fairly interested immunotherapy oncology include gilead acquisition kite celgene plan acquire juno be work drug know car therapy immune system identify fight cancer have be lot activity oncology space term immunotherapy say larger company be try gobble promising technology still affordable be also see quite few testing company be acquire celgene acquisition juno follow common storyline behren say celgene invest juno create immunotherapy cancer autoimmune disease duo be furthest jcar potential treatment hodgkin lymphoma celgene pull trigger juno jan make sense be premium juno close price prior trading day biotechs even more high tech tend come significant premium trading price say re somewhat risky be huge payoff event re successful nektar therapeutic nktr bristol myer squibb bmy be similar plot september duo pair test nektar drug call nktr bristol opdivo patient melanoma kidney cancer lung cancer november nektar present strong early datum combo loncar peg nektar potential takeover target call nktr revolutionary day later bristol announce pay nektar upfront comprise cash purchase share test nktr opdivo opdivo yervoy deal allow bristol remain leader immuno oncology immuno oncology combination risk bid nektar evercore analyst umer raffat say feb note client have doubt nektar phone have be ring hook november datum be so interesting loncar say someone be bold enough buy put acquirer class own immuno oncology drug call parp inhibitor also look interesting loncar say clovis oncology clvs tesaro tsro have drug approve class be small enough acquire astrazeneca azn also work space sarepta therapeutic srpt neurocrine bioscience nbix biomarin pharmaceutical bmrn have also have successful launch recently company want revenue growth buy rare disease drug say have best sale ramp think type company be really interesting right now wouldn be surprised get buy related biotech investor flee drove market correction rock groupthese biotechs spring back market correction analystwhy biotech stock outperform peer
58,CELG,stock market correction begin major average lead stock show more weakness other index rebound solid weekly gain nvidia nvda plunge halter autonomous drive test just several negative headline tesla tsla facebook fb continue slide datum privacy furor amazon amzn tumble day move average lululemon athletica lulu rh rh rally strong earning retail remain relative source strength baidu bidu stream video unit iqiyi iq come public major average rebound monday trade war fear ease other index tumble tuesday trigger stock market correction fuel thursday rally dow jone rise week testing day move average nasdaq composite rise many tech giant be big loser nvidia nvda uber suspend self drive test tesla tsla nvidia supplier also face federal probe model involve autopilot system moody also cut tesla debt model production wo amazon com amzn tumble day line first time month fear president trump go commerce giant retail apparel remain relative bright spot quarter dow lose nasdaq add uber technology suspend self drive test federal probe recent fatal crash involve autonomous vehicle nvidia nvda also say halt test share chipmaker plunge help trigger stock market correction tesla tsla used nvidia chip fall sharply bad news national transportation safety board say be probe fatal crash march involve model moody downgrade tesla credit rating concern cash burn model production delay alphabet googl unit waymo be sticking plan roll commercial robotaxi service phoenix year waymo also plan order many luxury autonomous electric car jaguar land rover subsidiary india tata motor ttm waymo jaguar plan move production crossover sport utility daimler bmw announce combine self drive service asset form joint venture structure facebook chief executive mark zuckerberg be expect testify congress pressure mount datum privacy scandal have roil company stock congressional hearing be prompt revelation datum consultancy cambridge analytica have wrongfully obtain personal information million facebook user knowledge facebook beef privacy control say halt selling datum third party broker facebook share initially tumble rise modestly week amazon fall wednesday undercut day line report president trump want go commerce giant trump have long be critical amazon perhaps part ceo jeff bezos own washington post white house deny plan target amazon trump tweet concern regard amazon thursday amazon initially fall thursday close fellow fang netflix nflx find support day line share lululemon lulu soar record high week athletic apparel maker retailer beat estimate board raise full year guidance ep rise revenue grow nearly north america peer nike nke have struggle lululemon sale grow low single digit online sale pop constant currency top prior year growth analyst say new product improve marketing investment fuel quarterly apparel maker retailer be pocket market strength linux open source software provider earning growth accelerate fiscal fourth quarter revenue rise gradually accelerate fourth straight quarter top view red hat rht guide low earning see full year earning revenue consensus red hat push container software cloud compute workload drive growth analyst say red hat share initially soar tuesday settle fractional gain share rise week concho resource cxo buy rsp permian rspp stock deal worth takeover create largest drill completion operation permian concho share tumble crude inventory rise barrel more expect energy information administration say production hit new high barrel day saudi crown prince moham bin salman tell reuter opec be look extend oil production cooperation russia year baidu bidu video stream unit iqiyi iq fall nearly thursday trading debut selling share apiece line expect range raise ipo be just shy january ipo pagseguro digital pag call netflix nflx china iqiyi have licensing deal netflix subscriber iqiyi have market share china rival alibaba baba tencent tcehy have own stream service hotly contest battle viewer fed favorite inflation gauge core personal consumption expenditure price index show slight uptick february annual inflation rate edge month high inflation be far fed target enough doubt corporate pricing power so inflation have rise further pressure fed policymaker hike rate more time year commerce department datum thursday show disposable personal income rise february spending rise modest suggest person initially be save tax cut consumer end strong note fourth quarter gdp be revise biotech stock collectively rise sixth group track ibd last week news be more mixed big mover monday celgene celg lift nearly analyst suggestion be settlement dr reddy laboratory rdy generic version cancer drug revlimid same time pharmaceutical bhvn tank unveil late stage trial migraine drug lag result rival drug allergan agn tesaro tsro slip tuesday split view combination zejula merck mrk blockbuster keytruda ovarian cancer patient also tuesday anaptysbio anab topple result peanut allergy drug study celgene celg bluebird bio blue agree jointly market advanced cancer treatment know bb expand deal sport retail giant jd sport pay athletic apparel chain finish line finl soar slightly share offer finish line pull back thursday follow mixed result build material company usg usg have rebuff buyout offer germany knauf offer get support warren buffett berkshire hathaway brkb be usg top shareholder usg share shot speculation provider wall ceiling flooring roofing product be have higher price shire pharmaceutical shpg shot confirm japan takeda make offer finally audio communication firm plantronic plt agree wednesday acquire company polycom polycom be buy private equity firm siris capital same price just year glaxosmithkline gsk agree buy stake consumer health unit novartis nvs blackberry bb report fiscal adjust profit cent share top expectation break even revenue fall line view rh rh formerly know restoration hardware report profit leap share sale growth top forecast home furnishing retail guide high signale more aggressive expansion plan design gallery share soar nearly week blast day day line constellation brand stz earning share rise revenue climb beating beer sale grow constellation brand increase quarterly dividend cent share rise close recent buy point cross intraday apple aapl introduce lower price ipad chicago high school company seek regain ground lose google owner alphabet microsoft education market new inch retina display ipad have start price gigabyte wi fi model discount school
59,CELG,here weekly investing action plan need know investor come week earning season get first taste result silicon valley lead netflix nflx intel intc other chip company biogen biib celgene celg lead report biotechs northrop grumman noc raytheon rtn
60,CELG,celgene celg comfortably spend acquire juno therapeutic juno analyst say wednesday juno share soar rumor biotechs be merger talk analyst applaud potential deal make strategic sense firm juno need celgene size compete bigger rival treat blood cancer celgene be face patent cliff blood cancer drug revlimid say be rarely fan high premium takeover deal probably make sense celgene win surprise company shareholder leerink analyst geoffrey porge say note client midday trading stock market today juno share race record high end day nearly celgene sank finish juno celgene already partner car program car therapy use patient immune cell fight cancer deal celgene own juno stock pay development cost own right duo be face stiff competition car arena follow gilead science gild nearly acquisition kite pharma october now gilead novartis nvs have car drug approve meaning juno be trail potential approval year ibd take juno have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup look better rate biotech stock leerink porge compare juno kite be car player work develop therapy target cd protein tumor claim have proprietary element construct manufacturing process give edge commercialize similar product similar indication month other approximately similar clinical result say suggest be much more similar other biopharma company be juno face setback march patient die receive car therapy juno have scrap particular therapy be work kite gilead get market first porge suggest celgene juno settle price similar gilead acquisition kite juno see technology best class argue premium celgene argue discount note gilead have first market advantage tuesday close acquisition rumor crop juno have market cap just north wednesday stock movement juno market cap rise close end juno recognize be now compete novartis gilead probably need resource least celgene be successful market say neither seem incline let deal fail price hubris add juno gilead novartis isn go stop first car approval car therapy have show promise blood cancer number biopharmas also be look potential use solid tumor juno look likely gain approval later year therapy jcar treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead already have therapy approve novartis be also seek approval use juno look other possible used include other leukemias lymphomas leerink analyst michael schmidt say note client total estimate peak sale assume best case scenario schmidt expect juno capture third market car drug target cd protein diffuse large cell lymphoma primary mediastinal cell lymphoma mantle cell lymphoma chronic lymphocytic leukemia acute lymphoblastic leukemia latter indication novartis already have approval schmidt also see juno get market multiple myeloma fellow celgene partner bluebird bio blue be work related blood disease datum send biotech stock flyingdoe gilead now have new multus dollar franchise novartis fda cancer also be boon rival
61,CELG,juno therapeutic juno surge late trading tuesday report celgene celg be talk acquire accord wall street journal unnamed source say celgene be talk buy juno have long partner cancer treatment include car drug immune system identify fight cancer talk pan deal come week source say potential deal acquire juno come heel gilead science gild nearly purchase car drugmaker kite pharma late last year now gilead novartis nvs have only approve car drug market juno follow car drug approval later year company have say so far car drug look best poise treat blood cancer firm be also look used therapy solid tumor gilead buy kite help stem gap decline hepatitis drug sale celgene buy longtime partner juno give leg prepare lose patient protection revlimid treat blood cancer know multiple myeloma ibd take hematology focuse biotechs have pique investor interest late see firm be work visit ibd industry theme representative juno decline comment investor business daily representative celgene didn immediately return request comment hour trading stock market today juno rocket close celgene sank end regular session bluebird bio blue car company also partner celgene see stock pop hour related biotech stock see cheapest rival cancer drugswhy biotech stock be defy hematology related pitfalldoe gilead kite acquisition offer new buy opportunity
62,CELG,biotech giant celgene celg offer preliminary fourth quarter result monday look come ahead analyst estimate profit announcement company make shortly agree buy privately hold impact biomedicine celgene say expect adjust earning anywhere share year figure revenue be expect climb analyst poll thomson reuter expect earning sale celgene share drop close monday company say late sunday be purchasing impact biomedicine upfront payment celgene make additional milestone payment impact fedratinib win fda approval have strong sale bring total potential price tag roughly fedratinib be potential treatment myelofibrosis type bone marrow cancer myelofibrosis be disease high unmet medical need number patient be ineligible become resistant exist therapy continue increase say nadim ahm president hematology oncology celgene statement announce celgene impact deal believe fedratinib be uniquely position potential treatment myelofibrosis provide strategic option build leadership disease other pipeline asset impact bio founder have sell fedratinib france sanofi sny give development treatment due serious side effect impact later buy right back successful fedratinib compete similar drug incyte incy know jakafi celgene have have disappointing sale trial new drug recently blockbuster cancer fighter revlimid face challenge celgene cut full year outlook late october send share plunge stock have rise somewhat then only line index also be interested biotech stock outperform peer best stock group boast biogen unlikely see spinraza rival avexis delayedwhy biotechs outperform hyper competition beware price war big pharma biotechs horizonfive stock winner have carved new basis new run
63,CELG,stock open thin loss monday merger news analyst action stir early trade ahead start fourth quarter report season later week dow jone industrial average dip apple aapl pfizer pfe jpmorgan jpm turn lower nasdaq composite reversed open loss narrow gain fang stock tech leader post early advance edge lower big name include citrix system ctxs intel intc drag early action week news get slow start medical stock be motion news spin jpmorgan day health conference economic earning calendar pick later week begin quarterly report homebuilder lennar len delta air line dal wednesday thursday report friday jpmorgan jpm pnc financial pnc well fargo wfc mark official start fourth quarter earning season dow unite technology utx jump caterpillar cat climb goldman sachs upgrade unite technology buy neutral cite tax reform benefit ease trouble unite pratt whitney jet engine unit company pending acquisition rockwell collin unite share be take new high be extend buy point cup handle base caterpillar receive upgrade jpmorgan lift stock overweight neutral boost price target stock new tax rule implement gop late last year be likely boost company cash flow extend cycle north american construction business note say stock open new high caterpillar be extend buy point late november seagate technology stx spiked more open news report reiterate storage datum leader stake ripple cryptocurrency owner valuestreet research value seagate position move marked past cup handle buy chip stock show early momentum nvidia nvda more gain send ibd name nvidia buy point week cup base apply material amat open higher stock also ibd list be back support week line climb right side week cup base base micro focus international mfgp dive open legacy software leader component london ftse index forecast lower expect revenue announce change chief financial officer company be struggle acquisition hewlett packard enterprise hpe software business complete late celgene celg share rise more company say make upfront payment acquire privately hold impact biomedicine deal include potential milestone payment raise possible total value celgene share be october low still deep month consolidation belgium base biotech ablynx ablx spiked higher premarket trade october ipo reportedly receive share takeover offer nordisk nvo management say offer significantly undervalue company asian stock market post stout gain monday china shanghai composite japan tokyo nikkei soar benchmark be mixed europe london ftse sag cac paris gain frankfurt dax be afternoon trade monday schedule economic news federal reserve consumer credit datum november be due et atlanta federal reserve bank president raphael bostic speak atlanta et san francisco fed president john william be schedule speak et related celgene pay impact stock winner have carved basis new runsdividend hike largest ipo ever lead oil story top china stock surge fast move start bitcoin blockchain business ain see nothing yet
64,CELG,be orderly day trading major stock index monday perfectly fine performance bull nasdaq composite jump last week higher volume so call fang name facebook fb amazon com amzn netflix nflx alphabet googl outperformed gain range facebook
65,CELG,major stock index be mixed mostly unchanged monday afternoon perfectly fine performance bull nasdaq composite jump last week higher volume nasdaq lead way edge higher dow fall fractionally volume nyse nasdaq be tracking close friday level caterpillar cat be strong gainer dow more jpmorgan make positive comment stock be well extend too late buy early december buy point buyer be fang stock again name facebook fb amazon com amzn netflix nflx alphabet googl show gain range just amazon lead way recent buy point have come light volume baird raise price target amazon maintain overweight ratingin stock market today apple aapl ease hedge fund jana partner urge company take more active role combat youth smartphone addiction gopro gpro trim intraday loss cnbc report company have hire jpmorgan put sale share crumble early company announce job cut give weak guidance ibd more name be more help lift innovator ibd ffty gain bullish move last week see share surge higher volume nvidia nvda gap cup shape base rise nearly conventional entry be weekly chart show lag relative strength line however call quality question monday move be fuel news company be team volkswagen vlkay uber driverless car technology meanwhile jpmorgan healthcare conference kick san francisco monday headline flow be busy wasn good day ishare nasdaq biotechnology ibb be nearly biotechs be worst performer nasdaq name alexion alxn regeneron regn biogen biib shire shpg show loss range share celgene celg give back nearly news plan acquire san diego base impact biomedicine certain milestone be hit impact be work experimental drug type blood cancer call myelofibrosis bright spot share insulet podd gap flat base jump midcap name show solid sale growth recent quarters not profitable yet company specialty be tubeless insulin pump technology related nvidia rev ce consumer tech show autonomous car newsjust many more blockchain pretender bring seagate stock soar report investment ripple cryptocurrency
66,CELG,gilead science gild plunge late tuesday report fourth quarter revenue earning top wall street expectation decline seventh consecutive period challenged hepatitis drug sale hour trading stock market today gilead sank much be more recent action regular session gilead pop biotech stock rally pare earlier loss close fourth quarter gilead report adjust profit share sale decline respectively metric top consensus adjust income share sale total product sale fall gilead feel most pain outside europe product revenue decline europe sale product decline lead dip product sale sale hiv hepatitis drug increase year year ibd take bull market be now year affair pundit have be call downfall presidential election be time review stock selling rule head investor corner hepatitis drug sale topple decline major market gilead say blockbuster harvoni sovaldi have be decline third quarter high cure rate market maturation epclusa be approve june have grow year year quarters fall first time fourth period harvoni biggest see sale decline epclusa now second most important trio fall sovaldi bring revenue gilead guide product sale consensus have forecast revenue rbc analyst brian abraham note competitive dynamic be expect shrink hepatitis market product sale guidance be lower expect operational expense outlook come higher abraham say note client still remain bullish gilead other program overall street begin look hepatitis expectation come believe stage remain set term earning nadir visibility growth drive hiv car pipeline say october gilead close acquisition kite pharma investor have long push gilead make acquisition dwindle hepatitis drug sale day later gilead kite get approval car drug call yescarta treat blood cancer car drug be type treatment patient cell be change laboratory attack cancer fourth quarter yescarta bring sale beating consensus abraham say car landscape now include other major player include celgene celg plan acquire juno therapeutic juno novartis nvs latter be first gain approval car drug kymriah related biotechs spring back market correction analystallergan pop consensus top quarter strong migraine biotech stock dife more be sell overdo
67,CELG,biotech investor collectively pull sector week analyst say friday byproduct broader market correction not malaise health care tie stock week end feb health care biotech fund see net outflow represent decrease asset piper jaffray analyst christopher raymond write note client same time equity post dip asset reason biotech stock tend experience worst market correction say brad loncar portfolio manager run cancer immunotherapy base fund biotech stock hit multiyear high late january have lose nearly believe be totally normal think biotech be just do so terrible week volatile sector entire stock market have bad week biotechs be likely do little bit tell investor business daily most pundit say market correction be overdue general market experience very mild gradual rise few interruption now head risk scenario investor seek lower risk position evercore analyst umer raffat tell ibd email close stock market today biotech group eke small gain pare earlier loss fall much week group be nearly hardest hit week be therapeutic cort lop come rivalry teva pharmaceutical teva treatment cush syndrome affect pituitary gland prothena prta dove chief medical officer announce departure amgen amgn celgene celg biogen biib lose north regeneron pharmaceutical regn top fourth quarter view plunge nearly gilead science gild topple more guidance miss large cap fourth quarter metric guidance be largely line expectation credit suisse analyst alethia young tell ibd describe fourth quarter decent show fire strained third quarter ibd take dow jone industrial average topple lower thursday nasdaq composite tumble respectively be bear take bite bull market head big picture more hopefully trend continue say be biotech risky space thing happen young loncar agree market correction isn indicative outlook biotech group say fundamental look strong group be poise buy spree begin late last year gilead acquisition kite pharma january celgene say buy juno therapeutic juno sanofi sny announce acquisition biogen spinoff bioverativ bivv belgium ablynx ablx sanofi beat nordisk nvo ablynx smart company go asset valuation go loncar say many bigger player be face payer scrutiny saturate area rheumatology diabetes gilead decline hepatitis drug sale lead kite purchase celgene be face competition inflammation drug larger company have slow growth so need buy growth need buy innovation say tax reform deal just pass kind add fuel fire make much more easy do deal related gilead pop fda approve glaxo rivale hiv drugthese biotechs spring back market correction analystalexion top quarterly view guidance lag alnylam dip loss
68,CELG,index later nasdaq composite fall sharply day move average join dow jone industrial average key support president donald trump impose big china tariff provide sweeping exemption delay earlier tariff steel aluminum earlier facebook fb crash datum privacy scandal drag google parent alphabet googl other techs tencent tcehy plunge revenue miss big investor selling oracle orcl dove decelerate cloud revenue growth federal reserve keep rate hike outlook step economic forecast plan raise concern nasdaq composite tumble dow jone index president trump china tariff announcement trigger sharp sell thursday friday facebook crash week take alphabet other big consumer internet tencent sell hit many chinese internet especially industrial such boee ba heavy china exposure investor also be worry hawkish forecast federal reserve meanwhile treasury yield fall safe haven flow stock dove trade war fear crude oil price rise significantly chief executive mark zuckerberg day silence respond wave criticism cambridge analytica obtain million user profile abuse social medium giant datum sharing ability post facebook page zuckerberg say responsible happen platform then layer step company take prevent further abus facebook share plunge google parent alphabet googl twitter twtr sell respectively get newsletter deliver inbox more info product service privacy policy term fed raise key rate quarter point expect slim majority fed policymaker still expect rate hike see total hike more project end last year step pace reflect expectation stronger economy propel tax cut federal spending hike now policymaker expect core inflation rise next year just fed target tencent holding tcehy report fourth quarter earning ahead expectation sale growth come short chinese messaging gaming giant send stock wednesday major early investor company nasper next day announce sell tencent share worth cut stake nasper say sell share fund other business have plan further reduce holding next year tencent plunge thursday alibaba baba other top china internet tumble database software giant top quarterly earning view oracle reveal reveal transition cloud be progress slower expect cloud revenue growth be less expect decelerate once again oracle say cloud gain fall further quarter share plunge salesforce com crm make biggest acquisition date purchasing mulesoft mule cash stock salesforce paid high multiple nearly time mulesoft estimate revenue set high bar other potential deal involve saas software service company mulesoft sale jump last year deal be expect be earning dilutive mulesoft software automate integration new tool legacy enterprise platform speed application development salesforce com share fall announcement abbvie abbv crater nearly thursday scuttle plan seek accelerate approval lung cancer drug perform poorly midstage trial drug rova be be test third treatment achieve objective response rate median month overall survival be median month drug be still be test first second treatment same form cancer memory chip giant earn adjust share fiscal second quarter year year sale quarter end march analyst expect current quarter micron technology mu expect earn adjust share sale wall street be modele micron see strong demand continue dram flash memory chip cite cloud datum center smartphone automotive chip growth driver invest boost production facility micron share tumble friday smart global holding sgh smaller player rate datum storage group include micron also easily beat quarterly estimate guide higher share soar friday arena pharmaceutical jump tuesday wednesday ulcerative colitis drug prove strong phase trial component scale patient achieve clinical remission vs just placebo patient drug belong same class celgene celg drug ozanimod regulator refuse review last month multiple sclerosis southwest airline luv cut first quarter unit revenue outlook cite part competitive fare environment analyst cowen see direct result unite airline ual plan expand flight regain relevance market share share southwest other airline fall unite also suspend pet cargo travel fly few dog wrong destination die be store overhead bin carrier say hope complete review pet cargo travel program report ep revenue same store sale rise beating analyst expectation ep revenue focuse discounter see ep cent view cent revenue also view issue full year ep revenue analyst estimate also approve stock repurchase program rise thursday near buy zone nike nke report flat earning share exclude tax related charge defy view drop sale grow also top view china sale pop lead gain geographic segment revenue important north america segment slide ceo mark parker point significant reversal trend north america share initially jump friday close only stock undercut day line thursday datum storage service firm shot friday pricing ipo share upwardly revise range dropbox dbx sell share late thursday raise dropbox let user store share collaborate document photo other file online many user opt free service dropbox have pay subscriber macy say retail conference shoptalk store mobile checkout system be location year end look keep tech savvy rival online player summer macy store offer virtual reality furniture shopping same conference walmart wmt commerce head marc lore reiterate not be go anywhere holiday online sale slowdown be largely plan entry home specialist earn cent share dime view revenue rise slightly miss view net order rise more expect strong start spring selling season strong demand be give kb home kbh pricing power offset higher commodity cost kb home stock climb meanwhile new home sale fall third straight month december january figure be revise higher exist home sale climb accenture acn report fiscal adjust earning rise year revenue rise top consensus estimate accenture raise full year profit target margin be hit few big contract renewal health public service field be less profitable well higher acquisition cost area share fall thursday fedex fdx beat earning revenue forecast raise full year ep outlook shipping giant set shop walmart wmt store year general mill gis report ep cent line view revenue fall just short cereal maker lower growth outlook rise cost stock sank nearly year lows general mill be latest package food giant weaker growth report send several peer fall sharply well china ipo lexinfintech lx fall far short estimate earn adjust cent share revenue share tumble be hold ipo price online lender cater educate young chinese adult winnebago wgo plunge rv maker miss fiscal earning view sale beat surge demand smaller towable rvs tesla tsla shareholder vote approve massive pay package chief executive elon musk design ensure iconic leader remain electric car maker next year darden restaurant dri owner olive garden report fiscal earning beat expectation revenue same store sale come short full year ep outlook imply weak darden stock leap ibd stock healthequity hqy make big gain beating fourth quarter estimate monday close report ep cent revenue health saving account asset account jump share rise child place plce struggle recover plunge tuesday weak guidance beating earning post ep share revenue share fall apple aapl reportedly be develop own display used microled technology likely be several year start show device such apple watch iphone chip gear maker kla tencor klac announce agreement acquire orbotech orbk cash stock kla tencor be seek diversify business process control system equipment used production print circuit board flat panel display semiconductor device be interested best growth stock buy watch see update ibd stock listsnews analysis dow jone industrial average component invest stock market start simple routine
69,CELG,celgene celg vertex pharmaceutical vrtx incyte incy be worth watch broader market correction see biotech stock lose collective previous day analyst say tuesday biotech stock rebound stock market today diving monday bmo capital market analyst brian belski say note client investor be reap sow intent purpose majority client market pundit especially increasingly boisterous set naysayer have be predict bull market imminent demise day presidential election say doesn mean bull market be dead belski say rbc analyst brian abraham agree see opportune entry point certain biotechs stock datum approval expect thing be look celgene few misstep second half include major miss sale psoriatic arthritis drug otezla third quarter abraham say sale drug rebound fourth quarter believe market cap reduction more reflect believe fourth quarter number guidance point reassure stabilization key revlimid otezla sale say ibd take bull market be good time review stock selling smart once begin stall uptrend too late catch head investor corner brush stock selling rule cancer drug revlimid be celgene biggest drug analyst have worry generic rival take sale start contend celgene recently announce plan acquire remainder juno therapeutic juno didn already own add juno coffer put celgene car space compete novartis nvs gilead science gild latter acquisition kite pharma car therapy immune system identify fight cancer even juno celgene look poise generate enough cash flow buy back virtually entire enterprise value revlimid go completely generic abraham say outside abraham see number catalyst include additional datum revlimid treat lymphoma late stage datum drug partner acceleron pharma xlrn blood disorder celgene rise tuesday abraham say vertex be victim bad timing vertex recently report strong datum triple combination regimen cystic fibrosis datum come just broader market be begin turn stock fall hard past day vertex rebound tuesday rise strong effectiveness drug know vx vx triple regimen head phase study support likelihood vertex expand tough treat population cystic fibrosis patient say also enable multiple additional shot goal set bar be difficult match beat significant lead time likely render mid year competitive datum galapago glpg overhang vertex share much less impactful raise price target vertex macro weakness be mask improve fundamental abraham argue incyte be set read datum phase trial know echo first half study combine incyte immuno oncology drug epacadostat dow stock merck mrk keytruda late stage melanoma drug class know immuno oncology treatment epacadostat work block interaction involve ido enzyme immune system keytruda be call pd inhibitor have similar interaction pd protein instinet analyst christopher marai expect trial read positively be similar regimen bristol myer squibb bmy drug opdivo yervoy bristol be also combine drug treat other cancer include advanced lung cancer so epacadostat become part standard care metastatic melanoma broad adoption augment current pd use say note client lead peak worldwide sale north melanoma alone epacadostat rbc abraham say eventually nearly value epacadostat soon be go incyte share see share jakafi treat bone marrow disorder share olumiant rheumatoid arthritis drug co develop eli lilly lly suggest downside upcoming epacadostat datum be negative be now likely only share fundamental upside now potentially more say make upside downside level much more interesting incyte advanced tuesday related allergan pop consensus top quarter strong migraine biotech stock dive more be sell overdo crispr small biotechs cure disease
70,CELG,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
71,CELG,abbvie abbv surge record high friday issue beat raise earning report include guidance tax rate prompt analyst suggest yet industry behemoth become acquisitive fourth quarter abbvie report adjust income share sale rise respectively metric top consensus analyst adjust profit share sale close bell stock market today abbvie soar close help drug stock rise collective guidance lower tax rate have be expect leerink analyst geoffrey porge write note client december white house approve legislation lower corporate tax rate tax rate company revenue growth margin performance expect significant increase free cash flow attendant leverage thus set stage more active business development activity yet industry behemoth say investor have previously expect abbvie guide tax rate porge say merger activity have be heating recently biopharma group week celgene celg say buy remainder juno therapeutic juno didn already own gilead science gild spend nearly acquire kite pharma abbvie expect effective tax rate increase next year due increase domestic income investment piper jaffray analyst christopher raymond say note client abbvie result sale humira treat several form arthritis crohn disease plaque psoriasis increase sale humira be abbvie most important drug sale beat consensus raymond say ibd take abbvie lead group ibd composite rating best possible make leader stock term key growth metric more drug stock rank visit ibd stock checkup cancer drug imbruvica bring revenue grow nearly be ahead analyst collective view raymond say worldwide sale abbvie hepatitis drug viekira mavyret advanced more vs year earlier period beating consensus say porge lower tax rate also boost other guidance year abbvie call adjust income share top consensus sale be expect approach street consensus view related intuitive surgical top fourth quarter sale earning viewscelgene reverse fourth quarter otezla sale reboundbiogen revenue top spinraza ms drug deliver upside
72,CELG,puma biotechnology pbyi licensing agreement breast cancer drug nerlynx win inhibit takeover interest puma analyst say tuesday share tumble follow deal early tuesday puma say allow medison pharma commercialize nerlynx israel be not yet approve nerlynx be used treat breast cancer patient specific genetic condition make more susceptible cancer investor be seemingly key puma be acquire rbc analyst kennen mackay say takeover interest biopharma have spiked recently celgene celg be plan buy juno therapeutic juno sanofi sny be buy bioverativ bivv ablynx ablx importantly do not see partnership remove merger acquisition interest puma view critical bull thesis stock say note client term deal puma receive upfront milestone payment well double digit royalty nerlynx sale israel new agreement medison demonstrate commitment bring nerlynx patient world continue focus commercial resource market chief executive alan say written statement mackay call deal largely incremental israel be breast cancer case diagnosed annually vs only patient have specific gene amplification require nerlynx use mackay see potential peak sale nerlynx expect nerlynx bring fourth quarter sale consensus view ibd take drug treat rare disease often cost quite bit insurer aren scramble push back cover drug see go industry snapshot puma have struggle nerlynx recently earlier month european authority say be unlikely approve nerlynx use breast cancer patient come vote next month share topple third day close bell stock market today puma slide close fall much earlier trade biotech stock collectively dip be more amazon amzn berkshire hathaway brkb jpmorgan chase jpm announce collaboration cut cost health care related valeant climb month make sense dow topple judge toss patent blockbuster drugwhy biotech stock outperform peer
73,CELG,median tenure chief executive large cap biotech company be just year plunge year key transition period amgen amgn celgene celg biogen biib vertex pharmaceutical vrtx analyst say wednesday new chief executive also tend hold less power biotech chief have dual title ceo board chairman compare pharma chief leerink analyst geoffrey porge write note client believe investor understandably find hard have confidence new executive give lack track record recent history group be unlikely inspire confidence say investor be also likely view executive have less power broker merger acquisition contribute expectation relatively modest deal activity improve cash position most large cap porge say biotech company be operated chief executive long tenure mostly scientific background proven track record familiarity investor porge say number ceo be founder scientist carefully choose successor ibd take large cap biotechs be frustrated smaller play newer medicine start take share analyst say trend continue head ibd industry theme breakdown mean biggest stock collapse median large cap biotech ceo tenure past year follow uptick year year meanwhile pharma company see rotation ceo business law degree median duration experience year however imbalance reversed early median biotech ceo tenure have decline match pharma year porge say median ceo tenure large cap pharmaceutical be year ceo pharmas have maintain dual role chief executive chairman time biotech ceo have dual role just time be likely result high prevalence physician scientist founder often have senior business leader chairman position porge say see pro con company combine chief executive chairman position hat believe lack strong authority leadership position biotech company be certainly suggestive lack immediate opportunity change company industry structure say investor be dissatisfied company performance be also likely find divide title arrangement more vulnerable challenge change entrench ceo chairman related company be now outperform stock stock rise apple bitcoin fall play pay big tax reform impact tax bracket rate
74,CELG,year semiconductor energy internet homebuilding other industry have moment be biotechs have most winner nearly third best perform stock be biotechs far more other industry group group also account top stock year whole industry finished year top ibd track nearly link list top stock be end article biotechnology company be curious bunch many be unprofitable share soar hope drug re develop become blockbuster fact best perform biotechs be post loss year have be least few year see list best stock investing company profit be risky be ibd slim method seek company not only be profitable be one highest earning growth historically be characteristic best exemplify wall street winner special report personal finance action plan stock market reviewit be vast industry group company average ep rating be lousy highest possible even company profitable history be susceptible sell off celgene celg crash day period october first news halter trial crohn disease drug then disappointing sale dim outlook few industry have risk reward equation biotechs get drug market be fraught risk include chance clinical trial fail regulator win approve other hand successful drug result billion sale biogen biib multiple sclerosis drug tecfidera have sale third quarter alone successful trial result often send share rocket even actual sale be year away anaptysbio anab year top new issue top overall stock double oct follow announcement successful test eczema drug anaptysbio go public share be now analyst expect company lose share lose share exact science exas top stock year make cologuard home test colon cancer oct company report sale increase raise sale guidance other stock top give glimpse big story market overstock com ostk make top not necessarily online shopping success overstock enrich shareholder thank connection blockchain electronic network used cryptocurrency such bitcoin overstock ceo patrick byrne be part joint venture build blockchain base global registry property right develop world sale overstock com fund project be possibility also overstock com accept bitcoin roku roku share soar reflection cut cord movement home entertainment consumer shedding cable satellite tv service have opted internet deliver video service be cheaper sometimes better tailor viewer taste roku go public share be now trading company make hardware software internet video service netflix nflx hulu amazon com amzn prime video ibd take make money catch etf uptrend require knowledge read chart learn ibd university chinese stock be hot much year especially internet company social medium firm yy inc yy weibo wb online retailer baozun bzun craigslist com clone com wuba produce gain nearly year tencent holding tcehy china lead online messaging gaming provider more double outstanding advance strong profit profit recovery be factor bloc success chinese stock earn reputation wild volatility problem be largely absent top china base equity rise interest rate possibility banking regulation ease give financial fuel few make top couple argentine bank loan marketplace lendingtree tree mobile payment company square sq be sampling sector find best stock ibd screen begin year trading share new issue initial public offer price be filter stock currently trade fewer share day also be eliminate click here list top stock related best stock often follow industry political trend stock market do now be remarkable year stock check chart timeline
75,CELG,celgene celg topple late thursday drug regimen fail phase study patient form hodgkin lymphoma hour trading stock market today celgene dove close trial investigate regimen revlimid rituximab follow maintenance treatment rituximab compare standard care rituximab chemotherapy regimen be test patient follicular lymphoma revlimid be celgene blockbuster blood cancer drug rituximab be sell brand name rituxan roche rhhby genentech biogen biib treatment didn achieve superiority complete response unconfirmed complete response week progression free survival preplan analysis key goal trial related biogen share drop alzheimer drug miss biotech stock launch join smallcapwhy biotech stock be take
76,CELG,camille callais be diagnosed spinal muscular atrophy neurologist tell parent nothing do be year biogen biib ionis pharmaceutical ion spinraza become first ever drug approve treat spinal muscular atrophy camille parent try supplement label use medication highly specialize diet
77,CELG,major stock index hold modest loss late afternoon trading friday ahead long holiday weekend session wasn entirely incident bitcoin speculator suffer more pain straight decline see bitcoin investment trust gbtc lose nearly value plunge friday re-cover touch day move average bitcoin slump point friday start week close bitcoin major exchange coinbase suspend transaction temporarily dow jone industrial average nasdaq composite be mostly flat volume nyse nasdaq be tracking well thursday level stock market today money continue flow oil gas name friday even crude oil future be mostly unchanged barrel concho resource cxo follow thursday buy point share rise group peer ibd name diamondback energy fang be also show good follow week share be diamondback be pace weekly gain more be add leaderboard earlier week ibd take trade ibd click innovator ibd fund ffty manage innovator capital management downside celgene celg gap former biotech leader disclose treatment form hodgkin lymphoma fail phase trial celgene gap oct stopping phase trial drug treat crohn disease elsewhere shake shack shak hold relatively well downgrade jeffery underperform hold share lose significantly pare early plunge strong run shake shack be still hold comfortably buy point related bitcoin dife again crypto rout coinbase halt tradestrump tax reduction make grubhub web clearest winner invest stock market used simple routine
78,CELG,stock close record high monday stretch january rally point investor have wonder get late party index be dull early trading picked pace headline flash news congressional leader have reach agreement end government shutdown many federal office be
79,CELG,biotech internet related large cap help nasdaq composite forge solid gain monday general electric ge be try put skid sharp day slide suck nearly worth company market value meanwhile oil gas share continue advance drove energy price remain strong wti crude oil future reversed small early loss edge higher barrel diamondback energy fang ibd leaderboard play jump more extend gain past buy point nearly ge focus front page story latest ibd weekly have market cap share outstanding end devastate bear market ge trade low share equivalent market value time nasdaq lead gain tech heavyweight alphabet googl intel intc microsoft msft lift gain dow jone industrial average lag nearly apple aapl largest company nasdaq dow component fall volume be dull iphone giant get new downgrade be not trigger sell signal share be clear fine second stage cup handle oct slightly more recent entry megacap tech recently hop day move average week justify follow buy holder nice profit cushion stock russell rise nearly volume rise nasdaq be sharply nyse accord preliminary datum ge part stock dow industrial be now trading day move average too have be fall hard last year exclude brief flash crash august last time ge fall hard important long term level be way back march tail end market severe slide top november notice rally early january year fail keep ge share day move average long healthy stock trade day move average turn lead day move average higher ge opposite be occur technically speaking ge find buyer value investing crowd however note ge feature ibd ge face unenviable task decide maintain position power aviation health care market sell more part become leaner meaner ge attractiveness dividend play have definitely lose luster board approve haircut quarterly dividend cent share november dow jone industrial average fellow component verizon communication vz make ibd dividend leader screen telecom giant have annualize yield terrific year earning stability factor scale rise nearly fast turnover move past cent high handle long saucer base present timely buy point street expect verizon post rise fourth quarter profit cent share lift revenue result come tuesday market open check ibd earning calendar other company set report result meanwhile fellow dow component intel intc goldman sachs gs continue do well gain former be still form new base latter appear be build shallow new base much longer saucer handle furnished past nov elsewhere stock market today biotechs help lead upside follow news french pharma giant sanofi sny be buy biogen biib spinoff bioverativ bivv more celgene celg confirm rumor buy juno therapeutic juno least company ibd biotech industry group hold solid composite rating higher trade least share include ligand pharmaceutical lgnd vertex pharmaceutical vrtx hold awesome score respectively ligand run nearly afternoon trading extend gain buy point week flat base so bit extend price vertex report result jan close be try clear stubborn resistance build long flat base also be view saucer pattern standard buy point be follow saito chung twitter ibd_dchung more analysis growth stock chart financial market related stock buy zonewhere be stock market head read column first dayfind great growth stock ibd stock break have amazing earning outlook
80,CELG,celgene celg reversed third quarter fallout thursday report key inflammation drug otezla tack nearly growth fourth quarter top consensus report contain surprise time leerink analyst geoffrey porge say note client follow third quarter celgene stock tank otezla sale broadly miss expectation fourth quarter psoriatic arthritis drug otezla bring sale grow vs year earlier period sale grow international sale advanced porge credit otezla rebound quarter quarter volume gain say gain be view positively very disappointing third quarter result make many investor question long term potential product close bell stock market today celgene stock gain close total sale come grow top consensus adjust profit increase share beat expectation adjust income share cancer revlimid sale beat consensus porge say sale beat outside revlimid sale lag pomalyst sale be line abraxane bring miss celgene guide total sale lag street view biotech see revlimid pomalyst otezla grow respectively vs prior year ibd take biogen celgene kick biotech earning season thursday other be expect provide even more upside head ibd industry theme closer look biotechs be expect outperform third quarter expectation adjust earning be expect rise midpoint share consensus have modeled guidance doesn include celgene plan merger juno therapeutic juno be expect have cent dilutive impact earning lead drug juno jcar be expect be third class know car therapy hit market novartis nvs gilead science gild be first still celgene plan acquire long term partner juno have be laud wall street view deal celgene announce monday acquire juno be relatively straightforward make lot sense celgene already have make significant investment car space porge say rbc analyst brian abraham say report acquire juno help celgene diversify biggest moneymaker revlimid revlimid be expect begin lose exclusivity key patent expire expect sentiment celgene shift back positively fourth quarter earning guidance reaffirm potential strong term growth execution say pipeline development support revenue sustainability post revlimid related valeant climb month make sense abbott spike record top quarterly top high crush fourth quarter expectation
81,CELG,sanofi sny second deal week spur robust buy period biopharma analyst say monday french drugmaker outbid nordisk nvo belgium ablynx ablx deal come week sanofi say spend acquire biogen biib spinoff bioverativ bivv hemophilia drug specialist also last week celgene celg say buy juno therapeutic juno leerink analyst seamus fernandez say signal begin active time biopharma deal view sanofi aggressiveness merger acquisition precede more robust period deal biopharma effect tax reform be feel valuation late stage asset continue drive higher say note client specifically sanofi plan spend acquire ablynx ablynx be near approval drug treat rare blood clot disorder be already partner abbvie abbv dow merck mrk sanofi other number potential drug various partnership program offer upside prospect ablynx wholly own asset fernandez say note drug fight virus cause infection lung respiratory tract be expect have phase datum second half year ibd take analyst don expect payer push back drug treat rare disease consider small population tend treat see company be work arena visit industry snapshot acquisition also add drug know caplacizumab sanofi pipeline drug be be test treatment acquire thrombotic purpura rare clot disorder cause impair activity enzyme ablynx estimate market disorder also know acquire ttp be euro expect gain approval europe sanofi fall close stock market today ablynx other hand rocket finish nordisk lose chance acquire ablynx sank nordisk have put bid earlier month ablynx related biopharma behemoth soon become surgical dip lackluster guidance analyst bullishwhy biotech stock outperform peer
82,CELG,abbvie abbv follow footstep gilead science gild celgene celg analyst suggest monday abbvie guide unexpectedly low tax rate expect narrative stock come month develop buy story similar gilead celgene more recently leerink analyst geoffrey porge write note client acquisition narrative follow abbvie fourth quarter earning friday biopharma giant top quarterly expectation beat guidance prediction also guide tax rate tax rate term also follow announcement last week celgene acquire juno therapeutic juno sanofi sny acquire biogen biib spinoff bioverativ bivv today sanofi also say buy ablynx ablx abbvie do seek acquisition likely be neuroscience early stage immuno oncology solid tumor medicine porge say abbvie seek deal build complement early stage alzheimer disease pipeline ahead key readout so far abbvie be play card close vest firm doesn seem incline make large disruptive transaction porge say credit suisse analyst vamil divan note firm be constantly look asset believe already have strong pipeline further do not have burn platform need acquire asset say isn compelling need company be deal many other thing probably be not best time do merger acquisition ibd take celgene abbvie have already report fourth quarter earning slew biopharmas be still slate issue report head ibd industry theme closer look analyst expect biotech drug group put abbvie slightly different boat gilead celgene gilead acquire kite pharma slow hepatitis drug sale last week celgene say buy juno year begin lose exclusivity cancer drug revlimid divan comment follow conversation abbvie management post fourth quarter earning analyst suggest lower expect tax rate mean abbvie have extra cash hand engage merger acquisition abbvie say look earlier stage single asset build pipeline find anything timeframe even neuroscience readout not necessarily feel need divan say note client divan boost price target abbvie keep neutral rating porge also up price target downgrade abbvie market perform rating outperform current valuation prefer celgene abbvie larger cap name coverage say growth name such vertex pharmaceutical vrtx alexion pharmaceutical alxn regeneron pharmaceutical regn continue offer more upside view abbvie close bell stock market today abbvie dip fraction related celgene reverse fourth quarter otezla sale sanofi ablynx deal spur biopharma buy spree biotech merger spigot turn juno bioverativ
83,CELG,ligand pharmaceutical lgnd be biotech worth doesn market single drug yet expect approach sale stock be breaking reason be ligand operate unique business model acquire early stage technology necessary drug development then license platform biotechs pharmas dow jone stock merck mrk pfizer pfe well amgen amgn novartis nvs total ligand have more program development north partner firm say fourth quarter conference call february craig hallum capital group analyst matt hewitt praise model feb report client give larger ever expand portfolio current potential future royalty generate asset broad pipeline partnership model inherently gear deliver very high profit margin believe be tremendous value creation motion ligand say shareholder seem agree hewitt assessment ligand stock have pop more begin year outperform broader biotech group have rise roughly same time period thursday share jump early morning trade break second stage week flat base share end regular session ligand share have be run last week jump least day stretch straight trading session meanwhile biotech group have be red past session stock have ibd composite rating best possible meaning perform top stock term key growth metric biotech group rank third vertex pharmaceutical vrtx halozyme therapeutic halo have rating ligand demonstrated dominance fourth quarter total revenue grow top consensus roth capital partner analyst scott henry write recent note client royalty main driver sale increase line expectation henry say upside revenue drive adjust earning share spiking vs year earlier quarter beating analyst view cent better expect sale amgen kyproli novartis promacta lead revenue charge ligand get royalty sale promacta oral medicine increase number platelet blood royalty sale multiple myeloma drug kyproli total ligand be tie dozen commercial product have technology platform biotechs pharmas use develop drug firm also have handful early stage drug plan license interested company further development ligand goal be create diversify company more licensing opportunity lower impact individual patent expiry firm say protect scenario now face biotech leader celgene celg see patent cancer drug revlimid begin expire mid use ibd marketsmith free march
84,CELG,see stock buy point get chart pattern recognition run custom screen start nowamong recent success ligand announce week have partner drug hold firm roivant science diabetes drug lgd roivant company metavant develop drug have strong phase datum second half be major partnership have potential generate substantial medical value type type diabetes patient ligand chief executive john higgin say prepared statement lgd be successfully develop license roivant have potential be ligand largest financial asset possibility annual royalty continue late offer upside guidance royalty revenue sale related captisol compound used pharma development related milestone license fee analyst say ligand tend promise deliver come annual guidance roth capital henry say expect be more same revenue earning share target view conservative surpass company guidance henry expect kyproli promacta sale moderate call kyproli sale grow promacta sale increase sustain movement drug provide upside guidance say ligand be bullish drug ceo higgin call kyproli promacta become blockbuster promacta have be market year so see level growth be particularly impressive say earning call promacta become molecule analyst project continue strong growth say kyproli give recently report sale number drug appear also be track exceed worldwide sale ligand partner currently have handful drug late stage testing include brexanolone postpartum depression drug sage therapeutic sage slew other phase trial partner program be preclinical be phase study firm expect benefit current trend include new tax law reduce ligand project tax rate more third higgin say earning call ligand also get boost bump fda drug approval recent study massachusett institute technology find success rate drug program advance approval have increase believe be attribute many factor include better decision advance program more favorable regulatory environment say be very meaningful ligand have program stage development related tame volatile swing trade half trade stock most penny stock fail make investor richlook best stock buy watch start here
85,CELG,couple relatively obscure biotechs be challenge like novartis nvs gilead science gild new form treat cancer not only undercut bigger rival render recently approve oncology drug drug giant obsolete novartis gilead be still early stage launch respective drug call kymriah yescarta be know car drug cellectis cll crispr therapeutic crsp tiny fraction rival market cap already be creep shelf variation car therapy used healthy donor cell create less expensive version cancer drug make treatment novartis gilead less attractive obsolete instinet analyst christopher marai tell investor business daily never mind pricing be dose more effectively marai say car therapy be form oncology treatment currently create extract immune cell patient blood used empty virus drugmaker affix be know chimeric antigen receptor immune system cell receptor also know car be protein recognize other protein used cancer cell hide body re engineer cell be reintroduce body be direct seek destroy cancer cell carry protein process be complex costly also tailor individual meaning drug be mass produce often take week manufacture patient die re wait crispr chief executive sam kulkarni tell investor business daily shelf approach car be aim change shelf car also know allogeneic used healthy donor cell prompt same immune response first generation car ts novartis gilead be used know autologous kulkarni say donor cell be typically healthier allow more robust response patient manufacturing process be less complex run make hundred dose kulkarni say process be uniform less costly cellectis have estimate cost good less patient autologous car run hundred thousand dollar expert say kulkarni marai note benefit allogeneic car be huge theory pan late stage clinical testing healthy donor cell also prompt better response used compromise cell cancer patient say patient also potentially receive repeat dose benefit doesn persist dose difficult much pricier autologous car overall allogeneic be so much more powerful shelf kulkarni say patient be treat very next day allogeneic car ts have good chance work better autologous car ts be accessible broadly patient theory be still little short tooth december cellectis partner servier pfizer pfe dow jone industrial average component unveil result first clinical trial used donor cell create car treatment form leukemia brad loncar run biotech fund know loncar cancer immunotherapy etf cncr call result mixed patient form acute lymphoblastic leukemia drug know ucart result complete remission rate adult pediatric patient use ibd marketsmith free march
86,CELG,see stock buy point get chart pattern recognition run custom screen start datum weren strong result juno therapeutic formally acquire celgene celg earlier week be point phase datum present december juno jcar first generation car drug achieve remission rate child same form leukemia have equal effectiveness course shelf car make first generation car obsolete loncar tell investor business daily have equal effectiveness gigantic thing say far proven reason believe never be so allogeneic car be holy grail oncology therapy say nadeem sheikh vice president research development privately hold dendreon pharmaceutical dendreon make immunotherapy treatment call provenge advanced prostate cancer entire cancer field love something allogeneic approach tell investor business daily allogeneic approach be take cell give holy grail know lot problem approach used donor cell introduce potential condition know graft versus host disease sheikh say disease donor immune cell don recognize surrounding begin attack everything appear foreign crispr kulkarni think have answer company gene editing process used technique call crispr receptor donor cell be remove prevent cell wildly attack unintended target essentially used crispr change genetic healthy donor cell say do longer attack patient cell only attack tumor patient perform second edit donor cell be then engineer appear body so patient own immune cell win try destroy donor cell kulkarni say allow donor cell persist longer body think crispr blow torch say actually cut metal weld metal here add gene remove gene cell essentially take healthy person cell make car ts add subtract gene cellectis be class own allogeneic car loncar say servier pfizer partner drug ucart already have preliminary phase datum own drug ucart be testing acute myeloid leukemia form leukemia know blastic plasmacytoid dendritic cell neoplasm february cellectis be grant pair patent use crispr gene editing genetic engineering cell cellectis say plan make patent available licensing other company willing use crispr technology cell theory be catch quickly even biggest first generation car player gilead announce acquisition kite late august merger close oct just fda approve kite drug yescarta oct now gilead be eyee allogeneic approach last month gilead partner sangamo therapeutic sgmo front develop cellular therapy used technique gene editing call zinc finger nuclease process gene editing be more complex costly crispr technology used crispr edita medicine edit intellium therapeutic ntla term deal gilead sangamo be eligible potential payment more product work autologous allogeneic approach cellular therapy crispr biotech also be work allogeneic car therapy call ctx yescarta gilead kymriah novartis target cd protein meaning potentially be used treat similar blood cancer so far firm have have meeting fda discuss filing investigational new drug application kulkarni say such application allow crispr begin clinical trial kulkarni expect file application end year begin clinical testing bullish crispr prospect note take lot front time energy think re still early day say have see datum bear autologous car have head start number trial allogeneic start work tumor type very scalable program related chart read basic buy point mark time real tame volatile swing trade half positionlook best stock buy watch start here
87,CELG,retail investor turn more leery volatile february yet used stock market pullback opportunity buy apple aapl amazon amzn general electric ge rather flee customer online brokerage td ameritrade amtd be net buyer stock month see dow jone industrial average nasdaq composite fall more recent high worry rise bond yield inflation spark sharp sell stock lead brief market correction stock bottom feb index rebound day move average major average do fall february breaking long monthly winning streak meanwhile volatility measure cboe volatility index vix spiked period vix rise first time august decrease relative volatility many widely hold stock include ge apple facebook fb accord new td ameritrade report lead investor significantly limit volatility risk market change game plan less speculative more low beta weight say jj chief market strategist td ameritrade note rocky start come tame use ibd marketsmith free march
88,CELG,see stock buy point get chart pattern recognition run custom screen start brokerage firm recently rank ibd best online broker share additional insight client trade month general electric ford motor near multiyear lows be net buy apple amazon com amzn report better expect earning period trade lower follow market volatility be also net buy boee ba trade higher follow better expect earning stronger demand outlook plane be also net buy microsoft msft be net buy earning beat prove cloud compute software service initiative be success alibaba group baba be almost recent high volatile period be also net buy nvidia nvda berkshire hathaway brkb netflix nflx count other popular name investor buy february gilead science gild be net sell reach week high receive approval fda new hiv treatment facebook fb reach time high feb better expect earning be also net sell bristol myer squibb bmy hit month high follow analyst upgrade immuno oncology growth prospect be net sell snap snap report revenue increase lead stock spike be also net sell target tgt be net sell follow analyst upgrade increase price estimate conocophillip cop juno therapeutic juno bioverativ bivv be also dump celgene celg agree acquire juno france sanofi sny be buy bioverativ apple share close stock market today close buy point amazon rise tuesday fresh time high general electric continue rally follow bullish analyst report add ge tumble last week worst level july ge apple be member dow jone industrial average so be boee microsoft investor lessen exposure equity market february td ameritrade say investor movement index proprietary measure client behavior brokerage fall level not see january week end feb be second monthly decline row index make record high fall increase score tend mean investor be get more bullish decrease mean investor be become bearish less bullish td ameritrade advise be best review index trend time rather focus month score more detail index be here be interested invest learn use day move expand bitcoin amazon nvidia alibabayy earning jump china livestream boomtarget earning miss outlook weak strong online sale growththese tech leader have break more be buy top chip play poise break re riskygeneral electric reason worst be ge stock
89,CELG,stock extend gain senate vote end day government shutdown biotechs soar merger deal celgene celg sanofi sny bitcoin fall powershare qqq trust qqq lead gain spdr spy add spdr dow jone industrial average dium climb biotech energy utility be top sector fund gainer stock market today bank industrial homebuilder lag spdr biotech xbi leap nearly ishare nasdaq biotechnology ibb rise week high celgene announce deal buy cancer drug maker juno therapeutic juno juno soar celgene reversed fractional gain also biotechs sanofi offer buy biogen spinoff bivv roughly sanofi fall bioverativ surge more bitcoin slump accord coindesk earlier rise bitcoin investment trust gbtc give slip back day move average south korea reportedly try tax cryptocurrency market require user transaction detail be share other news td ameritrade amtd begin offer clock trading day week dozen etfs include spy dium qqq ishare msci emerge market eem be monumental first industry retail investor steve quirk executive vice president trading education td ameritrade say statement person have busy life want access finance anywhere anytime device online trading make market available anyone mobile trading make market available anywhere now hour trading make market available anytime lead tech fund hold bitcoin amazon amzn nvidia nvda continue outpace broader market so far year much have past year top list be ark innovation arkk ark web arkw respective year gain jan accord morningstar direct return respectively year date same date ahead gain september ark invest become first public fund manager invest bitcoin grayscale bitcoin investment trust gbtc re believer bitcoin currency bitcoin technology platform founder cio catherine wood say statement time also believe current price present attractive entry point investor last year alone gbtc surge more bitcoin price sky-rocket share investment trust be year cryptocurrency price have pull back sharply gbtc isn ark fund top holding now arkk top include tesla tsla stratasys ssys juno therapeutic juno arkw top holding include amazon amzn twitter twtr nvidia nvda graphic chip designer nvidia be hit new high bank america friday lift price target share be top buy zone entry nvidia be also player hot artificial intelligence field global fintech finx global social medium socl come third fourth respective year gain ytd basis finx be socl be ibd take nvidia be lead chip stock term price performance do fundamental rank group find now ibd stock checkup socl be top potential buy zone late december rebound day move average consistently find support line january share rise nearly prior bounce support line early december head south test day fund track solactive social medium total return index marked sixth anniversary november top holding jan include china tencent tcehy twitter twtr facebook fb netherlands base yandex yndx snap snap top name account asset etf be year jan accord morningstar direct ahead gain average annual return past year respectively also outperform benchmark index return period socl carry expense ratio related stock mixed nike lead dow ge apple weigh bitcoin quiettop chip stock defy market trend bitcoin play bounce backapple sit microsoft ibm boost dow bitcoin trim loss
90,CELG,future index fall slightly vs fair value monday morning investor weigh impact government shutdown sanofi sny pay bioverativ bivv celgene celg agree buy juno therapeutic juno netflix nflx kick fang earning report monday amazon com amzn be make news facebook fb investor mull latest move mark zuckerberg revamp social site news feed meanwhile alphabet googl isn make big news chart fourth fang stock be still worth review federal government begin partial shutdown saturday senate democrat block bill keep government operate few week democrat didn object funding bill be try force republican let person come country illegally minor remain originally president obama daca executive action sunday effort reach deal senate adjourn monday morning long shutdown have significant impact economy stock future slide vs fair value dow jone industrial average future lose nasdaq future fall less netflix be expect report earning share gain revenue climb wall street see netflix earning soar stream internet tv giant have largely complete global expansion investor also pay close attention subscriber follow recent price hike netflix previously forecast new user netflix clear flat base buy point jan day surge nearly blast day move average first trading session then netflix have continue climb close friday slightly extend buy point netflix relative price strength line track stock performance vs index have rise steadily hit new high make little headway july rs line be little blue line chart amazon open cashier less convenience store amazon go seattle public monday year testing company employee shopper get want leave have stand line checkout get store customer have download app scan qr code get turnstile computer watch item take shelve bill shopper once leave amazon go remain blip company financial work amazon open new location introduce such technology whole food market also spawn adoption other retailer wal mart store wmt have test cashier less shopping sam club location amazon friday raise amazon prime monthly membership fee annual prime fee be still amazon share end last week slightly extend late stage flat base amazon be featured leaderboard ibd premium service provide annotate chart handful top rate stock usually growth name buy zone amazon release fourth quarter earning feb fresh facebook announcement promote post friend family downplay publisher news feed ceo zuckerberg say friday afternoon facebook post social giant survey user determine trust news source decide have community determine source be broadly trust be most objective here work part ongoing quality survey now ask person re familiar news source so trust source idea be news organization be only trust reader watcher other be broadly trust society even don follow directly facebook appear have decide get embroil issue fake news russia involvement election headache try decide true not be simply not worth facebook share crash last week news original news feed change fall day line buy point heavy volume stock rs line have not make much headway month hit month low share do rally modestly close week back day facebook release fourth quarter earning jan alphabet share end friday new close high alphabet be well extend late october rs line have barely rise span alphabet rs line be time high early june stock largely track fast rise index google parent alphabet release fourth quarter earning feb be interested check stock buy first stage amazon monopoly problem prime time antitrust action vs internet giant winner be trigger sell signal not big picture stock break small item make big difference breakoutthese stock be race buy hottest group right now
91,CELG,major market average be modestly lower early friday dow jone industrial average tech heavy nasdaq fall apiece be right break even mark bitcoin plunge stock market today price bitcoin coindesk be price decline meanwhile bitcoin future cme plunge cnbc report state trading future contract appear have be halter limit riot blockchain riot decline bitcoin investment trust gbtc plummet cap week fall trading more time high set wednesday dow jone industrial component nike nke fall early friday top fiscal earning sale target earning decline second straight quarter fall year year analyst have forecast profit decline share remain cup handle entry also downside intel intc fall second straight day drop share be now cup shape buy point follow wednesday company report earning ibd member cinta cta beat street estimate guide fiscal year forecast spark initial rise reverse lower share be buy range flat base buy point friday early bearish reversal so far be not constructive former lead biotech celgene celg faltered drug regimen fail phase study stock have be trading day line gap oct pizza maker papa john pzza decline founder john schnatter announce be step ceo pizza chain stock have be rough shape fall year date ibd graphic chip maker nvidia nvda fall chip leader remain entrench day line meanwhile wingstop wing stumble nearly trimming loss jeffery downgrade restaurant hold underperform share be rebound day line first time flat base buy point related dow jone industrial average dow stock news outpace forecast north america sale fall againbitcoin future mainstream investor tame hysteria bitcoin cryptocurrency news oil mining stock hit buy zone global growth trump tax cut investing action plan
92,CELG,stock stumble mixed open friday nike nke pull hard dow datum show durable good order rise less expect november dow jone industrial average dip fraction nasdaq composite slip open trade defend narrow gain kroger kr capital cof post strongest early move bond market close early et today stock bond market be close monday congressional leader hammer stopgap extension agreement keep government funded jan avoid partial federal shutdown otherwise set take effect midnight friday massive tax overhaul pass congress thursday be president desk await final signature dow dowdupont dwdp rise nike trade more generally positive fiscal second quarter report deliver late thursday be once again tilt decline north american sale share end thursday extend almost past buy point cup handle base ibd name cinta cta slip open report thursday close show cincinnatus base uniform service fiscal second quarter sale revenue top analyst target stock end thursday upper edge buy range good clear flat base buy point nov celgene celg tank company have announce late thursday treatment revlimid rituximab form hodgkin lymphoma have fail phase trial celgene share have be attempt reclaim support week move average steep week sell october shake shack shak drop early action burger joint be cut underperform hold jeffery share be extend clear cup handle buy point nov personal income growth slow slightly november commerce department say increase october forecast november gain spending surge however october gain projection increase durable good order also jump rise november fall short advance project economist still be big step october dip be originally project drop transportation order dip be consensus view gain figure be upwardly revise gain october new home sale datum november come et well final read december consumer sentiment university michigan kansa city federal reserve release regional manufacturing index et baker hughe bhge weekly drill rig report be expect et related stock future rise bitcoin fall again here be new leadersthe big picture here be next potential pitfall intelligence software grow nearly time oil mining stock hit buy zone growth trump tax cut investing action plancapture bitcoin china solar new innovator ibd etfs
93,CELG,clovis oncology clvs sage therapeutic sage puma biotechnology pbyi stoke acquisitive appetite large cap biotechs struggle slow growth major patent cliff analyst say tuesday deal make have slow hit record high rbc analyst say note client number deal value hit year year have be merger include gilead science gild takeover kite pharma investor have expect gilead major buy stoke more acquisition didn come fruition biotech stock suffer pent demand prompt merger acquisition play next year analyst say many large cap company generate share overall revenue handful blockbuster drug many be face impending patent cliff come year rbc note say need make lose source revenue stimulate growth encourage future gilead buy kite suffering major decline hepatitis drug unit hiv drug tenofovir alafenamide be likely lose patent protection celgene celg cancer drug revlimid be face patent cliff amgen amgn inflammatory enbrel be likely lose protection also have most cash hand recent update amgen report celgene have gilead note remainder large cap biotech realm have ibd take analyst say monday large cap biotech franchise feel pain competition speeding number rival brand generic drug approval head ibd industry theme more mean like vertex pharmaceutical gilead amgen overall cash position be near year high analyst say tax reform help most recent proposal company repatriate earning tax rate amgen bristol myer squibb bmy dow johnson johnson jnj have excess cash currently overseas however think unlikely majority overseas cash be repatriate immediately institution tax reform rbc analyst say celgene instance have suggest chunk foreign earning be expect be reinvest permanently outside analyst also note average project revenue next year mid cap biotechs be likely do little offset loss patent cliff performance acquirer past year have be poor industry check also indicate large deal be out gilead kite be exception still expectation be high merger acquisition analyst say recent survey investor cite biggest tailwind group drug pricing be expect be biggest headwind rbc analyst be slightly bullish slightly bearish drug pricing expectation high major tailwind sector do not materialize first half see broad downside rbc say credit suisse analyst vamil divan too note be important big pharma group likely come result change tax rate repatriation top pick be also expect dow merck mrk allergan agn rebound additional fund dividend growth share repurchase also boost overall outlook sector investor perspective say see regulatory environment remain generally favorable provide more rapid path market product bring real innovation related beware price war big pharma biotech company biotech stock see cheapest rival cancer drugsgeneric drug maker face pricing issue other pharmas don
94,CELG,index other major average rally record high week asml asml taiwan semiconductor tsm other chip play surge earning apple pay taxe pay employee bonuse step manufacturing investment fund repatriate massive overseas cash holding general motor gm be upbeat future ford motor be not unitedhealth group unh kick health insurance earning lead many insurer stock record high cancer drug trial datum buzz moved drug stock general electric ge crash fresh year lows huge new charge speculation conglomerate break dow nasdaq rise week climb nasdaq hit record high friday chip gear maker lead way fuel asml asml other health insurer also be big winner unitedhealth unh trigger group rally energy stock pull back lithium play also sell apple aapl be expect bring home foreign profit draft overseas help pay domestic project thank recently enact corporate tax reform apple pledge contribute more economy next year include create new job funding new campus more datum center forge deal component manufacturer analyst say apple likely use foreign cash tuck acquisition increase stock buyback dividend semiconductor equipment group lead industry week asml hold asml ichor holding ichr electro scientific industry esio rally upbeat financial report asml report better expect fourth quarter result ichor electro scientific announce preliminary december quarter sale top view chip foundry taiwan semiconductor manufacturing tsm add party deliver better expect fourth quarter result guide strong sale growth general electric ge ceo john flannery say mull breakup separate business industrial giant announce take charge fourth quarter legacy insurance business double earlier guidance charge relate old long term care portfolio ge finance arm pay shore reserve raise worry ge industrial business have prop ge capital cash point flannery update investor portfolio review spring activist hedge fund trian fund management reportedly be push ge breakup ge share tumble lowest level more year investor question last original dow component have much value gm gm expect earning be largely line expect result high end range largest carmaker expect profit rise shift lineup more profitable next gen suvs truck analyst have expect ep decline ford go other way forecasting earning share estimate expect ep dip ford say monday invest electric vehicle next year more double earlier target gm share fall ford plunge recent buy point charle schwab schw earning share revenue rise meeting view new retail brokerage account jump vs year earlier help total account grow smaller online brokerage interactive broker ibkr see earning spike more revenue jump beating customer account grow total daily trade share schwab rise fraction week interactive fall unitedhealth group unh help spark dow run breaking record high easily clear earning estimate detail impact tax reform unitedhealth earning jump share revenue growth nation largest insurer say plan use tax windfall boost investment unitedhealth expect benefit tax cut go bottom line project ep range profit growth other health insurer rally new high unitedhealth strong report airbus eadsy have order last year beating boee ba sixth straight year european aerospace giant also keep make superjumbo emirate airline make order list price ceo tom ender be critical brexit president trump america first policy say brexit be more devastate airbus business boee announce joint venture auto car seat maker adient adnt build seat jet ease congestion zodiac aerospace have delay plane delivery bitcoin fall well wednesday rebound friday morning south korean finance minister kim yeon spook cryptocurrency market say ban trading digital currency be live option bitconnect shutter lend service exchange platform central bank excessive risk bitcoin company be embrace cryptocurrency ibm ibm announce blockchain joint venture danish shipping company maersk goldman sachs gs top ep revenue view large fix income desk see revenue drop once again rival bank america have mixed result morgan stanley ms citigroup result beat bitcoin value continue shrink week goldman cfo martin chavez say be respond client interest cryptocurrency exercise extreme prudence caution do not say anything bank have already say clear bitcoin future develop crypto trading platform own bofa ceo brian say customer be careful cryptocurrency juno therapeutic juno stock rocket wednesday report longtime partner celgene celg be talk acquire celgene juno be partner develop car drug rivale like gilead science gild recently buy kite pharma novartis nvs celgene blockbuster face multiple myeloma drug revlimid go patent bluebird bio blue car developer partner celgene rise wednesday dow stock merck surge tuesday release result trial immuno oncology drug keytruda chemotherapy advanced lung cancer well ahead expectation october merck have delay release phase trial merck regimen significantly improve overall survival progression free survival first treatment vs chemotherapy alone roche rhhby bristol myer squibb bmy astrazeneca azn have rival drug retreat tuesday atlassian team top fiscal earning revenue estimate collaboration software maker forecast current quarter profit cent share revenue vs consensus estimate cent analyst say light guidance be due annual salary increase higher payroll taxe jeffery hike price target expectation better future cash flow growth share have jump buy zone earlier week tumble just entry point initial jobless claim fall year low labor market continue tighten industrial production jump december manufacturing output rise just meanwhile new york fed empire state manufacturing index dip january philly fed gauge set month low lead new order housing start tumble december permit be strong homebuilder confidence remain year high month aluminum giant profit swell share revenue rise analyst have expect share revenue alcoa aa say see global aluminum demand growth share dove wynn resort wynn la vegas sand lvs mgm resort mgm melco resort entertainment mlco have be climb bernstein analyst predict year year gross gamble revenue gain macau january be best growth july macau gaming revenue take unexpected hit december thank vip streak revenue still rise breaking year period annual decline government crackdown corruption rail operator csx top earning miss sale report be first december death ceo hunter harrison veteran railroad executive know rein cost turn csx rival csx say performance continue strengthen build schedule railroad model launch harrison kansa city southern ksu miss ep view canadian pacific railway cp top profit revenue csx kansa city southern share fall canadian pacific rise sociedad química minera chile sqm reach deal chile let expand lithium production prospect more supply lithium stock tumble sqm fall albemarle alb fmc corp fmc global lithium battery tech etf lit american express axp suspend buyback program first half year asset repatriation tax gop new tax bill dent fourth quarter profit capital amex top profit revenue estimate amex fall friday close day line ibm ibm revenue rise vs year earlier snap quarter streak flat decline revenue ibm undergo major overhaul top view ibm share fall friday follow big gain earlier week amazon com amzn raise monthly prime membership exist monthly prime member face new rate feb annual prime membership be still
95,CELG,franchise be safe large cap biotechs be feel pressure food drug administration speed approval rival brand generic medicine analyst say monday theme be continuation leerink analyst geoffrey porge say note client record number drug approval large cap sector fall favor investor name more punish concentrated product portfolio loom brand generic competitor say head management confidence be low revenue trajectory high profile product face slowdown courtesy payer competitive pressure porge doesn see uncertainty lift possibly not ever competitive pressure slug like celgene celg gilead science gild celgene be feel pain inflammation unit mount competition eli lilly lly novartis nvs gilead see rival hepatitis drug sale abbvie abbv early next year porge expect guidance lion share large cap biotechs be conservative most stock move guidance come alexion pharmaceutical alxn gilead predict alexion be work drug dub alxn treat pair rare blood disease also undergo restructure meanwhile gilead hepatitis franchise again come microscope even attempt pivot further hiv drug bictegravir believe be share value gilead stock hepatitis stock price move hepatitis revenue guidance meaningfully differ consensus estimate porge say ibd take small cap biotechs perform well third quarter large cap suffer mount competitive concern see translate stock price visit industry snapshot note abbvie plan hepatitis product be likely hurt gilead stock abbvie recently launch mavyret treat genotype hepatitis abbvie likely provide guidance fourth quarter call ahead gilead porge expect sale outlook celgene alexion vertex pharmaceutical vrtx gilead amgen amgn abbvie miss analyst estimate biogen biib provide outlook encompass analyst view say later year large cap universe face political pressure porge predict midyear congressional midterm election be underway campaign be likely renew focus pharmaceutical company pricing policy say continue favor stock company be structural demand growth story product protected commercial scientific clinical legal barrier entry top pick be vertex alexion leerink analyst michael schmidt peg clovis oncology clvs puma biotechnology pbyi top pick small midsize biotechs focuse treat cancer group stock have outperformed broader biotech market thus far schmidt write note client dynamic be set continue favorable regulatory environment large cap expand portfolio acquisition incyte incy seattle generic sgen exelixis exel clovis agio pharmaceutical agio puma array biopharma arry be set launch key product count group set unveil pivotal trial result pending regulatory decision total firm emerge technology remain interest car therapy train patient immune cell fight cancer precision oncology have strong success immuno oncology combination cancer vaccine certain antibody have only be modest think next generation antibody drug conjugate be re emerge area interest represent clinically validate category significant room upside schmidt say antibody drug conjugate be antibody link cell kill agent antibody bound specific mark surface cancer cell immunogen imgn mersana therapeutic mrsn seattle be work area latter furthest say related big pharma biotech company be gird pricing knife fight teva restructure plan case be here do generic drug maker face pricing issue other pharmas don
96,CELG,juno therapeutic juno be now cheapest player now develop car cancer medication analyst say wednesday downgrade rival bluebird bio blue be work car therapy patient immune cell be extract taught fight cancer then reintroduce body juno bluebird have strong datum american society hematology conference atlanta juno datum drug jcar be just incremental maxim analyst jason mccarthy say note client jcar be test patient aggressive form hodgkin lymphoma response rate be positive believe expectation be see more datum more patient say share juno lose day follow presentation time juno see market cap drop nearly wednesday stock be value meanwhile bluebird stock pop nearly monday help valuation rise nearly almost wednesday market cap be close close bell stock market today bluebird sank finish juno climb end regular trading session mccarthy downgrade bluebird hold rating keep price target stock reiterate buy rating price target juno juno now have best value space view kite acquire bluebird now almost juno seem cheap call market capitalization company revenue cheap say ibd take presentation american society hematology prompt volatility biotech space week rocket other fall hard head ibd industry theme closer look week winner loser company have north cash manufacturing capability drug pipeline celgene celg partner mccarthy say catalyst include more datum jcar other car drug include pivotal trial bluebird remain significant player car gene therapy isn likely continue see spike valuation mccarthy say too be partner celgene mccarthy model already assume firm see success sickle cell disease multiple myeloma drug support price target additional news drug isn expect spring factor additional market share success region china japan don believe ash datum impressive justify change time say related biotech stock rocket human trial new cancer drugwhy biotech stock be defy hematology related pitfallwhy gilead have greatest ever hiv drug launch
97,CELG,index other major average hit record high wave earning weaker dollar greenback rebound somewhat netflix nflx sky-rocket blowout subscriber growth bullish outlook celgene celg buy juno therapeutic juno intel intc surge earning outlook texas instrument txn other top chip fail impress quarterly financial apple aapl continue lag grow chorus concern regard iphone sale production airline stock plunge unite airline ual say expand rapidly set stage renew price war index dow industrial nasdaq rally solidly hit fresh record high earning season heated fall dollar have act tailwind multinational stock profit rebound year lows thursday president trump say expect stronger greenback netflix nflx be big earning winner intel intc also do texas instrument txn lam research lrcx be several lead chip stock struggle earning airline stock plunge unite airline ual apple aapl iphone related stock sell several analyst cite evidence weaker iphone demand share rocket record high netflix nflx add stream subscriber worldwide crush fourth quarter target internet tv stream giant end total stream subscriber analyst predict netflix subscriber gain come netflix implement price hike service plan europe netflix credit hit original content such tv series stranger thing crown movie bright subscriber gain period march quarter netflix be predict add net new subscriber chipmaker intel intc maxim integrate product mxim stm xilinx xlnx beat december quarter target get mixed reviews investor texas instrument txn post line result share be punish sector continue wrestle concern chip cycle have ebb top chip gear maker lam research lrcx kla tencor klac beat view sell news meanwhile xilinx joined nvidia nvda amd amd benefit sale high performance chip mining bitcoin other cryptocurrency related intel beat fourth quarter target offer cheery outlookbiotech merger heated celgene celg agree pay car drug developer juno therapeutic juno didn already own sanofi sny reach deal biogen biib hemophilia spinoff bioverativ bivv celgene acquisition come prepare lose exclusivity cancer drug revlimid juno rival gilead science gild novartis nvs make car drug treat blood cancer sanofi deal follow fail merger early wednesday novartis nvs report core earning share sale respective constant currency basis easily beating consensus thursday biogen biib report sale grow top consensus adjust earning grow be short also thursday celgene beat lower analyst view abbvie abbv friday top expectation adjust profit sale climb sale unite airline ual send airline stock tailspin carrier tell analyst plan expand flight coverage investor fear move do part regain relevance smaller city unite once abandon risk more competition cheaper fare help passenger threaten profit american airline aal earning call signale wouldn change profit growth target base unite ambition now southwest airline luv jetblue jblu alaska air alk also report general electric ge miss earning disclose sec probe core unit do well ge keep outlook industrial member dow industrial caterpillar cat mmm unite technology utx report strong earning guidance insurer traveler trv consumer product giant procter gamble pg also beat earning view verizon vz miss ep top revenue johnson johnson jnj top view fall patent ruling vs blockbuster arthritis fighter remicade president trump slap tariff import large washing machine part solar panel tax washing machine decrease then expire year duty solar cell module phase year solar technology provider suniva solarworld charge china be provide unfair subsidy financing solar producer whirlpool whr complain korean maker be dump washing machine excessively low price whirlpool also report quarterly earning rally first solar fslr initially pop close less china base daqo new energy dq lose crude top barrel brent edge briefly oil inventory continue drop oilfield service provider halliburton hal crushed quarterly forecast international growth outpace domestic growth share shot clear buy point baker hughe bhge edge past earning estimate be upbeat spending customer share fall nearly market price possibility ge fully spin business northrop grumman noc raytheon rtn general dynamic gd top profit forecast raytheon general dynamic miss revenue northrop give strong guidance lift dividend raytheon gd say order backlog be strong defense firm surge record high lockheed martin lmt boee ba report next week steel dynamic stld earning rise top view modestly sale climb rank company ibd steel producer industry group say be shape be good year thank more moderate inventory level improvement global demand pricing incremental investment drive tax cut specialty steel producer allegheny technology atus nearly double profit estimate revenue grow fuel high performance material jet engine freeport mcmoran fcx benefit higher copper price boost earning ahead estimate revenue grow negotiation indonesia ownership massive grasberg mine be progress haven erased uncertainty company outlook casino operator wynn resort wynn la vegas sand lvs put result beat top bottom line help rebound macau world largest gaming market sand ceo sheldon adelson cite acceleration mass gaming market chinese administrative region only area nation gamble be legal wynn share plunge friday erase nearly weekly gain report allegation serious sexual misconduct ceo steve wynn ford motor see ep climb cent revenue grow analyst have expect ep cent sale accord zack investment research ford be buy mobility startup autonomic transloc share extend sell prior week ford outlook disappoint investor fiat chrysler fcau deliver strong result generally affirm ambitious financial target send share fresh week high new oriental education edu logged ep growth short view sale gain narrowly beat fiscal estimate student enrollment grow china base school education provider offer guide sale view higher share tumble recoup loss end week tal education tal meanwhile surge nearly thursday retake day ep jump revenue growth tal enrollment swell td ameritrade amtd trade financial etfc beat top bottom line fiscal earning share jump td ameritrade revenue expand see full year earning exclude item vs expectation td ameritrade also say allow customer buy sell certain etfs day week trade report ep revenue ll also acquire retail brokerage account capital financial cof asset share online broker fall modestly week millennial focuse free investing app robinhood let person buy sell bitcoin other cryptocurrency commission intuitive surgical isrg report adjust income share sale rise respective metric top expectation robot surgery gear maker give cautious guidance homebuilder nvr nvr miss earning sale view share tumble crash week line first time more year huge volume doj subpoena mortgage unit lennar len bigger expect new home sale decline other homebuilder also suffer notable decline
98,CELG,biogen biib be safe large cap biotech own analyst say thursday firm issue bullish full year guidance top fourth quarter sale forecast adjust profit lag expectation share be only slightly still investor have yet fully grasp future competitive dynamic surround biogen multiple sclerosis franchise ionis pharmaceutical ion partner spinal muscular atrophy drug spinraza rbc analyst brian abraham say note client overall nothing quarter see change perception biogen safe large cap name own do believe potential longer term ms sma competition be say fourth quarter biogen bring total sale adjust profit share respective year year basis analyst have see revenue adjust earning share piper jaffray analyst christopher raymond blame earning miss cent impact related impairment charge biogen have take multiple sclerosis drug zinbryta ibd take biogen have high ibd composite rating best possible mean perform top stock term key growth metric still isn rank first biotech group see stock do visit ibd stock checkup year biogen guide sale adjust profit share metric easily top consensus analyst poll zack investment research sale adjust earning share guidance suggest biogen have room additional growth rbc abraham say believe drive continue perception biogen lower risk large cap name say margin guidance be generally line expectation tax rate be slightly higher have modeled close bell stock market today biogen gain close total spinraza sale beat consensus view accord analyst instinet leerink sale be just expectation instinet analyst christopher marai say report outside spinraza bring sale top street view marai say international market lion share growth come germany turkey japan rbc abraham see term growth spinraza patient first go spinraza receive load dose maintenance dose administer month follow meaning first year treatment patient receive dose spinraza be approve december many patient be now receive maintenance dose month sale continue show lower growth potential patient convert load maintenance dose new patient start decline quarter quarter dynamic believe still be say biogen ionis be also face potential competitor future avexis avxs be work gene therapy know avxs treat type spinal muscular atrophy biogen multiple sclerosis portfolio bring combine sale higher consensus view leerink analyst geoffrey porge write note client biggest outlier be tysabri bring sale beating view tecfidera biogen biggest multiple sclerosis drug grow beat analyst collective view porge say number be somewhat temper fact fourth quarter be help inventory build piper jaffray raymond say so far biogen multiple sclerosis franchise isn suffering launch roche rhhby ocrevus rbc abraham say ocrevus be unique approve treat relapse primary progressive form multiple sclerosis most drug be just approve treat relapse form future porge expect competitive launch pressure biogen multiple sclerosis unit novartis nvs lose exclusivity gilenya meaning generic come play celgene celg be also expect have new drug ozanimod related valeant climb month make sense abbott spike record top quarterly top high crush fourth quarter expectation
99,CELG,here investing action plan thursday need know investor come day earning fire hose be full blast tomorrow report intel intc caterpillar cat biogen biib celgene celg starbucks sbux big name come quarterly result top defense contractor
100,CELG,stock market be mixed afternoon trading wednesday early gain fade quickly nasdaq composite outperformed be only rise intraday be dow jone industrial average slip volume nyse nasdaq be tracking close tuesday level fang name amazon com amzn hit new high rise company late tuesday announce plan acquire california base video doorbell maker home security play ring elsewhere baidu bidu add company announce plan spin iqiyi video stream service china similar netflix nflx separately music stream service spotify file ipo today raise much accord reuter stock market today earning report dominate headline volume be heavy square sq share rise more catalyst be better expect earning sale full year guidance be mostly line expectation square be try clear flaw cup handle base buy point base be flaw handle area correct more ibd research have show proper handle shouldn pull back more meanwhile etsy etsy soar also strong earning stock gap entry open keep mind buy stock gap price just try buy close open price possible etsy operate commerce focuse handmade vintage item goldman sachs bring company public april share track top stock market trend free ibd newslettersin retail space tjx co tjx gap alternate entry strong sale news raise dividend new share buyback program share pop nearly tjx be parent maxx marshall homegood ibd svb financial sivb be top gainer be consolidate gain week get support week move average downside celgene celg tank year low food drug administration reject company application ozanimod multiple sclerosis treatment related celgene gamble ozanimod didn pay offupbeat earning result spark potential leader new high amazon ring deal threaten security competitorshere square see bitcoin fitting company future
101,CELG,stock market be mixed afternoon trading wednesday early gain fade quickly nasdaq composite outperformed be only rise intraday be dow jone industrial average slip volume nyse nasdaq be tracking close tuesday level fang name amazon com amzn hit new high rise company late tuesday announce plan acquire california base video doorbell maker home security play ring elsewhere baidu bidu add company announce plan spin iqiyi video stream service china similar netflix nflx separately music stream service spotify file ipo today raise much accord reuter stock market today earning report dominate headline volume be heavy square sq share rise more catalyst be better expect earning sale full year guidance be mostly line expectation square be try clear flaw cup handle base buy point base be flaw handle area correct more ibd research have show proper handle shouldn pull back more meanwhile etsy etsy soar also strong earning stock gap entry open keep mind buy stock gap price just try buy close open price possible etsy operate commerce focuse handmade vintage item goldman sachs bring company public april share track top stock market trend free ibd newslettersin retail space tjx co tjx gap alternate entry strong sale news raise dividend new share buyback program share pop nearly tjx be parent maxx marshall homegood ibd svb financial sivb be top gainer be consolidate gain week get support week move average downside celgene celg tank year low food drug administration reject company application ozanimod multiple sclerosis treatment related celgene gamble ozanimod didn pay offupbeat earning result spark potential leader new high amazon ring deal threaten security competitorshere square see bitcoin fitting company future
102,CELG,stock be once again strong start wednesday early rally tuesday erode bearish reversal dow jone industrial average stake early lead just level nasdaq composite add tuesday loss market due breather federal lawmaker wrestle fashion spending extension keep government operate friday night budget deadline wary investor be also watch weak spot wednesday early gain apple aapl decline further buy point general electric ge continue weakness goldman sachs gs early loss follow fourth quarter report raise red flag open gain early flag come ford motor slump nearly company revise earning outlook analyst target late tuesday say restructure effort take longer initially expect ibm ibm bolt higher lead early action dow barclay raise stock overweight rating underweight ibm announce tuesday plan launch blockchain joint venture dutch shipping giant moller maersk group mean tracking manage company shipping container entire industry ibm share be august low climb right side possible month base pattern apple slump downgrade neutral buy longbow research stock slunk buy point tuesday have be fight decisively clear mark mid december juno therapeutic juno ahead open news report say company be discuss possible takeover celgene celg company have partner number drug include car cancer treatment report say deal be reach come week celgene share dip premarket action earning news bank america bac rise charle schwab schw slip pinnacle financial partner pnfp be unchanged report quarterly result goldman sachs slip report forecast earning smaller expect revenue decline currency commodity fix income trading revenue sunk year level revenue equity trading be goldman remain buy range late tuesday buy point cup handle base bancorp usb trim early gain fraction minneapoli base bank fourth quarter performance be stronger expect boost surge retail lease revenue stock end tuesday very top buy range cup handle buy point chip equipment maker asml hold asml power nearly netherlands base outfit report strong fourth quarter revenue earning beat management first quarter revenue guidance be consensus expectation stock briefly clear cup base buy point strong trade tuesday close fraction entry base be second stage pattern wednesday premarket move imply start bell not premarket move carry regular trade bitcoin continue sell trading just vs late tuesday level accord coinbase cryptocurrency blockchain related stock be mild pressure industrial production rise december accord federal reserve be slip november more double consensus estimate increase factory capacity utilization surge vs november estimate uptick january builder confidence index energy information administration report weekly oil inventory datum fed beige book report et overseas china market post modest gain just enough hong kong hang seng index top october record move new high japan tokyo nikkei dip europe market be negative turf frankfurt dax london ftse more afternoon trade other important market news wednesday stock reverse lower pullback now seem more likelystock future rally back top chip stock blast past buy pointanother day more top stock buy pointsfalse leader apple lose buy point iphone chip stock pop
103,CELG,stock fall new high tuesday apple aapl microsoft msft reversed lower bitcoin sank further spdr spy slide powershare qqq trust qqq slip spdr dow jone industrial average dium be fractionally lower small cap get slam ishare russell iwm tumble apple clear flat base entry friday average volume iphone maker be still buy point relative strength have lag remain consolidation lows microsoft rs line have be flat recent advance record high sector fund real estate healthcare semiconductor lead upside stock market today health care select sector spdr xlv rise record high component stock merck lead dow industrial pop retake day move average marked best level nearly month drugmaker relative strength line be turn rs rating be weak result show cocktail merck keytruda chemotherapy drug stop lung cancer advance extend patient life ishare nasdaq biotechnology ibb be featured later column reversed lower build right side shallow cup handle buy point energy retail home construction lag west texas intermediate crude price slip barrel spdr gold share gld ishare iau hold small gain rise month high friday gold future edge higher ounce bitcoin extend drop accord coindesk earlier high bitcoin ripple ethereum be get hit continue talk south korea potential cryptocurrency ban bitcoin investment trust gbtc be find support day line dec intraday peak large cap growth fund hold apple microsoft be solid start year continue stay ahead broader market top performer base year return jan be ishare edge msci usa momentum factor mtum fund year date gain put third place base measure be jan accord morningstar direct mtum top holding make asset be jpmorgan jpm microsoft apple bank america bac boee ba apple soar last year break past flat base entry friday first clear buy point dec ahead pullback day move average microsoft advanced friday price target upgrade keybanc capital market share be record high powershare qqq trust qqq track tech heavy nasdaq index score year ytd return respectively year old fund count apple microsoft amazon facebook alphabet top holding have amassed nearly asset third place go ishare russell top growth iwy have gather asset september launch iwy hold same top name qqq be less top heavy top account iwy total asset vs qqq etfs have low expense ratio mtum qqq iwy also earn star rating morningstar indicate well fund return have compensate investor amount risk incur rating range star best performer base risk adjust return relative similar fund receive star fund be trading time high be extend ideal buy point fact other etfs accompany table be also record high not too surprising give re now ninth year bull market ibd take make money catch etf uptrend require knowledge read chart learn ibd university so let take look etf not list big cap category be set new base ishare nasdaq biotech fund be shape right side shallow cup handle base potential buy point share advanced june shallow base oct intraday high fund track nasdaq biotechnology index mark anniversary next month biotech represent biggest sector weight asset pharmaceutical life science tool service smaller health care related position make rest top holding jan be gilead science gild celgene celg amgen amgn biogen biib regeneron pharmaceutical regn top stock account nearly total asset most have outperformed broader market so far year gilead amgen biogen have gain respectively vs return ibb year return slightly lag gain etf average annual return past year lag benchmark index lead past year ibb carry expense ratio friday pick powershare low volatility portfolio splv remain buy zone jan rebound day line related apple microsoft fuel dow record bitcoin rebound last apple rise bitcoin dife time buy nvidia ai stock china hit stock buffett vs bitcoin new high cannabis
104,CELG,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
105,CELG,index other major average hit record high energy stock continue lead nvidia nvda rally ce news intel intc continue slump ongoing chip flaw jpmorgan chase jpm lead bank earning rise bond yield buoy financial delta air line dal earning guidance lift airline stock homebuilder lennar len kb home kbh soar earning bitcoin tumble south korea mulled crackdown nasdaq do edge lower wednesday first decline report china slow halt treasury buy major average rise sharply week hit record high oil group lead thank soar crude price delta air line fuel big boost airline lennar kb home show builder remain lead group many big retailer rally solid holiday sale intel many chip equipment stock struggle alphabet googl unit google amazon com amzn battle spotlight ce tech show la vegas google assistant be build wide range consumer device include tvs headphone third party home speaker also roll car feature android auto software amazon echo device remain connect home market leader estimate share amazon say have create new division call alexa voice service kohler strut smart mirror used alexa play music report resurface ce amazon begin testing ad alexa autonomous vehicle also be ce spotlight chipmaker nvidia nvda announce pact ride hail service uber well expand ty volkswagen vlkay baidu bidu nvidia cite customer feedback say self drive car begin be deploy wide scale uber rival lyft also be active disclose partnership intel say vehicle bmw nissan nsany vw leverage mobileye technology build high definition map autonomous vehicle intel buy mobileye last year intel intc ceo brian ce keynote speech address chip security flaw rattle investor early january frame chip problem industrywide issue say progress have be make patch vulnerability meanwhile microsoft report setback effort fix security issue suspend issue patch guard threat user pcs advanced micro device amd chip complain software update freeze computer banking giant jpmorgan chase pnc financial service pnc well fargo wfc top fourth quarter earning view well revenue be estimate jpmorgan report big drop trading revenue include huge loss single equity trade client asset management giant blackrock blk earning rise top view asset top target tgt jwn kohl kss report strong november december holiday sale follow macy penney jcp prior week share target kohl penney enjoy double digit weekly gain macy leap nearly american eagle aeo urban outfitter urbn express expr add string generally weak holiday report specialty apparel retailer long ailing sear holding shld say ll close more additional location holiday sale be weak wal mart wmt raise base wage hour offer bonus employee more employer hike wage follow trump tax cut labor market continue tighten sam club location be close already affect thousand worker wal mart warehouse membership chain crude future rise barrel hit highest level late brent future break first time december domestic production fall barrel day last week bpd prior week energy information administration say inventory fall barrel gasoline stockpile rise barrel analyst poll global platt have forecast barrel drop crude barrel increase gasoline supply eia raise global crude demand growth outlook barrel day short term energy outlook report delta air line dal report better expect fourth quarter earning sharply raise ep outlook cite strong demand business fare airline stock soar report delta move buy zone american airline aal breaking bitcoin price fall sharply south korea moved ban cryptocurrency trading billionaire investor warren buffett say cryptocurrency come bad end even jpmorgan ceo jamie dimon say regret call bitcoin fraud moneygram mgi rally least briefly announce pilot program test used ripple digital currency network transfer fund commercial jet delivery rise last year boee ba ramp production start delivery new max total delivery climb delivery dreamliner dip boee have net order year value list price customer boee emphasize importance asia record airplane backlog year production be customer asia pacific region boee share shot fresh record high ibd tipp economic optimism index climb solidly optimistic territory hit month high january close decade high february reading be positive subindex american view personal financial outlook hit year high tax cut loftier stock price yet view government policy soured disaffection democrat independent swamp republican giddiness lennar len report surprise earning decline only due shift timing transaction take advantage tax cut revenue rise double expectation strong economy tight supply fast recovery recent hurricane lennar be set become nation largest homebuilder calatlantic acquisition close next month say order backlog rise kb home more double year profit cent share order backlog grow lennar kb home share soar spacex say falcon rocket do everything correctly sunday spy satellite make northrop grumman noc be reportedly lose launch launch have be delay november so spacex analyze protective nose cone datum launch northrop decline comment cite classify nature zuma mission higher usual secrecy surround zuma satellite little be know be make government customer be suppose be launch low earth orbit meanwhile spacex delay plan test falcon heavy most powerful rocket apollo program saturn report surface disk drive company seagate technology stx make early investment cryptocurrency call ripple have recently soar value wave venture capital investment be pour blockchain technology startup ripple lab be founder used ripple protocol move money internationally seagate be interested used supply chain management seagate also guide fiscal second quarter revenue forecast higher seagate shot just clear buy point facebook fb announce change news feed promote post friend family more expense publisher business goal be make social interaction more meaningful internet giant say say engagement fall facebook share fall friday drop recent buy point celgene celg buy cancer drugmaker impact biomedicine only upfront celgene preliminary earning be slightly view biotech keep recently lower long term outlook tesla tsla kick production long await electricity produce shingle elon musk say transform rooftop solar industry manufacturing textured glass tile begin last month tesla gigafactory buffalo sprout farmer market sfm see full year ep slightly previously announce guidance cent addition sale growth comp year zack say consensus be cent ep sale growth share natural food grocer rise nearly clear buy point akamai technology akam be explore strategic alternative include sale bloomberg report cite unnamed source networking cloud solution provider have be pressure hedge fund elliott management own maximize shareholder value share spiked news then turn lower akamai biggest customer include apple aapl amazon amzn be bypass company diy route
106,CELG,glycomimetic glyc defy hematology biotech pitfall tuesday breaking strong cancer drug datum share global blood therapeutic gbt spark therapeutic once trend opposite direction stock market today glycomimetic rocket much rushed past buy point consolidation share end day nearly follow presentation key blood disease conference other tumble presentation american society hematology conference atlanta global blood plummet close share spark continue day tumble fall finish juno therapeutic juno topple nearly agio pharmaceutical agio lose seattle genetic sgen slide early tuesday glycomimetic unveil result drug know gmi group patient acute myeloid leukemia type cancer bone marrow make abnormal white blood cell red blood cell platelet ibd take several biotech stock make impressive gain monday follow presentation american society hematology head ibd industry theme closer look stock pop topple patient cancer relapse hadn respond other therapy treatment gmi result remission rate median overall survival be month vs month historical treatment median duration remission be month older patient newly diagnosed disease clinical remission rate be median overall survival be month vs month chemotherapy alone traditional therapy median duration remission be month group patient gmi be well tolerate obvious incremental toxicity observed late monday global blood unveil datum study drug voxelotor patient severe sickle cell disease hospitalization pain associate disease fall week voxelotor treatment vs week therapy number transfusion decrease week treatment compare week begin voxelotor patient receive transfusion voxelotor therapy receive transfusion treatment patient study die have co morbidity advanced organ injury treatment voxelotor treat physician don believe voxelotor contribute death nomura analyst christopher marai note drug be well tolerate compliance be high symptom return short period discontinuation expect voxelotor fill unmet need elderly sickle cell disease patient patient death underscore severity sickle cell disease say note client patient previously respond well therapy reduction transfusion hospitalization substantial quality life improvement derive drug say spark continue day plunge close monday present datum hemophilia gene therapy drug show major reduction bleed rate show smaller expect increase key clot protein investor compare spark drug know spk rival therapy biomarin pharmaceutical bmrn spk reduce bleed first hemophilia patient treat demonstrated mixed factor viii level factor viii be clot protein miss hemophilia patient biomarin drug reduce bleed event patient dose biomarin drug reach normal factor viii level week group patient be threshold week spark trial patient have unexplained spike factor viii level week patient high dose spk require steroid have lower factor viii level fourth patient lower dose continue have low factor viii level juno celgene celg present strong result drug know jcar patient aggressive form hodgkin lymphoma drug be car therapy patient own immune cell be reprogram fight cancer cell phase trial call transcend patient respond treatment sign cancer disappear patient month cancer disappear completely half core group patient month juno say press release dose core group patient achieve complete response month stay month group still response month remain datum cutoff only patient experience adverse event know cytokine release syndrome characterize flulike symptom experience neurotoxicity be common side effect associate car therapy leerink analyst michael schmidt say report juno present datum show response variety patient refute notion strong effectiveness achieve transcend have be result cherry pick easy patient juno be trail novartis nvs gilead science gild already have car therapy approve related do gilead kite acquisition offer new buy opportunity biotech industry small innovator outflank big cap blockbuster drug patent cliff loomsneurocrine exelixis juno stock rocket crush view
107,CELG,couple biotechnology stock vault double digit gain monday report clinical datum blood disorder medication industry conference pleased investor blueprint medicine bpmc bluebird bio blue add nearly fifth value atlanta base bluebird end day nearly report improvement patient used lentiglobin gene therapy treat severe sickle cell disease scd well transfusion dependent beta thaslassemia tdt be blood disorder bluebird say monday patient study testing therapy show more improvement hemoglobin level patient study continue experience notable clinical improvement dr marina cavazzana professor medicine paris descarte university primary investigator study say news release issue bluebird study suggest lentiglobin have potential be time therapy person scd tdt prompt goldman sachs analyst richter raise price target bluebird share richter also cite positive news bluebird bb now be test treat multiple myeloma share drop more hour deal company say issue new share news have side effect aid share celgene celg be bluebird news celgene be partner bluebird bb hurt share juno therapeutic juno release datum celgene hodgkin lymphoma treatment juno share plunge more close meanwhile blueprint jump nearly sunday report response rate control rate phase study drug avapritinib treat blood disorder advanced systemic mastocytosis disorder create uncontrolled number type white blood cell various organ lead damage dysfunction ibd take share bluebird blueprint gap monday result news bluebird emerge cup base end august hasn look back blueprint break early september have pretty much behaved same ibd relative strength rating be respectively possible be rank low stock crowd biotech field top sector be sucampo pharmaceutical scmp new clinical trial result avapritinib report american society hematology plenary scientific session represent exciting milestone systemic mastocytosis community datum show remarkably high response rate favorable tolerability profile suggest avapritinib have potential transform treatment devastate rare disease dr daniel deangelo associate professor medicine harvard medical school investigator trial say news release blueprint discuss result conference call monday biotech stock make big gain announcement hematology conference be biomarin pharmaceutical bmrn surge finish be reveal spark therapeutic once gene therapy hemophilia lag biomarin medication know currently valoctocogene roxaparvovec share spark plummet news fall spark experimental drug be know spk
108,CELG,day outperformance nasdaq composite monday be help part strength select biotech name several positive headline come american society hematology annual meeting market take news botch terrorist attack new york city stride dow jone industrial average
109,CELG,nasdaq composite be lead afternoon trading monday gain wall street look past attempt terrorist attack new york city dow jone industrial average stock apple aapl picked company confirm buy shazam popular song recognition app technically apple look solid get support week move average first time buy point dow jone industrial average rise add volume nyse nasdaq be tracking slightly lower friday level stock market today fiber optic coal mining solar oil gas related group outperformed food build retail related group underperform day federal reserve meeting start tomorrow decision interest rate be wednesday et accord cme group fedwatch tool market think chance fomc lift federal fund rate buyer come tesla tsla share rise nearly tesla have be struggle lately stock show positive action monday breaking trend line reclaim day move average meanwhile news golden globe nomination wasn much help netflix nflx share underperform fall level generally have be tough level stock conquer buy point be still play netflix be also work new flat base conventional entry bluebird blue partner celgene celg be winner biotech space bluebird report positive trial datum car therapy patient advanced multiple myeloma share bluebird soar celgene add nearly car drug be make used patient own extract immune system cell cell be reprogram seek destroy cancer cell
110,CELG,goldman sachs raise price target bluebird elsewhere nci build system ncs be latest example buy stock gap base nci break last week be pace third straight gain share be nearly rise nearly last week related fidelity give mutual fund manager more money investbitcoin cryptocurrency news trendsbiotech stock soar trial datum hematology conference
111,CELG,major market index turn positive nvidia nvda tesla tsla boost techs bitcoin other cryptocurrency sank powershare qqq trust qqq rise spdr spy gain spdr dow jone industrial average dium be fractionally higher small cap lead downside ishare core small cap ijr ishare russell iwm dip respectively biotech health care bank be biggest sector fund loser stock market today ishare nasdaq biotechnology ibb fall shape right side base top hold biogen biib sank celgene celg second biggest position give biogen report result jan utility semiconductor homebuilder outperformed vaneck vector semiconductor smh ishare phlx semiconductor soxx advanced respectively track fifth straight session etfs have regain day line ibd take important investor get feel just speculative digital money bitcoin be right now investing directly currency related exchange trade fund stock lead chip stock nvidia rise more break past cup base entry still buy range graphic chip designer announce uber self drive partner well new deal volkswagen vlkay baidu bidu apply material amat also pop needham upgrade chip equipment maker strong buy buy price target share regain day line tesla also have partnership nvidia surge retake day day line fast trade tesla ceo elon musk tweet weekend plan put old school drive roller skate rock restaurant electric car maker new supercharger location los angele gold fund be lower gold future bitcoin also fall digital currency lose accord coindesk early rise south korea announce launch probe curb speculation bitcoin investment trust gbtc gap fall more level ripple cryptocurrency see recent torrid rise slump accord coinmarketcap related seagate share soar report investment blockchain private industry ain see nothing yet
112,CELG,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
113,CELG,postelection year climb dow jone industrial surge market top stock do far better investor have search farther big return
114,CELG,deliver year rally more year follow big gain averaged more modest advance say money manager strategist still see plenty investment opportunity seem already be hand scarcely day new year dow have charge ahead process top first time ever best gain full year come overseas stock market value equity abroad click here timeline detailed chart remarkable stock market rotation big portfolio more foreign stock be expect take place economic uncertainty due brexit escalate tension russia vladimir putin china xi jinp not mention north korea nuclear threat big reason be prospect faster economic growth abroad cheaper valuation many foreign equity gdp growth likely continue strong china europe european central bank ecb president mario draghi say monetary stimulus continue least september special report personal finance action plan stock market economy look positive too investor be hearten incoming federal reserve chairman jerome powell re jazzed drum roll move president trump include tax reform open way oil drill arctic national wildlife refuge throttle back federal regulation withdraw paris climate accord many stock sharply year investment strategist fund manager expect more modest stock price gain return be more double big cap bogey average annual gain past year nasdaq composite index shot dow jone industrial gain align technology algn part nasdaq member ibd list top perform growth stock jump company be know computer assist design approach straighten tooth banking giant jpmorgan chase jpm key cog dow rise ibd market editor juan carlos arancibia analyze top perform stock separate article backdrop money pro say best opportunity lie stock abroad see good potential value oriented stock include cyclical stock performance swing economic condition stock be better bond once again say david joy chief market strategist broker financial advisor ameriprise financial amp international market better domestic include develop market eurozone not include japan joy cite reason foreign stock shine economic growth relative potential growth appear be stronger international market even be do well say central bank foreign geography be more accommodative federal reserve everyone know be raise interest rate third reason valuation stock group have grow expensive joy say other market be more attractively value so more upside potential stock overall joy add do think stock go higher ameriprise currently forecast hit level year end joseph davis vanguard global chief economist head investment strategy group say vanguard expect lowest return equity roughly decade group expect annual gain stock next year ameriprise forecast gdp growth excess inflation congress pass tax reform ameriprise be predict china pace remain eurozone economy grow vs interest rate ameriprise other expect fed continue raise rate be lid earning multiple corporation bring multiple joy say research firm action economic see fed fund rate end band june tax reform be wild card add incrementally earning growth economic growth joy say provide little tailwind stock joblessness drop end lowest rate ameriprise say unemployment rate be november david polak equity investment specialist capital group parent american fund see investment opportunity several geographic market asia remain lead site technology innovator say manufacturer logic chip be group innovator industry consolidation have left key player include taiwan semiconductor tsm california base intel intc year be taiwan semi intel be dominant polak say consolidation have left space more discipline lead more visibility earning more pricing power asia stock like be japan murata manufacturing ceramic capacitor be crucial component smartphone relatively inexpensive so manufacturer stuff phone impact margin much say capacitor be used apple iphone well samsung galaxy other android phone way invest growth element have bet phone do better polak say gaming like way japan nintendo ntdoy have diversify addressable market take intellectual property away just hardware polak say used have play game only hardware now available multiple device then tencent tcehy china lead provider messaging mobile gaming service tencent also own popular app polak key tencent trait be leadership china mobile payment service enable consumer use smartphone pay bill make online purchase peter bourbeau co manager clearbridge large cap growth sblyx see opportunity stock say time switch faang stock price run up have left less room rise clearbridge fund be track become ibd best mutual fund award winner outperform well trail year schlumberger slb benefit bottom energy stock bourbeau say oil gas service company have regain pricing power add slb currently generate incremental margin highest history be benefit onestim joint venture weatherford international wft pressure pump say slb be only global service company be used balance sheet invest customer health care stock bourbeau like alexion pharmaceutical alxn call leader ultrarare genetic disease treatment company recently clear deck new management refocuse research development profile alexion also receive additional approval lead compound soliris treat other malady solaris also be be test new way be administer financial service stock group like visa visa be make very good progress recent acquisition visa europe synergy client engagement say incremental margin be extremely strong visa continue innovate core debit credit portfolio well create new way integrate merchant cardholder big stock padded mutual fund recent gain faang stock amazon amzn be top holding so be microsoft msft rise year amazon continue execute plan disrupt adjacent vertical margin rich opportunity bourbeau say continue focus marketplace amazon web service aw prime company have huge opportunity outside focus country india be more hospitable western technology company still see large opportunity aw be early stage generational shift technology be create consume regard microsoft bourbeau say expect more same strong growth trend microsoft software maker help client move workload cloud azure cloud business be run rate sale grow double digit company continue focus partnership service provider compete technology departure strategy previous management celgene celg top hold be inexpensive stock say add celgene have strategy cope patent expiration flagship product cancer drug revlimid middle next decade biotechnology company have late stage clinical readout say cash continue build expect business development opportunity acquisition further bolster clinical pipeline more ibd coverage stock market forecast read prediction top stock tax reform impact tax bracket rateyou need much retirement saving age incomeai business be future holdsbefore buy bitcoin read
115,CELG,alexion pharmaceutical alxn pop tuesday vertex pharmaceutical vrtx be list top biotech stock pick hyper competition pricing pressure uncertain merger activity likely dominate year leerink analyst geoffrey porge peg vertex alexion leader rival struggle mount competition rely pricing hike sustain top line growth have strong management team attractive franchise garner takeover interest analysis lead believe best perform stock foreseeable future be participate category high barrier entry rely volume growth rather positive price contribution say note client close bell stock market today alexion climb finish vertex rise finish vertex share end alexion meanwhile broader biotech group wrapped year vertex be second best performer top biotechs market cap easily lead amgen amgn gilead science gild celgene celg end year respective flat alnylam pharmaceutical alny lead top rocket vertex have monopolized cystic fibrosis category drug know kalydeco orkambi porge say nearest competitor galapago glpg be time disadvantage product haven show same effectiveness vertex lucrative commercial opportunity cystic fibrosis present high barrier entry therapeutic indication have preclude emergence clear viable threat vertex cystic fibrosis franchise say ibd take median tenure chief executive large cap biotechs fall just year plunge year have impact merger acquisition analyst say last week head ibd industry theme closer look first quarter vertex be likely gain approval combination drug know tezacaftor ivacaftor treat cystic fibrosis patient gain traction patient discontinue treatment orkambi due tolerability year also be key vertex triple pill regimen treat cystic fibrosis say vertex be plan begin pivotal trial first half most analyst expect triple pill gain approval alexion meanwhile have see revenue growth drug know soliris past year treatment pair blood disorder increase sale be mostly due volume increase little price contribution porge say october food drug administration approve soliris treat muscle disease help continue sale trend say alexion be also work follow drug know alxn favorable dose schedule potentially better effectiveness porge expect alxn prove superior soliris treat blood disease know paroxysmal nocturnal hemoglobinurium phase testing result high conversion rate alxn soliris likely approve catalyst also extend terminal cash flow horizon alexion key franchise mid mid patent alxn expire say further alexion say late tuesday board director agree work activist investor elliott management identify new board member november alexion say have search underway fill open board seat be look candidate range background skill expertise related vertex chief talk company year biotech stock feel lovewhy biotech see upside second quarter
116,CELG,biotech pharma stock dip monday senate pass version gop tax reform bill leave fate key research development tax credit air tax credit confusion be unintended consequence hour re addition corporate alternative minimum tax parallel system company pay low rate get fewer tax break senate plan tax credit longer be available company used alternative minimum tax system say joe panetta chief executive biocom advocate research life science firm panetta be unsure many biocom member use alternative minimum tax system say number biotech company group aren profitable therefore claim tax credit dow jone index dji close key biotech index go reverse ishare nasdaq index ibb lose spdr biotech index xbi dip proshare ultra nasdaq biotechnology etf bib dove meanwhile ibd company ethical drug industry group topple collective company biotech group broadly fall stock market today still panetta say congress be still long way final bill expect side effect be right side final draft go president desk congress be pressure top have do christmas ibd take large cap biotechs see number drug slow third quarter smaller cap benefit sale outpaced consensus view head industry snapshot breakdown group performance post earning analyst observer say not necessarily tax credit confusion alone cause pain biotech sector also matter call orphan drug tax credit incentivize development treatment especially rare disease november house republication propose eliminate credit entirely senate committee propose reduce credit current biocom panetta be hopeful house senate find middle ground matter orphan drug tax benefit be boon patient biotech company say senator orrin hatch have be really adamant carry lot weight credit suisse analyst alethia young note repatriation be forefront investor mind heavy hitter amgen amgn celgene celg have billion cash store overseas bring back lower tax rate consider acquisition merger acquisition be miss biotech space young tell investor business daily key product be slow investor be look biotechs deliver new strategy growth company amgen example have cash overseas say seem strategy potentially be little bit different bring back unite state have bigger opportunity asset acquire related amazon reportedly talk mylan novartis pharma biotech launch record high cancer test approvalamgen regeneron prep battle cholesterol drug
117,CELG,gilead science gild catch upgrade thursday follow kite pharma buyout likelihood new car cancer medication allow diversify away mature hepatitis franchise maxim group analyst jason mccarthy upgrade gilead buy rating hold have price target stock close bell stock market today advanced finish car drug be make used patient own extract immune system cell be reprogram seek destroy cancer cell be reintroduce patient due nature take week manufacture drug visit kite manufacturing facility china left mccarthy impressed entire process take day gilead kite car drug kite facility el segundo calif handle patient treatment year program call kite konnect give healthcare provider patient gilead access real time tracking car process production be now semi automate gilead have plan automate production future increase capacity decrease cost be impressed left clear notion gilead kite overcome manufacturing challenge commercialize globally especially china new innovative therapy say note client now time buy gilead mccarthy say investor get access recently buy car drug free gilead hepatitis franchise gilead hepatitis drug set record be strongest drug launch history ibd take novartis be first cross finish line car therapy other be tail head ibd industry theme breakdown grow car market competitor be set turn market head more recent year hepatitis unit have struggle market mature high cure rate now market be enter fourth year comparison be get easier mccarthy say important be not lose sight fact gilead have free cash flow last quarter say buy car help diversify gilead gilead finished acquire kite october just food drug administration approve kite drug know yescarta adult large cell lymphomas approval be also expect europe china japan mccarthy expect gilead generate more come year global presence late stage cell cancer further car therapy be now be integrate other form cancer treatment kite be first keep give say gilead isn alone car offer novartis nvs be first gain approval drug call kymriah approve treat form acute lymphoblastic leukemia patient age juno therapeutic juno bluebird bio blue be also partner celgene celg develop own car therapy related amgen have edge rival prevent celgene gilead pricing wo continue haunt biotech stocksdow stock merck topple withdraw keytruda application europe
118,CELG,celgene celg topple month low friday scrap trial crohn disease late stage failure throw cold water biotech effort treat inflammatory bowel disease xby close bell stock market today celgene plunge finish share hit low last see mid june decision terminate phase extension trial crohn disease follow interim analysis celgene also say win initiate phase trial testing drug mongersen crohn fate trial ulcerative colitis be air leerink analyst geoffrey porge say clear mongersen fail reproduce earlier efficiency larger international trial be safety imbalance interim analysis celgene say celgene acquire mongersen also know ged deal private irish company nogra pharma later buy immune metabolic biopharma player receptos hedge bet mongersen porge say thursday news throw cold water celgene inflammatory bowel disease business development strategy say suggest investor take advantage weakness stock much be temptation question value other investment company have make tend view particularly bad investment decision then inexperienced inflammation immunology team celgene write ibd take president donald trump sign executive order curb drug price day accord washington base expert head ibd industry theme closer look mean biotechs drugmaker still disappointment be likely cost celgene long term revenue value porge say cut price target celgene keep outperform rating note prospect still look strong ozanimod ozanimod acquire receptos be be study treat relapse multiple sclerosis ulcerative colitis celgene strategy inflammatory bowel disease have be largely reduce ulcerative colitis ozanimod have potential crohn porge say rbc analyst brian abraham estimate opportunity mongersen crohn ulcerative colitis have be significant see peak revenue mongersen consensus have modeled peak revenue sale start ozanimod emergence suggest celgene be able capture crohn disease market drug instead abraham say do not believe be significant consensus estimate ozanimod crohn disease point expectation mongersen be low write note client news leave room higher probability catalyst include cancer drug revlimid lymphoma ozanimod crohn ulcerative colitis multiple sclerosis otezla ulcerative colitis credit suisse analyst alethia young too remain bullish prospect ozanimod mongersen be very different mechanism have greater confidence ozanimod mechanism action inflammatory disease write note client keep outperform rating celgene stock lower price target abraham young note celgene look buy something flagship product revlimid lose patent protection next decade analyst be look celgene diversify revlimid account more sale related celgene fall scrapping crohn disease drug trialsdoe gilead now have new multibillion dollar franchise celgene blood cancer treatment just tip disruptive science
119,CELG,celgene celg stock fall late late thursday biotech discontinue pair trial win begin third late stage drug be investigate treat crohn disease xa phase trial dub revolve extension trial know sustain discontinue third trial crohn disease phase study call define not be initiate trial involved drug know mongersen thank patient investigator involved revolve trial chief operate officer scott say news release be disappoint result revolve remain commit advance portfolio novel medicine patient suffering disease other inflammatory bowel disorder decision come follow recommendation datum monitoring committee assessed overall benefit risk recent interim analysis celgene say note be meaningful safety imbalance identify analysis celgene be wait review datum phase trial mongersen ulcerative colitis determine next step celgene share fall late trading stock market today celegene have close related do gilead now have new multus dollar franchise celgene blood cancer treatment just tip disruptive science exelixis earn relative strength rating upgrade
120,CELG,biotech industry behemoth celgene celg gilead science gild struggle third quarter accord quarter report result left room smaller player neurocrine bioscience nbix exelixis exel juno therapeutic juno swipe headline crush street even large cap beat sale earning expectation
121,CELG,stock open higher monday early morning apparent bombing attempt new york city snarl morning commute drug maker show early strength bitcoin future jump debut tech stock generally post mild gain dow jone industrial average open fractional gain walt disney climb top index nasdaq composite gain inched news report confirm new york city polouse have take custody suspect be reportedly injured attempt set explosion device new york port authority bus terminal device be only partially detonate accord report other injury property damage be report market head unusually busy mid december week revolve federal reserve rate policy decision wednesday include sunday evening launch bitcoin future trade share balance thursday ongoing congressional effort reconcile house senate version tax reform package apple aapl edge ahead fang stock tech leader weaken alphabet googl give early gain dip minor loss alphabet remain buy range less flat base buy point biotech stock be highly active early trade blueprint medicine bpmc bluebird bio blue soar biomarin pharmaceutical bmrn higher rise release positive trial datum celgene celg lead advance celgene juno therapeutic juno release additional information phase study joint venture treatment hodgkin lymphoma juno share rise fraction bitcoin hold steady bitcoin future launch cboe global market cboe sunday evening soar more ease gain future be set begin trade cme group cme exchange next week bitcoin related stock riot blockchain riot spiked marathon patent group mara vault bitcoin investment trust gbtc pop overstock ostk online retailer accept bitcoin transaction premarket trade china market post strong session monday weibo wb gain almost social networking platform be rise test support week move average buy point late stage flat base earning action be light monday primarily limit thinly trade name report due close include casey general store casy be climb right side month consolidation be september low kmg chemical kmg stock end friday buy point cup handle base be also report related big pic nasdaq tell different talesbitcoin future surge cboe trading startsibd time buy stock new sector
122,CELG,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be lead contract research organization hold ranking medical research equipment service industry group ahead
123,CELG,gilead science gild top sale adjust profit view third quarter share drop late thursday hepatitis drug franchise decline again narrowly miss consensus expectation xin hour trading stock market today gilead fall share close biotech stock widely sell close bell thursday follow celgene celg sale miss guidance cut total sale decline top consensus analyst poll zack investment research adjust profit come share beat expectation adjust earning share sale hiv hepatitis drug climb nearly flagship hiv drug genvoya post yearly gain beat consensus rbc analyst brian abraham write note client gilead hepatitis drug meanwhile continue struggle fall third miss analyst view loncar investment chief executive brad loncar say note follow entry abbvie abbv mavyret treat genotype hepatitis rbc abraham note hepatitis drug harvoni come considerably lighter expectation vs consensus epclusa also miss post be consensus ibd take gilead currently have ibd relative strength rating best possible earlier month rs rating rise high visit ibd datum story more go rating stock even explicit guidance believe directionally help bring street hepatitis number next year welcome reduction lessen overhang share abraham say other product sale include drug treat high blood pressure lung angina fungal infection decline gilead increase low end net product sale guidance see hepatitis drug sale comprise firm also lower top end hepatitis guidance reflect sale related biotechs amgen sarepta vertex top third quarter scientific dife abbott rivalry hit pacemaker salescelgene crash sale miss alexion bristol result mixed
124,CELG,biotech stock topple last week follow disappointing third quarter result like celgene celg gilead science gild analyst say monday note competition pricing concern start take toll arrival new competition form abbvie abbv mavyret force gilead hepatitis drug franchise lose share third quarter meanwhile celgene note otezla treat psoriasis psoriatic arthritis be increasingly competitive market gilead top total sale view revenue hepatitis drug decline third narrowly miss analyst forecast celgene alarm result be drive major miss sale otezla lead total sale lag guidance cut instinet analyst christopher marai say competitive pricing concern take hit broad biotech market nasdaq biotechnology index finished nasdaq wrapped week less higher meanwhile ibd company biotech industry group lose nearly slip third group track ibd last week have be rank first then second ibd take celgene cut many element guidance include inflammation immunology drug head ibd industry theme more celgene result mean broader group alnylam pharmaceutical alny avexis avxs be more expose competitive concern marai say note client alnylam be work drug call patisiran treat rare disease cause buildup abnormal material rival ionis pharmaceutical ion prothena prta avexis be work therapy spinal muscular atrophy rival biogen biib ionis sell spinraza treat same condition marai list spinraza sarepta therapeutic srpt exondys duchenne muscular dystrophy fundamentally strong launch continue look strength select name opportunity take profit biotech reinvest less macro expose name be rich potential stock catalyst next month say avoid price perfection name include alnylam avexis next year marai see prothena deciphera pharmaceutical dcph cellectis cll macrogenic mgnx have slew potential catalyst related dow merck plunge month low grow keytruda worriesgilead beat third quarter sale earning viewsthree biotech firm top third quarter view only pop
125,CELG,bluebird bio blue juno therapeutic juno release preliminary datum early wednesday respectively sickle cell disease aggressive lymphoma send stock skyward xby close bell stock market today bluebird initially surge more settle back gain finish juno pop end regular trading day well buy point flat base begin form late september duo release preliminary datum ahead american society hematology annual meeting december bluebird stock movement come fact biotech report third quarter sale adjust loss share lag wall street preliminary datum show bluebird be able boost number gene correct bone marrow cell patient sickle cell disease used update version therapy call lentiglobin mean patient produce healthier red blood cell bluebird say also plan present update datum study drug call bb patient advanced multiple myeloma blood cancer bluebird be work drug follow bb celgene celg ibd take biotechs have largely offer mixed quarter celgene third quarter sale be call alarm head ibd industry theme closer look firm have report thus far quarterly result lag consensus bluebird report adjust loss share sale vs analyst call adjust loss share sale juno be set report quarterly result close release early datum study drug dub jcar diffuse large cell lymphoma blood cancer study patient respond specific dose jcar sign cancer disappear patient core group month dose core group best overall response rate be best complete response rate be jcar belong class know car drug novartis nvs gilead science gild virtue acquisition kite pharma already have drug approve gilead yescarta be already approve treat large cell lymphoma include diffuse large cell lymphoma primary mediastinal large cell lymphoma novartis drug kymriah be approve treat form acute lymphoblastic leukemia patient age tuesday novartis say aim have kymriah approve treat diffuse large cell lymphoma related celgene gilead pricing wo continue haunt biotech stocksgilead top sale profit view miss hep share falldow stock merck topple withdraw keytruda application europe
126,CELG,celgene celg share go free fall thursday biotech giant turn third quarter result analyst call alarm sale miss force biotech cut outlook many element forecast xby close bell stock market today celgene have crash finish hit lowest point july meanwhile share alexion pharmaceutical alxn bristol myer squibb bmy also offer mixed third quarter result fall respectively leerink analyst geoffrey porge characterize celgene third quarter performance alarm revenue gain year year lag consensus analyst poll zack investment research recently install new management be likely face tough question investor company direction leadership operational guidance disappointment quarter write note client celgene biggest pain come otezla treat psoriatic arthritis moderate severe plaque psoriasis revenue otezla grow year earlier period miss consensus view porge say otezla bring miss however accord health care tracker otezla prescription grow quarter quarter suggest surge prescription volume second quarter force major price concession third quarter bright spot celgene be adjust income share grow beat expectation share ibd take washington base expert say president donald trump sign executive order tug drug price day have big hit drug biotech stock head ibd industry theme breakdown altogether result prompt celgene cut sale guidance earlier view now see otezla bring earlier forecast analyst have modeled total sale celgene also trim most element guidance otezla shortfall terminate several trial drug dub mongersen treat crohn disease fate midstage trial mongersen ulcerative colitis be air result celgene cut guidance inflammation immunology drug forecast more issue hematology treatment be expect account oncology drug be guide total sale be now expect come earlier view north adjust profit be now project more share vs earlier expectation more share guidance adjustment be likely weigh stock term more clarity pipeline program be establish porge say essence celgene have load midterm future revlimid market increasingly anticipate face generic competition alexion wrapped quarter adjust profit share revenue respectively revenue miss consensus adjust earning beat analyst average view share sale soliris drug approve treat blood disease chronic condition cause muscle weakness grow year year lag most analyst view rbc leerink analyst say firm boost sale guidance earlier expectation guidance soliris rise slightly analyst have modeled total sale adjust earning be modeled share alexion prior forecast share consensus be forecasting average alexion plunge close thursday bristol post adjust income cent share sale sale top consensus call adjust profit miss cent share view bottom line miss be lower gross margin leerink analyst seamus fernandez say key immuno oncology drug opdivo bring global sale grow top analyst view fernandez write note client opdivo sale grow be consensus model eliquis anticoagulant post yearly sale gain worldwide be line consensus lag fernandez expectation sale immuno oncology drug yervoy come miss street view bristol boost adjust profit guidance share share share lose close related biotechs amgen sarepta vertex top third quarter lifescience crash heart valve sale miss lofty glaxosmithkline scoop pfizer counter unit
127,CELG,nasdaq composite index close week record high heaviest week earning season amazon amzn alphabet googl mmm caterpillar cat be big winner celgene celg boee ba baidu bidu be notable loser nasdaq composite have be week rally friday hit time high rise week amazon amzn alphabet googl microsoft msft surge friday earning apple aapl facebook fb hit buy point ahead earning next week index also rise new high friday week dow climb week hit record level earlier week celgene celg merck mrk several other biotech drug stock sell earning guidance week so do boee ba several defense giant treasury yield rise multimonth high solid economic datum european central bank voting taper bond buy president trump loom decision be next federal reserve chief amazon amzn share soar commerce leader report third quarter adjust earning share cent vs view cent revenue rise include whole food market acquisition amazon complete aug amazon web service revenue soar account well operate profit amazon soar hit record high related amazon blow past earning view beat sale share soargoogle parent alphabet googl vault time high internet giant profit smash estimate google say gaap earning be share year revenue jump top consensus estimate google traffic acquisition cost pay partner website carry ad rise alphabet say grow tac have be overhang google stock share rise friday record high back buy point related google shoot time high beating earning viewsboee ba take charge kc refueling tanker bring total cost overrun taxe taxe charge aerospace giant raise full year cash flow outlook full year core ep prior view ep midpoint be still analyst view boee ep fall top forecast revenue rise estimate boee share fall week related boee shake air force tanker cost outlook imply weak blue chip caterpillar cat mmm throttle earning estimate hike guidance make clear global economy have shift higher gear caterpillar earn share year cent ahead estimate revenue leap construction equipment firm earning guidance share be cent ahead prior estimate see broad growth industrial health care electronic energy segment beating ep cent say expect full year ep earlier outlook week caterpillar rise raise outlook strong earning dow stock gap highcaterpillar soar blowout earning raise martin lmt raise full year outlook earning revenue cut guidance sale aeronautic unit defense giant miss estimate northrop grumman noc also raise ep outlook report result wall street estimate global hawk maker announce wouldn submit bid navy unmanned tanker competition be see major player raytheon rtn report mixed result also raise full year ep outlook however raise guidance be still analyst consensus general dynamic gd quarterly result beat view lockheed raytheon general dynamic share fall northrop rally related lockheed grow leap bound sale slow northrop win bid navy drone contract result beat viewsraytheon report mixed result raise ep outlookbiogen biib slide tuesday beating top bottom line expectation sale spinraza lag view amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx deliver board beat third quarter report late wednesday up sale guidance amgen sank sale top drug enbrel fall year year vertex say late stage cystic fibrosis trial fail celgene celg crash thursday revenue miss otezla sale lag consensus lead biotech cut sale guidance alexion pharmaceutical alxn fall weak sale gilead science gild top sale adjust earning view late thursday hepatitis drug sale decline third narrowly miss estimate big pharma giant merck mrk bristol myer squibb bmy novartis nvs eli lilly lly glaxosmithkline gsk fall follow earning report biotech firm top third quarter view only popscelgene result call alarm alexion bristol mixedgilead top sale profit view narrow miss hepatitis drugssoftware giant microsoft msft race past wall street target september quarter point sale view december quarter send stock record high territory friday day microsoft earn cent share year year sale fiscal first quarter analyst expect cent microsoft credit growth cloud compute business related microsoft top september quarter sale earning targetsinvestor cheer intel intc stm teradyne ter september quarter earning report jeered advanced micro device amd ultra clean holding uctt intel top wall street target third quarter sale earning guide analyst higher current quarter rival amd deliver better expect third quarter result disappoint guidance flat gross profit margin current quarter biggest loser be ultra clean plummet thursday mixed third quarter result related intel beat third quarter goal guide highergeneral motor gm ep fall revenue shrank broad slowdown car sale plan reduction fleet sale retreat certain european african asian market result crushed forecast ep revenue gm also guide full year earning consensus gm share have be rally investor see automaker combine strong profit now be lead pack autonomous drive electric car ford earning surge cent revenue rise automotive revenue top estimate ep cent revenue management narrow profit outlook remain consensus fiat chrysler fcau report mixed result china base school operator tal education tal fall short earning estimate penny report flat ep cent revenue climb enrollment more double outlook be line forecast fellow heavyweight new oriental education edu turn mixed result better expect guidance tal education plunge new oriental related china leader be flash long term sell signalsexxon mobil xom report ep rise cent revenue nearly expectation credit higher oil price production refinery margin fellow dow energy stock chevron cvx fall short earning send share friday recent buy point exxon rise friday crude future hit month high mcdonald mcd same store sale beat estimate help drink line signature craft sandwich see thinner margin invest training technology whopper deal burger king likely help comp owner restaurant brand qsr share reversed lower record high friday cost cut promotional switch boneless wing help buffalo wild wing bwld fly nearly thursday even sport bar chain contend elevated price traditional chicken wing question ceo transition chipotle grill cmg share crash concern sale recovery higher menu price next month plan slow new store addition next year visa fiscal fourth quarter result beat top bottom line help solid payment cross border volume strong show visa europe payment volume growth be strong country russia india australia come worry state retail mizuho analyst note mobile tmus sprint call earning call avoid discussion raise speculation merger announcement come november regulatory hurdle mobile add postpaid phone subscriber september quarter sprint add lose report flat profit revenue drop say expect purchase time warner twx close year end analyst say sell be related equity dilution expect twx deal be issue stock finance half deal side analyst say carrier include verizon vz have be restrain promotion soon be release high end apple aapl iphone improve margin december quarter cable tv firm comcast cmcsa charter chtr report higher video subscriber loss lower customer addition comcast have lower guidance early september send stock ahead earning charter stock fall disclose similar trend company aim hike price service video subscriber switch internet tv charter add customer vs estimate charter acquire time warner cable last year comcast add customer vs year earlier baidu bidu crushed third quarter earning estimate chinese search engine giant give weak guidance share plunge friday cisco system csco acquire broadsoft bsft maker communication software telecom company include debt share cisco pass buy ringcentral rng rival software firm fortinet ftnt sank friday maker computer security software forecast december quarter revenue expectation september quarter result beat view grubhub grub report third quarter earning beat estimate provide fourth quarter guidance also top view share surge week breaking buy point td ameritrade amtd top earning view gain revenue growth accelerate fourth straight quarter share online brokerage rise record high servicenow now report earning revenue top expectation billing growth disappoint share enterprise software provider fall earning release close week slightly higher earning call management indicated be strong start aid part few more deal closing normal be push december quarter whirlpool whr crash weak earning news sear longer sell appliance twitter twtr share soar week high better expect adjust earning rise monthly user forecast possible gaap profit
128,CELG,stock be mixed celgene celg dive hurt biotechs investor await amazon amzn alphabet googl earning due close spdr dow jone industrial average dium spdr spy rise respectively powershare qqq trust qqq slip home construction financial semiconductor lead upside sector fund stock market today ishare home construction itb advanced spdr homebuilder xhb add biotech oil real estate play underperform spdr biotech xbi ishare nasdaq biotechnology ibb sank respectively moved further day move average line biotechs celgene gap sank month low sale miss view amgen amgn pare loss alexion pharmaceutical alxn vertex pharmaceutical vrtx fall more apiece respective quarterly report most gold etfs fall underlie commodity price oil fund be mostly higher west texas intermediate crude price reversed upward want invest same stock billionaire investor warren buffett so watch fund soon trigger buy point ishare russell value iwd be get close buy point month flat base pull back broader market wednesday be still less entry etf advanced mid february start current base fund track market cap weight index bearing same name turn year old russell value index be compose large midcap stock be consider undervalue market vs comparable equity iwd target cheaper stock index base price book project growth historical sale growth accord morningstar direct financial represent biggest sector weighting oct asset health care be next nearly follow energy just apiece industrial consumer staple information technology iwd top position include berkshire hathaway brkb jpmorgan chase jpm exxon mobil xom johnson johnson jnj top name account nearly portfolio fund year date return oct lag gain average annual return longer haul have also underperform benchmark index year return be roughly line period ibd take look improve chance successful investing watch video learn follow simple routine increase odd iwd annualize dividend yield be ahead average payout half fund top stock be dividend aristocrat company have raise annual payout least past consecutive year top be also hold buffett berkshire hathaway june iwd carry expense ratio wednesday pick vanguard small cap vb schwab small cap scha remain buy range respective entry related dow sell boee ge weigh chance buy small cap earning fuel dow new record high fang play buy zonedow hold gain wal mart rise nvidia lead hot chip sector
129,CELG,major index recoup wednesday moderate loss investor await deluge quarterly result big cap tech firm biotechs slide celgene celg plunge follow disappointing result xibd biotech biomedical industry subgroup fall more join military defense ethical drug hospital medical software firm downside et nasdaq composite be lag lift dow jone industrial average nearly rise smallcap padded early gain rally nearly volume decrease vs same time main exchange apple aapl meanwhile quietly position potential rebound back critical day move average share rise nearly edge back prior flat base buy point megacap tech leader report fiscal result late monday still hold solid gain initially break first stage bottom base jan cup handle show entry share have rally much then street expect earning rise share extend streak low double digit ep growth third quarter growth be expect accelerate fiscal year profit be expect rise share apple ibd rating have improve start year jan iphone ipad giant show lousy earning share rating relative price strength rating today ve rise respectively scale apple example be good lesson stock chart help investor spot excellent turnaround situation quarters company post drop earning share slump revenue third straight year year drop such result lag stock price wonder apple ibd rating plunge mediocrity however leadership ceo tim cook company continue create innovative popular new product company also have set goal double service related revenue decade end sale have rise past quarters street see sale rise continue slow yet steady acceleration top line growth fiscal year end september next year be even better apple revenue be see increase expect gain just end fiscal year celgene report respectable jump profit share beat consensus estimate perhaps wall street have be hope bigger beat meanwhile gain top line marked weakest year year increase more year do celgene give investor sell signal thursday tumble fact yes back june cancer treatment specialist bolt somewhat lopsided cup base then rally high sharp gap heavy trading oct give strong hint change character action just day later oct celgene then trip day move average volume balloon day average sign institution be locking gain ibd take case great stock punctuate end rally multiple sell signal cover frequently ibd investor corner daily market column check article spot multiple sell signal lock profit raise cash maximize portfolio return fortinet ftnt be work new handle double bottom base security software firm be industry peer palo alto network panw currently member leaderboard ibd premium stockpicking chart annotate service fortinet slate report result close today have moved past buy point week double bottom base base second low undercut first low fortinet break oct heavy volume remain buy range buy zone go meanwhile fortinet have not yet climb new high possibility alternate buy point exist notice daily chart stock have pull back mildly past several session good handle feature such action run lower lows stock trade lightly proper handle decline usually never exceed more however handle also be minimum trading day long fortinet have pull back just session see ibd stock checkup midcap stock sport good composite rating scale mediocre rs rating volume ratio point heavy volume buy institution past session other top rate stock ibd computer software security industry group include nice nice composite thinly trade symantec symc composite also post big turnaround qualys qlys composite testing support day move average follow aug past flat base elsewhere stock market certain consumer spending play thrive group automotive gpi break past buy point long cup handle share rise volume be run more time day average buy zone go earning rise share snap quarter streak fall profit revenue rise match biggest increase quarters downside raytheon rtn undercut day move average heavy volume late june share missile maker drop more stock have rally much clear flat base pattern nov last year raytheon report increase earning share beating view also third quarter single digit ep growth past quarters revenue rise continue dive day line trigger key ibd sell signal raytheon face such challenge soon nov last year stock spiked day move average dec jan year immediately rebound related know cup handle make chart pattern special psychological market indicator just make mini spikewhat be slim find excellent stock nvidia begin search here
130,CELG,major market index trade mixed early morning trade thursday european central bank decision hold interest rate unchanged taper bond buy program start january dow jone industrial average set morning pace surge moved tech heavy nasdaq decline dow jone industrial component dowdupont dwdp set pace rise nearly company announce preliminary result top estimate stock be now flat base entry meanwhile iphone maker apple aapl advanced higher battle regain day line stock have etch handle cup base move risk optimal entry fang stock amazon com amzn alphabet googl report earning result close analyst expect commerce giant earn cent share year year decline revenue be expect grow share be battle support day line build right side potential base meanwhile alphabet be flat base entry share inched higher thursday also close today internet giant baidu bidu also announce result consensus estimate show china base firm profit grow share jump revenue share be well extend cup base entry share slip company report earning biotech stock be pressure stock market today slew disappointing result amgen amgn trim heavy loss mere decline former lead biotech celgene celg follow plunge miss sale meanwhile alexion pharmaceutical alxn vertex pharmaceutical vrtx be alexion report mixed result sale come bit light vertex top street earning sale target alexion give day line last week vertex fall level monday drugmaker bristol myer squibb bmy adjust income come short compare analyst forecast share drop nearly stock be build right side giant cup handle base potential buy point ibd earning result weigh many lead issue china base education provider tal education tal crash rival new oriental education edu fall sympathy stock plunge day line heavy volume upside pra health science prah reclaim flat base entry rise almost solid earning result related dow jone industrial average dow stock news top chinese school operator miss earning view stock divesfang stock news quote facebook amazon netflix googlethese tech giant ecb dominate thursday investing action planbiotech pharma industry stock news
131,CELG,stock market close mixed thursday dow jone industrial average again take lead dow industrial climb add month outperformance major index nasdaq fall rise russell rise bell dow utility edge dow transport be stand out rally trucking logistic railroad be top industry group today market volume be sightly lower board accord early datum advancer decliner be even earning report stream copious pace many stock moved sharply celgene celg top list stock move plummet lowest level july biotech miss sale expectation be biggest factor biotech industry group loss nearly thursday other drug group hospital medical software maker also be sharply tal education tal ultra clean holding uctt nutrisystem ntri charter communication chtr be stock sell earning report utility regional bank make good chunk thursday breakout also many announce earning wec energy group wec moved buy point flat base volume be third less normal spire sr climb past entry flat base volume be half usual amount natural gas utility report earning nov columbia banking system colb top buy point cup handle base connectone bancorp cnob clear buy point long pattern first commonwealth financial fcf break past entry cup handle beat profit expectation health care icon iclr surge nearly triple average volume vaulting past buy point flat base provider outsource service pharmaceutical company top estimate sale earning related top rate stock break strong earning
132,CELG,blue chip lead market again afternoon trading thursday dow component nike nke show healthiest gain blue chip index nearly move come heel rise wednesday company forecast midteen earning growth next year dow jone industrial average picked add nasdaq composite rise volume nyse be tracking close wednesday level nasdaq volume be stock market today lendingtree tree gap day move average soar strong earning quarterly profit jump share sale growth accelerate third straight quarter surge don chase last time lendingtree break proper base be late april stock be extend twitter twtr shareholder be good mood thursday company deliver earning report plenty bright spot include earning beat slight increase monthly active user share vault monthly active user be mostly line expectation prior quarter meanwhile seller swarm celgene celg again share plunge last week wall street didn news company be discontinue late stage trial promising drug treat crohn disease share plunge thursday company report increase quarterly profit rise sale sale be consensus estimate celgene outlook also disappoint ibd couple china base profit school stock get whack flash sell signal tal education tal gap day move average crumble report earning competitor new oriental education edu fall sympathy tal share lose also gap day line normally support level lead stock ibd take follow sell rule protect portfolio catastrophic loss learn more sell stock section ibd university close watch earning report trio tech heavyweight include amazon com amzn alphabet googl microsoft msft amazon have be consolidate gain late july be currently tread water day move average recent high alphabet be only recent high trade level microsoft be extend late august buy point new york mercantile exchange wti crude oil future december delivery add nearly barrel month high year treasury yield add basis point related celgene result call alarm alexion bristol invest stock market simple routinebest stock buy watch
133,CELG,future index nasdaq dow industrial rise slightly tuesday morning major average close session lows monday top rate medical biom biotech group fall again several lead biotech stock test key level biogen biib amgen amgn gilead science gild celgene celg vertex pharmaceutical vrtx alexion pharmaceutical alxn be tap earning week future rise vs fair value dow future climb nasdaq future edge fraction nasdaq composite lead monday retreat lose index fall dow industrial medical biom biotech group fall ninth straight decline hit month high oct even so still rate industry ibd track biogen report better expect earning tuesday morning amgen vertex follow wednesday celgene alexion gilead science report thursday addition biogen slew big earning report tuesday include mcdonald mcd unite technology utx lockheed martin lmt general motor gm open biogen earning rise nearly share sale climb analyst have expect ep revenue biogen be leader multiple sclerosis drug have new hit spinraza only spinal muscular atrophy drug market investor be also bullish prospect aducanumab have indicated early testing reduce cognitive decline early alzheimer patient biogen share rise market open tuesday monday stock fall monday stock market trading third straight decline close just buy zone entry initially clear end august ibd take buy hold stock be risky head earning report here earning option strategy help cash post earning stock gain minimize risk weak quarter amgen vertex gilead science fall day move average monday amgen close old buy point first time amgen vertex gilead be new flat basis vertex bust july promising datum new cystic fibrosis drug gilead science be best know hiv aids hepatitis drug last week win fda approval car drug treat aggressive form hodgkin lymphoma drug yescarta come gilead recent acquisition kite pharma gilead earning be expect fall hepatitis drug sale tumble amgen ep be see vertex earning be expect go vertical surge cent celgene share rise monday tumble friday celgene scrap late stage trial crohn disease treatment wall street forecast ep gain alexion retreat monday undercut low short flat base alexion drop day move average friday alexion earning be expect rise popular way avoid stock specific risk biotech be etfs ishare nasdaq biotech ibb fall drop day move average buy point clear end august related stock buy zone earning due investing action big picture nasdaq add rd distribution day sessionsbiogen biomarker mark way alzheimer parkinson abandon crohn drug other take spot do gilead now have new multibillion dollar franchise top biotech company innovation earn recognition new award
134,CELG,relative strength rs rating gilead science gild enter new percentile friday get lift unique rating identify technical performance show stock price action last week compare other stock database year market history reveal best stock typically have higher rs rating early stage move see gilead science continue rebound hit benchmark look best stock buy watch start heregilead science be work flat base buy point see stock clear price heavy volume earning sale growth come respectively latest report marked acceleration earning share sale company be expect report next quarterly number nov gilead science earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
135,CELG,innoviva inva see welcome improvement relative strength rs rating friday rise ibd proprietary rating track share price movement worst best score grade show stock price behavior trail week compare other stock database history show market biggest winner tend have rs rating north early stage move look best stock buy watch start hereinnoviva break earlier be now prior entry cup handle stock re watch clear buy point then decline more original entry price consider fail base best stock form new pattern also keep mind most recent consolidation be later stage base make riskier establish new position add share exist earning growth decrease last quarter revenue rise prior report next quarterly number be expect oct company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
136,CELG,loxo oncology loxo deal bayer bayry have bigger impact biotech sector expect industry observer tell investor business daily tuesday key exchange trade fund fall flat basis xearly tuesday loxo announce deal bayer co develop cancer drug agreement pay loxo term deal loxo bayer split profit equally drug know larotrectinib loxo sector be hope buyout say brad loncar portfolio manager loncar investment interview ibd loncar cancer immunotherapy etf cncr topple fellow etf peer fall loxo have be not most successful small biotech company year say person be hope buyout even weren hope buyout give pretty clear guidance be go hold right loxo stock be year monday close easily outperform ibd company biotech industry group have climb year date stock market today loxo topple close share be much earlier day collectively biotech group dove near month low hit highest point december october third quarter earning season be rough number player celgene celg gilead science gild weigh heavily group biotech centric etfs also take pitfall biotech etf xbi fall flat base buy point diving ishare nasdaq biotechnology etf ibb have be form flat base entry fall proshare ultra nasdaq biotechnology etf bib dove ibd take loxo have ibd composite rating best possible meaning perform middle stock term key growth metric head ibd stock checkup look better rate player biotech group loncar say merger acquisition really help biotech group loxo have be buy today everybody be say next smaller company go be buy probably be bidding stock say fact loxo be willing give away profit drug work target gene fusion cancer suggest biotech negotiating be bit weaker expect loncar say revaluation be hurt sector put tesaro tsro clovis oncology clvs same bucket have approve drug know parp inhibitor target ovarian cancer loxo larotrectinib isn yet approve big pharmas struggle quarter need buy revenue growth loncar say possible market have push valuation so high buyout doesn make sense like loxo tesaro clovis add biotech industry group be now rank group track ibd first just month gilead acquisition kite pharma announce august complete october help spike group nearly year high then group have pull back investor react harshly surprisingly news group loncar say prime therapeutic fprx dove nearly nov unveil abstract immuno oncology combination bristol myer squibb bmy pancreatic cancer overall patient respond combination prime cabiralizumab bristol opdivo pancreatic cancer be particularly hard treat typically doctor have expect response combination now duo have time refine treatment regimen wall street person demand instant gratification instant success drug loncar say be disappointing be big phase trial end road be literally first human trial dynavax technology dvax also have suffer follow food drug administration approval drug dub heplisav treat hepatitis stock fall monday loncar say investor be look dynavax be buy find partner think probably find deal say expect literally day approval so now first quarter re actually launch drug think chance good news add lot investor expect big pop soon wasn run exit don think reflective quality company related biotech just near year high strong cancer regimenwhy tesaro cancer drug miss prompt rival biotech just rise third earning be trouble
137,CELG,celgene celg pioneer lead player blood cancer treatment have become biotech juggernaut thank largely drug prove key fight tricky disease multiple myeloma xin multiple myeloma cancerous plasma cell bone marrow elude immune system fighter punch change way look act produce immune suppress molecule enter celgene revlimid so call immune modulating drug help immune cell attack cancer cell starve myeloma cell bone marrow prevent new blood vessel form drug also become big weapon equally dread disease lymphoma drug battle disease such lupus multiple sclerosis ulcerative colitis also be celgene potential hit list arsenal earn company recognition investor business daily inaugural ibd innovator award biotech ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report revlimid continue dominate company revenue now multiple myeloma remain incurable cancer revlimid have prove extend survival rate drug be go do sale next year make biggest drug biotech say analyst michael yee manage director investment house jeffery have buy rating celgene price target celgene estimate sale lead revlimid exceed more nearly expect revenue year roughly celgene notch sale last year company stock soar year revlimid win fda approval treat relapse mantle cell lymphoma then record mid year revlimid gain approval patient newly diagnosed multiple myeloma high hold early september early october celgene stock touch record high early year fda approve revlimid maintenance treatment subset patient multiple myeloma need maintenance stem cell transplant market cap celgene rank company ibd biotech industry group trail only amgen amgn celgene growth start licensing controversial drug bad reputation thalidomide decade earlier have be link birth defect thalidomide be approve infective treat lesion patient leprosy scientist also start look drug possible therapy multiple myeloma meanwhile celgene scientist work improve efficacy side effect thalidomide treat multiple myeloma result thalidomide be approve patient newly diagnosed myeloma follow shortly approval lenalidomide orally administer thalidomide analogue trade name revlimid patient relapse refractory multiple myeloma receive least prior therapy ibd take biggest company still produce big stock gain often volatility smaller stock ibd big cap have recently include celgene be place track biggest recent mover big boy revlimid be first approve late subset patient rare blood cancer know mds celgene didn stop innovate many drug candidate be small molecule compound also meant modulate immune system drug target source disease rather symptom aren just do too drug yee say celgene executive say company favor disruptive science ceo mark alle explain ibd celgene core purpose be apply unique scientific insight underlie source mechanism disease provide new treatment patient significant medical need celgene spend nearly annually research development drug pipeline especially target blood cancer solid tumor inflammatory immune disease research portfolio include molecule support different clinical program alle point investor conference spring be approve have multibillion dollar blockbuster potential say alle also tell ibd celgene partner other promising innovator enhance accelerate discovery new medicine many more partnership be small biotechs include juno therapeutic juno bluebird bio blue acceleron pharma xlrn july celgene say collaborate china base beigene bgne develop market investigational protein inhibitor patient solid tumor cancer business model be drive internal well distribute research yee say seek license acquire complementary product be focuse novel mechanism action try treat underlie cause disease analyst say most notable drug celgene internally develop war chest be fast grow otezla autoimmune treatment psoriasis psoriatic arthritis be company current blockbuster drug annual sale leader revlimid other blockbuster be pomalyst second generation version revlimid approve patient didn respond other therapy abraxane used treat breast cancer lung cancer pancreatic cancer celgene be also study otezla potential use ulcerative colitis behcet disease other new indication celgene hope revlimid prove effective treat hodgkin lymphoma lymphoma be equal greater size myeloma leerink analyst geoffrey porge write recent research report follow celgene better expect second quarter result porge raise price target rate stock outperform cite number pivotal trial result emerge year next new drug be crucial celgene lose patent protection revlimid not worry say analyst yee be find new blockbuster drug diversify revenue base potential blockbuster be ozanimod come way celgene acquisition receptos oral drug show positive result late stage trial relapse multiple sclerosis celgene estimate ozanimod generate annual sale treat ms equal amount treat ulcerative colitis crohn disease provide further revenue clinical trial prove positive base emerge datum ozanimod also have potential serve anchor neuro franchise future celgene president scott tell analyst company earning call closely watch potential blockbuster late stage trial be oral compound ged treatment crohn disease ulcerative colitis development drug be license privately hold nogra pharma small molecule drug know ag idhifa be license agio pharmaceutical agio be first approve product celgene collaboration august food drug administration approve ag subset adult patient relapse acute myeloid leukemia most patient aml eventually relapse estimate have mutation ag target analyst leah cann oppenheimer estimate drug expect hit market fourth quarter garner annual sale meanwhile compound cc be show encourage clinical datum lupus alle tell analyst july note autoimmune disease have large dramatically underserved patient population have pretty exciting initial datum positive late stage result new indication several immunology oncology combination trial breathe new life celgene top drug abraxane sale have be grow slowly late just second quarter contrast otezla sale jump celgene boast many other drug early stage potential blockbuster example treat aggressive cancerous brain tumor glioblastoma recently diagnosed sen john mccain celgene expect start pivotal trial year proteasome inhibitor marizomib combination standard therapy celgene buy marizomib last year privately hold triphase accelerator internally develop way partner celgene therapy say analyst yee be most novel innovative biotech related get detail biotech innovator award winning company workcelgene be big cap solid celgene immuno oncology effort help small biotech stocka look recent celgene stock
138,CELG,welcome move alexion pharmaceutical alxn see relative strength rating rise wednesday proprietary rating track technical performance show stock price action last week compare other stock database history show best perform stock often have rs rating early stage move see alexion pharmaceutical continue show renew price strength hit benchmark look best stock buy watch start herealexion pharmaceutical be work flat base entry see clear price volume least higher normal alexion pharmaceutical show earning growth last quarter revenue increase company be expect report latest number oct alexion pharmaceutical earn rank peer medical biom biotech industry group celgene celg be top rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
139,CELG,stock stage split open thursday swarm early earning action name include ford american airline group aal twitter twtr dow jone industrial average angled start bell future add nasdaq composite open lower then climb narrow gain celgene celg gap loss third quarter report dow be almost unanimously positive dowdupont dwdp seize early lead adjust third quarter sale earning guidance move send share new high extend buy range clear flat base mid september apple aapl punch alphabet googl lead advance fang stock climb ahead third quarter report schedule today close quarterly report again drive much premaket action american airline open higher result meet beat analyst expectation third quarter impact hurricane texas florida stock be just buy point cup handle base ford motor rise more early action dearborn mich automaker report solid beat third quarter earning revenue management raise full year guidance analyst estimate ford share be august low back key level technical support work reverse year decline buffalo wild wing bwld soar blow past analyst third quarter earning view revenue come just short estimate management also boost full year earning guidance well consensus view buffalo wild wing share have be try start right side deep month consolidation twitter spun gain open third quarter earning decline beat analyst target revenue slip line expectation guidance point potential earning growth stock have be fight hold support converge week move average attempt build right side possible month base pattern earning news have place chip developer early pressure xilinx xlnx shed start trade san jose calif chip designer report par earning revenue line estimate fiscal second quarter third quarter guidance be light side xilinx share be extend wednesday close just buy range cup handle buy point mellanox technology mlnx drop jp morgan cut stock rating neutral overweight chip designer report late wednesday third quarter earning slip less expect revenue decline miss estimate guidance be weak side consensus view chip equipment maker teradyne ter pop deliver solid third quarter result fourth quarter guidance last wednesday stock be extend cup handle buy point auto part chain reilly automotive orly stumble weak fourth quarter guidance china base stock appear set day selling pressure suffering heavy selling wednesday session tal education tal swoon lower early trade new oriental education technology edu dive more baidu bidu alibaba group baba post smaller decline houston base utility dynegy dyn pop open trade news report late wednesday company have be discuss possible combination vistra energy vst vistra share climb more higher early trade first time unemployment claim edge week end oct labor department estimate be first increase week less claim anticipate economist week move average ease fourth straight decline pending home sale stat be expect national association realtor et minneapoli federal reserve bank president neel kashkari speak et europe market be important global picture thursday stock add early gain european central bank vote hold target interest rate unchanged only slowly decrease asset buy effort cac paris lead frankfurt dax jump london ftse hold gain afternoon trade china stock market be mixed thursday japan tokyo nikkei rebound wednesday loss japan be expect september consumer price datum evening related big picture distribution grow fear gauge rise income investor dow dividend play just halter long earning decline rule buy stock facebook earning seasonibd investor research tool get start ibd
140,CELG,bluebird bio blue topple week low monday analyst downgrade stock doubt regard sickle cell disease drug send share rival crispr therapeutic crsp edita medicine edit skyrocket xby close bell stock market today bluebird dove finish earlier hit low last see aug biotech stock broadly rise touch high last see january group be now rank second group track crispr rally end regular trading session edita pop close bluebird downgrade be work therapy treat sickle cell disease group inherited blood disorder therapy crispr edita be show promise say morgan stanley analyst matthew harrison investor don appreciate risk bluebird face december set unveil further datum drug lentiglobin treat sickle cell disease harrison say meanwhile therapy crispr edita use different mechanism less variability bluebird do not believe american society hematology datum bluebird demonstrate significant improvement hemoglobin production necessary increase investor confidence sickle cell gene therapy harrison write note client ibd take vertex pharmaceutical be partner crispr work solution genetic disease used gene editing include sickle cell disease head new america closer look vertex have plan cystic fibrosis journey come end harrison downgrade bluebird underweight rating keep price target be more bullish bluebird chance treat multiple myeloma used drug know bb partnership celgene celg bluebird be crowd field car therapy aim immune system identify cancer cell novartis nvs just gain approval drug kymriah gilead science gild be acquire kite pharma kite drug juno therapeutic juno be also work celgene still bluebird have significant lead partner celgene be clear leader myeloma space harrison say importantly expect bb be grant breakthrough designation term cause bluebird rally related bluebird hit high bullish report highlight blood drugswhy amgen drug send abbvie stock acquire biotech deal be very logical
141,CELG,build watch list focus stock higher rs rating ionis pharmaceutical ion now meet criterium increase friday proprietary rating identify technical performance used worst best score identify stock price performance last week match other publicly trade company year market history show market biggest winner tend have higher rs rating early stage move look best stock buy watch start stock be try complete cup handle buy point see stock break heavy trading sale growth fall last quarter earning share grow prior report ionis pharmaceutical earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
142,CELG,warning big cap have lose advantage late july big cap be year date tie nasdaq pop be dow jone industrial average small cap be only year xsince then market tilt have change
143,CELG,relative strength rs rating acceleron pharma xlrn climb new percentile friday increase exclusive rating investor business daily identify share price action worst best score rating show stock price performance trail week compare other stock database history reveal stock go make biggest gain tend have rs rating begin biggest price move look best stock buy watch start hereacceleron pharma break earlier be now trading prior entry cup handle case stock break then fall more entry price consider fail happen best new pattern form also keep mind most recent pattern be later stage base such basis be more prone failure earning sale growth come respectively latest report marked acceleration earning share sale company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
144,CELG,important metric look stock be higher relative strength rating pharmaceutical adms just hit mark jump friday ibd proprietary rs rating track market leadership used worst best score indicate stock price action trail week match rest market year market history show stock go make biggest gain tend have rs rating north begin biggest run look best stock buy watch start hereadamas pharmaceutical be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week line company post negative growth top bottom line last quarter company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
145,CELG,relative strength rs rating flexion therapeutic flxn enter higher percentile friday get lift proprietary rating track technical performance used worst best score indicate stock price action trail week stack other stock database year market history reveal market biggest winner typically have higher rs rating begin largest climb see flexion therapeutic continue rebound clear threshold look best stock buy watch start hereflexion therapeutic be not currently show potential buy point see stock go build promising consolidation kick new price move company show earning growth latest quarterly report revenue rise flexion therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
146,CELG,bluebird bio blue rocket year high thursday analyst bullish report outline biotech blood disease pipeline include tie biotech celgene celg xby close bell stock market today bluebird have pop finish earlier rise touch high last see september meanwhile broader biotech industry rise highest point month leerink analyst michael schmidt keep outperform rating bluebird stock follow investor dinner executive celgene bluebird be work drug dub bb treat blood cancer know multiple myeloma drug belong class agent call car therapy novartis nvs be first gain approval drug class august duo begin pivotal trial multiple myeloma year end schmidt say note client small study suffice bb continue show same strength show earlier testing say ibd take car therapy like bluebird juno therapeutic kite pharma have excited wall street ability immune system fight cancer head industry snapshot breakdown segment bluebird unveil result initial trial patient conference december next generation version drug call bb remain track application food drug administration year end longer term bluebird reiterate optimism regard potential development opportunity bb earlier treatment line potentially context instead bone marrow transplant write firm be also work drug call lentiglobin treat blood disorder cause severe anemia ongoing trial be expect form basis application europe study be track begin year form basis filing update american society hematology meeting december also provide first insight effect lentiglobin treat sickle cell disease firm expect have datum patient time related celgene break giant close buy much biotech pop fda ok drug bid investor be mute gilead acquisition kite pharma
147,CELG,clovis oncology clvs see positive improvement relative strength rs rating thursday upgrade ibd unique rs rating identify market leadership show stock price movement last week compare other stock database decade market research reveal market biggest winner typically have rs rating early stage move look best stock buy watch start hereclovis oncology have climb more past entry second stage cup handle meaning now proper buy range look stock create new buy opportunity week tight pullback day week line earning growth rise last quarter revenue gain fall company hold rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
148,CELG,important metric look stock be higher relative strength rating prothena prta now clear threshold jump wednesday ibd proprietary rs rating identify technical performance show stock price action last week compare other stock major index decade market research reveal top perform stock often have better rs rating begin biggest climb look best stock buy watch start hereprothena be try complete entry see stock break heavy trading regard top bottom line number company have post quarters rise earning growth sale growth have also rise same time frame prothena hold rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
149,CELG,sarepta therapeutic srpt have relative strength rs rating upgrade wednesday ibd unique rs rating measure technical performance show stock price action last week compare other stock database year market history reveal best stock tend have rs rating north early stage move look best stock buy watch start heresarepta therapeutic be trading buy zone breaking past buy point cup handle proper buy range be initial entry once stock move range best hold investing set buy opportunity earning growth increase last quarter sale fall look next report oct sarepta therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
150,CELG,consider name put watch list look stock higher rs rating innoviva inva just clear benchmark upgrade ibd proprietary rs rating track technical performance used worst best score show stock price action last week match other publicly trade company year market history reveal market biggest winner typically have rs rating north early stage move look winning stock try simple routineinnoviva be build cup handle entry see stock clear price volume least average earning growth drop last quarter top line rise next quarterly number be expect oct innoviva earn rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
151,CELG,acceleron pharma xlrn see positive improvement relative strength rs rating wednesday rise ibd proprietary rating track market leadership worst best score rating show stock price performance trail week hold other stock database decade market research reveal best stock often have rs rating launch biggest run look best stock buy watch start herewhile acceleron pharma be not ideal buy zone right now see manage form break proper consolidation earning sale growth come respectively latest report show improvement earning share sale acceleron pharma hold rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
152,CELG,relative strength rs rating global blood therapeutic gbt climb new percentile tuesday increase ibd unique rating track market leadership worst best score score show stock price behavior trail week stack other stock database history show stock go make biggest gain typically have rs rating north early stage move look best stock buy watch start herewhile now be not ideal time buy share see stock be able establish enter buy zone heavy trade term top bottom line number company have post rise ep growth last quarters sale gain have not follow same trajectory come latest report company earn rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
153,CELG,major stock index hold decent gain midday friday weak result general electric ge didn have much effect price weight dow jone industrial average dow outperformed rise nasdaq composite add picked volume nyse nasdaq be tracking higher thursday level stock market today be skewer somewhat option expiration positive sentiment be fuel part renew optimism tax reform become reality year treasury yield be basis point dow name be more help offset decline share ge earning share miss wide margin fuel fear ge do away quarterly dividend cent share ge currently yield share be much strong gainer dow include unitedhealth group unh goldman sachs gs jpmorgan jpm cisco system csco ibd atlassian team dominate action soar strong earning base software name close just buy point thursday stock gap friday so new buyer ve have opted buy stock open price ibd take atlassian have several trait see past market winner big price move see be check section ibd university skecher skx be winner surprisingly strong earning earning share jump cent share well consensus estimate cent sale hit quarterly record year quarter downside celgene celg be news biotech giant discontinue pair late stage trial drug be investigate treat crohn disease related invest stock market used simple routinege earning miss badly cash flow dive add dividend fearswill earning launch monster move stock
154,CELG,acorda therapeutic acor see welcome improvement relative strength rs rating tuesday rise ibd unique rating measure market leadership worst best score rating show stock price performance trail week hold other stock database history show best stock often have rs rating north early stage move see acorda therapeutic continue show renew price strength hit benchmark look best stock buy watch start herewhile stock be not proper entry right now see manage form break proper base company see earning sale growth rise last quarter earning share increase revenue rise acorda therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
155,CELG,acceleron pharma xlrn have relative strength rs rating upgrade tuesday welcome improvement still higher score prefer see ibd unique rs rating measure technical performance show stock price movement last week measure other stock database year market history reveal best stock tend have rs rating north launch biggest run see acceleron pharma continue rebound hit benchmark look best stock buy watch start hereacceleron pharma be not currently potential buy area see stock go build promising consolidation launch new move earning sale growth come respectively latest report marked acceleration top bottom line acceleron pharma hold rank peer medical biom biotech industry group celgene celg therapeutic cort alexion pharmaceutical alxn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
156,CELG,advanced accelerator application aaap launch record high thursday rumor swiss drug giant novartis nvs attempt take potential deal analyst call very logical xadvanced accelerator gap much time high settle back gain close novartis lift fraction finish potential deal fit well novartis exist franchise include sandostatin approve treat symptom associate tumor afinitor approve treat cancer affect breast kidney hormone nervous system canaccord analyst mark massaro say advanced accelerator be work gain approval drug call lutathera treat tumor tract december lutathera be delay food drug administration approval be now expect january expect final european medicine agency approval lutathera come day fda approval schedule jan push share higher massaro write note client expand access program help launch ibd take cellular therapy also know car therapy be get leg wall street novartis gain first approval earlier year kite pharma be next head industry snapshot closer look medicine be make massaro expect lutathera offer long tail revenue consider limit supply material go drug extreme efficiency model peak sale peak european sale model conservative pricing line current therapy lutathera significant efficacy advantage say massaro keep buy rating price target advanced accelerator novartis gain access lutathera be very logical say cancer drug be staple novartis pipeline advanced accelerator also have drug treat neuroendocrine prostate breast cancer pipeline novartis just gain approval drug call kymriah cellular therapy treat form acute lymphoblastic leukemia patient age competition be come gilead science gild be work acquire kite pharma kite be close approval similar drug gilead kite juno therapeutic juno bluebird bio blue be work celgene celg develop similar cellular therapy treat blood cancer related biotechs beating market be buy range galapago pop eczema drug show promise vs regeneronfda chief gottlieb address opioid cancer new therapiesabbvie new hepatitis drug chip away gilead share
157,CELG,dow industrial rally strongly thank ibm ibm turnaround johnson johnson jnj several other blue chip earning general electric ge be big miss adobe system adbe also be big winner bullish outlook netflix nflx hit new high boom subscriber growth ipos be hot dow industrial rise week fuel ibm predict return revenue growth johnson johnson unitedhealth unh be also notable blue chip contributor general electric crash big ep miss have little impact price weight dow rise nasdaq help senate first step big tax cut adobe system soar outlook paypal pypl beat netflix pull back record high high subscriber gain unite airline ual crash carrier have few answer question few new ipos impressed internet television network netflix cheer investor third quarter subscriber addition trounce expectation earning growth miss view sign net new stream subscriber third quarter beating wall street target december quarter netflix expect add new subscriber edge consensus view end september quarter stream subscriber worldwide netflix share hit record high tuesday morning sank week remain buy range related netflix stock fall third quarter subscriber beatadobe system share surge record high maker digital medium marketing software announce upbeat sale earning target fiscal san jose calif base adobe be target adjust earning share year year sale wall street be modele related adobe system rocket outlookibm share soar tech icon report quarterly earning beat estimate indicated sale growth return first time more year ibm do not provide formal quarterly guidance management indicated revenue snap quarter string revenue decline related ibm get price target hike earning report outlookgeneral electric earn just cent share far cent expect revenue rise more expect organic industrial revenue dip industrial operate margin shrank ge power business be big drag industrial cash flow operate activity plunge adjust due weakness power business ge slash full year earning cash flow guidance raise concern dividend cut ge share fall soon friday open close related ge earning miss badly cash flow dive add dividend fearsunited airline tumble more management carrier third quarter earning call be unable provide detail longer term plan drive profit lack clarity lead analyst believe carrier be walking back target outlined last year grow earning higher expect cost be also concern drop fare compete ultra low cost carrier morgan stanley ms top estimate help strong stable wealth management business rival investment bank goldman sachs gs also beat analyst raise concern result be help more volatile capital intensive line business goldman trading result continue struggle morgan outperformed other big bank morgan stanley rise retake buy point goldman sachs climb dow component johnson johnson top wall street view report adjust earning share sale pharmaceutical sale jump worldwide medical device revenue rise miss estimate abbott laboratory narrowly beat expectation early wednesday lion share beat come abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product share rise clear buy point hit record high abbott advanced also time best related dow component pop top view pharma strengthqudian qd china base online credit firm backed alibaba baba rise debut raise pricing expect range singapore base online gaming company sea backed chinese internet giant tencent tcehy edge higher debut raise upsized ipo mongodb mdb provide open source database software platform business pop ipo top just raise price range qudian be profitable sea be poise start make money related sea upsized ipo raise millionmongodb price high qudian strong debut play new ipostop semiconductor industry player deliver generally upbeat report september quarter past week taiwan semiconductor manufacturing tsm beat target third quarter sale earning guide higher current quarter sale maxim integrate product mxim beat wall street target earning sale be tad short however maxim guide earning sale december quarter be well view chip gear vendor lam research lrcx beat view guide higher current quarter rival asml asml beat sale earning target third quarter revenue guidance be light unitedhealth group unh share vault record high tuesday then keep climb insurer report earning growth cent ahead estimate show enviable strategic position have exit obamacare exchange unitedhealth say benefit president trump executive order make low cost plan more widely available amazon com amzn want enter retail prescription business analyst say unitedhealth be ideal partner company signale willing meanwhile anthem antm insurer follow example unitedhealth announce broaden offer include pharmacy benefit management anthem share near buy point news dump express script esrx utilize cvs health cvs process retail distribution start related anthem jump prescription business amazon speculation signal openness amazon partnership earning beatpaypal report september quarter profit revenue top view forecast current quarter sale estimate send share commerce payment processor paypal say adjust earning be cent share year revenue rise current quarter paypal forecast revenue growth midpoint guidance gaap profit cent vs consensus estimate cent paypal jump friday new record high related paypal earning revenue top expectation share slb say friday investment demand north america be moderate baker hughe bhge warn challenge year end customer remain cautious spending due volatile oil price suggest shale other operator be rein production growth plan schlumberger meet ep view gain baker hughe report first quarter merger general electric oil gas unit july crude price hold barrel inventory fall yet again production plunge due gulf shutdown hurricane nate charle schwab schw trade etfc beat wall street consensus third quarter earning schwab miss revenue trade meet expectation schwab report ep cent revenue trade post earning cent share revenue schwab undercut buy point report sharp fall trading revenue share rebound friday trade share fall be still buy range past entry ebay ebay meet third quarter earning estimate revenue be slightly forecast online marketplace fourth quarter ep outlook fall short estimate share sank close day move average recent buy point undercut intraday thursday related ebay meet earning view share tumble weak outlooksap sap report quarterly earning top estimate german enterprise software giant raise guidance year base cloud compute strength bombardier bdrbf agree sell stake struggle series jet airbus eadsy commerce department call tariff narrow body jet deliver boee ba accuse canadian company receive unfair government subsidy gilead science gild win fda approval car drug dub yescarta treat aggressive form hodgkin lymphoma yescarta come gilead recent kite pharma deal gilead rise thursday be little change weekcelgene celg scrap trial crohn disease drug win start third cite internal futility review celgene fall friday intuitive surgical isrg top expectation late thursday report sale adjust profit share share rise friday atlassian team surge maker project management software report fiscal first quarter sale profit handily top estimate atlassian up full year revenue guidance midpoint guidance earlier forecast share surge nearly verizon communication vz add more postpaid wireless phone subscriber expect revenue also top estimate proofpoint pfpt report earning revenue top estimate fiscal outlook disappoint share rise friday video game publisher electronic art ea disappoint news be delay star war action adventure game have be set release fiscal run april march do not give new release time frame ea share be so far week rv maker winnebago wgo exceed forecast profit growth cent share revenue increase company also approve share buyback share close american express axp exceed earning estimate longtime ceo kenneth chenault retire stephen squeri set take place feb unite rental uri steamrolled estimate cent share ep rise revenue boost hurricane rebuild be reason nation largest equipment rental company boost guidance capital spending plan procter gamble pg profit grow share top view cent organic sale rise just result follow narrow proxy fight trian fund management nelzon peltz share fall friday unilever report weak sale thursday european consumer food product giant fall week related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start here
158,CELG,major market index be quietly higher early morning trade tuesday tech heavy nasdaq edge higher rise less meanwhile dow jone industrial average inched slightly higher dow jone industrial component johnson johnson jnj unitedhealth unh rise respectively upbeat earning result be track reclaim flat base buy point unitedhealth surge new high downside boee ba decline fall back buy range flat base entry fang stock facebook fb reach flat base buy point social medium giant briefly touch record high morning company report earning netflix nflx have hover positive negative territory be much earlier late monday company release strong result late monday see video streamer add more subscriber expect earning fall short street target come cent share compare cent share estimate global investment bank goldman sachs gs morgan stanley ms beat top bottom line estimate early tuesday spark early advance share goldman turn red fall goldman sachs be still build saucer handle pattern entry morgan stanley add gain recent cup handle featured buy point morgan reach new week high blue chip jpmorgan jpm trade unchanged hold recent gain flat base buy point recent issue despegar com desp faltered more trigger sell signal recent ipo base entry ibd celgene celg attempt regain day line advance biotech be still flat base entry downside lead chip stock apply material amat beat hasty retreat fall almost morning trade share be still extend cup handle buy point related dow stock report earning tuesday investing action plandow jone industrial average dow stock news analysisnetflix beat third quarter subscriber gain stock climbsfang stock news quote facebook amazon netflix googlegoldman sachs morgan stanley top view trading still weak
159,CELG,first stage basis be scarce ibd big cap go friday session only few stock carry first stage label be stage xas stock advance pause consolidate see most easily weekly chart first basis be more likely
160,CELG,friday supernus pharmaceutical supn get upgrade relative strength rs rating unique rating measure technical performance used worst best score indicate stock price action last week match other stock year market history reveal market biggest winner typically have higher rs rating early stage move see ibd help make more not currently ideal time jump see stock manage form base break earning growth fall last quarter revenue rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
161,CELG,friday neurocrine bioscience nbix hit noteworthy performance benchmark see relative strength rs rating jump percentile improvement day ibd unique rating identify share price performance worst best score score show stock price performance trail week hold other stock database year market history reveal best perform stock typically have higher rs rating begin new climb see ibd help make more money bioscience have climb more past entry first stage cup handle meaning now proper buy zone look stock offer new buy opportunity week tight pullback day week line neurocrine bioscience show earning growth last quarter sale growth come company earn rank peer medical biom biotech industry group celgene celg therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
162,CELG,potential cancer cure disclosure propel loxo oncology loxo stock day june additional day september indicate innovation cancer research treatment many investor say keep loxo aloft potential blockbuster cancer treatment make loxo be recognize investor business daily inaugural ibd biotech innovator award lead drug look medically promising target relatively small patient population so annual revenue be expect fall short define commercial blockbuster get close loxo stock make big leap june company disclose progress phase phase trial lead drug candidate larotrectinib leap loxo stock follow word disclose phase trial datum tumor fighter annual meeting international association study lung cancer set start saturday oct loxo stock touch time high company expect file new drug application larotrectinib early food drug administration approve nda month loxo expect company begin sale specific patient almost immediately ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report loxo focus develop highly selective precision medicine patient genetically defined cancer be gain ground researcher patient doctor fund manager rather look attack specific cancer say used compound lung tumor sometimes don work healthy cell too loxo used increasingly popular gene sequence identify patient host specific gene mutation result tropomyosin receptor kinase trk fusion be abnormal protein tell tumor cell grow used loxo novel compound inhibit trk fusion activity call trk inhibitor kinase inhibitor loxo clinical trial therapy demonstrated improvement patient different type cancer hence loxo larotrectinib be gain attention research clinic wall street well become first drug initially approve fda target mutant protein many cancer rather target cancer loxo spokesman dan budwick call approach tumor agnostic note merck mrk keytruda be indeed approve treatment unresectable metastatic solid tumor specific genetic quality first fda keytruda be initially approve metastatic melanoma then small cell lung cancer then head neck squamous cell carcinoma be already widespread use merck apply fda also use keytruda gene sequence tumor agnostic approach rather old tumor specific approach contrast loxo larotrectinib be first time fda initially approve cancer drug used tumor agnostic gene sequence approach ibd take loxo recently hit time high company be do so moment ibd new high list track mover also rank ibd composite rating loxo potential have wall street attention number mutual fund hold loxo share jump support market cap secondary offer late june marked straight quarters rise fund ownership loxo late sport highest possible ibd relative strength rating putt top stock price performance past month week loxo june report american society clinical oncology asco meeting chicago world biggest cancer conference loxo sell more share common stock secondary offer pricing share stock have trade well recently november company raise expense stock performance loxo rival be rival however have be spotty time most be roll late loxo peer ignyta rxdx go public early month loxo have mostly trade ipo price thursday ignyta stock touch month high loxo partner array biopharma arry peaked shortly ipo stock be way touch year low february month hit month high blueprint medicine bpmc loxo develop kinase inhibitor go public hit new time high september run asco june loxo report objective response rate tumor size be reduce patient many cancer type clinical trial patient tumor hold trk fusion larotrectinib deliver consistent durable response trk fusion patient age regardless tumor context do so few side effect dr david hyman research team principal investigator loxo larotrectinib trial tell asco conference hyman be chief early drug development memorial sloan ketter cancer center way larotrectinib trk fusion story fulfill promise precision medicine tumor genetic rather tumor site origin define treatment approach cowen analyst eric schmidt say loxo estimate patient annually benefit larotrectinib treatment trial datum disclose asco patient greatest tumor shrinkage include soft tissue sarcoma lung colon cancer melanoma salivary gland cancer type cancer be be treat trial patient have least thing common gene mutation cause kinase trk fusion tell cancer cell grow larotrectinib earn breakthrough therapy designation fda july meaning fda give priority early trial suggest new therapy offer serious advantage exist treatment person life threaten disease breakthrough be not necessarily fda highest priority however fast track priority review designation accelerate approval pathway be fda urgent alternative larotrectinib then call loxo receive breakthrough designation unresectable metastatic solid tumor neuronal trk fusion protein adult pediatric patient require systemic therapy have progressed worsen follow prior treatment have acceptable alternative treatment note friend cancer research nonprofit count fda breakthrough designation include larotrectinib target cancer analyst schmidt say recent efficacy datum larotrectinib be best ever have see oncology estimate peak larotrectinib market annual sale year morgan stanley analyst matthew harrison see larotrectinib peak annual sale loxo go public august share conceivably get acquire blockbuster premium buyout talk have surface biotechs end be purchase most be acquire become profitable say schmidt cowen estimate loxo win escape red ink thing have transpire asco june be celgene celg pricing idhifa month new high niche oncology market schmidt tell ibd give loxo breathe room perhaps lead consider higher price larotrectinib idhifa be approve fda aug treat aml most common form acute leukemia adult celgene estimate new aml case be diagnosed annually june secondary offer more double loxo cash pile nearly june help loxo make acquisition bruton tyrosine kinase btk inhibitor program redx pharma rename redx drug candidate loxo loxo acquisition release chief business officer jacob van naarden call deal program pipeline so nicely align larger strategic vision capability redx team have create novel chemical matter selectively reversibly inhibit btk validate molecular target numerous cell leukemias lymphomas analyst schmidt tell ibd price tag look right btk target be validate be unmet need patient fail imbruvica abbvie abbv johnson johnson jnj commercial name ibrutinib treat complication stem cell bone marrow transplant know chronic graft versus host disease gvhd research note morgan stanley harrison praise btk acquisition call logical addition loxo pipeline rate loxo stock overweight price target cowen schmidt rate loxo outperform doesn offer price target cowen analyst be unfazed loxo financial loss greater estimate cash burn biotech earning rarely be interesting schmidt say loxo report wider loss share cent loxo be slate post result oct cash hoard loxo be danger run money year investor expect sale profit then cowen schmidt meet least twice recently loxo top brass say company be track speedy approval larotrectinib loxo be work other potential drug include btk inhibitor buy redx target leukemia lymphoma pipeline partner array biopharma kinase inhibitor target too early suggest approach blockbuster status related get detail biotech innovator award winning company loxo oncology stock hit record small cap biotech stock pop new high
163,CELG,alnylam pharmaceutical alny have relative strength rs rating upgrade thursday proprietary rating track technical performance used worst best score indicate stock price performance last week match other stock database history show stock go make biggest gain typically have rs rating north begin new climb look best stock buy watch start herealnylam pharmaceutical have moved more past entry second stage flat base meaning now proper buy zone look stock create new buy opportunity week tight pullback day week line alnylam pharmaceutical report earning growth last quarter sale gain come company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
164,CELG,future index nasdaq dow industrial rise friday morning senate approve budget resolution late thursday pave way tax cut next year xs future rise vs fair value dow future climb nasdaq future advanced unclear much tax cut be already price stock market have rally significantly president trump election large part hope lower corporate tax rate other reform also trump gop lawmaker have unrealistic expectation size tax cut give budget constraint budget blueprint pass vote be still key step allow republican push deficit finance tax cut democratic support afford only defection budget vote highly rate celgene celg paypal pypl atlassian team be active late trading earning other news meanwhile thursday stock market trading index dow erased loss close slightly higher nasdaq retreat fang stock facebook fb google parent alphabet googl drift recent entry point paypal celgene trade financial etfc atlassian have composite rating better composite rating run combine several proprietary ibd rating number time stock winner often have composite rating least start big run facebook fall close intraday lows still end buy point clear tuesday thursday slide wasn impressive neither be tuesday upside move come average volume alphabet dip thursday entry top oct again google parent retreat be rather modest do come volume be trend problem lackluster breakout have be too common recent month be suggest lack institutional support creep just buy point not advance stock such facebook google be vulnerable go underwater modest market industry company specific news then again piece good news market momentum push stock back buy zone facebook rise premarket trading friday alphabet be paypal composite rating paypal report earning share gain revenue better expect online payment processor give ep revenue guidance basically line analyst view paypal rise early trading paypal close cent thursday be so far celgene composite rating celgene announce be discounting trial crohn disease drug not start third say mongersen ged fail interim futility analysis celgene have spend obtain mongersen share biotech giant tumble early friday celgene undercut buy point week last friday fall day move average atlassian composite rating atlassian earn cent share fiscal revenue top consensus maker project management collaborative software raise guidance atlassian be not yet active friday morning jump hour trading thursday regular session stock dip intraday recent buy point rally close related big picture bear lose grip stock continue break outcelgene fall scrapping crohn disease drug trialspaypal earning revenue top expectation share riseatlassian revenue profit blow past estimate share jumpfang stock news quote facebook amazon netflix google
165,CELG,exelixis exel see positive improvement relative strength rs rating tuesday rise ibd proprietary rs rating identify market leadership show stock price action last week measure other stock database decade market research reveal best stock tend have higher rs rating begin new run look winning stock try simple routineexelixis break earlier have fall back prior entry consolidation case stock break then fall more entry price consider fail happen best new base take shape also keep mind most recent consolidation be later stage base make riskier establish new position add share exist earning growth rise last quarter sale fall keep eye company next round number nov exelixis hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd celgene celg be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
166,CELG,ptc therapeutic ptct see welcome improvement relative strength rs rating tuesday increase proprietary rating measure market leadership show stock price movement last week measure other stock database year market history show best perform stock tend have rs rating early stage move see ibd help make more money stock be build consolidation buy point see clear price heavy volume earning grow last quarter prior report revenue also increase keep eye company next round number nov company hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd celgene celg be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
167,CELG,stock jump start bell friday global market rebound earning news rolled senate vote late thursday moved congress further budget resolution potential tax reform dow jone industrial average pop nasdaq composite scale paypal pypl maxim mxim lead nasdaq list stock receive early uplift washington senate republican late thursday pass budget measure set stage tax reform next decade house have pass separate resolution earlier year opt pass senate proposal otherwise quiet day economic news show national association realtor release september exist home sale number et baker hughe bhge report weekly oil gas rig count et cleveland federal reserve bank president loretta mester be schedule speak et cisco system csco vault take early lead dow industrial general electric ge pare open loss report third quarter earning full year earning guidance analyst target new chief executive chairman john flannery company carved earning guidance halved project cash flow announce plan trim more portfolio business year stock be nearly december high apple aapl rebound fall more cut week move average heavy trade thursday big tech fang stock trade higher facebook fb amazon com amzn lead group gain skecher skx be friday surprise package vaulting positive fiscal fourth quarter report turn quarters earning decline move suggest open buy point month base pattern not premarket move hold start bell ibd stock atlassian team rumble higher open trade project management software developer fiscal first quarter result easily outpaced expectation move send share well buy range buy point cup base commerce payment processor paypal rolled gain report third quarter result late thursday be expectation ibd stock be extend more flat base buy point profit take zone also ibd list celgene celg dump nearly pair analyst downgrade stock follow drugmaker announcement late thursday halt phase trial crohn disease treatment resolve recommendation trial datum monitoring committee celgene share have pull back past week have be struggle maintain support week move average ncr ncr get wallop early action duluth ga company report mixed third quarter result late thursday fourth quarter earning revenue guidance consensus view stock have recently climb august low remain deep month consolidation action china show hong kong rebound hard thursday sell lift hang seng index tokyo nikkei post fractional gain sixth straight weekly gain just ahead japan parliamentary election schedule sunday europe market be positive pare gain afternoon investor worry plan spanish government assume federal control saturday rebel region catalonia london ftse dax frankfurt be respectively related big picture stock continue break csx invest stock market used simple routinetop analog chip stock get price target hike strong weapon biggest stealth be come
168,CELG,kite pharma be edge closer approval cut edge cancer treatment fight disease rebuild patient own cell technology benefit thousand person pave way blockbuster drug xkite ultracustomized treatment be key entry area great promise cancer research have attract dozen drugmaker include bluebird bio blue juno therapeutic juno celgene celg novartis nvs latter get major fda approval august give novartis lead emerge field firm other be develop own cancer fight system harness same underlie process used kite be now unit gilead science gild approach call car therapy used bioengineering retrain patient infection fight white blood cell seek destroy cancer cell analyst say kite manufacturing process stand car field shorter turnaround time treatment success rate kite groundbreaking work investor business daily name company ibd biotech innovator inaugural edition award ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report david chang kite chief medical officer tell ibd current cell therapy be just begin be area really set undergo big change next few year kite have recently enlist powerful ally late august gilead foster city calif agree acquire santa monica calif base kite share cash deal value deal close oct kite already be trading time high start summer go public share mid gilead stock rise company announce merger close friday alliance bring kite establish partner financial heft industry breadth just biotech ingenue prepare beef production distribution flagship drug treatment axi cel short axicabtagene ciloleucel be design fight aggressive form hodgkin lymphoma type blood cancer affect immune system be sixth most common cancer kite be expect get drug approval year gilead be hitching star kite expectation gain string successful cancer fight product time gilead strongest portfolio medication treat hepatitis be lose steam kite expect manufacturing process hone develop axi cel serve foundation future treatment include destroy solid cancer tumor cancer cervix head neck pharmaceutical company typically look fill product pipeline acquire company technology don have gilead purchase kite come wasn just do kind acquisition be more long term play multiple product opportunity see play decade come gilead ceo john milligan say conference call analyst follow purchase announcement even sale hepatitis product crimped revenue be grow gilead hiv aids drug company be expect end year revenue last year gilead be company market cap company ibd biotechnology industry group trail leader amgen amgn just celgene gilead have substantial balance sheet help fund launch kite product europe help expand kite manufacturing capacity facility el segundo calif help propel other early stage project forward jeffery analyst biren amin tell ibd return amin say gilead get early midstage oncology pipeline didn have kite allow diversify away hepatitis longer term kite isn say much charge treatment product be approve amin say analyst estimate cost range person full course therapy company have build capacity produce patient therapy year kite spokeswoman christine cassiano say food drug administration be expect make decision kite axi cel drug nov kite hasn disclose brand name drug timeline hold kite drug reach blockbuster status annual sale more accord amin kite win be first biotech company receive fda approval car drug novartis get green light fda aug therapy certain type leukemia child young adult kite axi cel drug be approve fda become first therapy kind treat hodgkin lymphoma patient advanced case disease hodgkin lymphoma be type blood cancer originate immune system therapy involve extract filter patient blood remove key component immune system call cell engineering cell lab so express chimeric antigen receptor car be programme escort intruder destroy cell directly protein find surface cancer cell modify cell be infuse back patient multiply become body cancer fighter researcher affiliated national institutes health develop early science underpin process license kite kite be dozen biotech firm have receive permission use agency version technology accord amin kite study find month single infusion treatment be administer patient advanced hodgkin lymphoma chemotherapy longer work be complete remission sign malignancy rocket science say kite chang company multistep manufacturing process say take day vein vein say be shortest turnaround time company try develop own version car drug be art manufacturing process observer say kite deft approach high success rate clinical trial have set company apart thing paid lot attention be make sure manufacturing be successful so be cell product be give back patient chang say be able treat everybody enrolled clinical study exception single patient patient less be not able be treat kite aim automate more drug development process part collaboration general electric ge offshoot ge global research initiative help kite reduce manufacturing cost speed process time minimize variability result kite also be research way change cell be manipulate growth factor make supercharged cell more effective once be return patient chang say company be investigate equip person cell so be able go more just type cancer say kite be even look develop shelf car product be used patient say talk innovation execution well make right choice hopefully guide program say analyst amin re do related kite pharma company rise ibd biotech innovator status get detail biotech innovator award winning company workbluebird be biotech stock new biotech stock have catch rallywill novartis acquire company
169,CELG,biotech company celgene celg biogen biib gilead science gild put drug extensive trial gain fda approval turn clinical research firm pra health science prah pra health be world lead global contract research organization hold ranking medical research equipment
170,CELG,tuesday axovant science axon earn upgrade relative strength rs rating ibd unique rating identify share price performance worst best score score show stock price movement trail week compare other stock database year market history show top perform stock often have rs rating early stage move look winning stock try simple routineaxovant science be try complete consolidation buy point see clear price volume least average company show earning growth most recent report sale growth come company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
171,CELG,major market index be higher early morning trade friday tech heavy nasdaq set pace rise dow jone industrial average rise just apiece dow jone industrial component wal mart store wmt be track extend recent streak trading session advance share be now extend flat base entry tuesday downside unitedhealth group unh drop almost high turnover fall further day line company report earning global bank well fargo wfc drop report mixed result bank be back day line further away potential double bottom entry meanwhile bank america bac reversed early loss rise report better expect earning sale share be attempt remain cup shape base entry fang stock netflix nflx see second price target boost many day jpmorgan raise ahead next week result share jump almost be barely extend cup handle buy point share also notch fresh record high meanwhile facebook fb rise almost be approach flat base entry stock be less away mark fellow fang amazon com amzn google parent alphabet googl advanced higher amazon be continue build right side potential base facebook be once again approach flat base alphabet be back flat base entry former highflier apply optoelectronic aaoi plunge early friday preannounce weak earning late thursday share be late july high ibd video game maker electronic art ea rise attempt regain control day line share be build flat base potential buy point downside grubhub grub decline appear be stick day line food deliver service now have modest gain entry be much meanwhile lead biotech celgene celg be day line today decline be much flat base entry share be now level related hit high wal mart nvidia soar dife jpmorgan up reserve week reviewdow jone industrial average dow stock news retail banking lift bofa profit well fargo revenue missesfang stock news quote facebook amazon netflix google
172,CELG,monday prothena prta get positive adjustment relative strength rs rating ibd unique rs rating track market leadership show stock price action last week compare other stock database decade market research reveal market biggest winner often have higher rs rating launch biggest climb look winning stock try simple routineprothena be work entry see clear price heavy volume take look revenue profit performance prothena have post rise ep growth last quarters top line growth have also rise same time frame company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
173,CELG,monday miratus therapeutic mrtx receive positive adjustment relative strength rs rating exclusive rating investor business daily identify market leadership worst best score score show stock price movement trail week hold other stock database history reveal stock go make biggest gain typically have rs rating north begin new run look winning stock try simple routinemiratus therapeutic be not currently potential buy area see stock go form sound pattern launch new move miratus therapeutic post ep growth last quarter revenue rise miratus therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
174,CELG,gilead science gild jump early thursday food drug administration approve be know car drug dub yescarta treat aggressive form hodgkin lymphoma late wednesday approval follow week gilead close acquisition kite pharma develop drug novartis nvs car drug be approve late august make first class approval close bell stock market today gilead climb close share be currently form flat base entry car drug be make used patient own immune cell cell be extract reprogram fight cancer be then reintroduce patient body juno therapeutic juno bluebird bio blue be also work car drug partnership celgene celg gilead drug be approve treat adult patient know large cell lymphoma more previous treatment include diffuse large cell lymphoma most common form aggressive hodgkin lymphoma accounting case gilead say ibd take washington base expert expect president donald trump sign executive order bring drug price day make thing harder biotechs drugmaker head ibd industry theme breakdown be estimate patient hard treat diffuse large cell lymphoma eligible car therapy gilead say fda estimate case hodgkin lymphoma diagnosed year roughly be new case diffuse large cell lymphoma yescarta be new option patient relapse refractory large cell lymphoma have run treatment option face dire prognosis say loui degennaro chief executive leukemia lymphoma society statement rbc analyst brian abraham say gilead be begin be potential multibillion dollar franchise approval come month ahead expectation demonstrate high unmet need patient diffuse large cell lymphoma say note client gilead be pricing yescarta be price tag novartis drug kymriah kymriah be approve late august treat form acute lymphoblastic leukemia patient age younger leerink analyst geoffrey porge note novartis be take outcome base approach pricing center medicare medicaid service firm only be paid patient respond month treatment kymriah base response rate pivotal trial estimate real list price be less treatment place yescarta less discount novartis drug net price basis write note client rbc abraham estimate gilead pull gradual launch expect yescarta sale grow least solely third treatment diffuse large cell lymphoma car drug be be investigate treat myriad blood cancer increase pricing assume approval indication second treatment diffuse large cell lymphoma mantle cell lymphoma pediatric adult acute lymphoblastic leukemia current model see peak revenue potential say leerink porge be less bullish gilead yescarta list price be higher expect gilead core business be still face competitive challenge patent expiry keep market perform rating stock get most kite acquisition require expand yescarta use porge say announcement do not provide justification premium gilead paid kite cellular therapy platform say gilead be depend broaden earlier line treatment expand other indication development additional product generate adequate return acquisition label yescarta warn cytokine release syndrome neurological toxicity former be associate flulike symptom include fever cytokine release syndrome be see patient clinical trial more severe case patient comparison label novartis kymriah note more severe cytokine release syndrome occur patient porge say due potential cytokine release syndrome neurological toxicity yescarta be available only restrict program call risk evaluation mitigation strategy mean facility administer drug be certify abide specific rule administration program require dose drug be available prior yescarta infusion patient be monitored facility week follow treatment sign cytokine release syndrome follow monitoring be require week infusion ultimately gilead plan have medical center capable administer yescarta drug have median turnaround time day manufacturing success rate facility el segundo calif gilead say related top biotech company innovation earn recognition new novartis cancer approval validate gilead kite dealanalyst mixed gilead kite key rival stand benefit
175,CELG,prime therapeutic fprx have relative strength rs rating upgrade monday unique rating track market leadership show stock price movement last week compare other stock database decade market research reveal market biggest winner often have rs rating north begin biggest price move see ibd help make more stocksfive prime therapeutic be not currently offer proper buy opportunity see stock go build base launch new move prime therapeutic report negative growth sale earning last quarter company be expect release next quarterly number nov prime therapeutic hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
176,CELG,cure be strong word come treat cancer other deadly disease brad loncar be biotech stock analyst investor ready employ term first time biotech company be not think technology incrementally say loncar portfolio manager biotech focuse etf re not think alleviate symptom disease re think fix genetic mutation cause disease loncar be speaking cancer comment apply other terrible disease claim thousand life include alzheimer parkinson lou gehrig disease multiple sclerosis muscular dystrophy year first fda approve biotech drug biotech industry be roll innovation breakneck pace new drug pipeline be burst treatment clinical trial industry be grow leap bound many biotech stock be score superior return investor recognize biotechnology industry contribution science patient health investor business daily have create ibd biotech innovator award inaugural edition name award winning biotech company choose groundbreaking treatment recently introduce market well new product pipeline company be celgene celg biogen biib regeneron pharmaceutical regn kite pharma incyte incy loxo oncology loxo winner aren rank way only company trade share be consider biogen have sight firmly cure cancer other intractable disease biogen be target like alzheimer parkinson ms ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report company be just few player huge field closely track investor ibd count publicly trade company biotech industry group doesn include many other company biotech operation aren main focus have combine market cap nearly sale most recent month more thank biotech industry pipeline new drug kind have explode clinicaltrial org count more drug file phase late stage trial food drug administration year fda have more late stage study register ibd biotech industry stock group have climb year shuck pain politically charge election season concern president trump work lower drug price group wednesday hit month high be time high july currently rank group track ibd term performance past month boost group performance be celgene loxo recently hit new high incyte touch record high year biogen touch month high friday regeneron year touch nearly year high biotech focuse fund brad loncar head be loncar cancer immunotherapy etf cncr track biotechs work immunotherapy exchange trade fund be near year anniversary be year comment ibd come series regulatory approval acquisition cancer treatment include gilead science gild foray cellular therapy august agreement acquire kite nearly kite purchase be complete oct kite now operate wholly own gilead unit count loncar bullish today drug immune system identify fight precisely target cancerous cell technology turn edit gene correct genetic condition trial datum be jaw drop say example be car technology kite be leader field be young biotech company be take patient have week month live case be see complete remission loncar say ve never see anything loncar liken chemotherapy bomb kill enemy everything else sight loxo be used smart bomb precision medicine target gene fusion cancer jmp security analyst mike king explain cancer gene be call passenger other driver king tell ibd driver become fuse normal cell normal cell transform cancerous loxo identify target fusion american society clinical oncology conference june loxo show impact work photo sarcoma protrude child chest king say target call trk fusion loxo be able treat cancer tumor shrink away nothing surgery radiation other therapy contribute say be remarkable be pretty staggering even person audience be kind used see kind thing patient drug dub larotrectinib be able partly shrink tumor sign cancer disappear patient drug have breakthrough rare pediatric disease orphan drug designation fda also grab headline be immuno oncology work dow component merck mrk well incyte bristol myer squibb bmy roche rhhby astrazeneca azn kite car therapy be get due like novartis nvs juno therapeutic juno bluebird bio blue immuno oncology car be method teach immune system fight cancer immuno oncology drug do so block specific interaction otherwise prevent immune response car drug individualize process reprogramming patient own extract immune cell ibd take car drug be snag major attention gilead announce plan acquire kite novartis get major drug approval open sector head ibd industry snapshot feature closer look emerge car sector result have impressed immuno oncology drugmaker be take step further combine compound hope see more robust response merck have have success drug keytruda have win approval first treatment chemo lung cancer incyte drug epacadostat be particularly intriguing analyst say prevent interaction involve ido enzyme merck bristol be pairing drug keytruda opdivo class drug know pd inhibitor incyte epacadostat regeneron too be work pd inhibitor regn develop partnership sanofi sny june regeneron sanofi say patient form skin cancer respond treatment regn phase trial car side novartis gain fda approval late august drug treat form acute lymphoblastic leukemia patient age approval help spike gilead just day have announce deal acquire kite kite be near approval car drug treat aggressive form hodgkin lymphoma juno be just drug call jcar treat same cancer kite drug bluebird be work multiple myeloma drug juno bluebird have partner celgene program jmp king call best breed approach celgene put money line potential innovation such partnership be celgene excel wedbush analyst david nierengarten tell ibd ve have innovative deal sector small molecule cell therapy say re innovative cast net widely new technology potential therapy other be reap benefit decade old project map human genome first human genome map cost dollar take almost year complete today cost closer map individual entire genetic makeup gene therapy editing be have renaissance jmp king say analyst point crispr therapeutic crsp make ipo year leader field crispr be also name technology crispr therapeutic audente therapeutic bold intellium therapeutic ntla also be make wave sector technology make much easier edit gene needham analyst alan carr tell ibd btig analyst dane leone see company enter clinic technology used enzyme be actually bacterial organism target area genome dna want make change dna say do used enzyme complex be give direction term target insert cell end enzyme complex attach dna make alteration tell ibd jmp analyst king describe crispr technology have ability repair break gene cut replace defective gene insert functional gene re desire other side gene spectrum rna interference antisense be responsible cut edge drug alnylam pharmaceutical alny biogen partner ionis pharmaceutical ion biogen ionis december win fda approval spinraza first drug type approve treat spinal muscular atrophy needham carr liken rna interference way turn gene have potential be more robust gene therapy most cell body be effective september alnylam stock spiked day drug patisiran prove effective treat rare disease know hereditary attr amyloidosis polyneuropathy disease result buildup abnormal protein cause systemic problem patisiran used rna interference analyst call late stage datum alnylam big concept bluebird be work gene therapy treat blood disorder list innovation go era biotech today gain have be decade make usually steady build then have wave innovation kind collide emerge similar point time jmp king say not traditional tech thing happen overnight related get detail award winning biotech innovator workgilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite cure cancer look blood
177,CELG,investor business daily have create ibd biotech innovator award recognize lead company groundbreaking treatment already market close final approval xrecipient inaugural award be celgene celg biogen biib regeneron pharmaceutical regn kite pharma be recently acquire gilead science gild incyte incy loxo oncology loxo man woman research create testing marketing biotech drug represent often medical field best hope conquer cancer alzheimer other hard cure ailment company face many hurdle significant cost get drug approve federal drug administration fda hand prescribe doctor patient ibd biotech innovator award honor ingenuity effort related biotech stock watch pharma industry news
178,CELG,thursday ionis pharmaceutical ion hit important performance benchmark relative strength rs rating move percentile improvement increase day ibd unique rating measure market leadership worst best score grade show stock price behavior trail week compare other stock database history show market biggest winner often have rs rating begin new climb look best stock buy watch start hereionis pharmaceutical be work cup handle entry see stock break volume least average sale growth fall last quarter earning share grow prior report keep eye company next round number nov ionis pharmaceutical earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
179,CELG,thursday intra cellular therapy itci reach important technical milestone relative strength rs rating jump percentile upgrade rise day exclusive rating investor business daily track price performance worst best score rating show stock price performance last week hold other stock database decade market research show best stock often have rs rating early stage move see ibd help make more intra cellular therapy be not ideal buy zone right now see be able form break proper base earning growth rise company latest report top line fall look next report nov company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
180,CELG,thursday aerie pharmaceutical aeri hit important technical milestone relative strength rs rating jump percentile improvement rise day exclusive rating investor business daily measure market leadership worst best score score show stock price behavior last week compare other stock database year market history show market biggest winner typically have rs rating begin new price run look best stock buy watch start hereaerie pharmaceutical be now consider extend buy range clear buy point second stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week line aerie pharmaceutical post ep growth last quarter sale growth come company be expect report latest number nov aerie pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
181,CELG,consider name put watch list focus stock higher rs rating aerie pharmaceutical aeri now meet criterium jump wednesday ibd proprietary rating track market leadership worst best score grade show stock price behavior last week stack other stock database decade market research show top perform stock typically have rs rating launch biggest price move look best stock buy watch start hereaerie pharmaceutical have climb more past entry second stage consolidation meaning now proper buy range look stock create new chance get week tight pullback day week move average aerie pharmaceutical post ep growth most recent report sale increase company be expect report latest number nov aerie pharmaceutical earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
182,CELG,monday flexion therapeutic flxn receive upgrade relative strength rs rating proprietary rating measure technical performance used worst best score indicate stock price performance trail week match rest market history reveal stock go make biggest gain tend have better rs rating begin new climb look best stock buy watch start hereflexion therapeutic have climb more past entry third stage cup handle meaning now proper buy range look stock create new buy opportunity week tight pullback day week move average company report earning growth last quarter sale growth come next quarterly number be expect nov flexion therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
183,CELG,stock index be narrowly mixed friday head final trading day september xpowershare qqq trust qqq hold gain spdr spy be fraction spdr dow jone industrial average dium be emerge market rally stock market today ishare msci emerge market eem rise find support day move average bank homebuilder telecom lead upside sector fund energy biotech gold miner lag spdr bank kbe spdr regional banking kre gain nearly etfs have advanced past session re back day move average line continue consolidate ishare home construction itb climb highest level more decade component stock kb homekbh soar report earning late thursday now just shy buy point month base gold oil play dip underlie commodity price very different equity play hold big name be buy range stock market resume march record high powershare buyback achiever pkw be buy range clear entry flat base wednesday climb june prior flat base start most recent pattern fund have attract december launch track nasdaq buyback achiever index pkw invest company have trim share outstanding more trail month stock buyback holding be then weight market cap industrial represent biggest sector weighting asset accord morningstar direct financial service consumer cyclical weigh respectively technology health care make apiece pkw count boee ba gilead science gild mcdonald mcd general electric ge unite technology utx top holding holding be subject initial cap top stock make asset fund lag year date return vs benchmark index gain average annual return past year be roughly line year return be ahead advance expense ratio be ibd take keep eye industry group action be vital investing check ibd daily industry sub group ranking list find biotechs rank industry group track ibd ishare nasdaq biotechnology ibb be still buy range flat base clear aug rise nearly prior flat base mid june start most recent pattern fund be featured aug etf column seek support day move average take dip line form bottom flat base share advanced much retake day ibb have amassed february launch track nasdaq biotechnology index top holding include amgen amgn celgene celg gilead science gild biogen biib top name account nearly total asset fund be beating year date return lag year average annual return vs have outperformed past year respective gain fund bear expense ratio related biotechs beating market be buy range stock pare early loss be alibaba baidu back play goldman jpmorgan lead dow equity play break
184,CELG,otonomy otic stock crash record low wednesday meniere disease drug fail reduce vertigo phase trial prompt biotech scrap development close bell stock market today otonomy have plummet hit time low earlier trade previous bottom otonomy be file initial public offer year firm be work ear disease drug include otividex late stage medicine treat inner ear disease call meniere result vertigo otonomy say wednesday otividex miss key goal phase trial patient be treat otividex placebo course week otividex patient report reduction baseline vertigo frequency third month vs reduction placebo patient now otonomy say news release review pipeline commercial effort order identify opportunity extend cash runway build shareholder value second ongoing trial otividex be also suspend ibd take otonomy have have ibd composite rating best possible putt top biotechs still trail leader celgene have cr head ibd stock checkup look other high ranking biotechs be greatly disappoint result surprised higher placebo response lower otividex improvement observed previous trial otonomy chief executive david weber say prepared statement plunge otonomy share slice firm market cap more broadly biotech sector be flat morning trading related analyst mixed gilead kite key rival stand benefitbiogen alzheimer drug show promise break investor be mute gilead acquisition kite pharma
185,CELG,biotechs continue outmuscle broader stock market nonleveraged leverage exchange trade fund be show healthy gain xdespite recent pullback ishare nasdaq biotechnology ibb remain buy range flat base clear aug rise early prior flat base mid june start most recent pattern ibb have amassed february launch track nasdaq biotechnology index top holding include amgen amgn celgene celg gilead science gild biogen biib top name account nearly total asset fund be beating year date vs benchmark index accord morningstar direct ibb lag year average annual return vs have outperformed longer haul carry expense ratio proshare ultra nasdaq biotechnology bib aim twice return nasdaq biotechnology index have generate big return year fund have rally ytd year average annual return come year gain be leverage play bib tend have more exaggerate move upside downside thus tend carry higher risk nonleveraged fund expense ratio be higher nonleveraged peer share have pull back week high be head test day move average bib rally late august bounce day line ibd take keep eye industry group action be vital investing check ibd daily industry sub group ranking list find biotechs rank industry group track ibd spdr biotech xbi be top buy zone flat base entry clear aug gain more breaking flat base june start most recent base year old fund track biotechnology select industry index have gather asset top holding include alnylam pharmaceutical alny exact science exas puma biotechnology pybi alynylam surge report positive result late stage trial patisiran drug used treat rare disease xbi be equal weight etf top holding make less total asset average market cap xbi portfolio be much smaller ibb xbi have deliver solid performance year ytd year average annual return year year have expense ratio leverage play direxion biotech bull labu be trading highest level january have return ytd fund seek provide performance biotechnology select industry index launch expense ratio be related novartis acquire biotech deal be very logical hot biotech play reach be apple still buy range think miss big biotech rally check play
186,CELG,alnylam pharmaceutical alny topple month low thursday suspend development hemophilia drug celgene celg astrazeneca azn lift series decision regulator put several trial hold xin midday trading stock market today alnylam plummet close other hand astrazeneca pop celgene rise broadly biotechs lift fraction early thursday alnylam say temporarily suspend testing hemophilia drug call fitusiran pending review patient die patient be enrolled phase trial hemophilia type die form blood clot alnylam aim resume test review safety fitusiran develop risk mitigation strategy firm also say reach agreement regulator regard phase trial design drug know givosiran potential treatment disorder involve buildup chemical produce porphyrium body pending review program interim analysis assume positive result alnylam say expect file application givosiran food drug administration end fda place trial involve drug celgene astrazeneca immuno oncology drug imfinzi partial clinical hold put full clinical hold cite issue similar combo used rival drug dow component merck mrk astrazeneca imfinzi merck keytruda class drug know checkpoint inhibitor work block specific interaction immune system otherwise prevent immune response bristol myer squibb bmy opdivo be same class ibd take alnylam be still expect provide datum rare disease trial be part stock rally september analyst say head ibd industry theme see september be make break month sector celgene drug revlimid pomalyst be know immuno modulary agent leerink analyst geoffrey porge write note client july trial combine merck keytruda revlimid pomalyst multiple myeloma be place clinical hold follow patient death fda cite issue combination merck celgene drug rationale place trial astrazeneca imfinzi celgene revlimid full clinical hold well patient trial discontinue treatment celgene say news release suggest checkpoint immuno modulary agent combination be associate increase rate fatal nonfatal serious adverse event combination somehow diminish efficacy immuno modulary agent give individually toxicity combination so reduce drug exposure undermine potential clinical benefit porge say patient enrolled trial place partial clinical hold continue treatment investigator determine be receive clinical benefit new patient be enrolled trial trial place partial clinical hold include several other multiple myeloma chromic lymphocytic leukemia aggressive form hodgkin lymphoma celgene continue enroll patient trial acute myeloid leukemia myelodysplastic syndrome related top biotech stock buy zone fda drug approvalfour reason keep bet biotech stock bristol myer cancer help boost rival
187,CELG,major market index fall negative territory early trade thursday major index tech heavy nasdaq dow jone industrial average decline nearly dow industrial home depot hd extend streak trading session advance almost stock have quickly moved striking distance flat base entry downside general electric ge decline be trading just lows fang member amazon com amzn rally almost higher stock market today analyst firm davidson initiate coverage retailer buy rating price target premium wednesday close price stock try recover back day line correction share look build right side potential cup shape base meanwhile fellow commerce giant alibaba baba advanced stock continue form rare ascend base potential entry leaderboard member have be strong performer rise much cup handle entry other lead growth stock graphic chip maker nvidia nvda rise be hold day line stock be currently week potential flat base so need close week reach new high finish pattern company report earning rh rh surge easily beating earning estimate late wednesday company also raise full year earning revenue guidance stock reclaim day line have be trading aug ibd lgi home lgih advanced attempt reclaim day line stock look build right side potential base sharp pullback week line meanwhile celgene celg moved report food drug administration have place trial partial full clinical hold stock break flat base buy point last friday share be trading just entry downside regeneron pharmaceutical regn drop almost plunge back day line heavy volume stock have be build double bottom buy point today action bring pattern doubt related dow jone industrial average dow stock news analysis stock buy point market rebound investing action planfang stock news quote facebook amazon netflix googlerh stock soar ceo tout revolutionary new retail model
188,CELG,global blood therapeutic gbt have relative strength rs rating upgrade friday ibd proprietary rs rating measure market leadership show stock price action last week measure other stock database year market history show market biggest winner tend have rs rating least begin new run global blood therapeutic be not currently potential buy area see stock go form promising consolidation kick new climb regard top bottom line number company have post rise ep growth last report revenue gain have be different story come last quarter global blood therapeutic hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
189,CELG,important metric look stock be higher relative strength rating bioverativ bivv just hit mark jump wednesday exclusive rating investor business daily track market leadership worst best score score show stock price behavior last week compare other stock database history show top perform stock typically have rs rating launch biggest run now be not ideal time jump see stock go establish enter buy zone heavy volume earning grow last quarter prior report revenue also increase bioverativ hold rank peer medical biom biotech industry group celgene celg be top rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
190,CELG,tuesday acceleron pharma xlrn reach important technical milestone relative strength rs rating move percentile upgrade rise day ibd unique rating measure share price performance worst best score score show stock price movement last week stack other stock database history show best stock typically have rs rating north early stage move acceleron pharma be try complete cup handle entry see stock break volume least average earning sale growth come respectively latest report marked acceleration earning share sale acceleron pharma hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
191,CELG,nasdaq composite rise record close thursday index climb fifth straight session fuel several breakout biotech play clear buy point biogen biib bluebird bio blue supernus pharmaceutical supn biotech etf ishare nasdaq biotechnology ibb xbe lookout celgene celg close just entry thursday several biotechs have form new basis nasdaq composite so far week be now just july time high dow industrial be less record level biogen shot thursday stock market trading nearly double normal volume follow gain wednesday biogen soar past buy point consolidation go way back early august biotech long consolidation strong market gain mean stock relative strength line have lag be not great sign biogen report encourage early stage datum alzheimer treatment earlier week ishare nasdaq biotechnology etf better know ibb ticker jump crest buy point short flat base really base base formation ibb other biotech etfs such spdr biotech xbi be way play sector rally avoid company specific blowup weak earning fail drug trial more bluebird bio rocket huge volume month high full point cup base entry bluebird bio be develop car gene therapy treatment cancer have surge week big car news gilead science gild be buy kite pharma kite novartis nvs win first ever fda approval car therapy supernus rise thursday retake flat base entry rebound day move average supernus originally moved buy zone aug have pull back somewhat fashion celgene rise just buy point flat base base base formation celgene edge premarket trading friday suggest open celgene be bigger biotechs partner car play bluebird bio juno therapeutic juno amgen amgn vertex pharmaceutical vrx regeneron pharmaceutical regn be other notable biotechs set new basis related big picture reason be bullish nowbiogen alzheimer drug show promise break breakout prevail new high market pick upbiotech pharma industry newsstock buy watch top ipos big small cap growth stock
192,CELG,stock be session high afternoon trading friday market look cap solid week index reach time high nasdaq composite rise aim new high dow jone industrial average also climb russell add rise past day move average first time aug dow transport lead increase volume be lower nasdaq slightly higher nyse compare same time thursday winner lead loser ratio nyse nasdaq energy consumer banking stock be leader friday biotech industry have have strong week especially leader composite rating better celgene celg break base base pattern top buy point active trading be latest series positive move industry group have be top group many week thursday biogen biib break new high alexion pharmaceutical alxn be rise past short consolidation other leader be new high find support near new buy point automaker post strong august sale beat forecast general motor gm break cup handle base buy point prospect be uncertain however stock have be horizontal range year industry leader fiat chrysler fcau ferrari race make new high palo alto network panw break base buy point heavy volume cybersecurity company quarterly earning beat expectation analyst follow solid report multiple price target increase palo alto network rally be main force rise security software industry group today trading stock be add ibd leaderboard premium service august soundly beat universal display oled fall active turnover trading just buy point double bottom loss be relatively minor compare big gain earlier week positive analyst comment related celgene flirt giant soon join palo alto network soar earning analyst raise price targetsgm stock buy zone ford surge robust auto sale defy harvey
193,CELG,build watch list look stock higher rs rating intra cellular therapy itci just clear benchmark upgrade exclusive rating investor business daily identify market leadership worst best score grade show stock price performance trail week hold other stock database decade market research reveal market biggest winner typically have higher rs rating early stage move look winning stock try simple routineintra cellular therapy be not currently offer proper buy opportunity see stock go build sound pattern launch new move revenue growth fall last quarter earning share grow prior report intra cellular therapy hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
194,CELG,consider name put watch list look stock higher rs rating flexion therapeutic flxn now meet criterium increase friday ibd unique rating track share price performance worst best score score show stock price performance last week hold other stock database decade market research show top perform stock typically have rs rating north launch biggest run look winning stock try simple routineflexion therapeutic have rise more past entry third stage cup handle meaning now proper buy range look stock create new chance pick share week tight pullback day week line flexion therapeutic report ep growth last quarter sale growth come flexion therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
195,CELG,innoviva inva see positive improvement relative strength rs rating friday rise exclusive rating investor business daily identify market leadership worst best score score show stock price performance last week stack other stock database decade market research reveal best stock typically have rs rating north launch biggest price move look best stock buy watch start hereinnoviva be trading buy range clear buy point cup handle once stock move higher original entry consider buy range company bottom line growth decline company most recently report quarter top line rise previous report company be expect report latest number oct innoviva earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
196,CELG,pharmaceutical adms see positive improvement relative strength rs rating friday upgrade ibd unique rating identify market leadership worst best score score show stock price performance last week stack other stock database decade market research show best stock tend have rs rating north early stage move look best stock buy watch start hereadamas pharmaceutical have moved more past entry first stage consolidation meaning now proper buy range look stock offer new buy opportunity week tight pullback day week move average pharmaceutical post negative growth sale earning last quarter company be expect report next quarterly number nov company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
197,CELG,intra cellular therapy itci see welcome improvement relative strength rs rating thursday rise ibd unique rating track share price performance worst best score grade show stock price behavior last week hold other stock database decade market research show best perform stock typically have rs rating early stage move see intra cellular therapy continue show renew price strength clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock be able establish enter buy range heavy trade sale growth fall last quarter ep grow prior report company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
198,CELG,case favor actively manage stock mutual fund fund rowe price blue chip growth fund trbcx be exhibit run larry puglium inception mid fund gain year go thursday top large cap growth rival track morningstar inc xthat blister pace be achieve portfolio june include electronic art ea netflix nflx celgene celg mastercard occasional lag last year fund trail peer rally outperform be norm puglium fund outlegged peer past year have averaged yearly return nearly quarter century puglium have be helm outpace peer averaged blue chip growth win long term strategy fund literature distill few key point fund primarily invest common stock large medium size blue chip company have potential average earning growth be well establish respective industry blue chip part name do not mean focus stodgy stock judge result instead puglium look company have carved lead market position be lead seasoned management team stand solid financial foundation have average earning growth profitability growth stock historically have be more volatile cyclical company slower growth company puglium aim sector diversification dampen up down technology be largest sector shareholder money allocate july tech stock electronic art be so far year trading share be buy range entry flat base online software game producer be forefront gaming industry stock be member ibd list stock strong relative price strength fundamental earning share rise past quarters ibd take electronic art be rank stock ibd computer software gaming industry group thank trait highest possible composite rating ibd quarters row ep acceleration compare electronic art other technical fundamental strength rival ibd easy use stock checkup tool netflix technology retail name be leaderboard ibd premium service spotlight play play top stock trading share video stream service be testing support day move average stock pull back record high follow news apple aapl spend heavily original content video health care be blue chip growth second largest sector weighting celgene flagship be cancer drug revlimid be year slip day move average first time mid june sit july high stock be rank name ibd medical biom biotech industry group also have top notch composite rating be member ibd company have straight year annual ep growth consensus analyst be ep tack ep growth quarter grow prior stanzas financial be fund third biggest weighting little mastercard be year trading share be just buy zone clear buy point company expect growth transaction mixed economy stock be yet member ibd analyst expect credit card network ep rise year gain revenue mark company best performance line improve fraud detection technology mastercard recently agree acquire artificial intelligence software developer brighterion move be also response competitive threat blockchain public digital ledger record transaction make bitcoin other cryptocurrency ibd have report related stock market do now lead stock help jpmorgan mutual fund top peerswhat make top mutual fund winner veeva system other lead stock
199,CELG,important metric look stock be higher relative strength rating juno therapeutic juno now clear threshold jump friday exclusive rating investor business daily track share price action worst best score score show stock price behavior last week compare other stock database decade market research show best stock tend have rs rating north launch biggest run juno therapeutic be try complete consolidation buy point see clear price heavy volume juno therapeutic report negative growth sale earning last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
200,CELG,abbvie abbv newly launch hepatitis drug mavyret have already grab total new prescription further chip away gilead science gild struggle hepatitis franchise analyst say friday xas result wall street see gilead hepatitis drug sale decline vs year earlier period evercore analyst umer raffat write note client drop be sharper plunge sale be expect fall wholesale basis mavyret be price roughly half competitor month vs gilead epclusa sovaldi harvoni respectively dow stock merck mrk zepatier abbvie viekira pak cost respective monthly gilead contend discount rebate mavyret be price similarly harvoni differ treatment duration wide array hepatitis drug mavyret treat genotype have shortest treatment duration week most patient ibd take novartis be first finish line car drug do mean gilead plan acquire kite head ibd industry theme deeper dive segment contend likelihood further erosion hepatitis franchise gilead be pivot cellular therapy acquisition kite pharma kite kite doesn have approve drug merger be announce day rival drug novartis nvs gain approval novartis drug be approve treat form acute lymphoblastic leukemia patient age analyst now expect similar drug kite treatment aggressive form hodgkin lymphoma grab approval later year bluebird bio blue juno therapeutic juno be partner celgene celg work similar treatment know car therapy create drug immune cell be extract patient reprogram fight cancer cell be reintroduce related abbvie gauntlet squeeze gilead drug hepatitis cure cancer look bloodwhy biotech catch rally add september be make break month partnership bit dust gilead kite competition
201,CELG,thursday neurocrine bioscience nbix receive positive adjustment relative strength rs rating ibd unique rs rating identify technical performance used worst best score indicate stock price performance last week stack other stock database year market history reveal stock go make biggest gain typically have rs rating north early stage move see neurocrine bioscience continue rebound hit benchmark stock be try complete cup handle buy point see stock break volume least higher normal company report earning growth most recent report sale growth come neurocrine bioscience earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
202,CELG,wednesday alexion pharmaceutical alxn earn upgrade relative strength rs rating exclusive rating investor business daily identify market leadership worst best score score show stock price movement trail week compare other stock database decade market research show stock go make biggest gain tend have rs rating north begin biggest price move alexion pharmaceutical be not currently potential buy zone see stock go build chart pattern kick new price move alexion pharmaceutical show earning growth most recent report sale gain come alexion pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
203,CELG,relative strength rs rating agio pharmaceutical agio climb new percentile wednesday increase proprietary rating identify technical performance used worst best score indicate stock price performance last week match other stock year market history reveal stock go make biggest gain typically have better rs rating launch biggest climb stock be try complete consolidation entry see stock break heavy trading earning growth decrease most recent report revenue gain moved higher company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
204,CELG,cara therapeutic cara have relative strength rs rating upgrade wednesday exclusive rating investor business daily track market leadership worst best score score show stock price behavior trail week hold other stock database history reveal best perform stock often have rs rating least early stage move stock be not proper buy zone right now see go form break proper base term top bottom line number cara therapeutic have post rise ep growth last report top line growth have not follow same trajectory come most recent report company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
205,CELG,epizyme epzm have relative strength rs rating upgrade wednesday unique rating measure market leadership show stock price movement last week measure other stock database decade market research reveal top perform stock typically have rs rating begin new price run epizyme be work consolidation entry see stock clear price volume least average top bottom line growth moved higher last quarter earning be compare prior report revenue increase epizyme earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
206,CELG,wednesday nektar therapeutic nktr hit important technical benchmark see relative strength rs rating jump percentile improvement day proprietary rating track market leadership used worst best score identify stock price action trail week match other publicly trade company history reveal best stock typically have rs rating north begin biggest run nektar therapeutic be try complete cup handle entry see stock break heavy trade note third stage base such later stage pattern involve more risk be more have higher likelihood fail earlier stage consolidation ep growth drop company most recent report sale rise company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
207,CELG,regeneron pharmaceutical regn see positive improvement relative strength rs rating wednesday increase exclusive rating investor business daily identify market leadership worst best score score show stock price performance trail week compare other stock database year market history show stock go make biggest gain tend have higher rs rating early stage move regeneron pharmaceutical be try complete consolidation entry see stock clear price volume least higher normal earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
208,CELG,blueprint medicine bpmc see positive improvement relative strength rs rating wednesday rise proprietary rating track market leadership used worst best score identify stock price action last week match other publicly trade company year market history reveal best stock often have better rs rating begin new run not currently ideal time buy share see stock go establish enter buy range heavy trade company post earning growth latest quarterly report sale growth come blueprint medicine hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
209,CELG,emergent biosolution ebs have relative strength rs rating upgrade wednesday unique rating measure technical performance show stock price movement last week compare other stock database history show best stock typically have rs rating north begin new climb emergent biosolution be still buy range climb entry saucer handle once stock move higher initial entry consider buy range earning growth moved company most recent report top line fall emergent biosolution hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
210,CELG,global blood therapeutic gbt see positive improvement relative strength rs rating thursday rise unique rating track technical performance used worst best score show stock price action trail week match rest market decade market research show stock go make biggest gain tend have better rs rating early stage move look winning stock try simple routinewhile now be not ideal time invest see stock go form base break regard top bottom line number company have post rise ep growth last report revenue growth have be less impressive come last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
211,CELG,welcome move amgen amgn see relative strength rating improve thursday proprietary rating identify market leadership used worst best score identify stock price performance trail week stack other stock database history show best stock typically have better rs rating launch largest climb see amgen continue show renew price strength clear threshold see ibd help make more stocksamgen be still buy range clear buy point cup handle once stock move higher initial entry consider buy range earning grow last quarter prior report revenue also increase keep eye company next round number oct amgen earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
212,CELG,major index finished month witch ghoul goblin good note tuesday wasn just big cap techs nasdaq composite drive part third straight solid gain apple aapl rally finished session high apple benefit price target hike report strong order
213,CELG,thursday aerie pharmaceutical aeri clear key technical benchmark relative strength rs rating jump percentile improvement rise day ibd proprietary rating track market leadership worst best score score show stock price performance last week compare other stock database year market history reveal stock go make biggest gain tend have rs rating begin biggest run look best stock buy watch start herewhile not currently ideal time buy share see stock be able offer clear proper buy point company show ep growth last quarter revenue rise keep eye company next round number nov company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
214,CELG,nasdaq charge new high thursday open add dow jone industrial average battle remain positive general electric ge unitedhealth group unh pull hard early trade xmicrosoft msft easily lead dow canaccord genuity upgrade stock buy hold microsoft have be attempt muster volume support necessary break clear flat base buy point apple aapl jump fang stock post strong early gain netflix nflx lead gain stock post sole advance wednesday lift share buy point crane maker manitowoc mtw hoist open advance auto racecourse operator international speedway isca rolled gain biotech drugmaker biogen biib pop morgan stanley upgrade stock overweight equal weight raise price target jump put share buy range rebound test support week move average celgene celg drop morgan stanley trim rating underweight equal weight ibd stock end wednesday just buy range clear buy point constellation brand stx spiked early action fiscal second quarter earning soar past consensus target revenue be also better expect sale beer brand drive beat share end wednesday buy range buy point week flat base shopify shop dive start session maker online platform small business plunge massive trade wednesday negative report short seller citron move pierce stock week move average trigger sell signal market receive healthy dose economic news federal reserve commentary today investor be likely limit response labor department september payroll report roll friday number layoff announce employer drop august september accord consultant challenger gray christmas number be year level bring total layoff third quarter second quarter lower last year third quarter first time unemployment claim drop week end labor department report prior week consensus view new claim continue claim increase slightly trade deficit narrow slightly august accord commerce department estimate be july slightly better estimate august factory order number be also due commerce department et federal reserve governor jerome powell fed bank president john william patrick harker be schedule speak separate conference start time set et related nasdaq day row more important be happeningwatch apple fang stock don ignore hottest groupstock apple base investor not sell shopify shortshopify fall short seller citron criticize marketing modelibd investor research tool get start ibd
215,CELG,celgene celg abbvie abbv be likely be biggest beneficiary inflammatory bowel disease market be expand rapid clip analyst say wednesday biologic market disease generate sale leerink analyst geoffrey porge write note client abbvie humira johnson johnson jnj remicade tnf drug used fight inflammation dominate market today believe market be likely continue exceed recent growth rate significant share value likely accrue celgene offset value available also abbvie inevitable erosion abbvie dominant humira franchise say new class inflammatory bowel disease drug be arise like celgene roche rhhby galapago gplg gilead science gild abbvie be look make mark drug now phase trial crohn disease ulcerative colitis common form disease earlier trial benefit clinical datum back be have difficulty recruit patient porge say many trial also exclude sicker patient include patient ve stop respond current treatment ibd take earlier year abbvie say expect humira hit peak international sale face erosion head ibd technology page breakdown abbvie see biggest drug go plan offset competition tnfs humira remicade be first truly disease modify treatment approach many patient don respond stop respond tnf drug porge say study suggest tnf patient don respond lose response year estimate show be patient inflammatory bowel disease have crohn disease have ulcerative colitis patient number europe be higher provide large opportunity drug base new mechanism write related perrigo beat raise lift generic drug buck teva mylan trendcould small biotech break tie eli lilly abbvie topple humira sale brake third straight quarter
216,CELG,top rate biotech stock vertex pharmaceutical vrtx be try set breakthrough move get new food drug administration fda approval cystic fibrosis drug kalydeco aug vertex announce fda approve kalydeco use person cystic fibrosis have certain residual function mutation base approval
217,CELG,market confirm uptrend gain steam monday tech heavy nasdaq composite jump monday market surge send lead stock much higher market leader be approach buy point stock market today previous base fail nvidia nvda be back striking distance new buy point
218,CELG,acceleron pharma xlrn see welcome improvement relative strength rs rating thursday increase unique rating track market leadership show stock price action last week measure other stock major index decade market research show market biggest winner often have rs rating least begin biggest climb acceleron pharma be try complete cup handle entry see break volume least higher normal earning sale growth come respectively latest report marked acceleration earning share sale company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
219,CELG,biogen biib spiked week high wednesday analyst upgrade stock buy rating development alzheimer drug note overblown reaction competition face treat multiple sclerosis close bell stock market today biogen gain rise much earlier trade more broadly biotech stock lift fraction come back relatively flat trading tuesday goldman sachs analyst terence flynn upgrade biogen buy rating neutral keep price target phase datum alzheimer drug aducanumab be expect late early be first disease modify drug reach market write note client flynn see peak sale aducanumab biogen partner eisai be expect have datum phase trial similar drug year end flynn note drug know ban be license eisai march deal biogen readout provide lateral catalyst biogen ibd take biotechs have struggle late hit month high late july long term view look uncertain several player fact many biotechs outperformed consensus view second quarter head ibd industry theme breakdown drug be work reduce amount amyloid deposit brain thought be associate alzheimer analyst also look see ban have effect cognition flynn write multiple sclerosis flynn see investor worry competition roche rhhby novartis nvs celgene celg overblown flynn see biogen benefit royalty payment roche new multiple sclerosis drug ocrevus analyst have note ocrevus be likely take share away biogen other multiple sclerosis drug tecfidera tysabri related biotech nearly triple street expectation key drugbiotech find strength number treat multiple sclerosiswhy biotechs outperformed pharma brother june quarter
220,CELG,relative strength rs rating ionis pharmaceutical ion enter higher percentile thursday get lift ibd proprietary rating track share price performance worst best score rating show stock price behavior trail week compare other stock database decade market research reveal best stock often have rs rating north launch largest climb see ionis pharmaceutical continue show renew price strength clear threshold ionis pharmaceutical be not currently offer proper buy opportunity see stock go build promising consolidation ignite new run earning growth picked last quarter revenue gain fall ionis pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
221,CELG,hurricane harvey irma index other major index edge lower week prior week big gain walt disney comcast cmcsa alert medium news old medium be old news bank tumble fall interest rate tax cut hope unite technology utx agree buy rockwell collin col boee ba objected equifax efx say american be expose massive cyber intrusion index fall week nasdaq composite dow jone industrial average big gain prior week nasdaq test day move average tuesday close key level bank stock break key support treasury yield hit postelection lows medium stock tumble warning be several breakout setup lead stock unite technology utx announce buy aircraft supplier rockwell collin col share share cash rest stock include assume debt make biggest aerospace deal ever boee ba indicated try block deal look keep share lucrative maintenance repair business analyst say unite tech sell build business help unlock more shareholder value unite tech share fall related boee challenge unite tech buyout rockwell credit tracking service discover massive intrusion july disclose incident late thursday american be expose name birthday social security number other datum threaten credit card number consumer certain dispute document personal identify information approximately consumer be also expose top exec include cfo sell share day breach discovery equifax efx claim be not aware cyberattack equifax tumble thursday several cybersecurity stock rally pare gain friday close related equifax american affected huge datum breachwalt disney ceo bob iger say los angele base medium conference earning share current fiscal year end september be line fiscal analyst have see gain disney also say expect stream network now set late have exclusive online right marvel star war content dash hope extend deal netflix nflx meanwhile comcast cmcsa same conference warn video subscriber loss disney share tumble low thursday comcast lose several other medium stock sell well related disney warn profit keep star war marvel netflixcomcast stock plunge video subscriber loss hurricane impactdelta air line dal unite airline ual southwest luv spirit airline save jetblue jblu cut third quarter unit revenue forecast steeper airfare competition rise fuel cost spirit be engage fare war unite cowen say last mid say discounting have spread market represent sale base impact hurricane irma remain unclear friday follow hurricane harvey unite say deliver largest operational impact ve have company history crude stockpile rise barrel latest week energy information administration say slightly more expect gasoline inventory fall barrel less view refinery capacity run well normal many gulf mexico site shut ahead hurricane harvey domestic crude output fall barrel day barrel day week prior crude future edge higher week give nearly gain friday hurricane irma close florida gasoline future tumble spiking prior week luxury furnishing retailer rh rh earn cent share revenue adjust net revenue well estimate cent ep comparable brand revenue grow also top rh up outlook management have bold word ceo tout revolutionary new retail model include restaurant store distribution house last mile delivery initiative share spiked thursday biotech stock be relatively flat rise ibd group track eighth several rise sharply result strong clinical trial datum tuesday insm insm bellerophon therapeutic blph ligand pharmaceutical lgnd pop strong drug trial datum cellect biotechnology apop lift fda grant orphan drug status treatment organ transplant rejection sarepta therapeutic srpt hit month high positive datum duchenne muscular dystrophy trial thursday alnylam pharmaceutical alny sank suspend testing hemophilia trial celgene celg astrazeneca azn rise fda putt several cancer trial full partial clinical hold abbvie abbv rally positive trial datum eczema drug hit share regeneron regn have own eczema treatment largest pure play grocer narrowly top sale same store sale forecast earning come just view margin come pressure kroger kr other grocer be face intense competition long threat online deliver amazon amzn have already cut price just acquire whole food wal mart wmt largest grocery seller have be key driver food price deflation kroger share fall friday related kroger report mixed result shadow amazon wal martthe nissan nsany leaf debut tuesday give popular electric vehicle long overdue design refresh japanese automaker tout new model longer range lower price better performance semi autonomous technology sale nissan leaf have drop fourth place ev segment year tesla tsla model model general motor gm chevy bolt accord edmund tesla less expensive model just roll initial reviews new leaf be mixed call big improvement model tesla sale begin early hewlett packard enterprise hpe report fiscal adjust earning revenue expectation restructure continue ceo meg whitman say not go anywhere have interview uber ceo position recently hpe update guidance account sale software business do not discuss plan return cash shareholder bank america downgrade maker computer networking datum storage system say free cash flow growth be challenged next year hpe share fall arcade restaurant chain dave buster splay raise full year net income guidance previously cut same store sale growth forecast prior view comp growth fall well short estimate ep jump cent easily top view cent revenue climb narrowly miss view share sank nearly week insurance industry software provider guidewire software gwre earn cent share exclude item fiscal fourth quarter year year revenue analyst expect cent fiscal first quarter guidewire guide loss cent share sale wall street be modele profit cent share sale however full year outlook be ahead view guidewire share rise record high close coupa software coup report narrower expect fiscal loss revenue top view competition oracle orcl sap sap enterprise software firm stock initially pop close week fractionally higher target tgt announce friday be slash price thousand item retail competition get tougher target share fall wal mart wmt lose mobile tmus announce exclusive partnership netflix nflx include popular video stream service family plan provide unlimited datum start line monthly exist mobile netflix customer also opt have wireless firm pay bill mastercard touch record high thursday credit card giant raise full year adjust net revenue outlook growth high end low double digit compare earlier outlook low double digit growth china solar company jinko solar jks report second quarter revenue beating consensus adjust earning cent miss consensus estimate cent solar module shipment rise gigawatt industrial distributor hd supply hds report ep rise just beating view adjust revenue climb line management see ep cent better consensus cent revenue midpoint slightly consensus
222,CELG,alexion pharmaceutical alxn have relative strength rs rating upgrade wednesday welcome improvement still shy higher score prefer see exclusive rating investor business daily identify price action worst best score rating show stock price performance last week stack other stock database decade market research reveal best stock often have rs rating early stage move see alexion pharmaceutical continue show renew price strength hit benchmark alexion pharmaceutical be not currently potential buy area see stock go form base ignite new run company post earning growth most recent report sale growth come company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
223,CELG,relative strength rs rating epizyme epzm enter higher percentile wednesday get lift proprietary rating track technical performance used worst best score indicate stock price action trail week compare other publicly trade company decade market research show stock go make biggest gain typically have higher rs rating launch largest climb see epizyme continue show renew price strength hit benchmark stock be not ideal buy zone right now see manage form break proper chart pattern top bottom line growth moved higher last quarter earning be compare prior report revenue increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
224,CELG,relative strength rs rating aerie pharmaceutical aeri moved new percentile tuesday get lift ibd unique rs rating identify market leadership show stock price movement last week measure other stock database history reveal market biggest winner typically have rs rating early stage move see aerie pharmaceutical continue rebound clear threshold see ibd help make more stocksnow be not ideal time jump isn proper buy zone see stock go offer clear proper buy point aerie pharmaceutical post earning growth last quarter sale growth come company be expect report latest earning sale number nov company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
225,CELG,important metric look stock be higher relative strength rating ionis pharmaceutical ion clear benchmark tuesday jump tuesday ibd unique rs rating identify market leadership used worst best score identify stock price performance trail week match other publicly trade company year market history show market biggest winner often have rs rating north early stage move look best stock buy watch start stock be build cup handle entry see break volume least average company top line growth fall last quarter bottom line grow prior report company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
226,CELG,relative strength rs rating innoviva inva jump new percentile tuesday increase exclusive rating investor business daily track market leadership worst best score rating show stock price behavior last week compare other stock database year market history show market biggest winner often have rs rating begin biggest run look best stock buy watch start hereinnoviva break earlier have fall back prior entry cup handle stock re tracking clear buy point then fall more original entry price consider fail base stock set new chart pattern buy point also keep mind latest pattern be later stage base involve more risk ep growth decrease last quarter revenue rise prior report keep eye company next round number oct innoviva earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
227,CELG,acorda therapeutic acor see welcome improvement relative strength rs rating tuesday rise exclusive rating investor business daily track share price action worst best score grade show stock price behavior trail week compare other stock database decade market research reveal top perform stock tend have rs rating begin new price run see ibd help make more money stock be not ideal entry right now see be able form break proper consolidation top bottom line growth moved higher last quarter earning be compare prior report revenue increase keep eye company next round number oct acorda therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
228,CELG,accord latest list new buy top perform mutual fund lead money manager appear be focuse build sector related stock homebuilder nvr nvr toll bro tol kb home kbh well construction equipment maker graco ggg wood product producer louisiana pacific lpx steel maker allegheny technology atus xmastec mtz manufacture home builder patrick industry patk also earn spot list do kimball international kbal make furniture office hospitality industry home furniture maker bassett furniture industry bset institutional investor also continue show demand top chip stock ibd member apply material amat lam research lrcx make cut cohu cohu texas instrument txn cohu lam research also be find ibd latest list stock expect earning growth tension rise north korea president trump promising significantly boost defense spending surprise major defense contractor boee ba northrop grumman noc heico hei be also find list last month report top fund manager invest stock unite health unh apple aapl electronic art ea celgene celg latest list doesn include bet largest total investment be boee fund pick approximately share next line be bank america bac fund investing company get additional vote confidence berkshire hathaway brkb ceo warren buffett tell cnbc oct hold bofa share long long long time bank america report earning oct boost recent institutional buy most stock list include thor industry tho winnebago industry wgo kb home have already break be now extend several remain potential buy zone include mastec boee toll bro new york time nyt have pull back recent day be now testing support day line note toll bro be trading upper limit buy range boee be now extend general motor gm make list new buy fund investing also lead list new sell net number fund selling gm selling buy be diesel gas engine maker cummin cmi have second most net seller follow axle suspension maker dana inc dan number fund selling stock have be rise cummin enter buy zone last week related earning preview stock expect growthu small cap foreign stock favore fundsfind track best mutual fundslooking next nvidia start simple routine
229,CELG,major index rise modestly tuesday market continue pattern dull trade look earning report spark dow jone industrial average rise nasdaq edge weakness internet software industry group offset fine gain semiconductor biotech group
230,CELG,grind higher market apple aapl microsoft msft biogen biib electronic art ea alexion pharmaceutical alxn wynn resort wynn be highly rate big cap stock hold buy zone breaking several day week xideally stock blast basis then rapidly add gain be breakout current market environment many stock just edge past entry point share soon pull back least temporarily apple chipmaker skywork solution swks chip gear maker teradyne ter fall back entry area monday breaking friday breakout aren failure high volume retreat aren encourage apple break flat base buy point aug day report strong earning guidance iphone giant do dip entry point few time next few week aug stock have stay buy zone apple have trend lower unveil new iphone high end iphone not set release nov share fall monday stock market trading report say iphone preorder appear so so perhaps buyer hold model apple day move average offer further support key line have rise entry level microsoft have be grind higher modestly outpace index microsoft have be breaking then pull back entry area finally move higher sometimes form new consolidation microsoft clear base base formation entry back aug true form microsoft pull back follow day didn hold entry share hit record high intraday monday reversed close biogen soar aug blow past buy point month consolidation share continue advance become slightly extend time only close chase zone then biogen have retreat past session slide nearly monday still comfortably buy zone celgene just edge past buy point capped huge weekly gain celgene rally investor optimism drugmaker ty car immuno oncology treatment aside intraday drop next session celgene have basically hold buy range slowly trend higher celgene rise monday set record intraday video game publisher clear buy point july just nasdaq hit short term high electronic art test entry point several time close aug then ea have generally stay buy zone share edge monday ea day line have rise just entry level offer possible backstop stock alexion last biotechs highlighted here sell july then stock have rebound share clear first stage base buy point week later alexion close just entry hasn do alexion cut staff biotech say last week spend more research alexion fall monday casino giant rise strongly past flat base buy point then share have stay buy zone aside flirt become extend wynn resort rise monday fellow macau centric casino melco resort mlco la vegas sand lvs have form cup basis melco just carve handle monday just stock have generally hold buy zone doesn mean ll stay way begin move sharply higher other falter investor want keep close eye holding well lead stock generally major market average related big picture be market pattern set repeat apple iphone demand isn look so hot sign defense giant just break rival be buyscitigroup break other banking giant be buysbiotech pharma industry newsstock buy watch top ipos big small cap growth stock
231,CELG,halozyme therapeutic halo see welcome improvement relative strength rs rating friday rise exclusive rating investor business daily identify market leadership worst best score grade show stock price movement last week stack other stock database year market history show market biggest winner typically have higher rs rating begin new price run see ibd help make more stockshalozyme therapeutic have climb more past entry first stage double bottom meaning now proper buy zone look stock create new chance get week tight pullback day week move average earning share growth drop last quarter top line rise halozyme therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
232,CELG,neurocrine bioscience nbix have relative strength rs rating upgrade wednesday welcome improvement still shy higher score look proprietary rating track technical performance show stock price action last week compare other stock database year market history show market biggest winner often have higher rs rating launch largest climb see neurocrine bioscience continue show renew price strength clear threshold stock be build cup handle buy point see clear price volume least higher normal neurocrine bioscience report earning growth last quarter revenue rise neurocrine bioscience hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
233,CELG,relative strength rs rating juno therapeutic juno jump new percentile thursday get lift ibd proprietary rs rating measure technical performance show stock price movement last week compare other stock database history reveal best perform stock often have rs rating north begin biggest price move see juno therapeutic continue show renew price strength hit benchmark juno therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average sale growth fall last quarter bottom line grow prior report look next report aug company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
234,CELG,thursday paratek pharmaceutical prtk earn positive adjustment relative strength rs rating ibd unique rating identify market leadership worst best score rating show stock price movement last week hold other stock database decade market research show stock go make biggest gain tend have rs rating north begin new run paratek pharmaceutical be not ideal buy point right now see manage form break proper chart pattern term top bottom line number paratek pharmaceutical have post rise ep growth last report top line growth have not follow same trajectory come last quarter paratek pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
235,CELG,thursday spark therapeutic once receive positive adjustment relative strength rs rating ibd unique rating identify market leadership worst best score grade show stock price performance last week stack other stock database decade market research show best stock often have rs rating early stage move spark therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth fall company most recent performance report revenue rise prior report company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
236,CELG,global blood therapeutic gbt have relative strength rs rating upgrade thursday exclusive rating investor business daily measure price action worst best score score show stock price movement last week compare other stock database decade market research reveal market biggest winner often have rs rating launch biggest climb now be not ideal time jump isn proper buy zone see stock go offer clear proper buy point global blood therapeutic show earning growth latest quarterly report sale rise company be expect report latest performance number aug company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
237,CELG,spark therapeutic once therapeutic cort defy downtrend biotech sector wednesday instead rocket fresh high strong second quarter report stock market today spark top year high rise share touch high last see april pop earlier rise first time initial public offer broader biotech sector third straight session ibd company biotech industry group recent stock market darling hit month high july slip sixth group track last week be rank fifth second quarter end june spark report sale adjust loss share revenue grow top expectation loss widen loss share year earlier period miss consensus loss share spark also report initial datum patient form hemophilia bleed disorder cause miss defective clot protein know factor viii participant treat drug dub spk achieve stable factor viii average north spontaneous bleed ibd take biotech fever be cool second quarter earning season wind long term view look weak uncertain head ibd industry theme deep dive late tuesday report sale adjust income cent share respective vs year earlier period analyst have call sale adjust income expectation be not immediately available income share cent beat analyst view cent be continue enroll phase trial drug treat cush syndrome result body be expose high level hormone cortisol long time symptom include abdominal obesity high blood pressure stretch mark weak muscle bone acne also have cortisol modulator enter phase trial future be combine xtandi drug pfizer pfe acquire buy medivation last year population patient prostate cancer enrollment be also ongoing phase phase trial drug combine celgene celg abraxane treat patient solid tumor cancer related small biotech launch month high today here sanofi earning spook regeneron share week lowbiotech gain last week keep go
238,CELG,welcome move global blood therapeutic gbt see relative strength rating rise thursday ibd proprietary rs rating identify market leadership show stock price movement last week measure other stock database history reveal market biggest winner typically have higher rs rating begin biggest climb see global blood therapeutic continue show renew price strength clear threshold global blood therapeutic be not currently potential buy area see stock go build chart pattern launch new move term revenue profit global blood therapeutic have post quarters rise earning growth sale gain have be different story come latest report company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
239,CELG,biotech stock have show somewhat predictable pattern ibd first identify biotech stock industry group innovative power new medicine biotech stock naturally have period steep climb also have sharp sell off monthly chart be easiest place see pattern most recent sell start june
240,CELG,alexion pharmaceutical alxn cut workforce reinvest research biotech say tuesday just month hire new chief executive away baxalta xby close trading stock market today alexion be alexion have trend past month be year biotech expect deliver pretax saving year result cost cut measure plan reinvest year build pipeline business development add new complement indication approve drug streamline operation create leaner organization greater financial flexibility be highly focuse deliver patient grow rare disease business leverage leadership complement pursue discipline business development expand pipeline chief executive ludwig hantson say statement ibd take alexion recently stage happen head new high stock list closer look potential well competitor alexion have have tough year overall share plummet early year low exec announce departure just month ludwig come alexion baxalta baxalta be acquire shire pharmaceutical shpg last year july alexion confirm investigation department health human service leerink analyst recently list alexion top pick celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx related biotech catch rally add biotechs outperformed pharma brother june quarteralexion pharma stock dife report federal scrutiny
241,CELG,axovant science axon have relative strength rs rating upgrade tuesday proprietary rating measure technical performance used worst best score identify stock price performance last week match other publicly trade company history show best stock tend have rs rating north early stage move stock be build consolidation entry see clear price volume least higher normal axovant science post earning growth latest quarterly report sale growth come axovant science hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
242,CELG,monday acorda therapeutic acor receive positive adjustment relative strength rs rating unique rating identify technical performance show stock price action last week measure other stock database history reveal best stock tend have rs rating launch biggest run see acorda therapeutic continue show renew price strength hit benchmark acorda therapeutic be not proper entry right now see be able form break proper base top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
243,CELG,flexion therapeutic flxn see positive improvement relative strength rs rating tuesday rise exclusive rating investor business daily measure share price movement worst best score rating show stock price movement trail week compare other stock database year market history show stock go make biggest gain often have rs rating early stage move see ibd help make more stocksflexion therapeutic be trading buy zone clear entry cup handle once stock move higher original entry consider proper buy area flexion therapeutic show earning growth most recent report sale gain come company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
244,CELG,major market index be modestly higher early morning trade thursday tech heavy nasdaq advanced look extend winning streak trading day hold more minor gain dow jone industrial average edge major index hit record high dow jone industrial component apple aapl set pace rise more hit new week high iphonemaker remain stick day line flat base entry share have be act substantially better recent week rise low downside unitedhealth group unh backed away high fall health care provider be day line well extend latest base flat base buy point fang stock be move higher stock market today netflix nflx moved almost clear cup handle entry facebook fb be battle support day line rise amazon com amzn rise look regain day line google parent alphabet googl trade higher online search giant be build right side potential base buy point analyst action ibd stock suffer downgrade early thursday celgene celg see rating cut equal weight underweight morgan stanley share decline almost lead biotech be back buy range just flat base entry potential investor sign strength avoid try catch fall dagger meanwhile citigroup downgrade leaderboard member grubhub grub buy neutral food delivery service have just reclaim day line be back fall almost company report earning constellation brand stz jump report strong fiscal earning sale result early thursday alcoholic beverage maker be top buy range flat base buy point bell costco cost report result analyst expect rise profit revenue totale stock be trading day line high shopify shop continue precipitous decline thursday drop wednesday short seller citron criticize commerce solution provider spark retreat share pierce day line heavy volume wednesday yesterday action be sell signal ibd paypal pypl moved stock be just time high flat base entry downside alibaba baba decline almost fall back ascend base entry related airline stock set buy point rebound investing action plandow jone industrial average dow stock news stock news brand beat lift earning outlook stock jump
245,CELG,juno therapeutic juno crushed wall street second quarter revenue expectation loss share widen miss analyst forecast penny xin hour trading stock market today juno lift close fraction share hit buy point consolidate extend more late june stock have retreat gain buy point quarter end june juno report adjust loss cent share sale loss miss analyst view cent widen cent loss year earlier period sale fall top forecast juno also reaffirm full year guidance adjust cash burn operate burn capital expenditure quarter juno note unveil result drug dub jcar phase trial patient form hodgkin lymphoma jcar belong experimental class drug call car therapy aim reprogram immune system cell fight cancer trial be do patient cutoff date see tumor shrinkage sign cancer disappear patient ibd take car therapy involve reprogramming immune system cell extract body fight cancer then reintroduce patient get breakdown lead sector look strong term ibd technology page month mark patient have tumor shrinkage sign cancer patient respond month continue respond treatment month mark juno say just total patient experience severe form call cytokine release syndrome show form fever patient experience severe toxicity nervous system patient die result side effect novartis nvs kite pharma kite bluebird bio blue celgene celg be also work car therapy umbrella immuno oncology related novartis fda cancer also be boon rivalsnovartis grab key fda panel approval experimental cancer drugnovartis face key fda panel cancer drug kite be winner
246,CELG,ironwood pharma irwd have relative strength rs rating upgrade monday ibd unique rs rating track market leadership show stock price movement last week measure other stock major index history reveal top perform stock typically have rs rating least early stage move ironwood pharma be not currently potential buy area see stock go build promising consolidation ignite new run ironwood pharma report negative growth top bottom line last quarter company be expect release next quarterly number aug company earn rank peer medical biom biotech industry group celgene celg supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
247,CELG,acorda therapeutic acor have relative strength rs rating upgrade friday ibd unique rs rating identify market leadership show stock price action last week measure other stock database year market history show stock go make biggest gain tend have better rs rating early stage move stock be not proper entry right now see be able form break proper base earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
248,CELG,sarepta therapeutic srpt break thursday flirted month high report consensus crush second quarter sale cut loss expectation half xat close bell stock market today sarepta stock be earlier rise much share rushed past buy point consolidation begin form march stock action follow sarepta late wednesday second quarter earning report sarepta beat wall street sale view only approve drug exondys exondys be approve treat duchenne muscular dystrophy sarepta also report adjust loss cent share best consensus view cent loss year earlier period sarepta report adjust loss share revenue biotech also boost guidance sale earlier view rbc analyst matthew eckler call guidance conservative neurologist survey publish earlier week suggest rate patient start exondys be ahead street expectation write note client however tonight print provide definitive confirmation drug robust launch ibd take sarepta have ibd composite rating meaning perform middle stock term key growth metric trail leader celgene celg best possible cr head ibd stock checkup closer look top rate performer eckler model new patient start exondys mid low teen month second half predict patient exondys year end previous view boost sale view previously raise price target sarepta stock expand access program north america south america europe open door bigger sale say new chief executive dougla ingram call sarepta most undervalue company pipeline opportunity leerink analyst joseph schwartz write note client likely reintroduce merger premium sarepta share say also up price target sarepta stock reiterate outperform rating rbc eckler schwartz see sarepta guidance more modest realistic assume key growth driver continue evolve sarepta favor schwartz see beat raise company future management admit set more conservative guidance growth trajectory come more predictable so investor likely be draw robust growth story sarepta write note client more realistic outcome sarepta sale be line needham analyst chad messer say research report expect sarepta achieve profitability early second quarter messer keep buy rating price target sarepta stock related sarepta rocket consensus crush sale narrowing biotechs be dodge payor pushback muscular dystrophy star align biotechs crush earning consensus
249,CELG,baidu bidu former market leader market bottom march be campaigning rejoin spotlight top perform chinese internet play monday stock break long saucer handle rise much session high base be first stage base go
250,CELG,european drugmaker astrazeneca azn roche rhhby early thursday deliver better expect earning astrazeneca share plummet more key lung cancer drug trial fail xbiotech celgene celg alexion pharmaceutical alxn also report market open astrazeneca report adjust income cent share sale compare cent share sale year earlier period analyst poll zack investment research forecast adjust earning cent share sale astrazeneca say combination immuno oncology drug fail shrink lung cancer tumor so call mystic drug trial astrazeneca have pin hope trial immuno oncology generally mystic trial continue look hit different longer term goal cause share plunge early trading stock market today related news astrazeneca tagrisso meet goal late stage lung cancer trial tagrisso be approve treat certain population lung cancer patient specific mutation trial test tagrisso erlotinib gefitinib current standard care first treatment astrazeneca also announce team dow merck mrk roche report core earning first month come share constant currency exchange rate top forecast sale grow regardless exchange rate be largely line ibd take biotech sector be now rank third industry group track ibd merger acquisition send rocket say industry observer check potential war path ibd industry theme drugmaker raise full year sale forecast mid single digit growth constant currency core earning rise similar amount roche share tick slightly morning trade thursday celgene dip beating second quarter expectation sale come top consensus adjust income share rise top view alexion surge easily top wall street expectation second quarter sale rise top analyst view adjust profit increase share beating cent bristol myer squibb bmy stock tank reaction astrazeneca trial have read through similar immuno oncology program bristol drug giant report adjust income cent share sale meeting expectation year year basis revenue rise adjust profit increase growth be drive anticoagulant eliquis immuno oncology drug opdivo see sale bristol say news release fellow immuno oncology med yervoy grow related biotech rally still tack upsidebiotechs find strength number treat multiple sclerosisamgen topple increase forecast still lag view
251,CELG,long absence apple aapl make ibd latest monthly list new buy top perform mutual fund get ready unveil latest iphone analyst say launch be delay due production issue tech giant be joined slew medical sector stock include manage care provider unitedhealth unh aetna aet well lead biotech company celgene celg regeneron regn defense contractor boee ba raytheon rtn heico hei also make list tension north korea anticipate defense spending increase be expect drive demand last month top fund manager invest stock list unitedhealth fund invest apple electronic art ea celgene heavy institutional buy have help push apple electronic art celgene new buy zone have already lift unitedhealth buy range see stock watch list be be buy mutual fund manager proven track record success be positive sign mean ve do due diligence see doesn mean stock be necessarily proper buy zone right now more time be need set proper buy opportunity addition apple celgene stock month list be form base buy range also include boee medical software firm cerner cern casino operator mgm resort mgm apple have distinction make new buy screen also top list new sell month net number fund selling apple selling buy be mastercard have second most net seller follow nxp semiconductor nxpi biotech giant amgen amgn number seller stock continue show strength amgen be testing new potential buy zone monday amgen jump past entry heavy volume buy range extend related mutual fund manager be bet tech quality stocksfind track best mutual fund
252,CELG,cara therapeutic cara have relative strength rs rating upgrade friday ibd proprietary rs rating track market leadership used worst best score show stock price performance last week match other stock database history show market biggest winner tend have rs rating begin new price run now be not ideal time invest see stock go establish enter buy range heavy volume term fundamental health company have post quarters accelerate earning growth revenue gain have be different story come last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
253,CELG,medical consumer play continue furnish investor new breakout new high thursday celgene celg be certainly most notable giant biotech base therapy cancer other disease be flash luster have shine market leadership day early august
254,CELG,putt together watch list look stock higher rs rating acorda therapeutic acor just clear benchmark upgrade ibd unique rs rating identify technical performance show stock price action last week compare other stock major index history reveal best stock often have higher rs rating early stage move acorda therapeutic be not currently potential buy area see stock go form base spark new run acorda therapeutic see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
255,CELG,relative strength rs rating heron therapeutic hrtx jump higher percentile wednesday get lift exclusive rating investor business daily identify price performance worst best score rating show stock price movement trail week hold other stock database history show stock go make biggest gain often have rs rating least begin biggest price move see heron therapeutic continue rebound hit benchmark stock be try complete consolidation buy point see stock clear price heavy trading regard top bottom line number heron therapeutic have post rise ep growth last quarters revenue gain have be less impressive come last quarter heron therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
256,CELG,biotech news aplenty have breathe renew life sector drive stock new high xzogenix zgnx friday spiked more near year high report positive phase datum epilepsy drug bluebird bio blue thursday soar year high year end biotech celgene celg start pivotal trial multiple myeloma drug ve be work accord leerink bluebird give back gain friday advanced accelerator application aaap leap new high wednesday rumor swiss drug giant novartis nvs acquire french biotech advanced accelerator be expect get european approval soon fda approval january lutathera drug audente therapeutic bold surge much intraday wednesday fda grant drug fast track designation drug call be be test potential treatment rare disease affect skeletal muscle also wednesday galapago glpg pop eczema drug show favorable result phase trial galapago be partner morphosys drug thank recent flurry positive news biotech have moved industry group track ibd week boost biotech etfs well ibd take keep eye industry group action be vital investing check ibd daily industry sub group ranking list find group have make biggest move spdr biotech xbi be top buy zone flat base entry clear aug deliver year date gain fund track biotechnology select industry index top holding include alnylam pharmaceutical alny exact science exas puma biotechnology pbyi accord morningstar direct proshare ultra nasdaq biotechnology bib aim twice return nasdaq biotechnology index have generate big return year fund have rally year date share have ease week high leverage play bib tend have more exaggerate move upside downside thus tend carry higher risk nonleveraged fund expense ratio leverage fund be often higher nonleveraged peer direxion biotech bull labu leverage play be trading highest level january have return year date fund seek provide performance biotechnology select industry index ishare nasdaq biotechnology ibb year remain buy range flat base entry clear aug fund track nasdaq biotechnology index top holding include amgen amgn celgene biogen biib related zogenix rocket seizure drug trip rival gw pharmabluebird hit high bullish report highlight blood drugsnovartis acquire biotech deal be very logical biotech make bold move potential speedier drug okgalapagos pop eczema drug show promise vs beating market be buy range
257,CELG,innoviva inva see welcome improvement relative strength rs rating tuesday increase ibd proprietary rs rating measure technical performance used worst best score show stock price performance last week match other publicly trade company history reveal market biggest winner typically have higher rs rating early stage move stock be not proper buy zone right now see manage form break proper base earning growth decrease last quarter top line rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
258,CELG,acadium pharmaceutical acad have relative strength rs rating upgrade friday welcome improvement still better score look ibd unique rs rating track technical performance show stock price action last week compare other stock database decade market research show stock go make biggest gain often have higher rs rating early stage move see acadium pharmaceutical continue rebound hit benchmark now be not ideal time jump isn proper buy zone see stock be able establish enter buy range heavy volume earning growth rise last quarter sale fall acadium pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
259,CELG,acceleron pharma xlrn see welcome improvement relative strength rs rating friday rise unique rating track technical performance show stock price movement last week compare other stock database decade market research show best stock typically have rs rating least begin new climb stock be build cup handle buy point see stock break heavy trade earning sale growth come respectively latest report marked acceleration earning share sale company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
260,CELG,thursday flexion therapeutic flxn get positive adjustment relative strength rs rating proprietary rating track market leadership show stock price action last week compare other stock database year market history reveal best stock often have rs rating begin new price run flexion therapeutic be build cup handle buy point see stock break volume least higher normal keep mind later stage consolidation entail more risk company show ep growth latest quarterly report revenue gain come company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
261,CELG,thursday paratek pharmaceutical prtk reach important technical milestone relative strength rs rating move percentile upgrade increase day unique rating track market leadership used worst best score identify stock price action last week match other publicly trade company year market history show stock go make biggest gain often have better rs rating begin new run not currently ideal time invest see stock be able offer clear proper buy point regard fundamental company have post quarters accelerate earning growth revenue growth have be different story come last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
262,CELG,life be simple rachel martin day work accounting firm way become cpa night run start notice foot feel strangely stiff xthat lead bit news day soon be good yet odd still stack day get notice multiple sclerosis get notice sell condo get notice receive cpa license tell investor business daily number haven go martin way ever be diagnosed half lifetime hasn work year have spend hour life work cpa take least medication treat ms exactly none have fully contain ailment barrage new drug be take aim ms however offer hope martin other debilitating illness medication be offer lower cost expect market heat offer prospect fewer side effect most critically greater effectiveness several heavy hitter industry be get involved biopharma battle roche rhhby have new drug swipe share market leader biogen biib meanwhile celgene celg number generic drug manufacturer be expect pile pressure mainstay field novartis nvs roche share be fractionally monday close biogen tick finish celgene be marginally novartis be slightly ms sector have be dominate biogen bring just shy sale medication arsenal include inventory be ms drug martin recently stop used avonex well other top seller tysabri tecfidera now paradigm shift especially roche ms drug ocrevus be concern accord michael analyst evercore ocrevus be approve earlier year treatment relapse remit primary progressive form ms offer medication primary progressive be breakthrough form ms comprise just market have not be target treatment past ocrevus twice year infusion look attractive patient martin discontinue used certain drug due ms related tremor martin first medication be interferon be medicine month shake hand become so severe couldn administer injection analyst say roche drug put biogen tysabri tecfidera greatest risk market share loss wall street estimate see ocrevus take away tysabri sale tecfidera revenue year ocrevus market have threat share be steal tell ibd also have possibility look generic version novartis gilenya teva pharmaceutical teva copaxone so lot move part ibd take ibd company biotech industry group be now rank fourth group track share have rise year ride high june rally still see upside accord estimate benefit spike head ibd industry theme closer look novartis case celgene be heap pressure company potential blockbuster ms drug now have test phase name ozanimod celgene biotech market cap be bill ozanimod safer version gilenya be target latter half file application approval food drug administration ozanimod gilenya class drug call receptor modulator work prevent specific white blood cell move central nervous system do so have be show improve outcome reduce ms relapse ms be disease central nervous system disrupt flow information brain brain body patient fatigue easily have difficulty walking go run walking walker then wheelchair say martin wasn muscular ability add be balance be able exercise hold something say medication have bring martin moderate success point generally walk cane belong ms group call let play los angele disease be steady say doctor take time physical therapy experimentation medicine medicine cause debilitating headach be chemotherapy today doctor know cause heart damage martin manage avoid martin current medication be make bayer bayry sell novartis require self injection other day begin used medicine april quit used biogen avonex year due headach biogen have most lose battle sale tysabri tecfidera avonex line second quarter be expect be biogen first real test mizuho analyst salim sy tell ibd result be due be report tuesday biogen drug tysabri roche ocrevus be consider highly efficient ms treatment tysabri label contain black box warning deadly virus attack brain ocrevus label doesn case virus progressive multifocal also call pml have be record single ocrevus user patient have just come tysabri year have only be treat once ocrevus most analyst don consider case be related ocrevus risk pml be likely enough prod number tysabri patient switch ocrevus sy say further biogen have estimate third patient tysabri test positive ailment know john cunningham virus patient have weak immune system be more susceptible pml analyst say erosion tysabri use be slow biogen isn particularly worry ms franchise franchise grow expand include zinbryta launch partner abbvie abbv first quarter end march biogen ms drug sale grow just sale tysabri zinbryta fall chief executive michel vounatsos doesn see biogen ms drug decline franchise evercore analyst umer raffat write june note client meeting vounatsos believe biogen lose market share roche ocrevus believe be plenty opportunity grow top line raffat say vounatsos do not believe generic copaxone teva drug generic gilenya novartis drug impact biogen ms franchise copaxone gilenya face own battle celgene other celgene ozanimod successfully reduce relapse rate vs traditional interferon treatment phase trial company present milligram milligram oral dose be safe tolerable year period novartis gilenya also have own safety issue mizuho sy say label patient undergo monitoring hour immediately follow first dose ensure heart rate don slow dangerous level gilenya have also be show have toxic effect liver enzyme so gilenya be not perfect drug say celgene say be safer gilenya just see top line datum ozanimod go come market get approve so ozanimod successful gouge gilenya sale analyst say second quarter gilenya sale grow constant currency basis follow major growth exclude impact foreign exchange rate celgene be optimistic chance multiple sclerosis market report leerink analyst geoffrey porge note management hasn commit first dose monitoring say unique dose schedule minimize need requirement safety celgene management expect show multiple point safety differentiation gilenya safety profile have label be consistent phase result say then potential generic competition novartis face slew generic have be approve pending patent litigation like teva mylan myl analyst consensus model see gilenya sale drop generic approve tentatively gilenya price point wait break evercore raffat say video raffat say unlikely gilenya go generic patent litigation likely push generic entry even then gilenya have patent set expire hasn really be vet say patent cover dose schedule only currently face challenge earlier stand challenge apotex novartis be also study low dose version gilenya milligram gilenya be now approve milligram dose trial work likely very patentable raffat say fda review fda say not clear milligram dose work alone be reason know milligram dose do work novartis trial be patentable not obvious new patent gilenya be obstacle generic competition evercore say note nullify gilenya go generic help broader ms industry stave cheaper generic tug drug pricing market ultimately competition be godsend patient martin be hopeful better ms medicine fewer side effect multiple sclerosis be something difficult describe person most look re do well martin say bubble look fine outside don feel fine related biogen takeover prospect soured mere novartis ms drug stomp celgene even hit market roche game changer drug chip away biogen novartis
263,CELG,nektar therapeutic nktr stock near monday announce deal eli lilly lly develop drug stoke immune system fight autoimmune inflammatory condition xin morning trading stock market today nektar pop close earlier rise much share be year begin form cup buy point late march same time lilly stock be fractionally lilly nektar codevelop drug know nktr drug work stimulating specific pathway body generate greater immune system response activate certain cell nktr act bring immune system back balance firm say drug be enter phase testing determine correct dose be be develop once twice monthly self administer injection number autoimmune disease company say news release evercore analyst umer raffat see nktr potential treatment lupus crohn disease ulcerative colitis rheumatoid arthritis perhaps even multiple sclerosis graft versus host disease type diabetes ibd take nektar have ibd composite rating meaning outperform just half stock term key growth metric lag leader celgene celg therapeutic cort supernus pharmaceutical supn have best possible crs head ibd stock checkup list top rate biotechs phase trial information be due third quarter raffat write research report term deal lilly pay nektar upfront fee make milestone payment lilly foot bill research development cost phase wrapped nektar be response phase cost nektar receive double digit royalty increase commensurate phase investment product sale company say nektar be able co promote certain treatment raffat note nektar main program be actually drug know nktr be be combine drug bristol myer squibb bmy roche rhhby bristol nektar be look tumor type roche nektar be work lung bladder cancer related biotech dethrone oxycodone treat painis small biotech head market cap pitfall bristol incyte match beat dow merck combination trial
264,CELG,here weekly investing action plan need know investor come week china largest internet company alibaba baba tencent tcehy jd com jd report quarterly earning other highflying chinese peer wal mart wmt target tgt have turn pummeling department store stock
265,CELG,key index fund be thursday stock sell hard north korea concern xpowershare qqq trust qqq sank head potential test support day move average line spdr spy fall spdr dow jone industrial average dium lose dium fall back level sell wasn restrict equity ishare msci emerge market eem ishare msci eafe efa tumble respectively retail lead downside sector play spdr retail xrt sell more department store drop earning report dd plunge kohl kss macy lose apiece bank biotechs chip be also biggest loser gold rally investor seek safe haven vaneck vector gold miner gdx vaneck vector junior gold miner gdxj rise respective powershare db gold dbo ishare gold trust iau spdr gold trust gld be biotechs have be take rest recent run best level well year etfs hold celgene celg biogen biib gilead science gild have contribute pause such several biotech etfs have be pull back day move average set fresh buy opportunity solid bounce line early thursday be trading slightly line first be ishare nasdaq biotechnology ibb total net asset year old fund be head potential test day line gain nearly june july intraday high ibb track nasdaq biotechnology index count celgene biogen gilead science amgen top holding aug celgene amgen have beaten broader market year respective gain wednesday fund be bit top heavy top name account asset portfolio contain stock north america primarily represent europe ibb have outpaced year date return vs aug accord morningstar inc lag benchmark index past year vs have solidly outperformed past year ibb have expense ratio spdr biotech xbi bounce day line last week soon test support again share rise much june flat base july high xbi launch january have attract asset fund track biotechnology select industry index modify equal weight index comprise stock top holding aug include exelixis exel kite pharma kite alexion pharmaceutical alxn celgene top account asset exelixis biggest position make etf have rally ytd aug return past year have outpaced wide margin xbi have expense ratio wednesday pick vanguard mega cap value mgv ishare edge msci usa value factor vlue continue trade just respective buy point related sector avoid sell be apple microsoft better value play apple microsoft lift dow equity play buydow go apple clear buy point nvidia hit high
266,CELG,catch rally biotech sector tack stock celgene celg alexion pharmaceutical alxn regeneron pharmaceutical regn lead charge analyst say week xyear date ishare nasdaq biotechnology etf ibb be same time spdr biotech etf xbi be be currently buy zone strong performance biotech multiple be only just historical time trough leerink analyst geoffrey porge say recovery be underway large cap biotech stock be april beat market handily second quarter still biotechs continue trading significant discount pharma medtech brother porge say note client premium biotechs have enjoy pharma medtech respectively have erode reversed porge be banking return sentiment biotech sector compare revenue multiple group be be still additional upside sentiment sector return prior level say ibd take industry observer say september be make break month biotech sector base number upcoming investor health care conference well expectation nearly dozen trial readout excel be face pitfall head ibd industry theme closer look recovery be already underway late august gilead science gild say pay acquire cancer play kite pharma kite day later rival novartis win approval key treatment set stage key drug kite be approve november announcement ibd company biotech industry group have climb porge call catch rally significant extend be rally investor have be hope look follow surprisingly tepid july group strong second quarter operate result porge say consensus expectation third quarter be pick porge say revenue view be modest call average growth earning share forecast be trend first time year porge be more bullish consensus top pick be outperform rate alexion celgene regeneron vertex pharmaceutical vrtx january even slow grow large cap have deliver outperformance standout include regeneron vertex celgene have more pipeline optionality have not appreciate much lately alexion say be also recommend regeneron vertex current valuation see less upside name celgene alexion related alnylam topple celgene astrazeneca rise drug setbackstop biotech stock buy zone fda drug abbvie chip away regeneron potential blockbuster
267,CELG,big jump crude oil future related exploration company be lead market upside index sell tuesday yet analysis stock hit new high show growth investor want keep sharp eye medical sector alexion pharmaceutical alxn have stage
268,CELG,last week market rally bring nasdaq striking distance fresh record high tuesday general market sell be setback further upward price progress high profile growth stock remain just high xall lead growth stock be just proper buy point stock
269,CELG,tuesday major average fall average volume index close day move average lead group generally hold well lead stock apple aapl wal mart wmt fang stock facebook fb netflix nflx biotech breakout such celgene celg biogen biib act normally outperformed negative session xs future rise fair value early wednesday morning nasdaq future climb dow future advanced index fall tuesday stock market trading nasdaq composite retreat dow industrial volume higher friday market add distribution day be not good be first distribution day mid august meanwhile index dow industrial find support day line undercut key level intraday nasdaq composite heel best week hold day tuesday session investor pay close attention action major average also lead stock lead stock show strength apple fall tuesday still comfortably flat base buy point apple iphone chipmaker skywork solution swks peek past buy point tuesday morning skywork pull back still finished solid gain wal mart rise rebound day line discounter try retake cup base buy point facebook dip pop last week still only buy point newly form flat base netflix dip hold day own flat base biotechs celgene biogen car drug specialist bluebird bio blue cede ground tuesday surge last week close buy point last week breakout most top industry group fall less include video game publisher homebuilder biotechs higher rate group lose more most be finance related financial be big loser tuesday bank be hit treasury yield yield spread fall pre election level property insurer fall hurricane irma grow strength florida sight airline stock be hit irma delta air dal cut forecast unit revenue profit margin current third quarter tuesday action be better first impression market be confirm uptrend stock grind higher choppy action difficult investor make much headway top stock rally buy point then clear then quickly pull back entry even general trend be positive so investor be cautious act decisively make purchase take profit cut loss related big picture sign market bouncestock falter here be reason apple be finewhich fang stock be first break facebook boee lead top stock buy bullish patternu market back work top stock be race buysstock buy watch top ipos big small cap growth stock
270,CELG,emergent biosolution ebs have relative strength rs rating upgrade friday ibd unique rating identify price action worst best score score show stock price movement trail week stack other stock database year market history reveal stock go make biggest gain often have rs rating north begin new run emergent biosolution have climb more past entry first stage saucer handle meaning now proper buy range look stock offer new chance pick share week tight pullback day week move average revenue growth fall last quarter bottom line grow prior report company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
271,CELG,important metric look stock be higher relative strength rating ionis pharmaceutical ion now clear threshold jump wednesday ibd proprietary rating track share price action worst best score rating show stock price movement last week hold other stock database history reveal best perform stock tend have rs rating launch biggest climb ionis pharmaceutical be not proper entry right now see manage form break proper chart pattern sale growth fall last quarter ep grow previous report ionis pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
272,CELG,important metric look stock be higher relative strength rating regeneron pharmaceutical regn just hit mark jump monday ibd unique rs rating track market leadership used worst best score indicate stock price action last week match rest market year market history show top perform stock tend have rs rating launch biggest price move now be not ideal time jump isn proper buy zone see stock go offer clear proper buy point earning grow last quarter prior report revenue also increase regeneron pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
273,CELG,epizyme epzm have relative strength rs rating upgrade friday unique rating measure market leadership used worst best score identify stock price performance trail week match rest market year market history show best perform stock often have rs rating north early stage move epizyme have moved more past entry first stage cup handle meaning now proper buy range look stock offer new buy opportunity week tight pullback day week line earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
274,CELG,welcome move momenta pharmaceutical mnta see relative strength rating rise wednesday exclusive rating investor business daily track share price performance worst best score grade show stock price movement trail week compare other stock database history show top perform stock often have rs rating north begin largest climb see momenta pharmaceutical continue rebound clear threshold stock be build cup handle entry see clear price heavy trade company report negative growth top bottom line last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
275,CELG,top biotech supernus pharmaceutical supn flirted buy point late tuesday beat rival twi pharmaceutical patent suit epileptic drug oxtellar xr supernus end regular trading session rise much close entry point flat base begin form late june share slip less hour trading stock market today tuesday action new jersey district court solidify protection generic oxtellar xr extend release april janney analyst ken say note client court find patent valid rule twi pharmaceutical infringe patent propose manufacture sale generic oxtellar xr say ibd take supernus have best possible ibd composite rating be rank third biotechs trail only celgene celg therapeutic cort also have crs visit ibd stock checkup full breakdown top ranking biotechs prior twi lawsuit supernus emerge victorious similar battle actavis actavis generic arm have be acquire teva pharmaceutical teva supernus have patent protect oxtellar xr related stock watch acceleron pharma see rs rating jump perrigo beat raise lift generic drug buck teva mylan trendibd rating upgrade ionis pharmaceutical show improve technical strength
276,CELG,friday cara therapeutic cara hit important technical milestone relative strength rs rating jump percentile upgrade increase day ibd unique rs rating identify market leadership show stock price action last week compare other stock database history reveal stock go make biggest gain typically have rs rating north early stage move cara therapeutic be not proper buy zone right now see manage form break proper base term revenue profit cara therapeutic have post rise ep growth last quarters sale gain have not follow same trajectory come most recent report company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
277,CELG,acorda therapeutic acor have relative strength rs rating upgrade friday welcome improvement still shy higher score prefer see ibd unique rs rating identify market leadership used worst best score identify stock price action last week match other stock decade market research show market biggest winner often have rs rating north launch largest climb see acorda therapeutic continue show renew price strength hit benchmark not currently ideal time buy share see stock be able offer clear appropriate buy point top bottom line growth moved higher last quarter earning be compare prior report revenue increase company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
278,CELG,biogen biib have relative strength rs rating upgrade friday ibd proprietary rating measure share price action worst best score score show stock price performance trail week compare other stock database decade market research reveal market biggest winner typically have rs rating begin biggest price move biogen be not currently potential buy area see stock go form base ignite new run ep growth decline last quarter revenue rise biogen hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
279,CELG,prothena prta see welcome improvement relative strength rs rating friday upgrade ibd unique rating measure share price movement worst best score grade show stock price behavior trail week stack other stock database history reveal best stock tend have rs rating least early stage move prothena be build buy point see stock clear price volume least higher normal regard fundamental company have post quarters rise earning growth revenue growth have also increase same time frame company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
280,CELG,many stock breakout have be malfunctioning include relatively high number ibd member include chip industry darling nvidia nvda xof stock composite rating least have top buy point be entry other be fall back ibd find
281,CELG,tuesday nektar therapeutic nktr earn upgrade relative strength rs rating proprietary rating identify market leadership show stock price movement last week compare other stock database year market history reveal market biggest winner tend have rs rating north launch biggest price move nektar therapeutic be try complete cup handle entry see clear price volume least average later stage pattern investor be aware be less likely launch sustain new run ep growth decline company most recent report sale rise company earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
282,CELG,stock fail react much enthusiasm surprise deal white house democrat avert federal budget fiasco month end wednesday modest rebound mixed volume help keep market uptrend intact latest beige book report federal reserve meanwhile do not appear shed much new light most
283,CELG,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
284,CELG,key index fund be board stock market today overseas market stay ahead xishare msci eafe efa ishare msci emerge market eem rise spdr dow jone industrial average dium spdr spy lead index fund gain apiece powershare qqq trust qqq add energy retail bank be biggest gainer sector fund gold telecom utility underperform spdr gold share gld ishare gold trust iau give vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx lose gold future dip ounce spdr retail xrt advanced retake day move average first time nearly month component stock kohl kss jump department store operator say open amazon amzn shop store oil play advanced boost rise west texas intermediate crude price barrel spdr oil gas exploration production xop vaneck vector oil service oih surge nearly unite state oil uso powershare db oil dbo add apiece health care exchange trade fund be just respective buy point pull back time high spdr health care xlv ease second straight session tuesday close slightly buy point flat base etf advanced nearly early june prior flat base start most recent pattern fund mark anniversary december have attract asset track health care select sector index be comprise health care name pharmaceutical account biggest chunk asset nearly biotech weigh health care provider service health care equipment supply contribute respectively top holding include johnson johnson jnj pfizer pfe unitedhealth group unh biotechs score big gain last week also make top list amgen amgn gilead science gild celgene celg biotech industry track ibd surge last week spur part gilead acquisition kite pharma kite gilead share soar kite rocket week xlv have outperformed year date gain accord morningstar direct also outpaced benchmark index past year respective return vs gain same period etf carry expense ratio ibd take biotech be rank base fundamental technical metric track ibd find now ibd stock checkup vanguard health care index fund vht be also trading slightly flat base buy point case be fund launch january track msci investable market health care index pharma make biggest sector weighting july asset biotech health care equipment manage health care follow respective weighting top holding include many same name xlv johnson johnson pfizer unitedhealth amgen celgene gilead vht have return year date past year respectively expense ratio be tuesday etf pick first trust equity opportunity fpx ishare russell midcap growth iwp close respective flat base buy point related think miss big biotech rally check playsgold oil rally stock sell long term winner buygilead kite deal boost biotech etf clear buy pointbiotech extend gain breakout put apple amazon focus
285,CELG,amgen amgn have relative strength rs rating upgrade friday welcome improvement still shy better score prefer see exclusive rating investor business daily measure market leadership worst best score rating show stock price movement last week hold other stock database year market history reveal stock go make biggest gain tend have better rs rating early stage move see amgen continue rebound hit benchmark amgen be work entry see stock break volume least average company see earning sale growth rise last quarter earning share increase revenue rise amgen earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
286,CELG,incyte incy see welcome improvement relative strength rs rating thursday increase ibd proprietary rating identify market leadership worst best score grade show stock price movement last week compare other stock database history show top perform stock typically have higher rs rating begin largest price move stock be work consolidation entry see stock clear price heavy volume incyte report earning growth latest quarterly report sale growth come company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
287,CELG,celgene celg see welcome improvement relative strength rs rating thursday upgrade unique rating measure market leadership show stock price action last week measure other stock major index decade market research show best stock tend have rs rating north early stage move stock be build flat base entry see clear price volume least higher normal earning growth slow most recent report revenue moved higher celgene earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd be also group highest rate stock related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
288,CELG,thursday gilead science gild reach important technical milestone relative strength rs rating rise percentile improvement increase day ibd proprietary rating measure share price movement worst best score rating show stock price performance trail week hold other stock database history show stock go make biggest gain often have rs rating least begin biggest run stock be not proper buy range right now see be able form break proper consolidation earning sale growth come respectively latest report show improvement top bottom line company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
289,CELG,wednesday halozyme therapeutic halo receive upgrade relative strength rs rating ibd unique rs rating measure market leadership show stock price movement last week compare other stock database history reveal best perform stock typically have higher rs rating launch largest climb see halozyme therapeutic continue rebound clear threshold halozyme therapeutic be build consolidation entry see break heavy trading ep growth fall company latest report revenue rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
290,CELG,major stock index trade session lows thursday afternoon stock market complexion worsen nasdaq composite slide lose index slip day move average indicate change market direction downside russell fall dow jone industrial average be dow component cisco system csco wal mart wmt be company report earning give soft outlook cisco sank back lows pattern have be shape wal mart chart be more concern stock be now buy point cup shape base volume exchange be tracking higher wednesday level stock market today add day bearish tone indicate institutional investor be selling more share normal also worsen trend institutional selling past couple week breadth be bearish also loser top winner nearly nyse nasdaq few top rate stock suffer significant loss flash sell signal otherwise behaved bearishly netapp ntap plunge big volume breaking day move average stock also fall more buy point july storage technology company report quarterly profit revenue growth expectation current quarter guidance be light celgene celg fall day move average trouble move volume be only average meaning stock still have chance hold buy point still gain nearly entry be now go chinese internet retailer jd com jd tumble day line more time average volume jd com have find support day line june july so today break support be bearish sign stock jd com have be weaken earning report monday rival alibaba baba surge new high company beat profit expectation investor run other lead chinese stock china lodging htht weibo wb make new high heavy trading be extend buy zone related netapp earning beat view guidance light stock fallswal mart earning top online sale jump guidance weakcisco line earning guidance not good enough stock fall
291,CELG,alexion pharmaceutical alxn have relative strength rs rating upgrade monday welcome improvement still short better score prefer see unique rating identify technical performance show stock price movement last week measure other stock database decade market research reveal market biggest winner often have rs rating north early stage move see alexion pharmaceutical continue rebound clear threshold alexion pharmaceutical be not currently offer proper buy opportunity see stock go form promising consolidation ignite new run alexion pharmaceutical show ep growth latest quarterly report sale growth come alexion pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
292,CELG,ionis pharmaceutical ion have relative strength rs rating upgrade monday welcome improvement still shy higher score prefer see ibd unique rating measure price action worst best score score show stock price movement trail week compare other stock database decade market research reveal top perform stock often have rs rating north launch biggest run see ionis pharmaceutical continue show renew price strength clear threshold ionis pharmaceutical be not currently potential buy area see stock go form sound pattern kick new climb sale growth fall last quarter ep grow previous report ionis pharmaceutical earn rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
293,CELG,thank gilead kite merger biotechs have big week ve also rally year longer haul top health sector etfs rank year date return aug be biotech focuse accord morningstar direct top performer spdr biotech xbi post gain well ahead advance etf featured monday etf leader column break past flat base entry thursday remain buy range share run june flat base start just clear pattern fund launch january have asset bear expense ratio come second be first trust nyse arca biotech fbt ytd gain etf be buy zone past flat base entry year old fund track nyse arca biotechnology index have attract asset carry expense ratio count top holding aug kite pharma kite juno therapeutic juno illumina ilmn kite gap soar aug gilead science gild announce buy kite xbi mentioned also get boost kite ishare medical device ihi take third place ytd return etf recently regain day move average line shape flat base potential buy point fund marked anniversary track dow jone select medical equipment index ibd take gilead science have be news lately due kite pharma acquisition do rank biotechs find now ibd stock checkup top holding aug include medtronic mdt abbott laboratory thermo fisher scientific tmo ihi expense ratio be ishare nasdaq biotechnology ibb round top ytd gain price action be similar other biotech etfs buy range follow thursday flat base buy point case be etf sport expense ratio ibb oldest biotechs year have amassed asset top holding aug be gilead biogen biib celgene celg kite account position portfolio fund have beaten past year return vs gain fund have outperformed past year related gilead science buy kite pharma sector boost stock breakout put apple amazon focusretail lead broad stock sell biotechs find support celgene flirt giant soon join
294,CELG,nasdaq post best weekly gain sixth best stock index friday shield recent gain xsmall cap lead friday action russell advanced blue chip dow jone industrial average follow gain nasdaq inched volume be
295,CELG,important metric look stock be higher relative strength rating acadium pharmaceutical acad clear benchmark wednesday jump wednesday ibd proprietary rating identify market leadership worst best score grade show stock price movement last week hold other stock database history reveal stock go make biggest gain tend have better rs rating launch biggest run stock be work cup handle buy point see stock clear price volume least average earning growth rise last quarter revenue fall company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
296,CELG,important metric look stock be higher relative strength rating neurocrine bioscience nbix clear benchmark wednesday jump wednesday ibd unique rating measure share price movement worst best score rating show stock price movement last week stack other stock database history show best stock typically have higher rs rating launch biggest climb neurocrine bioscience be try complete cup handle entry see break heavy trade company report ep growth last quarter revenue gain come company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
297,CELG,wednesday agio pharmaceutical agio earn upgrade relative strength rs rating exclusive rating investor business daily track share price movement worst best score grade show stock price performance last week stack other stock database year market history show best perform stock tend have rs rating north early stage move stock be build consolidation buy point see break heavy volume earning growth drop most recent report revenue gain moved higher company earn rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
298,CELG,perrigo prgo shot month high thursday buck weakness generic drug business industry overall top second quarter expectation raise guidance xin morning trading stock market today perrigo pop earlier spiking much touch high last see late february meanwhile generic drug stock collectively rebound generic drug stock have be pressure month teva pharmaceutical teva mylan myl lead group report lackluster quarterly result cut guidance entire group trade straight day begin recover wednesday early thursday perrigo report sale adjust earning share top consensus cent respectively canaccord analyst dewey steadman write note client generic unit be become less important steadman say perrigo beat arrived back consumer business generic decline year year part lower sale crohn disease drug entocort ibd take biotechs be better rate generic drug stock perrigo have ibd composite rating best possible meaning underperform most stock term key growth metric celgene celg lead biotech group cr head ibd stock checkup look top rate stock year year basis consumer sale americas internationally decline respective perrigo sell unprofitable business last year exclude impact sale revenue grow respectively be stark contrast perrigo current large generic peer set face significant pricing challenge existential growth issue recent quarterly announcement steadman say consumer unit behave materially different generic steadman note expect perrigo shift further consumer drive business time significant opportunity keep buy rating price target perrigo perrigo also raise guidance adjust income share vs earlier view top consensus view steadman say related generic drug stock catch break mylan crash teva crash day be hurt generic drugmakersteva crash year low very tough quarter
299,CELG,nasdaq composite breach day move average geopolitical uncertainty here look top tech stock big cap nasdaq be find support key level netflix nflx have be pressure disney announce plan cut ty stream service favor own top platform share thursday threaten round trip flat base entry coincide day line stock rebound friday climb microsoft msft also shot higher friday rise testing support day line thursday share be now less buy point be initially clear several day company july earning report ibd take stock research take too much time make easy several way leaderboard be curate list strong growth stock actionable trading opportunity complete annotation marketsmith screener tool allow filter stock base variety metric stock list page find sector leader stock hit new high more celgene celg be back buy range entry initially clear june stock drop almost thursday hit day line edge higher friday activision atvi adobe adbe be well extend last base breakout activision be just add week tight entry find support day line adobe be pivot higher day line well look weekly chart adobe fourth test line january related earning preview play dow retailer buy rangestock buy watch top ipos big small cap growth stock
300,CELG,macrogenic mgnx topple friday dow component johnson johnson jnj terminate agreement develop cancer treatment have rivale drug gilead science gild kite pharma kite novartis nvs xin midday trading stock market today macrogenic dove much week low be close johnson johnson fall finish cite increase competition space well neurotoxicity associate drug duvortuxizumab decision bail pact duvortuxizumab show cancer activity phase trial note duvortuxizumab belong class drug know bispecific antibody stimulate immune cell direct target antigen drug be be investigate potential treatment several lymphomas leukemias bispecific antibody hold tremendous promise think news highlight remain development challenge agent particular context recent emergence highly effective car cell therapy leerink analyst michael schmidt say ibd take novartis be first gain approval car therapy other be just tail get scoop major player break visit ibd industry theme car drug be create extract immune cell patient then reprogramming fight cancer reintroduce patient case bispecific antibody car drug have same target schmidt say note client earlier week novartis nvs be first gain approval car treatment kite be be acquire gilead be expect be next celgene celg be also partner separately juno therapeutic juno bluebird bio blue car drug various bispecific antibody platform currently development differentiate clinically remain unknown schmidt say macrogenic have total bispecific antibody program have enter phase trial recent year possible bispecific antibody be more potent treat solid tumor area remain challenge car drug schmidt say schmidt reiterate outperform rating macrogenic doesn expect macrogenic continue develop duvortuxizumab wake competition car drug other therapy cancer affect be know cell related celgene flirt giant soon join gilead kite deal boost biotech etf clear buy pointanalyst mixed gilead kite key rival stand benefitthese biotechs just moved buy zone be giant next novartis cancer approval validate gilead kite deal
301,CELG,momenta pharmaceutical mnta have relative strength rs rating upgrade thursday exclusive rating investor business daily track share price action worst best score grade show stock price performance trail week stack other stock database decade market research show best stock often have rs rating early stage move stock be try complete cup handle buy point see stock clear price volume least average company report negative growth sale earning last quarter momenta pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
302,CELG,index nasdaq composite near record high even hurricane harvey devastate houston south texas part louisiana gasoline future spiked refinery be shut consumer expect see bigger increase come week biotech stock break gilead science gild kite pharma kite takeover deal historic fda approval economy add fewer job expect august nasdaq composite rise week close fraction time record high index dow industrial also rally time level north korea missile test spook investor briefly quickly shrug latest provocation fang internet giant be strong biogen biib bluebird bio blue be notable biotech breakout construction material other stock see benefit post harvey rebuild purchase rebound barrel day refine capacity total capacity be offline due hurricane harvey accord global platt send gasoline future soar year high refinery be shut several week gas buddy say national gasoline average jump cent gallon prior week more price hike way crude future fall fewer refiner be available convert oil gasoline other product crude inventory fall barrel latest week gasoline supply flat energy information administration report doesn reflect harvey impact domestic production be essentially flat barrel day still record high reach june day gilead science gild say pay share kite pharma kite pivot cellular therapy novartis nvs be first grab fda approval car treatment kymriah be treat form acute lymphoblastic leukemia patient age kite drug be expect be approve fall treat aggressive form hodgkin lymphoma gilead soar year high novartis car approval appear validate plan acquire kite shot drug giant novartis climb other car player include bluebird bio blue rise clear buy point juno therapeutic juno pop be partner celgene celg gain edge past own buy point related investor be mute gilead acquisition kite pharmaanalyst mixed gilead kite key rival stand benefitnovartis car drug help gilead spike post kite add just job august fewer expect june july payroll growth be revise jobless rate tick vs view steady ism manufacturing index jump best level more year meanwhile gdp growth be revise annual rate best more year related add just job august jobless rate rise takeover be complete mark day ownership whole food commerce titan discount number produce dairy meat offering upscale grocer bring price banana egg butter several variety milk fish ground beef other thing amazon echos be also display prominently whole food store amazon com amzn share climb general motor gm report bigger expect sale gain ford sale fall less expect even hurricane harvey likely cut texas sale fiat chrysler fcau sale fall sharply toyota tm miss view harvey destroy vehicle auto sale pricing get boost share automaker generally rally gm breaking past buy point friday consumer electronic retailer best buy bby top fiscal second quarter estimate guide higher current quarter full year same store sale rise vs view best buy ceo hubert joly caution not expect recent gain be new normal best buy have gain business recently struggle sear shld bankrupt hhgregg be likely face tougher competition amazon com amzn holiday quarter best buy crash nearly tumble buy point ciena cien top view fiscal third quarter sale earning fiscal fourth quarter fiber optic network supplier expect adjust earning rise cent share sale increase base midpoint guidance wall street be modele cent soft guidance be shocker give ciena previously bullish stance nomura instinet say ciena tumble thursday workday wday report second quarter earning cent share trouncing estimate cent revenue rise ahead consensus estimate cloud base human resource finance software firm raise full year subscription revenue forecast workday share rise best level early box report second quarter earning beat estimate top bottom line revenue rise beating consensus estimate adjust earning cent loss beat consensus estimate cent loss box share fall week related box second quarter revenue earning top viewsnew ceo dara khosrowshahi promise change take ride sharing pioneer next level set ipo timeline month khosrowshahi come uber expedia expe travel book site cfo mark take ceo rein khosrowshahi departure uber board take more month settle new chief follow exit co founder former ceo travis kalanick accusation discrimination sexual harassment mismanagement finish line finl crash nearly hit year low week sporting good retailer slash full year profit same store sale outlook say athletic footwear business become much more promotional second quarter forecast follow weak quarterly showing foot locker fl dick sporting good dks hibbett sport hibb news follow retail sector struggle online shopping summer agreement amazon nike nke shoemaker test sale product directly amazon nike armour uaa share fall sharply centric discount retailer second quarter result beat estimate cite continue notable contribution spinner trend hike full year outlook value retailer ollie bargain outlet olli also beat estimate raise outlook dollar general dg revenue same store sale beat ep higher full year profit outlook miss expectation share specialty discounter fall significantly week well fargo wfc hike number unauthorized customer account review expand time period cover otonomy otic crash time low wednesday drug treat inner ear disease fail phase trial analog device adi report fiscal third quarter sale earning easily beat view chipmaker also see current ep sale rise midpoint guidance higher wall street model analog device rise nearly share jill jill fall hit record lows week woman apparel retailer offer disappointing full year guidance adjust ep rise line view sale grow vs estimate lululemon athletica lulu report surprise profit growth adjust cent share revenue better estimate cent ep sale yogawear maker retailer same store sale rise well estimate share jump friday
303,CELG,bull august roam thursday stock hammer healthy gain rise trade nasdaq rise add fourth day run end less july high grab gain fifth row give breathe room day move average put peak notch aug dow jone industrial average turn third straight gain hold comfortably day line also aug high water mark august nasdaq gain notch gain past month tune positive manage gain ninth advance month dow haul increase also ninth gain october canadian oil producer post strongest gain industry group track ibd energy remain center stage due factor tie tropical storm harvey impact gulf coast fairfax va base colonial pipeline announce be force shut pipeline gallon day throughput gasoline other refine fuel flow gulf coast refinery north massive market east coast truck barge be likely be used heavily make lose supply colonial conduit reopen help send gasoline future more higher now nearly week port houston announce begin resume operation friday port south louisiana continue report normal operation closure medical industry group post day strongest move industry outpatient home care group top list lead amedisys am gain discount variety retailer take session hardest hit industry dollar general dg retreat drop report quarterly result china base yy yy hold place ibd list rise big volume rebound support week move average goldman sachs initiate coverage social medium platform buy rating price target biotech name celgene celg surge more healthy trade place ibd stock just breath away buy point flat base dow dupont dd lead advance prepared wrap merger dow chemical dow schedule close today combine company name dowdupont be schedule begin trading friday ticker dwdp change require alteration dow value be calculate begin friday dow jone index report change not have effect level index fang stock news facebook fb amazon com amzn google parent alphabet googl score gain better facebook add fourth straight gain continue weak volume rebound week line alphabet retook week line weak trade work sixth week possible base amazon also sixth week consolidation remain week line apple aapl add take new high left apple very top buy range buy point related friday job report be double whammy marketsthese stock be less buy big picture nasdaq rally pave way strength top stock absolutely have itibd investor research tool get start ibd
304,CELG,major market index marched squarely higher early thursday look close month august high note tech heavy nasdaq rise dow jone industrial average follow advance dow industrial only blue chip be trading red early thursday upside nike nke pace advancer rise stock remain well recent high fail flat base buy point meanwhile apple aapl notch record high rise iphone maker be pace extend winning streak trading session fang member amazon com amzn lead fang brother higher stock market today commerce giant moved try snap week lose streak have bring stock almost record high next test resistance be day line company report earning workday wday report better expect earning result late wednesday send share higher human resource software provider be now almost cup handle buy point multiple successful day test semtech smtc weak guidance current quarter send chipmaker almost early thursday stock recently reclaim day line construct flat base buy point today decline put stock back lows base meanwhile ciena cien plunge guide fiscal revenue forecast stock join fiberoptic companion apply optoelectronic aaoi lumentum lite recent sell off dollar general dg drop more report mixed result early thursday stock have be consolidate well high year today fall move deep discount retailer back day line finally ctrip com ctrp decline back day line tumble late wednesday chinese provider travel booking post beat early thursday raymond james cut stock price target ibd action be predominantly positive only handful lead growth stock trading negative territory upside china base yy yy jump extend rebound week line meanwhile biotech celgene celg rise build new flat base entry related semtech fall weak sale guidance october quarterdow jone industrial average dow stock news ciena notable earning due thursday investing action planfang stock news quote facebook amazon netflix google
305,CELG,biomarin pharmaceutical bmrn hit week high wednesday wake food drug administration decision review biotech company application rare disease drug fda say late tuesday application also grant biomarin priority review drug know pegvaliase pegvaliase be treatment rare disorder miss enzyme lead buildup amino acid blood result variety mental behavioral neurological physical problem biomarin say investor have be cautious pegvaliase effectiveness safety profile thus far believe tonight news tuesday begin thaw investor sentiment particularly aid fda decision grant priority review leerink analyst joseph schwartz say potential approval date feb be likely get push back however fda request additional information regard chemistry manufacturing control write note client phase datum pegvaliase show meaningful reduction specific amino acid biomarin have note injection site reaction associate treatment say prompt fda run panel determine risk benefit drug point have see agency give further pushback credit suisse analyst alethia young say note client ibd take biotechs stock be more month gilead science announcement week acquire kite pharma industry observer say july acquisition gilead spike sector head ibd industry theme more theory pan leerink schwartz see probability success pegvaliase assume peak sale be conservative expect biomarin enter market respective patient europe close bell stock market today biomarin have pop finish earlier rise much highest point week broadly biotech share hit highest mark july riser include bluebird bio blue jump close novartis nvs gain approval car drug likely help gilead science gild kitepharma kite celgene celg partner bluebird juno therapeutic juno gain similar approval future related novartis car drug help gilead spike post kite dealbiotech near dizzy plunge fail vertigo biotech get price hike seesaw day run
306,CELG,try recover long slump alexion pharmaceutical alxn get improvement ibd smartselect composite rating tuesday upgrade mean biotech stock currently top other stock term key performance metric technical strength alexion pharmaceutical be not currently proper entry be form week tight pattern see complete formation offer new buy opportunity alexion have ep rating meaning recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company post ep growth sale growth fall previous quarter alexion pharmaceutical earn rank peer medical biom biotech industry group celgene celg therapeutic cort hutchison china meditech hcm be top highly rate stock group related company be now outperform stock
307,CELG,myokardium myok have relative strength rs rating upgrade tuesday ibd proprietary rs rating identify technical performance used worst best score show stock price action trail week match other stock database history reveal market biggest winner often have better rs rating launch biggest run myokardium have climb more past entry first stage cup handle meaning now proper buy range look stock offer new chance pick share week tight pullback day week line company report earning growth latest quarterly report revenue rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort hutchison china meditech hcm be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
308,CELG,tuesday paratek pharmaceutical prtk receive positive adjustment relative strength rs rating exclusive rating investor business daily identify market leadership worst best score score show stock price movement last week compare other stock database year market history show best perform stock tend have better rs rating begin new climb paratek pharmaceutical be not currently potential buy area see stock go form promising consolidation launch new move term top bottom line number company have post quarters accelerate earning growth revenue gain have be less impressive come latest report paratek pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort hutchison china meditech hcm be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
309,CELG,tuesday acceleron pharma xlrn hit important performance benchmark relative strength rs rating move percentile upgrade increase day exclusive rating investor business daily identify market leadership worst best score rating show stock price behavior last week hold other stock database year market history reveal top perform stock often have rs rating north early stage move acceleron pharma be work cup handle entry see clear price heavy volume earning sale growth come respectively latest report show improvement ep revenue acceleron pharma hold rank peer medical biom biotech industry group celgene celg therapeutic cort hutchison china meditech hcm be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
310,CELG,important metric look stock be higher relative strength rating heron therapeutic hrtx now clear threshold jump wednesday ibd proprietary rs rating track technical performance used worst best score identify stock price action trail week match rest market history show top perform stock often have rs rating north early stage move heron therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average term fundamental company have post rise ep growth last report revenue gain have not follow same trajectory come last quarter company hold rank peer medical biom biotech industry group celgene celg therapeutic cort ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
311,CELG,celgene celg break friday join biogen biib bluebird bio blue enter buy zone thursday biotechs broadly gap major merger cancer space xin afternoon trading stock market today celgene rise clear entry flat base bluebird continue rise soar top buy point cup thursday bluebird be now extend biogen climb look vertex pharmaceutical vrtx join list biotech breakout near entry flat base begin form late july share lift close amgen amgn advanced potentially close buy point biotech stock have broadly rally week pop nearly announcement gilead science gild acquire kite pharma kite aftermath rival bluebird juno therapeutic juno have enjoy increase ibd take novartis nvs beat kite finish line know car drug therapy teach immune system identify fight cancer approval open new sector cancer treatment head ibd industry theme deeper dive implication novartis new treatment rally be less definitive friday juno rise gilead inched biogen rise remain buy zone top entry yearlong consolidation major exchange trade fund spdr biotech etf xbi ishare nasdaq biotechnology index ibb climb breaking thursday respective ibd biotech industry group rise related biotechs just moved buy zone be giant next biogen alzheimer drug show promise break gilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite dealanalyst mixed gilead kite key rival stand benefit
312,CELG,stock index fiercely refuse give back recent gain flurry miss friday economic datum blue chip dow jone industrial average small cap russell rise respectively midday friday nasdaq edge volume stock market today rise nyse fall nasdaq bull have deal miss monthly payroll unemployment rate construction spending consumer sentiment manufacturing be bright spot ism manufacturing gauge come stronger expect stock market have be chief item be stronger expect success hasn be reason president trump recent handle north korea flap exceed critic expectation storm harvey actually give congress cover debt ceiling hike trump be push tax cut issue hard be issue ultimately give market additional thrust midday friday breakout include casino operator wynn resort wynn network security firm palo alto network panw biotech celgene celg insurer athene general motor gm stock continue flirt buy point be concrete uscr blue chip be mostly component dow jone industrial average general electric ge goldman sachs gs jpmorgan chase jpm score gain ibd industry group solid gainer include oil driller retail apparel superregional bank metal ore miner downside food dairy group be top loser related chipmaker never hear be make movecelgene break biotech giant close buy pointspalo alto network soar earning analyst raise price casino giant break typhoon stop macau gaming
313,CELG,incyte incy see positive improvement relative strength rs rating tuesday rise ibd unique rating track market leadership worst best score score show stock price behavior trail week compare other stock database year market history reveal best stock tend have rs rating north launch largest climb see incyte continue show renew price strength hit benchmark incyte be try complete consolidation entry see stock break heavy trading incyte report earning growth most recent report sale growth come incyte hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
314,CELG,tuesday global blood therapeutic gbt reach important performance benchmark relative strength rs rating move percentile improvement day proprietary rating measure market leadership used worst best score show stock price performance trail week match other publicly trade company year market history reveal market biggest winner tend have rs rating north begin new run global blood therapeutic be not ideal buy zone right now see be able form break proper chart pattern term top bottom line number global blood therapeutic have post rise ep growth last report sale growth have be less impressive come most recent quarterly report global blood therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
315,CELG,ultragenyx rare topple month low wednesday drug know aceneuramic acid fail phase trial rare muscle disease prompt ultragenyx scrap development xin early trading stock market today ultragenyx fall much low last see july recent trade be more broadly biotech stock dip fraction street wasn particularly bullish drug ultragenyx withdraw conditional application european medicine agency fourth quarter leerink analyst joseph schwartz write note client late tuesday sentiment tank ultragenyx say aceneuramic acid extend release form fail meet key goal trial patient gne myopathy inherited condition lead weakness wasting muscle leg arm schwartz have see just likelihood success aceneuramic acid extend release note small size phase trial problematic trial design contribute investor low view drug ibd take ultragenyx have ibd composite rating best possible meaning underperform quarters stock term key growth metric leader celgene celg have cr head ibd stock checkup closer look top rate biotechs be stark contrast other rare disease asset phase development generally garner probability success contingent quality depth supportive clinical datum write even aceneuramic acid have prove successful gne myopathy have reach less peak sale estimate be minor contribution company more market cap schwartz keep outperform rating ultragenyx cut price target see ultragenyx enter commercial stage drug treat skeletal disorder tissue organ disease related millennial aren kill health marketmedtronic sink sale lag earning beat viewsteva mylan pressure rivalry loom key drug
316,CELG,tuesday nektar therapeutic nktr receive positive adjustment relative strength rs rating unique rating track technical performance used worst best score show stock price action trail week match rest market decade market research show stock go make biggest gain tend have rs rating north launch biggest climb stock be try complete cup handle entry see break heavy trading note third stage base later stage pattern work have higher chance fail point stock have already rise significantly earning growth decrease last quarter sale moved higher nektar therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
317,CELG,agio pharmaceutical agio launch month high wednesday food drug administration approve blood cancer drug development bode well similar medicine pipeline xin early trading stock market today agio pop rise intraday best level last november share partner celgene celg dip approval be agio first drug know idhifa be approve treat patient blood bone marrow cancer call acute myeloid leukemia approval be patient specific enzyme mutation cancer recur hasn respond other therapy term agio deal celgene celgene have worldwide development right idhifa agio have co promotion royalty right similar drug know ivosidenib belong agio alone leerink analyst michael schmidt upgrade agio stock outperform rating boost price target cite higher conviction agio drug target enzyme mutation associate cancer acute myeloid leukemia view fda approval idhifa also reduce regulatory risk ivosidenib acute myeloid leukemia latter be proprietary agio hence represent more significant value driver company write note client ibd take agio have ibd composite rating best possible mean agio be narrowly top half stock term key growth metric see better rate biotechs include celgene cr ibd stock checkup agio expect file fda ivosidenib year end look drug acute myeloid leukemia patient similar mutation cancer have recur fail respond other therapy schmidt see grab approval mid read approval idhifa be positive schmidt say idhifa approval follow phase phase trial patient idhifa have black box label condition cause difficulty breathe fever weight gain hypotension abnormally low blood pressure schmidt doesn expect be hurdle widespread adoption acute myeloid leukemia specialist be familiar condition know differentiation syndrome management strategy such treatment corticosteroid think regulatory outcome idhifa validate agio regulatory strategy acumen risk path market ivosidenib say needham analyst chad messer estimate patient acute myeloid leukemia have mutation address agio idhifa ivosidenib idhifa work total acute myeloid leukemia case ivosidenib work patient trial lead idhifa approval cancer disappear disappear partial improvement blood patient median duration response be month related sanofi earning spook regeneron share week lowwill pfizer cancer drug help grow merger astrazeneca beat stock dife drug failure more report
318,CELG,relative strength rs rating acorda therapeutic acor jump new percentile tuesday rise ibd unique rs rating measure technical performance used worst best score indicate stock price action trail week match other publicly trade company decade market research reveal best perform stock tend have rs rating north early stage move now be not ideal time jump isn proper buy zone see stock go offer clear appropriate buy point company see earning sale growth rise last quarter earning share increase revenue rise acorda therapeutic hold rank peer medical biom biotech industry group celgene celg therapeutic cort hutchison china meditech hcm be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
319,CELG,ligand pharmaceutical lgnd have relative strength rs rating upgrade monday welcome improvement still short higher score look exclusive rating investor business daily measure market leadership worst best score score show stock price behavior last week compare other stock database decade market research reveal stock go make biggest gain typically have rs rating north begin largest price move see ligand pharmaceutical continue show renew price strength hit benchmark ligand pharmaceutical break earlier have fall back prior entry cup handle case stock break then fall more entry price consider fail happen best new pattern take shape also understand most recent consolidation be later stage base make riskier establish new position add share exist ligand pharmaceutical post negative growth sale earning last quarter company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
320,CELG,hutchison china meditech hcm see ibd smartselect composite rating jump tuesday day new score indicate company be now outperform stock term most important fundamental technical stock pick criterium top perform stock tend have better grade start significant move hutchison china meditech be currently form flat base buy point see stock break heavy trade least higher normal be aware be very thinly trade stock average daily dollar volume stock sport ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post earning share growth sale be flat match prior quarter hutchison china meditech earn rank peer medical biom biotech industry group celgene celg be top rank stock group related company be now outperform stock
321,CELG,acceleron pharma xlrn see welcome improvement relative strength rs rating monday increase exclusive rating investor business daily measure market leadership worst best score grade show stock price behavior last week hold other stock database year market history reveal market biggest winner typically have rs rating north begin biggest climb stock be build cup handle entry see stock clear price heavy trading earning sale growth come respectively latest report show improvement top bottom line company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
322,CELG,friday halozyme therapeutic halo get upgrade relative strength rs rating ibd proprietary rs rating identify market leadership show stock price action last week measure other stock database decade market research show market biggest winner tend have rs rating begin biggest run see halozyme therapeutic continue rebound hit benchmark halozyme therapeutic be not currently offer proper buy opportunity see stock go form promising consolidation launch new move company post ep growth last quarter sale rise keep eye company next round number aug company earn rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
323,CELG,relative strength rs rating heron therapeutic hrtx moved higher percentile tuesday get lift ibd unique rs rating track market leadership used worst best score show stock price action last week match other stock decade market research show best perform stock tend have better rs rating early stage move see heron therapeutic continue show renew price strength hit benchmark heron therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average term fundamental health company have post rise ep growth last quarters sale gain have be less impressive come most recent report company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
324,CELG,novartis nvs approval price tag key cancer treatment have unusual effect help gilead science gild ride high thursday continue support gilead acquisition rival kite pharma kite be develop similar drug novartis approval come just day gilead say pay share acquire kite pivot similar cancer drug wake struggle hepatitis drug sale novartis be first get approval know car cancer treatment approval also validate gilead deal kite be also develop car drug also wednesday food drug administration approve drug roche rhhby genentech treat cytokine release syndrome common side effect car therapy present fever sometimes be fatal cytokine release syndrome be cause overactive immune system genentech explain happen car therapy patient own immune cell be extract reprogram seek destroy cancer today have never be fda approve treatment manage severe cytokine release syndrome associate car cell therapy be marked rapid onset cause life threaten complication genentech chief medical officer sandra horning say release ibd take novartis be first gain approval car drug other player be horizon head ibd industry theme battle break kite gilead juno bluebird aim approval emerge sector tell create perfect storm gilead other car drug player accord brad loncar chief executive loncar investment kite drug be expect get approval later fall various drug celgene celg partner juno therapeutic juno bluebird bio blue just new technology certain disease not stretch start used word cure loncar tell investor business daily re not think alleviate symptom disease re think fix genetic mutation cause disease technology look promising several different blood cancer today novartis charge time car treatment form acute lymphoblastic leukemia patient age kite drug be be review treatment aggressive form hodgkin lymphoma gilead see cell therapy car become cornerstone treat cancer big claim loncar say be just first iteration car therapy result so far initial cancer be truly amazing say re take patient have week month live case be reach complete remission ve never see anything close bell stock market today gilead lift novartis meanwhile rise kite tick cent close biotech stock have broadly rise week wednesday close be early trading fulfill prediction acquisition gilead help spike sector share touch month high fervor related much biotech pop fda ok drug bid analyst mixed gilead kite key rival stand benefitwhy investor be mute gilead acquisition kite pharma
325,CELG,biogen biib stock jump near buy point monday alzheimer disease treatment show promise year year mark close bell stock market today biogen share climb rise much hit intraday high share be consolidate buy point haven top early march common theory ty alzheimer buildup plaque deposit brain call beta amyloid biogen be work drug reduce amyloid deposit last year eli lilly lly amyloid drug fail prove theory ibd take biogen have ibd composite rating meaning outperform stock term key growth metric still trail top rate biotech celgene celg have best possible cr head ibd stock checkup other highly rate biotechs biogen be close prove hypothesis scan show amyloid reduction be consistent patient treat adjust dose compare fix dose year patient treat year show continue benefit rate amyloid decline phase long term trial most common side effect be headache fall abnormality amyloid related imaging biogen say firm plan share more datum upcoming medical congress related shire near year low cfo announce plan jump shipbiogen teva slip democrat launch ms drug pricing probebiogen alzheimer drug be ms worry overblown
326,CELG,monday acorda therapeutic acor earn positive adjustment relative strength rs rating unique rating identify technical performance show stock price movement last week compare other stock database history show stock go make biggest gain typically have better rs rating begin new run acorda therapeutic be not ideal buy range right now see manage form break proper chart pattern top bottom line growth moved higher last quarter earning be compare prior report revenue increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
327,CELG,monday juno therapeutic juno reach important technical benchmark see relative strength rs rating jump percentile improvement day unique rating identify technical performance used worst best score indicate stock price performance trail week match rest market decade market research reveal best stock typically have rs rating north launch largest climb juno therapeutic be try complete consolidation buy point see clear price heavy volume juno therapeutic report negative growth top bottom line last quarter juno therapeutic earn rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
328,CELG,nasdaq composite boost gain commerce leisure internet select software industry group hold thin gain roughly hour go tuesday session solar energy stock meanwhile have be tear lately group rise more past session name include first solar fslr jinko solar jks canadian solar csiq appear be exit bottom base pattern first solar have crack stubborn resistance late june share moved past buy point elongate double bottom handle base stretched back term peak see october middle peak base be first solar huge winner late ipo still have sloppy fundamental earning drop vs year level past quarters revenue jump first quarter then result have be mixed ibd energy solar industry group vivint solar vslr be only stock composite rating higher trade share be virtually flat homebuilder heavy construction apparel auto retail banking name slump dow jone industrial average fall least component stock blue chip average lose point more include goldman sachs gs goldman drop more heavy trading notch fourth quarter row rebound earning revenue net margin slip basis point however stock continue fashion right side potential new base notice stock be find support day line now meanwhile biotechs continue flex strength ibd biotech group continue rank top industry group month relative performance see current ranking access day ibd datum table stock list section investor com biotech group be now join other medical group top ranking medical sector meanwhile rank most recent ibd weekly be more year date current sector leader hail sector abiom abmd expert heart pump edge nearly light turnover stock continue perform well april past cup handle entry celgene celg meanwhile be hold cup handle entry specialist blood cancer other difficult disease fall less precise buy point savvy investor do not chase stock once already moved more past proper point however normal look pullback proper buy zone give investor second chance scoop share celgene be expect grow second quarter earning share prior quarters earning rise vs year level revenue be see increase follow top line gain prior period apple aapl continue reflect steady institutional support wipe away early loss rise slightly note recent stock market today column pronounce move back day move average boost prospect fresh apple be show limit decline recent time peak fall more sort correction usually see flat base pattern current prospective shareholder watch see stock take high rise least cent more signale new concern be strength continue sponsorship mutual fund hedge fund accord datum william neil co fund build new position fund add stake second quarter year fund trim completely sell position related sector gain netflix lift nasdaq goldman hurt dow top perform stock today ibd stock spotlightwill apple furnish new buy point investor corner be easy method spot major market top
329,CELG,dow jone industrial average have modest loss friday hurt weakness share general electric ge microsoft msft blue chip report earning xvisa be bright spot dow rise nearly strong earning nice bounce day move average visa be still buy range recent buy point dow close loss nasdaq composite fall fraction small cap lag russell volume nyse be higher thursday level stock market today volume nasdaq be slightly lower ipo market serve big winner friday share small cap petiq petq soar debut maker medication well other health product dog cat price last night high end propose range share open close software space athenahealth athn gap big earning beat head report have be find support week move average first time make candidate call option trade ibd name be more include lumentum lite share rise fiber optic name be get solid support day move average buy point couple other ibd name outperformed ahead earning report next week nutrisystem ntri jump extend buy point report wednesday close celgene celg report thursday open add flirt time high set nearly year new york mercantile exchange september crude oil settle week oil lose related ge dife month low industrial giant enter buy zonebiotechs find strength number treat multiple sclerosisbest stock buy watch
330,CELG,nektar therapeutic nktr stock pop month high tuesday biotech say chronic pain drug nktr show significantly less abuse potential compare oft abused opioid stock market today nektar stock lift earlier rise much touch high last see march nektar be lead biotech share puma biotechnology pbyi jump approval cancer drug drug know nktr prove be less likable vs oxycodone commonly abused chronic pain drug sell purdue pharmaceutical oxycontin nktr aim treat pain induce euphoria associate opioid be clear new study result nktr be highly differentiate respect oxycodone be choice drug abuse nektar chief medical officer ivan gergel say news release opioid act specific receptor brain relieve pain also target dopamine reward system brain produce euphoria psychoactive effect nektar say nearly american abused be dependent prescription opioid ibd take nektar stock have ibd composite rating best possible meaning perform middle stock term key growth metric ibd company biotech industry group be lead celgene celg have cr visit ibd stock checkup look other strong name sector phase study unveil march patient lower back pain treat nktr report average pain score reduction more nektar say nktr avoid abuse potential strategic alteration brain entry kinetic nektar result follow month food drug administration ask endo endp pull opioid pain medicine extend release version opana market fda cite potential abuse related endo opioid pitfall be boon drugmakersis small biotech head market cap pitfall biotech hit year high potential dethrone oxycodone
331,CELG,kite pharma kite valeant pharmaceutical vrx tuesday top forecast report second quarter earning ionis pharmaceutical ion mallinckrodt mnk say sale be light period valeant cut full year revenue target ionis up operate profit guidance mallinckrodt outlook be line view meanwhile kite submit key application food drug administration second quarter kite report adjust loss share sale loss grow cent loss year earlier period top view share loss revenue spiked beat analyst forecast kite also say have submit application fda begin phase trial car drug know kte multiple myeloma bone marrow cancer drug block interaction immune system involve bcma antigen bluebird bio blue celgene celg be work similar drug analyst suspect kite be month away approval car drug dub kte treatment aggressive form hodgkin lymphoma blood cancer rival novartis nvs look likely grab approval october car drug bone marrow cancer kite rise morning trade stock market today ionis report adjust loss cent share sale spike compare adjust loss cent revenue year earlier quarter sale top view loss just miss cent loss share forecast ibd take do cancer focuse biotechs live expectation get more analyst expect visit ibd technology page spinraza spinal muscular atrophy drug license biogen biib have total sale vs first quarter payer be now broadly cover spinraza launch momentum outside be build ionis say news release thank strong spinraza royalty revenue ionis now see full year operate profit vs prior projection break even ionis topple recent action valeant report adjust earning share revenue compare share sale year earlier period analyst forecast adjust profit cent share sale valeant cut full year revenue target vs prior forecast drugmaker keep earning interest taxe depreciation amortization forecast impact divestiture year valeant shot morning deal mallinckrodt sank report sale fall lag consensus adjust earning share plunge top analyst view cent brand drug grow mallinckrodt generic unit advanced uk base drugmaker also reiterate full year guidance adjust earning share line expectation analyst poll zack investment research share irina koffler mizuho analyst credit mallinckrodt lower quality bottom line beat taxe specialty generic outperformed expectation be positive development view hopefully start stabilization write note client keep buy rating mallinckrodt related biotech be jump today rival cannabis tie druggilead be make acquisition not surprising reason regeneron topple beat raise
332,CELG,regeneron pharmaceutical regn gilead science gild be most likely beat wall street view june quarter sale profit analyst say monday xleerink analyst geoffrey porge say star align widespread beat biopharma result large cap also see abbvie abbv celgene celg biogen biib gilead most likely top revenue expectation quarter quarter sale abbvie alexion pharmaceutical alxn biogen vertex pharmaceutical vrtx be likely be slow say abbvie biogen be face competition pricing pressure alexion vertex be still high growth company temporary slow revenue growth trajectory pending new indication formulation product write note client health tracker im see abbvie leukemia drug imbruvica testosterone gel androgel likely come materially north consensus humira landing street view other major project be expect miss im datum suggest biogen multiple sclerosis drug tysabri tecfidera beat porge estimate respectively tecfidera however be expect miss street ms drug plegridy avonex be forecast be light come grow competition ms field like roche rhhby novartis nvs sanofi sny roche drug ocrevus be approve earlier year treat relapse remit well primary progressive ms first industry ibd take biotech stock be rank group track sentiment tick ahead second quarter earning season make sure bookmark ibd biotech stock watch pharma industry news latest sector major drug celgene be expect top consensus chemotherapy revlimid likely come consensus porge write pomalyst drug treat blood cancer be expect be higher consensus gilead be likely be biggest second quarter surprise im datum gilead sale top be largely dependent reliability recent hepatitis datum have be unreliable past hepatitis drug sale topple high cure rate accounting highly variable sale hepatitis drug gilead total sale miss porge forecast analyst consensus target same time gilead genvoya hiv drug beat consensus porge write note client amgen amgn be most likely match slightly underperform consensus porge say rheumatoid arthritis drug enbrel be expect be line consensus view top porge view much im datum bone health drug prolium bone marrow stimulating aranesp be project beat help offset expect sale miss bone health drug xgeva other bone marrow stimulant drug porge say however change price dynamic many amgen product make im adjustment factor less reliable porge write call amgen hike price july bump price cancer drug kyproli april adjust profit share side gilead have chance beat consensus view porge say regeneron vertex also top expectation respectively biogen miss earning view due time research development expense not fully recognize analyst estimate porge say abbvie too be likely miss adjust earning share say afternoon trading stock market today ibd medical biom biotech group be fractionally related surprise spike beleaguered biotech stock gilead acquire biotech vertex be still better analystwhy biotech be poise run topple june
333,CELG,novartis nvs be first drugmaker cross finish line develop cancer treatment know car drug wednesday food drug administration approve drug kymriah child adult type bone marrow cancer xkymriah cell base gene therapy be approve treat patient age call cell acute lymphoblastic leukemia approval be likely set stage fda approve slew car drug next several year re enter new frontier medical innovation ability reprogram patient own cell attack deadly cancer fda commissioner scott gottlieb say news release follow approval new technology such gene cell therapy hold potential transform medicine create inflection point ability treat even cure many intractable illness approval come day gilead science gild announce plan acquire kite pharma kite be also close approval car therapy treatment immune cell be extract patient reprogram fight cancer ibd take biotech stock broadly dip mid august have rally be month be inflection point need top earlier outlined ibd industry theme analyst expect kite drug grab approval treat aggressive form hodgkin lymphoma later year analyst see juno therapeutic juno drug get approval next year follow closely celgene celg partner bluebird bio blue close bell stock market today novartis drop gilead spiked close kite be relative standstill marginally gilead takeover price reflect share kite stock juno sank bluebird pop related analyst mixed gilead kite key rival stand novartis fda cancer also be boon cure cancer look blood
334,CELG,analyst be mixed tuesday gilead science gild takeout kite pharma kite thing be certain say rival juno therapeutic juno bluebird bio blue stand benefit headline xnovartis nvs kite be expect gain food drug administration approval fall blood cancer drug know car treatment celgene celg partner juno bluebird be just wedbush analyst david nierengarten write note client believe juno bluebird lead independent car developer be obvious acquisition play follow kite takeout say other earlier stage potential target include intellium ntla fate therapeutic fate tesaro tsro juno stock rushed month high midday stock market today pop reach high last see june bluebird sank end trading session gilead climb kite slip novartis lift be work treatment patient own immune cell be reprogram seek destroy cancer novartis car treatment look likely gain approval treat bone marrow cancer follow closely kite treatment aggressive form hodgkin lymphoma ibd take biotech sector close monday help news gilead deal kite head big picture more gilead kite boost sector other sector ride monday nierengarten boost price target juno upgrade stock outperform rating neutral juno closely rival kite car drug know jcar gilead entry space likely help boost adoption rate jcar say expect juno jcar grab fda approval year end doesn see last disadvantage be later market initial launch gilead kite drug know axicabtagene ciloleucel be hung investment transplant center reimbursement talk believe juno capitalize gilead novartis effort later arrival say see jcar profile sufficiently differentiate efficacy safety enable broader adoption relative axicabtagene ciloleucel nierengarten forecast peak sale juno car drug blood cancer exceed expectation peak sale gilead kite drug blood cancer see juno drug be prefer choice novartis gilead kite way cut kite deal be expensive nierengarten say deal value kite time peak sale expectation axicabtagene ciloleucel compare typical time sale takeout biotech do not believe buyer emerge kite price point indicate gilead be not deal position strength write long term rationale assume kite drug be able expand other cancer leerink analyst geoffrey porge classify deal hardly surprise hardly triumph hardly keep market perform rating gilead cut price target pivot represent new look gilead perhaps kite be well position car space do not believe change underlie fundamental have plague gilead stock past year write note client gilead have be pressure buy something hepatitis drug franchise have begin decline high cure rate still driver gilead outlook remain hepatitis hiv treatment porge say kite do little fend expect revenue decline respectively gilead axicabtagene ciloleucel related product be only expect add respective gilead top line inevitable stumble logistical snafu ultimately uncertain dynamic single treatment market be hard see axicabtagene ciloleucel provide much revenue offset erosion say credit suisse analyst alethia young like kite deal reiterate outperform rating gilead stock boost price target think deal mark begin new chapter write note client minimum lift overhand question be gilead go do related investor be mute gilead acquisition kite pharmagilead science buy kite pharma novartis fda cancer also be boon cure cancer look blood
335,CELG,kite pharma kite win be gilead science gild next pharmasset analyst say monday gilead announce merger send kite stock stratosphere xby close bell stock market today kite rocket finish hit record high year file initial public offer gilead stock be less enthusiastic rise close evercore analyst umer raffat say guarantee acquire kite be gilead bet pharmasset pharmasset deal give gilead access key drug kick blockbuster hepatitis franchise deal be generally comparable size enormous commercial success pharmasset deal be still very fresh investor eye raffat write note client pharmasset be clear leader class kite be just pack company work be know car therapy harness body own immune system fight cancer novartis nvs juno therapeutic juno bluebird bio blue celgene celg be also work arena further logistic be different hepatitis drug be pill take once daily car therapy patient blood be draw vial then immune system cell be reprogram fight cancer be reintroduce body require specific infrastructure raffat note proof concept blue sky scenario kite be trail novartis car therapy expect gain approval blood cancer later year firm have yet prove similar concept solid tumor call cell receptor technology ibd take biotech stock have slow july spike long term view several player look dim gilead acquisition kite help recover head ibd industry theme closer look still true inflection point kite story be yet come say kite be close approval drug axicabtagene ciloleucel treat aggressive form hodgkin lymphoma have first mover advantage set deal be set close fourth quarter gilead say news release mean now become very important year raffat say street be very focuse validate purchase leerink analyst geoffrey porge say consensus be call kite drug reach peak sale see initial approval blood bone marrow cancer note trial be ongoing other blood cancer transaction be not complete surprise give earlier commentary write note client premium kite stock share have rise year date be brace suggest gilead be expect revenue kite car platform kite be already short list potential acquisition gilead first quarter gilead have say want do deal cancer analyst suggest kite incyte incy tesaro tsro clovis oncology clvs be list recently several week kite chief executive john milligan reportedly say firm end do nothing oncology right deal doesn present street have be push gilead make deal hepatitis drug sale have begin decline gilead key strategy go forward be cell therapy firm have suggest seek buy asset enhance car engineering immuno oncology drug augment drug different combination related gilead science buy kite pharma billionwhy gilead do nothing oncology key drug topplehow novartis fda cancer also be boon rival
336,CELG,important metric look stock be higher relative strength rating juno therapeutic juno clear benchmark friday jump friday proprietary rating track technical performance show stock price action last week compare other stock major index decade market research reveal best stock tend have rs rating north begin biggest price move juno therapeutic have climb more past entry first stage consolidation meaning now proper buy zone look stock create new chance get week tight pullback day week line juno therapeutic report negative growth top bottom line last quarter company earn rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
337,CELG,acceleron pharma xlrn see welcome improvement relative strength rs rating friday increase ibd unique rs rating measure technical performance used worst best score show stock price action trail week compare rest market decade market research reveal stock go make biggest gain typically have rs rating north early stage move see acceleron pharma continue rebound hit benchmark acceleron pharma be try complete cup handle entry see stock break volume least higher normal earning sale growth come respectively latest report show improvement ep revenue acceleron pharma earn rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
338,CELG,ibd smartselect composite rating therapeutic anik increase friday upgrade mean stock currently top other stock term key performance metric technical strength therapeutic be trading entry cup handle keep mind later stage base such basis be more prone failure understand be thinly trade stock average daily dollar volume such stock show wider daily weekly fluctuation stock greater liquidity stock have ep rating mean recent quarterly annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company report earning growth have now post accelerate ep increase consecutive quarters sale growth climb prior report mark consecutive report rise growth therapeutic hold rank peer medical biom biotech industry group celgene celg therapeutic cort bioverativ bivv be top highly rate stock group related company be now outperform stock
339,CELG,acorda therapeutic acor see welcome improvement relative strength rs rating thursday upgrade exclusive rating investor business daily measure share price performance worst best score rating show stock price behavior trail week hold other stock database history show top perform stock tend have rs rating north launch biggest price move now be not ideal time jump isn proper buy zone see stock be able establish enter buy range heavy trade earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
340,CELG,thursday agio pharmaceutical agio earn upgrade relative strength rs rating unique rating track market leadership show stock price action last week measure other stock database decade market research reveal best perform stock often have rs rating least early stage move stock be work consolidation entry see break heavy trading agio pharmaceutical post negative growth top bottom line last quarter company be expect report next quarterly number aug agio pharmaceutical hold rank peer medical biom biotech industry group celgene celg therapeutic cort supernus pharmaceutical supn be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
341,CELG,biotech stock celgene celg regeneron regn biogen biib spinoff bioverativ bivv move cancer drug developer exelixis exel be track new several day big gain biotech sector regeneron bluebird bio blue pull back friday celgene bioverativ continue climb afternoon trading friday stock
342,CELG,big cap have lose luster even have gain biotech stock such celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx xso far year big cap still lead advantage have fluctuated recent session low percentage point
343,CELG,hum mainstay large cap growth fund mlaax be have fund setback last year badly lag gain trail large cap growth peer track morningstar inc gain year go thursday more double big cap bogey return trump direct rival fund rally reflect market shift away defensive low growth staple provider higher dividend stock dominate much last year sort higher growth stock fund favor fund co manager patrick burton job early say lead technology stock particular have be buoy market share gain strong earning burton lead manager justin kelly be subadvisor capital reflect market tilt fund have be boost year such holding alibaba group baba be fund also hold graphic chipmaker nvidia nvda be year digital medium marketing software firm adobe system adbe be biom celgene celg be be fast grower health care alibaba be player commerce china burton say be benefit shift mobile device gross sale be still grow rapidly size alibaba cloud amazon web service be grow very fast say nvidia be benefit shift use graphic process unit gpu away regular cpu computer chip faster process speed application such artificial intelligence self drive car burton say adobe be shift selling software license annual subscription customer churn less buy more model burton say celgene stock be due combination decent earning attractive valuation biotech have be pressure couple year burton say past year fund average annual gain top rival kelly have be helm late fund aim navigate various market phase adjust allocation type growth stock bucket hold stock manager see long term sustainable earning grower second bucket hold quality cyclical grower be more volatile third hold stock newer industry rapid growth visa be sustainable grower takeover visa europe boost economy scale lead better coordination global marketing campaign burton say add really steady eddie consistent grower skywork solution swks be fund cyclical supply radio frequency filter apple aapl samsung chinese cellphone change be be move other product need wireless application tesla tsla car burton say be push get involved internet thing servicenow now be new industry stock be expand management client new area cybersecurity human resource celgene cancer drug revlimid be flagship be rank ibd medical biom biotech industry group group be rank wall street expect earning share climb year pretax margin last year be highest least year ibd take check more celgene fundamental technical strength ibd easy use stock checkup tool illumina ilmn netflix nflx be new addition fund portfolio second quarter illumina be leader low cost gene sequence equipment burton say believe illumina demonstrate accelerate growth profile course year next drive launch new gene sequence instrument novaseq believe acceleration drive upside analyst consensus earning estimate netflix return portfolio be sell ep rise past quarters netflix be face increase competition hulu stock amazon com amzn youtube owner google googl also own mainstay large cap growth netflix driver be original programming global expansion burton say related mainstay large cap growth see market tilt favorite type growth stock
344,CELG,xu stock index rally midday wednesday strength biom space nasdaq advanced add less blue chip dow jone industrial average be barely day break even line volume rise major exchange biom stock show exceptional strength nasdaq day top gainer be biom stock regeneron pharmaceutical regn rise incyte incy biomarin pharmaceutical bmrn biogen biib celgene celg celgene break consolidation clear buy point volume soar more average pattern be first stage celgene have be consolidate almost year consolidation long push relative price strength rating be have happened celgene rs rating see ibd stock checkup be mean stock be lag third market price performance ibd style investor put less emphasis rs rating come long consolidation celgene earning picture be solid street expect earning rise year pretax margin last year be best least year blue chip meanwhile be mostly loser lead winner ratio intel intc caterpillar cat be day biggest loser stock dow fall day top gainer be inc business software provider gap volume stock usual pace stock be move rumor potential merger privately hold bmc software related real secret stock be so simple forget itprice target raise boee red hat adobe lower chevronis bull market still healthy be sign major correction see ibd big picture
345,CELG,talk hot brian demain be lead manager janus henderson enterprise janex be ibd best mutual fund award winner so be fund twin aspen enterprise jaagx also be skipper portfolio win best fund honor outperform time period end dec trail year do so not just category diversify equity mutual fund growth mutual fund midcap mutual fund put small group gem mere diversify stock mutual fund asset least prevailed winner time span demain cody wheaton run fund little turnover just now accord morningstar inc portfolio holding be crown castle cci microchip technology mchp global payment gpn sensata technology st td ameritrade amtd be form base pattern buy range enterprise be open investor already own share also open old new shareholder plan already offer fund well old new investor client brokerage offer identical strategy separately manage account twin sister aspen enterprise be buy old new investor insurance company midcap fund janus henderson be still open new investor be mid cap value jmivx demain be year old talk investment approach several key stock holding recent interview ibd ibd brian summarize investment approach demain first look call sustainable growth want company be growth company today be year now not be fastest grower grow long term second re look company sustainably high return invest capital great company grow not earn high return invest capital not increase shareholder value so try understand company competitive advantage drive long term return invest capital third care quality company management team management team focus right area be good leader find company meet criterium buy attractive valuation hold long term outperform peer ibd fund performance be consistent show be ibd best mutual fund award winner be key outperformance market market demain ve generally be able keep market outperform market try have predict beta measurement volatility relative market benchmark russell midcap growth index benchmark so have less absolute risk benchmark higher don want only outperform market want shine do market well ibd do midcaps demain re not mature large cap so have real growth opportunity ahead business model be more establish small cap many have withstand competitive challenge small cap not have tend be less volatile small cap ibd ve get asset technology industrial health care sector do expect find so many opportunity space demain tech health care be power innovation tech ve be overweight hardware semiconductor mobile internet be drive semiconductor growth re see lot innovation software push life health own biotechs pharmaceutical life science tool diagnostic company age baby boomer emerge middle class globally be drive innovation drug development diagnostic ibd ve note corporate tax cut infrastructure spending deregulation not occur fast many investor have hope have hedge bet area demain take tax cut sensata be netherlands domicile company make sensor aircraft car other product do business pay low tax rate be domicile so not benefit lower rate also own td ameritrade be brokerage pay full tax rate so reform benefit policy change cut way ameritrade also benefit rise interest rate sweep client cash balance td bank earn more money spread rate rise own crown castle reit own wireless cell tower have high level borrow so be hurt high interest rate ibd lam research lrcx be semiconductor play describe please demain be semiconductor capital equipment manufacturer last few year ve go everything be etch plane microchip effectively stack layer chip so lot growth have go etching deposition player lam addition demand memory market be robust drive uptake solid state drife re go old disk drife solid state flash drive drife demand lot chip be good lam valuation stock trade time forward earning back cash be close time market multiple be north time several high quality semiconductor company be trading time ibd celgene celg be best know revlimid blood cancer treatment do other product demain re right revlimid be workhorse continue grow due longer treatment duration find new patient do do revlimid go patent outlook other celgene product pomalyst otezla abraxane be constructive re excited pipeline new treatment also ve do business development deal cash revlimid build emerge franchise immunology inflammation immunology thing make patent cliff revlimid manageable event ibd take celgene be rank stock ibd medical biom biotech industry group be rank very strong group celgene earn top dog status thank such trait best possible composite rating ibd annual pretax margin be highest be least year compare other technical fundamental strength rival ibd easy use stock checkup tool ibd microchip technology earning share growth have accelerate quarters row do thesis revolve fact chip be used variety product demain majority revenue be microcontroller be very simple computer go sort device airplane microwave oven kid toy have great growth dynamic be function growth internet thing company sustainable growth business have very fragmented customer base re not just selling ton chip customer apple aapl re selling thousand end market competitive advantage good management team company be lead steve sanghi have high regard value creation company recently acquire atmel be large microcontroller competitor have good asset be poorly manage sanghi have improve operate margin drive strong earning growth valuation be not demand time forward earning ibd do ss technology ssnc illustrate investment approach demain be example sustainable growth competitive advantage strong management ss provide back office service financial company asset management mature more company want focus core competency rather run back office house look outsource once be embed customer other department customer outsource well ss be run bill stone have proven record value creation valuation be reasonable ibd global payment earning share growth have sped demain think visa mastercard electronic payment highway global payment be offramp have relationship merchant credit card terminal run restaurant example global give software not only accept credit card also help run restaurant global have benefit consolidation ibd make heico heia design repair part aircraft engine attractive demain only certain approve supplier sell part airline plane be service year need servicing only relatively small number company have part manufacturing approval pma federal aviation administration european regulatory body faa have limit resource only approve so many part year heico have best position pma market earn healthy margin also mendelson family own large percentage company most liquid net worth so care lot create shareholder value so partner ibd drive share price uptrend contact lens developer cooper coo demain sustainable growth contact lens be grow category contact get more comfortable also benefit international growth be only player bausch lomb johnson johnson jnj alcon cooper once consumer pick usually stick win change small price difference ibd be index operator msci attractive demain way think be benefit growth etfs active manager janus henderson pay fix fee access benchmark operator msci fee dollar move active passive fund dollar become more profitable once be standard index be hard user change ibd way plan reopen enterprise fund investor demain be manage include money aspen enterprise separately manage account used enterprise strategy make larger midcap strategy first priority be work behalf exist client think be close be best interest ve do related winning mutual fund focus lead stock marketaxess step millennial want become rich retiree
346,CELG,biomarin pharmaceutical bmrn stock pop tuesday strong datum hemophilia study plan do solution upcoming phase trial likely discomfit investor biomarin stock rise stock market today earlier bound much share have be consolidate last august buy point pop follow biomarin release international society thrombosis hemostasis germany biomarin say drug know bmn increase presence key protein patient severe hemophilia hemophilia be bleed disorder typically cause lack blood clot protein call factor viii normal range factor viii activity level healthy patient be patient severe hemophilia have less factor viii activity level blood patient treat high dose bmn achieve average factor viii activity level week biomarin say week patient have average factor viii activity level be normal range ibd take biomarin stock have ibd composite rating best possible base key growth metric stock lag better rate player celgene celg supernus pharmaceutical supn head ibd stock checkup closer look patient lower dose hit average factor viii activity level week mild range hemophilia biomarin be advance higher dose phase trial plan fourth quarter leerink analyst joseph schwartz say investor likely be concern dose be higher necessary rationale believe be deliver true do curative therapy high likelihood achieve normal factor viii level long last efficacy garner favorable decision reimbursement discussion write note client be alarm side effect bmn half low dose patient receive taper course corticosteroid help contend increase enzyme call alanine blood base multiple hemophilia study elevation alanine now appear be common theme say investor find corticosteroid intervention be linger concern view transient nature lack repercussion factor viii level encourage related biotechs be grab bullish view wake earningssanofi acquire biotech be too low do sanofi just bag biotech
347,CELG,dow component merck mrk stock topple late wednesday food drug administration put clinical trial hold involve drugmaker immuno oncology med keytruda blood cancer know multiple myeloma trial keytruda low dose dexamethasone combine pomalyst revlimid celgene celg be place full clinical hold similar combination study be place partial clinical hold last month merck pause enrollment trial more patient receive keytruda die wednesday fda say risk combination outweighed potential benefit ibd take merck have ibd composite rating meaning outperform nearly stock term key growth metric head ibd stock checkup list best rate drugmaker hour trading stock market today merck stock be additional end regular trading session fraction share have be form flat base early march merck be company dow jone industrial average related dow merck pause cancer trial investigate keytruda tie deathsbristol beat cancer test conquer dow merck astrazeneca cancer trial help rival analyst say
348,CELG,biotech boom peaked july industry slowly recover slump biggest biotech etfs be look more attractive spdr biotech etf xbi be trading week high approach potential buy point flat base etf have moved back day move average past couple week strengthen chart ibd biotech industry group have be top group many week reflect industry comeback yet be still short stock superior fundamental be proper buy point even many stock high ibd composite rating be low price stock otherwise lack few be still unprofitable company spdr biotech etf provide way invest sector broad advance have find specific stock buy index also provide buffer company specific risk be big biotechs poor clinical trial reject drug application be risk top usual investor worry such earning report fund own stock include industry heavyweight such biogen biib gilead science gild celgene celg amgen amgn largest holding term portfolio weight be small cap midcap company such ionis pharmaceutical ion exelixis exel tuesday exelixis break base retreat right back buy point next day etf select stock mainly revenue earning market perception be also consider accord prospectus stock be picked total market index broad domestic gauge have market capitalization certain liquidity ratio requirement average weight market cap be spdr biotech rise more first month have average annual gain past year past year compare favorably ishare nasdaq biotechnology ibb widely hold etf fund rise first quarter year average return be year average return be ishare biotech etf be more heavily weigh industry giant industry outlook be difficult measure much depend new drug hit market be pressure drugmaker cut price costly medicine growth prospect sector have be decline drug pricing debate be extremely difficult handicap golub chief equity strategist rbc capital market say health care sector report last monday ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related etf near new high apple largest holdingbiotech cruise day upswing price target cut duo
349,CELG,share biotech leader supernus pharmaceutical supn briefly break tuesday struggle remain key level support ibd company biom biotech industry group broadly fall stock market today supernus stock lift much top buy point ascend base begin february share settle back buy point close bell end regular session meanwhile biotech stock collectively lose agio therapeutic agio audente therapeutic bold galapago glpg stock be biggest loser drop respective supernus be rank second biotech industry group composite rating meaning outperform stock term key growth metric trail celgene celg be tie bioverativ biiv therapeutic cort vertex pharmaceutical vrtx cytokinetic cytk group ibd take want more information highly rate stock head ibd stock checkup smartest pick biotech stock drop day move average april group be still rank group track last week still big boost just week related biotech unveil breakthrough treatment movebiotech bolt higher drug result
350,CELG,drug stock topple month low tuesday dow component johnson johnson jnj report first quarter pharma sale only advanced offer weak harbinger sector late afternoon trading stock market today ibd company ethical drug industry group be fraction earlier lose much touch low not see november biotech stock be less injured be still collectively lose much report light first quarter sale cent beat bottom line leerink analyst geoffrey porge say result highlight multiple issue large biotechs worldwide pharma sale grow just vs year earlier quarter miss expectation international drug sale beat pharma sale miss porge write research report oncology sale lead growth legacy product remicade stelara xarelto offset volume decline low growth price hike alexion pharmaceutical alxn abbvie abbv celgene celg derive large portion sale international market benefit worldwide pharma growth be reflect sector porge have outperform rating alexion stock market perform rating abbvie celgene stock ibd take ibd ethical drug industry group be now rank group track just week biotech industry group be perform much better rank seventh week head ibd stock checkup list strongest stock higher utilization independent patient assistance program timing medicare part cost higher drug access discount leave celgene amgen amgn vulnerable biotechs porge say cite commentary have market perform rating amgen stock pricing power appear remain strong do report lower price government manage care channel impact annual comparison write do not anticipate issue be isolate alone impact broader biopharma industry drugmaker evercore analyst umer raffat note struggle diabetes unit invokana sale be year year be reflect eli lilly lly diabetes franchise leerink analyst seamus fernandez earlier say unit help lilly overcome struggle rheumatoid arthritis drug raffat note pricing pressure cardiovascular drug xarelto be reflect bristol myer squibb bmy eliquis xarelto sale fall vs year earlier period silver line report year year growth imbruvica cancer drug partnership abbvie company be now look have imbruvica approve treat patient suffering graft versus host disease occur foreign tissue be introduce body organ transplant related dow johnson johnson set lackluster result lilly survive rheumatoid arthritis flop breast cancer drug
351,CELG,just ace baseball pitcher mix throw top mutual fund manager vary investment manager columbia large cap growth fund be mingle semiconductor stock biotech stock online travel agency chinese fast food chain good effect be benefit investor retirement account other portfolio fund be work way back multiyear top notch outperformance year go wednesday fund gain top large cap growth rival track morningstar inc advance improvement show past month fund outpaced just direct rival nonetheless decent rise so year date relative performance be turn back accomplish past year beat direct rival key piece credit go fund stake technology stock be portfolio largest sector feb weighting nearly double second largest sector then consumer discretionary have tech weighting fund semiconductor stock include lam research lrcx so far year micron technology mu year broadcom avgo ibd take broadcom be rank ibd electronic semiconductor fabless industry group composite rating be highest possible earning share growth have accelerate quarters row see additional easy understand fundamental technical datum stack rival ibd stock checkup biotech bet include vertex pharmaceutical vrtx celgene celg fund consumer discretionary play be online travel agency priceline pcln expedia expe be respectively year china base restaurant chain yum china yumc be security consumer discretionary space year ve also try make play multicategory straddler alibaba baba amazon amzn lam have benefit trend be grow complexity semiconductor manufacturing equipment say peter deininger manager fund second be consolidation semiconductor equipment space have cut inventory volatility smooth industry cycle mean higher margin higher return lam deininger say addition lam be leader etching deposition segment semiconductor equipment field help increase market share rate excess other player deininger say combine have put company good situation anticipate have leg go micron make memory datum storage device industry have go enough consolidation pricing be stable rise micron key dram product deininger say lead rise margin add industrywide earning share price do so well last year segment be top explain recent pullback space affected micron other stock deininger be not ready retreat yet continue be very balanced supply pricing remain firm lead time product be modestly extend say combine lack significant new capacity argue share price strength hold time go forward fund manager tchintcia barro like vertex exist treatment cystic fibrosis well development vertex gap march news favorable result late stage trial new treatment combination therapy vertex plan add drug create drug cocktail treat thousand more cystic fibrosis patient barro say several month competitor galapago create fear investor vertex have portfolio treatment barro say datum show galapago be year vertex fund manager have mixed feeling consumer discretionary space hand end last year have shift underweight overweight sector vs russell growth index ve sell position brand apparel manufacturer vf vfc yogawear chain store lululemon athletica lulu pharmacy operator cvs health cvs online company have put lot pressure traditional retail area manager john wilson say other hand fund still like online travel agency priceline expedia manager yum china pure play china restaurant stock yum china gap april day release first quarter financial result earning share grow slip sale sale nose consensus estimate company open new store quarter include little sheep east dawn outlet guidance fiscal company say open least new store operate profit grow double digit pace yum brand yum fund also hold say have complete spinoff yum china nov begin trading day share new company be related top columbia fund load stock leadersyou need much retirement saving age income
352,CELG,biotech investor likely be key launch biogen biib spinraza regeneron regn dupixent first quarter result roll analyst say wednesday sector preview ibd company biotech industry group be rank group track just week first quarter be choppy inventory seasonality challenge leerink analyst geoffrey porge say wednesday analysis suggest be not go be particularly impressive quarter large cap name coverage universe neither be go be disaster slow result suggest write note client give flux shipping day inventory level investor be likely pay most attention key launch already underway anticipate biogen spinal muscular atrophy drug ionis pharmaceutical ion be likely be scrutinize recent payer pushback meanwhile investor be look commentary roche rhhby multiple sclerosis drug ocrevus hurt biogen ms franchise celgene celg be also work ms drug ozanimod expectation be still high regeneron sanofi sny dupixent eczema injection launch end first quarter initial feedback company physician month be critical assess launch sale trend especially anecdote accessibility patient price announcement write ibd take gilead science be suffering slow hepatitis drug franchise buy decline head ibd industry theme better look gilead have sight acquire amgen amgn regeneron be also likely get question reimbursement change medicine lower bad ldl cholesterol amgen show recent study lower ldl cholesterol reduce risk heart attack stroke street be hope push payer reimburse drug upcoming filing investor look amgen commentary migraine drug erenumab romosozumab drug treat osteoporosis postmenopausal woman alexion pharmaceutical alxn be work soliris neuromuscular disease vertex pharmaceutical vrtx be testing tezacaftor cystic fibrosis gilead science gild be likely comment hiv drug bictegravir gilead be push hiv drug potential replacement decline sale hepatitis drug company hepatitis unit rake north year fall related gilead hiv franchise plan be dash trumpcare gilead be pay price actually cure diseasebiotech etfs defy trump tweet rally send higher
353,CELG,nasdaq composite rise record high thursday morning pull back somewhat dow jone industrial average index turn slightly negative nasdaq cling gain late morning trade blue chip dow jone industrial average fall chip stock show strength philadelphia semiconductor index skip ahead volume stock market today be run higher nasdaq lower nyse blue chip be almost evenly split advance issue decline issue cisco system csco mcdonald mcd rise respectively dupont dd ride caboose lose other action railroad union pacific unp break jump fast trade gain clear flat pattern top street earning estimate earning rise union pacific best gain quarters revenue rise also best performance quarters raytheon rtn also clear shallow consolidation beating earning estimate domino pizza dpz gap retook day move average line company earning beat view almost biotech play celgene celg dip heavy volume beat earning sale miss unite parcel service up erased early loss turn slightly positive heavy volume earning top consensus number american airline group aal gap torrid trade top consensus earning estimate southwest airline luv gap quick trade earning come lower expect bristol myer squibb bmy advanced strong volume beating earning target hour starbucks sbux report street expect earning rise cent share revenue be expect increase starbucks buy range edge higher related cold pizza not domino deliver hot result
354,CELG,very busy week news stock rally solidly market worldwide cheer result first round france presidential election amazon com amzn alphabet googl dow stock mcdonald mcd hit record high earning intel intc starbucks sbux tumble hundred other company report president trump big tax cut plan have lift market anticipation didn move needle outline be finally release major market average jump monday tuesday emmanuel macron lead first round voting french presidential election poll suggest easily defeat nationalist marine le pen early runoff stock largely consolidated gain rest week individual stock sector be active flurry earning internet chip restaurant casino be leader baidu bidu intel starbucks show even lead group have loser nasdaq composite hit record high week climb dow jone industrial average rise index be just time best commerce giant say adjust income rise year year share beating consensus estimate revenue rise top view maintain steady streak double digit revenue gain go back more year amazon web service amazon cloud compute unit continue deliver huge gradually slow growth amazon share rise record high friday clear new buy point close well intraday peak earning google parent alphabet rise revenue rise analyst expect company report earning share sale revenue google other advertising business include cloud compute unit pixel smartphone play store rise mobile advertising growth be bright spot google rise traffic acquisition cost be concern tac refer google pay partner website carry ad pay partner apple aapl generate search traffic alphabet share gap fresh record high friday mcdonald first quarter result beat view burger giant talk tech effort include expand delivery try mobile order pay new digitize restaurant layout share jump record high domino pizza dpz also beat say be testing gps tracking technology chipotle grill cmg beat well analyst debate progress follow food bear illness scare starbucks match profit expectation miss sale worry stall growth starbucks share undercut recent buy point intraday friday close level software leader microsoft msft deliver earning share view fiscal third quarter sale come tad short sale guidance june quarter also be analyst estimate microsoft earn cent share exclude item year year adjust revenue march quarter analyst expect cent current quarter microsoft guide sale wall street have be modele intel earning top chip giant sale fall shy weakness datum center market send share gapping friday macom technology solution mtsi mellanox technology mlnx kla tencor klac skywork solution swks be chip play retreat cavium cavm monolithic power system mpwr rally chipmaker top earning gear maker teradyne ter ultra clean uctt boom result lockheed martin lmt see more international demand fighter missile defense system global tension heat raytheon rtn see significant demand signal munition increase military operation syrium lockheed sale fall short expectation give weak guidance northrop grumman noc general dynamic gd top ep sale defense stock be buy range point week friday close be slightly entry area core boee ba earning jump beating view revenue fall defense revenue fall free cash flow soar aerospace giant raise full year ep outlook midpoint still fall analyst view industrial conglomerate unite technology utx top slim ep sale gain otis elevator revenue aerospace system sale pratt whitney jet engine sale rise boee share rise flat base buy point unite tech be month high edge buy range western digital wdc seagate technology stx largest provider disk drife have differ earning seagate revenue miss estimate stock fall reaction western digital earning beat top bottom line announce very bullish guidance send share friday wynn resort wynn pull ahead forecast cent ep sale macau gaming activity continue rebound la vegas sand lvs ep rise cent top revenue growth meeting view mgm resort mgm top handily top bottom line help takeover borgata hotel casino spa mgm national harbor open wynn resort hit year high mgm rise best share buy range sand advanced consolidation exxon mobil xom report mixed first quarter result say have plan adjust capital expenditure guidance oil major have identify capture capital efficiency exxon warn still need be cautious rebalance oil market chevron cvx swung profit revenue beat wall street estimate overall production rise management say oil remain barrel then future spending be low end capex forecast oil price be modestly barrel baker hughe announce oil rig operation rise straight week foreshadow further production gain mobile tmus top earning estimate continue streak grab most new subscriber wireless operator mobile add postpaid phone subscriber vs year earlier period top estimate mobile share rise new high buy range be expect ramp advertising bundle wireless pay tv offer report line ep revenue fall more expect lose wireless postpaid subscriber more expect subscriber growth directv now stream service help offset surprising weakness directv traditional pay tv business share fall low separately cable giant comcast cmcsa rise new high strength movie business customer gain recall cost slow sale hurt ford earning fall still beat view ford say higher commodity cost particularly steel weigh worst hit profit cost year likely happened general motor gm beat forecast solid truck crossover sale fiat chrysler fcau hold full year outlook keep debt check result come concern slow auto sale rise inventory fall used car price dow jone industrial average equipment maker caterpillar cat earn share more double estimate raise revenue range vs estimate caterpillar good news come lack progress president trump infrastructure program border wall initiative have make caterpillar trump stock ahead earning caterpillar finally break month streak fall retail sale gain be drive construction equipment sale asia pacific region caterpillar share soar buy zone biotechs drugmaker report en masse thursday abbvie abbv alexion pharmaceutical alxn bristol myer squibb bmy deliver board beat pump stock day astrazeneca azn top earning sale slide adjust profit grow top cent top biotechs amgen amgn celgene celg report lag sale thursday acorda therapeutic acor stock hit year low light sale cent share loss ex item also miss even house make push repeal obamacare plan include steep cut medicaid raft insurer moved buy zone flirted breakout push new high catalyst be especially strong earning report anthem antm investor have judge trumpcare remain doom humana hum preview earning raise guidance centene cnc top estimate ceo michael neidorff say expect medicaid heavy insurer thrive reform be pass congress note republican senator come state expand medicaid pultegroup phm top earning estimate revenue fall short meanwhile president trump impose tariff canadian softwood import raise construction cost home new home sale rise march second fastest rate current business cycle pulte tumble do not close prior buy point horton dhi lennar len fall day line well
355,CELG,boost explosive earning growth recent quarters recent gain fellow biotech stock celgene celg exelixis exel regeneron regn innoviva inva see sharp improvement relative strength rs rating monday rise ibd unique rs rating measure market leadership used worst best score indicate stock price action last week match other stock decade market research show stock go make biggest gain often have rs rating north launch biggest climb see innoviva continue rebound clear threshold innoviva be try complete cup handle buy point monday rise light trade close entry see stock break volume least average company show ep growth latest quarterly report putt average gain last quarters sale growth have slow triple digit growth recent quarters still strong company earn rank peer medical biom biotech industry group celgene supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
356,CELG,nasdaq composite index dow industrial rise slightly thursday more stock set new possible entry sound basis here be big cap stock be buy point amgen amgn general motor gm visa mastercard asml asml pnc financial service pnc xgeneral motor have market cap smallest visa amgen gm mastercard asml edge past entry point intraday close market uptrend be pressure earning season kick high gear so investor be especially cautious take new position now amgen rise thursday stock market trading biotech stock rise high briefly pass buy point cup handle base couldn hold level volume be normal highest week amgen hasn be market leader lately relative strength line be well recent high amgen lag index several other biotechs include celgene celg regeneron regn have already break general motor rise high thursday afternoon briefly pass cup handle entry gm settle gain slightly average volume meanwhile fiat chrysler fcau volkswagen vlkay clear buy point thursday follow move ferrari race wednesday general motor rs line have be lag meanwhile auto sale have peaked shift suv truck purchase be support profit visa climb intraday new time high not quite trigger buy point flat base visa reversed close mastercard edge cent rise intraday briefly top flat base entry volume be average visa mastercard rs line be high reflect strong performance short consolidation however several other payment stock have break week include paypal pypl square sq visa have earning next week few other card firm such american express axp be still range june meanwhile jpmorgan chase jpm citigroup well fargo wfc pnc financial provide insight credit card trend friday second quarter earning report conference call chip equipment giant fall second straight day asml inched past buy point flat base go back nearly month asml rs line be high good sign asml report quarterly earning next week pnc financial be superregional bank be overshadowed money center bank jpmorgan citigroup well fargo pnc be expect deliver ep gain larger rival deliver essentially flat profit pnc rise build entry shallow cup handle base jpmorgan be still range double bottom base citigroup be extend well fargo be close buy point cup handle pattern related big picture analyze apple stock big bank earning duepeak auto auto stock be buy zone be group smaller stock outshine big gunsjpmorgan citigroup well fargo earning be tepid so be bank stock hot
357,CELG,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
358,CELG,wall street remain bullish tuesday merck mrk even dow drugmaker suspend enrollment pair cancer trial note more patient die group used keytruda medication other group merck say late monday pause enrollment trial keytruda immuno oncology drug combine corticosteroid dexamethasone pomalyst revlimid celgene celg chemotherapy trial treat multiple myeloma blood cancer merck be look patient have never be treat patient cancer have relapse hadn respond previous treatment independent committee recommend merck suspend enrollment trial discover more patient die used keytruda comparison group merck say collect more information close bell stock market today merck stock dip finish regular trading session earlier fall much share biggest rival bristol myer squibb bmy be marginally ibd take keep tab biotech pharma industry bookmarking ibd biotech stock watch pharma industry news page company watcher likely aren figure much multiple myeloma sale merck ub analyst marc goodman write note client estimate risk adjust sale keytruda multiple myeloma importantly merck indicated other study keytruda continue unchanged say do not expect issue multiple myeloma carry other study important keytruda chemo combo advanced lung cancer credit suisse analyst vamil divan say note client be inevitable least keytruda combination ongoing trial wouldn work expect doesn expect pause multiple myeloma have material impact merck date keytruda have have clean safety profile number study ongoing very sick patient population be reasonable assume certain combination indication yield negative safety result say divan keep outperform rating price target merck stock ub goodman have buy rating price target share merck evercore analyst umer raffat note prior patient trial keytruda dexamethasone celgene revlimid be very effective patient show reduction tumor size be hint safety issue prior study say bigger question be rival bristol be see similar issue immuno oncology drug opdivo merck combination be month ahead bristol raffat write note so far update bristol trial related dow host diabetes study lilly benefit mosthere be winner loser year biggest cancer meetingdow merck clearly win vs bristol roche cancer trial
359,CELG,slew biotechs drugmaker take closer look epizyme epzm small cap biotech present strong datum lymphoma trial wednesday switzerland analyst say thursday finding international conference malignant lymphoma attract like gilead science gild abbvie abbv celgene celg johnson johnson jnj roche rhhby leerink analyst geoffrey porge say note client epizyme be testing drug dub tazemetostat form hodgkin lymphoma interim datum show tazemetostat have clinically meaningful benefit patient call follicular lymphoma buildup cell lymph node tumor shrink follicular lymphoma patient patient aggressive form hodgkin lymphoma specific genetic mutation tazemetostat prove safe patient population leerink porge call study proof principle expect drug accelerate approval food drug administration follicular lymphoma accelerate approval allow drug be market still clinical trial few cancer drug have response rate clinical benefit rate disease say investor debate big group patient really be long treatment duration be not be surprised see epizyme start show potential takeout candidate list epizyme be appeal abbvie celgene roche porge write roche be leader immuno oncology method treat tumor block certain interaction hide cancer cell gilead be better know virology drug include target hepatitis hiv gilead hepatitis franchise decline high cure rate now gilead have say open seek acquisition oncology incyte tesaro be also rumore takeout candidate now molecule tazemetostat have be risk expect more investor get involved stock build position ahead further datum disclosure porge say ibd take seattle genetic chief executive clay siegall say company be aim change year method treat hodgkin lymphoma head ibd technology page exclusive ceo same conference see bristol myer squibb bmy seattle genetic sgen team phase trial classical hodgkin lymphoma also robust result only epizyme stock spiked news bristol myer seattle genetic too have strong datum classical hodgkin lymphoma tumor shrink patient treat combination bristol opdivo seattle adcetris sign cancer disappear patient combo prove safe well bristol say afternoon trading stock market today epizyme stock soar more share have run past day bristol myer stock other hand dip less seattle genetic stock be flat related analyst plead gilead buy have seattle genetic adcetris grab blockbuster status trial dow merck pause cancer trial investigate keytruda tie death
360,CELG,bluebird bio blue stock rocket month high tuesday strong datum present monday cancer trial biotech celgene celg bluebird stock pop morning trading stock market today break consolidation period buy point finished regular session level bluebird rise day heavy trading be stock fourth day row gain monday bluebird say evaluable patient trial drug know bb respond treatment nearly patient see tumor shrink see evidence tumor disappear have be disease progression patient ongoing trial datum cutoff bb belong class drug call chimeric antigen receptor cell therapy used drug certain immune system cell be remove patient then modify be able recognize cancer cell be then reintroduce patient ibd take bluebird celgene datum be present american society clinical oncology meeting chicago also player merck bristol myer squibb roche present datum analyst say merck clearly win battle head ibd industry theme closer look setup immuno oncology treatment phase trial bluebird celgene be look identify safe dose take phase trial so far have find dose limit toxicity drug bluebird say news release celgene stock dip tuesday related
361,CELG,here be winner loser year biggest cancer meetingdow merck make massive strike keytruda say analysttesaro crash beating astrazeneca stronger datum
362,CELG,major stock index close mixed wednesday fed raise key lend rate quarter point also agree detail start shrink balance sheet year nasdaq lose fall pare loss final hour dow jone industrial average climb russell small cap index give back volume nyse be higher tuesday level nasdaq volume be lower early figure show economic datum release open didn do anything strengthen argument more rate hike consumer price be tame fall vs consensus estimate flat exclude food energy price rise vs expectation gain meanwhile retail sale unexpectedly fall worst drop january dollar weaken news year treasury yield tumble basis point fed dot plot be mostly unchanged march meeting committee member expect more quarter point hike end year stock market today homebuilder health care even retail group outperformed celgene celg rebound day move average rise stock work new base vertex vrtx gain nearly continue show support action week move average pultegroup phm be pace fourth straight gain cup handle base still buy range benchmark crude oil july delivery slump nearly barrel oil be weak news gasoline inventory rise barrel last week accord energy information administration crude inventory fall barrel starbucks sbux look poise eighth straight decline wedbush downgrade share neutral outperform maintain price target share fall close day move average first time march related stunning economic report give fed pausebank stock test buy point support weak datum fed odd
363,CELG,food drug administration panel unanimously vote recommend approval experimental immuno oncology treatment novartis nvs panel attendee tell investor business daily novartis drug know ctl go full fda early october spokesperson previously tell ibd approve pave way similar drug kite pharma kite dub kte grab approval well say brad loncar chief executive loncar investment loncar attend oncologic drug advisory committee meeting panel agree benefit ctl outweigh risk cancer treatment ctl be be consider drug treat pediatric young adult patient cell acute lymphoblastic leukemia bone marrow cancer don think embellishment say be historic day say voter panel vote go table explain vote person say be most exciting thing ever see entire life don hear thing very often fda meeting novartis kite drug class treatment call car therapy create drug researcher extract immune system cell patient blood used empty virus affix be know chimeric antigen receptor immune system cell ibd take cure cancer be blood possible biotechs drugmaker say car therapy take deep dive experimental drug visit ibd technology page chimeric antigen receptor car be protein recognize protein cancer cell use hide patient body re programme immune system cell be reintroduce body be direct seek destroy cancer cell largely fda panel focuse safety morning wrapping late wednesday loncar say biggest issue be purity cell say introduce back patient want make sure immune system cell be disaster infuse cell cancer cell cause someone have cancer never show clinical trial note most patient undergo car therapy be do so last resort follow number treatment course include chemotherapy stem cell transplant car therapy be time treatment be meant be long last long term treatment always long term unknown say be such sick patient benefit drug be so black white so clear fda be schedule vote approve kite kte november drug be treatment aggressive form hodgkin lymphoma blood cancer further juno therapeutic juno bluebird bio blue partnership celgene celg be also work car drug novartis close stock market today buy range entry novartis rise late trading fda panel news be confirm kite pharma climb close rise slightly hour related celgene bluebird keep lead rival champ bit novartis face key fda panel cancer drug kite be small biotech soar celgene partner trial
364,CELG,celgene celg revlimid continue carry biotech even lose patent exclusivity analyst say friday note chemotherapy be most adaptable oncologic mixer leerink analyst geoffrey porge call revlimid tonic water oncology revlimid be often combine other cancer drug create stronger treatment method have proven particularly robust myeloma blood cancer porge upgrade celgene stock outperform rating boost price target stock market today celgene stock climb synergy combination antibody continue surprise research community application utility be only begin be realize porge write note client eventually revlimid be combine roche rituxan porge say combination hasn be proven clinical trial analyst expect have promise treat lymphomas family blood cancer lymph node ibd take analyst expect smaller oncology centric biotechs pull interest year know car treatment number blood cancer head industry snapshot deep dive forecast revlimid continue grow mid high teen patent life product benefit ability combine most establish emerge biologic myeloma category say porge expect revlimid sale bring then grow hit peak revlimid account celgene sale gross profit estimate related small biotech pique interest gilead other small biotech be save develop anemia drug dow merck pause cancer trial investigate keytruda tie death
365,CELG,big tech stock lead morning advance new high major market average reversed turn sharply lower afternoon action nasdaq morning time best trade apple aapl netflix nflx alphabet googl many other retreat turn dow jone industrial average be just break even volume stock market today be higher board company report quarterly result start strong then stage negative reversal mastercard pop almost first minute trade then stock reversed loss mastercard report revenue earning top street consensus estimate also mastercard ceo ajay banga announce takeaway visa kroger kr currently co brand credit card visa switch mastercard new card be issue spring biotech celgene celg spark higher open then reversed loss celgene report small beat earning revenue stock be buy range june past buy point biotech alexion pharmaceutical alxn gap more first minute trade then pare gain early afternoon alexion report increase earning vs year quarter top street consensus target revenue rise also beating view facebook fb advanced much morning lose more half advance facebook report wednesday close trouncing earning view revenue blue chip be mostly gain dow jone industrial average verizon vz gap support stock dow positive company beat profit estimate morning report verizon pay dividend annualize yield earning be expect slip year rise only next year estimate be revise today result related verizon cfo customer pay unlimited plan stock jumpstop rate payment stock still buy zone strong former leader be back buy zonemelt melt way prepare
366,CELG,index nasdaq composite dow jone industrial average hit record high week techs fuel selling start thursday afternoon federal reserve signale not worry stock price facebook fb dow boee ba verizon vz mcdonald other company be hailed strong earning alphabet googl amazon com amzn other have less ideal result tobacco stock such altrium mo crash friday fda say reduce nicotine level cigarette sub addictive level nasdaq composite index fall week week retreat thursday morning record high flood earning report dow industrial rise fuel boee verizon facebook leap earning amazon alphabet fall result oil price soar treasury yield rise dollar continue trend lower treasury yield rise week dollar continue trend lower boee ba swung profit take charge year quarter revenue decline miss view boee raise full year ep outlook analyst view aerospace giant say have talk customer new midmarket plane see demand aircraft northrop grumman noc general dynamic gd raytheon rtn also raise full year earning outlook report earning result estimate northrop say aerospace system sale climb higher manned aircraft demand include work advanced hawkeye aircraft raytheon see higher air defense missile smart bomb sale general dynamic revenue get support strong gulfstream defense product demand boee share soar week raytheon rise northrop be lower general dynamic tumble related boee put midrange demand plane stock hit sell signfacebook jump week hit record high earning revenue growth blow past expectation facebook exceed view various metric include user growth monthly active user twitter twtr earning beat view monthly active user be flat vs first quarter twitter share plunge snapchat operator snap fall hit record lows related facebook earning surge fang duo monopolize digital adsamazon earn cent share vs year earlier way view due heavy spending commerce giant operate income wasn great revenue be growth accelerate second straight quarter amazon web service revenue swell amazon share retreat friday close recent buy point undercut intraday related be winter come amazon shareholder big investment google parent alphabet stock retreat internet search giant earning fall short heighten expectation report higher expect traffic acquisition cost pay partner website google recognize nondeductible european union fine worry eu regulator crack more google say second quarter earning be share year revenue rise exclude time charge google say earn share related food drug administration announce fda aim require nicotine level cigarette sub addictive level roil tobacco stock friday altrium mo sell marlboro cigarette lose british american tobacco bti recently buy rest reynold american fall philip morris international pm sell marlboro cigarette overseas initially tumble close related fda act vs cigarette tobacco giant be hold federal reserve keep wall street prefer script wednesday leave key interest rate unchanged putt announcement begin unwinding balance sheet fed patience come economy be perform pretty well real gdp grow pace second quarter inflation wage gain have be more muted expect combination have be good stock market partly prospect low interest rate have weigh dollar be boon earning multinational second half year decision fed september announce shift reinvestment policy gradual pullback current stance reinvest principal mature mortgage treasury bond portfolio also send signal policymaker aren overly concern financial market be too exuberant next interest rate hike be expect december real uncertainty hinging inflation outlook be fed policy look flurry chip industry player post beat raise june quarter result include chipmaker advanced micro device amd cypress semiconductor cy intel intc texas instrument txn well chip gear supplier lam research lrcx teradyne ter amd earn adjust cent share sale analyst expect break even sale current quarter amd forecast sale rise vs wall street target cypress earn cent share ex item sale vs estimate cent cypress expect earn cent ex item sale vs view cent intel earn cent share ex item sale top view cent intel forecast adjust earning cent share sale analyst be look cent ti earn share ex item sale june quarter vs analyst expectation cent current quarter ti expect earn share sale vs wall street target lam earn adjust share sale june quarter analyst be expect september quarter lam expect earn share sale wall street be modele teradyne earn cent share ex item sale top expectation cent teradyne expect earn cent share ex item sale analyst have be expect cent paypal pypl earning rise year revenue rise slightly top consensus estimate digital payment processor member ibd raise full year outlook analyst view share rise record high pare gain crude future spiked barrel sign supply be fall revive shale boom be peter nigeria say ll eventually join rest opec curb production saudi arabia agree cut oil export crude inventory tumble barrel domestic production dip energy company trim capital spending plan month sub oil halliburton hal warn see exploration production company tap brake rig count plateau exxon mobil xom chevron cvx earning miss general motor gm report adjust profit grow beating view revenue drop view gm reaffirm full year ep guidance cut second half production swell inventory fall industry sale ford motor top view raise guidance largely lower tax rate gm fall further buy point ford fall back multiyear lows fiat chrysler fcau hold buy point adjust ep swell sale fall short maseratus luxury brand do well biogen biib obliterate sale expectation spinal muscular atrophy drug spinraza amgen amgn fall late tuesday boost ep ex item guide lag view gilead science gild report hepatitis drug franchise decline be partially offset growth hiv hepatitis drug sale vertex pharmaceutical vrtx say total cystic fibrosis sale gap celgene celg alexion alxn also beat view latter bust ep expectation cent astrazeneca azn crash thursday report mystic lung cancer trial immuno therapy combination fail drugmaker also announce deal merck mrk gain access latter blockbuster keytruda merck rise thursday bristol myer squibb bmy have have several setback drug opdivo slide concern mystic failure bode ill similar opdivo combo study wall street soured casino player mgm resort international mgm wynn resort wynn melco resort entertainment mlco sector overall put mixed result guidance concern mass market gaming macau weigh wynn result nonetheless beat estimate mgm offer weak revenue available room outlook also cite higher anticipate disruption monte carlo be be revamp park mgm challenge comparison la vegas strip la vegas sand lvs top result melco focuse boyd gaming byd penn national gaming penn be mixed share verizon communication vz soar telecom report better expect wireless result stiff competition narrow loss high spending postpaid phone subscriber verizon add more forecast say strategy packaging video wireless service be jell verizon say consumer be willing pay premium unlimited datum service high perform network comcast cmcsa report second quarter profit revenue top estimate nbcuniversal film entertainment business deliver strong box office result video subscriber loss be higher expect citigroup speculate comcast acquire verizon charter communication chtr miss earning sale share soar speculation be acquire well mcdonald mcd earning same store sale top estimate help cheap drink offering premium menu item chipotle cmg be testing queso face concern sale recovery have stumble follow food bear illness scare begin sale impact report customer fall ill july remain unclear domino pizza dpz crash part disappointing international comp lower margin ep help tax rate already high stock valuation starbucks sbux tumble fiscal same store sale revenue miss ep match view coffee chain say close teavana retail store several industrial dow giant rolled past estimate tuesday thank part improve global growth caterpillar cat surge week high company see ep revenue unite technology utx see earning climb share revenue rise share tumble lowest level raise full year ep revenue guidance dupont dd also beat top bottom line dow peer mmm be outlier overall miss share tank proofpoint pfpt report profit revenue top expectation forecast current quarter sale earning just consensus estimate sunnyvale calif base proofpoint specialize email datum loss protection corporate network cloud compute infrastructure proofpoint rise modestly friday morning fortinet ftnt post mixed result beat ep revenue billing growth disappoint outlook provider computer security software have yet improve recent ransomware attack fortinet share tumble tal education tal top earning sale estimate share profit cent revenue come ahead forecast cent current quarter china base education company see revenue view yahoo finance estimate meanwhile peer new oriental education edu also pull ahead forecast cent ep addition bump total student enrollment midpoint revenue guidance pull just ahead current view tal new oriental share rise respectively latter fail thursday mastercard report better expect second quarter earning revenue share reversed modestly lower record high remain buy range baidu bidu earning rise well view revenue climb line share chinese search giant rise friday electronic art ea report better expect quarterly earning video game publisher give cautious revenue guidance ea share rise friday briefly fall recent buy point
367,CELG,biotech stock topple midday thursday line broader index include pitfall large player vertex pharmaceutical vrtx unite therapeutic uthr spark therapeutic once long term view look weak uncertain xon stock market today vertex dove unite therapeutic fall spark dip broadly ibd company biotech industry group lose reflect major index trend follow beat amgen amgn biogen biib gilead science gild vertex celgene celg alexion pharmaceutical alxn week vertex increase guidance vertex keep full year view see slowdown third quarter leerink analyst geoffrey porge trim third quarter view vertex cut sale forecast keep outperform rating vertex price target stock get haircut second quarter sale cystic fibrosis drug orkambi kalydeco beat expectation porge note be due inventory stocking ahead anticipate summer slowdown vertex be also work triple pill cystic fibrosis outside cystic fibrosis franchise vertex say earning conference call look make small technology base early stage acquisition likely avoid large stage large investment many investor fear porge say report unite therapeutic second quarter sale be highest company have ever see resumption growth be not guarantee leerink analyst joseph schwartz say note client unite be work drug treat rare blood disease know pulmonary arterial hypertension pah schwartz increase third fourth quarter sale model strong second quarter report ibd take biotechs be now rank fourth group track ibd merger acquisition send higher vertex consider takeover target acquirer circle get deep dive ibd industry theme due lack curative therapy pah provide suite pah medicine keep patient transition unite product say however be reluctant assume rebound product sale quarter materialize resumption growth trajectory other unite product also thursday alexion celgene top expectation alexion rise celgene still dip investor be likely look celgene raise top line guidance instead celgene lift adjust profit forecast year share main surprise result be lack increase top line guidance normally have expect time year leerink porge say second quarter be only time celgene have not increase revenue guidance second quarter elsewhere biotech analyst be more bullish gilead see hepatitis drug sale fall collective slower revenue harvoni sovaldi beat analyst view predict fall porge say raise price target magnitude beat point stabilize hepatitis drug sale say windfall be short live however abbvie abbv next generation doublet be set enter market week be likely represent first real competition gilead hepatitis dominant market position related astrazeneca beat stock dife drug failure more reportthis biotech nearly triple street expectation key druggilead hepatitis franchise topple again share beat
368,CELG,major market index advanced higher early trading wednesday tech heavy nasdaq dow jone industrial average lead way move respectively meanwhile edge higher index hit record high xamong dow industrial verizon communication vz merck mrk boee ba rise solidly early trading verizon jump nearly result remain day line merck look reclaim day line advanced early thursday biotech competitor astrazeneca azn report late stage trial failure cause share plummet meanwhile boee add wednesday earning related surge airplane maker be flat base buy point longtime lead stock fang member facebook fb surge top top bottom line estimate beating view ad revenue user growth meanwhile fellow social medium company twitter twtr snap snap trade mixed twitter report earning beat street estimate monthly active user be flat vs send share share twitter have be comeback trail recent month rise almost mid april lows meanwhile analyst firm summit redstone call competition facebook snap contest facebook favor due facebook increase pricing power respect ad price share snapchat parent be trading post ipo high almost ipo price trade higher thursday fellow fang member amazon com amzn report earning bell thursday analyst expect commerce giant quarterly profit fall year year share rise revenue share advanced stock market today be flat base entry casino operator take hit early thursday mixed earning result mgm resort mgm melco resort entertainment mlco mgm fall nearly be still hold day line melco edge be still day line build new base ibd paypal pypl jump almost pare gain strong result late wednesday lead payment processor be flat base entry downside celgene celg decline beating estimate lift full year earning guidance stock remain extend flat base buy point level related facebook vs snap call contest boee surge far too little twitter dife stagnant user solid earningsdow jone industrial average dow stock news stock news quote facebook amazon netflix googlefacebook earning surge fang duo monopolize digital ad
369,CELG,biotech group be spotlight thursday wall street weigh earning beat sale miss celgene celg celgene be still widely regard high quality name group top fundamental price action have be sluggish buy point didn go anywhere good news be
370,CELG,xhere investing action plan thursday need know investor come day week earning frenzy reach climax report amazon amzn microsoft msft alphabet googl intel intc starbucks sbux ford flood other big name be thursday well include drugmaker astrazeneca azn bristol myer
371,CELG,axovant science axon oncomed pharmaceutical omed diverged ibd company biotech industry group monday axovant stock ride chief executive swap month high oncomed stock topple fail drug trial close bell stock market today axovant stock pop announce former medivation ceo david hung succeed vivek ramaswamy top job axovant ramaswamy move lead axovant parent roivant science hung appointment be effective friday head medivation acquisition pfizer pfe september ramaswamy say news release axovant hadn initially be look new ceo approach david take role mindset study say add david decide want join now mindset study look axovant drug intepirdine mild moderate alzheimer patent result be expect september axovant stock bust cup handle formation begin august pass entry point share be now extend buy point touch high last achieve december meanwhile share oncomed plunge time low drug demcizumab fail extend progression free survival late stage pancreatic cancer patient oncomed stock hit record low fall point session be close oncomed trial look combination demcizumab gemcitabine abraxane oncomed also miss second goal improve overall survival trial compare demcizumab gemcitabine chemotherapy first develop eli lilly lly celgene celg chemo abraxane gemcitabine abraxane placebo ibd take ibd biotech industry group be rank group track just week biotechs celgene stock be clear leader ibd composite rating best possible head ibd stock checkup list top best perform biotechs also monday bayer pharma bayry drop deal license oncomed drug vantictumab strategic reason oncomed say news release drug aim treat solid tumor prove safe effective alone combination chemo early trial have look forward collaborate bayer team late stage development biotherapeutic be very pleased have worldwide right promising phase ready asset ceo paul hasting say statement related axovant confidence not sway rival alzheimer drug fail
372,CELG,xit be good day bull stock market today more bullish breakout emerge dow jone industrial average be driver seat help strong earning report mcdonald mcd dupont dd caterpillar cat firm top earning sale expectation caterpillar break bullishly flat base entry meanwhile nasdaq composite show gain russell small cap index gain volume nyse nasdaq be tracking slightly higher monday level big gainer nasdaq include netflix nflx jump news licensing agreement china base baidu bidu provide content baidu iqiyi stream video platform biogen biib celgene celg also outperformed nasdaq gain respectively help solid earning biogen gap day move average approach early entry celgene be close buy point ibd china base new oriental education edu be top performer report strong earning monday wall street like look big earning beat second straight quarter accelerate sale growth athm also base china rise nearly back day move average work new base buy point homebuilder have rough go lag monday market gain share pultegroup phm gap day move average fall other thing wall street didn news sale growth decelerate third straight quarter group peer horton dhi be day move average fall hard last week earning defense firm lockheed martin lmt paid visit day move average share slump nearly weak earning guidance be culprit close watch earning chipotle grill cmg chipmaker macom mtsi related mcdonald top forecast comp show surprise strengthdow caterpillar break buy zone steamroll earning enter china alliance baidu iqiyi stock hit buy
373,CELG,xhere weekly investing action plan need know investor come week market get broader view economy lead edge company tech heavy industry defense energy medical sector have turn earning microsoft msft amazon com amzn alphabet googl boee ba caterpillar cat exxon mobil xom
374,CELG,xstock tiptoed modest gain lighter trade thursday investor multiple concern range talk president trump china xi jinp news federal reserve be get ready deleverage monster balance sheet debt ongoing nuclear threat north korea dow jone industrial average edge point less nasdaq composite outperformed rise nearly rise small cap outperformed mile russell gain help part rebound smaller bank federal reserve signale get more commit tighter monetary policy lighten debt load balance sheet later year future monetary action be likely keep interest rate upward path boost profit margin many lender march central bank push fed fund rate basis point target range currently top industry group be dominate computer technology finance build medical sector just hail defensive utility sector gas distributor top ranking group steel superregional bank mortgage service scientific measure equipment education integrate computer system enjoy biggest gain more financial medium talk head have sound plenty worry risk serious trade war hurt global economy ibd screen be see continue fine action number stock be show good relative strength see robust increase demand product go forward celgene celg draw majority revenue north america europe developer therapy battle cancer immunological disease be trading tightly lately hold buy point somewhat choppy cup base base form celgene share pop big nov then stall even great recession demand excellent medicine be so fierce celgene revenue still grow double digit year then earning share rise share wall street see celgene earning jump year share then keep watch stock weekly chart new handle have form create potential point cent march intraday high caterpillar cat be not top group increase construction activity rest world provide bullish backdrop construction mining equipment giant dow component aid bullish comment goldman sachs earlier week rise third straight session gain nearly thin volume more importantly stock regain north side day move average cat profit have withered hit peak street see earning rebound big way rise share expect dip year ibd name also likely suffer less future trade spat retaliatory measure take china due incredible demand product priceline group pcln ulta beauty ulta arista network anet have do well so far fuel need traveler beauty conscious woman company rely fast datum network run business priceline be extend clear resistance nifty gap heavy volume aug notice stock have hug day line most way inventor name price rate hotel room reservation have branch new field such private car rental restaurant reservation investment have paid revenue grow vs year level past quarters earning share rise go ibd see latest concise chart analysis potential buy sell point ulta arista well rest ibd few new ipos be cool snap snap briefly touch level china be unlikely become target market already have highly popular social medium site snapchat operator have more press issue find way turn big sale growth healthy earning snap be expect lose cent share year cent adient adnt car supplier bounce intraday lows rise fast turnover watch see rebound back critical day move average keep uptrend intact car seat specialist debut nyse october immediately form narrow ipo base entry share rolled past buy point day spurt begin nov just day trump surprise election related growth stock turn next cisco system decade income investor hot chipmaker keep uptrend go stock first invest time understand logic cup handle
375,CELG,stock index start strong note thursday morning then stage ugly reversal still index battle back close fairly high day range xwild swing take nasdaq then trimming loss close middle day range drop
376,CELG,donald trump discuss drug price biotech big pharma company celgene celg merck mrk amgen amgn health care ipo tabula rasa healthcare trhc be enter new buy zone provider datum drive technology help health care organization optimize medication regimen see ibd smartselect composite rating jump friday day new score mean company go public last september be now outperform stock term most important fundamental technical stock pick criterium history show top market performer tend have higher score launch major climb tabula rasa healthcare clear entry thursday close friday still buy range note thinly trade stock average daily dollar volume such stock show wider daily weekly fluctuation stock greater liquidity accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company post ep gain second straight quarter triple digit earning growth top line growth have range last report tabula rasa healthcare hold rank peer computer software medical industry group medidata solution mdso be top rank stock group related company be now outperform stock
377,CELG,chinese biotech beigene bgne be strongest beneficiary celgene celg gamble immuno oncology analyst say friday beigene stock touch fresh high term deal beigene obtain right commercialize celgene cancer drug abraxane revlimid vidaza china be not yet approve be be test advanced solid tumor blood cancer hodgkin lymphoma leerink analyst geoffrey porge call deal great news beigene merely reasonable celgene celgene say chinese business bring annually deal retain half future chinese profit drug beigene beigene go development company commercial company overnight very little cost home market have raise significant cash future development funding asset have struggle develop commercialize independently say return celgene acquire right develop commercialize beigene immuno oncology drug know bgb drug belong same class keytruda dow merck mrk opdivo bristol myer squibb bmy ibd take biotechs exelixis be work treatment advanced kidney cancer exelixis be great position retire nearly debt head new america breakdown exelixis stock celgene partner astrazeneca azn april develop commercialize imfinzi blood cancer imfinzi be know pd inhibitor have slightly different mechanism keytruda opdivo bgb pd inhibitor deal astrazeneca doesn give celgene access imfinzi solid tumor lung breast ovarian cancer other celgene appear have conclude expand portfolio solid tumor future require pd current agreement astrazeneca imfinzi exclude indication solid tumor porge write note client porge keep outperform rating price target celgene stock timing deal beigene look inspire lucky say follow day merck confirm food drug administration have put keytruda trial hold cite patient death celgene share end regular trading session friday related dow merck stumble fda put keytruda trial holdnovartis face key fda panel cancer drug kite be winnerdeal help celgene rival dow merck bristol cancer drug
378,CELG,kite pharma kite benefit food drug administration panel hearing experimental cancer treatment rival novartis nvs later month analyst say thursday share drop xon stock market today share drugmaker work be call car therapy be broadly bluebird bio blue stock fall hardest close kite stock lose follow share juno therapeutic juno novartis slip canaccord analyst john newman remain bullish kite stock novartis follow kite be closest have car therapy approve blood cancer july fda panel be set review key question surround novartis treatment car therapy involve remove immune cell patient blood then programming seek destroy cancer cell therapy have proven toxic nervous system meanwhile lag turnaround time remain sector wide challenge newman say discussion regard manufacturing novartis drug ctl help differentiate kite newman say car therapy be mass produce kite have industry lead turnaround time day vs day novartis day juno accord various analyst report discussion manufacturing novartis ctl highlight difficulty benefit kite have have issue failure long turnaround time say note fda opt discuss manufacturing directly novartis potentially result approval delay fda also be likely focus safety novartis ctl hasn show magnitude death see juno discontinue jcar adult acute lymphocytic leukemia cancer affect bone marrow juno adult patient die result brain hemorrhage however believe fda utilize panel focus physician thought regard severe neurotoxicity sometimes see car especially long term effect newman write note client ibd take car therapy help spike biotech stock analyst have say cancer rare disease specialist have gain handsomely year early innovator amgen biogen gilead science have struggle head industry snapshot closer look trial patient novartis drug experience call cytokine release syndrome common side effect car therapy result high fever case be mild moderate be moderate severe be serious result death more quarter develop brain disease alter structure function have complete neurological recovery long term issue newman say adult patient die first day follow treatment ctl serious case cytokine release syndrome result brain hemorrhage believe fda panel conclude most case cytokine release syndrome occur car therapy be manage intracranial hemorrhage be discuss newman write novartis currently be expect have approval date late september treat blood cancer know acute lymphocytic leukemia child young adult kite drug kte be expect be approve treat form aggressive hodgkin lymphoma blood cancer late november meanwhile bluebird bio partner celgene celg be work drug treat blood cancer call multiple myeloma trial present june bluebird celgene drug know bb achieve overall response rate multiple myeloma patient analyst have estimate duo be year ahead used immuno oncology target call bcma bb work block immune system interaction involve bcma antigen likely drug win get fda later analyst have say canaccord newman keep buy rating price target kite stock related celgene bluebird keep lead rival champ bit cure cancer look bloodbiotechs surge generalist return subside trump wo
379,CELG,celgene celg rival dow component merck mrk bristol myer squibb bmy cancer fight drug analyst say biotech announce deal give access key immuno oncology treatment xunder term deal celgene pay beigene bgne upfront license fee make equity investment acquire right develop drug know bgb solid tumor globe bgb belong class immuno oncology drug call pd inhibitor drug include merck keytruda bristol opdivo work block specific interaction involve pd protein body prevent immune response cancer cell deal allow celgene develop commercialize bgb treat solid tumor europe japan rest world outside asia beigene keep right drug blood cancer worldwide solid tumor asia celgene already have immuno oncology play blood cancer acquisition right astrazeneca azn imfinzi hematological tumor evercore analyst umer raffat say call deal small upfront cost get access pd inhibitor begin trial next year also deal beigene acquire celgene commercial operation china exclusive license commercialize cancer drug abraxane revlimid vidaza china celgene say news release early thursday ibd take several drugmaker be work create car therapy individualized form immuno oncology immune system reprogram fight cancer lead sector head industry snapshot deal come day food drug administration put merck keytruda trial hold several patient death celgene be partner trial still question linger regard much celgene be willing put finish development bgb raffat say celgene perspective very important understand big research development undertaking be many additional immuno oncology target look bring potential combo write note client number company merck bristol include be work combine immuno oncology drug other boost potency beigene say pd inhibitor be more efficient be engineer minimize interaction other target outside pd protein celgene be work number immuno oncology target outside pd raffat expect need add more include ido inhibitor incyte incy epacadostat ctla inhibitor bristol yervoy stock market today celgene stock dip nearly close share merck fall bristol myer stock slide finish beigene stock rocket end regular session record close intraday beigene hit record high related dow merck stumble fda put keytruda trial holdbristol beat cancer test conquer dow merck cure cancer look blood
380,CELG,stock get weak launch thursday apple aapl microsoft msft general electric ge drag dow lbrand lb post worst decline dow jone industrial drop future dive nasdaq slump open trade apple fang stock trade lower start thursday session apple be tracking fourth week week move average dow stock general electric take hardest early hit european union accuse industrial conglomerate withhold information link recent merger ge also receive price target cut jpmorgan note cite uncertain outlook lag growth potential maintain stock underweight rating also dow merck mrk shed report late wednesday food drug administration have suspend series clinical trial merck blood cancer treatment keytruda victorium secret owner brand lb crumble weak read june same store sale lb lead downside tesla tsla retreat more early action follow tumble heavy trade trigger warning goldman sachs wednesday weaker expect delivery figure late monday tesla model do not receive highest iihs safety rating wednesday loss send share tumble week line support trip sell signal trimming gain buy point earning result report late wednesday send pricesmart psmt yum china yumc lower electrical component maker azz azz dive report broad first quarter miss early thursday china beigene bgne spiked open announce strategic partnership celgene celg develop immuno oncology compound target solid tumor deal provide beigene upfront license fee capital investment gain put thinly trade beigene february ipo price celgene share open lower mazor robotic mzor bolt higher late wednesday update second quarter revenue guidance company now see revenue prior guidance advance hoist share back week move average seventh week possible base layoff announce employer drop june job cut mark lowest level year accord monthly job cut report challenger gray christmas unemployment rate stand lowest level give company stronger incentive hold worker report say nonfarm private employer add new worker june accord national employment report adp be hiring well new job project economist consensus adp also revise estimate downward add worker first time unemployment claim rise week end july labor department estimate economist expectation steady go tally week move average edge higher commerce department trade deficit narrow april trade gap just miss consensus estimate pullback researcher markit june service purchasing manager index institute supply management service index be schedule energy information administration report weekly inventory estimate natural gas inventory oil et related big picture sloppy second half start stockschip stock jump industry see strongest growth yearsapple iphone demand soft analyst contendsq earning preview stock expect growth
381,CELG,stock market re-cover soft start thursday be still negative territory wall street digest weaker expect adp private payroll datum ahead friday job report nasdaq composite be fall much intraday give back dow jone industrial average ease volume nasdaq be tracking slightly higher wednesday level nyse volume be slightly lower so call fang stock facebook fb amazon com amzn netflix nflx alphabet googl follow nasdaq path overcome early weakness facebook netflix show mild loss amazon alphabet edge higher generic drug maker retail related group lag metal ore steel foreign bank stock outperformed investor sell bond again thursday lift year treasury yield higher basis point bond market seem convince higher rate go forward trader fed fund future aren so sure market currently think chance fed hike rate more time year accord cme group fedwatch tool benchmark crude oil add just barrel energy information administration report barrel drop crude inventory catch analyst surprise echo report late wednesday american petroleum institute also show unexpectedly sharp decline oil inventory news home shopping network hsni surge news be acquire qvc group qvca just qvc reversed lower fall less stock market today costco cost outperformed rise company report rise june same store sale stock be still damage good technical perspective fall sharply news amazon plan acquire whole food market wfm think be costco food business suffer result merger biotech space celgene celg ease company announce deal acquire beigene bgne give access key immuno oncology treatment celgene be still buy range buy point ibd china name outperformed momo momo athm tal education tal netease nte outperformed gain related costco sale strong amazon whole food future loomsfiber optic stock rate strong buy get big price target hike
382,CELG,future nasdaq dow jone industrial average turn higher friday nasdaq composite close thursday day move average microsoft msft google parent alphabet googl fall back day line join apple netflix many other stock such facebook fb amazon amzn be hold support be fight tide nasdaq future rise vs fair value fall much overnight session future advanced dow future climb crude future rise nearly gain several day row year broad tech rally be fuel several big trend fang facebook amazon netflix nflx google parent alphabet apple china internet chipmaker optical gear play more recently enterprise software firm more more stock be breaking day line round trip breakout apple tumble day move average june hasn find way back even recent struggle include thursday loss apple be still third best performer dow jone industrial average microsoft alphabet tuesday close just day line bounce back wednesday thursday microsoft google parent fall more decisively key support line microsoft alphabet be biggest cloud compute rival much larger amazon web service ibd take market direction be still uptrend pressure mean investor be cautious take new position ready take profit cut loss quickly pay attention lead stock major average read big picture daily facebook trade day line intraday fifth time june once again close line facebook announce week have top monthly user make even more amazing be social giant be block china world largest internet market amazon have pull back day line have find support so far amazon continue roil retail apparel broader consumer field nike nke confirm thursday night earning call sell shoe directly commerce giant weibo wb momo momo have fall day line netease nte be once again round trip late stage tencent tcehy pull back week tight pattern alibaba baba remain strong yy yy find support day be still buy range ibd semiconductor manufacturing semiconductor fabless group have fall day move average few day chip equipment group undercut level apple iphone chipmaker particular be struggle broadcom avgo finally fall day line thursday several other apple chip play do same include skywork swks qorvo qrvo texas instrument txn analog device adi slew top rate chip equipment maker include lam research lrcx apply material amat be day line nvidia nvda remain standout fiber optic stock have be volatile leader past year internet giant ramp datum center china beef infrastructure verizon vz expand high speed metro network telecom fiber optic group have fall day line apply optoelectronic aaoi hottest stock group be find resistance week lumentum lite be see possible apple iphone sensor play be close round trip salesforce crm shopify shop sap sap be day move average oracle orcl adobe adbe have strong earning last week be hold well so far many techs be weak financial be make gain jpmorgan chase jpm notable week big bank announce huge dividend hike stock buyback late wednesday pass second round federal reserve annual stress test meanwhile higher treasury yield negative broader stock market housing stock particular also be give lift financial meanwhile biotechs have be big winner june celgene celg regeneron regn be big name breakout have be other defense aerospace firm boee ba lockheed martin lmt have hold well buy range just extend asian market japan nikkei fall australia asx china shanghai composite rise european trading intraday ftse rise germany dax climb france cac related be dow top stock apple isn big picture be summer pullback underway stock market today time take gain apple big cap chip cybersecurity stock near buy point investing action plandraghi drama undercut key stock market support
383,CELG,future nasdaq index dow jone industrial average be mixed wednesday morning big techs continue slide come slew top rate techs include google parent alphabet googl microsoft msft netflix nflx undercut day move average tuesday join recent laggard apple aapl major average nasdaq composite fall index dow industrial tuesday heavy selling lead stock major average trigger shift market direction uptrend pressure market come pressure earlier month apple other big techs sell june most lead techs apple be notable exception find support day line tuesday alphabet fall level first time april microsoft close day first time month big cap nasdaq hadn finished support zone early december facebook fb announce now have more monthly user do manage hold day line so do amazon amzn final member fang facebook amazon netflix google parent alphabet ibd leaderboard stock future dow industrial rise fair value future climb nasdaq future fall big techs continue lag apple facebook netflix alphabet be fractionally lower amazon edge ibd take don try predict market be go listen market pay attention major average lead stock read big picture day timely time test analysis brief sojourn day line be not always fatal sheer number highly rate stock apply optoelectronic aaoi coherent cohr lam research lrcx have cut level be worrisome more half ibd fall more tuesday true market leader tend fall twice much major average correction still isn gloom jpmorgan chase jpm advanced move buy point fed chief janet yellen say tuesday doesn expect huge financial crisis lifetime good sign go bank second round stress test due wednesday evening fed be expect approve dividend buyback many big bank meanwhile biotech stock pull back tuesday have largely hold recent big gain celgene celg fall be comfortably buy range current environment investor be very cautious make new purchase be ready take partial full profit follow action major average lead stock even ignore broader market broader market win ignore market continue stock trip sell signal own japan nikkei fall wednesday china shanghai composite retreat hong kong hang seng lose ftse be unchanged intraday germany dax slide france cac lose related apple chip lead stock be tech leader issue sell big picture uptrend far lead stock fall here number checkf chief yellen bullish bank ahead stress test alphabet stock break key support eu record fine
384,CELG,stock market be trading record high doesn mean too late get exposure big name amazon com amzn apple aapl celgene celg major index etfs be be still buy range recent buy point
385,CELG,guggenheim equal weight rsp first clear flat base buy point june continue trade entry now form break basis past month gain fund track equal weight index have underperform benchmark year date past year return vs year june accord morningstar inc year average vs slightly outpaced past year top sector weighting include consumer cyclical financial service industrial health care technology top hold whole food market wfm soar june amazon announce buy natural food grocery chain biotech celgene surge last week be top name expense ratio be schwab broad market schb climb past entry flat base have stay buy range fund track dow jone broad stock market index have attract december launch schb have return year june average annual past year average annual past year vs respective period expense ratio be technology nearly account biggest sector weighting follow financial service health care consumer cyclical industrial big cap techs apple microsoft msft amazon facebook fb be top holding friday etf pick remain firmly buy range vaneck vector mortgage reit income mort flat base entry ishare mortgage real estate rem flat base buy point related beat market twice lead sector playswhich foreign stock play own top beer maker big dividend play buy point own microsoft
386,CELG,celgene celg amgen amgn biogen biib supernus pharmaceutical supn biotech stock have long history launch huge price run biogen have struggle recently spinoff ipo bioverativ bivv be get ready launch move own bioverativ develop therapy treat hemophilia other blood disorder
387,CELG,name abbvie abbv celgene celg tear past week many biotech sector etfs hit week longer high friday take breather retain bulk big weekly gain most biotech fund be extend buy point several be still have pull back respective buy zone instance ishare nasdaq biotechnology ibb rise much entry ease friday be top buy range fund have rally year june accord morningstar inc well slight week decline ytd return same period bioshare biotechnology clinical trial bbc ytd be buy range cup base entry fund be thinly trade average daily volume share vaneck vector biotech bbh nearly year be waffle top buy zone entry year old fund have attract asset analyst attribute rally subside drug price concern be further growth ahead cfra be positive fundamentally biotech industry see strong revenue growth aid robust pipeline todd rosenbluth director etf mutual fund research cfra tell ibd email have buy recommendation abbv amgen amgn biogen biib biomarin pharmaceutical bmrn celg gilead science gild stock fall big cap category market cap north be more favorable larger cap biotechs such think ibb offer best exposure stock say other etfs offer more stock diversification smaller cap exposure provide potential reward also additional risk leverage etfs try magnify return double triple benchmark index day post double digit gain week end june instance direxion daily biotech bull labu seek investment result triple performance biotechnology select industry index lead return bring year date haul proshare ultrapro nasdaq biotechnology ubio aim time nasdaq biotechnology index daily performance rally week ytd return proshare ultra nasdaq biotechnology bib score gain ytd return be well extend such leverage play make big gain go be good tend carry higher risk most traditional biotech sector fund other end spectrum be inverse etfs be design give opposite performance index track fund provide result similar shorting stock index show accompany chart have see loss biotechs have rally likely outperform sector head south don have view leverage inverse etfs other investor easily get hurt hold too long rosenbluth say risk be compound much faster investor appreciate related biotech stock keep new lead top biotech stock remain just buy range
388,CELG,relatively quiet week market be anything quiet ibd stock ibd index be week friday morning easily outpace general market boost handful breakout rash new high group end week only few chart show valid basis
389,CELG,key index fund be modestly higher thursday biotechs help regeneron pharmaceutical regn lead upside oil gold bank homebuilder lag xsmall cap outperformed ishare russell iwm powershare qqq qqq add spdr spy spdr dow jone industrial average dium be slightly higher remain buy range respective flat base entry financial homebuilder semiconductor be lower spdr regional banking kre spdr banking kbe fall breach day move average line continue shape flat basis ishare home construction itb slip remain multiyear high spdr homebuilder xhb be back flat base buy point vaneck vector semiconductor smh ishare phlx semiconductor soxx be slightly hold day line biotechs extend gain ishare nasdaq biotechnology ibb rise nearly spdr biotech xbi add etfs be extend recent flat base buy point regeneron pharmaceutical gain celgene celg advanced gold play advanced gold future gain ounce vaneck vector junior gold miner gdxj vaneck vector gold miner gdx be respectively spdr gold trust gld ishare gold trust iau climb apiece oil fund be mixed spdr oil gas exploration production xop pare gain vaneck vector oil service oih be flat powershare db oil dbo unite state oil uso lift stem recent slide be trading more week high related find happen stock market today celgene regeneron breakout biotech stock be next top biotech stock just buy range boom continue
390,CELG,chinese internet top rate medical play show strength dull show major index late afternoon trading monday meanwhile nasdaq composite gain more upside final half hour trading rise apple aapl look poise post sixth straight session north side day move average action apple be critical not only stock greater market give apple heft iphone ipad giant have market cap recent action represent opportunity buy share stock stage second follow entry point breaking bottom base pattern jan first follow entry come late march apple surpass week tight pattern justify addition small number share already profitable core position stock entry come add cent handle high cup handle base form oct jan year jan apple have gain much trigger key ibd rule sell least partial position share gain hit apple featured ibd stock market today column last week retook day line gain help nasdaq composite edge more higher nasdaq rise tack new time high be fractionally be try avoid third straight decline give trifling time frame dow jone industrial slip less hurt loss point more least component include home depot hd fall further day move average sell signal recent new holder johnson johnson jnj hold day line cup handle buy point goldman sachs gs build new potential saucer pattern still significantly october past russell eke small gain nearly volume be run touch lower nasdaq sharply slower nyse vs same time prior session chinese consumer commerce play continue surge even hong kong mainland china equity market be close holiday baidu bidu past buy point be gain more momentum stock rally nearly volume be run more higher normal read more chinese search engine chart action other market leader ibd new high feature permissible buy zone baidu go past handle entry baozun bzun have emerge runaway small cap winner monday share gap more fast turnover be now more clear long cup handle base notice daily chart stock see volume zoom day average day time volume trade average share day baozun expertise lie help multinational brand such nike nke succeed marketing campaign china earning jump cent share jump sale ibd take baozun be featured earlier year new america new america index see market index table page latest ibd weekly print edition be jan pummeling major index see other company have qualify proprietary ibd screen hot growth company celgene celg abiom abmd bioverativ bivv be also act well abiom heart pump innovator be close breaking narrow flat base pattern stock ibd be tie medical sector abiom nearly be expect grow full year earning share fy end march next year fy other financial market wti crude oil future rise barrel dollar have show weakness recent week dollar be currently worth yen appear be testing buy support level last see mid june yield benchmark year treasury bond dip basis point begin year related new high analysis biotech play be extend new buy point emerge bottom base part help savvy investor make moneythe bottom base part ii apple form
391,CELG,here investing action plan thursday need know investor come day economic indicator xexpect few economic report worth watch include adp private sector employment figure challenger job cut report precede june job report labor department due friday look ism index
392,CELG,wall street be concern delay food drug administration amag pharmaceutical amag generic competition drug meant prevent preterm birth company stock overcome deficit close monday fda say monday take month review amag quick shot version drug makena makena be already approve intramuscular injection prevent premature birth pregnant woman ve already deliver preterm baby previously fda have say review auto injector version makena month give amag nearly month switch patient new iteration now generic competition be set gouge amag company earlier guide sale makena leerink analyst joseph schwartz now model year year decrease sale makena today announcement month regulatory review put makena franchise risk lose market share schwartz write note client keep market perform rating amag stock amag be grant orphan drug exclusivity first generation makena exclusivity expire feb meanwhile fda review newest makena put approval date feb midday trading stock market today amag stock fall much pare loss finished day unchanged share have trade well day move average early ibd take amag pharma stock have ibd composite rating meaning underperform quarters stock term key growth metric trail celgene celg stock be rank first biotech group best possible cr head ibd stock checkup most actionable player janney analyst ken note amag previously switch patient preservative free version makena month period sufficient time switch patient possible amag have cut expectation needham analyst serge belanger note development auto injector have be anything early january amag have discontinue trial show patient experience more pain auto injector vs current version february new version makena miss key chemical goal require fda related amag pharma pre eclampsia drug potential stock day run
393,CELG,be salad day biotech sector number industry leader be hit new high group whole be top game term stock performance xstock inflow hit last week have be number clinical trial success new industry friendly food drug administration regime be place result investor business daily company biotech industry group have claw way group track ibd sixth just last week share look likely close month high stock market today slew earning next week just everything be go right biotech lately have be go right brad loncar chief executive loncar investment tell ibd friday onslaught biotech earning next week really give investor fodder say thing miss say loncar merger acquisition last piece fit puzzle then biotech sector really be cook gas say gilead science gild be likely linchpin loncar call gilead poster child large biotech need do deal gilead multibillion dollar hepatitis drug franchise topple first time now gilead say interested deal cancer space analyst have key vertex pharmaceutical vrtx smart acquisition loncar see gilead more likely buy early cancer asset something develop commercialize rather putt money work buy develop revenue stream vertex be already hugely successful biotech own right say earlier year vertex deliver best news year space point have exceptional result phase trial look triple pill treat cystic fibrosis stock gap nearly wednesday ibd take rare disease cancer play have be front center biotech sector late cut edge firm keep rally go head industry snapshot deeper dive multibillion dollar stock loncar say company vertex go something everybody stock market notice gilead be set report second quarter earning wednesday be sandwich slew strong contender biotech space include celgene celg amgen amgn biogen biib alexion pharmaceutical alxn biotech celgene be slate report second quarter earning open thursday stock have ibd composite rating lead peer be sit high last see july leerink analyst geoffrey porge say celgene alexion be bellwether group time same way dow johnson johnson jnj be often see proxy pharmaceutical group call celgene beat raise alexion rise top low view alexion be slate thursday tuesday amgen overtake month high jump record high second quarter earning report prove strong share break cup handle july buy point still remain buy zone trio help catapult sector analyst say meanwhile pharma side investor key astrazeneca azn early thursday recent week rumor have emerge chief executive pascal soriot jump ship teva pharmaceutical teva loncar note timing rumor be bad astrazeneca astrazeneca be set day now report result immuno oncology combination trial lung cancer lung cancer treatment be huge commercial opportunity astrazeneca be take player merck mrk bristol myer squibb bmy regardless rumor controversy do think not overstatement say pascal soriot job be line trial be make break astrazeneca say study be most important thing astrazeneca last year biotech stock be year still room run cfra research analyst jeffrey loo tell investor business daily valuation hit historic lows presidential election be still overall health care sector relative historical valuation biotech sector be still attractively price say late june sector get massive push president donald trump release draft proposal drug pricing initiative didn include much really tug drug price loo say didn credit entire gain proposal certainly help loo say clinical trial term fda approval strong launch trend have also help prod sector year include cystic fibrosis news vertex gene therapy novartis nvs duchenne muscular dystrophy drug sarepta therapeutic srpt latter development loncar say sarepta second quarter sale beat exondys bode well broader sector sarepta also raise guidance year most analyst have call conservative everybody be watch sign drug launch be go payor be push back thing say fact launch exondys be go well be good sign not just sarepta biotech company related biotechs find strength number treat multiple sclerosistoo late catch biotech rally trump fear subside biotech rally get second wind small cap near break outwhy biotech rally still tack upside
394,CELG,xu stock index score weekly gain big name biotechs biogen biib celgene celg pop roughly week nasdaq advanced friday add blue chip dow jone industrial average be flat volume be run lower most session close russell reconstitution
395,CELG,apple aapl continue prove rally bottom base october last year january not be yet biotechs select chip stock help sustain rebound stock wednesday nasdaq composite rally more et outperform gain dow jone industrial average small cap be do even better smallcap gain turnover be run mildly lower vs same time tuesday main exchange note latest big picture column ibd downgrade outlook market uptrend pressure due sell nasdaq higher volume tuesday know distribution flurry big distribution day be enough halt bull market advance even turn bear market lower turnover less hour remain stock market today volume have be average past trading session nasdaq banking stock meanwhile resume advance follow comment federal reserve chief janet yellen appear indicate hike short term interest rate be card rest year yield year treasury benchmark bond edge highest wti crude oil future add more barrel silver future rise gold edge fractionally higher nearly troy ounce comex apple nearly be still hold large portion gain jan excellent cup handle base furnished buy point cent handle high apple then gain much space just month further rebound iphone giant produce new buy point share be hop back day move average currently watch see stock retake line street see apple sale rebound current fiscal year end september follow rare slide fy profit be expect climb share apple hold annualize dividend yield ibd take apple be get boost top line recent quarters due strong demand service observer question apple need make acquisition fuel continue revenue gain area business fulfill goal double business read ibd latest tech team coverage increasingly vital part apple business model see ibd stock checkup apple relative price strength rating continue be positive meaning now beating publicly trade company term month relative price performance meanwhile biotech industry group be show not intend backtrack leadership position stock market today large industry group biggest name celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx be behave well be trading respective day move average sign strength celgene more be wipe away loss prior session break cup base buy point last week chase zone go celgene sport highest possible composite rating earning share rating accumulation distribution mean past week stock have show evidence heavy share accumulation mutual fund bank insurer pension regeneron vertex be extend now provide follow buy point future watch mild pullback day week move average make sure ibd current outlook be show confirm uptrend uptrend pressure signify odd make money be higher vertex more be now extend more past recent past entry long deep first stage base similar bottom base pattern base vertex crumble create massive shakeout chip sector broadcom avgo nvidia nvda be also show leadership quality gain former be also find continue support day line recent flat base nvidia composite ep be extend have yet challenge holder test day move average have be climb sharply more week street see fiscal second quarter earning jump cent share be very impressive light fact nvidia score increase adjust ep year quarter accord research william neil co related buy sell latest investor cornerwhen do current market outlook go uptrend pressure see big top growth stock be perform ibd invest new ipos avoid initial trap
396,CELG,stock buy range swiss drugmaker novartis nvs dow industrial component johnson johnson jnj report better expect second quarter earning early tuesday xnovartis earn share exclude various item year earlier sale fall grow generic competition cancer drug gleevec number be better analyst forecast earning share revenue exclude gleevev gilvec sale cancer drug rise exclude impact foreign exchange rate bone marrow stimulant promacta revolade pull sale advanced melanoma advanced lung cancer combination tafinlar mekinist grow consentyx be driver grow exclude impact foreign exchange rate novartis say news release drug be approve treat plaque psoriasis psoriatic arthritis inflammation spine joint broaden competition multiple sclerosis treatment include like biogen biib roche rhhby sanofi sny novartis ms drug gilenya bring exclude impact foreign exchange rate celgene celg be now work drug directly rival gilenya novartis alcon eye care unit report small sale increase novartis raise full year alcon sale target slightly hint possible spinoff division sale contact lense grow fifth consecutive quarter evercore analyst umer raffat note report stock market today novartis end day novartis clear cup handle buy point last month chase zone run johnson johnson meanwhile clear flat base entry early june stock rise finish tuesday regular session company report adjust earning share vs year earlier beating analyst view cent revenue be slightly year earlier just miss view ibd take small biotechs perform well past few week biotech rally see sector hit month high june head ibd technology page look look strong pop worldwide pharma sale decline fraction vs year period miss third straight quarter rbc analyst glenn novarro tell client note drug sale dip growth sale outside help partially offset decline meanwhile consumer medical device segment grow respectively pharma sale miss novarro estimate revenue consumer medical device unit be line expectation see full year earning share revenue analyst see earning share revenue novarro say guidance be likely take advantage favorable foreign exchange rate second half year related novartis fda cancer also be boon rivalsnovartis grab key fda panel approval experimental cancer drugnovartis face key fda panel cancer drug kite be set record high strong earning raise full year targetbank america goldman sachs earning top trading weak
397,CELG,xshare biotech celgene celg break wednesday executive patrick flanigan characterize celgene identity momentum inflection barclay global healthcare conference miami momentum business have be build last year be continue year key driver say flanigan celgene corporate vice president investor relation flanigan note strength celgene revlimid otezla drug revlimid be fda approve chemotherapy several cancer type include multiple myeloma bring nearly sale accounting total product sale otezla be approve treat plaque psoriasis psoriatic arthritis worldwide sale grow total sale reach grow more third vs prior year ibd take ibd predict celgene stock last week head ibd stock analysis take sign celgene expect hit target match exceed view sale adjust earning share next year be inflection point celgene flanigan tell conference attendee investor lap celgene stock aftermath share rise high stock market today breaking month flat base buy point stock end day level related pfizer take celgene other rival leukemia drug
398,CELG,major index mainly tread water late tuesday relatively quiet session dow jone industrial average however be show bullish action maintain strength day move average dow jone industrial enjoy strong gain like industrial giant caterpillar cat unite technology utx edge day narrow range trading contrast monday stock blue chip index fall intraday low bounce higher challenge support key day move average dow show earlier test strength intermediate term support line march cat try fail tuesday climb back day move average lead stock tend travel day line preparation potential good news cat shareholder be stock be trading less week high unite tech meanwhile have make limit upside progress stock rally past cup handle entry point late november early december nasdaq composite be practically flat however lose stock be outpace winning issue nearly margin nasdaq nyse winner loser be roughly evenly match russell lose volume be run mildly lower vs same time monday main exchange medical sector remain laggard here be stock consider watchlist pra health prah be rank ibd stock edge lower be show gain bust stubborn resistance raleigh clinical trial firm have grow earning share vs year level past quarters due part tough year year comparison wall street see earning just cent share pra hold good composite rating scale ibd stock checkup celgene celg have be trading quietly lately top perform biotech be still nominally feb past cup handle entry celgene be trading firmly day move average have be rise more week relative price strength rating be not superb meaningful improvement low week rs rating mean large cap biotech specialize treatment cancer immunological disorder be now outperform stock ibd database past month other notable leader ibd biotech group be incyte incy small cap epilepsy adhd specialist supernus pharmaceutical supn be sharply year so far fourth member biotech group be vertex pharmaceutical vrtx rise heavy trading day zoom massive trading positive clinical trial datum regard pill treatment cystic fibrosis colo base heska hska thinly trade expert veterinary product continue soar clear buy point huge volume nov keep mind heska trade just share day elsewhere stock market today interactivecorp iac roar day line rise more heavy volume search engine operator have find nice support day month stock clear buy point long bottom base pattern october last year feb interactivecorp stage profit turnaround fourth quarter earning rise share crush consensus analyst estimate nearly drop sale halter quarter streak shrink profit now wall street have revise full year ep estimate higher earning see share earning related stock market today be time take profit lead techs income investor dividend leader finish big ibd leader be thrive even testing week move average
399,CELG,many part president trump federal government have yet take shape leaner meaner food drug administration seem almost certain way agency watcher see trump blueprint nation pharmaceutical gatekeeper point funding cut budget outline also suggest user fee charge industry process approval much double yet trump also want speedier fda push more generic drug boost competition have deride astronomical outrageous drug price call competitive fair drug approval process drugmaker analyst say re re just not sure leaner fda accomplish support fda get more funding so approve generic drug faster ll bring drug cost say john maraganore ceo alnylam pharmaceutical alny alnylam make expensive specialty drug treat hemophilia other rare ailment acknowledge more competition generic market help tug rise drug price competitive marketplace base way do preserve market base time limit award really need innovation maraganore tell investor business daily irina koffler analyst mizuho agree fda now face drug backlog generic application tell ibd make dent backlog agency need more funding more staff legislation clear thicket law legal decision slow drug approval koffler say generic submission be sit languish be not enough competition koffler say situation ll have supply monopoly company be only manufacturing certain generic drug therefore charge lot biotech drug stock be touchy come trump march tweet president promising more drug competition send ibd company generic drug industry group generic drug company actually favor more competition say chip davis chief executive association accessible medicine advocate maker generic drug maker generic be know biosimilar drug experience constant price deflation say backlog generic application mean drug provide new revenue stream stay stick hold await fda review action only way time company be financially successful be be able get approval new generic help offset continue deflation see year year current mature portfolio tell ibd fully recognize more competition create downward pressure pricing prescription drug price rise re project jump year active employee early retiree american workforce accord advisory firm segal consult retiree age older price be expect rise slowdown likely take congressional push speed fda approval most recent iteration american health care act gop bill seek replace obamacare didn touch pharmaceutical trump pledge march kentucky rally work legislation bring pricing ibd take swearing trump have continue call drugmaker lower price do biotech drug stock read ibd industry theme trump budget blueprint hint package administrative action design achieve regulatory efficiency speed development safe effective medical product trump be same page alnylam maraganore imagine system fda incentive approve generic quickly congress enact legislation fda be incentivize approve second third manufacturer generic drug faster maraganore say imagine help speed lower drug price fda have prioritize second third drug approval other generic drug action trump not do be reduce drug testing safety effectiveness mizuho koffler say recall thalidomide crisis thalidomide be first market germany counter medication nausea pregnant woman ensue year child worldwide be born phocomelium malformed limb half survive be turn point drug approval process koffler say thalidomide wasn well test be sell vulnerable population pregnant woman result unexpected side effect newborn fda strengthen drug review process drug re take have assume terrible thing happen child take pregnant woman take person have bad kidney bad heart take say so have test drug more realistic representative population patient trump pick fda commissioner dr scott gottlieb have talk overhaul fda process generic complex drug have allow brand drug create monopoly perpetuity generic complex drug have more complex active ingredient formulation route delivery drug device combination typical generic gottlieb be industry insider formerly hold position fda center medicare medicaid service nomination have draw support aisle trump gottlieb support more competition generic market cut brand monopoly march article forbe gottlieb note older generic drug be sell cheaply be sometimes very costly prime example be turing pharmaceutical purchase decade old hiv medicine company spiked price pill overnight be often result failure way fda be regulate generic medicine say agency long costly approach regulate generic drug be reduce competition generic market increase cost manufacturing generic medicine maraganore identify more brand side aisle draw distinction generic groundbreaking treatment fda approve brand drug rare disease biogen biib spinraza spinal muscular atrophy even new treatment come now actually cure cancer drug receive patent protection number year generic make copy period maraganore call market base time limit award need innovation generic market be be greatest amount competition say address challenge system drug price drug approval process need be careful reform look good sound good be fact good preserve innovation engine have country january trump tell exec celgene celg eli lilly lly johnson johnson jnj novartis nvs merck mrk cut regulation fda approval process accord regulatory affair professional society trump pledge streamline process so standpoint actually have drug actually get approve instead wait many many year mizuho koffler note least law be revise drug price competition patent term restoration act stay generic drug application month allow patent holder time litigate generic filer protect patent month clock be place regardless dire need be drug legislate stay away mandatory month help expedite litigation process brand generic company create lot more competition say davis generic drug maker advocacy group argue congress tackle decade old law require maker fda take additional safety measure drug have risky side effect not properly administer brand company be take advantage risk evaluation mitigation strategy law prevent generic purchasing sample drug say davis contend company have used risk evaluation program create limit distribution program doesn allow generic company legally purchase sample drug need do clinical testing so submit application fda compete originator product say need be legislation make sure risk evaluation only be used intend purpose not delay competition generic biosimilar go forward say bill house now just study matter reality be everyone have know year be problem trump budget blueprint offer clearest view yet want run fda doesn clear away smoke trump argue industry benefit fda approval pay share constrain budget environment proposal doesn detail specific budget figure fda fda budget grow year fda have ask increase industry be brace potential cut agency funding indicated propose jump user fee law fda collect fee drugmaker brand generic biosimilar fund drug approval process trump blueprint propose boost fee agree user fee industry fda isn publicly available say davis so difficult know mesh trump blueprint deal be form month month dialogue generic biosimilar come away satisfied say trump blueprint likely include brand generic biosimilar be set pay fee year unclear trump plan include other type user fee fda user fee amount alliance stronger fda coalition consumer patient group health professional trade association call trump user fee jump neither wise realistic march statement not wise fda core responsibility safe effective medical product safe food need be support large measure public be primary beneficiary group say not realistic drug device industry have recently complete user fee agreement negotiation fda
400,CELG,vertex pharma vrtx see ibd smartselect composite rating jump thursday day revise score mean stock currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb vertex hold spot peer medical biom biotech industry group celgene corp celg therapeutic cort cytokinetic cytk supernus pharmaceutical supn vertex soar wednesday positive result cystic fibrosis drug be add gain thursday now outside proper buy range so see stock go form new chart pattern stock have ep rating meaning recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company report ep growth top line growth come prior quarter related vertex rocket month high cystic fibrosis drug resultswhich company be now outperform stock
401,CELG,stock finished mixed topsy turvy session monday also spur least key question key sector medical health care stock thrive again do have paul ryan president trump congress thank be strangest session equity market so far year
402,CELG,celgene celg bluebird bio blue stock sustain downgrade friday rival kite pharma kite juno therapeutic juno look likely chip away lead immuno oncology drug duo be year ahead drug call bb part class treatment aim reprogram immune system fight cancer used be know car therapy drug do target antigen call bcma landscape bcma car drug be evolve btig analyst dane leone write note client leone downgrade celgene bluebird stock neutral buy think bluebird have good lead competition be smart quick start second generation effort bb begin phase study second half say say competitive effort be ramp kite be begin bcma car therapy human third quarter juno begin work february bone marrow cancer drug dow component johnson johnson jnj genmab start bcma effort update be expect soon novartis nvs related company be outperform stock relative visit ibd datum story formula correctly identify stock leader bluebird case leone be more optimistic most drug call lentiglobin treat blood disorder expect drug generate combine disorder still oncology shift be divisive investor competitiveness cell base therapy oncology be much more intense area rare disease say early success bb be supportive broader effort larger market better defined patient population celgene leone cut expectation crohn disease drug mongersen vs earlier view consensus model also expect celgene multiple sclerosis drug know ozanimod penetrate less market cut view vs earlier expectation still top broader wall street model think take longer expect ozanimod differentiate vs rest class multiple sclerosis specifically siponimod say latter be drug novartis close bell stock market today celgene lose dip bluebird fall related cure cancer look small biotech be defy today sectorwide doldrumsbiotech hit pause day rally regeneron bluebird topple
403,CELG,breakout biotech stock celgene celg clovis oncology clvs bioverativ bivv ireland base ethical drug firm jazz pharmaceutical jazz be try return former wall street glory launch big run developer specialty drug narcolepsy oncology pain psychiatry earn upgrade relative strength rs rating friday year market history reveal best perform stock tend have rs rating least early stage move jazz pharmaceutical make big multus year move run steam february long slump stock have be climb last december be now build flat base buy point see stock break heavy trading revenue growth fall last quarter bottom line grow prior report company earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
404,CELG,imagine be tell have cancer have month live usual step be take round chemotherapy perhaps stem cell transplant be avail half patient diagnosed aggressive hodgkin lymphoma form blood cancer die month say christine cassiano spokeswoman kite pharma kite developer cancer treatment say doctor have access experimental treatment be custom tailor immune system remove vial blood send lab immune system cell be reprogram fight cancer day week later cell be reintroduce body call car therapy once sound concoction straight mary shelley novel be rapidly come fruition month follow up kite pharma novartis nvs have see strong result patient specific type blood cancer mean major payout half dollar patient treat company also go so far put cancer remission select patient kite pharma be founder most person actually feel idea car therapy used commercial set be science fiction cassiano tell investor business daily be something ceo believe firmly novartis look likely cross car finish line first ctl set go food drug administration july novartis drug gain approval pave way kite kte later year juno therapeutic juno bluebird bio blue be likely follow own car drug possibility success have send kite bluebird juno stock rocket past month bluebird stock be more june kite share jump more juno soar novartis stock be june rise prior month israeli immunologist zelig eshhar american immunologist steven rosenberg theorize harness immune system seek destroy cancer challenge cancer cell be good camouflage eshhar rosenberg head national cancer institute tumor immunology section develop first car therapy first look treat melanoma scientist have find car drug work particularly well blood cancer car be best form immuno oncology accord janney analyst debjit chattopadhyay immuno oncology drug harness immune system treat cancer create drug researcher extract immune system cell patient blood used empty virus affix be know chimeric antigen receptor immune system cell chattopadhyay tell ibd chimeric antigen receptor also know car be protein recognize protein cancer cell use hide body immune system cell be reintroduce body be direct seek destroy cell carry specific protein process be so complex individualized car drug be mass produce so be multiple step involved chattopadhyay say bigger challenge really be just put everything mixture have something come other side patient be different add challenge most patient undergo car therapy be do so last resort study patient blood cancer multiple myeloma present june bluebird car drug development partner biotech giant celgene celg patient have receive prior therapy ibd take car drugmaker help biotech sector recover several year sideway performance analyst say head industry snapshot deeper dive stock look strong harvesting enough healthy immune system cell patient be tricky chattopadhyay say lymphomas kite novartis have discover cancer mutate once happen initial protein target longer work render car therapy moot still rosenberg theorize car therapy become standard therapy cell malignancy include number blood cancer car hasn yet show promise solid tumor chattopadhyay say future be dollar question say drugmaker also be look call cell receptor technology tcr find right protein target be struggle often protein show other tissue meaning immune system attack organ novartis be lead car market chattopadhyay say drugmaker market cap have meeting fda july discuss approval ctl young adult pediatric patient cell acute lymphoblastic leukemia bone marrow cancer common child month later kite be set discuss application drug currently designate kte blood cancer know diffuse large cell lymphoma kite have first mover advantage set spokeswoman cassiano say set precedence pricing company want price drug payer want pay chattopadhyay say go be interesting time car first kind be complex make be expensive initially imagine car therapy eventually replace stem cell transplant likely be price line initial adoption likely take place transplant center lot infrastructure be already place see price tag therapy cassiano wouldn discuss pricing emphasize strong result kite see recent trial patient aggressive form hodgkin lymphoma month patient see tumor shrink complete remission response still ongoing patient really dramatic rate response look patient population say normally happen reach point diagnosis have roughly chance die month juno also be work car drug treat aggressive hodgkin lymphoma compare trial month juno jcar show overall response rate vs novartis kite drug respectively leerink analyst michael schmidt say june note jcar look very competitive novartis kite datum diffuse large cell lymphoma compare apple apple write jury be still durability response compare month think too early declare product differentiate bluebird lag novartis kite term car drug have have arguably strongest trial result janney chattopadhyay leerink schmidt say follow american society clinical oncology conference month chicago bluebird celgene say drug now know bb testing result overall response rate patient multiple myeloma cancer form white blood cell call plasma cell accord mayo clinic patient evaluate sign cancer disappear datum bluebird celgene be most impressive early datum set have see car space date schmidt write june note client duo set high bar rival novartis kite juno be year ahead response occur fast be durable patient be still remission year follow car cell persist same time frame schmidt write only patient experience serious side effect kite novartis case cancer hasn mutate chattopadhyay say so patient relapse possible patient undergo second car treatment chinese company also work multiple myeloma car drug have similar result say bluebird celgene program look quite remarkable say something different program not be program just be disease ll have better picture end year phase study related small biotech soar celgene partner trialpuma lead massive biotech surge esperion hit month highsmall biotech pop rival novartis struggle keep pace
405,CELG,major market index open higher gain quickly fade final trading session second quarter tech heavy nasdaq composite be just fractionally higher meanwhile dow jone industrial average be respectively xamong dow industrial nike nke be big winner early trade surge nearly inking deal amazon com amzn sell shoe clothe accessory directly amazon com apparel company also report fiscal earning late thursday exceed street top bottom line forecast analyst action lead biotech celgene celg be downgrade neutral buy btig research share fall fellow leader industry include regeneron pharmaceutical regn vertex pharmaceutical vrtx regeneron fall vertex rise nearly stock be extend proper buy point company report earning micron technology mu fall beating earning sale target late thursday memory chip maker be look test day line trade buy range flat base entry have be rather choppy move lead chip stock look regain recently lose momentum stock market today apply material amat broadcom avgo be fractionally higher rise early friday stock have fall day line recent trading session be attempt reclaim action ibd be mixed thursday bloodbath coherent cohr jump list lead share pierce day line june trigger sell signal grubhub grub rise early turn flat food delivery service trigger sell rule june fail flat base entry related micron technology beat earning sale target stock risesnike deal amazon send dow stock soaringdow jone industrial average dow stock news analysis
406,CELG,even nasdaq reversal monday trading many lead stock have significantly rebound past week sector rotation have continue rout technology stock biotechs homebuilder see increase institutional interest biotech stock once again rotate back favor celgene celg be lead stock head charge big
407,CELG,key index cool tuesday volume heated vantage point daily chart action appear be more step forward step back nature nasdaq composite still premier index lead broad decline drop follow tuesday gap
408,CELG,stock advanced nasdaq composite retake support dow jone industrial average claim fresh high fed chief janet yellen help amazon amzn prime day be success target tgt show strength facebook fb hit record high snapchat parent snap snap hit new low fiber optic play jump paypal pypl payment stock break first wave bank earning include jpmorgan chase jpm citigroup lead first wave bank earning nasdaq composite rise best weekly gain retake day move average continue rise dow industrial hit record high somewhat dovish fed chief janet yellen help lift market fang stock rebound retake key level energy stock climb oil price jpmorgan chase jpm citigroup report better expect earning friday morning jpmorgan net interest margin loan growth weren strong expect well fargo wfc also top ep revenue come light share bank fall friday federal reserve chief janet yellen say inflation be only partially due short term factor signale central bank be hurry interest rate do say expect reduce fed balance sheet appreciably time meanwhile june retail sale unexpectedly fall decline be revise somewhat consumer inflation also remain tame yellen commentary economic datum push treasury yield dollar lower amazon amzn make prime day shopping festival blockbuster sale year period hour event amazon call biggest day ever company history say record number prime member shop country also score victory subscription amazon prime loyalty program cite strong echo smart speaker sale amazon share rise week retake day move average related amazon prime day sale rocket set new recordamazon be start home appliance repair service see possible step compete geek squad service best buy bby best buy share tumble monday undercut day line low recent consolidation best buy pare weekly loss finishing just day meanwhile amazon shell page hire realtor be spot amazon take page now real estate information site zillow fall wednesday day move average stock rebound close cent week related amazon mull move real estate knock top stockbest buy stock bestseller monday amazon craft geek squad rivalfacebook fb climb record high snap snap fall ipo price first time then tumble so far week meanwhile twitter twtr clear buy point heavy volume advance month high twitter be push more aggressively livestream video related facebook set new high snap new low social rival hit buy zoneapple aapl open itune app store user paypal pypl send share digital payment processor more thursday hit record high breaking past buy point paypal do not disclose term deal such revenue sharing apple apple have enabled iphone ipad user make purchase used credit card network bank debit card paypal user be able buy apps music movie tv show book well apple music subscription icloud storage loop capital analyst meanwhile say report paypal acquire square sq send stock buy zone ebay ebay spun paypal be also speculation target square square make credit card reader plug mobile phone tablet visa mastercard clear buy point friday help big bank commentary consumer lend visa report earning next week related second payment stock break time apple top payment stock be buy zone analyst say paypal buy itoil price rally week still well barrel energy information administration say crude inventory fall barrel domestic production rise barrel day barrel prior week eia also cut crude output forecast bpd opec expect demand oil next year fall bpd bpd opec supply be see climb bpd bpd opec compliance production cut deal fall lowest rate year accord international energy agency report earlier iea report warn shale drill win be enough offset drop conventional drill investment just hit lowest mark year iea say supply squeeze be horizon share optical component maker rally apply optoelectronic aaoi preannounce june quarter profit revenue earlier guidance consensus estimate apply optoelectronic shot week lumentum holding lite finisar fnsr oclaro oclr rally thursday apply optoelectronic customer include amazon amzn microsoft msft facebook fb be upgrading datum center superfast communication cloud base service china remain wild card telecom fiber optic group china market be bright spot last year telecom upgrade optical technology wireless network landline service demand have weaken analyst expect rebound late acacia communication acia preannounce weak result cite manufacturing wo acacia share fall friday related fiber stock rally apply optoelectronic preannounce big box discounter see modest increase same store sale second quarter end july cite improve traffic june target tgt have forecast low single digit decline comp have be work cut price keep pace wal mart wmt amazon amzn target now expect earning share top old range cent target share rise remain long downtrend amazon whole food deal trigger new bout selling related target pop positive same store sale earning guidancea food drug administration panel vote wednesday recommend novartis car therapy approval drug know ctl go full fda oct possible approval treat bone marrow cancer child young adult panel vote bode well other car therapy kite pharma kite juno therapeutic juno celgene celg bluebird bio blue other analyst say related novartis fda cancer also be boon rivalsdelta air line dal forecast positive third quarter unit revenue growth not have be enough wall street higher cost hurt carrier estimate miss result be see analyst hold back margin growth delta indicated worst unit cost trouble be delta also tout effort divide flight cabin different fare class different amenity say drive profit management add addition larger jet allow offer more premium service delta share fall thursday be just meanwhile unite airline ual american airline aal release solid june traffic unit revenue guidance unite report earning come week once seemingly untouchable stock ulta beauty ulta continue descent cut day line monday wake wall street journal report say major department store be discounting prestige beauty product ulta be not name discounter report perhaps fluster investor confidence beauty space ulta fall week high end cosmetic maker estee lauder el dip re-cover week end meanwhile fashion house michael kor kor drop sell rating mkm partner price target related macy hit year low ulta slice day beauty get air force say lockheed martin lmt be most cost effective way modernize age fighter platform day congress be warn program rise cost select acquisition report submit monday acquisition cost platform be see rise currently air force extend acquisition time frame year total program cost be see rise nearly lockheed terminal high altitude area defense thaad successfully intercept intermediate range ballistic missile first time so far system have perfect record test state department approve sale raytheon rtn patriot defense system nearly lockheed pac missile nato partner romania deal still need congressional approval national beverage fizz maker la croix sparkling water other beverage fall thursday close right buy point earning share gain better expect sale growth national beverage break short base july do rebound friday much larger pepsico pep report ep gain revenue climb organic revenue exclude currency swing structural change advanced pepsi be week fall day line related national beverage dife buy point strong earning sale
409,CELG,xu stock index saunter pedestrian volume thursday biotechs medical issue sprint ahead brisk trade small cap post biggest gain index meanwhile nasdaq pocket less dow jone industrial average lose less modest market rally fade final hour
410,CELG,dow component merck mrk clearly win battle trial demonstrate cancer treatment weekend american society clinical oncology meeting analyst say monday investment bank leerink note combination datum incyte incy look strong merck keytruda incyte still unapproved epacadostat be combine treat array tumor type sign cancer disappear lung cancer patient already undergo prior round therapy epacadostat be know ido inhibitor keytruda be call pd inhibitor be immuno oncology drug work block specific interaction prevent immune response merck incyte be far alone immuno oncology scene annual meeting chicago bristol myer squibb bmy roche rhhby newlink genetic nlnk celgene celg exelixis exel be also look combine drug better cancer bust efficiency bristol opdivo yervoy be combine advanced lung cancer patient year datum show combo have little incremental benefit vs opdivo monotherapy yervoy be far dead leerink analyst say opdivo be similar merck keytruda yervoy work inhibit immune reaction involve ctla protein receptor patient be more susceptible pd inhibitor due genetic cancer disappear patient regardless gene roche be also combine tecentriq attack cancer cell camouflage pd protein newlink genetic ido inhibitor result look safe consistent epacadostat leerink analyst say overall patient have response datum be still new ibd take keep track biotech industry bookmarking ibd biotech pharma industry stock news page bristol be also work emerge immuno oncological target combination trial treat multiple tumor type include rival incyte epacadostat bristol be partner incyte several ongoing trial outside immuno oncology alone company tesaro tsro be combine be call parp inhibitor pd inhibitor merck keytruda evercore analyst say vein half ovarian cancer patient respond remainder reach disease stability afternoon trading stock market today ibd company biom biotech industry group be less ethical drug stock fall nearly related tesaro crash beating astrazeneca stronger clovis astrazeneca muddy potential deal tesarodow merck beat rival bristol melanoma study
411,CELG,stock index grip slender gain midday thursday strength biotechs offset weakness chip stock celgene celg be lead big cap biotechs add gain recent nasdaq composite dow jone industrial average rise et small cap russell add just volume stock market midday be run higher nyse lower nasdaq biotech industry group be track fifth consecutive daily gain action group be bullish regeneron pharmaceutical regn push higher stock be now buy point celgene head ninth gain session stock add almost midday thursday clear buy point wednesday buy zone be capped bioverativ bivv february initial public offer new member leaderboard slow gain breaking monday stock remain buy zone buy point bioverativ regeneron celgene have ep rating respectively mean be grow earning faster entire ibd database publicly trade company biotechs hustle higher past few day be still post annual loss investing company be lose money be not prudent action point conviction group go thursday market biotech group be group week biotechs be meanwhile chip designer chipmaker chip equipment maker group be moderately oil stock be rebound west texas intermediate crude oil pop price crude oil recently touch month lows blue chip be evenly split day day dow jone industrial average component wal mart store wmt drop unitedhealth unh rise ahead news senate be set unveil new plan reform affordable care act ibd proxy lead stock medical software provider medidata solution mdso lead thrust president trump be work executive order ease regulation drugmaker new york time report tuesday related morgan stanley say trump tax plan be delayedapple face delay smartphone update
412,CELG,key index fund be mixed midday wednesday health care mainland china equity etfs outperformed powershare qqq qqq rise nasdaq hold gain thank surge biotechs ishare russell iwm spdr etf trust spy reversed respective loss spdr dow jone industrial average dium be intel intc downgrade weigh blue chip several china etfs rally msci decide late tuesday include chinese share company list shanghai shenzhen exchange emerge market benchmark index ishare msci emerge market eem track index advanced ishare core msci emerge market iemg also climb kraneshare bosera msci china kba gap rise continue shape flat base entry deutsche tracker harvest csi china share ashr vaneck vector chinaamc csi pek gain more morgan stanley china share fund caf fall health care fund show strength ishare nasdaq biotechnology ibb surge more month high buy range flat base entry clear intraday tuesday top hold celgene celg soar amgen amgn add biogen biib leap nearly spdr biotech xbi rally be now buy range flat base entry health care select sector spdr xlv add trading top buy zone flat base entry climb prior cup handle pattern start flat base vaneck vector junior gold miner gdxj vaneck vector gold miner gdx be be least week high oil play be mixed vaneck vector oil service oih slide nearly well spdr oil gas exploration production xop etfs be trading week lows west texas intermediate crude price fall barrel related find go stock market today msci give green light china share fourth try
413,CELG,nasdaq composite wednesday deflect yet pound crude oil future related company stock market move moderately higher dow jone industrial average harbore light loss late wall street regular session nasdaq composite new york time be stretch year date lead fractionally wednesday dow jone industrial show distribution day past session volume wednesday be run higher nyse vs same time tuesday lower nasdaq ibd big picture column track heavy institutional selling form distribution day witness nasdaq tuesday higher volume monday sudden rash big decline heavier volume prior session be enough bull market nasdaq be nearly jan towering advance dow jone industrial average be also lag gain so far year buy biotech software sector continue unabated aftermath solid quarterly result like adobe system adbe extend january red hat rht also extend early entry long choppy first stage base biotech group jump ibd industry group term month relative price performance celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx pump more higher heavy turnover show kind action see iphone giant apple aapl big run mid early part celgene have market value regeneron be vertex vs iphone ipad macbook maker stock break tend already be close week time high already be trading day move average show tremendous increase share volume show strong finish session price definitely case biomedical name mentioned be highly profitable developer novel therapy address difficult disease chronic condition celgene run higher power past cup base buy point volume be currently triple usual level stock day average volume be share cup be see part long saucer base go way back july peak notice weekly chart celgene have break month saucer pattern july do hairpin curve lower undercut low base such action be healthy shakeout uncommitted investor reset base count back street see first quarter profit summit firm rise share celgene have post ep increase prior quarters celgene sport outstanding composite rating ep rating ibd stock checkup watch see relative price strength score improve term regeneron composite rating ep rating be extend first stage bottom base entry share have soar more so far week however notice weekly chart stock run upside resistance price level vertex composite ep surge fast turnover be move further past recent handle long base give solid entry cent intraday high handle stock slope lower intraday lows correct more back apple megacap tech be show still have wherewithal recover sharp sell prior week trigger key sell signal read stock market today column learn more exact sell rule apple gain volume be light stock be limit drop day move average apple relative price strength rating remain strong now much better lowly see start year however keep mind rs rating cover month worth price action vs rest market extra weight be give most recent month worth action be plenty reason long term holder thick profit cushion keep hold apple be still well long term day move average earning picture be improve fy profit see fy profit revenue growth apple service unit be currently solid double digit pace likelihood major iphone replacement cycle begin fourth quarter current calendar year be very high ibd take way track emerge industry sector rotation market be watch change ibd right now still chock full electronic internet computer networking related stock medical biotechs stage larger presence go here day watch new leader unfold present wonderful new opportunity investing profit ibd tech leader nvidia nvda coherent cohr apply optoelectronic aaoi have re-cover nicely price spill prior week remain solid uptrend related investor corner bottom base make money astute tradersinvestor corner ii apple form bottom base be market head correction soon check big simple way detect key stock market best brightest large cap land today big cap
414,CELG,nasdaq continue hold leadership baton afternoon trading wednesday help solid show biotech stock well couple strong earning report high profile software name biotechs celgene celg soar past buy point rise more gain past session daily chart have straight bottom look make celgene latest base bit lopsided nasdaq add dow jone industrial average show modest loss volume exchange be tracking close tuesday level west texas intermediate crude oil july lose nearly barrel government datum show second straight weekly decline crude inventory rise domestic production wall street cheer earning report well run software name have transition successfully cloud red hat rht soar report rise quarterly profit increase sale extend price point meaning too late buy share adobe system adbe jump adjust earning rise share sale grow software name work cloud base model be oracle orcl report today close share rise ahead result work flat base buy point elsewhere rv maker winnebago industry wgo break downtrend conviction rise report better expect earning fourth straight quarter accelerate sale growth aggressive investor get early entry winnebago wednesday even stock be still high carmax kmx operate used car superstore reversed spectacular fashion share edge higher rise intraday head report carmax be work cup handle base buy point be flaw pattern recent uncertain action day move average handle area always form comfortably day line economic news exist home sale come slightly better expect homebuilder didn move much news ishare home construction itb exchange trade fund be mostly unchanged etf be get support day move average january buy point related carmax beat estimate drop price hit gm fordboee adobe red hat price target hike chevron stock watch pharma industry news
415,CELG,new high featured former leader wednesday enough time have pass put fresh glow stock biotech stock celgene celg break awkward look consolidation wednesday heavy volume peg new high stock pop buy point be celgene last offer profitable easy hold
416,CELG,biotechs software lead solid nasdaq advance dow jone industrial average index hit record high boee ba announce slew paris air show order oil price keep fall fed clear big bank annual stress test china crack weibo wb amazon amzn spook more retailer nasdaq rise week biotechs other medical soar ease fear price control also reaction senate gop health bill celgene celg be biotech breakout regeneron pharmaceutical regn soar buy range desktop software also be big winner oracle orcl breaking earning amazon fear intensified apparel sporting good story dow industrial index hit record high monday pare gain weakness oil retail stock dow finished fractionally higher rise biotech stock surge week concern president trump tamp drug price begin subside big winner rally include regeneron pharmaceutical regn celgene celg pop nearly respectively clovis oncology clvs spiked strong trial datum suggest much wider use ovarian cancer drug analyst call growth stock gain most see rally continue traditional drug giant also fared well novartis nvs breaking buy point merck mrk near entry boee ba beat airbus eadsy commercial jet order paris air show event typically win european aerospace giant boee say have incremental order commitment airplane value list price analyst say staggering boee order show weren firm airbus say book firm order plane value memorandum understand aircraft value analyst weren expect many deal paris order be double see last year show farnborough england boee share rise week hit new high airbus set record high monday pare weekly gain related boee paris air show order be staggering hybrid design new boee midrange jet hit sweet spotwhy lockheed move production india texasoracle orcl earning easily top view revenue advanced software giant overall cloud revenue shot vs year earlier oracle have be latecomer demand cloud software shift transition be full force now share surge breaking record high meanwhile other software database leader soar record high stronger expect earning adobe system adbe raise guidance report ep gain fiscal red hat rht ep climb fiscal revenue rise open source linux software provider also give bullish current quarter guidance adobe rise red hat climb crude oil price fall month lows week continue oversupply concern weekly crude stockpile fall barrel energy information administration say double be expect domestic crude production nudge barrel day meanwhile libyan oil production rise sharply dispute end german oil company export nigeria be expect hit bpd august vs bpd july accord reuter saudi arabia deputy crown prince moham bin salman be appoint heir kingdom throne be widely expect continue current oil policy be major force riyadh saudi vision reform initiative aim curb country reliance crude related oil reverse sharply lower supply fearsjpmorgan jpm bank america bac nation biggest global bank have enough capital continue lend economic meltdown first round federal reserve annual stress result show none bank test have key capital level minimum set fed bank stock generally edge lower friday wall street attention turn result second portion exam come wednesday portion determine bank give buyback dividend ultimately firm pass fail test quantitative qualitative ground jpmorgan bofa goldman citi well fargo pass fed stress testchina order weibo wb other online platform shut audiovisual stream presumably user content violate country political standard weibo tumble thursday majority owner sina corp sina lose alibaba baba own big minority stake twitter twtr weibo edge lower momo momo yy yy social medium firm lot stream video sell initially momo close yy pare loss sina momo yy be ibd stock related weibo crackdown spur selling not panic china internetsamazon strike fear more retail group slam many apparel sporting good chain commerce giant announce amazon prime wardrobe home try system let user have more item ship free try home then be charge keep hit macy jwn tjx tjx more meanwhile bloomberg source say nike nke sell footwear directly amazon brand registry program send share already reel dick sporting good dks foot locker fl other sharply lower finish line finl rebound friday mixed quarterly result meanwhile whole food market wfm push little further share takeover price amazon lead wonder bidder be ready emerge even bigger offer barclay say not be surprised be be bidding war jpmorgan analyst have peg wal mart wmt possible contender reuter report late friday wal mart be not plan whole food bid whole food close week hit friday afternoon related here latest group have amazon induced anxiety attackprime wardrobe be amazon kill macy fashion game uber technology founder travis kalanick resign chief executive officer follow shareholder revolt ride hail company have be expose have workplace culture include sexual harassment discrimination uber also have be lose market share lyft twitter twtr stock rise bullish research report say struggle company have improve video strategy execution report come same day twitter announce way person earn money stream live periscope video service snapchat operator snap snap be increase pressure instagram story feature facebook fb have grow user vs snapchat snap be trading close ipo price advanced micro device amd surge nearly week launch latest server processor datum center amd new epyc server chip compete processor industry leader intel intc join amd launch event austin texas be customer partner back epyc include microsoft msft azure baidu bidu dell technology dvmt hewlett packard enterprise hpe intel share fall low share fedex fdx rise week hit record high move buy range package delivery giant easily top expectation fiscal fourth quarter tuesday shake ep miss last quarters earning climb jump revenue investment modernize aircraft fleet expand ground operation paid fedex guide full year profit high rival up announce monday charge retailer extra fee holiday delivery fedex say consider shipping giant be challenged key customer amazon amzn expand own delivery service related fedex easily top earning revenue forecast guide profit highstrong suv truck sale help drive board beat wednesday used car superstore carmax kmx first quarter ep climb almost year year rise revenue total unit sale used vehicle jump even large medium suvs truck accounting bigger share mix average used vehicle price fall vs year earlier accelerate drop prior quarter flood lease car be hit pricing reason new car sale be slumping carmax rise week msci msci tuesday finally greenlighted inclusion mainland china stock key emerge market index wall street have be closely watch decision several fund include ishare emerge market etf eem track be benchmark index china weight benchmark jump upward current move surprised market msci have give red light mainland stock share previous try eqt corp eqt agree buy rice energy rice deal set close create largest natural gas producer strengthen eqt position marcellus utica shale region accenture acn report line fiscal profit report top line growth slightly view new digital cloud security product service reach revenue management commentary weakness health care market send share
417,CELG,stock index cough small loss midday tuesday several homebuilding stock reach new high nasdaq retreat dow jone industrial average be just volume midday be lower nyse higher nasdaq compare previous session homebuilder lennar len knife higher volume roar normal major player industry report fiscal result end big cap surpass street expectation revenue earning ep come cent share almost higher expect revenue rolled almost consensus view order sign future activity rise almost stock clear shallow base base pattern score new high buy point offer buy range other homebuilder gather courage apparently lennar strength nvr nvr peg new high toll brother tol kb home kbh stock reversed early high volume be heavy toll kb horton dhi try break past buy point couldn hold still stock gain heavy volume taylor morrison home tmhc inched buy point then retreat entry volume be average pulte group phm advanced fast trade midcap stock remain buy zone entry build sector exchange trade fund spdr homebuilder xhb ishare home construction itb be so far year ibd homebuilder industry group be so far year difference ibd industry group list be price weight nvr biggest weighting homebuilder group be year etfs offer more realistic picture ibd industry group biggest percentage gainer day include biotechs drugmaker carmaker generic drug homebuilder downside oil stock be most painful position biotech stock be back top tuesday midday biogen biib pop almost higher heavy volume retake day line former leader be high celgene celg advanced strong volume stock be buy point semiconductor stock rank sector be mostly not decisively so chip stock stumble previous week be so far week related new high mcdonald show strengthwhy logmein next be heavy construction play be buy ibd industry group be lead market today
418,CELG,biogen biib spin ipo bioverativ bivv break fellow biotech stock celgene celg be also close new buy zone get upgrade ibd smartselect composite rating tuesday new score tell developer cancer treatment be now outperform stock term most important fundamental technical stock pick criterium top perform stock tend have better grade kick significant move celgene be currently form flat base entry tuesday stock give back portion session gain still close just higher leave buy point volume be lighter monday well average third straight day stock earn ep rating meaning recent quarterly longer term annual earning growth be outpace stock celgene also sport annual pretax profit margin accumulation distribution rating show moderate buy institutional investor last week company report earning share growth revenue growth increase prior report mark quarter increase revenue gain celgene hold rank peer medical biom biotech industry group supernus pharmaceutical supn be top rank stock group related cut edge cancer killer reignite biotech rally company be now outperform stock
419,CELG,analyst action friday include downgrade nike nke kroger kr upgrade celgene celg price target hike lam research lrcx athenahealth athn jpmorgan downgrade dow jone industrial average component neutral overweight trimming price target nike say thursday cut global workforce implement organizational change analyst matthew boss say encourage forward think initiative cost reduction think north america sale be likely get change bear fruit share nike fall stock market today hit lowest level year ibd take visit ibd stock checkup find footwear company be rank industry group base fundamental stock performance share flirted wednesday be sit just buy zone goldman sachs downgrade supermarket chain neutral buy cut price target kroger slash full year earning guidance thursday analyst stephen tanal see high level uncertainty earning come year due disruption grocery space note expansion european discounter well fargo cut price target keep outperform rating say kroger discounting preserve market share be more aggressive expect tough competition wal mart wmt cut price amazon amzn invest grow grocery business share kroger fall friday hit year low tumble thursday downgrade didn help kroger other grocery seller tumble amazon deal buy whole food market wmt stifel raise price target cloud base provider medical record bill management software keep hold rating analyst david grossman come away more positive outlook company growth strategic direction meeting ceo bush thursday citi analyst garen sarafian say apple aapl be potential acquirer recent report have say apple be try make iphone central store personal health information integrate datum hospital other health care organization share athenahealth rise needham co raise price target chip equipment maker keep buy rating analyst edwin mok note improve outlook second half see shape strong year datum point suggest strengthen position wafer fabrication equipment market share lam research fade close leerink upgrade biotech outperform market perform raise price target analyst geoffrey porge see celgene value discount relative rival expect significant upward revision consensus estimate share celgene rise related kroger trash rival grocer spoil earning shrink workforce store see cancele armour lam research exit march quarter lionwill cut edge cancer killer reignite biotech rally
420,CELG,xbiotech stock regeneron regn amgen amgn biogen biib spin bioverativ bivv have be boom week celgene celg have also joined party now trading upper end buy zone follow wednesday important metric look stock be higher relative strength rating celgene now clear threshold jump thursday ibd proprietary rating identify market leadership worst best score rating show stock price behavior trail week compare other stock database year market history reveal top perform stock often have rs rating least begin biggest price move celgene break wednesday first stage flat base end thursday session just upper end buy range once stock be more initial entry price consider extend earning growth decrease last quarter revenue gain moved higher company earn rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx be also group highest rate stock related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
421,CELG,celgene celg stock dip month low monday wall street disappointment potential blockbuster drug ozanimod fail delay accumulation physical disability multiple sclerosis patient compare interferon ozanimod do meet primary goal reduce annual relapse rate patient relapse multiple sclerosis celgene say news statement plan file application food drug administration end year stock market today celgene stock be earlier fall much touch low last see jan share begin form flat base mid march drop lower level monday rival novartis nvs stock be ozanimod be compare fda approve interferon avonex year trial patient relapse multiple sclerosis milligram mg dose ozanimod demonstrated statistically significant clinically meaningful reduction annual relapse rate celgene drug also reduce new enlarge lesion year vs avonex pooled analysis phase phase study ozanimod drug fail show statistically significant improvement disability vs avonex put disadvantage novartis gilenya ibd take seem get handle biotech market head ibd technology page closer look be complex sector best stock bet year not be biggest name game leerink analyst geoffrey porge doesn expect disability point hamper ozanimod approval safety be similar trial earlier phase study ozanimod celgene say full result be present future medical conference lack disability benefit be disappointing do not believe limit ozanimod chance approval give significance clinical benefit primary endpoint write note client however limit ozanimod competition vs novartis gilenya porge say ozanimod gilenya belong class drug modulate specific receptor treat relapse multiple sclerosis gilenya be approve note indicate delay accumulation physical disability evercore analyst umer raffat call disability question investor focus celgene trial dub radiance still expectation be displace raffat write note client novartis rival drug gilenya never show extraordinary statistically significant disability benefit vs avonex bigger question ozanimod be gilenya remain brand generic competitor creep begin look market realistic chance gilenya remain unchallenged generic number important patent be place celgene novartis also have contend roche recently grab approval game changer multiple sclerosis drug ocrevus ocrevus alone be approve form multiple sclerosis relapse remit primary progressive related roche game changer drug chip away biogen novartisdid regeneron sanofi just launch blockbuster drug celgene topple small cap biotech ragged quarter
422,CELG,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
423,CELG,biogen biib be pay bristol myer squibb bmy upfront license palsy drug market opportunity potential use treat alzheimer analyst say thursday deal be announce early thursday conjunction separate agreement roche rhhby roche license duchenne muscular dystrophy drug bristol accord news release bristol agreement be expect close second quarter licensing asset biogen roche enable bristol myer squibb prioritize other promising opportunity asset development have advanced diversify portfolio say mike burgess head bristol cardiovascular fibrosis immuno science development close bell stock market today investor only reward biogen gain bristol be fraction roche stock fall biogen deal biotech pay bristol milestone payment tiered double digit royalty license drug know only bms drug just complete phase testing progressive supranuclear palsy palsy also call steele richardson olszewski syndrome be rare brain disorder cause difficulty walking balance eye movement accord mayo clinic drug biogen be licensing be know tau taus have be investigate treatment alzheimer alzheimer taus be protein build brain process cause tangle nerve cell breaking communication expert say bristol biogen drug cut tau plaque buildup brain healthy volunteer phase testing ibd take biogen share have be flat base reach high aug stock get composite rating investor business daily meaning outperform stock currently rank ibd medical biom biotech group celgene celg top spot phase trial patient be underway readout expect mid palsy drug biogen see market evercore analyst umer raffat estimate market be bigger alzheimer biogen be already work other drug used tau palsy alzheimer treatment biogen face abbvie abbv abbvie be also phase testing drug know abbv be similar timeline raffat note phase trial begin january patient second deal roche license bristol drug call bms drug be be develop treatment duchenne muscular dystrophy rare disease characterize muscle degeneration weakness roche pay upfront potential milestone payment tiered double digit royalty drug be approve related roche game changer drug chip away biogen novartisthese biotechs save drug sector dow stock merck undercut astrazeneca lung cancer
424,CELG,largest biotech etfs serve reminder march investor high growth industry expect bumpy ride hit best level year early then take nasty tumble bounce back smartly loss tuesday spdr biotech xbi ishare nasdaq biotechnology ibb be modestly lower hold week move average bullish sign recent test critical marker support stumble march so far be hold double digit gain first quarter vs nice turnaround plunge more many biotech exchange trade fund prior quarter coincide hawkish election rhetoric price gouge drug industry latest rally come major setback month include trump tweet drug price serious blow big name biotechs amgen amgn biogen biib cast pall entire industry biotechnology etfs rally sharply january february higher beta name swung favor president trump shock election investor see stock value play growth industry say matthew bartolini head research spdr americas market analyst still see fair attractive valuation sector year date outperformance help ibb earn upgrade recently light improve valuation however thing be key next leg industry bartolini view first biotechs have deliver promise growth many smaller firm kite pharma kite esperion espr be unprofitable have sale even industry bellwether such gilead science gild incyte incy be earning slump however earning momentum sector whole be start look more favorable analyst say top biotech celgene celg earn extremely high ep rating ibd have score upward revision forward estimate secondly merger acquisition come fruition boost share price intercept icpt regeneron regn biogen be name be bandy takeover target xbi have outpaced peer so far have consistently past year be year date march vs gain ishare rival be cap weight skews larger company bartolini consider spdr biotech be well place look ahead well equal weight indexing method give small cap tilt be beneficial industry such biotechnology smaller more speculative company have strong potential long term growth play say relative cap weight rival xbi be less tie fortune largest name industry hand make spdr etf more immune single stock risk tweet risk bartolini word however also benefit less big price gain industry giant trump tweet drug pricing hit xbi ibb hard march related etfs be make big move
425,CELG,stock be show impressive rebound monday open sell nasdaq composite turn loss gain nasdaq reflect resilience large megacap techs rise dow jone industrial average be turn drop nearly loss just fall more last week early monday dow jone industrial average briefly clip day move average first time fall south side key support resistance line back then take nearly month stock dow rebound back day line help dow be dupont dd be sole component rise point more diversify manufacturer be legitimate leader stock market today jan share also be recent nov past flat base buy point be less ibd best mutual fund award view winner categoryamong new issue snap snap be get plenty attention back positive comment analyst new buy rating share stride more higher possibly set highest close more week market debut snapchat social medium site operator leap past share ipo finish then catapult high come earth next session snap slide low normal cup double bottom base decline usually run more high low base ibd research big winner past bull bear market cycle so snap case decline be heavy side especially give fact gain share ipo do not exceed more recent positive wall street comment snap be course lose money consensus estimate net loss cent share still stock deserve close watch rebound continue stock get peak most excellent cup handle pattern stock tend form handle last final shakeout uncommitted holder big new high trading more week time high trump support american health care act never see light day friday investor continue watch lead name medical health care service industry group celgene celg intuitive surgical isrg regeneron pharmaceutical regn be day biggest point winner celgene rank big cap see whole list latest ibd weekly page failure american health care act future change former president obama affordable care act be unlikely suppress demand superior medicine treat patient deadly disease such multiple myeloma celgene be field also be become force treatment chronic illness such psoriasis celgene get wonderful ep rating ibd stock checkup due consistent pattern long term profit increase solid gain short term well past quarters earning share rise vs year level average ep gain be outstanding company market cap higher celgene have market value share outstanding be large not excessively so point comparison pfizer pfe have share outstanding street see fiscal year profit rise share lift revenue revenue rise vs year level prior year intuitive meanwhile remain top hill field robotic surgery system wall street see earning rise share current quarter accelerate increase see sale be see rise growth intuitive present buy point so far feb stock spurt past cup base entry volume expand nearly day average sign healthy demand mutual fund large investment adviser pension insurer go daily chart ll also see very narrow handle form jan feb create hard see early buy point add cent highest price handle obtain handle entry point notice daily chart stock gap huge volume jan reaction decent fourth quarter result ep revenue intuitive currently get solid composite rating better regeneron score watch see regeneron muster strength rise back day day line create space key resistance line earnest start form right side new base pattern related invest add week line pullback trading invest key great cup handle basestock market today do lead chipmaker deserve spot watch list ibd do big winner have common tech news ibd snap be get love wall street
426,CELG,technology industry experience nothing short revival first quarter end barely toehold rank stock market lead industry tech group bounce back broad dominance start multiple reason explain turn chief political promise tie november presidential election appear be longer
427,CELG,biotech celgene celg be get too reliant revlimid revenue cancer drug account nearly third company sale first quarter analyst say friday revlimid driver celgene have account average company sale previous quarters be last quarter argus analyst david toung say note client be concern risk revenue concentration revlimid write note downgrading celgene share hold buy drug treatment multiple myeloma other condition account revenue proportion be grow part problem be celgene total first quarter sale grow come light company psoriasis drug otezla face steep discounting celgene say have lower price otezla boost purchase large institution thus sale drug miss view other word company increase gross net discounting otezla enable be place ahead biologic drug treatment plaque psoriasis psoriatic arthritis toung say otezla retain advantage biologic oral solid vs competitor be typically infuse inject say still diminish price otezla have impact celgene gross margin ibd take biotech stock be now rank group track keep space be tricky relatively unknown stock esperion therapeutic rocket nearly mere month outplay leader amgen get better breakdown sector ibd technology page revlimid patent be good settlement allow natco pharma begin selling generic version march first quarter revlimid sale grow company multiple myeloma drug pomalyst lead pack growth otezla be next chemotherapy drug abraxane gain stock market today celgene stock close hit month low intraday related do regeneron sanofi just launch blockbuster drug vertex big winner biopharma abbvie astrazeneca dipcelgene dip lag psoriasis sale earning top
428,CELG,celgene celg stock topple second day run monday partner acceleron pharma xlrn report first quarter loss sale not only lag wall street fall vs year earlier quarter celgene stock close lower stock market today entry point flat base begin form march volume be huge run more typical level acceleron stock too be quarter acceleron report adjust loss cent share sale compare cent year analyst have modeled cent loss sale lackluster first quarter result come day acceleron celgene unveil strong phase result drug dub patient lower risk bone marrow disorder know myelodysplastic syndrome form leukemia ibd take celgene have ibd composite rating best possible underperform just stock term key growth rate rank first group head ibd stock checkup closer look lower risk patient have not previously receive medication stimulate red blood cell production achieve red blood cell transfusion independence show clinically meaningful improvement hematological response related do celgene have too many egg drug basket
429,CELG,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
430,CELG,major index ease dull trading dow jone industrial average edge barely positive ground follow emmanuel macron sunday french presidential election also serve moral victory eurozone volume market be run lower et vs same time friday however even nasdaq composite dow jone industrial average harbore thin loss monday session be notable handful highly rate leadership quality name fall sharply heavy volume such action force decision investor hold share sell half current position completely sell lock gain cut loss name deserving close watch be celgene celg install build product ibp mortgage insurance firm essent group esnt rv giant thor industry tho argentine oil gas explorer ypf ypf company be sink heavy volume testing buy support day move average thor industry have already issue sell signal stock break day line march huge volume stock market today thor be now testing long term support day move average thor remain long term uptrend clear buy point long first stage base march then thor gain much install build product specialize insulation garage door rain gutter continue sell report strong result friday profit jump cent share revenue grow ep jump revenue yet stock nearly be drive day line first time launch month base base pattern buy point feb ypf be actively pursue frac opportunity home country argentina fall more volume run usual level stock drop low recent point be find buyer day line ypf have market cap appear be emerge long bottom base pattern peak way back december negative ypf integrate oil gas industry group be laggard stock market today currently rank well bottom quartile ibd industry group table see entire table go ibd datum table section stock list section investor com elsewhere celgene have surrender small gain feb past entry sloppy cup handle base biotech partner firm acceleron pharma xlrn announce result monday note begin phase trial first line treatment blood related disorder mds lower risk patient early upside coach coh continue strong turnaround apparel sector striking deal buy rival kate spade kate much lower price share then kate have trade earlier year coach gapping high retreat bit early morning buy rush stock be still more extend more past buy point long first stage saucer handle coach rs rating have improve scale prior week also see ibd stock checkup volume ratio be now neutral level mean volume day price have now exceed turnover day past trading session street currently see coach earning rebound share fiscal end june then rise fy watch see acquisition news spur boost analyst estimate come week month related stock market today coach rocket do beaten industry group sparkle stock market today ii be snap nvidia poise break soon stock market today iii time sell small cap buy income investor reason dividend rich reit sector be far latest ibd tech coverage go here
431,CELG,video game maker activision blizzard atvi score price target hike post first quarter earning biotech celgene celg be downgrade zillow zg price target be hike stronger expect earning lumentum holding lite downgrade speculation apple aapl contract jeffery hike price target video game publisher piper jaffray up pt activision blizzard late thursday report first quarter sale earning top estimate activision revenue forecast top view ep outlook be expectation activision post huge beat key game overwatch drive robust growth game spending impressive performance come investor fear weak frontline holiday sale call duty translate weak first half performance say timothy shea jeffery analyst report share activision blizzard rise stock market today related activision blizzard beat sale earning targetsrbc capital price target online real estate canaccord genuity up pt cowen co zillow late thursday report ep cent revenue top expectation zillow stock shot related universal display zillow beat guide high impinj veeco guide lowargus research downgrade biomedical company hold buy celegene stock sank friday related biotech surge survive volatile marketcitigroup up price target arista network rival cisco system csco follow earning needham co hike pt arista late thursday report adjust first quarter earning top view arista say ep item be cent share year revenue rise arista stock rise tumble earlier related arista network earning top view revenue outlook light downgrade maker fiber optic component market perform slash revenue guidance fiscal weak demand china tim savageaux analyst set price target even lumentum win order sensor smartphone maker such apple savageaux say weaken demand china be worry lumentum lumentum stock advanced friday pop thursday related lumentum have apple iphone sensor design bag analystin other analyst move barclay increase price target ansys anss rbc capital cut cbs cbs price target baird downgrade akamai technology akam neutral canaccord genuity up price target universal display oled citigroup increase price target motorola solution msi jeffery hike varonis vrn related software maker break buy design flaw
432,CELG,biotech stock celgene celg bluebird bio blue regeneron regn biogen biib spinoff bioverativ bivv move cancer treatment developer exelixis exel be poise pop new buy zone exelixis share price have soar week follow confirmation positive result phase trial so call cabosun trial compare cabozantinib exelixis used
433,CELG,celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx lead biotech sector more upside follow second quarter analyst say thursday share trek fifth straight day xat close bell stock market today ibd company biotech industry group be trading month high leerink analyst geoffrey porge credit lack drug pricing headwind day uptrend current rally reflect lift perceive fear pricing regulation favorable tone fda do not yet reflect more positive operate result not mention industry consolidation still expect write note client porge expect industry tack upside follow likely be strong second quarter earning season biotech stock have add june thursday leader include number small cap trading riser porge prefer call growth stock celgene regeneron vertex alexion pharmaceutical alxn mid regeneron stock have add follow gain celgene vertex stock gilead science gild perform worst only gain be still higher overall market say major biotech index have add last month broader market have only tack growth ibd take analyst begin predict biotech rally last month be sign benefit most head industry snapshot closer look analyst have say reason sector surge be fear be subside prospect president donald trump take action curb pricing analyst now say trump rhetoric tamp pricing appear be lip service wall street expectation amgen amgn gilead regeneron second quarter earning have dip last month revenue view have be largely flat decline amgen gilead large cap biotechs have beat second quarter view gain upside porge say last year large cap have beat second quarter expectation time amgen celgene gilead beating view time guidance increase be more likely second quarter first say expect biotech sector rally much compare long term relative multiple vs medtech pharma sector related small biotech pique interest gilead other biotechs surge generalist return subside trump biotechs be lead sector month high today
434,CELG,future index nasdaq dow jone industrial average be mixed early thursday software biotech stock have become key leader ongoing market rally oracle orcl surge overnight strong earning report regular session celgene celg roar buy zone amgen amgn regeneron regn biogen biib peer show bullish action investor pay attention sector rotation stock performance be closely tie broader industry stronger industry sector performance reflect improve business condition company be momentum shift market become more enamored disenchant group nasdaq future rise more fair value overnight high future dow industrial climb nearly index future turn slightly higher crude oil future have plunge week edge last session medical biom biotech group have be top performer ibd industry group soar amgen regeneron biogen celgene be more just week biogen regeneron more ibd take celgene be rate ibd biom biotech group best possible composite rating find be other top rate biotechs stack vs objective critera go ibd stock checkup several other drug group be big recent winner ethical drug group include dow stock merck mrk merck rise wednesday new approval immuno oncology treatment keytruda merck have conventional buy point aggressive entry meanwhile ibd software desktop group home oracle be fourth best industry past day dow microsoft msft adobe system adbe red hat rht be also member other software group include enterprise software medical software also have have big gain celgene leap blast past buy point hold just chase zone grow feel investor president trump not crack drug price various comment have make campaign regeneron rise further extend buy point trading best level begin amgen advanced build right side base biogen gain retake day move average day vaulting day recent biogen spinoff bioverativ bivv edge be hold buy zone monday bioverativ be leaderboard ibd premium service highlight select cull stock mostly growth play buy zone clovis oncology clvs have sky-rocket week report strong trial datum suggest ovarian cancer drug get much wider use gilead science gild rise day line hepatitis hiv biotech try break downtrend go back more year good way play biotech boom be etfs such spdr biotech xbi ishare nasdaq biotech ibb xbi ibb break consolidation week oracle report much stronger expect earning late wednesday revenue growth also edge past view share business software giant shot premarket trading stock market today be record high well buy point overnight trading doesn always carry regular session still oracle already top aggressive entry wednesday rise heavy volume addition desktop software name microsoft adobe red hat be long time time high several other business software stock have be breaking hit high recent month include cloud base payroll software player such workday wday paylocity pcty paycom payc well servicenow now salesforce com crm veeva system veev asian trading thursday japan nikkei dip china shanghai composite slide europe intraday ftse retreat germany dax be flat france cac fall related big picture biotechs lift nasdaq oil bloodbath breakout biogen spinoff bioverativ buy zoneoracle earning come ahead top bottom linesbiotech surge generalist return subside trump dow merck be still beating bristol roche immuno oncologyis medical cloud compute play set rebound crash
435,CELG,nasdaq composite end solidly higher wednesday help day outperformance biotech stock solid earning report adobe system adbe red hat rht price action nyse index be more subdue weigh weakness financial sell oil gas stock nasdaq composite end
436,CELG,biotech stock have best day january political headwind subside generalist investor return sector drive price big cap smaller name company analyst tell investor business daily number company see double digit high single digit gain share price help ibd company biotech industry group rise so far week pop also offer unique opportunity specific big cap biotechs such celgene celg break flat base begin form mid march rush past buy point share jump close janney analyst debjit chattopadhyay say generalist investor be begin return sector depart november election newly elect president trump begin talk way tamp drug price brad loncar ceo loncar investment tell ibd earlier month biotech sector lose late follow election now chattopadhyay say appear trump plan control drug price be mere lip service generalist investor have own biotech vs tech now be seek more exposure drug pricing headwind dissipate tell ibd also recall last summer contrary expectation biotechs outperformed esperion therapeutic espr spiked stock market today cara therapeutic cara pop top buy point cup handle begin form late march blueprint medicine bpmc rise elsewhere exelixis exel climb near buy point cup begin shape other strong riser include pacira pharmaceutical pcrx agio pharmaceutical agio ibd take earlier week analyst question biotechs be head takeoff follow american society clinical oncology meeting highlighted cancer focuse company kite pharma kite bluebird bio blue head industry snapshot get look news predate week pop leerink analyst geoffrey porge predict resurgence note last month cite more achievable revenue earning view head third quarter well likelihood subside political risk lead generalist back biotech year political anxiety uncertainty health care reform drug pricing restriction major federal intervention believe probability material negative change be recede write report porge model month surge biotech sector see stock coverage universe subject upside predict jump follow year sideway performance wednesday porge tell ibd prediction be come fruition new food drug administration commissioner scott gottlieb regulatory path be be ease robust drug launch be underway investor be also likely excited potential acquisition space likelihood tax reform loom say top spike be result short cover panic say related biotechs be lead sector month high todaycan cancer treatment stock ride biotech boom new small biotech soar celgene partner trial
437,CELG,acceleron pharma xlrn stock rebound tuesday afternoon announce monday scrapping development kidney cancer drug putt wall street focus squarely celgene celg partner rare disease drug close bell stock market today acceleron stock pop earlier fall much nearly week low share bound day move average afternoon janney analyst debjit chattopadhyay call acceleron kidney cancer drug headline risk be unlikely deliver acceleron late monday acceleron say drug fail increase progression free survival patient advanced kidney cancer leerink analyst geoffrey porge say failure be largely expect give tepid view acceleron management cut price target acceleron stock remain outperform rate chattopadhyay keep price target buy rating acceleron drug be trial celgene treat anemia associate rare blood disorder group blood cancer call myelodysplastic syndrome company be set report datum phase trial mid ibd take immuno oncology drugmaker merck bristol myer squibb incyte roche be presenter american society clinical oncology meeting earlier month chicago head ibd industry theme breakdown several key trial trial be pivotal unlock value stock price target additional upside be possible myelodysplastic syndrome label expansion opportunity leerink porge write note client credit suisse analyst alethia young too cut price target acceleron stock have outperform rating share model sale unadjusted basis related celgene topple small cap biotech ragged quarterdow merck pause cancer trial investigate keytruda tie small biotech soar celgene partner trial
438,CELG,alexion pharmaceutical alxn stock pop thursday top biotech crushed wall street expectation first quarter sale adjust profit grow revenue drug soliris close bell stock market today alexion stock jump share top day move average have trade key level support mid march stock touch week high intraday first quarter end march alexion report adjust income share revenue compare cent year earlier quarter analyst have modeled share sale soliris alexion biggest moneymaker bring sale include benefit change revenue recognition grow year year basis remove adjustment soliris grow top analyst view leerink analyst geoffrey porge say keep outperform rating alexion stock ibd take alexion have ibd composite rating meaning outperform nearly stock term key growth metric still lag lead biotech celgene celg have top cr head ibd stock checkup list best rate biotechs alexion note have file application fda europe japan have soliris approve treatment autoimmune neuromuscular disorder characterize muscle weakness be third disorder soliris be approve company reiterate guidance sale earning share certain item year year basis sale grow ep be midpoint guidance related abbvie hover buy point earning sale topcelgene dip lag psoriasis sale earning topamgen trip rival sale miss earning top
439,CELG,nasdaq trek record high territory almost daily remain vigilant new breakout leader continue power ahead follow stock be show strong potential appear poise move higher late wednesday servicenow now easily surpass earning sale target result almost move higher thursday software company quarterly
440,CELG,regeneron regn sanofi sny eczema drug dupixent outstripped psoriasis drug rival company fourth week prescription analyst write monday suggest consensus view drug be beatable friday sanofi say earning call prescription have be written physician dupixent first month market health care tracker im suggest prescription be filled fourth week dupixent launch comparison prescription psoriasis drug novartis nvs cosentyx taltz eli lilly lly have be written point follow launch celgene celg otezla have script most successful drug have be otezla fourth week dupixent launch be double prescription volume otezla leerink analyst geoffrey porge write note client also note recent successful launch cholesterol lower drug amgen amgn repatha regeneron sanofi praluent see prescription otezla estimate monthly net price period be be likely net price dupixent porge write adjust only higher price dupixent sale be base otezla sale record however dupixent indeed continue see double prescription volume otezla revenue be closer beat compare consensus say early post launch information thus far be very encourage ibd take do survive investing market relatively unheard company esperion therapeutic espr launch nearly mere month matter identify right catalyst analyst say head ibd technology page more base sanofi disclosure written dupixent prescription first month porge model fill rate april grow fill rate december more payer open access lead potentially prescription filled fifth week be not unreasonable give prior week week growth prescription porge say analyst broadly model dupixent sale second quarter third fourth porge see dupixent sale grow comparatively otezla cosentyx bring first quarters market comparison dupixent be more expensive otezla significantly cheaper cosentyx be enter much less competitive category more untreated patient appear be faster access major pharmacy benefit manager formulary write porge reiterate outperform rating price target regeneron stock stock market today regeneron stock be sanofi stock fall related amgen trump regeneron sanofi post trial cholesterol drug scriptsamgen payer pushback likely sting battle regeneron sanofiregeneron sanofi get approval eczema drug price
441,CELG,vertex pharmaceutical vrtx be big winner friday wake slew biotechs drugmaker issue first quarter report thursday stock market today vertex rise climb much best level january meanwhile ibd company biom biotech industry group edge higher celgene celg bristol myer squibb bmy rise respectively abbvie abbv stock drop buy point temporarily achieve thursday share fall friday astrazeneca azn stock fall vertex investor be now key triple pill treatment cystic fibrosis leerink analyst geoffrey porge say report friday see chance vertex successfully bring triple pill regimen market ibd take navigate biotech trading world be tricky relatively unknown name esperion therapeutic espr launch nearly mere month head ibd technology page primer industry player look good vertex decide phase strategy triple regimen latter half biotech be currently evaluate next generation drug be used combination tezacaftor ivacaftor cystic fibrosis drug porge raise price target keep outperform rating vertex stock note investor likely prod vertex stock raise guide cystic fibrosis drug kalydeco separate report porge boost price target celgene stock keep market perform rating miss sale psoriasis psoriatic arthritis drug otezla lead overall sale miss porge note catalyst celgene future celgene portfolio be undoubtedly broader peer management appear be focuse create long term shareholder value focus later stage clinical program write note celgene have key trial multiple myeloma hodgkin lymphoma brain tumor crohn disease have generally be cautious view several late stage candidate celgene pipeline however now expect several key inflection point late stage candidate celgene pipeline next couple year say abbvie buck rocky earning season trend meeting consensus view first quarter sale grow revenue humira porge say report adjust income beat cent result other biopharma name drug immuno oncology market have be volatile notable miss mainly attribute overall market weakness say abbvie result suggest part trend also come share loss give solid performance humira abbvie biggest moneymaker porge be more constructive abbvie outlook year year abbvie see sale top porge boost price target abbvie stock keep market perform rating related acorda topple year low street lag sale lossesalexion beat first quarter sale profit top cent
442,CELG,do get handle biotech market unknown stock esperion therapeutic espr nearly january outperform like industry top name amgen amgn sure esperion have have breakthrough cholesterol medication amgen recently have own moment cholesterol drug prove decrease bad ldl cholesterol also cut risk heart attack stroke still amgen isn get respect smaller biotech player be get comparatively paltry year don get discourage analyst say just amgen isn get lot love doesn mean other biotech stock be slouch really question navigate be complex sector leerink analyst geoffrey porge say biotechs have do well election stock be subject whim political debate drug pricing health care re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say just doesn seem accumulate worry be go go away hurry overall group look strong now rank group track week be rank ibd take drugmaker allergan be sweeping medical aesthetic market hologic want play head industry snapshot breakdown battle porge mizuho analyst salim sy call stock picker market biotechs be bound do well number catalyst still ahead other be more likely struggle macroeconomic politic be still pressure investor need be cognitive drug pricing sy tell ibd folk thought be presidential platform topic keep come now postelection ibd company biom biotech industry group be year major exchange trade fund ishare nasdaq biotechnology index ibb spdr biotech xbi be respectively top biotechs include amgen gilead science gild celgene celg biogen biib regeneron pharmaceutical regn have be news none stock price amgen have gain most gilead lag january sy have buy rating amgen celgene gilead stock neutral rating biogen stock smaller player potential takeout candidate incyte incy tesaro tsro have see big gain wall street tesaro be likely remain stand alone company grab fda approval ovarian cancer drug zejula stock rise much mid february be now only year incyte other hand have tack january rumor biotech gilead be look acquire incyte open gilead oncology world hepatitis franchise struggle high cure rate once again re start year best perform stock be be cheapest more takeout candidate porge tell ibd so make prediction have definitely be somewhat challenge earlier month nektar therapeutic nktr stock hit year high strong datum pain pill be alternative potentially addictive oxycodone nektar stock catapult single day share extend cup handle formation late march have give back gain stock remain year other big stock earner include kite pharma kite bluebird bio blue be work drug class call car cell therapy drug engineer patient immune cell treat cancer kite stock be whopping lead rise bluebird stock esperion rocket amgen heart study so too do medicine company mdco share be january porge list medicine co stock watch note spectacular return have right stock right set event then still generate incredibly attractive return excitement biotech porge say be company be approach critical readout ongoing development program investor think reasonable chance critical trial critical milestone turn positively mizuho sy suggest look individual stock equity rather hope broad biotech resurgence see good number catalyst market note drug pricing debate be likely still weigh market president trump have key drug pricing debate limit detail say have plan competitive base system bring price drug trump pick run fda scott gottlieb have say drug pricing need be more transparent struggle unfold porge layer rule pick biotech stock likely have better return want be growth company early life cycle treat very serious illness say follow rule be generally go end portfolio go perform better average better index better benchmark rule porge say epizyme epzm vertex pharmaceutical vrtx alexion pharmaceutical alxn be interesting epizyme stock be january have top buy point cup handle formation early february vertex stock have gain year alexion stock be actually year date stock fit bill used porge rule rare disease company be work drug treat disorder central nervous system blood disease genetic disorder worst thing do biotech investing be sell just stock be porge say don hesitate buy stock same reason axiom investing biotech be always never want say not go buy stock be industry routinely see tenfold increase value cycle emergence product say so often see stock investor say only go market cap market cap scheme thing be pretty small say have real drug re go be company related esperion medicine co recover amgen induced edward best stock own gilead be pay price actually cure disease
443,CELG,corporate earning result grab front center stage be help propel equity higher late afternoon trading tuesday major index be padding last week nice gain dow jone industrial average boost better expect result several component include caterpillar cat ep dupont dd ep rise more better gain nasdaq composite dow jone industrial be now nearly jan nasdaq composite breaking first time be ahead nearly gain big cap techs select consumer oriented stock have help nasdaq cause keep monitoring earning result see more money flow blue chip type large cap outside tech realm caterpillar also notch surprise gain revenue first year year increase quarters last time construction mining gear titan see top line lift come third quarter cat share vault past flat base buy point gap open enjoy heavy institutional buy share see triple normal turnover stock open day proper buy zone follow tuesday russell rally more volume be run firmly higher vs same time monday main exchange sign heavy institutional demand equity crude oil future meanwhile rebound get hammer monday wti future rise barrel be still more year date gold mining stock other defensive play lead market downside newmont mining nem sank nearly heavy volume mining giant grow first quarter profit cent share pickup revenue month clear institutional investor be favore certain industrial sector other good news stock picker here be stock addition high growth name ibd sector leader show more mature fundamental be turnaround situation have potential beat nvidia nvda market value leader graphic processor have step nicely new growth market include self drive automobile ai artificial intelligence nvidia nearly be try retake key day move average get slam bearish analyst comment april stock be huge leader rise cup handle back march year nvidia sport solid earning share rating scale earning april end fiscal first quarter be see rise impressive cent share top gain year quarter keep mind next quarters nvidia face absolutely steep year year comp profit rise respectively give giant gain nvidia current correction be very respectable fall more time high celgene celg market value highly respect biotech pioneer treatment chronic difficult disease include multiple myeloma stock jump find vital support day line slightly earlier cup handle entry street see full year earning rise share chipotle grill cmg former large cap burrito taco chain report result close tuesday watch expect positive change comparable restaurant sale see restaurant level operate margin show stability improve intuitive surgical isrg robotic surgery firm recently post double digit top bottom line growth be more jan bolt base late february intuitive get rock solid composite rating ibd stock checkup top ibd medical system equipment industry group group be rank industry group subgroup month relative price performance watch potential new buy point emerge form new base gentle pullback week move average see weekly chart case stock not fall back day line find support week line so crucial study stock price action daily weekly chart related case future new bull market goldearning result today chipotle lead big report closestock market today be time buy hasbro now rite aid sink more income investor top perform stock large dividend yield
444,CELG,xcelgene celg stock topple thursday biotech miss otezla sale expectation lead overall revenue come light profit top view nickel stock market today celgene stock be earlier dip much share be form flat base possible buy point first quarter end march celgene report sale vs year earlier period lag consensus adjust profit share climb top view cent key product multiple myeloma drug pomalyst imnovid grow sale cancer drug revlimid abraxane grow sale respectively otezla drug psoriasis psoriatic arthritis grow sale lag analyst mizuho analyst salim sy note research report keep buy rating price target celgene stock note biotech expand share psoriasis vs prior quarter ibd take want latest ibd biotech pharma stock coverage head biotech pharma industry stock news page freshest news company cite market contraction psoriasis psoriatic arthritis increase gross net adjustment small inventory drawdown first quarter miss otezla sale otezla bring international sale grow celgene raise adjust earning share target earlier view line consensus expectation celgene also expect have datum phase study multiple sclerosis drug ozanimod end second quarter also thursday astrazeneca azn top earning view have line sale alexion pharmaceutical alxn bristol myer squibb bmy abbvie abbv top metric acorda therapeutic acor have miss late wednesday amgen amgn report better expect earning sale fall short amgen share drop hit soon open early tuesday biogen biib top earning sale forecast biogen fall thursday related amgen trip rival sale miss earning topbiogen earning top drug start wellabbvie hover buy point earning sale top
445,CELG,top biotech stock amgen amgn celgene celg regeneron regn bluebird bio blue have rally week biogen biib spinoff ipo bioverativ bivv have jump new buy zone developer treatment hemophilia other disorder see positive improvement relative strength rs rating tuesday increase exclusive rating investor business daily identify market leadership worst best score score show stock price performance last week hold other stock database decade market research reveal stock go make biggest gain typically have higher rs rating begin new run bioverativ be still buy range breaking past buy point cup handle wednesday stock be fractionally day still entry once stock move more initial buy point consider buy range revenue growth fall last quarter ep grow prior report company hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx celgene be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
446,CELG,nasdaq composite follow monday bullish gain lower volume decline higher volume late trading tuesday dow ease buoy strength merck mrk pfizer pfe lose hurt weakness oil gas name distribution day be take shape nasdaq stock market today volume be tracking quite bit higher monday level benchmark west texas intermediate crude oil hit multimonth low settle barrel big biotech rally lift share ibd name regeneron regn share pop well extend buy point other biotechs move include celgene celg share rise right side current base show nice accumulation higher volume gain celgene approach buy point contract research organization provide outsourced service biotech big pharma get lift parexel prxl agree be take private private equity firm share parexel rise tesla tsla be session lows still rise report release national safety transportation board find fault tesla automate pilot system involved highly publicize crash model driver be kill chipotle cmg tumble company offer lukewarm same store sale guidance also warn higher cost earning news lennar len jump nearly early fade share gain company report better expect earning third straight quarter accelerate earning growth financial be pressure year treasury yield ease basis point loss select sector spdr financial xlf be tame set nice base buy point many other financial have do good job hold gain recent breakout related netflix price target hike nvidia upgrade nike pt loweredlennar earning top view share eye buy pointthese biotechs be lead sector month high today
447,CELG,bluebird bio blue clovis oncology clvs kite pharma kite climb higher fellow biotech stock incyte incy be try regain foot launch new run tuesday developer small molecule drug treat cancer see relative strength rs rating jump new percentile tuesday increase ibd unique rs rating track market leadership used worst best score indicate stock price performance last week match other stock year market history reveal market biggest winner tend have rs rating least launch biggest price move stock be try complete consolidation potential buy point see break heavy trade tuesday stock be move back day line volume be trend average ep growth have fall last quarters revenue rise company hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx celgene celg be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
448,CELG,monday shorten trading session picked left last week tech stock fall financial biotechs remain relatively strong uptrend pressure global investment bank continue see buy demand stock market today morgan stanley ms leap close cup handle entry
449,CELG,acorda therapeutic acor be aim save annually cut loose workforce drugmaker say judge invalidate patent protect multiple sclerosis drug ampyra cut have be still be much deeper janney analyst ken write note client thursday cut price target acorda stock keep neutral rating share acorda have previously speak cost save contingency plan be enact ampyra long term patent protection be lose say add have assume first round cut be deeper second round come time generic launch next year wall street have long suspect company mylan myl teva pharmaceutical teva be wait wing make copy ampyra ampyra be approve improve walking patient multiple sclerosis bring net sale estimate acorda employee feb be layer month acorda say majority head count reduction take place april expect severance related cost layoff be not expect person sale force say cut be expect effect research development department restructure be expect save month begin second quarter restructure allow acorda refocu parkinson disease drug cvt tozadenant acorda also work push ampyra milligram extend release pill july lose patent protection last several year have strategically diversify portfolio believe cvt tozadenant be platform significant future growth chief executive ron cohen say news release ibd take acorda therapeutic have ibd composite rating meaning underperform more stock term key growth metric better rate leader be celgene top class cr find best pick stock checkup acorda plan update financial guidance first quarter earning conference call april close stock market today acorda stock be flat day red similar news biogen biib recently win interference case vs forward pharma fwp ms drug tecfidera competitor roche rhhby celgene celg be line rival biogen ms market related acorda biogen forward fall multiple sclerosis drug fightacorda forward stock fall multiple sclerosis court rulingsacorda stave mylan teva generic protect ampyra rbc
450,CELG,acorda therapeutic acor forward pharma fwp biogen biib stock continue feel fallout monday several fda district court decision regard multiple sclerosis drug tecfidera ampyra close bell stock market today acorda stock plunge stock dive follow judge decision friday toss patent cover ms drug ampyra alk manufacture ampyra acorda get royalty global sale see share topple close response analyst be bit more bullish stock note drug vivitrol treatment opioid dependence be biogen stock be fraction win friday interference case vs forward biogen be likely feel competitive pressure roche rhhby win fda approval drug ocrevus type ms forward stock skid monday share touch week low remain well day move average seventh consecutive day likelihood acorda winning appeal be slim janney analyst ken say timing appeal be month meaning decision come time remain patent ampyra be set expire generic version ampyra have already receive approval other grab tentative approval leerink analyst paul matteis write note client now acorda be prep cut spending analyst expect acorda turn parkinson next big sector acorda have pair drug know cvt tozadenant be now first second priority matteis say acorda plan file approval cvt end second quarter ibd take biogen spinoff bioverativ say not typical biotech startup head new america breakdown good thing investor approval cvt clean long term safety datum now look fairly risk view matteis say expect approval see tozadenant come strong topline phase datum first quarter cvt tozadenant be expect have overlapping prescriber base downgrade acorda stock neutral buy rating have price target stock matteis keep market perform rating acorda stock outperform rating stock biogen have win case forward look likely struggle roche celgene celg leerink analyst geoffrey porge say biogen get royalty sale roche ocrevus ocrevus probably swipe share biogen tecfidera tecfidera account biogen sale include half ms drug sale be expect bring total sale tecfidera be only approve treat relapse remit ms ocrevus be approve relapse remit primary progressive form biogen stand gain royalty ocrevus particularly incremental revenue primary progressive ms also stand lose revenue profit relapse remit ms cannibalization exist product porge write report primary progressive ms market be small treat patient vs relapse remit ms market biogen have lead share relapse remit market scenario suggest primary progressive ms market be too small biogen royalty too low offset profit erosion ocrevus cause biogen exist brand relapse remit ms market porge say meanwhile celgene be work own ms drug ozanimod drug be currently phase testing investment bank jeffery keep hold rating biogen stock downgrade forward stock hold rating buy forward have be slate receive royalty tecfidera sale hinge positive outcome interference case related acorda forward stock plunge multiple sclerosis court rulingsroche multiple sclerosis drug bittersweet beleaguered biogen
451,CELG,high profile name visa texas instrument txn adobe system adbe facebook fb touch new high friday action be plentiful elsewhere quiet session overall major stock index celgene celg reversed lower fall high quality biotech name be still buy range early buy point well
452,CELG,xwhile wall street be focuse big name biotech stock amgen amgn celgene celg investor also keep eye lesser know highly rate fast grow therapeutic cort ipo develop drug treat severe metabolic oncologic psychiatric disorder modulating effect cortisol december report encourage result phase trial
453,CELG,xlead biotech stock celgene celg be striking distance report encourage result unveil first prospective randomize controlled study evaluate clinical efficacy safety otezla patient moderate plaque psoriasis celgene march announcement follow company forecast back january otezla generate revenue
454,CELG,abbvie abbv stock rocket month high hover thursday top drugmaker report first quarter sale profit top wall street expectation stock market today abbvie rise close buy point flat base begin mid march share rise high intraday first quarter end march abbvie report adjust income share sale respective vs year earlier period analyst have modeled share sale sale humira abbvie biggest moneymaking drug grow humira sale be consensus view line leerink analyst geoffrey porge view pricing volume challenge note biopharma company immunology drug do not seem have impact humira same degree suggest humira formulatory position have remain largely unchanged reduce risk subsequent revenue miss say ibd take johnson johnson jnj first quarter report be expect have highlighted multiple issue biotechs drugmaker thursday bristol myer squibb bmy alexion pharmaceutical alxn also deliver board beat head ibd technology page deeper dive result porge keep market perform rating abbvie stock imbruvica cancer drug bring sale year year basis imbruvica bring line consensus view leerink forecast porge write note client abbvie note fda accept application imbruvica treatment graft versus host disease quarter graft versus host disease occur foreign tissue be introduce body organ transplant drug be be develop johnson johnson company later confirm guidance adjust earning share midpoint guidance also thursday celgene celg report better expect first quarter earning sale come short fellow biotech giant amgen amgn beat earning miss revenue late wednesday celgene amgen fall respectively related amgen trip rival sale miss earning topcelgene earning top biotech sale missbiogen earning top drug start well
455,CELG,market momentum seem have stall bit past week new leadership candidate be prepare move higher include big cap chip leader be look hit new high new issue have set stage higher stock price ahead june earning release broadcom avgo
456,CELG,wall street be key tuesday biogen biib earning first look payer pushback hinder sale spinraza first drug approve spinal muscular atrophy go treatment mizuho survey investor find street generally expect biogen pull spinraza sale first quarter full year be just chunk project total sale period leerink analyst geoffrey porge say spinraza coverage have be slam dunk price treatment first year subsequent year have payer balk accord numerous report spinraza be approve type spinal muscular atrophy most payer be just cover most severe form disease affect primarily infant child cause muscle weakness wasting investor poll mizuho expect spinraza bring peak worldwide sale spinraza sale miss first quarter show solid underlie demand drug investor poll say buy stock biogen be set report first quarter earning market open tuesday period analyst expect biogen report sale adjust earning share respectively share biogen have be consolidate august stock have trade day move average march stock market today biogen tick close early thursday fellow biotechs celgene celg alexion pharmaceutical alxn be set announce quarterly report intraday celgene be fraction alexion stock fall celgene investor look strong sale revlimid pomalyst otezla celgene biggest moneymaker potentially more commentary ozanimod multiple sclerosis drug phase trial likely rival novartis nvs ibd take ve read biotechs drugmaker cloud service company provide backbone clinical study head new america more veeva system veev thursday see stock hit record high chemotherapy drug revlimid bring celgene total product sale grow fda european commission recently approve revlimid maintenance treatment patient multiple myeloma stem cell transplant street also look commentary abraxane chemotherapy drug often used combination trial recent trial however used oncomed omed demcizumab abraxane pancreatic cancer fail meet primary endpoint first quarter analyst broadly expect celgene report adjust earning share sale respectively vs year earlier period alexion report early thursday investor look strength sale soliris approve treat immune system disorder destroy red blood cell other cause formation excess blood clot alexion have drug approve soliris make lion share sale bring revenue alexion be work expand approval soliris just submit application japan use soliris treat autoimmune neuromuscular disease march ub analyst martin call alexion stock watch sector recover alexion stock be year have trade day move average mid march quarter analyst call alexion report year year sale growth share adjust earning vs last year related biogen takeover prospect soured mere monthsdow johnson johnson highlight multiple issue drug biotechswhich biotechs be buyable sector recover
457,CELG,biotech boom peaked july industry slowly recover slump biggest biotech etfs be look more attractive spdr biotech etf xbi be trading week high approach potential buy point flat base etf have moved back day move average past couple week strengthen chart ibd biotech industry group have be top group many week reflect industry comeback yet be still short stock superior fundamental be proper buy point even many stock high ibd composite rating be low price stock otherwise lack few be still unprofitable company spdr biotech etf provide way invest sector broad advance have find specific stock buy index also provide buffer company specific risk be big biotechs poor clinical trial reject drug application be risk top usual investor worry such earning report fund own stock include industry heavyweight such biogen biib gilead science gild celgene celg amgen amgn largest holding term portfolio weight be small cap midcap company such ionis pharmaceutical ion exelixis exel tuesday exelixis break base retreat right back buy point next day etf select stock mainly revenue earning market perception be also consider accord prospectus stock be picked total market index broad domestic gauge have market capitalization certain liquidity ratio requirement average weight market cap be spdr biotech rise more first month have average annual gain past year past year compare favorably ishare nasdaq biotechnology ibb widely hold etf fund rise first quarter year average return be year average return be ishare biotech etf be more heavily weigh industry giant industry outlook be difficult measure much depend new drug hit market be pressure drugmaker cut price costly medicine growth prospect sector have be decline drug pricing debate be extremely difficult handicap golub chief equity strategist rbc capital market say health care sector report last monday ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related etf near new high apple largest holdingbiotech cruise day upswing price target cut duo
458,CELG,bristol myer squibb bmy celgene celg stock rocket thursday biotechs report metric wall street expectation up earning guidance bristol myer stock rise close stock market today celgene stock jump follow announcement fellow biotech alexion alxn also report thursday surge almost bristol myer report sale cent earning share ex item respective vs year earlier period consensus analyst poll factset have expect cent sale drive bristol myer quarter grow year year vs growth worldwide revenue drug cancer med opdivo lead bristol myer pipeline sale more triple year figure opdivo treat nonsmall cell lung cancer nsclc compete merck mrk keytruda european regulator recently approve opdivo treat adult relapse refractory hodgkin lymphoma bristol myer be look use opdivo treat unresectable metastatic urothelial carcinoma bristol myer also boost guidance ep ex item expect worldwide revenue grow high teen percentage introduce guidance ep ex item help alleviate nervousness go evercore analyst john scottus write research note ibd take political angst have draw biotechs ibd company medical biom biotech industry group fall group track just week keep eye ibd etfs fund section potentially hot sector celgene report ep ex item sale top consensus analyst poll thomson reuter year year basis metric grow chemotherapy drug revlimid drive lion share celgene sale bring revenue vs year earlier quarter revlimid sale top consensus expectation be drive new patient gain scottus write separate report revlimid be be examine maintenance treatment newly diagnosed multiple myeloma patient ve already receive autologous stem cell transplant european regulator be due make decision review revlimid ndmm first half growth be stoutest otezla celgene drug treat psoriasis other inflammatory disease otezla bring grow year year otezla growth be drive market share gain increase prescriber adoption company say otezla beat sale expectation be almost completely offset internationally sale miss broad analyst view scottus write celgene also update guidance sale include contribution revlimid ep item celgene see sale revlimid top ep item related alexion crush expectation stock bound drug trial planscelgene pit gilead biogen crohn drug battlecan top biotechs climb wall worry rbc call rallymerck crush expectation follow lung cancer drug winmerck topple bristol myer lung cancer drug
459,CELG,alexion pharmaceutical alxn top wall street expectation early thursday announce plan begin enrolling patient new drug trial quarter send stock bound month high stock jump close stock market today share fellow biotechs bristol myer squibb bmy celgene celg jump too board beat bristol myer rise celgene climb alexion report sale earning share ex item respectively vs year earlier quarter metric top consensus analyst poll factset modeled soliris used treat paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring lion share alexion sale vs last year top consensus view rbc analyst simo simeonidis say hpp drug strensiq also beat consensus sale beating consensus simeonidis write research report compare strensiq launch pull kanuma drug treat patient lysosomal acid lipase deficiency fall just expectation sale vs consensus view simeonidis write kanuma be approve late last year pull sale simeonidis keep outperform rating alexion stock alexion also raise full year guidance upper end top side ep item soliris sale guidance be reiterate metabolic sale franchise view be lift begin enrolling patient trial alxn soliris be used treat pnh ahus ibd take eyee right biotech take more just investment earning growth get hand formula here related stock index hesitate celgene leap result
460,CELG,stock rally big gain head lunch hour wednesday market continue digest president elect donald trump surprise victory dow jone industrial average run ahead rise nasdaq add volume be higher board vs same time tuesday dow future have plunge much point wednesday night steel medical drug stock lead upside stock market today hospital solar automaker underperform west texas intermediate crude price rise barrel gold future be ounce merck mrk pfizer pfe caterpillar cat be top gainer dow rally north apple aapl be have pare loss nearly stock be still day move average breach nov just shy cup handle buy point first clear iphone maker well other tech company include microsoft msft cisco system csco benefit donald trump cash repatriation proposal congress permit cisco be microsoft be fractionally lower biotechs have be target presidential candidate hillary clinton high pricing jump amphastar pharmaceutical amph soar surge past day line triple average trade share be now well extend past cup handle buy point initially clear aug injectable drugmaker tuesday report adjust earning cent share top view reverse loss same year quarter other biotechs celgene celg hold gain earlier spiking much week high incyte incy rise biogen biib leap related apple microsoft cisco eye trump overseas cash tax plan
461,CELG,election year have add pressure hit biotechnology stock hard look hood sibling biotech etfs be reveal show more speculative company extremely heterogeneous industry cause much hurt bioshare biotechnology product bbp be year date oct invest establish company have bring least drug market stock holding exchange trade fund include biogen biib amgen amgn celgene celg gilead science gild regeneron regn ibd take largest cap weight biotech etfs stand benefit most top company climb wall worry have build industry bioshare biotechnology clinical trial bbc be so far invest young smaller company drug be experimental testing stage portfolio include sarepta therapeutic srpt share rocket september fda approve drug treat duchenne muscular dystrophy approval mean sarepta move bbp portfolio bioshare etfs next rebalance december etf pair allow investor decide much mix term combine more risky less risky biotechs say paul yook founder bioshare bbp focus household name make relatively less volatile fund contrast bbc hold riskiest biotechs highflying company share double triple overnight crash burn just well yook describe bbp bbc only exchange trade fund separate clinical trial company product company distinct stand alone investment investor don seem much enamored idea custom tailor risk fund be extremely small thinly trade nearly year debut have however see combine net inflow first quarters bbp fund be best performer biotech etfs so far year bbc worst meanwhile bellwether ishare nasdaq biotechnology ibb have give year date sit december high biotechnology etfs crumble past year come pressure lackluster earning well negative scrutiny health care peer valeant pharmaceutical vrx mylan myl politically charge season wall worry industry group least analyst have favorable outlook biotechs nov presidential election yook point promising sign pickup mouthwater sticker price target company allergan agn announce september acquire vitae pharmaceutical vtae roughly premium share biotechs be attractively price too be rare corner stock market valuation be cheaper have be historically yook tell ibd phone interview many etf investor be wait buy biotechnology stock november election believe fear hillary clinton presidency be price democratic presidential contender remark drug price gouge have trigger sharp biotech decline yook add most political scrutiny be face specialty pharmaceutical company such valeant mylan horizon hznp bioshare fund avoid related top biotechs climb wall worry rbc call rally
462,CELG,be etf investor fret day whole lot mostly stubborn fact be few bargain be have broad stock market broad fix income market have be confront almost client conversation have story soar high valuation say martin small head ishare exchange trade fund blackrock nothing be cheap etf investor borrow popular dog dow strategy find value investment tell ibd phone interview dog theory recommend investing annually highest yielding company blue chip index think be dog be oversold likely rebound price research show strategy outperform overall stock market long term have inspire several etfs include alp sector dividend dog sdog small believe investor be reward similar different approach used etfs take advantage granular exposure specific region industry etfs offer goal be find dog etfs have sell irrationally offer value relative market be process involve used ishare etfs example screen list fund used price return rather dividend yield traditional dog strategy dog base fund do poorest performer include fund be cheap oversold offer attractive opportunity small suggest investor evaluate performance fund shorter term year date example longer period year example here investor learn look current ishare etf dog worst perform ishare etfs year date show broad area have be beaten foreign develop market health care nasdaq biotechnology ibb crumble nov ishare msci europe financial eufn same period ishare core ivv track broad stock market advanced small ibb seem oversold sector favorable intellectual property strong sale fund stock holding include celgene celg gilead science gild biogen biib negative trend coincide scrutiny drug pricing ahead nov presidential election mean rally be store drugmaker political risk abate case eufn turnaround be likely depend monetary policy have desire effect have asset brexit continue cause uncertainty italy embroil bank loan trouble important look long fund decline well fast deep decline be factor such magnitude speed decline be additional piece information help round story decide be opportunity want tap small say idea type analysis be decide etf loser be unduly punish well revert be more attractive normal incredibly sell investment return very quickly mean other take very long period time small say add value investing often require patience suggest value investor not only ask much be dog also think long take get dog trained put etf dog opportunistic sleeve portfolio carve apart core holding higher growth investment extent need take higher risk best do strategy do type value seek small say other word do be hard most fund investor buy low sell high opposite buy high sell higher strategy slim investor know love value dog etfs approach be require investor understand underlie driver portfolio holding say todd rosenbluth director fund research cfra basically make investor buy etf look forward not backward consider past performance be limit value predict future performance etf investing not chase winner not discard loser understand etfs have perform way have say etf perform well be not relevant continue rise index base etf merely reflect performance market target case active mutual fund index fund manager have control stock portfolio related dog etf hit record high dividend portfolio
463,CELG,celgene celg biotech market cap rival johnson johnson jnj galapago glp gilead science gild biogen biib crohn disease drug top efficacy expectation company say sunday prompt boost share monday stock market today celgene stock lift briefly slip month low share be year rbc analyst michael yee say politic be tamp biotech stock ibd take biotechs be worst perform group last wednesday supernus pharmaceutical prothena stock topple keep tab industry theme best stock bet yee be bullish ged celgene drug combat crohn recent study patient ged show improvement cdai crohn disease activity index se cd simple endoscopic score crohn disease wall street eye be more tune latter week trial patient show least reduction se cs be clinically meaningful endoscopic improvement say yee cdai metric show response be remission week be good higher expect doctor expert say datum patient achieve be good particularly convenient oral drug yee write research report monday gilead galapago filgotinib be phase testing phase didn look se cd endpoint so be compare celgene ged yee write stelara show same improvement patient week study include placebo biogen also have mt drug treat inflammatory bowel disorder go phase testing crohn well ulcerative colitis be major category inflammatory bowel disorder yee model ged add sale time celgene world move pill treat crohn stelara be injection believe celgene promising early endoscopic improvement get better time ged be otezla crohn disease meaning even not most potent drug still be drug celgene well tolerate good safety convenient good efficacy write credit suisse analyst alethia young model peak sale ged have price target outperform rating celgene stock next catalyst celgene stock likely be firm present week datum young say provide important clue sustainability mucosal heal write research report see effect early be positive have suggest mucosal heal be therapeutic endpoint testing crohn drug mucosal heal endoscopic remission be associate increase rate clinical remission accord national library medicine related celgene biotechs top wall worry trio new celegene drug bring
464,CELG,dow jone industrial average nasdaq composite end gain less thursday ahead friday job report preliminary datum show volume nyse nasdaq come slightly higher wednesday level crude oil slide level plunge wednesday news crude supply rise barrel highest record april wti crude oil slide settle barrel hit low earlier session hour mover earning include finisar fnsr ulta beauty ulta finisar have be set cup handle base buy point share crash hour trading ulta beauty give extend trading ulta have be struggle make progress recent buy point stock market today earning report be mixed beauty soar company report better expect earning sale also issue bullish guidance elsewhere earning national beverage fizz best know lacroix sparkling water brand jump just entry cup shape base meanwhile celgene celg continue make case more upside share rally nearly positive comment ub accord cnbc still buy range buy point approach recent high ibd restaurant chain dave buster play have good day prior entry stall buy point be back play thank thursday heavy volume gain year treasury yield basis point close quickly level not see mid december related ulta beauty earning sale strong guidance isn prettyfinisar flub earning revenue outlook miss stock plungesdow exxon mobil royal dutch shell announce energy deal oil undercut
465,CELG,xno drugmaker pfizer pfe be angle take biotechs celgene celg juno therapeutic juno kite pharma kite treatment type leukemia partnership french pharmaceutical servier thursday servier announce fda have grant application pfizer begin develop drug know ucart treatment blood cancer know acute lymphoblastic leukemia acute lymphoblastic lymphoma cause certain white blood cell be overproduced bone marrow inhibit production spread normal red white blood cell accord emedicine com disease largely inflict child pfizer servier ucart belong class drug help immune system identify specific protein cancer cell thus allow immune system destroy cancer engineer immune system cell be grow lab then infuse patient ibd take celgene be near breakthrough technology head ibd stock analysis breakdown company strong growth last week juno be force end trial treat disease juno have plan test new drug next year partnership celgene meanwhile kite be testing drug know kte same disease late trading stock market today pfizer stock be fraction kite stock lift announce wednesday public offer common stock share juno stock be help prompt jump celgene stock be related celgene unveil breakthrough treatment movejuno tank end leukemia trial rival kite topple downgrade
466,CELG,stock hold modest gain early thursday oil slow slide european central bank left rate unchanged apple meantime provide bit drag dow jone industrial average nasdaq composite dow jone industrial average nasdaq composite climb less small cap russell advanced volume edge higher board vs same time wednesday agricultural chemical airline biotech issue be top gainer today stock market action office supply oil datum storage stock lag west texas intermediate crude price slip more barrel tumble more wednesday ibm ibm caterpillar cat be dow biggest loser respectively goldman sachs gs jpmorgan jpm lead upside also blue chip apple aapl dip stock breach short term day move average first time late january remain time high be extend cup handle buy point apple iphone launch be delay usual september launch due component supply issue accord wednesday report french apple news igeneration beauty soar gapping day line tremendous volume cosmetic maker late wednesday report result top view guide better expect earning revenue share be work right side consolidation potential buy point cosmetic retailer ulta beauty ulta report close be stock be buy range flat base entry clear last month celgene celg rise fast turnover near buy point flat base biotech march announce encourage trial result otezla psoriasis treatment economic news employer announce layoff february last year january initial weekly jobless claim rise prior week expectation new claim related ulta beauty earning see jump stock soar dow exxon mobil royal dutch shell announce energy deal oil undercut wait apple iphone have even longertop biotech unveil breakthrough treatment move
467,CELG,market midst mild pullback many lead stock be fall other stock continue attempt move higher market pause burlington store burl celgene celg texas instrument txn have hold well brief moment market weakness be try move higher burlington store
468,CELG,president trump rail outrageous drug price monday send biotech pharma stock reel midday tuesday appear gop bill repeal replace obamacare doesn touch pharmaceutical newest iteration american health care act doesn mention trump plan curb spiraling drug price speech monday send ibd company generic drug industry group tailspin drop month low generic drugmaker dr reddy laboratory rdy stock sank stock market today eagle pharmaceutical egrx tumble aclaris therapeutic acrs dip ani pharmaceutical anip lose ibd company biom biotech industry group crash collective la jolla pharmaceutical ljpc puma biotechnology pbyi kite pharma kite stock particularly hard respectively lose specialty drugmaker endo pharmaceutical endp fall mallinckrodt mnk drop depome depo topple trump unspecified plan call bring cost medicine have fair competitive bidding process president say late monday rally kentucky medicine price be come way way way way go happen fast say re just add bill say ve get add bill call cost medicine country outrageous say many time higher country europe elsewhere ibd take drug approval slump least company add new drug wheelhouse see one ibd industry theme somebody be get very rich say later comment drug price aren include first version american health care act legislation address drug issue follow closely trump have have love hate relationship drugmaker early presidency call drugmaker lower pricing later meeting ceo celgene celg johnson johnson jnj merck mrk novartis nvs other pledge cut fda regulation speed drug approval process last week trump unveil blueprint propose increase user fee collect fda drugmaker more do so squeeze already thin margin generic drugmaker related pharma stock be big loser trump drug pricing tweetbiotechs leap trump call innovation speedy fda approvalj ceo underwhelm investor trump dodge drug pricing
469,CELG,stock market wake bit cranky monday be better mood close major stock index pare early loss news north korea fire ballistic missile sea japan fuel investor angst morning dow jone industrial average hold best fall just
470,CELG,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
471,CELG,ibd company medical biom biotech industry group drop past week rbc analyst michael yee expect stock rally lackluster earning election season wrapped sector still have nearly week choppiness nov election recent blowout have have investor take profit yee suggest recent video buy dip biotechs climb wall worry earning not be hugely great biotechs combination uncertainty election understand trade choppy spdr biotech etf xbi get clarity election say ibd take biotechs be worst perform group wednesday ibd track group last month biotechs be major roll keep tab industry theme sector grab attention company group share spdr biotech etf have plunge dramatically month past week thursday share be flat entry point flat base biggest biotech player yee be most confident amgen amgn biogen biib respectively no market cap stock market today amgen biogen rise fraction respectively consensus analyst poll thomson reuter expect amgen report sale earning share ex item flat respectively vs year earlier quarter analyst model biogen report sale ep ex item biogen be stock own next month yee say chance biogen get take still lack ceo company announce july rumor george scango step yee also see chance eli lilly lly alzheimer drug trial yield positive result tug rival biogen other catalyst include biogen partnership ionis pharmaceutical ion drug treat type muscular dystrophy spinal muscular atrophy sma ionis be enrolling infant child phase trial sma wall street underappreciate catalyst yee say celgene celg too have number trial stoke stock yee say analyst model jump sale ep ex item celgene share be rise small fraction thursday yee only expect line quarter early next year celgene be expect release result trial drug treat muscular dystrophy crohn disease ulcerative colitis be likely stock catalyst gilead gild biotech market cap be rough quarter shadowy visibility hepatitis drug yee say drug epclusa win fda approval june be used pill form treat type hep lack greater visibility gilead stock be range bound yee say consensus expectation be too high hep sale ep write research report consensus analyst poll thomson reuter model ep ex item yee estimate be broadly analyst be bearish gilead forecasting sale dip ep item share be past week end thursday flat smaller intercept pharmaceutical icpt market cap likely print board beat yee predict share have be pressured recently gilead novartis nvs allergan agn be jump nash alcoholic steatohepatitis train nash drug have make big headline past month allergan buy tobira therapeutic tbra bulk nash battle say yee intercept drug belong class call fxr agonist be more potent intercept drug get liver activate fxr farnesoid receptor liver say other don get much fxr effectivity liver just do gut not potent intercept yee also call prothena prta own likely positive parkinson drug psoriasis drug datum spring respectively prothena stock be sell zone thursday entry point achieve rise nearly thursday related gilead try buy next poll offer incyte prothena build psoriasis science arthritis treatmentincyte stoke fire deep durable melanoma drug result
472,CELG,be huge week earning apple aapl amazon amzn alphabet googl be list headliner slew industrial medical restaurant more also report tesla motor tsla report surprise profit qualcomm qcom buy nxp semiconductor nxpi nasdaq fall week amazon miss apple modest beat fail impress tech heavy index drop day line retake level last week sank dow rise bond continue fall world push year treasury yield multimonth high september quarter apple earn share year year sale analyst expect apple earn share sale holiday quarter apple guide wall street higher revenue profit margin outlook come short apple also unveil new macbook pro notebook computer feature touch screen strip application command shortcut replace function key apple fall week remain day line amazon report earning cent share big gain well short estimate cent commerce giant plow money amazon web service cloud compute unit big expansion fulfillment center head holiday season revenue rise meeting view aw be bright spot earning report revenue rise year year beating consensus revenue guidance also lag amazon share fall friday close day line first time month earning share item rise total revenue climb vs consensus estimate google parent alphabet signale higher investment cloud compute business higher marketing cost tie september launch pixel brand smartphone smart home speaker compete amazon echo google net revenue higher traffic acquisition cost tac cost be top view alphabet share nearly hit record high friday morning close day fractionally higher week fractionally lower still buy range tesla motor earn cent share exclude item soundly beating consensus estimate cent loss revenue climb top estimate elon musk have push tesla boost delivery turn profit analyst be skeptical effort be sustainable tesla maintain guidance vehicle delivery second half plan just tesla solarcity scty late friday be expect unveil integrate product offer solar panel battery storage charger tesla be process buy solarcity elon musk be top shareholder company well spacex tesla find resistance day line reversed end week cent solarcity climb gigamon gimo report third quarter profit revenue blow past estimate raise current quarter guidance santa clara calif base gigamon say ep item rise cent revenue jump analyst have project cent current quarter gigamon forecast ep cent revenue midpoint guidance vs consensus estimate cent profit revenue growth analyst say be new customer join mobile tmus gigamon shot friday hit record high intraday share have fall thursday day line lumentum lite say ep rise cent revenue climb top expectation current quarter revenue guidance be light telecom component shortage unnamed supplier ep guidance cent midpoint be consensus estimate cent lumentum fall late thursday report follow fall thursday acacia communication acia crash day week chinese telecom gear giant zte key acacia customer report weak revenue qualcomm announce deal buy nxp semiconductor create chipmaker revenue intel intc include debt deal be worth mobile communication chipmaker qualcomm say acquisition expand footprint key growth market include automotive internet thing security networking qualcomm nxp transaction mark biggest semiconductor deal ever surpass technology purchase broadcom avgo new oriental education technology edu meet fiscal ep view gain cent revenue climb analyst expectation enrollment boom ibd stock see revenue analyst guidance fellow chinese profit school stock tal education xrs result top estimate total student enrollment jump guide revenue wall street view new oriental stock rise more week blast base new high tal education climb also high related new oriental education break strong revenue guidancetal education stock enter profit take sell territory beatchipotle grill cmg earn cent share revenue fall nearly expect same store sale tumble fast casual burrito chain still struggle recover late food bear illness outbreak share fall wednesday hit year low panera bread pnra beat view send stock higher intraday wednesday reversed lower fall month low thursday buffalo wild wing bwld meet ep view miss sale share rise thursday recent lows food delivery service provider grubhub grub report ep rise revenue top grubhub active diner rise miss estimate slightly share have be month high fall nearly wednesday tumble day line biogen biib post sale ep ex item top view prod share nearly thursday bristol myer squibb bmy rise celgene celg alexion alxn beating earning amgen amgn late thursday beat share tumble nearly friday concern key drug enbrel go forward also friday nordisk nvo dive sanofi sny rise european drugmaker have different view outlook insulin treatment meanwhile drug distributor mckesson mck crash friday big miss blame rival abc heavy competition further pressure political attention drug price fall cardinal health cah nearly report earning next week related bristol myer celgene stock rocket sweeping top alzheimer datum vs eli lilly positivealexion crush expectation stock bound drug trial plansabiom abmd fall short earning send share tumble thursday edward lifescience ew revenue come light sale guidance also light send share plunge boston scientific bsx stock fall modestly ep meet sale top stryker syk narrowly top ep sale view late thursday send share friday third quarter gdp growth top forecast fastest growth year consumer spending growth slow significantly business investment remain weak real final sale exclude inventory gain next export slow separately durable good order edge lower core capital good demand fall most february boee ba say realistic possibility launch new midsize plane longer version max seek counter gain airbus eadsy boee result top analyst view revenue commercial airplane division fall defense revenue fall boee share rise week breaking base high related boee realistic possibility midsize jet stretch stock buy zonelockheed martin lmt top view defense giant raise full year outlook next production batch be split separate contract northrop grumman noc raise full year guidance report result analyst view send stock buy territory raytheon ep top estimate revenue be light patriot missile system maker improve guidance still fall short wall street view related lockheed soar outlook payout next contract see splitnorthrop stock enter buy range strong outlook beatbomb lift raytheon outlook be dud stock divesexxon mobil xom top ep estimate revenue fall well short capital spending fall oil production dip chevron cvx crushed ep view revenue miss slightly downstream profit be oil major refine margin weaken conocophillip cop loss wasn bad expect company raise full year production outlook lower capital spending guidance general electric ge be talk oil service firm baker hughe bhi partnership not purchase baker hughe break buy zone tuesday report better expect earning add friday industrial giant unite technology utx caterpillar cat mmm issue weak financial forecast global economic uncertainty hurt sector broadly general electric ge several other notable industrial firm already have cut guidance general motor gm meanwhile warn impact brexit plateau auto market strong full year ep guidance overall athletic apparel maker earning rise sale top view gross margin dip negative impact timing liquidation increase promotion foreign exchange rate armour ua see revenue growth consensus armour vow invest aggressively share fall more wee hit year low related armour dife growth target exec vow invest aggressively
473,CELG,celgene celg stock lift friday biotech market cap investment bank rbc say trio drug phase testing tack sale drug help celgene expand oncology treatment inflammation disease alzheimer genetic disease cystic fibrosis evercore isi analyst john scottus say separate research note view scottus rbc analyst michael yee follow celgene first deep dive protein homeostasis dysfunction protein pathway have be tie cancer pathogenesis celgene work treatment breast lung pancreatic cancer yee say celgene have unique opportunity discovery engine say celgene be expert inhibit cereblon protein encode crbn gene have parlay research treatment slew disease include arthritis cancer blood disease inflammation big picture be celgene have unique engine focuse generate new drug expertise inhibition cereblon protein inhibition degradation go oncology even potential candidate yee write research report yee keep outperform rating celgene stock finished trading stock market today share be still year however yee note wealth candidate celgene have work include new generation version revlimid treatment lupus acute myeloid leukemia celgene new revlimid replacement be wrapped end yee write revlimid be used treat myelodysplastic syndrome multiple myeloma mantle cell lymphoma other catalyst include phase datum multiple sclerosis drug chemo combo partnership roche rhhby readout new irritable bowel disorder drug celgene be also plan additional study cc cereblon modulator combat acute myeloid leukemia scottus write report ibd take drugmaker include celgene potentially see drop earning california pass ballot initiative november require state medicaid agency other state player buy prescription drug similar rate department veteran affair related amgen biogen gilead spike va pricing skirt california measurebiotech etf best level january
474,CELG,here weekly investing action plan need know investor come week tech darling apple aapl tesla motor tsla amazon amzn alphabet googl report earning well aerospace defense leader boee ba lockheed martin lmt industrial giant big biotechs medical device maker weigh too oil
475,CELG,california ballot initiative require state medicaid arm buy drug comparable price department veteran affair pay backfire thus preserve sale nation biggest drugmaker rbc analyst michael yee say thursday proposition california drug price relief act cdpra sound good theory yee write research report assume drugmaker don simply eliminate steep discount already provide va say happened year congress pass law require drugmaker grant medicaid similar discount give manufacturer larger customer write law ultimately prompt manufacturer raise price paid larger customer include va likely be fate cdpra write californian appear overwhelmingly support initiative early month university southern california los angele time survey find respondent approve cdpra san francisco firm poll july find support drugmaker amgen amgn gilead gild celgene celg biogen biib regeneron regn vertex vrtx cdpra offer merely headline risk yee write assume large price cut medicaid sale earning decrease only company product be expose medicaid state enact such measure mean earning share risk large cap player yee write year california be alone initiative ohio proposition didn make ballot however va price discount then probably become nonexistent lower va price lead reduce medicaid price write note medicaid already get discount date cdpra opposition have only spend donation yee expect spending ramp significantly ahead nov ballot rbc research show proposition be win side have most funding cdpra supporter have raise only supporter include former presidential candidate bernie sander say cdpra save californian taxpayer year va pay less other government agency prescription drug opponent argue cdpra invalidate exist contract state drugmaker force increase state drug price reduce funding medi cal initiative also increase state expense employee spend time resource match state price va pay ibd take ibd company medical biom biotech industry group rank group track have climb just week stock have heated wall street expectation major big pharma action however stock market today group close hurt intra cellular therapy stock plunge
476,CELG,bristol myer squibb bmy stock crash year low monday competitor merck mrk unveil phase result show lung cancer drug keytruda be twice effective chemotherapy spark stock close bell stock market today bristol myer squibb stock plunge end trading merck stock other hand lift much year high end monday trading share briefly hit entry point flat base add gain january new buy be risky current volatile market environment ibd take merck stock be buy zone far alone check ibd stock buy zone find player be recommend bet share ramp merck presentation european society medical oncology conference copenhagen merck unveil result phase testing keytruda drug treat small cell lung cancer keytruda alone extend progression free survival month vs month chemotherapy lung cancer patient express specific type protein merck say merck also combine keytruda eli lilly lly chemo drug alimta study patient respond combination vs patient receive chemo median progression free survival be month longer combo bristol myer squibb nivolumab rival treatment lung cancer show virtually benefit evercore isi analyst john scottus write research report left investor scratch head say credit suisse analyst vamil divan expect merck take major leadership position lung tumor market vs bristol myer astrazeneca azn roche rhhby say roche pile pressure tecentriq tecentriq have show overall survival benefit second line lung cancer regardless protein expression write estimate peak sale probability success rbc analyst michael yee expect celgene celg fly potential chemo combo merck test keytruda see celgene grow revenue only first line lung cancer patient be treat chemo combo other news conference credit suisse divan expect novartis nvs face pressure post esmo novartis drug combat metastatic breast cancer be effective pfizer pfe ibrance have serious safety concern efficacy appear line ibrance safety observation hy law risk fatal drug induced liver injury qtc prolongation mild cardiac arrhythmia put drug disadvantage pfizer ibrance eli lilly abemaciclib be approve write novartis stock lose end monday trade bristol myer eli lilly astrazeneca roche pfizer novartis merck be ibd ethical drug industry group group have be slumping rank related celgene trio new drug tack rbcamgen biogen gilead spike va pricing skirt california measureroche drug score lung cancer challenge bristol myer
477,CELG,investor toast third quarter strongest year september alone be exciting bottle bubbly go flat third quarter rise lift diversify stock mutual fund average broad market advanced barely breaking even september nose upward modest stock fund edge ahead mere last month raise stock fund gain year date stock market start stop motion third quarter have prompt many fund manager plan ahead sticking name drive strong trend such shift cloud compute company seem capable grind growth matter blah growth be broader economy click here see list ibd mutual fund quarterly leader first half year see more defensive lead rally say lew piantedosi manager eaton vance fund total asset reversed cyclical tech industrial do better click here see list mutual fund month leadersworld equity fund advanced outperform diversify stock fund last month world equity fund rise china regional fund gain lead world equity market september rac return cyclical sector stay hot then stock tie transportation industrial good commodity continue third quarter gain piantedosi hold norfolk southern nsc gain third quarter focuse growth opportunity class eifgx july tax manage growth eitmx hold union pacific unp rolled gain most cyclical lose head steam piantedosi prefer long view focus big picture growth trend be sustainable shift macro noise say facebook fb amazon amzn alphabet googl be sustainable grower benefit great secular tailwind say name have do well especially amazon still runway ibd take ibd brian deagon analyze tailwind drive amazon buy sell column julie mak point lead mutual fund have be selling alphabet amazon tech sector be acquisition seem be pick say click here see list mutual fund category say investor brace volatility election democratic white house senate house republican hand mean continue gridlock say still impression be support tax reform be grow party be huge positive say health care wary many drugmaker due political call price regulation still like celgene celg vertex vrtx biogen biib biotechs feel little safer biotech drugmaker say be do wonderful thing cure big disease combine positive reward risk re beaten trading valuation attractive valuation retail like few name area watch head holiday especially more apparel oriented stock piantedosi say be short term theme macy have go markdown have discount last year overstock say mild winter dampen consumer demand warm clothe competition be stiff amazon company have do great job manage inventory go holiday year piantedosi say expectation be low ve be monetize real estate selling close unneeded location continue home improvement giant lowe low home depot hd housing be still strong say interest rate be still low consumer be stock price have come little fear housing slowdown jeff rottinghaus rowe price manager growth income prgix large cap core trulx say stock price general seem fairly price like name health care price have be push call becton dickinson bdx medtronic mdt unitedhealth group unh quiet none be political pressure drug pricing becton develop medical supply medtronic develop implantable cardiac device other product unitedhealth be industry biggest manage care provider yet rottinghaus be shopping biotechs price be so beaten be underweight tech sector like company benefit secular trend cloud compute growth include alphabet microsoft msft also like sustainable secular growth visa facebook rottinghaus also like nextera energy nee have dividend yield largest renewable energy generator say dividend yield be roughly wouldn own low double digit earning growth expect growth oriented sector lead stock fund third quarter charge science technology fund zoom ahead quarter top september gain health biotechnology fund be also strong manufacturing gain quarter small cap growth fund gain average lead diversify stock fund category left year september gain be related stock fund manager seek scarce profit durable growth stocksmarket tread water august investor shift growth stock
478,CELG,major index etfs finished flat tuesday investor shrug weak housing datum await federal reserve decision interest rate biotechnology exchange trade fund rise health care lead advance sector share sarepta therapeutic srpt have nearly double price monday just federal regulator approve company drug muscular dystrophy ishare nasdaq biotechnology ibb pop stock market today spdr biotechnology xbi add best level early january etf be play biotechnology sector take bigger risk potentially larger reward xbi give stock equal weight importance so small cap company sarepta have roughly same stake portfolio biotech giant amgen amgn celgene celg contrast cap weight ibb focus first foremost biotech major more half asset be tie top holding stock include amgen celgene biogen biib third quarter date xbi be vs ibb former also have modest edge term annual average gain past year price biotech stock have re-cover so have investor interest small cap biotech etf say david mazza head research spdr etfs year date investor have add fresh money xbi recently price action have be drive company specific news influence presidential election mazza tell ibd email investor brace continue influence external factor head november caution biotech stock be sensitive certain remark political nature rhetoric price gouge drug industry tend intensify ahead vote ibd take sarepta muscular dystrophy drug face long controversial march fda approval mean company growth story be just begin energy lead decline sector thursday energy select sector spdr xle post loss unite state oil uso commodity etf investing month wti future reversed solidly higher catalyst be opec statement tie potential output freeze major world oil producer meet algier next week crude price be gut past year worry oil glut global growth mount spdr gold share gld re-cover tuesday early loss help lower odd september rate hike commodity etf track price gold here major exchange trade fund major asset class perform today ibd relative strength rating rs rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
479,CELG,biotech gilead gild be most likely scoop incyte incy next month accord survey industry watcher evercore isi investment bank ahead presidential election pit donald trump hillary clinton survey say most see gilead purchase incyte identify incyte biopharma most likely be acquire next year nearly respectively see biogen biib biomarin pharmaceutical bmrn target gilead acadium pharmaceutical acad celgene celg kite pharma kite be least likely be target only industry expert identify likely takeover candidate departure needham analysis last week identify potential suitor acadium incyte takeover likely come heavy price june gilead have cash equivalent market security hand market cap gilead be biotech trail only amgen widely view big biotechs most need be active front incyte have market capitulation smaller coalition say gilead buy vertex vrtx bristol myer squibb bmy outside lion share expert expect biotechs outperform broader market next month respondent say biopharmas merely be line trade election say expert ibd company medical biom biotech industry group be year loss be early year overall market tumble group be more late june now rank group track just week close stock market today group be more buck day downtrend ibd take latest industry snapshot explore biotech promising new drug stock be lead biotech sector drug pricing initiative rout stock year rbc analyst say thursday acknowledge drugmaker amgen amgn gilead celgene biogen regeneron regn vertex easily find loophole skirt new regulation still fewer person poll evercore expect government take meaningful action drug pricing nearly largest chunk say government win ever push reduction drug price other prediction stem specific company only expect eli lilly lly alzheimer drug solanezumab hit cognition function endpoint more broadly say hit cognition miss function more half say celgene phase testing ged oral mongersen treatment crohn fail reach overwhelming efficacy see phase testing phase patient take milligram be clinical remission day small say celgene see better result phase testing only expect study fail entirely result show endoscopic improvement respondent say celgene stock pop third expect share remain stagnant related gilead paralyzed likely hep share lossamgen biogen gilead spike va pricing skirt california pharmaceutical fall combo therapy eylea alone
480,CELG,strength biotech stock buoy nasdaq composite wednesday strong show apple aapl didn help dow much afternoon selling remind investor market uptrend be pressure close nasdaq rise dow jone industrial average lose fall less sell oil gas stock preliminary datum show volume nyse nasdaq come lower tuesday level solar oil gas airline stock underperform stock market today dow component apple surge past buy point heavy volume rise nearly extend gain tuesday move be fuel news strong preorder iphone skywork swks broadcom avgo outperformed nasdaq several biotech name alexion alxn celgene celg regeneron regn several recent ipos outperformed name impinj pi penumbra pen lumentum lite rise more ibd name rise more gigamon gimo have nice day presentation positive comment william blair ibd take gigamon be top performer ibd internet network solution group plenty other competitor be act well see be ibd stock checkup ibd component netease nte continue assault new high rise share be so far week report tuesday say company plan divest news business focus fast grow online gaming sector new york mercantile exchange wti crude oil future october delivery fall barrel year treasury yield be basis point
481,CELG,biotechs celgene celg agio pharmaceutical agio be trading wednesday company say ll be filing fda approval blood cancer drug earlier expect agio say sec filing ahead presentation citi annual biotech conference year end celgene file application enasidinib ag acute myeloid leukemia aml previously timeline filing be unclear newest batch clinical trial datum isn expect next year last batch come year datum cancer drug ag also be year end agio celgene also file early approval drug filing say agio stock catapult nearly close stock market today stock have take even bigger beating most biotechs last month analyst commentary have generally be cautious face strong look competition aml abbvie abbv roche rhhby venetoclax well seattle genetic sgen sgn cd celgene stock be close ibd take celgene have be crank steady financial growth stock be still look buy point spending year consolidate learn find buy point see buy stock related agio upgrade anemia drug datum soothe safety concern
482,CELG,diversify stock mutual fund extend rally february pick steam tack average gain january accord lipper inc reflect gain broad stock market measure advanced last month notch gain january market leadership rotate back more defensive sector reflect grow caution investor more defensive stock do well cyclical energy material do not outperform say lew piantedosi be lead manager eaton vance fund totale asset be complete reversal postelection market rally be cyclical rally sentiment flip back favor growth oriented cyclical president trump address congress last night february tilt earlier february cyclical reflect investor concern trump republican majority congress have harder time previously expect implement pro growth policy reflect optimistic portion february market performance health biotechnology fund lead sector last month gain diversify stock fund category index fund lead way gain world equity fund lag diversified advance just lead india region fund climb taxable bond fund eke gain average last month emerge market local currency fund outpaced other taxable category rise piantedosi be guardedly bullish go forward bull market be place proven otherwise say many investor market observer have try call market top economy keep get better piantedosi say corporate earning keep get better earning support market add wild card derail rally be political landscape warn long economy stay track piantedosi like shift digital advertising benefit facebook fb alphabet googl say amazon amzn dominate online retail area like be biotech be produce parade treatment disease celgene celg be leader cancer treatment say have unbelievable pipeline be grow earning north annually trade time forward multiple just market multiple ibd take celgene be rank ibd medical biom biotech industry group see biom biotech firm be check easy understand fundamental technical datum ibd stock checkup energy like energy explorer producer anadarko petroleum apc field service provider halliburton hal say anadarko be once again profitably grow production generate significant cash flow be attractively value add halliburton exposure be mainly north american shale oil price steady mid re start see rig count increase increase need field service put rig together service replace break part so add consumer discretionary hard find good name advance auto part aap re auto part retailer sector be less susceptible be amazon business doesn require lot capital expenditure so good cash flow type business advance get new ceo month supply chain expert be advance need key reason be hard investor find consumer discretionary name be so many big box retailer be get kick online retailer say james abate chief investment officer centre asset management manager select equity dhamx add risk many be force cope higher cost stem border adjustment tax basically value add tax import propose trump abate say name sector do still include medium company cbs cbs specialty food retailer whole food market wfm sporting composite rating ibd cbs be try clear consolidation run start fall whole food have very weak composite rating ibd be trading less half late high supermarket chain january reinstal co founder john mackey sole ceo also trump push infrastructure construction benefit number utility company include comcast cmcsa verizon vz abate say comcast have be run election be time high verizon range bound july be trading week high flow control system manufacturer parker hannifin ph also stand gain infrastructure spending likewise quanta service pwr provide engineering construction service benefit increase spending pipeline energy transmission project say market face risk form geopolitical uncertainty possible trade war rise stock valuation abate say lot downside risk face market say expect lot volatility go forward related mutual fund manager cite tech financial energy industrial name
483,CELG,stock market end monday modest gain be different story small cap russell add strong performance russell also help ibd name rise more close growth stock index end gain nasdaq composite add
484,CELG,aerospace industry group send letter congress friday back republican plan overall tax system member dow jone industrial average component boee ba break ground new finishing plant china end month urge enact legislation modernize tax system allow america business better compete global marketplace encourage job creation innovation unite state aerospace industry association america say letter congress say accord reuter letter make public aia group say propose house corporate tax reform blueprint benefit american business american worker board blueprint lower corporate tax rate add border adjustment tax last month boee ceo dennis muilenburg dow industrial peer general electric ge ceo jeffrey immelt other industrial exporter drugmaker celgene celg eli lilly lly other write own letter congress urge support bill boee have lot gain propose tax overhaul morgan stanley ms analyst release note monday say boee stock jump border adjustment tax alone boee share be stock market today ge stock fall not business support house blueprint wal mart wmt dow stock strongly oppose border adjustment tax most retailer good become more expensive wal mart share be retake day move average tax blueprint be suppose support job home boee break ground finishing plant end march accord report china business medium outlet caixin tuesday boee announce plan facility finish start preliminary work look build market share rapidly grow aerospace market worker plant paint plane install flight entertainment other system work be be outsourced china boee have argue plant create more not less american job finishing center be location add value china airplane go be build ceo dennis muilenburg say january great example growth china create growth manufacturing job related trump tariff idea isn bat crazybusiness big small enthusiastic trump economic check boee gop tax reform
485,CELG,dow jone industrial average component boee ba be downgrade monday analyst be bullish propose border tax boost share morgan stanley ms downgrade boee equal weight overweight light order flow raise price target aerospace giant share hit congress pass border adjustment tax back december morgan stanley analyst say boee pay little corporate income tax bat even get treasury cut check aerospace giant president trump have backed idea border adjustment tax hasn endorse specific version include house gop plan separately boee announce order cbd aviation lease finance max airplane order be previously unidentified boee be list current price boee share reversed higher close stock market today european rival airbus eadsy list share finished lower boee ceo dennis muilenburg dow industrial peer general electric ge ceo jeffrey immelt other industrial exporter drugmaker celgene celg eli lilly lly other write letter last month urge congressional support house corporate tax reform blueprint include border adjustment tax border tax face battle washington sen tom cotton ark call border tax orwellian last month say hit arkansa base wal mart wmt raise consumer price sen david perdue ga have also speak tax wal mart dow stock strongly oppose border adjustment tax most retailer wal mart share fall ibd take trump budget plan be release thursday give more detail increase defense spending putt defense stock buy range fellow dow industrial stock exxon mobil xom have push back tax say continue advocate free market principle globally competitive stable tax framework integrate global oil major exxon dow industrial peer chevron cvx well bp bp royal dutch shell rdsa import oil refinery operation exxon share retreat chevron share fall morgan stanley analyst be also bullish lead economic stimulus possibility grow global military spending rise budget ally match spending peer well new program bid boee related boee shop new midrange aircraft design potential customerswhy trump tariff idea isn bat crazytreasury check boee gop tax reformthese dow component back border tax shallow support show trouble
486,CELG,market be quiet monday ahead federal reserve day meeting commence tuesday however be lead stock make strong move higher other hover buy point veeva system veev rank ibd break shallow cup handle early trading
487,CELG,general electric ge cfo jeffrey bornstein say wednesday industry sit hand wait not invest lawmaker deliver promise change taxe regulation provide more clarity health care policy warning come house republican corporate tax revamp be run opposition congress more gop lawmaker balk propose import tax see key piece overhaul president trump have yet unveil own tax plan trump also want repeal replace obamacare republican have turn squeamish sweeping change health law barclay industrial select conference miami bornstein say be reasonably confident change get pass say investor be very disappoint aren don get corporate tax reform goal line don provide visibility health care be go don deliver regulatory change administration have talk think end very difficult place say tuesday ge ceo jeffrey immelt ceo boee ba unite technology utx other industrial exporter well drugmaker celgene celg eli lilly lly merck mrk pfizer pfe write letter urge congressional support house tax reform blueprint include border adjustment tax total company sign letter more company include wal mart wmt target tgt nike nke dozen trade group have sign american affordable product group create oppose import tax ge share fall stock market today boee share be unite tech rise last month talk repeal obamacare begin ramp ge immelt also indicated customer become more cautious take segment affordable care act be get most attention medium customer say conference call report mixed result think see caution affordable care act go forward haven really see much happen trump say rally florida weekend replacement plan obamacare win be come couple week warn earlier process last next year meanwhile market be still wait white house detail own tax proposal congressional republican take more flak last week trump tell retail ceo massive tax plan come not too distant future follow remark airline ceo prior week vow announce something phenomenal term tax come week related border tax die trump corporate tax cut collapsetrump silent ex im bank hint big boee super hornet order
488,CELG,biotech celgene celg bolster sale receptos ozanimod multiple sclerosis credit suisse analyst alethia young say friday celgene unveil strong phase trial result drug ozanimod be acquire celgene purchase receptos late stage trial drug show statistically significant clinically meaningful benefit reduce annualize relapse rate milligram mg dose compare biogen biib rival drug anovex drug also hit secondary endpoint include reduction gadolinium enhance mri lesion number new enlarge mri lesion month accord celgene news release indication safety be similar result show phase celgene say specific datum be release upcoming international scientific meeting celgene say potentially american academy neurology annual meeting rbc analyst michael yee say research report ibd take celgene ceo mark alle defend pharmaceutical biotechs drug pricing debate say innovation require incentive be sure head ibd biotech pharma stock page latest headline sector safety profile ozanimod be particularly important differentiate rival biogen tecfidera novartis nvs gilenya also hit legion gilenya label include safety information bradycardia liver toxicity yee say possible celgene have similar safety datum label regard bradycardia say much impact sale drug be unclear give gilenya be go generic first dose monitoring be bit hassle write ultimately celgene bigger opportunity ozanimod be ulcerative colitis be slate be only pill so far credit suisse young say most focuse celgene ms datum first half year uc datum ged crohn disease readout give wall street confidence celgene ability replace revlimid patent loss say stock market today celgene stock rise share pop day move average wednesday trading mark past month share biogen fall friday related roche ceo shrug trump drug stance sale narrowly misslilly hijack diabetes share trump rattle sector dipscelgene lilly merck sit trump call manufacture
489,CELG,biotech celgene celg set lofty goal thursday tack annual ep growth even cancer blockbuster revlimid lose patent exclusivity investor be seemingly disappoint celgene didn update guidance celgene also announce agreement acquire privately hold biotech delinia initial payment contingent payment development delinia lead program del il mutation fc fusion protein design regulate cell acquisition be expect close next quarter celgene expect expand company pipeline autoimmune treatment drug stock market today celgene stock fall finish share fall much earlier trading evercore analyst mark schoenebaum note celgene have see upside view jpmorgan healthcare conference month celgene reiterate upside verbiage earning conference call analyst thursday morning company didn boost guidance company have preannounce most result jpmorgan conference earlier month ibd take biotech leader kick earning season biogen also report morning see analyst expect group largest company do ibd industry theme early feedback ve get client be folk thought celgene officially raise guidance today schoenebaum say note client do not fact raise target believe apparently have do so bullish comment jpm potential upside target celgene report sale earning share ex item respectively vs year earlier quarter preannouncement consensus be still more bullish sale modele ep beat view year revenue rise ep ex item rise company reiterate guidance present earlier month sale revlimid be expect come grow otezla psoriasis med be product expect have best growth related celgene ceo drug pricing debate hinge incentive sidestep sale miss strong ex hemophilia guidebristol myer topple guidance cut merck competition
490,CELG,juno therapeutic juno stock dove biotech end leukemia trial see key ongoing rivalry kite pharma kite have own problem investor thursday share fall hard kite sink analyst downgrade early trading juno stock topple much be halter stock later re-cover somewhat fall kite share fall stock market today day touch month high thursday juno say major setback last year force end rocket trial blood cancer acute lymphoblastic leukemia drug be see key competition kite be currently testing kte drug same disease juno be lag competitor effort get cancer treatment know chimerical antigen receptor market leerink analyst michael schmidt say class drug help immune system cell see protein often camouflage cancer cell kite share meanwhile be pummeled thursday downgrade citigroup neutral rating buy come strong result drug know kte treat lymphatic system cancer know diffuse large cell lymphoma drug have complete response rate cell lymphoma patient share hit month high response wednesday ibd take juno stock have low ibd composite rating meaning underperform quarters stock term growth metric better bet be celgene have cr head stock checkup rundown top biotech leader juno plan begin new trial later year cell lymphoma new trial acute lymphoblastic leukemia next year full result terminate rocket trial be present upcoming medical meeting juno didn say outside cell lymphoma juno have number chimeric antigen receptor candidate underway hodgkin lymphoma astrazeneca azn acute lymphoblastic leukemia celgene celg schmidt write research report keep price target outperform rating juno stock related kite ionis outplay med sector perrigo tenet valeant pharma cancer drug poise approval say rbc
491,CELG,final trading day february be rough russell small cap index be late trading weakness come day index jump higher volume selling be more contain nyse index dow jone industrial average lower nasdaq composite lose volume nyse nasdaq be tracking slightly higher monday level dow be threaten end day winning streak investor be cautious head president trump speech congress tuesday evening be expect discuss taxe health care infrastructure spending more coca cola ko mcdonald mcd hold well dow rise respectively wal mart wmt intel intc lag loss earning news priceline pcln domino dpz outperformed report solid result be extend recent breakout priceline report fourth straight quarter double digit earn sale growth domino deliver strong double digit same store sale growth share priceline jump domino add nearly ibd take performance restaurant stock have be mixed bag recently group be home plenty name be execute well see top rate restaurant stock be ibd stock checkup priceline be top performer nasdaq celgene celg share celgene rise work base entry also nasdaq tesla tsla bounce back fall prior session get support day move average volume be only average tuesday retail space target tgt crater company report lackluster earning same store sale growth also issue weak outlook current quarter full year stock market today charle schwab schw give day move average fall company lower commission fee follow lead competitor fidelity close top rate growth name be earning include palo alto network panw salesforce com crm veeva system veev chart be mar weak relative strength rating lag relative strength line related target slash price wal mart bargain see winning trafficonline broker price war fidelity schwab slash stock etf commission ross store palo alto salesforce veeva ambarella earning due late
492,CELG,wake late afternoon major market average picked little momentum head monday close dow jone industrial average index hit time high dow jone industrial average nasdaq composite show gain shortly market close small cap make noise russell volume nyse be tracking lower friday level nasdaq volume be pace be slightly higher caterpillar cat chevron cvx outperformed dow gain close big gainer nasdaq include celgene celg share biotech rise back week move average work flat base buy point strength russell help cause several ibd name include healthequity hqy eagle material exp nivdia nvda rise respectively stock market today apple aapl edge higher somewhat muted response warren buffett tell cnbc increase stake iphone maker share more twice own end steel producer aggregate firm rally ahead president trump address congress tuesday trump pledge big spending boost last week ibd steel producer group dive nearly aggregate give close publish report say infrastructure bill be delay steel look poise end session slide rise nearly get support day move average be still prior buy point aggregate provider martin marietta mlm vulcan material vmc also jump be still day line harsher sell off tesla tsla paid visit day move average fall more goldman slap sell rating stock ub reiterate sell rating last week just ahead company earning report wagework wage follow nicely friday flat base share surge friday monday extend now buy point wagework compete healthequity area health saving account pocket medical expense earning report watch close include priceline pcln workday wday have show relative price strength ahead result market have show recent week healthy chart don always equate continue price strength tuesday see domino dpz report open palo alto network panw salesforce com crm veeva system veev due close related workday sale momentum see continue earning stock jump president trump vow spend big salesforce com earning preview billing outlook eyedbest stock buy palo alto earning add security stock momentum
493,CELG,typically slow stretch late august biotech news be bound pick company prepare fall season conference investor day most stock move event likely be update key clinical trial several expect september celgene celg be due release long await midstage trial result ged mongersen drug crohn disease license drug initially spark excitement wall street strong week remission rate beat even lead inject tumor necrosis factor drug such abbvie abbv humira johnson johnson jnj remicade amgen amgn enbrel next datum set cover full year evaluate patient endoscopy rather just symptom investor confidence be somewhat shake celgene refuse provide interim analysis trial interpreted lack confidence number leerink analyst geoffrey porge write close inspection earlier datum also raise red flag trial be consistent earlier phase ii result original investment be make endoscopic remission rate be range be well see even best biological immunomodulator porge write july research note fact assessment earlier result lack crp reactive protein response be biomarker crohn disease inflammatory activity suggest result be materially lower tnfs remission rate more likely be range note ged be oral rather inject still find market niche not be mega blockbuster initially hope ibd take medical biotech group have be roll lately rise ibd industry group ranking last week see other industry be hot follow industry theme column kite pharma kite be expect release headline datum zuma phase trial car cell therapy kte diffuse large cell lymphoma car cell chimeric antigen receptor cell be genetically engineer attack cancerous cell trial result be crucial kite hope use file fda approval treatment make first car therapy hit market next year rbc capital market analyst michael yee estimate friday study yield overall response rate percent tumor shrank perhaps complete response rate tumor disappearance base earlier datum initiation report tuesday btig analyst dane leone write much depend datum stack result competitor juno therapeutic juno novartis nvs be yet unknown novartis present pivotal datum set ash potential first datum cd specific antibody write leone refer american society hematology conference december juno be also expect present clinical update ongoing cd trial vertex pharmaceutical vrtx provide report triplet pill cystic fibrosis consist already market drug ivacaftor kalydeco combine experimental drug vx additional drug vx vx trial ivacaftor vx alone recently fail do present clean safety profile analyst have be expect triplet be next generation treatment case also month fda be due render verdict expand label vertex already market cf drug orkambi child age related be epipen price fda fault hold new generic novartis close cell therapy unit car stock tumblebiotech stock seesaw hope meet new pricing fear
494,CELG,ve ever search thousand stock trade wonder be just have trouble find good stock buy have fear be not alone money manager janus jdcax have chalk best performance gain multiple time period mutual fund limit holding stock reason don think be many great idea point time say lead manager dougla rao compare mutual fund own more stock janus also get know company own better say click here see list mutual fund month leaderstalk reason like gaming company activision blizzard atvi rao say invest owner operator manager act way think long term activision ceo bobby kotick be guy management team buy close company janus be ibd best mutual fund award winner have outperformed year period end dec only diversify stock fund meet standard click here see list mutual fund category performancetop perform holding year include boston scientific bsx facebook fb time warner wtx amazon amzn fund have lighten position boston facebook latest report period hold steady time warner increase amazon general electric ge top hold asset be flat year yielding hasn be janus best year fund be year aug vs have month performance rating ibd meaning share price performance be top mutual fund time rao have be board nick schommer become co manager year helmsman talk ibd approach current investing climate office ibd fund be concentrated do focus just best idea rao don think be many great idea point time take cue warren buffett call diversification di worsification say know idea better idea idea have more conviction be naturally comfortable level term have ability know company invest ibd do concentration entail greater risk volatility schommer wouldn say strongly help manage volatility hold different bucket growth stock ibd do stock bucket differ schommer percent portfolio be compound growth company be company well defined competitive moat have year growth ahead high earning visibility lower risk trade slight premium market have much better growth percent be blue sky company be growth company have less well defined competitive moat compound growth stock expect blue sky company solidify moat graduate compound growth company have big opportunity make position small manage risk third bucket hold special situation stock be future compound growth stock meanwhile be business issue financial leverage issue company have execute example ge past year have be divest ge capital business hasn be very attractive ge have be reinvest remain industrial nonfinancial business return capital shareholder key success blue sky special situation company be have graduate be compound growth company want ge ibd other key trait do stock bucket share rao start same filter do company have competitive advantage do believe be sustainable bucket stock be look same way ibd percent blue sky special situation company do graduate rao guess maybe ibd fund be top morningstar large cap growth category year more middle pack have year be more challenge schommer general market year reward lower volatility sector area lot growth sector naturally tend take pass investing sector be reward year be consumer staple utility energy tend be sector be not large position portfolio company meet business model hurdle not lot meet growth hurdle now particularly be not attractive valuation perspective market have treat income substitute give premium valuation due low yield fix income have instead focuse investment zoetis zts animal health care company have characteristic similar consumer staple company better growth prospect more reasonable start valuation energy be area have be good performer year difficult be limit number energy company meet business model criterium most be price taker tie commodity price ibd ve slightly trim stake facebook be concern rao hard talk talk google googl alphabet have become dominant platform advertising dollar shift traditional channel digital reason facebook have be so effective monetize digital advertising dollar be have high consumer usage property chief operate officer sheryl sandberg team leadership ceo mark zuckerberg have do good job pivot company away be desktop computer base be dominant app provider global basis outside china whatsapp instagram facebook consumer be engage such extent advertising dollar move ibd bucket be boston scientific rao compound growth buy maybe year start special situation have fairly significant legal overhang johnson johnson sue thought case be questionable bring new ceo name mike mahoney have be johnson johnson come reinvigorate cardiology franchise have miss product cycle feel be pipeline need be push market be concern litigation factor little growth cardiology product soon settle johnson johnson suit ve accelerate revenue growth margin growth have be half competitor ve close gap execution have be fantastic expect more ibd be activision blizzard position ve increase rao be special situation buy king digital have popular candy crush game market soured king go public ceo bobby kotick have make number strategic pivot king acquisition get mobile ve go be company serve consumer desktop console serve consumer person watch game play also ve transition more digital download dependence customer buy console remove middle man so activision margin become higher still special situation mobile user king acquisition have be shrink top see re engage consumer ibd amazon amzn have go size portfolio be rao have reduce exposure end last year have disappointing announcement january stock get punish add back sank dramatically amazon be dominant player commerce commerce percentage retail sale continue increase amazon continue deliver faster fulfillment time gain market share leg stool be amazon web service get idea investing owner operator many person see aw money pit fast forward today most analyst see worth microsoft be do nice job web service aw be dominant provider everyone cia ge be move more business aw don have have electricity plant house so do need own datum center ibd celgene celg be yet company ve build stake thesis rao reduce position middle last year then year go high mid analyst feel confident be trading big discount view intrinsic value ibd do trim priceline pcln stake slow global growth mean less travel rao be business benefit network effect core business be book com be hotel book europe have similar business asia call agoda reduce give exposure europe terrorist attack higher level management turnover be comfortable ibd ve also trim nxp semiconductor nxpi be concern schommer special situation be merger lead semiconductor company freescale nxp be end market give share profit line invest more competitor merger financial leverage business increase level be normalize operate level so part be special situation be re watch reduce balance sheet more comfortable level ibd adobe adbe be trim thesis rao be first transition selling software shrink wrap subscription model transition be much larger market transition revenue margin decline trim company have largely make transition subscription business market be now reward higher quality revenue related top fund manager like type growth stockswhat do fund get new managermutual fund award top equity fund
495,CELG,spectacular rise even more spectacular collapse valeant pharmaceutical have multiple cause heart story be much biotech company rely big drug price increase growth not only do price hike make valeant vrx politically unpopular also meant business be ultimately unsustainable money manager prefer biotechs pharmas produce drug grow customer demand signale growth sale volume think preferable avenue revenue growth be volume significant price increase have see past year only be repeat few year leonard yaffe health care portfolio manager kessef capital tell ibd email more revenue increase be due volume more value be assign drug re hunting big growth stock biotechs catch eye look past headline revenue number help see company have more sustainable even accelerate growth volume growth lag sale increase company be lean price not last most price increase be far more moderate valeant price hike heart drug nitropress isuprel respectively many company regularly lift price well past inflation rate prop revenue disguise actual demand ibd take big cap deliver still deliver big gain often less volatility smaller cap stock also true biotech have strong big cap company amgen biogen be current resident ibd big cap compare volume revenue be worthwhile reason volume growth be more overall revenue growth signal company be have rebate more list price do last year move product be roll drug country extract lower price be often case europe investor don signal insurer other payor be putt thumbscrew company payor mix obviously be very critical well large consolidated payor cover many many life have negotiating power pick choose rationalize product base price efficacy alternative etc thomas vandeventer portfolio manager tocqueville asset management tell ibd email second quarter earning report conference call comment reveal biotech giant hot stock rely almost solely price increase growth other expand mostly volume increase still other credit mix amgen amgn be classic example lean price revenue rise volume growth be much stem age amgen lead drug top seller rheumatoid arthritis drug enbrel be decade old volume shrank quarter still contribute growth thank pricing drug be even older epogen neupogen shrank price volume re face new biosimilar competition newer drug prolium xgeva make difference grow front be reason fact beat estimate raise guidance amgen stock initially drop earning report contrast amgen celgene celg revenue rise percentage point come volume growth accord company didn break percentage individual drug amgen do company say demand be good board celgene also beat forecast raise guidance future sale profit stock jump report medivation mdvn demonstrate sneaky power rebate list price prostate cancer drug xtandi now medivation only market drug rise second quarter revenue overall rise bit less analyst expect volume grow growth underlie demand xtandi be partially offset lower net price xtandi due year year increase gross net rate say cfo jennifer jarrett earning conference call gross net be industry speak rebate level xtandi have be tight competition johnson johnson jnj zytiga prostate cancer market have be undercut price cvs health cvs recently release drug formulary pass xtandi zytiga reason follow report here rundown other big biotechs be fare price vs volume question unite state lion share change year year basis be price be pretty stable unit trend tecfidera pretty stable unit trend tysabri modest gradual decline interferon franchise include avonex plegridy clancy say ex unite state be not see pricing increase year year basis gain be attributable volume unit expansion biogen overall revenue rise quarter beating expectation lead drug soliris provide vast majority revenue volume rise hike sale rest top line come newly launch drug have year year comparison incyte revenue jump year year beating expectation related be biotechs make comeback stock watchbiotech be make case leadership be good
496,CELG,big pharma merck mrk be now look possible buyout medivation mdvn accord anonymously source report reuter report wednesday afternoon merck be big pharmas have submit indication interest buy medivation other be sanofi sny pfizer pfe celgene celg gilead science gild sanofi have be very public attempt acquire medivation last month medivation say have enter confidentiality agreement sanofi well other unnamed potential buyer earlier anonymously source report say pfizer celgene gilead be interested buyer have be speculation merck be interested bmo capital research note assert merck be prepare medium size buyout medivation be target merck have be focuse much energy cancer lately medivation have fast grow drug market treat prostate cancer other cancer therapy development medivation stock have be trading flat stock market today pop week high news come close merck rise ibd take medivation be ibd stock last earning report year year profit growth flattened deliver big hit ep rating analyst expect growth pick again start however
497,CELG,biotech giant celgene celg be trading modestly tuesday abandon plan expand label flagship blood cancer drug include form lymphoma late monday celgene report result clinical trial remarc test drug revlimid maintenance diffuse large cell lymphoma dlbcl study do hit primary endpoint improve progression free survival didn improve overall survival be generally most important metric cancer drug result celgene say not seek approval indication continue study revlimid other lymphomas revlimid be currently approve only different blood cancer multiple myeloma ibd take celgene financial have provide solid growth story year stock larger industry group be important factor performance so far year have be tough biotechs however last couple week big money have be flow back group ibd etfs fund section recently explain celgene stock fall stock market today expectation success remarc trial weren high go so most wall street analyst shrug news nonetheless evercore isi analyst mark schoenebaum note make celgene guidance reiterate monday little harder reach recall celgene include revenue revlimid expansion indication guidance schoenebaum write celgene have other revlimid lymphoma trial ongoing remarc represent largest opportunity continue growth lead product estimate potentially enough meet guidance indication dlbcl be not critical hit target put pressure other revlimid expansion trial show clear success largest remain indication investigation be follicular lymphoma study relevance trial be now likely be necessary meet guidance result trial be expect next year
498,CELG,biotech celgene celg win seek approval expand use revlimid be approve combination dexamethasone multiple myeloma patient revlimid achieve study primary endpoint prolong progression free survival interim analysis overall survival show benefit maintenance treatment diffuse large cell lymphoma celgene share fall hour trading close stock market today celgene report quarterly earning thursday
499,CELG,drug stock slip wednesday rally earlier day politic drug pricing resurface ibd biotech biomedical group hit month high wednesday morning group continue momentum start monday announcement pfizer pfe deal buy medivation mdvn raise hope more biotech continue especially incyte incy biomarin bmrn gabelli co argue make especially attractive target incyte rise more early trading stock market today end day just fraction biomarin initially gain almost then sharply reversed end proximate cause decline seem be presidential candidate hillary clinton criticize generic drug giant mylan myl pricing allergy treatment epipen mylan multiple price hike epipen have already attract discussion industry week senate get act demand mylan ceo heather bresch explain epipen high price clinton weigh midday wednesday ibd take long term outlook get cloudy look ibd swing trader tip short term trading note month biotech stock rally last week have be drive partly fact drug pricing have fade political debate group hit month high aug surpass early wednesday rbc capital market analyst randall stanicky write research note drug pricing comeback politic be be also stark reminder political scrutiny pricing remain high sector unlikely dissipate anytime soon head november election stanicky write nonetheless familiar ibd chart read technique be still lead biotechs be worth keep eye incyte have be bounce buy sell zone pop cup handle base last month financial be also improve turn more consistently profitable last few quarters biogen biib also break cup handle start month then blast right past buy point next day buyout rumor then moved sideway wednesday reversal bring close buy zone again be more celgene celg have be upslope consolidation start july last year still hasn form specific buy point celgene biogen be strong stock overall composite rating putt top stock generic drug group also have be rally last week still low rank go ibd list industry group group be again wednesday lannett lci beat expectation late tuesday lannett stock jump wednesday generic drug however be most direct target senate inquiry group fall wednesday earlier hit month high mylan stock fall wednesday fall tuesday related hunting biotech stock understand earning formula first
500,CELG,pfizer pfe announce deal monday morning buy medivation mdvn share enterprise value move follow month takeover speculation cancer drugmaker well widespread report sunday imminent pfizer medivation deal medivation rise nearly soon open bell stock market today pfizer fall cent propose acquisition medivation be expect immediately accelerate revenue growth drive overall earning growth potential pfizer pfizer ceo chairman ian read say statement pfizer say deal boost earning share cent first year close additional gain medivation close friday market valuation be slightly extend buy point flat base medivation trade low feb be subject widespread buzz possible buyout biotech earlier year reject share offer france sanofi sny last week report have pfizer merck mrk gilead science gild celgene celg sanofi possible medivation buyer ibd take biotechs deliver great growth be generate profit revenue gain higher sale volume price increase here hunt biotech stock medivation make xtandi prostate cancer drug annual sale rate already have other cancer fighter development pfizer attempt buy allergan agn fall apart earlier year obama administration change rule make tax inversion merger deal less attractive related medivation affirm guidance earning growth make case leadership be convince
501,CELG,celgene celg be upgrade alibaba baba get bullish mark ahead earning price target be raise square sq electronic art ea tableau software datum celgene be upgrade buy btig research celgene last week narrowly beat analyst estimate drug company raise full year guidance celgene raise sale guidance lead drug revlimid even blood cancer treatment narrowly miss analyst estimate quarter share be close stock market today mkm partner set price target alibaba buy rating china commerce giant report quarterly result next thursday alibaba stock rise square have price target raise morgan stanley equal weight rating provider payment process service report result late wednesday adjust revenue top view square raise full year revenue guidance square say net revenue rise beating consensus expect full year net revenue midpoint guidance range share jump electronic art have price target raise form mkm partner maintain buy rating electronic art late tuesday post better expect revenue earning june quarter video game publisher earn cent share exclude item beating consensus cent sale fiscal first quarter ea stock fall close ibd take electronic art moved buy range wednesday clear entry point long consolidation ea be rank ibd computer software gaming group do ea stack vs top peer be leaderboard stock be group find ibd stock raise price target tableau software neutral rating datum analytic provider report earning late tuesday beat revenue expectation fall short earning revenue rise cent share loss share fall
502,CELG,ibd biotech industry group have rally february low move group be filled leader right be group house more stock only have composite rating higher tuesday session still noteworthy group have jump
503,CELG,biotech stock haven be fainthearted last month hope comeback have noticed re move again ibd biomedical biotech industry group be most improve last week rise ibd ranking industry group certainly fact earning season have so far be good especially compare lower expectation start year big cap biogen biib celgene celg amgen amgn have already beaten expectation raise guidance alexion pharmaceutical alxn affirm guidance still rise good quarter more make gilead science gild guidance cut biogen be also boost monday unexpected good news drug development front biogen stock be close stock market today month high biomedical biotech group finished day nearly month high still be larger factor work weekend rbc capital market analyst michael yee release video theorizing political fear lead last year crash spark presidential candidate hillary clinton tweet threat do something high drug price have largely be price stock now help republican democratic presidential convention have go barely word say drug pricing so investor be think win be such big deal yee add yee also note medical device stock have be perform well year unusual huge gap device drug stock be sustain indeed medical product group rank have moved round good earning report last week ibd take abiom be medical product earning beater week trading record high be buy zone sport coveted spot ibd swing trader identify stock fundamental technical product short term gain leerink analyst geoffrey porge also note gap biotech device valuation detailed analysis last week compare medtech pharma biotech be trading discount growth adjust basis price growth biotech be price other medical product sector porge write report growth outlook large cap biotech ex gilead be better pharma better medtech biotech stock trade only marginally greater multiple pharma stock porge say be parallel recent panic december biotech stock decline few week investor worry growth not be sustain december growth expectation have fall porge write however sector aggregate net income grow year year also note sector grow net income future growth expectation have steadily decline june year year believe downward estimate revision be not fully drive fundamental include political fear currency effect expect growth recover back half impact pricing power volume demand be realize profit growth still worth note ve be here monday collective value biotech group be hover have be something ceiling year group bump twice april again early june head south again
504,CELG,biotechs look re start make comeback just week medical biom biotech group be rank industry group ibd track now sit noteworthy stock biotech group be biogen biib supernus pharmaceutical supn ligand pharmaceutical lgnd medivation mdvn therapeutic anik biogen partner ionis pharmaceutical ion monday announce surprise success phase clinical trial spinal disease treatment biogen climb close heavy volume stock market today breaking cup handle base buy point hit high stock be also recently able retake downward slope day line few week report earning ibd take further evidence broader biotech sector recovery ishare nasdaq biotech etf ibb be best level early january clear resistance last week retake day move average supernus pharmaceutical report quarterly result tuesday earning expect jump mark second straight quarter faster growth share have be big run gain more february low stock have find support day line make climb now trading time high set year supernus close flat monday ligand pharmaceutical be set issue quarterly report thursday analyst expect bottom line fall impressive gain share clear cup handle buy point heavy volume several week be now extend buy zone stock hit new time close high gain medivation be set report quarterly result aug bottom line expect fall medivation have be subject buyout interest several potential buyer include sanofi sny rise february low stock be member ibd list lead growth stock share have be hover just buy range nearly month hit month high heavy volume thursday firmly re enter buy zone medivation edge monday therapeutic be try rebound day line strong volume breach level thursday earning report share jump much monday morning have pare gain close big name biotechs amgen amgn celgene celg be also rise issue quarterly report last week amgen be trading week high breaking cup handle base celgene be hit month high heavy volume amgen rise celgene climb
505,CELG,stock crawl higher thursday deluge quarterly result celgene raise hope biotech investor superb gain follow robust report top bottom line second quarter nasdaq composite rise add tuesday gain third straight session nasdaq be now almost year date edge nearly higher dow jone industrial average be slightly lower back sharp decline boee ba caterpillar cat former be reverse wednesday gain report adjust net loss cent share lift revenue accord william neil co datum small cap more less follow suit russell ease crude oil future slump week lop barrel gold silver moved higher volume fall nyse nasdaq accord preliminary datum celgene celg gap open rise mark highest close jan open biotech report adjust earning share second quarter net product sale rise total revenue be celgene also give bullish outlook rest year see full year net product sale prior target range adjust ep outlook also increase range celgene also boost adjust operate margin forecast stock earlier week take back day move average important development former big winner try end long downtrend bottom last year late july celgene have break later stage base get high quickly turn tail year low celgene fall just maximum range allow ideal cup base give long celgene have be correct also keep eye potential saucer pattern form learn more bullish chart pattern read investor corner column celgene get composite rating ibd stock checkup good not great however stock continue climb improve relative strength rating accumulation distribution grade hoist composite score higher financial service industry mastercard sprang highest level more month rise credit debit card processor post rise profit cent share be mastercard second quarter double digit ep growth quarters revenue lift watch see mastercard keep rebound potentially surpass proper buy point buy point come add cent interim peak somewhat lopsided double bottom base such base stock encounter distinct sell off second sell stock undercut first low mastercard case first low be base have form larger consolidation mastercard fall high low decline fall normal range most key chart pattern monitored ibd ibd take stock market today finance mortgage retail internet medical product industry group help lead upside check industry group subgroup fared look entire list stock list section investor com hover stock list then click datum table link
506,CELG,several big cap drugmaker report solid earning thursday morning continue be fairly positive earning season medical industry celgene celg end trading stock market today narrowly beat analyst estimate top bottom line raise full year guidance notably raise sale guidance lead drug revlimid even blood cancer treatment narrowly miss analyst estimate quarter most celgene other drug more make difference celgene expect roughly sale growth earning growth year line growth rate last year celgene stock take modest hit tuesday company decide not pursue label expansion revlimid follow mixed trial result lymphoma bounce back quickly be nearly thursday afternoon bristol myer squibb bmy also deliver modest beat raise stock fall be much quarterly beat come hepatitis drug daklinza be threaten obsolescence now gilead science gild have release pan genotypic hep pill epclusa daklinza be used treat minority genotype usually combination gilead sovaldi also outperformed sale bristol myer fast grow cancer drug opdivo slightly beat expectation worldwide rise sevenfold year earlier quarter be bit light yervoy bristol be hope combine opdivo make standard care lung cancer be also bit short expectation bristol myer stock finished regular session ibd take bristol myer earning growth wasn much expect accelerate company be guide growth full year positive sign ibd slim system look least annual earning growth preferably accelerate rare disease biotech alexion pharmaceutical alxn close thursday trade fractionally even profit technically miss consensus be apparently due sec recent change gaap report requirement gaap ep miss be due modification definition gaap income tax result cent share reduction write rbc capital market analyst simo simeonidis research note importantly adjustment have impact amount income tax company pay cash flow cent add back alexion have beat consensus still have be slight year year decline company have invest new drug launch however revenue rise top wall street number alexion affirm previous full year guidance
507,CELG,ceo dow stock general electric ge boee ba other big exporter be warning republican embrace controversial tax import once generation chance tax reform fail american worker be loser tax code penalize american worker make product provide service sell abroad favore international competitor ceo write letter leader party congress other company ceo co sign letter be caterpillar cat dow chemical dow raytheon rtn unite technology utx oracle orcl biggest drug biotech company celgene celg eli lilly lly merck mrk pfizer pfe caterpillar merck pfizer unite technology also be member dow jone industrial average addition general electric boee letter put largest company squarely house speaker paul ryan other house gop leader argue levele international play field cut corporate tax rate lower be impossible plan tax import raise decade yet biggest surprise letter be just few company sign more company include wal mart wmt target tgt nike nke american subsidiary toyota tm dozen trade group have sign american affordable product create oppose house border tax proposal wal mart nike be also dow industrial stock retail stock be pressure early december prospect border tax be rise ve make modest recovery lately prospect fade tuesday perhaps help more wal mart positive earning report well receive macy earning weigh rev lobbying campaign tax retail share be rise wal mart rise close stock market today target add ibd take supporter border tax plan say dollar rise vs other currency meaning wouldn harm corporate profit consumer do risk investor hold share company alibaba international etfs house proposal border adjust tax company pay tax rate full value import good export revenue be tax free border tax raise more decade offset cost lower statutory tax rate conservative tax foundation have say border tax ability congress reduce corporate tax rate be limit incremental tweak not level play field american worker dramatically reinvigorate economic growth ceo letter say not clear precisely so few company come favor border tax proposal seem be run buzz see republican senate possible letter wasn widely circulate however caroline freund senior fellow peterson institute international economic have predict many more big lobby be bat border adjust tax favor tax favor labor intensive industry export more import aerospace be rare example nagging question company such ge boee be so dependent export back border tax most trade expert have look tax have big doubt comply world trade organization rule so lead trade war give uncertainty possible consequence hard understand company so dependent trade support border tax yet partly explain list supporter be so small related border tax die trump corporate tax cut collapse gop border tax plan sock tourism include trump hotel
508,CELG,stock be mixed mostly unchanged friday afternoon major stock index continue trade tightly high nasdaq composite be poise fourth straight weekly price gain unitedhealth unh lag dow jone industrial average weigh accusation department justice overcharge medicare share gap day move average fall other insurer fall sympathy include humana hum wellcare wcg dow component apple aapl edge higher several publish report say company start assemble iphone india start april dow jone industrial average give lose nasdaq inched volume be run higher nyse lower nasdaq stock market today share unilever ul soar kraft heinz khc offer buy company share kraft heinz slump thursday earning stock break friday rise high end buy range buy point ibd manufacturing vision system provider cognex cgnx gap powerfully earning be already well extend price last base be september skywork solution swks be big gainer nasdaq rise nearly clear week tight pattern buy point also nasdaq biotech celgene celg add nearly help new key multiple sclerosis drug ozanimod do well phase trial celgene acquire drug acquisition receptos celgene be back day move average work new base buy point related arista network stock soar hour earning sale beat unitedhealth health insurer fall doj join whistleblower suitkraft heinz unilever bid lift clorox colgate kimberly clark gbest stock buy watch
509,CELG,eli lilly lly heist johnson johnson jnj type diabetes share leerink analyst seamus fernandez say wednesday day lilly stock outplay mixed quarter president trump related boost lilly stock ramp tuesday continue black wednesday close bell stock market today share end regular session earlier touch nearly month high lilly stock react softer tone trump tuesday pledge deregulate industry cut taxe trump also call drugmaker manufacture meeting executive celgene celg merck mrk lilly novartis nvs trump reportedly backed call revisit allow federal government negotiate behalf medicare medicaid fernandez research note say be reluctant call first event victory be not bad prior commentary keep outperform rating price target lilly stock note drugmaker sale diabetes drug improve lilly sale top estimate tuesday earning miss fernandez credit growth diabetes product sale performance sale diabetes drug trulicity jardiance grow respectively ibd take trump commentary have send drug stock run tuesday immigration ban monday topple airline stock fall survive read ibd industry theme deeper look trulicity belong class drug call glp receptor inhibitor have new brand share year year growth space fernandez write jardiance have new therapy share endocrinologist exceed invokana barclay analyst geoff meacham be less bullish boost price target lilly stock keep outperform rating trump rattle drug industry meacham say investor prefer product drive company lilly give difficulty triangulating drug pricing debate settle continue prefer product drive story lilly relatively low reliance price revenue concentration risk write research report lilly be likely struggle emerge immuno oncology market write company be partner merck combine drug keytruda chemotherapy alimta treat small cell lung cancer fda look likely approve combo write anticipate approval kn phase study keytruda recent favorable patent ruling drive pickup alimta growth meacham say outside oncology meacham expect lilly add drug pipeline baricitinib rheumatoid arthritis galcanezumab cgrp migraine market latter arena lilly compete teva pharmaceutical teva pharmaceutical aldr amgen amgn related eli lilly novartis challenge pfizer potential breast cancer drugpfizer report lag ep rebound trump round trip trump inspire rally fda appointment key
510,CELG,roche rhhby ceo severin schwan shrug president trump crackdown drug price wednesday say swiss drugmaker expect reap benefit literally billion invest market focus truly differentiate medicine medicine make real difference patient say accord cnbc have doubt whatsoever be continue demand such solution particularly convince reward kind innovation market be important roche nearly half roche pharmaceutical sale stem diagnostic tool be sell north america tuesday trump reaffirm pledge go rise drug price have get lower price tell slew pharma bigwig include ceo celgene celg eli lilly lly merck mrk novartis nvs johnson johnson jnj executive also be reportedly attendance president trump promise deregulate drug industry cut taxe trump also abandon proposal revisit idea allow federal government negotiate drug price behalf medicare medicaid cover million american be largest purchaser drug health care service world ibd take trump commentary momentarily boost drug stock tuesday day earlier president ban immigration take bite airline stock read ibd industry theme column more safer entry point travel sector drug stock rise tuesday follow report trump softened stance big pharma ibd company ethical drug industry group edge small fraction stock market today roche stock rise touch nearly month high schwan commentary come roche report growth sale consensus analyst poll thomson reuter expect core earning share rise revenue breast cancer rheumatoid arthritis drug help outplay dip sale drug treat hepatitis pancreatic small cell lung cancer wet age related macular degeneration eye disease hep sector have suffer recently sale dip third fourth quarters accord market researcher ihs share gilead science gild have be pressure recently hep unit hep sale dip virtually nothing fourth quarter swiss roche see similarly painful decline sale hep drug lucentis be only sell fall offset sale breast cancer drug perjeta rheumatoid arthritis drug actemra rise respectively roche also list new launch include oncology drug tecentriq tecentriq be approve previously treat small cell lung cancer previously treat advanced cancer urinary tract compete bristol myer squibb bmy merck small cell lung cancer sector related gilead clobber hep little value too late nash hiv unitsroche gouge bristol myer lung cancer share merck rivalrywill merck let incyte go astrazeneca bristol roche team up too
511,CELG,president trump call drugmaker manufacture effort curb rise price meeting big pharma executive white house mere week accuse industry get away murder trump also promise cut regulation appoint fantastic person lead food drug administration tight regulation slow fda often jam approval process drugmaker say last year fda approve new molecular entity year low tenor be reportedly different earlier call have federal government negotiate price behalf medicare medicaid agency cover million american be biggest purchaser health care product service world same meeting trump pledge increase international competition cut taxe business lure company back trump have pledge put america first inaugural speech say decision be make benefit american worker american family ibd take isn first time trump have pledge bring rise drug price actually mean biotech drug stock take look ibd industry theme deeper dive pharma bigwig include ceo eli lilly lly merck mrk celgene celg novartis nvs reportedly attend meeting johnson johnson jnj exec ceo pharmaceutical research manufacturer america also reportedly attend pricing have be astronomical trump say accord bloomberg folk have do very great job year have get price drug biotech stock reversed earlier loss news trump meeting emerge ibd company biom biotech industry group jump more close stock market today ibd company ethical drug industry group gain meanwhile spdr biotech xbi exchange trade fund be more move day line ishare nasdaq biotechnology index ibb etf also be get day day line related biotechs round trip trump inspire rally fda appointment key stock set new high biotechs give back most trump rally
512,CELG,here investing action plan thursday need know investor come day ford fiat chrysler fcau google parent alphabet googl microsoft msft starbucks sbux intel intc celgene celg biogen biib dominate earning news report schedule see heaviest day week ford automaker report result
513,CELG,here investing action plan thursday need know investor come day earning remain focus amazon amzn alphabet googl baidu bidu ford celgene celg bristol meyer squibb bmy royal dutch shell rdsa conocophillip cop be due report quarterly result amazon earning pop amazon report earning close
514,CELG,week bring boatload earning large cap drugmaker here be popular stock face turn point company growth cycle key unknown hep front be much veteran administration have be buy isn available analyst usual source prescription datum ibd take ibd slim investment system stand new new management new condition other new thing such new product so wise keep abreast upcoming drug trial datum biotech company gilead share have languish company be expect release key datum possibly big hep drug later year ibd report va have budget hcv drug spending fiscal year write evercore isi analyst mark schoenebaum email friday note gilead have historically have share va prescription va revenue quarter be important help gilead not miss consensus estimate gilead science share rise late morning trade stock market today leerink analyst seamus fernandez lift opdivo sale estimate preview note last week together yervoy bristol myer maintain share checkpoint inhibitor market fernandez write refer class cancer drug opdivo belong base trend have increase full year opdivo sale expect strong uptake japan improve royalty revenue ono bristol myer squibb stock fall intraday have lower term estimate keytruda januvia franchise base sale prescription datum respectively however see greater long term opportunity relative previous forecast fernandez write recent announcement overall survival benefit keytruda keynote trial raise prospect drug first line small cell lung cancer nsclc merck share fall nearly intraday leerink analyst geoffrey porge write july note trial bring significant revenue upside revlimid succeed lead addition diffuse large cell lymphoma dlbcl exist product label study be controversial write be start development testing more responsive less responsive patient also treatment regimen not be best use revlimid disease nonetheless porge assessed modest positive outcome most likely celgene stock fall monday morning abbvie rise
515,CELG,proof more risk mood stock market investor look further resurgence growth oriented fund biotech etfs past month broad volatile biotech sector recover drubbing earlier year ishare nasdaq biotech ibb monday hit best level early january clear resistance last week regain day move average flagship health care exchange trade fund have jump month end aug sharp turnaround performance have help trim year date loss wobble stock market today ibb sit roughly late june low signal new bull market biotechs investor trader other biotechs remain fool play profit still issue investing exchange trade fund be smart way buy volatile high risk high reward biotech industry etfs hold basket stock help mitigate company specific risk ibb have nearly quarter asset biotech heavyweight amgen amgn celgene celg biogen biib have moved higher respective quarterly report last week biogen share spiked further monday company partner ionis pharmaceutical ion surprised investor success phase clinical trial spinal disease treatment ishare biotech fund also have smaller stake medivation mdvn ligand pharmaceutical lgnd supernus pharmaceutical supn highly rate ibd stock be trading best level past year ahead earning smaller company such hot biotech name have help etfs outperform larger sibling ibb past month relatively new etf equal weight stock holding include ionis give smaller size skew market cap weight benchmark such index track ibb ibd take earning have give biotechnology stock fund boost be other factor play too bioshare biotech product etf have jump past month have inched year date put well ahead ibb period also have hold far better older peer past year biotech stock get batter do not have year history additionally expense ratio trading volume bid ask spread give hope be successful investor pause fact almost half name etf be company drug market yet write morningstar analyst robert goldsborough note early stage biotech firm have very uncertain prospect well explosive upside potential xbi have gain past month give so far too be outpace ibb year date performance etfs be almost even longer period time just week medical biom biotech group be rank industry group ibd track now sit
516,CELG,major index go separate way monday energy sector decline weigh dow technology biotechnology sector push nasdaq higher powershare qqq qqq tracking tech heavy nasdaq nickname cube strike week high stock market today top stock holding biotech giant biogen biib amgen amgn celgene celg be rise recent quarterly report powershare qqq also have exposure energy sector have come selling pressure again energy stock etfs crumble monday first trading day august uptick production rig count rattle investor unite state oil uso fall nearly stock market today west texas intermediate crude settle hair barrel lowest level month fall level intraday increase opec production lead part nigeria iraq yet increase rig count have renew worry persistent supply glut crude oil gasoline accord news report oil etf share price rally sharply february market lows peak early june skid lower again energy major exxon mobil xom chevron cvx be hard hit dow jone industrial monday exxon mobil chevron remain cautious continue downturn oil price keep pressure business rebound oil price first quarter lows didn benefit second quarter result much lindsey bell senior analyst global market intelligence write monday energy select sector spdr xle slip more monday sector contribute most decline xle be largest exchange trade fund hold energy stock spdr oil gas exploration production xop dump more so do vaneck vector oil service oih etfs sit more week high even broad market trade highest level more year investor market watcher see buy opportunity bruise energy etfs uso take lat wk most feb rare etf flow inversely correlated return bottom caller pic twitter com sfw eric balchuna ericbalchuna august ibd take unite state oil etf be see price trend decelerate sharply find highly rate etfs best commodity group check etf center other etf market action spdr gold share gld reversed higher monday eke gain gld commodity etf track price gold here major exchange trade fund major asset class perform today ibd rs rating rs relative price strength rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
517,CELG,apple aapl get price target cut friday nvidia nvda chipotle grill cmg delta air line dal be downgrade iphone maker be subject price target trim courtesy barclay follow price target cut pacific crest monday sale apple smartphone cool earning be expect see decline next few quarters apple share fall cent stock market today rise graphic chipmaker receive downgrade underperform market perform well fargo cite possible growth headwind due competition amd amd intel intc mizuho initiate nvidia buy rating price target share fall day hit record high ibd take nvidia share be extend march well follow buy opportunity graphic chipmaker involved gaming console autonomous drive artificial intelligence be part ibd list very best stock check screen find top stock entry point ahead chipotle earning result thursday morgan stanley downgrade beleaguered fast casual burrito chain equal weight price target analyst say be year chipotle fully recover series foodborne illness outbreak late last year chipotle be expect report mere cent share profit share prior year quarter share be lose evercore partner handed delta downgrade hold carrier report result thursday top earning fall short revenue projection delta share retreat travel stock dip deadly terror attack nice france late thursday stifel nicolaus initiate coverage biotech buy share have be bob day move average several month celgene celg rise back day line celgene have not close day so far year
518,CELG,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
519,CELG,largest biotechnology etfs be poise critical juncture trouble growth story be too early call reversal fortune re certainly stock investment idea once again spdr biotech xbi thursday break first stage base climb highest level early june industry giant biogen biib trounce analyst estimate profit sale growth stock jump heavy trading volume report global growth multiple sclerosis hemophilia business largest biotech fund ishare nasdaq biotechnology ibb follow xbi footstep week retake day move average do so etfs manage hold critical line strength suggest investor be rekindle love affair biotech earning week play part success failure attempt industry heavyweight gilead science gild report monday edward lifescience ew tuesday amgen amgn wednesday celgene celg step friday spdr biotech exchange trade fund be mired price investor be willing pay year have rebound past month outpace virtually other segment stock market jeffrey loo equity analyst global market intelligence consider biotechnology subindustry attractively price sharp sell couple biogen solid report be recent rally suggest ibd take biotech exchange trade fund offer diversify exposure high risk high reward industry lower single stock risk fund investor get know individual company own learn stock be top rate biotechnology group check ibd leaderboard march report loo write biotech industry sustain healthy growth next several year breakthrough drug gilead sovaldi harvoni hepatitis be help drive sale loo also have positive outlook issue key interest investor industry pipeline be also solid several drug have blockbuster sale potential write potential headwind come month november election email ibd loo note scrutiny high drug price fall have weigh heavily biotechnology company now hillary clinton tweet price gouge trigger scrutiny be poise become official democratic candidate next president unite state ibb have see asset shrink year net inflow first month fund hold stock skews large cap such amgen celgene well gilead biogen xbi have also see asset diminish have take new investor money first half year offer more exposure smaller cap name ibb well lower expense ratio performance be neck neck longer period time have produce annual average gain past year comparison spdr proxy broad market averaged gain same period
520,CELG,biotech juno therapeutic juno say late thursday midstage leukemia trial have be put clinical hold patient die send share juno kite pharma kite other so call car stock sharply lower hour action juno say death occur last week patient have relapse refractory cell acute lymphoblastic leukemia take drug fludarabine receive chimeric antigen receptor car cell juno have take body re engineer better attack cancer cell patient have die earlier trial confound factor spur juno continue study time fludarabine be common chemotherapy blood cancer juno recently decide add regimen have be used precondition juno say have propose fda drop fludarabine regimen fda ask juno submit complete response clinical hold revise patient inform consent form revise investigator brochure revise trial protocol copy presentation make agency yesterday accord juno press release juno say do week be trading juno stock be halter hour later resume be news hit other stock work car sector kite pharma bluebird bio blue kite pharma tumble hour trading bluebird bio pipeline be less dependent car be biotech giant celgene celg last year invest juno part year car alliance celgene fall more late thursday
521,CELG,here investing action plan need know investor come week more tech giant apple aapl facebook fb amazon amzn alphabet googl report earning do biggest name oil such exxon mobil xom chevron cvx fast food leader mcdonald mcd aerospace giant boee ba federal reserve policymaker
522,CELG,leerink offer mostly bullish preview come earning season big biotechs wednesday offer hope lag sector analyst geoffrey porge raise estimate alexion pharmaceutical alxn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn write prescription datum im health im indicate flat slightly trend celgene standing year year volume growth drive new psoriasis drug otezla top drugmaker evidently shrug recent political criticism raise price number product wac wholesale acquisition cost price celgene otezla increase april follow raise january increase last june represent year year cumulative increase celgene also raise price abraxane april year year cumulative increase porge write other price increase include amgen kyproli yoy biogen tecfidera avonex plegridy medivation mdvn xtandi leerink nonetheless lower estimate medivation base lower xtandi sale well lower royalty sale outside also modestly lower forecast amgen amgn vertex pharmaceutical vrtx add be still consensus company celgene stock climb stock market today stock also have be help anonymously source report be company sign disclosure agreement medivation ahead possible buyout regeneron stock climb alexion advanced biogen rise gilead vertex stock rise announce licensing deal moderna therapeutic develop cystic fibrosis treatment used moderna messenger rna technology vertex agree cash investment upfront milestone payment drug succeed
523,CELG,major average reversed higher soft start wednesday release minute mid june federal reserve meeting come go much fanfare biotechs celgene celg incyte incy buoy nasdaq facebook fb also outperformed facebook rise close day line first time june fall early nasdaq end gain add dow jone industrial average rise preliminary datum show nyse nasdaq volume come slightly higher tuesday level advance stock outnumber decliner exchange less dow leader include merck mrk home depot hd cisco system csco merck rise home depot cisco touch intraday low barrel benchmark west texas intermediate crude oil add nearly barrel year treasury yield be mostly unchanged minute june fed meeting be release et brexit vote fed have signale couple rate hike end year change decide exit european union currently future trader see little chance rate hike year year treasury yield be recently basis point hit time low tuesday stock market today edward lifescience ew be strong performer ibd screen lead growth stock edward lifescience reclaim day move average rise nearly average volume homebuilder horton dhi also do well rise strong turnover still buy range early flat base entry horton be select group leader ibd home build group see other be ibd stock checkup
524,CELG,here quick rundown tuesday hour action nike nke hit new time high extend trading athletic shoe apparel giant report rise earning beat expectation boost gross margin expansion lower effective tax rate lower share count nike also report strong future order revenue rise slightly miss view
525,CELG,big biotech gilead science gild agree license immunology drug smaller counterpart galapago glpg thursday deal be worth more galapago drug be filgotinib be due start phase trial rheumatoid arthritis crohn disease next year gilead agree pay license fee buy galapago stock upfront promise milestone payment drug succeed clear regulatory process launch gilead pay tiered royalty start sale split profit filgotinib be jak inhibitor class abbvie abbv several other drugmaker be develop abbvie once have own licensing deal galapago september opted right license filgotinib so focus develop house drug time abbvie cite rat study indicate filgotinib be toxic testicle lead galapago discussion fda proceed new trial however phase result human be positive competitive other rheumatoid arthritis drug development write rbc capital market analyst michael yee research note add crohn disease result seem lag celgene celg ged hard compare cross trial different geography galapago stock jump early trading stock market today midafternoon be more gilead stock be flat follow amy reeve twitter ibd_areeve facebook
526,CELG,biotech bluebird bio plunge week low monday latest datum gene therapy severe anemia fail live promise earlier datum lead several downgrade sunday annual american society hematology ash conference bluebird blue detailed early stage finding patient sickle cell disease scd beta thalassemia
527,CELG,father time be hand rein baby new year top executive google parent alphabet googl dish network dish palo alto network panw salesforce com crm sell surrender company share final hour tick alphabet chief executive officer larry page monday inform security exchange commission sale share other alphabet executive have similar notion week tuesday chief financial officer ruth porat disclose surrender share worth sundar pichai ceo alphabet subsidiary google wednesday disclose surrender share worth mountain view calif base search engine giant be finishing year positive note share climb close week alphabet have be trading time high steadily day average google subsidiary reportedly be talk ford motor develop self drive car autonomous drive be likely be big topic upcoming consumer electronic show salesforce com founder chairman ceo marc benioff wednesday inform sec plan sale share nearly block company vice chairman president monday announce sale share worth san francisco base cloud compute company have be trading slightly record high steadily day line stock rise week finish week salesforce com announce purchase steelbrick palo alto calif base quote cash software company steelbrick software be primarily aim small midsize business palo alto network director jim goetz wednesday announce sale share worth cybersecurity software company be set finish note stock fall week close dish network director david moskowitz wednesday announce plan sale share worth dish time warner cable twc subsidiary directv reportedly be increase rate new year dish network share fall week close regeneron pharmaceutical regn vice president dougla mccorkle tuesday disclose plan sale share worth tarrytown base regeneron stock rise week finishing celgene celg director ernest mario wednesday inform sec sale share worth monday michael casey celgene director disclose have sell share worth company stock be week last week christmas gift settlement lengthy patent dispute blockbuster blood cancer drug revlimid natco indian company want market generic version drug nike nke president product merchandising jeanne jackson wednesday disclose have sell nike share worth beaverton ore base athletic apparel giant share slip week close boston beer sam co founder chairman jim koch tuesday disclose plan sale share worth brewer sam adam lager have have not so sudsy week share fall close company have have bit hangover late stock steadily trading day move average fall day line june insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
528,CELG,tuesday etf investor cheer upbeat datum consumer confidence housing well sign steadying oil gas price upbeat mood spdr spy rise conviction day line first time more week etfs tracking dow nasdaq also retook key move average average
529,CELG,biotech stock analyst ponder potential impact brexit friday morning find most big biotechs have low exposure run other headach exposure european union general range regeneron pharmaceutical regn celgene celg accord jeffery celgene nevertheless tell evercore isi less revenue come gilead science gild eu exposure be exposure be accord evercore calculation vertex pharmaceutical vrtx eu exposure be britain rbc capital market note expect grow vertex latest cystic fibrosis drug orkambi be suppose get reimbursement next year rbc analyst michael yee say research note not clear reimbursement negotiation be impact way however edison investment analyst maxim jacob opined research note measurement exposure be look wrong kind risk risk be global bear market kill biotech funding needham analyst alan carr write britain separation eu also bring regulatory complication road european medicine agency ema conduct centralize drug review process europe be base london carr write research note article withdrawal clause be invoked ema need move need establish new separate regulatory organization do not expect meaningful impact company drug now review ema brexit lead less efficient more expensive potentially lengthier regulatory process company seek approval eu biotechs be hammer rest market stock market today celgene fall regeneron be lowest level october gilead faltered year low vertex shed ibd biotech industry group plunge
530,CELG,treasury department annual financial review medicare find growth rate win trigger cost cut panel week send drug stock higher wednesday ahead report tuesday speculation have break growth be high enough trigger independent payment advisory board ipab come way cut spending brooking institution have schedule event thursday discuss issue last year report project hospital insurance trust fund be deplete just year now brooking say report also predict more immediate controversial event independent payment advisory board ipab famously nickname death panel be require submit proposal reduce medicare spending reduction take place report medicare board trustee actually moved depletion date year earlier say still wasn enough growth cost trigger ipab seem turn major medical group biotech stock have head south tuesday afternoon mid morning announcement ibd medical biotech group rise ethical drug group be even ipab have be trigger analyst doubt impact have be big give restriction sort cut panel make late tuesday rbc capital market michael yee run number note dual eligible add medicaid patient thus grow yee write research note take amgen amgn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn vertex pharmaceutical vrtx medicaid exposure grow get larger medicaid rebate calculation show change revenue more so happened celgene stock fall heavy trading tuesday rise more intraday close stock market today regeneron stock climb intraday set rise drop tuesday amgen biogen share rise fractionally sank nearly tuesday timing hedge fund manager leonard yaffe wasn convince ipab business be actual reason stock move biotechs have be trend downward early june rebound biopharma stock today be much more offset concern mentioned yesterday well likelihood fund redemption stock have become very attractive prospect several company be bright yaffe write email
531,CELG,drugmaker medivation mdvn say late tuesday have enter confidentiality agreement several potential buyer include sanofi sny latter raise bid company medivation have previously reject sanofi bid share cash inadequate lead sanofi late propose candidate take medivation board tuesday medivation say board have also reject offer share contingent value right cvr sale medivation drug candidate talazoparib share nonetheless medivation go ahead enter confidentiality agreement sanofi unspecified number other unnamed party confidentiality agreement include customary month standstill provision subject limit early termination event medivation expect provide party opportunity term review public information meet medivation management say medivation press release early anonymously source report say medivation have enter confidentiality agreement pfizer pfe amgen amgn celgene celg gilead science gild astrazeneca azn also have be leak prospective buyer tuesday announcement be leak reuter half hour market close send medivation stock share be fraction hour stock have be form flat base hit month high day pfizer amgen news come hold spot ibd list top perform stock past month friday medivation schedule conference call wednesday market close say focus talazoparib drug late stage development breast cancer belong class drug call parp inhibitor get boost last week biotech tesaro tsro announce surprise success parp inhibitor ovarian cancer
532,CELG,drug pricing be wall street mind again friday well fargo tap mylan myl next target activist rbc consider impact potential new law limit price california well fargo analyst david maris write valeant pharmaceutical vrx turing pharmaceutical be haul front congress scrutinize press policy drastically hike price recently acquire drug be keep eye other company universe have be do lot price increase last month mylan have raise price more product more product maris write research note late thursday mylan have take exceptionally large price increase include increase ursodiol generic medication used treat gallstone increase metoclopramide generic medication commonly used treat reflux disease gerd gastroparesis increase dicyclomine medication used treat irritable bowel syndrome maris add last month mylan add price tag biggest product contribute revenue most recent quarter believe give regulatory environment pricing action bring greater regulatory scrutiny headline risk additionally wonder aggressive price increase be be used make ep target offset disappointing sale other area mylan respond follow statement mylan have always be know have industry broadest most globally diversify business model portfolio have successfully manage balancing numerous variable include natural price reduction have always be inherent generic industry flaw analysis focuse small number product more product mylan sell globally approx product sell north america be simply self serve mislead investor be especially true give generic product represent extremely small percentage mylan approx north american generic business mylan business model be not today have ever be premised price hike mylan stock fall stock market today fall low valeant retreat friday week rbc capital market biotech analyst michael yee be also ponder drug pricing friday calculate potential impact california drug price relief act cdpra stock universe include amgen amgn gilead science gild celgene celg biogen biib vertex pharmaceutical vrtx cdpra go popular vote california proposition system november require state health care payer medical buy drug similar price veteran administration usually obtain large discount believe cdpra create slippery slope measure encourage other state follow suit ohio have also propose be get signature yee write think such attempt reduce drug cost merely prompt drug maker just raise va drug price thus help less person not result real saving benefit nonetheless yee estimate similar law pass state shave annual ep cover company discussion large cap biotech company suggest firm be aware wouldn be surprised proposal pass so note investor very least be inform potential headline model pricing risk write drug stock be friday rest market amgen fall gilead biogen celgene vertex pharma dip
533,CELG,small drugmaker medivation mdvn continue battle sanofi sny hostile takeover bid wednesday latter try replace board big biotechs celgene celg gilead science gild be say be think join fray sanofi propose candidate be willing fully fairly evaluate medivation strategic option believe medivation current board do not do unanimously reject sanofi unsolicited bid april medivation respond statement urge shareholder reject attempt call tactic sanofi facilitate substantially inadequate time proposal acquire medivation sanofi be only suitor go public anonymous source have be tell medium variety other company be think make bid medivation reportedly sign disclosure agreement pfizer pfe amgen amgn imply be open be buy somebody other sanofi wednesday bloomberg say celgene gilead be talk advisor idea hadn actually approach company celgene gilead have be urge investor analyst make sizable acquisition especially gilead massive hepatitis franchise be already erode face competition medivation current month sale wouldn make big impact gilead top line much interest come medivation future prospect prostate cancer drug xtandi be still ramp company study use other disease also have few earlier stage drug pipeline medivation stock have lately go tight sharp run buyout speculation fall stock market today sanofi climb gilead edge celgene be
534,CELG,most stock mutual fund extend rally begin march strategist be figure way deal expect stock market headwind summer month average diversify stock fund rise vs setback january february follow rally march inch april leave higher year date comparison advanced go forward most investor speak ibd expect market volatility summer re ready click here see list mutual fund month leaderslew piantedosi manager eaton vance mutual fund total asset have guardedly optimistic glass half full outlook believe core portfolio secular grower say include name amazon amzn facebook fb alphabet googl such name like be nxp semiconductor nxpi provide semiconductor content automobile industrial space say piantedosi be manager focuse growth elcix focuse growth opportunity eifgx tax manage growth eitgx tax manage multus cap growth eacpx huge secular shift area automation other new technology be drive demand new semiconductor content add car new feature include crash avoidance music rear view camera driver assist sensor other safety system overall trend electrical vehicle industrial product comparable shift robotic other form automation say area nxp be lead provider say click here see list mutual fund category more cautious investor glass half empty view be james lead manager payden equity income fund pyvlx brace volatility say re enter summer do not take lot bad news move market so equity income investor drink own kool aid say investor be serve well focuse company continue provide income low volatility manner theme park operator flag entertainment be sort stock like right now come bankruptcy start decade say re improve revenue stream management have improve quality park introduce new ride ve increase membership rate mean person go more often spend more money ve introduce go front line pass person gobble change have help ve improve recur revenue model say so re steady cash generate company able maintain grow dividend yield market notch modest gain investor be embolden stock market news turn be less scary have fear month outset say earning season be negative not bad person have expect say prospect brexit exit european union fade slightly add price oil rise just barrel april just addition many investor grow more comfortable prospect interest rate hike soon june july small cap growth fund lead tack science technology fund pace sector jump investor be optimistic gravitate growthier area market piantedosi say tech world equity fund fared far lose japanese fund do best abroad gain taxable bond fund lose treasury fund edge tax exempt fund gain capped streak month row market gain fear dominate start year keep fading piantedosi say add consumer have be strong housing be robust europe be look better term investor focus day day event such brexit decision federal reserve meeting november election monthly jobless report monthly purchasing manager index pmi indicator health manufacturing sector noise remember fed raise rate see sign strengthen economy help corporate earning say karyn cavanaugh senior market strategist voya investment management member multiasset strategy solution group end day stock buy boil buy corporate earning cavanaugh expect uptick corporate earning still fail occur don expect consumer spending stay strong warn cavanaugh be also manager voya global perspective iwpvx say market winning streak be likely end valuation be high earning growth be weak note piantedosi expect disruptive innovator continue grab market share so like amazon instead brick mortar department store macy dd kohl kss report lower quarterly earning share suffer stock price decline amazon report ep gain april accelerate prior frame share gain like facebook google similar reason huge shift continue advertising spending traditional medium online social medium say ditto health care political talk potential drug price regulation bullish long term big cap biotechs gilead science gild celgene celg vertex pharmaceutical vrtx know pricing issue shake say plenty growth company continue innovate piantedosi be not confine bet high flyer diversify portfolio don want be pedal metal time say name consumer staple not cheap provide stability predictability yield philip morris international pm be favorite say be focuse overseas smoking headwind be less have lot pricing power currency headwind be diminish likely turn tailwind dividend yield be pinnacle food pf be like nice steady eddie food company decent growth characteristic food group doesn show great characteristic say pinnacle dividend yield be
535,CELG,gopro gpro be downgrade friday chip supplier ambarella amba have price target cut action camera maker face headwind robert baird downgrade gopro neutral outperform slash price target thursday cleveland research analyst say gopro face order cut busy holiday shopping season
536,CELG,biggest medical meeting year be weekend american society hematology ash convene orlando fla hear latest attack world most intractable blood cancer already abstract presentation release ahead conference have make splash tiny french biotech cellectis cll offer detail
537,CELG,pharmaceutical etfs pop friday news pfizer pfe takeover irish drugmaker allergan agn reportedly biggest tax inversion deal history largest ever health sector allow pfizer new york base pharma giant redomicile ireland have much lower corporate tax rate exchange trade fund track major index stumble investor eye gdp inflation datum due later week spdr pharmaceutical xph jump stock market today etf equal weight stock holding include pfizer allergan stock holding fall today investor soured term deal prestige brand holding pbh lead upside xph holding gain xph have gain momentum recent week be july high powershare dynamic pharmaceutical pjp nose etf provide broad exposure stock include highly rate ibd stock allergan gilead gild celgene celg etf select weight holding base various fundamental risk factor allocate roughly asset allergan pfizer combine pjp have rally significantly september interim low post gain last week retake line move average even trade july high year date pjp be nearly vs xph loss gold price fall again monday dollar rise fraction major world currency etfs backed physical gold have peg straight weekly loss stagnate multiyear lows higher expectation interest rate hike december be weigh precious metal bear yield bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
538,CELG,biotech etfs charge ahead wednesday broad stock market struggle gain holiday shorten week investor digest mixed economic datum oil report show stockpile rise less expect best perform sector equity etf so far give etf investor more be thankful alp medical breakthrough sbio rise stock market today
539,CELG,seller be back market tuesday nasdaq close high session erase good portion early loss nasdaq give fall much lose close top half intraday range add distribution day count bring
540,CELG,several industry etfs packed wicked punch recent week robust earning here look standout report season wind ishare nasdaq biotechnology ibb ishare pharmaceutical ihe past month respectively biotech pharma exchange trade fund sell aggressively third quarter political rhetoric fear
541,CELG,midcap drugmaker jazz pharmaceutical halozyme therapeutic depome be move stock market tuesday report earning late monday round mixed earning season beleaguered sector jazz pharmaceutical jazz get downgrade several price target cut lead drug xyrem decline sequentially first time ever lead quarterly miss sale rise year earlier quarter miss analyst consensus more earning gain share cent shy consensus jazz narrow full year guidance way lower midpoint revenue ep now expect earning share vs last year revenue be guide vs jazz also say earning conference call analyst monday have be disruption production xyrem narcolepsy treatment xyrem be classify potentially addictive substance distribute central pharmacy risk evaluation mitigation strategy rem new rem go effect late august bring different form procedure temporarily snarl work jazz executive say executive also say jazz drug candidate leukotac have fail late stage trial graft vs host disease halt development drug mizuho analyst irina koffler downgrade jazz neutral outperform partly revise valuation methodology also soft outlook model consensus ep longer support buy rating spite cautiously optimistic outlook xyrem generic settlement koffler write canaccord genuity cut price target piper jaffray cut leerink cut investment bank maintain buy equivalent rating jazz stock xyrem miss leukotac failure be time event shouldn affect jazz ongoing fundamental write canaccord analyst corey davis respect valuation specialty pharma sector be period significant volatility be increase discount rate dcf discount cash flow analysis account risk associate market jazz plunge early trading stock market today afternoon trading be depome hike drug maker depome depo be head opposite direction beat estimate raise guidance revenue more double beating wall street average estimate earning jump way cent cent share exclude time item top consensus cent depome add full year product sale guidance range now do not guide ep say total earning be previous range depome ceo james schoeneck credit growth pain medicine nucynta company relaunch june acquire johnson johnson jnj schoeneck reiterate opposition horizon pharma hznp unsolicited stock bid depome note depome have file confidentiality suit horizon be due hearing nov depome stock pop almost early trading tuesday be afternoon trading halozyme fall shortbiotech halozyme therapeutic halo be tuesday afternoon result miss expectation affirm guidance halozyme revenue climb year earlier quarter miss consensus more lose cent share cent more street expect halozyme maintain full year revenue guidance last year do not guide ep say operate expense be burn cash jpmorgan analyst jessica fye write more consequential news call be description halozyme phase trial sole product pegph aids delivery injectable drug combination celgene celg cancer drug abraxane generic drug gemcitabine newly diagnosed pancreatic cancer study have adaptive design pfs progression free survival os overall survival primary endpoint include interim look once pfs be reach depend magnitude benefit potentially support registration point fye write research note net net remain positive opportunity pegph first line high hyaluronan pancreatic cancer well potential broaden additional tumor type halozyme stock touch time high july halozyme biom biotech group general be hit hard stock market late summer downturn ibd company medical biom biotech industry group be touch record high july now rank group track follow amy reeve twitter ibd_areeve facebook
542,CELG,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
543,CELG,stock extend gain boost major index session high head last hour regular trading session nasdaq rally rise dow jone industrial average be volume be tracking slightly lower board vs same time friday
544,CELG,computer hardware biotechs automaker be top gainer stock market today retail apparel maker stock lag
545,CELG,ibd stock celgene celg regeneron pharmaceutical regn gain respectively celgene be shape right side consolidation buy point biotech report thursday open say friday european official approve vidaza treatment patient age acute myeloid leukemia
546,CELG,regeneron be buy zone double bottom entry clear oct also friday biotech say bayer healthcare unit win european approval eylea treat visual impairment due myopic choroidal regeneron report wednesday open
547,CELG,tesla motor tsla cruised higher average volume ahead earning due tuesday close analyst expect electric car maker post cent loss sale jump share be still well day day line
548,CELG,fitbit fit jump fast pace turnover ahead quarterly report close soar friday bullish analyst report fitness tracking device maker be expect earn cent share sale expect revenue gain be
549,CELG,ryanair holding ryaay gap rise fast trade shape flat base buy point irish discount airline report fiscal profit sale top view say expect full year earning upper end forecast
550,CELG,other carrier volume jetblue airway jblu lift virgin america va
551,CELG,follow nancy gondo twitter ibd_ngondo stock extend gain boost major index session high head last hour regular trading session nasdaq rally rise dow jone industrial average be volume be tracking slightly lower board vs same time friday computer hardware biotechs automaker be top gainer stock market today retail apparel maker stock lag ibd stock celgene celg regeneron pharmaceutical regn gain respectively celgene be shape right side consolidation buy point biotech report thursday open say friday european official approve vidaza treatment patient age acute myeloid leukemia regeneron be buy zone double bottom entry clear oct also friday biotech say bayer healthcare unit win european approval eylea treat visual impairment due myopic choroidal regeneron report wednesday open tesla motor tsla cruised higher average volume ahead earning due tuesday close analyst expect electric car maker post cent loss sale jump share be still well day day line fitbit fit jump fast pace turnover ahead quarterly report close soar friday bullish analyst report fitness tracking device maker be expect earn cent share sale expect revenue gain be ryanair holding ryaay gap rise fast trade shape flat base buy point irish discount airline report fiscal profit sale top view say expect full year earning upper end forecast other carrier volume jetblue airway jblu lift virgin america va follow nancy gondo twitter ibd_ngondo
552,CELG,celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum
553,CELG,celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter
554,CELG,celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane
555,CELG,company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea
556,CELG,celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting
557,CELG,believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say
558,CELG,otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient
559,CELG,stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year
560,CELG,celgene stock fall thursday
561,CELG,abstract move stock
562,CELG,release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell
563,CELG,ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage
564,CELG,abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis
565,CELG,cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall
566,CELG,also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia
567,CELG,previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year celgene stock fall thursday abstract move release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion
568,CELG,stock dip further red little more hour left regular trading session nasdaq fall be dow edge lower volume be mixed tracking slightly higher nyse lighter nasdaq
569,CELG,decliner outpaced winner major exchange
570,CELG,gold miner telecom service security software stock underperform stock market today ship transporter apparel maker internet retailer post gain
571,CELG,amazon com amzn rise average volume second straight new high stock be far extend past buy point initially clear oct online retail giant be expand same day service accord financial time tuesday amazon open first brick mortar bookstore seattle
572,CELG,facebook fb lead ibd gap new high fast trade many analyst boost price target follow social network late wednesday earning beat share be extend buy point
573,CELG,celgene celg cyberark software cybr epam system epam be biggest loser ibd decline respectively analyst expect cyberark ep fall cent higher sale report close
574,CELG,also security software group fireeye feye gap sank new low revenue miss disappointing guidance
575,CELG,earning due close include walt disney apple aapl chip supplier skywork solution swks tripadvisor trip analyst expect disney boost profit share higher sale share be fraction
576,CELG,follow nancy gondo twitter ibd_ngondo stock dip further red little more hour left regular trading session nasdaq fall be dow edge lower volume be mixed tracking slightly higher nyse lighter nasdaq decliner outpaced winner major exchange gold miner telecom service security software stock underperform stock market today ship transporter apparel maker internet retailer post gain amazon com amzn rise average volume second straight new high stock be far extend past buy point initially clear oct online retail giant be expand same day service accord financial time tuesday amazon open first brick mortar bookstore seattle facebook fb lead ibd gap new high fast trade many analyst boost price target follow social network late wednesday earning beat share be extend buy point celgene celg cyberark software cybr epam system epam be biggest loser ibd decline respectively analyst expect cyberark ep fall cent higher sale report close also security software group fireeye feye gap sank new low revenue miss disappointing guidance earning due close include walt disney apple aapl chip supplier skywork solution swks tripadvisor trip analyst expect disney boost profit share higher sale share be fraction follow nancy gondo twitter ibd_ngondo
577,CELG,celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum
578,CELG,celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter
579,CELG,celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane
580,CELG,company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea
581,CELG,celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting
582,CELG,believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say
583,CELG,otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient
584,CELG,stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year
585,CELG,celgene stock fall thursday
586,CELG,abstract move stock
587,CELG,release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell
588,CELG,ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage
589,CELG,abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis
590,CELG,cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall
591,CELG,also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia
592,CELG,previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion celgene beat analyst earning expectation come short sale thursday several stock blood cancer market moved new clinical trial datum celgene early thursday say earning item climb year earlier quarter share beating analyst consensus penny revenue rise consensus poll thomson reuter celgene celg affirm previous full year guidance sale midpoint ep midpoint vs expectation revenue mix change slightly however celgene add sale guidance lead drug revlimid now lower guidance abraxane company earning conference call hematology oncology chief jacqualyn fouse admit firm original guidance hadn account impact new immuno oncology drug treat lung cancer drug be bristol myer squibb bmy opdivo merck mrk keytruda have be take market share abraxane indication fouse however say see great potential combination trial abraxane drug such opdivo abraxane trial breast cancer launch collaboration bristol myer also tout licensing deal develop newer immuno oncology drug astrazeneca azn juno therapeutic juno be inked yea celgene be also seek get immuno oncology bandwagon study new drug combination revlimid sister drug pomalyst fouse say datum several trial combine revlimid merck keytruda pembrolizumab multiple myeloma blood cancer revlimid become blockbuster treat be thursday part general release abstract ahead next month american society hematology ash meeting believe abstract re go see overall response rate tumor shrinkage revlimid trial pomalyst pembro trial crs disappearance tumor fouse say otezla treatment psoriasis psoriatic arthritis celgene launch last year wall street skepticism beat consensus sale call executive say otezla be take market share bring significant number new patient stock trade reaction just be line change guidance be probably just reaction expectation stock have run recent week write rbc capital market analyst michael yee research note big picture here be growth story be still well intact ep guidance be maintain really longer term possible settlement program pipeline give celgene best growth story large cap biotech next year celgene stock fall thursday abstract move release ash abstract also moved other stock thursday mostly earlier stage biotechs cellectis cll report first human patient receive cell therapy ucar baby suffering acute lymphoblastic leukemia disease be go day patient be infuse ucart cell ucar be chimeric antigen receptor cell car therapy similar be develop celgene partner juno well kite pharma kite novartis nvs other however other player have develop individual treatment patient extract patient cell alter re inject cellectis car therapy be allogeneic develop other cell shelf potentially bring economic advantage abstract be submit july patient continue remain disease free be eligible receive stem cell transplant approximately month receive ucart write jeffery analyst biren amin research note view provide first clinical evidence clinical activity ucart provide confidence allogeneic gene editing approach develop cellectis cellectis stock already have be rise steeply ahead abstract release rise much thursday month high sell news seem take afternoon close juno stock fall thursday kite fall also downside bluebird bio blue tumble month low several study early stage gene therapy lentiglobin sickle cell disease beta thalassemia inherited condition cause severe anemia previous datum have get investor hope lentiglobin be possible cure sickle cell disease particular most recent study however suggest patient beta subtype beta thalassemia do not respond well other type patient remain dependent blood transfusion
593,CELG,stock end seesaw session slightly lower thursday ahead friday key job report nasdaq lose dip dow jone industrial average end fraction lower stock market today volume be little change compare wednesday nyse nasdaq accord preliminary datum
594,CELG,chip designer qualcomm qcom be biggest loser plunge lowest level year disappointing quarterly earning report
595,CELG,ibd biotech celgene celg fall post mixed result
596,CELG,stock be still week move average work new base buy point however much pattern have form week line be flaw
597,CELG,upside facebook fb jump nearly new high number analyst raise price target follow social medium giant strong quarterly result stock be extend past buy point
598,CELG,close monster beverage mnst spiked much maker energy drink say profit rise cent share cent wall street estimate revenue rise also beating view currency headwind corona calif base monster say revenue be boost advance purchase make customer ahead price increase take effect aug
599,CELG,monster finished regular session fraction sixth straight loss be converge day day line work new base
600,CELG,walt disney dip fraction post session trading follow quarterly earning report stock be work cup type base potential buy point still form handle yield lower entry
601,CELG,stock recently undercut prior flat base reset base count
602,CELG,manage health care company humana hum home builder tri group tph be company due report quarterly earning friday
603,CELG,economic report due friday include labor department key nonfarm payroll report october economist poll econoday predict gain job jobless rate edge percentage point consumer credit figure september be also due friday stock end seesaw session slightly lower thursday ahead friday key job report nasdaq lose dip dow jone industrial average end fraction lower stock market today volume be little change compare wednesday nyse nasdaq accord preliminary datum chip designer qualcomm qcom be biggest loser plunge lowest level year disappointing quarterly earning report ibd biotech celgene celg fall post mixed result stock be still week move average work new base buy point however much pattern have form week line be flaw upside facebook fb jump nearly new high number analyst raise price target follow social medium giant strong quarterly result stock be extend past buy point close monster beverage mnst spiked much maker energy drink say profit rise cent share cent wall street estimate revenue rise also beating view currency headwind corona calif base monster say revenue be boost advance purchase make customer ahead price increase take effect aug monster finished regular session fraction sixth straight loss be converge day day line work new base walt disney dip fraction post session trading follow quarterly earning report stock be work cup type base potential buy point still form handle yield lower entry stock recently undercut prior flat base reset base count manage health care company humana hum home builder tri group tph be company due report quarterly earning friday economic report due friday include labor department key nonfarm payroll report october economist poll econoday predict gain job jobless rate edge percentage point consumer credit figure september be also due friday
604,CELG,president elect donald trump slam drugmaker wednesday get away murder pricing news be gut punch big cap stock incyte incy drop celgene celg drop shareholder sell let look chart be say be second time trump have denounce drug company slam dec
605,CELG,dow jone industrial average give start week president trump immigration policy other move worry investor moved back level friday job report apple aapl boom return earning growth investor didn care facebook fb amazon amzn result guidance unite parcel service up be struggle commerce boom charle schwab schw launch new stock trading pricing war dow jone industrial average fall back key level regain friday january job report trump move ease dodd frank other financial regulation dow fall week nasdaq rise end week record high trump immigration order create conflict tech firm trading partner earning be mixed bag cboe volatility index vix rally extreme level not much related dow component apple earn share sale quarter end dec be better expect marked return growth straight quarters year year decline apple current quarter guidance be conservative usual apple say iphone demand outstripped supply service revenue apple share rise nearly week hit month high related advanced micro device amd report smaller expect loss forecast sale bullish outlook share shot nearly hit year high nvidia nvda compete amd graphic other market jump ahead earning come week apple chip supplier cirrus logic crus qorvo qrvo top quarterly view give bearish guidance stock sell thursday related facebook ep soar revenue rise easily beating view decelerate second straight quarter mobile ad account ad revenue facebook reiterate ad revenue growth rate come meaningfully deliberate move avoid ad saturation now see heavy expense growth step hire facebook fall week snap parent snapchat file publicly upcoming ipo snap report soar revenue growth also slow user growth facebook instagram imitate key snapchat feature snap use ticker snap win sell voting share related amazon top earning forecast revenue revenue outlook be lower expect amazon web service cloud compute unit generate most commerce giant profit report revenue gain forecast aw be feel pressure rival cloud effort alphabet googl microsoft msft amazon share fall nearly friday undercut recent buy point related amazon result miss revenue beat ep stock fallsunited parcel service up report modest earning revenue growth holiday fourth quarter fall short forecast up also guide profit target lower cite impact strong dollar up see significant shift mix lower revenue product residential delivery accounting total package volume up ceo say result indicate up quicken pace investment network shift handle increase commerce meanwhile amazon announce set air hub cincinnatus northern kentucky international airport seek lessen dependence up fedex fdx up share plunge fedex lose related mastercard edge past earning view revenue be light share have be buy zone pull back nearly even regain day friday larger rival visa late thursday report better expect quarterly result strong payment growth visa rise friday push dow stock past buy point record high related federal reserve left interest rate alone give indication policymaker be hurry raise rate add strong job january well estimate slim wage gain ease fear economy be overheat ism manufacturing index rise fresh year high january related exxon mobil xom report adjust ep view oil major plan boost capital spending activity heat royal dutch shell rdsa say cut spending year report ep view conocophillip cop say plan raise spending energy information administration say crude stockpile rise barrel analyst expect russia opec seem be comply promise output cut accord reuter datum related auto sale decline december longtime high even automaker offer hefty incentive general motor gm ford fiat chrysler fcau report year year decline only gm miss forecast datum offer new evidence auto demand have peaked related charle schwab schw cut stock etf commission trade lower fidelity td ameritrade amtd trade etfc schwab fall thursday td ameritrade trade rely more stock trade schwab tumble interactive broker ibkr charge cent share trade sank related president trump meeting tuesday ceo exec celgene celg eli lilly lly johnson johnson jnj merck mrk novartis nvs say drug price be astronomical reiterate aim bring drug price also urge drugmaker manufacture also promise deregulate industry cut taxe drug stock pop day response related drugmaker eli lilly pfizer pfe disappoint tuesday earning lag consensus sale top meet respectively roche rhhby sale be light revenue earning rise mid single digit merck follow thursday line sale earning include time defer revenue amgen amgn late thursday report better expect earning say ldl cholesterol fighter reduce cardiovascular risk study related miss merger deadline expire walgreen boot alliance wba rite aid rad extend agreement end date july walgreen cut takeover price share share depend many rite aid store have be divest order new term get regulatory walgreen fall rite aid fall concern ftc win approve deal fred have agreement buy rite aid store edge lower related armour uaa miss estimate top bottom ep fall penny cent sale rise revenue guidance be light athletic apparel brand cfo be step personal reason share tumble year low related
606,CELG,biotech gilead science gild likely guide decline sale hamstrung limit hepatitis visibility rbc analyst michael yee say wednesday note expectation be better amgen amgn biogen biib earning season get underway yee expect gilead guide product sale bracketing consensus view be midpoint guidance vs early guidance appreciate visibility be tough hep right now buy side consensus be also fairly low gilead give know uncertainty yee write research report predict decline more hep sale gilead make sovaldi harvoni combat hep prescription hep drug fall quarter quarter accord market tracker im europe remain wild card volume patient fall markedly yee write be ongoing concern give bolus continue wear eu launch have occur major region past year so write note client merck be now launch number region possible lower pricing ibd take small biotech ipos outlast giant amgen biogen top stock gain company start year trade average daily volume share be pick check ibd industry theme yee expect gilead report sale tick broader consensus view consensus analyst poll thomson reuter expect gilead report earning share ex item yee see gilead be set report earning issue guidance hour feb big biotechs amgen biogen be set well earning share guidance be current investor uncertainty nervousness yee say amgen be schedule report late feb be widely modeled sale ep item then amgen report datum cardiovascular outcome trial cvot pcsk inhibitor repatha yee write cvot datum be see cvot benefit higher end stock trading write street want own name hit earning give good guidance cvot datum be risk biogen analyst poll thomson reuter view sale ep item yee see biogen be set report early jan biogen story be clearer settle patent dispute tecfidera forward pharma fwp company also likely discuss spinoff hemophilia unit bioverativ spinoff cut sale ep item cent vertex pharmaceutical vrtx celgene celg be slate report earning late jan early jan respectively preannounce financial result annual jpmorgan healthcare conference san francisco cystic fibrosis drug sale grow vertex say cf drug orkambi kalydeco pull celgene preannounce net sale company also guide sale midpoint outlook full year company see ep item grow midpoint related investor siphon biogen ionis gain spinal disease drug okcelgene ceo drug pricing debate hinge incentive innovation
607,CELG,san francisco celgene celg ceo mark alle parry back tuesday so call social contract patient allergan agn face drug pricing debate spiked last year mylan myl epipen turing pharmaceutical hiv medication debate be not new just new social medium say many pharma company have become public proclaim free access program interesting principle have be play celgene year speaking medium panel tuesday morgan healthcare conference san francisco alle outlined series program celgene offer less expensive free access revlimid key chemotherapy treat multiple myeloma myelodysplastic syndrome mantle cell lymphoma alle estimate celgene medicine go patient free year subsidize well reinvest cfo peter kellogg say celgene reinvest north accounting partnership company hike price year ibd take celgene stock have ibd composite rating meaning have outperformed stock key metric past month rank company ibd medical biom biotech industry group see company lead sector visit ibd stock checkup person think lower price be answer drug pricing debate say meant longer have threshold provide access patient don have safety net trouble be celgene isn alone annual price hike last july wall street journal find drug price have jump vs year earlier figure alle say number factor be play complicate matter consumer generally don understand costly drug development process instance run pivotal late stage trial cost average drug fail firm be million alle say welcome comprehensive transparency look forward evolve say incentive have exist company take risk create return biopharmas generic alike simply agree price illegal alle note late monday pair former heritage pharmaceutical executive admit price fix scheme april december involve generic antibiotic diabetes drug accord philly com ex ceo jeffrey glazer jason malek former senior vice president commercial operation plead guilty federal court philadelphia conspire manipulate drug price federal investigator be also look mylan teva pharmaceutical teva other drugmaker suspicion price fix do industry person want do alle say assured be pay list price drug celgene share fall stock market today celgene work consolidation buy point rise monday raise profit forecast
608,CELG,cancer treatment biotech jounce therapeutic jnce turn strong initial public offer friday pricing estimate range raise be ipos friday energy company jagged peak energy jag slip pricing door window maker jeld wen hold jeld specialty vehicle maker rev group revg open strong vaccine developer visterra do not price plan now be day day status week ipos be suppose be big include high tech unicorn appdynamic be set price wednesday look raise valuation expect approach tuesday developer app performance monitoring tool announce have be acquire cisco system csco cisco acquisition give boost new relic newr splunk splk idea become acquisition target well appdynamic be be year first ipo unicorn highly anticipate ipo snapchat owner snap be expect march unleash stampede unicorn ibd take ipos be seedbed innovation be huge stock winner stock also reverse quickly so keep track ibd ipo leader column also read investor corner maximize chance success ipos jounce therapeutic be early stage biotech be develop cancer therapy used cell immunotherapy treatment celgene celg raise offer share expect range jounce open end day strike price stock market today jagged peak energy be expect be largest ipo week come estimate independent oil gas company focuse west texas production raise plan raise offer share expect range open jagged peak stock end day flop jagged peak jeld wen be biggest ipo raise offer share high end range jeld wen stock open finished trading rev group raise offer share expect range rev group stock open close regular trading right strike price rev group be lead designer manufacturer distributor specialty vehicle related aftermarket part service vehicle cover category fire emergency recreational commercial related new ipos show superior return equity ipo leader see today top perform ipo stocksbuying ipo stock be tricky so do homework
609,CELG,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
610,CELG,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
611,CELG,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
612,CELG,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
613,CELG,worst performer ibd be regeneron pharmaceutical regn more
614,CELG,energy name be day best perform industry group push oil price be higher
615,CELG,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
616,CELG,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
617,CELG,stock be try claw way back morning sell trading head noon hour thursday nasdaq fall dow jone industrial average drop stock market today nasdaq have be earlier session
618,CELG,economic news productivity rise third quarter better expect forecast gain lower increase
619,CELG,lead stock facebook fb gap higher be trading almost new high multiple analyst raise price target stock
620,CELG,close wednesday facebook report earning cent share vs estimate cent issue guidance wall street view
621,CELG,facebook be best performer ibd stock be higher be lower celgene celg ibd name be report result adjust ep be increase year damage be limit stock attempt build new base stock be find support day move average
622,CELG,airbnb competitor homeaway away explode gain expedia expe announce be buy company expedia rise average volume have touch new high
623,CELG,elsewhere pacific ocean container ship operator matson matx part dow jone transportation average jump more huge volume report result stock be try claw way back morning sell trading head noon hour thursday nasdaq fall dow jone industrial average drop stock market today nasdaq have be earlier session economic news productivity rise third quarter better expect forecast gain lower increase lead stock facebook fb gap higher be trading almost new high multiple analyst raise price target stock close wednesday facebook report earning cent share vs estimate cent issue guidance wall street view facebook be best performer ibd stock be higher be lower celgene celg ibd name be report result adjust ep be increase year damage be limit stock attempt build new base stock be find support day move average airbnb competitor homeaway away explode gain expedia expe announce be buy company expedia rise average volume have touch new high elsewhere pacific ocean container ship operator matson matx part dow jone transportation average jump more huge volume report result
624,CELG,apple aapl iphone chip supplier skywork solution swks qorvo qrvo be top company report quarterly result thursday here rundown store skwywork qorvo walt disney cyberark software cybr celgene celg more apple iphone chipmaker growth slow skywork chip help iphone other mobile device connect wireless network company
625,CELG,year multiple sclerosis have be field good produce blockbuster drug roche look be latest entrant clique strong trial result candidate ocrelizumab come market just lead player be start look vulnerable roche rhhby biotech division genentech present result
626,CELG,stock hold solid gain be session high early afternoon trading monday cheer busy day merger acquisition nasdaq gain rise dow jone industrial average picked small cap do well again russell volume nyse nasdaq be tracking slightly lower friday level stock market today chevron cvx pfizer pfe be top performer dow chevron be help price target raise credit suisse credit suisse maintain neutral rating biotechs celgene celg regeneron regn be top percentage gainer nasdaq rise respectively regeneron report earning wednesday open celgene report thursday open economic news come mostly line expectation read marked fourth straight monthly decline october job report be due friday bond price fall monday lift yield year treasury note merger news dyax dyax soar ireland base shire shpg agree buy orphan drug specialist meanwhile medasset mda surge agree be take private private equity firm cash other gainer include interactive broker ibkr share rise climb time high work right side base online brokerage offer pretty compelling growth story latest quarter earning jump year cent share sale jump downside visa slump earning miss expectation company also announce plan buy visa europe follow ken shreve twitter ibd_kshreve facebook
627,CELG,medical sector have be ailing lately be ibd sector monday issue sector leader hail health care regeneron pharmaceutical regn be featured friday column have pull back buy zone briefly climb range last week stock fall sharply wednesday
628,CELG,major average kick week fine fashion monday end solid gain commodity stock outperformed thank big rally china stock overnight
629,CELG,dow jone industrial average outperformed rise lead caterpillar cat apple aapl apple get lift analyst report say recent bearish sentiment stock be overdo
630,CELG,picked nasdaq gain preliminary datum show volume nyse nasdaq come lower friday level more so nasdaq
631,CELG,oil gas name do well rebound oil price new york mercantile exchange benchmark crude oil end barrel
632,CELG,refine industry group tesoro tso valero vlo alon usa energy alj rise score new high heavy volume mining steel stock also outperformed
633,CELG,stock market today precision castpart pcp soar warren buffett agree buy company share head monday aerospace firm stock have be downtrend more year
634,CELG,ibd cyberark software cybr regain day move average rise nearly security software name report tuesday close cyberark be ibd name rise least monday
635,CELG,celgene celg ross store rost also outperformed ibd be buy point try break basis
636,CELG,pra group praa add just ahead earning report close be trading tightly hold high ahead result
637,CELG,also close watch report shake shack shak fast grow china name vipshop vip major average kick week fine fashion monday end solid gain commodity stock outperformed thank big rally china stock overnight dow jone industrial average outperformed rise lead caterpillar cat apple aapl apple get lift analyst report say recent bearish sentiment stock be overdo picked nasdaq gain preliminary datum show volume nyse nasdaq come lower friday level more so nasdaq oil gas name do well rebound oil price new york mercantile exchange benchmark crude oil end barrel refine industry group tesoro tso valero vlo alon usa energy alj rise score new high heavy volume mining steel stock also outperformed stock market today precision castpart pcp soar warren buffett agree buy company share head monday aerospace firm stock have be downtrend more year ibd cyberark software cybr regain day move average rise nearly security software name report tuesday close cyberark be ibd name rise least monday celgene celg ross store rost also outperformed ibd be buy point try break basis pra group praa add just ahead earning report close be trading tightly hold high ahead result also close watch report shake shack shak fast grow china name vipshop vip
638,CELG,news medicine company mdco monday be reminder innovation be alive well biotech space share surge company announce positive phase trial datum experimental cholesterol drug develop alnylam pharmaceutical alny ibd medical biom biotech group have slip bit ibd industry group ranking still hold own
639,CELG,major index etfs downshift further monday china federal reserve have continue weigh stock market last trading day august exchange trade fund tracking dow jone industrial average nasdaq post largest monthly loss last week turbulence stock market whipsaw investor even intensified worry global slowdown raise doubt wisdom fed rate hike next month spdr dow jone industrial average dium slip stock market today etf hold blue chip industrial leader merck mrk pfizer pfe ibd leaderboard stock visa be dium lead decliner hold goldman sachs gs intel intc be only stock dium advanced dium peg decline august worst monthly loss year so do spdr spy proxy broad market powershare qqq qqq track largest nonfinancial stock nasdaq composite index spy fall monday sector energy red qqq give qqq top holding biotech stock gilead science gild amgen amgn celgene celg regeneron pharmaceutical regn be hardest hit monday close lose ishare nasdaq biotechnology ibb take hit market vector biotechnology bbh worst sector industry focuse etfs so call death cross spy daily chart be first appearance year pattern occur short term move average week move average slip long term line week move average see bearish signal warning loss momentum more loss ahead accord market watcher interview cnbc cross daily chart be less relevant longer term cross be more worrisome therefore weekly chart spy dium also show pattern here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs vanguard ftse emerge market vwo rs ishare russell iwm rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs powershare qqq qqq rs follow aparna narayanan twitter ibd_anarayanan
640,CELG,wall street wild ride week doesn necessarily signal end bull market say ub wednesday report note similar volatility spike presage buy opportunity firm produce list stock cash cushion enable ride current volatility believe current year bull
641,CELG,ibd medical biom biotech group hold spot list industry group track several member top street forecast past week
642,CELG,today screen day focus top fundamental stock year earning revenue growth rate more
643,CELG,gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni
644,CELG,success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance
645,CELG,exclude item share gilead earning climb trouncing street view cent sale growth beat forecast
646,CELG,gilead share close stock market today stock be build flat base buy point
647,CELG,gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth
648,CELG,regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating
649,CELG,portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue
650,CELG,tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top
651,CELG,regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday
652,CELG,other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp
653,CELG,thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble
654,CELG,wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect
655,CELG,specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday
656,CELG,industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib
657,CELG,related
658,CELG,regeneron abiom hit new high strong guidance
659,CELG,gilead get wall street love earning beat
660,CELG,gilead set flat base bullish reversal
661,CELG,company be fastest grow big cap biotech ibd medical biom biotech group hold spot list industry group track several member top street forecast past week today screen day focus top fundamental stock year earning revenue growth rate more gilead science gild have year ep growth rate develop medicine life threaten condition include cancer hiv aids heart disease gilead be perhaps most well know blockbuster hepatitis treatment sovaldi harvoni success hepatitis drug have fuel sale foster city calif base company last week soundly top consensus view boost full year guidance exclude item share gilead earning climb trouncing street view cent sale growth beat forecast gilead share close stock market today stock be build flat base buy point gilead have earn ibd highest possible composite rating mean have outperformed other publicly trade company mix fundamental technical factor include earning revenue growth regeneron pharmaceutical regn have even higher year ep growth rate too have ibd composite rating portfolio include cholesterol treatment praluent eye drug eylea latter make most regeneron revenue tuesday stock hit time high follow view top result bump guidance earning grow share beating estimate cent revenue climb top regeneron stock have break flat base buy point mid july hover buy range tuesday result boost share right buy territory finished thursday other drugmaker top fundamental list include lannett lci insys therapeutic insy ligand pharmaceutical lgnd sucampo pharmaceutical scmp thursday insys report ep drop cent miss penny revenue climb estimate insys share tumble wednesday sucampo report earning cent share just cent year earlier quarter cent analyst consensus revenue grow more analyst expect specialty drug maker also raise full year ep guidance cent top street estimate cent sucampo share gain wednesday rise thursday industry peer fellow medical biom biotech group member include celgene celg amgen amgn biogen biib related regeneron abiom hit new high strong guidancegilead get wall street love earning beatgilead set flat base bullish reversalwhat company be fastest grow big cap biotech
662,CELG,drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year
663,CELG,celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder
664,CELG,meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus
665,CELG,other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say
666,CELG,celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market
667,CELG,next major mover
668,CELG,piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock
669,CELG,note celgene be return name top large cap pick share have climb year
670,CELG,celgene have be especially active develop drug various cancer immune inflammatory disease
671,CELG,drug fight least common disease multiple myeloma be fastest grow
672,CELG,first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell
673,CELG,sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june
674,CELG,other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis
675,CELG,sale second quarter prior year abraxane be celgene slower grow drug
676,CELG,goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow
677,CELG,analyst expect new indication geographic expansion keep abraxane peter
678,CELG,sale otezla food drug administration approve march totale
679,CELG,total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter
680,CELG,lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start
681,CELG,biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis
682,CELG,biggest biotech merger
683,CELG,higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva
684,CELG,celgene offer receptos amount share expire august
685,CELG,receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total
686,CELG,phase datum ms be expect ulcerative colitis
687,CELG,oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan
688,CELG,have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say
689,CELG,earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease
690,CELG,celgene pay upfront buy share juno stock share also have right take stake juno
691,CELG,not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected
692,CELG,celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway
693,CELG,yee expect side settle case go court drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market next major mover piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock note celgene be return name top large cap pick share have climb year celgene have be especially active develop drug various cancer immune inflammatory disease drug fight least common disease multiple myeloma be fastest grow first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis sale second quarter prior year abraxane be celgene slower grow drug goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow analyst expect new indication geographic expansion keep abraxane peter sale otezla food drug administration approve march totale total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis biggest biotech mergersif higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva celgene offer receptos amount share expire august receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total phase datum ms be expect ulcerative colitis oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease celgene pay upfront buy share juno stock share also have right take stake juno not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway yee expect side settle case go court
694,CELG,stock rolled narrowly mixed action muted trade thursday earning report drive number dramatic early move dow jone industrial average gain apiece nasdaq ease
695,CELG,trade be quiet nyse nasdaq exchange relative action same time wednesday
696,CELG,stock market today receive mixed job news weekly unemployment claim jump more expect layoff slow sharply october labor department also estimate productivity slow cost rise vs second quarter however figure be still better street expect
697,CELG,dow be primarily positive jpmorgan jpm apple aapl lead bit less autodesk adsk lead nasdaq gain
698,CELG,morning biggest move fashion brand ralph lauren rl surge mattress retailer select comfort scss bounce argentina base online retailer mercadolibre meli logged gain report quarterly result homeaway away spiked expedia expe agree pay acquire vacation rental site expedia share rise take new high cup base buy point
699,CELG,facebook fb bolt ahead gain early action solid report late wednesday include better expect revenue earning average daily user climb mark stock plow easily fresh high be extend buy point
700,CELG,also ibd list noah noah knock gain move further right side cup base
701,CELG,be plenty loser go early action
702,CELG,qualcomm qcom dive report healthy fiscal fourth quarter result offer weak guidance
703,CELG,leader epam system epam crumble profit rise cent share view cent sale growth miss estimate loss send share buy point trigger automatic sell rule
704,CELG,new jersey base biotech celgene celg slump earning narrowly beat expectation revenue stop short forecast management pare full year sale guidance breast lung pancreatic cancer treatment abraxne tumble pull share back test stock converge week move average stock rolled narrowly mixed action muted trade thursday earning report drive number dramatic early move dow jone industrial average gain apiece nasdaq ease trade be quiet nyse nasdaq exchange relative action same time wednesday stock market today receive mixed job news weekly unemployment claim jump more expect layoff slow sharply october labor department also estimate productivity slow cost rise vs second quarter however figure be still better street expect dow be primarily positive jpmorgan jpm apple aapl lead bit less autodesk adsk lead nasdaq gain morning biggest move fashion brand ralph lauren rl surge mattress retailer select comfort scss bounce argentina base online retailer mercadolibre meli logged gain report quarterly result homeaway away spiked expedia expe agree pay acquire vacation rental site expedia share rise take new high cup base buy point facebook fb bolt ahead gain early action solid report late wednesday include better expect revenue earning average daily user climb mark stock plow easily fresh high be extend buy point also ibd list noah noah knock gain move further right side cup base be plenty loser go early action qualcomm qcom dive report healthy fiscal fourth quarter result offer weak guidance leader epam system epam crumble profit rise cent share view cent sale growth miss estimate loss send share buy point trigger automatic sell rule new jersey base biotech celgene celg slump earning narrowly beat expectation revenue stop short forecast management pare full year sale guidance breast lung pancreatic cancer treatment abraxne tumble pull share back test stock converge week move average
705,CELG,stock end modestly lower wednesday federal reserve chief janet yellen say be live possibility interest rate hike next month fall dow jone industrial average edge nasdaq dip volume be mixed dip nyse rise nasdaq compare tuesday accord preliminary datum maker consumer stock be biggest loser stock market today motorola solution msi make way radio other communication product plunge more better expect profit sale result stock have be work flat base crash day move average finally steadying just day line tesla motor tsla lead share automaker higher soar electric vehicle maker delivery outlook trump weaker expect quarterly earning report stock be testing resistance day line remain week higher homeaway away rocket post session trading expedia expe agree buy online marketplace vacation rental deal be expect close first quarter next year pending regulatory approval be expect help expedia compete home rental business such airbnb meanwhile facebook fb rise hour trading follow earning report profit period rise cent share gain revenue top wall street estimate company say number daily active user rise year average september mobile daily active user jump average month facebook rise regular session buy range buy point qualcomm qcom be sharply hour outlook fiscal first quarter end december trail analyst estimate outweighed better expect result latest period disney celgene celg cyberark software cybr nvidia nvda be company schedule report quarterly earning thursday economic report due thursday include initial jobless claim week end oct productivity datum
706,CELG,stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing
707,CELG,dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain
708,CELG,stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday
709,CELG,investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs
710,CELG,current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal
711,CELG,relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance
712,CELG,philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september
713,CELG,conference board be set release lead economic indicator index october et
714,CELG,dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag
715,CELG,seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade
716,CELG,keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high
717,CELG,salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point
718,CELG,china base play chalk strong premarket move
719,CELG,ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base
720,CELG,china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september conference board be set release lead economic indicator index october et dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point china base play chalk strong premarket move ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base
721,CELG,valeant pharmaceutical vrx late wednesday say have receive subpoena attorney massachusett southern district new york related drug pricing help patient pay drug send valeant share already pressure sharply lower thursday pre market trading come valeant slew biotechs such biogen biib
722,CELG,stock kick week solid ground score big gain busy day merger news small cap outperformed nasdaq hit year high russell small cap index jump nasdaq add rise dow picked volume fall friday level breadth be solid
723,CELG,know old say be right place right time better yet rather leave chance manager allianzgi focuse growth fund pgwax have aim add boost putt right place overall investment approach ve pivot stock think benefit trump presidency new congress reaction already seem be pay fund gain past month go thursday top large cap growth rival track morningstar inc big jump relative performance past month fund gain beat just peer group election fund have boost overweight financial add stake industrial say lead manager karen hiatt also have shift underweight consumer staple addition anticipate uptick inflation fund be shift smaller end large cap stock smaller cap typically outperform higher inflation environment hiatt say financial such bank especially midsize regional bank benefit rise rate levele reduction regulatory burden hiatt say fund bet space include ibd stock first republic bank frc signature bank sbny first republic signature be same theme hiatt say first republic be really high quality regional bank service high net worth individual lot exposure big city new york san francisco bay area los angele share close wednesday initiate position hiatt say sell well fargo wfc first republic sell bank issue concern lend buy bank know quality lend be very conservative have high client retention high loan growth well fargo say month new credit card application have plunge new check account be fourth quarter vs year earlier wake last year bad publicity concern bank creation fake customer account regional bank be already get boost congressional move raise threshold dodd frank act systemic risk designation exist rule apply bank least asset subject costly regulation be political push move threshold hiatt say good shot get help midsize regional bank lower threshold be costly pull ability smaller bank grow fund other holding also illustrate best idea approach hiatt co manager raphael edelman fund run concentrated portfolio try keep stock hiatt say now manager look innovative company find many technology sector broadcom avgo be ibd leaderboard company make analog digital semiconductor system wireless communication other application ibd take ibd leaderboard point broadcom stock have rally week trading thursday morning share be extend buy point stock relative strength line have climb lot month mean broadcom be outperform ibd recently report least investment bank recently increase price target stock key reason be broadcom quarters row accelerate earning growth thank largely gain stem broadcom merger hiatt edelman also facebook fb alphabet googl be continue move advertising dollar traditional medium digital hiatt say google alphabet be do youtube example facebook actually measure return advertiser get dollar greater visibility dollar return continue fuel shift advertiser facebook mobileye mbly be innovator company develop supply technology interpret car camera see anticipate avoid collision product enhance vehicle safety company do not need advent fully self drive car average now car use safety equipment content be rise hiatt say big driver mobileye fund be skeptical appeal most health care stock repeal rollback obamacare undermine earning growth potential many stock so do potential regulatory intervention spawn drug pricing controversy hiatt be guardedly comfortable fund celgene celg hold long drug pricing be concern hard see multiple expansion many health care company say don have see multiple expansion celgene work already trade project consensus multiple annual growth next year look intriguing related lead stock be drive hot mutual fund rallyfacebook edward allianzgi fund cope stingy marketwhere mutual fund bigwig expect see stock gain
724,CELG,dow jone industrial average hit major average rally fresh record high president trump early policy move earning report generally be positive google parent alphabet googl starbucks sbux be disappointing result deal buzz rejection be rife dow jone industrial average rise week top first time nasdaq also hit record high respectively slew earning include intel intc alphabet googl microsoft msft alibaba baba boee ba president trump authorize border wall key oil pipeline lift wide variety construction material related firm such caterpillar cat martin marietta material mlm not steel maker amazon amzn facebook fb break join other fang stock year treasury yield rise lift bank stock google parent alphabet say earning share item rise view total revenue rise top forecast revenue growth slow prior year period internet search advertising giant face tough comparison prior year quarter launch new advertising product capital spending soar much related cloud compute effort marketing cost google new pixel smartphone also be heavy alphabet share fall friday hit record high earlier week related alphabet ep miss earning rise cent share revenue climb beating view cent credit boom cloud compute business include azure microsoft guide revenue forecast higher microsoft share rise nearly week hit record high related microsoft beat target cloud compute chipmaker ep rise top view sale growth be best year intel also give bullish guidance intel share rise friday breaking base earlier week ahead earning texas instrument txn also report strong earning samsung electronic credit memory chip gain overall profit revival microsemi mscc also have good result chip gear maker lam research lrcx kla tencor klac mobile chipmaker qualcomm qcom face ftc charge apple lawsuit licensing practice report mixed result related intel earning sale top expectation revenue guidance also economy expand annual rate fourth quarter view not much more half gain gdp grow just straight year meanwhile durable good order unexpectedly fall second straight month december new home sale tumble month low several homebuilder remain bullish report solid earning starbucks sbux report weakest earning growth year meet view sale miss forecast customer traffic coffee shop giant also cut revenue outlook say mobile order pay be so popular create bottleneck order pick turn patron starbucks share fall friday meanwhile mcdonald mcd top ep sale target comp fall investor question momentum day breakfast menu have run mcdonald test key support level initially close week related too much good thing weigh starbucks stock test key support turnaround doubtsa federal judge rule aetna aet humana hum merger violate antitrust law unduly reduce competition health insurer aetna owe humana breakup fee appeal deal also throw doubt propose anthem antm cigna ci merger deal justice department also oppose related aetna deal humana block federal judgeseveral steel maker sell week breaking day line earning report fail support stock postelection run even president trump tout various infrastructure plan signale more protectionism ak steel ak top view tuesday share reversed sharply lower weak pricing outlook steel dynamic stld have decent earning late tuesday tumble wednesday larger peer steel nucor nue report jan also sell many steel maker rebound thursday friday upside specialty steel firm allegheny steel atus deliver stellar earning tuesday send share day related steel stock break key support even trump rally resumesak allegheny earning top steel dynamic meet steel stock bend waysboeing ba emphasize importance trade china aerospace industry job be bullish president trump tax reform regulation boee report ep revenue analyst view guidance be cautious dreamliner be now cash flow positive bode well future stock buyback dividend increase boee share break base hit record high lockheed martin lmt report earning revenue analyst view aeronautic revenue include sale soar expect surge delivery year lockheed give weak guidance continue concern cost send share lower northrop grumman noc beat view raytheon rtn fall short boee lockheed give weak guidance general dynamic gd report strong earning give bullish long term guidance related boee back china trade trump protectionism loomslockheed see jump guide profit low cost flapnorthrop raytheon join lockheed weak view new budget loomsverizon communication vz stock sell disappointing guidance also spark speculation possible merger cable firm charter chtr well dish network dish walt disney verizon report mixed revenue fall beating estimate ep be light wireless margin miss management push back goal return wireless service growth close verizon purchase yahoo yhoo be delay regulator look datum breach report line ep revenue ebitda slightly consensus again lose wireless postpaid phone subscriber remain upbeat regulatory approval time warner twx acquisition comcast cmcsa earning top view solid subscriber gain cable tv firm plan buy back share hike dividend announce stock split comcast plan launch wireless service buy midyear comcast rise week new high related verizon stock fall ep revenue outlook more sameverizon charter talk heating malone vision keycomcast top earning hike dividend offer wireless hintswill cross selling success spur comcast wireless buy johnson johnson jnj agree pay swiss biotech actelion report weak sale guidance earlier week celgene celg miss sale even preannounce result biogen biib stock pop light sale better fear guidance follow hemophilia unit spinoff bristol myer squibb bmy miss earning give weak ep guidance weaker lung cancer drug prospect related johnson johnson buy actelion billionbristol myer topple guidance cut merck aim hurdle revlimid patent lossdisk drive maker western digital wdc seagate technology stx report quarterly result top view bullish guidance result suggest multiyear slump disk drive shipment have bottom company be also investing heavily flash base chip storage follow market need seagate share shot western digital set month best related western digital get positive reviews crisp execution alibaba baba revenue rise local currency ep rise view revenue cloud compute unit rise share commerce giant rise more week alibaba build right side base related alibaba crush earning estimate raise guidanceford top fourth quarter result expectation see sluggish ceo mark field say automaker have right amount plant need president trump call day earlier big build more factory fiat chrysler fcau meanwhile say net income double help cost saving revenue tick ford ceo say plant appropriate profit meet sale topcisco system csco late tuesday announce buy appdynamic day latter be expect price ipo top target valuation appdynamic be go be year first tech unicorn go public provide cloud base software measure analyze performance business critical application cisco system nabs appdynamic just ipo
725,CELG,load player here investing action plan wednesday need know investor come day drug biotech stock be motion week jpmorgan healthcare conference continue already volatile group make dramatic swing discernible pattern be take shape celgene celg gw pharmaceutical gwph cara therapeutic cara meanwhile
726,CELG,san francisco less hour president elect donald trump wednesday refer drug industry disastrous aldr ceo randall schatzman classify tone annual jpmorgan healthcare conference cautiously optimistic wide departure event time say sentiment be decidedly pessimistic enter turn be raucous election year drug pricing debate be alive biotech sentiment be grow stronger year schatzman tell ibd interview conference drug industry major event hold week san francisco talk biotech industry whole think finally come maturity say last year almost drug have be approve have come innovation biotechnology not large pharma so dollar be really pay back re see real game changer schatzman include cgrp migraine drug compete directly similar med eli lilly lly teva pharmaceutical teva amgen amgn migraine market be big enough grab sizable share drug hit shelve likely acknowledge trump comment didn help stock price hold phone schatzman pull screen biotech stock red arrow indicate descent point ishare nasdaq biotechnology index ibb exchange trade fund fall wednesday rise fraction thursday friday ibd take trump commentary send drug stock tailspin wednesday get deep dive mean drug biotech pick ibd industry theme so rally wall street expect jpmorgan event didn unfold here be key takeaway investor note trump take office drug firm look sidestep lilly alzheimer flop get early start trump isn alone fixation drug price celgene celg ceo mark alle parry back reporter question biotech follow allergan agn footstep apply so call social contract not raise price more annually celgene have offer free access program year alle say estimate biotech give away drug year free drug price increase help fund new drug add cfo peter kellogg estimate celgene reinvest fund accounting partnership alle say celgene go thoughtful process accounting innovation spending bring drug market price new med schatzman used same word describe plan price cgrp drug once near fda approval head market healthprize technology ceo tom kottler call pricing spike easy way drug company healthprize be software service firm marry behavioral economic consumer marketing analyze improve patient adherence prescription pharma leave worldwide revenue table year not push patient take med kottler tell ibd bridge gap company bring new product market prompt doctor more prescription raise price typically choose latter re miss easy money kottler say raise price be easiest thing say drugmaker merck mrk announce immuno oncology io drug keytruda combination chemo eli lilly alimta have win priority review fda small cell lung cancer have prescription drug free user act pdufa date meanwhile merck incyte incy be move keytruda epacadostat phase trial tumor type small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck incyte stock jump jan news bristol myer squibb bmy be merck tail analyst say bristol myer be testing combination opdivo yervoy io therapy nsclc analyst expect bristol myer readout first half io combo be likely be more effective durable io chemo say monday japan takeda pharmaceutical put share bid ariad pharmaceutical ariad oncology firm base massachusett ariad stock fly news help share oncology firm tesaro tsro lift tesaro stock ipos lead ibd company medical biom biotech industry group stock see triple digit gain tesaro jump group overall fall painful election cycle now analyst wonder tesaro success oncology mind atmosphere reiterate takeda offer ariad garner bid tesaro leerink analyst seamus fernandez see potential takeout price share tesaro stock close friday rise tesaro remain well position grow independently validate parp inhibitor niraparib ovarian cancer drug still development offer durable strategically important product opportunity multiple suitor fernandez write research report jan regeneron regn sanofi sny be ask federal judge stay ban ldl bust drug praluent aftermath patent battle land biotech amgen praluent infringe amgen patent pcsk inhibitor repatha judge say meanwhile ldl buster alnylam pharmaceutical alny medicine co mdco be slowly advance jan medicine co announce day interim analysis study examine pcsk inclisiran datum show inclisiran significantly lower ldl day rbc analyst adnan butt expect month datum be similar efficacy safety detail be expect american college cardiology conference march washington inclisiran do well strong datum patent litigation amgen regeneron sanofi inclisiran be differentiate have patent litigation overhang butt say research report wednesday axovant axon ceo vivek ramaswamy say biotech drug industry have utterly fail alzheimer oncology inflammation cardiology ve see significant advancement last year disease alzheimer dementia include lewy body haven say don find treatment major threat society tell ibd interview wednesday be single area health care have fail deliver major advancement last decade ramaswamy say be root eli lilly december lilly highly laud solanezumab fail meet primary endpoint late stage trial cause lilly stock plunge day announcement lilly drug drug development biogen biib work remove plaque buildup brain associate alzheimer silver bullet theory ramaswamy doesn buy instead see necessary treat various behavioral psychological neurological piece alzheimer dementia axovant be aim build new therapy top older one axovant be next be alzheimer field deliver readout datum be slate say ramaswamy be look just major piece news alzheimer advancement say ramaswamy rise tide lift boat
727,CELG,thalidomide be infamous cause birth defect celgene celg transform blood cancer treatment know revlimid bring year trouble be celgene didn know exactly revlimid work just know kill myeloma cell gangbuster say robert hershberg celgene chief scientific officer now company say finally figured revlimid play key role help body dispose certain protein celgene harness discovery company say lead new treatment other cancer autoimmune disorder even disease alzheimer not mention pile profit far do deal company scientist fail drugmaker look stick past unable let go drug make great celgene share be more wednesday president elect donald trump vow lower drug price also be left gap fill celgene finished day patent protection revlimid expire next decade revenue be expect fall cliff give year take develop drug lab market celgene be pressure show investor pipeline feed company growth stake be big not only celgene bottom line million patient treatment be elusive also test new protocol call precision medicine aim match patient drug base factor such genetic understand exactly drug work individual patient body be critical successful prescribe medicine future be not used sledgehammer approach say celgene board member gilla kaplan go be ability identify group patient respond best minimize toxic effect celgene be try do be stay top crest kaplan work thalidomide revlimid predecessor originally develop leprosy treatment time thalidomide be taint be take market be link thousand child born flipper limb mother take drug nausea medication pregnancy kaplan fellow researcher rockefeller university show thalidomide inhibit molecule make warrior aids side effect be major hurdle other company bring aids drug market first nobody want drug celgene be pay attention drugmaker buy year work remove toxic effect revlimid become available sale revlimid cousin pomalyst thalidomide derivative have increase steadily pomalyst be also used fight multiple myeloma have be successful patient relapse take revlimid do drug work answer lie garbage disposal system cell live cell be constantly manufacturing protein watch viruse carry message body help repair damage cell cell also need way discard unwanted protein trash man case be molecule group call ligase ligase have molecule call cereblon stick hook grab match protein ligase get hold protein tag trip dump thalidomide revlimid pomalyst work modify shape hook way hook tag different type protein garbage heap now celgene understand work redesign shape hook so tag different protein theory celgene modify drug snag tag sort unwanted protein destruction summit base company have say publicly have drug currently pipeline cc diffuse large cell lymphoma cc lupus cc acute myeloid leukemia hershberg say company also have myeloma drug work more potential treatment company hasn reveal ibd take steadily decline july celgene share break day trump election prospect favor biotechs statement week say take drugmaker cause share drop again wednesday celgene rank fifth company ibd biom biotech group biospecific technology bstc rate first celgene investor observer have show different level excitement next generation revlimid celgene be do everything right say jeff ross radiologist founder vailshire capital management llc family fund management say revlimid next generation successor continue be celgene golden goose have collaborative partnership internal research development cement leadership next decade more skeptical be cowen co analyst eric schmidt write scathing note attend september celgene presentation be cereblon optimal target pathway write be connection cereblon specific disease state other word other fact cereblon turn be molecular target great myeloma drug revlimid pomalyst investor believe target have utility other indication celgene be still shooting dark come apply class compound drug development schmidt write not so say mark alle celgene chief executive officer say re room dark be several night light give insight future be alle say interview feel re much better position opposed serendipity past schmidt still have outperform rating equivalent buy recommendation celgene more convince celgene other bet partnership smaller biotechnology firm acquisition outside asset make year so celgene still have business even revlimid next generation fail alle say revlimid remain heart soul company doubt cornerstone therapeutic be today alle say understand protein creation destruction be sun solar system re build strategic future
728,CELG,best mutual fund july performance report ibd new buy list show country lead stock mutual fund past month have continue gobble top rate medical stock such allergan agn celgene celg regeneron pharmaceutical regn molina healthcare moh acadium healthcare achc stock market july most part help mutual fund make
729,CELG,want do something cash nervous buy stock choppy market ibd big cap list appear tuesday contain stock have minimum market capitalization stock be less volatile high growth stock taser tasr soar day fall sharply next
730,CELG,behemoth big cap be capable produce steady not large gain
731,CELG,ibd screen emphasis stock have decent stable profit growth year period
732,CELG,also show price appreciation sound chart pattern many stock pay dividend
733,CELG,stock appear big cap list week week be most promising check stock analysis bottom weekly minichart accompany stock see be form basis be secondary buy area stock avoid have rise more buy point order minimize risk
734,CELG,buy only market pulse locate page today paper show market be confirm uptrend
735,CELG,previous big cap winner include starbucks sbux celgene celg mastercard biogen biib
736,CELG,example be online travel stock priceline pcln appear big cap april be try clear buy point long cup handle base
737,CELG,also clear alternate entry heavy volume week end
738,CELG,weekly minichart accompany priceline entry big cap show stock enjoy composite rating earning share rating line best growth stock
739,CELG,profit growth be accelerate lead climb quarters march sale growth rise span
740,CELG,priceline climb high week end march gain just month
741,CELG,big cap column offer more analysis include commentary overall market industry sector be show strength
742,CELG,sale profit growth rate other key metric stock be find stock checkup page investor com want do something cash nervous buy stock choppy market ibd big cap list appear tuesday contain stock have minimum market capitalization stock be less volatile high growth stock taser tasr soar day fall sharply next behemoth big cap be capable produce steady not large gain ibd screen emphasis stock have decent stable profit growth year period also show price appreciation sound chart pattern many stock pay dividend stock appear big cap list week week be most promising check stock analysis bottom weekly minichart accompany stock see be form basis be secondary buy area stock avoid have rise more buy point order minimize risk buy only market pulse locate page today paper show market be confirm uptrend previous big cap winner include starbucks sbux celgene celg mastercard biogen biib example be online travel stock priceline pcln appear big cap april be try clear buy point long cup handle base also clear alternate entry heavy volume week end weekly minichart accompany priceline entry big cap show stock enjoy composite rating earning share rating line best growth stock profit growth be accelerate lead climb quarters march sale growth rise span priceline climb high week end march gain just month big cap column offer more analysis include commentary overall market industry sector be show strength sale profit growth rate other key metric stock be find stock checkup page investor com
743,CELG,stock jump broad gain early tuesday rate cut china trump raft forecast housing datum nasdaq grab early lead gain swung dow jone industrial average climb
744,CELG,volume be run well monday blister pace major exchange nasdaq lower nyse
745,CELG,stock market today rolled news china mainland market have again take deep dife tuesday hong kong lead index post narrow gain country market close china central bank announce interest cut loan loss reserve requirement change aim boost monetary liquidity chinese economy
746,CELG,america case shiller city home price index rise june equal upwardly revise growth just consensus view gain
747,CELG,housing gauge federal housing finance agency june housing price index show gain be less half upwardly revise increase well consensus projection gain
748,CELG,new home sale climb annualize rate july commerce department report analyst expect increase june pace be home sell
749,CELG,researcher markit preliminary read service sector show slowdown august be july second lowest read january survey point marked slowdown new business growth month high record july markit say statement
750,CELG,early stock action be wild nearly unanimously positive
751,CELG,best buy bby spiked start trade better forecast result acorda therapeutic acor knock gain federal regulator knock challenge patent relate multiple sclerosis treatment ampyra mining powerhouse bhp billiton bhp surge deep earning miss fiscal year
752,CELG,apple aapl muscle netflix nflx rac gain jpmorgan jpm jump
753,CELG,mansion builder toll bro tol backed nearly heavy trade fall short analyst fiscal sale earning forecast move show stock find resistance day move average undercut heavy action monday
754,CELG,ibd list universal insurance uve jump heavy trade mark clear support day move average stock be trading august high
755,CELG,icon iclr facebook fb starbucks sbux celgene celg be stock rise more stock jump broad gain early tuesday rate cut china trump raft forecast housing datum nasdaq grab early lead gain swung dow jone industrial average climb volume be run well monday blister pace major exchange nasdaq lower nyse stock market today rolled news china mainland market have again take deep dife tuesday hong kong lead index post narrow gain country market close china central bank announce interest cut loan loss reserve requirement change aim boost monetary liquidity chinese economy america case shiller city home price index rise june equal upwardly revise growth just consensus view gain housing gauge federal housing finance agency june housing price index show gain be less half upwardly revise increase well consensus projection gain new home sale climb annualize rate july commerce department report analyst expect increase june pace be home sell researcher markit preliminary read service sector show slowdown august be july second lowest read january survey point marked slowdown new business growth month high record july markit say statement early stock action be wild nearly unanimously positive best buy bby spiked start trade better forecast result acorda therapeutic acor knock gain federal regulator knock challenge patent relate multiple sclerosis treatment ampyra mining powerhouse bhp billiton bhp surge deep earning miss fiscal year apple aapl muscle netflix nflx rac gain jpmorgan jpm jump mansion builder toll bro tol backed nearly heavy trade fall short analyst fiscal sale earning forecast move show stock find resistance day move average undercut heavy action monday ibd list universal insurance uve jump heavy trade mark clear support day move average stock be trading august high icon iclr facebook fb starbucks sbux celgene celg be stock rise more
756,CELG,big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday
757,CELG,analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news
758,CELG,hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note
759,CELG,gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength
760,CELG,deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix
761,CELG,have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing
762,CELG,karnauskas raise price target gilead stock
763,CELG,maxim group analyst jason kolbert lift price target
764,CELG,be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late
765,CELG,midday stock market today gilead stock be
766,CELG,follow amy reeve twitter ibd_areeve big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing karnauskas raise price target gilead stock maxim group analyst jason kolbert lift price target be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late midday stock market today gilead stock be follow amy reeve twitter ibd_areeve
767,CELG,character do whole lotta damage hillary clinton tweet deplore outrageous price gouge specialty drug market see largest biotech etf tank fear pricing control end third quarter ishare nasdaq biotechnology ibb have give gain year date back roughly loss september august rally tad unsettling decline health care sector belie outlook say capital iq analyst higher enrollment cost management prescription drug sale continue drive best earning growth health care sector index analyst lindsey bell write indeed ibb produce annual average gain past year oct period sector etfs track ibd top target health sector fact now more ever biotech pharma etfs trading much week high capital iq see buy opportunity solid biotech name such gilead gild celgene celg ibd stock nearly person be newly insure obamacare health exchange firm note recent report drive sale health care provider service strong dollar be likely weigh large cap pharmaceutical big pfizer pfe merck mrk bristol myer squibb bmy eli lilly lly once again post top line growth first time year pass patent cliff report say health care index be nicely value vs year average upside be especially attainable biotech pharma equipment subindustry report add big upside potential have see sometimes risky biotech drug stock make way many investor etf strategy now china global slowdown mind investor be more focuse downside risk be right be cautious value stock be risk economic growth estimate continue come momentum company be expose more spike volatility have weigh biotechs lately russ global chief investment strategist blackrock write recently suggest investor consider quality stock generally have strong return equity low debt successful investing market stay choppy analyst bofa lynch global research agree new report say health care rate most attractive sector base measure have historically be best predict result such ep sale revision guidance prior quarter result stick health care stick quality bofa lynch advise
768,CELG,stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange
769,CELG,biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker
770,CELG,big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split
771,CELG,telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume
772,CELG,automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average
773,CELG,robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag
774,CELG,nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect
775,CELG,follow nancy gondo twitter ibd_ngondo stock climb back session high go last hour trading nasdaq be dow jone industrial average rise volume be mixed run higher nyse slightly lower nasdaq winner trump loser more margin exchange biotechs be mend big player alexion pharmaceutical alxn celgene celg gilead science gild regeneron pharmaceutical regn score better gain other industry group lead wednesday session include wholesale food nonalcoholic beverage maker big gainer ibd include global payment gpn gap soar cup handle base heavy trade fiscal result top view electronic payment processor also declare stock split telecom contractor dycom industry dy chinese wealth management service firm noah noah rise respectively also big volume automaker software meat product stock lag stock market today tesla motor tsla again drag automaker group slide look support day move average robert baird lower tesla rating neutral outperform price target morgan stanley tuesday cut model delivery forecast higher expect price tag nu skin enterprise nus gap sank massive volume personal care product marketer slash revenue forecast due currency headwind china weakness analyst be expect follow nancy gondo twitter ibd_ngondo
776,CELG,major stock etfs post narrow loss monday investor continue read interest rate tea leave home abroad apple aapl slump chipmaker sell weigh dow nasdaq index iphone maker be prepare step earning dock close tuesday major benchmark rally sharply last week spdr spy largest list etf push positive territory year exchange trade fund punch day line first time august friday investor cheer hope more stimulus europe thursday unexpected china rate cut friday meanwhile day federal reserve meeting conclude wednesday offer more clue policy maker think rate lift apple lead technology stock report tuesday ultimate software group ulti member ibd elite leaderboard list company develop sell ultipro cloud base human capital management solution business powershare qqq qqq edge stock market today allocate asset apple stock hold surge health care biotech stock offset apple decline qqq stock portfolio celgene celg gain nearly apple be also top hold spy approximately portfolio weighting seventh largest hold spdr dow jone industrial average dium weighting apple loss reportedly come base supplier dialog semiconductor tank much report earning miss technology select sector spdr xlk retreat monday gap new high friday financial result tech giant microsoft msft alphabet googl amazon com amzn smash analyst view apple have portfolio weighting xlk other broad base tech focuse etfs big stake apple include fidelity msci information technology ftec weighting vanguard information technology vgt ishare technology iyw cupertino base apple be largest stock hold technology etfs china etfs see mixed action monday accounting biggest gainer biggest decliner internationally focuse peer gold price tick fraction so do dollar etf greenback ease euro yen here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
777,CELG,material etfs track higher tuesday get boost spike chemical giant dupont dd investor digest news dupont ceo ellen kullman step oct even company announce plan curb expense overall stock etfs follow nasdaq index fail extend recent rally investor eye weak trade datum start earning season gold price rise dollar ease vs euro yen british pound meanwhile ishare silver trust slv largest silver etf hit month high close session low have surge past day spdr dow jone industrial average dium eke gain stock market today cushion gain dupont well caterpillar cat microsoft msft however ibd leaderboard stock visa inched lower dow tracking etf hold industrial leader be high material select sector spdr xlb pop material energy sector lead index higher xlb hold company chemical metal mining paper forest product container packaging construction material industry chemical company dominate third asset accord morningstar inc dow chemical dow dupont largest holding alone account combine portfolio weighting etfs hold biotech stock get slam tuesday rally lows ishare nasdaq biotechnology ibb tumble nearly close midpoint day range ibb top holding take hit illumina ilmn tank revenue miss gene sequence firm preannounce quarterly result monday report final number oct ibb top holding celgene celg biogen biib give ibd stock regeneron pharmaceutical regn fall indonesia brazil russia top international etfs china india trail here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs spdr gold share gld rs ishare core aggregate bond agg rs ishare msci eafe efa rs spdr dow jone industrial average dium rs vanguard ftse emerge market vwo rs spdr spy rs ishare core mid cap ijh rs powershare qqq qqq rs powershare db bullish uup rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
778,CELG,facebook fb revenue growth be see decelerate compare estimate be goldman sachs list largest stock rank growth exclude financial utility social networking leader be expect see sale growth next year vs estimate rise goldman analyst see
779,CELG,red hot biotechnology semiconductor etfs be cool dramatically lead friday sell sector equity fund head second week steep decline have analyst wring hand red wash biotech stock mean investor be overdue correction frothy sector mere blip rally ishare nasdaq biotechnology ticker
780,CELG,nantkwest nk soar first day trading raise upsized initial public offer nantkwest be hot field immunotherapy deploy patient own immune system fight cancer other disease nantkwest offer share initial plan be offer share
781,CELG,best mutual fund july performance report
782,CELG,large cap growth mutual fund leap ahead peer markedly volatile month equity july investor shun risk worry grow greece china earning season get fitful start
783,CELG,tcw select equity large cap growth fund be top perform mutual fund last month vault eke less gain previous month stock holding include facebook fb google googl starbucks sbux visa
784,CELG,average large cap growth mutual fund rise july be month end
785,CELG,market move uncertainty investor move growth stock safety say david kali senior co portfolio manager calamo growth fund
786,CELG,calamo growth be year date vs index fund gain july
787,CELG,internet biotech stock drive performance large cap growth fund kali add merger acquisition continue propel biotechs
788,CELG,july celgene celg top hold tcw select calamo growth acquire receptos rcpt
789,CELG,almost week doesn pass don have deal kali say pretty easy way make money market be reflection low interest rate environment not fundamental
790,CELG,factor buoy large cap annual russell index rebalance june
791,CELG,several poor perform energy stock such halliburton hal pioneer pxd moved rebalance russell growth index value counterpart
792,CELG,give additional boost growth fund july kali say
793,CELG,diversify equity fund rise average july re year date growth fund crowd top end value fund bring rear
794,CELG,comparison world equity fund give nearly full percentage point july gain month end
795,CELG,mutual fund hold china stock sell violently last month
796,CELG,shanghai composite index slump late july peg worst day drop weak industrial profit aggravate concern stock market bubble world second largest economy
797,CELG,china region fund overall plunge close last month worry slowdown re still year date big run chinese equity first half
798,CELG,emerge market fund stumble more july almost year date july end
799,CELG,ve be hurt big stake china latin america
800,CELG,latin american fund shrank nearly july take loss stock region have be gut rout oil gas price
801,CELG,energy commodity fund suffer hit july make worst performer commodity fund
802,CELG,precious metal commodity fund also underperform stumbling last month precious metal equity fund such gold mining company give nearly
803,CELG,make biggest laggard sector fund gold silver equity be leverage play commodity
804,CELG,backdrop health biotech fund rise relatively tidy july science technology counterpart gain year date sector continue outperform advance respectively
805,CELG,invest
806,CELG,health sector outperformance be draw caution
807,CELG,kali point health care stock have rise rise due multiple expansion not earning increase only tech sector run period be expansion
808,CELG,health care stock right now be catch issue biotechs fda approval say create speculation market cautious health care valuation perspective very positive technology
809,CELG,kali believe growth stock continue do relatively well global uncertainty linger be hard cyclical do well year end add sharply decline commodity price weigh economy
810,CELG,russell investment strategist urge caution ahead fed move raise rate dollar treasury equity be expensive ahead fed shift outlook corporate profit be far more subdue write update report global equity favore exposure be europe be neutral japan emerge market well underweight add best mutual fund july performance report large cap growth mutual fund leap ahead peer markedly volatile month equity july investor shun risk worry grow greece china earning season get fitful start tcw select equity large cap growth fund be top perform mutual fund last month vault eke less gain previous month stock holding include facebook fb google googl starbucks sbux visa average large cap growth mutual fund rise july be month end market move uncertainty investor move growth stock safety say david kali senior co portfolio manager calamo growth fund calamo growth be year date vs index fund gain july internet biotech stock drive performance large cap growth fund kali add merger acquisition continue propel biotechs july celgene celg top hold tcw select calamo growth acquire receptos rcpt almost week doesn pass don have deal kali say pretty easy way make money market be reflection low interest rate environment not fundamental factor buoy large cap annual russell index rebalance june several poor perform energy stock such halliburton hal pioneer pxd moved rebalance russell growth index value counterpart give additional boost growth fund july kali say diversify equity fund rise average july re year date growth fund crowd top end value fund bring rear comparison world equity fund give nearly full percentage point july gain month end mutual fund hold china stock sell violently last month shanghai composite index slump late july peg worst day drop weak industrial profit aggravate concern stock market bubble world second largest economy china region fund overall plunge close last month worry slowdown re still year date big run chinese equity first half emerge market fund stumble more july almost year date july end ve be hurt big stake china latin america latin american fund shrank nearly july take loss stock region have be gut rout oil gas price energy commodity fund suffer hit july make worst performer commodity fund precious metal commodity fund also underperform stumbling last month precious metal equity fund such gold mining company give nearly make biggest laggard sector fund gold silver equity be leverage play commodity backdrop health biotech fund rise relatively tidy july science technology counterpart gain year date sector continue outperform advance respectively health sector outperformance be draw caution kali point health care stock have rise rise due multiple expansion not earning increase only tech sector run period be expansion health care stock right now be catch issue biotechs fda approval say create speculation market cautious health care valuation perspective very positive technology kali believe growth stock continue do relatively well global uncertainty linger be hard cyclical do well year end add sharply decline commodity price weigh economy russell investment strategist urge caution ahead fed move raise rate dollar treasury equity be expensive ahead fed shift outlook corporate profit be far more subdue write update report global equity favore exposure be europe be neutral japan emerge market well underweight add
811,CELG,earning season have be unkind number recent leader taser international tasr have spur plenty other stock breakout big gain market uptrend be still pressure stock aren let get way ibd index rise week
812,CELG,ellie mae elli wednesday issue post biggest gain ibd friday gapping new high prior move stock have pull back week move average first time june past buy point now extend secondary opportunity buy pullback
813,CELG,close thursday electronic mortgage service provider report earning rise cent share higher revenue top street forecast
814,CELG,universal health service uhs gain new high clear buy point week flat base twice normal trade hospital operator late thursday report ep last year cent view revenue increase also best view universal raise full year ep guidance prior outlook consensus estimate
815,CELG,valeant pharmaceutical vrx rise stock gap rally july heavy volume break past buy point late stage flat base still high end buy zone entry
816,CELG,day canadian drugmaker report adjust earning share year earlier quarter well view revenue increase also beating estimate
817,CELG,valeant be pay buy egyptian drugmaker amoun pharmaceutical say organic growth exclude acquisition be quarter
818,CELG,other medical stock ibd remain buy range recent breakout celgene celg be hold just cup base buy point clear july day move be fuel news biotech be buy receptos july celgene hit time high profit top view
819,CELG,jazz pharmaceutical jazz have break past flat base buy point ahead earning report slate wednesday close stock be just entry buy zone earning season have be unkind number recent leader taser international tasr have spur plenty other stock breakout big gain market uptrend be still pressure stock aren let get way ibd index rise week ellie mae elli wednesday issue post biggest gain ibd friday gapping new high prior move stock have pull back week move average first time june past buy point now extend secondary opportunity buy pullback close thursday electronic mortgage service provider report earning rise cent share higher revenue top street forecast universal health service uhs gain new high clear buy point week flat base twice normal trade hospital operator late thursday report ep last year cent view revenue increase also best view universal raise full year ep guidance prior outlook consensus estimate valeant pharmaceutical vrx rise stock gap rally july heavy volume break past buy point late stage flat base still high end buy zone entry day canadian drugmaker report adjust earning share year earlier quarter well view revenue increase also beating estimate valeant be pay buy egyptian drugmaker amoun pharmaceutical say organic growth exclude acquisition be quarter other medical stock ibd remain buy range recent breakout celgene celg be hold just cup base buy point clear july day move be fuel news biotech be buy receptos july celgene hit time high profit top view jazz pharmaceutical jazz have break past flat base buy point ahead earning report slate wednesday close stock be just entry buy zone
820,CELG,well fargo downgrade several medium stock tuesday include walt disney cbs cbs st century fox foxa cite dismal earning season group second quarter downgrade come couple week medium stock get slam ongoing fear competition netflix nflx other stream service lead subscriber loss lower cable ad revenue share disney close fox cbs tuesday netflix fall biotech startup juno therapeutic juno inked deal biotech giant celgene celg last month be initiate outperform rating price target fbr capital juno stock have be afternoon trading end day flat elsewhere auto part retailer advance auto part aap get upgrade steep price target hike tuesday cosmetic giant estee lauder el also receive upgrade day stock price tank disappointing quarterly sale cautious outlook argus upgrade advance auto buy hold price target advance auto share edge last week stock set new high better expect quarterly earning estee lauder heavy trade monday close telsey advisory group upgrade stock outperform market perform blue buffalo pet product buff be initiate morgan stanley equal weight rating day recent ipo pet food supplier be initiate top rating citigroup barclay jpmorgan well fargo blue buffalo share rally
821,CELG,nasdaq composite session streak be jeopardy late afternoon trading wednesday weigh weakness biotech stock dow jone industrial average rise add nasdaq be flat volume nasdaq nyse be tracking higher tuesday level stock market today biotechs take heat president elect donald trump take aim pharmaceutical industry first press conference say new bidding procedure be need drug price meanwhile lockheed martin lmt give day move average trump vow increase competition fighter jet bring cost alexion alxn incyte incy mylan myl biogen biib celgene celg be top decliner nasdaq fall anywhere ishare nasdaq biotechnology ibb give merck mrk be high still bright spot dow rise fda be consider immunotherapy drug keytruda chemotherapy treat advanced lung cancer decision be expect merck be work new base buy point small cap barracuda network cuda rebound tuesday reversal high solid earning share rise nearly still buy range double bottom entry ibd take security software group have be lag market recent month group be home intriguing name solid fundamental see be ibd stock checkup ibd chipmaker microchip technology mchp add work tight flat base buy point sale growth have accelerate straight quarters market cap firm new york mercantile exchange february west texas intermediate crude oil future settle barrel nearly related trump say drugmaker get away murder cite ford fiateconomic optimism hit new year high trump rally continuestrump vow fighter jet competition big thing lockheed
822,CELG,stock continue search direction early afternoon trade wednesday president elect donald trump send biotechs lockheed martin lmt nasdaq lag apple aapl nvidia nvda pull back nasdaq shed fall dow jone industrial average be flat volume be tracking higher board vs same time tuesday solar oil metal stock lead upside stock market today west texas intermediate oil future surge barrel biotechs other drugmaker get hammer president elect donald trump sharply criticize drug price blue chip drug giant pfizer pfe be dow biggest loser slide lose day move average fast trade merck mrk buck selloff healthy volume lead dow winner pare gain earlier pop share be build flat base buy point food drug administration accept supplemental filing merck immunotherapy keytruda be used chemotherapy treat advanced lung cancer apple meantime backed weak trade stock have so far be unable follow monday past entry cup handle remain buy range nvidia too be hesitate attempt recoup drop late december early january point recent stock market today column stock be due correction heady run march hold well day line overall trend be higher canaccord genuity jeffery raise price target graphic chip maker tuesday monday respectively tesla tlsa announce have hire apple executive include year veteran chris lattner lead electric car maker autopilot software effort tesla share dip stock be shape right side cup base lockheed martin lmt fall breach day line trump vow increase competition fighter jet bring cost share have be consolidate flat base try recover tough december trump blast cost twitter ibd biotechs unite therapeutic uthr celgene celg sank respective heavy volume unite remain extend buy point celgene slip day line be still build flat base related trump say drugmaker get away murder cite ford fiatmusk go tesla graveyard hire away apple exec trump vow fighter jet competition big thing lockheed nvidia stock get price target hike valuation concern
823,CELG,vertex pharmaceutical vrtx fall early monday reverse sharply later session company forecast sale cystic fibrosis drug orkambi lag wall street expectation sunday vertex say expect full year sale drug analyst have be forecasting evercore isi analyst john scottus say email client sunday scottus say vertex number be likely closer expectation buy side analyst mutual fund pension fund hedge fund other vertex release forecast ahead presentation monday annual jpmorgan jpm healthcare conference be biggest event year biotech other drug company conference san francisco start monday end thursday most major company be present other company executive make presentation monday include amgen amgn biogen biib celgene celg ibd take rare not single drugmaker be ibd list top perform stock be case time uncertainty industry face possibly change health care law perhaps ibd have report legislation drug price check ibd learn stock have be perform better other vertex stock fall much early trading stock market today end day regain day move average first time november vertex stock have rough share fall more quarterly result disappoint have mixed result drug trial company sale outlook orkambi launch also miss wall street forecast case sale orkambi be blockbuster combination ivacaftor treatment cystic fibrosis vertex market separately kalydeco lumacaftor booster make drug effective treat much larger population ivacaftor alone annual treatment orkambi kalydeco cost vertex guidance sale kalydeco also miss wall street expect scottus say related trump pledge bring drug priceswhich biotechs outperformed tough
824,CELG,major stock index be mostly unchanged late afternoon trading friday low volume session procter gamble pg unitedhealth unh outperformed dow gain small cap outpeformed again russell volume nyse nasdaq be tracking lower thursday level stock market today biotechs other health care related group outperformed steel stock few retail related group underperform biotech space celgene celg reclaim prior buy point rise incyte incy meanwhile add trading tightly day move average work flat base buy point financial deutsche bank db edge higher help news settlement department justice mortgage backed security lockheed martin lmt halved intraday loss call boee ba high cost new air force president elect trump shift attention lockheed martin say tweet fighter jet be price more line boee earning front uniform maker cinta cta be trading tightly high ahead earning share gap lose stock day move average currently be key support level watch ibd dave buster play be mostly unchanged trade tightly high featured today new america economic news consumer confidence hit highest level year november new home sale come better expect healthier chart homebuilding group be find smaller more speculative name beazer home bzh home mho stock market be close monday observance christmas holiday related trump drop bomb lockheed seek pricedeutsche bank settle mortgage probe doj sue barclaysnew home sale jump buyer rush lock rate
825,CELG,here weekly investing action plan need know investor come week earning season get underway delta air line dal jpmorgan chase jpm bank america bac well fargo wfc biggest name due year biggest event automotive sector health stock begin senate be
826,CELG,datum biotech amgen amgn ldl bust drug boost regeneron regn disappoint too high expectation amgen investor credit suisse analyst alethia young say tuesday young upgrade regeneron stock outperform rating up price target cite april launch dupixent eczema drug sanofi sny pcsk datum top rival amgen due also also be catalyst regeneron own pcsk drug write research report amgen investor however have set expectation too high repatha amgen pcsk inhibitor follow successful datum study september say coronary intravascular imaging trial repatha meet primary secondary endpoint coronary artery disease still see upside repatha outcome datum write research note think risk reward be unfavorable expectation be pretty high success glagov study ibd take trump break republican pressure drug price look more more likely biotechs survive political pressure young downgrade amgen stock neutral rating cut price target see amgen base business rheumatoid arthritis drug enbrel become weaker trim total product sale view enbrel sale come flat contract negotiation next year enbrel sale be drive volume rather net selling price company say earning conference call analyst company up guidance time celgene celg vertex pharmaceutical vrtx top young biotech watchlist be cautious general however give comment president elect donald trump go escalate drug price week follow election biotech drug stock have nearly round trip first rise then fall ibd company medical biom biotech industry group hit week high nov trump election be then still share remain close nov rise stock market today amgen stock fall tuesday regeneron stock slip don expect drug pricing chatter moderate especially consider comment already make president elect young write think company best execution have best stock performance related amgen biogen celgene eye trump pro biotech worldbiotech climb third straight day leader be buyable
827,CELG,stock remain session high go last hour trading stage positive reversal midday nasdaq lead gain dow jone industrial average be volume be tracking higher stock market today vs same time thursday winner be outpace loser margin nyse nasdaq lead group include gold energy stock west texas intermediate rebound back barrel earlier slide chevron cvx exxonmobil xom rise respectively dow nearly half stock blue chip index be start session red apple aapl be nearly slip much early stock be still day day move average appear have find support level target tgt become biggest retailer sell apple watch hit store week target share be dave buster play moved fast trade recover buy point shape base extend recent bounce day line ibd stock rise thursday pricing secondary offer share biotechs continue recent bounce celgene celg reversed upward gain volume track extend recovery streak fourth straight session stock be still consolidate day day line other top rate biotechs sucampo pharmaceutical scmp rally alexion pharmaceutical alxn group advance make session biggest gainer gilead science gild fall volume morgan stanley downgrade biotech equal weight overweight share be june peak follow nancy gondo twitter ibd_ngondo
828,CELG,stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday
829,CELG,major average have seesaw mixed economic datum
830,CELG,medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose
831,CELG,elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group
832,CELG,post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern
833,CELG,follow vincent mao twitter ibd_vmao stock weaken be narrowly mixed late tuesday dow jone industrial average be nasdaq lose turnover be run lower major exchange stock market today compare same time monday major average have seesaw mixed economic datum medical stock be comeback mode be slam monday biogen biib celgene celg regeneron pharmaceutical regn have gain range fraction amn healthcare service universal health service uhs impax laboratory ipxl lose elsewhere chuy chuy ease be still share restaurant operator be nearly be start outperform give price target research firm telsey advisory group post holding post drop lowest level aug monday stock have already tumble trigger sell rule entry week tight pattern follow vincent mao twitter ibd_vmao
834,CELG,apple aapl chip supplier qorvo qrvo skywork swks get split rating thursday lead biotech celgene celg be upgrade qorvo supply chip apple iphone see share close stock market today be initiate neutral citigroup last week new apple iphone hit store shelve apple selling more iphone handset open weekend meanwhile fellow apple supplier skywork be initiate buy rating citigroup stock price end lower thursday apple share fall celgene stock price rise be upgrade overweight jpmorgan biotech market cap have bounce back last couple day follow session selloff tie partly negative industry comment make democratic presidential candidate hillary clinton microsoft msft climb bank america upgrade stock neutral wednesday microsoft say plan open flagship store new york city only block south apple flagship manhattan store sandisk sndk rise be upgrade overweight morgan stanley give price target be recent price target provide other analyst wednesday sandisk share pop nearly report chinese tech firm unisplendour take stake western digital wdc bring share sandisk other memory hard drive maker gene sequence technology developer illumina ilmn sank be downgrade market perform leerink swann shoe designer steven madden shoo be upgrade outperform brother share lose follow vance cariaga twitter ibd_vcariaga
835,CELG,investor etfs be start show appetite risk lavish money defensive dividend pay stock month end few segment stock market have fed such craving much biotech spdr biotechnology xbi jump past week thursday growth stock begin act better quarter date steep sell biotechs first quarter xbi sit week high still market watcher think biotech group strike winning note again flow investor money be say follow performance xbi certainly need have leak second quarter so far asset have shrink nearly biotech etf be investor hungry return not afraid take more risk portfolio be skewer more smaller cap early stage biotech firm have decidedly uncertain prospect explosive upside potential write morningstar analyst robert goldsborough xbi hold highly rate ibd stock be spearhead recent rebound biotech group ligand have grow earning annual rate past year sale have ibd composite rating best possible thank part share price jump past month heavy institutional buy earning growth slow most recent quarter averaged past stanzas sale growth accelerate last quarters drugmaker be embroil fend sanofi sny hostile takeover bid biotech giant celgene celg gilead science gild be also say be possibly join fray company plan separate publicly trade company company focus biodefense product other revolve oncology hematology therapeutic emergent have year ep growth rate year sale growth rate help comp rating ligand medivation emergent be stock xbi portfolio xbi be cheapest biotech etfs expense ratio have produce annual average gain past year vs flagship ishare nasdaq biotechnology ibb ibb be cap weight skews larger player biotech industry include celgene gilead have lower beta xbi make slightly safer way play volatile industry past week ibb add quarter date etf be
836,CELG,sentiment biotech stock overall ebb flow biotech company carve very individual path drug company investor look product pipeline spot potential growth especially scientifically novel asset stand pack biotech stock have outperformed group past few month thank potential blockbuster drug juno therapeutic juno be early february time low be also ibd medical biom biotech group nearly year low point investor have regain confidence cancer fight pipeline juno be work cut edge field cell therapy patient own cell be re engineer help immune system cancer cell case chimeric antigen receptor car cell be biotech stock explode againjuno lead candidate jcar be midstage testing acute lymphoblastic leukemia show stunning success rate earlier trial last month partner celgene celg say exercise option commercialize jcar similar candidate outside north america china year partnership company inked last summer also last month juno show earlier stage car candidate annual meeting american association cancer research target different receptor other type blood cancer abstract meeting be release march leerink analyst michael schmidt write juno stock be support clinical datum readout support juno business strategy develop differentiate potentially best class car product generate translational insight hematologic solid tumor indication biomarin pharmaceutical bmrn be early february month low re-cover fda rejection muscular dystrophy drug kyndrisa january day last month biomarin rolled strong early datum pipeline candidate hemophilia achondroplasia form dwarfism hemophilia datum bring particular attention be first ever evidence gene therapy disease human therapy bmn be deliver once patient condition go severe mild moderate be far better expect video record client couple week later evercore isi analyst john scottus describe mood biomarin event start present datum jaw just go floor be audible gasp room market hemophilia most common type run year analyst say successful gene therapy massively disrupt market clot factor have be infuse weekly least intercept pharmaceutical icpt be month low february lead drug ocaliva pass major hurdle market last month fda advisory committee vote grant accelerate approval liver condition call primary biliary cholangitis pbc agency have decide pbc market be expect bring healthy revenue stream intercept potential blockbuster indication be nonalcoholic steatohepatitis nash liver scarring disease affect million american have treatment intercept be conduct large phase trial ocaliva disease launch not expect several year fda panel vote do imply expert see benefit outweigh drug know safety issue ocaliva potential have drive buyout speculation intercept stock have also help push share particular burst come feb anonymous source suggest company be explore sale nothing yet come
837,CELG,big cap drug stock bristol myer squibb bmy celgene celg be rise earning report early thursday celgene initially drop deliver long expect guidance cut bristol myer report earning cent share time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue rise wall street average estimate bristol myer add cent full year ep guidance now expect revenue grow low double digit range be first time annual sale gain much recently launch cancer drug opdivo beat sale estimate substantial margin vs analyst just year earlier quarter clot drug eliquis also handily beat expectation sale more double bristol myer stock be more afternoon trading stock market today highest point october celgene meanwhile report sale gain last year almost consensus other hand ep beat estimate cent rise celgene add cent full year earning guidance now share raise low end product sale guidance however trim guidance account foreign exchange headwind now expect sale vs previously celgene also cut ep target company affirm previously issue guidance celgene stock drop early trading be more early afternoon thursday wall street have anticipate guidance cut investor be look update guidance follow fx headwind top line revenue mentioned call write evercore isi analyst mark schoenebaum preview note wednesday celgene neither revise reaffirm guidance time provide update current guidance conference call analyst thursday celgene management say constant currency basis financial be tracking hit original target
838,CELG,be worst perform sector last summer biotechnology firm have show few encourage sign march etf flow sector be positive march accord mizuho security usa datum then last week april see additional inflow trimming outflow month net be biotech etfs total control almost asset first month be risk momentum board depart say monish shah mizuho security usa executive director head etf trading last week april be again risk momentum biotech etfs do not see major outflow technically so be propitious time start look biotech etfs again flow biotech etfs be positive second week give way outflow third week thursday shah advise investor be careful term even sector long term prospect be good trend seem be hold advise term caution be many positive well negative factor largest biotech etfs ishare nasdaq biotechnology ibb spdr biotech etf xbi be positive flow territory end april add net respectively ibb be past month xbi be be still respective week high ibb have slip day move average bearish sign xbi be testing resistance own day line next line be first trust nyse arca biotech etf fbt vaneck vector biotech etf bbh re roughly respective past month however fbt experience strong outflow first month result net outflow bhh see positive flow april end net outflow same period first fund fbt bbh be also testing resistance day line series positive factor be however pipeline biotechs ratio have be come suggest investor stock be more reasonably value say michael cohick etf product manager van eck global also note biotechs be poise benefit continue demographic factor age population also affordable care act more person be now cover insurance afford new therapy incredible continue innovation come company sector think point potential entry point say cohick say sector be know display very high volatility terrible terrible negative performance january slightly negative february positive performance march april vaneck vector biotech etf short term performance story have return say cohick suggest investor always continue monitor biotech company earning well activity prefer concentrated portfolio largest most liquid biotech stock such represent bbh want safety larger company be better way play sector say fund top holding be gilead science gild amgen amgn celgene celg biogen biib medivation mdvn together represent fund asset
839,CELG,analyst think good time take ride electric carmaker tesla motor tsla fossil fuel giant exxon mobil xom price target be raise tjx co tjx agio pharmaceutical agio cigna ci goldman sachs say tesla not reach production target vehicle still upgrade luxury electric car maker buy neutral keep price target say more ground investor expectation now offer good entry point goldman doesn see big term catalyst next model update not come goldman saystesla share close stock market today drop late trading tesla announce secondary stock offer argus research raise exxon rating buy hold price target crude oil future have rally recent week sign global supply glut be ease well production disruption canada nigeria exxon share close crude future dip tjx beat earning tuesday see lot room expand store base see price target bump rbc capital market price retailer stock fall rise tuesday cigna be aim close merger rival health insurer anthem antm be keep sector perform rbc price target hike last week cigna reach deal pay sanofi sny regeneron regn base well customer respond drugmaker cholesterol lower treatment cigna share fall sun trust keep buy agio raise target late tuesday agio expand cancer drug partnership celgene celg agio share jump pre market action fall celgene rise
840,CELG,hillary clinton vow cap patient pocket prescription cost month sound populist way help consumer sticking drug company
841,CELG,reality be raise premium modestly reduce rank insure partly push small business drop coverage believe not exactly drug company want
842,CELG,example plan work clinton presidential campaign point cover california start state obamacare insurance exchange cap individual cost single cover drug month benchmark silver level plan
843,CELG,california plan raise premium year state official have acknowledge clinton plan go further cap consumer total pocket cost more drug month not cost single drug
844,CELG,intend unintended
845,CELG,cowen co analyst point ordinary american don face significant monthly prescription cost end subsidize do premium co pay rise clinton month limit
846,CELG,think significant unintended maybe intend consequence arise cap face significant opposition accord cowen report tuesday
847,CELG,implication democratic front runner plan be make low cost employer plan pricier increase incentive employer pay mandate penalty figure way avoid such hire more part time worker
848,CELG,key be obamacare employer mandate require company offer coverage be least comprehensive bronze level exchange plan still leave customer hook drug cost year california
849,CELG,mean clinton proposal hold pocket drug cost month have apply bronze plan well
850,CELG,higher premium result cap then result more cost be shift relatively young healthy big prescription bill be much less common
851,CELG,risky strategy consider young adult enrollment obamacare exchange be target partly result relatively older not so healthy group enrollee average premium be expect rise more
852,CELG,drugmaker support cap
853,CELG,additional premium hike get healthy young adult subsidize more cost prescription further dampen enrollment more person choose go coverage see bad deal
854,CELG,biotech stock continue slide tuesday due part clinton attack outrageous drug pricing ishare nasdaq biotechnology etf ibb close fall monday amgen amgn dip add monday loss
855,CELG,yet drugmaker have be quietly support campaign cap pocket cost drug help expand access product
856,CELG,pfizer pfe celgene celg have provide funding group push co pay limit include cap copay leukemia lymphoma society number state have enact such limit past couple year include montana delaware louisiana maine
857,CELG,meanwhile insurance industry have be firmly idea warn cap low level control drug price raise premium
858,CELG,clinton want rein drug price too analyst be highly skeptical proposal allow import prescription drug let medicare negotiate drug price get enough support congress republican have opposed idea discourage innovative cure hillary clinton vow cap patient pocket prescription cost month sound populist way help consumer sticking drug company reality be raise premium modestly reduce rank insure partly push small business drop coverage believe not exactly drug company want example plan work clinton presidential campaign point cover california start state obamacare insurance exchange cap individual cost single cover drug month benchmark silver level plan california plan raise premium year state official have acknowledge clinton plan go further cap consumer total pocket cost more drug month not cost single drug intend unintended cowen co analyst point ordinary american don face significant monthly prescription cost end subsidize do premium co pay rise clinton month limit think significant unintended maybe intend consequence arise cap face significant opposition accord cowen report tuesday implication democratic front runner plan be make low cost employer plan pricier increase incentive employer pay mandate penalty figure way avoid such hire more part time worker key be obamacare employer mandate require company offer coverage be least comprehensive bronze level exchange plan still leave customer hook drug cost year california mean clinton proposal hold pocket drug cost month have apply bronze plan well higher premium result cap then result more cost be shift relatively young healthy big prescription bill be much less common risky strategy consider young adult enrollment obamacare exchange be target partly result relatively older not so healthy group enrollee average premium be expect rise more drugmaker support capsadditional premium hike get healthy young adult subsidize more cost prescription further dampen enrollment more person choose go coverage see bad deal biotech stock continue slide tuesday due part clinton attack outrageous drug pricing ishare nasdaq biotechnology etf ibb close fall monday amgen amgn dip add monday loss yet drugmaker have be quietly support campaign cap pocket cost drug help expand access product pfizer pfe celgene celg have provide funding group push co pay limit include cap copay leukemia lymphoma society number state have enact such limit past couple year include montana delaware louisiana maine meanwhile insurance industry have be firmly idea warn cap low level control drug price raise premium clinton want rein drug price too analyst be highly skeptical proposal allow import prescription drug let medicare negotiate drug price get enough support congress republican have opposed idea discourage innovative cure
859,CELG,health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount
860,CELG,china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view
861,CELG,ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive
862,CELG,ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more
863,CELG,ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly
864,CELG,spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault
865,CELG,here look benchmark exchange trade fund tracking various asset class perform today
866,CELG,follow daily etf market action be key successful investing
867,CELG,bellwether etfs
868,CELG,ishare msci eafe efa rs
869,CELG,spdr dow jone industrial average dium rs
870,CELG,powershare db bullish uup rs
871,CELG,spdr spy rs
872,CELG,ishare core aggregate bond agg rs
873,CELG,ishare core mid cap ijh rs
874,CELG,spdr gold share gld rs
875,CELG,powershare qqq qqq rs
876,CELG,vanguard ftse emerge market vwo rs
877,CELG,ishare russell iwm rs
878,CELG,follow aparna narayanan twitter ibd_anarayanan health care etfs get slam early action monday investor continue agonize exacting timing interest rate lift global growth concern mount china industrial profit fall nearly august vs year largest drop accord news report fed official say rate likely rise year also note international outlook be clouding view ishare nasdaq biotechnology ibb largest exchange trade fund hold biotech stock plunge nearly red hot sector continue sell friday ibb dump late trade etf investment strategy hold small cap biotechs dive ibb top holding celgene celg amgen amgn gilead science gild biogen biib lose nearly intraday trade regeneron pharmaceutical regn give more ishare pharmaceutical ihe shed more etf hold largest pharmaceutical name top holding merck mrk pfizer pfe fall nearly spdr gold share gld give more gold future fall morning trade etf track spot gold price used gold bar hold london vault here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs ishare msci eafe efa rs spdr dow jone industrial average dium rs powershare db bullish uup rs spdr spy rs ishare core aggregate bond agg rs ishare core mid cap ijh rs spdr gold share gld rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare russell iwm rs follow aparna narayanan twitter ibd_anarayanan
879,CELG,most major index picked steam last hour trading close decent gain monday well intraday high dow jone industrial average rise respectively nasdaq manage eke fractional gain spending time red biotechs get hammer
880,CELG,volume be lower board expect friday quadruple witching winner top loser ratio nyse decliner outpaced advancer nasdaq slight margin
881,CELG,software food financial stock outperformed stock market today biotechs other drugmaker be biggest loser presidential candidate hillary clinton tweet high cost specialty drug send stock hard
882,CELG,cyberark software cybr gap rise fast trade stock have find support level be still slide day move average deutsche bank upgrade network security software maker buy hold say recent sell be overdo
883,CELG,apple aapl climb flurry news iphone maker have set ship date electric vehicle accord wall street journal sprint say sell apple watch friday same day iphone iphone canaccord genuity raise price target apple
884,CELG,ibd biotechs volume valeant pharmaceutical vrx fall downward reversal give day line have regain earlier session stock be work new consolidation celgene celg give slice day line intraday too be shape new base
885,CELG,ibd end advancer decliner unchanged
886,CELG,follow nancy gondo twitter ibd_ngondo most major index picked steam last hour trading close decent gain monday well intraday high dow jone industrial average rise respectively nasdaq manage eke fractional gain spending time red biotechs get hammer volume be lower board expect friday quadruple witching winner top loser ratio nyse decliner outpaced advancer nasdaq slight margin software food financial stock outperformed stock market today biotechs other drugmaker be biggest loser presidential candidate hillary clinton tweet high cost specialty drug send stock hard cyberark software cybr gap rise fast trade stock have find support level be still slide day move average deutsche bank upgrade network security software maker buy hold say recent sell be overdo apple aapl climb flurry news iphone maker have set ship date electric vehicle accord wall street journal sprint say sell apple watch friday same day iphone iphone canaccord genuity raise price target apple ibd biotechs volume valeant pharmaceutical vrx fall downward reversal give day line have regain earlier session stock be work new consolidation celgene celg give slice day line intraday too be shape new base ibd end advancer decliner unchanged follow nancy gondo twitter ibd_ngondo
887,CELG,lead industry group market be start show sign wear tear not surprising selling pressure continue build major average top rank group ibd database finance mortgage related service fall thursday week end aug plunge lendingtree tree former big leader group
888,CELG,european union medical advisory committee endorse several key drug lead stock friday make eu approval likely potential blockbuster committee medicinal product human use know french abbreviation chmp adopt positive opinion gilead science gild genvoya manage hiv infection genvoya be drug combo pill identical gilead popular treatment stribild place ingredient viread gilead have put new drug tenofovir alafenamide taf taf be know wall street son viread similar compound alter so lower dose be used turn reduce side effect crucially gilead also win hit viread patent expiry be due start stribild sale pass last year be expect top next year be key revenue driver even company big gilead chmp also endorse blood cancer drug amgen amgn kyproli amgen get acquire onyx pharmaceutical be first approve multiple myeloma hasn yet hit market european union be first approve lone treatment amgen have be push combo kyproli celgene celg revlimid dexamethasone base successful new trial patient ve receive least prior therapy fda approve combo july kyproli isn big revenue driver big biotech now analyst expect annual sale hit chmp also backed newer drug blincyto certain type acute lymphoblastic leukemia blincyto be bispecific cell engager bite antibody combine bit different antibody engage body cell attack cancer cell analyst expectation aren huge blinctyo amgen recently cut licensing deal use xencor xncr longer last bite technology develop newer better drug vertex pharmaceutical vrtx orkambi cystic fibrosis also get chmp thumb friday orkambi gain fair bit medium attention win approval july cystic fibrosis be devastate disease few treatment give vertex considerable pricing power consensus call annual sale pass model already reflect orkambi launch europe early cf patient older write maxim group analyst jason kolbert research note however anticipate slower launch trajectory due need obtain reimbursement country country basis speaking orphan disease horizon pharma hznp ravicti also get chmp endorsement treatment ultra rare urea cycle disorder ucds ravicti be drug horizon acquire hyperion therapeutic year piper jaffray analyst david amsellem highlighted potential growth driver march deal be announce ravicti be approve fda february now have sale annualizing amsellem write accord hyperion prevalence ucd be hyperion have estimate only ucd patient be actually diagnosed only be treatment ravicti cost year amsellem point not steep orphan drug horizon price higher do not estimate european pricing however endorsement stock be stock market today drug stock continue recent bumpy ride afternoon trading friday gilead amgen share be vertex horizon stock be follow amy reeve twitter ibd_areeve facebook
889,CELG,clue way fight current market take look investment strategy mutual fund have outperformed long haul american century ultra fund twcux beat large cap growth rival track morningstar inc past week go friday past year fund average annual gain top peer averaged averaged fund seek highly profitable company look poise keep grow aim large industry lead company have sustainable accelerate earning growth positive price momentum do fund expect best odd find such company look fund portfolio weighting offer clue march manager lee michael li jeff bourke have key overweight information technology health care sector tech fund be find opportunity internet software service service communication equipment fund top holding reflect tilt tech health care apple aapl alphabet googl amazon amzn facebook fb be top feb top also include health care name unitedhealth group unh gilead science gild celgene celg social networking giant facebook be still buy range buy point gapping april strong earning recent action stock market be not perfect ibd accumulation distribution rating have improve worst possible weak rating be still sign more recent selling buy mutual fund past week earning share growth have sped go quarters past frame respectively stock ibd composite rating be solid composite rating combine ibd performance rating include ep relative strength rating be highest manage health care service provider unitedhealth ep rebound growth most recent stanza fall previous quarter share be past week even fall nearly thursday federal judge rule obama administration be spending federal money fund obamacare share many key health care stock go decision district judge rosemary collyer ruling be house republican bring legal challenge government be slate pay year health insurer lower copayment lower income person robotic surgical system developer intuitive surgical isrg be health care name be unharmed obamacare ruling share rise nearly thursday re more past week stock ep grow respective past quarters bank america lynch recently say intuitive be stock soon start pay dividend cite company low debt compare industry least market cap come cash stable earning trend ep growth prior fiscal year well growth expect current year
890,CELG,valeant pharmaceutical recently crack accounting management issue most controversial aspect business model be attitude research development spending valeant vrx typically pare bone operation company acquire chide big pharmas allegedly wasteful spending research historically spending be just sale contrast budget bristol myer squibb bmy last year totale sale pfizer pfe be nearly big biotech celgene celg be whopping be really appropriate spending level be spend ibd recently ask gertler former biotech entrepreneur advise company just issue manage partner back bay life science advisor ibd look pharma general do think re spending right amount too much too little gertler tend divide category broadly really be focuse new technology true biologically drive solution disease think level spending be appropriate think increasingly collaboration smaller larger company collaboration be truly advance company academia really be focuse go be meaningful term overall national health international health really drive significant solution be still tendency company look follow commercial pharmaceutical solution see range private equity world way large pharma specialty pharma probably less innovation drive dollar be still well spend term company viability term primary research agenda re probably less important new biologically drive therapy ibd issue be company want do house basically buy buy company do have general guideline gertler categorize main group smaller company be innovation drive somewhat capital constrain midcaps have have success aspect platform have chance focus platform alone start diversify platform course global pharma company think be lot emphasis last number year outsource entirely system doesn work way system be juncture very continuous ecosystem have many academic have go big pharma drive significant effort academic be involved early stage company seasoned executive large company move small company lifeblood small company be identify really develop base platform asset capital constraint then relationship larger company become outsourced be critical expertise large company not be eradicate have do then ultimately commercial development influence way smaller company act flip side be large company have focus just way re judge investor street term commercial commercial success still have make sure pipeline be intact eradicate functionality large company significantly hamper win have proper mean identify smaller platform be go be truly valuable year line also win be able help smaller platform maintain own organic growth same time partner licensing broaden way platform have impact so think discussion outsourced vs house have become artificial world juncture be too fluid too sophisticated justify binary type approach ibd also be lot talk efficiency company be wasting resource impression gertler first think drug development be nature somewhat messy business try have extremely strict receptor drive drug development inevitably have too small impact term disease outcome have too promiscuous effect other system then have too much collateral damage associate development so inevitably just virtue biology go be significant inefficiency process think smaller company sometimes do suffer inefficiency platform be very promising smaller company sometimes lose sight best way prove concept platform be economically smaller tighter yet still really open platform once ve go first inflection point hurdle larger thing large company perspective think be certainly many step way early stage discovery preclinical early clinical development many thing help year come include biomarker include imaging process disease greater understand selective biology disease advance knowledge make system more efficient doubtless be inefficiency system be due bureaucracy way thing be judge think primary inefficiency be drug discovery be messy business ibd sort advice give nonspecialist investor judge company program gertler re look large company be lot driver value public investor probably go well still think used even simple formula percentage spend be probably not way investor look company think divide area be focuse really not primary pharmaceutical biotech have more do too drug repurpose reformulate drug think be less attractive investment look larger company be really try fill pipeline way make clinical sense be one regardless percentage spend be probably greater interest have long term support reason say be health care system change continually inevitably ll have have system drug have have higher impact better outcome truly be differentiate justify reimbursement support re not company focuse sort target innovation long run re not go do well also have look company say be come term news term be news go be impactful sector target meaning be too drug be sixth market drug really be go have prove huge differentiation make difference think be less appeal be drug actually be address significant unmet need more incremental mechanistic change success also offer broader opportunity be still metric even generalist investor public pharma company bring bear midcap company think same principle apply midcaps tend have less diversify portfolio have have type think apply even more stringently image provide shutterstock
891,CELG,biotech stock fall deepest crater history start last summer rumbling recovery be sound year bull run more quadruple value peak last july ibd medical biom biotech industry group plunge early february hurt backlash high drug price merger seek lower corporate taxe group have gain feb low lead stock have do better biotech stock buoy potential blockbuster drugsbiomarin pharmaceutical bmrn be feb low incyte incy have gain low point same week ligand pharmaceutical lgnd have climb medivation mdvn boost buyout talk be group be even more take hit past week negative earning news several industry player fund manager tell ibd rebound be here say spate bad news have already be factor stock price more see climate favore rejuvenate hot drug new product pipeline pricing power innovate product bottom line positive factor drive runup never go away say just get drown noise very key point be group be very high beta group particularly small midcap stock don have sale don have earning say tom vandeventer portfolio manager tocqueville asset management history group be elevated macro uncertainty definitely hit vandeventer say own opinion be group trade more sentiment fundamental time period vandeventer point trouble china emblematic macroeconomic concern hit biotech stock sentiment drive factor be politic many candidate presidential race have bash drugmaker high price have propose way clamp wall street have dismiss idea impossible ineffective seem be generate most concern be democrat proposal let medicare medicaid negotiate drug price be not allow do now already center medicare medicaid service have show tooth announce pilot program change reimbursement medicare part cover drug administer hospital clinic part reimbursement scheme be long criticize encourage use expensive drug reimburse health care provider entire cost drug top propose scheme reduce premium add flat fee unrelated price drug theory encourage doctor choose cheaper option front treasury department last month issue new guideline tax inversion deal derail have be drug industry biggest ever merger pfizer pfe allergan agn tax inversion have become popular way drugmaker boost bottom line get access cash allergan earlier merger be base ireland have low taxe think tax regulation call inversion bottom bad press associate health care industry create bottom mind say robert bombace senior portfolio manager frost investment advisor lot bad news have already be baked company fact number industry insider say breakup pfizer allergan merger turn be good biotech stock make acquisition target company allergan have long history acquisitiveness pfizer be think splitting innovative drug business other product evercore isi analyst mark schoenebaum say pfizer want bulk innovative business make valuable standalone pipeline be modest compare big pharma competitor schoenebaum have also say biotech board be balk buyout offer much valuation have drop so ve be unwilling sell market price suspect lead hostile takeover deal big player be willing do partly come fruition late april sanofi sny make unsolicited bid medivation rumor swirl astrazeneca azn pfizer be also interested medivation response reflect attitude schoenebaum speak market be underprice stock sanofi time proposal come period significant market dislocation several important term event company be design seize sanofi value rightly belong stockholder medivation founder ceo david hung say statement reject offer bombace however say biotechs reluctance be show think just bargaining chip say reality be most company have partner anyway larger pharma biotech name reach point pipeline be so dry force hand bombace see lot exciting biotechnology science go fill pipeline put re go model stage space shuttle stage decline name specific company point work biomarker include pd inhibitor such bristol myer squibb bmy opdivo merck mrk keytruda also cite work genetic mutation focus many rare disease firm such biomarin bluebird bio blue discovery be keep money flow biotechnology say leonard yaffe manage health care hedge fund kessef capital management tell ibd specialty drug largely biologic drug prescribe specialist opposed primary care doctor contribute only prescription last year dollar spend drug year earlier thing think drive biotech stock be look drug introduce last year revenue derive drug be biological yaffe say so most attractive sector pharmaceutical area also most publicly trade biotech stock don have earning have successfully launch drug remain highly profitable top biotechs market cap gilead science gild amgen amgn celgene celg biogen biib regeneron pharmaceutical regn have ibd ep rank range putt top stock ep growth regeneron have ep rank number however reflect pricing power biologic drug be precisely political attack day vandeventer say price uncertainty be biggest risk bull thesis group right now also point democratic presidential front runner hillary clinton attempt previous overhaul health care system back mid depress drug stock short term be follow late boom boom be drive first wave biotech innovation company amgen roche rhhby genentech prove biotechnology produce blockbuster vandeventer say innovation remain key maintain pricing power even political pressure point gilead portfolio hepatitis drug start late launch sovaldi much political criticism sovaldi high price stop drug be so superior anything else market company have do research ll continue get price increase say company be particularly rare disease orphan disease arena oncology space company have drug era target medicine have higher efficacy rather shotgun try hit disease be go have pricing power promise such drug still make small stock explode celator pharmaceutical cpxx have surge march favorable late stage trial result acute myeloid leukemia treatment company also see hedge fund take position stock attract favorable initial coverage analyst be sign even generalist investor think biotech stock have get cheap say yaffe first quarter common lament be biotech stock get punish bad news good news get reward biogen issue mixed earning report draw mostly negative reaction wall street april stock rise more biogen have fall even harder other big cap biotechs drop march high feb low so be ready bounce say yaffe overview comment be sector have correct point get level stock be very attractive say
892,CELG,new ibd tech leader index look company technology field be highly rate used ibd proprietary rating current market condition be uptrend pressure name be approach higher caution especially be tie more performance nasdaq composite april list electronic sector stand dominant representation industry group make more list scientific measurement electronic group ibd industry group electronic part manufacturer many stock sector serve support role so part analysis include area exposure company be focuse life science exposure biotech industry biotechs have great run group have fall considerably big winner celgene celg gilead gild top summer company dhr have exposure multiple industry segment serve life science diagnostic vs segment focuse industrial technology petroleum business make analysis little easier complete tax free spinoff third quarter company retain name keep life science exposure new spinoff name fortive take industrial side exposure foreign market bruker brkr not only have strong link life science pharmaceutical research also accord company revenue come outside first quarter earning season have unfold company have often point currency headwind create strong dollar be culprit soft earning
893,CELG,stock stay positive wednesday afternoon oil stock rebound drop crude oil supply push price crude nasdaq pop dow jone industrial average rise respectively small cap russell add volume stock market today be run higher nasdaq lower nyse vs same time tuesday blue chip dow be mostly volume be sluggish biotech celgene celg be biggest percentage gainer volume faster usual small cap lgi home lgih rumble higher heavy volume low end homebuilder report home closing rise year year basis texas base lgi launch ipo november company have market presence texas arizona georgia florida early december company have expand reach north carolina south carolina colorado new mexico washington state earning share jump last year revenue gain street expect ep rise year pop revenue federal reserve release minute march meeting minute show fed appear reluctant raise rate april member refuse rule april rate hike market show little reaction image provide shutterstock
894,CELG,ligand pharmaceutical lgnd be already diversify biotech year now make new claim technology base alter genetic ratsit seem distasteful not very profitable prove be turn point january early stage biotech company acquire omt firm develop technology omt stand open monoclonal technology be used rodent dna human antibody therapeutic use move give ligand avenue growth venture forth hottest area medicine say larry solow analyst cjs security also use animal antibody develop drug human used model solow tell investor business daily rat model lead human drug top selling drug humira remicade mabthera rituxan avastin herceptin used human antibody development omt be believe be only company world offer transgenic animal platform know name omnirat omnimouse omniflic ligand acquire omt drug company have license technology emergent biosolution ebs tizona therapeutic abba therapeutic swiss biotech come top licensee omt have previously line include biopharma giant merck mrk pfizer pfe celgene celg name few typical licensing partnership provide royalty milestone payment omt partner have be pay access technology eventually pay milestone payment royalty too ligand have expect omt add revenue year next year total more be addition emergent tizona abba client list deal ligand likely update guidance next earning report set omt deal positive news other ligand license drug haven diminish investor sentiment share have rise roughly year early april european commission approve expand use european version ligand top license drug promacta use pediatric patient rare blood disorder drug be sell partner novartis nvs mid march licensee spectrum pharmaceutical sppi win food drug administration approval evomela use treat certain case multiple myeloma form blood cancer drug earn ligand higher normal royalty positive clinical datum year other ligand license drug also bode well future revenue growth analyst say anticipate current revenue stream partner product broad development portfolio be poise drive significant growth longer term write analyst joseph pantginis recent research note roth capital partner addition royalty ligand already generate significant revenue proprietary formulation technology call captisol sugar molecule help absorb drug body especially helpful harmful side effect captisol other material sale vary quarter quarter depend be need clinical trial commercial use fourth quarter lower material sale vs year earlier cause overall revenue decline last year still revenue full year rise top growth royalty revenue rise more lumpy material sale related quarterly decline do not concern solow say expect royalty revenue grow year analyst poll thomson reuter see total revenue rise year go next year earning rise prior year cent share analyst expect flat ep growth year then increase next year share nearly half ligand drug partnership be base captisol technology solow say include top seller kyproli used treat multiple myeloma kyproli promacta oral drug boost platelet blood generate sale more last year solow say figure ligand last year receive royalty promacta sale vs kyproli roughly promacta be sell novartis krypoli amgen amgn kyproli ultimately have bigger commercial potential royalty be higher promacta so more important drug solow say ligand have dozen other early stage drug have find partner take next stage target multitude disease such hepatitis diabetes cancer anemia alzheimer kidney disease other ligand have more partner program different company ligand essentially pass heavy lift need bring drug market enjoy royalty milestone relatively little investment cost ligand cash operate expense last year totale partner spend research development say solow show power business model say note company overhead be relatively low yield commercial drug get royalty ligand partner be expect spend close add half growth come omt more shot goal partner program ligand have numerous avenue growth write analyst draw jone stephen initiation report mid april rate stock overweight jone expect promacta kyproli generate more royalty ligand next few year compare addition estimate several company next biggest program provide potential royalty move expect ligand management team continue shrewd capital deployment strategy technology focuse acquisition note
895,CELG,biotech regeneron pharmaceutical regn core ophthalmology business still have huge upside eylea sale grow treat variety eye disease say rbc capital rbc also say legal settlement amgen amgn praluent drug intend lower bad ldl cholesterol be positive most regeneron sale come eylea launch treat age related vision loss elderly regeneron aim build sale eylea market treat diabetic macular edema dme cause blindness work age person well related eye disease affect older person turn dme market opportunity be important likely adnan butt rbc capital analyst say research report tuesday dme eylea compete roche hold rhhby lucentis regeneron typically report earning early roche novartis nvs bayer bayry report earning april respectively commentary provide insight eylea growth say rbc butt say consensus expectation recently launch cholesterol drug praluent have only december quarter sale still need come amgen make rival drug call repatha march federal jury upheld validity amgen patent related cholesterol drug deal blow regeneron partner sanofi sny settlement amgen be positive butt say report rate regeneron stock outperform price target regeneron stock be more early afternoon trading stock market today amgen report earning april follow sanofi april earning call provide read status praluent litigation say butt regeneron stock have plunge broad sell biotech stock include celgene celg gilead science gild regeneron share touch month low last month jump april company announce strong phase clinical result dupilumab drug eczema itchy skin condition regeneron be develop drug sanofi landmark deal sanofi provide year fund antibody discovery year give regeneron profit defer development cost partnership be profitable add butt startup intellium therapeutic late monday announce licensing deal regeneron cambridge mass base intellium have develop gene editing technology treat liver blood disease plan go public regeneron have ibd composite rating possible lower celgene gilead ibd medical biom biotech group rank just industry group month past week best span therapeutic anik supernus pharmaceutical supn ligand pharmaceutical lgnd have highest ibd composite rating biotech group
896,CELG,new year prediction last almost long new year resolution year federal reserve be forecasting rate hike hillary clinton be favorite presidency unknown start tone set washington investor see good trump bad trump republican repeal replace obamacare economic front opec ally carry oil production cut fast shale company boost output tesla tsla be suppose begin delivery model road be get crowd electric vehicle apple aapl hope iphone consumer revive sale snapchat be set go public uber other big unicorn follow new year be unpredictable here be key issue challenge watch affect investment economy investor business daily ed carson jed graham allison gatlin elaine low gillian rich patrick seitz brian deagon bill peter contribute article donald trump promise ambitious agenda corporate tax rate repeal obamacare dodd frank other regulation infrastructure program economy have be stick second gear year business reluctant invest prospect trump administration already have revive animal spirit ibd tipp economic optimism index other business survey show soar confidence populist president elect have zeal conduct ad industrial policy public used twitter tv target unite technology utx boee ba lockheed martin lmt well drug price protectionist instinct have serious consequence give president broad authority trade trump adopt few dump duty china expand action president bush obama withdraw nafta trigger full blow trade war china roil global economy so far investor be bet trump pro growth low tax agenda carry day stock have rally strongly election day sector bank steel mining have fared better other election federal reserve worry slow growth have become chronic condition economy fed shift role traffic cop try keep economy blow past speed limit trump fiscal fuel spark inflationary pressure fed raise rate more quarter point hike central bank be predict positive scenario play trump policy boost productivity essentially raise speed limit so economy drive faster upsurge inflation fed likely follow financial market lead recent year fed have speak loudly carry wiffle bat policymaker goal rate hike be whittle quarter point move year end large part due concern global market fed include new trump appointment fill vacancy trump appointee be especially open idea deregulation corporate tax cut help revive productivity growth increase labor force participation year end trump likely nominate choice fed chief janet yellen term end february related fed play traffic cop trump hit fiscal appear intent kick vote repeal obamacare delay actually replace system year health exchange have be struggle younger healthier person decline sign even individual mandate republican get rid law sweeping tax spending provision only vote senate gop leader couldn overturn coverage mandate least democratic support republican repeal obamacare medicaid expansion perhaps block grant give state much more flexibility federal fund yet many health policy expert industry player have warn repeal replacement blow individual insurance market operate obamacare rule many health insurer such unitedhealth unh aetna aet be already pull most exchange tired suffering loss peer throw towel entirely law be largely repeal long term replacement wide swathe country lack individual market insurer government do related trump gop face huge now obamacare momentafter rough drug price campaign spotlight slew potential fda approval big trial datum particularly cancer arena catalyze biotech stock fda be slate examine parp inhibitor tesaro tsro clovis oncology clvs treat ovarian cancer duo compete multibillion dollar market already approve lynparza astrazeneca azn celgene celg have multiple myeloma drug fda priority review fda also look ariad pharmaceutical aria brigatinib fight small cell lung cancer kite pharma kite be expect seek approval refractory hodgkin lymphoma drug early car treatment seattle genetic sgen aim change traditional hodgkin lymphoma therapy unveil phase datum meanwhile axovant science axon biogen biib have datum alzheimer treatment due drug significantly slow cognitive decline be huge blockbuster biom company make announcement drug financial annual jpmorgan healthcare conference january related top biotech stock be slate triple digit gain seattle genetic ceo angle hodgkin lymphoma eurekaoil stock have rally crude price bottom early industry have reason cautious optimism year effort drive shale producer largely fail organization petroleum export country top opec producer agree cut production nearly barrel day start january prop oil price cartel member have history breaking production quota russia already have say only gradually lower production analyst expect iraq be first opec member cheat output target even opec plan fail international energy agency see oil market balancing second half help rise demand crude price more double early lows continue climb depend quickly shale production revive crude output start climb number oil rig use rise sharply recent week month many shale player have cut cost profit lower oil price level trump pick secretary state exxon mobil xom ceo rex tillerson be bullish sign oil company head give tillerson experience international energy trade deal lot ride apple generation smartphone due fall unofficially call iphone anniversary model sport radical redesign glass sandwich look borderless oled display invisible home button wireless charge bullish analyst believe iphone create supercycle upgrade activity generation similar look iphone iphone shipment fall apple fiscal end vs decrease overall premium smartphone market many analyst see apple return smartphone sale growth next year thank iphone apple fast grow service business include apple music apple pay icloud more be expect bright spot other be more pessimistic oppenheimer analyst andrew uerkwitz have predict apple be embark decadelong malaise apple fortune be reliant iphone company lack courage lead next generation innovation ai cloud base service messaging say initial public offering be expect rebound year low first high profile new stock be likely be snapchat owner snap widely watch tech unicorn value snap ipo expect first quarter raise value company snapchat be grow rapidly parent company have struggle turn profit face competition facebook fb photo sharing instagram site be adopt snapchat feature other unicorn expect go public be music service provider spotify software maker appdynamic datum analytic company palantir uber value be not expect ipo neither be airbnb renaissance capital believe activity pick significantly breaking long ipo recession start august ipos raise number dollar value fall top perform ipo be optical component supplier acacia communication acia be ipo price have lose more half value early september end year month low overall stock market trend be critical ipo activity success postelection rally continue more company go public likely fare well stock index move sideway correct unicorn be rare related ipo outlook mixed prediction focus chart electric car race intensify tesla motor introduce long await model second half be tesla most affordable car base model cost far less more upscale model sedan model crossover suv tesla be track deliver vehicle aim ramp auto production delivery year tesla have history miss deadline cut production target ceo elon musk strive get least model vehicle door next year musk also be busy integrate recently acquire solarcity well complete tesla battery gigafactory meanwhile general motor gm ford mercede benz bmw toyota tm volkswagen vlkay be selling plan introduce electric vehicle target many same potential buyer model model have self drive feature tesla also face threat tech giant such alphabet googl apple alphabet have spun self drive car effort own unit waymo google parent have backed plan create vehicle steering wheel pedal favor partnership exist carmaker apple have never acknowledge project titan effort reportedly have shift make self drive electric car develop operate system autonomous vehicle mobileye mbly delphi dlph showcase turnkey autonomous drive technology ce early january still unclear electric car be ready mass adoption be more expensive gas power vehicle federal tax credit soon expire new tesla buyer charge take far longer fill tank fear cord cut pay tv subscriber cancele cable package continue abound medium space recent pwc survey find respondent be pay tv subscriber vs year suggest cord cut continue much slower rate predict still subscriber loss espn own walt disney raise concern power live sport programming discourage viewer dump inclusive cable package hulu own disney st century fox foxa comcast cmcsa unit nbcuniversal time warner twx plan roll live stream service new year include broadcast cable network google youtube be also say be work stream tv service go live player join crop top tv competitor include sling tv dish network dish playstation sony sne directv now long slog year low rate weak economic growth post crisis regulation bank appear set better trump transition team have say incoming president dismantle dodd frank tax spending program boost demand also lift inflation trigger more federal reserve rate hike wider yield spread expand bank net interest margin send bank stock soar treasury yield late especially presidential election bank america bac be see most expose big bank meaning be most likely benefit rate hike fed faster economic growth meanwhile citigroup still have significant international operation be hurt trump set trade deal ablaze dozen smaller bank have hit multiyear high bank investor be pricing aggressive fed trump move bond yield continue climb action do not occur bank earning stock disappoint related personal finance action plan stock market review
897,CELG,stock index book solid gain wednesday afternoon biom stock dive president elect donald trump vow bring drug price nasdaq advanced dow jone industrial average gain respectively small cap russell rise volume stock market today be run higher major exchange medical stock struggle trump say time magazine interview doesn happened drug price bring price trump make mention investment research development be never free company such celgene celg regeneron pharmaceutical regn put revenue research development big cap stock incyte incy put revenue last year strong growth revenue profit budget shrink odd develop new drug also fade high end biomed rely most lead retreat wednesday group meanwhile rest market be business usual bank stock have lead trump rally be little change exchange trade fund powershare kbw bank kbwb inched bank etf have gain election day close steel have be area strength stock market continue wednesday afternoon gainer steel producer include unite state steel ak steel ak nucor nue steel alloy stock also show strength carpenter technology crs pop retook day line allegheny technology atus rise try clear base economic news labor department job opening labor turnover survey be little change october layoff slip so do rate hire job opening gauge be federal reserve chief janet yellen watch closely cme group fedwatch tool be unchanged wednesday chance interest rate hike december related trump target drug price apple seek minute offshore firm chip stock get buy air delta break basis
898,CELG,stock market extend gain close wednesday stock market today dow jone industrial average blast new high respectively nasdaq be tuesday top performer russell follow gain volume be higher board starbucks sbux rise depart ceo howard schultz outlined vision coffee company next year response slow sale schultz propose roastery location world series reserve store more retail footprint reserve bar starbucks reserve be company new high end retail location serve sell exotic coffee downside biotechs miner fall heavy volume ibd stock celgene celg fall further cup buy point follow president elect donald trump comment drug price be too expensive lower cost freeport mcmoran fcx leaderboard member fall still remain cup base entry point ibd take apple big internet stock rally wednesday most have be market laggard presidential election be apple fang stock ready join trump rally other lead growth stock arista network anet rise stock continue gain momentum flat base stock be now pivot dave buster play gap follow tuesday quarterly earning release addition surpass top bottom line estimate company raise full year guidance prompt analyst raise price target company stock initially break double bottom base mid november healthequity hqy initially fall wednesday morning rebound positive territory earning announcement close tuesday earning sale exceed analyst expectation share be close crude price continue decline wednesday fall follow bearish oil inventory datum doubt persist production cut opec russia be sufficient end supply overhang dollar fall tuesday rebound notable earning report be close today broadcom avgo finisar fnsr broadcom chip designer have struggle gain traction current market relative price strength rating have suffer result mediocre rating estimate be earning share revenue finisar fiber optic company have be hold most recent flat base entry point analyst expect ep cent sale european central bank be set meet thursday investor expect ecb extend eur monthly bond buy program datum front weekly jobless claim be due be et new consensus estimate be related starbucks layer most aspirational plan historyecb broadcom finisar ciena lead thursday investing action plananalyst tout dave buster western digital
899,CELG,market be relatively calm afternoon trading holiday weekend approach modest loss narrowing dow industrial nasdaq be less stock market today russell be laggard trading trading volume decline significantly board twitter twtr fall heavy volume management turnover social medium firm continue tuesday senior employee announce be depart company mizuho reiterate underperform rating base amount executive turnover stock be time high set back december netflix nflx moved more close buy point stifel raise video stream company price target analyst firm boost net subscriber addition forecast back deeper catalog original content oil gas stock be big winner day oil price fall energy information association report surprise rise crude stockpile top stock be energy related halliburton hal complete week tight last week stock rise intraday be constructively hold high be well cup buy point chesapeake energy chk pull back double bottom entry last week find support have bounce higher stock be lead growth stock stock be mostly quiet upside dave buster rise stock have consolidate high gapping earning couple week downside stock fall more celgene celg wingstop wing celgene leaderboard member be rebound day line wingstop fall further buy point be now week high related apple google alphabet netflix buy investing action planoil dip crude stockpile unexpectedly end week slide
900,CELG,bluebird bio blue stock rocket month high thursday biotech celgene celg be see life post revlimid patent cliff new method blast multiple myeloma rival juno therapy juno kite pharma kite amgen amgn stock market today bluebird bio stock jump earlier touch year high tough day drug tech stock overall share partner celgene rise fraction bluebird celgene be develop bbb target bcma protein find cancerous plasma cell treatment be boon celgene credit suisse analyst alethia young say celgene patent revlimid be set expire mid revlimid be drug imid used treat multiple myeloma model revlimid sale celgene be poise allow natco sell generic rival month ahead patent expiry celgene bull case depend maintain hematology myeloma franchise post revlimid say young have outperform rating price target celgene stock ibd take be get most investment not check investor corner tip manage portfolio bbb be interesting young say chimeric antigen receptor cell car therapy car cell therapy engineer patient immune cell treat cancer accord national cancer institute car be protein allow cell recognize specific antigen tumor cell grow lab car cell be later infuse patient billion infusion cell multiply patient body guidance engineer receptor recognize cancer cell harbor antigen surface nci explain celgene bluebird aren alone car cell effort juno stock tank nov announce patient die car cell trial prompt firm place trial clinical hold kite be partner amgen develop car cell therapy base kite aact engineer autologous cell therapy amgen slate cancer target kite stock fall nov rival juno trial wo share juno kite fall fraction thursday ibd company biotech industry group fall day line rbc analyst michael yee call car cell therapy most potent approach hit myeloma hardest efficacy be key refractory myeloma have outperform rating price target celgene stock follow bluebird phase study announcement late wednesday patient phase study patient fail average round treatment blood cancer bbb show overall response rate orr mid high dose patient highest dose cell show complete response key bbb yee note be high efficacy side effect relatedbluebird bio celgene multiple myeloma therapy strong patient studyamgen biogen celgene eye trump pro biotech worldcelgene kite spark look sidestep lilly alzheimer flop
901,CELG,bluebird bio blue announce late wednesday small study show multiple myeloma treatment deliver significant benefit major side effect patient have run other option share bluebird bio share sky-rocket thursday morning larger partner celgene celg also rise phase study have just patient have fail average round other treatment blood cancer patient get lowest dose cell show reduction sign cancer meanwhile patient get medium dose cell get largest dose cell show least cut show virtually cancer system be pleased early datum ongoing phase study bb demonstrate objective tumor response heavily pre treat patient multiple myeloma patient car cell dose cohort achieve response include patient stringent complete response elimination minimal residual disease say david davidson chief medical officer bluebird bio statement treatment be call bb go bcma protein find cancerous plasma cell bluebird bio share shot shortly open bell stock market today highest dec bluebird close wednesday celgene rise intraday bluebird bbb be numerous promising chimeric antigen receptor cell car therapy addition positive benefit lack major side effect be huge earlier month juno therapeutic juno halter car cancer drug trial patient die send share crash nov kite pharma kite car player report bullish result aggressive hodgkin lymphoma treatment late september kite have alliance biotech giant amgen amgn kite edge higher intraday juno fall fraction bluebird kite juno be suffering deep loss not much revenue be not unusual small biotechs approve treatment car therapy offer prospect blockbuster miracle treatment cure celgene kite be biotechs expect release datum american society hematology conference saturday tuesday related juno stock plummet patient pharma soar cancer drug trial supportive fda approval
902,CELG,slate thursday be quarterly earning report amazon amzn linkedin lnkd baidu bidu gilead science gild close market open investor get first look first quarter economic growth commerce giant be expect earn cent share swing profit cent loss last year revenue be project climb last quarter amazon fall well short earning estimate come light revenue send share much high follow week cloud compute division amazon web service be bright spot haul revenue quarter year year share be flirt be lower boundary buy range cup handle base buy point initially break few week amazon fall fall intraday professional social network earning be project grow cent ex item sharp drop growth see prior quarter revenue be expect jump share drop linkedin last quarterly report show weak guidance linkedin stock have climb low reach follow day be now trading week high social networking leader facebook fb crushed earning revenue projection late wednesday send share late trade facebook positive action continue thursday session stock likely be buy range cup handle base buy point china internet giant baidu be project see ep ex item fall rmb cent revenue be estimate rise rmb baidu mobile ecosystem be strong accord itg research analyst henry guo say week firm datum indicate baidu mobile search app dominate mobile search market more installation penetration chinese mobile user well ahead key competitor sogou search qihoo technology qihu search baidu be trading just buy range cup handle base break recently trading week high biotech earning be estimate rise share slower last quarter growth revenue be see rise also deceleration prior quarter comparison be get tougher gilead earning sale sky-rocket hepatitis treatment gilead retook day line last week breach level wednesday session share be trading week high fellow big cap biotech amgen amgn also report quarterly result thursday analyst expect ep gain amgen fall thursday be buy point cup shape base market open biotechs alexion pharmaceutical alxn celgene celg report big pharma bristol myer squibb bmy abbvie abbv make rival hepatitis treatment not great gain couple ongoing issue regard strong dollar weak energy sector sluggish manufacturing weak growth be expect wall street expect scant annualize gain
903,CELG,stock higher flat start wednesday enough lift nasdaq narrowly back day move average nasdaq rise add dow industrial tack gain stock market today volume be quiet nyse lower nasdaq relative action same time tuesday pfizer pfe run head dow more breaking takeover allergan agn nixing pfizer allergan inversion reportedly cost pfizer breakup fee avoid run afoul treasury department launch inversion regulation monday allergan stock also rise more uninverted drug medical play lead nasdaq celgene celg illmina ilmn vertex pharmaceutical vrtx jump more ibd stock acuity brand ayi padded early gain press higher big fiscal sale earning gain put share past cup handle buy point baker hughe bhi spiked halliburton hal pop justice department file antitrust lawsuit challenge plan acquisition baker hughe halliburton suit claim merger eliminate competition specific product service related oil gas field production
904,CELG,facebook fb get higher price target tuesday netflix nflx see series negative analyst move follow weak forecast ebay ebay be downgrade needham raise price target facebook maintain buy rating stock last week facebook ceo mark zuckerberg unveil year plan social medium giant include way enhance connectivity power experience transaction artificial intelligence facebook share close stock market today netflix fall be hit numerous price target cut internet tv giant price target be lower topeka capital market pivotal research group mizuho late monday netflix beat first quarter earning subscriber growth estimate disappoint weak subscriber guidance current quarter expect add only subscriber international subscriber be smallest customer growth year ebay be downgrade underweight morgan stanley have price target stock share online marketplace fall biotech celgene celg have price target cut credit suisse rate stock outperform celgene stock price dip bank america downgrade illumina ilmn neutral cantor fitzgeraldd downgrade stock hold gene sequence giant announce weak preliminary revenue cut full year outlook late monday illumina sank tuesday alliance datum system ad price target be lower credit suisse maintain neutral rating stock share fall panera pnra be upgrade buy jeffery share fast casual restaurant chain rise image provide shutterstock
905,CELG,delaware select growth fund dveax pull stop search growth go anywhere fund invest company size look name be expect grow faster economy long term asset fund be sub advise team manager san francisco base jackson square partner year date go tuesday fund be vs average decline peer large growth fund track morningstar last decade delaware select growth have churn annual average return vs large growth category fund hold stock feb spread vary market cap category fund count technology consumer discretionary health care be top weighting fund have annual turnover rate versus category average delaware select growth primarily bet company asset invest top holding paypal pypl be top holding fund better recent performer digital mobile payment provider be so far year stock be top hold feb earning share rise past quarter vital signsat end february fund top hold be company celgene celg january company report fourth quarter earning share growth jump revenue celgene top line have benefit strong sale top selling cancer drug revlimid share celgene be year date earlier month biotech release drug trial datum disappoint investor celgene report phase disappointing result experimental oral treatment psoriasis delaware select position have also be make gain pharmaceutical space allergan agn be come impressive own botox be company top revenue generator quarter figure amount total revenue november company agree blockbuster merger pfizer pfe allergan have see stock price slide begin year ep growth have decelerate grow past quarters qualcomm qcom be fund third largest hold have be portfolio delaware select growth team state commentary believe company mobile chip business bounce back product cycle issue be unlikely recur show strength company recently up dividend qualcomm have see stock price rise zebra technology zbra be add delaware select growth portfolio company sell tracking computer printing technology such barcode scanner specialty printer zebra recently say be project full year net sale growth also expect pay least debt principal zebra share have decline so far year commentary delaware select growth team note progress microsoft msft top hold shift cloud base technology believe transition be beneficial software be better utilize multiple platform team write share microsoft have tick so far year
906,CELG,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
907,CELG,amazing diversity etfs allow investor bird stone consider ishare nasdaq biotechnology ibb largest exchange trade fund segment ibb debut ibd leaderboard march make first etf be add short sale idea shorting etf allow investor profit holding continue decline exchange trade fund downward slope relative strength line reflect weakness find chart most major biotechs investor also use proshare ultrashort nasdaq biotech bis achieve same goal etf leader current market relative strength rating mean recent price performance be top percentile stock etfs track ibd bis seek daily investment result correspond time inverse daily performance nasdaq biotechnology index etf investor legitimately ask be better short largest biotech etf take long position inverse counterpart inverse etf be probably best left alone sophisticated etf investor day trader investor be look dollar dollar gain fall etf price then be appropriate short specific etf monish shah head etf trading mizuho security recently tell ibd instance short share particular etf then price drop unrealized profit be however major risk short selling be profit be capped risk be unlimited short position etf price rise indefinitely force investor cover higher price inverse etf loss be capped amount have invest inverse etfs bring risk challenge average investor be critical understand inverse return underlie index be expect match only daily basis shah add longer term significant disconnect likely arise return inverse etf return underlie index due compound effect type investing strategy have potential amp portfolio return restrain investing climate however require more molly coddling ensure loss don run away be key successful investing overall picture ibb other biotech etfs major holding ibb include celgene celg biogen biib gilead science gild stock be deep correction industry fundamental aren so bad accord ibd market team heath care sector have best ep sale growth estimate analyst revision biotech be best part sector drug pipeline remain well stock licensing deal remain hot question sale growth have slow sharply peak ibb be fall stock market today bis add intraday year date ibb plunge march see net outflow first month year comparison bis be same period leak
908,CELG,well fargo downgrade several medium stock tuesday include walt disney cbs cbs st century fox foxa cite dismal earning season group second quarter
909,CELG,downgrade come couple week medium stock get slam ongoing fear competition netflix nflx other stream service lead subscriber loss lower cable ad revenue
910,CELG,share disney close fox cbs stock market today netflix finished lower
911,CELG,biotech startup juno therapeutic juno inked deal biotech giant celgene celg last month be initiate outperform rating price target fbr capital juno stock price have be afternoon trading end day flat
912,CELG,meanwhile highly rate auto part retailer advance auto part aap get upgrade steep price target hike tuesday cosmetic giant estee lauder el also receive upgrade day stock price tank disappointing quarterly sale cautious outlook
913,CELG,argus upgrade advance auto buy hold price target advance auto share edge last week stock set new high better expect quarterly earning
914,CELG,estee lauder stock price close telsey advisory group upgrade stock outperform market perform coach coh be upgrade buy hold jeffery analyst say maker luxury accessory be investor coach rise
915,CELG,blue buffalo pet product buff be initiate morgan stanley equal weight rating day recent ipo pet food supplier be initiate top rating citigroup barclay jpmorgan well fargo blue buffalo share have be flat intraday end higher well fargo downgrade several medium stock tuesday include walt disney cbs cbs st century fox foxa cite dismal earning season group second quarter downgrade come couple week medium stock get slam ongoing fear competition netflix nflx other stream service lead subscriber loss lower cable ad revenue share disney close fox cbs stock market today netflix finished lower biotech startup juno therapeutic juno inked deal biotech giant celgene celg last month be initiate outperform rating price target fbr capital juno stock price have be afternoon trading end day flat meanwhile highly rate auto part retailer advance auto part aap get upgrade steep price target hike tuesday cosmetic giant estee lauder el also receive upgrade day stock price tank disappointing quarterly sale cautious outlook argus upgrade advance auto buy hold price target advance auto share edge last week stock set new high better expect quarterly earning estee lauder stock price close telsey advisory group upgrade stock outperform market perform coach coh be upgrade buy hold jeffery analyst say maker luxury accessory be investor coach rise blue buffalo pet product buff be initiate morgan stanley equal weight rating day recent ipo pet food supplier be initiate top rating citigroup barclay jpmorgan well fargo blue buffalo share have be flat intraday end higher
916,CELG,biogen beat second quarter earning estimate friday big cap biotech stock crash weak sale sharply lower guidance report failure clinical trial biogen biib earning exclude time item rise vs year earlier share beating analyst view cent revenue climb short consensus biogen
917,CELG,israeli drug giant teva pharmaceutical industry drop hostile bid mylan instead agree buy global generic drug business allergan monday teva allergan stock jump new high mylan drop teva teva agree pay cash stock allergan agn actavis business
918,CELG,suffer mild distribution day tuesday semiconductor stock weigh nasdaq wasn bad broad market sell china stock overnight nasdaq fall ease dow give ironically selling wasn intense higher volume still result
919,CELG,etf investor biotechnology stock be rattle nose dive first heavyweight earning gate ishare nasdaq biotechnology ibb biotech exchange trade fund have lose past trading session illumina ilmn stumble ahead celgene celg biogen biib report week ibd speak tushar
920,CELG,celgene celg stock be fly stock market today big biotech announce late tuesday acquire peer receptos rcpt share cash enhance inflammation immunology portfolio deal celgene announce view top preliminary earning share gap huge volume wednesday hit
921,CELG,hot market biotech ipos be get hotter upcoming debut nantkwest developer cancer therapy set record market valuation
922,CELG,nantkwest nk be st initial public offer health care field year price monday evening plan more triple next most active sector technology finance ipos health care also have most ipos last year
923,CELG,ve have great extend ipo window opportunity company get financing public market say david miller portfolio manager alpine bioventure invest public early stage private company company be go first human trial fda drug approval faster ever say part be fda be more understand company be also smarter drug development
924,CELG,nantkwest adopt ticker symbol nk plan raise offer share price range midpoint have fully diluted market value top record set biotech juno therapeutic juno market valuation trading debut dec ipo accord renaissance capital manager renaissance ipo exchange trade fund
925,CELG,industry
926,CELG,be several reason surge health care initial public offering help fan flame be record number merger acquisition include blockbuster deal
927,CELG,include big cap biotech alexion pharmaceutical alxn paid acquire synageva biopharma deal close last month synageva come public december be teva pharmaceutical teva paid acquire auspex pharmaceutical pact auspex come public february big deal be celgene celg month announce pay acquire receptos rcpt receptos come public
928,CELG,reason be strong flow money come venture capital firm well ipos follow offering analyst also say biotech company be innovate pace never see
929,CELG,re now golden age biotechnology say paul yook portfolio manager bioshare biotechnology product fund bbp biotechnology clinical trial fund bbc capital be widely available record number drug be be approve
930,CELG,venture capital industry pump biotech company second quarter accord report national venture capital association prior quarter largest amount group begin keep record year
931,CELG,largest funding round biotech company be receive denali therapeutic be follow aduro biotech adro receive adaptive biotechnology get aduro come public april raise stock price pop first day trading now trade
932,CELG,have be lot takeover tremendous premium be enable biotech company good venture capital back good insider buy be next great wonder say scott sweet senior manage partner ipoboutique com research firm
933,CELG,funding follow high return
934,CELG,past decade emerge therapeutic company have receive venture capital receive proceed ipos more follow offering accord biotechnology industry organization largest biotech industry trade group
935,CELG,money be come return have be strong outlook be good say yook
936,CELG,biotech sector get blast attention nantkwest ipo ipo boutique say channel check show investor demand nantkwest be high deal expect be multiple time oversubscribed
937,CELG,nantkwest have several key ingredient make high profile ipo be affiliate drug giant celgene be exist stockholder plan purchase nantkwest share private placement concurrent ipo exist stockholder be mutual fund giant franklin templeton intend buy worth share
938,CELG,perhaps biggest attraction attention get ipo be billionaire patrick soon chairman ceo physician surgeon scientist plan invest ipo soon previously acquire control stake company last december be know conkwest
939,CELG,soon connection
940,CELG,soon have long track record success sell generic drug company controlled american pharmaceutical partner german health care company fresenius
941,CELG,invented develop abraxane be approve food drug administration treat metastatic breast cancer lung cancer pancreatic cancer celgene acquire drug buy abraxis bioscience
942,CELG,nantkwest be also draw attention area work hot field immunotherapy deploy patient own immune system fight cancer
943,CELG,be pioneer clinical stage immunotherapy company focuse harness power innate immune system used natural killer cell treat cancer infectious disease inflammatory disease nantkwest say ipo prospectus natural killer cell be also call nk cell hence nk stock symbol
944,CELG,go immunotherapy be absolutely revolutionary say miller
945,CELG,juno therapeutic be perhaps first high profile ipo immunotherapy field price raise juno currently trade be kite pharma kite be june ipo price kite now trade
946,CELG,drug development field be also full risk historically say miller drug enter oncology pipeline just get fda approval
947,CELG,stock big cap biotech biogen biib plunge friday company slash profit outlook due slow sale multiple sclerosis drug report failure clinical trial alzheimer disease drug hot market biotech ipos be get hotter upcoming debut nantkwest developer cancer therapy set record market valuation nantkwest nk be st initial public offer health care field year price monday evening plan more triple next most active sector technology finance ipos health care also have most ipos last year ve have great extend ipo window opportunity company get financing public market say david miller portfolio manager alpine bioventure invest public early stage private company company be go first human trial fda drug approval faster ever say part be fda be more understand company be also smarter drug development nantkwest adopt ticker symbol nk plan raise offer share price range midpoint have fully diluted market value top record set biotech juno therapeutic juno market valuation trading debut dec ipo accord renaissance capital manager renaissance ipo exchange trade fund industry athere be several reason surge health care initial public offering help fan flame be record number merger acquisition include blockbuster deal include big cap biotech alexion pharmaceutical alxn paid acquire synageva biopharma deal close last month synageva come public december be teva pharmaceutical teva paid acquire auspex pharmaceutical pact auspex come public february big deal be celgene celg month announce pay acquire receptos rcpt receptos come public reason be strong flow money come venture capital firm well ipos follow offering analyst also say biotech company be innovate pace never see re now golden age biotechnology say paul yook portfolio manager bioshare biotechnology product fund bbp biotechnology clinical trial fund bbc capital be widely available record number drug be be approve venture capital industry pump biotech company second quarter accord report national venture capital association prior quarter largest amount group begin keep record year largest funding round biotech company be receive denali therapeutic be follow aduro biotech adro receive adaptive biotechnology get aduro come public april raise stock price pop first day trading now trade have be lot takeover tremendous premium be enable biotech company good venture capital back good insider buy be next great wonder say scott sweet senior manage partner ipoboutique com research firm funding follow high returnsover past decade emerge therapeutic company have receive venture capital receive proceed ipos more follow offering accord biotechnology industry organization largest biotech industry trade group money be come return have be strong outlook be good say yook biotech sector get blast attention nantkwest ipo ipo boutique say channel check show investor demand nantkwest be high deal expect be multiple time oversubscribed nantkwest have several key ingredient make high profile ipo be affiliate drug giant celgene be exist stockholder plan purchase nantkwest share private placement concurrent ipo exist stockholder be mutual fund giant franklin templeton intend buy worth share perhaps biggest attraction attention get ipo be billionaire patrick soon chairman ceo physician surgeon scientist plan invest ipo soon previously acquire control stake company last december be know conkwest soon connectionsoon have long track record success sell generic drug company controlled american pharmaceutical partner german health care company fresenius invented develop abraxane be approve food drug administration treat metastatic breast cancer lung cancer pancreatic cancer celgene acquire drug buy abraxis bioscience nantkwest be also draw attention area work hot field immunotherapy deploy patient own immune system fight cancer be pioneer clinical stage immunotherapy company focuse harness power innate immune system used natural killer cell treat cancer infectious disease inflammatory disease nantkwest say ipo prospectus natural killer cell be also call nk cell hence nk stock symbol go immunotherapy be absolutely revolutionary say miller juno therapeutic be perhaps first high profile ipo immunotherapy field price raise juno currently trade be kite pharma kite be june ipo price kite now trade drug development field be also full risk historically say miller drug enter oncology pipeline just get fda approval stock big cap biotech biogen biib plunge friday company slash profit outlook due slow sale multiple sclerosis drug report failure clinical trial alzheimer disease drug
948,CELG,biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance
949,CELG,share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high
950,CELG,look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run
951,CELG,drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate
952,CELG,share gap quick turnover stock be look support day line currently buy range cup base buy point
953,CELG,valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week
954,CELG,follow alissa william twitter ibd_awilliam biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate share gap quick turnover stock be look support day line currently buy range cup base buy point valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week follow alissa william twitter ibd_awilliam
955,CELG,acquisition hungry valeant pharmaceutical vrx rise more stock market today record high weak earning guidance neatly step analyst second quarter revenue earning expectation valeant be several drugmaker biotechs report thursday morning include celgene celg eli lilly lly shire shpg bristol myer squibb bmy laval quebec base
956,CELG,turn millennium human genome project potential therapy be big factor huge move biotech stock extracellular proteome immunome prime therapeutic fprx have library more human extracellular protein proteome have be isolate importance immune cell interaction
957,CELG,drug stock fall wednesday wall street sort impact propose change medicare part reimbursement design drive price expensive hospital drug late tuesday center medicare medicaid service propose pilot program testing new reimbursement scheme medicare part cover drug administer hospital doctor office currently cms pay back price drug health care provider critic say encourage doctor prescribe more expensive drug propose rule doctor get just premium flat fee drug day somewhat reduce disparity different price drug cms also propose reduce eliminate portion patient have pay drug tie reimbursement level effectiveness drug give indication thus same drug work well condition only so so cms reimburse different level condition agency also want create online decision support tool help physician determine most effective drug use give situation test let cms enter voluntary risk sharing agreement drug maker link price adjustment patient outcome be comment period cms proposal point cms plan place provider different group used old reimbursement method new study difference group course year plan start testing other idea start january reimbursement proposal draw most attention wall street cover drug be mostly infuse inject treatment serious condition opposed pill patient take own so potentially affect drug industry biggest cash cow big biotechs most notable drug fall theoretical test be drug include amgen amgn neupogen neulasta also kyproli xgeva prolium vectibix total sale celgene celg abraxane be revenue other notable drug be oral write rbc capital market analyst michael yee research note credit suisse analyst vamil divan agree amgen add regeneron pharmaceutical regn biogen biib also depend drug medicare part umbrella new immunotherapy drug bristol myer squibb bmy merck mrk such opdivo keytruda yervoy also be cover part yee argue aren choose price reason consensus understand drug be choose high efficacy aren equivalent drug aren also infuse not reimbursement yee write amgen stock hit month low end day regeneron tumble celgene fall biogen be bristol myer stock fall merck slip fraction
958,CELG,hardest thing champion do again again again just ask repeat super bowl titlist baseball horse race triple crown winner tennis grand slam champ just hard best mutual fund too relatively few fund be able pull feat deserve recognition deserve consideration addition replacement retirement account ira well taxable account help identify special mutual fund ibd be introduce best mutual fund award stock mutual fund qualify exclusive recognition only have beaten broad market past year period not just award be earn mutual fund category top rank year performance top case sector fund be highlighted best best deserving special recognition be time winner be easy task mutual fund meet criterium have least asset year operation only beat benchmark period diversify stock mutual fund business entire decade track morningstar inc only pull feat growth mutual fund only emerge award winner category be much harder only value mutual fund beat benchmark time period just small cap fund get award winning stock mutual fund include category growth blend value well large mid small cap be compare index period dec international stock fund have beat msci eafe index best taxable bond fund trump barclay aggregate bond index tax exempt fund conquer barclay municipal index foreign taxable bond fund outperformed barclay global aggregate click here view table top fund categorywhether be look mutual fund strengthen current portfolio just start ibd award list be great place start here ll find top perform fund run smartest portfolio manager award winner be array category stock bond fund be most often used build core position diversify portfolio large mid small cap growth blend value stock foreign stock equity sector bond re market large cap growth foreign bond fund check category award winner be available plan get fund prospectuse quarterly report manager commentary see choice make best fit term investment horizon risk tolerance start top take time consider award winner category re interested already be familiar fund company have fund top mutual fund add confidence selection fund own be not award winner win want rush dump be perfectly good fund run competent portfolio manager fit unique need portfolio consider outperformed benchmark most period narrowly miss exactly do fund outperform so consistently achieve award status fund have show ability survive market correction bear market rac loss ruin long term return several manager claim secret involve ability ignore short term zig zag market individual expect short term performance not be type person invest fund say lee manager brown capital management small company fund explain team preference stock provide fund consistently superior growth long run have also outperformed past year aim strong long term return really mean be ability put together portfolio build weather market storm many fund mean focus company be not highly cyclical business such involve commodity many also mean sticking business strong balance sheet little debt many mean look sustainable earning not short term flash pan gavin baker manager fidelity otc portfolio focpx have similar view have long term time horizon be look year think be big advantage baker tell reporter billy fisher profile gavin fund be also best stock mutual fund large cap stock mutual fund many award winning manager take step further not only do ignore call short term noise market also stick own long term game plan tim parton manager jpmorgan growth advantage vhiax top fund large cap category helm team look lead stock regardless market capitalization work closely colleague run small large cap fund parton team mix name midcap stock focus other beauty strategy be re never force sell good stock just get too big be perennial problem small midcap manager parton say past fund have have bigger weighting small midcap stock team be find more growth opportunity attractive valuation market cap parton think long term team do not ignore here now tough period focus fundamental company say make sure name be not too affected environment re trim size position reduce risk volatile market ve be experience make name team like even more attractively price parton nibble only very cautiously only margin say explain caution stock have be knock price reason already have slightly higher risk portfolio value fund manager parton invest stock stock still sector weight show expect find leader biggest sector be information technology weighting feb nearly double second largest sector consumer discretionary tech holding range small cap medical software maker veeva system veev midcap database software maker splunk splk large cap gaming software maker electronic art ea giant cap microsoft msft winning manager many diversify stock fund category make point think long term base investment decision individual stock much more hot sector sector fund manager plumb respective pond fish hot trend land dominant shark water ibd nancy gondo explain diagnosis top perform sector fund biotech health science have be clear outperformer past year stock alexion pharmaceutical alxn regeneron pharmaceutical regn celgene celg gilead science gild pop recent portfolio disclosure top rank sector fund trait share best best focus well manage company able maintain pricing power even toughest time report scott stoddard examination best best international stock fund sector fund success bond fund often hinge ability play hottest part fix income market avoid segment be favor marie beeren report special report tcw total return bond tglmx be year outperformer thank large part surfing recovery mortgage credit crisis tcw manager bryan whalen tell beeren fund also avoid headwind have almost exposure corporate credit market dramatically lag similar duration treasury so be best best mutual fund need portfolio not stand alone fund parton say portfolio be growth fund do not give holistic exposure be exposure part market be used other other better choice consider ibd award winner have proven mettle year various market segment again again
959,CELG,cable tv leader comcast cmcsa coffee king starbucks sbux innovative drug company such bristol myer squibb bmy few biotechs make morgan stanley list company pricing power low inflation environment worry global recession stock pricing power get serious look say morgan stanley report list also include american tower amt amgen amgn biogen biib celgene celg constellation brand stz equinix eqix brand lb mindbody mb phillip morris pm reynold american rai sally beauty holding sbh sherwin william shw here morgan stanley take company have pricing power american tower tower effectively offer local monopoly be little alternative wireless carrier wish add capacity improve network quality amgen drug pricing have be topic debate presidential candidate raise focus topic late summer continue see pricing power large cap biotech biogen management take gross price increase portfolio celgene management take gross price increase portfolio expect similar net price trend comcast be positive cmcsa growth story see improve result video give set top box deployment sherwin william pricing power relate control own distribution well outsized leverage professional painting contractor starbucks sbux remain category leader high margin premium coffee segment benefit selling often crave habitual product
960,CELG,stock have be move line price oil year wednesday be different major average end higher nasdaq rise dow jone industrial average edge volume stock market today fall nyse nasdaq compare tuesday accord preliminary datum investor have used oil price barometer global economy selling oil price fall then buy crude rise crude price jump more wednesday rise back barrel be expect oil stock lead gain chevron cvx pace dow industrial rise more outside dow tesoro tso refiner rise more be pocket success elsewhere lgi home lgih pop nearly huge volume homebuilder post gain profit cent share beating wall street forecast sale rise slightly view meanwhile biotech stock take hit government announce test program lower medicare drug cost regeneron pharmaceutical regn plunge amgen amgn drop nearly celgene celg lose more dollar general dg el pollo child place plce be due report quarterly result thursday economic datum schedule thursday include initial jobless claim week end march treasury budget february meanwhile european central bank hold policy meeting thursday image provide shutterstock
961,CELG,biotech bluebird bio blue be trading sharply wednesday company say start testing cell therapy blood cancer trigger payment partner celgene celg celgene partner juno therapeutic also be wednesday get upgrade last june bluebird celgene agree year collaboration develop bluebird chimeric antigen
962,CELG,celgene celg kite pharma kite spark therapeutic once be look sidestep eli lilly lly recent alzheimer flop ahead annual american society hematology conference saturday tuesday san diego rbc evercore analyst say wednesday ibd biotech group be markedly nov eli lilly announce solanezumab have fail show statistically significant effect cognition alzheimer patient failure surprised analyst investor nov group actually rebound side first fall investor be try look thing more glass half full optimism rbc analyst write research report ahead ash conference be buyer look accumulate biotech give ve come past year ibd take celgene be rank fourth ibd company medical biom biotech industry group composite rating meaning perform top stock term key growth metric also check ibd ranking top perform stock get stock checkup best bet biotech rbc like celgene kite spark prothena prta alexion pharmaceutical alxn seattle genetic sgen evercore analyst john scottus be keep track car cell therapy juno therapeutic juno kite combination datum celgene celgene be expect unveil phase datum revlimid post stem cell transplant multiple myeloma patient expand use drive additional annual revenue help revlimid become standard care rbc say celgene stock drop close bell stock market today touch year high nov ibd company biom biotech group be close wednesday fall lilly alzheimer trial announcement evercore scottus look celgene discuss early clinical datum next generation drug used chemical cereblon cc be aim diffuse large cell lymphoma dlbcl cc treat sarcoidosis growth inflammatory cell different body part other area celgene have partner acceleron pharma xlrn anemia patient rare blood disorder agio pharma agio ag treat mutate protein be tie certain cancer scottus expect update partnership look car cell datum kite acute lymphoblastic leukemia juno last week place jcar trial clinical hold follow death patient kite also have phase dlbcl datum previous datum show overall response rate transplant chemo relapse patient likely support broad label assume presentation cr complete response remain strong rbc analyst write month durability datum be also important win be available note other key report include amyloidosis datum prothena hemophilia datum spark paroxysmal nocturnal hemoglobinurium pnh datum alexion graft vs host datum incyte incy hodgkin lymphoma datum seattle genetic rbc write related kite pharma soar cancer drug trial supportive fda approvaleli lilly alzheimer drug fail key trial lilly biogen diveamgen biogen celgene eye trump pro biotech world
963,CELG,stock index push fresh time high thursday afternoon volume continue rise nasdaq pop blue chip dow jone industrial average add respectively small cap lead russell jump volume stock market today be board turnover have trend mostly upward recent session past session winning group include steel maker consumer loan chip stock retail apparel shoe retail be bit surprise retail sector be laggard sector score new high wednesday tally surpass only red hot banking sector apparel shoe featured big gainer thursday tailor brand tlrd formerly man owner jos bank gap small cap company report surprisingly strong quarterly result wednesday close lululemon athletica lulu leap unexpectedly strong quarterly result report late wednesday rotation retail apparel be healthy stock market strength retail stock suggest increase consumer spending be ahead recent ibd tipp survey find economic optimism have surge year high stock moved early trump rally have do well example stock ibd break week presidential election go double digit gain be sometimes breakaway gap only stock didn pay be biotech celgene celg be now buy point downward move be largely fallout president elect donald trump critical comment drug price successful breakout elsewhere confirm wisdom old ibd rule stock market go uptrend do nov individual investor try buy least buy additional breakout first stock work then uptrend come pressure dec then signale resume uptrend wednesday individual investor again be shopping breakout buy related be apple fang stock ready join trump rally
964,CELG,share rival kite pharma kite juno therapeutic juno tank tuesday follow presentation annual american society hematology ash conference spark therapeutic once stock enjoy third day black compelling gene therapy datum kite juno be investigate chimeric antigen receptor cell therapy therapy treat variety cancer compete like celgene celg bluebird bio blue amgen amgn car cell therapy engineer patient immune cell treat cancer monday tuesday ash juno kite present result car cell therapy battle aggressive hodgkin lymphoma face result juno treatment be stronger show overall response complete response vs kite objective response complete response rbc analyst michael yee be skeptical competitive wise come away ash juno jcar do not look significantly better kite lead kte kite be least year ahead view write research report juno be say market early believe be stretch think ibd take allergan recently buy gene therapy world acquisition retrosense therapeutic analyst say company approach differ meanwhile allergan ceo have pledge abstain predatory pricing gene therapy yee be await month datum kite juno see complete response drop month cr fall month mark write research report suggest be erosion kite month anything be still very good juno strong hodgkin lymphoma result follow death patient car cell trial relapse refractory cell acute lymphoblastic leukemia juno temporarily place trial clinical hold share topple nov result strong result kite juno stock fall stock market today kite stock fall earlier plunge much yee blame short seller take profit deluge juno stock topple much record low end day spark stock other hand continue gain tuesday share rise third day follow spark pfizer pfe hemophilia gene therapy presentation sunday spark make ipo share price hemophilia patient have miss defective factor ix clot protein patient infuse spark pfizer gene therapy spk show mean factor ix activity level greater week post infusion first patient reach year post treatment show factor ix level normal spark say key opinion leader kol lunch yee call spark pfizer therapy compelling phase datum show factor ix then kol absolutely consider patient write related celgene kite spark look sidestep eli lilly alzheimer flop
965,CELG,amgen amgn biogen biib celgene celg gilead science gild look follow donald trump election set fewer regulatory hurdle likely biotech resurgence rbc analyst michael yee say monday biotech stock have surge trump election largely notion be less likely pressure drug price hillary clinton likely push business friendly legislation include tax incentive repatriate cash election uncertainty yee expect big biotechs make good plan capital remain inexpensive organic growth slow trump appear poise embrace innovation administration yee write research report monday ibd take biotechs aren alone experience trump effect defensive stock be furious upswing follow election get defensive stock now get ibd industry theme answer end trump meet patrick soon weekend soon be biotech exec former ceo abraxis bioscience celgene acquire tell come trump meeting soon yee note regardless investor be start key pro biz environment election share ibd company medical biom biotech industry group spdr biotech etf xbi be nearly ishare nasdaq biotech etf ibb be more bar big policy surprise trump be increase feel pro business include pro biotech gop yee write so see unlikely major legislation derail innovation increase be merely begin yee write note good thing happen believe stock go much higher alzheimer datum late early eli lilly lly be catalyst biotechs also likely update guidance january potentially push stock higher biotech celgene be most risk postelection world term catalyst fear big disappointment yee write celgene have multiple sclerosis datum due first half likely win raise guidance january celgene stock dip dilutive deal note view pullback buy opportunity long term tail question be sufficient pipeline long term investor want see term earning variance be less important tail question write meanwhile amgen biogen likely be uncertainty remain share biomarin pharmaceutical bmrn vertex pharmaceutical vrtx yee write biogen stock bound strong alzheimer result eli lilly amgen stock be still suffering fallout commentary enbrel pricing stock market today celgene stock lift share amgen biogen gilead be fraction vertex stock be biomarin share related small cap biotech take gilead celgene biogen alzheimer
966,CELG,half big cap be bank finance insurance sector first sector be sometimes lump together insurance also be closely related major determinant success insurance company be well invest fund aren be paid satisfy claim related sector have receive plenty attention recently partly
967,CELG,big pharma bristol myer squibb bmy rise briefly early mixed day stock market thursday guidance beat analyst expectation announce success trial cancer drug opdivo bristol myer say profit fourth quarter exclude time item be cent share year earlier quarter beating analyst consensus
968,CELG,biotech giant amgen beat analyst estimate late thursday send share fraction hour trading rough day drug stock amgen amgn earning totale year earlier quarter soundly beating analyst consensus estimate accord thomson reuter revenue rise vs analyst full year
969,CELG,biotech pharma stock sell sharply thursday busy earning week even overall market rise ibd medical biom biotech industry group hit month low stock market today be early afternoon separately ethical drug group be number company group report earning thursday
970,CELG,stock rebound early afternoon trading thursday strong earning report rebound oil price nasdaq be climb dow jone industrial average rise volume be run higher nyse nasdaq compare same time wednesday oil be climb barrel russia energy minister reportedly say saudi arabia propose oil produce country cut output bolster plunge crude price report boost oil stock such devon energy dvn jump oil gas transporter kinder morgan kmi rise more yet stock remain batter more week high elsewhere stock market today social medium giant facebook fb athleticwear maker armour ua soar quarterly earning report armour rocket report profit rise better expect same period last year gain sale chief financial officer brad dickerson also dismiss concern possible decline market share volume be huge stock retook downward slope week line facebook soar more lead ibd stock rebound day line approach new high company report profit jump cent share revenue rise figure easily beat wall street estimate facebook also report increase number daily active user downside biotech stock celgene celg drop fall further downward trend day day line disappointing quarterly earning report hawaiian holding provide passenger cargo service hawaii mainland drop more heavy volume stock be work cup type base possible buy point drop day line thursday be setback
971,CELG,big biotech biogen biib beat analyst earning estimate early wednesday send batter stock early trading biogen earning exclude time item rise year earlier quarter share beating consensus cent accord thomson reuter revenue climb wall street average estimate
972,CELG,time increase market volatility pay have manager run slightly complementary investment strategy fund say just more way diversify usaa aggressive growth fund usaux have be name suggest aggressive growth mutual fund invest large cap company strong growth trajectory mutual fund focus primarily equity also invest foreign stock fund charge fee require minimum investment top holding represent nearly fund include company such apple aapl amazon amzn google parent alphabet googl visa facebook fb home depot hd celgene celg fund carry month performance rating ibd meaning have outperformed other mutual fund period fund have return average past year be so far year vs decline large cap growth peer track morningstar inc fund advisor be usaa asset management subadvisor be actually make day day investment decision fund wellington management lead paul capital management lead clark fund long term allocation tend remain manager slight deviation couple percent major market swing have manager approach investing growth company slightly different way say wasif latif head global multus asset usaa investment so investment result be not complementary do have complementary feature time offset other degree excess return standpoint take path very aggressive growth manager seek really high growth company buy aggressively explain style say be more typical aggressive growth space wellington other hand even work same universe company used same russell growth index benchmark be not aggressive style process have additional dimension look quality company pay little bit attention valuation wellington select growth company also look stability earning growth rate valuation end happen be have manager complement other way market be very strong high momentum really focuse nothing growth then expect do really well wellington do continue match try keep market flip side choppier environment growth begin get question high growth company don get reward stock market wellington do somewhat better company use bottom approach select stock hold same name part portfolio have skilled manager actively manage space expect long course time performance add value own say latif fund have annual turnover rate low side growth fund typically hit fund have fall stock market manager haven be sit idle period end dec trim back several position include apple celgene re more week high
973,CELG,illumina ilmn surpass second quarter earning estimate late tuesday miss revenue first time year analyst expect beat raise maker gene sequence system so share suffer stock market today illumina stock gap huge volume wednesday breach day move average intraday stock be
974,CELG,new lows have mostly have strong hand week now go tuesday session combine new lows nasdaq nyse averaged previous session astounding number particularly ibd screen be abbreviated quality
975,CELG,new high
976,CELG,same period new high averaged
977,CELG,now number deserve qualifier last week new high recapture dominant position be last week monday new lows be back control
978,CELG,get stranger many day triple digit new high coexist triple digit new lows have happened half session
979,CELG,be peculiar action market uptrend peculiar be seldom word associate healthy bull market
980,CELG,context lessen worry tuesday oil mining steel utility stock laggard populate new lows tally group provide day new lows accord preliminary datum
981,CELG,laggard have be do quite bit lately be good thing market laggard be selling activity rotate money stronger group
982,CELG,still bull see situation change normal uptrend new high hold upper hand new low tally fade digit peculiar have place table
983,CELG,niche normalcy be find top rate stock continue make new high
984,CELG,tuesday google googl bound new intraday high strong volume reversed modest gain
985,CELG,facebook fb add score new high sixth time session volume be heavy
986,CELG,celgene celg pop new high volume be only moderately higher
987,CELG,edward lifescience ew also poke new high volume be fifth slower usual
988,CELG,total system service tss thrust more new high strong volume midcap company be payment system provider
989,CELG,tally new high lows engender concern be secondary gauge more certain guidance stay focuse market
990,CELG,click here view full list week new high lows new lows have mostly have strong hand week now go tuesday session combine new lows nasdaq nyse averaged previous session astounding number particularly ibd screen be abbreviated quality new high same period new high averaged now number deserve qualifier last week new high recapture dominant position be last week monday new lows be back control get stranger many day triple digit new high coexist triple digit new lows have happened half session be peculiar action market uptrend peculiar be seldom word associate healthy bull market context lessen worry tuesday oil mining steel utility stock laggard populate new lows tally group provide day new lows accord preliminary datum laggard have be do quite bit lately be good thing market laggard be selling activity rotate money stronger group still bull see situation change normal uptrend new high hold upper hand new low tally fade digit peculiar have place table niche normalcy be find top rate stock continue make new high tuesday google googl bound new intraday high strong volume reversed modest gain facebook fb add score new high sixth time session volume be heavy celgene celg pop new high volume be only moderately higher edward lifescience ew also poke new high volume be fifth slower usual total system service tss thrust more new high strong volume midcap company be payment system provider tally new high lows engender concern be secondary gauge more certain guidance stay focuse market click here view full list week new high lows
991,CELG,handful big cap stock be due report quarterly earning week only be expect post accelerate profit growth starbucks sbux report fiscal earning thursday profit be see rise cent share mark second straight quarter acceleration sale be forecast climb
992,CELG,day major average thursday session weak breadth top rate growth stock make presence feel new high list day wall street respond positively earning report chipotle grill cmg rally pop top week consolidation end low
993,CELG,major stock etfs pull modest gain close tuesday choppy trading session volume run low major exchange volatile oil price uncertain fed rate hike outlook keep most investor sideline wti crude future dive barrel international energy agency warn demand oil ease considerably
994,CELG,linkedin lnkd be downgrade friday report weak guidance thursday celgene celg other biotechs be start market perform rating linkedin be downgrade sector perform outperform rbc capital market professional social networking site beat estimate guide earning view share plunge stock market today close lowest level december leerink swann start amgen amgn biogen biib celgene market perform rating amgen close biogen fall celgene lose tableau software datum price price target be cut security goldman sachs cut price target stock baird maintain outperform rating tableau lower price target thursday maker big datum analytic software guide loss revenue consensus forecast analyst say consumer want product amazon amzn aw quicksight vs tableau offering tableau share sank end day lowest ever close price ipo conocophillip cop price target cut rbc capital market analyst still maintain outperform rating oil company thursday conoco cut dividend oil price stay lower longer cut come just month company say dividend remain highest priority use cash conoco share fall image provide shutterstock
995,CELG,san francisco celgene celg be trading monday big biotech issue preliminary result guidance miss expectation also unveil change top management annual jpmorgan healthcare conference san francisco celgene say ep totale share year earlier quarter miss analyst
996,CELG,early stage biotech be see buyout target drug industry juno therapeutic have be do buy juno juno be several company develop chimeric antigen receptor car cell therapy cancer involve reprogramming patient cell be part immune system recognize cancer cell
997,CELG,stock reversed higher close bell monday end session skid rout china stock market further drop oil price
998,CELG,dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum
999,CELG,energy mining biotech stock lag department store hospital tobacco stock lead upside
1000,CELG,aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session
1001,CELG,macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd
1002,CELG,sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman
1003,CELG,company due report quarterly result tuesday include csx csx ihs ihs
1004,CELG,labor department be due release closely watch job opening labor turnover survey jolt tuesday stock reversed higher close bell monday end session skid rout china stock market further drop oil price dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum energy mining biotech stock lag department store hospital tobacco stock lead upside aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman company due report quarterly result tuesday include csx csx ihs ihs labor department be due release closely watch job opening labor turnover survey jolt tuesday
1005,CELG,biotechs be once again strong wednesday nyse arca biotechnology index hit time high top rate name stage breakout celgene celg gap rally share be much intraday stock stage breakaway gap past buy point cup handle base volume swell
1006,CELG,stock future be generally higher ahead wednesday open busy earning calendar kick premarket trade
1007,CELG,dow future be high still point fair market value nasdaq future be also hour earlier high point point respectively
1008,CELG,small cap lag russell future show point loss
1009,CELG,federal open market committee policy announcement be main distraction barrage earning activity stock market today fed isn expect stance raise rate sometime year offer clarity timing ramp future increase play
1010,CELG,decent rally tuesday left nasdaq fractional gain so far week be vs friday close uptrend be struggle nasdaq be just be just respective day move average be back midsection dead zone trading range have box market march
1011,CELG,fed economic calendar be otherwise light june pending home sale number be expect national association realtor et weekly oil inventory report energy information administration be
1012,CELG,quarterly report merger news bring stock low broil ahead open big name make dramatic move right left
1013,CELG,upside buffalo wild wing bwld leap citrix system ctxs jump cytec industry cyt spiked belgium base solvay svyzy agree buy specialty chemical maker deal value
1014,CELG,yelp yelp slam report second quarter earning miss weak full year guidance company also say max levchin have resign effective immediately role chairman director immediate replacement be name deutsche bank cut stock rating hold buy lower price target yelp share be deep month correction
1015,CELG,twitter twtr drop report sale earning consensus expectation late tuesday microblogging service follow ep gain surge revenue guidance revenue gain
1016,CELG,gain member disappoint expectation stock have be chop deep correction month end tuesday november ipo price
1017,CELG,security software developer vasco datum security international vdsi tumble premarket trade oakbrook ill base firm report late tuesday earning revenue comfortably top consensus expectation management hold prior guidance full year revenue be analyst consensus stock have pull back sharply june high have be struggle hold support week move average
1018,CELG,tableau software datum also dive bell developer business analytic software easily clear revenue estimate adjust earning rise cent beating expectation penny decline unadjusted figure show cent share loss share end tuesday extend early july rebound week support
1019,CELG,overseas china market bounce even day gain shanghai composite left index nearly vs friday close japan tokyo nikkei dip europe top index hadn moved much start level midday
1020,CELG,dollar edge oil be west texas intermediate barrel less so far week gold be steady ounce friday settle price bond be shade lift year yield basis point stock future be generally higher ahead wednesday open busy earning calendar kick premarket trade dow future be high still point fair market value nasdaq future be also hour earlier high point point respectively small cap lag russell future show point loss federal open market committee policy announcement be main distraction barrage earning activity stock market today fed isn expect stance raise rate sometime year offer clarity timing ramp future increase play decent rally tuesday left nasdaq fractional gain so far week be vs friday close uptrend be struggle nasdaq be just be just respective day move average be back midsection dead zone trading range have box market march fed economic calendar be otherwise light june pending home sale number be expect national association realtor et weekly oil inventory report energy information administration be quarterly report merger news bring stock low broil ahead open big name make dramatic move right left upside buffalo wild wing bwld leap citrix system ctxs jump cytec industry cyt spiked belgium base solvay svyzy agree buy specialty chemical maker deal value yelp yelp slam report second quarter earning miss weak full year guidance company also say max levchin have resign effective immediately role chairman director immediate replacement be name deutsche bank cut stock rating hold buy lower price target yelp share be deep month correction twitter twtr drop report sale earning consensus expectation late tuesday microblogging service follow ep gain surge revenue guidance revenue gain gain member disappoint expectation stock have be chop deep correction month end tuesday november ipo price security software developer vasco datum security international vdsi tumble premarket trade oakbrook ill base firm report late tuesday earning revenue comfortably top consensus expectation management hold prior guidance full year revenue be analyst consensus stock have pull back sharply june high have be struggle hold support week move average tableau software datum also dive bell developer business analytic software easily clear revenue estimate adjust earning rise cent beating expectation penny decline unadjusted figure show cent share loss share end tuesday extend early july rebound week support overseas china market bounce even day gain shanghai composite left index nearly vs friday close japan tokyo nikkei dip europe top index hadn moved much start level midday dollar edge oil be west texas intermediate barrel less so far week gold be steady ounce friday settle price bond be shade lift year yield basis point
1021,CELG,earning season be now high gear eye apple aapl report tuesday iphone maker deliver quarter solid profit sale growth apple isn ibd list very best stock come week company elite ibd be tap report earning starbucks sbux
1022,CELG,week list lead stock buy point include healthy dose medical name biotechs manage care provider biotech revival begin prior celgene celg jump wednesday buy receptos rcpt celgene be extend past cup handle buy point gilead science gild be still play entry find support week move average move didn create new buy opportunity occur buy point stock be buy zone also buy range be regeneron pharmaceutical regn trading just flat base buy point pattern be late stage be not surprising give eye drug maker advance past year unite therapeutic uthr hasn yet break near buy point late stage flat base ibd stock lead drug be orenitram remodulin get composite rating biotechs moved ibd industry group week hospital claim top spot vs week back represent rank generic drug group allergan agn be just handle buy point clear monday formerly know actavis botox makerad double chin injection kybella june buy kythera mallinckrodt mnk also generic drug maker be work month consolidation buy point stock look poise third straight weekly gain close week line other medical stock ethical drug maker valeant pharmaceutical vrx be build flat base entry canadian company be leader rank group highest possible composite rating molina healthcare moh provider manage health care service low income family be near flat base buy point stock sharing composite manage care group
1023,CELG,be savvy equity portfolio manager let get more specific do consistently practice sound technique follow smart rule time enable boost wealth outperform market ibd be only major news organization country regularly present reader set proven buy sell rule investor corner educational column enter stock timeliest way possible capture much gain upside best merchandise market minimize drawdown raise cash selling loser quickly take gain way market be top buy sell rule however be just facet practice smart portfolio management else learn know biggest debate investment history be much little invest particular stock let alone much be devote equity first place investor be often advise diversify stock portfolio minimize risk ibd research show actually less risky more reward own just several carefully choose stock monitor carefully watch free ibd webinar portfolio management nov best result be achieve concentration putt egg few basket know well watch very carefully ibd founder chairman william neil write make money stock be sure diversification lower risk reduce investor exposure stock big portfolio name be unwieldy lead confusion weak return keep thing manageable more stock own harder be keep track neil write enter full blow bear market just sit think stock be fine strategy prove disastrous wall street debacle industry group market be spare even dow utility average fall more correlation risk sector equity market be too high ignore remember market have gallop higher year stock bottom choose limit number stock be follow easily involve first create watch list focuse industry lead company top notch fundamental matter be individual trader financial advisor always conduct thorough research buy stock person invest limit holding stock consider buy most stock limit holding stock neil write once watch list have be create investor job be make sure market be confirm uptrend choose stock be hit buy point form sound basis big picture column accompany market pulse table stock checkup tool find research section investor com be excellent place research current market condition individual stock research doesn end stock have be buy important keep eye fundamental development chart pattern difficult task big portfolio often stock have break go form week tight pattern other structure offer secondary buy point allow investor add share concentrate more money such winner be effect give portfolio chance compound gain very best decision now call give portfolio fuel power big total return other case further research reveal new stock look poise strong run result be best sell lag stock move cash new better perform stock portfolio winning investor objective be have big winner rather dozen very small profit neil say diversification add be plainly simply often hedge ignorance gain much jan high april accompany table stock break dec market follow show possible beat market priceline group pcln invensense invn other be able enrich investor portfolio faster priceline moved buy point high cut day line investor sell still reap profit celgene celg go become big winner ibd leaderboard breaking again january en route big gain next year editor note column originally run june edition ibd related arrive trump case new secular bull marketknow follow buy pattern week tight other advanced chart pattern
1024,CELG,market go back confirm uptrend latest week ibd soar mean growth investor ve make money hand fist right maybe still challenge environment growth stock especially donald trump presidential victory see money rotate several high profile technology name financial steel infrastructure health
1025,CELG,president elect donald trump be likely take affordable care act meaning biotech drug stock aren clear follow hillary clinton defeat analyst say wednesday year political pressure industry clinton be see more likely wage bureaucratic battle excessive drug price trump republican ally have repeatedly blast aca know obamacare president elect promising repeal replace get something great legislation have tragically predictably result runaway cost website don work greater rationing care higher premium less competition fewer choice trump say obamacare have raise economic uncertainty single person reside country trump propose system base free market principle hasn delve specific tuesday republican also retain majority house senate make trump path repeal aca easier such repeal hurt drug stock be unknown add uncertainty industry weigh ibd take biogen be head experimental spinal muscular atrophy drug partnership ionis close be biogen stock check industry theme skinny hospital stock tank wednesday trump biotech drug stock ride clinton wave rise likelihood trump win go excessive drug price republican congress probably win touch medicare reform ibd company biom biotech industry group jump midday trading stock market today company ethical drug climb company generic drug group surge tuesday close group have be respectively year lift likely be short live rbc analyst michael yee say advise investor buy brexit dip broader market likely assume risk environment sell short term trump uncertainty emotion say biotechs bounce don see anything fundamentally be negative biotech yee write research report recommend celgene celg biogen biib vertex pharmaceutical vrtx biomarin bmrn prothena prta stock biomarin vertex lead way midday wednesday vertex soar biomarin surge celgene stock skip gain prothena catapult biogen climb tuesday election result best case scenario biotechs yee say president congress less likely meddle drug pricing proposition california fail prop have limit state agency spending prescription department veteran affair pay sen bernie sander lose clinton primary be major proponent prop republican senate sander name be likely lose power yee see unlikely ll be tap chair health labor education pension help committee related drug stock rally relief clinton didn white houseclean energy stock plunge trump winapple microsoft eye trump overseas cash tax plan
1026,CELG,small cap biotech axovant science axon pull sale alzheimer drug rbc analyst michael yee say tuesday pit big player gilead science gild celgene celg biogen biib eli lilly lly early tuesday axovant report loss tell investor expect wrap key phase trial alzheimer drug intepirdine year end yee expect datum mid see probability success phase intepirdine alzheimer drug result time potential upside yee write research report have outperform rating price target axovant stock axovant stock topple stock market today share be month low follow earning report loss share ex item widen cent cent year earlier quarter analyst expect cent loss axovant make initial public offer june pricing share company hasn yet report sale ibd take biotech stock be trading positively third consecutive day biogen be leader pack early efficacy phase trial spinal muscular atrophy drug conjunction ionis get full scope industry theme alzheimer market be huge big player gilead celgene biogen eli lilly look take chunk axovant most closely rival danish drugmaker lundbeck have phase trial due drug idalopirdine intepirdine idalopirdine have similar mechanism be ht antagonist aim assist cognition memory lundbeck idalopirdine have safety issue yee give only probability success lundbeck idalopirdine be used dose level need due safety issue drug thus not overly read be negative yee write research report axovant be also testing nelotanserin treat visual hallucination symptom alzheimer lewy body dementia datum be expect february phase trial patient yee note consensus have expectation trial consider size datum be great strong numerical reduction hallucination believe see move axovant vs minor downside negative write note alzheimer datum later year be more important stock related eli lilly revenue ep miss ceo praise drug pipeline
1027,CELG,biotech stock climb third consecutive day tuesday mid cap tesaro tsro forge way largest company amgen amgn gilead science gild celgene celg be buyable now say mizuho analyst salim sy sy initiate coverage tuesday amgen gilead celgene stock buy rating also initiate biogen biib neutral rating lack medium term catalyst uncertainty former ceo george scango resign july be clear still think biogen have good program be matter time get excited again just not right now sy write research report have price target biogen stock slip cent tuesday ibd company medical biom biotech industry group lift fraction stock market today volatile election season have strangle share cause group topple past week ibd take sy have neutral rating biogen stock share be look better biogen ionis announce early efficacy phase testing spinal muscular atrophy drug check industry theme full take sy liken amgen jogger have price target stock fraction tuesday amgen most recent call thought amgen largely hum steady stock jogger write however amgen call week stock have come enbrel commentary call spook investor say sale be flat give contract negotiation amgen expect relatively little benefit net selling price change enbrel wall street have be predict decline amgen legacy business time sy see silver line new drug amgen repatha cholesterol bust pcsk rival sanofi sny regeneron regn praluent repatha already have food drug administration approval sale have suffer restrict access sy write repatha be currently phase testing treat cardiovascular outcome september meet primary secondary endpoint phase test coronary artery disease cv datum be expect sy call most important datum event amgen positive event pull amgen stock dump share hit year low friday manage close fractionally day gilead manage impossible launch hepatitis hcv drug sovaldi harvoni triple revenue become company sy write separate report duo be cure hcv therefore win last forever flip side develop cure be eventually disease be eradicate write great patient mean decline revenue time have be weigh gilead stock answer slope decline isn exactly clear gilead hep trio sovaldi harvoni epclusa bring sale vs year earlier quarter epclusa launch june july europe help offset decline sovaldi harvoni sy model year year decline hcv sale gilead gilead be work next leg growth sy say have price target gilead stock nonalcoholic steatohepatitis nash hepatitis hbv drug be still too early pipeline gilead be face nash competition intercept pharmaceutical icpt allergan agn gilead isn table pound buy stock be undervalue company likely perform time reward patient investor sy write gilead stock rise cent tuesday celgene be castle chemotherapy drug revlimid be moat sy say revlimid sale grow vs last year drive new market share gain increase duration revlimid be used treat myelodysplastic syndrome mds multiple myeloma mantle cell lymphoma mcl revlimid allow celgene grow next source revenue sy write separate report revlimid be still grow part business value add celgene part business be fairly well establish mature moat celgene have cancer drug durvalumab car conjunction astrazeneca azn juno therapeutic juno respectively celgene be also work next generation replacement revlimid be expect go generic be fully generic core celgene have ozanimod currently phase testing multiple sclerosis ulcerative colitis ged investigational crohn disease drug be central celgene investment thesis say sy have price target celgene stock rise tuesday related biotechs be derisked buyable ahead election day amgen gilead eli lilly eat abbvie humira sale analystgilead nash drug active promising lag challenge intercept tobira nash drug
1028,CELG,lead tech stock tumble last week mutual fund sell share like facebook apple amazon google manager franklin dynatech fund ibd best mutual fund award winner isn panic judge dynatech fkdnx lowly portfolio turnover rate comment lead manager matthew moberg power drive growth several key holding fund remain hitch big way market lead stock dynatech have outsized bet technology weighting june accord franklin templeton sort megabet single sector make fund volatile fund performance be consistent well strong fund be so far year oct be dynatech return top peer track morningstar inc averaged gain fund generate average annual return past year fund be ibd best mutual fund award winner have outperformed year period end dec only diversify stock fund meet standard be top category equity large cap growth fund click here see list ibd mutual fund month leadersmoberg year old have be shepherd dynatech talk ibd investment approach office san mateo calif ibd matthew do fund have such large technology weighting moberg fund focus innovation growth name dynatech stand dynamic technology define dynamic force stimulate change progress innovation be bulk wealth creation occur view broad mandate re able look innovation anywhere believe need active management invest innovation part market be often misunderstand person believe be too expensive too unknown so area look mean opportunity get overlooked click here see list mutual fund category performance leadersibd be current tech weighting typical fund moberg be high sector classification change amazon amzn be now classify consumer discretionary stock early be tech visa mastercard be holding re still consider information technology company argue be financial look innovation be find lot place ibd health care be second largest sector weighting hotbed innovation right moberg not great year health care election candidate talk price control yes lot innovation see possibly emerge treatment disease hepatitis cystic fibrosis even cancer ibd be name space moberg celgene celg incyte incy click here see list biggest mutual fund rank performanceibd be fund performance consistent be diversify expose other sector not just tech health care else moberg yes be diversify consistency be also due fundamental research sometimes find stock market doesn appreciate quickly come market best example be facebook fb launch mobile ad first quarter only do revenue be total revenue year month later mobile be do more advertising revenue cbs similar quarter technology adoption be accelerate world be more global investor often don appreciate fast new technology rise so try think long term short term performance be just byproduct think long term ibd take see facebook other highly rate stock be proper buy point visit ibd leaderboard ibd part facebook story do most now moberg first mobile usage mobile ad be more effective other ad argue facebook probably have best set mobile application runway growth second re start monetize instagram person share picture next step be monetize messenger whatsapp usage have be explosive good chance go commerce rather remain solely social activity finally re think monetize year oculus make virtual reality headset be interesting acquisition facebook didn pay much probably monetize year have long runway messenger whatsapp ibd edward lifescience ew seem be benefit new management fiscal discipline key new product transcatheter aortic value replacement tavr moberg yes right now re go very nice product cycle tavr have rough start now tavr be example sensational innovation enable patient avoid need open heart surgery crack open rib cage make giant incision instead put tavr artery small incision patient spend less time hospital go less pain iteration valve get smaller easier insert product cycle last year re also work something mitral valf be harder reach hope expect be leader field well do double addressable market ibd edward have disappointing sale stock plummet have change outlook company stock moberg remain positive edward lifescience edward be still early stage capture transcatheter aortic valve replacement opportunity share so market be only third penetrate stock also fail account potential transcatheter mitral valve replacement opportunity mitral valve disease be twice prevalent aortic valve disease have face misstep new product again world doesn work linearly believe be excellent business ibd ll make wild guess be not investor find amazon product experiment wasteful moberg re incredibly innovative re continually investing new thing ve have big success first be prime get money upfront consumer drive usage amazon significantly second be let third party sell fulfillment amazon require investment inventory generate higher margin addition have amazon web service be increasingly important fastest grow software service company ever amazon continue invest find new idea ve have quite few failure way understand need take risk succeed attitude give confidence continue growth ibd concern amazon miss result sign more weakness come moberg have go many investment cycle past step up investment don always fact rarely work quarterly report cycle understand long term amazon have have very good return invest capital prefer grow organically have culture innovation didn see anything quarter suggest be longer case ibd pioneer natural resource pxd be somewhat new portfolio have straight quarters slow earning thesis moberg invest small position see do try hold long term anything fundamental change right add pioneer be best position oil service be lowest price producer think oil stabilize barrel range ibd do chinese online gaming company netease nte moberg believe gaming space be secular winner netease have game have do well secular trend gaming be better china be very strong see more virtual reality different kind game way person spend leisure time play game ibd do still broadcom avgo much used moberg don believe be innovative used be most accelerate earning share be due consolidation prefer company innovation be first still be do great job buy company rationalize cost raise price ceo be incredibly well thought chipmake industry execute strategy extremely well re pleased someone be take lead start consolidation industry ibd nvidia nvda be relative newcomer portfolio do chipmake moberg be view provider graphic chip pcs then expand make chip game console now re break free prison make central process unit virtual reality re also need car autonomous drive also hyperscale server re used co processor cad cam artificial intelligence total addressable market be explode think lot sustainability company long trajectory earning growth ibd have exposure pet care industry do moberg shocking well treat animal now vs year cancer treatment ct scan be unavailable year so secular trend company most have own longer have largest position be idexx lab idxx idexx be particularly well position business competitively give unique ability single handedly bundle outsourced diagnostic practice diagnostic instrument idexx also offer superior information management capability regard animal diagnostic report record keep relative competitor ibd special aspen technology azpn software firm moberg do supply chain management process industry software be so important even company go bankrupt pay aspen bill be backbone many company have tremendous operate margin profitability competition be serious large company need technology customer be incredibly sticky ibd tell co manager moberg be lead manager fund be founder rupert johnson co manager be fund first manager know be also vice chairman franklin resource ibd matthew person often wonder portfolio manager do hour moberg used run mile week used have hobby now have year old re hobby forget mention avid reader history be history major college find useful look micro trend adoption rate period major minor innovation pattern recognition new technology well macro trend low interest rate federal reserve action period government response related top mutual fund manager capture solid return messy top mutual fund manager win flavor growth hartford growth opportunity fund target stock fidelity contrafund manager play downturn
1029,CELG,san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday
1030,CELG,news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction
1031,CELG,celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate
1032,CELG,celgene be schedule report final earning jan
1033,CELG,celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue
1034,CELG,nonetheless celgene add cent ep guidance have already raise last summer
1035,CELG,celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business
1036,CELG,scott head inflammation immunology business add role chair global management committee
1037,CELG,regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line
1038,CELG,speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch
1039,CELG,analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early
1040,CELG,believe investor debate change result alle do go forward yee say research note
1041,CELG,celgene stock slide monday
1042,CELG,illumina team bill gate
1043,CELG,illumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample
1044,CELG,monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference
1045,CELG,also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year
1046,CELG,flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however
1047,CELG,flatley also say expect revenue grow year line consensus ep guidance share be street estimate
1048,CELG,vertex key drug beat
1049,CELG,vertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore
1050,CELG,new cf drug orkambi launch summer sell hair consensus
1051,CELG,year company forecast kalydeco sale operate expense didn forecast orkambi sale
1052,CELG,kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year
1053,CELG,say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate celgene be schedule report final earning jan celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue nonetheless celgene add cent ep guidance have already raise last summer celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business scott head inflammation immunology business add role chair global management committee regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early believe investor debate change result alle do go forward yee say research note celgene stock slide monday illumina team bill gatesillumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however flatley also say expect revenue grow year line consensus ep guidance share be street estimate vertex key drug beatsvertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore new cf drug orkambi launch summer sell hair consensus year company forecast kalydeco sale operate expense didn forecast orkambi sale kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year
1054,CELG,month so talk big pharmas shire baxalta early monday announce merger value say create company drug treat rare disease
1055,CELG,ireland base shire shpg pay baxalta bxlt shareholder cash shire ad american depositary share share own say come baxalta share base friday close price
1056,CELG,shire stock fall monday be july peak baxalta stock fall monday baxalta stock hit time high thursday gain last week expectation takeover be market worst first week trading ever shire stock fall last week
1057,CELG,company expect deal close midyear pending regulatory shareholder approval say transaction value bannockburn ill base baxalta premium stock price aug have disclose aug negotiation have be ongoing least july shire make unsolicited offer baxalta baxalta share
1058,CELG,baxter international bax spun baxalta july bid unlock shareholder value biopharma operation hold medical product business baxalta retain franchise bloodderive treatment disease such hemophilia primary
1059,CELG,shire ceo flem ornskov statement monday say deal allow realize vision build lead biotechnology company focuse rare disease
1060,CELG,together have leadership position multiple high value franchise become clear partner choice rare disease expand portfolio presence more country drive growth anticipate annual revenue
1061,CELG,baxalta ceo ludwig hantson statement say baxalta shareholder receive substantial immediate value well ongoing stake combine global leader rare disease strong growth prospect
1062,CELG,company say combination emerge rare disease platform revenue pipeline depth product especially hematology immunology neuroscience lysosomal storage disease endocrine treatment hereditary angioedema
1063,CELG,shire say merger create operate cost synergy gaap earning be accretive month so talk big pharmas shire baxalta early monday announce merger value say create company drug treat rare disease ireland base shire shpg pay baxalta bxlt shareholder cash shire ad american depositary share share own say come baxalta share base friday close price shire stock fall monday be july peak baxalta stock fall monday baxalta stock hit time high thursday gain last week expectation takeover be market worst first week trading ever shire stock fall last week company expect deal close midyear pending regulatory shareholder approval say transaction value bannockburn ill base baxalta premium stock price aug have disclose aug negotiation have be ongoing least july shire make unsolicited offer baxalta baxalta share baxter international bax spun baxalta july bid unlock shareholder value biopharma operation hold medical product business baxalta retain franchise bloodderive treatment disease such hemophilia primary shire ceo flem ornskov statement monday say deal allow realize vision build lead biotechnology company focuse rare disease together have leadership position multiple high value franchise become clear partner choice rare disease expand portfolio presence more country drive growth anticipate annual revenue baxalta ceo ludwig hantson statement say baxalta shareholder receive substantial immediate value well ongoing stake combine global leader rare disease strong growth prospect company say combination emerge rare disease platform revenue pipeline depth product especially hematology immunology neuroscience lysosomal storage disease endocrine treatment hereditary angioedema shire say merger create operate cost synergy gaap earning be accretive
1064,CELG,stock fall red early afternoon trading initially shrug rout china stock market nasdaq shed dow jone industrial average volume be mixed tracking lower nyse higher nasdaq loser top winner margin nyse nearly nasdaq energy gold miner biotechs lag stock market today department store hospital tobacco stock lead upside macy rise volume struggle stock be week high investment advisory firm starboard value monday say support department store recent joint venture mall base real estate property report say other department store stock kohl kss rally dd cruise ship operator also sail ahead carnival ccl jump heavy volume find support day move average now back buy point initially clear dec analyst expect earning grow fiscal rival cruise line royal caribbean cruise rcl lift fast trade track snap session decline stock be still day line have slip back flat base biggest loser ibd be celgene celg sank lowest level month stock have be consolidate july now slump day line biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman top ibd gainer be aerospace gear maker transdigm tdg retake day day line share be work flat base potential buy point follow nancy gondo twitter ibd_ngondo facebook
1065,CELG,etf investor get taste snap back market action be hope tuesday choppy trading session major index steady modestly sharp drop kick stock reversed lower intraday oil briefly dip barrel first time december however etfs tracking dow finished higher well session lows health care help lead advance sector utility real estate post loss powershare qqq qqq tech biotech heavy exchange trade fund pop stock market today etf be dec high stock holding celgene celg jump illumina ilmn vertex pharmaceutical vrtx give regeneron regn investor seem have digest monday biotech related news big biotechs celgene vertex have offer mixed outlook major investor conference cause disappointment illumina meanwhile announce new unit call grail focuse detect cancer early simple blood sample apple aapl hold qqq portfolio weighting gain tuesday iphone maker stock briefly re-cover level first time day buoy analyst upgrade well rumor cheaper base model iphone apple electric car stock be week high diving deeply day move average december spdr biotech xbi surge massive volume however equal weight etf hold stock be july high xbi monday undercut late september lows be spur presidential candidate hillary clinton comment price gouge drug industry recent slump analyst rbc capital market be report reaffirm confidence growth prospect biotech sector tuesday note ishare nasdaq biotechnology ibb advanced cap weight etf also breach late september low monday be week high hold stock biggest stake celgene biogen biib amgen amgn gilead gild regeneron regn xbi smaller cap skew help give performance boost rise vs gain ibb gold dollargold price fall third straight session tuesday gold price be moderately lower tuesday more profit take chart consolidation follow recent gain see price hit month high late last week jim senior technical analyst write commodity monitor kitco news less anxious world market scene day firmer dollar index be also help pressure safe haven gold market etf bullish dollar extend gain retake day line monday greenback rise vs other major world currency bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
1066,CELG,stock end strong gain higher volume wednesday bullish reversal nasdaq kick gear rise lag portion session add help strength energy stock dow jone industrial average gain blue chip index lead exxon mobil xom chevron cvx preliminary datum show volume nyse nasdaq come slightly higher wednesday level stock market today advance stock top decliner major exchange slightly more year treasury yield be unchanged investor be better mood oil price firm day top perform industry group ibd database hailed oil gas sector crude oil future settle barrel cent earlier day st loui fed president james bullard say oil precipitous drop have implication fed monetary policy go forward also say inflation expectation be fall dow component intel intc rise nearly regular session fall more hour trading report better expect earning sale health care name particularly biotech stock lead nasdaq alexion alxn amgen amgn biogen biib celgene celg regeneron regn rise connect ken shreve twitter ibd_kshreve facebook
1067,CELG,new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch
1068,CELG,capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight
1069,CELG,fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year
1070,CELG,intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer
1071,CELG,biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast
1072,CELG,enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share
1073,CELG,biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni
1074,CELG,celgene celg stock jump new high wednesday morning get several price target increase wake deal buy receptos rcpt celgene agree pay receptos announce preliminary earning beat estimate receptos lead drug candidate ozanimod be clinical testing different immunological disease be
1075,CELG,stock trade higher go lunch hour wednesday world financial market expect greece package reform demand european union
1076,CELG,nasdaq rise gain dow jone industrial average be volume be mixed nyse tracking higher tuesday nasdaq tracking lower stock market today
1077,CELG,euro be midnight deadline approach greek parliament condition impose european union get bailout market be close clock strike midnight athen news account say package reform be expect pass revolt syriza faction
1078,CELG,global ftse greece grek etf track basket greek stock rise nearly nyse
1079,CELG,federal reserve chief janet yellen tell congress fed expect economy improve interest rate rise year appear be little new testimony little discernible effect market
1080,CELG,celgene celg gap be trading higher announce purchase money lose receptos rcpt rise nomura security analyst ian somaiya say celgene get great deal
1081,CELG,news make celgene day top performer ibd index stock be higher be lower
1082,CELG,intrexon xon break cup handle base solid volume be
1083,CELG,bank america bac gap be trading higher upbeat quarterly report stock trade higher go lunch hour wednesday world financial market expect greece package reform demand european union nasdaq rise gain dow jone industrial average be volume be mixed nyse tracking higher tuesday nasdaq tracking lower stock market today euro be midnight deadline approach greek parliament condition impose european union get bailout market be close clock strike midnight athen news account say package reform be expect pass revolt syriza faction global ftse greece grek etf track basket greek stock rise nearly nyse federal reserve chief janet yellen tell congress fed expect economy improve interest rate rise year appear be little new testimony little discernible effect market celgene celg gap be trading higher announce purchase money lose receptos rcpt rise nomura security analyst ian somaiya say celgene get great deal news make celgene day top performer ibd index stock be higher be lower intrexon xon break cup handle base solid volume be bank america bac gap be trading higher upbeat quarterly report
1084,CELG,stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute
1085,CELG,dow jone industrial nasdaq climb grab gain
1086,CELG,volume be quietly mixed nasdaq lower nyse relative trade same time tuesday
1087,CELG,stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase
1088,CELG,dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list
1089,CELG,norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more
1090,CELG,conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year
1091,CELG,base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly
1092,CELG,array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum
1093,CELG,china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result
1094,CELG,leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average
1095,CELG,citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute dow jone industrial nasdaq climb grab gain volume be quietly mixed nasdaq lower nyse relative trade same time tuesday stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base
1096,CELG,etf investor be incline let big hit miss earning season pass buy exchange trade fund instant diversification sidestep single stock risk
1097,CELG,not so fast
1098,CELG,earning season be particularly important investor industry sector focuse etfs say todd rosenbluth director etf research capital iq product tend be more concentrated stock level be definitely more concentrated industry level
1099,CELG,not unusual company story revenue growth be replicate multiple time same industry
1100,CELG,earning beat not be relevant look landscape rosenbluth say
1101,CELG,company rein cost beat earning have less control person buy product service
1102,CELG,take illumina ilmn wednesday leaderboard stock report sale miss earning beat be send ibd cut list maker genetic testing equipment be top stock ishare nasdaq biotechnology ibb
1103,CELG,give illumina glum revenue picture etf investor want watch spillover effect other life science company
1104,CELG,ibb allocate asset subindustry
1105,CELG,ibb hold stock roughly asset top holding celgene celg biogen biib together company report week
1106,CELG,heavyweight be also find broadly diversify ishare core ivv far smaller amount combine portfolio weighting be
1107,CELG,etf concentration
1108,CELG,care more result ve choose ibb biotech exposure concentrated bet rosenbluth say
1109,CELG,many successful investor have biotechnology company deliver steady growth ibb have soar build past year double digit gain
1110,CELG,broader etf such ivv rosenbluth add question ask be be most company beating expectation
1111,CELG,equally important biotech investor keep mind company have earning like synergy pharmaceutical sgyp radius health rdus prothena prta ibb have small stake have early stage drug yet come market
1112,CELG,price move be tie success lack thereof clinical trial have nothing do earning
1113,CELG,more mature company stock move base well company earning revenue come relative expectation rosenbluth say
1114,CELG,ibb fall wednesday disappointing stock market news new alzheimer drug development biogen illumina nose dive post earning etf investor be incline let big hit miss earning season pass buy exchange trade fund instant diversification sidestep single stock risk not so fast earning season be particularly important investor industry sector focuse etfs say todd rosenbluth director etf research capital iq product tend be more concentrated stock level be definitely more concentrated industry level not unusual company story revenue growth be replicate multiple time same industry earning beat not be relevant look landscape rosenbluth say company rein cost beat earning have less control person buy product service take illumina ilmn wednesday leaderboard stock report sale miss earning beat be send ibd cut list maker genetic testing equipment be top stock ishare nasdaq biotechnology ibb give illumina glum revenue picture etf investor want watch spillover effect other life science company ibb allocate asset subindustry ibb hold stock roughly asset top holding celgene celg biogen biib together company report week heavyweight be also find broadly diversify ishare core ivv far smaller amount combine portfolio weighting be etf concentration care more result ve choose ibb biotech exposure concentrated bet rosenbluth say many successful investor have biotechnology company deliver steady growth ibb have soar build past year double digit gain broader etf such ivv rosenbluth add question ask be be most company beating expectation equally important biotech investor keep mind company have earning like synergy pharmaceutical sgyp radius health rdus prothena prta ibb have small stake have early stage drug yet come market price move be tie success lack thereof clinical trial have nothing do earning more mature company stock move base well company earning revenue come relative expectation rosenbluth say ibb fall wednesday disappointing stock market news new alzheimer drug development biogen illumina nose dive post earning
1115,CELG,be year forget far sector leader be concern most elite ibd stock screen lose year go thursday final trading session compare unfavorably eke rise same period most damage be do second half
1116,CELG,lead christmas child world dream quiet marshmallowy snowscape gift fresh santa sleigh full grow adult investor meanwhile dream santa rally so call santa rally start christmas eve end week later be often abuzz holiday cheer tend drive stock market higher ibd apple aapl chip supplier technology avgo biotech celgene celg alaska air group alk coffee giant starbucks sbux be best performer day christmas nike nke lag settlement take load celgenecelgene stock get huge lift week company settle lengthy patent dispute blood cancer blockbuster revlimid natco company base india want market generic version drug settlement other thing allow natco sell much generic version drug want begin celgene share finished week stock have be consolidation july jump resultsavago best know chip apple iphone jump earlier month solid report boost recent acquisition effort be more just apple supplier share jump dec day report quarterly result have be make way consolidation concern lukewarm demand iphone share climb higher week apple gain season starbucksmany compulsive coffee drinker probably get gift card holiday season starbucks ubiquitous coffee chain tuesday starbucks predict sale gift card set record christmas eve person rush buy last minute present seattle base company have cultivate loyal fan base not only coffee also newer food offering loyalty program advancement mobile payment starbucks share climb week have be grind way flat base begin november home christmas alaska airairline be busy holiday be set reap strong profit cheap oil keep fuel cost alaska air group company run alaska airline be strongest ibd airline stock week finishing week stock clear flat base dec share have settle lower still stock have find support day line nike struggle strong ordersathletic wear giant nike tuesday report fiscal earning beat view sale miss report strong growth future order be order be set be deliver next several month be key indicator demand share jump initially news concern high inventory future gross margin later sank stock stock dip week follow bill peter twitter ibd_bpeter
1117,CELG,stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe
1118,CELG,dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain
1119,CELG,stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week
1120,CELG,personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance
1121,CELG,durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change
1122,CELG,et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november
1123,CELG,dollar be mixed early wednesday vs euro yen bond slip send year yield basis point
1124,CELG,crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed
1125,CELG,mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade
1126,CELG,stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point
1127,CELG,devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp
1128,CELG,celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july
1129,CELG,micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast stock future point sharply higher be early high ahead wednesday start trade follow mixed early economic news market rally europe dow future steer point nasdaq future trade point fair market value future show point gain small cap be positive steady russell future hold point gain stock market today open day rally belt nasdaq end higher trading range tuesday index remain day move average nasdaq be position possible test line week personal spending rise november commerce department say welcome improvement october gain show line economist expectation personal income rise tad october gain better view advance durable good order be flat month sharply october downwardly revise gain better contraction project economist consensus transportation order dip vs estimate change et university michigan be schedule report final consumer sentiment estimate december commerce department give new home sale number november dollar be mixed early wednesday vs euro yen bond slip send year yield basis point crude price moved higher brent crude west texas intermediate benchmark trading tandem just barrel crude price see effect weekly inventory datum energy information administration due et metal agricultural commodity be mixed mining company appear poise rally day bhp billiton bbl rio rio freeport mcmoran fcx vale vale jump bounce oil mining issue trip rally european market send london ftse more cac paris frankfurt dax nearly much midday trade stock nike nke vault nearly lead dow well ibd list premarket action athletic wear maker report late tuesday fiscal second quarter earning top consensus forecast revenue rise just shy expectation gross margin increase more forecast primarily due higher selling price stock have be testing support week move average just flat base buy point devon energy dvn spiked devon have be highly active acquisition front month pay asset anadarko powder river basin sell san juan river holding new mexico bp bp celgene celg muster gain open drug maker announce settlement litigation vs india natco pharma partner arrow international subsidiary allergan agn pertain patent oral cancer drug revlimid celgene share have be consolidate july micron technology mu tank hurt fiscal earning result deliver late tuesday idaho base chip maker score narrow earning beat revenue miss analyst target management guide revenue earning consensus forecast
1130,CELG,week ibd list top rate growth stock add business social network linkedin lnkd computer networking company arista network anet also join be paycom software payc cloud base payroll hr company raft biotech medical technology firm strong growth also make ibd tough sector leader screen arista be new kid block sport best ep rating best year sale growth ibd company computer networking industry cloud compute trend putt network switch work datum center paycom be enterprise software industry group rank group ibd track meanwhile linkedin also leaderboard stock be sporting double digit ep revenue growth rate internet content group more tech company clamber ibd week biotech celgene celg unite therapeutic uthr musculoskeletal implant maker globus medical gmed robotic surgery system maker intuitive surgical isrg laser manufacturer ipg photonic ipgp monday biggest mover new ibd tech stock be arista network gap fifth straight trading day rise celgene give back last week rally related resolution patent dispute blood cancer blockbuster drug revlimid stock paycom be most so far year cumulative performance ibd be gain so far year index be flat follow donna howell twitter ibd_dhowell related ibd tech stock alibaba add web shopping jump
1131,CELG,celgene celg late tuesday say pay share cash receptos rcpt announce strong earning sale figure biotech giant say deal significantly enhance celgene inflammation immunology portfolio receptos have potential multibillion dollar drug ozanimod treat multiple sclerosis ulcerative colitis rise hour action
1132,CELG,good stock idea isn much use don understand re look be institutional quality stock be cyclical play probably only profit industry cycle be turnaround story involve fix company problem be fad stock run hot person tire novelty
1133,CELG,strategy target differ situation vary kind uptrend market be peg stock wrong market wrong probably lose money least make less investor be go make big money institutional quality stock operate strong uptrend most often be investor best choice however be time cyclical stock turnaround fad stock deliver good gain investor find identify great stock idea weekly review ywr also know list be good place look friday ibd screen stock score ep rating relative price strength rating mean stock be top percentile stock ibd database stock also be month high chart be list industry group chart aren print stock additional stock be list fine print list last page ywr today big net make good place look stock idea low hurdle screen pick more cyclical turnaround fad stock high hurdle screen person sneer fad stock argue such stock be dangerous win last aren serious investor well stock be dangerous fad stock have shorter life sometimes re talk be solid company indirectly benefit fad example egg producer distributor cal maine food calm ride atkin diet big stock gain other case fad develop longer last trend instance decker outdoor deck buy ugg holding august eventually turn ugg boot once popular mostly surfer broader fashion trend october october decker outdoors share rise ugg deserving much credit be used let look screen be publish ibd oct not long market low oct follow day follow day soon market low be often best time breakout retake buy point bounce week move average see minichart investor ve find institutional quality stock soon set valid entry apple aapl celgene celg ulta beauty ulta illumina ilmn skywork swks gain varied cyclical eventually offer entry landstar system lstr old dominion freight line odfl fedex fdx lennar len gain run turnaround fad be scarce market be have be choppy be take profit apple be prudent
1134,CELG,stock market often do least expect certainly have be case lately consider recent occurrence heavy distribution day count nasdaq recent week didn do much damage market fact market uptrend resume thursday nasdaq marked time close high rise higher volume show sign climax top last month ambarella amba find support week move average again rise nearly week regeneron regn be hold high series breakout late stage basis right look centene cnc be go roll massive price run back day move averageso go today market good news be action several other ibd name have be far confuse ibd rise week ahead gain gain nasdaq celgene celg gap week cup shape base wednesday rise strong volume announce plan acquire receptos rcpt just receptos key drug be multiple sclerosis ulcerative colitis treatment ozanimod not approve yet early trial have be promising celgene weekly chart look solid still buy range just buy point small cap fleetmatic fltx member wednesday list be high end buy range cup handle buy point monster beverage mnst be similar boat trade buy point meanwhile several ibd name be report earning week illumina ilmn blackhawk network hawk report tuesday close celgene valeant vrx report thursday close valeant be work late stage flat base buy point base be strengthen several tight weekly close valeant have pursue aggressive growth acquisition strategy recent year earlier year buy salix pharmaceutical scoop bausch lomb nearly profit valeant be see rise year share
1135,CELG,top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis
1136,CELG,share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move
1137,CELG,allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition
1138,CELG,also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average
1139,CELG,biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july
1140,CELG,regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break
1141,CELG,alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring
1142,CELG,ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open
1143,CELG,abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target
1144,CELG,analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early
1145,CELG,biotechs continue rebound medical related stock remain center stage week big cap accounting half list edward lifescience ew gap past cup handle buy point initially clear tuesday rbc capital market upgrade heart valve maker outperform sector outperform lift price target friday
1146,CELG,american century ultra twcux marquee name mutual fund industry have dynamite third quarter gain pop past average surge large cap growth rival track morningstar fund soar tack relatively modest advance so far mutual fund be go thursday lot be due slide technology tech related name dominate fund top holding have be investor favor recent week past week be sustain rebound name give nice boost fund tuesday wednesday name show sign do tech tech related name be top holding have ibd composite rating higher so do top new buy xilinx xlnx ibd take composite rating start run combine ibd performance rating stock poise move higher often have comp rating higher mean ve outperformed other stock term composite rating apple aapl top hold aug be oct alphabet googl be amazon com amzn be facebook fb be have portfolio weighting aug gain ground tuesday wednesday facebook xilinx rise tuesday have sell investor worry multinational company be high profile target retaliation foreign government president elect donald trump spark trade war big change fund ibd last profile information technology remain largest sector now weighting consumer discretionary have replace health care second slot weighting health care still have weighting have fall sixth position amazon combine online retail amazon web service aw cloud service platform be biggest consumer discretionary name starbucks sbux be coffee shop chain have modest comp rating share recently retook week move average sign recent downtrend be end meanwhile health care holding have already provide lift american century ultra run begin day election manage care provider unitedhealth group unh biotech celgene celg be fund top holding have comp rating respectively benefit investor rotate health care stock expectation republican congress white house ease pressure new pricing rule drug investor also expect obamacare be re-form addition market react favorably unitedhealth profitable third quarter report last month earning share rise raise guidance celgene revenue jump ep grow addition productive product revlimid pomalyst otezla abraxane celgene get multiple sclerosis treatment ozanimod acquisition receptos also be test treat ulcerative colitis mongersen be be study treatment crohn disease wall street analyst be forecasting earning growth next year donaldson dci also get postelection boost maker air liquid filtration system be expectation trump administration seek infrastructure improvement ep grow past quarters stanzas slow growth scripps network sni run national medium network have comp rating break flat base buy point monday pursuit time warner twx trump administration green light deal not show value medium content ibd take take look ibd stock checkup learn consecutive year ep growth annual return equity help make scripps stock ibd diversify medium industry group xilinx october pull back set week high have regain most loss chip designer have comp rating have ep growth past quarters step follow frame decline ep growth most recent result beat many analyst expectation stock also have dividend yield california base chipmaker industrial defense division sale rise benefit boost defense spending trump related top mutual fund play volatile marketamerican century ultra stay focuse leader
1147,CELG,president elect donald trump republican congress likely seek faster drug pipeline buoy medidata solution mdso other medical software firm keybanc analyst donald hooker say monday drug stock rise again emphasis faster pipeline come reduce drug pricing scrutiny trump plan incentivize repudiate cash credit suisse analyst kennen mackay write separate research report predict trump presidency likely keenly boost biotech sector stock market today medidata stock help lead ibd company computer software medical industry group be medidata stock be seventh straight gain hooker have overweight rating price target share say macro backdrop have improve medidata follow trump election ibd take biotech drug stock have fly trump uncertainty exist intention affordable care act check ibd industry theme full skinny rise drug price have become major political issue year hooker write research report monday instead price control suspect republican solution more likely involve regulatory reform speed approval new drug create greater competition trump make drug development great again quip hooker see organic growth medidata give likely improve regulatory legislative landscape information technology drug development medidata have enterprise deal bristol myer squibb bmy celgene celg biogen biib boehringer ingelheim ibd biotech industry group rise day election fall thursday friday company group be monday ibd company generic drug group have rise day election be monday hope trump regulation help industry democratic nominee hillary clinton be see tougher runaway drug price september biotech industry see stock tumble clinton call former turing pharmaceutical ceo martin shkreli boost cost decade old hiv pill september mylan myl draw national ire raise price pair epipen mylan allergan agn teva pharmaceutical teva be handful drugmaker currently investigation department justice allege price collusion trump likely win push back drug pricing mackay say investor be more bullish sector give trump proposal incentivize return cash still caution health care pricing be area mr trump make concession democrat write research report seattle genetic sgen stock react richly trump election note related incyte recoup loss price fix fracas strong chemo resultsmylan third quarter earning fall short stock steady
1148,CELG,stock index slip midday thursday surprisingly strong volume eve gdp report nasdaq clip be essentially flat blue chip dow jone industrial average add volume stock market today exchange be tracking higher wednesday level market risk remain elevated distribution day nasdaq sign institutional selling make tough environment stock make meaningful headway ibd take investor shouldn trash other investment strategy still best be aware argument surround market timing buy hold first take gdp be release friday morning open street expect growth be best past quarters range estimate span index weren do much thursday few stock outperformed big cap biotech celgene celg gap volume more average company top street estimate earning nearly revenue come more expectation maker therapy cancer inflammatory disease also raise guidance celgene chart have work do stock be week high stock most recent come july celgene clear base larger consolidation however double bottom pattern entry lack prior uptrend fail qualcomm qcom gap news mega cap company acquire nxp semiconductor nxpi regulatory reviews deal isn expect close late nxp rise thursday news have be rumore late september stock make big move pipeline play antero midstream partner be gap hit week high stock be somewhat thinly trade have deliver triple digit earning gain past quarters antero report quarterly result wednesday beating street estimate top bottom line economic news first time jobless claim be bit more expect durable good order september miss consensus target prior read be revise upward pending home sale september top street estimate
1149,CELG,stock remain well underwater head final hour trading tuesday global growth concern fall commodity price fed uncertainty continue weigh nasdaq slump dow volume be tracking higher nyse lower nasdaq stock market today vs same time monday nearly industry group track ibd be few buck decline be auto part retailer group get lift autozone azo gain fast trade auto part store operator report fiscal result open top view mobile home recreational vehicle maker biotechs drugmaker be biggest loser thor industry tho weigh mobile home group drop heavy trade late monday airstream maker fiscal result miss view biotechs continue bleed aftermath democratic presidential candidate hillary clinton monday tweet price gouge specialty drug maker highly rate biotechs sucampo pharmaceutical scmp sank amgen amgn lose celgene celg slide aside handful gainer ibd stock decline board biggest loser be horizon pharmaceutical hznp illumina ilmn valeant pharmaceutical vrx alaska air group alk lose more facebook fb fall day move average threaten end session streak share be work new consolidation potential buy point follow nancy gondo twitter ibd_ngondo
1150,CELG,stock be still hard pare loss head last hour thursday trading session nasdaq lose dow jone industrial average fall give volume swell board vs same time wednesday decliner outpaced advancer nearly nyse more nasdaq gold miner utility nonalcoholic beverage stock lead scant list outperformer stock market today downside be lead construction gear maker solar medical stock biotechs continue take beating democratic presidential candidate hillary clinton tweet monday allege price gouge specialty drug maker lead biotechs sizable loss include sucampo pharmaceutical scmp celgene celg gilead science gild regeneron pharmaceutical regn be upside diamond food dmnd reclaim day move average soar month high massive trade maker emerald nut pop secret popcorn other snack have tap credit suisse explore potential sale accord kellogg snack food jjsf pepsico pep be potential suitor ibd stock paycom software payc be biggest loser slumping heavy trade day move average first time month company provide cloud base payroll human resource software also enterprise software group paylocity hold pcty gap fall fast turnover breach day line payroll software maker late wednesday announce secondary offer share follow nancy gondo twitter ibd_ngondo
1151,CELG,health care etfs revive tuesday major stock index trade mixed investor eye higher oil price stock sell china surprise interest rate cut india spdr spdr dow jone industrial average ishare russell close monday correction territory more week high biotech stock take chin monday lead rally tuesday morning ishare nasdaq biotechnology ibb pop be week high largest most popular exchange trade fund segment ibb hold roughly nasdaq list biotech stock biogen biib stock ibb have largest stake lead advance top holding gain gilead gild celgene celg amgen amgn regeneron pharmaceutical regn climb health care select sector spdr fund xlv rise stock market today boost biotech surge international etfs india marched ahead japan bring rear india earning epi jab higher top holding hdfc hdb india largest private bank advance nearly infosys infy outsource firm oil energy fund lead commodity higher gold ease fraction here look benchmark exchange trade fund be perform today follow daily etf market action be critical investment success bellwether etfs spdr spy rs powershare qqq qqq rs ishare russell iwm rs sdpr dow jone industrial average dium rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs ishare core mid cap ijh rs spdr gold share gld rs powershare db dollar bullish uup rs ishare core aggregate bond agg rs follow aparna narayanan twitter ibd_anarayanan
1152,CELG,strong open stock fade early afternoon trading monday
1153,CELG,nasdaq reversed early gain fall tech rich composite be hurt weakness biotech stock apparently trigger tweet presidential candidate hillary clinton complain exorbitantly high price certain ethical drug edge higher dow jone industrial average rise nearly nyse nasdaq volume be tracking lower friday level stock market today economic news exist home sale drop sharply august national association realtor say annualize pace economist consensus have expect mild slowdown july pace lennar len pop early reversed loss more open miami base homebuilder report stronger expect fiscal sale earning tesla motor tsla be high still gain work new base buy point chipmaker atmel atml soar germany base dialog semiconductor say buy atmel cash stock deal value deal be expect close wedbush topeka fbr capital downgrade atmel follow news oil gas stock outperformed new york mercantile exchange crude oil future rise barrel downside volkswagen vlkay plunge federal state regulator say german automaker used software diesel vehicle cheat emission test ibd biotechs regeneron regn celgene celg take hit fall
1154,CELG,major stock etfs rally close wednesday choppy session buoy health care stock volatility oil dominate much today market action crude stockpile rise more expect oil price pull back surge tuesday highest level late august opec signale reduction supply spdr oil gas exploration production xop close lower give much intraday etf offer target exposure energy company explore produce oil gas many top holding claw back loss finish higher stock market chesapeake energy chk rise conocophillip cop chevron cvx investor grapple muddle price action ahead alcoa aa report close thursday unofficially usher earning season stock be trading week high set november ishare nasdaq biotechnology ibb gain top holding celgene celg regeneron regn ibd stock be biggest advancer ishare north american tech software igv end essentially flat top half day range top hold adobe system adbe take tumble profit outlook disappoint analyst stronger dollar be see part weigh photoshop maker transition web base subscription model technology select sector spdr xlk gain top holding apple aapl facebook fb google parent alphabet googl sustain damage microsoft msft notch gain largest gold etf lose fraction here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs vanguard ftse emerge market vwo rs ishare russell iwm rs ishare core mid cap ijh rs ishare msci eafe efa rs spdr spy rs spdr dow jone industrial average dium rs powershare qqq qqq rs powershare db bullish uup rs ishare core aggregate bond agg rs spdr gold share gld rs follow aparna narayanan twitter ibd_anarayanan
1155,CELG,solid open stock fade hour wednesday session afternoon rally close high be welcome development bull camp early rise nasdaq fade loss morning trade buyer lift tech heavy index gain close
1156,CELG,initial post fed statement relief rally fuel major index bigger advance fade stock sharply pare gain close nasdaq hold slim gain biotechs outperformed give dow jone industrial average shed volume be higher board stock market today accord preliminary datum widely expect fed left rate unchanged record lows recent global economic financial development restrain economic activity somewhat be likely put further downward pressure inflation term say statement biotechs drugmaker airline stock be day biggest gainer bank toy maker machinery related stock lag unite continental ual soar reclaim day move average fast trade analyst think chicago base carrier multiyear credit card deal extension jpmorgan chase jpm visa announce wednesday boost full year profit virgin america va rise also average volume share november ipo be dec high more offer price biotechs sucampo pharmaceutical scmp surge new close high stock be now extend cup base buy point clear july biotech be featured thursday industry theme column ibd biotechs celgene celg regeneron pharmaceutical regn advanced winner ibd edge loser margin follow nancy gondo twitter ibd_ngondo
1157,CELG,time most lead biotechs be still try recover aug market sell sucampo pharmaceutical scmp be run far ahead pack share specialty drugmaker be well extend past buy point subsequent rebound week move average re more year vs nasdaq
1158,CELG,stock be quietly mixed midday tuesday reasonable performance strong session dow jone industrial average add buoy dupont dd surge more news ceo ellen kullman abruptly retire wall street take mean breakup company be horizon
1159,CELG,ease nasdaq fall weigh weakness illumina ilmn share crash gene sequence gear maker preannounce sale consensus estimate
1160,CELG,former chip leader skywork swks avgo face more selling so do biotech name celgene celg biogen biib
1161,CELG,nyse volume be tracking lower monday stock market today nasdaq volume be pace be slightly higher
1162,CELG,advance stock outnumber decliner nyse less decliner have slight edge advancer nasdaq
1163,CELG,oil gas related group extend gain oil rise again new york mercantile exchange crude oil future jump barrel
1164,CELG,day gainer autobytel abtl follow rise nearly monday double bottom base buy point
1165,CELG,ibd sector leader lgi home lgih score time high rise be solid performer base early august buy point extend bounce week week move average
1166,CELG,pretty quiet week economic datum market be look closely tone fed minute meeting re release thursday stock be quietly mixed midday tuesday reasonable performance strong session dow jone industrial average add buoy dupont dd surge more news ceo ellen kullman abruptly retire wall street take mean breakup company be horizon ease nasdaq fall weigh weakness illumina ilmn share crash gene sequence gear maker preannounce sale consensus estimate former chip leader skywork swks avgo face more selling so do biotech name celgene celg biogen biib nyse volume be tracking lower monday stock market today nasdaq volume be pace be slightly higher advance stock outnumber decliner nyse less decliner have slight edge advancer nasdaq oil gas related group extend gain oil rise again new york mercantile exchange crude oil future jump barrel day gainer autobytel abtl follow rise nearly monday double bottom base buy point ibd sector leader lgi home lgih score time high rise be solid performer base early august buy point extend bounce week week move average pretty quiet week economic datum market be look closely tone fed minute meeting re release thursday
1167,CELG,big cap biotech biogen biib say wednesday have license drug candidate japan mitsubishi tanabe pharma treat multiple sclerosis other autoimmune disease send biogen stock rise candidate mt be oral modulator similar novartis nvs ms drug gilenya rpc late stage drug candidate celgene celg just acquire buyout
1168,CELG,top rate drugmaker such valeant pharmaceutical international vrx celgene celg have be busy lab wall street take part big merger deal today ibd list feature top rate drugmaker addition valeant celgene list include regeneron pharmaceutical regn lannett lci allergan agn friday biogen idec biib price
1169,CELG,exchange trade fund jab higher wednesday investor cheer biotech rally strong performance overseas market major asian market close higher release positive datum chinese consumer sentiment upbeat mood ripple europe wednesday open most benchmark defy be historically worst trading day year etfs tracking
1170,CELG,large cap growth opportunity fund be make best tough year mutual fund outperformed large cap growth rival track morningstar inc average first second quarters first half gain nearly match return even broad market
1171,CELG,market be still correction mean not best time buy never hurt keep eye top performer such hot drugmaker ibd valeant pharmaceutical vrx say start month shell psoriasis drug licensing
1172,CELG,biotech etfs get smash late trade friday bank diversify financial etfs maintain gain rate liftoff bogey dominate investor mood major index etfs reversed early gain close lower session week upbeat number gdp datum consumer confidence thursday ceo lead etf sponsor expressed disappointment
1173,CELG,major index etfs shave loss late trade thursday close lower session high global growth concern weigh investor demand gold safe haven asset send exchange trade fund hold physical bullion week high spdr dow jone industrial average dium lose stock market today climb hour
1174,CELG,patent trademark office rule wednesday patent challenge biogen biib blockbuster drug tecfidera hold hope denial similar challenge other drug hedge fund manager kyle bass biogen stock rise uspto decline hold trial response bass request parte review ipr tecfidera patent number end expire office cite failure establish likelihood success challenged claim reason challenge shorter live patent be still pending patent expire ipr filing be make coalition affordable drug group create bass part short activist strategy claim also reduce drug price group have also file iprs jazz pharmaceutical jazz xyrem abbvie abbv imbruvica celgene celg revlimid shire shpg lialda gattex other last month however uspto also deny ipr acorda therapeutic acor amypra biogen ruling be further evidence strategy win work write rbc capital market analyst michael yee research note today be unexpected positive expect decision mid nov base filing date come heel acorda consensus ipr institution yee write street view further positive derivative give less credit other iprs file similar patent group yee note however drug startup forward pharma fwp be also challenge patent have develop own similar drug biogen stock have be severely batter massive guidance cut back july ibd relative strength rating just ep rank afternoon trading stock market today biogen stock be follow amy reeve twitter ibd_areeve facebook
1175,CELG,high rate tech stock ibd leaderboard amazon com amzn palo alto network panw get lift early monday rise market turn choppy midday hillary clinton tweet price gouge prescription drug slam biotechs general stock market direction uptrend pressure warrant caution amazon introduce new tablet thursday power back more gain monday afternoon stock be consolidate potential buy point palo alto cybersecurity research uncovered xcodeghost malware apps apple aapl app store see more lift largely disappear stock be become buy point cup base big techs ibd growth stock list facebook fb be more monday google googl less drugmaker biotechs celgene celg valeant vrx allergan agn other be several percentage point follow donna howell twitter ibd_dhowell related top big tech stock trading fast buy point
1176,CELG,high rate tech stock ibd leaderboard amazon com amzn palo alto network panw get lift early monday rise market turn choppy midday hillary clinton tweet price gouge prescription drug slam biotechs general stock market direction uptrend pressure warrant caution amazon introduce new tablet thursday power back more gain monday afternoon stock be consolidate potential buy point palo alto cybersecurity research uncovered xcodeghost malware apps apple aapl app store see more lift largely disappear stock be become buy point cup base big techs ibd growth stock list facebook fb be more monday google googl less drugmaker biotechs celgene celg valeant vrx allergan agn other be several percentage point follow donna howell twitter ibd_dhowell related top big tech stock trading fast buy point
1177,CELG,volatility be word day stock market drugmaker strong growth prospect proven long term stability such ibd member valeant pharmaceutical vrx be good stock watch list candidate ibd spotlight top performer list stock base combination factor include sale profit growth today roster
1178,CELG,stock sell broadly tuesday index start swerve monthlong uptrend nasdaq gap loss fall be second decline more past session index trim loss afternoon price chart be left distinct
1179,CELG,stock be lower volatile trading monday have cut half loss be less nasdaq lose be much respectively stock market today turnover be tracking lower friday pace loss market few leader be big volume netease nte lose nearly rebound effort fade more stock regain day line thursday lose next day celgene celg fall almost wipe friday move then stock be almost back day move average upside ambarella amba rise extend gain past session chip designer report result tuesday close ambarella be gopro gpro supplier be expect post quarter triple digit profit growth cal maine food calm gap rally more be upgrade buy hold bb capital market stock be now back day line potential base form accord department agriculture egg price have surge year due avian flu outbreak follow vincent mao twitter ibd_vmao
1180,CELG,be wild wild week stock market elite ibd much close friday facebook fb apple aapl iphone supplier technology avgo celgene celg ibd other most liquid stock base average dollar volume finished higher trading just day
1181,CELG,biotech stock continue slide thursday prompt analyst weigh cause prognosis sector piper jaffray joshua schimmer note same thing happened year spark price debate gilead science gild hepatitis drug sovaldi also valuation concern long runup obviously turn be stellar year biotech believe industry fundamental remain strong write research note still be good year industry once pass latest round selling schimmer write profitable big cap such celgene celg biogen biib alexion pharmaceutical alxn be attractively value relative peer other hand say money lose big cap such vertex pharmaceutical vrtx biomarin pharmaceutical bmrn be more difficult value rbc capital market analyst michael yee report write reasonable make sense correction profit take have be possible give significant outperformance first month yee note be exaggerate move smaller biotechs last week such car stock juno therapeutic juno jump kite pharma kite rise turn revive long run concern biotech bubble kite stock be midday trading stock market today juno stock be fall more wednesday yee add however real bear market be drive poor fundamental say aren evident yet biotech re watch pillar risk biosimilar flux pricing rebate ip risk seem be risk individual company not whole sector write thursday mark fifth straight trading day decline ibd company medical biom biotech group have slump nearly span now still rank group track ibd follow amy reeve twitter ibd_areeve related biotechs track worst week year
1182,CELG,best mutual fund first quarter performance report michael kotlarz take rein oppenheimer capital appreciation fund july fund relative performance have jump year kotlarz take rein fund average annual gain be hold humble return bear market performance lag
1183,CELG,stock reaffirm market upward bias wednesday broad gain higher volume strength market leader be hardly question well ibd gain observer federal reserve appear unsurprised surprised central bank announcement interest rate policy be unsurprised deletion phrasing used prior statement
1184,CELG,biotech stock be fire be rank group track ibd past year industry group have gain vs industry group be sixth straight week advance week so far biotechs be more have
1185,CELG,stock fall mildly monday seller pounce final hour lead stock get ding otherwise quiet session snap week lose streak last week slip hold modest gain much session benchmark index be less feb record high nasdaq waver
1186,CELG,new research note rbc capital market offer bullish take biogen idec biib experimental drug alzheimer disease predict make big splash upcoming international conference alzheimer parkinson disease conference schedule march nice france attract medical scientific professional globe biogen be expect
1187,CELG,columbia large cap growth fund be smokin fund gain month go thursday be rank top large cap growth stock mutual fund track morningstar inc averaged return be past year fund average annual gain be
1188,CELG,recent flurry deal make drug sector have put spotlight other top rate drugmaker have grow help savvy merger acquisition just past week abbvie abbv agree buy pharmacyclic pcyc beating johnson johnson jnj mallinckrodt mnk announce deal acquire privately
1189,CELG,do know harness power ibd have be read investor business daily know important be find edge battle superior investment return ibd supply edge
1190,CELG,consider stock play computer generate proprietary list premier growth stock present key juncture market
1191,CELG,chipotle grill cmg burrito taco restaurant chain be rank aug edition ibd list become ibd jan day later market turn higher powerful follow nasdaq composite rally
1192,CELG,day chipotle throttle perfect cup handle base buy point little more year later stock have rise high today stock be
1193,CELG,armour ua athletic apparel maker rank ibd week end baltimore base company leap week flat base structure april armour catapult begin new significant correction
1194,CELG,qihoo qihu sherwin william shw celgene celg stock rank respectively nov ibd few day later market follow again stock bolt big gain
1195,CELG,ibd be effect lead benchmark most dynamic growth company economy here abroad
1196,CELG,chart show top growth company outperform general market index more country mile
1197,CELG,do ibd do so well
1198,CELG,typical ibd firm have outstanding profit growth big sale increase wide profit margin high return equity ibd have world most robust databasis search growth stock
1199,CELG,firm tend see heavy accumulation institutional money manager savvy one excel find fastest grow company respective industry then buy share month even year time provide rocket fuel major stock advance
1200,CELG,list do not hold bias industry do index heavily favor group stock subjective emotional reason rather ibd be cold hard look truly lead stock market
1201,CELG,index conduct dispassionate process hold true leader weed laggard stock show sudden price weakness volume rush higher fundamental wither simply get kick promising new leader replace former big winner
1202,CELG,ibd ability refresh emerge market leader also give reader edge
1203,CELG,ibd reader see ibd update monday wednesday edition newspaper eibd ibd leaderboard subscriber see list update daily market close do know harness power ibd have be read investor business daily know important be find edge battle superior investment return ibd supply edge consider stock play computer generate proprietary list premier growth stock present key juncture market chipotle grill cmg burrito taco restaurant chain be rank aug edition ibd list become ibd jan day later market turn higher powerful follow nasdaq composite rally day chipotle throttle perfect cup handle base buy point little more year later stock have rise high today stock be armour ua athletic apparel maker rank ibd week end baltimore base company leap week flat base structure april armour catapult begin new significant correction qihoo qihu sherwin william shw celgene celg stock rank respectively nov ibd few day later market follow again stock bolt big gain ibd be effect lead benchmark most dynamic growth company economy here abroad chart show top growth company outperform general market index more country mile do ibd do so well typical ibd firm have outstanding profit growth big sale increase wide profit margin high return equity ibd have world most robust databasis search growth stock firm tend see heavy accumulation institutional money manager savvy one excel find fastest grow company respective industry then buy share month even year time provide rocket fuel major stock advance list do not hold bias industry do index heavily favor group stock subjective emotional reason rather ibd be cold hard look truly lead stock market index conduct dispassionate process hold true leader weed laggard stock show sudden price weakness volume rush higher fundamental wither simply get kick promising new leader replace former big winner ibd ability refresh emerge market leader also give reader edge ibd reader see ibd update monday wednesday edition newspaper eibd ibd leaderboard subscriber see list update daily market close
1204,CELG,special report best mutual fund february performance report stock mutual fund manager andrew acheson paul cloonan have be kick higher gear pioneer fundamental growth fund average annual return fund rank top large cap growth rival track morningstar inc year end
1205,CELG,medivation mdvn stock be early thursday company better expect fourth quarter earning biotech benefit strong sale xtandi prostate cancer drug report wednesday close medivation post earning share just cent well consensus analyst estimate revenue nearly triple
1206,CELG,unite therapeutic uthr early tuesday top fourth quarter sale profit view maker therapy treat cardiovascular disease infectious disease cancer benefit strong performance new orenitram drug treat high blood pressure
1207,CELG,unite therapeutic logged fourth quarter earning share reversed cent share loss year earlier quarter wall street consensus estimate cent
1208,CELG,revenue climb top view be company biggest top line gain quarters
1209,CELG,growth be drive part sale orenitram pill treat pulmonary arterial hypertension pah be high blood pressure artery lung
1210,CELG,orenitram receive food drug administration approval late be launch contribute sale
1211,CELG,company top seller quarter be remodulin pah treatment used diminish symptom associate exercise have sale fourth quarter sale fellow pah drug tyvaso adcirca be respectively
1212,CELG,fourth quarter be especially distinguish orenitram exceed adcirca sale tyvaso sale fact december be only seventh month orenitram launch other product be launch unite therapeutic ceo martine rothblatt say statement
1213,CELG,unite therapeutic stock be early trading stock market today stock touch record high monday be nearly past month extend buy point flat base touch december
1214,CELG,research note earlier year initiate coverage unite therapeutic neutral rating btig analyst hartaj singh say silver spring md base company face late patent cliff top product
1215,CELG,risk however be offset blue sky potential orenitram singh say reach peak sale pass regulatory hurdle more type treatment
1216,CELG,last fall unite therapeutic score victory year old patent case sandoz novartis nvs generic drug unit sandoz be try bring generic version remodulin market september district judge upheld unite therapeutic patent last late
1217,CELG,unite therapeutic have ibd composite rating possible be part ibd medical biom biotech group rank industry group track
1218,CELG,other highly rate stock group be biogen idec biib celgene celg insys therapeutic insy
1219,CELG,unite therapeutic uthr early tuesday top fourth quarter sale profit view maker therapy treat cardiovascular disease infectious disease cancer benefit strong performance new orenitram drug treat high blood pressure unite therapeutic logged fourth quarter earning share reversed cent share loss year earlier quarter wall street consensus estimate cent revenue climb top view be company biggest top line gain quarters growth be drive part sale orenitram pill treat pulmonary arterial hypertension pah be high blood pressure artery lung orenitram receive food drug administration approval late be launch contribute sale company top seller quarter be remodulin pah treatment used diminish symptom associate exercise have sale fourth quarter sale fellow pah drug tyvaso adcirca be respectively fourth quarter be especially distinguish orenitram exceed adcirca sale tyvaso sale fact december be only seventh month orenitram launch other product be launch unite therapeutic ceo martine rothblatt say statement unite therapeutic stock be early trading stock market today stock touch record high monday be nearly past month extend buy point flat base touch december research note earlier year initiate coverage unite therapeutic neutral rating btig analyst hartaj singh say silver spring md base company face late patent cliff top product risk however be offset blue sky potential orenitram singh say reach peak sale pass regulatory hurdle more type treatment last fall unite therapeutic score victory year old patent case sandoz novartis nvs generic drug unit sandoz be try bring generic version remodulin market september district judge upheld unite therapeutic patent last late unite therapeutic have ibd composite rating possible be part ibd medical biom biotech group rank industry group track other highly rate stock group be biogen idec biib celgene celg insys therapeutic insy
1220,CELG,persistently mild distribution broad market turn harsh wednesday major average drop sharply higher volume selling also find way lead stock lead industry group putt market uptrend back pressure nasdaq slump still day move average be tech index largest daily percentage decline
1221,CELG,growth stock have blowout week fifth ibd list rise more top list akorn akrx rebound week take back prior week loss end comfortably week move average biogen idec biib spiked end far new high edward lifescience ew
1222,CELG,stock shift higher gear friday nasdaq score new high nasdaq pop beat gain ibd lead surge volume rise major exchange compare thursday pace friday be quadruple witching day tend inflate volume ibd market pulse
1223,CELG,large cap stock fund drop less small midcap fund summer stock market sell help large cap fund shrink gap year performance average large cap stock mutual fund rise annual average past year vs average midcap fund small cap fund
1224,CELG,stock reversed higher close bell monday end session skid rout china stock market further drop oil price
1225,CELG,dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum
1226,CELG,energy mining biotech stock lag department store hospital tobacco stock lead upside
1227,CELG,aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session
1228,CELG,macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd
1229,CELG,sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman
1230,CELG,company due report quarterly result tuesday include csx csx ihs ihs
1231,CELG,labor department be due release closely watch job opening labor turnover survey jolt tuesday stock reversed higher close bell monday end session skid rout china stock market further drop oil price dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum energy mining biotech stock lag department store hospital tobacco stock lead upside aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman company due report quarterly result tuesday include csx csx ihs ihs labor department be due release closely watch job opening labor turnover survey jolt tuesday
1232,CELG,stock market bounce session lows tuesday new sign last week bottom hold nasdaq rise erase morning loss apple aapl composite largest component climb nearly news be plan tv subscription service also pare loss still close lower russell
1233,CELG,single stock screen be best uptrend different uptrend reward different kind stock screen reflect reality example last bear market aggressive growthy complexion ibd then ibd fade stock make list oct include el paso electric ee campbell soup cpb procter gamble pg johnson johnson jnj mention equity alone say bear market early november screen have be top perform screen past month be gain ibd be make be way use screen micro approach macro approach micro approach study list find stock be buy point have few miss slim standard macro approach look pattern list kind stock be make list small cap big cap sector industry group be plentiful be stock make screen aggressive defensive let contemplate screen ibd also know weekly review friday newspaper generally ibd be collection stock have higher rating screen ibd have higher rating stock do better long strong uptrend quality growth stock likely correct more sharply defensive stock market run trouble be advantage screen pick more turnaround stock ibd turnaround stock be less likely have strong annual rating past year looser standard mean also more likely pick stock benefit sector rotation also pick more small thinly trade stock ibd sector rotation angle have be apparent recently small bank industry group account stock end october yet only bank stock make ibd bank ozark ozrk signature bank sbny many bank stock be thinly trade still attract quality mutual fund holder table show
1234,CELG,biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate
1235,CELG,gilead doesn give ep guidance add full year product sale target now
1236,CELG,essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast
1237,CELG,evercore isi analyst mark schoenebaum say guidance raise be especially significant
1238,CELG,company tend be conservative so raise revenue guidance early year speak volume write email client
1239,CELG,conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach
1240,CELG,bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash
1241,CELG,cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product
1242,CELG,gilead stock rise hour trading share have close
1243,CELG,abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week
1244,CELG,earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent
1245,CELG,sale dip beat estimate exclude currency headwind divestment sale rise
1246,CELG,teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september
1247,CELG,teva stock slide
1248,CELG,celgene sale miss
1249,CELG,celgene celg report mixed quarter ep rise penny view sale grow miss consensus more
1250,CELG,big biotech affirm full year guidance product sale ep last year make share revenue
1251,CELG,sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus
1252,CELG,celgene stock dive close
1253,CELG,danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus
1254,CELG,nordisk hike profit growth guidance add percentage point low end sale growth guidance
1255,CELG,president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen
1256,CELG,stock rise biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate gilead doesn give ep guidance add full year product sale target now essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast evercore isi analyst mark schoenebaum say guidance raise be especially significant company tend be conservative so raise revenue guidance early year speak volume write email client conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product gilead stock rise hour trading share have close abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent sale dip beat estimate exclude currency headwind divestment sale rise teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september teva stock slide celgene sale misscelgene celg report mixed quarter ep rise penny view sale grow miss consensus more big biotech affirm full year guidance product sale ep last year make share revenue sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus celgene stock dive close danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus nordisk hike profit growth guidance add percentage point low end sale growth guidance president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen stock rise
1257,CELG,big cap drugmaker report mostly solid first quarters thursday morning market give decidedly mixed reception israeli generic drug giant teva pharmaceutical teva report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter sale decline fraction beat
1258,CELG,biotech stock fall hard monday trouble rate group overshadowed rally commodity stock nasdaq biotechnology index lose stock retreat average volume include biogen biib insys therapeutic insy celgene celg stock carry ibd composite rating better putt stock least top
1259,CELG,nasdaq suffer distribution day monday harsh reminder institutional selling be still daunting issue market even major average perch high early gain nasdaq fade loss close erased smaller gain close lower small
1260,CELG,friday gain notwithstanding latest week show doesn take long market condition go good not so good least growth stock perspective exactly week space several compelling ibd chart be highlighted market be confirm uptrend be still challenge environment make
1261,CELG,week bring first quarter earning report top rate large cap drug stock be expect report strong growth tuesday open unite therapeutic uthr be expect report revenue year earlier quarter accord thomson reuter earning be expect climb share give
1262,CELG,biogen biib friday morning be expect report earning share vs year earlier end quarter string accelerate growth sale show advance solid gain fourth straight quarter decelerate growth biogen rely heavily multiple sclerosis drug such tecfidera
1263,CELG,etf investment strategy tip buy best etfs etf trading offer way buck conventional wisdom investing stock other financial market conventional wisdom say time stock market remain fully invest bull bear market ll prosper long run work
1264,CELG,market sell close thursday earning continue take toll spate lead stock nasdaq sank hurt ailing biotechs dow jone industrial average give shed volume swell board stock market today hammer baidu bidu celgene celg harman international har yelp yelp
1265,CELG,close linkedin lnkd give regular session dive more sale earning beat view full year revenue outlook disappoint
1266,CELG,visa be hour report fiscal result top forecast stock breach day move average fall regular session
1267,CELG,only ibd stock advanced decline apple aapl continue descent third straight session average volume fall day line iphone maker recently warn ongoing tax probe ireland have material impact earning
1268,CELG,meanwhile apple supplier skywork solution swks be extend trading report better expect fiscal result chipmaker also guide earning sale estimate
1269,CELG,ism manufacturing index april university michigan consumer sentiment april march construction spending be economic datum tap friday morning
1270,CELG,follow nancy gondo twitter ibd_ngondo market sell close thursday earning continue take toll spate lead stock nasdaq sank hurt ailing biotechs dow jone industrial average give shed volume swell board stock market today hammer baidu bidu celgene celg harman international har yelp yelp close linkedin lnkd give regular session dive more sale earning beat view full year revenue outlook disappoint visa be hour report fiscal result top forecast stock breach day move average fall regular session only ibd stock advanced decline apple aapl continue descent third straight session average volume fall day line iphone maker recently warn ongoing tax probe ireland have material impact earning meanwhile apple supplier skywork solution swks be extend trading report better expect fiscal result chipmaker also guide earning sale estimate ism manufacturing index april university michigan consumer sentiment april march construction spending be economic datum tap friday morning follow nancy gondo twitter ibd_ngondo
1271,CELG,major average extend loss afternoon trading earning continue take lead stock nasdaq slump dow jone industrial average be volume be tracking higher nasdaq lower nyse stock market today biotechs internet stock weigh nasdaq celgene celg lose sale miss
1272,CELG,baidu bidu gap fall more slice day move average fast trade close wednesday chinese online search giant report profit beat revenue miss view sale guidance come forecast
1273,CELG,harman international har gap report fiscal earning revenue miss estimate car infotainment system maker say business be affected stronger dollar ibd stock recently clear cup base buy point sank early pare loss midday
1274,CELG,upside taser international tasr gap surge mark new intraday high stunning volume share be now extend past buy point stun gun maker result trump street forecast help strong sale weapon camera
1275,CELG,oil stock be outperform again crude price continue rise sign oil glut be ease atwood oceanic atw soar triple usual trade houston base driller report fiscal result top view other driller diamond offshore drill do ensco esv transocean rig rise more
1276,CELG,follow nancy gondo twitter ibd_ngondo major average extend loss afternoon trading earning continue take lead stock nasdaq slump dow jone industrial average be volume be tracking higher nasdaq lower nyse stock market today biotechs internet stock weigh nasdaq celgene celg lose sale miss baidu bidu gap fall more slice day move average fast trade close wednesday chinese online search giant report profit beat revenue miss view sale guidance come forecast harman international har gap report fiscal earning revenue miss estimate car infotainment system maker say business be affected stronger dollar ibd stock recently clear cup base buy point sank early pare loss midday upside taser international tasr gap surge mark new intraday high stunning volume share be now extend past buy point stun gun maker result trump street forecast help strong sale weapon camera oil stock be outperform again crude price continue rise sign oil glut be ease atwood oceanic atw soar triple usual trade houston base driller report fiscal result top view other driller diamond offshore drill do ensco esv transocean rig rise more follow nancy gondo twitter ibd_ngondo
1277,CELG,seller be nasdaq most thursday session selling intensified late major average end sharply lower
1278,CELG,nasdaq slump weigh weakness biotechs again dow jone industrial average fall give preliminary datum show nyse nasdaq volume come higher wednesday
1279,CELG,economic news weekly jobless claim drop last week lowest level april
1280,CELG,nymex crude oil rise barrel month oil rise biggest monthly gain
1281,CELG,stock market today oil driller outperformed seller swarm biotechs again ibd medical biom biotech group slump additional bring weekly decline celgene celg slump revenue miss expectation
1282,CELG,martin marietta material mlm be bright spot share jump nearly adjust earning come cent share estimate cent sale rise try clear flat base buy point
1283,CELG,taser tasr soar also nice earning
1284,CELG,apple aapl slump day move average fall nearly company recently warn ongoing tax probe ireland have material impact earning operate result cash flow
1285,CELG,meanwhile apple supplier nxp semiconductor nxpi add report disappointing sale issue weak guidance apple supplier skywork solution swks report close today
1286,CELG,abaxis abax hold firm ahead earning report close share ease just day move average slightly prior buy point
1287,CELG,other top rate growth name set report close include fleetcor flt visa linkedin lnkd seller be nasdaq most thursday session selling intensified late major average end sharply lower nasdaq slump weigh weakness biotechs again dow jone industrial average fall give preliminary datum show nyse nasdaq volume come higher wednesday economic news weekly jobless claim drop last week lowest level april nymex crude oil rise barrel month oil rise biggest monthly gain stock market today oil driller outperformed seller swarm biotechs again ibd medical biom biotech group slump additional bring weekly decline celgene celg slump revenue miss expectation martin marietta material mlm be bright spot share jump nearly adjust earning come cent share estimate cent sale rise try clear flat base buy point taser tasr soar also nice earning apple aapl slump day move average fall nearly company recently warn ongoing tax probe ireland have material impact earning operate result cash flow meanwhile apple supplier nxp semiconductor nxpi add report disappointing sale issue weak guidance apple supplier skywork solution swks report close today abaxis abax hold firm ahead earning report close share ease just day move average slightly prior buy point other top rate growth name set report close include fleetcor flt visa linkedin lnkd
1288,CELG,stock turn lower early afternoon trading monday loss be contain wall street prepared day fed meeting busiest week yet corporate earning
1289,CELG,nasdaq reversed gain fall weigh biotechs lose dow jone industrial average ease nasdaq volume be tracking higher friday level nyse turnover be tracking close friday
1290,CELG,mining stock oil driller outperformed ibd medical biom biotech group lose
1291,CELG,stock market today top rate biotechs celgene celg unite therapeutic uthr amgen amgn fall anywhere
1292,CELG,apple aapl rise ahead earn report close
1293,CELG,volume be heavy twitter twtr share rally more report result tuesday close
1294,CELG,meanwhile china base name ibd outperformed auto information athm clear buy point rise noah holding noah add nearly trigger ibd week hold rule last week
1295,CELG,earning news inc research incr surge contract research organization cro report surge quarterly profit sale rise company provide clinical development service big pharma biotechs medical device firm stock turn lower early afternoon trading monday loss be contain wall street prepared day fed meeting busiest week yet corporate earning nasdaq reversed gain fall weigh biotechs lose dow jone industrial average ease nasdaq volume be tracking higher friday level nyse turnover be tracking close friday mining stock oil driller outperformed ibd medical biom biotech group lose stock market today top rate biotechs celgene celg unite therapeutic uthr amgen amgn fall anywhere apple aapl rise ahead earn report close volume be heavy twitter twtr share rally more report result tuesday close meanwhile china base name ibd outperformed auto information athm clear buy point rise noah holding noah add nearly trigger ibd week hold rule last week earning news inc research incr surge contract research organization cro report surge quarterly profit sale rise company provide clinical development service big pharma biotechs medical device firm
1296,CELG,first quarter earning report correct market have shake industry group rank here look winner loser week biotech group outperformed re-cover portion prior week harsh loss group member ligand pharmaceutical lgnd be trading buy point cup handle base find support
1297,CELG,stock shift sideway quiet volume friday end difficult week light note nasdaq rise add ibd pop volume fall board index chart be little change friday stay day line nasdaq hold day day gain
1298,CELG,stock be lower tuesday morning early push mixed territory be short live hurt chip software stock nasdaq fall dow jone industrial average lose briefly poke positive territory turnover be run mixed stock market today
1299,CELG,nasdaq trade be run higher compare same time monday nyse volume be tracking lower
1300,CELG,stock jazz pharmaceutical jazz pare loss miss view late monday monday close drugmaker post earning rise miss view cent sale climb also view top bottom line decelerate third straight quarter share gap fall more tuesday low
1301,CELG,skywork solution swks gap drop nearly trimming loss microsemi mscc announce press release pmc sierra pmcs favor buyout offer skywork skywork microsemi announce plan acquire pmc sierra last month
1302,CELG,upside horton dhi rally beating view open homebuilder post fiscal earning cent share cent view sale come vs view horton close home quarter year stock hit resistance day move average
1303,CELG,follow vincent mao twitter ibd_vmao stock be lower tuesday morning early push mixed territory be short live hurt chip software stock nasdaq fall dow jone industrial average lose briefly poke positive territory turnover be run mixed stock market today nasdaq trade be run higher compare same time monday nyse volume be tracking lower stock jazz pharmaceutical jazz pare loss miss view late monday monday close drugmaker post earning rise miss view cent sale climb also view top bottom line decelerate third straight quarter share gap fall more tuesday low skywork solution swks gap drop nearly trimming loss microsemi mscc announce press release pmc sierra pmcs favor buyout offer skywork skywork microsemi announce plan acquire pmc sierra last month upside horton dhi rally beating view open homebuilder post fiscal earning cent share cent view sale come vs view horton close home quarter year stock hit resistance day move average follow vincent mao twitter ibd_vmao
1304,CELG,market index extend gain midday trade score leader bounce back tough week
1305,CELG,nasdaq rally climb back dow jone industrial average be volume be tracking lower board stock market today winner be lead loser exchange
1306,CELG,airline cement producer chipmaker outperformed industry group track ibd internet content software auto related stock lag
1307,CELG,continue decline harman international har linkedin lnkd share dive full year revenue outlook disappoint late thursday most lead stock be higher
1308,CELG,celgene celg re-cover find support day move average biotech group be snap session lose streak monster beverage mnst gain nearly recoup loss past session then
1309,CELG,skywork solution swks gap surge double usual volume work right side flat base potential buy point apple aapl chip supplier late thursday report better expect fiscal result guide earning revenue forecast
1310,CELG,jetblue airway jblu soar new high fast trade stock be rebound week move average be far extend november multiple visit support line credit suisse thursday raise carrier outperform neutral boost price target
1311,CELG,martin marietta material mlm advanced clear flat base buy point heavy volume extend gain thursday now entry crushed stone sand aggregate producer thursday report mixed result
1312,CELG,follow nancy gondo twitter ibd_ngondo market index extend gain midday trade score leader bounce back tough week nasdaq rally climb back dow jone industrial average be volume be tracking lower board stock market today winner be lead loser exchange airline cement producer chipmaker outperformed industry group track ibd internet content software auto related stock lag continue decline harman international har linkedin lnkd share dive full year revenue outlook disappoint late thursday most lead stock be higher celgene celg re-cover find support day move average biotech group be snap session lose streak monster beverage mnst gain nearly recoup loss past session then skywork solution swks gap surge double usual volume work right side flat base potential buy point apple aapl chip supplier late thursday report better expect fiscal result guide earning revenue forecast jetblue airway jblu soar new high fast trade stock be rebound week move average be far extend november multiple visit support line credit suisse thursday raise carrier outperform neutral boost price target martin marietta material mlm advanced clear flat base buy point heavy volume extend gain thursday now entry crushed stone sand aggregate producer thursday report mixed result follow nancy gondo twitter ibd_ngondo
1313,CELG,baidu tumble mixed result take internet focuse etfs intraday trade tuesday major exchange trade fund rally early action series decline bring tepid earning season thus far ugly china sell yesterday baidu bidu stock nosedive earning miss late monday china base search engine
1314,CELG,exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs
1315,CELG,online retail giant stunned market post profit give upbeat guidance current quarter
1316,CELG,be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business
1317,CELG,amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt
1318,CELG,first trust dow jone internet fdn technology etf jump time high hold amazon lead advance
1319,CELG,don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout
1320,CELG,consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset
1321,CELG,health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy
1322,CELG,several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb
1323,CELG,big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial
1324,CELG,ibb have lose week set new high recently monday
1325,CELG,market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer
1326,CELG,manufacturing datum also show business be struggle europe july hit greece debt crisis
1327,CELG,spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal
1328,CELG,here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing
1329,CELG,bellwether etfs
1330,CELG,powershare db bullish uup rs
1331,CELG,ishare core aggregate bond agg rs
1332,CELG,powershare qqq qqq rs
1333,CELG,spdr gold trust gld rs
1334,CELG,ishare core mid cap ijh rs
1335,CELG,spdr spy rs
1336,CELG,spdr dow jone industrial average dium rs
1337,CELG,ishare russell iwm rs
1338,CELG,ishare msci eafe efa rs
1339,CELG,vanguard ftse emerge market vwo rs
1340,CELG,follow aparna narayanan twitter ibd_anarayanan exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs online retail giant stunned market post profit give upbeat guidance current quarter be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt first trust dow jone internet fdn technology etf jump time high hold amazon lead advance don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial ibb have lose week set new high recently monday market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer manufacturing datum also show business be struggle europe july hit greece debt crisis spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs powershare db bullish uup rs ishare core aggregate bond agg rs powershare qqq qqq rs spdr gold trust gld rs ishare core mid cap ijh rs spdr spy rs spdr dow jone industrial average dium rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs follow aparna narayanan twitter ibd_anarayanan
1341,CELG,old hat biotech etfs be beating stock market be new launch fly radar many investor bioshare biotechnology product bbp hold stock such celgene celg anacor pharmaceutical anac have shine late other focus business clinical trial stage be very innovative etfs investing company cut edge medical research say neena mishra director etf research zack investment research think keep beating peer have december launch alp medical breakthrough sbio invest company least drug clinical trial top health care sector etfs spike year bbp score stock market gain bioshare biotechnology clinical trial bbc comparison more establish ishare nasdaq biotechnology ibb be year date biotechs have lead stock market several year still steep ascent be draw caution analyst worry lofty valuation not mishra be still many reason be positive industry say cite merger uptick positive drug trial result more industry friendly fda approval debutante etfs share common be skew small midcap biotech player equally weight etf bbp invest stock average market cap anacor outperformer past year make headline week positive datum experimental skin ointment other holding triple digit gain last year include momenta mnta dyax dyax biomarin bmrn retrophin rtrx cap size skew be pay bigger more well know biotech company rely new therapy smaller firm acquire give time consume nature drug development alarm rate failure involved mishra say flip side smaller company tend be more volatile price company clinical trial stage chance failure be high make etfs hold company high risk high reward bet investing success still strong inflow etfs reflect investor hope gain absorb roughly combine new money first month year asset have grow rapid clip especially sbio start roughly now hold new etf strategy involve inherent risk fund sponsor shut product fail gather sizable asset investor face higher trading cost form wide bid ask spread investor lower risk tolerance focus broader biotech etfs mishra say
1342,CELG,jazz pharmaceutical get heavy border today sector leader chart see page buy point don let make give fellow drugmaker gilead science short shrift back week move average work flat base buy point share gilead gild gap
1343,CELG,biotechs be get hit hard stock market today group have be group ibd industry track worst weekly decline year top rate biotech stock take beating include celgene celg biogen biib regeneron regn watch video ibd chart analysis
1344,CELG,stock struggle thursday major index test day move average line nasdaq cut early loss ibd end volume rise nyse fall nasdaq major index open lower then stage positive reversal nasdaq bounce day line
1345,CELG,medical biom biotech group straight week have be rank industry group ibd track mean group be bolster best perform stock market video analyze chart top rate abc group alexion pharmaceutical alxn biogen idec biib celgene celg biogen
1346,CELG,joe fath take driver seat rowe price growth stock fund little more year jan recently thismutual fund have shift higher gear fund be fath take charge vs large cap growth rival track morningstar inc stock market today
1347,CELG,past month vs peer group big cap bogey
1348,CELG,fath say take month reposition portfolio liking performance then reflect shift stock investment idea
1349,CELG,portfolio hold name take top account money tail end portfolio take money
1350,CELG,aim be weather growth company expand earning matter happen macro environment surround
1351,CELG,see linkedin lnkd core recruit business be mature continue do well say
1352,CELG,addition fath like new opportunity linkedin be nurture be bizo acquisition aim help advertiser reach business professional
1353,CELG,be new version sale navigator be sale lead facilitator tool provide nice tailwind back half year say
1354,CELG,improvement help linkedin boost revenue make current expensive valuation look more reasonable fath say
1355,CELG,head cloud
1356,CELG,fath also like servicenow now core business be information technology service management itsm software deliver cloud service platform let client create customize application fath see firm createnow development suite set tool manage lifecycle app promising revenue source
1357,CELG,also servicenow be find new user human resource operation maintenance facility department core client say
1358,CELG,fath begin stake vipshop vip last year second quarter have increase stake quarter then
1359,CELG,fath see vipshop unique retailer china be discounter line ross store rost tjx tjx marshall maxx
1360,CELG,sale be entirely online be marshall maxx ross store online brick mortar china say
1361,CELG,add celgene
1362,CELG,fath fund have boost weighting celgene celg least quarters row like company have expand heavy reliance cancer drug revlimid
1363,CELG,november celgene get european approval first immunology drug otezla treat psoriasis psoriatic arthritis
1364,CELG,also ramp sale other cancer drug pomalyst abraxane
1365,CELG,company gd drug treatment crohn disease show promise game changer fath say also like celgene investment smaller biotechs joe fath take driver seat rowe price growth stock fund little more year jan recently thismutual fund have shift higher gear fund be fath take charge vs large cap growth rival track morningstar inc stock market today past month vs peer group big cap bogey fath say take month reposition portfolio liking performance then reflect shift stock investment idea portfolio hold name take top account money tail end portfolio take money aim be weather growth company expand earning matter happen macro environment surround see linkedin lnkd core recruit business be mature continue do well say addition fath like new opportunity linkedin be nurture be bizo acquisition aim help advertiser reach business professional be new version sale navigator be sale lead facilitator tool provide nice tailwind back half year say improvement help linkedin boost revenue make current expensive valuation look more reasonable fath say head cloudfath also like servicenow now core business be information technology service management itsm software deliver cloud service platform let client create customize application fath see firm createnow development suite set tool manage lifecycle app promising revenue source also servicenow be find new user human resource operation maintenance facility department core client say fath begin stake vipshop vip last year second quarter have increase stake quarter then fath see vipshop unique retailer china be discounter line ross store rost tjx tjx marshall maxx sale be entirely online be marshall maxx ross store online brick mortar china say add celgenefath fund have boost weighting celgene celg least quarters row like company have expand heavy reliance cancer drug revlimid november celgene get european approval first immunology drug otezla treat psoriasis psoriatic arthritis also ramp sale other cancer drug pomalyst abraxane company gd drug treatment crohn disease show promise game changer fath say also like celgene investment smaller biotechs
1366,CELG,close new high tuesday technically put market back uptrend condition remain difficult dow jone industrial average extend winning streak session nasdaq couldn keep weigh burst institutional selling biotech space dow hit milestone
1367,CELG,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
1368,CELG,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
1369,CELG,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
1370,CELG,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
1371,CELG,worst performer ibd be regeneron pharmaceutical regn more
1372,CELG,energy name be day best perform industry group push oil price be higher
1373,CELG,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
1374,CELG,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
1375,CELG,stock edge higher fourth straight session monday bring positive start holiday shorten trading week rise new close high just point away dec time high help strength chip stock nasdaq climb philadelphia semiconductor index rally dow jone industrial
1376,CELG,stock stay hesitant mode thursday nasdaq show stall action nasdaq close rise morning add less ibd fall volume rise board action nasdaq amount stall point distribution day count
1377,CELG,ibd have be land second chance many stock have rebound sell signal
1378,CELG,several case stock trigger sell rule hit sell signal yet lot have rally back reclaim buy point today be act be never sell signal chart
1379,CELG,investor handle situation be sell signal wrong be higher risk second chance entry
1380,CELG,first never ignore clear sell signal cut loss short be essential more often not best decision never know far stock fall know fed james bullard hadn suggest extend qe maybe market still be fall
1381,CELG,unusual see so many stock back buy point so soon tank
1382,CELG,provide be new issue company fundamental fund sponsorship market investor consider buy stock again
1383,CELG,be sure share be back proper buy point best volume be well average moment happen
1384,CELG,celgene celg provide good example stock look re enter buy area
1385,CELG,stock plunge much buy point oct certainly loss shake reasonable shareholder stock drop week move average be worry
1386,CELG,just biotech touch week move average share start rebound celgene be back entry last monday
1387,CELG,volume day be nearly more average strong upside volume rebound continue be proof institutional investor weren go miss celgene ride new high stock be now buy point
1388,CELG,interestingly volume last monday far outweighed volume celgene original aug
1389,CELG,celgene meet resistance september part october be clear base consolidation
1390,CELG,week ibd jump best week year so far list medical lead
1391,CELG,akorn akrx surge alexion pharmaceutical alxn celgene ibd top nasdaq rally gain ibd have be land second chance many stock have rebound sell signal several case stock trigger sell rule hit sell signal yet lot have rally back reclaim buy point today be act be never sell signal chart investor handle situation be sell signal wrong be higher risk second chance entry first never ignore clear sell signal cut loss short be essential more often not best decision never know far stock fall know fed james bullard hadn suggest extend qe maybe market still be fall unusual see so many stock back buy point so soon tank provide be new issue company fundamental fund sponsorship market investor consider buy stock again be sure share be back proper buy point best volume be well average moment happen celgene celg provide good example stock look re enter buy area stock plunge much buy point oct certainly loss shake reasonable shareholder stock drop week move average be worry just biotech touch week move average share start rebound celgene be back entry last monday volume day be nearly more average strong upside volume rebound continue be proof institutional investor weren go miss celgene ride new high stock be now buy point interestingly volume last monday far outweighed volume celgene original aug celgene meet resistance september part october be clear base consolidation week ibd jump best week year so far list medical lead akorn akrx surge alexion pharmaceutical alxn celgene ibd top nasdaq rally gain
1392,CELG,celgene alexion pharmaceutical stock jump thursday big cap biotechs beat third quarter estimate raise guidance
1393,CELG,celgene earning rise vs year earlier cent share exclude time item beating analyst estimate cent sale grow more wall street forecast
1394,CELG,biotech guide full year revenue line consensus add nickel ep guidance now also line last year
1395,CELG,celgene do trim outlook cancer drug abraxane have expect abraxane sale miss consensus do sale newly launch psoriatic arthritis drug otezla
1396,CELG,worry miss yet
1397,CELG,investor have be ask abraxane vs consensus otezla miss vs consensus rbc be cause concern write rbc capital market analyst michael yee note thursday don think so yet especially otezla be very early launch
1398,CELG,celgene also announce collaboration sutro biopharma develop antibody antibody drug conjugate create immuno oncology drug new deal expand december pact celgene increase stake sutro sutro receive upfront
1399,CELG,celgene stock hit record intraday close stock have rise week help upbeat datum new crohn disease drug
1400,CELG,alexion earning rise share time item cent estimate sale climb more consensus
1401,CELG,biotech raise narrow full year sale guidance range vs last year add more cent ep guidance now vs last year
1402,CELG,soliris still attract patient
1403,CELG,alexion stock soar break month base trading just february record high
1404,CELG,usual revenue come soliris alexion launch rare disease paroxysmal nocturnal hemoglobinurium pnh equally rare hemolytic uremic syndrome ahus conference call discuss result ceo leonard bell remark soliris be still acquire newly diagnosed pnh patient same rate do launch ahus ultimately look be even larger market
1405,CELG,bell also say alexion have complete last component roll fda submission approval second drug alfa start process earlier year need complete study natural history genetic bone disease alfa treat other disease alexion target very rare so fda want datum disease normal progress contrast patient alfa clinical trial
1406,CELG,alexion didn release study result martin mackay head research development say be consistent company expect say drug launch europe early next year japan later celgene alexion pharmaceutical stock jump thursday big cap biotechs beat third quarter estimate raise guidance celgene earning rise vs year earlier cent share exclude time item beating analyst estimate cent sale grow more wall street forecast biotech guide full year revenue line consensus add nickel ep guidance now also line last year celgene do trim outlook cancer drug abraxane have expect abraxane sale miss consensus do sale newly launch psoriatic arthritis drug otezla worry miss yet investor have be ask abraxane vs consensus otezla miss vs consensus rbc be cause concern write rbc capital market analyst michael yee note thursday don think so yet especially otezla be very early launch celgene also announce collaboration sutro biopharma develop antibody antibody drug conjugate create immuno oncology drug new deal expand december pact celgene increase stake sutro sutro receive upfront celgene stock hit record intraday close stock have rise week help upbeat datum new crohn disease drug alexion earning rise share time item cent estimate sale climb more consensus biotech raise narrow full year sale guidance range vs last year add more cent ep guidance now vs last year soliris still attract patientsalexion stock soar break month base trading just february record high usual revenue come soliris alexion launch rare disease paroxysmal nocturnal hemoglobinurium pnh equally rare hemolytic uremic syndrome ahus conference call discuss result ceo leonard bell remark soliris be still acquire newly diagnosed pnh patient same rate do launch ahus ultimately look be even larger market bell also say alexion have complete last component roll fda submission approval second drug alfa start process earlier year need complete study natural history genetic bone disease alfa treat other disease alexion target very rare so fda want datum disease normal progress contrast patient alfa clinical trial alexion didn release study result martin mackay head research development say be consistent company expect say drug launch europe early next year japan later
1407,CELG,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1408,CELG,pop top hold celgene celg drive ishare nasdaq biotechnology ibb second largest health care etf new high stock market today celgene announce late tuesday acquire san diego base receptos rcpt celgene robust earning revenue result also beat analyst consensus estimate new jersey base
1409,CELG,stock future head firmly higher ahead tuesday open lean rebound monday steep loss
1410,CELG,dow future be rise point fair market value nasdaq future be solid point future climb point
1411,CELG,be deadline day greece market continue keep careful eye development eurozone stock market today head european commission pressed greek prime minister alexis tsipra last minute bailout deal rather popular referendum vote schedule sunday
1412,CELG,reuter report tsipra say be consider move quote greek official say have be lot movement last few hour direction new proposal
1413,CELG,european market be mild selling pressure midday show loss range
1414,CELG,nasdaq shift sharply lower monday nasdaq breaking day move average diving test day line
1415,CELG,movement be encourage average act shake month long trading range stock future leane higher early tuesday suggest market just be make comfortable slightly larger box
1416,CELG,economic calendar get roll et case shiller city composite home price index april kingsbury international june chicago purchasing manager index be due conference board consumer confidence index also june be expect
1417,CELG,stock small drugmaker be busy premarket action cancer genetic cgix vault higher cellectis cll kite pharma kite jump juno therapeutic juno spiked news receive payment enter year agreement celgene celg regard cancer autoimmune disease treatment celgene share slip fraction
1418,CELG,number china base issue be rebound suggest attempt take back ground sharp loss monday
1419,CELG,soufun sfun leap ahead open real estate drop moderate trade monday test support converge day move average real estate site leju leju pop
1420,CELG,security software maker cheetah mobile cmcm climb preopen action stock drop nearly heavy trade monday end day thursday close
1421,CELG,majority ibd stock be unmoved ahead open motion energy drink market monster beverage mnst rolled ahead nearly stock end monday almost buy point climb right side month cup base
1422,CELG,taser international tasr grab premarket gain stun gun polouse camera maker drop moderate trade monday end day line support trigger sell rule fall more buy point
1423,CELG,china mainland market snap back day rout regulator floated possibility measure aim shore liquidity issue shanghai shenzhen exchange shanghai composite leap hong kong hang seng index rise japan tokyo nikkei edge
1424,CELG,dollar be mixed euro rise commodity be mixed europe brent crude more west texas intermediate half percent higher gold ease wheat corn be fraction stock future head firmly higher ahead tuesday open lean rebound monday steep loss dow future be rise point fair market value nasdaq future be solid point future climb point be deadline day greece market continue keep careful eye development eurozone stock market today head european commission pressed greek prime minister alexis tsipra last minute bailout deal rather popular referendum vote schedule sunday reuter report tsipra say be consider move quote greek official say have be lot movement last few hour direction new proposal european market be mild selling pressure midday show loss range nasdaq shift sharply lower monday nasdaq breaking day move average diving test day line movement be encourage average act shake month long trading range stock future leane higher early tuesday suggest market just be make comfortable slightly larger box economic calendar get roll et case shiller city composite home price index april kingsbury international june chicago purchasing manager index be due conference board consumer confidence index also june be expect stock small drugmaker be busy premarket action cancer genetic cgix vault higher cellectis cll kite pharma kite jump juno therapeutic juno spiked news receive payment enter year agreement celgene celg regard cancer autoimmune disease treatment celgene share slip fraction number china base issue be rebound suggest attempt take back ground sharp loss monday soufun sfun leap ahead open real estate drop moderate trade monday test support converge day move average real estate site leju leju pop security software maker cheetah mobile cmcm climb preopen action stock drop nearly heavy trade monday end day thursday close majority ibd stock be unmoved ahead open motion energy drink market monster beverage mnst rolled ahead nearly stock end monday almost buy point climb right side month cup base taser international tasr grab premarket gain stun gun polouse camera maker drop moderate trade monday end day line support trigger sell rule fall more buy point china mainland market snap back day rout regulator floated possibility measure aim shore liquidity issue shanghai shenzhen exchange shanghai composite leap hong kong hang seng index rise japan tokyo nikkei edge dollar be mixed euro rise commodity be mixed europe brent crude more west texas intermediate half percent higher gold ease wheat corn be fraction
1425,CELG,lag biotech stock epizyme epzm suddenly come life monday jump more wake positive weekend datum lymphoma drug
1426,CELG,saturday annual international conference malignant lymphoma epizyme say advanced hodgkin lymphoma nhl patient phase study respond tazemetostat epz first class drug call ezh inhbitor patient diffuse large cell lymphoma respond do patient follicular lymphoma
1427,CELG,epizyme say start enrolling patient phase trial nhl
1428,CELG,breadth depth durability response see nhl patient multiple histology continue impress do safety tolerability tazemetostat phase study say dr vincent ribrag present study press release patient dose escalation cohort have see noteworthy deepen response time
1429,CELG,leerink analyst howard liang write research note monday presentation reveal number patient enrolled trial same drug solid blood tumor be larger expect make solid tumor datum dose escalation portion phase trial second half especially interesting give potential accelerate regulatory path addition further update tazemetostat liquid tumor datum epz dot inhibitor create partnership celgene celg mg dose cohort datum year end write
1430,CELG,liang point celgene be due decide renew partnership epizyme july
1431,CELG,do not expect celgene decision way have material impact epizyme pipeline development impact sentiment therefore serve potential catalyst write
1432,CELG,afternoon stock market today epizyme be trading month high celgene stock be more
1433,CELG,follow amy reeve twitter ibd_areeve lag biotech stock epizyme epzm suddenly come life monday jump more wake positive weekend datum lymphoma drug saturday annual international conference malignant lymphoma epizyme say advanced hodgkin lymphoma nhl patient phase study respond tazemetostat epz first class drug call ezh inhbitor patient diffuse large cell lymphoma respond do patient follicular lymphoma epizyme say start enrolling patient phase trial nhl breadth depth durability response see nhl patient multiple histology continue impress do safety tolerability tazemetostat phase study say dr vincent ribrag present study press release patient dose escalation cohort have see noteworthy deepen response time leerink analyst howard liang write research note monday presentation reveal number patient enrolled trial same drug solid blood tumor be larger expect make solid tumor datum dose escalation portion phase trial second half especially interesting give potential accelerate regulatory path addition further update tazemetostat liquid tumor datum epz dot inhibitor create partnership celgene celg mg dose cohort datum year end write liang point celgene be due decide renew partnership epizyme july do not expect celgene decision way have material impact epizyme pipeline development impact sentiment therefore serve potential catalyst write afternoon stock market today epizyme be trading month high celgene stock be more follow amy reeve twitter ibd_areeve
1434,CELG,big cap biotech celgene celg say late monday investing more partnership startup juno therapeutic juno send latter stock soar hour trading celgene buy juno share have option buy juno total stock course year
1435,CELG,most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy
1436,CELG,qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting
1437,CELG,top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more
1438,CELG,skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm
1439,CELG,successful investor keep eye cost qqq have expense ratio par iwm more spy
1440,CELG,asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow
1441,CELG,qqq rise thestock market today grasp distance old high
1442,CELG,follow aparna narayanan twitter ibd_anarayanan most heavily trade etfs have rally early month lows powershare qqq qqq be so far july past month year date compare ishare russell iwm gain period spdr spy qqq hold asset roughly largest nonfinancial stock nasdaq composite index technology sector account more half asset biotechnology company get hefty portfolio weighting top perform holding past month include netflix nflx electronic art ea tesla motor tsla also have big stake highly rate stock facebook fb regeneron pharmaceutical regn gilead science gild starbucks sbux celgene celg have ibd composite rating more skew technology sector large growth stock have help qqq edge most actively trade rival most past year average annual gain past year trail spy iwm successful investor keep eye cost qqq have expense ratio par iwm more spy asset qqq spy have shrink year iwm have grow smidge june exchange trade fund have leak more combine investor outflow qqq rise thestock market today grasp distance old high follow aparna narayanan twitter ibd_anarayanan
1443,CELG,flem ornskov have be shire only month term have be quite adventure already
1444,CELG,january close anglo irish drugmaker biggest acquisition buy biotech viropharma
1445,CELG,bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout
1446,CELG,year shire biggest drama be role have be biggest tax inversion deal drug industry
1447,CELG,north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain
1448,CELG,treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee
1449,CELG,undaunted oct shire report result beat expectation
1450,CELG,ornskov recently speak ibd abbvie adventure shire strategy
1451,CELG,ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now
1452,CELG,ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor
1453,CELG,deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company
1454,CELG,have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company
1455,CELG,long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team
1456,CELG,ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business
1457,CELG,ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean
1458,CELG,think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline
1459,CELG,ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point
1460,CELG,ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus
1461,CELG,put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development
1462,CELG,more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition
1463,CELG,ibd size acquisition expect
1464,CELG,ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful
1465,CELG,not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset
1466,CELG,ll look opportunity do other area flem ornskov have be shire only month term have be quite adventure already january close anglo irish drugmaker biggest acquisition buy biotech viropharma bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout year shire biggest drama be role have be biggest tax inversion deal drug industry north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee undaunted oct shire report result beat expectation ornskov recently speak ibd abbvie adventure shire strategy ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition ibd size acquisition expect ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset ll look opportunity do other area
1467,CELG,stock drift mostly lower friday little more hour left session medical stock lead way volume stock market today be run lighter thursday level
1468,CELG,nasdaq rise less lose dow jone industrial average drop
1469,CELG,chinese internet gaming service provider netease nte rise strong trade time high wednesday report estimate beating earning share year
1470,CELG,medical stock best performer recent year be worst performer friday top rank biotech industry group fall celgene celg lose biogen idec biib be biogen plunge day move average heavy volume
1471,CELG,oil service giant halliburton hal baker hughe bhi gain respectively thursday report merger negotiation energy stock be generally higher oil gain more barrel
1472,CELG,ibd stock rank bitauto bita vault heavy volume report earning cent share improvement year street have forecast cent action cause late stage cup handle base stock drift mostly lower friday little more hour left session medical stock lead way volume stock market today be run lighter thursday level nasdaq rise less lose dow jone industrial average drop chinese internet gaming service provider netease nte rise strong trade time high wednesday report estimate beating earning share year medical stock best performer recent year be worst performer friday top rank biotech industry group fall celgene celg lose biogen idec biib be biogen plunge day move average heavy volume oil service giant halliburton hal baker hughe bhi gain respectively thursday report merger negotiation energy stock be generally higher oil gain more barrel ibd stock rank bitauto bita vault heavy volume report earning cent share improvement year street have forecast cent action cause late stage cup handle base
1473,CELG,stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange
1474,CELG,hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating
1475,CELG,amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say
1476,CELG,amazon report earning close thursday analyst forecast loss cent share
1477,CELG,facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook
1478,CELG,ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock
1479,CELG,worst performer be egg producer cal maine food calm fall pull back hit new high monday
1480,CELG,follow ken hoover twitter ibd_khoover stock slip mixed trade go noon hour tuesday trader continue handicap upcoming earning report nasdaq be dow jone industrial average rise smidgen stock market today volume run higher same time monday nyse nasdaq exchange hawaiian holding parent hawaiian airline be only claw way back loss morning stock report earning beat estimate close monday sidoti co downgrade stock neutral cowen raise price maintain market perform rating amazon amzn fall tuesday morning report consumer intelligence research partner say amazon prime have customer spend average year site triple size year research organization say amazon report earning close thursday analyst forecast loss cent share facebook fb have carved similar pattern amazon be slightly touch new intraday high stock be find resistance century mark open jeffery lift price target facebook ibd company be higher be lower best performer be bank ozark ozrk nearly break cup handle base late monday announce have buy atlanta base community southern holding stock worst performer be egg producer cal maine food calm fall pull back hit new high monday follow ken hoover twitter ibd_khoover
1481,CELG,select stock have superior profit sale growth be not sole key success market neither be simply buy stock outstanding price strength
1482,CELG,invest stock make sure also be favorite biggest investor market mutual fund investment advisor bank critical component be know institutional sponsorship
1483,CELG,proof heavy institutional buy be way confirm sponsorship be time consume find ibd
1484,CELG,paper mutual fund etfs section provide instrument help many feature do double duty reveal top perform fund long term investor help stock strong buyer have target
1485,CELG,mutual fund be design more passive investing tool stock professional fund manager research crew pick time purchase stock so fund client don have sweat detail
1486,CELG,ibd narrow field list lead fund stock holding carry high average ibd composite rating have tend outperform index low
1487,CELG,growth fund lead market feature mutual fund page spotlight fund day be often case ibd feature make worth pull read glass diving fine print box provide basic bio fund volatility rating average ep relative price strength rating stock holding
1488,CELG,perhaps even more importantly box provide fund largest holding well top new buy top sell daily section also provide list other top perform fund screen accord various criterium
1489,CELG,delve even deeper ibd mutual fund monthly quarterly report usually publish first week month feature slice dice top perform fund accord size sector type investment such vital sign point warm cool movement global economy offer clue want tinker fund portfolio
1490,CELG,stock buy perspective monthly quarterly datum stock buy sell be pure gold mine datum table put radio collar smart money prior month stock be top fund buy much
1491,CELG,top fund latest sell table provide number fund buy vs selling net total seller spot stock list closely monitor chart key sell signal
1492,CELG,buy side stock name be familiar ibd big cap weekly review table list industry group name several key ibd rating detail many fund be buy total amount invest
1493,CELG,ibd mutual fund monthly special publish list alaska air alk skywork solution swks zebra techology zbra one top fund pour most dollar most recent month have trace solid gain year nov edition list celgene celg baidu bidu hca holding hca allergan agn select stock have superior profit sale growth be not sole key success market neither be simply buy stock outstanding price strength invest stock make sure also be favorite biggest investor market mutual fund investment advisor bank critical component be know institutional sponsorship proof heavy institutional buy be way confirm sponsorship be time consume find ibd paper mutual fund etfs section provide instrument help many feature do double duty reveal top perform fund long term investor help stock strong buyer have target mutual fund be design more passive investing tool stock professional fund manager research crew pick time purchase stock so fund client don have sweat detail ibd narrow field list lead fund stock holding carry high average ibd composite rating have tend outperform index low growth fund lead market feature mutual fund page spotlight fund day be often case ibd feature make worth pull read glass diving fine print box provide basic bio fund volatility rating average ep relative price strength rating stock holding perhaps even more importantly box provide fund largest holding well top new buy top sell daily section also provide list other top perform fund screen accord various criterium delve even deeper ibd mutual fund monthly quarterly report usually publish first week month feature slice dice top perform fund accord size sector type investment such vital sign point warm cool movement global economy offer clue want tinker fund portfolio stock buy perspective monthly quarterly datum stock buy sell be pure gold mine datum table put radio collar smart money prior month stock be top fund buy much top fund latest sell table provide number fund buy vs selling net total seller spot stock list closely monitor chart key sell signal buy side stock name be familiar ibd big cap weekly review table list industry group name several key ibd rating detail many fund be buy total amount invest ibd mutual fund monthly special publish list alaska air alk skywork solution swks zebra techology zbra one top fund pour most dollar most recent month have trace solid gain year nov edition list celgene celg baidu bidu hca holding hca allergan agn
1494,CELG,nasdaq composite serve guidepost market health ignore own peril
1495,CELG,day ibd analyze action major stock average determine market be uptrend healthy correction not so healthy very weak
1496,CELG,investor know status overall market decide buy sell stock best stock tend break basis success confirm uptrend conversely most stock fall correction matter strong recent fundamental
1497,CELG,failure heed market trend make difference rac nice profit take significant loss investment
1498,CELG,nasdaq help distill action thousand publicly trade stock be generally broader base nasdaq term industry sector yet many big winner hail nasdaq market so watch
1499,CELG,membership consist solely big cap stock nasdaq be weight more technology issue be broader term market capitalization offer large help small cap midcap stock
1500,CELG,ibd reader track action nasdaq day chart market trend page today ibd also provide chart dow jone industrial average value market barometer be limit track only large cap stock
1501,CELG,daily big picture today provide roundup daily market action discuss lead stock moved heavy volume market pulse box accompany column give quick snapshot day action describe market status
1502,CELG,market status change oct nasdaq jump climb volume be higher previous day marked fourth day follow change current outlook correction market confirm uptrend
1503,CELG,growth stock thrive confirm uptrend ibd jump oct small cap russell rise action growth oriented index support birth new uptrend
1504,CELG,drugmaker akorn akrx lannett lci celgene celg insurance firm amtrust financial afsi auto part retailer reilly automotive orly be growth stock break basis soon new uptrend begin not work market biggest winner often emerge early uptrend
1505,CELG,wednesday paper market pulse show distribution day nasdaq distribution day occur major average fall least higher volume prior session high distribution count say more be sign market uptrend be get tired due pullback
1506,CELG,excessive number distribution day poor action leader mean serious correction have arrived point investor raise cash sell stock especially one aren perform well have small profit cushion nasdaq composite serve guidepost market health ignore own peril day ibd analyze action major stock average determine market be uptrend healthy correction not so healthy very weak investor know status overall market decide buy sell stock best stock tend break basis success confirm uptrend conversely most stock fall correction matter strong recent fundamental failure heed market trend make difference rac nice profit take significant loss investment nasdaq help distill action thousand publicly trade stock be generally broader base nasdaq term industry sector yet many big winner hail nasdaq market so watch membership consist solely big cap stock nasdaq be weight more technology issue be broader term market capitalization offer large help small cap midcap stock ibd reader track action nasdaq day chart market trend page today ibd also provide chart dow jone industrial average value market barometer be limit track only large cap stock daily big picture today provide roundup daily market action discuss lead stock moved heavy volume market pulse box accompany column give quick snapshot day action describe market status market status change oct nasdaq jump climb volume be higher previous day marked fourth day follow change current outlook correction market confirm uptrend growth stock thrive confirm uptrend ibd jump oct small cap russell rise action growth oriented index support birth new uptrend drugmaker akorn akrx lannett lci celgene celg insurance firm amtrust financial afsi auto part retailer reilly automotive orly be growth stock break basis soon new uptrend begin not work market biggest winner often emerge early uptrend wednesday paper market pulse show distribution day nasdaq distribution day occur major average fall least higher volume prior session high distribution count say more be sign market uptrend be get tired due pullback excessive number distribution day poor action leader mean serious correction have arrived point investor raise cash sell stock especially one aren perform well have small profit cushion
1507,CELG,biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis
1508,CELG,tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock
1509,CELG,juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money
1510,CELG,celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating
1511,CELG,stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share
1512,CELG,celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma
1513,CELG,gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group
1514,CELG,gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi
1515,CELG,gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic
1516,CELG,enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually
1517,CELG,enanta have composite go public march have be profitable
1518,CELG,intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be
1519,CELG,other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually enanta have composite go public march have be profitable intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week
1520,CELG,stock set tightly mixed start friday nasdaq trading lower so far week
1521,CELG,nasdaq pull dow jone industrial average manage gain hung fractional loss
1522,CELG,volume be mixed nasdaq lower nyse compare trade same time thursday
1523,CELG,economic news researcher markit report purchasing manager index rise july suggest increase manufacturing vs read june economist have expect advance
1524,CELG,new home sale slow annualize pace june commerce department say be downwardly revise rate far expectation
1525,CELG,stock market today jump turbulent start stock stripe post dramatic move follow quarterly earning report
1526,CELG,chipmaker maxim integrate product mxim surge visa juniper network jnpr vault apiece tripadvisor trip dive capital financial cof tank
1527,CELG,amazon com amzn be blowout du start trade clobber consensus expectation quarterly report deliver late thursday stock be now thoroughly extend flat base buy point
1528,CELG,airline be pressure earning report american airline aal reversed early gain drop look positive second quarter result spirit airline save shed quarterly result
1529,CELG,biogen biib plummet report healthy profit increase revenue growth well consensus projection management also ratchete full year revenue guidance flagship drug tecfidera tysabri miss sale expectation stock have be consolidate march high struggle hold week line support
1530,CELG,chipmaker ambarella amba front ibd list rise heavy early trade share be trading just thursday high be extend sharp rebound week support
1531,CELG,group worst loss go celgene celg not quite ease thursday high drugmaker have gain recent session be extend buy point
1532,CELG,anthem antm cigna ci fall announce anthem pay acquire smaller peer stock set tightly mixed start friday nasdaq trading lower so far week nasdaq pull dow jone industrial average manage gain hung fractional loss volume be mixed nasdaq lower nyse compare trade same time thursday economic news researcher markit report purchasing manager index rise july suggest increase manufacturing vs read june economist have expect advance new home sale slow annualize pace june commerce department say be downwardly revise rate far expectation stock market today jump turbulent start stock stripe post dramatic move follow quarterly earning report chipmaker maxim integrate product mxim surge visa juniper network jnpr vault apiece tripadvisor trip dive capital financial cof tank amazon com amzn be blowout du start trade clobber consensus expectation quarterly report deliver late thursday stock be now thoroughly extend flat base buy point airline be pressure earning report american airline aal reversed early gain drop look positive second quarter result spirit airline save shed quarterly result biogen biib plummet report healthy profit increase revenue growth well consensus projection management also ratchete full year revenue guidance flagship drug tecfidera tysabri miss sale expectation stock have be consolidate march high struggle hold week line support chipmaker ambarella amba front ibd list rise heavy early trade share be trading just thursday high be extend sharp rebound week support group worst loss go celgene celg not quite ease thursday high drugmaker have gain recent session be extend buy point anthem antm cigna ci fall announce anthem pay acquire smaller peer
1533,CELG,biotech agio pharmaceutical agio continue selloff monday canaccord genuity lower price target base skepticism cancer drug
1534,CELG,agio stock drop friday ag clinical trial result investment bank cowen co say research report number be misinterpret
1535,CELG,report monday canaccord analyst john newman agree focuse concern different project report european hematology association conference last week ag drug agio be co develop celgene celg
1536,CELG,newman note ag effect blood cancer seem be moderate time really worry be phase datum solid tumor most cancer other blood be due second half year
1537,CELG,earlier year agio suggest solid tumor datum ag not surface be surprised give length time trial have be run write research note monday be also skeptical agio put molecule same mechanism action clinic such ag datum ag look promising
1538,CELG,factor suggest agio be see sub par datum ag phase study solid tumor company access trial be open label
1539,CELG,newman lower price target agio maintain hold rating morning trading stock market today agio stock be look be form cup handle agio stock touch more month high june celgene stock be fraction
1540,CELG,follow amy reeve twitter ibd_areeve biotech agio pharmaceutical agio continue selloff monday canaccord genuity lower price target base skepticism cancer drug agio stock drop friday ag clinical trial result investment bank cowen co say research report number be misinterpret report monday canaccord analyst john newman agree focuse concern different project report european hematology association conference last week ag drug agio be co develop celgene celg newman note ag effect blood cancer seem be moderate time really worry be phase datum solid tumor most cancer other blood be due second half year earlier year agio suggest solid tumor datum ag not surface be surprised give length time trial have be run write research note monday be also skeptical agio put molecule same mechanism action clinic such ag datum ag look promising factor suggest agio be see sub par datum ag phase study solid tumor company access trial be open label newman lower price target agio maintain hold rating morning trading stock market today agio stock be look be form cup handle agio stock touch more month high june celgene stock be fraction follow amy reeve twitter ibd_areeve
1541,CELG,share biotech startup juno therapeutic rise much tuesday close analyst weigh deal celgene announce late monday celgene celg agree pay upfront buy juno therapeutic juno share more double monday close price
1542,CELG,biotech agio pharmaceutical agio friday report positive early stage datum blood cancer drug develop celgene celg stock tumble more response rate seem miss investor expectation agio say patient acute myeloid leukemia aml other advanced blood cancer take ag response rate tumor shrinkage be
1543,CELG,nasdaq kick week solid performance monday lift semiconductor biotech stock micron technology mu rise try break free week consolidation show time high caveat be gain traction be late stage big price run
1544,CELG,big pharma firm such alexion pharmaceutical biogen idec continue outperform market develop market new treatment treat long time target such alzheimer well rare illness
1545,CELG,today screen day be big cap leader top rate stock large market capitalization stock be price
1546,CELG,today screen feature big drugmaker have report strong quarterly earning recently
1547,CELG,alexion pharmaceutical alxn continue grow steady clip blockbuster drug soliris so call orphan drug used treat rare blood disease dose pricey effective widely used alexion stock jump more oct break month base strong third quarter result
1548,CELG,earning call ceo leonard bell say alexion have complete last phase roll fda submission approval second drug alfa treatment genetic bone disease alexion rise fractionally tuesday trading stock market today
1549,CELG,biogen idec biib say day earlier ep rise crush estimate cent sale rise line view
1550,CELG,biogen lift full year earning guidance sale best selling treatment multiple sclerosis drug tecfidera fall short consensus share fall day stock have re-cover drop be trading day average just day average tuesday
1551,CELG,jazz pharmaceutical jazz say tuesday market close iyd ep rise beating consensus cent sale climb more analyst expect
1552,CELG,company lift full year profit outlook consensus view beat raise forecast come largely strong performance defitelio specialty drug treat rare condition afflict person undergo stem cell transplantation jazz acquire drug buy italian biotech gentium january
1553,CELG,jazz share rise late tuesday close
1554,CELG,celgene celg oct say ep climb cent beating analyst estimate cent share sale grow more wall street expect
1555,CELG,biotech guide full year revenue prior year line analyst view trim outlook flagship cancer drug abraxane investor weren worry take celgene stock day celgene stock be ibd leaderboard list top rate stock fall tuesday
1556,CELG,allergan agn buyout target lose round court tuesday bid defend takeover bid valeant vrx district judge david carter deny allergan motion sue valeant activist investor bill ackman persh square capital management insider trading bid block persh voting stake allergan special meeting slate dec
1557,CELG,allergan share rise tuesday hit new high investor see greater chance valeant takeover
1558,CELG,oct allergan report solid earning raise guidance ep rise beating estimate sale rise line guidance firm see ep vs year analyst consensus
1559,CELG,bonus stock
1560,CELG,actavis act be slate report financial result wednesday morning market open wall street expect ep jump surge revenue specialty drugmaker say oct be acquire biotech startup durata therapeutic cash
1561,CELG,follow james detar twitter ibd_jdetar big pharma firm such alexion pharmaceutical biogen idec continue outperform market develop market new treatment treat long time target such alzheimer well rare illness today screen day be big cap leader top rate stock large market capitalization stock be price today screen feature big drugmaker have report strong quarterly earning recently alexion pharmaceutical alxn continue grow steady clip blockbuster drug soliris so call orphan drug used treat rare blood disease dose pricey effective widely used alexion stock jump more oct break month base strong third quarter result earning call ceo leonard bell say alexion have complete last phase roll fda submission approval second drug alfa treatment genetic bone disease alexion rise fractionally tuesday trading stock market today biogen idec biib say day earlier ep rise crush estimate cent sale rise line view biogen lift full year earning guidance sale best selling treatment multiple sclerosis drug tecfidera fall short consensus share fall day stock have re-cover drop be trading day average just day average tuesday jazz pharmaceutical jazz say tuesday market close iyd ep rise beating consensus cent sale climb more analyst expect company lift full year profit outlook consensus view beat raise forecast come largely strong performance defitelio specialty drug treat rare condition afflict person undergo stem cell transplantation jazz acquire drug buy italian biotech gentium january jazz share rise late tuesday close celgene celg oct say ep climb cent beating analyst estimate cent share sale grow more wall street expect biotech guide full year revenue prior year line analyst view trim outlook flagship cancer drug abraxane investor weren worry take celgene stock day celgene stock be ibd leaderboard list top rate stock fall tuesday allergan agn buyout target lose round court tuesday bid defend takeover bid valeant vrx district judge david carter deny allergan motion sue valeant activist investor bill ackman persh square capital management insider trading bid block persh voting stake allergan special meeting slate dec allergan share rise tuesday hit new high investor see greater chance valeant takeover oct allergan report solid earning raise guidance ep rise beating estimate sale rise line guidance firm see ep vs year analyst consensus bonus stock actavis act be slate report financial result wednesday morning market open wall street expect ep jump surge revenue specialty drugmaker say oct be acquire biotech startup durata therapeutic cash follow james detar twitter ibd_jdetar
1562,CELG,big cap name week be medical related field reveal leadership name past few year have continue october correction whittle more nasdaq alexion pharmaceutical alxn develop drug treat blood disorder be extend buy point cup handle base
1563,CELG,stock post decent gain thursday shake weak start nasdaq tack add dow jone industrial average surge mostly thank visa gain ibd rise volume fall board market confirm uptrend individual investor be look stock
1564,CELG,tuesday announcement celgene celg agree acquire receptos rcpt pleased investor stock investor gilead science gild be rumore be interested receptos mean wait edge seat literally only question get gilead be be go buy say evercore isi analyst mark schoenebaum monday video record client stock have moved broker meeting month say re ready do deal crucial question gilead future sign be blockbuster hepatitis franchise be already hit ceiling record launch month however launch do give gilead enormous pile cash buy next major drug line have set wall street collective imagination overdrive target be here be most prominent suggestion have come last few month incyte incy be suggest tuesday nomura analyst ian somaiya note mainly celgene receptos deal incyte drug jakafi treat rare form bone marrow cancer well blood disease call polycythemia vera gilead recently enter blood cancer market zydelig launch just shy year chronic lymphocytic leukemia kind lymphoma somaiya note incyte also have promising pipeline include drug solid tumor incyte month revenue totale mostly jakafi company have have inconsistent quarters bottom line analyst expect record first annual profit next year however grow rapidly stock have reflect bullish expectation relative strength rating accumulation distribution grade incyte stock hit new high early stock market today retreat back yesterday close vertex pharmaceutical vrtx bernstein analyst geoffrey porge cause minor commotion endorse combination back april vertex own hepatitis blockbuster be stomp existence gilead be position dominant player cystic fibrosis only company proven have disease alter treatment devastate condition porge point gilead already sell product market call cayston so have foot door gilead need promise high probability incremental revenue reassure investor future outlook porge write time fact year be many predict vertex cf drug be go do eventually however other analyst doubt such deal happen ground vertex be expensive market cap be hover porge suggest price be gilead prefer buy development stage asset then launch vertex stock have be flat base porge floated idea achillion pharmaceutical achn buy achillion be go opposite direction term size achillion be startup market cap be just however have be subject speculation give have promising hepatitis drug candidate own potentially help gilead extend franchise come next generation treatment november achillion candidate yielded excellent week result clinical trial combine gilead sovaldi fbr capital analyst andrew beren argue buy achillion get gilead expect trend hcv intervention shorten treatment duration currently available week week course then twitter storm speculation erupt achillion abruptly pull investor conference suggest be announce something big turn be achillion have actually sign licensing deal johnson johnson jnj diminish chance gilead buyout bristol myer squibb bmy biotech buy big pharma well actually gilead be bigger bristol now do almost sale last year vs bristol bristol hottest new drug be biologic cancer drug opdivo be thestreet com adam feuerstein be think propose idea back january not sure exactly company gilead buy acquisition focus be oncology be just pharmasset be hepatitis business potential be certainly vast give opdivo alone be expect pass annual sale however price be even more staggering vertex bristol market value have continue go feuerstein prediction now stock hit new year high wednesday close more follow amy reeve twitter ibd_areeve
1565,CELG,health care fund be top perform sector past year wasn full speed ahead health care fund build much lead consumer staple technology fund mid here play investment make june average health care stock mutual fund have mushroomed
1566,CELG,sector beat earning forecast lead health care stock accord market researcher capital iq health care sector post gain well april forecast increase capital iq say june report biotech stock be best performer gilead science gild post
1567,CELG,person get older be more prone vision loss age related macular degeneration severe wet version condition be lead cause blindness afflict million person cause leaky abnormal blood vessel grow back eye treatment prognosis be dim biologic drug eylea
1568,CELG,major average never find foot monday end session lows sluggish open selling picked pace et close nasdaq lose give dow jone industrial average fall weak economic datum china be partly blame import shrank unexpectedly november
1569,CELG,major average extend gain late morning trading earning report surprisingly strong consumer confidence read
1570,CELG,nasdaq rally gain dow be volume be tracking higher nasdaq lower nyse stock market today compare same time monday
1571,CELG,conference board consumer confidence index jump year high well economist forecast other economic report include mixed september durable good datum decline case shiller city home price index
1572,CELG,automaker group be fastest mover ibd industry group tesla tsla lead charge advanced recoup monday loss then tesla ceo elon musk tweet september be record high ww worldwide year year north america reference model sale
1573,CELG,celgene celg rise new high triple normal trade stock be now extend past buy point reclaim earlier month revlimid vidaza maker have string together least quarters double digit profit sale growth analyst expect streak continue earning gain higher sale
1574,CELG,biotech be top rank industry group track ibd amgen amgn rocket report earning late monday top view biotech also raise earning sale forecast boost dividend say resume share buyback
1575,CELG,alibaba group baba extend gain seventh straight session add mark time high breaking past buy point short ipo base jack founder chairman chinese online retailer expressed interest work apple aapl apple pay mobile payment system
1576,CELG,follow nancy gondo twitter ibd_ngondo major average extend gain late morning trading earning report surprisingly strong consumer confidence read nasdaq rally gain dow be volume be tracking higher nasdaq lower nyse stock market today compare same time monday conference board consumer confidence index jump year high well economist forecast other economic report include mixed september durable good datum decline case shiller city home price index automaker group be fastest mover ibd industry group tesla tsla lead charge advanced recoup monday loss then tesla ceo elon musk tweet september be record high ww worldwide year year north america reference model sale celgene celg rise new high triple normal trade stock be now extend past buy point reclaim earlier month revlimid vidaza maker have string together least quarters double digit profit sale growth analyst expect streak continue earning gain higher sale biotech be top rank industry group track ibd amgen amgn rocket report earning late monday top view biotech also raise earning sale forecast boost dividend say resume share buyback alibaba group baba extend gain seventh straight session add mark time high breaking past buy point short ipo base jack founder chairman chinese online retailer expressed interest work apple aapl apple pay mobile payment system follow nancy gondo twitter ibd_ngondo
1577,CELG,celgene rolled more upbeat datum new crohn disease drug send biotech giant share higher tuesday monday celgene celg release abstract phase trial ged also call mongersen show good result patient week take drug share rise monday news tuesday present
1578,CELG,health care stock have be give stock market health care mutual fund shot arm much past year more so end investment average health care mutual fund have mushroomed same investment
1579,CELG,ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn
1580,CELG,valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance
1581,CELG,valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell
1582,CELG,valeant share ease tuesday be extend past cup handle base buy point initially clear last december
1583,CELG,actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval
1584,CELG,last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval
1585,CELG,actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best
1586,CELG,gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll
1587,CELG,last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency
1588,CELG,share barely close tuesday be buy point month long price consolidation
1589,CELG,celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc
1590,CELG,stock be form price consolidation buy point
1591,CELG,biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation
1592,CELG,regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating
1593,CELG,shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating
1594,CELG,illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level
1595,CELG,follow alissa william twitter ibd_awilliam ibd big cap leader screen filter highly liquid large cap stock strong record earning growth top notch medical stock make screen cut be valeant pharmaceutical vrx gilead science gild celgene celg actavis act biogen biib regeneron regn shire shpg illumina ilmn valeant pharmaceutical have highest possible ibd composite rating meaning share outperform stock market measure fundamental technical factor factor be earning sale growth profit margin return equity relative price performance valeant complete acquisition salix pharmaceutical april salix partner pharm group come monday good interim datum phase clinical trial conestat alfa drug ruconest develop treatment angioedema attack allergy related swell valeant share ease tuesday be extend past cup handle base buy point initially clear last december actavis partner perrigo prgo announce tuesday new drug application guaifenesin pseudoephedrine tablet mucinex alternative be give fda approval last week eluxadoline drug viberzi treatment irritable bowel syndrome also receive fda approval actavis be try stay cup handle base buy point initially clear last wednesday close tuesday actavis have composite rating best gilead have ibd composite rating biotech announce sunday phase trial result idelalisib drug zydelig combination ofatumumab show improvement progression free survival previously treat patient chronic lymphocytic leukemia cll last week european medicine agency validate gilead marketing application emtricitabine tenofovir alafenamide combination hiv treatment investigational combination be now evaluation european medicine agency share barely close tuesday be buy point month long price consolidation celgene be biotech composite rating bmo capital last week reiterate outperform rating celgene part future prospect pleiotropic modulator cc stock be form price consolidation buy point biogen biotech earn composite rating be now trading march peak price be reach nearly month long run price consolidation regeneron break cup handle base buy point mid gain much level tuesday session biotech share dip back buy range regeneron boast composite rating shire clear buy point flat base ethical drug maker stock be now trading back level shire have composite rating illumina make gene sequence system be work price consolidation buy point last week share get pivot be now trading level follow alissa william twitter ibd_awilliam
1596,CELG,study company fundamental often good idea check spending stand research development ibd look cost percentage annual sale find figure ibd minichart such friday weekly review marketsmith chart
1597,CELG,company spend money improve product process service develop new product hard imagine past decade global advance technology commerce
1598,CELG,not company have expense example wouldn expect cal maine food calm largest egg producer have cost report none
1599,CELG,isn top fundamental metric investor study such earning growth sale return equity still worth look
1600,CELG,play key role slim component slim stand something new such new product service good growth stock prospect have something new drive earning sale growth often be go take come new product service
1601,CELG,company be biotech technology field hard imagine enjoy continue success competition be likely surpass company technology quickly
1602,CELG,name last week ibd elite list growth stock report expense nearly be technology biotech drug industry group
1603,CELG,cost enormous amount money develop important new drug get approval regulator so perhaps surprise top ibd stock expense sale ratio be regeneron pharmaceutical regn celgene celg last year stock boast strong composite other ibd rating
1604,CELG,investor be carefully watch regeneron pipeline drug praluent cholesterol fighter fda review be expect be approve july regeneron be develop drug partnership sanofi sny
1605,CELG,celgene have rely cancer drug revlimid account third sale company say most recent earning report expect new drug expand used exist drug result sale sale be study company fundamental often good idea check spending stand research development ibd look cost percentage annual sale find figure ibd minichart such friday weekly review marketsmith chart company spend money improve product process service develop new product hard imagine past decade global advance technology commerce not company have expense example wouldn expect cal maine food calm largest egg producer have cost report none isn top fundamental metric investor study such earning growth sale return equity still worth look play key role slim component slim stand something new such new product service good growth stock prospect have something new drive earning sale growth often be go take come new product service company be biotech technology field hard imagine enjoy continue success competition be likely surpass company technology quickly name last week ibd elite list growth stock report expense nearly be technology biotech drug industry group cost enormous amount money develop important new drug get approval regulator so perhaps surprise top ibd stock expense sale ratio be regeneron pharmaceutical regn celgene celg last year stock boast strong composite other ibd rating investor be carefully watch regeneron pipeline drug praluent cholesterol fighter fda review be expect be approve july regeneron be develop drug partnership sanofi sny celgene have rely cancer drug revlimid account third sale company say most recent earning report expect new drug expand used exist drug result sale sale be
1606,CELG,drugmaker stock be move monday american society clinical oncology asco meeting continue produce key datum cancer trial top mover be immunogen imgn stock soar much month high base saturday report phase trial mirvetuximab soravtansine imgn ovarian cancer
1607,CELG,best mutual fund performance report highly profitable health care stock be hit mutual fund investor innovative drug merger even obamacare be fuel like actavis act centene cnc akorn akrx momentum grow health biotech fund spiked average top other domestic foreign category health
1608,CELG,stock hold session high afternoon trading fuel fresh breakout big gain positive jobless claim datum nasdaq rally ease record intraday high dow jone industrial average rise be volume be tracking higher board compare time wednesday
1609,CELG,weekly jobless claim release open fall prior week come sharply lower expect consumer price inched higher also forecast
1610,CELG,biotechs bigger gain biogen biib celgene celg regeneron regn be ibd lead industry group stock market today follow security stock airline energy steel stock lag
1611,CELG,supernus pharmaceutical supn vault heavy trade now extend more cup base buy point rockville md base biotech develop drug treat epilepsy attention deficit hyperactivity disorder jeffery upgrade stock buy hold
1612,CELG,fitness monitoring device maker fitbit fit continue hold most healthy first day gain offer price
1613,CELG,hain celestial hain gain new high breaking past flat base buy point average volume lynch earlier week add natural organic food product maker list top idea place price target stock
1614,CELG,blackhawk network hawk soar nearly fast trade track eighth straight advance stock clear flat base buy point wednesday volume be average payment network operator last week say buy achiever provider employee recognition reward product
1615,CELG,ibd stock manhattan associate manh rise new high clear buy point late stage flat base volume be just average supply chain management software maker have post double digit profit sale growth past quarters
1616,CELG,follow nancy gondo twitter ibd_ngondo stock hold session high afternoon trading fuel fresh breakout big gain positive jobless claim datum nasdaq rally ease record intraday high dow jone industrial average rise be volume be tracking higher board compare time wednesday weekly jobless claim release open fall prior week come sharply lower expect consumer price inched higher also forecast biotechs bigger gain biogen biib celgene celg regeneron regn be ibd lead industry group stock market today follow security stock airline energy steel stock lag supernus pharmaceutical supn vault heavy trade now extend more cup base buy point rockville md base biotech develop drug treat epilepsy attention deficit hyperactivity disorder jeffery upgrade stock buy hold fitness monitoring device maker fitbit fit continue hold most healthy first day gain offer price hain celestial hain gain new high breaking past flat base buy point average volume lynch earlier week add natural organic food product maker list top idea place price target stock blackhawk network hawk soar nearly fast trade track eighth straight advance stock clear flat base buy point wednesday volume be average payment network operator last week say buy achiever provider employee recognition reward product ibd stock manhattan associate manh rise new high clear buy point late stage flat base volume be just average supply chain management software maker have post double digit profit sale growth past quarters follow nancy gondo twitter ibd_ngondo
1617,CELG,large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore
1618,CELG,recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint
1619,CELG,linkedin lnkd look solid report strong earning last week close just buy point monday
1620,CELG,quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year
1621,CELG,company end quarter member year period new member come outside china be burgeon market linkedin
1622,CELG,elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software
1623,CELG,earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters
1624,CELG,meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise
1625,CELG,regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema
1626,CELG,regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis
1627,CELG,alriocumab meanwhile be show promise ldl cholesterol lower treatment
1628,CELG,caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage large cap stock often get labele bore overall sluggish price action latest ibd big cap list lead large cap growth be far bore recent health care related name alexion pharmaceutical alxn illumina ilmn celgene celg regeneron pharmaceutical continue trade well post technology name haven disappoint linkedin lnkd look solid report strong earning last week close just buy point monday quarterly profit rise year cent share sale rise total revenue come talent solution segment get fee company headhunter seek hire sale rise year company end quarter member year period new member come outside china be burgeon market linkedin elsewhere big cap salesforce com crm be trading well recent enterprise software maker recently enter boom datum analytic market wave software earning growth have be bit choppy recent quarters full year earning be expect ramp fiscal fiscal sale growth have be remarkably consistent recent quarters range past quarters meanwhile headline have be positive lately regeneron regn ahead earning report tuesday open thomson reuter consensus estimate call profit share year sale be see rise regeneron blockbuster drug be eylea popular treatment age related wet macular degeneration lead cause blindness elderly fda recently approve eylea additional indication treatment diabetic macular edema regeneron pipeline be strong company partner sanofi recently announce start phase study dupilumab patient atopic dermatitis drug also perform well phase study patient chronic sinusitis alriocumab meanwhile be show promise ldl cholesterol lower treatment caveat regeneron be lengthy uptrend regeneron never reset base count latest be stage base argue however recent consolidation start october start earlier year march be enough shake seller stock go line thought then regeneron latest be consider early stage
1629,CELG,medical stock be flex muscle latest big cap list ve more double number prior week even few medical sector make cut biotechs be well represent group earn top ranking monday issue industry group track ibd big improvement week alexion pharmaceutical alxn reversed upward edge higher follow last week gain stock be extend past entry second stage base trigger sell rule oct quickly re-cover buy point biotech thursday beat view earning year increase sale also lift full year profit sale guidance cheshire conn base company sole commercial drug soliris treat rare blood disease now submission process fda approval second drug alfa treat genetic bone disease call amgen amgn new high be extend cup handle buy point clear late july stock correct oct didn undercut entry share be hour oak calif base biotech be announce earning rise share sale increase consensus estimate amgen recently say work bill melinda gate foundation other group try find alternative method produce zmapp experimental ebola drug make mapp san diego celgene celg close slightly lower striking new high intraday monday be still extend past buy point surpass mid august alexion trigger sell rule oct quickly bounce back summit base biotech thursday report earning top view revenue line forecast celgene focus drug treat chancer immune inflammatory related disease revlimid vidaza abraxane be biggest seller regeneron pharmaceutical regn extend gain fifth straight session be now extend past flat base buy point tarrytown base biotech develop drug treat eye disease inflammatory disease cancer oct report clinical trial result eylea eye drug outperformed compete treatment patient diabetic macular edema other health care stock big cap include genetic analysis system maker illumina ilmn valeant pharmaceutical vrx maker dermatology neurology eye health drug
1630,CELG,big biotech celgene celg announce monday present datum crohn disease drug ged conference tuesday post abstract top line result high side expectation celgene stock be morning trading stock market today drug be potential blockbuster phase trial compare different dose
1631,CELG,stock advanced quiet volume friday nasdaq close day line first time late september nasdaq rise ibd lead gain volume fall board nasdaq retook day move average further testing be likely remain just
1632,CELG,stock swagger higher midday trade thursday major index moved closer test day move average line
1633,CELG,nasdaq climb add index be less day line critical area index need convert resistance support order rally further
1634,CELG,volume stock market today be run slightly higher nyse slightly lower nasdaq
1635,CELG,apple aapl add market recently renew bullish tone rise heavy volume move be good enough past buy point flat base apple isn market darling once be earning revenue growth have step recent quarters
1636,CELG,slew top rate stock be score new high thursday include facebook fb union pacific unp celgene celg advance auto part aap
1637,CELG,bear be clearly run advancer lead decline issue ratio nyse ratio nasdaq
1638,CELG,crude oil recently have reach week lows rise low oil price be bad news oil stock be good news airline plastic manufacturer consumer gain more discretionary income spending less gasoline stock swagger higher midday trade thursday major index moved closer test day move average line nasdaq climb add index be less day line critical area index need convert resistance support order rally further volume stock market today be run slightly higher nyse slightly lower nasdaq apple aapl add market recently renew bullish tone rise heavy volume move be good enough past buy point flat base apple isn market darling once be earning revenue growth have step recent quarters slew top rate stock be score new high thursday include facebook fb union pacific unp celgene celg advance auto part aap bear be clearly run advancer lead decline issue ratio nyse ratio nasdaq crude oil recently have reach week lows rise low oil price be bad news oil stock be good news airline plastic manufacturer consumer gain more discretionary income spending less gasoline
1639,CELG,stock notch solid open tuesday tech transportation stock lead energy mining issue bring rear
1640,CELG,nasdaq climb add dow jone industrial average tack gain
1641,CELG,volume be briskly mixed stock market today nasdaq nyse inverse early trading action monday
1642,CELG,air transport issue lead fedex fdx unite parcel service up notch best early gain industry group track ibd gold coal oil group post worst loss list
1643,CELG,commerce department report construction spending surge october reversed revise decline september easily outpaced economist expectation increase
1644,CELG,early stock action showedbiogen biib skip company report positive result phase study alzheimer treatment plan aggressively move phase trial gain lift share back converge week move average left stock still month consolidation
1645,CELG,cypress semiconductor cy power punch month high agree be acquire sunnyvale calif base spansion code stock deal value cypress share have be wallow consolidation mid spansion share fire ahead well new high
1646,CELG,leader ambarella amba celgene celg jump front ibd list
1647,CELG,ambarella pop start trade retake portion tumble take monday video chip maker be trading friday high extend strong october rebound week support
1648,CELG,biotech drug maker celgene climb nearly move new high now buy point double bottom base stock notch solid open tuesday tech transportation stock lead energy mining issue bring rear nasdaq climb add dow jone industrial average tack gain volume be briskly mixed stock market today nasdaq nyse inverse early trading action monday air transport issue lead fedex fdx unite parcel service up notch best early gain industry group track ibd gold coal oil group post worst loss list commerce department report construction spending surge october reversed revise decline september easily outpaced economist expectation increase early stock action showedbiogen biib skip company report positive result phase study alzheimer treatment plan aggressively move phase trial gain lift share back converge week move average left stock still month consolidation cypress semiconductor cy power punch month high agree be acquire sunnyvale calif base spansion code stock deal value cypress share have be wallow consolidation mid spansion share fire ahead well new high leader ambarella amba celgene celg jump front ibd list ambarella pop start trade retake portion tumble take monday video chip maker be trading friday high extend strong october rebound week support biotech drug maker celgene climb nearly move new high now buy point double bottom base
1649,CELG,new product introduction swipe trade secret chipmaker have steal spotlight so far week let not forget biotech stock be highlighted ibd screen day big cap leader semiconductor counterpart large cap biotechs include celgene celg regeneron pharmaceutical regn gilead science gild celgene have
1650,CELG,share highly rate drugmaker celgene celg lannett lci akorn akrx rise monday pair small drug company plunge negative report
1651,CELG,celgene partner acceleron pharma xlrn say food drug administration grant fast track designation treat patient have blood disease beta thalassemia result transfusion other cause
1652,CELG,fda fast track status allow company submit result faster enable drug come market sooner
1653,CELG,celgene rise stock market today acceleron be
1654,CELG,lannett maker generic drug come play announce agree acquire privately hold silarx pharmaceutical maker liquid generic drug
1655,CELG,deal close lannett portfolio exist pipeline product expand add fda approve manufacturing facility
1656,CELG,price other detail agreement be not disclose lannett climb
1657,CELG,be unclear specialty drugmaker akorn rise maker eye pain management drug say have receive delinquency notice nasdaq fail file quarterly form report march end period
1658,CELG,akorn say monday restate previously issue quarterly report fix error share be monday company expect file amend form prior filing quarter end march
1659,CELG,sharp contrast biotherapeutic ebio fall much company say lead drug candidate fail phase study treat moderate severe dry eye disease
1660,CELG,kite pharma kite have initial public offer june slump report disappointing first quarter earning late friday
1661,CELG,follow james detar twitter ibd_jdetar share highly rate drugmaker celgene celg lannett lci akorn akrx rise monday pair small drug company plunge negative report celgene partner acceleron pharma xlrn say food drug administration grant fast track designation treat patient have blood disease beta thalassemia result transfusion other cause fda fast track status allow company submit result faster enable drug come market sooner celgene rise stock market today acceleron be lannett maker generic drug come play announce agree acquire privately hold silarx pharmaceutical maker liquid generic drug deal close lannett portfolio exist pipeline product expand add fda approve manufacturing facility price other detail agreement be not disclose lannett climb be unclear specialty drugmaker akorn rise maker eye pain management drug say have receive delinquency notice nasdaq fail file quarterly form report march end period akorn say monday restate previously issue quarterly report fix error share be monday company expect file amend form prior filing quarter end march sharp contrast biotherapeutic ebio fall much company say lead drug candidate fail phase study treat moderate severe dry eye disease kite pharma kite have initial public offer june slump report disappointing first quarter earning late friday follow james detar twitter ibd_jdetar
1662,CELG,be brain top hedge fund buy valeant vrx actavis act other stock have help health care top other sector rise so far
1663,CELG,etfs offer access best idea hedge fund manager global guru guru peek form hold disclosure large successful hedge fund publish quarter sift pick high conviction idea mean stock hedge fund guru have major position shut hedge fund turn holding frequently cut risk replicate outdated pick
1664,CELG,peer alphaclone alternative alpha alfa employ similar strategy be slightly more complex try assess well hedge fund have do position rank manager partly base monthly return excess broad market index etf give more weight stock hold more manager
1665,CELG,be opportunity see smart money have be buy selling say todd rosenbluth director etf research capital iq successful investing idea guru have look past david einhorn greenlight capital john paulson paulson co seth klarman baupost capital
1666,CELG,first quarter health care be most actively buy sector largest hedge fund accord new research capital iq valeant pharmaceutical be top buy bill ackman persh square capital management grab share total purchase actavis be second biggest purchase buy
1667,CELG,guru asset hold stock health care holding include actavis shire plc shpg pharmaceutical stock ibd composite rating respectively get allocation equally weight portfolio
1668,CELG,etf have expense ratio fee invest
1669,CELG,alfa hold asset give apple aapl top bill holding portfolio weight valeant vrx year date be alfa top stock biogen biib celgene celg select medical holding sem unite therapeutic uthr also health care sector be stock high ibd rating
1670,CELG,etf have expense ratio
1671,CELG,guru alfa be trading time high stock market today
1672,CELG,rosenbluth caution etfs mimic hedge fund stock pick be relatively new small expensive etfs sponsor point hedge fund charge far more typically management fee performance fee
1673,CELG,guru alfa launch mid difference method be reflect performance alfa be year date gain annual average past year compare guru same period
1674,CELG,full capital iq report hedge fund be available online be brain top hedge fund buy valeant vrx actavis act other stock have help health care top other sector rise so far etfs offer access best idea hedge fund manager global guru guru peek form hold disclosure large successful hedge fund publish quarter sift pick high conviction idea mean stock hedge fund guru have major position shut hedge fund turn holding frequently cut risk replicate outdated pick peer alphaclone alternative alpha alfa employ similar strategy be slightly more complex try assess well hedge fund have do position rank manager partly base monthly return excess broad market index etf give more weight stock hold more manager be opportunity see smart money have be buy selling say todd rosenbluth director etf research capital iq successful investing idea guru have look past david einhorn greenlight capital john paulson paulson co seth klarman baupost capital first quarter health care be most actively buy sector largest hedge fund accord new research capital iq valeant pharmaceutical be top buy bill ackman persh square capital management grab share total purchase actavis be second biggest purchase buy guru asset hold stock health care holding include actavis shire plc shpg pharmaceutical stock ibd composite rating respectively get allocation equally weight portfolio etf have expense ratio fee invest alfa hold asset give apple aapl top bill holding portfolio weight valeant vrx year date be alfa top stock biogen biib celgene celg select medical holding sem unite therapeutic uthr also health care sector be stock high ibd rating etf have expense ratio guru alfa be trading time high stock market today rosenbluth caution etfs mimic hedge fund stock pick be relatively new small expensive etfs sponsor point hedge fund charge far more typically management fee performance fee guru alfa launch mid difference method be reflect performance alfa be year date gain annual average past year compare guru same period full capital iq report hedge fund be available online
1675,CELG,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
1676,CELG,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
1677,CELG,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
1678,CELG,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
1679,CELG,worst performer ibd be regeneron pharmaceutical regn more
1680,CELG,energy name be day best perform industry group push oil price be higher
1681,CELG,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
1682,CELG,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
1683,CELG,best etfs performance update
1684,CELG,several sector etfs have solar power investor double digit gain so far brightest gain american turn foreign shore china lord
1685,CELG,equity exchange trade fund re-cover recent trading session broad loss april give way higher interest rate mixed earning weigh stock
1686,CELG,don expect more modest increase rate even be enough push volatility higher be likely be headwind many most popular so call momentum stock russ global chief investment strategist blackrock write
1687,CELG,cite biotech social medium stock example peaked april then tumble hard uptick volatility
1688,CELG,spdr spy proxy broad market gain past month year date
1689,CELG,spdr biotech xbi be be month have soar so far similarly global social medium socl inched past month year date recent high back day move average bullish sign
1690,CELG,think loss momentum continue suggest increase value oriented stake namely integrate oil company trade deep discount rally recent lows
1691,CELG,eog eog pioneer pes plan resume drill rig deployment new supply slow rally stabilize oil price say
1692,CELG,overall investor expect good not great growth allocate healthy amount international stock advise
1693,CELG,indeed even best perform sector etf year date guggenheim solar tan trail foreign focuse etfs margin market vector chinaamc sme chinext cnxt surge past month alone take year date return
1694,CELG,invest small midsize china share have explode popularity asian nation open economy also be help tilt tech consumer startup sector company drive innovation growth china expense ratio be lower rival share etfs
1695,CELG,deutsche tracker harvest csi china share small cap ashs so far be more diversify hold roughly company
1696,CELG,past month several etfs hold single country european equity turkey russia austria portugal have peg tidiest profit
1697,CELG,re feel directly indirectly benefit aggressive monetary ease eurozone
1698,CELG,peter westaway chief european economist vanguard say optimistic outlook region light measure expect recovery be slog
1699,CELG,go be long haul lot bump way say recently only need look political turmoil greece moment see be still unresolved issue
1700,CELG,growth stock still rule
1701,CELG,broadly diversify domestic etfs growth oriented focus continue pay first trust dorsey focus fv fund fund have benefit health care biotech tilt
1702,CELG,hold ibd sector leader stock such regeneron regn biogen biib celgene celg fv be best perform diversify etfs so far advance
1703,CELG,fix income front investor have show appetite riskier asset interest rate be mired historic lows several emerge market high yield bond fund have outperformed
1704,CELG,precious metal etfs have rebound strongly gold silver price shot dollar sank weak job datum ishare silver trust slv have rise past month take gain powershare db dollar bullish uup have give past month gap tuesday stock market newsbest etfs performance updateseveral sector etfs have solar power investor double digit gain so far brightest gain american turn foreign shore china lord equity exchange trade fund re-cover recent trading session broad loss april give way higher interest rate mixed earning weigh stock don expect more modest increase rate even be enough push volatility higher be likely be headwind many most popular so call momentum stock russ global chief investment strategist blackrock write cite biotech social medium stock example peaked april then tumble hard uptick volatility spdr spy proxy broad market gain past month year date spdr biotech xbi be be month have soar so far similarly global social medium socl inched past month year date recent high back day move average bullish sign think loss momentum continue suggest increase value oriented stake namely integrate oil company trade deep discount rally recent lows eog eog pioneer pes plan resume drill rig deployment new supply slow rally stabilize oil price say overall investor expect good not great growth allocate healthy amount international stock advise indeed even best perform sector etf year date guggenheim solar tan trail foreign focuse etfs margin market vector chinaamc sme chinext cnxt surge past month alone take year date return invest small midsize china share have explode popularity asian nation open economy also be help tilt tech consumer startup sector company drive innovation growth china expense ratio be lower rival share etfs deutsche tracker harvest csi china share small cap ashs so far be more diversify hold roughly company past month several etfs hold single country european equity turkey russia austria portugal have peg tidiest profit re feel directly indirectly benefit aggressive monetary ease eurozone peter westaway chief european economist vanguard say optimistic outlook region light measure expect recovery be slog go be long haul lot bump way say recently only need look political turmoil greece moment see be still unresolved issue growth stock still ruleamong broadly diversify domestic etfs growth oriented focus continue pay first trust dorsey focus fv fund fund have benefit health care biotech tilt hold ibd sector leader stock such regeneron regn biogen biib celgene celg fv be best perform diversify etfs so far advance fix income front investor have show appetite riskier asset interest rate be mired historic lows several emerge market high yield bond fund have outperformed precious metal etfs have rebound strongly gold silver price shot dollar sank weak job datum ishare silver trust slv have rise past month take gain powershare db dollar bullish uup have give past month gap tuesday stock market news
1705,CELG,year biggest cancer meeting bring raft update hot oncology market send stock move wall street sort winner loser biggest upside surprise american society clinical oncology meeting chicago end tuesday probably come immunogen imgn beleaguered biotech come back life thank
1706,CELG,top stock mutual fund manager recent month have be feast mostly tech medical stock be top gainer november nation lead fund past month have be pour money apple aapl yahoo yhoo alibaba baba baidu bidu technology avgo latest report period medical big gun actavis act
1707,CELG,top company report earning thursday have high ibd composite rating grade stock base fundamental technical factor stock be also steadiest earning grower stock market armour ua be expect grow share earning cent revenue be see rise
1708,CELG,stock market bounce back tuesday try keep week uptrend go further nasdaq climb close session high erased practically monday drop nasdaq make less half loss small cap rebound more energy russell jump
1709,CELG,big cap biotech celgene make name cancer fighter now branch disease immune system biggest test new strategy come weekend unite european week vienna run saturday oct celgene celg be set present phase datum ged treatment crohn disease inflammatory disease gi tract celgene license drug april privately hold nogra pharma upfront payment regulatory development milestone payment sale milestone payment drug launch price raise eyebrow wall street few have hear nogra pharma be most celgene have ever paid upfront licensing deal only information have be publicly release be phase trial have only subject be not placebo controlled celgene however say already know phase datum be worth price ged be potentially therapy demonstrated striking clinical activity phase trial crohn disease scott celgene global head inflammation immunology say press release time date ged release near wall street curiosity optimism have be build accord rbc capital market analyst michael yee combine sale world lead immunology drug abbvie abbv humira johnson johnson jnj remicade come treatment crohn disease cause disease be still mysterious treatment be more management cure accord yee third patient don respond drug do relapse be frequent so potentially huge opportunity celgene drug work still drug have take get much attention recently aug deutsche bank analyst robyn karnauskas assert ged be not modeled wall street consensus number therefore bring huge potential upside then bandwagon have get more crowd nomura security analyst ian somaiya report interview investigator participate clinical trial study be double blind so didn know patient get ged get placebo investigator report patient go clinical remission response time be less half usual week humira take somaiya also observed safety problem strong efficacy expect believe full phase datum reflect clinical site finding confirm strong efficacy see phase trial rapid benefit durable remission clean safety profile somaiya write research note estimate ged reach peak worldwide sale drive upside celg share anticipation drug have boost celgene stock be trading record high week market crash evidence ged be drive celgene rise come stock drop trading day wasn apparent reason short note put late isi group analyst mark schoenebaum report meeting have celgene management new crohn disease drug be unlikely be once daily product schoenebaum write be due theoretical risk fibrotic change long term exposure however company very interested study re treatment intermittent dose month month fibrosis harden thicken bowel wall be common symptom crohn disease idea long term exposure ged make seem have spook investor schoenebaum apparently blame stock drop next day put clarification emphasize word theoretical note note such problem have be report trial go well ged be expect launch be celgene second immunology drug first otezla hit market march psoriatic arthritis be also approve psoriasis larger market street estimate peak annual sale otezla pass
1710,CELG,big cap biotech alexion pharmaceutical alxn beat estimate report lower expect guidance thursday announce change leadership vertex pharmaceutical vrtx celgene celg also moved new earning report
1711,CELG,alexion sale rise year earlier quarter more ahead analyst consensus profit exclude time item gain share beating estimate penny
1712,CELG,full year sale rise profit share
1713,CELG,year alexion expect sale miss consensus guide ep street have expect
1714,CELG,so many other company earning season alexion cite big foreign exchange hit sale cent ep
1715,CELG,company also announce ceo leonard bell retire april be replace chief operate officer david hallal bell continue chairman
1716,CELG,conference call analyst thursday bell emphasize be plan leadership transition now company have reach size operate quality happy
1717,CELG,join alexion year david role have expand entire organization last several year have increasingly share responsibility bell say now be right time david lead alexion
1718,CELG,hallal part allay worry guidance say pretax operate margin year be similar last year constant currency sale growth be also underline lower tax rate previously guide just
1719,CELG,news seem mollify investor et call share be stock market today time call finished alexion stock be afternoon trading alexion share rise try retake day move average
1720,CELG,other drug news vertex pharmaceutical plunge report mixed close wednesday get couple downgrade company bestselling hepatitis drug be crushed competition last year lose cent share cent more expect other hand revenue prior year beat consensus
1721,CELG,maxim group analyst jason kolbert downgrade vertex hold buy largely have rebuild model not earning report point risk associate vertex cystic fibrosis program be main focus now hep be derive price target be right stock close wednesday
1722,CELG,needham analyst alan carr also downgrade hold valuation concern stock be trading time high thursday drop
1723,CELG,meanwhile celgene report result line have preannounce month sale turn be slightly higher vs affirm previous guidance late morning celgene stock be intraday
1724,CELG,fellow big cap biotech biogen idec biib be due report close thursday analyst estimate biogen earning jump share sale rise
1725,CELG,biogen stock fall intraday
1726,CELG,follow amy reeve twitter ibd_areeve big cap biotech alexion pharmaceutical alxn beat estimate report lower expect guidance thursday announce change leadership vertex pharmaceutical vrtx celgene celg also moved new earning report alexion sale rise year earlier quarter more ahead analyst consensus profit exclude time item gain share beating estimate penny full year sale rise profit share year alexion expect sale miss consensus guide ep street have expect so many other company earning season alexion cite big foreign exchange hit sale cent ep company also announce ceo leonard bell retire april be replace chief operate officer david hallal bell continue chairman conference call analyst thursday bell emphasize be plan leadership transition now company have reach size operate quality happy join alexion year david role have expand entire organization last several year have increasingly share responsibility bell say now be right time david lead alexion hallal part allay worry guidance say pretax operate margin year be similar last year constant currency sale growth be also underline lower tax rate previously guide just news seem mollify investor et call share be stock market today time call finished alexion stock be afternoon trading alexion share rise try retake day move average other drug news vertex pharmaceutical plunge report mixed close wednesday get couple downgrade company bestselling hepatitis drug be crushed competition last year lose cent share cent more expect other hand revenue prior year beat consensus maxim group analyst jason kolbert downgrade vertex hold buy largely have rebuild model not earning report point risk associate vertex cystic fibrosis program be main focus now hep be derive price target be right stock close wednesday needham analyst alan carr also downgrade hold valuation concern stock be trading time high thursday drop meanwhile celgene report result line have preannounce month sale turn be slightly higher vs affirm previous guidance late morning celgene stock be intraday fellow big cap biotech biogen idec biib be due report close thursday analyst estimate biogen earning jump share sale rise biogen stock fall intraday follow amy reeve twitter ibd_areeve
1727,CELG,stock be hold session high late monday stage big upside reversal morning weak job report pressured equity open
1728,CELG,rally nasdaq gain blue chip dow jone industrial average lead gain
1729,CELG,epam system epam stretched gain push further new high territory stock be monday ibd earlier clear buy point flat base epam have trade tightly recent week show support action stock previously break february have now reach profit zone buy point cup base
1730,CELG,jd com jd rise clear resistance area thursday jd com announce former yahoo china executive chen zhang have joined company head research development jd mall share jd com be past buy point cup handle base clear march
1731,CELG,lennar len lose reverse multiyear high stock be pace snap session streak reversal stock be still past buy point cup base
1732,CELG,recent real estate article real estate agent expect sale new home surge year
1733,CELG,ambarella amba be fractionally lower volatility earlier stock market today stock have be intraday have price target hike pacific crest security stock be hold session high late monday stage big upside reversal morning weak job report pressured equity open rally nasdaq gain blue chip dow jone industrial average lead gain epam system epam stretched gain push further new high territory stock be monday ibd earlier clear buy point flat base epam have trade tightly recent week show support action stock previously break february have now reach profit zone buy point cup base jd com jd rise clear resistance area thursday jd com announce former yahoo china executive chen zhang have joined company head research development jd mall share jd com be past buy point cup handle base clear march lennar len lose reverse multiyear high stock be pace snap session streak reversal stock be still past buy point cup base recent real estate article real estate agent expect sale new home surge year ambarella amba be fractionally lower volatility earlier stock market today stock have be intraday have price target hike pacific crest security
1734,CELG,share biotechs moved lower afternoon trading wednesday broader market even amgen amgn top quarterly earning revenue view tuesday close analyst expect strong result biogen idec biib celgene celg report thursday
1735,CELG,wednesday dip come otherwise robust recent run ibd medical biom biotech group rank industry track group set record high tuesday be month
1736,CELG,amgen second biggest biotech market cap gilead science gild logged fourth quarter ep prior year cent consensus view revenue climb also estimate
1737,CELG,amgen overall product sale rise only year year company drug enjoy double digit sale increase include blockbuster enbrel treatment rheumatoid arthritis other immune disorder see sale rise
1738,CELG,note release wednesday morning rbc capital market analyst michael yee say amgen quarterly revenue beat be partly due boost inventory enbrel
1739,CELG,expect be reversed usual lead seasonally weaker yee say
1740,CELG,meanwhile sale amgen neupogen used treat neutropenia associate chemotherapy fall quarter wednesday note leerink analyst howard liang say decline be apparently result competition teva pharmaceutical teva granix
1741,CELG,celgene be due report result open thursday analyst poll thomson reuter expect company post earning cent share year earlier happen mark celgene biggest earning gain quarters revenue be see climb
1742,CELG,biogen be slate report fourth quarter earning thursday close cambridge mass base company have push report back day due severe blizzard hit boston area
1743,CELG,analyst expect biogen log ep gain revenue increase
1744,CELG,biogen own top ibd composite rating put medical biom biotech group celgene also have composite rating amgen have composite rating share biotechs moved lower afternoon trading wednesday broader market even amgen amgn top quarterly earning revenue view tuesday close analyst expect strong result biogen idec biib celgene celg report thursday wednesday dip come otherwise robust recent run ibd medical biom biotech group rank industry track group set record high tuesday be month amgen second biggest biotech market cap gilead science gild logged fourth quarter ep prior year cent consensus view revenue climb also estimate amgen overall product sale rise only year year company drug enjoy double digit sale increase include blockbuster enbrel treatment rheumatoid arthritis other immune disorder see sale rise note release wednesday morning rbc capital market analyst michael yee say amgen quarterly revenue beat be partly due boost inventory enbrel expect be reversed usual lead seasonally weaker yee say meanwhile sale amgen neupogen used treat neutropenia associate chemotherapy fall quarter wednesday note leerink analyst howard liang say decline be apparently result competition teva pharmaceutical teva granix celgene be due report result open thursday analyst poll thomson reuter expect company post earning cent share year earlier happen mark celgene biggest earning gain quarters revenue be see climb biogen be slate report fourth quarter earning thursday close cambridge mass base company have push report back day due severe blizzard hit boston area analyst expect biogen log ep gain revenue increase biogen own top ibd composite rating put medical biom biotech group celgene also have composite rating amgen have composite rating
1745,CELG,wonder put dollar bill work stock market year service health care technology consumer discretionary be sector largest project percentage increase earning growth year compare say dow jone index
1746,CELG,earning be rise stock market stock price increase usually follow
1747,CELG,so stock mutual fund manager other investor be pay close attention earning season play
1748,CELG,forecast whopping jump earning telecom stock equally whopping decline estimate be feb company have report result
1749,CELG,health tech consumer discretionary be expect post gain
1750,CELG,allergan agn earning contribute sector result rise year year beating consensus estimate
1751,CELG,earning mallinckrodt mnk drugmaker be also upside surprise
1752,CELG,tech apple aapl earning be also better expect
1753,CELG,pocket strength be visible even sector investor expect weakness
1754,CELG,dollar get stronger think impede unit volume higher value add good airplane turbine machinery say jim swanson mfs investment management chief investment strategist unit volume be hold revenue be rise not spectacularly
1755,CELG,take flight
1756,CELG,earning lockheed martin lmt be also exceed expectation
1757,CELG,several segment have grow pricey social medium stock have achieve nosebleed valuation swanson say find datum storage cloud software more attractively price
1758,CELG,health care hospital rehabilitation facility benefit expansion insurance coverage affordable care act
1759,CELG,yet congressional intervention supreme court decision threat aca say brad sorensen charle schwab director market sector analysis biotechs have grow pricey long run add
1760,CELG,other hand be bipartisan support possible rollback tax certain medical device benefit equipment maker sorensen say
1761,CELG,currency fluctuation be risk company foreign sale say margaret vitrano co manager clearbridge large cap growth fund
1762,CELG,impact large cap drugmaker say have little impact centric name cvs health cvs amgen amgn add
1763,CELG,company unitedhealth unh celgene celg biogen idec biib have strong franchise protect pricing foreign exposure say
1764,CELG,microsoft msft other software maker have fx exposure vitrano caution
1765,CELG,other tech company benefit secular tailwind more make fx risk add
1766,CELG,facebook fb be monetize instagram help stablemate atla be gain advertising dollar akamai akam benefit increase demand online security online video wonder put dollar bill work stock market year service health care technology consumer discretionary be sector largest project percentage increase earning growth year compare say dow jone index earning be rise stock market stock price increase usually follow so stock mutual fund manager other investor be pay close attention earning season play forecast whopping jump earning telecom stock equally whopping decline estimate be feb company have report result health tech consumer discretionary be expect post gain allergan agn earning contribute sector result rise year year beating consensus estimate earning mallinckrodt mnk drugmaker be also upside surprise tech apple aapl earning be also better expect pocket strength be visible even sector investor expect weakness dollar get stronger think impede unit volume higher value add good airplane turbine machinery say jim swanson mfs investment management chief investment strategist unit volume be hold revenue be rise not spectacularly take flightq earning lockheed martin lmt be also exceed expectation several segment have grow pricey social medium stock have achieve nosebleed valuation swanson say find datum storage cloud software more attractively price health care hospital rehabilitation facility benefit expansion insurance coverage affordable care act yet congressional intervention supreme court decision threat aca say brad sorensen charle schwab director market sector analysis biotechs have grow pricey long run add other hand be bipartisan support possible rollback tax certain medical device benefit equipment maker sorensen say currency fluctuation be risk company foreign sale say margaret vitrano co manager clearbridge large cap growth fund impact large cap drugmaker say have little impact centric name cvs health cvs amgen amgn add company unitedhealth unh celgene celg biogen idec biib have strong franchise protect pricing foreign exposure say microsoft msft other software maker have fx exposure vitrano caution other tech company benefit secular tailwind more make fx risk add facebook fb be monetize instagram help stablemate atla be gain advertising dollar akamai akam benefit increase demand online security online video
1767,CELG,earning season be really shift high gear week dozen major company report important focus very best
1768,CELG,let take look most notable ibd stock upcoming earning
1769,CELG,apple aapl report close tuesday result be sure be boost iphone lineup
1770,CELG,next have biogen biib report open wednesday biotech recently add neuropathic pain medication portfolio
1771,CELG,then facebook fb report close wednesday social network be try beef video ad revenue
1772,CELG,alexion alxn report thursday morning alexion have new drug launch year peak annual sale estimate range
1773,CELG,celgene celg also report thursday morning pre announce result drugmaker guide sale view preliminary ep top wall street target
1774,CELG,check video find just much analyst expect earning grow lead stock
1775,CELG,follow alissa william twitter ibd_awilliam earning season be really shift high gear week dozen major company report important focus very best let take look most notable ibd stock upcoming earning apple aapl report close tuesday result be sure be boost iphone lineup next have biogen biib report open wednesday biotech recently add neuropathic pain medication portfolio then facebook fb report close wednesday social network be try beef video ad revenue alexion alxn report thursday morning alexion have new drug launch year peak annual sale estimate range celgene celg also report thursday morning pre announce result drugmaker guide sale view preliminary ep top wall street target check video find just much analyst expect earning grow lead stock follow alissa william twitter ibd_awilliam
1776,CELG,major average further extend gain little more hour left tuesday regular session
1777,CELG,nasdaq rally advanced dow industrial add volume be tracking sharply higher board stock market today compare same time monday
1778,CELG,stock get early start help flurry earning report economic news exist home sale improve september annualize rate forecast august
1779,CELG,medical research gear solar transportation stock be big gainer industry group track ibd mortgage service wood product restaurant lag chipotle grill cmg weigh eatery group drop concern same store sale growth outlook
1780,CELG,illumina ilmn lead medical research equipment service group gain gap surge retake day move average nearly quadruple usual trade gene sequence company report earning revenue top view
1781,CELG,other ibd stock celgene celg gap rise heavy volume stock be flat base buy point clear aug pull back much entry last week vienna conference biotech present full datum phase trial ged drug crohn disease
1782,CELG,airline stock be fly high report industrywide domestic fare hike american airline group aal soar spirit airline save southwest airline luv rise unite continental holding ual fast turnover
1783,CELG,follow nancy gondo twitter ibd_ngondo major average further extend gain little more hour left tuesday regular session nasdaq rally advanced dow industrial add volume be tracking sharply higher board stock market today compare same time monday stock get early start help flurry earning report economic news exist home sale improve september annualize rate forecast august medical research gear solar transportation stock be big gainer industry group track ibd mortgage service wood product restaurant lag chipotle grill cmg weigh eatery group drop concern same store sale growth outlook illumina ilmn lead medical research equipment service group gain gap surge retake day move average nearly quadruple usual trade gene sequence company report earning revenue top view other ibd stock celgene celg gap rise heavy volume stock be flat base buy point clear aug pull back much entry last week vienna conference biotech present full datum phase trial ged drug crohn disease airline stock be fly high report industrywide domestic fare hike american airline group aal soar spirit airline save southwest airline luv rise unite continental holding ual fast turnover follow nancy gondo twitter ibd_ngondo
1784,CELG,market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week
1785,CELG,biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental
1786,CELG,medical biom biotech group be top rank group industry group ibd track
1787,CELG,biotechs be screen report earning week start biogen early wednesday
1788,CELG,analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise
1789,CELG,biogen share rise nearly stock market today climb monday
1790,CELG,celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue
1791,CELG,tuesday celgene report strong phase trial result mongersen drug treat crohn disease
1792,CELG,view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note
1793,CELG,celgene share rise more tuesday follow monday advance
1794,CELG,alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb
1795,CELG,alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development
1796,CELG,alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease
1797,CELG,share alexion be nearly week
1798,CELG,gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment
1799,CELG,gilead ep be see soar revenue climb
1800,CELG,gilead share also be nearly so far week
1801,CELG,regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis
1802,CELG,regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly
1803,CELG,share regeneron jump new high tuesday
1804,CELG,follow gillian rich twitter ibd_grich market new confirm rally investor pay close attention lead stock new buy opportunity biogen idec biib other medical company hold well correction have be leader week biogen idec be pharmaceutical company featured today ibd big cap screen day screen feature institutional quality stock be highly liquid have excellent fundamental medical biom biotech group be top rank group industry group ibd track biotechs be screen report earning week start biogen early wednesday analyst poll thomson reuter expect maker multiple sclerosis drug report jump earning seventh straight quarter double digit ep growth revenue be see rise biogen share rise nearly stock market today climb monday celgene celg report earning thursday oct analyst expect cancer therapy maker report jump earning cent rise revenue tuesday celgene report strong phase trial result mongersen drug treat crohn disease view bottom line be have high chance work phase ultimately read be key growth driver think upside long term guidance eventually be give rbc capital market analyst michael yee write note celgene share rise more tuesday follow monday advance alexion pharmaceutical alxn be also expect report earning result thursday analyst expect rise earning share revenue climb alexion make only drug soliris treatment blood disease paroxysmal nocturnal hemoglobinurium company have other drug development alexion show biotechs make enormous profit orphan drug medication treat extremely rare deadly disease share alexion be nearly week gilead science gild be slate report result oct earlier month fda approve gilead hepatitis combo pill harvoni combine megablockbuster sovaldi interferon treatment gilead ep be see soar revenue climb gilead share also be nearly so far week regeneron pharmaceutical regn round top monday company announce have start phase study possible drug dupilumab treatment moderate severe atopic dermatitis regeneron isn slate report earning nov analyst expect earning double share revenue jump nearly share regeneron jump new high tuesday follow gillian rich twitter ibd_grich
1805,CELG,share biotech startup agio pharmaceutical agio soar stock market today new high say report datum key clinical trial earlier expect lead analyst believe news be good agio say provide first datum ongoing phase study ag product develop treatment blood cancer nov symposium barcelona trial start march agio have say datum first come next year agio like present datum only reasonable conclusion be draw compound activity write cowen analyst eric schmidt research note friday hence be optimistic early datum release be associate strong efficacy signal agio be develop ag collaboration celgene celg currently biggest player blood cancer also backed celgene be agio lead product ag be somewhat further phase positive datum report earlier year last month fda grant fast track designation treatment leukemia even expedite review still year market agio have turn be most successful recent glut biotech ipos now trading more triple july ipo price follow amy reeve twitter ibd_areeve
1806,CELG,market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere
1807,CELG,latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year
1808,CELG,biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue
1809,CELG,biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake
1810,CELG,stock boast highest possible composite rating ep rating earning growth last quarters
1811,CELG,alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue
1812,CELG,company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year
1813,CELG,earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly
1814,CELG,last wednesday alexion submit application medical official japan approval drug
1815,CELG,company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating
1816,CELG,celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna
1817,CELG,wall street be look hike ep cent rise sale
1818,CELG,july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer
1819,CELG,illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx
1820,CELG,analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue
1821,CELG,stock have also weather market sell be near day line well
1822,CELG,several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh
1823,CELG,follow james detar twitter ibd_jdetar market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake stock boast highest possible composite rating ep rating earning growth last quarters alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly last wednesday alexion submit application medical official japan approval drug company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna wall street be look hike ep cent rise sale july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue stock have also weather market sell be near day line well several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh follow james detar twitter ibd_jdetar
1824,CELG,lower full year revenue forecast report earning sale consensus estimate market close wednesday
1825,CELG,be early trading stock market today
1826,CELG,short interest stock have climb ahead financial result ibd report
1827,CELG,cut outlook revenue growth
1828,CELG,least investment bank lower price target stock canaccord genuity oppenheimer lower rbc capital lower
1829,CELG,say ep fall year earlier quarter cent revenue rise analyst poll thomson reuter have estimate profit cent
1830,CELG,say add postpaid wireless subscriber include tablet computer user leave net add split phone digital life likely range home phone connect customer likely range say schildkraut analyst evercore partner research report
1831,CELG,result fall just shy consensus estimate add
1832,CELG,apple aapl iphone go sale likely affect earning phone company more so september quarter analyst say
1833,CELG,verizon communication vz tuesday say adjust ep rise cent miss estimate penny wireless service margin slip
1834,CELG,verizon say add postpaid wireless subscriber include mobile phone account tablet computer user
1835,CELG,response aggressive marketing mobile tmus have promote wireless plan make easier customer upgrade new smartphone equipment installment plan eip have reduce upfront retail subsidy mobile phone portion revenue be book upfront new eip offer usually come discount datum service lower average revenue subscriber
1836,CELG,increase postpaid wireless business due repricing eip be start show paul sa bernstein research analyst write research note
1837,CELG,drop revenue growth guidance emphasize role accounting installment plan rather organic performance have have prior upward revision revenue growth recently downward revision write citigroup analyst michael rollin report lower full year revenue forecast report earning sale consensus estimate market close wednesday be early trading stock market today short interest stock have climb ahead financial result ibd report cut outlook revenue growth least investment bank lower price target stock canaccord genuity oppenheimer lower rbc capital lower say ep fall year earlier quarter cent revenue rise analyst poll thomson reuter have estimate profit cent say add postpaid wireless subscriber include tablet computer user leave net add split phone digital life likely range home phone connect customer likely range say schildkraut analyst evercore partner research report result fall just shy consensus estimate add apple aapl iphone go sale likely affect earning phone company more so september quarter analyst say verizon communication vz tuesday say adjust ep rise cent miss estimate penny wireless service margin slip verizon say add postpaid wireless subscriber include mobile phone account tablet computer user response aggressive marketing mobile tmus have promote wireless plan make easier customer upgrade new smartphone equipment installment plan eip have reduce upfront retail subsidy mobile phone portion revenue be book upfront new eip offer usually come discount datum service lower average revenue subscriber increase postpaid wireless business due repricing eip be start show paul sa bernstein research analyst write research note drop revenue growth guidance emphasize role accounting installment plan rather organic performance have have prior upward revision revenue growth recently downward revision write citigroup analyst michael rollin report
1838,CELG,morning rally lose steam leave stock narrowly mixed midday
1839,CELG,apple aapl be still nearly follow late tuesday quarterly result nasdaq pare gain just
1840,CELG,dow jone industrial average be slip volume be tracking mixed stock market today nyse volume be tracking higher nasdaq trade be run lower
1841,CELG,biotechs celgene celg biogen idec biib reversed lower loss respectively former report result thursday morning
1842,CELG,elsewhere silicon motion technology simo lose reverse earlier gain stock have stage huge upside reversal tuesday silicon motion clear buy point cup handle base last week
1843,CELG,big fade market electronic art ea be still reaction late tuesday much better expect fiscal earning stock be well extend bounce week line break double bottom base late october electronic art be recently featured ibd industry theme
1844,CELG,paycom software payc come well session high still hold gain earlier stock clear buy point double bottom base cloud base human resource management software provider be featured wednesday stock spotlight morning rally lose steam leave stock narrowly mixed midday apple aapl be still nearly follow late tuesday quarterly result nasdaq pare gain just dow jone industrial average be slip volume be tracking mixed stock market today nyse volume be tracking higher nasdaq trade be run lower biotechs celgene celg biogen idec biib reversed lower loss respectively former report result thursday morning elsewhere silicon motion technology simo lose reverse earlier gain stock have stage huge upside reversal tuesday silicon motion clear buy point cup handle base last week big fade market electronic art ea be still reaction late tuesday much better expect fiscal earning stock be well extend bounce week line break double bottom base late october electronic art be recently featured ibd industry theme paycom software payc come well session high still hold gain earlier stock clear buy point double bottom base cloud base human resource management software provider be featured wednesday stock spotlight
1845,CELG,stock remain depress monday hour left trading session modest rally attempt day fail gain momentum nasdaq fall dow jone industrial average drop stock market today volume be tracking higher friday level ibd stock be higher be lower easily worst performer be volatile bitauto bita run automobile related website china chinese automaker say sale rise compare best performer ibd be celgene celg offer upbeat forecast beat analyst estimate say currency effect have negative effect revenue share be heavy trading share rise support day move average medical research equipment maker illumina ilmn drop sharply et be mount recovery be make presentation jpmorgan healthcare conference stock fall much buy point rebound energy stock be worst perform industry group oil drop barrel gold miner be best performer precious metal rise tif drop reduce outlook cite disappointing holiday sale fall sharply day move average well past buy point
1846,CELG,big cap biotech celgene celg provide preliminary fourth quarter earning report monday top estimate warn foreign exchange currency impact year ahead result be present prior presentation early monday annual jpmorgan healthcare conference san francisco fourth quarter celgene forecast net product sale be approximately include
1847,CELG,stock market close lower monday retailer have bumpy session nasdaq dow jone industrial average fall slip volume rise be surprise friday half session decline stock lead advancer nyse nasdaq stock market today transportation medical retail industry group be weakest monday energy mining stock be strongest lululemon athletica lulu gap loss sink right back day move average analyst fbr capital market downgrade lululemon underperform market perform cut price target investor grow pessimistic early holiday shopping indication other retailer sell heavy trading include ulta beauty ulta urban outfitter urbn regeneron pharmaceutical regn have worst loss ibd bid past buy point have unraveled close unitedhealth group unh say be back forecast earning share revenue be project be health insurer warn nov earning hit obamacare exchange related business cite higher medical cost individual market customer soft enrollment outlook unitedhealth share rise slightly extend trading several economic report be due tuesday manufacturing report purchasing manager institute supply management be due morning automaker report november sale earning report tuesday include fifth street finance fsc guidewire software gwre follow juan carlos arancibia twitter ibd_jarancibia
1848,CELG,nasdaq have make habit touch fresh high recent day be more same tuesday early strength fade nasdaq show stall action close nasdaq edge higher ease dow jone industrial average fall less volume
1849,CELG,many lead stock have be form flat basis market undergo series fairly shallow pullback flat base stock correct less ideal buy point typically cent high left side leader hold market correction be have trouble advance thus remain flat base
1850,CELG,remember new issue buy awhile back year be breaking first stage ipo base heavy volume solid fundamental thing beauty instead rise even more stock reversed higher volume then fall again again know be sit loss just few day go wrong be market boost portfolio performance immediately invest only trend be upward rise not downward fall major average show sign distribution time confirm uptrend selling intensify ibd current outlook see market pulse today quickly switch uptrend pressure even market correction time be cautious sell stock better condition never underestimate slim just last letter acronym doesn mean carry least importance fact arguably most important be great identify name have potential be big market leader institutional investor be selling major average be go great stock have difficult time make headway monitor health broad market top ll find quick summary day action section market trend page show big daily chart nasdaq key datum keep tab market lead industry group past month day top mover big picture also today guide investor day day market action provide unique market commentary tiered market outlook scale market confirm uptrend uptrend pressure market correction money be put work stock confirm uptrend cash be favore market correction be scary heavy selling start hit major average market enter corrective phase growth stock tend fall least twice much broad market so important keep tight leash selling start intensify same time also important be ready market confirm new uptrend follow day confidence not be high try buy least stock get vehicle motion follow day be strong ll gain more confidence be totally ready scoop more opportunity market latest follow day catch market pro guard be viable oct nasdaq soar higher volume fourth day rally attempt plenty individual growth name be ready participate ibd name netease nte clear buy point same day nasdaq follow be hit new high then share remain accumulation other name start move follow day include lennar len celgene celg apple aapl boise cascade bcc solarwind swi lennar have prove leader ibd home build group still hold comfortably cup handle buy point clear last month
1851,CELG,stock market close higher thursday index pare gain
1852,CELG,nasdaq climb dow jone industrial average add
1853,CELG,volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse
1854,CELG,computer trucking financial rank day top perform sector retail metal energy stock lag
1855,CELG,weak forecast send homebuilding stock stock market today
1856,CELG,meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february
1857,CELG,be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company
1858,CELG,homebuilder industry group have be market leader be worst group thursday ibd track
1859,CELG,day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december
1860,CELG,google googl rise share continue rise support day move average volume google be light
1861,CELG,close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low
1862,CELG,follow juan carlos arancibia twitter ibd_jarancibia stock market close higher thursday index pare gain nasdaq climb dow jone industrial average add volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse computer trucking financial rank day top perform sector retail metal energy stock lag weak forecast send homebuilding stock stock market today meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company homebuilder industry group have be market leader be worst group thursday ibd track day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december google googl rise share continue rise support day move average volume google be light close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low follow juan carlos arancibia twitter ibd_jarancibia
1863,CELG,stock suffer biggest loss nearly month thursday mixed datum weekly jobless claim durable good
1864,CELG,hurt drop apple aapl nasdaq tumble lose index breach support day move average thursday marked worst day july dow jone industrial average fall accord preliminary datum volume end mixed stock market today nasdaq trade jump nyse volume end lower
1865,CELG,big loss market leader big volume be relatively few
1866,CELG,loser biogen idec biib drop erase just wednesday move stock stay buy point
1867,CELG,celgene celg fall give open gain erased early wednesday move still past buy point flat base
1868,CELG,skecher skx rise recoup wednesday nearly loss bring sale concern shoemaker issue statement issue statement address worry early thursday skecher end thursday high meeting resistance day move average
1869,CELG,gopro gpro squeeze gain volatile session stock score third straight new high close past buy point ipo base gopro upcoming wearable camera hero be expect be mid october
1870,CELG,university michigan consumer sentiment index be friday et stock suffer biggest loss nearly month thursday mixed datum weekly jobless claim durable good hurt drop apple aapl nasdaq tumble lose index breach support day move average thursday marked worst day july dow jone industrial average fall accord preliminary datum volume end mixed stock market today nasdaq trade jump nyse volume end lower big loss market leader big volume be relatively few loser biogen idec biib drop erase just wednesday move stock stay buy point celgene celg fall give open gain erased early wednesday move still past buy point flat base skecher skx rise recoup wednesday nearly loss bring sale concern shoemaker issue statement issue statement address worry early thursday skecher end thursday high meeting resistance day move average gopro gpro squeeze gain volatile session stock score third straight new high close past buy point ipo base gopro upcoming wearable camera hero be expect be mid october university michigan consumer sentiment index be friday et
1871,CELG,major average rally lows be session high more hour wednesday session
1872,CELG,nasdaq lead way touch day move average dow jone industrial average add nyse volume be tracking higher tuesday level nasdaq volume be lower
1873,CELG,economic news august new home sale come well expectation
1874,CELG,stock market today bed bath bbby soar retailer report better expect earning late tuesday
1875,CELG,crush partner hclp rebound recent sign institutional selling share gain fast trade upgrade stock buy hold company make sand used frac process extract gas hard reach shale
1876,CELG,celgene celg leaderboard name investor com gain nearly tuesday food drug administration approve expand use psoriatic arthritis drug otezla treat patient moderate severe plaque psoriasis ibd medical biom biotech group be day top performer
1877,CELG,buyer be mattress firm mfrm early wednesday share rise stock gap consolidation mid august then clear week tight pattern early september full year earning be see rise fiscal fiscal small cap be thinly trade boast solid fund sponsorship
1878,CELG,downside skecher skx gap day move average huge volume fall accord briefing com weakness be be attribute weekly sale datum point market datum firm provide point sale datum outdoor active lifestyle market skecher show straight quarters accelerate sale growth straight quarters triple digit earning growth major average rally lows be session high more hour wednesday session nasdaq lead way touch day move average dow jone industrial average add nyse volume be tracking higher tuesday level nasdaq volume be lower economic news august new home sale come well expectation stock market today bed bath bbby soar retailer report better expect earning late tuesday crush partner hclp rebound recent sign institutional selling share gain fast trade upgrade stock buy hold company make sand used frac process extract gas hard reach shale celgene celg leaderboard name investor com gain nearly tuesday food drug administration approve expand use psoriatic arthritis drug otezla treat patient moderate severe plaque psoriasis ibd medical biom biotech group be day top performer buyer be mattress firm mfrm early wednesday share rise stock gap consolidation mid august then clear week tight pattern early september full year earning be see rise fiscal fiscal small cap be thinly trade boast solid fund sponsorship downside skecher skx gap day move average huge volume fall accord briefing com weakness be be attribute weekly sale datum point market datum firm provide point sale datum outdoor active lifestyle market skecher show straight quarters accelerate sale growth straight quarters triple digit earning growth
1879,CELG,top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal
1880,CELG,ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record
1881,CELG,illumina outlook cautious
1882,CELG,gene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say
1883,CELG,monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average
1884,CELG,biogen buy convergence
1885,CELG,cambridge mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease
1886,CELG,sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain
1887,CELG,biogen rise high tuesday whisker time high set dec close
1888,CELG,shire buy nps pharma
1889,CELG,january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease
1890,CELG,shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate
1891,CELG,shire have partly re-cover stock fall monday stock close tuesday day line
1892,CELG,actavis see exceptional sale
1893,CELG,actavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter
1894,CELG,actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close
1895,CELG,celgene bullish revlimid
1896,CELG,monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale
1897,CELG,celgene expect overall sale climb
1898,CELG,term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer
1899,CELG,celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average
1900,CELG,follow james detar twitter ibd_jdetar top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record illumina outlook cautiousgene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average biogen buy mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain biogen rise high tuesday whisker time high set dec close shire buy nps pharmain january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate shire have partly re-cover stock fall monday stock close tuesday day line actavis see exceptional salesactavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close celgene bullish revlimidon monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale celgene expect overall sale climb term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average follow james detar twitter ibd_jdetar
1901,CELG,stock step healthy gain early trade tuesday analyst upgrade positive earning report appear trump decline oil price
1902,CELG,nasdaq punch dow jone industrial average grab gain jump
1903,CELG,stock market today show comparatively mild reaction further decline oil price energy sector lead much monday selling be not show particular weakness energy stock dow bothexxon mobil xom chevron cvx be positive territory top dow microsoft msft merck mrk unite technology utx be nearly
1904,CELG,economic news be light dominate labor department november job opening labor turnover survey jolt report show employer report position unfilled october analyst consensus expect slight increase
1905,CELG,earning front kb home kbh rise fraction report revenue top expectation earning receive steep boost tax benefit new order average selling price also rise stock have be looping deepen correction month
1906,CELG,other homebuilder also climb lennar len horton dhi
1907,CELG,ibd list celgene celg drugmaker agio pharmaceutical agio announce late monday celgene exercise option exclusive licensing right outside ag oral cancer treatment gain send celgene new high leave extend rebound support week move average agio share rise
1908,CELG,alaska air group alk also hop take new high heavy volume gain push share buy point october
1909,CELG,railroad csx csx be schedule report fourth quarter result close stock step healthy gain early trade tuesday analyst upgrade positive earning report appear trump decline oil price nasdaq punch dow jone industrial average grab gain jump stock market today show comparatively mild reaction further decline oil price energy sector lead much monday selling be not show particular weakness energy stock dow bothexxon mobil xom chevron cvx be positive territory top dow microsoft msft merck mrk unite technology utx be nearly economic news be light dominate labor department november job opening labor turnover survey jolt report show employer report position unfilled october analyst consensus expect slight increase earning front kb home kbh rise fraction report revenue top expectation earning receive steep boost tax benefit new order average selling price also rise stock have be looping deepen correction month other homebuilder also climb lennar len horton dhi ibd list celgene celg drugmaker agio pharmaceutical agio announce late monday celgene exercise option exclusive licensing right outside ag oral cancer treatment gain send celgene new high leave extend rebound support week move average agio share rise alaska air group alk also hop take new high heavy volume gain push share buy point october railroad csx csx be schedule report fourth quarter result close
1910,CELG,cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide
1911,CELG,celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo
1912,CELG,celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen
1913,CELG,analyst have expect sale
1914,CELG,be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement
1915,CELG,celgene estimate ep product sale wall street have see ep sale
1916,CELG,celgene long term outlook
1917,CELG,forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus
1918,CELG,sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma
1919,CELG,celgene expect total revenue ep hematology franchise top
1920,CELG,celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate
1921,CELG,opdivo superior survival
1922,CELG,ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early
1923,CELG,several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise
1924,CELG,other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate
1925,CELG,illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth
1926,CELG,illumina share close trading low stock hit record friday
1927,CELG,actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday
1928,CELG,actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result cancer therapy bullish earning forecast take spotlight monday open jpmorgan healthcare conference week san francisco largest annual biotech conference worldwide celgene celg provide bullish forecast cancer drug revlimid generally positive preliminary result long term financial outlook bristol myer squibb bmy announce positive trial result lung cancer drug opdivo celgene expect ep vs year earlier wall street see cent net product sale be include negative foreign currency shift dollar hit multiyear high vs euro yen analyst have expect sale be exceptional year celgene momentum core business position year outstanding execution say ceo bob hugin statement celgene estimate ep product sale wall street have see ep sale celgene long term forecast net product sale wall street estimate be strong dollar other currency shift hurt net product sale celgene forecast adjust ep consensus sale core drug revlimid climb celgene gain wider approval treat more type cancer ongoing global expansion revlimid be used treat multiple myeloma type lymphoma celgene expect total revenue ep hematology franchise top celgene outlook be impressive write michael yee analyst rbc capital market report reason cite celgene beat narrowing guidance upper end most importantly long term guidance well previously publish estimate opdivo superior survival ahead jpmorgan event bristol myer squibb say sunday phase trial drug opdivo result superior overall survival lung cancer patient take pharma giant rise monday hit year high early several sunday pharma announcement swiss drug giant roche rhhby say buy foundation medicine fmi foundation make genomic test cancer shot roche share rise other jpmorgan news monday gene sequence equipment maker illumina ilmn report preliminary revenue estimate illumina expect revenue rise ep slightly cautious vs wall street forecast ep sale growth illumina share close trading low stock hit record friday actavis act say expect gaap earning top wall street estimate cite exceptional sale drugmaker share rise hit record intraday actavis recently win bidding war botox maker allergan agn offer trumping valeant pharmaceutical vrx valeant share shot new high last week give upbeat preliminary result
1929,CELG,stock remain vastly lower late thursday have trim loss nasdaq have cut early loss shave deficit dow jone industrial average dip volume run sharply higher board
1930,CELG,gray television gtn come session low be still intraday stock slump more buy point flat base mark sell signal
1931,CELG,amc network amcx trim early deficit damage have also be do earlier trigger sell rule buy point cup handle base
1932,CELG,medium stock be hammer stock market today weak quarterly sale viacom viab share diversify medium firm be session lows still almost
1933,CELG,upside fleetcor technology flt buck market weakness be have jump much follow late wednesday better expect earning susquehanna upgrade share positive neutral thursday fleetcor be flat base buy point
1934,CELG,arista network anet bitauto bita fleetmatic fltx jack box jack middleby midd monster beverage mnst nvidia nvda ubiquiti network ubnt be few notable company report earning close stock remain vastly lower late thursday have trim loss nasdaq have cut early loss shave deficit dow jone industrial average dip volume run sharply higher board gray television gtn come session low be still intraday stock slump more buy point flat base mark sell signal amc network amcx trim early deficit damage have also be do earlier trigger sell rule buy point cup handle base medium stock be hammer stock market today weak quarterly sale viacom viab share diversify medium firm be session lows still almost upside fleetcor technology flt buck market weakness be have jump much follow late wednesday better expect earning susquehanna upgrade share positive neutral thursday fleetcor be flat base buy point arista network anet bitauto bita fleetmatic fltx jack box jack middleby midd monster beverage mnst nvidia nvda ubiquiti network ubnt be few notable company report earning close
1935,CELG,most actively trade etfs have tumble recent time high be trading day move average line
1936,CELG,spdr spy be old high set december ishare russell iwm be record be powershare qqq qqq
1937,CELG,spy qqq etfs have large cap stock bent qqq offer much stronger tech stock tilt vs spy also allocate far more top stock holding such apple aapl microsoft msft vs spy
1938,CELG,allocation combine strong presence biotech name qqq top stock such gilead science gild amgen amgn celgene celg biogen idec biib help power gain stock market spy rise last year
1939,CELG,allocation financial real estate energy utility sector qqq entail higher sector concentration risk
1940,CELG,look ahead etf expert expect tech health care sector tooutperform
1941,CELG,many fund tracking small cap equity iwm lag last year climb iwm hold stock small cap make small fraction total stock market
1942,CELG,result fund be regard suitable satellite hold investor portfolio technology health care account more iwm asset
1943,CELG,etfs spy expense ratio make cheapest own iwm qqq charge investor most actively trade etfs have tumble recent time high be trading day move average line spdr spy be old high set december ishare russell iwm be record be powershare qqq qqq spy qqq etfs have large cap stock bent qqq offer much stronger tech stock tilt vs spy also allocate far more top stock holding such apple aapl microsoft msft vs spy allocation combine strong presence biotech name qqq top stock such gilead science gild amgen amgn celgene celg biogen idec biib help power gain stock market spy rise last year allocation financial real estate energy utility sector qqq entail higher sector concentration risk look ahead etf expert expect tech health care sector tooutperform many fund tracking small cap equity iwm lag last year climb iwm hold stock small cap make small fraction total stock market result fund be regard suitable satellite hold investor portfolio technology health care account more iwm asset etfs spy expense ratio make cheapest own iwm qqq charge investor
1944,CELG,stock stumble monday early go mixed economic report
1945,CELG,nasdaq slump lowest level aug biotech solar software be day worst group slip dow jone industrial average edge
1946,CELG,volume be run sharply higher major exchange stock market today trade be nearly compare same time friday nasdaq turnover be tracking only smidgen higher nyse
1947,CELG,economic news industrial production dip august first drop january economist poll econoday have expect gain capacity utilization ease july too miss view
1948,CELG,earlier monday empire state factory survey come much stronger expect
1949,CELG,leader celgene celg fall slip buy point flat base appear be find support day line celgene have now erased gain breaking aug
1950,CELG,baidu bidu lose putt pace sixth straight loss now early buy point flat base stock be close potential support day line
1951,CELG,stock ibd be lower
1952,CELG,athm rally extend rebound effort prior session stock find support day line wednesday past buy point deep cup fizzle benzinga report hedge fund tiger global management own stake chinese auto information provider
1953,CELG,mobileye mbly rise bounce back straight loss now past buy point ipo base stock trigger ibd key week hold rule mobileye be israeli maker camera base driver assistance system analyst poll thomson reuter see earning jump year stock stumble monday early go mixed economic report nasdaq slump lowest level aug biotech solar software be day worst group slip dow jone industrial average edge volume be run sharply higher major exchange stock market today trade be nearly compare same time friday nasdaq turnover be tracking only smidgen higher nyse economic news industrial production dip august first drop january economist poll econoday have expect gain capacity utilization ease july too miss view earlier monday empire state factory survey come much stronger expect leader celgene celg fall slip buy point flat base appear be find support day line celgene have now erased gain breaking aug baidu bidu lose putt pace sixth straight loss now early buy point flat base stock be close potential support day line stock ibd be lower athm rally extend rebound effort prior session stock find support day line wednesday past buy point deep cup fizzle benzinga report hedge fund tiger global management own stake chinese auto information provider mobileye mbly rise bounce back straight loss now past buy point ipo base stock trigger ibd key week hold rule mobileye be israeli maker camera base driver assistance system analyst poll thomson reuter see earning jump year
1954,CELG,manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc
1955,CELG,biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market
1956,CELG,sector theme be play be semiconductor
1957,CELG,fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks
1958,CELG,food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund
1959,CELG,ibd spot top perform fund have recently buy ulta beauty ulta investing estimate
1960,CELG,mainstay large cap growth fund add ulta holding latest report period
1961,CELG,bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america
1962,CELG,stock be month second stage base small handle fail attempt break last week put buy point
1963,CELG,ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period
1964,CELG,more depth coverage drive ulta growth see monday edition manage success page
1965,CELG,first half october spook investor sharp drop major stock index
1966,CELG,most correction earlier year market rebound quickly resume uptrend late october
1967,CELG,sell side
1968,CELG,america top notch fund lighten credit card payment firm visa mastercard latest report period
1969,CELG,have rally past week set get new high
1970,CELG,few retailer have be sell such lowe low petsmart petm william sonoma wsm manager lead mutual fund recent month have continue stock large medical stock such illumina ilmn alexion pharmaceutical alxn celgene celg jazz pharmaceutical jazz allergan agn centene cnc biotech biom group be rank industry tuesday big cap biotech medical stock hold better volatile market sector theme be play be semiconductor fabless chipmaker such technology avgo nxp semiconductor nxpi ambarella amba have be top performer also act well be chipmaker skywork solution swks food beverage stock such keurig green mountain coffee gmcr monster beverage mnst cal maine food calm hain celestial group hain be also favore best perform fund ibd spot top perform fund have recently buy ulta beauty ulta investing estimate mainstay large cap growth fund add ulta holding latest report period bolingbrook ill base ulta be beauty retailer provide stop shopping beauty product salon service america stock be month second stage base small handle fail attempt break last week put buy point ulta increase earning healthy double digit pace past quarters revenue growth also be robust range same period more depth coverage drive ulta growth see monday edition manage success page first half october spook investor sharp drop major stock index most correction earlier year market rebound quickly resume uptrend late october sell sideamerica top notch fund lighten credit card payment firm visa mastercard latest report period have rally past week set get new high few retailer have be sell such lowe low petsmart petm william sonoma wsm
1971,CELG,stock close narrowly mixed monday many leader show better action nasdaq rise thank strength datum storage networking stock be much intraday year high monday marked index first close bottom half trading range session small sign slack
1972,CELG,stock add recent gain friday dow jone industrial average moved further time high territory nasdaq touch week high
1973,CELG,hour session dow add add nasdaq rise less volume be heavy nyse nasdaq due option expiration
1974,CELG,stock market today oracle orcl paid visit day move average fall company report disappointing earning late thursday ceo larry ellison step ceo assume role chairman chief technology officer
1975,CELG,meanwhile big merger make headline software sector friday germany base sap sap announce plan buy concur technology cnqr share concur soar news sap lose
1976,CELG,gaslog glog extend gain friday heavy volume friday recently find support day move average stock reclaim day move average rise still recent high gaslog be fast grow liquefy natural gas carrier
1977,CELG,reclaim buy point tuesday celgene celg add gain rise just past buy point high end buy range
1978,CELG,technology avgo skywork solution swks give back early gain firm chip be new iphone
1979,CELG,meanwhile wall street be still await alibaba baba news investor com technology alibaba group ipo raise record htmopen highly anticipate ipo price thursday night be expect open stock add recent gain friday dow jone industrial average moved further time high territory nasdaq touch week high hour session dow add add nasdaq rise less volume be heavy nyse nasdaq due option expiration stock market today oracle orcl paid visit day move average fall company report disappointing earning late thursday ceo larry ellison step ceo assume role chairman chief technology officer meanwhile big merger make headline software sector friday germany base sap sap announce plan buy concur technology cnqr share concur soar news sap lose gaslog glog extend gain friday heavy volume friday recently find support day move average stock reclaim day move average rise still recent high gaslog be fast grow liquefy natural gas carrier reclaim buy point tuesday celgene celg add gain rise just past buy point high end buy range technology avgo skywork solution swks give back early gain firm chip be new iphone meanwhile wall street be still await alibaba baba news investor com technology alibaba group ipo raise record htmopen highly anticipate ipo price thursday night be expect open
1980,CELG,mainstay large cap growth fund be roll portfolio be month end go tuesday be fund large cap growth rival track morningstar inc averaged gain mainstay mutual fund recent gain top own relative performance past
1981,CELG,stock start quietly higher friday high volume hot spot shine early trade nasdaq hop ahead dow jone industrial average add gold miner post top early gain industry stock market today lead almost entirely gain thinly trade low price stock standout be agnico eagle mine aem moderate trade science gild celgene celg rise more apiece top gain nasdaq list nike nke rise nearly lead dow continue rebound test support week move average gopro gpro pop massive trade maker wearable action camera be week fight back steep month sell ibd list china base noah holding noah leap more start trade financial asset manager be still more high set early december ambarella amba jump surge volume boost rebound week support
1982,CELG,special report best mutual fund january performance report
1983,CELG,fall oil price greece possible exit eurozone stock market start first month year volatility
1984,CELG,best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market
1985,CELG,top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg
1986,CELG,ibd industry medical subgroup rank top tuesday biotech biom group rank
1987,CELG,top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu
1988,CELG,real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain
1989,CELG,ibd spot lead mutual fund add nautilus nls investing estimate
1990,CELG,jpmorgan small cap value fund add share latest report period
1991,CELG,vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer
1992,CELG,nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product
1993,CELG,stock be currently form handle third stage cup handle base trading buy point
1994,CELG,sell side
1995,CELG,lead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa
1996,CELG,top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis special report best mutual fund january performance reportamid fall oil price greece possible exit eurozone stock market start first month year volatility best perform mutual fund past month slow buy january outlook ibd market pulse toggle correction market pressure stock market top mutual fund have be add heavy hit medical issue such celgene celg biogen idec biib latest report period other include actavis act illumina ilmn shire shpg ibd industry medical subgroup rank top tuesday biotech biom group rank top perform fund continue give much love airline stock include southwest airline luv unite continental holding ual jetblue airway jblu real estate stock make way new buy list property reit such pebblebrook hotel peb extra space storage exr regency center reg be stellar performer lipper real estate mutual fund category be second best perform group january notch gain ibd spot lead mutual fund add nautilus nls investing estimate jpmorgan small cap value fund add share latest report period vancouver wash base firm make market fitness product include home gym free weight equipment treadmill indoor cycling equipment elliptical fitness accessory portfolio fitness brand include bowflex nautilus schwinn universal sell retail direct sale consumer nautilus have be pump sale growth past quarters analyst see growth opportunity nautilus continue deliver innovative product stock be currently form handle third stage cup handle base trading buy point sell sidelead fund have be take profit several big reit stock such simon property group spg federal realty investment trust frt aviv aviv public storage psa top perform fund be also selling biotech stock include gilead science gild isis pharmaceutical isis
1997,CELG,biotech industry be set hit ground run january alone bring passel potentially stock move event biggest player second full week month bring annual jpmorgan healthcare conference san francisco many company release product financial news first thing morning
1998,CELG,ibd just capped best week performance more year run produce batch breakout index rally past week best week period july ibd roar last week ibd add be comparable nasdaq
1999,CELG,major average be sharply lower hour thursday session nasdaq slump apple cast pall tech sector
2000,CELG,dow jone industrial average lose small cap take hit russell crater nyse volume be tracking close wednesday level nasdaq volume rise sharply
2001,CELG,stock market today apple aapl slump heavy volume fall day move average report surface wednesday io smartphone software update cause iphone user lose cellular service company also receive complaint warp phone
2002,CELG,apple be biggest decliner nasdaq illumina ilmn celgene celg biogen biib
2003,CELG,elsewhere valeant pharmaceutical vrx jump nearly issue upbeat guidance late wednesday
2004,CELG,smart final sfs extend gain rise wednesday debut price tuesday night close first day trading company operate grocery food service store western state northern mexico cash carry store
2005,CELG,ibd selling pressure be scant name ulta beauty ulta tal education xrs polaris pii
2006,CELG,economic news weekly jobless claim rise economist expect slightly bigger increase week move average claim fall second straight week meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate
2007,CELG,tomorrow final revision gdp be release et economist expect growth last estimate major average be sharply lower hour thursday session nasdaq slump apple cast pall tech sector dow jone industrial average lose small cap take hit russell crater nyse volume be tracking close wednesday level nasdaq volume rise sharply stock market today apple aapl slump heavy volume fall day move average report surface wednesday io smartphone software update cause iphone user lose cellular service company also receive complaint warp phone apple be biggest decliner nasdaq illumina ilmn celgene celg biogen biib elsewhere valeant pharmaceutical vrx jump nearly issue upbeat guidance late wednesday smart final sfs extend gain rise wednesday debut price tuesday night close first day trading company operate grocery food service store western state northern mexico cash carry store ibd selling pressure be scant name ulta beauty ulta tal education xrs polaris pii economic news weekly jobless claim rise economist expect slightly bigger increase week move average claim fall second straight week meanwhile durable good order plunge august bit consensus estimate drop weakness be attribute plunge aircraft order ex transportation order rise just consensus estimate tomorrow final revision gdp be release et economist expect growth last estimate
2008,CELG,putnam investor fund be old geezer dec inception date make industry second oldest stock fund
2009,CELG,act spry spring chicken lately
2010,CELG,jerry sullivan take mid fund average annual gain be top beat large cap blend fund track morningstar
2011,CELG,same length period prior sullivan take charge fund average annual gain lag large cap blend peer
2012,CELG,sullivan credit outperformance appetite growth value stock also target type stock one follow year push smart money special situation focus valuation
2013,CELG,addition apply lesson learn mentor former boss former fidelity investment superstar peter lynch run now magellan fund sit fund world strong performance rapid growth
2014,CELG,putnam investor fund asset peaked august shrank low september asset have be rise then
2015,CELG,sullivan be year old speak ibd office boston financial district invest
2016,CELG,ibd be mention have distinct brooklyn accent
2017,CELG,sullivan be born brooklyn grow long island dad grow brooklyn dodger fan grow new york met fan dodger have just moved hate yankee relish mention accent
2018,CELG,ibd have flexible style right invest growth value stock
2019,CELG,sullivan core manager here putnam investor fund be mix value growth so be multus cap core fund asset be year old same style even more flexible go market cap spectrum investor fund have least security large cap multus cap have more category large mid small cap stylewise re same
2020,CELG,ibd be type stock investor fund buy
2021,CELG,sullivan call first bucket legacy stock re large cap research earlier career even recently be depth research then give minute research week year refine understand factor move stock help understand make move most bore bucket most important
2022,CELG,second bucket have do smart money main factor be insider buy follow closely have many year
2023,CELG,early mid work peter lynch be factor defer look right timing buy stock
2024,CELG,ibd be role fidelity
2025,CELG,sullivan be do research european chemical stock basf imperial chemical holland akzo nobel big stock be important magellan look big liquid stock
2026,CELG,be also much harder follow insider transaction have check sec filing paper be week old rule be looser insider have file
2027,CELG,sarbane oxley moved hour rule now watch information flow internet real time
2028,CELG,doesn tell buy give idea
2029,CELG,third bucket be special situation most common be follow stock offering used be call secondary offering be file clock typical day xyz company be do follow ve get minute decide want play not file close book
2030,CELG,ibd recent do
2031,CELG,sullivan latest be hd supply hds be part home depot hd former ceo bob nardelli start build distributor big equipment ipo left buy ipo do secondary offer put offer ask price
2032,CELG,ibd often do work
2033,CELG,sullivan cdw cdw be technology distributor sell midsize company don have big department go public last year please specify still own sell lot
2034,CELG,be maybe first institutional investor meet be never fast grow underwriter be ask maybe say want buy lot underwriter say maybe miss detail re selling say didn miss not be trading time earning time earning not warrant
2035,CELG,anyway go road show have difficulty get audience lot guy thought be overpriced week come back say work say now only want go public then ve meet meager expectation do grab larger audience investor stock have slowly migrate ish great special situation
2036,CELG,ibd buy stock price weakness give example please
2037,CELG,sullivan buy weakness be old peter lynch rule
2038,CELG,buy southwest airline luv year be trading
2039,CELG,rest airline be do well charge everything southwest didn so get depress be selling replacement cost airplane figured have climb always start charge individual service baggage load much go
2040,CELG,ibd ve add apple aapl stake
2041,CELG,sullivan start buy apple again june quarter have pull back high take biggest position
2042,CELG,year half year apple google googl go then separated apple pull back google shot everyone fall love google used source fund apple have hair hadn come anything new now come again not expensive earning quasi value name meaningful growth
2043,CELG,ibd celgene celg be trend again do investor decide biotech be oversold
2044,CELG,sullivan be several large biotechs start position more year look value name growth now pipeline be still meaningful ve get good top bottom line growth big pharmaceutical firm don have growth basis still attractive be stronger sell biotechs biogen biib gilead gild add celgene weakness earlier year
2045,CELG,ibd facebook fb have have nice run mid be still attractive
2046,CELG,sullivan underweight now weighting be less basis point have good move place eyeball be be slow get mobile application work ve do still growth story trading time next year estimate earning so point neutral don want make position bigger stock pull back
2047,CELG,ibd thesis cbre group cbg
2048,CELG,sullivan re play commercial real estate rebound re not expensive
2049,CELG,re big broker maybe biggest manage big office building be dead area come back nonresidential construction be come back occupancy rate be get better ve get earn share year next year re not fancy name re bit sleeper
2050,CELG,ibd gilead earning share growth have explode be sovaldi hepatitis treatment entire story
2051,CELG,sullivan real attraction be more ve get drug liver heart disease good platform aids real nice thing be stock be inexpensive earning re expect earn share year next year
2052,CELG,very attractive time next year earning company grow teen re fan whole pipeline
2053,CELG,ibd be spirit airline save driver frill approach
2054,CELG,sullivan yes frill approach be key
2055,CELG,interesting thing be re not target competition larger airline be important avoid price war
2056,CELG,larger airline see ultralow cost carrier go new market actually expand market big competitor see get person fly don normally college student person tight budget person don mind fly midnight person don mind be charge extra bag maybe overhead compartment
2057,CELG,airline go other get market share re not do now old management engage price war have disappear airline bankruptcy be fresh airline manager head
2058,CELG,ibd be railcar maker trinity industry trn economic cycle
2059,CELG,sullivan cycle still continue work re only halfway
2060,CELG,make kind railroad car most interesting margin be car carry sand frac typical well take rail car stuff
2061,CELG,trinity be few player business stock be not expensive putnam investor fund be old geezer dec inception date make industry second oldest stock fund act spry spring chicken lately jerry sullivan take mid fund average annual gain be top beat large cap blend fund track morningstar same length period prior sullivan take charge fund average annual gain lag large cap blend peer sullivan credit outperformance appetite growth value stock also target type stock one follow year push smart money special situation focus valuation addition apply lesson learn mentor former boss former fidelity investment superstar peter lynch run now magellan fund sit fund world strong performance rapid growth putnam investor fund asset peaked august shrank low september asset have be rise then sullivan be year old speak ibd office boston financial district invest ibd be mention have distinct brooklyn accent sullivan be born brooklyn grow long island dad grow brooklyn dodger fan grow new york met fan dodger have just moved hate yankee relish mention accent ibd have flexible style right invest growth value stock sullivan core manager here putnam investor fund be mix value growth so be multus cap core fund asset be year old same style even more flexible go market cap spectrum investor fund have least security large cap multus cap have more category large mid small cap stylewise re same ibd be type stock investor fund buy sullivan call first bucket legacy stock re large cap research earlier career even recently be depth research then give minute research week year refine understand factor move stock help understand make move most bore bucket most important second bucket have do smart money main factor be insider buy follow closely have many year early mid work peter lynch be factor defer look right timing buy stock ibd be role fidelity sullivan be do research european chemical stock basf imperial chemical holland akzo nobel big stock be important magellan look big liquid stock be also much harder follow insider transaction have check sec filing paper be week old rule be looser insider have file sarbane oxley moved hour rule now watch information flow internet real time doesn tell buy give idea third bucket be special situation most common be follow stock offering used be call secondary offering be file clock typical day xyz company be do follow ve get minute decide want play not file close book ibd recent do sullivan latest be hd supply hds be part home depot hd former ceo bob nardelli start build distributor big equipment ipo left buy ipo do secondary offer put offer ask price ibd often do work sullivan cdw cdw be technology distributor sell midsize company don have big department go public last year please specify still own sell lot be maybe first institutional investor meet be never fast grow underwriter be ask maybe say want buy lot underwriter say maybe miss detail re selling say didn miss not be trading time earning time earning not warrant anyway go road show have difficulty get audience lot guy thought be overpriced week come back say work say now only want go public then ve meet meager expectation do grab larger audience investor stock have slowly migrate ish great special situation ibd buy stock price weakness give example please sullivan buy weakness be old peter lynch rule buy southwest airline luv year be trading rest airline be do well charge everything southwest didn so get depress be selling replacement cost airplane figured have climb always start charge individual service baggage load much go ibd ve add apple aapl stake sullivan start buy apple again june quarter have pull back high take biggest position year half year apple google googl go then separated apple pull back google shot everyone fall love google used source fund apple have hair hadn come anything new now come again not expensive earning quasi value name meaningful growth ibd celgene celg be trend again do investor decide biotech be oversold sullivan be several large biotechs start position more year look value name growth now pipeline be still meaningful ve get good top bottom line growth big pharmaceutical firm don have growth basis still attractive be stronger sell biotechs biogen biib gilead gild add celgene weakness earlier year ibd facebook fb have have nice run mid be still attractive sullivan underweight now weighting be less basis point have good move place eyeball be be slow get mobile application work ve do still growth story trading time next year estimate earning so point neutral don want make position bigger stock pull back ibd thesis cbre group cbg sullivan re play commercial real estate rebound re not expensive re big broker maybe biggest manage big office building be dead area come back nonresidential construction be come back occupancy rate be get better ve get earn share year next year re not fancy name re bit sleeper ibd gilead earning share growth have explode be sovaldi hepatitis treatment entire story sullivan real attraction be more ve get drug liver heart disease good platform aids real nice thing be stock be inexpensive earning re expect earn share year next year very attractive time next year earning company grow teen re fan whole pipeline ibd be spirit airline save driver frill approach sullivan yes frill approach be key interesting thing be re not target competition larger airline be important avoid price war larger airline see ultralow cost carrier go new market actually expand market big competitor see get person fly don normally college student person tight budget person don mind fly midnight person don mind be charge extra bag maybe overhead compartment airline go other get market share re not do now old management engage price war have disappear airline bankruptcy be fresh airline manager head ibd be railcar maker trinity industry trn economic cycle sullivan cycle still continue work re only halfway make kind railroad car most interesting margin be car carry sand frac typical well take rail car stuff trinity be few player business stock be not expensive
2062,CELG,stock look poise end week positive note friday
2063,CELG,dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge
2064,CELG,nasdaq still have day move average conquer nasdaq be point line same
2065,CELG,stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet
2066,CELG,constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise
2067,CELG,edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance
2068,CELG,drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain
2069,CELG,thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar
2070,CELG,downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning
2071,CELG,economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be stock look poise end week positive note friday dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge nasdaq still have day move average conquer nasdaq be point line same stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be
2072,CELG,generic drug maker lannett beat wall street fiscal expectation guide sale shy estimate close tuesday lannett lci earning totale cent share quarter end june year earlier quarter sale analyst expect earning cent share revenue
2073,CELG,stock open substantial loss have do repair work global equity market extend last week sell china shanghai composite plunge erased gain year
2074,CELG,nasdaq trim deficit pare loss meanwhile dow jone industrial average be point issue red blue chip gauge be nearly point monday low volume be run higher board stock market today especially nasdaq
2075,CELG,ibd name be water ebix ebix celgene celg sucampo pharmaceutical scmp more sucampo erased gain buy point cup base trigger sell rule
2076,CELG,pinnacle entertainment pnk public storage psa suffer least damage
2077,CELG,elsewhere nike nke be session low still telsey advisory group upgrade outperform market perform telsey also raise price target nike erased gain buy point flat base fall entry stock open substantial loss have do repair work global equity market extend last week sell china shanghai composite plunge erased gain year nasdaq trim deficit pare loss meanwhile dow jone industrial average be point issue red blue chip gauge be nearly point monday low volume be run higher board stock market today especially nasdaq ibd name be water ebix ebix celgene celg sucampo pharmaceutical scmp more sucampo erased gain buy point cup base trigger sell rule pinnacle entertainment pnk public storage psa suffer least damage elsewhere nike nke be session low still telsey advisory group upgrade outperform market perform telsey also raise price target nike erased gain buy point flat base fall entry
2078,CELG,halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug
2079,CELG,halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product
2080,CELG,san diego base halozyme be also testing product call pegph combination other drug treatment various cancer
2081,CELG,analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year
2082,CELG,recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention
2083,CELG,ibd have drug delivery product hylenex enhanze seem similar be difference
2084,CELG,torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin
2085,CELG,product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic
2086,CELG,hylenex be product halozyme go get approve promote small field force have
2087,CELG,basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue
2088,CELG,now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule
2089,CELG,ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection
2090,CELG,same base sugar just license call enhanze product call hylenex
2091,CELG,ibd drug re develop cancer treatment be also base same substance
2092,CELG,torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein
2093,CELG,so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day
2094,CELG,example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient
2095,CELG,exactly re try do here have drug last longer so doesn have be give frequently
2096,CELG,ibd so be necessarily combine drug do do anything
2097,CELG,torley pegph have modest cancer effect type effect believe be important patient need be used therapy
2098,CELG,ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed
2099,CELG,be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone
2100,CELG,theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor
2101,CELG,administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work
2102,CELG,early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar
2103,CELG,today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement
2104,CELG,connect amy reeve ibd_areeve facebook halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product san diego base halozyme be also testing product call pegph combination other drug treatment various cancer analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention ibd have drug delivery product hylenex enhanze seem similar be difference torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic hylenex be product halozyme go get approve promote small field force have basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection same base sugar just license call enhanze product call hylenex ibd drug re develop cancer treatment be also base same substance torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient exactly re try do here have drug last longer so doesn have be give frequently ibd so be necessarily combine drug do do anything torley pegph have modest cancer effect type effect believe be important patient need be used therapy ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement connect amy reeve ibd_areeve facebook
2105,CELG,surge biotech stock late trade help several etfs close wednesday trading session high note most major international index etfs jab higher stock market today rally day rout chinese market calm domestic datum show job productivity gain powershare qqq qqq jump trimming loss week
2106,CELG,best mutual fund august performance report
2107,CELG,sophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc
2108,CELG,year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor
2109,CELG,fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock
2110,CELG,late summer volatility have make harder find gainer
2111,CELG,fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader
2112,CELG,ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete
2113,CELG,fath want be tail end fund be half used be fund now top decrease little bit middle be bigger
2114,CELG,ibd do segment differ
2115,CELG,fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company
2116,CELG,middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold
2117,CELG,last section be generally characterize special situation be primary area
2118,CELG,first stock transition value growth
2119,CELG,second company underway last industry structural change have be go last several year airline sector
2120,CELG,third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition
2121,CELG,bucket typically be portfolio
2122,CELG,top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own
2123,CELG,ibd give example special situation please
2124,CELG,fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business
2125,CELG,airline be industry structural change category own american airline aal unite continental ual
2126,CELG,valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy
2127,CELG,ibd name example secular bucket please
2128,CELG,fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa
2129,CELG,ibd name cyclical bucket please
2130,CELG,fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift
2131,CELG,industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part
2132,CELG,ibd have fund performance zoom year least broad sell
2133,CELG,fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost
2134,CELG,re start see google googl
2135,CELG,year ve take health care weighting significantly ve take energy move paid
2136,CELG,have number biotech manage care big pharma name play well be activity space
2137,CELG,ibd so have bigger bet growth year have paid
2138,CELG,fath slowdown growth happened prior sell
2139,CELG,be position cyclical recovery didn play be reverse
2140,CELG,ve be slow growth environment world have be throw exogenous shock greece china be devalue currency
2141,CELG,external factor help make growth more valuable bid valuation company be deliver growth
2142,CELG,ve get be discipline position size
2143,CELG,google priceline outlook look good ve go heavy investment cycle
2144,CELG,google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide
2145,CELG,ibd let talk interesting name latest disclosure do share concern person have apple aapl
2146,CELG,fath do well ve be underweight stock peaked be sort trading sideway guard
2147,CELG,most constructive part be valuation capital structure
2148,CELG,worry have be company iphone cycle
2149,CELG,ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be
2150,CELG,remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple
2151,CELG,ll see go watch doesn look be success least not move needle enough do own don have overweight
2152,CELG,ibd anyone facebook fb earning share growth have slow lot quarters
2153,CELG,fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine
2154,CELG,have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate
2155,CELG,ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement
2156,CELG,fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade
2157,CELG,ibd visa thesis
2158,CELG,fath ty durability growth be center online payment movement cash check digital disruption
2159,CELG,card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information
2160,CELG,lot retailer have be reluctant make change have change payment hardware register re finally start change
2161,CELG,visa europe be potential driver visa visa takeover look come fruition maybe be announcement october
2162,CELG,ibd ve build stake celgene celg least quarters do
2163,CELG,fath biotechs want own be go big market
2164,CELG,time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise
2165,CELG,now ve get otezla immunology drug psoriasis psoriatic arthritis
2166,CELG,ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis
2167,CELG,drug acquire be gd treatment crohn disease early trial be promising
2168,CELG,patent cliff ahead revlimid ll protect long possible
2169,CELG,recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn
2170,CELG,ibd have be trimming stake gilead science
2171,CELG,fath re victim own success turn be chronic disease acute disease be treatable
2172,CELG,treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient
2173,CELG,ibd ve also pare stake regeneron regn outlook
2174,CELG,fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion
2175,CELG,ve get powerful pipeline
2176,CELG,ibd ve pare starbucks sbux be concern
2177,CELG,fath still feel good core story trim be just position size management
2178,CELG,have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden
2179,CELG,next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready best mutual fund august performance reportsophomore slump not joe fath take helm rowe price growth stock fund year half jan first calendar year charge fund gain top only large cap growth rival mutual fund track morningstar inc year broad market have imitate buck bronco fund have climb aug outperform whopping peer investor fath be more concern longer term broad market rally nearly year have make increasingly hard find attractively value growth stock late summer volatility have make harder find gainer fath be celebrate birthday talk ibd office baltimore mutual fund be perform so much better year last year be search new market leader ibd take charge fund cut size overall portfolio top name initially trim more recently re july be initial retool complete fath want be tail end fund be half used be fund now top decrease little bit middle be bigger ibd do segment differ fath describe philosophy upside pyramid top slice be secular growth name typically make portfolio be innovative disrupter be most dynamic growth company middle section be more cyclical opportunity typically be portfolio re likely be more opportunistic have shorter hold period fund average hold last section be generally characterize special situation be primary area first stock transition value growth second company underway last industry structural change have be go last several year airline sector third roll up strong management team be good capital allocator be apply discipline efficiency fragmented industry acquisition bucket typically be portfolio top name be generally most compelling secular idea tail portfolio have smallest holding be typically farm team earlier stage growth name private company own ibd give example special situation please fath gilead science gild go value growth transition buy pharmasset get treat hep addition core hiv business airline be industry structural change category own american airline aal unite continental ual valeant pharmaceutical vrx be roll category bring capital allocation discipline pharma industry assertive allocation strategy ibd name example secular bucket please fath amazon amzn be poster child tesla tsla be bit more extreme come story other name include priceline pcln mastercard visa ibd name cyclical bucket please fath stuff financial td ameritrade amtd morgan stanley ms degree be also shift business model look more value growth shift industrial hold name fedex fdx canadian pacific railway cp flowserve fls energy industrial most part ibd have fund performance zoom year least broad sell fath be drag last year secular growth name sell lot be due person want see more transparency big name want see amazon break core commerce business amazon web service company be become more discipline expense cost re start see google googl year ve take health care weighting significantly ve take energy move paid have number biotech manage care big pharma name play well be activity space ibd so have bigger bet growth year have paid fath slowdown growth happened prior sell be position cyclical recovery didn play be reverse ve be slow growth environment world have be throw exogenous shock greece china be devalue currency external factor help make growth more valuable bid valuation company be deliver growth ve get be discipline position size google priceline outlook look good ve go heavy investment cycle google have new cfo ruth porat come morgan stanley re create new hold company call alphabet give more visibility profitability core company go forward person want more transparency google be start provide ibd let talk interesting name latest disclosure do share concern person have apple aapl fath do well ve be underweight stock peaked be sort trading sideway guard most constructive part be valuation capital structure worry have be company iphone cycle ve do well iphone now issue be replacement cycle underestimated be impactful replacement cycle be remain concern ability innovate do drive enough replacement ve do so well grow fast base hard drive higher multiple ll see go watch doesn look be success least not move needle enough do own don have overweight ibd anyone facebook fb earning share growth have slow lot quarters fath ve do everything right right now thing be transition mobile get big base user revenue growth be slow invest new initiative want lot user turn monetization engine have user instagram lot whatsapp have user facebook ll monetize time so profit reaccelerate ibd thesis facebook oculus be buy israel pebble interface specialize depth sense tool track hand movement fath oculus be virtual reality play interesting not needle mover come green banana still need ripen show mark zuckerberg be think multidecade ibd visa thesis fath ty durability growth be center online payment movement cash check digital disruption card still use magnetic swipe be move chip pin card be reissue chip imbed make much harder steal card information lot retailer have be reluctant make change have change payment hardware register re finally start change visa europe be potential driver visa visa takeover look come fruition maybe be announcement october ibd ve build stake celgene celg least quarters do fath biotechs want own be go big market time celgene have build arsenal go multiple thing revlimid have be anchor do ve acquire company build own franchise now ve get otezla immunology drug psoriasis psoriatic arthritis ve also get cancer drug pomalyst chemotherapy treatment abraxane acquire abraxis drug acquire be gd treatment crohn disease early trial be promising patent cliff ahead revlimid ll protect long possible recent acquisition receptos be view pretty reasonable price relative other deal attack multiple indication most promising appear be disorder colitis crohn ibd have be trimming stake gilead science fath re victim own success turn be chronic disease acute disease be treatable treatment hepatitis be monster drug cure rate be almost week once someone be cure ve get find new patient ibd ve also pare stake regeneron regn outlook fath probably shouldn have trim ve get good core franchise eylea be used treat wet age related macular degeneration eye now also used diabetic macular edema retinal vein occlusion ve get powerful pipeline ibd ve pare starbucks sbux be concern fath still feel good core story trim be just position size management have lot presence not just globally ve introduce nice food purchase la boulange re drive new traffic afternoon evening ve get good china story menu be be broaden next big thing be move body line re roll mobile order pay system pay cellphone dictate delivery time then walk store coffee be ready
2180,CELG,little bit little bit be fine re putt together spice mix put roast re add topping frozen yogurt
2181,CELG,trading stock shouldn mix slim investment methodology other trading system
2182,CELG,slim be already try true investment system combine fundamental technical factor
2183,CELG,follow system
2184,CELG,mix thing system already base quality see past greatest stock market history
2185,CELG,nutshell slim focus buy stock lead company breakthrough product service be rapidly grow earning sale
2186,CELG,stock be only buy break certain price pattern ideally have other positive technical trait also be heavy accumulation institution biggest force stock market
2187,CELG,perhaps most important market timing aspect slim long trade have better chance work market be uptrend
2188,CELG,mix slim other trading system just make thing more complicate already large amount work involved find monitoring breakout slim stock add more stringent criterium cause overlook potential winner
2189,CELG,hazard mix trading strategy give contradict signal oscillator such relative strength index rsi stochastic be used tell stock be overbought territory be sell stock just be breaking base rush new high
2190,CELG,develop renown technical analyst welle rsi be standard technical indicator find just charting platform have relative strength name rsi compare average price gain single stock market index average loss
2191,CELG,be used determine stock be oversold due bounce overbought due pullback indicator also be used spot divergence new high be not accompany new high rsi be bad sign new low not confirm indicator be good sign
2192,CELG,mean strength
2193,CELG,celgene celg leaderboard stock break cup handle base buy point june strong volume stock hit month high day stock be buyable accord slim rule
2194,CELG,day rsi be already reading be typical signal stock be overbought
2195,CELG,likewise rsi indicator be also overbought zone palo alto network panw clear buy point double bottom base rsi be day
2196,CELG,palo alto develop next generation security software have be ibd leaderboard mainstay aug rise pull back day move average mild trade little bit little bit be fine re putt together spice mix put roast re add topping frozen yogurt trading stock shouldn mix slim investment methodology other trading system slim be already try true investment system combine fundamental technical factor follow systemwhy mix thing system already base quality see past greatest stock market history nutshell slim focus buy stock lead company breakthrough product service be rapidly grow earning sale stock be only buy break certain price pattern ideally have other positive technical trait also be heavy accumulation institution biggest force stock market perhaps most important market timing aspect slim long trade have better chance work market be uptrend mix slim other trading system just make thing more complicate already large amount work involved find monitoring breakout slim stock add more stringent criterium cause overlook potential winner hazard mix trading strategy give contradict signal oscillator such relative strength index rsi stochastic be used tell stock be overbought territory be sell stock just be breaking base rush new high develop renown technical analyst welle rsi be standard technical indicator find just charting platform have relative strength name rsi compare average price gain single stock market index average loss be used determine stock be oversold due bounce overbought due pullback indicator also be used spot divergence new high be not accompany new high rsi be bad sign new low not confirm indicator be good sign mean strengthcelgene celg leaderboard stock break cup handle base buy point june strong volume stock hit month high day stock be buyable accord slim rule day rsi be already reading be typical signal stock be overbought likewise rsi indicator be also overbought zone palo alto network panw clear buy point double bottom base rsi be day palo alto develop next generation security software have be ibd leaderboard mainstay aug rise pull back day move average mild trade
2197,CELG,stock be mixed monday afternoon reverse early gain nasdaq add dow jone industrial average lose volume be mixed lower nyse slightly higher nasdaq
2198,CELG,nasdaq backtrack strong start week retrace back level small cap hold better stock market today russell gain
2199,CELG,lead stock netflix nflx share benefit analyst upgrade soar heavy trade ub upgrade stream video service buy neutral boost price target cite strong international growth prospect netflix report earning wednesday close
2200,CELG,facebook fb add more be buy range past entry flat base stock recent pullback buy point come light volume positive sign
2201,CELG,criteo crto top ibd better gain stock be back day move average work consolidation buy point base france company provide target advertising product commerce firm
2202,CELG,noah holding noah epam system epam also outperformed ibd extend recent price run new high territory stock be mixed monday afternoon reverse early gain nasdaq add dow jone industrial average lose volume be mixed lower nyse slightly higher nasdaq nasdaq backtrack strong start week retrace back level small cap hold better stock market today russell gain lead stock netflix nflx share benefit analyst upgrade soar heavy trade ub upgrade stream video service buy neutral boost price target cite strong international growth prospect netflix report earning wednesday close facebook fb add more be buy range past entry flat base stock recent pullback buy point come light volume positive sign criteo crto top ibd better gain stock be back day move average work consolidation buy point base france company provide target advertising product commerce firm noah holding noah epam system epam also outperformed ibd extend recent price run new high territory
2203,CELG,biotech bluebird bio blue see stock fly time high tuesday follow researcher report annual meeting american society hematology patient killer blood disease have be able forgo blood transfusion least month be treat company technique replace defective gene
2204,CELG,brutal correction several lead biotech member ibd find support day move average correction kick monday express script esrx nation largest health benefit manager announce exclusively use abbvie abbv hepatitis drug left gilead science gild recent growth have be fuel hepatitis
2205,CELG,stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point
2206,CELG,stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally
2207,CELG,economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et
2208,CELG,st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi
2209,CELG,nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end
2210,CELG,management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point
2211,CELG,retail industry group have take serious beating past week continue make splashy move
2212,CELG,abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast
2213,CELG,ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation
2214,CELG,foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high
2215,CELG,william sonoma wsm slip nearly beating sale earning expectation guide result estimate
2216,CELG,intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base
2217,CELG,morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point retail industry group have take serious beating past week continue make splashy move abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high william sonoma wsm slip nearly beating sale earning expectation guide result estimate intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point
2218,CELG,stock turn tail wednesday halter recent comeback effort nasdaq end lower respectively fall first time session dow jone industrial average slump accord preliminary datum turnover end lower board stock market today fortinet ftnt yelp yelp citrix system ctxs be active hour report quarterly result share security software provider fortinet slip regular session then rally hour company better expect result fortinet deliver earning cent share sale view be cent revenue citrix system slump regular session then fall additional hour company report sale analyst poll thomson reuter have expect adjust earning top street estimate cent share meanwhile yelp fall regular session then plunge extend trading weak sale outlook trump better expect result company peg revenue vs view nearly alexion pharmaceutical alxn amazon com amzn carter cri celgene celg synaptic syna armour ua be notable company report earning thursday initial jobless claim lead economic indicator also be thursday
2219,CELG,dow jone industrial average trade tight range monday nasdaq take beating profit take hit several recent highflier
2220,CELG,nasdaq moved lows still fall hurt weakness tesla motor tsla share dive morgan stanley reiterate overweight rating remove price target basically say stock have get ahead
2221,CELG,biotechs also face more selling pressure high quality name biogen idec biib alexion alxn celgene celg be trading day line
2222,CELG,fall fractionally dow rise investor turn defensive nasdaq volume be tracking sharply higher friday nyse volume fall bit
2223,CELG,stock market today apple aapl add first day pre order iphone top double number iphone year
2224,CELG,egg producer cal maine food calm extend gain reclaim week move average last month share rise heavy volume
2225,CELG,big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week
2226,CELG,meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba
2227,CELG,economic news industrial production contract unexpectedly august fall vs consensus estimate growth meanwhile latest read empire state manufacturing survey have better news soar september august consensus estimate be read
2228,CELG,day fed meeting start tuesday policy statement be due wednesday et dow jone industrial average trade tight range monday nasdaq take beating profit take hit several recent highflier nasdaq moved lows still fall hurt weakness tesla motor tsla share dive morgan stanley reiterate overweight rating remove price target basically say stock have get ahead biotechs also face more selling pressure high quality name biogen idec biib alexion alxn celgene celg be trading day line fall fractionally dow rise investor turn defensive nasdaq volume be tracking sharply higher friday nyse volume fall bit stock market today apple aapl add first day pre order iphone top double number iphone year egg producer cal maine food calm extend gain reclaim week move average last month share rise heavy volume big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba economic news industrial production contract unexpectedly august fall vs consensus estimate growth meanwhile latest read empire state manufacturing survey have better news soar september august consensus estimate be read day fed meeting start tuesday policy statement be due wednesday et
2229,CELG,earning growth fuel stock price performance not only ingredient stock success rise mutual fund sponsorship also help stock solid sponsorship aren hard find week ibd sponsorship run gamut newer company be still light sponsorship other be show bullish sponsorship trend other be own
2230,CELG,major average show modest loss little hour remain thursday session
2231,CELG,nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall
2232,CELG,small cap fared well add
2233,CELG,day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose
2234,CELG,ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise
2235,CELG,stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive
2236,CELG,meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market
2237,CELG,economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline
2238,CELG,close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale major average show modest loss little hour remain thursday session nasdaq lose hurt somewhat fresh round selling dow jone industrial average give respectively nyse volume be tracking close wednesday level nasdaq volume fall small cap fared well add day outperformance wednesday biotech stock face renew selling pressure nasdaq firm celgene celg fall have almost re-trace gain buy point other nasdaq biotechs be pressured include regeneron regn biogen idec biib gilead science gild lose ibd firm akorn akrx be bright spot maker ophthalmic injectable pharmaceutical bounce day move average heavy volume rise stock market today stratasys ssys gain approach buy point earlier week company analyst day be well receive meanwhile huntsman hun follow wednesday share rise clear early flat base point wednesday still buy range company make organic inorganic chemical product broad range consumer industrial end market economic news weekly jobless claim unexpectedly rise month high claim increase upwardly revise prior week economist expect small decline close watch earning ulta beauty ulta share edge higher ahead result former leader have be rally mode still sit high quarterly profit be see rise cent share sale
2239,CELG,stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be
2240,CELG,volume be run higher nyse nasdaq compare same time wednesday
2241,CELG,economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast
2242,CELG,mining energy stock be hit hardest stock market today decline oil metal price
2243,CELG,newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop
2244,CELG,most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy
2245,CELG,total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october
2246,CELG,chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base
2247,CELG,stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be volume be run higher nyse nasdaq compare same time wednesday economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast mining energy stock be hit hardest stock market today decline oil metal price newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug
2248,CELG,stock market close mixed friday index bounce back early slump nasdaq rise thank strength biotechs security software solar stock fall dow jone industrial average lag drop close session lows small cap pace market small cap russell climb volume rise nyse edge lower nasdaq accord early figure serious decline prior day friday price reversal be encourage yet market remain lock long sideway trend stock sank open better expect job report trigger slide bond price energy stock rise opec left output target unchanged expect solar share jump china base ja solar jaso chief executive offer buy company take private financial also help lead stock market today bank america bac rise more close back buy point jpmorgan jpm rise hit new high thinly trade bofi holding bofi rise top buy point long cup handle base be strong day ibd average component volume be just average light most stock
2249,CELG,wednesday short trading session open note dow pressed further fresh high
2250,CELG,nasdaq lead approach nov high dow jone industrial average tick add
2251,CELG,stock market today open early boost labor department report larger expect drop weekly unemployment claim today session wrapped et exchange remain close christmas day reopen normal schedule friday morning
2252,CELG,stock drugmaker be rebound broadly couple day hard selling biom issue post nasdaq largest gain early trade gilead science gild celgene celg lead ibd list gain
2253,CELG,airline stock also gain oil price backed more recent lows ibd stock alaska air group alk spirit airline save gain unite continental ual pop
2254,CELG,virgin america va spiked lead group november new issue quiet period end raft analyst initiate coverage deutsche bank initiate buy rating price target barclay open coverage overweight rating price target cowen co put outperform rating also price target raymond james initial rating stock be market perform
2255,CELG,jump put virgin just high november ipo price stock be fourth week first consolidation
2256,CELG,early loss be generally mild leader worst hit ibd list go noah holding noah china base financial adviser be still buy point cup handle base wednesday short trading session open note dow pressed further fresh high nasdaq lead approach nov high dow jone industrial average tick add stock market today open early boost labor department report larger expect drop weekly unemployment claim today session wrapped et exchange remain close christmas day reopen normal schedule friday morning stock drugmaker be rebound broadly couple day hard selling biom issue post nasdaq largest gain early trade gilead science gild celgene celg lead ibd list gain airline stock also gain oil price backed more recent lows ibd stock alaska air group alk spirit airline save gain unite continental ual pop virgin america va spiked lead group november new issue quiet period end raft analyst initiate coverage deutsche bank initiate buy rating price target barclay open coverage overweight rating price target cowen co put outperform rating also price target raymond james initial rating stock be market perform jump put virgin just high november ipo price stock be fourth week first consolidation early loss be generally mild leader worst hit ibd list go noah holding noah china base financial adviser be still buy point cup handle base
2257,CELG,stock finished mixed tuesday dow jone industrial average trade time high rest market be tame biotechs longtime leader bull market be pummeled
2258,CELG,dow gain rise nasdaq fall volume stock market today track lower exchange accord preliminary datum
2259,CELG,investor be look good holiday spending bid department store stock make day best perform industry group boost dd be top performer group nearly macy gain
2260,CELG,biotechs be day worst perform group drop nearly several biotechs have lead market month fall hard
2261,CELG,gilead science gild fall sharply second day lose support day line celgene celg be heavy volume be seek support day move average
2262,CELG,ibd stock be evenly split best performer be volatile chinese investment manager noah holding noah more
2263,CELG,oil finished higher help energy stock dow component chevron cvx exxon mobil xom rise respectively stock finished mixed tuesday dow jone industrial average trade time high rest market be tame biotechs longtime leader bull market be pummeled dow gain rise nasdaq fall volume stock market today track lower exchange accord preliminary datum investor be look good holiday spending bid department store stock make day best perform industry group boost dd be top performer group nearly macy gain biotechs be day worst perform group drop nearly several biotechs have lead market month fall hard gilead science gild fall sharply second day lose support day line celgene celg be heavy volume be seek support day move average ibd stock be evenly split best performer be volatile chinese investment manager noah holding noah more oil finished higher help energy stock dow component chevron cvx exxon mobil xom rise respectively
2264,CELG,solid day market monday lower volume result shortage new high several growth name be early stage breaking basis other be hold gain post just want see nascent uptrend celgene celg clear flat base entry rise
2265,CELG,big cap biotechs moved strong volume stock market today deutsche bank add several short term buy list citi report back visit medical expert celgene celg hit new high deutsche bank analyst robyn karnauskas tout short term investment idea say read clinical trial datum new
2266,CELG,stock be moderately higher monday biotech stock lead way nasdaq dow jone industrial average rise gain close amazon amzn announce be pay buy twitch live video platform gamer viewer watch other person play video game amazon rise nearly regular session wasn active market investor be weigh impact several economic indicator tuesday open estimate durable good order vary greatly consensus call increase increase ex auto case shiller home price index city be expect rise year year prior month conference board consumer confidence index be expect come vs last month biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week ibd biotech industry group be monday top performer industry group rise
2267,CELG,fattest annual profit margin come drugmaker product be meant make person healthier today screen day be healthy profit margin include highly rate drug stock don miss jazz pharmaceutical jazz annual profit margin narcolepsy treatment xyrem have rocket success contribute
2268,CELG,celgene have pull back market have come increase selling pressure long term prospect biotech leader remain healthy celgene celg develop cancer immune inflammatory related disease therapy include multiple myeloma treatment revlimid generate total revenue new jersey base firm be report have most product phase phase
2269,CELG,tesla motor tsla be start top rating wednesday solarcity scty first solar fslr other solar company get bullish rating oppenheimer initiate coverage tesla outperform rating price target tesla share close stock market today oppenheimer start coverage several solar stock outperform rating solarcity also
2270,CELG,week list lead big cap issue feature emerge strength technology long time biotech leader be hold well food beverage play biotech field gilead science gild be build new flat base buy point gilead share be try bounce back trigger sell signal july
2271,CELG,have hand institutional quality name google googl celgene celg tough environment overall growth stock name be hold just fine
2272,CELG,google hasn give much back robust earning report fuel gain stock week end july buyer be back stock tuesday search giant announce new parent company alphabet core internet business be separated other business nest fiber google
2273,CELG,celgene recently pull back buy range bullish gap price july investor like news company plan acquire receptos
2274,CELG,receptos have promising drug late stage clinical trial treatment multiple sclerosis ulcerative colitis
2275,CELG,homebuilder continue outperform not surprising see fortune brand home security fbhs do well company make product home faucet cabinet window door
2276,CELG,approach high end buy range buy point share surge july company report earning sale growth accelerate nicely
2277,CELG,meanwhile small cap midcap be trading tightly bullish move last week price action presage future strength
2278,CELG,stamp com stmp soar last week strong earning provider internet base postage solution be hold gain bullishly week report yet quarter accelerate earning sale growth
2279,CELG,amsurg amsg heath care space be show similar price action soar last week strong earning provider ambulatory physical service show straight quarters triple digit sale growth help acquisition sheridan healthcare last year have hand institutional quality name google googl celgene celg tough environment overall growth stock name be hold just fine google hasn give much back robust earning report fuel gain stock week end july buyer be back stock tuesday search giant announce new parent company alphabet core internet business be separated other business nest fiber google celgene recently pull back buy range bullish gap price july investor like news company plan acquire receptos receptos have promising drug late stage clinical trial treatment multiple sclerosis ulcerative colitis homebuilder continue outperform not surprising see fortune brand home security fbhs do well company make product home faucet cabinet window door approach high end buy range buy point share surge july company report earning sale growth accelerate nicely meanwhile small cap midcap be trading tightly bullish move last week price action presage future strength stamp com stmp soar last week strong earning provider internet base postage solution be hold gain bullishly week report yet quarter accelerate earning sale growth amsurg amsg heath care space be show similar price action soar last week strong earning provider ambulatory physical service show straight quarters triple digit sale growth help acquisition sheridan healthcare last year
2280,CELG,report mixed quarterly result top rate biotech celgene celg look have unraveled base build effort
2281,CELG,stock drop stock market today fall month low
2282,CELG,celgene earning grow beat estimate penny sale increase miss view
2283,CELG,group peer biogen biib have yet retake day line gap area result miss estimate last friday
2284,CELG,fellow biotech gilead gild face same result
2285,CELG,watch video chart analysis celgene gilead biogen
2286,CELG,follow alissa william twitter ibd_awilliam report mixed quarterly result top rate biotech celgene celg look have unraveled base build effort stock drop stock market today fall month low celgene earning grow beat estimate penny sale increase miss view group peer biogen biib have yet retake day line gap area result miss estimate last friday fellow biotech gilead gild face same result watch video chart analysis celgene gilead biogen follow alissa william twitter ibd_awilliam
2287,CELG,health care stock fund be top perform sector category past year be bruise monday sharp decline biotech medical stock health care fund performance have soar gain runner communication consumer discretionary recent year
2288,CELG,investment march make average health care fund have grow april year accord morningstar inc datum same investment have grow average consumer discretionary fund average communication fund
2289,CELG,proxy broad stock market turn initial amount
2290,CELG,fidelity select biotech portfolio have rise average annual past year vs mutual fund manage rajiv kaul rise last year be so far year
2291,CELG,several biotech stock be fund recent top holding take beating monday gilead science gild have mildest drop slip nearly developer treatment respiratory cardiovascular disease be week high stock have be move sideway october ibd composite rating remain lofty rs rating have slip
2292,CELG,biogen biib tumble friday monday day decline bring stock day move average week high
2293,CELG,celgene celg fall monday meet resistance day line be now week high health care stock fund be top perform sector category past year be bruise monday sharp decline biotech medical stock health care fund performance have soar gain runner communication consumer discretionary recent year investment march make average health care fund have grow april year accord morningstar inc datum same investment have grow average consumer discretionary fund average communication fund proxy broad stock market turn initial amount fidelity select biotech portfolio have rise average annual past year vs mutual fund manage rajiv kaul rise last year be so far year several biotech stock be fund recent top holding take beating monday gilead science gild have mildest drop slip nearly developer treatment respiratory cardiovascular disease be week high stock have be move sideway october ibd composite rating remain lofty rs rating have slip biogen biib tumble friday monday day decline bring stock day move average week high celgene celg fall monday meet resistance day line be now week high
2294,CELG,best mutual fund april performance report generally muddle month mutual fund april see asset class soar selfie stick diversify stock fund slip average accord lipper inc datum china stock mutual fund notch gain lead world equity fund rise month view
2295,CELG,stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open
2296,CELG,dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain
2297,CELG,volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading
2298,CELG,start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action
2299,CELG,drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss
2300,CELG,leader leane generally higher gain be limit
2301,CELG,airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october
2302,CELG,drugmaker post list worst decline early trade
2303,CELG,gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction
2304,CELG,celgene biogen also ibd list drop amgen amgn slip lower
2305,CELG,economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss leader leane generally higher gain be limit airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october drugmaker post list worst decline early trade gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction celgene biogen also ibd list drop amgen amgn slip lower economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale
2306,CELG,stock big cap screen be work basis have form secondary pattern earning report loom mylan myl maker generic drug be work flat base base pattern buy point stock rebound day move average monday heavy volume profit fourth quarter
2307,CELG,biotech investor always seem be look next big thing day many be go hood car
2308,CELG,car be short chimeric antigen receptor cell therapy version immunotherapy deploy patient own immune system fight cancer first develop academic lab car therapy have be picked big pharma novartis nvs well number small startup
2309,CELG,kite pharma kite bluebird bio blue bellicum pharmaceutical blcm juno therapeutic juno be car stock have come public last year aftermarket performance new issue have stand even biotech ipo boom especially one ve find big name partner
2310,CELG,kite partner amgen
2311,CELG,bluebird partner celgene celg develop car therapy go public kite month make deal amgen amgn worth much send stock new high
2312,CELG,so be technology get everyone so excited other form immunotherapy aim overcome way cancer cell fool immune system pass realize re threat
2313,CELG,cell be immune cell blood normally attack intruder be genetically engineer produce receptor antigen specific tumor cell allow recognize enemy
2314,CELG,make different other immunotherapy such pd inhibitor be method produce treatment actually form cell therapy involve harvesting patient own cell cell case engineering car multiply lab then inject back patient thus company develop isn drug specific type car
2315,CELG,be number different possible antigen target get most attention day be cd antigen appear cell malignancy cause several different kind blood cancer research be still early stage very intriguing result start come last year
2316,CELG,novartis car advance
2317,CELG,study publish new england journal medicine october novartis partner university pennsylvania report patient acute lymphoblastic leukemia show complete remission treatment car cell ctl
2318,CELG,american society hematology ash conference early december different ctl study report child have be rid even tinier study also point promise other blood cancer follicular lymphoma diffuse large cell lymphoma
2319,CELG,same conference researcher memorial sloan ketter cancer center present datum phase study cd target candidate develop juno again stand target disease disappear more patient adult pedatric study
2320,CELG,person have describe result stunning remarkable morningstar analyst stefan quenneville tell ibd re just phenomenal result very tough hematological cancer
2321,CELG,quenneville add reason upturn optimism be greater confidence doctor manage car therapy most alarm side effect cytokine release syndrome cytokine be chemical messenger produce cell suddenly release en masse big cell infusion bring high fever drop blood pressure fact earlier study patient die syndrome however then physician have figured manage problem strong inflammatory drug such amgen enbrel
2322,CELG,car work tumor
2323,CELG,still be great many unknown give early stage testing go novartis be farthest phase study other range phase preclinical be especially important really matter cancer be duration response especially company go blood solid tumor make majority cancer
2324,CELG,solid tumor metastase often reside different tissue different site write leerink analyst howard liang jan initiation report juno car cell have engage initial tumor expand circulate body find metastase adequate persistence cell not live long enough accomplish
2325,CELG,great unknown hang industry be price be basically sank only cell therapy so far hit market dendreon provenge personalize therapy be expensive produce provenge degree superiority other treatment be deem many be too low justify price tag
2326,CELG,normally drug company don talk price early game so many be surprised kite cfo cynthia butitta say jpmorgan healthcare conference month expect treatment cost say company plan start talk insurer reimbursement year
2327,CELG,however kite product come market well not be kite anymore quenneville say factor drive stock be car well provide next hunting ground big acquirer
2328,CELG,think way person be think extent say person think viable platform biotech investor always seem be look next big thing day many be go hood car car be short chimeric antigen receptor cell therapy version immunotherapy deploy patient own immune system fight cancer first develop academic lab car therapy have be picked big pharma novartis nvs well number small startup kite pharma kite bluebird bio blue bellicum pharmaceutical blcm juno therapeutic juno be car stock have come public last year aftermarket performance new issue have stand even biotech ipo boom especially one ve find big name partner kite partner amgenbluebird partner celgene celg develop car therapy go public kite month make deal amgen amgn worth much send stock new high so be technology get everyone so excited other form immunotherapy aim overcome way cancer cell fool immune system pass realize re threat cell be immune cell blood normally attack intruder be genetically engineer produce receptor antigen specific tumor cell allow recognize enemy make different other immunotherapy such pd inhibitor be method produce treatment actually form cell therapy involve harvesting patient own cell cell case engineering car multiply lab then inject back patient thus company develop isn drug specific type car be number different possible antigen target get most attention day be cd antigen appear cell malignancy cause several different kind blood cancer research be still early stage very intriguing result start come last year novartis car advancesin study publish new england journal medicine october novartis partner university pennsylvania report patient acute lymphoblastic leukemia show complete remission treatment car cell ctl american society hematology ash conference early december different ctl study report child have be rid even tinier study also point promise other blood cancer follicular lymphoma diffuse large cell lymphoma same conference researcher memorial sloan ketter cancer center present datum phase study cd target candidate develop juno again stand target disease disappear more patient adult pedatric study person have describe result stunning remarkable morningstar analyst stefan quenneville tell ibd re just phenomenal result very tough hematological cancer quenneville add reason upturn optimism be greater confidence doctor manage car therapy most alarm side effect cytokine release syndrome cytokine be chemical messenger produce cell suddenly release en masse big cell infusion bring high fever drop blood pressure fact earlier study patient die syndrome however then physician have figured manage problem strong inflammatory drug such amgen enbrel car work tumor still be great many unknown give early stage testing go novartis be farthest phase study other range phase preclinical be especially important really matter cancer be duration response especially company go blood solid tumor make majority cancer solid tumor metastase often reside different tissue different site write leerink analyst howard liang jan initiation report juno car cell have engage initial tumor expand circulate body find metastase adequate persistence cell not live long enough accomplish great unknown hang industry be price be basically sank only cell therapy so far hit market dendreon provenge personalize therapy be expensive produce provenge degree superiority other treatment be deem many be too low justify price tag normally drug company don talk price early game so many be surprised kite cfo cynthia butitta say jpmorgan healthcare conference month expect treatment cost say company plan start talk insurer reimbursement year however kite product come market well not be kite anymore quenneville say factor drive stock be car well provide next hunting ground big acquirer think way person be think extent say person think viable platform
2329,CELG,dow jone industrial average hold ground record territory afternoon trading friday nasdaq poke level just smidgen nearly year intraday high set nov
2330,CELG,nasdaq rise gain dow climb volume be run lighter stock market today compare same time wednesday
2331,CELG,select airline have strong day ryanair ryaay rise volume be high break base early november
2332,CELG,virgin america va break ipo base wednesday follow friday nearly
2333,CELG,lead biotech stock be pummeled earlier week rally friday have find support day move average include celgene celg gilead science gild alexion pharmaceutical alxn rise be still day line
2334,CELG,cal maine food calm fall still feel effect tuesday report revenue come wall street forecast
2335,CELG,gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday dow jone industrial average hold ground record territory afternoon trading friday nasdaq poke level just smidgen nearly year intraday high set nov nasdaq rise gain dow climb volume be run lighter stock market today compare same time wednesday select airline have strong day ryanair ryaay rise volume be high break base early november virgin america va break ipo base wednesday follow friday nearly lead biotech stock be pummeled earlier week rally friday have find support day move average include celgene celg gilead science gild alexion pharmaceutical alxn rise be still day line cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday
2336,CELG,christmas spirit hover stock market midday friday lift stock moderately dull trading dow jone industrial average be record high nasdaq be not far nov intraday high index best level march nasdaq lead way gain dow climb stock market today dow be work seventh straight day advance virgin america va soar ipo base wednesday climb ibd stock ambarella amba celgene celg rise stock recently find support day move average gilead science gild hammer earlier week rise nearly be trading day line analyst rbc capital suggest company initiate new stock buyback program cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire monday
2337,CELG,growth stock have come increase selling pressure recent day quick scan week ibd show plenty institutional quality name hold just fine support bullish thesis still market have make habit send mixed message recent week weak breadth stubbornly high distribution day count
2338,CELG,biotech industry group currently rank group ibd track gilead science share best group score composite rating fellow drugmaker celgene regeneron regn be shortage activity biotech industry recently include celgene celg acquisition receptos july buyout
2339,CELG,volatile market tuesday weak economic datum china several ipos have be hold own planet fitness plnt share close ahead result wednesday first report go public aug gym operator have ibd composite rating receive slew positive
2340,CELG,nasdaq russell small cap index joined new high party friday dow jone industrial average extend winning streak session nasdaq outperformed rise gain dow add russell picked week dow add nasdaq gain crude oil lose barrel week lose fifth straight weekly decline gold meanwhile surge ounce stock market today biotechs padded gain tuesday nasty sell regeneron regn amgen amgn celgene celg outperformed show solid support action day move average elsewhere tesla motor tsla rise ceo elon musk say christmas day tweet new roadster production vehicle have battery range mile twice car current range gopro gpro capped fourth straight gain share rise day post ipo lockup period expire week share be strengthen anticipation robust holiday sale wildly popular wearable camera ambarella amba chip power gopro camera jump new issue virgin america va follow wednesday powerful share rise nearly have quickly become extend buy point
2341,CELG,biotech stock take bath holiday shorten week catalyst be announcement express script esrx nation largest benefit manager use abbvie abbv hepatitis drug exclusively hurt gilead science gild stock have soar sale own ground breaking hepatitis treatment gilead be hammer loss week so far
2342,CELG,celgene celg drug abraxane outperformed predecessor large study early stage breast cancer make potential market bigger previously thought accord analyst celgene stock be morning trading stock market today san antonio breast cancer symposium thursday leerink analyst howard liang write german study
2343,CELG,stock backed early gain be mixed early tuesday investor wrestle jumble economic news
2344,CELG,dow jone industrial average rise add index reach new high nasdaq shed early gain slip
2345,CELG,volume be soft second day tracking nyse nasdaq compare same time monday
2346,CELG,stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october
2347,CELG,personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase
2348,CELG,consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate
2349,CELG,stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq
2350,CELG,retailer be show strength lead dd punch heavy trade stock be buy point double bottom base
2351,CELG,leader be moderately positive third ibd move higher start trade
2352,CELG,asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall stock backed early gain be mixed early tuesday investor wrestle jumble economic news dow jone industrial average rise add index reach new high nasdaq shed early gain slip volume be soft second day tracking nyse nasdaq compare same time monday stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq retailer be show strength lead dd punch heavy trade stock be buy point double bottom base leader be moderately positive third ibd move higher start trade asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall
2353,CELG,dow jone industrial average notch fresh time high tuesday nasdaq lag biotech stock sell hard
2354,CELG,dow add third component more rise nasdaq ease volume nyse nasdaq be tracking just monday level
2355,CELG,breadth be pretty good nyse advance stock beating decliner nasdaq winner beat loser margin
2356,CELG,economic news final revision gross domestic product come much better expect heel growth
2357,CELG,stock market today biotechs come pressure ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively
2358,CELG,biogen idec biib also take hit fall still hold day line be well recent buy point sharp decline biotechs be sign institutional investor be ready rotate group be lead market month
2359,CELG,biogen recent attempt have stall many other include baidu bidu fleetcor technology flt valeant pharmaceutical vrx other
2360,CELG,selling wasn just confine biotechs tuesday day worst perform group ibd database hailed medical sector
2361,CELG,top gainer ibd include noah holding noah asbury automotive abg cdw cdw
2362,CELG,close watch earning egg producer cal maine food calm profit be see rise cent share cal maine reclaim day move average last week heavy volume share be mostly unchanged ahead result dow jone industrial average notch fresh time high tuesday nasdaq lag biotech stock sell hard dow add third component more rise nasdaq ease volume nyse nasdaq be tracking just monday level breadth be pretty good nyse advance stock beating decliner nasdaq winner beat loser margin economic news final revision gross domestic product come much better expect heel growth stock market today biotechs come pressure ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively biogen idec biib also take hit fall still hold day line be well recent buy point sharp decline biotechs be sign institutional investor be ready rotate group be lead market month biogen recent attempt have stall many other include baidu bidu fleetcor technology flt valeant pharmaceutical vrx other selling wasn just confine biotechs tuesday day worst perform group ibd database hailed medical sector top gainer ibd include noah holding noah asbury automotive abg cdw cdw close watch earning egg producer cal maine food calm profit be see rise cent share cal maine reclaim day move average last week heavy volume share be mostly unchanged ahead result
2363,CELG,dow jone industrial average notch fresh time high tuesday cheer robust upward revision gross domestic product
2364,CELG,dow be driver seat early afternoon trading nasdaq have hard time keep due sell biotech stock
2365,CELG,dow add buoy dupont dd boee ba rise nasdaq ease volume nyse nasdaq be tracking just monday level same time
2366,CELG,economic news final revision gross domestic product come much better expect heel growth
2367,CELG,stock market today biotechs sell again ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively sharp decline be sign institutional investor be ready rotate group be lead market month
2368,CELG,day worst perform group ibd database hailed medical sector
2369,CELG,ibd epam system epam continue firm day move average rise
2370,CELG,group peer cdw cdw also do well rise nearly recent cup handle continue work well dow jone industrial average notch fresh time high tuesday cheer robust upward revision gross domestic product dow be driver seat early afternoon trading nasdaq have hard time keep due sell biotech stock dow add buoy dupont dd boee ba rise nasdaq ease volume nyse nasdaq be tracking just monday level same time economic news final revision gross domestic product come much better expect heel growth stock market today biotechs sell again ibd biotech group fall more follow loss monday regeneron regn celgene celg slice day line fall respectively sharp decline be sign institutional investor be ready rotate group be lead market month day worst perform group ibd database hailed medical sector ibd epam system epam continue firm day move average rise group peer cdw cdw also do well rise nearly recent cup handle continue work well
2371,CELG,stock build early gain go last hour trading friday little way corporate announcement economic datum many trader take day volume be dull nasdaq rise gain dow jone industrial average climb stock market today industry group gold precious metal automaker be top performer gold rise oil driller be worst performer west texas intermediate oil drop tesla motor tsla rise ceo elon musk say christmas day tweet new roadster production vehicle have battery range mile twice car range today select airline have strong day ryanair ryaay rise solid volume be high break base early november virgin america va break ipo base wednesday follow friday nearly lead biotech stock pummeled earlier week rally friday several be find support day line include celgene celg amgen amgn regeneron regn cal maine food calm fall still feel effect tuesday report revenue come wall street forecast gopro gpro rise fourth straight advance day lock period insider be prohibit selling share expire earlier week
2372,CELG,everyone get sick drastic health problem call more drastic treatment partly several top rate biotech stock today ibd list have hold well recent market pressue alexion pharmaceutical alxn fourth stock today screen develop treatment neurological other disorder company have year strong ep sale gain
2373,CELG,stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high
2374,CELG,nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light
2375,CELG,best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again
2376,CELG,fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base
2377,CELG,gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly
2378,CELG,time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market
2379,CELG,dow component financial giant visa bank america bac rise stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market dow component financial giant visa bank america bac rise
2380,CELG,top perform sector mutual fund category past year health care have come long way catch other leader real estate energy investment health care fund have grow dec year result trail real estate fund
2381,CELG,medical stock have be mainstay new high screen recent session more score fresh milestone tuesday alexion pharmaceutical alxn bolt time high heavy trading share close best gain more month still buy range week tight buy point alexion be
2382,CELG,stock remain mixed monday afternoon broader index continue be little change blue chip show life dow jone industrial average rise help gain pfizer pfe apple aapl exxon mobil xom meanwhile edge nasdaq slip volume be run sharply lower nasdaq nyse friday expiration fuel heavy pace sonic sonc ramp new high clear buy point rare ascend base company run drive thru fast food restaurant report fiscal earning tuesday close expect post cent share year red robin gourmet burger rrgb bounce back early weakness rise new high share restaurant operator have be tear come low october rise more stock have yet form proper base february red robin report rise fiscal sale mark biggest gain year well second straight period acceleration technology avgo cool new high trimming gain more half earlier stock market today citigroup raise price target stock be still well extend buy point week tight pattern rebound week move average downside vertex pharmaceutical vrtx be session low still disappointing trial study share be nearly monday low
2383,CELG,stock stretched loss head final hour trading monday
2384,CELG,stock market today nasdaq fall drop dow trim volume be tracking higher board compare friday level
2385,CELG,dow mcdonald mcd be worst performer fall more heavy volume investor be disappoint same store sale drop november
2386,CELG,unite technology utx outperformed dow rise heavy volume share be climb right side long consolidation company have report double digit profit growth last quarters
2387,CELG,medical name find ibd celgene celg jazz pharmaceutical jazz akorn akrx gain celgene be star jump more new time high heavy volume
2388,CELG,tesla tsla continue slide fall nearly slip further day move average lower oil price have hurt relative appeal electric vehicle
2389,CELG,oil gas industry group be again worst performer market today oil extend recent plunge fall more stock stretched loss head final hour trading monday stock market today nasdaq fall drop dow trim volume be tracking higher board compare friday level dow mcdonald mcd be worst performer fall more heavy volume investor be disappoint same store sale drop november unite technology utx outperformed dow rise heavy volume share be climb right side long consolidation company have report double digit profit growth last quarters medical name find ibd celgene celg jazz pharmaceutical jazz akorn akrx gain celgene be star jump more new time high heavy volume tesla tsla continue slide fall nearly slip further day move average lower oil price have hurt relative appeal electric vehicle oil gas industry group be again worst performer market today oil extend recent plunge fall more
2390,CELG,juno therapeutic soar friday trading debut latest sign investor demand new class cancer cure firm biotechs overall juno juno raise late thursday ipo initial market capitalization highest valuation biotech ipo accord ipo etf manager renaissance capital juno sell
2391,CELG,euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level
2392,CELG,nasdaq be rise dow jone industrial average gain volume be trend lower exchange
2393,CELG,befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning
2394,CELG,department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today
2395,CELG,biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose
2396,CELG,gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi
2397,CELG,alexion pharmaceutical alxn fall also fall day line
2398,CELG,ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level nasdaq be rise dow jone industrial average gain volume be trend lower exchange befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi alexion pharmaceutical alxn fall also fall day line ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base
2399,CELG,company medivation mdvn recently turn profitable big way
2400,CELG,company new entrant ibd stock spotlight screen focus develop therapy treat serious illness few treatment option exist
2401,CELG,nov medivation report third quarter earning cent share compare loss year earlier period sale growth accelerate second straight quarter gain number come analyst expectation investor still cheer push stock sharply higher next day
2402,CELG,company be expect earn first annual profit share year analyst forecast gain ep
2403,CELG,medivation only commercial drug xtandi be treatment certain type prostate cancer drug be recently approve expand use company be seek further expansion product
2404,CELG,sale drug third quarter be report astella pharma company development partner include sale outside america
2405,CELG,stock be extend so investor pullback week move average new base form consider purchasing share
2406,CELG,aug stock clear cup handle pattern climb more pull back week move average
2407,CELG,present buy opportunity october find support bounce week line
2408,CELG,medivation have highest possible composite rating peer alexion alxn celgene celg china biologic producs cbpo highly rank biotech industry group
2409,CELG,stock have accumulation distribution rating volume ratio indicate big demand company medivation mdvn recently turn profitable big way company new entrant ibd stock spotlight screen focus develop therapy treat serious illness few treatment option exist nov medivation report third quarter earning cent share compare loss year earlier period sale growth accelerate second straight quarter gain number come analyst expectation investor still cheer push stock sharply higher next day company be expect earn first annual profit share year analyst forecast gain ep medivation only commercial drug xtandi be treatment certain type prostate cancer drug be recently approve expand use company be seek further expansion product sale drug third quarter be report astella pharma company development partner include sale outside america stock be extend so investor pullback week move average new base form consider purchasing share aug stock clear cup handle pattern climb more pull back week move average present buy opportunity october find support bounce week line medivation have highest possible composite rating peer alexion alxn celgene celg china biologic producs cbpo highly rank biotech industry group stock have accumulation distribution rating volume ratio indicate big demand
2410,CELG,stock stutter thursday post small loss nasdaq dow jone industrial average trim small cap lose ibd rise volume fall board small cap have lag uptrend be mid october low vs gain nasdaq also
2411,CELG,celgene amgen be highly rate company ibd screen day bolt rs line relative strength line measure stock perform compare index rs line hit new high actual stock be bullish sign today screen feature drugmaker relative strength line be bolt higher
2412,CELG,stock pare gain midday wednesday mixed economic datum europe
2413,CELG,nasdaq be pare earlier gain dow jone industrial average rise volume be tracking tuesday level nasdaq lower nyse
2414,CELG,european stock rise healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect however retail sale be flat april sale auto gas rise just trail wall street forecast
2415,CELG,stock market today cal maine food calm continue spike higher bird flu spread nebraska state affected deadly avian virus have force rancher million hen stock be new high share be week be extend well past buy point cup handle base
2416,CELG,vipshop holding vip chinese online discount retailer jump deny allegation manipulate financial datum stock erased much tuesday loss follow claim short seller mithra forensic research report seek alpha
2417,CELG,downside resm rmd make equipment treat sleep disorder plunge massive turnover report disappointing result therapy severe sleep apnea chronic heart failure stock slice day move average undercut prior base stock pare gain midday wednesday mixed economic datum europe nasdaq be pare earlier gain dow jone industrial average rise volume be tracking tuesday level nasdaq lower nyse european stock rise healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect however retail sale be flat april sale auto gas rise just trail wall street forecast stock market today cal maine food calm continue spike higher bird flu spread nebraska state affected deadly avian virus have force rancher million hen stock be new high share be week be extend well past buy point cup handle base vipshop holding vip chinese online discount retailer jump deny allegation manipulate financial datum stock erased much tuesday loss follow claim short seller mithra forensic research report seek alpha downside resm rmd make equipment treat sleep disorder plunge massive turnover report disappointing result therapy severe sleep apnea chronic heart failure stock slice day move average undercut prior base
2418,CELG,stock market close higher thursday index pare gain
2419,CELG,nasdaq climb dow jone industrial average add
2420,CELG,volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse
2421,CELG,computer trucking financial rank day top perform sector retail metal energy stock lag
2422,CELG,weak forecast send homebuilding stock stock market today
2423,CELG,meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february
2424,CELG,be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company
2425,CELG,homebuilder industry group have be market leader be worst group thursday ibd track
2426,CELG,day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december
2427,CELG,google googl rise share continue rise support day move average volume google be light
2428,CELG,close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low
2429,CELG,follow juan carlos arancibia twitter ibd_jarancibia stock market close higher thursday index pare gain nasdaq climb dow jone industrial average add volume rise nyse fall nasdaq accord early figure advance stock lead decliner nasdaq winner barely edge loser nyse computer trucking financial rank day top perform sector retail metal energy stock lag weak forecast send homebuilding stock stock market today meritage home mth cut forecast earning cite rise labor cost delay closing slower expect business company newer market southeast stock fall heavy trading lowest level early february be shortage skilled labor many market subcontractor struggle catch increase demand continue recovery homebuilding say chairman ceo steven hilton competition labor be raise cost lengthen construction time statement add bad weather part texas colorado further hurt company homebuilder industry group have be market leader be worst group thursday ibd track day biggest loser be lululemon athletica lulu plunge yoga style apparel chain guide full year earning expectation share fall lowest level december google googl rise share continue rise support day move average volume google be light close share action sport retailer zumiez zumz slide company announce quarterly result stock close regular trading week low follow juan carlos arancibia twitter ibd_jarancibia
2430,CELG,stock be session lows early afternoon trading oil price fall hard again
2431,CELG,nasdaq lose fall dow jone industrial average give also
2432,CELG,nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel
2433,CELG,stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump
2434,CELG,ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well
2435,CELG,meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk
2436,CELG,gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week
2437,CELG,meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively stock be session lows early afternoon trading oil price fall hard again nasdaq lose fall dow jone industrial average give also nasdaq nyse volume be tracking slightly higher friday level crude oil sell again fall barrel stock market today dow component mcdonald mcd fall nearly soft november global same store sale burger giant sale fall more expect domestic sale slump ibd biotech industry group be once again day top performer rise nearly top rate name group celgene celg regeneron regn gilead science gild unite therapeutic uthr be do well meanwhile cubist pharmaceutical cbst soar news be acquire merck mrk gopro gpro slump be clear news account downdraft stock have be act weak not abnormal action big run past ipo base buy point ambarella amba chip be find gopro wearable camera also give heel strong earning report last week meanwhile couple high profile ipos be set week lendingclub alibaba backed momo debut thursday symbol lc momo respectively
2438,CELG,chip stock fuel day outperformance nasdaq monday
2439,CELG,composite be afternoon trading buoy strength nasdaq chip name kla tencor klac nxp semiconductor nxpi sandisk sndk intel intc add dow jone industrial average picked less nyse nasdaq volume be tracking well friday level volume be heavy friday due option expiration
2440,CELG,stock market today biotechs also do well top rate name celgene celg medivation mdvn enanta enta lead charge score gain least
2441,CELG,retail sector extend gain report earning dec share rise still deep lengthy consolidation recently clear alternative entry year annualize earning growth rate sale growth rate be stranger fast growth
2442,CELG,elsewhere drugmaker lannett lci reclaim prior buy point heavy volume rise retake buy point coincide support day move average lannett be trading buy point lannett have be pressure most november report quarter triple digit earning sale growth nov
2443,CELG,palo alto network panw outperformed rise ahead earning report close expectation be high solid quarter provider network security infrastructure product thomson reuter consensus estimate be profit cent share year sale be see rise
2444,CELG,oil gas related group be pressured again day worst performer hailed sector
2445,CELG,result be also due close china base qihoo technology qihu workday wday workday isn profitable yet have show strong sale growth recent quarters work cup handle base buy point share lose
2446,CELG,economic calendar be light week due thanksgiving holiday tuesday watch second estimate gross domestic product first estimate growth economist expect gdp growth bit softer chip stock fuel day outperformance nasdaq monday composite be afternoon trading buoy strength nasdaq chip name kla tencor klac nxp semiconductor nxpi sandisk sndk intel intc add dow jone industrial average picked less nyse nasdaq volume be tracking well friday level volume be heavy friday due option expiration stock market today biotechs also do well top rate name celgene celg medivation mdvn enanta enta lead charge score gain least retail sector extend gain report earning dec share rise still deep lengthy consolidation recently clear alternative entry year annualize earning growth rate sale growth rate be stranger fast growth elsewhere drugmaker lannett lci reclaim prior buy point heavy volume rise retake buy point coincide support day move average lannett be trading buy point lannett have be pressure most november report quarter triple digit earning sale growth nov palo alto network panw outperformed rise ahead earning report close expectation be high solid quarter provider network security infrastructure product thomson reuter consensus estimate be profit cent share year sale be see rise oil gas related group be pressured again day worst performer hailed sector result be also due close china base qihoo technology qihu workday wday workday isn profitable yet have show strong sale growth recent quarters work cup handle base buy point share lose economic calendar be light week due thanksgiving holiday tuesday watch second estimate gross domestic product first estimate growth economist expect gdp growth bit softer
2447,CELG,time year world be gear winter olympic sochi russia few thing put perspective contrast experience global market vast squander political capital follow sochi game send president vladimir putin economy desperate recession russia ukraine come rise
2448,CELG,ibd week winning streak come end friday index lead growth stock lose week be tough week broad market too lose ibd generally have have hard time keep recent week result
2449,CELG,profit margin be much company make earning dollar sale profit margin mean company earn cent sale strong profit margin give indication well company leverage rise demand additional profit fuel share ibd screen day be healthy profit margin
2450,CELG,stock struggle direction end narrowly mixed wednesday better expect new home sale second day testimony fed chief janet yellen stock make wave hour
2451,CELG,salesforce com crm bolt extend trading post result meet view earning come cent share double year sale rise more
2452,CELG,technology avgo rally deliver fiscal result view chip designer also announce be buy emulex elx be soar hour
2453,CELG,mercadolibre meli be also extend trading post mixed quarterly result
2454,CELG,regular session nasdaq ease fraction end day run slip dow jone industrial average rise accord preliminary datum volume end higher major exchange stock market today
2455,CELG,aruba network arun soar report talk be buy hewlett packard hpq report quarterly result late tuesday late surge send aruba buy point consolidation intraday
2456,CELG,leaderboard name grubhub grub rally nearly strong volume clear cup handle buy point earlier month provider online food order service beat view earning surge sale jump
2457,CELG,system ddd air lease al iconix brand group icon kohl kss ross store rost splunk splk be lead stock report earning thursday
2458,CELG,weekly jobless claim consumer price durable good be thursday morning atlanta fed president dennis lockhart also be speaking thursday stock struggle direction end narrowly mixed wednesday better expect new home sale second day testimony fed chief janet yellen stock make wave hour salesforce com crm bolt extend trading post result meet view earning come cent share double year sale rise more technology avgo rally deliver fiscal result view chip designer also announce be buy emulex elx be soar hour mercadolibre meli be also extend trading post mixed quarterly result regular session nasdaq ease fraction end day run slip dow jone industrial average rise accord preliminary datum volume end higher major exchange stock market today aruba network arun soar report talk be buy hewlett packard hpq report quarterly result late tuesday late surge send aruba buy point consolidation intraday leaderboard name grubhub grub rally nearly strong volume clear cup handle buy point earlier month provider online food order service beat view earning surge sale jump system ddd air lease al iconix brand group icon kohl kss ross store rost splunk splk be lead stock report earning thursday weekly jobless claim consumer price durable good be thursday morning atlanta fed president dennis lockhart also be speaking thursday
2459,CELG,european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster
2460,CELG,abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient
2461,CELG,viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir
2462,CELG,abbvie say expect european commission make final decision first quarter next year start negotiating price country country
2463,CELG,pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month
2464,CELG,analyst expect abbvie take minority share market gilead dominate still amount several dollar year
2465,CELG,abbvie be midday trading stock market today new high
2466,CELG,chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system
2467,CELG,otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical
2468,CELG,celgene stock be midday trading friday
2469,CELG,sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option
2470,CELG,leerink analyst seamus fernandez model slow liftoff drug expect annual sale
2471,CELG,sanofi stock be more midday friday
2472,CELG,follow amy reeve twitter ibd_areeve
2473,CELG,related sanofi bullish pipeline forecast underwhelm european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir abbvie say expect european commission make final decision first quarter next year start negotiating price country country pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month analyst expect abbvie take minority share market gilead dominate still amount several dollar year abbvie be midday trading stock market today new high chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical celgene stock be midday trading friday sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option leerink analyst seamus fernandez model slow liftoff drug expect annual sale sanofi stock be more midday friday follow amy reeve twitter ibd_areeve related sanofi bullish pipeline forecast underwhelm street
2474,CELG,select stock have superior profit sale growth be not sole key success market neither be simply buy stock outstanding price strength invest stock make sure also be favorite biggest investor market mutual fund investment advisor bank critical component be know institutional sponsorship proof heavy institutional buy be way confirm sponsorship be time consume find ibd paper mutual fund etfs section provide instrument help many feature do double duty reveal top perform fund long term investor help stock strong buyer have target mutual fund be design more passive investing tool stock professional fund manager research crew pick time purchase stock so fund client don have sweat detail ibd narrow field list lead fund stock holding carry high average ibd composite rating have tend outperform index low growth fund lead market feature mutual fund page spotlight fund day be often case ibd feature make worth pull read glass diving fine print box provide basic bio fund volatility rating average ep relative price strength rating stock holding perhaps even more importantly box provide fund largest holding well top new buy top sell daily section also provide list other top perform fund screen accord various criterium delve even deeper ibd mutual fund monthly quarterly report usually publish first week month feature slice dice top perform fund accord size sector type investment such vital sign point warm cool movement global economy offer clue want tinker fund portfolio stock buy perspective monthly quarterly datum stock buy sell be pure gold mine datum table put radio collar smart money prior month stock be top fund buy much top fund latest sell table provide number fund buy vs selling net total seller spot stock list closely monitor chart key sell signal buy side stock name be familiar ibd big cap weekly review table list industry group name several key ibd rating detail many fund be buy total amount invest ibd mutual fund monthly special publish list alaska air nyse alk skywork solution nasdaq swks zebra techology nasdaq zbra one top fund pour most dollar most recent month have trace solid gain year nov edition list celgene nasdaq celg baidu nasdaq bidu hca holding nyse hca allergan nyse agn
2475,CELG,nasdaq have be set record market recover correction september october ibd have lag still trading slightly intraday high set
2476,CELG,be hallmark usually market lead index year relative strength line have fail recover high set february
2477,CELG,ibd index have good week rise vs
2478,CELG,leader aren lead have negative implication general market stock elite index be choose computer base fundamental technical characteristic be make good advance
2479,CELG,chip stock be category skywork solution swks ambarella amba nxp semiconductor nxpi extend basis have rise straight week
2480,CELG,ambarella make system chip used video surveillance camera include fast selling hero line action camera make gopro gpro ambarella make new high friday most recent advance begin find support week line gain nearly last week
2481,CELG,skywork close last week new high nearly gain skywork make component used variety industry
2482,CELG,nxp close week nearly gain netherlands base company design chip used several industry
2483,CELG,drug related stock have be strong celgene celg gain week close new high drop week line october come back surprising strength trading support line
2484,CELG,develop drug fight cancer immune inflammatory related disease
2485,CELG,abc hit new high friday be breaking base oct company be distributor brand name drug health care product
2486,CELG,ibd transportation name be benefit lower oil price sharp drop crude friday
2487,CELG,old dominion freight line odfl gain more reach time high
2488,CELG,airline be strong friday spirit airline save gap close nearly put cap week stock be also time high sport composite rating nasdaq have be set record market recover correction september october ibd have lag still trading slightly intraday high set be hallmark usually market lead index year relative strength line have fail recover high set february ibd index have good week rise vs leader aren lead have negative implication general market stock elite index be choose computer base fundamental technical characteristic be make good advance chip stock be category skywork solution swks ambarella amba nxp semiconductor nxpi extend basis have rise straight week ambarella make system chip used video surveillance camera include fast selling hero line action camera make gopro gpro ambarella make new high friday most recent advance begin find support week line gain nearly last week skywork close last week new high nearly gain skywork make component used variety industry nxp close week nearly gain netherlands base company design chip used several industry drug related stock have be strong celgene celg gain week close new high drop week line october come back surprising strength trading support line develop drug fight cancer immune inflammatory related disease abc hit new high friday be breaking base oct company be distributor brand name drug health care product ibd transportation name be benefit lower oil price sharp drop crude friday old dominion freight line odfl gain more reach time high airline be strong friday spirit airline save gap close nearly put cap week stock be also time high sport composite rating
2489,CELG,half day trading wednesday result listless session major average end mostly flat nasdaq add dow rise less fall fraction volume be naturally light due shorten session base hour trading nyse volume end fairly close tuesday level nasdaq
2490,CELG,few medical lead stock have slide otherwise ibd remain good shape last week illumina ilmn akorn akrx have fall buy point alexion pharmaceutical alxn celgene celg exhibit weakness own even fall short trigger clear sell signal few other ibd stock outside health
2491,CELG,biotech stock be well represent week big cap linkedin lnkd facebook fb be pace rebound internet stock medical biomedical biotech industry have erased slightly more half loss fall sharply february high concern stock group be overvalue once high fly group be still depress rank
2492,CELG,stock backed session high monday be still nicely higher early afternoon trading dow jone industrial average rise nasdaq add gain nasdaq hit intraday turnover be mixed stock market today nasdaq trade be run high nyse volume be tracking lower biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week elsewhere gentherm thrm climb find support day line friday stock be past buy point rare ascend base earlier month maker climate controlled car seat blow past view pop earning marked third triple digit gain past quarters grubhub grub tumble news sell share follow offer april new issue erased gain past buy point mark sell signal grubhub be briefly halter earlier
2493,CELG,stock market clock slight gain last full month summer uptrend be pressure second half september
2494,CELG,manager top perform fund past month continue add share medical issue market pullback
2495,CELG,industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday
2496,CELG,large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period
2497,CELG,lead fund also biotech firm such gilead science gild biogen idec biib celgene celg
2498,CELG,transportation stock remain spotlight airline luv fedex fdx union pacific unp
2499,CELG,few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta
2500,CELG,ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm
2501,CELG,fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale
2502,CELG,chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july
2503,CELG,stock breakaway gap july share have be trading steadily tight range
2504,CELG,earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share
2505,CELG,sell side
2506,CELG,nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm stock market clock slight gain last full month summer uptrend be pressure second half september manager top perform fund past month continue add share medical issue market pullback industry group track ibd medical subgroup hospital ethical drug biotech biom be rank top thursday large drug firm allergan agn jazz pharmaceutical jazz actavis act salix pharmaceutical slxp continue grab top fund interest latest report period lead fund also biotech firm such gilead science gild biogen idec biib celgene celg transportation stock remain spotlight airline luv fedex fdx union pacific unp few notable buy top fund worth mention include social medium giant facebook fb burrito chain chipotle grill cmg retailer ulta beauty ulta ibd find best perform fund add chipotle investing estimate latest report period rowe price blue chip growth fund own big stake firm fast casual chain run restaurant canada also venture southeast asian flavor new concept call southeast asian kitchen december chipotle announce plan expand pizza segment pizzeria locale chipotle menu be simple serve burritos taco burrito bowl salad used fresh organic ingredient rival similar menu el pollo make ipo debut july stock breakaway gap july share have be trading steadily tight range earning have be grow steadily double digit least quarters third quarter earning result be due market close oct analyst currently see earning rise share sell nation top perform fund have be take profit handful retailer include cvs health cvs dollartree dltr costco cost william sonoma wsm
2507,CELG,stock market be moderately higher monday top intraday first time biotechs lead way strength major takeover
2508,CELG,nasdaq dow industrial rise gain nasdaq volume run heavier friday pace nyse volume be lighter be first day nasdaq volume be higher previous day aug
2509,CELG,stock market today ibd stock stock rise fall best performer be chinese automobile website bitauto bita athm break very deep base new issue come market last december
2510,CELG,bitauto have more double breaking cup handle base june
2511,CELG,worst ibd performer be chinese name qihoo technology qihu nearly highest volume month decline come company report better expect earning revenue receive raise price target citigroup
2512,CELG,biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket
2513,CELG,gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week
2514,CELG,medical biom biotech industry group be monday top performer industry group track ibd rise
2515,CELG,restaurant order online mobile platform grubhub grub sank news sell additional share stock come public april monday decline take stock buy point ipo base stock market be moderately higher monday top intraday first time biotechs lead way strength major takeover nasdaq dow industrial rise gain nasdaq volume run heavier friday pace nyse volume be lighter be first day nasdaq volume be higher previous day aug stock market today ibd stock stock rise fall best performer be chinese automobile website bitauto bita athm break very deep base new issue come market last december bitauto have more double breaking cup handle base june worst ibd performer be chinese name qihoo technology qihu nearly highest volume month decline come company report better expect earning revenue receive raise price target citigroup biotechs be strong news swiss drugmaker roche buy intermune itmn share intermune sky-rocket gilead science gild climb time high akorn akrx celgene celg meanwhile rise hit time high celgene be now past buy point flat base clear week medical biom biotech industry group be monday top performer industry group track ibd rise restaurant order online mobile platform grubhub grub sank news sell additional share stock come public april monday decline take stock buy point ipo base
2516,CELG,major average hold decent gain little hour remain monday session
2517,CELG,top level rally dow jone industrial average also gain nasdaq tack nasdaq volume be tracking higher friday level nyse volume fall
2518,CELG,stock market today biotech stock take center stage news big acquisition weekend swiss firm roche rhhby reach deal buy intermune itmn intermune soar news
2519,CELG,ibd medical biom biotech group be day best performer rise nearly top rate name group outperformed include gilead science gild celgene celg biogen idec biib alexion alxn
2520,CELG,china base auto operator athm be top performer ibd share jump news clear deep cup shape base buy point
2521,CELG,earning news qihoo technology qihu slump report better expect earning sale stock be weak margin concern cost sale surge year operate expense more double qihoo be provider internet search mobile security product china
2522,CELG,meanwhile ikang healthcare group kang fast grow china name rally fast trade ahead earning report close
2523,CELG,economic news july new home sale come consensus estimate june new home sale be revise higher unit major average hold decent gain little hour remain monday session top level rally dow jone industrial average also gain nasdaq tack nasdaq volume be tracking higher friday level nyse volume fall stock market today biotech stock take center stage news big acquisition weekend swiss firm roche rhhby reach deal buy intermune itmn intermune soar news ibd medical biom biotech group be day best performer rise nearly top rate name group outperformed include gilead science gild celgene celg biogen idec biib alexion alxn china base auto operator athm be top performer ibd share jump news clear deep cup shape base buy point earning news qihoo technology qihu slump report better expect earning sale stock be weak margin concern cost sale surge year operate expense more double qihoo be provider internet search mobile security product china meanwhile ikang healthcare group kang fast grow china name rally fast trade ahead earning report close economic news july new home sale come consensus estimate june new home sale be revise higher unit
2524,CELG,stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high
2525,CELG,nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure
2526,CELG,european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting
2527,CELG,retailer medical apparel stock lead upside datum storage energy steel stock underperform
2528,CELG,nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average
2529,CELG,alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range
2530,CELG,downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting retailer medical apparel stock lead upside datum storage energy steel stock underperform nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report
2531,CELG,big biotech amgen amgn early monday report positive interim result crucial late stage trial blood cancer drug kyproli monday help justify acquisition onyx last year amgen be more early trading stock market today modest rise investor await result important second trial first trial call
2532,CELG,biotech pharmacyclic pcyc be seesaw stock market today sale beat consensus late thursday company decline update guidance pharmacyclic sale more double year earlier quarter higher consensus loss cent share be well consensus cent analyst
2533,CELG,fda say thursday have approve spectrum pharmaceutical sppi drug beleodaq patient peripheral cell lymphoma ptcl send spectrum stock much early thursday spectrum be more midday trading stock market today ptcl be rare aggressive form hodgkin lymphoma represent
2534,CELG,recent volatility stock market include outlook shift uptrend pressure back confirm uptrend have rattle investor nerve also help set new potential entry lead stock slip buy range pull back week move average line ibd gain week outperform
2535,CELG,biogen idec head second quarter earning report best roll year biotech continue benefit heavy demand drug treat multiple sclerosis cancer autoimmune disease biotech market cap have run straight quarters accelerate sale growth year year earning have rise least
2536,CELG,dow jone industrial average hold well monday nasdaq take hit ahead tuesday start day federal reserve meeting
2537,CELG,nasdaq slump weigh software solar name dow edge higher help strength share pfizer pfe traveler trv stock rise give
2538,CELG,stock market today tesla motor tsla dive nearly morgan stanley reiterate overweight rating remove price target basically say stock have get ahead
2539,CELG,anheuser busch inbev bud jump news interested buy privately hold brewer sabmiller group peer molson coor brewing tap soar speculation be takeover target line
2540,CELG,big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week
2541,CELG,meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba
2542,CELG,several growth name be threaten break day move average monday include yy yy baidu bidu armour ua celgene celg dow jone industrial average hold well monday nasdaq take hit ahead tuesday start day federal reserve meeting nasdaq slump weigh software solar name dow edge higher help strength share pfizer pfe traveler trv stock rise give stock market today tesla motor tsla dive nearly morgan stanley reiterate overweight rating remove price target basically say stock have get ahead anheuser busch inbev bud jump news interested buy privately hold brewer sabmiller group peer molson coor brewing tap soar speculation be takeover target line big buyer come steel producer nucor nue again news buy gallatin steel share rise nucor be still early stage clear long consolidation start november ibd steel producer group now rank ibd industry group ranking week week meanwhile china base commerce firm alibaba be schedule price thursday night start trading friday propose price range be share ll likely move higher due overwhelming demand alibaba trade symbol baba several growth name be threaten break day move average monday include yy yy baidu bidu armour ua celgene celg
2543,CELG,broad nyse composite trade quietly tight range monday be completely different story nasdaq profit take hit several lead growth stock tech heavy index fall higher volume register third distribution day day fourth aug follow rapid rise distribution
2544,CELG,stock market bounce back tuesday session provide encourage sign nasdaq jump close session high small cap continue lag comparison russell picked nasdaq advance be not well round volume nasdaq be lower advance stock top
2545,CELG,stock open narrowly mixed stance thursday
2546,CELG,dow jone industrial average inched fraction nasdaq dip qualcomm qcom celgene celg alexion pharmaceutical alxn dive deliver quarterly result
2547,CELG,volume be higher nyse nasdaq
2548,CELG,addition wave earning report stock market today appear receive least lift positive manufacturing datum china germany france overnight surprise drop weekly unemployment claim sweeten pot ahead thursday open
2549,CELG,preliminary july figure manufacturing be less bright markit flash purchasing manager manufacturing index dip june strong show forecast uptick
2550,CELG,new home sale june be also not so positive dip annualize rate accord commerce department be well downwardly revise rate even further forecast pace
2551,CELG,stock automaker ford tick general motor gm slip investor react second quarter report soda maker dr pepper snapple dps gain oil gas drill service operator patterson uti energy pten jump
2552,CELG,armour ua rocked ahead open maker high tech sportswear report fair weather june boost sale earning past analyst consensus forecast stock break buy point cup handle base be entry
2553,CELG,facebook fb jump gain place ibd stock buy point cup handle base social medium heavyweight result easily outdistance analyst revenue earning expectation
2554,CELG,also ibd network ffiv pulse massive trade fiscal third quarter sale earning comfortably top consensus estimate stock clear buy point cup handle base
2555,CELG,downside ibd stock celgene celg slip big trade new jersey base drugmaker report slightly better expect ep revenue growth management full year guidance be mixed dip put share less buy point stock open narrowly mixed stance thursday dow jone industrial average inched fraction nasdaq dip qualcomm qcom celgene celg alexion pharmaceutical alxn dive deliver quarterly result volume be higher nyse nasdaq addition wave earning report stock market today appear receive least lift positive manufacturing datum china germany france overnight surprise drop weekly unemployment claim sweeten pot ahead thursday open preliminary july figure manufacturing be less bright markit flash purchasing manager manufacturing index dip june strong show forecast uptick new home sale june be also not so positive dip annualize rate accord commerce department be well downwardly revise rate even further forecast pace stock automaker ford tick general motor gm slip investor react second quarter report soda maker dr pepper snapple dps gain oil gas drill service operator patterson uti energy pten jump armour ua rocked ahead open maker high tech sportswear report fair weather june boost sale earning past analyst consensus forecast stock break buy point cup handle base be entry facebook fb jump gain place ibd stock buy point cup handle base social medium heavyweight result easily outdistance analyst revenue earning expectation also ibd network ffiv pulse massive trade fiscal third quarter sale earning comfortably top consensus estimate stock clear buy point cup handle base downside ibd stock celgene celg slip big trade new jersey base drugmaker report slightly better expect ep revenue growth management full year guidance be mixed dip put share less buy point
2556,CELG,big cap biotech leader biogen idec biib gilead science gild easily beat second quarter earning estimate receive product approval wednesday stock react very differently
2557,CELG,biogenearning rise vs year earlier share top analyst consensus cent sale grow vs street
2558,CELG,company increase full year revenue range growth analyst average now see ep more prior guidance analyst expect
2559,CELG,upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst expect slow european launch novartis nvs enter market first ms pill gilenya however executive say uptake european country have gain reimbursement mainly germany be proceed similar pace
2560,CELG,sale tecfidera outside be vs consensus domestic sale rise top estimate
2561,CELG,biogen reach deal italy eliminate country reimbursement limit older ms drug tysabri retroactive february
2562,CELG,recognition revenue add cent ep
2563,CELG,ceo george scango disclose eu have approve biogen interferon base ms drug plegridy be still await approval america launch drug hemophilia drug alprolix eloctate lead biogen guide sale general administrative expense expectation revenue
2564,CELG,biogen slightly disappoint street say phase trial result lingo be first disease alter treatment ms be report not next year hope company want month result rather month still biogen stock rise
2565,CELG,sovaldi boom
2566,CELG,gilead earning release close vault share beating cent sale leap top view
2567,CELG,hepatitis drug sovaldi just launch december generate sale well consensus
2568,CELG,political industry protest day pill gilead say state medicaid program cover sovaldi
2569,CELG,gilead first time give full year guidance include sovaldi sale vs last year subtract prior guidance imply sovaldi rake
2570,CELG,gilead whisper number seem be much higher
2571,CELG,gild report soundly beat sell side consensus be roughly line perceive be buy side expectation write isi group analyst mark schoenebaum email client add new revenue guidance agree analyst estimate
2572,CELG,perhaps reason gilead stock fall fractionally late largely erase regular session gain
2573,CELG,gilead other major drug hiv medicine atripla truvada viread complera stribild modestly top consensus atripla
2574,CELG,bud field cancer medicine gilead also say fda approve drug idelalisib now brand zydelig chronic lymphocytic leukemia follicular lymphoma small lymphocytic lymphoma analyst expect be blockbuster more modest proportion sovaldi sale peak
2575,CELG,other major biotechs report thursday alexion pharmaceutical alxn celgene celg big cap biotech leader biogen idec biib gilead science gild easily beat second quarter earning estimate receive product approval wednesday stock react very differently biogenearning rise vs year earlier share top analyst consensus cent sale grow vs street company increase full year revenue range growth analyst average now see ep more prior guidance analyst expect upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst expect slow european launch novartis nvs enter market first ms pill gilenya however executive say uptake european country have gain reimbursement mainly germany be proceed similar pace sale tecfidera outside be vs consensus domestic sale rise top estimate biogen reach deal italy eliminate country reimbursement limit older ms drug tysabri retroactive february recognition revenue add cent ep ceo george scango disclose eu have approve biogen interferon base ms drug plegridy be still await approval america launch drug hemophilia drug alprolix eloctate lead biogen guide sale general administrative expense expectation revenue biogen slightly disappoint street say phase trial result lingo be first disease alter treatment ms be report not next year hope company want month result rather month still biogen stock rise sovaldi boomsgilead earning release close vault share beating cent sale leap top view hepatitis drug sovaldi just launch december generate sale well consensus political industry protest day pill gilead say state medicaid program cover sovaldi gilead first time give full year guidance include sovaldi sale vs last year subtract prior guidance imply sovaldi rake gilead whisper number seem be much higher gild report soundly beat sell side consensus be roughly line perceive be buy side expectation write isi group analyst mark schoenebaum email client add new revenue guidance agree analyst estimate perhaps reason gilead stock fall fractionally late largely erase regular session gain gilead other major drug hiv medicine atripla truvada viread complera stribild modestly top consensus atripla bud field cancer medicine gilead also say fda approve drug idelalisib now brand zydelig chronic lymphocytic leukemia follicular lymphoma small lymphocytic lymphoma analyst expect be blockbuster more modest proportion sovaldi sale peak other major biotechs report thursday alexion pharmaceutical alxn celgene celg
2576,CELG,big cap biotech biogen idec biib soundly beat analyst expectation substantially raise guidance early wednesday send share more midday trading stock market today month high biogen earning rise year earlier quarter share top analyst consensus cent sale increase vs street company increase full year guidance revenue growth earlier guide analyst average ep guidance be now more previous guidance analyst be expect upside come largely tecfidera oral multiple sclerosis drug approve last year europe early february management analyst have expect european launch be slow novartis nvs have get market first ms pill gilenya however conference call discuss result executive say uptake european country have gain reimbursement mainly germany point be proceed similar pace total sale tecfidera outside quarter be vs consensus domestic sale also outperformed take top estimate also benefit time event quarter biogen come agreement italian national medicine agency eliminate country reimbursement limit tysabri older ms drug retroactive february recognition revenue add cent ep good news item disappoint analyst be sale general administrative spending be guide higher expect revenue call cfo paul clancy say be necessary unprecedented amount drug launch underway not only be tecfidera still roll also biogen launch long act hemophilia drug alprolix also beat expectation sale vs analyst estimate just last week launch hemophilia counterpart eloctate company be also prepare launch new interferon base ms drug plegridy call biogen ceo george scango say just get word plegridy have be approve eu other disappointment be delay report result key clinical trial month street have be buzz biogen pipeline product call lingo be first disease alter treatment ms analyst have expect month result phase trial be next year management say report month result nonetheless isi group analyst mark schoenebaum be generally impressed point be largest beat biogen have report year overall really good call new disclosure diluted quality ep sale beat quarter write email client conference call biogen kick earning several top rate biotechs tuesday market close gilead science gild be expect report earning share sale blockbuster hepatitis drug sovaldi alexion pharmaceutical alxn celgene celg be tap thursday other biotech news puma biotechnology pbyi shot company report surprisingly strong phase trial result breast cancer drug follow amy reeve twitter ibd_areeve related biogen share rebound street have change heart
2577,CELG,stock begin modestly lower monday then reversed small gain
2578,CELG,nasdaq be barely break even line rise dow jone industrial average be flat volume be run higher stock market today vs friday sluggish pace
2579,CELG,blue chip be evenly split winner loser dow component chevron cvx home depot hd show biggest gain ibm ibm take hardest hit
2580,CELG,ibd proxy lead stock chip stock be retreat transportation related stock be advance
2581,CELG,schedule economic datum be thin dalla federal reserve manufacturing survey be expect be release morning
2582,CELG,west texas intermediate crude oil brent crude be cross mark respectively concern swirl supply disruption libya be struggle port blockade protest stock begin modestly lower monday then reversed small gain nasdaq be barely break even line rise dow jone industrial average be flat volume be run higher stock market today vs friday sluggish pace blue chip be evenly split winner loser dow component chevron cvx home depot hd show biggest gain ibm ibm take hardest hit ibd proxy lead stock chip stock be retreat transportation related stock be advance schedule economic datum be thin dalla federal reserve manufacturing survey be expect be release morning west texas intermediate crude oil brent crude be cross mark respectively concern swirl supply disruption libya be struggle port blockade protest
2583,CELG,highest rate market big cap biotechs be set report second quarter earning week own unique storyline biogen idec biib subject tuesday new america be first report open wednesday analyst consensus call sale year earlier quarter earning
2584,CELG,big cap biotech celgene celg report wednesday drug otezla fail trial inflammatory spinal disease stock rebound early drop analyst say news wasn surprise phase study look otezla ankylose spondylitis immunological disease cause pain sometimes fusion spinal cord be not
2585,CELG,ibd find few sign distress fair share success story even market uptrend moderate be month market start climb august lows main index have slow ascent little complain ibd nearly half
2586,CELG,new buy list top perform fund past month show heavy buy top rate stock nation lead fund have be stocking medical issue fared well market resume uptrend august large heavy hit medical stock be buy top fund latest report period include gilead science gild jazz pharmaceutical ticker
2587,CELG,stock close lower tuesday continue frustrate pattern ambiguous market signal nasdaq lose just fraction cushion strength biotechs software telecom computer other nasdaq lean sector fall plastic metal transportation stock particular weigh index ibd fall nasdaq close
2588,CELG,oil gas play make more half week big cap list yet again surprise give high worldwide demand fuel continue turmoil iraq result energy stock make cut be well extend buy point be few energy related leader be
2589,CELG,oil gas play make more half week big cap list yet again surprise give high worldwide demand fuel continue turmoil iraq result energy stock make cut be well extend buy point be few energy related leader be
2590,CELG,do follow legend
2591,CELG,be challenge sam peter have be lead manager clearbridge value take baton bill miller year
2592,CELG,miller still run legg mason opportunity run value april inception april famously beat broad stock market measure year row
2593,CELG,miller winning streak come end peter joined co manager late take lead april
2594,CELG,peter have make progress return value apex top mutual fund fund beat large cap blend peer be ahead year july say morningstar inc
2595,CELG,fund change brand name legg mason march
2596,CELG,peter discuss investment approach office overlook baltimore inner harbor
2597,CELG,ibd be crux strategy pursuit misprice stock
2598,CELG,peter look traditional growth stock traditional value stock go quality spectrum try come reasonable range business value stock future scenario valuation manager real expertise be look stock free cash flow analysis then time figure power stock return find price value gap
2599,CELG,ibd many person say do consistently long period
2600,CELG,peter time re active manager have take humble approach market tough beat once analyst come stock valuation be cent dollar ask be market get wrong look thing strengthen investment case look reason market expectation be wrong most time be not wrong look hundred stock find few market be wrong
2601,CELG,ibd come don end lot break stock
2602,CELG,peter don want frankenstein want most diversification get concentrated portfolio own only name don want pay ve get be discipline take time misprice stock price value converge average hold period be year
2603,CELG,ibd do approach differ bill miller
2604,CELG,peter become co manager november be good coach start change thing encourage cast net wider example be very underweight health care come board have health care stock background so go underweight vs overweight cut financial housing stock do also sell tech name
2605,CELG,re overweight energy weren come board re very overweight financial now re overweight tech health care peaked overweight earlier year
2606,CELG,ibd person not know be health care background
2607,CELG,peter manage global health care team fidelity manage fidelity select health care select medical equipment fund january april
2608,CELG,ibd else do approach differ miller
2609,CELG,peter take breadth let say be great price gap stock be home run hit park bill concentrate ll take more name even less upside ll add nice valuation bet diversify fund more
2610,CELG,ibd be purpose add diversification cut volatility
2611,CELG,peter not necessarily make fund less volatile result be be less volatile time
2612,CELG,ibd biggest bet
2613,CELG,peter ll answer way biggest overweight be bet higher interest rate moved year date still ahead market
2614,CELG,ibd do still pick miller brain
2615,CELG,peter be biggest mentor always be be very close friend have utmost respect
2616,CELG,be relieve chart own course contrarian streak buy negative price momentum be differentiate get reinforce learn lot bill learn be intellectually diverse read widely talk person not be dogmatic bill yet allow be different bill
2617,CELG,talk investing rarely talk individual name
2618,CELG,bill be huge contrarian too share common dna push really think look fact be essential be go have contrarian approach be contrary opinion not fact
2619,CELG,ibd much skin do have game
2620,CELG,peter larger shareholder fund be be largest chunk net worth sec disclosure have mark get bonuse add fund be largest individual shareholder fund institutional shareholder have more
2621,CELG,ibd june disclosure show stake apple aapl jump share april apple have split so do also trim
2622,CELG,peter yes apple have split ve actually be trimming
2623,CELG,typically buy negative narrative go too far get excited hurdle go foot high inch high be case apple tougher case post split apple be trading
2624,CELG,person be excited inch screen iphone watch be supposedly come
2625,CELG,apple be discounting flattish margin be discounting growth higher hurdle jump not massively overvalue less interesting be
2626,CELG,ibd celgene celg be recent split right
2627,CELG,peter be be classic get involved big biotech run be value stock joined fund health care be dump
2628,CELG,love positive price momentum just don want pay trim biotech get hit march then celgene get sell market add back expectation get reset think celgene be long term winner think celgene prevail revlimid patent court fight natco be develop generic rival revlimid
2629,CELG,ibd be frac bedrock halliburton hal play
2630,CELG,peter put straw mile ground go foot horizontally then blow rock underground drive more oil more complex well be better economic halliburton
2631,CELG,noticed shale revolution be rig productivity be double year be amazing halliburton be capture lot efficiency
2632,CELG,ibd do trim broadcom brcm april june
2633,CELG,peter be classic broadcom be do bad thing throw huge amount money chasing qualcomm qcom monopoly chip make headway diluted own fundamental uneconomical bet
2634,CELG,end lowest valuation large cap semiconductor stock buy everyone tell shouldn be high now trading high be so bad be good thought get pressure employee shareholder own board fix thing feel make change better stock go lot
2635,CELG,last quarter behold say uncle stop chasing qualcomm monopoly say give back more shareholder profit margin go so ll see positive earning revision
2636,CELG,still think business value be higher somewhere now have positive momentum have big position so ll see trim little
2637,CELG,ibd calpine cpn earning share growth have accelerate quarters thesis
2638,CELG,peter begin buy early year late first quarter early second quarter re take free cash flow yield be extremely high buy back lot stock so get effect high tax efficient yield year treasury world good way
2639,CELG,reward underbuild utility power supply especially pennsylvania new jersey re have lot coal utility retirement re not build new nuke power plant so power supply be get tighter think set lot power pricing volatility be great calpine
2640,CELG,ibd unitedhealth group unh be uptrending modest ep result view
2641,CELG,peter get hit negative earning revision due obamacare stock be cheap enough withstand now estimate have stabilize have growth service growth core manage care side mixed low valuation better earning look result nice stock low valuation let be timing agnostic
2642,CELG,ibd do expedia expe look value play
2643,CELG,peter buy last fall stumble earning last summer become very cheap
2644,CELG,meet management fall become comfortable have get technology platform good enough shape manage pressure priceline pcln feel see positive earning surprise lower bar
2645,CELG,think online travel space be good cash generator
2646,CELG,ibd do truck part maker paccar pcar
2647,CELG,peter trucking capacity be get tight get driver national fleet be get old so set replacement cycle big way build big fundamental tailwind paccar re good capital allocation
2648,CELG,ibd dr pepper snapple dps be uptrending so do still
2649,CELG,peter ve do good job turn top line growth bottom line growth smart capital allocation re buy back lot stock well business value
2650,CELG,ve drive profit margin higher rationalized business also bother little person have be look domestic play dr pepper be north american beverage play coke ko pepsi pep valuation be get less attractive re still hold
2651,CELG,ibd bother investor liking stock
2652,CELG,peter try find uncrowded game be see safe zone right now be true high investor expectation crowd make risk
2653,CELG,ibd well fargo wfc have meet top consensus expectation recent quarters else do
2654,CELG,peter re incredibly well manage last stress test regulator say basically return earning shareholder want be unprecedented citigroup hang re dominant mortgage market return equity be well double digit re selling business value get higher interest rate go be good large bank life insurer do follow legend be challenge sam peter have be lead manager clearbridge value take baton bill miller year miller still run legg mason opportunity run value april inception april famously beat broad stock market measure year row miller winning streak come end peter joined co manager late take lead april peter have make progress return value apex top mutual fund fund beat large cap blend peer be ahead year july say morningstar inc fund change brand name legg mason march peter discuss investment approach office overlook baltimore inner harbor ibd be crux strategy pursuit misprice stock peter look traditional growth stock traditional value stock go quality spectrum try come reasonable range business value stock future scenario valuation manager real expertise be look stock free cash flow analysis then time figure power stock return find price value gap ibd many person say do consistently long period peter time re active manager have take humble approach market tough beat once analyst come stock valuation be cent dollar ask be market get wrong look thing strengthen investment case look reason market expectation be wrong most time be not wrong look hundred stock find few market be wrong ibd come don end lot break stock peter don want frankenstein want most diversification get concentrated portfolio own only name don want pay ve get be discipline take time misprice stock price value converge average hold period be year ibd do approach differ bill miller peter become co manager november be good coach start change thing encourage cast net wider example be very underweight health care come board have health care stock background so go underweight vs overweight cut financial housing stock do also sell tech name re overweight energy weren come board re very overweight financial now re overweight tech health care peaked overweight earlier year ibd person not know be health care background peter manage global health care team fidelity manage fidelity select health care select medical equipment fund january april ibd else do approach differ miller peter take breadth let say be great price gap stock be home run hit park bill concentrate ll take more name even less upside ll add nice valuation bet diversify fund more ibd be purpose add diversification cut volatility peter not necessarily make fund less volatile result be be less volatile time ibd biggest bet peter ll answer way biggest overweight be bet higher interest rate moved year date still ahead market ibd do still pick miller brain peter be biggest mentor always be be very close friend have utmost respect be relieve chart own course contrarian streak buy negative price momentum be differentiate get reinforce learn lot bill learn be intellectually diverse read widely talk person not be dogmatic bill yet allow be different bill talk investing rarely talk individual name bill be huge contrarian too share common dna push really think look fact be essential be go have contrarian approach be contrary opinion not fact ibd much skin do have game peter larger shareholder fund be be largest chunk net worth sec disclosure have mark get bonuse add fund be largest individual shareholder fund institutional shareholder have more ibd june disclosure show stake apple aapl jump share april apple have split so do also trim peter yes apple have split ve actually be trimming typically buy negative narrative go too far get excited hurdle go foot high inch high be case apple tougher case post split apple be trading person be excited inch screen iphone watch be supposedly come apple be discounting flattish margin be discounting growth higher hurdle jump not massively overvalue less interesting be ibd celgene celg be recent split right peter be be classic get involved big biotech run be value stock joined fund health care be dump love positive price momentum just don want pay trim biotech get hit march then celgene get sell market add back expectation get reset think celgene be long term winner think celgene prevail revlimid patent court fight natco be develop generic rival revlimid ibd be frac bedrock halliburton hal play peter put straw mile ground go foot horizontally then blow rock underground drive more oil more complex well be better economic halliburton noticed shale revolution be rig productivity be double year be amazing halliburton be capture lot efficiency ibd do trim broadcom brcm april june peter be classic broadcom be do bad thing throw huge amount money chasing qualcomm qcom monopoly chip make headway diluted own fundamental uneconomical bet end lowest valuation large cap semiconductor stock buy everyone tell shouldn be high now trading high be so bad be good thought get pressure employee shareholder own board fix thing feel make change better stock go lot last quarter behold say uncle stop chasing qualcomm monopoly say give back more shareholder profit margin go so ll see positive earning revision still think business value be higher somewhere now have positive momentum have big position so ll see trim little ibd calpine cpn earning share growth have accelerate quarters thesis peter begin buy early year late first quarter early second quarter re take free cash flow yield be extremely high buy back lot stock so get effect high tax efficient yield year treasury world good way reward underbuild utility power supply especially pennsylvania new jersey re have lot coal utility retirement re not build new nuke power plant so power supply be get tighter think set lot power pricing volatility be great calpine ibd unitedhealth group unh be uptrending modest ep result view peter get hit negative earning revision due obamacare stock be cheap enough withstand now estimate have stabilize have growth service growth core manage care side mixed low valuation better earning look result nice stock low valuation let be timing agnostic ibd do expedia expe look value play peter buy last fall stumble earning last summer become very cheap meet management fall become comfortable have get technology platform good enough shape manage pressure priceline pcln feel see positive earning surprise lower bar think online travel space be good cash generator ibd do truck part maker paccar pcar peter trucking capacity be get tight get driver national fleet be get old so set replacement cycle big way build big fundamental tailwind paccar re good capital allocation ibd dr pepper snapple dps be uptrending so do still peter ve do good job turn top line growth bottom line growth smart capital allocation re buy back lot stock well business value ve drive profit margin higher rationalized business also bother little person have be look domestic play dr pepper be north american beverage play coke ko pepsi pep valuation be get less attractive re still hold ibd bother investor liking stock peter try find uncrowded game be see safe zone right now be true high investor expectation crowd make risk ibd well fargo wfc have meet top consensus expectation recent quarters else do peter re incredibly well manage last stress test regulator say basically return earning shareholder want be unprecedented citigroup hang re dominant mortgage market return equity be well double digit re selling business value get higher interest rate go be good large bank life insurer
2655,CELG,biotech etfs seesaw recent week slide grim fed comment perk blockbuster earning big cap leader gilead gild biogen biib slumping again more modest news celgene celg alexion alxn gyration underscored need investor caution volatile health subsector expert tell ibd see large distortion base
2656,CELG,rock band second album biotech second drug say lot long term prospect alexion pharmaceutical alxn be face test year old firm have become big cap perennial ibd list top rate stock thank market product soliris first launch treat blood disease
2657,CELG,recent announcement roche rhhby buy intermune itmn bring new life speculation biotech industry have be relatively neglected buzz focuse tax inversion deal company ibd have greater ability anyone else predict future here be biotech stock have be name
2658,CELG,ibd fall second straight week market recent turbulence biotech stock sell many lead stock continue hold well few have flash sell signal index top growth stock fall week edge still many ibd stock remain extend
2659,CELG,stock continue add broad gain late trading friday be pace end modestly higher week nasdaq stretched gain have erased thursday loss then meanwhile rally dow jone industrial average rise turnover be again run mixed stock market today nyse trade be tracking sharply higher nasdaq volume be run lower compare same time thursday aercap holding aer reversed early loss rally fast trade stock be get close resistance day line work potential flat base aercap last break double bottom base early analyst poll thomson reuter see profit rise cent share mark second straight quarter acceleration gilead science gild step gain more be pace end day pullback stock be now past buy point first stage cup handle base biotech report second quarter earning wednesday profit be expect share year mark second straight quarter triple digit growth gilead sovaldi hepatitis treatment be expect drive growth autonation rally also meet resistance day line share auto dealer tumble slice line thursday disappointing earning report seagate technology stx shave early loss be still thursday close hard drive maker report disappointing fiscal sale company peg sale current fiscal first quarter slightly view
2660,CELG,stock market continue advance tuesday subtle institutional selling surface nasdaq rise close session high highest level march add just give have be gain early volume rise board close
2661,CELG,ibd fall second straight week market recent turbulence biotech stock sell many lead stock continue hold well few have flash sell signal index top growth stock fall week edge still many ibd stock remain extend
2662,CELG,stock edge tightly mixed formation early trading thursday mixed economic news provide clear direction
2663,CELG,nasdaq dow jone industrial average be essentially flat russell inched fractional gain volume jump nasdaq slip nyse compare wednesday early action
2664,CELG,stock market today open welter earning news reasonably positive weekly unemployment datum
2665,CELG,manufacturing mid atlantic region pulse higher june send philadelphia federal reserve business outlook survey philly fed survey month be best level september significantly higher read far expectation slip
2666,CELG,economic indicator eke ahead conference board report lead economic index be fourth straight advance better april gain be consensus estimate increase
2667,CELG,stock action kroger kr bag gain massive trade earning revenue april end quarter easily clear forecast management raise full year earning guidance high end expectation move left share extend rebound week support
2668,CELG,biotech celgene celg pop shareholder approve stock split effective june stock clear buy point cup handle base volume swell
2669,CELG,other lead stock bitauto holding bita jump retake buy point provider online automotive information consumer china form late stage base several flaw
2670,CELG,emerge energy service emes notch new high brokerage stifel hoist stock price target company reportedly announce amendment agreement supply sand used hydraulic fracture process schlumberger slb emerge energy share be extend march stock edge tightly mixed formation early trading thursday mixed economic news provide clear direction nasdaq dow jone industrial average be essentially flat russell inched fractional gain volume jump nasdaq slip nyse compare wednesday early action stock market today open welter earning news reasonably positive weekly unemployment datum manufacturing mid atlantic region pulse higher june send philadelphia federal reserve business outlook survey philly fed survey month be best level september significantly higher read far expectation slip economic indicator eke ahead conference board report lead economic index be fourth straight advance better april gain be consensus estimate increase stock action kroger kr bag gain massive trade earning revenue april end quarter easily clear forecast management raise full year earning guidance high end expectation move left share extend rebound week support biotech celgene celg pop shareholder approve stock split effective june stock clear buy point cup handle base volume swell other lead stock bitauto holding bita jump retake buy point provider online automotive information consumer china form late stage base several flaw emerge energy service emes notch new high brokerage stifel hoist stock price target company reportedly announce amendment agreement supply sand used hydraulic fracture process schlumberger slb emerge energy share be extend march
2671,CELG,big cap biotechs biogen idec biib celgene celg be head opposite direction stock market today jpmorgan upgrade downgrade other
2672,CELG,jpmorgan analyst geoff meacham lift rating biogen overweight neutral price target write research note survey neurologist have yielded positive opinion tecfidera oral multiple sclerosis drug biogen launch last year
2673,CELG,also note strength biogen pipeline describe high risk second half year bring first human datum lingo ms treatment potentially rebuild miss myelin patient nerve cell be ultimate cause symptom
2674,CELG,physician feedback indicate be big deal remyelination be game changer meacham write
2675,CELG,other product meacham note include spinal muscular atrophy treatment phase testing multiple alzheimer disease asset
2676,CELG,other hand meacham write wasn see game changer celgene pipeline
2677,CELG,change rating isn reflective new fundamental concern indeed celgene growth rate be expect be robust next few year write say note upside driver long term guidance be widely know largely account
2678,CELG,meacham lower rating celgene neutral overweight trim price target
2679,CELG,afternoon trading thursday biogen stock be celgene stock be
2680,CELG,follow amy reeve twitter ibd_areevesbig cap biotechs biogen idec biib celgene celg be head opposite direction stock market today jpmorgan upgrade downgrade other jpmorgan analyst geoff meacham lift rating biogen overweight neutral price target write research note survey neurologist have yielded positive opinion tecfidera oral multiple sclerosis drug biogen launch last year also note strength biogen pipeline describe high risk second half year bring first human datum lingo ms treatment potentially rebuild miss myelin patient nerve cell be ultimate cause symptom physician feedback indicate be big deal remyelination be game changer meacham write other product meacham note include spinal muscular atrophy treatment phase testing multiple alzheimer disease asset other hand meacham write wasn see game changer celgene pipeline change rating isn reflective new fundamental concern indeed celgene growth rate be expect be robust next few year write say note upside driver long term guidance be widely know largely account meacham lower rating celgene neutral overweight trim price target afternoon trading thursday biogen stock be celgene stock be follow amy reeve twitter ibd_areeve
2681,CELG,daunting headline be hard find monday pave way buyer push nasdaq fresh high back day move average dow jone industrial average lead way rise nasdaq gain rally airline build steel retail stock lead upside
2682,CELG,week big cap list show few change last week apple aapl encana eca magna international mga fall be replace celgene celg spectra energy southwest airline luv
2683,CELG,energy play still dominate continue unrest iraq oil gas related stock comprise more half week list most extend gain re also extend past buy point
2684,CELG,health care technology account next biggest group rest be lone ranger hail various industry include airline restaurant operator maker keurig single cup brewer
2685,CELG,fact latter stock biotech happen be few big cap stock be base still buy range
2686,CELG,celgene be just record high clear cup handle buy point thursday average volume stock surge june shareholder approve stock split annual meeting prior day number authorize share double share outstanding june
2687,CELG,mark biotech fourth split go public year prior stock split be celgene best selling drug last year be revlimid revenue vidaza abraxane summit base company have grow sale profit double digit better
2688,CELG,chipotle grill cmg be still work right side cup base potential buy point stock advanced past week average trade logged heavy volume week left side base
2689,CELG,fast casual restaurant operator profit growth slow be expect further slow full year consensus estimate call growth year jump next
2690,CELG,chipotle lead stock retail restaurant group composite rating
2691,CELG,keurig green mountain gmcr emerge cup handle pattern june fast turnover hasn make much headway pull back buy point buckingham research last week cut single brewer cup maker neutral buy cite concern keurig sizable investment develop cold beverage system coca cola ko well other project work hamper earning growth
2692,CELG,quarterly profit gain have cool recently analyst expect further slowdown btig wednesday begin cover keurig recently announce deal install brewer privately hold subway sandwich shop neutral rating week big cap list show few change last week apple aapl encana eca magna international mga fall be replace celgene celg spectra energy southwest airline luv energy play still dominate continue unrest iraq oil gas related stock comprise more half week list most extend gain re also extend past buy point health care technology account next biggest group rest be lone ranger hail various industry include airline restaurant operator maker keurig single cup brewer fact latter stock biotech happen be few big cap stock be base still buy range celgene be just record high clear cup handle buy point thursday average volume stock surge june shareholder approve stock split annual meeting prior day number authorize share double share outstanding june mark biotech fourth split go public year prior stock split be celgene best selling drug last year be revlimid revenue vidaza abraxane summit base company have grow sale profit double digit better chipotle grill cmg be still work right side cup base potential buy point stock advanced past week average trade logged heavy volume week left side base fast casual restaurant operator profit growth slow be expect further slow full year consensus estimate call growth year jump next chipotle lead stock retail restaurant group composite rating keurig green mountain gmcr emerge cup handle pattern june fast turnover hasn make much headway pull back buy point buckingham research last week cut single brewer cup maker neutral buy cite concern keurig sizable investment develop cold beverage system coca cola ko well other project work hamper earning growth quarterly profit gain have cool recently analyst expect further slowdown btig wednesday begin cover keurig recently announce deal install brewer privately hold subway sandwich shop neutral rating
2693,CELG,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
2694,CELG,volume nasdaq nyse be tracking tuesday level
2695,CELG,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
2696,CELG,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
2697,CELG,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
2698,CELG,solar stock be day best performer lead first solar fslr jump new high heavy volume
2699,CELG,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
2700,CELG,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
2701,CELG,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
2702,CELG,stock market today appear poise mildly lower start upbeat chinese factory datum round deal news
2703,CELG,nasdaq future fall point vs fair value future edge less point dow future lose point
2704,CELG,stock have rally last week nasdaq rise more latter even hit record high number stock include celgene celg bit auto bita kapstone paper ks salix pharmaceutical slxp stage breakout last week
2705,CELG,preliminary read hsbc markit pmi rise june reading signal expansion june marked first read month top view
2706,CELG,domestic front factory gauge markit be et datum exist home sale be release et
2707,CELG,corporate news share integrys energy group teg shot premarket trade word wisconsin energy wec buy company cash stock deal worth include debt combine company be call wec energy group wec be nation eighth biggest natural gas distributor
2708,CELG,micro system mcrs rise premarket trading oracle orcl agree buy company deal value micro provide hardware software retail hospitality industry oracle share be fractionally higher preopen trade
2709,CELG,meanwhile miron technology mu report fiscal earning close chipmaker be expect earn cent share just cent year period share climb premarket trade stock recently hit profit take zone past buy point consolidation stock market today appear poise mildly lower start upbeat chinese factory datum round deal news nasdaq future fall point vs fair value future edge less point dow future lose point stock have rally last week nasdaq rise more latter even hit record high number stock include celgene celg bit auto bita kapstone paper ks salix pharmaceutical slxp stage breakout last week preliminary read hsbc markit pmi rise june reading signal expansion june marked first read month top view domestic front factory gauge markit be et datum exist home sale be release et corporate news share integrys energy group teg shot premarket trade word wisconsin energy wec buy company cash stock deal worth include debt combine company be call wec energy group wec be nation eighth biggest natural gas distributor micro system mcrs rise premarket trading oracle orcl agree buy company deal value micro provide hardware software retail hospitality industry oracle share be fractionally higher preopen trade meanwhile miron technology mu report fiscal earning close chipmaker be expect earn cent share just cent year period share climb premarket trade stock recently hit profit take zone past buy point consolidation
2710,CELG,stock be session lows late trading thursday be still poise snap session streak nasdaq be slip have be much respectively dow jone industrial average dip volume be tracking mixed stock market today nyse trade be run lower nasdaq volume be tracking higher keurig green mountain gmcr drop fall buy point cup handle base clear tuesday company announce today open plant dedicate make pod cold beverage wednesday btig start coverage stock neutral rating price target amazon com amzn fall nearly give early gain downside reversal erased bulk wednesday advance be inspire introduction long await smartphone upside celgene celg rise clear buy point cup handle base average trading earlier thursday biotech announce shareholder approve stock split be celgene fourth split come public oracle orcl wesson swhc be due report earning close be little change ahead result
2711,CELG,stock end almost flat thursday news president obama dispatch military adviser iraq nasdaq lose add ibd be flat volume fall board early session index be modestly slide further announcement obama have statement iraq word
2712,CELG,earning season full force investor focus very best company elite ibd rank top rate growth stock factor strong relative price strength top fundamental ibd have several company report earning come week here be top due report earning wednesday social networking giant facebook fb
2713,CELG,stock market start third quarter fine fashion tuesday solid percentage gain higher volume nasdaq notch year high marked close high close nasdaq rise add dow jone industrial average gain close point level
2714,CELG,biotech stock bounce back recently last month medical biom biotech group be rank ibd industry be dead last last week plunge partly reflect growth stock overall fall hard current market correction specific concern sky high drug price notably gilead science blockbuster hepatitis
2715,CELG,stock fought tightly mixed action early friday earning news economic datum power large share action
2716,CELG,nasdaq improve rise dow jone industrial average struggle decline volume be soft nasdaq lower nyse compare trade same time thursday
2717,CELG,economic news get generally positive start stock market today employee cost index dip year low second quarter datum be clear employer less so consumer commerce department datum release thursday estimate consumer spending be sharply higher quarter
2718,CELG,midwest manufacturing amp july kingsbury international chicago purchasing manager index rise dip june economist have expect minor uptick reading indicate economic expansion
2719,CELG,consumer sentiment be largely unchanged university michigan report consumer sentiment index ease july june economist consensus have target increase
2720,CELG,stock big oil put hurt dow exxon mobil xom chevron cvx drop disappointing result pfizer pfe post dow biggest gain
2721,CELG,expedia expe lead nasdaq leap healthy second quarter gap send share past flat base buy point heavy trade
2722,CELG,amgen amgn flex nearly massive trade biotech pioneer second quarter earning revenue easily top consensus projection management hoist full year earning revenue guidance high end analyst expectation gain send share buy point flat base
2723,CELG,ibd list universal health service uhs power hospital owner post better forecast second quarter revenue earning big volume gain send share back buy point week tight pattern
2724,CELG,newlink genetic nlnk rise more world health organization report publish medical journal lancet show positive result vsv zebov ebola vaccine develop jointly newlink merck mrk food drug administration have raise question study involved more participant guinea newlink have form deep cup handle base buy point merck share rise fraction
2725,CELG,low end list outerwall outr come tumble strong volume owner redbox coinstar kiosk franchise turn adjust earning number well consensus estimate revenue be flat far expectation loss send share far week move average test support stock week line stock fought tightly mixed action early friday earning news economic datum power large share action nasdaq improve rise dow jone industrial average struggle decline volume be soft nasdaq lower nyse compare trade same time thursday economic news get generally positive start stock market today employee cost index dip year low second quarter datum be clear employer less so consumer commerce department datum release thursday estimate consumer spending be sharply higher quarter midwest manufacturing amp july kingsbury international chicago purchasing manager index rise dip june economist have expect minor uptick reading indicate economic expansion consumer sentiment be largely unchanged university michigan report consumer sentiment index ease july june economist consensus have target increase stock big oil put hurt dow exxon mobil xom chevron cvx drop disappointing result pfizer pfe post dow biggest gain expedia expe lead nasdaq leap healthy second quarter gap send share past flat base buy point heavy trade amgen amgn flex nearly massive trade biotech pioneer second quarter earning revenue easily top consensus projection management hoist full year earning revenue guidance high end analyst expectation gain send share buy point flat base ibd list universal health service uhs power hospital owner post better forecast second quarter revenue earning big volume gain send share back buy point week tight pattern newlink genetic nlnk rise more world health organization report publish medical journal lancet show positive result vsv zebov ebola vaccine develop jointly newlink merck mrk food drug administration have raise question study involved more participant guinea newlink have form deep cup handle base buy point merck share rise fraction low end list outerwall outr come tumble strong volume owner redbox coinstar kiosk franchise turn adjust earning number well consensus estimate revenue be flat far expectation loss send share far week move average test support stock week line
2726,CELG,stock bolt higher soft trade tuesday open bell mixed housing market datum
2727,CELG,nasdaq jump gain alexion pharmaceutical alxn celgene celg lead nasdaq dow jone industrial average rise
2728,CELG,volume dip second straight session nyse nasdaq
2729,CELG,stock market today receive so so read housing market
2730,CELG,standard poor case shiller city home price index rise january slightly december increase just miss view gain be index third straight month slow increase
2731,CELG,federal housing finance agency january housing price index rise december downwardly revise gain economist have forecast increase index have gain past month november be exception
2732,CELG,stock caterpillar cat power lead dow news monday senate subcommittee hold hearing april examine company offshore tax strategy stock clear buy point cup handle base begin february
2733,CELG,leader surge strong start gate ibd stock rise early trade
2734,CELG,head list spirit airline save climb start gate stock be extend just march high work seventh straight weekly gain
2735,CELG,alexion pharmaceutical shed pre market loss jump buy back half monday loss left share still well day move average
2736,CELG,qihoo qihu climb mild trade find support day move average move put stock technical buy range rebound march high stock bolt higher soft trade tuesday open bell mixed housing market datum nasdaq jump gain alexion pharmaceutical alxn celgene celg lead nasdaq dow jone industrial average rise volume dip second straight session nyse nasdaq stock market today receive so so read housing market standard poor case shiller city home price index rise january slightly december increase just miss view gain be index third straight month slow increase federal housing finance agency january housing price index rise december downwardly revise gain economist have forecast increase index have gain past month november be exception stock caterpillar cat power lead dow news monday senate subcommittee hold hearing april examine company offshore tax strategy stock clear buy point cup handle base begin february leader surge strong start gate ibd stock rise early trade head list spirit airline save climb start gate stock be extend just march high work seventh straight weekly gain alexion pharmaceutical shed pre market loss jump buy back half monday loss left share still well day move average qihoo qihu climb mild trade find support day move average move put stock technical buy range rebound march high
2737,CELG,stock open modestly higher thursday mixed economic datum
2738,CELG,nasdaq climb best level early april rise record high meanwhile dow jone industrial average tick volume be tracking sharply lower board stock market today
2739,CELG,pending home sale rise april miss expectation increase stock have little reaction report
2740,CELG,earlier commerce department report economic growth contract first quarter jobless claim come better expect
2741,CELG,hillshire brand hsh gap bolt tyson food tsn offer buy maker jimmy dean sausage product share trump bid make pilgrim pride ppc earlier week pilgrim pride fall tyson jump
2742,CELG,palo alto network panw gap surge late wednesday result news lawsuit settlement stock open well buy point double bottom base
2743,CELG,michael kor kor fall fast trade stock stage big upside reversal day line wednesday wake fiscal result michael kor be form base buy point
2744,CELG,celgene celg be session low still be cut neutral overweight jpmorgan biotech fall back day move average stock open modestly higher thursday mixed economic datum nasdaq climb best level early april rise record high meanwhile dow jone industrial average tick volume be tracking sharply lower board stock market today pending home sale rise april miss expectation increase stock have little reaction report earlier commerce department report economic growth contract first quarter jobless claim come better expect hillshire brand hsh gap bolt tyson food tsn offer buy maker jimmy dean sausage product share trump bid make pilgrim pride ppc earlier week pilgrim pride fall tyson jump palo alto network panw gap surge late wednesday result news lawsuit settlement stock open well buy point double bottom base michael kor kor fall fast trade stock stage big upside reversal day line wednesday wake fiscal result michael kor be form base buy point celgene celg be session low still be cut neutral overweight jpmorgan biotech fall back day move average
2745,CELG,odd thing sometimes happen odd thing change odd world series boston future hall famer ted william bat miserable cardinal journeyman joe garagiola bat dazzling yet base ve bet garagiola outperform william follow season didn garagiola hit vs william quality doesn lag long investing be different want buy breakout ted william quality stock be likeliest work certainly thinly trade stock middle pack rating break basis advance smartly don want play odd be many factor tilt odd stock today ll look just accumulation distribution rating accumulation distribution rating appear ibd minichart stock table rating reflect stock institutional footprint accumulation point institutional buy distribution suggest institutional selling formula define rating be proprietary involve move average price volume datum day day action become irrelevant rating mean stock have be accumulation rating be neutral rating mean stock have be distribution gauge be perfect word paragraph point imperfection word be have be be way know stock continue be accumulation still rating be valuable clue even doesn guarantee success let look breakout rating be stock break ll look stock break july follow day accumulation distribution rating be close day sometimes lift rating sharply investor have way know advance figure be ibd database chart show stock rating eve almost stock show accumulation least neutrality exception be celgene celg rating july point institutional selling stock gap double volume july stock advanced only day close consolidate netflix nflx have rating july july stock fall buy point then find traction stock gain less month
2746,CELG,stock continue higher be pace finish gain tuesday first time session dow jone industrial average lead gain nasdaq rise respectively turnover be again tracking lower board stock market today alexion pharmaceutical alxn rise bounce back recent slide friday stock slice day line huge volume mark sell signal other lead biotechs drugmaker be also rebound recent weakness spanish drugmaker grifol grfs rally regain day line celgene celg rise actavis act edge elsewhere avnet avt add record high fast trade now past buy point cup handle base clear march market volatility stock have see strong accumulation recent session electronic component maker sale growth accelerate latest quarters downside iii apparel group giii be session low still heavy trading share be much intraday company give disappointing guidance earning sale
2747,CELG,buy stock have be beaten sound good idea actually very risky fact often better buy high sell higher here stock fall well previous high face difficult road back current shareholder be sit big loss tend sell share break even cut loss stock rally create stiff resistance further price gain concept know overhead supply especially strong stock rebound fast deep correction apple aapl priceline com pcln show come financial crisis most stock take much longer reach old high celgene celg lose half value financial crisis create large pool investor be underwater look sell once stock get back break even stock rise new bull market begin march get high march celgene trade mostly sideway nearly year time stock try climb resistance run seller finally reclaim post crisis high march month breaking cup base month earlier celgene have always be leader highly rate medical biom biotech industry group take long time exhaust overhead supply share come market time stock start show strength usually take month overhead supply diminish point still own stock be probably long term not likely bail old high celgene continue get back track final correction april high much less decline crash celgene jump base base pattern new high january celgene be add ibd leaderboard nov market confirm new uptrend more double next year peak strong fundamental justified move celgene earning grow share sale leap nearly threefold ep rating be now smr sale growth profit margin return equity grade be top notch more powerful ibd content exclusive stock list actionable investing tool take complimentary week trial eibd
2748,CELG,stock be higher unison once again friday halftime trading mixed earlier
2749,CELG,dow jone industrial average rise climb fall much earlier nasdaq have turn fractionally higher volume be run vastly higher board stock market today due quadruple witching
2750,CELG,ethanol refiner marketer green plain energy gpre add touch highest level august be well extend buy point cup handle base clear december
2751,CELG,longtime lead biotechs come pressure possibly news lawmaker ask gilead science gild more information pricing sovaldi hepatitis treatment cost
2752,CELG,alexion pharmaceutical alxn erased early gain slump fast trade stock appear be find support day line
2753,CELG,biogen idec biib fall get approval canadian regulator alprolix hemophilia treatment stock be still past buy point flat base
2754,CELG,alk have rise past session fall fast trade
2755,CELG,celgene celg fall slice day move average stock hit month low stock be higher unison once again friday halftime trading mixed earlier dow jone industrial average rise climb fall much earlier nasdaq have turn fractionally higher volume be run vastly higher board stock market today due quadruple witching ethanol refiner marketer green plain energy gpre add touch highest level august be well extend buy point cup handle base clear december longtime lead biotechs come pressure possibly news lawmaker ask gilead science gild more information pricing sovaldi hepatitis treatment cost alexion pharmaceutical alxn erased early gain slump fast trade stock appear be find support day line biogen idec biib fall get approval canadian regulator alprolix hemophilia treatment stock be still past buy point flat base alk have rise past session fall fast trade celgene celg fall slice day move average stock hit month low
2756,CELG,biogen idec finished high note highly tout oral multiple sclerosis drug tecfidera produce nearly sale fourth quarter company be pace generate more first year market tecfidera performance helpedbiogen biib deliver record overall revenue be
2757,CELG,ibd stock screen go ibd big cap be different stripe primary focus large capitalization stock distinguish high growth slant ibd weekly review doesn mean ibd big cap run tuesday paper win find fair share winning stock start big price advance big cap be also featured etable online product big company still produce robust gain earning share price look back stock make big cap aptly illustrate point more later find winner weekly feature investor follow systematic approach start study mini weekly chart be publish stock separate one be form basis secondary buy area not sure spot ve get help bottom chart show brief analysis written ibd market writer tell reader stock be buy point too far extend price be immediate interest many case analysis give correct buy point do not buy stock hit buy point more analysis read big cap column here learn more stock set attractive chart zone well industry sector be show leadership big cap june last year stock market be struggle yet top rate stock google googl biogen idec biib form basis time also make june big cap list google be find support week move average chart analysis note action google continue long consolidation break oct powerful gap spark solid earning report share surge peak february google ep gain be smaller investor have see internet giant halcyon day yet be line other big cap firm double digit growth large mature company denote market leadership strength biogen have find support eventually form cup handle base stock break few pullback gain march year june edition big cap fellow biotech celgene celg be form base july shot jan peak
2758,CELG,stock get hit hard monday prompt downgrade market outlook nasdaq tumble slump index suffer biggest hit nov gain follow dec resumption market uptrend have nearly be wipe potential support day line
2759,CELG,stock get hit hard monday prompt downgrade market outlook nasdaq tumble slump index suffer biggest hit nov gain follow dec resumption market uptrend have nearly be wipe potential support day line
2760,CELG,stock hold strong gain thursday little hour remain session help bullish earning report facebook fb better expect economic growth nasdaq rise climb dow jone industrial average add volume be tracking lower stock market today more so new york stock exchange alexion pharmaceutical alxn armour ua pace ibd rocket respectively follow blowout earning report facebook jump new high mobile ad revenue fuel better expect result google goog meanwhile gain get support week line first time october earlier today google sell motorola mobility hardware business lenova year google paid just business downside celgene celg be few loser ibd be heavy volume biotech company report profit rise share analyst expectation celgene be day line monday fall flat base entry trigger sell rule earlier thursday government report economy grow annual rate final quarter strong gain consumer spending wall street analyst have forecast smaller increase
2761,CELG,stock end modestly lower wednesday federal reserve chief janet yellen say be live possibility interest rate hike next month fall dow jone industrial average edge nasdaq dip volume be mixed dip nyse rise nasdaq compare tuesday accord preliminary datum maker consumer stock be biggest loser stock market today motorola solution msi make way radio other communication product plunge more better expect profit sale result stock have be work flat base crash day move average finally steadying just day line tesla motor tsla lead share automaker higher soar electric vehicle maker delivery outlook trump weaker expect quarterly earning report stock be testing resistance day line remain week higher homeaway away rocket post session trading expedia expe agree buy online marketplace vacation rental deal be expect close first quarter next year pending regulatory approval be expect help expedia compete home rental business such airbnb meanwhile facebook fb rise hour trading follow earning report profit period rise cent share gain revenue top wall street estimate company say number daily active user rise year average september mobile daily active user jump average month facebook rise regular session buy range buy point qualcomm qcom be sharply hour outlook fiscal first quarter end december trail analyst estimate outweighed better expect result latest period disney celgene celg cyberark software cybr nvidia nvda be company schedule report quarterly earning thursday economic report due thursday include initial jobless claim week end oct productivity datum
2762,CELG,mfs growth be batten hatch brace economic environment earning growth be more scarce borrow cost inch dec translate key bet often overweight vs russell growth index health care financial service leisure stock health care manager eric fischman like thermo fisher
2763,CELG,big cap biotech alexion pharmaceutical alxn beat estimate raise full year earning guidance thursday send stock morning trading stock market fellow biotech giant celgene celg miss however
2764,CELG,alexion report earning share year earlier quarter cent analyst consensus sale rise top estimate nearly
2765,CELG,year company affirm previous revenue guidance last year however lower forecast taxe sale general administrative spending lead cent increase ep guidance now vs last year
2766,CELG,company also say have start roll fda submission process alfa enzyme replacement product rare disease call alexion expect complete submission fall approve be company second commercial product blockbuster soliris be used treat other rare disease be be study several other
2767,CELG,same time celgene report decidedly softer quarter also announce be licensing late stage crohn disease drug candidate nogra pharma
2768,CELG,celgene earning rise beating street cent revenue come bit short expectation however rise
2769,CELG,company affirm previous guidance call roughly sale growth profit growth
2770,CELG,celgene say agree pay upfront milestone payment ged nogra crohn disease treatment antisense therapy target rna celgene core business be cancer recently branch immunology approval psoriasis drug otezla march
2771,CELG,be synergistic otezla work write rbc capital market analyst michael yee research note be interesting first antisense drug here celg beg question celg be broaden more antisense
2772,CELG,celgene also say expect have file eu approval lead drug revlimid first line treatment multiple myeloma currently be only approve relapse
2773,CELG,midmorning celgene stock be
2774,CELG,follow amy reeve twitter ibd_areevesbig cap biotech alexion pharmaceutical alxn beat estimate raise full year earning guidance thursday send stock morning trading stock market fellow biotech giant celgene celg miss however alexion report earning share year earlier quarter cent analyst consensus sale rise top estimate nearly year company affirm previous revenue guidance last year however lower forecast taxe sale general administrative spending lead cent increase ep guidance now vs last year company also say have start roll fda submission process alfa enzyme replacement product rare disease call alexion expect complete submission fall approve be company second commercial product blockbuster soliris be used treat other rare disease be be study several other same time celgene report decidedly softer quarter also announce be licensing late stage crohn disease drug candidate nogra pharma celgene earning rise beating street cent revenue come bit short expectation however rise company affirm previous guidance call roughly sale growth profit growth celgene say agree pay upfront milestone payment ged nogra crohn disease treatment antisense therapy target rna celgene core business be cancer recently branch immunology approval psoriasis drug otezla march be synergistic otezla work write rbc capital market analyst michael yee research note be interesting first antisense drug here celg beg question celg be broaden more antisense celgene also say expect have file eu approval lead drug revlimid first line treatment multiple myeloma currently be only approve relapse midmorning celgene stock be follow amy reeve twitter ibd_areeve
2775,CELG,stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor
2776,CELG,dow jone industrial average climb nasdaq add less split difference
2777,CELG,volume be mixed stock market today nasdaq lower nyse compare trade same time monday
2778,CELG,top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period
2779,CELG,housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be
2780,CELG,new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb
2781,CELG,bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month
2782,CELG,stock be good morning florida base company
2783,CELG,darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point
2784,CELG,citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base
2785,CELG,leader most ibd list post modest gain loss couple dramatic exception
2786,CELG,ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average
2787,CELG,bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base stock notch uneven early gain tuesday investor weigh solid new home sale mixed durable good datum potential deal greece eurozone creditor dow jone industrial average climb nasdaq add less split difference volume be mixed stock market today nasdaq lower nyse compare trade same time monday top line number commerce department durable good report show decline downward revision april number economist have forecast more mild slip bulk miss be apparently due sharp decline aircraft order month transportation durable good order rise line expectation so far year durable good order be run last year january period housing price improve steadily lift federal housing finance agency house price index increase be equal march increase just consensus forecast gain year year index be new home sale pop annualize rate accord commerce department be april upwardly revise pace well consensus expectation strongest number feb bit less rosy be preliminary june manufacturing estimate researcher markit purchasing manager manufacturing index be number forecast increase number point third month slow activity be gauge weakest gain month stock be good morning florida base company darden restaurant dri rise lead wide margin orlando base owner olive garden red lobster other chain report healthy fiscal fourth quarter result announce plan slice portion real estate asset separate real estate investment trust stock pop new high pare gain hold just cup base buy point citrix system ctxs peck gain best increase nasdaq stock fort lauderdale headquarter software developer be still buy range buy point cup handle base leader most ibd list post modest gain loss couple dramatic exception ambarella amba lead list rebound stock tumble monday follow short seller report friday question stock valuation stock remain extend mid rebound week support be well week move average bottom group burger joint sonic sonc dive massive trade fiscal third quarter sale profit meet consensus expectation full year earning guidance didn sell stop test stock week move average seriously damage effort shape month cup base
2788,CELG,san francisco biotechs celgene celg alnylam alny jazz jazz big pharma merck be move monday drugmaker pour news major investor conference
2789,CELG,annual jpmorgan healthcare conference san francisco celgene issue pre liminary result revise guidance upward executive say revenue totale bit analyst consensus earning share be cent short estimate company say be hit collaboration related payment partner tune cent share celgene didn specify many collaboration be responsible
2790,CELG,guidance be street be buzz go last year jpmorgan conference celgene electrify crowd bullish guidance way be widely expect raise year event indeed do add least sale guidance now ep be guide year company previously guide
2791,CELG,guidance cautious
2792,CELG,street be already profit side revenue guide be analyst consensus nearer term sale guidance be slightly view ep range fall short analyst
2793,CELG,celgene share briefly hit record high reversed close
2794,CELG,presentation celgene ceo bob hugin emphasize guidance raise be entirely due operate momentum celgene hematology franchise do not include revise estimate related pipeline bud oncology business
2795,CELG,rbc capital market analyst michael yee say celgene have history conservative guidance
2796,CELG,short term stock have already run lot thus day move so many investor be ask be likely just short term trading dynamic high expectation event yee write research note longer term see stock go higher think investor want own solid growth story year upside potential difficult find strong growth story large cap health care
2797,CELG,yee downplay nearer term ep shortfall note collaboration payment well likely heavy spending launch otezla expect be approve psoriasis quarter hugin affirm celgene guidance otezla sale analyst have long be skeptical number
2798,CELG,celgene release full result jan
2799,CELG,alnylam soar
2800,CELG,draw more positive buzz conference be alnylam pharmaceutical stock vault record high sanofi sny genzyme unit agree pay stake exchange right alnylam lead drug candidate patisiran outside north america western europe genzyme already have such right japan asia pacific alnylam close higher
2801,CELG,alnylam ceo john maraganore call deal game changer say company have product sale now have balance sheet come handy alnylam also agree sunday pay front milestone payment sirna therapeutic subsidiary merck mrk
2802,CELG,company focus rna interference rnai technology treat disease genetically patisiran treat rare disease call ttr mediate amyloidosis firm be also develop version product treat hemophilia cardiomyopathy high cholesterol
2803,CELG,meanwhile merck say have start submission process candidate mk advanced melanoma mk be pd antibody new class cancer fighter have inspire lofty sale estimate wall street merck move be earlier expect
2804,CELG,news today advanced melanoma be encourage larger market opportunity pd pdl antibody be lung cancer other tumor caution mark schoenebaum isi group also bear mind bristol myer squibb bmy have demonstrated combination pd yervoy lead better efficacy pd alone melanoma bmy be considerably ahead mrk develop combination
2805,CELG,merck stock rise year high
2806,CELG,jazz pharmaceutical leap record high say buy narcolepsy drug candidate aerial biopharma unspecified milestone payment drug adx have complete phase testing add jazz core franchise xyrem have become blockbuster treat same illness jazz stock rise san francisco biotechs celgene celg alnylam alny jazz jazz big pharma merck be move monday drugmaker pour news major investor conference annual jpmorgan healthcare conference san francisco celgene issue pre liminary result revise guidance upward executive say revenue totale bit analyst consensus earning share be cent short estimate company say be hit collaboration related payment partner tune cent share celgene didn specify many collaboration be responsible guidance be street be buzz go last year jpmorgan conference celgene electrify crowd bullish guidance way be widely expect raise year event indeed do add least sale guidance now ep be guide year company previously guide guidance street be already profit side revenue guide be analyst consensus nearer term sale guidance be slightly view ep range fall short analyst celgene share briefly hit record high reversed close presentation celgene ceo bob hugin emphasize guidance raise be entirely due operate momentum celgene hematology franchise do not include revise estimate related pipeline bud oncology business rbc capital market analyst michael yee say celgene have history conservative guidance short term stock have already run lot thus day move so many investor be ask be likely just short term trading dynamic high expectation event yee write research note longer term see stock go higher think investor want own solid growth story year upside potential difficult find strong growth story large cap health care yee downplay nearer term ep shortfall note collaboration payment well likely heavy spending launch otezla expect be approve psoriasis quarter hugin affirm celgene guidance otezla sale analyst have long be skeptical number celgene release full result jan alnylam soarsdrawing more positive buzz conference be alnylam pharmaceutical stock vault record high sanofi sny genzyme unit agree pay stake exchange right alnylam lead drug candidate patisiran outside north america western europe genzyme already have such right japan asia pacific alnylam close higher alnylam ceo john maraganore call deal game changer say company have product sale now have balance sheet come handy alnylam also agree sunday pay front milestone payment sirna therapeutic subsidiary merck mrk company focus rna interference rnai technology treat disease genetically patisiran treat rare disease call ttr mediate amyloidosis firm be also develop version product treat hemophilia cardiomyopathy high cholesterol meanwhile merck say have start submission process candidate mk advanced melanoma mk be pd antibody new class cancer fighter have inspire lofty sale estimate wall street merck move be earlier expect news today advanced melanoma be encourage larger market opportunity pd pdl antibody be lung cancer other tumor caution mark schoenebaum isi group also bear mind bristol myer squibb bmy have demonstrated combination pd yervoy lead better efficacy pd alone melanoma bmy be considerably ahead mrk develop combination merck stock rise year high jazz pharmaceutical leap record high say buy narcolepsy drug candidate aerial biopharma unspecified milestone payment drug adx have complete phase testing add jazz core franchise xyrem have become blockbuster treat same illness jazz stock rise
2807,CELG,biotech advance new investment merger activity have help lift drugmaker alexion pharmaceutical alxn celgene celg biogen idec biib past rest market have see up down recently
2808,CELG,company well perrigo prgo actavis act be ibd big cap screen day feature large stock strong earning price performance
2809,CELG,several also appear ibd leaderboard premium service lead stock annotate chart
2810,CELG,alexion develop treatment rare immune disorder currently have only drug market soliris company be look expand product offering give moderna therapeutic upfront cash payment
2811,CELG,investment give alexion right develop messenger rna therapy come moderna research
2812,CELG,alexion share shot new high stock market tuesday medical biom biotech group be industry group ibd track best perform group so far
2813,CELG,perrigo make generic store brand drug be expansion mode december company complete buyout irish drugmaker elan give access more european market
2814,CELG,late tuesday perrigo announce receive final approval abbreviated new drug application fluocinonide cream generic version valeant pharma vrx vano cream
2815,CELG,celgene develop therapy treat cancer jan biotech announce drug abraxane be approve treat metastatic pancreatic cancer combine eli lilly lly gemzar europe drug be originally approve use only treat breast cancer celgene continue gain additional approval drug buy abraxis bioscience
2816,CELG,monday celgene announce preliminary ep figure miss view cent biotech speaking jpmorgan healthcare conference san francisco cite collaboration cost cent share preliminary revenue be just forecast
2817,CELG,celgene see ep analyst estimate outlook be more bullish
2818,CELG,biogen make treatment multiple sclerosis cancer autoimmune disease tuesday joel sendek analyst stifel nicolaus say see strong sale biogen new drug
2819,CELG,project revenue avonex more prior estimate see sale tecfidera biogen ms drug
2820,CELG,sendek also expect fda approve drug plegridy more drug summer
2821,CELG,also big cap screen be actavis have see improve sale buy irish drugmaker warner chilcott october debut lidoderm pain patch
2822,CELG,actavis say tuesday morning expect earning come modestly high end prior estimate share cite gain warner chilcott deal analyst have expect share
2823,CELG,follow gillian rich twitter ibd_grich biotech advance new investment merger activity have help lift drugmaker alexion pharmaceutical alxn celgene celg biogen idec biib past rest market have see up down recently company well perrigo prgo actavis act be ibd big cap screen day feature large stock strong earning price performance several also appear ibd leaderboard premium service lead stock annotate chart alexion develop treatment rare immune disorder currently have only drug market soliris company be look expand product offering give moderna therapeutic upfront cash payment investment give alexion right develop messenger rna therapy come moderna research alexion share shot new high stock market tuesday medical biom biotech group be industry group ibd track best perform group so far perrigo make generic store brand drug be expansion mode december company complete buyout irish drugmaker elan give access more european market late tuesday perrigo announce receive final approval abbreviated new drug application fluocinonide cream generic version valeant pharma vrx vano cream celgene develop therapy treat cancer jan biotech announce drug abraxane be approve treat metastatic pancreatic cancer combine eli lilly lly gemzar europe drug be originally approve use only treat breast cancer celgene continue gain additional approval drug buy abraxis bioscience monday celgene announce preliminary ep figure miss view cent biotech speaking jpmorgan healthcare conference san francisco cite collaboration cost cent share preliminary revenue be just forecast celgene see ep analyst estimate outlook be more bullish biogen make treatment multiple sclerosis cancer autoimmune disease tuesday joel sendek analyst stifel nicolaus say see strong sale biogen new drug project revenue avonex more prior estimate see sale tecfidera biogen ms drug sendek also expect fda approve drug plegridy more drug summer also big cap screen be actavis have see improve sale buy irish drugmaker warner chilcott october debut lidoderm pain patch actavis say tuesday morning expect earning come modestly high end prior estimate share cite gain warner chilcott deal analyst have expect share follow gillian rich twitter ibd_grich
2824,CELG,stock be modestly lower late monday even nasdaq turn red stay green much day dow jone industrial average be respectively tech heavy nasdaq slip turnover be run sharply lower major exchange stock market today
2825,CELG,lead stock cirrus logic crus widen loss nearly stock breach day day move average medium report peg cirrus weakness disappointing quarterly result fellow apple aapl supplier dialog semiconductor cirrus report fiscal earning wednesday close other apple supplier be weak monday
2826,CELG,cal maine food calm drop fast trade putt close day move average intraday cal maine fall nearly buy point handle go bad investor cut loss maximum
2827,CELG,luxoft lxft slump almost fast trade erase gain prior session intraday stock fall buy point flat base clear friday
2828,CELG,lendingtree tree ease session high be still follow morning solid result open online lender post earning cent share year earlier revenue jump fourth straight period acceleration
2829,CELG,broadcom brcm cadence design system cdns edward lifescience ew be few notable company report earning close
2830,CELG,follow vincent mao twitter ibd_vmao stock be modestly lower late monday even nasdaq turn red stay green much day dow jone industrial average be respectively tech heavy nasdaq slip turnover be run sharply lower major exchange stock market today lead stock cirrus logic crus widen loss nearly stock breach day day move average medium report peg cirrus weakness disappointing quarterly result fellow apple aapl supplier dialog semiconductor cirrus report fiscal earning wednesday close other apple supplier be weak monday cal maine food calm drop fast trade putt close day move average intraday cal maine fall nearly buy point handle go bad investor cut loss maximum luxoft lxft slump almost fast trade erase gain prior session intraday stock fall buy point flat base clear friday lendingtree tree ease session high be still follow morning solid result open online lender post earning cent share year earlier revenue jump fourth straight period acceleration broadcom brcm cadence design system cdns edward lifescience ew be few notable company report earning close follow vincent mao twitter ibd_vmao
2831,CELG,strong year market result plenty big move high quality growth stock surprise move start way often do breaking basis heavy volume soon market follow nasdaq confirm new market uptrend just thanksgiving week follow several growth stock top fundamental emerge linkedin lnkd netflix nflx lumber liquidator ll profile space recent day be early mover so be celgene celg longtime leader biotech industry feature company now learn lot study winner celgene clear cup handle pattern early january pass buy point time be mainstay ibd big cap list lead large cap stock jan be list composite rating accumulation distribution rating fundamental be solid stock be show relative strength key ingredient emerge leader month january have shortage positive headline flow celgene jan company offer bullish revenue guidance ceo robert hugin forecast total product sale more say revenue double thank several news drug development stock break week base july then flat base september breakout help celgene continue advance celgene be best know blood cancer drug revlimid june drug receive additional approval food drug administration treat patient relapse refractory mantle cell lymphoma third quarter revlimid generate sale year make nearly third total revenue key drug celgene be abraxane used treat lung breast cancer september fda also approve drug treat patient metastatic pancreatic cancer third quarter sale abrazane jump be do well late stage trial treatment patient psoriatic arthritis
2832,CELG,stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be
2833,CELG,volume be run higher nyse nasdaq compare same time wednesday
2834,CELG,economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast
2835,CELG,mining energy stock be hit hardest stock market today decline oil metal price
2836,CELG,newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop
2837,CELG,most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy
2838,CELG,total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october
2839,CELG,chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base
2840,CELG,stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug stock extend loss midday thursday day federal reserve raise interest rate first time nearly decade fall dow jone industrial average nasdaq be volume be run higher nyse nasdaq compare same time wednesday economic news be mixed unemployment claim fall little less expect week end dec manufacturing mid atlantic region fall much more expect december conference board index lead economic indicator rise november prior month increase ahead analyst forecast mining energy stock be hit hardest stock market today decline oil metal price newmont mining nem colorado base miner gold silver lose lead lower oil transportation stock oneok oke also drop most ibd stock be lower lead global payment gpn fall more heavy volume stock plunge wednesday slice day line agree buy rival credit card payment processor heartland payment system hpy total system service tss credit card payment processor ibd fall remain well buy point cup handle base clear october chinese social medium stock weibo wb be bright spot jump more heavy volume close buy point deep cup shape base stock boast rise relative strength line accumulation distribution rating indicate strong demand share stock have more double fall low aug
2841,CELG,celgene celg kick slew major earning report even isn official calendar biotech present unaudited financial result update financial outlook monday morning morgan healthcare conference san francisco last year jpmorgan conference celgene issue bullish financial guidance well drug trial
2842,CELG,stock fall third straight day monday end worst level rocky session nasdaq slump close slightly day line heavyweight google goog celgene celg ebay ebay priceline com pcln lose drop fall further day line breach friday monday
2843,CELG,lead stock fall need read situation impartially
2844,CELG,however have position top stock top group emotion cloud judgment
2845,CELG,sell fear hold firm stubbornness
2846,CELG,drill be best way avoid subjective decision drill doesn change own stock question be be answer be be
2847,CELG,let look recent example
2848,CELG,biotech group begin rise briskly gain year biotech step pace biotech group be year late february mid april gain be virtually go
2849,CELG,pullback begin time drill arrived here be checkpoint
2850,CELG,length run ibd research show general lead stock bullish run last month medical biomedical biotech group be more year so age be work however group have significant pullback way drop fall decline fall
2851,CELG,group chart action have access marketsmith plug ticker biomedical group ticker be action be tight most run however weekly gain january action become less confident group chart show railroad track action week end march
2852,CELG,railroad track group chart not carry same meaning specific stock chart do reveal retrace action be not ideal
2853,CELG,rs line leader have lead bad sign leader group start show fading rs line celgene celg rs line begin flatten october begin slide late february celgene be first top rate biotech show weakness
2854,CELG,growth rate be growth quicken slow oct celgene report earning share growth slowest growth almost year growth slow further
2855,CELG,drop screen celgene drop ibd feb return feb be go feb other biomed hold longer alexion pharmaceutical alxn fall ibd april biogen idec biib fall april lead stock fall need read situation impartially however have position top stock top group emotion cloud judgment sell fear hold firm stubbornness drill be best way avoid subjective decision drill doesn change own stock question be be answer be be let look recent example biotech group begin rise briskly gain year biotech step pace biotech group be year late february mid april gain be virtually go pullback begin time drill arrived here be checkpoint length run ibd research show general lead stock bullish run last month medical biomedical biotech group be more year so age be work however group have significant pullback way drop fall decline fall group chart action have access marketsmith plug ticker biomedical group ticker be action be tight most run however weekly gain january action become less confident group chart show railroad track action week end march railroad track group chart not carry same meaning specific stock chart do reveal retrace action be not ideal rs line leader have lead bad sign leader group start show fading rs line celgene celg rs line begin flatten october begin slide late february celgene be first top rate biotech show weakness growth rate be growth quicken slow oct celgene report earning share growth slowest growth almost year growth slow further drop screen celgene drop ibd feb return feb be go feb other biomed hold longer alexion pharmaceutical alxn fall ibd april biogen idec biib fall april
2856,CELG,talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment
2857,CELG,group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi
2858,CELG,ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan
2859,CELG,position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged
2860,CELG,ultra do trim exposure gilead share
2861,CELG,stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary
2862,CELG,reflection fund faith biotech be overweight broader health care sector vs russell growth index
2863,CELG,fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn
2864,CELG,hold apple
2865,CELG,fund stake apple stand pat march vs jan be slightly oct share still well april
2866,CELG,go tuesday apple share be trading less past buy point
2867,CELG,emerge market account lot iphone sale growth
2868,CELG,earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid
2869,CELG,morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product
2870,CELG,other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters
2871,CELG,concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin
2872,CELG,fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters
2873,CELG,stock be form flat base entry
2874,CELG,new store opening have drive growth auto part retailer
2875,CELG,fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be
2876,CELG,past year fund average annual gain be vs peer group big cap bogey talk pain gain american century ultra fund be show manager faith downtrodden biotech market segment group begin sell february plunge picked steam march congressman question nosebleed price gilead science gild hepatitis drug sovaldi ultra have stick several holding add price decline ultra stake isis pharmaceutical isis soar share march jan position regeneron pharmaceutical regn rise share count celgene celg alexion pharmaceutical alxn be unchanged ultra do trim exposure gilead share stock gilead hurt fund performance first quarter investor rotate other growth stock value name ultra management team believe market overreact news be unlikely result problem gilead manager write commentary reflection fund faith biotech be overweight broader health care sector vs russell growth index fund largest overweight vs benchmark march be information technology top holding include apple aapl google googl qualcomm qcom amazon amzn hold fund stake apple stand pat march vs jan be slightly oct share still well april go tuesday apple share be trading less past buy point emerge market account lot iphone sale growth earning share grow past quarters latest earning report april ibd accumulation distribution rating apple have climb solid morgan stanley recently say see upside stock upcoming debut iphone iwatch maybe other product other holding concho resource cxo be so far year fund share hold steady jan march be oct ep grow past quarters concho seek extract oil gas texas benefit frac west texas shale formation rich permian basin fund stake reilly automotive orly be share march vs april ep growth have decelerate quarters stock be form flat base entry new store opening have drive growth auto part retailer fund approach have lead gain so far year go tuesday large cap growth rival track morningstar inc averaged gain be past year fund average annual gain be vs peer group big cap bogey
2877,CELG,biotech stock take beating friday lead gilead science concern grow blockbuster drug sovaldi gilead gild tumble close month low stock be already hit previous friday word congressional inquiry high price sovaldi launch december revolutionary treatment hepatitis
2878,CELG,stock finished friday mildly lower meander session ahead sunday crimea referendum join russia talk fate ukraine
2879,CELG,nasdaq fall dow jone industrial average finished volume be lower exchange accord preliminary datum nasdaq be be first week
2880,CELG,ibd stock rise fall day winner be notable move
2881,CELG,keurig green mountain gmcr generac gnrc rise more keurig announce deal peet coffee tea sell peet coffee cup packet start summer generac maker portable generator get bank america upgrade be
2882,CELG,alaska air alk be nearly report revenue passenger mile be february previous february
2883,CELG,worst performer ibd be hollysys automation holi chinese maker automation control equipment fall buy point cup handle base
2884,CELG,stock market today celgene celg fall be find support day move average stock finished friday mildly lower meander session ahead sunday crimea referendum join russia talk fate ukraine nasdaq fall dow jone industrial average finished volume be lower exchange accord preliminary datum nasdaq be be first week ibd stock rise fall day winner be notable move keurig green mountain gmcr generac gnrc rise more keurig announce deal peet coffee tea sell peet coffee cup packet start summer generac maker portable generator get bank america upgrade be alaska air alk be nearly report revenue passenger mile be february previous february worst performer ibd be hollysys automation holi chinese maker automation control equipment fall buy point cup handle base stock market today celgene celg fall be find support day move average
2885,CELG,middle earning season so smart investor need keep eye best company flurry report facebook fb la vegas sand lvs celgene celg biogen idec biib mastercard mckesson mck be strong large company be slate report earning week illumina ilmn vmware vmw have already
2886,CELG,stock further weaken monday halftime major stock average now negative territory mixed datum service sector factory order didn help
2887,CELG,nasdaq fall lowest level just week dow jone industrial average lose turnover be tracking sharply higher board stock market today especially nasdaq share sirius xm holding siri spiked huge turnover liberty medium lmca agree buy remain share sirius doesn already own
2888,CELG,celgene celg drop be downgrade sell neutral goldman sachs stock appear be find support day line
2889,CELG,athm be session low still volatile trading stock be much monday low deutsche bank start coverage hold rating place price target intraday fall buy point ipo base have surge past entry
2890,CELG,upside jinko solar jks bolt best level november clear buy point cup base chinese maker solar wafer cell say sign loan agreement china development bank solar plant project
2891,CELG,align technology algn rally heavy trading blow past early buy point flat base buy point flat base be cent left side high sometimes investor look alternative entry stock further weaken monday halftime major stock average now negative territory mixed datum service sector factory order didn help nasdaq fall lowest level just week dow jone industrial average lose turnover be tracking sharply higher board stock market today especially nasdaq share sirius xm holding siri spiked huge turnover liberty medium lmca agree buy remain share sirius doesn already own celgene celg drop be downgrade sell neutral goldman sachs stock appear be find support day line athm be session low still volatile trading stock be much monday low deutsche bank start coverage hold rating place price target intraday fall buy point ipo base have surge past entry upside jinko solar jks bolt best level november clear buy point cup base chinese maker solar wafer cell say sign loan agreement china development bank solar plant project align technology algn rally heavy trading blow past early buy point flat base buy point flat base be cent left side high sometimes investor look alternative entry
2892,CELG,big cap drug stock pharmacyclic valeant pharmaceutical celgene be move tuesday new year bring news promise more expansion pharmacyclic pcyc vault say clinical trial imbruvica be halter drug have already meet goal trial compare survival rate patient refractory
2893,CELG,stock be again red have pare large chunk day loss late trading monday
2894,CELG,nasdaq be fall much intraday meanwhile slip dow jone industrial average be fractionally lower volume continue track higher major exchange stock market today signale possible distribution day nasdaq
2895,CELG,china lodging htht drop fast trade give early gain now past buy point flat base have be much dec peak
2896,CELG,celgene celg pare loss come close day move average earlier goldman sachs downgrade biotech sell neutral even celgene find support key move average not be new buy area stock have already have several test line
2897,CELG,goldman also downgrade alexion pharmaceutical alxn neutral buy alexion share fall
2898,CELG,jinkosolar jks stretched gain push further year high earlier stock blow past buy point cup base chinese maker solar wafer cell say sign loan agreement china development bank solar plant project
2899,CELG,align technology algn be still hold gain clear early buy point flat base monday morning buy point flat base be cent left side high sometimes investor look alternative entry maker clear brace other dental product report earning jan analyst poll thomson reuter see profit rise cent share stock be again red have pare large chunk day loss late trading monday nasdaq be fall much intraday meanwhile slip dow jone industrial average be fractionally lower volume continue track higher major exchange stock market today signale possible distribution day nasdaq china lodging htht drop fast trade give early gain now past buy point flat base have be much dec peak celgene celg pare loss come close day move average earlier goldman sachs downgrade biotech sell neutral even celgene find support key move average not be new buy area stock have already have several test line goldman also downgrade alexion pharmaceutical alxn neutral buy alexion share fall jinkosolar jks stretched gain push further year high earlier stock blow past buy point cup base chinese maker solar wafer cell say sign loan agreement china development bank solar plant project align technology algn be still hold gain clear early buy point flat base monday morning buy point flat base be cent left side high sometimes investor look alternative entry maker clear brace other dental product report earning jan analyst poll thomson reuter see profit rise cent share
2900,CELG,biotech oncomed omed announce tuesday collaborate celgene celg jointly develop market cancer stem cell product send oncomed stock stock market today celgene agree pay oncomed front further payment contingent product meeting certain clinical regulatory commercial milestone oncomed say payment most
2901,CELG,mainstay large cap growth fund soar last year market tilt riskier less defensive stock favore fund rotation show third fourth quarters fund outperformed large cap growth peer group track morningstar inc have continue do so far
2902,CELG,biotech celgene celg receive double dose good news tuesday drug abraxane win key approval europe partner epizyme epzm produce positive result leukemia drug early trading celgene stock be epizyme vault stock market today european commission approve abraxane combine gemcitabine better
2903,CELG,stock hung mixed territory early monday company news drive lion share open trade nasdaq lead advance slip dow jone industrial average edge
2904,CELG,volume be soft nasdaq lower nyse compare option expiration boost level same friday
2905,CELG,economic news stock market today open national association homebuilder housing market index jump october be september read better consensus expectation change gauge best show late
2906,CELG,stock morgan stanley ms dive more disappointing third quarter report halliburton hal backed more beating earning forecast come short revenue line
2907,CELG,hasbro have crumble ep gain top expectation revenue rise only fraction shade forecast entertainment licensing revenue decline loss send share back day move average heavy trade
2908,CELG,valeant pharmaceutical vrx tank easily clear consensus earning revenue estimate third quarter fourth quarter sale earning guidance be line expectation
2909,CELG,sandisk sndk surge news report say maker memory chip be acquisition target south korea samsung electronic ssnlf sandisk have climb sharply past week be august low buoy largely chip industry consolidation
2910,CELG,hard drive manufacturer western digital wdc pop irvine calif company say decision china ministry commerce allow integrate china base hgst wd subsidiary parent company company say integration result significant opportunity growth synergy cost saving western digital be early october low still deep month consolidation
2911,CELG,leader cal maine food calm scramble upward seize new high powerful trade egg producer distributor be now almost buy point form handle double bottom base stock hung mixed territory early monday company news drive lion share open trade nasdaq lead advance slip dow jone industrial average edge volume be soft nasdaq lower nyse compare option expiration boost level same friday economic news stock market today open national association homebuilder housing market index jump october be september read better consensus expectation change gauge best show late stock morgan stanley ms dive more disappointing third quarter report halliburton hal backed more beating earning forecast come short revenue line hasbro have crumble ep gain top expectation revenue rise only fraction shade forecast entertainment licensing revenue decline loss send share back day move average heavy trade valeant pharmaceutical vrx tank easily clear consensus earning revenue estimate third quarter fourth quarter sale earning guidance be line expectation sandisk sndk surge news report say maker memory chip be acquisition target south korea samsung electronic ssnlf sandisk have climb sharply past week be august low buoy largely chip industry consolidation hard drive manufacturer western digital wdc pop irvine calif company say decision china ministry commerce allow integrate china base hgst wd subsidiary parent company company say integration result significant opportunity growth synergy cost saving western digital be early october low still deep month consolidation leader cal maine food calm scramble upward seize new high powerful trade egg producer distributor be now almost buy point form handle double bottom base
2912,CELG,evaluate stock watch list word need know volume volume number share trade tell mutual fund pension fund other deep pocket investor be buy selling passion important institution have power send stock soar sky plunge abyss want buy stock be breaking buy point volume least normal sure sign institutional support stock break lower volume be suspect stock fall heavy volume signal big fund be bail ibd track volume movement stock everyday stock move table locate make money section ibd home page investor com flag stock be move unusually heavy turnover don want miss screen be search emerge leader write ibd founder william neil best selling book make money stock add good way spot stock be happen shortly thereafter stock move help find stock breaking basis clear secondary buy point point one accumulation make table stock be price higher nyse higher nasdaq stock have price change least cent stock day average volume be share criterium stock rise price get more restrictive have earning share relative price strength rating least accumulation distribution rating be higher last stock next year ep estimate be higher prior year earning stock ep rs rating higher well be price day be boldface so quickly identify market best stock celgene celg appear ibd stock move table dec same day break flat base buy point volume be average day stock have go rise more celgene have also appear stock move dec give investor chance add watch list biotech be still build base not stock screen go be winner important check stock chart pattern rating show leadership potential celgene enjoy composite ep score day rs rating be accumulation distribution rating indicate positive demand share
2913,CELG,stock future step firm gain ahead thursday open market look wrap holiday shorten week dow future be point fair market value nasdaq future jump point future be ahead point rise small cap have also improve russell future turn early loss point gain payroll report be top piece economic news stock market today eye remain sharply focuse greece referendum vote sunday determine country remain part exit eurozone greece prime minister finance minister have make clear be firmly favor vote refuse so call austerity measure demand eurozone creditor exchange continue bailout support europe top stock index frankfurt paris be effectively flat midsession london ftse edge nonfarm payroll expand labor department report be sharp downtick april downwardly revise total new job expectation new hire private employer account addition labor force participation rate basis point unemployment rate dip april forecast average hourly earning be flat expectation gain initial jobless claim rise week end june increase prior week consensus forecast call slight decrease week move average increase first increase week factory order datum be due commerce department et early stock action show online international money transfer service xoom xoom vaulting premarket trade ebay ebay subsidiary paypal announce wednesday close acquire san francisco base startup approximately ebay announce last week complete spinoff paypal separately trade entity july ebay share rise tesla motor tsla jump ahead open palo alto calif base car battery maker report sale model sedan rise second quarter vs year period result top company own best case estimate vehicle unit tesla share end wednesday march low possible month cup base ibd stock centene cnc rise agree buy health net hnt cash stock transaction value centene say deal include debt boost company earning first year centene be extend re-cover new high high volume stab week line flash sell signal april health net share spiked thursday open overseas china mainland market take steep step shanghai composite shed friday loss week hong kong hang seng edge week japan tokyo nikkei gain take weekly loss thursday dollar be mixed vs euro yen commodity oil rise fraction west texas intermediate just barrel almost vs last friday settle price gold dip ounce friday bit more week wheat have have volatile week be slightly higher trading nearly week bushel
2914,CELG,tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen
2915,CELG,nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today
2916,CELG,economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation
2917,CELG,day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session
2918,CELG,meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain
2919,CELG,several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar
2920,CELG,qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday
2921,CELG,monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn tech stock outperformed tuesday hit time high intraday basis wall street digest dovish comment monday fed chief janet yellen nasdaq rise reclaim day move average dow jone industrial average rise nyse nasdaq volume be tracking higher monday stock market today economic news day disappointing read chicago purchasing manufacturer index ism manufacturing index come mostly line expectation day gainer former leader intuitive surgical isrg surge regulator approve new version da vinci robotic surgical system stock rise much news be session low hour session meanwhile casino operator exposure macau china have good day news gaming revenue region totale march year third highest record melco crown entertainment mpel rise wynn resort wynn la vegas sand lvs gain several other china base growth stock score gain heavy volume include athm bitauto bita operate website prospective car buyer china share rise bitauto soar qihoo technology qihu be best percentage gainer ibd rise nearly stock plunge day move average last week have be rally mode friday be just day move average early tuesday monday move higher ibd biotech group add heavy volume gainer group include gilead science gild celgene celg regeneron pharmaceutical regn biogen idec biib alexion pharmaceutical alxn
2922,CELG,share biotechs celgene celg infinity pharmaceutical infi be stock market today strong clinical datum blood cancer drug present american society hematology conference weekend
2923,CELG,celgene report detail mm trial revlimid be already blockbuster approve treat relapse multiple myeloma trial be study risk benefit profile revlimid long term maintenance therapy crucial piece information european authority reject use last year say want more information
2924,CELG,result show significant improvement overall survival longer duration therapy control group patient have survival rate rate be revlimid month year month treatment also bring average month progression free survival
2925,CELG,early monday rbc capital market analyst michael yee raise price target stock big picture conclusion ash be revlimid continuous treatment become standard care globe be use eu currently only use write note
2926,CELG,celgene stock be morning trading monday hit new high rank latest ibd list top perform stock
2927,CELG,infinity meanwhile be earlier report positive datum drug ipi cell acute lymphoblastic leukemia indolent hodgkin lymphoma chronic lymphocytic leukemia latter disease have be very busy area medicine lately recent approval pharmacyclic pcyc ibrutinib gilead science gild idelalisib expect come next year analyst yee say infinity datum so far stand competition
2928,CELG,bottom line be feedback docs here be early least good gild fine give such low expectation infi write research note sunday
2929,CELG,indeed infinity stock hold abysmal ibd relative strength rating get beating follow last round ipi datum medical conference june monday move be trading still more week high
2930,CELG,related celgene top rate drugmaker share biotechs celgene celg infinity pharmaceutical infi be stock market today strong clinical datum blood cancer drug present american society hematology conference weekend celgene report detail mm trial revlimid be already blockbuster approve treat relapse multiple myeloma trial be study risk benefit profile revlimid long term maintenance therapy crucial piece information european authority reject use last year say want more information result show significant improvement overall survival longer duration therapy control group patient have survival rate rate be revlimid month year month treatment also bring average month progression free survival early monday rbc capital market analyst michael yee raise price target stock big picture conclusion ash be revlimid continuous treatment become standard care globe be use eu currently only use write note celgene stock be morning trading monday hit new high rank latest ibd list top perform stock infinity meanwhile be earlier report positive datum drug ipi cell acute lymphoblastic leukemia indolent hodgkin lymphoma chronic lymphocytic leukemia latter disease have be very busy area medicine lately recent approval pharmacyclic pcyc ibrutinib gilead science gild idelalisib expect come next year analyst yee say infinity datum so far stand competition bottom line be feedback docs here be early least good gild fine give such low expectation infi write research note sunday indeed infinity stock hold abysmal ibd relative strength rating get beating follow last round ipi datum medical conference june monday move be trading still more week high related celgene top rate drugmaker
2931,CELG,many say drug industry be enter post blockbuster era mega seller such lipitor lose patent be drug pipeline expect pass traditional blockbuster benchmark global annual sale here preview expect launch next month have attract much interest
2932,CELG,big cap biotechs alexion pharmaceutical alxn celgene celg beat third quarter estimate raise guidance thursday stock head opposite direction
2933,CELG,alexion rise share come comparatively soft relative strength rating company also announce food drug administration grant breakthrough therapy designation drug candidate alxn be early stage testing treat rare genetic disease call molybdenum cofactor deficiency type
2934,CELG,fda create designation last year help speed approval drug bring major improvement exist treatment serious condition so far other drug have receive include alexion alfa rare condition call
2935,CELG,currently however alexion only other approve drug be soliris rake third quarter year earlier quarter more analyst consensus profit exclude time item rise cent share beating estimate cent
2936,CELG,alexion also add full year sale guidance now vs last year also add few cent ep guidance now
2937,CELG,conference call discuss result ceo leonard bell credit continue rollout soliris second disease indication be sell treatment ultra rare condition call paroxysmal nocturnal hemoglobinurium pnh last couple year be pick approval atypical hemolytic uremic syndrome ahus very rare serious condition
2938,CELG,call bell say patient uptake ahus be ramp faster do pnh rollout new indication be gain traction europe recently win approval japan
2939,CELG,bell also say company expect file approval alpha mid potentially end alexion single drug dependence
2940,CELG,celgene share slide rank latest ibd monday hit time high
2941,CELG,celgene say revenue rise year earlier quarter consensus estimate profit rise share beating estimate cent
2942,CELG,company say full year product sale be now expect exceed previously guide didn say much last year sale totale celgene lift tighten ep range be still bit shy analyst consensus
2943,CELG,conference call discuss result jmp security analyst michael king say guidance seem conservative give fourth quarter have traditionally be strong celgene
2944,CELG,company chief financial officer jacqualyn fouse say year be go suffer entrance generic version vidaza drug treatment myelodysplastic syndrome group bone marrow disease also say firm be ramp spending ahead expect launch psoriasis treatment await fda decision end first quarter
2945,CELG,investor also be put celgene be push next quarter much anticipate refile lead drug revlimid new indication europe rbc capital market analyst michael yee write research note thursday approve only relapse treatment blood cancer multiple myeloma company aim get approve front line treatment
2946,CELG,yee say be not really clear delay say firm guidance sale ep be still highly achievable big cap biotechs alexion pharmaceutical alxn celgene celg beat third quarter estimate raise guidance thursday stock head opposite direction alexion rise share come comparatively soft relative strength rating company also announce food drug administration grant breakthrough therapy designation drug candidate alxn be early stage testing treat rare genetic disease call molybdenum cofactor deficiency type fda create designation last year help speed approval drug bring major improvement exist treatment serious condition so far other drug have receive include alexion alfa rare condition call currently however alexion only other approve drug be soliris rake third quarter year earlier quarter more analyst consensus profit exclude time item rise cent share beating estimate cent alexion also add full year sale guidance now vs last year also add few cent ep guidance now conference call discuss result ceo leonard bell credit continue rollout soliris second disease indication be sell treatment ultra rare condition call paroxysmal nocturnal hemoglobinurium pnh last couple year be pick approval atypical hemolytic uremic syndrome ahus very rare serious condition call bell say patient uptake ahus be ramp faster do pnh rollout new indication be gain traction europe recently win approval japan bell also say company expect file approval alpha mid potentially end alexion single drug dependence celgene share slide rank latest ibd monday hit time high celgene say revenue rise year earlier quarter consensus estimate profit rise share beating estimate cent company say full year product sale be now expect exceed previously guide didn say much last year sale totale celgene lift tighten ep range be still bit shy analyst consensus conference call discuss result jmp security analyst michael king say guidance seem conservative give fourth quarter have traditionally be strong celgene company chief financial officer jacqualyn fouse say year be go suffer entrance generic version vidaza drug treatment myelodysplastic syndrome group bone marrow disease also say firm be ramp spending ahead expect launch psoriasis treatment await fda decision end first quarter investor also be put celgene be push next quarter much anticipate refile lead drug revlimid new indication europe rbc capital market analyst michael yee write research note thursday approve only relapse treatment blood cancer multiple myeloma company aim get approve front line treatment yee say be not really clear delay say firm guidance sale ep be still highly achievable
2947,CELG,most stock follow market trend monday action prove point member big cap give gain reversed close lower lockstep major index trigger atlanta fed president dennis lockhart comment favor further taper central bank bond buy program spook investor lead big loss
2948,CELG,saturday tuesday rep drugmaker world be gathering new orlean present datum blood disease drug american society hematology conference be top rate big cap biotechs abstract be already detail report have potential move stock celgene celg sunday afternoon
2949,CELG,biotech celgene celg beat analyst estimate raise guidance thursday morning celgene stock be nearly midday trading analyst have modeled higher earning expectation
2950,CELG,celgene say revenue rise year earlier quarter consensus estimate compile thomson reuter profit rise share beating estimate cent
2951,CELG,company say full year product sale be now expect exceed previously guide didn say much last year sale totale celgene also lift tighten ep range be still bit shy analyst consensus
2952,CELG,conference call discuss result jmp security analyst michael king say guidance seem bit conservative give fourth quarter have traditionally be strong celgene
2953,CELG,company cfo jacqualyn fouse say year be go suffer entrance generic version vidaza drug treatment myelodysplastic syndrome category bone marrow disease also say firm be ramp spending ahead expect launch psoriasis treatment await fda decision end first quarter
2954,CELG,nonetheless celgene executive be more optimistic ever hit financial target layer earlier year call revenue least ep
2955,CELG,firm lead product blood cancer drug revlimid continue grow celgene expect refile application use front line treatment europe first quarter
2956,CELG,sale related drug pomalyst rise just second quarter market company executive repeat claim be blockbuster least annual sale revenue lung cancer drug abraxane vault help partly new indication pancreatic cancer
2957,CELG,pomalyst continue rock be now handily outsell amgen amgn kyproli isi group analyst mark schoenebaum write email client refer drug amgen recently acquire buyout onyx pharmaceutical most person include mom de moine expect celg have good quarter so possible stock reaction today be muted perfectly good result
2958,CELG,celgene stock hit time high monday so expectation be bullish highest possible ibd composite rating rank wednesday midweek update ibd stock hit flat base buy point last month be now extend point biotech celgene celg beat analyst estimate raise guidance thursday morning celgene stock be nearly midday trading analyst have modeled higher earning expectation celgene say revenue rise year earlier quarter consensus estimate compile thomson reuter profit rise share beating estimate cent company say full year product sale be now expect exceed previously guide didn say much last year sale totale celgene also lift tighten ep range be still bit shy analyst consensus conference call discuss result jmp security analyst michael king say guidance seem bit conservative give fourth quarter have traditionally be strong celgene company cfo jacqualyn fouse say year be go suffer entrance generic version vidaza drug treatment myelodysplastic syndrome category bone marrow disease also say firm be ramp spending ahead expect launch psoriasis treatment await fda decision end first quarter nonetheless celgene executive be more optimistic ever hit financial target layer earlier year call revenue least ep firm lead product blood cancer drug revlimid continue grow celgene expect refile application use front line treatment europe first quarter sale related drug pomalyst rise just second quarter market company executive repeat claim be blockbuster least annual sale revenue lung cancer drug abraxane vault help partly new indication pancreatic cancer pomalyst continue rock be now handily outsell amgen amgn kyproli isi group analyst mark schoenebaum write email client refer drug amgen recently acquire buyout onyx pharmaceutical most person include mom de moine expect celg have good quarter so possible stock reaction today be muted perfectly good result celgene stock hit time high monday so expectation be bullish highest possible ibd composite rating rank wednesday midweek update ibd stock hit flat base buy point last month be now extend point
2959,CELG,day line be shape battlefield many big cap stock ideally stock trip back day line week line prefer be quiet volume stock bounce line fast trade then secondary buy zone be establish instance entry day line be early buy eventually become base example chipotle grill cmg be big cap dec return day line mid december volume be quiet descent dec stock bounce line twice usual volume investor have buy anywhere day chipotle consolidated week bounce line complete cup handle base entry be jan come volume average stock never find further traction fail investor buy day bounce have eventually exit trade small profit buy lose money point here isn day line be preferable case do illustrate key area sometimes give investor more tool play stock number stock monday preliminary list big cap be battle day line facebook fb retreat day line session first day involved loss average volume monday volume picked stock bounce touch line nadir stock fall almost buy point priceline pcln make week high last week then pull back monday priceline slice day line heavy volume alexion pharmaceutical alxn retreat day line average volume however monday stock rebound line strong volume celgene celg break day line fast trade friday lose more ground monday cognizant technology solution ctsh be back day line hasn make decisive move line google goog make decent move day line monday briefly violate line volume be strong netflix nflx close day line straight session then gap line big volume thursday stock recross buy point be buy zone softening market define outcome battle day line however federal reserve deliver surprise wednesday day meeting conclude become decide factor
2960,CELG,stock future step firm gain ahead thursday open market look wrap holiday shorten week dow future be point fair market value nasdaq future jump point future be ahead point rise small cap have also improve russell future turn early loss point gain payroll report be top piece economic news stock market today eye remain sharply focuse greece referendum vote sunday determine country remain part exit eurozone greece prime minister finance minister have make clear be firmly favor vote refuse so call austerity measure demand eurozone creditor exchange continue bailout support europe top stock index frankfurt paris be effectively flat midsession london ftse edge nonfarm payroll expand labor department report be sharp downtick april downwardly revise total new job expectation new hire private employer account addition labor force participation rate basis point unemployment rate dip april forecast average hourly earning be flat expectation gain initial jobless claim rise week end june increase prior week consensus forecast call slight decrease week move average increase first increase week factory order datum be due commerce department et early stock action show online international money transfer service xoom xoom vaulting premarket trade ebay ebay subsidiary paypal announce wednesday close acquire san francisco base startup approximately ebay announce last week complete spinoff paypal separately trade entity july ebay share rise tesla motor tsla jump ahead open palo alto calif base car battery maker report sale model sedan rise second quarter vs year period result top company own best case estimate vehicle unit tesla share end wednesday march low possible month cup base ibd stock centene cnc rise agree buy health net hnt cash stock transaction value centene say deal include debt boost company earning first year centene be extend re-cover new high high volume stab week line flash sell signal april health net share spiked thursday open overseas china mainland market take steep step shanghai composite shed friday loss week hong kong hang seng edge week japan tokyo nikkei gain take weekly loss thursday dollar be mixed vs euro yen commodity oil rise fraction west texas intermediate just barrel almost vs last friday settle price gold dip ounce friday bit more week wheat have have volatile week be slightly higher trading nearly week bushel
2961,CELG,stock slide monday seller come woodwork holiday period nasdaq drop respectively lowest level week fall third straight session fade higher open small cap suffer biggest blow russell lose
2962,CELG,broader index be mostly tread water monday afternoon blue chip continue outshine
2963,CELG,lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract
2964,CELG,lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base
2965,CELG,wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters
2966,CELG,downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain
2967,CELG,other biotechs celgene celg biogen idec biib be session lows still broader index be mostly tread water monday afternoon blue chip continue outshine lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain other biotechs celgene celg biogen idec biib be session lows still
2968,CELG,celgene celg be more heavy trading early thursday biotech report positive trial result immunology drug candidate
2969,CELG,result come late stage study celgene be conduct test psoriatic arthritis sufferer celgene already report good result july other show similar improvement symptom physical function subject
2970,CELG,company announcement say celgene expect file application approval fda early europe second half year also investigate use other immunological disorder such ankylose spondilitis type spinal arthritis rare syndrome call behcet disease
2971,CELG,stock move bring price first time april continue rebound low point hit june celgene halter attempt get big moneymaker revlimid approve new indication europe stock ibd relative strength rating be still only company good financial give highest possible ibd ep rank celgene celg be more heavy trading early thursday biotech report positive trial result immunology drug candidate result come late stage study celgene be conduct test psoriatic arthritis sufferer celgene already report good result july other show similar improvement symptom physical function subject company announcement say celgene expect file application approval fda early europe second half year also investigate use other immunological disorder such ankylose spondilitis type spinal arthritis rare syndrome call behcet disease stock move bring price first time april continue rebound low point hit june celgene halter attempt get big moneymaker revlimid approve new indication europe stock ibd relative strength rating be still only company good financial give highest possible ibd ep rank
2972,CELG,food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat
2973,CELG,fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade
2974,CELG,only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia
2975,CELG,analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll
2976,CELG,recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning
2977,CELG,delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month
2978,CELG,drug be co market johnson johnson jnj division janssen pharmaceutical
2979,CELG,ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month drug be co market johnson johnson jnj division janssen pharmaceutical ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break
2980,CELG,stock be trading session high friday afternoon lead biotech stock such biogen idec biib regeneron pharmaceutical regn nasdaq rally putt striking distance nov peak rise also near nov record high dow jone industrial average be volume be mixed turnover
2981,CELG,strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility
2982,CELG,course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return
2983,CELG,steven silver equity analyst capital iq say industry success be base pillar
2984,CELG,first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress
2985,CELG,second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition
2986,CELG,be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster
2987,CELG,finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm
2988,CELG,biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi
2989,CELG,composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science
2990,CELG,be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund
2991,CELG,comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover
2992,CELG,old school vs new school
2993,CELG,be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit
2994,CELG,xbi be more year ibb have perform better longer period average annual vs past year vs year
2995,CELG,ibb actually have better risk adjust return long term say goldsborough
2996,CELG,think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time strong performance biotech etfs past year recent market pullback still be room run investor stomach sector high volatility course lot depend stock market general direction biotech etfs continue selling monday further progress biotech etfs have market uptrend return steven silver equity analyst capital iq say industry success be base pillar first be very solid period late stage datum new drug come market say put together think be lot pocket significant progress second pillar state be much more accommodative food drug administration be focuse get more drug market last year fda start breakthrough therapy designation provide fast track development review drug serious life threaten condition be program have receive designation so far fda be only grant program designation so think long term be really big deal company be receive designation term get drug market faster finally sector have prospect increase activity traditionally big pharmas be acquirer smaller biotechs biotechs have grow so large be now market buy smaller firm create more competition market acquisition firm biggest biotech etfs be ishare nasdaq biotech ibb spdr biotech xbi be very liquid have reasonable expense ratio asset ibb xbi composition be somewhat different ibb hold nasdaq list stock be market cap weight etf be more diversify biotech accounting fund pharma life science be market cap weight top holding be large independent biotechs gilead science gild biogen idec biib amgen amgn celgene celg regeneron pharmaceutical regn fund comparison xbi be make stock nearly biotechs top holding be intercept pharmaceutical icpt ariad pharmaceutical aria neurocrine bioscience nbix sangamo bioscience sgmo novavax nvax fund be equal weight result bias smaller name meaning more volatility higher turnover old school vs new school be very different fund say robert goldsborough etf analyst morningstar xbi re go have more early stage biotech firm lot be publicly trade company have drug market yet have profit xbi be more year ibb have perform better longer period average annual vs past year vs year ibb actually have better risk adjust return long term say goldsborough think stock have do very very well base improve growth potential rather investor bidding company just say silver be exciting time do think continue be exciting time
2997,CELG,stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory
2998,CELG,dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss
2999,CELG,option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action
3000,CELG,broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be
3001,CELG,symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august
3002,CELG,lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base
3003,CELG,downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high
3004,CELG,generally tame week major index just trading day ahead thanksgiving holiday ibd continue showcase big mover upside downside strongest gainer be clear role slim ibd paradigm successful equity investing be vital biogen idec biib lead week advancer soar week positive news friday europe regard tecfidera new oral drug multiple sclerosis european govern body announce new drug receive additional datum protection contain new active substance decision give tecfidera longer patent protection rival generic drugmaker pave way long await launch european union nation see related story biogen be already global leader medicine used fight debilitating disease analyst see tecfidera become firm biggest revenue generator biogen weekly share volume surge week average stock probe time high reach high stock close jan rally past early buy point unusual month cup deep handle base composite rating be sale margin return equity rating be highest possible celgene celg composite note same story biotech winner today ibd also make new high favorable drug news cancer therapy specialist cruised higher week active turnover sale have grow vs year earlier level quarters row note stock have test week move average multiple time clear buy point such action be normal especially market show choppy action direct marketer nu skin enterprise nus last week new high continue thrive successful asia rollout new weight management product sharp decline noah holding noah lumber liquidator ll system ddd serve reminder solid sell rule always be implement noah chinese wealth management firm hasn necessarily trigger sell signal fall week stock swing wider most investor shouldn let decent gain turn loss
3005,CELG,celgene celg announce buyout early stage biotech early thursday also release final result line expectation target company avila therapeutic be privately hold startup develop hematology drug used proprietary platform call avilomic drug phase trial avl be design treat blood cancer much celgene lead
3006,CELG,buyer be back thursday score record high nasdaq hit year high sell cisco system csco do not spread much market seem focus instead testimony fed vice chairwoman janet yellen senate confirmation hearing expect yellen have soothing word market
3007,CELG,large well capitalize company such yandex yndx priceline com pcln celgene celg offer consistency strength smaller nimbler stock often today screen day be big cap leader company market capitalization more stock sell least share here be top stock big cap
3008,CELG,stock stumble start friday never regain balance close lower day nasdaq fall less dow jone industrial average lead retreat decline ibd add less volume rise nyse fall nasdaq
3009,CELG,stock backed moderately mixed volume friday investor focus seem rivet washington budget battle threat government shutdown dow jone industrial average fall nasdaq volume stock market today fall nasdaq climb nyse accord preliminary datum
3010,CELG,stock stumble start friday never regain balance close lower day nasdaq fall less dow jone industrial average lead retreat decline ibd add less volume rise nyse fall nasdaq
3011,CELG,share celgene celg be dancing time high biotech prepare report fourth quarter result early thursday extent not lot suspense result celgene release preliminary result jpmorgan health care conference earlier month number come bit shy analyst consensus company raise
3012,CELG,most stock ibd sector leader screen gain ground soft trade friday join market broad rally just stock lineup rise volume be well average celgene celg climb volume be higher normal drug developer have be make second pullback week move average
3013,CELG,stock climb second straight day friday dow jone industrial average hit record high
3014,CELG,be tech heavy nasdaq lead gain biotechs software be day strongest group rise dow edge volume end mixed stock market today accord preliminary datum nasdaq trade be slightly higher nyse volume slide
3015,CELG,biogen idec biib gap bolt new high massive volume key european regulatory body give drugmaker favorable ruling multiple sclerosis pill tecfidera stock soar week move average be extend buy point
3016,CELG,gilead science gild gain record high winning approval european advisory panel hepatitis drug sofosbuvir
3017,CELG,celgene celg climb record high also receive good news europe european medicine agency panel give positive opinion pancreatic drug abraxane pave way approval european commission be expect make final decision month
3018,CELG,downside proto lab prlb end session low still slump big volume share slump much intraday week proto lab tumble just shy biggest weekly loss more year stock climb second straight day friday dow jone industrial average hit record high be tech heavy nasdaq lead gain biotechs software be day strongest group rise dow edge volume end mixed stock market today accord preliminary datum nasdaq trade be slightly higher nyse volume slide biogen idec biib gap bolt new high massive volume key european regulatory body give drugmaker favorable ruling multiple sclerosis pill tecfidera stock soar week move average be extend buy point gilead science gild gain record high winning approval european advisory panel hepatitis drug sofosbuvir celgene celg climb record high also receive good news europe european medicine agency panel give positive opinion pancreatic drug abraxane pave way approval european commission be expect make final decision month downside proto lab prlb end session low still slump big volume share slump much intraday week proto lab tumble just shy biggest weekly loss more year
3019,CELG,health care stock have be strong performer year re largest group big cap entry actavis act be still buy range touch day move average form week tight pattern be most safely used add already successful position buy point week tight pattern be
3020,CELG,stock zoom early gain weak trade tuesday market focuse more earning report
3021,CELG,nasdaq step early lead grab gain dow jone industrial average lag less traveler trv johnson johnson jnj dip more deliver quarterly report
3022,CELG,volume be tracking sharply lower skewer friday heavy option expiration traffic
3023,CELG,earning report weigh heavy early action stock market today company diverse delta air line dal oilfield machinery service leader baker hughe bhi base consumer product company unilever ul open higher strong quarterly report
3024,CELG,lead stock rattle strong open nearly ibd stock advance open bell many quickly scrub early gain
3025,CELG,tal education group xrs bolt grab new high heavy trade china base school tutor provider be past flat base buy point christmas eve
3026,CELG,qihoo technology qihu pop moderate trade internet security software content provider be form base buy point
3027,CELG,downside invensense invn trip downgrade hold buy needham co note cite valuation developer motion process chip attempt clear month consolidation remain mid october high
3028,CELG,system ddd also open lower downgrade neutral outperform credit suisse cs report also cite valuation lower rating raise printer peer stratasys ssys outperform neutral
3029,CELG,move left system just day move average stratasys break day line last week stock zoom early gain weak trade tuesday market focuse more earning report nasdaq step early lead grab gain dow jone industrial average lag less traveler trv johnson johnson jnj dip more deliver quarterly report volume be tracking sharply lower skewer friday heavy option expiration traffic earning report weigh heavy early action stock market today company diverse delta air line dal oilfield machinery service leader baker hughe bhi base consumer product company unilever ul open higher strong quarterly report lead stock rattle strong open nearly ibd stock advance open bell many quickly scrub early gain tal education group xrs bolt grab new high heavy trade china base school tutor provider be past flat base buy point christmas eve qihoo technology qihu pop moderate trade internet security software content provider be form base buy point downside invensense invn trip downgrade hold buy needham co note cite valuation developer motion process chip attempt clear month consolidation remain mid october high system ddd also open lower downgrade neutral outperform credit suisse cs report also cite valuation lower rating raise printer peer stratasys ssys outperform neutral move left system just day move average stratasys break day line last week
3030,CELG,drugmaker celgene celg biogen idec biib be big cap drugmaker deep pocket proven product line process today screen day be big cap leader top rate large cap stock price drugmaker big cap leader list include biotechs celgene biogen idec well generic drugmaker actavis act perrigo ticker
3031,CELG,recently year thalidomide stoke fear many mother regulator ban drug cause severe birth defect didn stop celgene celg licensing thalidomide rival biotech firm celgene goal develop novel cancer treatment celgene have bold management like take calculate risk
3032,CELG,stock shave good chunk loss monday halftime slide early go lower oil price
3033,CELG,nasdaq lose be much monday low dow jone industrial average fall volume be tracking sharply higher board stock market today
3034,CELG,west texas intermediate crude oil february delivery drop nearly barrel first time april brent crude european benchmark be more earlier goldman sachs cut month price target wti barrel brent
3035,CELG,improvement main index bitauto bita widen loss have erased friday move spark news big investment jd com jd tencent tcehy then
3036,CELG,rival athm drop fast trade fall day day move average
3037,CELG,sandisk sndk be slightly low still hefty cut sale guidance due weaker expect demand retail product stock gap day move average slump lowest level nearly month
3038,CELG,upside lennar len rally month high close buy point flat base homebuilder report fourth quarter earning market open thursday lennar be featured monday ibd stock analysis stock shave good chunk loss monday halftime slide early go lower oil price nasdaq lose be much monday low dow jone industrial average fall volume be tracking sharply higher board stock market today west texas intermediate crude oil february delivery drop nearly barrel first time april brent crude european benchmark be more earlier goldman sachs cut month price target wti barrel brent improvement main index bitauto bita widen loss have erased friday move spark news big investment jd com jd tencent tcehy then rival athm drop fast trade fall day day move average sandisk sndk be slightly low still hefty cut sale guidance due weaker expect demand retail product stock gap day move average slump lowest level nearly month upside lennar len rally month high close buy point flat base homebuilder report fourth quarter earning market open thursday lennar be featured monday ibd stock analysis
3039,CELG,stock shave good chunk loss monday halftime slide early go lower oil price
3040,CELG,nasdaq lose be much monday low dow jone industrial average fall volume be tracking sharply higher board stock market today
3041,CELG,west texas intermediate crude oil february delivery drop nearly barrel first time april brent crude european benchmark be more earlier goldman sachs cut month price target wti barrel brent
3042,CELG,improvement main index bitauto bita widen loss have erased friday move spark news big investment jd com jd tencent tcehy then
3043,CELG,rival athm drop fast trade fall day day move average
3044,CELG,sandisk sndk be slightly low still hefty cut sale guidance due weaker expect demand retail product stock gap day move average slump lowest level nearly month
3045,CELG,upside lennar len rally month high close buy point flat base homebuilder report fourth quarter earning market open thursday lennar be featured monday ibd stock analysis stock shave good chunk loss monday halftime slide early go lower oil price nasdaq lose be much monday low dow jone industrial average fall volume be tracking sharply higher board stock market today west texas intermediate crude oil february delivery drop nearly barrel first time april brent crude european benchmark be more earlier goldman sachs cut month price target wti barrel brent improvement main index bitauto bita widen loss have erased friday move spark news big investment jd com jd tencent tcehy then rival athm drop fast trade fall day day move average sandisk sndk be slightly low still hefty cut sale guidance due weaker expect demand retail product stock gap day move average slump lowest level nearly month upside lennar len rally month high close buy point flat base homebuilder report fourth quarter earning market open thursday lennar be featured monday ibd stock analysis
3046,CELG,stock packed moderate gain so so volume thursday end session lose streak nasdaq rise higher dow jone industrial average add ibd jump keep wide lead major index year volume fall board be barely lower
3047,CELG,earning season ramp nu skin enterprise nus tripadvisor trip be ibd leader slate report result upcoming week profit be primary driver stock growth investor be pay close attention quarterly earning result company own watch list strong earning record
3048,CELG,stock sell higher volume tuesday renew concern federal reserve start scale back stimulus program dow jone industrial average slump lose nasdaq slide volume rise nyse nasdaq compare monday accord preliminary datum investor have become
3049,CELG,stock fall modestly tuesday market continue seek clear direction slip higher volume give index seventh distribution day recent week add already worrisome number higher volume decline nasdaq edge lower volume strength chip other technology stock help composite fare
3050,CELG,stock open higher friday then backtrack mixed terrain drugmaker lead stock add drag early trade
3051,CELG,dow jone industrial average remain ahead be nasdaq slip celgene celg vertex pharmaceutical vrtx biogen idec biib weigh nasdaq medical sector continue bout weakness
3052,CELG,volume start mixed nyse lower nasdaq
3053,CELG,stock market today receive early boost february payroll report show new hire january well forecast many have be braced disappointing job number harsh weather tamper other economic reading month
3054,CELG,leader edge broadly moderately higher open ibd qihoo qihu ubiquiti network ubnt jazz pharmaceutical jazz rexnord rxn open ahead more
3055,CELG,korn ferry international kfy gap gain executive headhunter late thursday top analyst fiscal expectation pop earning revenue advance los angele base company report year year growth line business region strongest top line result company history
3056,CELG,stock break week base be buy point
3057,CELG,downside qiwi qiwi slip putt share week stock continue be link investor reaction crisis ukraine
3058,CELG,ambarella amba drop report earning revenue gain latest quarter view stock have be work base stock hold week move average stock open higher friday then backtrack mixed terrain drugmaker lead stock add drag early trade dow jone industrial average remain ahead be nasdaq slip celgene celg vertex pharmaceutical vrtx biogen idec biib weigh nasdaq medical sector continue bout weakness volume start mixed nyse lower nasdaq stock market today receive early boost february payroll report show new hire january well forecast many have be braced disappointing job number harsh weather tamper other economic reading month leader edge broadly moderately higher open ibd qihoo qihu ubiquiti network ubnt jazz pharmaceutical jazz rexnord rxn open ahead more korn ferry international kfy gap gain executive headhunter late thursday top analyst fiscal expectation pop earning revenue advance los angele base company report year year growth line business region strongest top line result company history stock break week base be buy point downside qiwi qiwi slip putt share week stock continue be link investor reaction crisis ukraine ambarella amba drop report earning revenue gain latest quarter view stock have be work base stock hold week move average
3059,CELG,buyer be short supply stock fall hard close session lows several tepid distribution day recent week be follow unequivocal wednesday putt market uptrend pressure small cap take hardest hit russell slump nasdaq lose give volume
3060,CELG,share pharmacyclic pcyc jump new high stock market thursday deutsche bank jpmorgan launch coverage bullish rating stock have double price start year deutsche bank analyst robyn karnauskas write wall street be still underestimate potential pharmacyclic drug candidate ibrutinib
3061,CELG,celgene celg get high volume bump midday trading monday guidance exceed view even estimate fall short
3062,CELG,biotech say sale year increase high side analyst consensus set earning share vs analyst average celgene say expect cancer drug revlimid already provide third revenue drive growth sale increase
3063,CELG,share be monday more twice average volume most gain come celgene late morning announcement jpmorgan health care conference san francisco good outlook apparently make celgene estimate result come bit shy expectation firm say sale totale vs consensus see ep share vs view
3064,CELG,move bring stock back dip suffer friday clear cup shape base start october share hit year high thursday celgene celg get high volume bump midday trading monday guidance exceed view even estimate fall short biotech say sale year increase high side analyst consensus set earning share vs analyst average celgene say expect cancer drug revlimid already provide third revenue drive growth sale increase share be monday more twice average volume most gain come celgene late morning announcement jpmorgan health care conference san francisco good outlook apparently make celgene estimate result come bit shy expectation firm say sale totale vs consensus see ep share vs view move bring stock back dip suffer friday clear cup shape base start october share hit year high thursday
3065,CELG,company rely single product third sale bet wall street react quickly big news product surprise then share celgene celg get lift earlier fall european union health regulator give favorable opinion company revlimid cancer drug revlimid be used
3066,CELG,spending nearly tuesday session positive territory stock sell last hour finished mixed close bell rang nasdaq show gain much fall turn gain loss dow jone industrial average see gain
3067,CELG,celgene celg early thursday beat analyst expectation raise ep outlook send share early trading biotech say sale rise year quarter hair analyst consensus adjust earning rise share beating consensus cent sale main
3068,CELG,stock market shift growth have put tail wind american century ultra trail first second quarters russell growth index rise vs value counterpart be neck neck vs go tuesday accord russell investment
3069,CELG,investor get closer look new issue commscope hold comm enzymotec enzy report third quarter earning first half november enzymotec product include nutritional ingredient infant formula dietary supplement have climb debut stock be latest entrant highly rank medical biomedical biotech industry group include market leader such celgene celg israel base enzymotec be due report result market open nov profit be expect rise same period last year cent share mark fifth straight quarter company have turn profit prior suffer string loss weak result revenue quarter be see jump follow strong gain previous quarters stock be thinly trade however average just share change hand day riskier buy stock be so illiquid commscope maker equipment used wire wireless communication network be go public oct hickory base company be controlled private equity firm carlyle group plan release result market open nov profit sale estimate period be unavailable profit growth have be robust range past quarters sale growth have be less strong climb period oct moody upgrade commscope debt rating expectation debt reduction less aggressive financial policy follow company ipo yet commscope credit rating remain speculative grade
3070,CELG,stock be modestly higher choppy fashion bounce back lower start monday dow jone industrial average rise nasdaq be fractionally higher stock market today volume be tracking lower board compare same time friday
3071,CELG,stock noah noah paycom software payc rally nearly respectively lead upside action ibd latter retook buy point
3072,CELG,jd com jd rally sale outlook offset weaker expect result revenue current quarter be expect renminbi renminbi view be renminbi
3073,CELG,travel related stock be pressure follow friday attack paris priceline pcln fall fast trade putt further day line breach huge trade last week stock slide more buy point consolidation mark sell signal
3074,CELG,rival expedia expe gap day line lose cut loss
3075,CELG,delta air line dal drop nearly fall day line buy point consolidation
3076,CELG,american airline aal unite continental ual lose
3077,CELG,software maker nuance communication nuan apparel retailer urban outfitter urbn be couple notable firm report earning close ahead quarterly result urban announce plan buy vetri family group restaurant share be session lows still more
3078,CELG,follow vincent mao twitter ibd_vmao stock be modestly higher choppy fashion bounce back lower start monday dow jone industrial average rise nasdaq be fractionally higher stock market today volume be tracking lower board compare same time friday stock noah noah paycom software payc rally nearly respectively lead upside action ibd latter retook buy point jd com jd rally sale outlook offset weaker expect result revenue current quarter be expect renminbi renminbi view be renminbi travel related stock be pressure follow friday attack paris priceline pcln fall fast trade putt further day line breach huge trade last week stock slide more buy point consolidation mark sell signal rival expedia expe gap day line lose cut loss delta air line dal drop nearly fall day line buy point consolidation american airline aal unite continental ual lose software maker nuance communication nuan apparel retailer urban outfitter urbn be couple notable firm report earning close ahead quarterly result urban announce plan buy vetri family group restaurant share be session lows still more follow vincent mao twitter ibd_vmao
3079,CELG,investor be try identify potential winning stock recent earning growth matter
3080,CELG,paragraph ibd founder chairman william neil make money stock show
3081,CELG,model best perform stock show earning increase average more latest publicly report quarter begin major advance do not show solid current quarterly earning increase do so very next quarter average earning increase
3082,CELG,be current earning growth represent slim
3083,CELG,common misconception be investor see fast recent growth be too late buy too late condition have more do late stage basis fast earning growth
3084,CELG,let look winner breakout kind ep pop do show most recently report quarter break fast trade
3085,CELG,celgene celg clear buy point twice initial be dec stock then retreat celgene retook buy point jan earning growth be seventh consecutive quarter ep growth ideal entry stock rise much
3086,CELG,linkedin lnkd pop buy point jan earning growth most recently report quarter be ideal entry stock rise much
3087,CELG,lumber liquidator ll break past handle jan earning grow quarter report lumber rise month
3088,CELG,fleetcor technology flt hurry past buy point week tight pattern march earning grow then recent quarter stock marched month
3089,CELG,netflix nflx brushed past entry july time most recent earning growth be cent share vs loss cent share year period stock advanced month
3090,CELG,other such facebook fb la vegas sand lvs have earning growth respectively then recent quarter investor be try identify potential winning stock recent earning growth matter paragraph ibd founder chairman william neil make money stock show model best perform stock show earning increase average more latest publicly report quarter begin major advance do not show solid current quarterly earning increase do so very next quarter average earning increase be current earning growth represent slim common misconception be investor see fast recent growth be too late buy too late condition have more do late stage basis fast earning growth let look winner breakout kind ep pop do show most recently report quarter break fast trade celgene celg clear buy point twice initial be dec stock then retreat celgene retook buy point jan earning growth be seventh consecutive quarter ep growth ideal entry stock rise much linkedin lnkd pop buy point jan earning growth most recently report quarter be ideal entry stock rise much lumber liquidator ll break past handle jan earning grow quarter report lumber rise month fleetcor technology flt hurry past buy point week tight pattern march earning grow then recent quarter stock marched month netflix nflx brushed past entry july time most recent earning growth be cent share vs loss cent share year period stock advanced month other such facebook fb la vegas sand lvs have earning growth respectively then recent quarter
3091,CELG,share drugmaker celgene celg be early trading wednesday company announce board have repurchase additional company common stock effective immediately
3092,CELG,company share fall tuesday month close low now trade
3093,CELG,celgene have keep recent practice repurchase share appear depress reuter report brian abraham analyst well fargo security write research note
3094,CELG,financial report april biotech firm say buy share quarter be authorize buy stock then exist repurchase program
3095,CELG,company result miss revenue profit send share fall more news sale blockbuster drug revlimid used treat blood cancer multiple myeloma disappoint celgene be work get drug approve other treatment
3096,CELG,last week company say small study pancreatic cancer patient used abraxane drug yielded positive result drugmaker await result larger study later year report still share rise little more news
3097,CELG,celgene acquire abraxane buy abraxis bioscience drug be approve second line treatment breast cancer share drugmaker celgene celg be early trading wednesday company announce board have repurchase additional company common stock effective immediately company share fall tuesday month close low now trade celgene have keep recent practice repurchase share appear depress reuter report brian abraham analyst well fargo security write research note financial report april biotech firm say buy share quarter be authorize buy stock then exist repurchase program company result miss revenue profit send share fall more news sale blockbuster drug revlimid used treat blood cancer multiple myeloma disappoint celgene be work get drug approve other treatment last week company say small study pancreatic cancer patient used abraxane drug yielded positive result drugmaker await result larger study later year report still share rise little more news celgene acquire abraxane buy abraxis bioscience drug be approve second line treatment breast cancer
3098,CELG,drugmaker celgene celg early thursday report second quarter result beat expectation reverse string miss quarters raise profit guidance news lift stock earning share exclude time item rise year quarter beating analyst consensus estimate cent sale climb view management
3099,CELG,shoe store chain foot locker fl clear buy point friday retail biotech stock pace list stock hit new high foot locker soar company sale earning beat expectation stock be buy range end just buy point cup handle base
3100,CELG,buyer be nowhere be find wednesday major average extend loss second day wall street initially respond positively budget deal late tuesday enthusiasm be short live little hour remain session nasdaq slump fall dow jone industrial average ease small cap fared worst russell lose nyse nasdaq volume be tracking very close tuesday level stock market today china ipo soar debut athm provider online auto information soar pricing last night high end upwardly revise range downside biotechs take heat again ibd medical biom biotech group fall just leader group pressure include celgene celg biogen idec biib alexion pharmaceutical alxn solar stock also slump ibd energy solar group lose more solarcity scty fall week stock crash week move average rally back back line now upside ibd name buck trend mastercard surge late tuesday card giant announce stock split quarterly dividend hike share new share buyback meanwhile volume be heavy armour ua share rise head today athletic apparel maker be work cup handle base buy point break level today la vegas sand lvs meanwhile add deutsche bank make positive comment macau only place china gamble be legal la vegas sand have strong presence finally bear camp get more good news today latest investor intelligence survey newsletter writer bullish writer rise again highest year also read see april just market top bearish writer now stand good spread percentage point exceed high optimism market top week oct
3101,CELG,celgene celg announce monday small study abraxane yielded positive result patient pancreatic cancer
3102,CELG,abraxane celgene acquire buy abraxis bioscience be currently approve second line treatment breast cancer new study report asco conference take place chicago tuesday treat patient operable pancreatic cancer have be operated result be half patient see least decrease tumor marker level
3103,CELG,celgene note larger study abraxane pancreatic cancer patient call mpact trial be expect produce result later year company have also be investigate abraxane treatment lung cancer
3104,CELG,report didn stop celgene slide stock market share be late trading monday month low
3105,CELG,related drug stock spotlight cancer conference celgene celg announce monday small study abraxane yielded positive result patient pancreatic cancer abraxane celgene acquire buy abraxis bioscience be currently approve second line treatment breast cancer new study report asco conference take place chicago tuesday treat patient operable pancreatic cancer have be operated result be half patient see least decrease tumor marker level celgene note larger study abraxane pancreatic cancer patient call mpact trial be expect produce result later year company have also be investigate abraxane treatment lung cancer report didn stop celgene slide stock market share be late trading monday month low related drug stock spotlight cancer conference
3106,CELG,lead biotech celgene celg get stop track thursday morning miss wall street first quarter estimate top bottom line do however affirm previous guidance drugmaker say revenue rise year quarter analyst consensus call profit time item come
3107,CELG,several major biotech stock rally friday biogen biib free report report positive result phase study ban therapy seek reduce toxic amyloid protein associate cognitive decline alzheimer disease share biogen be more afternoon trading hour thursday japan eisai co esaly free report partner ban development see gain nearly momentum be enough lift rest biotech space evidence ishare nasdaq biotechnology index fund ibb free report add biotech giant biogen celgene celg free report amgen amgn free report gilead gild free report have underperform broader nasdaq index past year industry likely need positive news spark optimistic trading speaking street real money column atlantic equity analyst steve chesney say investor finally be notice value effort company be believe innovation company biogen come report positive clinical result disease alzehimer imply probability success rest industry pipeline move little bit higher chesney tell street celgene share add touch intraday month high meanwhile amgen moved higher gilead gain more biogen latest test include patient early alzheimer disease company share positive result group period month nevertheless trial be still only phase challenge phase additional regulatory hurdle be still loom still biogen hope commercialize ban timely manner new product likely inspire positive analyst sentiment lift growth prospect come year past month zack consensus estimate biogen earning have drop share share mark year year growth early estimate have company earning peg share represent increase year project total biib be currently sporting zack rank hold medical biomedical genetic industry be sit bottom zack industry rank want more market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3108,CELG,be pretty low key week biotech sector not too many major update key news gilead gild free report car therapy win chmp positive opinion keryx kerx free report plunge merger news recap important story gilead car therapy get positive chmp opinion gilead announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe read more gilead car therapy get positive chmp opinion amgen announce result remicade biosimilar migraine drug amgen inc amgn free report announce result phase iii study evaluate efficacy safety biosimilar candidate abp brand drug remicade result confirm abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve remicade be approve treatment moderate severe rheumatoid arthritis chronic severe plaque psoriasis moderate severe crohn disease moderate severe ulcerative colitis psoriatic arthritis ankylose spondylitis note amgen have broad portfolio biosimilar be approve unite state be approve european union addition amgen announce encourage result open label extension ole study migraine drug aimovig result year study chronic migraine patient reinforce establish safety efficacy profile aimovig long term use moreover year interim analysis ongoing year study episodic migraine patient also reinforce long term safety tolerability aimovig amgen carry zack rank buy see complete list today zack rank strong buy stock here celgene report positive datum celgene corporation celg free report partner acceleron pharma xlrn free report announce positive top line result phase iii multus center study medalist evaluate efficacy safety versus placebo patient very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent red blood cell rbc transfusion study show achieve highly statistically significant improvement primary endpoint red blood cell rbc transfusion independence least consecutive week first week compare placebo candidate also meet key secondary endpoint demonstrate highly statistically significant improvement rbc transfusion independence least consecutive week first week study also achieve modify hematologic improvement erythroid iwg mhi meaningful secondary endpoint regulatory submission be plan unite state europe first half read more celgene meet primary endpoint study keryx plunge merger deal akebia share keryx inc plunge follow announcement definitive merger agreement akebia therapeutic inc akba free report company have agree combine stock merger form new fully integrate company focuse chronic kidney disease ckd call akebia therapeutic deal be expect close end keryx already have fda approve drug auryxia kitty akebia have late stage candidate pipeline however investor be not much impressed merger news share company fall read more keryx inks merger deal akebia share fall cara therapeutic rally positive result share cara therapeutic inc cara free report soar company announce positive top line datum adaptive phase ii iii trial intravenous iv cr patient undergo abdominal surgery iv form cr achieve statistical significance study primary endpoint pain relief hour auc period post surgery combine surgery mcg kg dose addition treatment same also result statistically significant reduction secondary endpoint incidence nausea vomit hour post surgery mcg dose respectively datum demonstrate overall benefit cr provide pain relief surgery type hour post surgery reduce post operative nausea vomit significant medical need post operative set brand name drug be korsuva company have earlier inked licensing deal fresenius medical care renal pharma ltd license worldwide right commercialize korsuva cr difelikefalin injection treatment chronic kidney disease biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex have gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup pbyi soar mack crash gild biktarvy get ec nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3109,CELG,celgene corporation celg free report acceleron pharma inc xlrn free report announce top line result phase iii multus center study medalist medalist study evaluate efficacy safety versus placebo patient very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent red blood cell rbc transfusion study show achieve highly statistically significant improvement primary endpoint red blood cell rbc transfusion independence least consecutive week first week compare placebo also meet key secondary endpoint demonstrate highly statistically significant improvement rbc transfusion independence least consecutive week first week study also achieve modify hematologic improvement erythroid iwg mhi meaningful secondary endpoint datum medalist be submit future medical meeting base result company expect file submission regulatory submission be plan unite state europe first half approve candidate be boost company revenue company also plan evaluate esa naïve low intermediate risk mds patient phase iii command study year date share celgene decline compare industry decline celgene corporation price celgene corporation price celgene corporation quote zack rank stock considercelgene carry zack rank hold better rank stock same space be aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report aeglea ani pharmaceutical carry zack rank buy see complete list today zack rank stock here aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3110,CELG,sanofi sny free report announce have finalize negotiation private equity firm advent international sell zentiva sanofi generic business unit europe company have sign share purchase agreement worth euro signing share purchase agreement closure transaction be now subject approval relevant regulatory authority approval be expect fourth quarter sale zentiva be part sanofi plan streamline business discuss strategic roadmap however company continue generic business other part world share sanofi have lose so far year compare industry decrease sanofi several other large pharma company be shift focus high growth business biotechnology rare disease drug pharma sector be face pricing pressure regulator well rise competition many drug however rare disease drug command higher price due lower competition well rarity severity disease expect sanofi use proceed acquire biotechs boost pipeline fact company acquire bioverativ ablynx earlier year total cost add hemophilia treatment rare bleed disorder candidate pipeline moreover sanofi strengthen consumer healthcare swap animal health business boehringer ingelheim consumer healthcare business early remind investor other big pharma company be also lookout biotechs boost pipeline part consolidation business novartis ag nvs free report celgene corporation celg free report be other company announce acquisition deal year expect few other follow suit glaxosmithkline gsk free report streamline business transfer rare disease gene therapy portfolio private biotech orchard therapeutic sanofi price sanofi price sanofi quotesanofi currently carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3111,CELG,have be pretty hum first half biotech sector nasdaq biotechnology index nbi have lose so far performance biotech bigwig have be affected slowdown growth key drug competitive pressure continue impact sale nevertheless new drug approval boost investor sentiment key approval so far year include gilead science gild free report hiv regimen biktarvy vertex pharmaceutical symdeko tezacaftor ivacaftor ivacaftor treatment cystic fibrosis cf amgen aimoviq treatment migraine biomarin palynziq treatment other approval drug boost respective company top line few be struggle decline sale legacy drug increase amerger acquisition picked pace sector slowdown mature product have force company celgene celg free report eye lucrative acquisition bolster pipeline celgene acquire juno therapeutic gain traction promising car space february company acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline alexion acquire sweden base wilson therapeutic add late stage candidate wtx pipeline be currently phase iii treatment wilson disease rare genetic disorder most recently akebia therapeutic inc keryx inc announce merger agreement company combine stock merger expect many more such deal latter half well lie ahead medical biom genetic sub industry carry zack industry rank place bottom zack industry issue drug pricing threat biosimilar loom large healthcare sector large expect better performance second half new drug approval label expansion exist high profile drug pipeline progress grow demand drug especially rare treat disease age population increase health care spending be factor positively impact performance choiceshere list few biotech stock backed zack rank strong buy buy increase share price look fairly place good run second half amgen inc amgn free report be lead biotech company world amgen newer drug prolium xgeva blincyto vectibix kyproli be perform well recent approval migraine candidate aimovig be huge boost biosimilar portfolio look solid too approve product amjevita mvasi deep pipeline amgen key drug be face biosimilar competition expect newer drug offset decline company have already undertake restructure plan lower cost aid bottom line amgen share have gain so far year decrease register industry amgen carry zack rank see complete list today zack rank stock here athersys inc athx free report be primarily focuse regenerative medicine company patented proprietary allogeneic stem cell product multistem cell therapy be lead platform product be currently advanced stage clinical development treat neurological condition cardiovascular disease inflammatory immune disorder certain pulmonary condition other condition current standard care be limit inadequate many patient particularly critical care segment stem cell therapy have gain lot investor attention late company such candidate be spotlight athersys carry zack rank share company have gain year so far industry decline celsion corporation clsn free report be company prospect look good company be focuse develop portfolio innovative cancer treatment include direct chemotherapy immunotherapy rna dna base therapy pipeline progress have be encourage so far thermodox company lead program be proprietary heat activate liposomal encapsulation doxorubicin be currently phase iii development treatment primary liver cancer other candidate pipeline include gen dna base immunotherapy localize treatment ovarian brain cancer celsion have platform technology development novel nucleic acid base immunotherapy other cancer dna rna therapy immunotherapy hold lot potential now company impressive pipeline progress be big positive investor celsion carry zack rank share company have return year so far industry decline aeglea biotherapeutic inc agle free report be clinical stage biotechnology company focus innovative human enzyme therapeutic patient suffering rare genetic disease cancer lead experimental therapy pegzilarginase be be evaluate treatment deficiency monotherapy arginine dependent cancer combination immune checkpoint inhibitor keytruda small cell lung cancer company be also develop pipeline additional product candidate target key amino acid other metabolite include homocysteine oxidized form homocystine target rare genetic disease well cysteine oxidized form cystine methionine cancer indication aeglea carry zack rank share company have return year so far industry decline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3112,CELG,agio pharmaceutical inc agio free report have enter exclusive collaboration license agreement china cstone pharmaceutical develop commercialize pipeline candidate tibsovo ivosidenib ag mainland china hong kong macau taiwan territory leukemia indication term agreement agio receive upfront payment be eligible receive regulatory sale base milestone payment agio retain right tibsovo ivosidenib rest world cstone pharmaceutical lead development hematologic solid tumor indication territory initial focus acute myeloid leukemia aml tibsovo be study monotherapy combination other cancer drug notably last december agio submit new drug application nda fda tibsovo ivosidenib have be develop treat patient relapse refractory acute myeloid leukemia aml idh mutation subsequently february fda accept nda priority review give indication fda have set prescription drug user fee act pdufa action date aug regulatory filing candidate eu be expect fourth quarter same indication ivosidenib be currently be evaluate phase iii study front line aml patient idh mutant positive advanced remind investor agio be also conduct phase ii trial combination celgene celg free report vidaza treatment newly diagnosed aml patient not eligible intensive chemotherapy fda grant orphan drug designation ivosidenib treat aml patient share agio have surge year date outperform industry increase agio currently carry zack rank hold better rank stock same sector include crispr therapeutic ag crsp free report genomic health inc ghdx free report sporting zack rank strong buy see complete list today zack rank stock herecrispr therapeutic loss share estimate have be narrow last day stock have sky-rocket year date genomic health earning estimate have be revise upward past day stock have soar so far hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3113,CELG,drug stock value trap opportunity tracey top stock pick health service industry episode roundup podcast zack comwelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick recently investor stocktwit twitter have be ask drug stock look valuation see many be dirt cheap trading single digit es problem be street hate make perfect value investor retail energy stock be hate last several year too have stage big turnaround drug stock be next big turnaround success story definition value trapremember value trap be stock look cheap base basic value fundamental ratio doesn company trading earning sometimes reason cheapness investor have look value fundamental earning be rise fall rise earning low tell something right be go company earning decline be sign company have lose way value stock trap gilead science gild free report have forward just share be last year have gain time be earning expect do biogen biib free report be trading forward year date share be ve gain prior year estimate have be cut last day be earning growth celgene celg free report have take beating year share fall year date now trading forward just cheap be trap lannett lci free report be cheapest group have forward only take chance share be year date have fall prior year valeant vrx free report have have problem last few year share have rebound be compare return also cheap forward just be bottom earning decline be lot category healthcare sector include insurer hospital device manufacturer staffing other drug company have be hit especially hard just re cheap however doesn mean re good buy investor need do homework value stock trap find week podcast wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3114,CELG,biotech major amgen inc amgn free report gain fda approval include positive overall survival datum multiple myeloma late stage aspire study kyproli label final datum phase iii aspire study present july last year show triple combination regimen kyproli significantly improve overall survival os patient relapse refractory multiple myeloma overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli celgene celg free report revlimid lenalidomide dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd datum also show krd reduce risk death compare rd kyproli proteasome inhibitor be already approve use combination revlimid dexamethasone patient relapse multiple myeloma overall survival datum help drive usage boost sale amgen share have gain so far year decrease register industry similar application be also review eu april committee medicinal product human use chmp european medicine agency ema grant positive opinion recommend inclusion os datum aspire study label kyproli early amgen gain fda approval include overall survival datum head head endeavor study label approval include os result aspire study kyproli label now include os datum phase iii study drive sale drug future quarters kyproli have become key revenue driver amgen drug record sale first quarter represent growth year year drive increase demand robust uptake outside market kyproli represent significant commercial potential sale be likely be drive launch additional country expansion additional indication longer duration treatment amgen also have collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma amgen currently carry zack rank hold better rank biotech stock be biomarin pharmaceutical inc bmrn free report zack rank buy see complete list today zack rank strong buy stock here biomarin earning share estimate increase last day average earning surprise trail quarters be company share have rise year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3115,CELG,alexion pharmaceutical inc alxn free report announce partnership complement pharma co develop preclinical complement inhibitor cp disorder cp be humanize monoclonal antibody preclinical stage bound circulation inhibit function body prevent mac formation periphery central nervous system term partnershipper term alexion complement pharma collaborate development program cp complement pharma be responsible conduct preclinical phase study well manufacturing cp exchange alexion provide complement pharma milestone dependent payment phase ib development phased agreement extend completion phase ib development moreover alexion have option acquire complement pharma term agreement rationale be look diversify portfolio key growth driver soliris soliris be approve treatment severe ultra rare disorder result chronic uncontrolled activation complement component immune system paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris inhibitor have demonstrated significant impact inhibition have various disease cause uncontrolled complement activation company plan use expertise potentially treat additional disease target different component complement system company other pipeline candidate alxn be innovative long act inhibitor work inhibit protein terminal complement cascade takewhile underlie growth soliris have be robust alexion be look develop pipeline reduce dependence former partnership complement pharma be step same direction also augment alexion franchise earlier alexion announce acquire sweden base wilson therapeutic acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder candidate be first class oral copper bound agent unique mechanism action ability access bind copper serum promote removal liver company also plan use halozyme halo free report enhanze drug delivery technology develop next generation subcutaneous formulation alxn potentially further extend dose interval once week once month alexion share have gain last month compare industry decline late quite few company pharma biotech sector be look diversify bolster portfolio pipeline acquisition collaboration celgene celg free report recently acquire juno therapeutic gain traction promising car space sanofi sny free report acquire bioverativ inc focus therapy hemophilia other rare blood disorder zack rankalexion currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3116,CELG,investor biotech sector be glue last week highly await annual meeting american society clinical oncology asco overshadowed usual regulatory other update space meeting hold chicago jun jun provide company platform showcase datum scientist physician investment community other focus be mainly asco datum company biogen biib free report vertex vrtx free report remain limelight pipeline update recap important story biogen eisai report encourage datum elenbecestat biogen partner eisai announce encourage result alzheimer candidate elenbecestat bace inhibitor phase ii study study study be multicenter randomize double blind placebo controlled parallel group month study patient mild cognitive impairment mci due alzheimer disease mild moderate dementia due alzheimer disease confirm amyloid pathology pet positron emission tomography screening patient be randomize treatment arm receive elenbecestat mg placebo daily more half patient elenbecestat mg mg arm be switch mg arm month more datum show elenbecestat be generally safe well tolerate result demonstrated statistically significant difference amyloid beta aβ level brain measure amyloid pet suggest delay clinical symptom decline exploratory endpoint eisai biogen be jointly develop elenbecestat march company be currently conduct global phase iii study mission ad early alzheimer disease biogen currently carry zack rank hold see complete list today zack rank strong buy stock here vertex crispr sickle cell disease candidate put hold vertex pharmaceutical incorporate crispr therapeutic announce fda have place clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question raise fda company have submit ind fda april support plan initiation phase ii trial unite state adult patient sickle cell disease ctx be experimental gene edit autologous hematopoietic stem cell therapy be also be evaluate patient suffering thalassemia sickle cell disease fda clinical hold company plan initiate phase ii trial ctx europe adult patient transfusion dependent thalassemia crispr vertex equally share research development cost profit worldwide ctx read more vertex crispr sickle disease candidate put hold fda sarepta get negative chmp opinion exondys sarepta therapeutic inc srpt free report announce committee medicinal product human use chmp european medicine agency ema have adopt negative opinion duchenne muscular dystrophy dmd candidate exondys eteplirsen negative opinion be expect follow oral explanation trend vote consequently sarepta request re examination opinion result assignment new rapporteur co rapporteur additionally sarepta request scientific advisory group sag dmd be call turn allow neuromuscular specialist provide expert guidance insight other thing validity external control used importance certain functional endpoint re examination be complete end finally look asco result celgene celg free report have multiple presentation oncology drug revlimid pomalyst other experimental therapy american society clinical oncology asco annual meeting chicago il result transcend study experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl be encourage read more celgene present datum car therapy revlimid pomalyst regeneron regn free report partner sanofi also announce datum trial evaluate cemiplimab advanced cutaneous squamous cell carcinoma asco datum study show patient treat cemiplimab experience robust tumor effect cemiplimab treat patient show response rate median observed time response month datum cut date gilead gild free report kite also announce result ongoing phase study asco show clinical response be observed investigational cell receptor tcr cell therapy target human papillomavirus type hpv solid tumor cancer cause hpv meanwhile gilead have also collaborate hookipa biotech ag obtain exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv gilead partner galapago nv also announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week amgen amgn free report also announce result phase iii trial asco show kyproli administer once weekly mg dexamethasone achieve superior progression free survival pfs overall response rate orr compare twice weekly kyprolisat mg dexamethasone twice weekly kd patient relapse refractory multiple myeloma separately share amgen be fda approve biosimilar blockbuster drug neulasta biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gain past month celgene have lose alexion have gain see last biotech stock roundup here biotech stock roundup gild epclusa china approval bmrn palynziq fda nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3117,CELG,world cancer research be change fast space be see huge development company be take great stride treat variety cancer cancer research be definitely exciting area investor keep close watch come year be disease be lead cause morbidity mortality world precede only heart disease day asco conference chicago be basically most important annual cancer research event conclude yesterday conference featured clinical update several company latest development treat disease merck mrk free report steal limelight asco present datum several cancer study pd inhibitor keytruda datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be difficult treat lung cancer patient population datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector context mention roche rhhby free report also present datum similar late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone come back merck company also present datum pivotal lung cancer study keynote evaluate keytruda monotherapy first line nsclc patient pd expression least study also show treatment keytruda lead improve survival meanwhile year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc merck partner astrazeneca also present positive lynparza combo datum breast cancer share merck have go more friday jun asco strength nektar therapeutic nktr free report be biggest loser asco nektar partner bristol myer bmy free report present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result fall nektar stock jun be probably worst performance index member last year read more nektar bristol myer present datum cancer study merck bristol myer nektar currently have zack rank hold see complete list today zack rank strong buy stock here bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression celgene celg free report partner bluebird bio present early stage datum car cell therapy bb patient late stage relapse refractory multiple myeloma study show median pfs month heavily pre treat patient population datum do not impress investor celgene also present datum car therapy liso ce jcar acquire acquisition juno earlier year datum show month patient relapse refractory aggressive cell hodgkin lymphoma nhl remain remission maintain complete response read more celgene present datum car therapy revlimid pomalyst novartis nvs free report announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna abbvie abbv free report present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer amgen astrazeneca also make cancer datum presentation meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3118,CELG,celgene corporation celg free report present datum oncology drug revlimid pomalyst other experimental therapy presentation american society clinical oncology asco annual meeting chicago il celgene announce encourage update month safety efficacy datum open label multicenter phase study transcend nhl experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl asco transcend be be conduct determine safety pharmacokinetic antitumor activity liso cel adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal cell lymphoma follicular lymphoma grade mantle cell lymphoma base cutoff date patient remain remission maintain complete response cr cohort durability response month be evaluate dose level range car cell patient cr remain cr datum cut datum demonstrate potential candidate patient dlbcl have relapse be refractory prior treatment concurrently celgene also announce additional result phase iii randomize open label international study relevance asco study be conduct partnership lymphoma academic research organisation lysarc study evaluate revlimid roche rhhby free report rituxan rituximab follow maintenance investigational regimen compare standard care treatment rituximab chemotherapy follow rituximab maintenance patient previously untreated follicular lymphoma result show treatment chemotherapy free regimen offer numerically similar efficacy result primary endpoint progression free survival pfs complete response unconfirmed complete response cr cru week different safety profile treatment conventional chemo standard celgene have earlier report study do not achieve primary endpoint superior pfs cr cru company now await result augment study be evaluate important regimen previously treat patient indolent lymphomas earlier celgene partner bluebird bio inc blue free report announce encourage update result ongoing open label phase study crb bb experimental cell maturation antigen bcma car cell therapy patient late stage relapse refractory multiple myeloma study be evaluate preliminary safety efficacy bb bcma car cell therapy patient relapse refractory multiple myeloma patient study be heavily pre treat median prior myeloma treatment regimen min max dose escalation cohort prior regimen min max dose expansion cohort study result show response be dose related observed low high bcma expression level median progression free survival pfs estimate patient dose escalation phase treat active dose be month patient receive car cell have median pfs month remind investor bb have be grant breakthrough therapy designation unite state prime eligibility ema addition celgene have also sponsored open label single arm pivotal phase ii study karmma be currently recruit north america europe evaluate bb further patient relapse refractory multiple myeloma nct moreover celgene also present positive datum phase iii randomize open label study optimismm experimental combination regimen pomalyst bortezomib dexamethasone patient relapse refractory multiple myeloma rrmm have receive least prior treatment include lenalidomide asco trial evaluate efficacy safety pomalyst imnovid pomalidomide bortezomib low dose dexamethasone pvd versus bortezomib low dose dexamethasone vd patient early rrmm study datum show treatment pvd result significantly improve pfs earlier deeper more durable response patient compare vd treatment study meet primary endpoint pomalyst combination dexamethasone be indicated patient multiple myeloma have receive least prior therapy celgene be desperately look revamp portfolio due series setback last few month celgene stock have lose last month compare industry decline celgene suffer setback receive refusal file letter fda regard new drug application nda ozanimod relapse multiple sclerosis rm moreover threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition celgene be look new deal acquisition give lacklustre juno acquisition be same track celgene announce global collaboration prothena prta free report march develop new therapy broad range disease primarily focuse protein implicate pathogenesis several disease include tau tdp undisclosed target zack rankcelgene be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3119,CELG,spite strong start pharma biotech industry be struggle currently presumably due shift focus lower high drug price faster approval generic moreover quite few negative pipeline regulatory update announce year so far have probably have unfavorable impact industry however expect industry turn year progress demand drug be rise worldwide due increase ailing elderly population frequent approval new drug well line extension already market drug increase healthcare spending moreover reduction tax time low tax window cash repatriation have boost cash position large pharma company have lead increase merger acquisition activity boost innovation capital build biotech industry price tag propose acquisition shire plc shpg free report japanese firm takeda be biggest deal industry earlier year have see sanofi sny free report celgene corporation celg free report acquire smaller biotech company impax laboratory merged amneal other large pharma company be also lookout acquisition target large cap give current dampening mood focus large cap company lower portfolio risk putt money large cap company reduce risk due diversify portfolio large cash base moreover company stability dividend payment provide safety cushion portfolio moreover flat downtrend market be better focus specific stock large cap also give high return be less risky small mid cap however large cap pharma industry be so far year have rise large cap industry rank top half zack industry list mentioned stock have rise year so far outperform large cap pharma industry let discuss factor drive stock add portfolio astrazeneca azn free report share have gain so far year back several regulatory approval successful study result year company lynparza become first parp inhibitor be approve ovarian cancer fda approve label expansion metastatic breast cancer cancer drug imfinzi label be expand include advanced small cell lung cancer nsclc indication tagrisso eligible patient population be expand recently be now approve treat first line nsclc egfr mutation apart cancer drug astrazeneca asthma drug fasenra receive approval europe severe eosinophilic asthma moreover company add new drug portfolio approval lokelma formerly know zs triple combination therapy pt treatment chronic obstructive pulmonary disease copd significantly improve several lung function compare dual combination therapy datum late stage krono study approval new drug well line extension be likely boost company top line future quarters addition regulatory application seek label expansion forxiga oral adjunct treatment insulin adult type diabetes be accept review march europe thus expect stock momentum continue however negative regulatory update datum readout impact stock unfavorably key be final overall survival datum mystic study have already be delay merck co inc mrk free report stock have gain so far year backed encourage datum several clinical study evaluate keytruda well label expansion drug keytruda receive approval treat urothelial carcinoma japan moreover label expansion advanced cervical cancer be review unite state several other regulatory decision be pending unite state well europe drug have show encourage development clinical study keytruda significantly improve recurrence free survival rfs melanoma patient overall survival os nsclc patient monotherapy combination eli lilly alimta keytruda improve overall survival os progression free survival pfs first line nsclc positive datum readout increase probability keytruda label expansion moreover datum readout few clinical study evaluate keytruda include pivotal lung cancer study present annual meeting american society clinical oncology asco chicago be also encourage apart keytruda merck cancer drug lenvima be approve japan label expansion first line hepatocellular carcinoma hcc type liver cancer moreover label expansion astrazeneca lynparza breast cancer also boost merck revenue latter share development cost well sale astrazeneca meanwhile merck immunotherapy pipeline cancer treatment be expect get boost completion acquisition australian firm viralytic limit second quarter expect growth new drug continue offset loss sale certain product due loss market exclusivity drive company share higher go forward glaxosmithkline plc gsk free report influenza vaccine get approval label expansion infant month older unite state europe hiv treatment juluca be approve europe moreover company shingle vaccine near approval europe january committee medicinal product human use adopt positive opinion marketing authorization application fda approve label expansion asthma therapy arnuity ellipta maintenance treatment pediatric patient age year older moreover approval new product trelegy ellipta shingrix juluca quick succession unite state europe last year early year boost company top line drug uptake be encourage addition agreement acquire novartis nvs free report stake consumer healthcare jv be likely strengthen competitive position stock have rally so far year astrazeneca merck glaxo be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3120,CELG,have be month last earning report celgene corporation celg free report share have lose time frame recent negative trend continue lead next earning release be celg due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst celgene earning sale beat revlimid strengthcelgene report encourage first quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid revlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state international market growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale benefit buy pattern pomalyst imnovid come sale be drive increase volume due increase market share duration otezla sale be quarter sale unite state be primarily volume drive due increase demand improve access pull contract health plan sale international market be drive primarily increase adoption key ex market other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due higher spending related drug discovery clinical trial activity adjust selling general administrative expense decrease pipeline updatecelgene acquire acquire juno therapeutic inc approximately march february company also acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline celgene announce global collaboration prothena march develop new therapy broad range disease primarily focuse protein implicate pathogenesis several disease include tau tdp undisclosed target celgene partner bluebird bio opted co develop co promote bb experimental bcma car cell therapy treatment patient rrmm unite state march company have originally enter broad global strategic research collaboration develop commercialize novel therapy oncology include bb agreement be amend however celgene suffer setback receive refusal file letter fda regard new drug application nda ozanimod relapse multiple sclerosis rm celegne now plan resubmit nda first quarter follow type meeting fda early april company also plan submit marketing authorization application maa ozanimod rm first quarter outlook updatedcelgene now anticipate earning share compare earlier estimate zack consensus estimate earning be share net revenue be now estimate high end previously project range zack consensus estimate same be peg number include impact dilution juno acquisition revlimid sale be now project estimate earlier abraxane sale be estimate be pomalyst revenue be now project previous projection otezla sale continue be project have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower celgene corporation price consensus celgene corporation price consensus celgene corporation quotevgm scoresat time celg have poor growth score however momentum be do lot better charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor momentum investor outlookestimate have be broadly trend upward stock magnitude revision look promising notably celg have zack rank hold expect line return stock next few month
3121,CELG,drug sector be strong start have struggle thereafter probably market instability few negative update pipeline regulatory front also slowdown sale most high profile older drug courtesy payer competitive pressure brand generic drug be concern sector moreover concern pressure drug price continue cloud share pharma biotech company drug pricing have be spotlight once again month president donald trump announce plan lower prescription drug cost layer vision increase competition lower consumer pocket cost drug create incentive lower list price cut regulatory burden ask fda make compulsory drug company display price tv advertisement biotech industry have decline year so far underperform rise same time frame nonetheless ace investor know drug biotech sector have be best perform industry stock market be widely expect biotech drug sector rebound year progress believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result frequent fda approval grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit importantly merger acquisition activity be ramp tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity year biggest deal announce year be takeda propose acquisition shire deal be expect close first half sanofi sny free report celgene celg free report have already snap company impax laboratory amneal merged form new company amneal pharmaceutical inc amrx needless say biggy pfizer merck lilly other have consistently announce co development deal small biotech acquisition year outlook optimistic rest year here have highlighted stock prove be good buy stock carry zack rank strong buy buy have see share price earning estimate rise year so far see complete list today zack rank stock here crispr therapeutic ag crsp free report year date basis share crispr therapeutic have gain meanwhile loss estimate swiss gene editing company narrow past day crispr therapeutic sport zack rank biomarin pharmaceutical inc bmrn free report biomarin earning estimate rise past day share california base biotech make rare disease drug have rise year so far zack rank stock be expect record sale growth year next yearathersys inc athx free report athersys carry zack rank loss estimate cleveland base company narrow last day sale growth year biotech stock be expect be athersys share have return year so far aeglea biotherapeutic inc agle free report loss estimate rank stock narrow last day sale growth texas base biotech be expect be year aeglea share have return year so far ligand pharmaceutical lgnd free report rank stock earning share estimate increase last day california base company share have rally year date company be expect record sale growth year next year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3122,CELG,expect pfizer inc pfe free report beat expectation report first quarter result market open last quarter company deliver positive earning surprise pharma giant have strong record earning surprise company earning surpass expectation last quarters deliver average positive surprise pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotepfizer share have rise year so far decrease industry factor playin innovative health ih segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner contribute top line meaningfully zack consensus estimate sale ibrance worldwide lyrica ih xeljanz chantix be respectively essential health biosimilar emerge market be expect support sale however loss exclusivity associate generic competition product primarily pristiq unite state continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition zack consensus estimate sale enbrel be prevnar prevenar vaccine franchise continue see lower sale unite state lower demand generic competition continue hurt sale viagra pfizer be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue expect supply shortage continue hurt sale pfizer expect cut sterile injectable shortage new cancer drug bavencio avelumab besponsa inotuzumab ozogamicin mylotarg be likely contribute overall sale time xeljanz sutent bosulif be approve line extension fourth quarter new product line extension be boost sale bottom line be expect be drive cost saving share buyback also expect management provide update initial launch uptake pfizer partner merck mrk free report newly approve oral sglt inhibitor steglatro ertugliflozin tablet apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large health care stock worth consider model have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3123,CELG,performance drug industry first quarter have be encourage quite few company beating earning well revenue estimate overall investor sentiment pharma biotech stock have improve late investor be focuse more fundamental issue drug pricing drug pricing continue major deterrent thank government increase emphasis make drug affordable new drug approval label expansion exist drug help company maintain momentum year see number drug rhopressa tymlos ozempic vyzulta siliq trulance hemlibra other get approval lutathera ilumya symdeko biktarvy erleada have already be approve investor be expect keep focus same merger acquisition remain key area investor focus be pretty hum front just few key deal be expect see surge primarily due lower tax rate take clue gilead science gild free report acquisition kite pharma celgene celg free report recently acquire juno therapeutic gain traction promising car space sanofi sny free report acquire bioverativ inc focus therapy hemophilia other rare blood disorder company have also obtain trust clearance connection previously announce acquisition ablynx strong pipeline innovative treatment impressive result grow demand drug especially rare treat disease age population increase health care spending support growth sector caution be be exercise pick stock investing here be few sell rate stock be strictly avoid now valeant pharmaceutical international inc vrx free report canada base specialty pharma company valeant have be trouble water quite time now valeant guidance be disappointing tumultuous period valeant start rebuild process ceo joseph papa company have reduce total debt approximately end first quarter however dermatology business remain challenge be expect decline compare quite few drug be face generic competition hence be company turn around management have project company currently carry zack rank sell valeant share have decline last month compare industry fall endo international plc endp free report ireland base endo be global specialty pharmaceutical company focuse generic brand pharmaceutical endo guidance be way expectation generic business be tremendous pressure due loss marketing exclusivity first file product ezetimibe tablet quetiapine tablet first half brand pharmaceutical business be impact continue generic competition establish product product divestiture cease shipment opana be expect continue further endo withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june company divest core asset such belbuca restructure pain franchise focus particularly specialty brand business however zack rank strong sell company be expect face challenge business condition endo share have lose last month industry decline aerie pharmaceutical inc aeri free report irvine base aerie pharmaceutical focus development eye disease therapy include glaucoma other eye disease aerie receive significant boost recent approval lead drug rhopressa lower elevated intraocular pressure patient open angle glaucoma ocular hypertension however rhopressa face stiff competition establish brand generic pharmaceutical company such novartis simbrinza travtan allergan lumigan well other smaller biotechnology pharmaceutical company valeant vyzulta be recently approve open angle glaucoma ocular hypertension rhopressa face tough time gain market share due competition product hence advise investor steer clear zack rank stock time be aerie share have fall last month industry decline see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3124,CELG,be approach end first quarter let ass quarter unfold drug biotech sector year begin strong note drug biotech sector particularly expectation increase activity sanofi sny free report celgene celg free report have already announce deal also pfizer pfe free report be aggressively lookout buyer consumer healthcare unit british firm glaxo gsk free report reckitt benckiser group pull discussion solid run first month first quarter drug biotech sector struggle march probably broader market pressure few negative update pipeline regulatory front large cap pharma industry have decline year so far biotech industry have decline same time frame have underperform fall same time frame however please note first month year sector record gain so do however decline month march put break momentum abbvie rova fall short expectation key lung cancer study dermira acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint study celgene be issue refusal file letter fda ozanimod multiple sclerosis nda biogen partner abbvie announce voluntary decision withdraw multiple sclerosis drug zinbryta worldwide market due risk liver injury orexigen therapeutic meanwhile file bankruptcy solid bioscience mid stage study lead duchenne muscular dystrophy candidate sgt be put clinical hold protagonist therapeutic announce discontinuation mid stage study key ulcerative colitis treatment be recovery card be widely expect biotech drug sector rebound year progress believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit outlook optimistic rest year here highlight stock prove be good buy stock carry zack rank strong buy buy have see share price earning estimate rise year see complete list today zack rank stock here glaxoafter underperform broader industry glaxo share have picked year glaxo stock have rise year so far meanwhile estimate rise respectively past day zack rank buy stock be expect record sale growth year next yearadverum biotechnology advm free report adverum biotechnology carry zack rank buy loss estimate company narrow last day sale growth year biotech stock be expect be adverum share have return year so far ligand pharmaceutical lgnd free report rank stock have rise year earning estimate rise respectively past day company be expect record sale growth year next year lundbeck hluyy free report year date basis lundbeck share have gain meanwhile earning estimate increase past day rank stock today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3125,CELG,key highlight week include alexion gain positive datum pnh candidate arena surge ulcerative drug datum solid bioscience stock suffering crash prothena team celgene recap week most important storiesalexion positive datum pnh candidate share alexion pharmaceutical alxn free report gain company report positive datum candidate alxn pivotal phase iii study phase iii randomize open label active controlled multinational multicenter study evaluate efficacy safety alxn compare alexion lead drug soliris administer intravenous infusion adult patient paroxysmal nocturnal hemoglobinurium pnh be naïve complement inhibitor treatment alxn demonstrated inferiority soliris complement inhibitor treatment naïve patient pnh base co primary endpoint transfusion avoidance normalization lactate dehydrogenase ldh level addition study also demonstrated inferiority key secondary endpoint percentage change baseline ldh level change baseline quality life assessed functional assessment chronic illness therapy facit fatigue scale proportion patient breakthrough hemolysis proportion patient stabilize hemoglobin level alexion plan submit alxn pnh unite state eu japan second half read more alexion gain positive date lead candidate arena pharma gain positive result ulcerative colitis candidate arena pharmaceutical arna free report stock gain company selective sphingosine phosphate receptor modulator candidate etrasimod meet primary endpoint phase ii study oasis treatment ulcerative colitis trial meet primary secondary endpoint statistical significance patient receive mg dose etrasimod week clinical remission cr be achieve patient etrasimod versus placebo base component mayo clinic scale moreover patient achieve endoscopic improvement compare placebo candidate achieve cr patient compare placebo base point mayo clinic scale base datum arena be plan initiate phase iii program further development etrasimod treatment uc read more arena etrasimod meet phase ii colitis study goal solid bioscience plummet result lead drug share solid bioscience sldb free report plummet significantly fda notified company phase ii trial ignite dmd lead candidate sgt have be put clinical hold sgt be be evaluate underlie genetic cause duchenne muscular dystrophy dmd mutation gene result absence absence protein clinical hold be place patient be hospitalize due laboratory finding include decrease platelet count follow reduction red blood cell count evidence complement activation result enrolment dose have be stop phase iii study read more solid bioscience hit clinical hold lead drug regeneron eylea report positive datum proliferative diabetic retinopathy trial regeneron pharmaceutical regn free report announce phase iii trial panorama evaluate lead drug eylea moderately severe severe proliferative diabetic retinopathy npdr meet week primary endpoint result show patient treat eylea experience step greater improvement baseline diabetic retinopathy severity scale week compare patient receive sham injection positive datum trial form basis supplemental biologic license application be expect be submit fda later eylea be already approve treatment neovascular age related macular degeneration wet amd diabetic macular edema dme macular edema follow retinal vein occlusion include macular edema follow central retinal vein occlusion macular edema follow branch retinal vein occlusion potential label expansion further boost sale read more regeneron eylea hit week primary endpoint study regeneron be zack rank strong buy stock see complete list today zack rank stock here prothena gain deal celgene share prothena corporation prta free report moved follow news global collaboration celgene corporation celg free report develop new therapy broad range disease multus year agreementis focuse protein implicate pathogenesis several disease include tau tdp undisclosed target celgene own right license clinical candidate unite state investigational new drug ind filing exercise also have right expand license global right completion phase consequently celgene be responsible funding further global clinical development exchange prothena receive upfront payment celgene also make equity investment prothena subscribe approximately ordinary share share prothena be also eligible regulatory commercial milestone license program prothena also receive additional royalty net sale result market product read more prothena rally multus year collaboration celgene biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock amgen gilead lose last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup regn cut praluent price orex file bankruptcy next biotech world stay tune more regulatory pipeline update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3126,CELG,week focus be datum present annual conference american society hematology ash december company emerge winner other lose ground disappointing datum recap week most important storiesash roundup several company be ash datum approve pipeline drug company soar datum other be hit disappointing result company score be bluebird blue free report partner celgene celg free report announce update result ongoing phase study bb bcma car cell therapy patient late stage relapse refractory multiple myeloma company say overall response rate orr be patient active dose cohort complete response cr rate observed patient active dose cohort bluebird share shot celgene gain read more bluebird share jump strong datum car therapy bluebird be zack rank hold stock see complete list today zack rank strong buy stock here kite gilead gild free report company be also ash update result ongoing phase ii zuma study kte car cell therapy treatment adult patient relapse refractory acute lymphoblastic leukemia high rate response be observed patient kte achieve complete tumor remission long term datum be also present yescarta pivotal zuma study patient refractory large cell lymphoma patient continue respond therapy include complete remission median follow month yescarta be approve unite state recently be currently review eu potential approval expect first half read more gilead post update datum car therapy yescarta juno therapeutic major name car category provide additional datum transcend study jcar patient relapse refractory aggressive cell hodgkin lymphoma datum look good share decline reflect investor expectation better result company expect finish submit regulatory application unite state second half approval expect early end read more juno report additional datum car therapy share drop company be hit ash datum be spark therapeutic once free report see share plunge preliminary datum investigational hemophilia treatment spk read more spark therapeutic stock plunge hemophilia therapy datum gilead buy cell design lab strengthen cellular therapy effort gilead announce next acquisition deal come few month company acquire kite pharma approximately time round gilead be acquire cell design lab inc deal expect add new technology platform gilead portfolio gilead shell include upfront payment approximately additional payment be make occurrence certain event include achievement development approval milestone acquisition gilead be look enhance effort cellular therapy read more gilead science acquire cell design lab vertex select first gene edit treatment crispr collaboration vertex pharmaceutical vrtx free report announce selection ctx first gene edit treatment be co develop co commercialize agreement crispr therapeutic company split cost profit worldwide plan be commence phase ii study europe thalassemia investigational new drug ind application be submit unite state support commencement phase ii study sickle cell disease meanwhile cystic fibrosis cf front vertex say kalydeco meet primary endpoint open label phase iii study child year age cf vertex expect file approval unite state eu patient population first quarter read more vertex kalydeco study successful child age year vertex share be year date compare gain record industry belong repro be acquire allergan repro therapeutic see share gain news be acquire allergan cash payment cent share acquisition be expect close first quarter acquisition allergan be look boost woman health pipeline however repro proellex run trouble program be place partial clinical hold fda ask large pre approval safety datum base support future development biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock celgene gain amgen decline last month biogen be regeneron regn free report lose see last biotech stock roundup here fda nod amgen pcsk inhibitor revance rt datum next biotech world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3127,CELG,juno therapeutic inc partner celgene corporation celg free report announce additional datum phase study transcend lead pipeline candidate jcar lisocabtagene maraleucel treatment patient relapse refractory aggressive hodgkin lymphoma nhl result be present annual meeting american society hematology notably jcar be next generation chimeric antigen receptor high affinity cell car receptor product target cd company present separate datum transcend study full group patient enrolled well core group high risk patient population find multus center transcend trial demonstrated dose level patient aforementioned indication show overall response rate orr complete response cr rate month core group additionally patient show cr month figure be better previous datum orr cr report june moreover safety profile jcar remain impressive only patient experience severe cytokine release syndrome experience severe neurotoxicity be interesting note juno share drop almost follow news release probably investor expect better response rate however share juno have significantly gain value so far year compare favorably industry increase good news be safety efficacy outcome show better overall complete response compare gilead gild free report yescarta novartis nvs free report kymriah cart therapy have recently launch unite state company plan bring jcar market nhl end biologic license application expect be file second half note bluebird bio also announce month follow datum ongoing phase study car therapy candidate bb study be evaluate preliminary safety efficacy bb patient relapse refractory multiple myeloma patient active dose cohort study achieve objective response patient achieve complete response compare cr rate show datum release asco june year juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rankjuno carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3128,CELG,expect abbvie inc abbv free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise share abbvie have marginally outperformed industry so far year stock have decline industry have decrease notably abbvie earning history be quite impressive pharmaceutical company have outpaced estimate last quarters average beat let see thing be shape company quarter factor considerabbvie expect first quarter earning range share revenue be estimate grow mid range operational basis foreign exchange be anticipate gain favorable impact sale period be report company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally zack consensus estimate humira be peg significantly first quarter conference call investor focus also be performance level well label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica stand other drug namely duopa creon be also likely maintain encourage performance soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale affected intense pricing competitive pressure hcv market moreover march abbvie rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line therapy later small cell lung cancer sclc first quarter conference call expect management provide update same notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret secure approval unite state eu canada well japan second half importantly mavyret record global sale last year initial uptake drug have be commendable expect higher sale first quarter well earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp zack consensus estimate be share positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvieha zack rank increase predictive power esp together positive esp chance stock beating estimate upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision other stock warrant lookhere be couple other health care stock worth consider right combination element also surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report be schedule report earning apr company have earning esp zack rank celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank player abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3129,CELG,fourth quarter earning season have crossed halfway mark so far result reflect favorable trend average proportion company beating top bottom line expectation latest earning preview total earning member have release result be year quarter rise revenue beat ratio bottom line be top line be proportion company beating ep revenue estimate be biotech company alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report be expect report number feb let take look biotech company have edge other ahead release however look number let have look biotech industry glance biotech industry be see significant pickup merger acquisition deal late year start celgene celg free report announce plan acquire impact biomedicine company reveal plan acquire juno therapeutic approximately french pharma giant sanofi sny free report also announce buy biopharma company bioverativ january same month sanofi also announce plan acquire belgian biotech company ablynx fourth quarter biotech sector be well poise major player biotech sector biogen biib free report put mixed show report period earning lag estimate sale exceed same however celgene vertex vrtx free report outpaced metric expectation alexion new haven ct base alexion blockbuster drug soliris continue perform well alexion continue identify treat high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory gmg patient be acetylcholine receptor antibody positive drug be approve europe indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly company also announce restructure initiative context alexion plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year alexion track record be excellent have top estimate last quarters average positive earning surprise alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteregeneron regeneron key growth driver eylea be likely continue contribute company top line growth regeneron be work expand eylea label additional indication phase iii study panorama be evaluate eylea treatment moderately severe severe proliferative diabetic retinopathy patient dme phase iii study japan be evaluate neovascular glaucoma label expansion additional indication give eylea access higher patient population increase commercial potential drug apart eylea investor remain focuse uptake new drug kevzara dupixent fda also approve dupixent dupilumab injection treatment adult moderate severe atopic dermatitis initial uptake drug be encourage drug be approve europe also company be also evaluate drug treat asthma adult liberty asthma quest study hence focus be company performance particularly eylea dupixient uptake fourth quarter earning call investor be also expect await update company pipeline earning esp regeneron be company currently carry zack rank sell zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year company performance have be mixed so far last quarters surpass earning estimate occasion miss average positive surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc quoteour takedure fourth quarter alexion price decline compare regeneron fall however alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank strong buy stock here regeneron caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision therefore proprietary model believe alexion be poise better performance upcoming quarter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3130,CELG,acquisition once again remain focus week ablynx agree be acquire sanofi sny free report deal worth approximately seattle genetic sgen free report also announce intention acquire cascadian therapeutic meanwhile earning result be focus abbvie abbv free report report strong quarter provide upbeat outlook recap week most important storiesa look earning result company celgene celg free report abbvie biogen vertex vrtx free report report fourth quarter result last trading session celgene read more celgene earning sale beat solid revlimid vertex top earning well revenue estimate biogen top revenue miss earning read more biogen earning miss sale top view upbeat vertex also announce have select next generation corrector vx vx move late stage development part different triple combination regimen person cystic fibrosis cf last year vertex share be compare gain record industry belong abbvie share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret read more abbvie soar result key takeaway earning call abbvie be zack rank buy stock see complete list today zack rank strong buy stock here ablynx be acquire sanofi belgium base biopharma company ablynx have agree be acquire french pharma giant sanofi price share cash approximately announcement come just few week nordisk have announce interest acquire ablynx deal value approximately ablynx have reject nordisk offer company board say proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity company have more program pipeline nanobody clinical development acquisition be expect close end second quarter read more sanofi buyout spree month buy ablynx bellicum fda clinical hold bellicum pharmaceutical share be almost follow company announcement fda have place clinical hold study be conduct bpx hold be place case encephalopathy be deem possibly connect bpx company say case be complex certain factor prior fail transplant prior history concurrent infection administration rimiducid combination other medication bellicum be now wait receive formal notice fda step need be take resumption study clinical hold not impact ongoing registration study europe seattle genetic boost pipeline cascadian acquisition seattle genetic announce be acquire cascadian therapeutic share cash acquisition slate close first quarter seattle be add tucatinib pipeline tucatinib be investigational oral small molecule tyrosine kinase inhibitor tki be highly selective growth factor receptor be overexpressed several cancer include breast colorectal ovarian gastric candidate be currently pivotal phase ii program metastatic breast cancer complement seattle exist pipeline biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion decline gilead gild free report gain last month biogen be regeneron lose next biotech world watch amgen amgn free report fourth quarter result be market close today read more amgen benefit growth drug earning meanwhile fda be expect issue decision regard label expansion amag pharmaceutical feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3131,CELG,share celgene corporation celg free report surge report fourth quarter earning share surpass zack consensus estimate freeport mcmoran inc fcx free report share gain report fourth quarter earning share surpass zack consensus estimate inc eght free report share increase report fiscal third quarter revenue surpass zack consensus estimate millionshare alaska air group inc alk free report plunge report fourth quarter earning share lower share year quarter
3132,CELG,infinity pharmaceutical inc infi free report provide update lead pipeline candidate ipi also issue financial guidance infinity be currently focuse development lead immuno oncology candidate ipi be orally administer treatment selectively inhibit kinase pi gamma infinity have clinical trial collaboration bristol myer bmy free report evaluate ipi combination latter pd inhibitor opdivo nivolumab patient advanced solid tumor january company have announce achievement development milestone ipi company also plan report datum monotherapy expansion combination dose escalation component company expect announce initial datum combination expansion component phase ib study ipi opdivo second quarter second half infinity expect report more mature clinical datum combination expansion component study include translational insight pair tumor biopsy multiple disease company also announce expansion phase ib study ipi include combination cohort ipi opdivo enroll patient high baseline level myeloid derive suppressor cell ipi represent potentially complementary approach restore tumor immunity combination other immunotherapy such checkpoint inhibitor successfully develop approval ipi provide massive boost infinity portfolio company also provide financial guidance expect end year end cash investment balance range base current operational plan infinity expect exist cash cash equivalent available sale security december be adequate satisfy company capital need first quarter october infinity enter license agreement verastem inc grant exclusive worldwide right develop commercialize oncology candidate duvelisib latter october infinity receive cash payment verastem verastem plan submit new drug application duvelisib first quarter infinity progress candidate have be impressive moreover clinical trial collaboration bristol myer have provide infinity strong partner expertise field immuno oncology further allow infinity expedite development ipi however infinity face stiff competition field immuno oncology company bristol myer astrazeneca azn free report celgene celg free report merck novartis pfizer roche eli lilly other wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3133,CELG,johnson johnson jnj free report fourth quarter result be mixed beat estimate earning miss same sale announce fourth quarter result jan market open expect sale growth accelerate second half year backed higher sale pharmaceutical segment improve performance medical device organically exclude impact acquisition divestiture sale increase operational basis fourth quarter better increase see third quarter first half meanwhile acceleration underlie sale growth pharma segment see third quarter continue fourth quarter pharmaceutical segment sale rise year year fourth quarter also drug medical device giant issue bullish profit outlook estimate adjust earning share range reflect operational growth rate company guidance exceed then zack consensus estimate share positive factor share have decline earning release seem be investor disappointment revenue guidance expect revenue range reflect operational constant currency sale growth range however sale guidance fall slightly short then zack consensus estimate organic sale growth exclude impact acquisition divestiture be expect be range slightly higher see be short record fourth quarter organic sale growth outlook fall short investor expectation result share price drop understand investor concern project decline revenue growth however do believe outlook be conservative consider have history issue cautious outlook especially begin year believe be several tailwind year coax improve projection year progress new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher newly approve product also contribute sale also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year provide top line support launch year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda also several pivotal datum readout regulatory milestone be expect meanwhile pharma segment sale accelerate second half weak first half management seem confident positive trend continue also say call consumer medical device segment continue improve believe new product segment label expansion drug imbruvica darzalex contribution acquisition mainly actelion support top line growth wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3134,CELG,celgene corporation celg free report report encourage fourth quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid celgene corporation price consensus ep surprise celgene corporation price consensus ep surprise celgene corporation quoterevlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane decrease sale decline unite state sale oncology drug pomalyst imnovid come sale be drive increase volume due increase market share duration otezla report sale quarter other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease earlier week celgene announce acquire juno therapeutic inc share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno celgene also announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline december celgene partner bluebird bio blue free report present update datum phase trial evaluate bb patient relapse refractory multiple myeloma rrmm candidate be grant breakthrough therapy designation fda priority medicine eligibility european medicine agency company also initiate karmma trial evaluate bb rrmm be initiate resultssale come beat zack consensus estimate earning share come beat zack consensus estimate outlookcelgene anticipate earning range zack consensus estimate earning be share net revenue be project be range zack consensus estimate same be peg revlimid sale be project abraxane sale be estimate be pomalyst revenue be project otezla sale be now project takecelgene fourth quarter result be encourage company beat sale earning revlimid sale be impressive yet again abraxane sale decline unite state sale otezla have picked too slowdown third quarter celgene stock have decline last month industry loss share company be pre market trading due earning beat celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue celgene be look new deal acquisition give lacklustre announcement juno acquisition be same track note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way zack rankcelgene be zack rank sell stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3135,CELG,share company bluebird bio inc blue free report go almost company partner celgene corporation celg free report announce month follow datum ongoing phase study chimeric antigen receptor cell car therapy candidate bb open label phase crb study be evaluate preliminary safety efficacy bb patient relapse refractory multiple myeloma study also aim identify dose use phase ii study so far year bluebird share have sky-rocket compare industry gain cutoff date oct patient have be enrolled patient dose dose escalation phase study dose cohort patient study be heavily pre treat have fail median prior line patient active dose cohort study achieve objective response patient achieve complete response compare cr rate show datum release asco june year increase cr rate previous update lead increase share price study also show patient evaluable minimal residual disease mrd status be find be mrd negative study do not reach median progression free survival pfs median follow week active dose cohort encourage datum deepen response show bb study bode well candidate approve prove be groundbreaking car therapy multiple myeloma however bluebird competitor juno therapeutic inc release additional datum transcend phase study car candidate jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl transcend trial demonstrated high risk patient population patient achieve overall response rate achieve cr rate month also note company gilead science inc gild free report car therapy yescarta axicabtagene ciloleucel be approve fda october treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication also note novartis breakthrough gene transfer treatment kymriah receive fda approval treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse bluebird bio inc price bluebird bio inc price bluebird bio inc quotezack rank bluebird carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3136,CELG,share bluebird bio blue free report be nearly early morning trading monday investor respond company announcement car candidate bb produce encourage result patient deadly blood cancer presentation american society hematology annual meeting weekend representative bluebird bb co developer celgene corp celg free report reveal patient advanced form multiple myeloma exhibit positive response therapy recent study company also report least study participant be complete responder addition therapy unprecedented efficacy bb display remarkable safety datum latest study be relatively small bluebird celgene plan move therapy larger pivotal stage trial soon company get bb fast track approval pair become third group bring car treatment market car be newly emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell novartis nvs free report kymriah therapy treat lymphoblastic leukemia become first approve car therapy world late august gilead gild free report large cell lymphoma regimen yescarta be approve october gilead acquire yescarta purchase kite pharmaceutical earlier year now bluebird car progress have many investor hopeful be latest takeover target space accord note goldman sachs analyst publish response bluebird recent result firm have emerge attractive acquisition candidate innovative lead lentiviral base gene therapy car cell platform backed positive proof concept datum target large blood disorder beta thalassemia sickle cell disease multiple myeloma goldman raise price target stock new call represent gain friday close additional surge monday open price want more stock market analysis author make sure follow ryan_mcqueeney twitter today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3137,CELG,regeneron regn free report several mid small cap biotech stock report earning result company dynavax dvax free report abbvie abbv free report provide regulatory update recap week most important storiesa look earning result regeneron report strong quarter company surpass earning revenue estimate back eylea sale company raise outlook eylea well read more regeneron beat earning sale raise view immuno oncology focuse company juno read more juno therapeutic loss widen revenue surpass kite also report second quarter result kite have key regulatory event come later year fda expect respond approval status company car treatment axicabtagene ciloleucel nov investigational treatment have be submit review eu well treatment relapse refractory diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl patient be ineligible autologous stem cell transplant regeneron be zack rank strong buy stock see complete list today zack rank stock here dynavax hepatitis vaccine pdufa date push back month dynavax get favorable vote fda advisory panel investigational hepatitis vaccine heplisav be face delay get vaccine approve fda ask detailed information company propose post marketing study treatment advisory panel have vote favor safety datum heplisav have comment design dynavax propose post marketing study base company fda agree more time be need finalize key detail post marketing study result fda action date be push back month nov company still expect launch heplisav early dynavax share be whopping year date significantly outperform industry rally abbvie new hcv treatment get fda nod abbvie week pan genotypic ribavirin free once daily hepatitis virus hcv treatment mavyret gain fda approval use hcv patient cirrhosis be new treatment approval competition hcv market be go heat further accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history company say american be chronically infected hcv mavyret gain eu approval recently fibrogen hit week high ipf drug datum fibrogen fgen free report share shot positive datum company investigational idiopathic pulmonary fibrosis ipf drug pamrevlumab mid stage study well combination safety sub study proprietary first class connective tissue growth factor ctgf antibody be be evaluate fibrotic disease cancer ipf indication represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer approve pamrevlumab bring significant sale fibrogen currently approve ipf drug include esbriet ofev read more do fibrogen stock hit time high today biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene celg free report vertex vrtx free report record minimal gain gilead lose reflect impact approval abbvie new hcv drug last month vertex be see last biotech stock roundup here earning gilead celg more dynavax panel vote next biotech world watch earning report small mid cap biotechs well usual regulatory pipeline update more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3138,CELG,summit nj base celgene corporation celg free report be company focuse discovery development drug target cancer inflammatory disease celgene key growth driver be revlimid company portfolio also include pomalyst imnovid abraxane otezla istodax vidaza thalomid thalidomide however celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid force celgene look acquisition company recently announce acquire juno therapeutic celgene have excellent track record company beating earning estimate last trail quarters last quarter company top estimate overall company have deliver average positive surprise currently celgene have zack rank sell definitely change follow company earning report be just release have highlighted key stat just reveal announcement celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoteearning celgene beat fourth quarter earning company report adjust ep consensus call ep revenue revenue too beat expectation celgene post revenue beating consensus estimate key stat revlimid continue strong performance sale abraxane decline outlook celgene anticipate earning range zack consensus estimate earning be share net revenue be project zack consensus estimate stand pre market trading share be pre market trading check back later full celg earning report later today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3139,CELG,late biotech sector have be thrive slew deal flurry merger sector be always encourage such merger lend control market increase value reduce cost needless say also lead economy scale sharing resource reduce risk owing usage innovative technique well tax advantage buyout biotech space have be hog limelight be juno therapeutic inc celgene corporation celg free report sanofi sny free report bioverativ inc celgene agree buy juno therapeutic cash meanwhile sanofi agree acquire bioverativ french company insist pay cash share purchase meantime courtesy new tax overhaul policy biotech firm have be able repatriate hundred billion dollar strand overseas pay only tax instead current extra cash be used merger acquisition activity president trump business tax plan also benefit biotech company rate be lower be implement year instead be delay lower tax burden be expect boost profit large biotech company read more fancy biotech stock buyout buzz top pick play stellar growth biotech fundsas biotech sector be fire add sound mutual fund have significant exposure say sector seem judicious have thus highlighted fund carry zack mutual fund rank strong buy buy see complete list today zack rank stock here expect fund outperform peer future remember goal zack mutual fund rank be help investor identify potential winner loser most fund rating system zack mutual fund rank be not just focuse past performance also probable success fund question here be investor consider mutual fund reduce transaction cost diversification portfolio several commission charge be associate stock purchase be primarily be parking money mutual fund read more mutual fund advantage disadvantage make investor money franklin biotechnology discovery fbdix free report zack rank fund invest large portion net asset security biotechnology company discovery research firm fund predominantly invest equity security fbdix seek capital appreciation be diversify sector health fund last filing allocate fund major group large growth small growth high yield bond further last filing celgene alexion pharmaceutical incyte pharmaceutical be top holding fbdix franklin biotechnology discovery fund manage franklin temp carry expense ratio less category average moreover fbdix require minimal initial investment fbdix have history positive total return year specifically fund return year benchmark be respectively fidelity select biotechnology fbiox free report zack rank fund invest majority asset security company principally engage research development manufacture distribution various product service process company benefit significantly scientific technological advance biotechnology sector health fund last filing allocate fund major group large growth small growth high yield bond further last filing amgen celgene regeneron pharmaceutical be top holding fbiox fidelity select biotechnology fund manage fidelity carry expense ratio less category average moreover fbiox require minimal initial investment fbiox have history positive total return year specifically fund return year benchmark be respectively want key mutual fund info deliver straight inbox zack free fund newsletter brief top news analysis well top perform mutual fund week get free
3140,CELG,major benchmark hit record high monday senate give consent pass bill end current government shutdown meanwhile biotech sector rally follow major biotech merger deal lead nasdaq higher end record dow also end record territory dow jone industrial average dji increase close rise close tech laden nasdaq composite index close gain fear gauge cboe volatility index vix decrease close total share be trade monday higher last session average share advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue biotech etf surge push nasdaq ishare nasdaq biotechnology etf ibb surge monday follow couple merger deal biotech sector worth billion dollar tout be largest biotech etf ishare nasdaq biotechnology be trading highest level october share juno therapeutic inc sky-rocket monday enter agreement celgene corp celg free report be purchase whopping other deal news bioverativ inc agree purchase sanofi sny free report follow such news share bioverativ rally see complete list today zack rank strong buy stock here development lead broad base gain biotech sector also push nasdaq higher tech laden index surge point end session time high gain nasdaq be further support surge share netflix nflx free report dow post record gain point hit record high major segment end green consumer discretionary share lead advancer energy select sector spdr etf xle consumer discret sel sect spdr etf xly gain respectively dow amassed point finish record close such gain be rather broad base follow senate decision approve bill end government shutdown senate approve bill prevent shutdownon monday senate approve bill paved way ongoing government shutdown end house have already pass month spending bill jan keep government funded feb however bill do not find much favor senate therefore not reach vote mark clear senate senate adjourn further voting final outcome thursday funding keep government funded end saturday lead shutdown shutdown stretched monday lawmaker unite state fail reach resolution issue be due negotiation related immigration discussion bother republican lead congress most sunday stock make headlinesaig buy validus expand reach reinsurance international group inc aig free report have agree buy bermuda base reinsurer validus holding ltd validus deal see light mid read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3141,CELG,buyout speculation related bluebird bio inc blue free report be do round again rumor surface biotech giant celgene corporation celg free report announce deal buy juno therapeutic inc add latter car cancer therapy pipeline fact bluebird share be jan celgene announce deal buy juno remind investor last year gilead science inc gild free report acquire car therapy designer kite pharma back then juno bluebird bio be rumore be hot takeover target car therapy be most recent advanced form treat cancer strengthen body immune system get rid tumor be only approve car therapy date novartis kymriah acute lymphoblastic leukemia gilead yescarta hodgkin lymphoma nhl leave sufficient scope other company bring prospective therapy term celgene juno pharma dealper agreement celgene pay share cash total transaction value be approximately price represent premium close share price juno jan transaction be approve shareholder company be expect close first quarter share juno have shot celgene have go announcement fact past month juno stock have return decline register industry juno therapeutic juno car therapy jcar lisocabtagene maraleucel treat relapse refractory diffuse large cell lymphoma dlbcl most common form nhl boost celgene lymphoma pipeline regulatory approval be be anticipate jcar potential peak sale be expect be approximately datum phase study transcend announce last month demonstrated dose level patient aforementioned indication show overall response rate orr complete response cr rate month core group acquisition also add car candidate jcarh celgene pipeline be be develop multiple myeloma bluebird bio focuscar therapy represent immense potential juncture thereby attract attention big pharmas thus follow acquisition kite pharma juno investor be anticipate buyout offer bluebird have already start rally rumor bluebird be develop cell maturation antigen car cell therapy bb dose range phase study month follow datum announce december demonstrated patient treat bb active dose arm achieve objective response patient achieve complete response encourage datum deepen response show bb study bode well candidate share company be past month candidate be be develop collaboration celgene however acquisition juno celgene be less likely bid bluebird be several other big pharma company large cash pile be interested bluebird celgene juno deal have also lead rally stock other car therapy focuse company include fate therapeutic ziopharm oncology bellicum pharmaceutical bluebird carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3142,CELG,celgene corporation celg free report announce acquire juno therapeutic inc share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno detail transaction be expect close first quarter celgene expect fund transaction combination exist cash new debt acquisition be expect dilute company bottom line approximately cent be expect be incrementally additive net product sale strategic value acquisition be expect position celgene prominent company cellular immunotherapy space juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately other candidate include jcarh multiple myelomacelgene already have collaboration investment agreement juno development immunotherapy cancer autoimmune disease remind investor celgene juno enter strategic collaboration june company leverage cell therapeutic strategy develop treatment cancer autoimmune disease initial focus car tcr technology celgene exercise option develop commercialize juno cd program outside north america china april takecelgene be look new deal acquisition give lacklustre note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate celgene stock have tumble year industry gain celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition january celgene announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way meanwhile celgene also have partnership bluebird bio inc blue free report car therapy candidate however acquisition juno be risky proposition celgene juno have face setback pipeline candidate jcar july juno suffer huge setback fda place clinical hold company phase ii study rocket jcar adult patient relapse refractory cell acute lymphoblastic leukemia hold be place patient die week due severe neurotoxicity follow addition fludarabine pre conditioning regimen hold be lift week later study resume revise protocol company voluntarily place study hold again november patient suffer cerebral edema subsequently march juno announce have discontinue development candidate moreover price share represent huge premium juno share price rumor acquisition have surface biotech sector be likely see lot happen front give dull zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3143,CELG,celgene corporation celg free report announce positive result late stage study oncology drug abraxane combination roche rhhby free report immuno oncology drug tecentriq study be sponsored roche impassion phase iii multicenter randomize double blind study be evaluate efficacy safety pharmacokinetic tecentriq combination abraxane compare placebo combination abraxane patient suffering locally advanced metastatic triple negative breast cancer tnbc have not receive prior systemic therapy disease study meet co primary endpoint progression free survival pfs result show tecentriq abraxane significantly reduce risk disease worsening death pfs patient metastatic unresectable locally advanced tnbc intention treat itt pd positive population initial first line treatment overall survival be encourage pd positive population interim analysis follow continue next plan analysis result study be present upcoming medical meeting notably be third positive phase iii study demonstrate clinical benefit tecentriq abraxane part treatment regimen other study program evaluate experimental combination small cell lung cancer patient positive datum study demonstrate potential role abraxane prefer chemotherapy partner immunotherapy combination remind investor celgene be currently work label expansion drug pomalyst imnovid abraxane otezla other be encourage abraxane be currently various stage evaluation breast pancreatic small cell lung cancer nsclc drug maintain dominant market share unite state indication pancreatic cancer first line advanced nsclc metastatic breast cancer competitive pressure lung breast cancer market label expansion drug bode well celgene make desperate attempt revamp portfolio give recent pipeline setback company suffer setback early receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod late stage study lead cancer drug revlimid combination rituxan fail consequently share take hammer share celgene be year so far compare decline overall biotech industry nevertheless celgene have few promising candidate pipeline boost prospect celgene acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state potential global peak sale approximately promising candidate be bb experimental cell maturation antigen chimeric antigen receptor car cell therapy collaboration bluebird bio inc blue free report most recently celgene partner acceleron pharma inc xlrn free report announce back back positive result late stage study pipeline candidate zack rank celgene carry zack rank hold see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3144,CELG,positive datum release bigwig biogen inc biib free report mid stage study treatment alzheimer disease create stir biotech sector last week other news celgene corporation celg free report report positive datum key pipeline candidate late stage study axovant axon free report gain yet licensing deal recap important story biogen soar positive alzheimer study result share biogen soar company report encourage top line result mid stage study pipeline candidate ban treatment early alzheimer disease ad ban amyloid beta protofibril antibody be be evaluate phase ii study ad biogen be develop ban humanize beta amyloid antibody collaboration japan eisai co ltd candidate be be investigate see slow progression memory problem associate amyloid top line result final analysis phase ii study demonstrated statistically significant slow disease progression key clinical endpoint adcom month treatment patient receive highest treatment dose mg kg biweekly ban compare placebo meanwhile treatment high dose month also lead reduction amyloid beta accumulate brain read more biogen alzheimer disease candidate succeed phase ii positive result give investor much reason cheer ad have always be challenge market give spate study failure recent time so abovemention result be deem important breakthrough biogen eisai ad market raise hope possible cure biogen currently carry zack rank hold see complete list today zack rank strong buy stock here celgene report positive datum thalassemia drug late stage study celgene corporation partner acceleron pharma inc xlrn free report report positive result second randomize double blind multus center clinical phase iii study believe pipeline candidate result show achieve highly statistically significant improvement primary endpoint erythroid response be defined least reduction baseline red blood cell rbc transfusion burden reduction least unit protocol defined period consecutive week week week compare placebo moreover also meet key secondary endpoint demonstrate statistically significant improvement rbc transfusion burden baseline least reduction period week week notably be second positive phase iii study candidate last month company announce positive result phase iii study medalist meet primary key secondary endpoint compare placebo patient ipss very low low intermediate risk myelodysplastic syndrome mds chronic anaemia third study be also ongoing evaluate transfusion dependent beta thalassemia read more celgene acceleron report positive datum thalassemia drug meanwhile celgene also announce positive result phase iii study impassion experimental combination roche immuno oncology drug tecentriq abraxane former compare abraxane monotherapy significantly reduce risk disease worsening death pfs patient metastatic unresectable locally advanced triple negative breast cancer axovant gain yet gene therapy deal axovant science share gain announce licensing agreement benitec biopharma agreement axovant license exclusive global right experimental silence replace gene therapy program benitec biopharma treatment oculopharyngeal muscular dystrophy opmd axovant obtain right axo aav opmd utilize proprietary silence replace technology axo aav opmd be adeno associate viral aav vector gene therapy deliver time intramuscular administration silence mutant pabpn gene replace functional copy be currently preclinical development stage axovant plan initiate placebo controlled clinical study candidate enjoy orphan drug status unite state europe treatment opmd company have also enter research collaboration development additional gene therapy product neurological disorder agreement benitec bolster axovant pipeline innovative gene therapy serious neurological disease read more axovant benitec gain licensing deal gene therapy idera announce termination merger agreement biocryst idera pharmaceutical inc idra free report announce merger agreement biocryst pharmaceutical have be terminate stockholder latter vote same special meeting consequently biocryst reimburse idera connection termination company have enter merger agreement january biocryst gain news share idera slump majority idera stockholder vote favor adoption merger agreement biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock biogen have gain past month celgene have lose vertex have gain see last biotech stock roundup here biotech stock roundup gild positive chmp nod regulatory update more next biotech stay tune regulatory update pipeline development news more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3145,CELG,celgene corporation celg free report be schedule report fourth quarter result jan open bell celgene stock have tumble last year compare industry gain celgene have excellent track record company beating earning estimate last trail quarters last quarter company top estimate overall company have deliver average positive surprise likely positive surprise proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision revlimid drive growthearlier month celgene release preliminary result company expect earning share ep year year operate margin be anticipate fourth quarter ep be anticipate be increase year year operate margin be expect be zack consensus estimate earning fourth quarter be total revenue be expect fourth quarter zack consensus estimate revenue be fourth quarter revlimid revenue be expect fourth quarter revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma drug perform well first month combat challenge uneven buy pattern coverage gap market share gain key market longer treatment duration be contribute drug growth continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate revlimid currently stand fourth quarter pomalyst revenue be expect pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be update unite state europe include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function boost sale otezla revenue be expect fourth quarter deep persistent slow growth psoriatic arthritis psoriasis market especially entire third quarter lead weak performance otezla quarter impact sale fourth quarter also abraxane revenue be fourth quarter meanwhile approval idhifa treatment adult patient relapse refractory aml aml further boost celgene portfolio drug be develop collaboration agio pharmaceutical agio free report celgene be look new deal acquisition give recent setback january celgene announce acquire impact biomedicine company recently announce acquire smaller biotech juno therapeutic pipeline include cd cd direct car cell product candidate fourth quarter earning call investor be expect remain focuse company performance label expansion effort update recent acquisition stock considerhere be stock healthcare sector want consider model show have right combination element beat earning quarter vertex pharmaceutical inc vrtx free report have earning esp zack rank company be schedule release fourth quarter result jan see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3146,CELG,be good year pharma biotech stock sector witness positive development lead much await recovery key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy be major overhang remain headline risk investor seem more comfortable issue moreover significantly higher number fda approval have restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector hope more merger acquisition have also go tax reform place big player lookout company innovative pipeline technology have already be quite bit buzz year potential deal celgene rumore be interested buy juno biogen biib free report acorda sanofi sny free report bioverativ meanwhile nordisk recently confirm be look acquire belgium base biopharma company ablynx ablynx reject nordisk offer look forward new product sale ramp success innovation continue strong performance key product more activity grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum headwind include drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback biotech pharma stock keep eye earning seasonaccording zack earning trend article medical sector have be better perform sector last several quarters be expect record earning growth revenue growth fourth quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc alxn free report alexion have strong presence rare disease market market drug include soliris treatment patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus acetylcholine receptor achr antibody positive generalized myasthenia gravis gmg strensiq enzyme replacement therapy patient hpp kanuma enzyme replacement therapy patient lysosomal acid lipase deficiency lal alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder alexion have consistently surpass earning expectation last quarters average surprise zack rank stock report fourth quarter result february have earning esp quarter soliris revenue be expect range metabolic revenue be expect range celgene corporation celg free report celgene be focuse discovery development treatment cancer inflammatory disease next generation solution protein homeostasis immuno oncology epigenetic immunology neuro inflammation earlier month company announce preliminary result fourth quarter revenue expect be earning be approximately share celgene have surpass earning last quarters average surprise zack rank stock be report fourth quarter result january have earning esp abbvie abbv free report abbvie be know blockbuster drug humira be focuse development treatment primary therapeutic area immunology oncology virology neuroscience earning be expect be share revenue growth approximately humira be expect remain key growth driver sale expect cross abbvie be report fourth quarter result january company have decent track record have surpass earning expectation last quarters average surprise zack rank stock have earning esp fourth quarter abbvie share be last year significantly surpass rally industry belong merck mrk free report merck be report fourth quarter result february company have strong earning track record be expect deliver surprise fourth quarter growth driver include keytruda gardasil few hospital specialty product animal health division help offset impact genericization zetia vytorin merck be also zack rank stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3147,CELG,therapeutic incorporate cort free report adjust second quarter earning include stock base compensation expense cent share surpass zack consensus estimate cent report figure also top year adjust earning cent revenue increase year quarter figure slightly miss zack consensus estimate revenue grow sequential basis due increase korlym cush syndrome sale volume share price have increase year date compare zack classify industry gain research development expense shot likewise selling general administrative expense be fact increase operate expense be primarily owing greater compensation expense increase spending cort cort cort other pharmacy cost pipeline continue enroll patient phase ii study cort cush syndrome phase ii result be expect first quarter go forward company be also plan end phase ii meeting fda commencement phase iii study late plan open expansion cohort study cort celgene celg free report abraxane patient solid tumor cancer company state dose range study cort combine xtandi be study healthy subject third quarter patient castration resistant prostate cancer fourth quarter additionally plan initiate phase study aug cort show promise treatment metabolic disorder such fatty liver disease antipsychotic induced weight gain guidancecorcept raise revenue guidance company now project revenue be range previous guidance therapeutic incorporate price consensus ep surprise therapeutic incorporate price consensus ep surprise therapeutic incorporate quotezack rank stock currently carry zack rank hold better rank health care stock same space include exelixis inc exel free report enzo inc exelixis sport zack rank strong buy enzo carry zack rank buy see complete list today zack rank stock hereexelixis pull positive earning surprise trail quarters average beat share price company have increase year date enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3148,CELG,celgene corporation celg free report report encourage first quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter celgene corporation price consensus ep surprise celgene corporation price consensus ep surprise celgene corporation quotetotal revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid revlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state international market growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale benefit buy pattern pomalyst imnovid come sale be drive increase volume due increase market share duration otezla sale be quarter sale unite state be primarily volume drive due increase demand improve access pull contract health plan sale international market be drive primarily increase adoption key ex market other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due higher spending related drug discovery clinical trial activity adjust selling general administrative expense decrease pipeline updatecelgene acquire acquire juno therapeutic inc approximately march february company also acquire impact biomedicine add late stage candidate fedratinib highly selective jak kinase inhibitor pipeline celgene announce global collaboration prothena prta free report march develop new therapy broad range disease primarily focuse protein implicate pathogenesis several disease include tau tdp undisclosed target celgene partner bluebird bio blue free report opted co develop co promote bb experimental bcma car cell therapy treatment patient rrmm unite state march company have originally enter broad global strategic research collaboration develop commercialize novel therapy oncology include bb agreement be amend however celgene suffer setback receive refusal file letter fda regard new drug application nda ozanimod relapse multiple sclerosis rm celegne now plan resubmit nda first quarter follow type meeting fda early april company also plan submit marketing authorization application maa ozanimod rm first quarter outlook updatedcelgene now anticipate earning share compare earlier estimate zack consensus estimate earning be share net revenue be now estimate high end previously project range zack consensus estimate same be peg number include impact dilution juno acquisition revlimid sale be now project estimate earlier abraxane sale be estimate be pomalyst revenue be now project previous projection otezla sale continue be project takecelgene first quarter result be encourage company beat sale earning revlimid sale be impressive yet again pomalyst otezla result come breather investor bore brunt decline share price due series setback last few month celgene stock have lose last month compare industry decline nevertheless share company be pre market trading due earning beat celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail threat generic competition be also loom large revlimid lose patent protection force celgene look acquisition stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue company also suffer setback rm candidate ozanimod celgene be look new deal acquisition give lacklustre juno acquisition be same track note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate zack rankcelgene be zack rank buy stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3149,CELG,biotech corner broad healthcare sector be spotlight start new year new tax legislation have entice company bring offshore cash back home spark wave merger acquisition additionally slower growth mature drug have compel prominent biotechs acquire smaller one promising pipeline deal wheel celgene corp celg free report have be forefront join craze company announce deal acquire blood disease biotechnology company impact biomedicine much deal expect close first quarter add new drug fedratinib be highly selective jak kinase inhibitor be evaluate clinical trial include phase iii trial myelofibrosis polycythemia vera celegne pipeline read value biotech etfs buy now now celg be rumore be talk acquire smaller rival juno therapeutic inc quest bolster blood cancer drug portfolio best selling drug revlimid lose patent protection acquisition strengthen celgene drug pipeline blood cancer potentially broaden treatment include lung breast ovarian cancer celg juno have long partner cancer treatment include promising car drug immune system identify fight cancer talk lead deal come week other deal japan takeda pharmaceutical have agree acquire belgian biotech group tigenix euro aim strengthen late stage pipeline presence specialty care market danish drugmaker nordisk have also make bid buy belgian biotech ablynx beef wane performance haematology hormone treatment division latter reject offer give flurry deal so far activity biotech sector be expect be robust year ey expect deal value exceed give company increase financial firepower balance sheet strength see healthcare etfs here etfs trend have lead trading biotech sector loncar cancer immunotherapy etf cncr free report steal show thank gain be follow virtus lifesci biotech clinical trial etf bbc free report first trust nyse arca biotechnology index fund fbt free report powershare dynamic biotechnology genome portfolio pbe free report have rise respectively profile etfs detail discuss specific recent rally product track loncar cancer immunotherapy index provide exposure basket company develop therapy treat cancer harness body own immune system aum etf charge bps annual fee trade average daily volume share have zack etf rank buy high risk outlook read top rank etfs crush start fund have novel approach biotechnology investing exposure company be clinical trial stage easily be do tracking lifesci biotechnology clinical trial index bbc have amassed asset base charge bps fee year investor hold security basket trade light average daily volume share product have zack etf rank high risk outlook fund follow nyse arca biotechnology index hold security basket have accumulate asset base trade good volume share day etf charge investor bps fee year have zack etf rank hold high risk outlook read sector etf stock winner year great recession fund provide exposure firm tracking dynamic biotech genome intellidex index have manage asset base trade modest volume share day expense ratio come product have zack etf rank high risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3150,CELG,share johnson johnson jnj free report hit new week high jan eventually close day stock hit new high probably reuter news state chinese bidder be plan buy diabetes care unit country deal be worth billiona be stock have have great run past year share have rally year industry have register increase promising datum several pivotal study rapid progress pipeline line extension year keep stock growth trajectory positive trend be likely continue well company receive approval new drug last year guselkumab tremfyain unite statesas well eu plaque thefirst dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also receive fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene corporation celg free report multiple myeloma drug pomalyst sixth indication imbruvica other investor note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale sale company pharma segment accelerate third quarter trend be likely continue fourth quarter well asin believe new product segment label expansion drug imbruvica xarelto darzalex contribution recent acquisition mainly actelion support top line growth year expect file approval depression candidate esketaminewhile pre metastatic prostate cancerand symtuza darunavir base once daily single tablet regimen be approve fda several pivotal datum readout regulatory milestone expect bullish run stock be likely continue johnson johnson price johnson johnson price johnson johnson quote zack rank have zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3151,CELG,roche holding ag rhhby free report announce positive result phase iii study murano study evaluate venclexta combination rituxan patient suffering relapse refractory chronic lymphocytic leukemia cll datum show study meet primary endpoint result depict statistically significant improvement time patient live disease progress progression free survival pfs treat venclexta rituxan compare treanda rituxan note roche be develop venclexta collaboration abbvie inc abbv free report company be commercialize drug unite state abbvie commercialize outside country remind investor fda approve venclexta april treatment person cll have receive least prior therapy deletion detected fda approve test fda also grant breakthrough therapy designation venclexta combination rituxan treatment relapse refractory cll base promising result phase ib study company be conduct murano study convert current accelerate approval venclexta full approval datum study be present upcoming medical meeting submit global health authority estimate be more new case cll diagnosed unite state cll be most common type adult leukemia hence potential approval indication boost sale potential roche hematology portfolio include approve drug mabthera rituxan gazyva tecentriq venclexta pipeline candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg last week fda place partial clinical hold phase ib phase ii trial evaluate immuno oncology drug tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corp celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene roche stock have gain compare industry gain year so far roche have strong presence oncology market company dominate breast cancer space due strong demand franchise drug herceptin perjeta kadcyla however sale avastin tarceva continue decline generic competition xeloda continue hurt sale competition biosimilar loom large roche key drug herceptin avastin rituxan zack rankroche currently carry zack rank hold see complete list today zack rank stock here promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
3152,CELG,prothena corporation plc prta free report be schedule report first quarter result prothena corporation plc price consensus ep surprise prothena corporation plc price consensus ep surprise prothena corporation plc quote last report quarter company incur narrower expect loss result positive earning surprise notably prothena track record have be decent so far company report narrower expect loss last trail quarters average positive earning surprise prothena share have lose last month compare industry decline let see thing be shape announcement pipeline progress focusprothena top line primarily comprise collaboration revenue earn license development agreement fact company earn collaboration revenue mainly license agreement roche rhhby free report prx expect investor focus remain pipeline update company have approve product portfolio prothena have discontinue development lead pipeline candidate neod candidate antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study hence company decide discontinue study development neod include vital study well open label extension study decision come major blow investor company have very limit number candidate pipeline neod be lead candidate moreover disappointing result phase ib multiple ascend dose study pipeline candidate prx psoriasis patient be setback company primary objective study be achieve however advance prx mid stage clinical development require well defined relationship biological activity meaningful clinical effect prerequisite be not meet result investor focus prx prothena be evaluate prx collaboration roche treatment parkinson disease other related synucleinopathy company initiate phase ii study pasadena patient suffering parkinson disease second quarter initiation trigger milestone roche prothena company have also collaborate celgene corporation celg free report develop new therapy broad range disease multus year agreement be focuse protein implicate pathogenesis several disease include tau tdp undisclosed target other development stage biotechnology company prothena be likely see increase research development expense due higher spending pipeline earning whispersour proven model doesn show prothena be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank prothena currently carry zack rank however need have positive esp be confident earning beat conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be health care stock want consider model show have right combination element post earning beat quarter gw pharmaceutical plc gwph free report be expect report quarterly result company have earning esp zack rank see see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3153,CELG,celgene corporation celg free report partner acceleron pharma inc xlrn free report announce positive result second randomize double blind multus center clinical phase iii study believe pipeline candidate trial evaluate efficacy safety addition best supportive care compare placebo best supportive care adult transfusion dependent beta thalassemia result show achieve highly statistically significant improvement primary endpoint erythroid response be defined least reduction baseline red blood cell rbc transfusion burden reduction least unit protocol defined period consecutive week week week compare placebo moreover also meet key secondary endpoint demonstrate statistically significant improvement rbc transfusion burden baseline least reduction period week week treatment candidate also show least reduction period week week least reduction period week week also demonstrated mean change transfusion burden week week notably be second positive phase iii study candidate last month company announce positive result phase iii study medalist meet primary key secondary endpoint compare placebo patient ipss very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent rbc transfusion datum study be submit future medical meeting company intend submit regulatory application unite state europe first half third study be also ongoing be evaluate transfusion dependent beta thalassemia successful development bode well celgene make desperate attempt revamp portfolio give recent pipeline setback company suffer setback early receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail consequently share take hammer share celgene be year so far compare decline overall biotech industry nevertheless celgene have few promising candidate pipeline boost prospect celgene acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state potential global peak sale approximately promising candidate be bb experimental cell maturation antigen chimeric antigen receptor car cell therapy collaboration bluebird bio inc blue free report zack rank celgene carry zack rank hold see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3154,CELG,cti biopharma corp ctic free report privately hold partner servier announce failure pivotal phase iii study evaluate cancer drug pixuvri combination roche rhhby free report biogen biib free report rituxan rituximab treatment cell hodgkin lymphoma nhl cti biopharma share fall almost jul follow disappointing news however share company have rally so far year industry gain pivotal pix study compare pixuvri rituxan combination regimen combination chemo drug gemcitabine rituxan treatment aggressive cell nhl form blood cancer patient disease relapse follow chop chemotherapy datum study show patient treat pixuvri regimen fail achieve improvement progression free survival compare patient treat gemcitabine regimen however company have plan conduct thorough review datum study cti biopharma expect submit datum pix study european medicine agency review end pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state be approximately newly diagnosed nhl patient year unite state europe several company be develop drug treatment disease few be develop most advanced form cancer treatment car therapy treat nhl include celgene celg free report lisocabtagene disappointing datum pix study negatively impact pixuvri prospect already competitive market cti biopharma corp price cti biopharma corp price cti biopharma corp quotezack rankcti biopharma currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3155,CELG,biogen inc biib free report be star performer friday trading session stock rally much close little lower rise day trade massive gain biotech firm come encourage phase clinical study datum alzheimer treatment final analysis month patient phase clinical study ban early alzheimer disease demonstrated statistically significant slow cognitive decline reduction amyloid beta accumulate brain company press release amyloid beta protein fragment be find brain patient suffering disease believe cause alzheimer be most common form dementia affect person worldwide accord alzheimer association currently be treatment disease way stop progression however food drug administration have approve medication treat symptom related memory loss language other thought process see healthcare etfs here such result mark important milestone company quest tackle alzheimer disease fact analyst welcome news first trial study drug be disappointing result risk environment many investor pull capital high growth high beta sector other large cap biotech stock also gain gilead gild free report celgene celg free report amgen amgn free report suggest investor be pin hope fast grow company see trading come day etf trading stock world also send biotech etfs space green day particular ishare nasdaq biotechnology etf ibb free report steal show climb follow more gain first trust amex biotechnology index fbt free report invesco dynamic biotechnology genome etf pbe free report vaneck vector biotech etf bbh free report fund provide exposure firm tracking nasdaq biotechnology index biogen take top spot ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar fund follow nyse arca biotechnology index measure performance company biotechnology industry be primarily involved use biological process develop product provide service hold security basket biogen occupy fifth position share charge bps annual fee have accumulate asset base have zack etf rank buy high risk outlook read sector etfs crushed year bull run fund provide exposure firm tracking dynamic biotech genome intellidex index biogen take top spot asset etf have manage asset base charge expense ratio have zack etf rank high risk outlook read pharma biotech etfs soar trump drug plan fund offer exposure large biotechnology corporation tracking mvis list biotech index here biogen be fifth firm accounting share bbh have amassed asset base charge bps fee year have zack etf rank strong buy high risk outlook lie ahead uptrend sector be likely continue year tax reform rise positive regulatory backdrop read top rank sector etfs buy new tax legislation have entice large pharmaceutical company bring offshore cash back home reduce tax rate instead prior repatriate money lead increase merger acquisition activity share buyback dividend additionally slower growth mature drug have also compel prominent biotechs acquire smaller one even hefty premium promising pipeline further trump most await plan lower drug price have add strength be not enough sector cyclical nature be advantage current market be ruffle trade war fear china unite state well geopolitical tension want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3156,CELG,roche holding ag rhhby free report announce fda have put partial clinical hold phase ib phase ii trial evaluate tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corporation celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene fda be currently evaluate ongoing blood cancer trial investigate pd pdl drug combination drug order determine be class wide pd pdl concern multiple myeloma blood cancer specific concern certain combination drug study include cohort evaluate tecentriq combination medicine imid relapse refractory multiple myeloma relapse refractory follicular lymphoma result partial clinical hold patient be currently enroled trial be derive clinical benefit continue receive treatment additional patient be enroled note fda grant accelerate approval immuno oncology drug tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma initial uptake drug have be encourage october tecentriq become first only pdl cancer immunotherapy be approve fda treatment metastatic nsclc fda recently grant accelerate approval tecentriq treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug be previously approve patient suffering locally advanced muc have disease progression follow platinum contain chemotherapy month receive chemotherapy surgery neoadjuvant surgery adjuvant news come disappointment label expansion drug boost sale roche stock have gain industry gain year so far earlier fda also put partial clinical hold bristol myer squibb company bmy free report clinical trial checkmate checkmate same reason trial be investigate opdivo base combination patient relapse refractory multiple myeloma zack rankroche currently carry zack rank hold see complete list today zack rank stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
3157,CELG,celgene corporation celg free report announce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi durvalumab pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma fda have place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent result new patient be enroled trial nevertheless patient enroled trial partial hold receive clinical benefit same determine investigator remain treatment patient enroled trial full clinical hold be discontinue treatment remind investor celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other trial place partial clinical hold be medi mm medi mm medi mm medi nhl medi dlbcl trial place full hold include medi mm earlier week fda also put partial clinical hold bristol myer squibb company bmy clinical trial checkmate checkmate same reason note july fda place clinical hold keynote keynote keynote combination study keytruda multiple myeloma decision be take follow review datum datum monitoring committee higher death be report keytruda arm keynote keynote lead halt enrolment news come major setback label expansion drug have boost celgene top line celgene stock have moved year date compare industry gain share be pre market trading news regain ground thereafter meanwhile celgene revlimid continue outperform drive market share increase newly diagnosed myeloma treatment duration zack rank key pickcelgene currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3158,CELG,late biotechnology pharmaceutical company be investing immuno oncology research therapy remain key area focus thank vast growth potential last week immuno oncology space grab investor attention fda approve novartis ag nvs free report breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve novel immunocellular therapy time treatment kymriah used patient cell fight cancer long term impact treatment be yet be evaluate approval open new frontier treatment cancer start car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen approval kymriah investor have start shift focus number company have be develop pipeline candidate remain afloat highly competitive environment stock warrant lookkite pharma inc be expect receive approval car therapy axicabtagene ciloleucel axi cel shortly biologic license application candidate be submit march application be gr priority review unite state fda be expect give decision nov candidate be also review eu tentative approval expect candidate be be develop treatment refractory aggressive hodgkin lymphoma include diffuse large cell lymphoma transform follicular lymphoma primary mediastinal cell lymphoma give likely approval potential space gilead science inc gild free report have inked deal acquire kite pharma kite pharma stock have moved year date compare favorably increase register industry company presently carry zack rank hold see complete list today zack rank strong buy stock here juno therapeutic inc be also develop cell base cancer immunotherapy base car high affinity tcr technology genetically engineer cell recognize cancer cell company be currently conduct phase trial jcar adult aggressive nhl include dlbcl plan file ind plan phase ii trial jcar chronic lymphocytic leukemia cll company expect approval share company have rally year date company currently carry zack rank sell bluebird bio inc blue free report collaboration celgene corporation celg free report be evaluate bb car cell product candidate treatment multiple myeloma phase study company expect initiate phase study evaluate safety efficacy bb next bcma car cell product candidate share company have gain year date company presently carry zack rank ziopharm oncology inc ziop free report be develop car cell therapy advanced lymphoid malignancy company be currently enrole patient investigator lead phase study used second generation cd specific car cell revise car structure patient advanced lymphoid malignancy share company have rally year date company present carry zack rank simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
3159,CELG,pfizer inc pfe free report announce fda have grant approval mylotarg adult patient newly diagnosed cd positive acute myeloid leukemia aml drug also receive approval treat relapse refractory cd positive aml adult well child year older approval be expect fda oncologic drug advisory committee have vote favor mylotarg approval july however be note label drug include box warning hepatotoxicity include severe fatal hepatic veno occlusive disease pfizer share have gain so far year underperform industry increase approval be grant base datum multiple investigator lead clinical trial include alfa aml mylofrance alfa phase iii study evaluate mylotarg combination chemotherapy newly diagnosed aml patient drug show significant improvement event free survival ef achieve month compare month chemotherapy phase iii aml study compare mylotarg monotherapy best supportive care elderly aml patient be intolerant other therapy mylotarg achieve better median overall survival period month versus month best supportive care mylofrance phase ii study evaluate single agent mylotarg relapse aml patient study show almost patient achieve complete remission median relapse free survival achieve be month be evident study mylotarg achievement support risk benefit profile aml patient remind investor mylotarg be grant accelerate approval fda single agent treat cd positive aml patient have experience first relapse be year older however year later pfizer voluntarily remove mylotarg market datum post approval phase iii study swog show clinical benefit rate fatality due treatment related toxicity be significantly higher press release cd antigen occur nearly aml patient fact aml occur nearly acute leukemia patient moreover mylotarg be first approve therapy pediatric aml give mylotarg first mover advantage estimate patient unite state be expect be diagnosed aml include child datum publish press release chemotherapy be current prefer therapy treat aml mylotarg approval new therapy improve benefit be available patient however several other company be also develop therapy treat aml include seattle genetic inc sgen free report sgn cd intrexon corporation xon free report cd specific car therapy august fda approve celgene corporation celg free report idhifa oral treatment relapse refractory aml patient pfizer inc price consensus pfizer inc price consensus pfizer inc quotepfizer currently have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3160,CELG,biotech giant gilead science inc gild free report deal buy car cancer therapy designer kite pharma inc have make other lead independent car developer juno therapeutic inc bluebird bio inc blue free report hot takeover target term gilead kite pharma dealper agreement gilead pay share cash total transaction value be approximately price represent premium close share price kite pharma aug transaction be approve shareholder company be expect close fourth quarter share gilead have shot gilead have go almost announcement fact so far year kite pharma stock be compare favorably increase register industry kite pharma kite pharma car therapy axicabtagene ciloleucel treat aggressive hodgkin lymphoma nhl be priority review decision fda be expect nov believe solid efficacy profile demonstrated pivotal zuma study axicabtagene ciloleucel be likely support drug approval year europe regulatory application be file july approval launch expect next year accord company initial market opportunity axicabtagene ciloleucel include addressable car patient europe respectively new case be diagnosed japan year key urban eastern rural coastal area china meanwhile other study axicabtagene ciloleucel additional candidate include kite kite be also advance acquisition diversify gilead portfolio struggle hcv franchise position take share grow cellular therapy space hcv franchise be pressure competition pricing issue other car therapy maker focuscar be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment process cell be draw patient blood cell be then reprogram manufacturing facility create cell be genetically code express chimeric antigen receptor recognize fight cancer cell other bcell express specific antigen deal look expensive give premium gilead paid kite car space be expect be revolutionary treatment cancer represent immense potential juncture thereby attract attention big pharmas go say follow kite pharma acquisition gilead other small biotechs develop car therapy juno bluebird be buy larger biotech probably gilead even biggest partner celgene corporation celg free report juno be develop jcar partnership celgene nhl utilize car cell technology datum present june demonstrated complete response patient relapse refractory aggressive cd nhl company plan bring jcar market nhl early multiple indication end fact share juno be almost kite gilead deal be announce buyout speculation company share be year date bluebird be develop bcma car cell therapy bb also collaboration celgene candidate be only phase study however datum early stage refractory multiple myeloma study bb present june show evaluable patient active dose cohort achieve objective response overall response rate orr cohort be investment community believe datum early stage bode well candidate future development share company be year so far meanwhile other small biotechs tesaro inc tsro free report clovis oncology inc clvs free report puma biotechnology inc pbyi free report have launch innovative cancer treatment recently be also potential acquisition target now surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
3161,CELG,share prothena corporation plc prta free report moved market trading session follow news global collaboration biotech bigwig celgene corporation celg free report company have collaborate develop new therapy broad range disease however prothena stock have decline last month industry fall term multus year agreement be focuse protein implicate pathogenesis several disease include tau tdp undisclosed target tau be protein implicate alzheimer disease ad progressive supranuclear palsy psp frontotemporal dementia ftd chronic traumatic encephalopathy cte other tauopathy prothena have identify antibody target novel epitope tau ability block misfold tau bound cell inhibit cell cell transmission prevent downstream functional toxic effect other hand tdp be protein implicate amytrophic lateral sclerosis al most common subtype ftd behavioral variant ftd bvftd proportion ad other tdp proteinopathy prothena have generate antibody target multiple epitope tdp celgene own right license clinical candidate unite state investigational new drug filing stage exercise also have right expand license global right completion phase consequently celgene be responsible funding further global clinical development exchange prothena receive upfront payment celgene also make equity investment prothena subscribe approximately ordinary share share prothena be also eligible regulatory commercial milestone license program prothena also receive additional royalty net sale result market product takeprothena suffer setback decide not advance pipeline candidate prx mid stage development due disappointing datum psoriasis patient hence company be look revive pipeline give limit number candidate prothena pipeline antibody therapeutic candidate target number indication include al amyloidosis neod parkinson disease other related synucleinopathy prx rg attr amyloidosis prx prothena already have license agreement swiss pharma giant roche rhhby free report development select antibody target alpha synuclein include prx tie up well know company industry roche celgene make sense prothena company be highly dependent collaboration partner development candidate company do not have enough resource independently conduct study candidate celgene other hand be have share trouble too label expansion study lead drug revlimid fail phase iii stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue fda recently issue refusal file letter celgene new drug application nda ozanimod be development treatment patient relapse form multiple sclerosis fda determine nonclinical clinical pharmacology section nda be insufficient permit complete review hence celgene be desperate need revive pipeline collaboration acquisition company recently acquire juno therapeutic focus promising car space zack rank key pickprothena currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank strong buy stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3162,CELG,multiple sclerosis ms space hit headline once again follow biotech bigwig biogen biib free report partner abbvie abbv free report decision withdraw jointly own ms drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient treat november european medicine agency ema conclude review zinbryta review find unpredictable potentially fatal immune mediate liver injury occur treatment zinbryta month stopping treatment clinical trial patient receive zinbryta have serious liver reaction give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms rrm secondary progressive ms spms primary progressive ms ppms market ms change drastically introduction oral formulation be mostly prefer injection variety drug available ms come own set risk mostly biogen be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta however company have be scrutiny pricing ms drug earlier emergence progressive multifocal pml case type brain infection associate use tysabri tecfidera have mar prospect ms drug fda thereafter update label tecfidera nevertheless company be name reckon ms market earlier fda also issue warning novartis nvs free report gilenya pml drug be recently grant breakthrough therapy designation gilenya treatment child adolescent year age older relapse ms drug be already approve same adult novartis have ms drug portfolio glatopa generic version copaxone mg sandoz company generic arm recently win fda approval generic version copaxone mg israel base teva pharmceutical teva free report have long be ms market widely used drug copaxone be face stiff competition last few year meanwhile past seizure be know side effect ms drug ampyra seizure risk be see increase higher blood level drug result fda have update ampyra label clarify recommendation kidney function be checked patient start ampyra monitored least annually ampyra treatment continue nevertheless risk associate drug have not deter newer entrant claim better formulation lesser side effect consequently market have become too crowd march fda approve roche rhhby ocrevus treat adult relapse form ms primary progressive multiple sclerosis however be question ocrevus be new innovation reformulation roche older drug rituxan drug sale aren impressive yet fda recently issue refusal file letter celgene celg free report new drug application nda ozanimod be development treatment patient relapse form multiple sclerosis fda determine nonclinical clinical pharmacology section nda be insufficient permit complete review hence company be now gear meet fda determine future course action haven be safety issue report delay definitely open avenue competition give so much be happen space expect investor remain glue further update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3163,CELG,earning season pharma biotech sector be scatter few small biotech company yet report release so far provide clear picture sector performance overall sector perform reasonably well biotech pharma bigwig gilead gild free report celgene celg free report vertex vrtx free report beat earning revenue estimate meanwhile biogen biib free report announce mixed result earning beating estimate sale lag same however amgen amgn free report have rather weak quarter miss expectation earning sale also issue lower expect sale guidance drug biotech stock remain growth trajectory ramp new product sale successful innovation product line expansion favorable clinical study result frequent fda approval strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep drive sector faster drug approval process propose removal outdated regulation push cost slowdown innovation also prove beneficial year start expectation pick activity new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year sanofi sny free report earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech firm bioverativ banking positive trend impressive performance be perfect time cash bountiful prospect grow market here have picked biotech stock see positive estimate revision post earning release also flaunt zack rank strong buy buy see complete list today zack rank stock here earning estimate revision have greatest impact stock price stock rise estimate have significantly outperformed index year year hence investor safely bet stock have be see upward movement earning estimate company have also see steady rally share price post result ligand pharmaceutical incorporate lgnd free report san diego base biotechnology company ligand carry zack rank stock witness positive estimate revision last day company release fourth quarter earning feb have see zack consensus estimate earning rise company surpass earning revenue estimate fourth quarter mainly higher royalty revenue additionally share company have rally post earning release regeneron pharmaceutical inc regn free report tarrytown ny base company regeneron witness positive estimate revision last day company release fourth quarter earning feb zack rank stock have see zack consensus estimate earning rise respectively regeneron fourth quarter result be impressive earning sale beat estimate strong sale company key market drug eylea share company have rally release earning release horizon pharma plc hznp free report base dublin ireland horizon pharma carry zack rank company have see zack consensus estimate earning move last day company release fourth quarter earning feb share company have gain post earning announcement horizon pharma also beat earning sale estimate fourth quarter backed strong performance orphan unit company sale guidance be encourage well outlookwhile be strong year be expect be vital biotech sector company continue invest pipeline build global business drive new product growth zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3164,CELG,share celgene corporation celg free report have be year so far compare decline overall biotech industry setback recent timescelgene have be sailing trouble water quite time now notably thing have be downturn company last october celgene announce phase iii trial revolve cd pipeline candidate ged crohn disease discontinuation extension trial sustain cd follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis december late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail celgene key growth engine be revlimid revlimid sale continue be impressive be concern company dependence product growth drug be set lose patent exclusivity soon hence celgene be desperately try revive portfolio company suffer setback early receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod candidate be be develop treatment patient relapse form multiple sclerosis ms fda state nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor give potential ms market hold thereafter company president chief operate officer scott resign position pipeline look thing be look trouble biotech company celgene acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state potential global peak sale approximately candidate multiple myeloma be jcarh company also announce development co promotion agreement bluebird bio inc blue free report company have enter deal co develop co promote bb experimental cell maturation antigen chimeric antigen receptor car cell therapy potential treatment patient relapse refractory multiple myeloma unite state celgene be poise launch car therapy blood cancer next year bluebird bb myeloma jcar relapse lymphoma most recently celgene partner acceleron pharma inc xlrn free report announce positive top line result phase iii multus center study medalist medalist study evaluate efficacy safety versus placebo patient very low low intermediate risk myelodysplastic syndrome mds chronic anemia refractory intolerant ineligible treatment erythropoietin stimulating agent esa ring sideroblast positive require frequent red blood cell rbc transfusion study show achieve highly statistically significant improvement primary endpoint rbc transfusion independence least consecutive week first week compare placebo also meet key secondary endpoint demonstrate highly statistically significant improvement rbc transfusion independence least consecutive week first week study also achieve modify hematologic improvement erythroid iwg mhi meaningful secondary endpoint base result company expect file submission regulatory submission be plan unite state europe first half hence first half be dismal company do expect better performance second half thereafter zack rankcelgene carry zack rank hold see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3165,CELG,key highlight week include fda acceptance regeneron sanofi dupixent sbla asthma biogen abbvie decision withdraw multiple sclerosis drug zinbryta due risk liver failure celgene completion juno acquisition recap week most important sanofi dupixent sbla asthma accept fda regeneron regn free report partner sanofi sny free report announce fda have accept review supplemental biologic license application sbla dupixent dupilumab add maintenance treatment adult adolescent year age older moderate severe asthma fda have set target action date oct prescription drug user fee act sbla be support result pivotal trial liberty asthma clinical development program sanofi regeneron be study dupilumab broad range clinical development program disease drive type inflammation include pediatric atopic dermatitis phase iii nasal polyp phase iii eosinophilic esophagitis phase iii read more fda accept regeneron sanofi dupixent sbla asthma regeneron be zack rank strong buy stock see complete list today zack rank stock here biogen abbvie withdraw zinbryta biogen biib free report partner abbvie abbv free report announce company withdraw multiple sclerosis drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient be treat drug be currently available europe unite state switzerland canada australia abbvie distribute zinbryta unite state biogen distribute drug ex market european regulatory authority provisionally restrict use zinbryta adult patient highly active relapse disease full adequate course treatment least dmt rapidly evolve severe relapse ms be unsuitable treatment other dmts follow report case fatal fulminant liver failure well case serious liver injury gilead report new datum biktarvy gilead gild free report announce encourage result week phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history read more gilead announce positive datum new hiv therapy biktarvy celgene complete juno acquisition celgene corporation celg free report announce have complete previously announce acquisition juno therapeutic inc juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round celgene suffer setback gilead team sangamo next biotech world stay tune more regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3166,CELG,gilead science inc gild free report newly acquire cell therapy subsidiary kite pharma announce have inked agreement acquire cell design lab inc gilead also acquire cell design share be own kite pharma cell design lab be leader develop cell base therapy used synnotch throttle technology platform technological platform enhance gilead cellular therapy research effort gilead acquire kite pharma acquistion cell design lab be develop several pre clinical product candidate include car tcr therapy prostate cancer hepatocellular carcinoma use synnotch technology company lead pre clinical candidate target multiple myeloma addition cell lab enable gilead expand car space car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body deal include upfront payment additional payment be paid cell design lab shareholder other kite so far year share company have gain compare industry growth note gilead recently receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication drug be add gilead portfolio follow acquisition kite pharma further note be several other company novartis nvs free report breakthrough gene transfer treatment kymriah receive fda approval treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse company bluebird bio inc blue free report bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene celg free report gilead science inc price gilead science inc price gilead science inc quotezack rank gilead carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3167,CELG,sanofi inc sny free report announce start new phase iii study evaluate investigational biologic isatuximab combination other cancer medicine treatment multiple myeloma rare blood cancer first study ikema compare combination isatuximab amgen amgn free report kyproli carfilzomib dexamethasone kyproli dexamethasone second study imroz evaluate combination isatuximab dexamethasone celgene celg free report multiple myeloma drug revlimid lenalidomide japanese firm takeda velcade bortezomib combination velcade revlimid dexamethasone ikema study include patient relapse refractory multiple myeloma have be previously be treat line therapy imroz evaluate cancer combination newly diagnosed multiple myeloma patient not eligible transplant primary endpoint be progression free survival studiesplease note isatuximab be already be evaluate monotherapy phase iii study relapse refractory multiple myeloma phase ii acute lymphoblastic leukemia sanofi share have rise so far year compare unfavorably gain record industry sanofi carry zack rank sell better rank large cap pharma stock be johnson johnson jnj free report carry zack rank buy see complete list today zack rank strong buy stock here share have rise year so far earning estimate have go past day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3168,CELG,have be more month last earning report celgene corporation celg free report share have add time frame outperform market recent positive trend continue lead stock next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst celgene beat earning miss salescelgene report mixed result third quarter earning beat expectation sale fail meet estimate company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter miss zack consensus estimate revenue be boost consistent performance company key growth driver revlimid however sale otezla unite state be weak revlimid continue shinenet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth report quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale grow unite state international market sale oncology drug pomalyst imnovid come sale be drive increase volume duration gain otezla report sale report quarter sale unite state be impact increase gross net adjustment contract implement january slow overall category growth due more challenge market access environment other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale report quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease last month celgene announce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma celgene enter strategic collaboration astrazeneca plc medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other fda place hold trial due risk identify other trial pd antibody keytruda patient multiple myeloma combination agent outlook updatedcelgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share revenue be now project compare earlier projection revlimid sale be project abraxane sale be estimate be pomalyst revenue be project however otezla sale be now project previous projection have estimate be move then follow release investor have witness downward trend fresh estimate have be revision lower current quarter look back additional day see even more downward momentum have be move higher compare lower month celgene corporation price consensus celgene corporation price consensus celgene corporation quotevgm scoresat time celgene stock have average growth score be lag bit momentum front however stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable value investor growth investor outlookwhile estimate have be broadly trend downward stock magnitude revision have be net interestingly stock have zack rank hold be look inline return stock next few month
3169,CELG,johnson johnson jnj free report announce submission regulatory application fda european medicine agency ema seek label expansion multiple myeloma mm drug darzalex first line set potential approval allow darzalex be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treat mm treatment naïve patient have autologous stem cell transplantation bone marrow approve be fifth indication drug be encourage effort expand darzalex label further drug generate sixth company total oncology sale first month note darzalex be first approve november monotherapy mm patient treat least prior line therapy follow approval past year combination therapy second third line setting share have outperformed industry so far year company share have gain compare industry gain have submit top line datum phase iii alcyone study support regulatory application geography datum study show darzalex combination therapy reduce risk disease progression death compare treatment bortezomib melphalan prednisone standard care alone present datum annual meeting american society hematology schedule be hold dec dec note license darzalex genmab subsidiary janssen hold worldwide right develop manufacture commercialize drug have pay milestone payment genmab national cancer institute new patient be likely be diagnosed mm cause death unite state alone darzalex compete other approve market treatment mm include celgene corporation celg free report revlimid amgen inc amgn free report kyproli bristol myer bmy free report emplicti johnson johnson price johnson johnson price johnson johnson quotej carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3170,CELG,celgene corporation celg free report partner bluebird bio inc blue free report announce chimeric antigen receptor cell car therapy candidate bb target cell maturation antigen bcma previously treat patient multiple myeloma obtain breakthrough therapy designation fda candidate be also grant priority medicine prime eligibility european medicine agency ema breakthrough therapy designation be intend expedite development review drug be intend treat serious life threaten condition prime be program launch ema enhance support development medicine target unmet medical need remind investor celgene enter collaboration agreement bluebird bio march develop car cell therapy collaboration be amend restate focus develop product candidate target cell maturation antigen bcma june lead candidate program be bb bcma car program be currently be study phase trial treatment relapse refractory multiple myeloma company be also develop second bcma car program bb car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen therapy have be spotlight novartis ag nvs free report kymriah be first car get fda approval september last month gilead science inc gild free report also receive fda approval yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma long term impact treatment be yet be evaluate approval open new frontier treatment cancer meanwhile celgene stock have fall last month industry gain celgene third quarter result be mixed company beating earning miss sale estimate revlimid sale be impressive yet again otezla sale unite state be weak lead management reduce annual guidance drug zack rankcelgene be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3171,CELG,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3172,CELG,report biotech bigwig celgene corporation celg free report be look acquire smaller biotech juno therapeutic rationale dealcelgene be look new deal acquisition give lacklustre celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail earlier jan celgene announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf note slowdown mature product compel prominent biotechs acquire smaller one promising pipeline gilead science inc gild free report acquire kite pharma subsequently obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate be celgene mull acquisition celgene already have collaboration investment agreement juno development immunotherapy cancer autoimmune disease agreement become effective july term agreement celgene have option be partner juno oncology cell therapy auto immune product candidate include juno cd cd direct car cell product candidate deal juno have option enter co development co arrangement certain celgene originated development candidate target cell april celgene exercise option develop commercialize juno cd program outside north america china company also enter pre negotiate license agreement juno respect such program make license payment celgene stock have loss value last month compare industry decline juno stock surge significantly follow news car therapy hold car therapy space be spotlight fda approve first car therapy kymriah treatment patient upto year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage give immense potential therapy celgene too want go gilead way meanwhile celgene also have partnership bluebird bio inc blue free report car therapy candidate last month company also announce result ongoing crb phase clinical study investigational cell maturation antigen car cell therapy bb datum show orr patient active dose cohort dose car cell cr rate observed patient active dose cohort zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3173,CELG,share concert pharmaceutical inc cnce free report plunge more follow announcement patent trial appeal board ptab patent trademark office have refuse grant company post grant review petition dispute related incyte corporation incy patent however share company have gain past year significantly outperform industry gain period patent protect incyte jak inhibitor ruxolitinib be sell tradename jakafi treat myelofibrosis polycythemia vera concert pharma pipeline candidate ctp be modify version ruxolitinib be be develop treatment alopecia areata alopecia areata be auto immune disease result partial complete hair losson scalp body however company say challenge validity patent future federal court also continue develop ctp separate press release concert pharma announce fda have grant fast track designation ctp treatment moderate severe alopecia areata fda grant fast track designation expedite candidate development faster review treat serious unmet medical condition designation candidate be expect be grant priority review once file new drug application candidate be currently be evaluate phase iia study apart ctp concert pharma be also develop avp treat agitation associate alzheimer disease jzp collaboration jazz pharmaceutical plc jazz free report narcolepsy ctp collaboration celgene corporation celg free report inflammatory disease however asset purchase agreement company sell cystic fibrosis candidate ctp vertex pharmaceutical incorporate vrtx free report july last year zack rankconcert pharma carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3174,CELG,fourth quarter earning season be expect be strong earning growth likely pick continue accelerate dip precede quarter index be anticipate see earning growth revenue growth market be also record level scaling series high start year forecast compare favorably earning growth revenue growth revision trend have be favorable earning estimate hold better relative other comparable period earning estimate have moved percentage point start quarter additionally zack sector be likely be contributor earning growth suggest potential upside many corner market read etfs stock favorite sector earning give strong sentiment investor focus etfs large allocation stock have high chance surprising upcoming release result winning bet earning season find right etfs handpicking etfs portfolio stock be most likely beat earning be mean feat however proprietary methodology find earning esp stock calculate percentage difference most accurate estimate zack consensus estimate be solid build block uncover best stock buy sell re report earning esp filter bet etfs winning combination stock have positive earning esp favorable zack rank strong buy buy hold lead profit investor be especially true earning beat definitely draw investor attention propel stock price related etfs first run zack stock screener find stock positive earning esp favorable zack rank then narrow list select group stock higher positive earning esp accordingly choose etfs comprise few stock higher chance beating estimate particular industry see etf category here research show stock combination chance positive earning surprise be high result fund be excellent investor seek guarantee profit earning season vaneck vector biotech etf bbh free report fund offer exposure large biotechnology corporation tracking mvis list biotech index stock portfolio be expect beat earning quarter amgen amgn free report celgene celg free report illumina ilmn free report incyte incy be top holding have earning esp respectively firm have zack rank collectively account asset biomarin pharmaceutical bmrn free report account share basket also have zack rank earning esp bbh have amassed asset base charge bps fee year volume be moderate exchange share daily average have zack etf rank high risk outlook read value biotech etfs buy now powershare dynamic retail portfolio pmr free report fund follow dynamic retail intellidex index measure performance company engage operate general merchandise store such department store discount store warehouse club superstore specialty store include apparel electronic accessory footwear store home improvement home furnishing store total product hold security stock portfolio expect come earning beat suggest solid upside etf particular best buy bby dollar tree dltr home depot hd free report walgreen boot alliance wba be top holding account share have earning esp respectively fund have accumulate just asset base charge bps fee year average daily volume be paltry share etf carry zack etf rank medium risk outlook read holiday sale year high best consumer etfs stock powershare dynamic energy exploration production portfolio pxe free report product follow dynamic energy exploration production intellidex index thoroughly evaluate company base variety investment merit criterium include price momentum earning momentum quality management action value hold stock basket have higher chance beating estimate quarter firm continental resource clr conocophillip cop eog resource eog occidental petroleum corp oxy have earning esp respectively eog have zack rank rest have zack rank pxe be expensive choice energy space expense ratio fund have aum trade volume share day average have zack etf rank high risk outlook read energy etfs stock soar start ishare home construction etf itb free report fund provide pure play home construction stock tracking dow jone select home construction index asset basket be expect surprise quarter top firm dr horton dhi free report have zack rank esp dhi account nearly share basket other firm toll brother tol free report home depot hd free report lowes company low free report have earning esp respectively have zack rank product have amassed asset base trade robust volume more share day average charge bps annual fee have zack etf rank high risk outlook read top rank etfs stock crushed market want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3175,CELG,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3176,CELG,week focus be annual morgan healthcare conference several biotech pharma company provide preliminary look result have also provide pipeline update well outlook meanwhile celgene celg free report be news company announce intention acquire impact biomedicine recap week most important storiescelgene buy impact celgene have start year acquisition announcement company be acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera deal term include upfront payment approximately contingent payment base achievement regulatory approval milestone myelofibrosis celgene make additional payment base approval label expansion achievement sale base milestone plan be submit new drug application fda mid celgene be look boost pipeline acquisition company have rough share decline last year issue pipeline setback well weak performance otezla have be weigh stock read more celgene acquire impact biomedicine boost pipeline key takeaway morgan healthcare conference several biotech company be present annual morgan healthcare conference most company provide preliminary look fourth quarter result outlook key update acorda acor free report start face generic competition flagship drug ampyra time jul company be currently seek fda approval inbrija response be february read more acorda share disappointing ampyra view vertex vrtx free report hold strong position cystic fibrosis cf market be look strengthen position further potential approval tezacaftor ivacaftor unite state decision fda be expect feb vertex also be company pursue acquisition deal year celgene also provide preliminary result outlook read more celgene provide preliminary result view vertex be zack rank strong buy stock see complete list today zack rank stock here axovant plunge intepirdine discontinuation axovant science axon free report share lose more value company announce disappointing result lead pipeline candidate intepirdine candidate fail meet primary efficacy endpoint study be conduct patient dementia lewy body dlb patient dementia gait impairment base axovant have decide discontinue development intepirdine be not first time axovant have face setback development effort intepirdine last year september company have say intepirdine fail meet co primary efficacy endpoint late stage study be conduct mild moderate alzheimer disease ad patient be receive background donepezil therapy time too company share have plunge significantly axovant share be last year compare decline record industry belong regeneron sanofi boost investment dupixent cemiplimab regeneron pharmaceutical regn free report partner sanofi have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential indication include atopic dermatitis asthma chronic obstructive pulmonary disease abbvie eczema drug get btd abbvie abbv free report investigational once daily oral jak selective inhibitor upadacitinib have be grant breakthrough therapy designation btd fda use adult patient moderate severe atopic dermatitis be candidate systemic therapy breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint upadacitinib be schedule move late stage program atopic dermatitis first half year read more abbvie upadacitinib gain breakthrough therapy designation biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here gwph submit epidiolex eu sangamo inks deal pfizer next biotech world watch usual regulatory pipeline update well preliminary result announcement outlook ahead release fourth quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3177,CELG,therapeutic inc cort free report adjust third quarter earning include stock base compensation expense cent share miss zack consensus estimate cent however report figure improve year adjust earning cent revenue increase year quarter figure also surpass zack consensus estimate so far year share price have increase year date industry decline research development expense improve likewise selling general administrative expense be fact increase operate expense be primarily owing greater compensation expense pharmacy cost related higher revenue increase spending development relacorilant newly approve generic name cort cort cort pipeline expect result phase ii study relacorilant end first quarter meanwhile company be plan underway end phase ii fda meeting commencement phase iii study third quarter end plan begin dose range study cort combine xtandi treat patient castration resistant prostate cancer begin testing combination relacorilant celgene celg free report abraxane patient pancreatic cancer guidancecorcept raise revenue guidance company now project revenue be range prior expectation zack consenus estimate be therapeutic incorporate price consensus ep surprise therapeutic incorporate price consensus ep surprise therapeutic incorporate quotezack rank stock carry zack rank hold better rank health care stock same space include ligand pharmaceutical inc lgnd free report inc agen free report ligand sport zack rank strong buy hold zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3178,CELG,major biotech stock gilead gild free report celgene celg free report alexion abbvie abbv free report vertex vrtx free report report second quarter result last few day company gilead amgen amgn free report also provide regulatory update recap week most important storiesa look earning result gilead result be strong company hiv franchise putt strong performance hepatitis virus hcv franchise perform better expect company raise revenue outlook include hcv franchise read more gilead top earning revenue estimate stock celgene also top estimate raise earning guidance year read more celgene beat earning sale estimate up view do alexion read more alexion top earning revenue up view vertex read more vertex earning top solid cystic fibrosis sale abbvie too top expectation read more abbvie top earning revenue outlook intact earlier expect fda approval celgene agio cancer drug celgene partner agio agio free report gain fda approval idhifa enasidenib treatment adult patient relapse refractory acute myeloid leukemia aml idh mutation detected fda approve test approval come ahead fda action date aug make idhifa first only fda approve therapy patient population represent aml patient information provide company more new case aml be detected year majority patient see disease relapse eventually prognosis aml be poor overall survival patient population estimate be less month idhifa come box warning regard differentiation syndrome uptake be strong give significant unmet medical need be third time lucky dynavax heplisav dynavax dvax free report share shot favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter nov other feb decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share be whopping year date significantly outperform industry rally read more dynavax share jump fda committee approval vertex up cf outlook kalydeco label expansion vertex cystic fibrosis cf drug kalydeco label have be expand now be used more cf patient year older have residual function mutation result splice defect cystic fibrosis transmembrane conductance regulator cftr gene label expansion vertex up sale guidance drug old guidance vertex now expect total cf product revenue old guidance include orkambi sale unchanged regulatory update amgen gilead amgen provide quite few regulatory update last few day company say have submit regulatory application seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop prolium bring sale first half amgen partner allergan also say have file fda approval abp biosimilar candidate roche herceptin trastuzumab herceptin be approve treatment adjuvant breast cancer metastatic breast cancer metastatic gastric cancer meanwhile amgen pcsk inhibitor repatha get priority review inclusion fourier cardiovascular outcome study datum reduction risk cardiovascular event decision agency be expect dec amgen say second application expansion lipid lower indication include additional patient population study be also accept agency gilead also have update regulatory front company say hcv drug epclusa label be update include use patient co infected hiv epclusa initially gain approval jun be oral pan genotypic once daily single tablet regimen label expansion provide co infected patient convenient pill day regimen work hcv genotype be compatible widely used antiretroviral regimen epclusa sale crossed first half moreover gilead latest hcv offer vosevi gain approval eu treatment genotype marketing authorization harvoni eu be also extend allow use adolescent population vosevi be approve few week back july gilead be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion gain regeneron lose last month vertex be see last biotech stock roundup here amgen biogen top estimate update incyte ra drug next biotech world watch earning report company biomarin regeneron other more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3179,CELG,fda approve treatment last year have give approval drug so far include july key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month august new indication bristol myer opdivo bristol myer squibb bmy free report be look get label pd inhibitor expand use patient mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer crc prior oxaliplatin irinotecan base chemotherapy regulatory application be currently priority review response expect aug opidivo be currently approve wide range indication bring sale first half bristol myer have lose value year date ytd versus growth industry ra drug support fda panel fda arthritis advisory committee be meeting tomorrow discuss bla johnson johnson jnj free report investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person new treatment option have enter market last couple decade ra patient be still not adequately manage many left fewer therapeutic option due loss response available agent poor compliance due inconvenient dose earlier week fda have release briefing document meeting indicate lot emphasis be place safety profile drug especially imbalance cause death plivensia placebo approve plivensia enter pretty crowd market give presence drug humira actemra kevzara other once monthly dose schedule give advantage share have gain ytd outperform industry rally fda follow eu path give green signal abbvie maviret abbvie abbv free report also have important regulatory event come fda expect respond approval status company latest hepatitis virus hcv offer month maviret investigational pan genotypic regimen glecaprevir pibrentasvir be once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch note maviret gain eu approval just last week share abbvie have gain ytd outperform industry rally third time lucky dynavax heplisav be great week clinical stage immunology company dynavax technology corp dvax free report get favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote be third time lucky company have previously receive complete response letter heplisav nov other feb fda decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share shot positive panel vote be whopping ytd significantly outperform industry rally pfizer xeljanz be review fda advisory panelpfizer pfe free report have regulatory event month first be fda advisory panel meeting other pdufa date fda arthritis advisory committee be meeting aug discuss supplemental new drug application snda submit company jak inhibitor xeljanz xeljanz xr treatment adult patient active psoriatic arthritis efficacy safety datum benefit risk consideration be discuss panel xeljanz currently approve ra bring sale meanwhile fda be expect give response regard approval status pfizer besponsa recently gain approval eu approve besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less pfizer stock have gain ytd lag industry belong pfizer be zack rank hold stock see complete list today zack rank strong buy stock here other fda decision schedule month include response regard agio pharmaceutical inc agio free report partner celgene celg free report idhifa priority review relapse refractory acute myeloid leukemia aml idh mutation aug meanwhile fda be expect decide approval status valeant eye drug vesneo latanoprostene bunod ad treatment levodopa induced dyskinesia person parkinson disease aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3180,CELG,celgene corporation celg free report report second quarter earning share include share base compensation expense tax adjustment beating zack consensus estimate share year quarter celgene share price movement show stock outperformed industry last year specifically stock have gain period compare industry gain exclude share base compensation expense celgene earning climb approximately year year report quarter total revenue grow second quarter surpass zack consensus estimate revenue be boost consistently strong performance company key growth driver revlimid revlimid continue shinenet product sale increase year year net sale revlimid come reflect year year growth drug do well growth report quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale decline increase internationally sale oncology drug pomalyst imnovid come sale be drive increase volume duration gain otezla report sale report quarter drive market share gain increase contribution early launch market europe japan other product sale include istodax thalomid vidaza authorize generic version vidaza totale report quarter year quarter adjust research development expense increase adjust selling general administrative expense decrease outlook updatedcelgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share net product sale be still project revlimid sale be project abraxane sale be estimate be pomalyst revenue be project same otezla be estimate celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoteour takecelgene second quarter result be strong company beating earning sale estimate revlimid continue outperform back market share gain quarter other key product pomalyst imnovid abraxane otezla also perform well consecutive increase earning guidance be positive meanwhile company continue progress label expansion effort pipeline development revlimid be approve single agent maintenance therapy adult patient newly diagnosed multiple myeloma ndmm follow autologous stem cell transplantation asct eu ndmm market share continue grow outside positive uptake eu japancelgene partnership agio pharmaceutical inc agio free report submit new drug application nda fda idhifa enasidenib relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation nda be grant priority review prescription drug user fee act pdufa action date aug potential approval further boost topline celgene have also collaborate acceleron pharma xlrn free report jointly develop phase ii chronic kidney disease zack rank key pickcelgene be zack rank hold stock better rank stock healthcare sector be exelixis inc exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3181,CELG,summit nj base celgene corporation celg free report be company focuse discovery development drug target cancer inflammatory disease celgene key growth driver be revlimid company portfolio also include pomalyst imnovid abraxane otezla istodax vidaza thalomid thalidomide however celgene be face generic competition vidaza scenario investor focus remain performance revlimid otezla apart usual top bottom line number meanwhile celgene have be striking prudent acquisition inking strategic deal bolster pipeline company be also work label expansion approve drug celgene track record have be decent company beating earning estimate occasion trail quarters overall company have deliver average positive earning surprise currently celgene have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoteearning celgene beat second quarter earning company report ep include share base compensation expense tax adjustment consensus call ep revenue revenue too beat expectation celgene post revenue consensus estimate outlook celgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share net product sale be still project pre market trading share be pre market trading check back later full celg earning report later more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3182,CELG,celgene corporation celg free report provide preliminary result guidance annual morgan healthcare conference company expect earning share ep year year operate margin be anticipate fourth quarter ep be anticipate increase year year operate margin be expect zack consensus estimate earning fourth quarter be total revenue be expect fourth quarter zack consensus estimate revenue fourth quarter be revlimid revenue be expect fourth quarter pomalyst revenue be expect otezla revenue be expect fourth quarter abraxane revenue be fourth quarter guidance total revenue be expect be zack consensus estimate be revlimid net sale be project otezla net sale be project company expect submit snda fda revlimid combination bortezomib dexamethasone patient newly diagnosed multiple myeloma company also plan submit nda fda fedratinib myelofibrosis abraxane net sale be project ep be project company have also plan initiate few trial cc hodgkin lymphoma bgb tislelizumab small cell lung cancer phase iii trial bb third line multiple myeloma collaboration bluebird bio blue free report phase iii trial jcar transplant eligible second line diffuse large cell lymphoma dlbcl collaboration juno therapeutic other long term targetin long run revenue be expect celgene stock have decline last month compare industry loss celgene suffer series setback last few month company suffer setback last week late stage study lead cancer drug revlimid combination rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma celgene key growth engine be revlimid drug worldwide sale increase contribute almost total revenue revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing drug label expansion have boost sale potential boost oncology portfolio celgene announce acquire impact biomedicine upfront amount term agreement impact biomedicine shareholder receive contingent payment base regulatory approval sale base milestone maximum aggregate amount payable such milestone payment be aggregate tiered sale base milestone payment total maximum global annual net sale exceed acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis mf polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf august company obtain fda approval idhifa treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
3183,CELG,welcome back mind money kevin cook field guide story teller fascinating arena behavioral economic episode be risk reward mechanic decision make sometimes avoid make decision often never learn bad one be fortunate become high frequency currency trader year learn make lot decision hour never afford regret only learn doesn mean don still fall prey bad habit have face uncertainty risk do ever wonder great investor trader make decision put consistently ahead peer do not put category greatness know little ve spend considerable time past decade study great short term trader great long term investor now finance always have be careful talk success make sure be not just high light survivor always winner have make certain be look credible degree success time go mere randomness study short term trader commodity currency pit chicago read jack schwager market wizard book come away pillar behavior seem make difference time market be psychology not just awareness bias decision make continuous process improvement probability sound mechanic situational risk reward way too easy emotion bias take system not just computer spit signal system everything research process performance evaluation risk management precise rule capital allocation preservation be crucial long term survival discipline speak especially make dozen decision day require consistent rule follow consistency run process year survive vagary change market season happen trader investor doesn try master principle skill worst lose money quickly best get lucky survive not long middle be majority slowly watch money bleed away little week sometimes bigger chunk see hard be apply principle chaos market look different science help explain behavioral finance spear head nobel prize winner daniel kahneman look human decision make uncertainty risk experiment find do most person do give situation say researcher study outside explain behavior neuroscientist course study explain action read much important research science handle come stunning conclusion brain wasn make trade fit evolutionary biologist anthropologist be teach kind brain few year fit start natural selection give definitely weren make stare price move rapidly change wealth outlook second do know most naturally do exactly wrong thing especially short term trading hold lose trade take profit too soon be mathematical recipe make money go away time trading golden rule be cut thy loss short let thy winner run most human trader monkey do exactly opposite fear greed illogical biase ego take make money go away assume make rational decision money be best long term be big assumption most be very irrational come day money risk decision long term plan one cover much march episode irrational demand anchor pearl procrastination well back be pretty proud original idea brain wasn make trade then remember book have read probably help path new world new mind robert ornstein paul former latter biologist be famous alarm call population back book propose evolution brain ability sense cataclysmic change take place long period time be simply not go fast enough only thing make difference be accelerate cultural evolution here bright observer review book amazon describe more compelling point author make be not only be politician be elect reward basis short term decision be many measure intellectually morally financially corrupt so call knowledge worker scientist engineer other be blow whistle be so specialize be real lack integrative knowledge think area obvious climate change debate short term think blind long term effect change think education vs entertainment machine parent be far too likely let kid have electronic gadget tvs phone babysit mom dad have stuff do parent work be nuclear arm race seem be problem get put ice now north korea rattle sabre month feel old question again really happen be biggest example ornstein highlighted new world new mind remember exactly frame problem solution other new cultural political institution move warfare primary solution first thing come mind be be more irrational other do sleep tight think prevent nuclear war just very lucky idiot get hand missile scary stuff say sure ve figured good solution just ve go year incident stone age brain barely comprehend kind cataclysm so easier not think ornstein thought try anyway think have solution don be eternal optimist so rest episode mind money podcast share book dynamic duo year later care fate science just much ornstein also break week big trading immuno oncology stock such kite pharmaceutical be buy gilead science gild free report cause feverish rally related peer juno therapeutic bluebird bio blue free report tell play stock not celgene celg free report be next bidder little biotech wonder kevin cook be senior stock strategist zack investment research run healthcare innovator portfolio
3184,CELG,agio pharmaceutical inc agio free report be expect report second quarter result aug share have surge so far year compare favorably industry increase agio performance have be mixed company miss estimate twice trail quarters surpass same other occasion overall agio have average positive surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quotelast quarter company deliver positive surprise let see thing be shape quarter factor playas development stage company agio do not have approve product portfolio yet investor be thus expect keep eye pipeline update earning call be worth mention company have several interesting candidate pipeline cancer pipeline comprise idhifa enasidenib ag idh mutant inhibitor ag pan idh mutant inhibitor notably agio be develop enasidenib ag collaboration celgene corporation celg free report bring collaboration revenue idhifa be presently fda review treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company expect fda give decision aug idhifa be be evaluate several phase dose escalation study evaluate hematological solid tumor cancer idh mutation last month company announce positive efficacy safety datum ongoing phase dose escalation expansion study evaluate idhifa patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation agio celgene intend initiate high risk myelodysplastic syndrome study enasidenib apart idhifa agio be also plan initiate phase iii study ag front line aml patient idh mutation soon company plan explore similar regulatory path ag lead nda submission year earning whispersour proven model do not conclusively show agio be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be be most accurate estimate stand zack consensus estimate stand loss share uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp however company earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter zoetis inc zts free report be schedule release result aug have earning esp zack rank see complete list today zack rank stock here tesaro inc tsro free report be schedule release result aug company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
3185,CELG,aerie pharmaceutical inc aeri free report be schedule report first quarter result market close last quarter company report wider expect loss aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc price consensus ep surprise aerie pharmaceutical inc quoteaerie performance last quarters have be mixed company incur narrower expect loss trail quarters report wider expect loss remain average negative surprise aerie share have return year compare industry gain factor playaerie stock receive major boost december fda approval lead candidate rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension news be significant boost aerie give company have approve product portfolio fda approval come month ahead schedule prescription drug user fee act goal date feb glaucoma be largest segment global ophthalmic market accord national eye institute be estimate more individual unite state suffer glaucoma number be expect reach aerie expect rhopress revenue range company recently announce have launch drug unite state company have hire regional sale director district manager well more expect territory manager company expect gain prefer formulary coverage majority commercial payer rhopressa late most medicare part coverage expect commence expect management throw more light drug launch first quarter call meanwhile aerie second product candidate roclatan netarsudil latanoprost ophthalmic solution be fix dose combination rhopressa pfizer pfe free report xalatan achieve primary efficacy endpoint phase iii registration trial name mercury mercury candidate also achieve successful month safety efficacy result mercury company expect submit nda roclatan second quarter investor also be focus aerie update same earning whispersour proven model do not show aerie be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank aerie have zack rank be favorable however need have positive esp well be confident earning beat note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be few health care stock want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3186,CELG,jazz pharmaceutical plc jazz free report be schedule report first quarter result market close share company have outperformed industry so far year stock have rally industry decrease jazz have be showcase disappointing earning history late company surpass estimate only once last quarters miss same other average beat last quarter company deliver negative surprise let see thing have shape last complete quarter factor playon first quarter conference call investor be attentive management comment regard xyrem performance be jazz lead product cataplexy excessive daytime sleepiness ed also be keen know company pipeline progress business development plan be also expect draw notice xyrem have witness lower expect growth second half due negative impact payer mix operational change lead delay prescription fulfillment however fourth quarter conference management have increase sale outlook xyrem anticipate low mid single digit volume expansion drug remain be see be reflect xyrem sale performance be report quarter notably jazz be strive expand xyrem label company report positive top line datum phase iii study child adolescent ed mid last week company submit regulatory application drug fda give indication company drug defitelio veno occlusive disease be launch unite state early april drug performance be soft first half show improvement fourth quarter trend expect continue however jazz have be face challenge build sufficient inventory level product call erwinaze due constrain manufacturing capacity also have be supply disruption certain market company last complete quarter include unite state noticeably last report quarter company record impressive sale vyxeo launch august market treat adult acute myeloid leukemia aml drug be expect generate significant revenue be report quarter well give company aggressive effort same also jazz lead pipeline candidate jzp complement exist sleep disorder portfolio have be develop treatment ed march jazz announce fda accept company regulatory application jzp respect give indication response fda be await dec earning whispersour proven model do not conclusively show jazz be likely beat estimate earning season be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp jazz have earning esp represent percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank jazz have zack rank increase predictive power esp however company need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc quote stock considersome health care stock right combination element surpass estimate time be follow emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result see complete list today zack rank stock here celgene corporation celg free report have earning esp zack rank company be schedule release first quarter result adverum biotechnology inc advm free report have earning esp be zack rank player company be expect release first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3187,CELG,intrexon corporation xon free report be expect report first quarter result market close last report quarter company deliver positive earning surprise intrexon have mixed surprise history trail quarters company surpass estimate thrice trail average beat intrexon share have return year date outperform industry gain factor business model help commercialize technology exclusive channel collaboration ecc licensing agreement joint venture collaborator have market product development expertise well sale marketing capability facilitate company bring new improve product process market agreement help intrexon generate fund form technology access fee milestone other payment intrexon be collaborate various company develop several candidate company team fibrocell science inc fcsc free report complete enrolment phase ii study fcx recessive dystrophic epidermolysis bullosa january fibrocell receive approval fda initiate enrollment pediatric patient phase ii portion phase ii study fcx also second gene therapy candidate fcx be be develop fibrocell treatment linear scleroderma intrexon expand portfolio technology have enabled company develop robust pipeline company effort growth acquisition eccs be encourage therefore expect investor focus remain company performance other developmental update quarterly call model proven model do not show earning beat intrexon quarter be stock need have positive earning esp zack rank strong buy buy hold surpass estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg loss cent zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank intrexon have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result intrexon corporation price ep surprise intrexon corporation price ep surprise intrexon corporation quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3188,CELG,drug approval licensing deal be area focus biotech space last week gilead hcv drug eplcusa be approve china biomarin palynziq get fda approval other hand alexion offer acquire sweden base wilson therapeutcis be accept latter shareholder recap important story gilead epclusa get approval china china drug administration cda approve gilead gild free report epclusa sofosbuvir mg velpatasvir mg treatment adult genotype chronic hepatitis virus hcv infection cda also approve epclusa combination ribavirin rbv adult hcv decompensate cirrhosis approval be base positive result phase iii study astral astral astral astral astral high overall rate svr defined undetectable hcv rna week complete therapy range be achieve difficult cure patient population include treatment experience patient compensate decompensate cirrhosis approval further expand gilead geographic reach somewhat boost dwindle hcv portfolio gilead be zack rank hold stock see complete list today zack rank strong buy stock here biomarin get fda approval forpalynziq biomarin pharmaceutical inc bmrn free report obtain standard approval fda palynziq pegvaliase pqpz injection reduction blood phenylalanine phe concentration adult patient pku have uncontrolled blood phe concentration greater micromol exist management march european medicine agency also accept company marketing authorization application palynziq unite state palynziq be first enzyme therapy approve treatment pku drug complement sale biomarin other drug kuvan alexion offer wilson acquisition accept alexion alxn free report announce offer acquire sweden base wilson therapeutic have be accept shareholder represent total number share vote latter acquisition have also be approve relevant regulatory authority settlement tender share occur acquisition add late stage candidate wtx alexion pipeline company look diversify portfolio reduce dependence blockbuster drug soliris wtx enjoy fast track designation unite state orphan drug designation treatment wilson disease unite state europe union cara therapeutic gain licensing deal share cara therapeutic inc cara free report jump significantly last week follow announcement licensing deal fresenius medical care renal pharma ltd company license worldwide right commercialize korsuva cr difelikefalin injection treatment chronic kidney disease associate pruritus ckd ap dialysis patient unite state japan south korea remind investor fda grant breakthrough therapy designation korsuva injection indication term deal cara be entitle receive upfront payment cash equity investment acquire cara common stock price approximately share cara be also entitle receive additional payment include regulatory tiered commercial milestone company also receive tiered royalty base net sale license territory celgene repurchase share celgene corporation celg free report announce company repurchase common stock company also plan enter accelerate share repurchase asr agreement repurchase aggregate common stock plan asr use exist authorize share repurchase program well part new authorization biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose past month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup fda give nod amgen drug eu approve exelixis cabometyx next biotech stay tune regulatory update pipeline development news american society clinical oncology asco annual meeting chicago illinois today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3189,CELG,share prothena corporation prta free report be day company announce reorganization plan prothena stock have lose last month industry decline company have decide reduce workforce approximately result discontinuation lead candidate neod remind investor neod antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study consequently company decide discontinue study development neod include vital study well open label extension study earlier prothena announce disappointing result phase ib multiple ascend dose mad study pipeline candidate prx psoriasis patient primary objective study be achieve however advance prx mid stage clinical development require well defined relationship biological activity meaningful clinical effect prerequisite be not meet prothena expect workforce be approximately position plan be execute company plan align resource advance remain candidate neuroscience pipeline prx rg be develop collaboration roche rhhby free report proprietary program prx well discovery stage pipeline discovery stage lineup include proprietary program target aβ program be advanced part neuroscience collaboration celgene celg free report include tau tdp undisclosed target consequently prothena revise full year financial guidance now expect net cash burn operate investing activity be zack rank stock currently carry zack rank hold better rank stock healthcare sector be ligand pharmaceutical lgnd free report carry zack rank buy see complete list today zack strong buy rank stock here ligand earning share estimate be revise upward past day company come positive earning surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3190,CELG,issue update research report agio pharmaceutical inc agio free report agio only market drug be idhifa receive fda approval treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation august however apart idhifa agio do not have approve product portfolio yet hence company top line mainly comprise collaboration revenue milestone payment year date share company have increase compare industry increase company have several interesting candidate pipeline lead cancer pipeline include tibsovo ivosidenib ag priority review unite state most advanced candidate target mutate isocitrate dehydrogenase idh december agio submit new drug application nda fda tibsovo ivosidenib have be develop treat patient aml idh mutation subsequently february fda accept nda priority review give indication fda have set action date aug regulatory filing candidate european union be expect fourth quarter same indication other candidate include ag target mutate idh mutate idh mutation be find wide range hematological malignancy solid tumor include aml chondrosarcoma treatment option prognosis patient be poor company lead rare genetic disease candidate ag be evaluation phase ii study adult transfusion independent patient pyruvate kinase pk deficiency first quarter company initiate activate single arm pivotal study ag adult pk deficiency patient receive regular blood transfusion fact company plan initiate study activate ag adult pk deficiency do not receive regular blood transfusion second quarter candidate ag first class methionine mat inhibitor be be evaluate phase dose escalation study patient phosphorylase mtap delete tumor potential approval pipeline candidate be huge boost company agio celgene celg free report announce new global strategic collaboration discovery development novel therapy utilize agio innovative cellular metabolism research platform term celgene deal be lucrative agio be eligible receive clinical regulatory commercial milestone payment royalty net sale product result collaboration however company depend heavily celgene revenue earn form collaboration revenue company also face stiff competition zack rank stock consideragiosha zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3191,CELG,bluebird bio inc blue free report announce fda have grant breakthrough therapy designation lenti treatment patient cerebral cald note breakthrough therapy designation expedite development review drug intend standalone therapy combination more other drug treat serious life threaten disease preliminary datum suggest drug demonstrate substantial improvement exist therapy more clinically significant endpoint designation be support positive preliminary datum ongoing phase ii iii starbeam study ald evaluate lenti investigational gene therapy boy cald year age less do not have match sibling donor year study have assessed safety efficacy investigational gene therapy cald be hereditary neurological disorder note lenti investigational gene therapy enjoy orphan drug status unite state europe drug be also grant rare pediatric disease designation fda treatment ald fda rare pediatric disease priority review voucher program sponsor receive marketing application approval rare pediatric indication be generally eligible priority review voucher be redeem obtain priority review subsequent marketing application different product bluebird bio have build diverse pipeline lentiviral base gene therapy cell immunotherapy expertise gene editing capability bluebird bio gene therapy clinical program include lenti treatment cerebral lentiglobin treatment transfusion dependent thalassemia also know thalassemia major severe sickle cell disease oncology pipeline primarily focus develop novel cell base immunotherapy include chimeric antigen receptor car cell receptor tcr therapy lead oncology program include bb bb be bcma car program company be develop partnership celgene celg free report car therapy be focus approval gilead gild free report yescarta novartis nvs free report kymriah past month bluebird stock have return decline register industry zack rankbluebird carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3192,CELG,catalyst pharmaceutical inc cprx free report be expect report first quarter result market close last report quarter company earning be line estimate top expectation last quarters average beat year date catalyst share have decrease compare industry decline let see thing be shape quarter factor do not have revenue generate product portfolio investor focus be pipeline regulatory update first quarter earning call currently company have candidate development namely firdapse cpp cpp catalyst lead pipeline candidate firdapse have be develop symptomatic treatment lambert eaton myasthenic syndrome lem february company announce positive top line result second phase iii study firdapse study achieve statistical significance co primary endpoint quantitative myasthenia gravis score qmg subject global impression sgi secondary endpoint top line result show firdapse have significant magnitude effect treat symptom lem company meet fda type meeting february get firdapse approve lem minute meeting receive fda reflect fda advice catalyst propose filing package be sufficient resubmission nda firdapse march catalyst submit nda fda address issue raise refusal file letter include additional information request fda remind investor fda have give refusal file letter company submit nda ask additional information additionally company be work develop firdapse additional indication april company enrolled first patient phase iii study musk antibody positive myasthenia gravis company expect trial take month complete therefore expect announce topline result first half second half company expect report top line datum ongoing clinical trial evaluate firdapse treatment congenital myasthenic syndrome cms apart firdapse catalyst be also explore possibility develop cpp gaba inhibitor treatment epilepsy initially infantile spasm other select neurological indication such complex partial seizure tourette disorder moreover company be work lundbeck generic version sabril vigabatrin treatment infantile spasm complex partial seizure earning whispersour proven model do not show earning beat catalyst quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp catalyst have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank catalyst carry zack rank increase predictive power esp however need have positive esp be confident earning beat see complete list today zack rank stock here note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision catalyst pharmaceutical inc price ep surprise catalyst pharmaceutical inc price ep surprise catalyst pharmaceutical inc quotestock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3193,CELG,biotech sector have be attract lot investor attention lately sector be expect continue benefit increase activity new drug approval better innovation sector take beating last year owing drug price control trump plan tackle ever surge drug price get highlighted latest budget grow demand drug especially rare treat disease age population increase health care spending benefit industry economy backdropu market recently suffer sell owing fear rise rate enter correction territory decline more record high set january strong wage growth job datum introduce fear inflation make comeback lead investor bet aggressive rate hike consumer price increase year year january unchanged previous month economist forecast moreover president donald trump tax reform spending deal create further pressure price hence fed be expect hike interest rate multiple time year tame inflation jerome powell testimony be see indicative possibility fed raise rate more time gauge appropriate path monetary policy next few year fomc continue strike balance avoid over-heat economy bring pce personal consumption expenditure price inflation sustain basis financial time article cite statement powell such market be suffering anticipate rate hike cyclical nature biotech stock seem appeal investor moreover encourage industry trend positive earning be poise benefit etfs expose say sector read biotech crush market best etfs stock ytd let now discuss etfs focuse provide exposure sector spdr biotech etf xbi free report fund seek provide exposure biotech space track biotechnology select industry index have aum charge fee basis point year have holding bear less concentration risk less asset be allocate top holding fund top holding be bioverativ inc array biopharma inc arry free report juno therapeutic inc allocation respectively feb fund have return year year date xbi have zack etf rank buy high risk outlook ishare nasdaq biotechnology etf ibb free report fund seek provide exposure biotech space track nasdaq biotechnology index have aum charge fee basis point year have holding bear concentration risk more asset be allocate top holding fund top holding be gilead science inc gild free report amgen inc amgn free report celgene corp celg free report allocation respectively feb fund have return year year date ibb have zack etf rank hold high risk outlook bottom lineibb be more popular xbi be evident higher aum however xbi be more appeal investor owing cheaper expense ratio better zack rank same time xbi have significantly outperformed ibb come performance xbi have return almost more ibb so far year year outperformed ibb more however investor note xbi be focuse provide exposure small cap stock space ibb be more incline large cap player want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3194,CELG,key highlight week include fda refusal file letter celgene corp celg free report ozanimod gilead science inc gild free report collaboration sangamo therapeutic inc used latter technology positive chmp opinion amgen inc amgn free report xgeva incyte corp incy free report beat revenue strong jakafi sale fourth quarter recap week most important storiesfda refuse ozanimod nda follow announcement receipt refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod share celgene be pre market trading candidate be be develop treatment patient relapse form multiple sclerosis however fda determine nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor celgene be take desperate attempt bolster portfolio reduce overdependence lead drug revlimid company recently obtain antitrust clearance impending juno acquisition celgene be zack rank hold stock see complete list today zack rank strong buy stock here gilead collaborate sangamo gilead kite have enter collaboration agreement sangamo therapeutic inc agreement kite use sangamo zfn technology modify gene develop next generation cell therapy autologous allogeneic use oncology lieu sangamo receive upfront payment potential milestone payment sangamo be also entitle receive tiered royalty sale potential future product result collaboration other hand kite be responsible development manufacturing product collaboration sangamo share sky-rocket high news collaboration investor have lot cheer give gilead expertise biotech field chmp positive amgen xgeva label expansion committee medicinal product human use chmp european medicine agency have give positive opinion expand current indication amgen xgeva include skeletal related event patient multiple myeloma give positive result phase iii study candidate get approval aforementioned indication study result show xgeva successfully meet primary endpoint demonstrate inferiority zoledronic acid delay time first study skeletal related event patient multiple myeloma fda already approve company supplemental biologic license application xgeva expand currently approve indication prevention skeletal related event patient bone metastase solid tumor include patient multiple myeloma january vertex initiate phase iii triple combination study cf vertex pharmaceutical inc vrtx free report leader cystic fibrosis cf market announce initiation phase iii study vx tezacaftor kalydeco investigational triple combination regimen patient suffering cf have del mutation minimal function mutation study be be conduct support submission nda unite state used datum week primary efficacy endpoint together safety datum week treatment earlier month fda approve symdeko treatment underlie cause cf patient age older have copy del mutation cystic fibrosis transmembrane conductance regulator gene have least mutation be responsive tezacaftor ivacaftor biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain last month regeneron lose amgen gain see last biotech stock roundup here biotech stock roundup abbvie result impress ablynx be acquire sanofi next biotech world stay tune more regulatory pipeline update approach last leg earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3195,CELG,rise last year large cap pharmaceutical industry have rise year so far have however underperform gain same time frame sector be strong start struggle little thereafter probably broader market correction also mention high drug price president donald trump state union address hurt investor sentiment however sector be largely expect rebound year progress be good year pharma biotech stock sector witness positive development lead much await recovery nyse arca pharmaceutical index gain sharp contrast decline witness be tough year pharma stock give furor rise drug price key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy remain headline risk investor appear more comfortable issue moreover significantly higher number fda approval restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector come back believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit possibility more merger acquisition be also high now tax reform be place big player be lookout company innovative pipeline technology have already be quite bit buzz year potential deal sanofi sny free report celgene celg free report have already announce deal meanwhile large cap pharma industry be top zack rank industry make sense look buy rank stock space investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well look well poise earn higher profit here be look large cap pharma company sport favorable zack rank strong buy buy lundbeck hluyy free report denmark base lundbeck specialize psychiatric neurological disorder company key area focus include depression schizophrenia parkinson disease alzheimer disease accord lundbeck person world suffer psychiatric neurological disorder many receive inadequate treatment ytd lundbeck have outperformed large cap pharmaceutical industry share gain addition deliver revenue growth local currency lundbeck issue upbeat outlook estimate earning growth current year be meanwhile earning estimate be past day abbvie inc abbv free report abbvie beat estimate earning sale fourth quarter also raise earning expectation base continue strong operational performance abbvie key drug humira have be perform well base strong demand trend new competition abbvie share have outperformed industry past year support series positive news include promising datum several pivotal study regulatory nod include approval competitive hcv medicine mavyret approval imbruvica settlement humira patent dispute biotech major amgen amgn free report abbvie share be impressive year so far outperform industry estimate earning growth current year be meanwhile estimate be respectively past day pfizer inc pfe free report new york base pfizer be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product pfizer report better expect fourth quarter result beat estimate earning well sale provide upbeat outlook believe pfizer snew product ibrance contribution acquisition cost cut share buyback help company earn profit future quarters pfizer share have rise year so far estimate earning growth current year be meanwhile estimate be respectively past day nordisk nvo free report year be eventful denmark base pharma giant gain regulatory approval key pipeline drug candidate include fast act insulin aspart fiasp once daily pre filled pen ozempic hemophilia treatment rebinyn meanwhile strong performance victoza be drive top line growth believe new product solid pipeline pave way growth year company past day earning estimate have rise respectively estimate earning growth current year be pfizer abbvie nordisk be zack rank buy stock lundbeck be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3196,CELG,biomarin pharmaceutical inc bmrn free report report first quarter result apr market close biomarin deliver negative earning surprise last quarter biomarin earning track record have be decent company beating estimate past quarters deliver average positive surprise biomarin share have decline year so far compare favorably decrease register industry period let see thing be shape company quarter factor playkey orphan disease drug vimizim kuvan drive biomarin top line past few quarters be likely maintain trend quarter too robust patient growth penetration propel drug sale also naglazyme vimzin revenue vary quarterly basis primarily due inconsistent order pattern country fourth quarter conference call company have say be cautiously optimistic sale brazil be steady uneven buy pattern be observed quarter quarter nevertheless drug continue witness steady patient growth expect trend continue quarter expect management discuss pipeline be progress conference call brineura treatment child cln disease form batten disease be approve unite state eu last year brineura generate sale call company say focus initial stage launch be disease awareness early diagnosis company mentioned new site readiness take longer expect suggest slower revenue ramp investor call also expect management comment launch preparation pegvaliase pegvaliase develop treat pku be review unite state fda expect give decision regard pegvaliase launch call management have inform initial sale ramp pegvaliase be slow due education disease awareness lower dose patient induction titration phase also company mentioned expect price pegvaliase modest premium kuvan net annual treatment cost update be expect upcoming call earning whispersour proven model do not conclusively show biomarin be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate be cent most accurate estimate be peg lower cent uncover best stock buy sell re report earning esp filter zack rank biomarin zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report have earning esp zack rank company be schedule release result apr celgene corporation celg free report have earning esp zack rank company be schedule release result make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3197,CELG,expect vertex pharmaceutical inc vrtx free report beat expectation report first quarter result apr market close vertex share have increase so far year industry have record decrease vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi perform consistently sale rise almost expect positive trend continue soon be report quarter however company announce last quarter earning call first quarter revenue be unfavorably impact higher gross net revenue adjustment buildup channel inventory fourth quarter january vertex announce extension marketing application orkambi be approve europe approval orkambi marketing label eu now include use child cf age year have copy del mutation expand patient population expand patient population be expect boost sale drug zack consensus estimate orkambi sale first quarter be kalydeco receive approval line extension include patient year older certain residual mutation cftr gene drug generate significant sale last year due rapid uptake expand patient population expect trend continue zack consensus estimate first quarter kalydeco sale be peg millionin boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february drug be review europe however expect new drug contribute minimally first quarter sale expect company provide update symdeko plan initial uptake company remain focuse development triple combination regimen quarter vertex advanced vx vx phase iii development also phase iii study be initiate evaluate vx combination tezacaftor kalydeco ivacaftor cf patient investor focus call be triple combination cf regimen be crucial long term growth vertex company be also likely provide full year revenue guidance include symdeko sale call however operate expense be likely be higher side due initiation pivotal study launch symdeko likely positive surprise proven model indicate vertex be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3198,CELG,roche hold ag rhhby free report announce encourage datum multiple sclerosis ms drug ocrevus american academy neurology aan annual meeting hold apr los angele datum reveal efficacy ocrevus relapse multiple sclerosis rm several measure underlie disease activity disability progression include magnetic resonance imaging mri cognitive function spinal fluid biomarker inflammation datum show year continuous treatment ocrevus show sustain reduction underlie disease activity rm open label extension period patient continue ocrevus maintain low number gadolinium enhance gd lesion pre ole gd lesion scan year year ole phase new enlarge et lesion pre ole et lesion scan year ole phase safety datum be consistent drug favorable benefit risk profile relapse primary progressive multiple sclerosis additonally second year analysis present poster aan also reveal patient stay ocrevus year ole period sustain low annualize relapse rate week confirm disability progression switch interferon beta ocrevus experience significant decline arr year be maintain year further ocrevus reduce risk week confirm cognitive decline defined confirm worsening symbol digit modality test least point respectively week period person rm compare interferon beta pooled datum phase iii study opera opera ii datum show patient rm increase risk progressive disease determine baseline expand disability status scale pyramidal kurtzke functional system score least point respectively treat ocrevus experience significant improvement cognitive function compare take interferon beta week march fda approve ocrevus treat adult relapse form ms primary progressive multiple sclerosis however be uncertainty ocrevus be new innovation reformulation roche older drug rituxan drug sale aren impressive yet roche stock have lose year industry gain last week novartis nvs free report also announce encourage datum phase iii study expand oral once daily siponimod baf patient secondary progressive multiple sclerosis spms give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms spms primary progressive ms competition be also stiff market biogen biib free report be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta fda recently issue refusal file letter celgene celg free report new drug application ozanimod be development treatment patient relapse form multiple sclerosis zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3199,CELG,novartis ag nvs free report announce encourage datum phase iii study expand oral once daily siponimod baf patient secondary progressive multiple sclerosis spms siponimod be investigational selective modulator specific subtype sphingosine phosphate receptor result be present american academy neurology annual meeting los angele be schedule be hold apr randomize double blind placebo controlled expand study be compare efficacy safety siponimod versus placebo spms patient datum study show siponimod reduce risk disability progression largely disassociate relapse patient spms new post analysis also demonstrated risk reduction siponimod be largely disassociate relapse datum study show siponimod result significant benefit cognitive process speed key cognitive function impact ms impact affected patient meanwhile novartis have initiate submission siponimod unite state approval spms filing eu approval be plan follow later potential approval strengthen novartis ms portfolio include gilenya fingolimod modulator approve relapse form ms be also development pediatric ms interferon beta subcutaneous injection be approve unite state treatment relapse form ms novartis also have ms candidate pipeline apart siponimod ofatumumab omb fully human monoclonal antibody be evaluate phase iii study relapse ms generic division sandoz market glatopa glatiramer acetate injection mg ml mg ml generic version teva teva free report copaxone give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms spms primary progressive ms however competition be stiff market biogen biib free report be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta fda recently issue refusal file letter celgene celg free report new drug application ozanimod be development treatment patient relapse form multiple sclerosis novartis stock have lose last month compare industry decline share have decline further follow first quarter result be report yesterday revenue earning beat estimate sale psoriasis drug cosentyx fall short expectation sandoz revenue decline due pricing pressure zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3200,CELG,expect biotech major amgen inc amgn free report beat expectation report first quarter result apr market close amgen deliver negative earning surprise last quarter amgen share have decline past year still compare favorably decrease register industry period amgen performance have be modest company deliver positive surprise trail quarters average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc quotelet see thing be shape company quarter factor first quarter usually generate lowest product sale amgen amgen newer product prolium kyproli xgeva blincyto be likely perform well backed higher demand make lower sale mature brand enbrel aranesp epogen neulasta neupogen due competitive pressure early amgen gain fda approval include overall survival datum label kyproli blincyto reflect first quarter sale drug january xgeva gain fda approval prevention skeletal related event patient multiple myeloma label extension boost sale drug neulasta demand be be hurt competition pd other new cancer sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogenwe expect neulasta neupogen first quarter sale be hurt competitive dynamic neulasta epogen be expect start face biosimilar competition unite state year also sensipar sale be likely decline sharply soon be report quarter drug lose patent exclusivity march enbrel sale be expect be hurt increase pricing competitive pressure enbrel be main driver amgen revenue fourth quarter conference call amgen say sale enbrel first quarter be expect be lowest represent approximately full year sale also repatha sale first quarter be expect be relatively flat sequentially hurt insurance verification patient pocket cost also investor be keen know sale repatha have improve inclusion fourier outcome datum label amgen partner allergan agn free report biosimilar version roche cancer drug avastin mvasi be approve eu january boost first quarter sale drug investor focus call be management comment preparation potential launch migraine candidate aimovig fda be expect give decision aimovig biologic license application bla mid meanwhile higher investment support product launch be likely result higher sg cost be report quarter earning whispersour proven model show amgen be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank amgen have zack rank combination amgen zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerbiotech stock have positive esp favorable zack rank include alexion pharmaceutical inc alxn free report schedule release result apr have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report have earning esp zack rank company be schedule release result wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3201,CELG,biotechnology sector include fast grow company health care world be easily crush overall market broader health care sector so far year be especially thank wave merger acquisition encourage trend well new tax legislation merger merger acquisition talk rumor have give boost biotech stock celgene corp celg free report have agree buy juno therapeutic inc share cash sanofi sny free report announce deal acquire bioverativ give flurry deal so far activity biotech sector be expect be robust year ey expect deal value exceed give company increase financial firepower balance sheet strength read wave push biotech etfs higher encourage industry be clearly benefit solid corporate earning promising drug launch faster drug approval cost cut effort age population ever increase healthcare spending expansion emerge market trump tax reform particular new tax legislation have entice company bring offshore cash back home reduce tax rate instead prior repatriate money be used share buyback dividend acquisition capital spending additionally sector cyclical nature be advantage current environment concern higher inflation resultant increase interest rate be rise geopolitical tension washington turmoil well prospect end worldwide cheap money policy era be also compelling investor move defensive sector health care see health care etfs here play development be fuel growth biotech company lead rally share price impressive level momentum biotech etfs suggest tilt biotech be definitely good idea highlight biotech etfs stock have deliver double digit return year date time frame be excellent play investor believe biotech continue move upward continue lead health care space higher month ahead loncar cancer immunotherapy etf cncr free report product track loncar cancer immunotherapy index provide exposure basket company develop therapy treat cancer harness body own immune system hold stock heavy concentration top firm other firm account more share etf have amassed asset base trade lower average daily volume share expense ratio come product have soar so far year carry zack etf rank buy high risk outlook read biotech etf hit new week high virtus lifesci biotech clinical trial etf bbc free report fund have novel approach biotechnology investing exposure company be clinical trial stage easily be do tracking lifesci biotechnology clinical trial index bbc have amassed asset base charge bps fee year investor trade light average daily volume share hold security basket accounting less share product have gain carry zack etf rank high risk outlook read top rank etfs stock crushed market ark genomic revolution multus sector etf arkg free report be actively manage etf focuse company be expect benefit extend enhance quality human other life incorporating technological scientific development improvement advancement genomic business fund hold stock basket none accounting more share have amassed asset base trade good average daily volume share expense ratio come etf be year date time frame cascadian therapeutic inc washington base company specialize develop innovative therapeutic product candidate treatment cancer stock see earning estimate revision past day have expect earning growth rate year carry zack rank hold vgm score share casc have surge so far year see complete list today zack rank strong buy stock here atara biotherapeutic inc atra free report california base clinical stage company be focuse develop therapeutic serious unmet medical need initial focus muscle wasting condition oncology zack rank stock have gain year see zack consensus estimate move loss loss year however company be project post earning decline year have vgm score read best perform stock top etf january iovance biotherapeutic inc iova free report california base company be focuse development cancer immunotherapy product design harness power patient own immune system eradicate cancer cell zack consensus estimate have go loss loss past month estimate growth rate again stock have zack rank hold vgm score have gain year date time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3202,CELG,agio pharmaceutical inc agio free report post third quarter loss share narrower zack consensus estimate loss year loss agio share have significantly outperformed industry so far year company share have surge compare industry increase august agio partner celgene corp celg free report announce fda have grant approval lead candidate idhifa enasidenib treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation however apart idhifa agio lack sanction product portfolio hence company top line mainly comprise collaboration revenue royalty revenue total revenue third quarter amount marginally beating zack consensus estimate top line surge year figure swell revenue be primarily attributable reimbursement celgene idhifa effort unite state royalty revenue gain idhifa research development expense jump year year increase be largely drive escalate cost associate ivosidenib program general administrative expense climb year year due higher cost related idhifa launch potential launch ivosidenib pipeline updatesagio have several candidate pipeline include idh mutant inhibitor ivosidenib ag pan idh mutant inhibitor ag june agio present positive datum dose escalation expansion cohort phase study evaluate single agent ivosidenib mutant positive american society clinical oncology asco annual meeting agio also initiate phase iii study evaluate ivosidenib front line aml patient idh mutant positive advanced fda grant orphan drug designation ivosidenib treatment company say be track submit new drug application nda fda ivosidenib year end additionally agio be conduct phase study pipeline candidate ag treatment patient advanced idh idh mutant positive solid tumor include glioma notably company also plan initiate perioperative window study evaluate ivosidenib ag low grade glioma investigate effect brain tumor tissue first half agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc quotezack rank other key picksagio currently carry zack rank buy other top rank stock health care sector include ligand pharmaceutical inc lgnd free report exelixis inc exel free report ligand sport zack rank strong buy exelixis carry zack rank see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date exelixis earning share estimate have moved cent cent last day company come positive earning surprise trail quarters average beat share price company have soar year date zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
3203,CELG,major biotech company report earning result last trading day company amgen amgn free report vertex vrtx free report top expectation be mixed quarter company celgene celg free report alexion read more alexion top earning lag sale view biomarin read more biomarin loss narrow profit guidance raise recap week most important storiesa look earning result be earning week several key name report third quarter result amgen top expectation witness year year decline revenue company also announce not be develop oral cetp inhibitor amg be explore licensing opportunity candidate read more amgen earning top sale decline stock fall meanwhile celgene plunge follow release third quarter result celgene top earning estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook reflect impact discontinuation ged crohn disease market dynamic impact otezla opportunity risk associate late stage datum read out schedule read more celgene top earning sale miss update view vertex have strong presence cystic fibrosis cf market report strong quarter earning revenue surpass expectation company also raise guidance cf franchise sale read more vertex beat earning sale raise view vertex have gain year date outperform industry rally abbvie abbv free report top earning estimate revenue be line read more abbvie earning top revenue line view gilead surpass expectation company hepatitis virus hcv franchise remain immense pressure read more gilead weak hcv sale earning beat incyte epacadostat be study early lung cancer imfinzi incyte corporation incy free report report strong third quarter result also announce expansion clinical trial collaboration astrazeneca company say evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone company conduct late stage study patient locally advanced stage iii unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt study be co funded company be conduct astrazeneca patient enrolment schedule commence first half note incyte have clinical trial collaboration merck well bristol myer squibb epacadostat incyte be zack rank hold stock see complete list today zack strong buy rank stock here voyager sanofi exit parkinson disease program voyager therapeutic inc vygr free report share be sanofi exit company vy aadc program advanced parkinson disease deal sign february sanofi have exclusive option ex development commercial right vy aadc deal term include upfront payment well future potential development sale milestone payment tiered royalty product sale accord voyager sanofi decide exit deal option do not include right unite state voyager gain global right vy aadc program advanced parkinson disease company say remain track dose first patient second quarter gw finish roll drug submission epilepsy drug gw pharmaceutical plc gwph free report announce have complete roll submission new drug application nda unite state epidiolex cannabidiol adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy gw have rare pediatric disease orphan drug designation indication unite state dravet syndrome indication have fast track status well fda timely approval allow company launch product biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow release third quarter result alexion be last month vertex be celgene be see last biotech stock roundup here biogen top earning gilead car drug get fda nod next biotech world focus remain earning result several mid small cap biotech company more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3204,CELG,apr issue update report agio pharmaceutical inc agio free report development stage company focuse development treatment cancer rare genetic metabolic disorder rgd subset orphan genetic metabolic disease share agio have soar so far year outperform industry increase agio only market drug be idhifa receive fda approval last august treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation approval lend huge boost company back immense commercial potential target market moreover idhifa provide first ever treatment alternative patient live aforementioned indication unite state notably idhifa also enjoy orphan drug status eu treat aml agio progress pipeline have be quite impressive company have interesting candidate portfolio include idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag ivosidenib be presently priority review unite state treat patient aml idh mutation approval ivosidenib be expect third quarter additionally company anticipate regulatory filing candidate eu fourth quarter same indication ivosidenib be also be evaluate phase study address advanced hematologic malignancy phase ii combine celgene celg free report vidaza cure newly diagnosed aml patient be not eligible intensive chemotherapy meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma last october company announce positive finding study notably company also plan initiate perioperative window study analyze ivosidenib ag low grade glioma investigate effect brain tumor tissue first half company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii trial adult transfusion independent patient pyruvate kinase deficiency agio report positive datum program june fda grant fast track designation candidate give indication rgd market be still untapped newer therapy area hold huge potential successful development investigational candidate boost company top line go forward consider lucrative market be target agio pharmaceutical inc price consensus agio pharmaceutical inc price consensus agio pharmaceutical inc quote zack rank key picksagio carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved north last day company deliver positive surprise trail quarters average beat share price company have soar year infinity loss share estimate have narrow cent cent cent last day company pull positive surprise trail quarters average beat hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3205,CELG,alexion pharmaceutical inc alxn free report be latest company join ongoing acquisition spree biotech sector company recently announce acquire sweden base wilson therapeutic detail have offer sek cash outstanding share wilson therapeutic translate total transaction value alexion have already obtain shareholder support agreement largest shareholder accounting wilson therapeutic outstanding share additional shareholder accounting total company outstanding share transaction be expect close second quarter rationale acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder candidate be first class oral copper bound agent unique mechanism action ability access bind copper serum promote removal liver candidate have also obtain fast track designation unite state enjoy orphan drug designation treatment wilson disease unite state eu takealexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate however investor weren much impressed news acquisition add candidate pipeline not approve drug thus stock lose follow announcement moreover market opportunity such rare disease be limit not boost top line expect alexion share have lose last month compare industry decline late quite few biotech company have be look strengthen portfolio pipeline be pretty hum front just few key deal be expect see surge primarily due lower tax rate take clue gilead science gild free report acquisition kite pharma celgene celg free report recently acquire juno therapeutic gain traction promising car space sanofi sny free report acquire bioverativ inc focus therapy hemophilia other rare blood disorder zack rank alexion currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3206,CELG,celgene corporation celg free report announce acquire impact biomedicine upfront amount term agreement impact biomedicine shareholder receive contingent payment base regulatory approval sale base milestone maximum aggregate amount payable such milestone payment be aggregate tiered sale base milestone payment total maximum global annual net sale exceed acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis mf polycythemia vera fedratinib demonstrated statistically significant improvement primary secondary endpoint splenic response total symptom score respectively randomize placebo controlled phase iii pivotal trial jakarta treatment naïve mf addition multus center single arm phase ii trial jakarta evaluate fedratinib mf patient be find be resistant intolerant incyte corporation incy free report jakafi be jak jak inhibitor fedratinib demonstrated clinically meaningful improvement splenic response total symptom score second line set however remind investor jakarta be stop prematurely fda put clinical hold fedratinib program hold be put potential case wernicke encephalopathy be report patient receive more dose less percent treat patient fda withdraw clinical hold august base report benefit risk profile fedratinib jakarta jakarta clinical trial regulatory application mf be plan begin middle celgene be look new deal acquisition give lacklustre celgene stock have decline value last month compare industry loss celgene suffer series setback last few month company suffer setback last week late stage study lead cancer drug revlimid combination rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma celgene key growth engine be revlimid drug worldwide sale increase contribute almost total revenue revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing drug label expansion have boost sale potential addition october company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis meanwhile deep yet persistently slow growth psoriatic arthritis psoriasis market especially entire third quarter have lead weak performance otezla consequently company also reduce annual guidance challenge market condition be drive increasingly restrictive pbm formulary control positive note august company obtain fda approval idhifa treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report big biotechs be look strategic acquisition bolster portfolio pipeline gilead science inc gild free report also acquire kite pharma boost portfolio zack rankcelgene currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
3207,CELG,johnson johnson jnj free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well drive stock new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher future quarters also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda domestic pharma segment sale decelerate first half number key growth driver remicade concerta face competition however sale growth accelerate third quarter be likely see positive impact trend fourth quarter result probably believe new product segment label expansion drug imbruvica xarelto stelara darzalex contribution recent acquisition mainly actelion support top line growth factor bode well stock carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
3208,CELG,biotech industry have be comeback trail face number challenge last year include pricing pressure rise competition pipeline setback pricing pressure slowdown growth mature product generic competition certain key drug frequent fda approval new product sale ramp success innovation strong clinical study result continue strength legacy product have change scenario better year fact nasdaq biotechnology index have gain so far year sharp contrast last year decline notably medical biom genetic sub industry carry zack industry rank place top zack industry back testing show top zack rank industry outperform bottom factor more moreover medical biom genetic industry have increase year so far positive factor be expect continue contribute sector growth next year also dec senate republican pass tax overhaul bill exclude provision bill permanently slash corporate tax rate boost profit large drug biotech company further company be allow pay tax reinvest earning tax defer cash earning senate pass tax bill house representative re vote favor bill comply senate rule approval bill be advantage biotech company company be left more cash hand cash be utilize merger acquisition have be relatively less year have catch attention be smaller biotech company have do well see sharp rise share price company be continuously work bring innovative new treatment market be significant catalyst come quarters form important new product approval well major datum read out here discuss such company price have increase more year alnylam pharmaceutical inc alny free report alnylam have be news past few month base impressive progress pipeline candidate company be make fast progress goal achieve have market product end past few week company complete regulatory submission patisiran unite state europe potential approval patisiran be likely be huge boost alnylam be first approve product company alnylam also announce december fda lift clinical hold place ongoing study hemophilia candidate fitusiran continuous positive development have lead consistent rise share company carry zack rank hold share company have soar compare industry gain bluebird bio inc blue free report share company have increase year so far compare industry gain company car candidate bb produce encourage result patient deadly blood cancer result be present ash annual meeting hold december representative bluebird bb co developer celgene corp celg free report reveal patient advanced form multiple myeloma exhibit positive response therapy recent study company also report least study participant be complete responder company get bb fast track approval become third group bring car treatment market car be emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell company carry zack rank juno therapeutic inc washington base company focus development immuno oncology treatment carry zack rank company share have gain significant so far year last week company report additional datum phase study transcend lead pipeline car candidate jcar treatment patient relapse refractory aggressive hodgkin lymphoma nhl study demonstrated percentage person show overall response rate orr complete response cr rate month be more have show previous datum present june study also show safety profile jcar remain impressive only patient experience severe cytokine release syndrome experience severe neurotoxicity company plan bring jcar market nhl end biologic license application expect be file second half puma biotechnology inc pbyi free report share company have sky-rocket compare industry increase period fda approval puma cancer drug nerlynx neratinib unite state year couple strategic collaboration have lead consistent appreciation share price fda approval nerlynx breast cancer be huge boost puma give immense commercial potential target market drug be make commercially available unite state august be also review eu same indication opinion committee medicinal product human use chmp ema expect first quarter puma believe nerlynx also be develop treat other cancer include small cell lung cancer nsclc other tumor type express have mutation backed positive regulatory pipeline development xoma corp xoma free report pieris pharmaceutical inc pir free report have also more double year xoma sporting zack rank strong buy sky-rocket pieris carry zack rank buy surge remain be see small biotech company maintain bullish run see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3209,CELG,busy last week filled clinical trial datum presentation annual meeting american society hematology cancer space see regulatory approval label expansion drug week roche hold ag rhhby free report breast cancer drug perjeta receive fda nod label expansion post surgery breast cancer high risk recurrence bristol myer squibb company bmy free report blockbuster pd inhibitor drug opdivo receive approval intravenous administration patient completely resect melanoma lymph node involvement metastatic disease unite state meanwhile pfizer inc pfe free report bosulif have be approve treat philadelphia chromosome positive ph chronic myelogenous leukemia cml first line set exelixis inc exel free report also announce approval cabometyx label expansion previously untreated advanced renal cell carcinoma rcc however celgene corporation celg free report suffer setback key drug revlimid fail phase iii study evaluate maintenance therapy treatment naïve follicular lymphoma patient meanwhile astrazeneca azn free report announce acceptance supplemental new drug application snda fda seek label expansion tagrisso include first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation snda be also grant priority review suggest speedy review decision next month let see major news detail roche perjeta get approval post surgery breast cancer fda approve perjeta combination herceptin chemotherapy adjuvant therapy positive early breast cancer high risk recurrence drug regimen significantly reduce risk disease recurrence death compare herceptin chemotherapy alone read more roche perjeta get fda nod post surgery breast cancer also week roche enter agreement acquire base biotech company ignyta boost oncology portfolio ignyta be focuse develop therapy cancer rare mutation ignyta lead candidate entrectinib be currently phase ii study patient nsclc roche hold ag price roche hold ag price roche hold ag quotepfizer bosulif approve first line therapy leukemia bosulif label expansion first line set patient chronic phase ph cml be approve fda drug be already approve second later setting indication read more pfizer leukemia drug get fda nod first line set fda have also grant breakthrough therapy designation combination therapy bavencio inlyta be be investigate patient advanced rcc first line treatment combination therapy be currently be evaluate phase ib study pfizer inc price pfizer inc price pfizer inc quoteexelixis cabometyx approve first line kidney cancer exelixis rcc drug cabometyx be grant label expansion first line set fda approve label expansion base datum phase ii cabosun study demonstrated cabometyx be superior pfizer sutent treat first line kidney cancer read more exelixis cabometyx get fda nod first line kidney cancer exelixis carry zack rank hold see complete list today zack rank strong buy stock here exelixis inc price exelixis inc price exelixis inc quotecelgene revlimid fail phase iii lymphoma study celgene be follow news failure phase iii revlimid study study evaluate revlimid combination roche rituxan maintenance therapy treatment naïve patient follicular lymphoma combination fail achieve superiority complete response progression free survival standard care rituxan chemotherapy revlimid be primary growth driver celgene label expansion lymphoma have further boost potential celgene corporation price celgene corporation price celgene corporation quotebristol myer opdivo approve intravenous use metastatic melanoma fda approve intravenous administration pd inhibitor opdivo adjuvant treatment post surgery patient melanoma involve lymph node be metatstatic approval be base datum phase iii checkmate study datum study have demonstrated opdivo have significantly improve recurrence free survival compare yervoy opdivo be first drug receive approval adjuvant treatment indication bristol myer have also announce committee medicinal product human use have recommend approval yervoy europe treat pediatric patient year older unresectable metastatic melanoma read more bristol myer yervoy get positive chmp opinion melanoma bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotemeanwhile biolinerx initiate phase iii genesis study evaluate lead pipeline candidate bl study investigate mobilization stem cell patient undergo autologous transplant multiple myeloma juno therapeutic announce partnership thermo fisher scientific use latter cell therapy system activation reagent develop car therapy pipeline look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3210,CELG,share juno therapeutic continue soar tuesday stock have now gain nearly announcement fellow car cancer therapy designer kite pharma be be acquire biotech behemoth gilead science gild free report kite bluebird bio blue free report juno be leader development car cancer treatment therapy include make genetic change patient immune cell reinject body attack cancer cell kite be significantly further approval process juno bluebird lead candidate axicabtagene ciloleucel be currently review fda axicabtagene ciloleucel be expect be approve treatment aggressive hodgkin lymphoma decision come november monday gilead announce be acquire kite cash deal buyout value kite share premium company close price friday also read do kite pharma stock skyrocket today acquisition kite establish gilead leader cellular therapy provide foundation drive continue innovation person advanced cancer gilead president ceo john milligan say statement course acquisition immediately inspire speculation juno bluebird also become takeover target market cap just juno be cheapest car leader however company recently take step back approval process march juno announce be discontinue development lead car candidate have already reach phase development bluebird car program bb be still phase drug have pretty encourage datum so far bluebird market cap currently sit interestingly juno bluebird have partnership celgene celg free report global biopharma giant however bluebird partnership only extend bb project so more diversify buyout candidate especially consider company have gene therapy program target beta thalassemia sickle cell disease nevertheless juno emerge lowest price car pure play right now want know more kite read kite pharma be revolutionize fight cancer listen podcast want more stock market analysis author make sure follow ryan_mcqueeney twitter zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
3211,CELG,earning season draw close focus be back pipeline regulatory update regeneron pharmaceutical regn free report have several pipeline catalyst line second half year report datum late stage pipeline candidate gilead science gild free report get priority review investigational hiv treatment recap week most important shelve rsv antibody study failure regeneron investigational antibody suptavumab regn respiratory syncytial virus rsv fail meet primary endpoint late stage study conduct infant regeneron have decide not continue development candidate regeneron have several pipeline catalyst line second half year later quarter company expect report top line phase iii datum dupixent asthma positive datum allow company go ahead filing fourth quarter important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema expect fourth quarter year regeneron be zack rank strong buy stock see complete list today zack rank stock here priority review gilead hiv drug gilead gain priority review investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv gilead have used priority review voucher time filing regulatory application combination gain priority review response fda be feb combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera bring sale first half gilead share be year date lag industry rally also read gilead nda hiv combo regimen get priority review late stage failure ophthotech eye drug ophthotech opht free report be focuse development treatment eye disease announce fovista fail meet primary endpoint late stage study superiority study be evaluate fovista pdgf therapy combination eylea avastin bevacizumab vegf therapy compare eylea avastin monotherapy treatment wet age related macular degeneration amd study fail achieve primary endpoint company have anyway attribute low likelihood success study give fovista earlier failure phase iii study well failure mid stage study conduct competitor pdgf inhibitor vegf inhibitor combination amd ionis retain full right inotersen ionis fb lrx ionis pharmaceutical ion free report say glaxo have decline option drug inotersen ionis fb lrx keep decision reprioritize pipeline review rare disease business company however continue collaborate ionis ionis hbvrx ionis hbv lrx be be evaluate hepatitis virus hbv infection ionis retain right investigational drug company layer plan say be filing approval inotersen follow launch initial indication inotersen have be design treat patient ttr amyloidosis attr be expect be treatment patient polyneuropathy due hereditary ttr amyloidosis hattr pn ionis say be consider set commercial subsidiary commercialize co commercialize inotersen north america company be evaluate other option well include partnership deal meanwhile ionis fb lrx be slate move mid stage study patient dry age related macular degeneration amd later year also read ionis pharmaceutical retain right inotersen stock galapago ipf datum galapago nv glpg free report share be positive datum mid stage study company investigational idiopathic pulmonary fibrosis ipf drug glpg halter disease progression ipf patient study be first autotaxin inhibitor show effect ipf study galapago now intend move candidate late stage study be already discussion regulator regard study design galapago datum come shortly fibrogen investigational ipf drug pamrevlumab fared well mid stage study well combination safety sub study pamrevlumab be connective tissue growth factor ctgf antibody ipf market represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer currently approve ipf drug include esbriet ofev biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron be slightly celgene celg free report lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here earning regeneron kite more fibrogen ipf datum next biotech world second quarter earning season come end watch usual regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3212,CELG,agio pharmaceutical inc agio free report post second quarter loss share wider zack consensus estimate loss year loss agio share have significantly outperformed industry so far year company share have surge compare industry increase earlier month fda have grant approval lead candidate idhifa enasidenib treatment patient relapse refractory acute myeloid leukemia aml however apart idhifa agio do not have sanction product portfolio yet hence company top line mainly comprise collaboration revenue milestone payment total collaboration revenue second quarter amount marginally miss zack consensus estimate however revenue substantially surge year figure swell revenue be partially attributable reimbursement celgene corporation celg free report idhifa effort research development expense jump almost year year increase be largely drive increase cost associate ivosidenib program general administrative expense climb year year due higher headcount other professional cost support expansion operation pipeline updatesagio have several candidate pipeline include idh mutant inhibitor ivosidenib ag pan idh mutant inhibitor ag june agio present positive datum dose escalation expansion cohort phase study evaluate single agent ivosidenib mutant positive american society clinical oncology asco annual meeting second quarter agio initiate phase iii study evaluate ivosidenib front line aml patient idh mutant positive advanced subsequently april fda grant orphan drug designation ivosidenib treatment company plan submit nda fda ivosidenib year end additionally agio be conduct phase study pipeline candidate ag treatment patient advanced idh idh mutant positive solid tumor include glioma company complete enrollment study quarter agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc quotezack rank key picksagio currently carry zack rank hold better rank stock pharma sector include aduro biotech inc adro free report enzo inc stock carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat stock be so far year enzo loss estimate narrow cent cent last day company come positive earning surprise trail quarters average beat stock be so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
3213,CELG,third quarter report cycle be witness revenue acceleration positive revision trend result half member be already oct total earning member be same period last year higher revenue surpass earning revenue estimate respectively accord earning preview company account index total market capitalization report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig merck co inc mrk free report celgene corporation celg free report abbvie inc bristol myer squibb company bmy free report gilead science inc gild free report report third quarter result last week merck celgene abbvie outpaced zack consensus estimate earning lag same revenue however bristol myer gilead surpass expectation earning revenue notably bristol myer gilead raise earning outlook well merck raise previously issue adjust earning guidance up sale guidance marginally abbvie celgene also tighten earning guidance here have biotech pharma company be set report third quarter result oct let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning market open deliver positive earning surprise last quarter company earning performance have be mixed bottom line miss last quarters beating same other bring average surprise negative quarter pfizer have earning esp zack rank hold zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully meanwhile sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue well sale viagra be expect be affected lower demand read more be beat likely pfizer earning season previous article show pfizer be likely beat earning quarter however estimate change thereafter be not certain beat earning season pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteincyte corporation incy free report incyte be schedule release earning market open witness negative earning surprise last quarter company earning performance have be mixed so far have deliver positive surprise last quarters miss estimate unavailable average earning surprise last quarters be negative company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here company key growth driver jakafi have be perform well expect trend continue be report quarter well incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quoteacorda therapeutic inc acor free report acorda be schedule release earning market open witness negative earning surprise last quarter company earning performance have be disappointing so far company have incur negative surprise last quarters average earning surprise last quarters be negative company have earning esp zack rank strong sell make surprise prediction difficult zack consensus estimate be peg cent share be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision expect investor focus refusal file rtf relief late stage pipeline candidate inbrija be develop treatment patient be suffering parkinson disease acorda therapeutic inc price ep surprise acorda therapeutic inc price ep surprise acorda therapeutic inc quotezack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor
3214,CELG,agio pharmaceutical inc agio free report be schedule report third quarter result nov open bell share have surge so far year compare favorably industry increase agio earning track record show mixed result company have miss estimate twice trail quarters also surpass same twice overall agio have average positive surprise last quarter company deliver negative surprise let see thing be shape quarter factor playagio only market drug be idhifa enasidenib treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation idhifa receive fda approval earlier august be launch soon company expect draw revenue first time idhifa be report quarter drug fda approval expect management update launch plan idhifa third quarter conference call investor focus also be agio pipeline cancer pipeline include ag idh mutant inhibitor ag pan idh mutant inhibitor phase iii study ag be currently front line aml patient idh mutation company plan nda submission unite state year end other hand agio be conduct phase study ag treat patient advanced idh idh mutant positive solid tumor include glioma fda grant fast track designation candidate give indication notably agio be busy develop ag collaboration celgene corporation celg free report fetch collaboration revenue earlier august company complete agreement global regulator advance lead candidate ag rare genetic metabolic disorder rgd portfolio pivotal trial treatment patient pyruvate kinase pk deficiency study be expect start first half earning whispersour proven model do not conclusively show agio be likely beat estimate quarter be stock need have positive earning esp bullish zack rank strong buy buy hold happen be not case here see zack esp agio have earning esp represent difference most accurate estimate loss zack consensus estimate loss uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp however company need have positive esp be confident earning surprise hence leave case inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock worth consider consist right combination element surpass expectation quarter emergent biosolution inc ebs free report be schedule release result nov have earning esp also carry zack rank see complete list today zack rank stock here zoetis inc zts free report be schedule release result nov zack rank company have earning esp wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3215,CELG,prothena corporation plc prta free report report loss share first quarter wider zack consensus estimate loss year loss quarterly revenue come year quarter zack consensus estimate be prothena stock be trading market trading follow announcement result company share have lose last month industry decline quarter detailr expense be year year primarily due due higher consult expense higher personnel cost higher expense associate prx rg higher clinical trial cost general administrative expense be year year pipeline updatesprothena have discontinue development lead pipeline candidate neod candidate antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study hence company decide discontinue study development neod include vital study well open label extension study other hand prothena be evaluate prx collaboration roche rhhby free report treatment parkinson disease other related synucleinopathy company initiate phase ii study pasadena prx patient suffering parkinson disease trigger milestone payment roche prothena study be continue enrolment prothena be also work advance prx phase study patient attr amyloidosis phase study be initiate second quarter continue enroll patient preliminary datum be expect prothena also enter global neuroscience research development collaboration celgene corporation celg free report develop new therapy broad range disease collaboration be focuse target implicate pathogenesis several disease induce tau tdp third be undisclosed term prothena receive upfront payment equity investment celgene company be eligible receive future potential exercise payment milestone payment license program prothena be also eligible receive additional royalty net sale result market product wider expect loss first quarter be disappointing discontinuation development neod come major blow investor company have very limit number candidate pipeline neod be lead candidate prothena corporation plc price consensus prothena corporation plc price consensus prothena corporation plc quote zack rank stock carry zack rank hold better rank stock healthcare sector be exelixis exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate increase cent cent last day company report better expect first quarter result hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3216,CELG,problem do not seem end biotech bigwig celgene corporation celg free report company president chief operate officer scott have decide step position immediate effect result chairman ceo mark alle take responsibility sudden exit president have add wo be primarily responsible build inflammation immunology franchise particularly launch otezla celgene state company be reshuffle executive team enhance leadership focus news come time celgene be sailing trouble water celgene stock have lose last month industry decline share lose news last month celgene suffer yet setback receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod candidate be be develop treatment patient relapse form multiple sclerosis ms fda state nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor give potential ms market hold notably thing have be downturn company last october celgene announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd have be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis december late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail celgene key growth engine be revlimid revlimid sale continue be impressive be concern company dependence product growth drug be set lose patent exclusivity soon hence celgene be desperately try revive portfolio company recently announce development co promotion agreement bluebird bio inc blue free report company have enter deal co develop co promote bb experimental cell maturation antigen chimeric antigen receptor car cell therapy potential treatment patient relapse refractory multiple myeloma unite state earlier celgene acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma zack rank key pickcelgene currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3217,CELG,share celgene corporation celg free report moved company announce development co promotion agreement bluebird bio inc blue free report company have enter deal co develop co promote bb experimental cell maturation antigen bcma chimeric antigen receptor car cell therapy potential treatment patient relapse refractory multiple myeloma unite state remind investor company enter broad global strategic research collaboration develop commercialize novel therapy oncology currently bluebird bio celgene be collaborate develop car cell therapy target bcma lead target program be bb be be evaluate treatment relapse refractory multiple myeloma celgene be upbeat potential bb believe candidate revolutionize treatment approach outcome patient multiple myeloma term latest agreement company share cost profit unite state equally bluebird celgene have joint responsibility development manufacturing bb unite state addition celgene assume sole responsibility drug product manufacturing outside unite state addition bluebird also receive milestone royalty ex sale meanwhile bluebird bio celgene be also work together second clinical stage bcma car program bb news somewhat relieve wary investor celgene stock have lose last month industry decline celgene be make desperate attempt revive portfolio pipeline series pipeline setback recent time thing have be downturn company last october celgene announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd have be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis december late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail celgene suffer yet setback receive refusal file letter fda regard new drug application multiple sclerosis candidate ozanimod celgene be look new deal acquisition give lacklustre company recently acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state generate sale approximately hence bluebird deal further bolster celgene presence car space zack rank key pickcelgene currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
3218,CELG,celgene corporation celg free report be take desperate attempt bolster portfolio reduce dependence lead drug revlimid however thing do not seem be work favor company celgene stock have lose last month industry decline last month celgene suffer yet setback receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod candidate be be develop treatment patient relapse form multiple sclerosis ms fda state nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor give potential ms market hold notably thing have be downturn company last october celgene announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd have be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis december late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma however treatment arm not achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week term progression free survival observed pre plan analysis celgene key growth engine be revlimid revlimid sale continue be impressive be concern company dependence product growth drug be set lose patent exclusivity soon hence celgene be desperately try revive portfolio celgene be look new deal acquisition give lacklustre just gilead science gild free report acquire kite pharma juno acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma candidate be expect obtain regulatory approval unite state generate sale approximately acquisition juno surely boost celgene growth prospect give immense potential car therapy space be risky proposition celgene juno have face setback pipeline candidate jcar hence expect investor stay side line time be observe revival story celgene play zack rank key pickcelgene currently carry zack rank sell better rank stock same space be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3219,CELG,expect pfizer inc pfe free report beat expectation report second quarter result aug market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully xeljanz mg take twice daily be approve eu mar boost drug sale be report quarter also revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition be likely propel revenue hospira acquisition be expect be important growth driver well also pfizer launch inflectra biosimilar version johnson johnson jnj free report blockbuster drug remicade nov inflectra record sale globally first quarter biosimilar generate more sale soon be report quarter however pfizer continue face headwind form loss exclusivity key product pristiq zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be expect continue see lower sale lower demand continue hurt sale viagra meanwhile bottom line be drive cost saving share buyback however new product launch expense investment be expect hurt profit second quarter call investor focus be expect remain performance new product pipeline progress include biosimilar immuno oncology importantly key cancer candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer drug bring revenue second quarter management be expect shed light launch be progress conference call acute lymphoblastic leukemia candidate besponsa be also approve eu late jun expect management comment plan conference call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report earning esp zack rank company be schedule release result jul hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3220,CELG,issue update research report therapeutic inc cort free report jul share have surge year date compare favorably zack classify medical drug industry gain currently company be strive commercialize korlym mifepristone successfully deploy medical liaison sale representative fact korlym be only market drug be approve treatment patient cush syndrome notably person be newly diagnosed cush syndrome year result more new patient annually therefore believe increase awareness physician patient drug expand sale effort boost sale go forward be currently work develop drug additional indication be conduct phase ii safety efficacy study korlym combination eisai co ltd cancer drug halaven treatment triple negative breast cancer tnbc enrolment study be complete company announce encourage datum dec expect successful label expansion korlym boost top line significantly disease represent huge potential many woman be diagnosed year moreover university chicago be conduct phase ii study korlym combination pfizer pfe free report xtandi treatment metastatic castration resistant prostate cancer institution also plan conduct phase ii study korlym combination celgene celg free report abraxane treatment patient tnbc importantly apart korlym be also evaluate cort cush syndrome range solid tumor early datum candidate cush syndrome have be quite promising company have begin dose patient phase ii study cort combination abraxane treatment range solid tumor cancer possible target indication include triple negative breast cancer ovarian cancer pancreatic cancer sarcoma company expect open expansion cohort end additionally company have promising preclinical candidate cort metabolic disorder cort alcohol withdrawal cort castration resistant prostate cancer triple negative breast cancer ovarian cancer be expect enter clinic also first quarter earning release company raise revenue guidance now project revenue be range more prior expectation therapeutic incorporate price consensus therapeutic incorporate price consensus therapeutic incorporate quotezack rank stock currently carry zack rank hold better rank health care stock same space be enzo inc sporting zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3221,CELG,adverum biotechnology inc advm free report be expect report first quarter result possibly company have dismal track record miss estimate last quarters result average negative earning surprise last report quarter adverum beat estimate deliver positive surprise however adverum share have rally year date significantly outperform decline register industry let see thing be shape announcement factor consideradverum be clinical stage gene therapy company company approve product portfolio expect investor focus remain pipeline update first quarter earning call adverum pipeline consist gene therapy program rare disease alpha antitrypsin deficiency wet age related macular degeneration wamd hereditary angioedema hae adverum initiate phase ii study advm treatment deficiency december company expect report preliminary datum second half base positive pre clinical development result company be plan advance vegf gene therapy candidate advm clinical stage candidate be be develop treat wet amd adverum be plan file investigational new drug ind fda second half company be also develop advm pre clinical study treat hae be prepare file ind second half adverum extend collaboration agreement edita medicine third quarter january company develop treatment inherited retinal disease used latter crispr base genome editing technology company have also collaborate regeneron pharmaceutical regn free report develop distinct ocular therapeutic target include ava be be develop treat juvenile link retinoschisis likley positive surprise proven model show adverum be likely beat estimate quarter have right combination key ingredient stock positive earning esp zack rank strong buy buy hold have significantly higher chance beating earning zack esp earning esp represent difference most accurate estimate zack consensus estimate be zack consensus estimate quarter be peg loss cent most accurate estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank adverum currently carry zack rank combine positive esp make reasonably confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision adverum biotechnology inc price ep surprise adverum biotechnology inc price ep surprise adverum biotechnology inc quotestock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3222,CELG,celgene corporation celg free report be schedule report first quarter result open bell celgene have excellent track record company beating earning estimate last quarters average beat last report quarter company top estimate celgene corporation price consensus ep surprise celgene corporation price consensus ep surprise celgene corporation quote likely positive surprise proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision revlimid drive growthcelgene key growth driver revlimid continue drive revenue company revlimid be approve several indication include mm myelodysplastic syndrome mds mantle cell lymphoma mcl market share gain key market longer treatment duration be contribute drug growth meanwhile celgene be work expand revlimid label further revlimid receive fda approval use maintenance treatment ndmm patient receive autologous stem cell transplant drug be also approve eu same ndmm market share continue grow outside unite state positive uptake eu japan company be work further label expansion drug continue momentum core indication label expansion global launch help product keep contribute top line however december late stage study revlimid combination roche holding rhhby free report rituxan fail revlimid sale be project zack consensus estimate revlimid currently stand first quarter pomalyst revenue be project drug label be recently update unite state eu include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function pomalyst combination darzalex dexamethasone relapse refractory myeloma be recently approve fda propel sale further act growth driver lead share duration gain future abraxane sale be estimate be otezla sale be now project first quarter earning call investor be expect remain focuse company performance label expansion effort update recent acquisition pipeline earlier celgene acquire juno therapeutic add jcar lisocabtagene maraleucel liso cel lymphoma pipeline jcar be best class cd direct car candidate currently pivotal program relapse refractory diffuse large cell lymphoma quarter celgene suffer setback receive refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod candidate be be develop treatment patient relapse form multiple sclerosis ms fda state nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda revlimid be set lose patent exclusivity soon hence celgene be desperately try revive portfolio celgene also announce development co promotion agreement bluebird bio inc blue free report company have enter deal co develop co promote bb experimental cell maturation antigen chimeric antigen receptor car cell therapy potential treatment patient relapse refractory multiple myeloma unite state hence expect management throw further light plan go forward celgene stock have gain year so far compare industry decline stock considerhere be stock healthcare sector want consider model show have right combination element beat earning quarter vanda pharmaceutical inc vnda free report have earning esp zack rank company be schedule release first quarter result see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3223,CELG,month have go last earning report celgene corporation celg free report share have lose time frame underperform market recent negative trend continue lead next earning release be celg due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver celgene earning sale beat solid revlimidcelgene report encourage fourth quarter result earning sale top expectation company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter beat zack consensus estimate revenue be boost consistent performance company key growth driver revlimid revlimid key catalystnet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane decrease sale decline unite state sale oncology drug pomalyst imnovid come sale be drive increase volume due increase market share duration otezla report sale quarter other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease earlier week celgene announce acquire juno therapeutic inc share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno celgene also announce acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline december celgene partner bluebird bio present update datum phase trial evaluate bb patient relapse refractory multiple myeloma rrmm candidate be grant breakthrough therapy designation fda priority medicine eligibility european medicine agency company also initiate karmma trial evaluate bb rrmm be initiate resultssale come beat zack consensus estimate earning share come beat zack consensus estimate outlookcelgene anticipate earning range zack consensus estimate earning be share net revenue be project be range zack consensus estimate same be peg revlimid sale be project abraxane sale be estimate be pomalyst revenue be project otezla sale be now project have estimate be move then analyst be quiet last month none issue earning estimate revision celgene corporation price consensus celgene corporation price consensus celgene corporation quotevgm scorescurrently celg have strong growth score be lag lot momentum front stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable growth investor also be suitable look value lesser degree momentum outlookcelg have zack rank sell expect average return stock next few month
3224,CELG,merck co inc mrk free report have propose buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer australian dollar believe deal make strategic sense strengthen merck presence fast grow immuno oncology market immuno oncology immunotherapy be new class cancer therapy utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology drug combination be great deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell cavatak be be evaluate several phase ii cancer study include combination study merck pd inhibitor keytruda cavatak keytruda combination be be study melanoma prostate lung bladder cancer deal sign company november early clinical datum cavatak demonstrated robust potential wide variety tumor type monotherapy combination study past year merck share have underperform industry merck share have decline period increase industry merck have offer pay australian dollar share sydney base company represent premium viralytic average stock price past month merck acquire viralytic subsidiary transaction be expect be complete second quarter contingent viralytic shareholder approval importantly cavatak complement merck pipeline effort keytruda second largest drug keytruda be already market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer be also be study more type cancer more study include more combination study latest offer merck be many merger acquisition expect year now tax reform be place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year biotech pharma activity have start gain steam sanofi sny free report celgene celg free report announce deal sanofi earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech bioverativ celgene also announce deal buy juno therapeutic inc focus development car therapy impact biomedicine add late stage jak kinase inhibitor celgene pipeline merck carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3225,CELG,juno therapeutic inc be expect report fourth quarter result mar market close last quarter company deliver positive earning surprise juno share have significantly outperformed industry year time stock have sky-rocket compare industry decline company poor earning history show negative surprise last quarters positive just once average negative earning surprise trail quarters be let see thing be shape announcement factor playlast month celgene corporation celg free report announce acquire partner juno share cash total approximately net cash marketable security acquire notably former already own approximately latter outstanding share transaction be expect close first quarter expect investor approach management query merger approve product portfolio juno be yet generate product revenue thus investor focus primarily be company cash burn pipeline update be report quarter juno most advanced pipeline candidate include jcar jcar use car cell technology target cd cluster differentiation jcar be phase study hodgkin lymphoma nhl phase ii trial pediatric young adult acute lymphoblastic leukemia december company report positive result phase program demonstrate improve overall complete response core group company plan bring jcar market nhl early multiple indication end remind investor last year novartis car kymriah gilead yescarta receive fda approval august october acute lymphoblastic leukemia hodgkin lymphoma respectively hence fourth quarter conference call expect investor focus update company plan introduce jcar market space candidate jcar have already induced competition due mentioned approval earning whispersour proven model do not conclusively show juno be likely beat estimate quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp juno have earning esp most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank juno carry zack rank sell lower predictive power esp notably caution sell rate stock go earning announcement especially company be see negative estimate revision moreover company esp make surprise prediction difficult juno therapeutic inc price ep surprise juno therapeutic inc price ep surprise juno therapeutic inc quote stock warrant lookhere be couple health care stock right combination element beat earning time exelixis inc exel free report be schedule announce fourth quarter result feb company have earning esp zack rank see complete list today zack rank stock here puma biotechnology inc pbyi free report be slate release fourth quarter financial number mar company have earning esp zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3226,CELG,novartis ag nvs free report announce fda oncologic drug advisory committee odac have unanimously recommend approval immunocellular therapy candidate ctl ctl investigational chimeric antigen receptor cell car therapy be be evaluate treatment relapse refractory pediatric young adult patient cell acute lymphoblastic leukemia remind investor ctl be first develop university pennsylvania novartis enter collaboration agreement penn further research develop commercialize car cell therapy include ctl treatment cancer car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment process cell be draw patient blood cell be then reprogram manufacturing facility create cell be genetically code express chimeric antigen receptor recognize fight cancer cell other bcell express specific antigen earlier novartis submit biologic license application bla ctl fda mark first submission novartis car cell therapy remind investor ctl previously receive fda breakthrough therapy designation application be priority review fda consider odac vote reviews bla be not obligated follow recommendation decision be expect oct recommendation be base review ctl cell development program include pivotal phase ii global trial eliana first pediatric global car cell therapy registration trial ctl become first car cell therapy approve potential approval also open new frontier treatment cancer advance immunocellular therapy child young adult cell meanwhile novartis plan make additional filing ctl eu later year include application fda european medicine agency ema treatment adult diffuse large cell lymphoma dlbcl novartis have outperformed zack classify industry last month stock have rally compare large cap pharmaceutical industry gain go forward expect approval new drug label expansion exist one bode well novartis also strong performance growth product be able offset impact generic competition gleevec news bode well other company be develop car cell therapy kite pharma inc company submit bla fda mar approval lead candidate kte kte be car base therapy be evaluate treatment patient relapse refractory aggressive cell hodgkin lymphoma dlbcl fda have set prescription drug user fee act pdufa target action date nov meanwhile bluebird bio blue free report celgene corp celg free report also enter collaboration develop car cell therapy cancer collaboration be amend restate focus develop product candidate target cell maturation antigen bcma zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3227,CELG,pharma biotech sector have picked year be batter drug pricing controversy first half have be pretty strong company space nyse arca pharmaceutical index have rise almost year date ytd decline almost last year nasdaq biotechnology index be ytd slide sector do have share challenge form rise competition high profile pipeline setback slowdown growth mature product loss exclusivity certain key drug drug pricing issue still prevail investor lately be hope steep pricing not be damage fear previously nonetheless strong performance newer drug evolve pipeline impressive clinical trial result new drug approval continue strong performance legacy product rise demand be factor promise sustain recovery sector meanwhile have be many more fda drug approval so far year total drug have gain fda approval ytd beating total whole acceleration drug approval process more innovation surge new drug approval be expect activity collaboration deal have slow year chance be pick second half president trump promising major tax reform allow company bring back cash hold overseas acquisition activity be expect pick pace then again number deal still be less pharma industry have be many year finally republican administration vow repeal replace obamacare bode well sector growth pick likely winnersgiven enormity healthcare space select stock have potential beat estimate appear be quite daunting proprietary methodology make fairly simple way narrow list choice earning season be look stock have combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation earning esp be proprietary methodology identify stock have high chance surprising upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high uncover best stock buy sell re report earning esp filter here be healthcare stock be poise beat estimate second quarter accord methodology first pick be healthcare bellwether merck co inc mrk free report kenilworth nj base company have earning esp zack rank buy see complete list today zack rank strong buy stock here zack consensus estimate second quarter be cent share company have consistently top earning expectation fact merck earning surpass expectation last quarters average positive surprise merck be schedule report result jul next choice be biotech major celgene corporation celg free report carry zack rank stock have earning esp zack consensus estimate second quarter be peg share summit nj base company have pretty impressive earning surprise track record average earning surprise trail quarters be celgene be schedule announce result jul gilead science inc gild free report too have impressive track record company consistently beating earning expectation company earning surpass estimate last quarters average positive surprise look poise beat expectation second quarter well foster city base company carry zack rank have earning esp zack consensus estimate be peg share gilead be schedule report result jul seattle genetic inc sgen free report biotechnology company be solid bet zack rank stock have earning esp bothell wa base company deliver average positive earning surprise trail quarters seattle genetic be schedule release result jul zack consensus estimate second quarter peg loss cent share small company vanda pharmaceutical inc vnda free report make list likely outperformer second quarter virtue zack rank earning esp zack consensus estimate be peg loss cent share vanda be expect report result jul bottom line challenge form competitive pricing pressure remain healthcare sector however number company space have fared well pick outperformer space backed solid zack rank positive earning esp lead investor gain earning season more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
3228,CELG,stock market end negative territory monday broad base decline push major index red slide healthcare industrial stock more offset gain several merger acquisition telecom mega deal moreover strong first quarter earning result also fail uplift investor sentiment dow jone industrial average dji close decline point index inx decrease close nasdaq composite index ixic close decrease total share be trade first trading day week higher last session average share decliner outnumber advancer nyse ratio nasdaq decliner have edge advancer ratio cboe vix increase close do benchmark perform dow decrease stock stock blue chip index close red trade green decrease lead decline health care select sector spdr xlv decrease industrial select sector spdr xli material select sector spdr xlb sector benchmark index end negative territory index record new week high new week lows nasdaq composite lose index record new week high new week lows healthcare metal industrial stock pull metal industrial sector be worst performer last day trading april sector lead broad base market decline share celgene corp celg free report decline morgan stanley ms free report report state company require year more resubmit application approval company critical drug ozanimod relapse multiple sclerosis share allergen plc agn free report plunge chairman ceo brent saunder expressed view be opposed change company fundamental business structure read more however allergen first quarter earning come share beating zack consensus estimate revenue generate marginally exceed zack consensus estimate arconic inc arnc free report decline massive reduce outlook company adjust earning come share first quarter beat zack consensus estimate revenue surpass zack consensus estimate however arconic now expect adjust earning be range share prior guidance free cash flow be read more share price ak steel hold corp ak free report decline report strong first quarter result net earning come share beating zack consensus estimate revenue generate exceed zack consensus estimate investor be expect more especially president trump impose tariff import steel concern telecom mega deal overshadow slew asa number announcement help market advance initial hour trading share walmart inc wmt free report increase retail giant arm asda group ltd agree merge british supermarket chain sainsbury plc likewise share ilg inc ilg free report rise marriot vacation worldwide corp vac free report agree buy former also share logistic company dct industrial trust inc dct advanced prologis inc pld agree buy former likewise share andeavor andv advanced marathon petroleum corp mro agree buy former however investor concern regard approval merger deal mobile inc tmus sprint corp free report overshadowed investor positive enthusiasm share price mobile sprint decline respectively many industry watcher believe fcc not okay deal even deal be permit be detrimental consumer number national wireless operator come economic datum department commerce report personal consumption expenditure pce grow march first advance end personal income increase personal disposable income increase march pce price index key inflation barometer used fed rise month rate february hit central bank target first time year core pce exclude food energy increase march monthly month april major stock market index witness marginal gain reverse overall negative trend witness last straight month dow increase nasdaq composite gain year date nasdaq composite be trading green dow be red strong earning result most large corporate fail enthuse investor disappointing guidance taiwan semiconductor tsm largest contract chipmaker worldwide lead loss tech major especially apple inc aapl free report moreover caterpillar inc cat free report forecast economic growth decelerate later year also result broad base market decline rise bond yield also dent investor confidence april year treasury yield briefly hit psychological mark first time january additionally stock market fluctuate due fear global trade war geopolitical tension related syrium stock make haedlinesbp post strong earning record upstream businessbp plc bp free report report strong first quarter result oil price have start recover slump witness nearly year back read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3229,CELG,celgene corporation celg free report announce datum phase iii trial relief dermatology drug otezla late breaking oral presentation american academy dermatology aad annual meeting phase iii randomize placebo controlled double blind study relief be evaluate otezla twice daily bid patient active behçet disease be previously treat least topical systemic medication primary endpoint be area curve auc number oral ulcer week secondary objective study include change baseline pain oral ulcer behçet syndrome activity score behçet disease current activity index behçet disease quality life score week datum study show statistically significant reduction oral ulcer otezla versus placebo week consequently celgene plan submit supplemental new drug application otezla bid treatment active behçet disease oral ulcer unite state japan second half year company also plan submit type ii variation marketing authorization application eu otezla be already approve treatment patient moderate severe plaque psoriasis be candidate phototherapy systemic therapy unite state treatment adult active psoriatic arthritis sale otezla have increase fourth quarter slowdown third celgene stock have tumble last month compare industry slip celgene suffer series setback last few month company suffer setback late stage study lead cancer drug revlimid combination rituxan fail stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue threat generic competition be also loom large revlimid force celgene look acquisition january celgene announce plan acquire juno therapeutic share cash total approximately net cash marketable security acquire former already own approximately outstanding share juno car therapy space be spotlight fda approve first car therapy novartis nvs free report kymriah treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse stage zack rank key pickcelgene carry zack rank sell better rank stock health care space be exelixis exel free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
3230,CELG,market close mostly higher thursday backed strong earning prominent stock dow end green however biotech stock tank pull healthcare sector lower weigh nasdaq meanwhile house representative clear budget blueprint majority republican voting favor move further ecb announce plan extend quantitative ease program dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close increase advance issue outnumber decliner nyse ratio nasdaq advancer outnumber decliner ratio cboe vix decrease almost close dow continue dow amassed point wednesday finish positive territory gain blue chip index be power share nike nke free report gain shoe apparel retailer raise revenue growth target come year announcement be make company investor day nike share be biggest gainer dow also end green gain point process major segment finished green material lead gainer material select sector spdr etf xlb gain close such gain be make possible share union pacific corp unp free report surge follow earning beat third quarter company possess zack rank hold see complete list today zack rank strong buy stock here rail transportation provider third quarter earning beat zack consensus estimate share bottom line expand year year basis result be aid higher revenue operate revenue also surpass zack consensus estimate read more biotech share weigh nasdaqmeanwhile nasdaq suffer loss give point end red just ahead release earning major tech stock faamg group such alphabet googl free report microsoft msft free report amazon amzn free report loss nasdaq be incur biotech share tank have negative ramification overall healthcare sector well ishare nasdaq biotechnology etf ibb plummet pull overall healthcare sector lower biotech stock suffer loss share celgene corp celg free report tank surpass earning expectation third quarter company miss revenue expectation suffer loss celgene report mixed result third quarter earning beat expectation sale fail meet estimate read more house pass budget blueprinthouse representative pass budget blueprint thursday officially unlock procedure used tax code be change used simple majority only republican vote instead vote norm usually follow trump fellow republican have campaign bring much need tax reform such event get member gop even closer deliver promise vote house clear budget blueprint many republican voting meanwhile house way mean committee chairman kevin brad state budget bill be introduce nov apart tax repatriation framework also promise almost double standard deduction tax rate add much deficit period year ecb extend quantitative ecb announce thursday be slash level bond purchase month extend length time stimulus program run ecb promise buy bond begin january central bank intend extend monetary stimulus program least september ecb also reiterate interest rate remain current level well past end quantitative ease qe program economic datapending home sale month september remain unchanged august consensus estimate period be decline index hit half year low such lackluster show be attribute extremely short supply strong demand meanwhile initial jobless claim decrease still languish historically low level consensus estimate period be increase stock make headlinesdecker defy retail challenge top earningsit be not ugg sturdy sale performance hoka teva brand couple lower cost sale sg expense enabled decker outdoor corporation deck free report post better expect second quarter fiscal result read more pinnacle food earning beat stock downpinnacle food inc pf free report post third quarter result top bottom line outpaced zack consensus estimate latter also grow year year read more colgate dip hike charge view earning linecolgate palmolive co cl free report post adjust earning cent share third quarter line zack consensus estimate flat prior year quarter read more leggett narrow view mixed earningsleggett platt incorporate leg free report report mixed result third quarter read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3231,CELG,welcome fully open spigot earning season be single busiest day quarter bell see result googl msft intc other plenty company have already report earning open bell today not enough ve also get ton economic datum newsworthy financial information get so let get start european central bank ecb president mario draghi have extend quantitative ease program have help foster eurozone back good health euro buyback be schedule have expire december now taper begin january continue september next year buyback be cut half euro month result see euro fall value not drop range statement draghi expressed risk growth eurozone be broadly base economic expansion be solid initial jobless claim also stay range bound last week slightly revise previous week continue claim stay even few week see spike initial jobless claim follow double whammy hurricane harvey irma weekly claim have revert back favorable range ve see past couple year wholesale inventory rise latest read retail inventory fall growth inventory increase be widely consider weakest economic growth metric drawdown inventory make room new product hit market consider report modest positive current economy earning twtr free report share be spiking today pre market follow better expect earning report cent share top cent be expect quarterly sale modestly outpaced zack consensus monthly active user grow company have take step clean operation light allegation abuse platform ceo jack dorsey be also point twitter direction video stream increase usage go forward ford motor company free report follow recent strong report gm beating estimate top bottom line morning earning cent share outperformed cent expect zack consensus quarterly revenue improve estimate automotive giant also raise lower end full year guidance share record time high pre tax profit asia pacific region share go report unite parcel service up free report report share quarterly report morning beating estimate penny revenue come strongly ahead expectation surpass zack consensus up report cost result hurricane company also raise lower end earning guidance full year up also look forward potential record holiday season pre market trade have send share slightly negative territory however biopharma major celgene corp celg free report share have fall more today pre market quarterly revenue number come far short expectation profit beat estimate share versus anticipate sale miss estimate full year profit revenue guidance have be lower well long term target year
3232,CELG,celgene corporation celg free report report mixed result third quarter earning beat expectation sale fail meet estimate company report adjust earning share beat zack consensus estimate year quarter total revenue grow quarter miss zack consensus estimate revenue be boost consistent performance company key growth driver revlimid however sale otezla unite state be weak celgene stock have fall last month industry gain share company be pre market trading due revenue miss third quarter stock be hit earlier phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue revlimid continue shinenet product sale increase year year net sale revlimid come reflect year year growth drug perform well unite state growth report quarter be drive increase volume result increase duration treatment market share net sale cancer drug abraxane increase sale grow unite state international market sale oncology drug pomalyst imnovid come sale be drive increase volume duration gain otezla report sale report quarter sale unite state be impact increase gross net adjustment contract implement january slow overall category growth due more challenge market access environment other product sale include istodax thalomid vidaza authorize generic version vidaza unite state totale report quarter year quarter adjust research development expense increase due increase spending related drug discovery clinical trial activity adjust selling general administrative expense decrease last month celgene announce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other fda place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quote outlook updatedcelgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share revenue be now project compare earlier projection revlimid sale be project abraxane sale be estimate be pomalyst revenue be project however otezla sale be now project previous projection takecelgene third quarter result be mixed company beating earning miss sale estimate revlimid sale be impressive yet again otezla sale unite state be weak lead management reduce annual guidance drug consequently company update annual guidance august company obtain fda approval idhifa enasidenib treatment relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report go forward expect approval new drug boost top line zack rank celgene be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3233,CELG,teva pharmaceutical industry ltd teva free report report first quarter earning market open last report quarter company deliver positive earning surprise generic drug maker share have lose year so far compare industry decline teva earning surpass expectation only last quarters meet same miss expectation remain result average positive surprise teva pharmaceutical industry ltd price ep surprise teva pharmaceutical industry ltd price ep surprise teva pharmaceutical industry ltd quotelet see thing be shape announcement factor considerincreas pricing erosion volume decline generic unit rapid erosion sale copaxone decline sale several other product specialty segment be expect hurt teva top line first quarter significant competitive pricing pressure generic industry be hurt sale teva generic unit ongoing consolidation customer generic industry be result increase price erosion decrease volume accelerate fda approval additional generic version compete patent medicine increase competition largest product concerta authorize generic stringent government regulation be also hurt sale meanwhile specialty segment loss exclusivity key drug copaxone azilect nuvigil divesture core asset woman health business hurt sale sale blockbuster multiple sclerosis ms treatment copaxone be likely erode due lower volume mg mg formulation be face generic competition glatopa generic version copaxone mg be be market momenta sandoz novartis generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april combat rapid decline sale december teva announce restructure plan see more company global workforce be layer next year majority expect update progress make so far restructure plan be also expect call earning whispersour proven model do not conclusively show teva be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand cent share zack consensus estimate be peg lower cent share uncover best stock buy sell re report earning esp filter zack rank teva have zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be drug biotech stock have right combination element beat earning time amag pharmaceutical inc amag free report have earning esp zack rank company be schedule release result celgene corporation celg free report have earning esp zack rank company be schedule release result see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3234,CELG,expect agio pharmaceutical inc agio free report surpass expectation report first quarter result market open last report quarter company deliver negative earning surprise share agio have soar year time compare favorably industry increase company earning track record show mixed result company have outpaced estimate twice trail quarters miss same other overall agio come average negative surprise let see thing be shape quarter factor playagio only market drug be idhifa enasidenib receive fda approval last august treatment patient relapse refractory acute myeloid leukemia aml have isocitrate dehydrogenase idh mutation last report drug generate strong sale expect encourage revenue first quarter well moreover agio progress pipeline have be quite impressive fact investor focus remain same be report quarter interesting candidate company cancer portfolio be idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag ivosidenib be priority review unite state treat patient aml idh mutation approval ivosidenib be expect third quarter additionally company anticipate regulatory filing candidate eu fourth quarter same indication ivosidenib be also be evaluate phase study address advanced hematologic malignancy combine celgene celg free report vidaza be assessment phase ii cure newly diagnosed aml patient be not eligible intensive chemotherapy meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma second half company announce positive finding study notably company also plan initiate perioperative window trial analyze ivosidenib ag low grade glioma investigate effect brain tumor tissue first half company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii trial adult transfusion independent patient pyruvate kinase deficiency agio report positive datum program june fda grant fast track designation candidate give indication rgd market still remain unexplored newer therapy area hold huge potential nonetheless march agio announce commencement phase study evaluate first class methionine mat inhibitor ag patient solid tumor lymphoma deletion mtap expect management produce update same first quarter earning release earning whispersour proven model show agio be likely beat earning report cycle have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp agio have earning esp represent percentage difference most accurate estimate loss share zack consensus estimate loss positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp together positive esp chance earning beat stock upcoming release be peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quote other stock considerhere be other health care stock worth consider right combination element beat estimate time gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report be schedule release quarterly result company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3235,CELG,immunogen inc imgn free report be schedule report first quarter result market open last report quarter company deliver negative earning surprise immunogen earning performance have be mixed bag recent past company surpass expectation last quarters miss same other overall immunogen pull average negative surprise share immunogen have significantly outperformed industry so far year stock have sky-rocket industry decrease let see thing be shape quarter factor playin absence approve product immunogen portfolio investor focus remain company progress lead pipeline candidate mirvetuximab soravtansine other program immunogen have significantly advanced respect mirvetuximab soravtansine recently company successfully complete interim analysis phase iii study forward evaluate candidate single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha company have also finished full enrollment trial month ahead schedule expect top line result program first half also combination regimen mirvetuximab soravtansine address ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck keytruda initial finding study demonstrated candidate have potential complement available therapy indication update outcome program be expect first half apart mirvetuximab soravtansine immunogen be work develop couple early stage candidate include imgn imgn last december company present positive result ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml annual meeting american society hematology moreover january company moved imgn phase study treat hematological malignancy include aml fourth quarter earning call company issue cash guidance anticipate cash cash equivalent range end december immunogen have then state hoard enough fund run operation fourth quarter model proven model do not conclusively show immunogen be likely beat estimate report cycle be stock need have positive earning esp solid zack rank strong buy buy hold happen be not case here see zack esp immunogen have earning esp represent percentage difference most accurate estimate loss cent zack consensus estimate loss cent uncover best stock buy sell re report earning esp filter zack rank immunogen have zack rank increase predictive power esp however company need positive esp be confident earning surprise hence combination leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision immunogen inc price ep surprise immunogen inc price ep surprise immunogen inc quote stock considertwo health care stock right combination element beat estimate time be follow gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3236,CELG,agio pharmaceutical inc agio free report post fourth quarter loss share wider zack consensus estimate loss year loss total revenue report quarter amount lag zack consensus estimate revenue plunge year figure due lower collaboration revenue however agio share increase almost report wider loss lower revenue company sound bullish pipeline progress fact stock have outperformed industry year time have surge compare industry rally notably august agio only market drug idhifa enasidenib receive fda approval treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company earn royalty revenue celgene corporation celg free report net sale idhifa quarter review compare third quarter drug post revenue report quarter research development expense be year year largely drive escalate cost associate ivosidenib program general administrative expense increase year year due higher cost related investment increase commercial capability idhifa potential launch ivosidenib december agio submit new drug application nda fda ivosidenib ag have be develop treat patient aml idh mutation nda submission be base encourage datum dose expansion part ongoing phase study evaluate candidate single agent patient advanced hematologic malignancy idh mutation approval ivosidenib be expect third quarter additionally company anticipate regulatory filing candidate eu fourth quarter give indication resultsfull year sale decrease year year sale also miss zack consensus estimate full year loss share be also wider zack consensus estimate loss company have incur loss year pipeline updateagio have several candidate pipeline include pan idh mutant inhibitor ag genetic disease candidate ag meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma october company announce positive datum study company have interesting candidate ag portfolio lead rare genetic disease candidate be evaluation phase ii study adult transfusion independent patient pyruvate kinase pk deficiency last december agio report impressive datum trial demonstrate candidate potential first disease modify therapy patient pk deficiency company expect initiate global pivotal study ag pk deficiency first half agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc price consensus ep surprise agio pharmaceutical inc quote zack rank key picksagio carry zack rank hold better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have surge year time hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3237,CELG,agio pharmaceutical inc agio free report be schedule report fourth quarter full year result feb open bell share have soar year time compare favorably industry increase agio earning track record show strong result company have surpass estimate thrice trail quarters miss same once overall agio have average beat last quarter company deliver positive surprise let see thing be shape quarter factor playagio only market drug be idhifa enasidenib receive fda approval august last year treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation drug record nominal revenue last quarter be expect add significantly company top line fourth quarter release moreover agio progress pipeline have be quite impressive fourth quarter fact investor focus remain same be report quarter interesting candidate company cancer portfolio be idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag december agio submit new drug application nda fda ag have be develop treat patient aml idh mutation nda submission be base encourage datum dose expansion part ongoing phase study evaluate candidate single agent patient advanced hematologic malignancy idh mutation meanwhile agio be conduct phase program ag treat patient advanced idh idh mutant positive solid tumor include glioma october company announce positive datum study notably agio be busy develop ag collaboration celgene corporation celg free report fetch collaboration revenue company have interesting candidate ag portfolio lead rare genetic disease candidate be evaluation phase ii study adult transfusion independent patient pyruvate kinase pk deficiency last december agio report impressive datum trial demonstrate potential first disease modify therapy patient pk deficiency earning whispersour proven model do not conclusively show agio be likely beat estimate quarter be stock need have positive earning esp bullish zack rank strong buy buy hold happen be not case here see zack esp agio have earning esp most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank agio have zack rank increase predictive power esp however company earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision agio pharmaceutical inc price ep surprise agio pharmaceutical inc price ep surprise agio pharmaceutical inc quote stock warrant lookhere be couple health care stock worth consider right combination element beat earning time exelixis inc exel free report be schedule announce fourth quarter result feb company have earning esp zack rank see complete list today zack rank stock here plc alk free report be schedule release fourth quarter result feb company have earning esp zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3238,CELG,biotech major amgen inc amgn free report report second quarter earning share beat zack consensus estimate increase year period better revenue lower operate cost drive bottom line lower tax rate share count also pull profit total revenue rise quarter beating zack consensus estimate unfavorable impact foreign exchange hurt sale quarter revenue rise ex sale grow exclude currency headwind quarter detailtotal product revenue rise year quarter ex strong demand newer product prolium xgeva blincyto somewhat make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp rise year quarter due higher unit demand revenue other esa epogen decline due lower selling price owing recently negotiate contract davita inc neulasta revenue decline year period due lower unit demand follow competition pd other new cancer therapy neupogen record decline sale due biosimilar competition zarxio sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep be hurt sale company expect neulasta neupogen sale continue be hurt competitive dynamic rest however management do specify call new biosimilar competition be expect year suggest neulasta epogenmay not start face biosimilar competition year contrary previous expectation however neulasta onpro kit body injector continue perform well command market share neulasta sale enbrel deliver revenue year quarter due increase competition offset favorable change inventory price however quarter market volume growth improve rheumatology dermatology segment compare first quarter enbrel experience relatively stable unit share market prolium revenue come year quarter due higher demand osteoporosis drug witness market share gain international market meanwhile xgeva deliver revenue year quarter mainly due higher demand sensipar mimpara revenue increase due higher price increase vectibix revenue come drive higher demand kyproli record sale year year drive higher demand quarter amgen submit regulatory application eu include overall survival datum endeavor study label kyproli study demonstrated combination kyproli dexamethasone lead superior overall survival compare velcade overall survival datum approve help drive usage boost sale kyproli amgen also announce final datum phase iii aspire study kyproli month show triple combination regimen kyproli celgene corporation celg free report revlimid lenalidomide dexamethasone krd significantly improve overall survival os patient relapse multiple myeloma compare revlimidand dexamethasone rd blincyto sale surge year period reflect higher demand earlier month fda approve inclusion overall survival datum tower study label blincyto addition datum help boost sale amgen pcsk inhibitor repatha generate revenue higher first quarter drive higher demand uptake drug gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent remind investor phase iii cardiovascular outcome study fourier repatha have reveal significant reduction myocardial infarction stroke first quarter datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum amgen file regulatory application eu include fourier datum repatha label jun operate margin operate margin rise basis point bps due lower operate cost reflect continue benefit transformation process improvement effort expense decline quarter due lower late stage pipeline related cost sg spend decline due oct expiration enbrel residual royalty payment offset investment support new product launch amgen buy back share worth quarter end second quarter amgen have remain stock repurchase plan guidancewhile amgen slightly cut lower end previously issue sale outlook raise earning guidance account strong first half profit company expect total revenue range versus expect previously adjust earning be now expect range compare share expect previously zack consensus estimate earning revenue be peg share respectively operate expense be expect be higher second half takeit be rather strong quarter amgen beat expectation earning sale raise earning guidance share however lose market trading probably due concern related tighten revenue guidance however so far year amgen share be better increase register industry amgen newer product prolium xgeva vectibix nplate sensipar be perform well volume growth not be enough offset decline mature brand enbrel due competitive pressure however amgen restructure plan make leaner more cost efficient amgen be also progress pipeline include biosimilar drug give quite few regulatory datum update schedule second half amgen currently carry zack rank hold see complete list today zack rank strong buy stock here amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3239,CELG,second quarter earning season be strong start july approximately company index total membership have report result deep look result show earning company report so far be year year higher revenue have top earning estimate have beat revenue estimate however pace growth be first quarter line quarter average have improve quarter average go forward estimate third quarter be go estimate growth be start quarter pharma sector have more less combat overall decline financial market maintain momentum last week industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale swiss major novartis ag nvs free report report encourage second quarter result meanwhile biotech giant biogen inc biib free report surpass expectation earning sale second quarter raise annual guidance let take look biotech company be set report second quarter result jul bristol myer squibb company bmy free report be schedule report open bell last quarter company beat earning estimate bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat quarter uncover best stock buy sell re report earning esp filter bristol myer high profile immuno oncology drug opdivo be expect continue drive company top line be report quarter first quarter see stability second line lung cancer recent fda approval merck co inc mrk free report keytruda first line treatment metastatic nonsquamous nsclc impact sale read more offing bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report open bell last quarter company beat expectation celgene key product revlimid be expect continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm other key product pomalyst imnovid abraxane otezla continue perform well second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug celgene track record have be pretty decent company toppingearning estimate thrice trail quarters overall company have deliver average positive surprise currently company carry zack rank earning esp indicate likely earning beat quarter read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last report quarter company earning surpass zack consensus estimate alexion blockbuster drug soliris continue perform well label expansion drug additional indication be expect boost revenue new product strensiq be do well kanuma lag expectation management be reassess strategy drug go forward alexion track record be excellent company have consistently top expectation last quarters average positive earning surprise currently company carry zack rank earning esp indicate be likely beat estimate quarter read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
3240,CELG,celgene corporation celg free report be schedule report second quarter result jul open bell last quarter company beat expectation celgene have outperformed zacksclassify industry year so far stock have gain period industry gain celgene track record have be pretty decent company beating earning estimate thrice trail quarters overall company have deliver average positive surprise let see thing be shape company ahead announcement earning whispersour proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg lower uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision factor playconcurrent first quarter earning result celgene update outlook company now expect earning compare earlier forecast share net product sale be expect celgene key product revlimid continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm revlimid sale be project currently celgene be work expand revlimid label further fda approve use maintenance treatment ndmm patient receive autologous stem cell transplant drug be also approve eu same ndmm market share continue grow outside positive uptake eu japan label expansion drug be expect boost sale further meanwhile broad phase iii program evaluate revlimid hodgkin lymphoma nhl be underway other key product pomalyst imnovid abraxane otezla continue perform well otezla pomalyst achieve blockbuster status record sale otezla sale first quarter be impact manage care dynamic lead lower total marketplace prescription psoriasis therapy pressure be expect ease year go pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be recently update eu include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function pomalyst combination darzalex dexamethasone relapse refractory myeloma be fda review abraxane sale be estimate be pomalyst revenue be project same otezla be estimate meanwhile expense percentage revenue be expect increase year second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug note celgene have inked agreement agio pharmaceutical agio free report idhifa celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotestock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3241,CELG,expect vertex pharmaceutical inc vrtx free report beat expectation report second quarter result jul market close year date vertex share have soar industry have record increase vertex track record have be impressive so far company deliver positive earning surprise miss expectation last quarters average positive earning surprise last quarters be last report quarter vertex post positive surprise vertex pharmaceutical incorporate price ep surprisevertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotelet see thing be shape quarter factor playsale vertex cystic fibrosis cf drug kalydeco orkambi rise first quarter expect positive trend continue second well kalydeco gain fda approval use patient older have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene person have mutation follow approval vertex up kalydeco revenue guidance expect expand indication boost kalydeco sale second quarter orkambi sale growth be dependent reimbursement discussion europe last week vertex announce have strike re imbursement agreement italy orkambi thereby make medicine more accessible country reimbursement agreement not be beneficial second quarter contribute sale second half year first quarter company have also mentioned gain reimbursement france year contribute significantly revenue growth year vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study present earlier week have show combination lead pronounce improvement lung function phase ii study vx be expect be initiate early aug phase ii study fourth next generation corrector vx triple combination tezacaftor ivacaftor be already go datum vx vx phase ii study be expect early thereafter discussion regulatory agency vertex initiate pivotal study more triple combination regimen first half triple combo regime be successful vertex address significantly larger cf patient population investor focus call be triple combination cf regimen crucial long term growth vertex however operate expense be likely shoot vertex expand pipeline model proven model show vertex be likely beat estimate quarterbecause have right combination key ingredient astock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex currently flaunt zack rank strong buy so desirable combination make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter gilead science inc gild free report be schedule release result jul company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result jul company have earning esp zack rank proteostasis therapeutic inc pti free report be expect release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3242,CELG,hca healthcare inc hca free report be schedule report second quarter result jul market open last quarter hospital company post line result have however surpass earning estimate last quarters average positive surprise let see thing be shape announcement company commercial volume have be stress past few quarters have take effort build local network create greater patient access outpatient facility standpoint digital medium standpoint address issue however don expect see major improvement business second quarter last quarter company report consecutive quarter equivalent admission growth hca expect trend continue second quarter hca healthcare consistently make capital expenditure expansion service capacity large fast grow urban market incur regard expect invest company have also make number acquisition past many year expedite growth believe investment generate top line growth increase business volume share buy back company be report cushion bottom line company have not paid regular dividend ipo prefer share buyback dividend payment allocate capital maintain current policy dividend payout hca holding inc price ep surprise hca holding inc price ep surprise hca holding inc quoteearning whispersour proven model do not conclusively show hca healthcare be likely beat earning quarter be stock need have positive earning esp zack rank happen be not case here see zack esp hca holding have earning esp be most accurate estimate stand share zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank hca holding carry zack rank hold increase predictive power esp however negative earning esp make surprise prediction difficult caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock warrant lookhere be company healthcare sector consider model show have right combination element post earning beat quarter gilead science inc gild free report be expect report second quarter earning result jul company have earning esp zack rank see complete list today zack rank strong buy stock here celgene corporation celg free report have earning esp zack rank company be expect report second quarter earning result jul pfizer inc pfe free report have earning esp zack rank company be expect report second quarter earning result aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3243,CELG,biotech major amgen inc amgn free report report second quarter result jul market close amgen deliver positive earning surprise last quarter amgen share be so far year compare favorably increase register industry period amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be let see thing be shape company quarter factor playamgen growth product prolium xgeva kyproli vectibix nplate sensipar be likely perform well new patient adoption repeat injection drive prolium sale xgeva be likely benefit superior clinical profile versus competition parsabiv etelcalcetide treatment secondary shpt be approve feb eu nov drug be likely bring revenue second quarter however company have challenge store give presence biosimilar competition slowdown sale mature product epogen neulasta neupogen sale be expect be hurt competition eu note neupogen sale be also be hurt biosimilar competition mainly zarxio sandoz novartis ag nvs free report generic arm biosimilar version neupogen be launch sep neupogen be expect face continue competitive pressure year exist potential biosimilar neulasta epogen start face biosimilar competition year biosimilar be launch second quarter meanwhile blockbuster drug enbrel be face increase competition rheumatology dermatology segment hurt sale volume growth recently launch product not be enough offset decline mature bottom line however benefit company overall cost cut effort share buyback company restructure plan make leaner more cost efficient investor focus remain performance company pcsk inhibitor repatha uptake repatha gain fda approval aug have not be very encourage so far due pricing re imbursement issue payer restriction phase iii cardiovascular outcome study fourier repatha have reveal significant reduction myocardial infarction stroke first quarter datum be key commercial success repatha broaden use drug datum study look good be not very clear payer be willing improve access repatha base datum amgen file regulatory application eu include fourier datum repatha label jun earning whispersour proven model do not conclusively show amgen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank amgen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision amgen inc price ep surprise amgen inc price ep surprise amgen inc quotestock considersome stock biom genetic sector have positive esp favorable zack rank be celgene corporation celg free report earning esp zack rank company be schedule release result jul schedule release result jul gilead science inc gild free report have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3244,CELG,johnson johnson jnj free report report mixed second quarter result earning beat expectation sale miss same however drug consumer product giant raise sale profit outlook send share more pre market trading year so far share price be compare favorably increase witness zack classify large cap pharma industry earning beatj second quarter earning come share beating zack consensus estimate increase year period include time item report second quarter earning share year period sale miss againsale come miss zack consensus estimate sale increase year quarter reflect operational increase negative currency impact organically exclude impact acquisition divestiture sale increase operational basis second quarter sale grow domestic market international market reflect operational growth partially offset negative currency impact sale segment sale decline year year reflect operational growth negative currency impact higher sale international market offset weaker performance sale domestic market decline international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be xarelto stelara invega sustenna however sale invokana invokamet decline also concerta decline zytiga sale fall importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report launch inflectra injection biosimilar version remicade late last november do not have significant impact remicade sale past quarters management be expect comment impact biosimilar second quarter sale conference call pharma segment achieve clinical milestone quarter include fda approval darzalex be used combination celgene corporation celg free report pomalyst pomalidomide dexamethasone third line treatment multiple myeloma importantly last week announce fda approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya meanwhile last month complete previously announce acquisition swiss biotech actelion diversify revenuesto pulmonary arterial hypertension pah category actelion pah drug add top line quarter medical device segment sale come year period include operational increase negative currency movement sale gain mainly inclusion abbott medical optic acquisition exclude impact acquisition divestiture operational basis worldwide sale increase sale domestic market rise year year international market sale increase operational increase year year operational growth be drive advanced surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement negatively impact sale segment sale domestic market grow year period slower growth baby care product be partially offset growth counter product meanwhile international segment record decline reflect operational decline negative currency impact guidance raisedj raise earning guidance increase lower end sale outlook expect adjust earning share range include currency impact compare expect previously revenue guidance be range compare expect previouslyour takedespite third consecutive sale miss look optimistic better sale performance second half chief executive officer alex gorsky say sale growth accelerate second half year importantly sale medical device segment be pick make lower sale international consumer pharmaceutical segment quarter sale domestic pharma segment have decelerate year key growth driver have slow due competition quite few product portfolio remicade concerta be face generic competition however believe new product tremfya label expansion drug imbruvica darzalex contribution actelion lead better sale trend remain half year carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3245,CELG,car chimeric antigen receptor cell space get significant boost recently fda advisory panel issue positive recommendation experimental treatment corner immune oncology market last week swiss pharma giant novartis nvs free report experimental car therapy ctl get unanimous vote approval fda oncologic drug advisory committee odac novartis be look get ctl approve treatment relapse refractory pediatric young adult patient cell acute lymphoblastic leukemia ctl be currently priority review timely approval make first car cell therapy be available do car cell therapy work car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body car approach involve collection patient cell genetic modification outside body incorporation specific receptor target cancer cell finally re infusion modify cell back patient be lot enthusiasm car early stage study have show help achieve durable complete response leukemias lymphomas include patient have suffer multiple relapse car therapy come own set challenge include high level investment well safety issue serious immune toxicity crs neurotoxicity pricing be issue well treatment not come cheap however treatment have huge commercial potential well change treatment paradigm car stock increase focus corner immune oncology market possibility car drug enter market year end here be look company be work car cell treatment kite pharma inc santa monica base kite be cell therapy company engage development innovative cancer immunotherapy goal provide rapid long term durable response eliminate burden chronic care company focus be car cell receptor tcr engineer cell therapy kite be follow close heel novartis fda approval car treatment be concern lead pipeline candidate axicabtagene ciloleucel be currently priority review treatment patient refractory aggressive hodgkin lymphoma nhl response fda be expect nov company be filing eu approval third quarter axicabtagene ciloleucel target antigen cd protein expressed cell surface cell lymphomas leukemias accord company initial market opportunity axicabtagene ciloleucel include addressable car patient europe respectively new case be diagnosed japan year key urban eastern rural coastal area china kite have have strong run so far share skyrocket outperform zack categorize medical biomedical genetic industry be bellicum pharmaceutical inc blcm free report houston tx base bellicum be clinical stage biopharma company work novel controllable cellular immunotherapy different form cancer include hematological cancer well solid tumor orphan inherited blood disorder company proprietary chemical induction dimerization cid technology platform be design potentially offer better safety efficacy outcome compare other cellular immunotherapy company pipeline candidate include bpx adjunct cell therapy allogeneic hematopoietic stem cell transplantation registration study advance eu preparation be registration study bpx gocar candidate solid tumor design proprietary imc activation switch improve efficacy phase bpx high affinity tcr candidate solid tumor design caspacide safety switch phase bellicum share be almost year date ytd lag zack categorize medical drug industry be period juno therapeutic inc seattle wa base juno be key player cellular immunotherapy area company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar car cell product target cd juno be look get jcar market early nhl company also have strong partner celgene celg free report juno share be ytd ziopharm oncology inc ziop free report boston base ziopharm be biotech company used innovative gene expression control cell technology provide safe effective scalable cell viral base therapy cancer graft versus host disease ziopharm immune oncology platform include car well other adoptive cell base approach ziopharm be advance program multiple stage development together intrexon rheoswitch therapeutic system rt technology switch turn precisely modulate gene expression order improve therapeutic index car program company be continue phase second generation study cd specific car lymphoid malignancy expect move third generation cd mbil early stage study evaluate point care plan be also commence phase study cd specific car relapse refractory acute myeloid leukemia aml year ziopharm share be ytd nantkwest inc nk free report nantkwest be clinical stage immunotherapy company focuse used natural killer nk free report cell treat cancer infectious disease inflammatory disease company nk cell base platform have be design induce cell death cancer infected cell different mode action direct kill used activate nk cell ank antibody mediate kill used hank target activate kill used tank nantkwest share be so far kite ziopharm bellicum nantkwest be zack rank hold stock juno be zack rank buy stock meanwhile see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3246,CELG,acadium pharmaceutical inc acad free report be expect release first quarter result last report quarter acadium deliver positive earning surprise company deliver average positive earning surprise last quarters acadium share have tumble year date compare industry decline let see thing be shape announcement factor playacadium be focuse develop product treat unmet medical need central nervous system cns performance first approve drug nuplazid pimavanserin treat hallucination delusion associate parkinson disease pd psychosis have be impressive launch april company be also track multus year plan develop nuplazid indication pd psychosis company be study drug clinical program nuplazid alzheimer disease agitation alzheimer disease psychosis schizophrenia inadequate response schizophrenia negative symptom major depressive disorder october company initiate phase iii harmony study dementia related psychosis drp company also receive breakthrough therapy designation fda nuplazid treatment drp follow end phase ii meeting fda robust positive result phase iii study together support datum prior study nuplazid serve basis supplementary new drug application expect company provide further update progress study first quarter earning call company expect full year nuplazid net product sale be net sale first quarter company expect strong volume growth nuplazid model proven model do not show earning beat acadium quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp acadium have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank acadium currently have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc quote stock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank see complete list today zack rank stock here adverum biotechnology inc advm free report have earning esp currently carry zack rank company be expect release first quarter result emergent biosolution inc ebs free report have earning esp zack rank company be schedule release first quarter result wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3247,CELG,first month have come close time look back see be hot not time period case market behaved decently offer gain last month jan dow jone index return time frame backdrop let delve little deeper find winning lose etfs best performersunite state natural gas ung free report natural gas price shot winter chill ample supply be responsible downbeat natural gas price normally arctic chill give life commodity winter cold snap boost electricity demand region putt natural gas focus fund thus gain substantially january read polar blast warm natural gas etfs etfmg alternative harvest etf underlie index fund enable investor take advantage event drive news long term trend cannabis industry well industry likely be influenced medicinal recreational cannabis legalization initiative take place many location globally medical marijuana industry be grow leap bound lately amassing investor interest medical usage marijuana be legalize many area lately have be surge legalization recreational usage marijuana state election hold marijuana be declare legal recreational medical purpose additional state legal marijuana sale surge accord cannabis research firm arcview firm expect sale figure skyrocket clearly explain gain mjx read rush marijuana etfs get stronger first trust china alphadex etf fca free report chinese economy expand year year same previous month beating market expectation make china etf gainful investment tactic loncar cancer immunotherapy etf cncr free report buyout biotech space be spotlight currently celgene corporation celg free report buy juno therapeutic inc sanofi sa adr sny free report buy bioverativ inc recently be probably push space higher tax reform entail biotech company repatriate hundred billion dollar stack international economy extra cash be used buy back share pay dividend come day worst performersipath bloomberg sugar subtr etn higher supply weak demand probably weigh sugar price hurt sugar related exchange trade product ishare residential real estate capped etf rez free report rise interest rate real estate stock have underperform weigh fund ipath pure beta soft etn underlie index fund barclay commodity index soft pure beta tr reflect return be potentially available unleveraged investment future contract soft commodity trade exchange coffee sugar cotton be holding etn lower sugar price obviously weigh fund bloomberg dollar bullish fund usdu free report fund look provide total return expense surpass performance bloomberg dollar spot index treasury secretary steven mnuchin recently promote weaker greenback order boost nation trade turn weigh dollar read tale currency etf impact want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3248,CELG,expect vertex pharmaceutical inc vrtx free report beat expectation report third quarter result oct market close year date vertex share have soar industry have record increase vertex track record have be impressive so far company deliver positive earning surprise last quarters miss expectation average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi do well second quarter expect positive trend continue second well kalydeco gain fda approval use patient year older have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene person unite state have mutation august kalydeco receive approval cf patient have residual function mutation cause splice defect cftr gene person unite state have mutation follow approval label expansion vertex up kalydeco revenue guidance zack consensus estimate kalydeco third quarter be orkambi sale growth be dependent reimbursement discussion europe june july year vertex strike re imbursement agreement ireland italy respectively orkambi thereby make medicine more accessible country expand accessibility be expect bring more sale drug first quarter company have also mentioned gain reimbursement france year contribute significantly revenue growth however company be yet sign agreement consensus estimate orkambi third quarter be vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor investor focus call be triple combination cf regimen be crucial long term growth vertex however operate expense be likely shoot vertex expand pipeline model proven model show vertex be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex currently have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock warrant lookhere be biotech stock also want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be expect release result nov company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result oct company have earning esp zack rank trevena inc trvn free report be expect release result nov have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3249,CELG,immune design imdz free report announce plan initiate pivotal phase iii study support regulatory application cmb patient synovial sarcoma company plan start study mid enroll patient age year older decision be base discussion fda phase iii study evaluate cmb monotherapy comparison placebo patient ny eso locally advanced unresectable metastatic synovial sarcoma have evidence progression first line chemotherapy patent be randomize receive cmb monotherapy placebo study have progression free survival pfs follow overall survival os co primary endpoint study meet pfs endpoint candidate get approve fda so far year immune design stock have rally compare industry gain cmb be primary candidate be develop immune design cmb be be evaluate multiple clinical trial patient soft tissue sarcoma st cmb be be evaluate st patient monotherapy phase combination roche rhhby tecentriq phase ii august company announce positive topline datum interim analysis ongoing phase ii study evaluate cmb combination tecentriq tecentriq alone soft tissue sarcoma patient company have earlier receive orphan drug designation component cmb st unite state european union immune design corp price immune design corp price immune design corp quote zack rank stock considerimmune design carry zack rank hold better rank stock health care sector include adaptimmune therapeutic plc adap free report celgene corporation celg free report nordisk nvo free report hold zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss share estimate have narrow cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date celgene earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date nordisk earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3250,CELG,glaxosmithkline plc gsk free report announce vaccine shingrix have be approve canada prevention shingle herpes zoster older patient age year older be first regulatory approval key pipeline product glaxo have blockbuster potential so far year glaxo share have underperform industry stock have increase compare industry gain meanwhile shingrix be review unite state eu australia japan fact last month glaxo announce fda advisory panel unanimously vote recommend approval shingrix older patient company also add fda vaccine related biological product advisory committee be impressed efficacy safety datum shingrix study company expect approval shingrix unite state europe year shingrix be also be evaluate immuno compromise patient population include solid hematological cancer patient hematopoietic stem cell renal transplant recipient hiv infected person glaxo expect new pharmaceutical vaccine product include potential contribution shingrix deliver sale annum shingrix be also be evaluate immuno compromise patient population include solid hematological cancer patient hematopoietic stem cell renal transplant recipient hiv infected person nordisk price nordisk price nordisk quotezack rank stock considerglaxo carry zack rank hold better rank stock health care sector include adaptimmune therapeutic plc adap free report celgene corp celg free report nordisk nvo free report hold zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss share estimate have narrow cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date celgene earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date nordisk earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3251,CELG,bayer bayry free report have inked deal sell select crop science business basf eur notably company intend divest asset part strategy complete plan acquisition co divestiture be subject closure deal bayer be work relevant authority end acquisition early next year fact company plan utilize net proceed divestiture partially refinancing plan acquisition markedly asset be divest include bayer global glufosinate ammonium selective herbicide business related libertylink technology herbicide tolerancea well seed business key row crop select market transaction include respective research development capability well revenue business amount so far year bayer share have outperformed industry stock have rally compare industry gain more commercial breed production personnel be transfer bayer basf meanwhile bayer continue own operate maintain business close divestiture sep bayer sign definitive merger agreement acquire seed giant company deal worth approximately combine business be expect boost bayer crop science business provide accretion core earning first full year close transaction follow double digit percentage growth bayer also expect annual earning contribution synergy year close transaction well additional future benefit integrate offering believe propose acquisition be strategic move offer bayer broad set solution meet farmer current future need bayer ag price bayer ag price bayer ag quotezack rank stock considerbayer carry zack rank hold better rank stock health care sector include adaptimmune therapeutic plc adap free report celgene corporation celg free report hold zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss share estimate have narrow cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date celgene earning share estimate have moved company pull positive earning surprise trail quarters average beat share price company have increase year date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3252,CELG,janssen subsidiary johnson johnson jnj free report announce fda have approve label expansion plaque psoriasis drug stelara use adolescent year age older drug be approve adult indication company believe label expansion be significant achievement plaque psoriasis develop age year approximately third patient moreover number treatment available adolescent be limit patient be administer only dose year starter dose stelara have become lead therapeutic option share company be so far year almost line industry performance industry have gain same time frame latest approval stelara be base datum phase iii study evaluate subcutaneous administration drug adolescent patient datum show drug achieve minimal psoriasis clear skin least third patient safety datum be also consistent be achieve adult patient be almost person suffering psoriasis unite state american academy dermatology moreover national center biotechnology information state majority psoriasis patient suffer plaque psoriasis number represent huge opportunity drug follow label expansion moreover approval stelara have gain edge compete drug abbvie inc abbv free report humira novartis ag cosentyx celgene corporation celg free report otezla be only approve adult plaque psoriasis patient however pfizer inc pfe free report enbrel compete stelara adolescent segment johnson johnson price consensus johnson johnson price consensus johnson johnson quotejohnson johnson carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3253,CELG,valeant pharmaceutical international inc vrx free report announce division ortho dermatologic announce result long term phase iii extension study amagine study demonstrated siliq injection provide sustain high level skin clearance pasi more year patient moderate severe psoriasis result phase iii multicenter randomize double blind placebo controlled study amagine evaluate efficacy brodalumab subset patient prior exposure ustekinumab demonstrated siliq be similarly efficacious improve skin clearance patient prior ustekinumab exposure note siliq be approve treatment moderate severe plaque psoriasis adult patient be candidate systemic therapy phototherapy have fail respond have lose response other systemic therapy drug be approve february however weakness dermatology segment persist be expect impact top line valeant enter collaboration agreement astrazeneca plc azn free report grant former exclusive license develop commercialize siliq globally japan certain other asian country right be hold kyowa hakko kirin co ltd agreement be amend july entitle valeant right develop commercialize brodalumab europe valeant stock have lose year so far compare gain industry once acquisition giant valeant have be catch various controversy october follow substantial decline valeant share price first quarter bill ackman steve fraidin joined board march part persh square effort stabilize company thereafter joseph papa take charge new ceo new management take various effort turnaround company even be still early comment rebuild process company effort sell core asset lower debt be commendable divestiture core asset be expect help company streamline product portfolio focus core area dermatology lower debt approval new drug bring hope believe be still long road ahead valeant investor faith be restore stock earlier year bill ackman chairman perish square holding ltd state investing valeant be big mistake part zack rank key picksvaleant currently carry zack rank strong sell better rank stock health care sector be acadium pharmaceutical inc acad free report celgene corp celg free report carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat celgene earning estimate have inched past day stock have rally year outperform industry stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
3254,CELG,share intercept pharmaceutical inc icpt free report decline year date industry gain particular share have plunge month due safety issue regard approve drug ocaliva recent news article prescription drug have fall fda issue guideline regard incorrect dose ocaliva fda report death due ocaliva approve primary biliary cholangitis pbc state drug also affect liver however intercept conduct analysis conclude patient be prescribe once daily dose ocaliva be time higher recommend weekly dose analysis be conduct consultation fda company conclude death occur due overdose consequently intercept issue dear healthcare provider letter thereafter fda issue own safety communication reinforce recommend label dose intercept be also work tandem fda develop ocaliva label safety purpose note ocaliva be approve unite state subsequently european union canada treatment pbc inadequate response intolerant standard care udca dose recommend earlier stage pbc patient mild hepatic impairment be mg once daily be increase month mg once daily base tolerability treatment response other hand late stage patient moderate severe hepatic impairment child pugh cirrhosis recommend dose start mg once weekly possibility gradually increase maximum mg twice weekly warning come major setback intercept expect company sale be hurt third quarter due same company expect drug sale improve international demand be project pick second half ocaliva be company only approve drug such side effect limit sale potential zack rank key currently carry zack rank hold better rank stock health care sector be acadium pharmaceutical inc acad free report celgene corporation celg free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat celgene earning estimate have inched past day stock have rally year outperform industry aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3255,CELG,company amgen amgn free report regeneron regn free report be news amgen provide pipeline regulatory update regeneron partner sanofi get good news appeal court ruling favor pcsk inhibitor lawsuit amgen recap week most important storiesphase ii combination datum amgen imlygic publish positive datum amgen oncolytic viral therapy imlygic used combination bristol myer squibb yervoy be publish journal clinical oncology result mid stage study show objective response rate orr more double imlygic be used combination yervoy compare yervoy alone patient unresectable stage iiib iv melanoma versus moreover complete response rate be almost double combination arm compare yervoy alone versus response be observed inject uninjected lesion include visceral lesion advanced melanoma be highly aggressive most dangerous type skin cancer be need multiple treatment approach course disease datum be encourage open new avenue revenue imlygic eventually gain approval use combination checkpoint inhibitor sale imlygic approve october be yet pick meanwhile amgen say fda have accept regulatory application seek label expansion use prolium glucocorticoid induced osteoporosis most common form secondary osteoporosis response agency be prolium bring sale second quarter be important growth driver amgen company work improve diagnosis treatment rate duration order drive access greater number patient read more amgen label expansion application prolium accept fda amgen be zack rank buy stock share amgen have gain year date significantly outperform industry rally see complete list today zack rank strong buy stock here breather amgen neulasta biosimilar approval delay amgen get bit breather fda issue complete response letter crl mylan biocon biosimilar version amgen blockbuster drug neulasta pegfilgrastim agency do not raise query regard biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity myl crl relate pending update regulatory application certain cmc datum facility requalification activity post recent plant modification note mylan biocon be not only company get crl fda biosimilar version neulasta novartis sandoz have receive crl last year coherus be issue crl year june regeneron sanofi score pcsk inhibitor litigation regeneron partner sanofi get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state read more regeneron sanofi get favorable ruling amgen abbvie immuno oncology deal abbvie abbv free report have enter research option license agreement clinical stage immuno oncology company turnstone biologic deal provide abbvie exclusive option license turnstone next generation oncolytic viral immunotherapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor promising new datum biogen spinraza new phase iii datum present biogen biib free report spinraza show earlier initiation treatment therapy improve motor function outcome infant child spinal muscular atrophy sma biogen ionis spinraza be first approve medicine treatment sma spinraza be promising start unite state bring sale second quarter clovis seek label expansion parp inhibitor clovis oncology clvs free report have file label expansion parp inhibitor rubraca unite state company be look get drug approve maintenance treatment patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy company have present impressive late stage datum earlier year june rubraca show treatment significantly improve progression free survival ovarian cancer patient population evaluate ariel study rubraca have gain accelerate fda approval december use advanced ovarian cancer patient have be treat more chemotherapy have deleterious germline somatic brca mutation broader label boost rubraca sale potential read more clovis submit snda ovarian cancer drug rubraca biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen gain celgene celg free report lose last month vertex vrtx free report be see last biotech stock roundup here endocyte shoot deal amgen abbvie settle humira litigation next biotech world sector gear third quarter earning watch usual regulatory pipeline update spark therapeutic voretigene neparvovec be review fda cellular tissue gene therapy advisory committee ctgtac october spark be seek fda approval treatment patient vision loss due confirm biallelic rpe mutation associate retinal dystrophy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3256,CELG,agio pharmaceutical inc agio free report announce fda accept company new drug application nda isocitrate dehydrogenase idh mutant inhibitor ivosidenib ag company be seek get ivosidenib approve treatment patient relapse refractory acute myeloid leukemia aml idh mutation fda grant priority review candidate set action date aug year date agio share price improve compare industry gain priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease ivosidenib be be evaluate phase expansion cohort treatment patient idh aml datum study demonstrated durable response patient give indication enabled company submit nda fda ivosidenib december addition nda premarket approval application be also submit fda abbott laboratory free report fda review idh assay abbott realtime system assay automatically prepare sample analyze batch nucleic acid amplification detection idh mutation occur aml patient abbott assay serve companion diagnostic ivosidenib ivosidenib be also be evaluate phase study treatment advanced hematologic malignancy phase ii combination celgene celg free report vidaza treatment newly diagnosed aml patient be not eligible intensive chemotherapy potential approval candidate boost sale company agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote zack rank stock consideragio be zack rank hold stock better rank stock health care space be xoma corp xoma free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company sky-rocket year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3257,CELG,thursday october welcome fully open spigot earning season be single busiest day quarter bell see result googl msft intc other plenty company have already report earning open bell today not enough ve also get ton economic datum newsworthy financial information get so let get start european central bank ecb president mario draghi have extend quantitative ease program have help foster eurozone back good health euro buyback be schedule have expire december now taper begin january continue september next year buyback be cut half euro month result see euro fall value not drop range statement draghi expressed risk growth eurozone be broadly base economic expansion be solid initial jobless claim also stay range bound last week slightly revise previous week continue claim stay even few week see spike initial jobless claim follow double whammy hurricane harvey irma weekly claim have revert back favorable range ve see past couple year wholesale inventory rise latest read retail inventory fall growth inventory increase be widely consider weakest economic growth metric drawdown inventory make room new product hit market consider report modest positive current economy earning twtr free report share be spiking today pre market follow better expect earning report cent share top cent be expect quarterly sale modestly outpaced zack consensus monthly active user grow company have take step clean operation light allegation abuse platform ceo jack dorsey be also point twitter direction video stream increase usage go forward ford motor company free report follow recent strong report gm beating estimate top bottom line morning earning cent share outperformed cent expect zack consensus quarterly revenue improve estimate automotive giant also raise lower end full year guidance share record time high pre tax profit asia pacific region share go report unite parcel service up free report report share quarterly report morning beating estimate penny revenue come strongly ahead expectation surpass zack consensus up report cost result hurricane company also raise lower end earning guidance full year up also look forward potential record holiday season pre market trade have send share slightly negative territory however biopharma major celgene corp celg free report share have fall more today pre market quarterly revenue number come far short expectation profit beat estimate share versus anticipate sale miss estimate full year profit revenue guidance have be lower well long term target year mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3258,CELG,third quarter earning season be strong start result company have report number show earning revenue growth pace be accelerate first quarters particular revenue growth have show significant momentum evident proportion positive revenue surprise total earning index third quarter be expect be higher revenue oct company account index total market capitalization have report result result reveal earning company be year quarter increase revenue beat earning estimate beat revenue estimate medical sector medical sector have perform relatively well date quarter be not go be different estimate company have report so far beat revenue company surpass earning expectation go forward sector be expect record year year growth revenue earning bellwether sector johnson johnson jnj free report report better expect third quarter result raise outlook swiss giant novartis ag nvs free report too beat earning sale back new drug cosentyx entresto eli lilly company lly free report also report better expect result third quarter here have major biotech giant be set report third quarter result oct let see thing be shape gilead science inc gild free report be expect beat expectation report market close zack model stock need have positive earning esp zack rank strong buy buy hold beat zack consensus estimate gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead currently carry zack rank earning esp combination zack rank positive esp make confident earning beat uncover best stock buy sell re report earning esp filter strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotebristol myer squibb company bmy free report be likely beat expectation report result market open bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation company average positive earning surprise last quarters be company currently carry zack rank earning esp see complete list today zack rank stock here bristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report result open bell celgene have excellent track record company beating earning estimate last quarters last quarter company beat expectation overall company have deliver average positive surprise celgene currently carry zack rank esp combination zack rank positive esp make confident earning beat expect company beat estimate once again back strong performance key drug revlimid drug perform well first half combat challenge uneven buy pattern coverage gap continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate drug currently stand read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise company currently carry zack rank esp make surprise prediction difficult alexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotezack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3259,CELG,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
3260,CELG,celgene corporation celg free report be schedule report third quarter result oct open bell celgene stock have moved year date compare industry gain celgene have excellent track record company beating earning estimate last trail quarters last quarter company beat expectation overall company have deliver average positive surprise expect company beat estimate once again back strong performance key drug revlimid likely positive surprise proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoterevlimid drive second quarter earning result celgene raise guidance company anticipate earning range share compare previous guidance share net product sale be project zack consensus estimate product sale third quarter currently stand revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma drug perform well first half combat challenge uneven buy pattern coverage gap market share gain key market longer treatment duration be contribute drug growth meanwhile celgene be work expand revlimid label further revlimid receive fda approval use maintenance treatment ndmm patient receive autologous stem cell transplant ndmm market share continue grow outside unite state positive uptake eu japan continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate revlimid currently stand third quarter other key product pomalyst imnovid abraxane otezla continue perform well pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be update unite state europe include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function pomalyst combination darzalex dexamethasone relapse refractory myeloma be approve unite state propel sale further approval idhifa treatment adult patient relapse refractory aml aml further boost celgene portfolio drug be develop collaboration agio pharmaceutical agio free report otezla achieve blockbuster status drive solid demand unite state trend be expect continue increase contribution european country also impact sale positively be currently be evaluate phase iii study behçet disease atopic dermatitis expand indication psoriatic arthritis plaque psoriasis company be keen expand oncology franchise abraxane label geographical expansion approve drug additional indication increase commercial potential further abraxane sale be estimate be pomalyst revenue be project same otezla be estimate third quarter earning call investor be expect remain focuse company performance label expansion effort update pipeline front other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical inc vrtx free report have earning esp zack rank company be schedule release third quarter result oct see complete list today zack rank stock here glaxosmithkline plc gsk free report have earning esp zack rank company be schedule release third quarter result oct make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3261,CELG,conatus pharmaceutical inc cnat free report be slate report first quarter result market close company earning history have be disappointing so far have miss expectation occasion miss register line result average negative surprise last report quarter company deliver positive surprise share conatus have plunge year time versus industry rally let see thing be shape upcoming release factor approve product conatus portfolio moment company be yet generate revenue hence investor focus be company progress respect lead candidate emricasan orally active pan caspase protease inhibitor emricasan be evaluation various phase iib study treatment chronic liver disease include nash fibrosis be now ongoing emricasan phase iib trial consist other encore program patient fibrosis cirrhosis cause nonalcoholic steatohepatitis nash various patient population datum analysis be expect company also plan initiate new study call encore xt plan extension trial patient complete encore ph encore lf study continue monitoring efficacy safety clinical outcome healthy quality life apart emricasan company portfolio have idn presently undergo phase ii study treatment primary sclerosing cholangitis expect update same first quarter conference call emricasan have also be extensively profile test study many preclinical model human disease april conatus announce positive result vivo study demonstrate reduction hepatic tissue factor drive coagulation be important note conatus have exclusive option collaboration license agreement novartis ag nvs free report worldwide development emricasan novartis sharing half development cost related conatus phase iib study emricasan company now anticipate lower spending licensing internal pipeline earning whispersour proven model do not conclusively show conatus be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp conatus have earning esp most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank conatus carry zack rank increase predictive power esp however company earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision conatus pharmaceutical inc price ep surprise conatus pharmaceutical inc price ep surprise conatus pharmaceutical inc quote stock warrant lookhere be health care stock right combination element beat estimate time gilead science inc gild free report be schedule report first quarter financial number company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3262,CELG,gilead science inc gild free report be schedule report first quarter result market close gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quote gilead leader hepatitis virus hcv space have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise gilead stock have rally year outperform industry decline likely positive surprise proven model indicate gilead be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be case be here see zack esp earning esp gilead be uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combine positive esp make reasonably confident earning beat quarter conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor playconcurrent fourth quarter earning call gilead provide guidance gilead now expect net product sale range strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch taf base regimen now represent total gilead hiv prescription volume truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end moreover franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost zack consensus estimate sale genvoya be however gilead lose exclusivity viread country outside unite state impact sale other hand hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other franchise suffer significant plunge sale due new competition fewer patient start pricing market share be expect stabilize mid patient start be expect decline further hcv revenue be project decline further constitute smaller portion top line go forward zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range meanwhile kite acquisition be step right direction fda approval chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma however management state yescarta launch be controlled launch ensure patient safety car therapy be complicate sometimes be associate severe side effect gilead be also look build nonalcoholic steatohepatitis franchise expect management throw more light same first quarter call investor be also likely keep eye other pipeline update other stock considerhere be other health care stock want consider model show too have right combination element post earning beat quarter gw pharmaceutical plc gwph free report be expect report earning company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3263,CELG,immune design corp imdz free report isschedule report first quarter result market close last report quarter company deliver positive earning surprise immune design top earning estimate trail quarters average beat immune design share have lose year date compare industry fall let see thing be shape announcement factor playbee development stage company immune design have not generate product revenue yet earn revenue collaboration licensing agreement product sale investor remain focuse company progress base pipeline candidate immune design be develop multiple candidate used discovery platform zvex glaas treatment various type cancer company key pipeline candidate be cmb solid tumor merkel cell carcinoma mcc cmb have be design prime boost approach involve sequential dose complementary agent lv currently candidate be be evaluate soft tissue sarcoma patient monotherapy phase combination roche hold rhhby tecentriq phase ii company plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient mid progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma discussion fda be positive regard cmb consequently company have plan initiate pivotal phase iii trial study cmb monotherapy synovial sarcoma patient study be expect start mid enroll patient age older ny eso synovial sarcoma receive cmb monotherapy placebo progression free survival endpoint be meet company intend file biologic license application seek approval cmb treatment synovial sarcoma meanwhile be be evaluate multiple clinical trial include monotherapy local radiation complete phase study patient mcc ongoing investigator sponsored trial patient sarcoma be also be develop monotherapy combination therapy patient follicular hodgkin lymphoma nhl randomize phase ib ii study october receive orphan drug designation treatment follicular nhl european medicine agency potential approval pipeline candidate be boost company earning call expect immune design shed light progress ongoing trial model proven model do not show earning beat immune design quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate however be not case here see zack esp immune design have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank immune design have zack rank increase predictive power esp however need have positive esp be confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision immune design corp price ep surprise immune design corp price ep surprise immune design corp quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3264,CELG,keryx inc kerx free report be expect report first quarter result market open last quarter company report negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise keryx share have lose year date compare industry decline factor influence quarterapart license fee keryx top line comprise revenue generate only market product auryxia ferric citrate auryxia be used treat patient chronic kidney disease ckd dialysis november fda grant approval additional indication auryxia treat adult iron deficiency anemia ida chronic kidney disease not dialysis moreover keryx claim auryxia be only oral treatment option available indication auryxia be already approve control serum phosphorus level adult chronic kidney disease dialysis latest approval drug treat complication chronic kidney disease also represent significant opportunity physician treat patient earlier stage disease anemia become more severe hence approval significantly boost auryxia sale meanwhile company be look potential partner commercialize drug eu ferric citrate have be consider new active substance european commission provide year datum marketing exclusivity region company also remain focuse create rapid awareness new indication differentiate auryxia exist treatment option communicate favorable insurance access auryxia prescriber patient expect see further company support number ongoing trial include several investigator sponsored clinical study new phase iv study call compass compass study continue expand clinical dataset auryxia treatment iron deficiency anemia study person haven be treat previously low iron different dose regimen such twice day however auryxia be only approve product keryx portfolio company be entirely dependent auryxia growth model proven model do not show earning beat keryx quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp keryx have earning esp be most accurate estimate zack consensus estimate be peg loss cent uncover best stock buy sell re report earning esp filter zack rank keryx have zack rank increase predictive power esp however need have positive esp be confident earning beat note caution stock zack rank sell rate go earning announcement keryx inc price ep surprise keryx inc price ep surprise keryx inc quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report be schedule release result company have earning esp zack rank celgene corporation celg free report be schedule release result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3265,CELG,summit nj base celgene corporation celg free report be company focuse discovery development drug target cancer inflammatory disease celgene key growth driver be revlimid company portfolio also include pomalyst imnovid abraxane otezla istodax vidaza thalomid thalidomide however celgene be face generic competition vidaza scenario investor focus remain performance revlimid otezla apart usual top bottom line number meanwhile celgene have be striking prudent acquisition inking strategic deal bolster pipeline company be also work label expansion approve drug celgene track record have be decent company beating earning estimate occasion trail quarters overall company have deliver average positive earning surprise currently celgene have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoteearning celgene beat third quarter earning company report adjust ep consensus call ep revenue revenue however miss expectation celgene post revenue miss consensus estimate key stat revlimid continue strong performance otezla sale be impact increase gross net adjustment contract implement january slow overall category growth due more challenge market access environment unite state outlook celgene update guidance company anticipate earning range compare previous guidance share zack consensus estimate earning be share net product sale be now project compare earlier range pre market trading share be pre market trading check back later full celg earning report later look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3266,CELG,mallinckrodt plc mnk free report announce initiate new phase iv study acthar gel multus center randomize double blind placebo controlled study further assess efficacy acthar therapy option patient symptomatic sarcoidosis study evaluate acthar later line treatment option sarcoidosis patient persistent disease drug be already approve unite state indication company be conduct study determine class patient benefit most alternative treatment acthar acthar become part company portfolio follow questcor acquisition be currently approve indication mallinckrodt be work boost acthar sale approve indication include rheumatology pulmonology well underserved patient population company intend invest research development activity develop acthar indication lupus proteinurium nephrotic syndrome amyotrophic lateral sclerosis diabetic nephropathy performance drug have be impressive so far propel solid demand rheumatology pulmonology ophthalmology nephrology expand access more recently promote indication such lupus sarcoidosis well mature indication such infantile spasm nephrotic syndrome mallinckrodt stock price have decline year date compare industry fall note mallinckrodt be currently focuse reshape product portfolio strategic acquisition core asset divestiture transform portfolio become high perform specialty pharmaceutical company company recently acquire privately hold infacare pharmaceutical corp specialty pharmaceutical company focus development proprietary pharmaceutical neo natal pediatric patient company generic segment continue face weakness various product category be witness stiff competition be hurt volume price company expect double digit decline revenue segment addition continue expect weakness segment adversely impact gross profit margin also company sell nuclear imaging business due persistent challenge company also sell intrathecal therapy business focus key area acthar gel sale continue be strong back increase formulary position access appropriate patient commercial public environment sale therakos be expect decline zack rank stock currently carry zack rank hold better rank stock health care sector be acadium pharmaceutical inc acad free report celgene corp celg free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here acadium loss share estimate have narrow last day company deliver positive earning surprise trail quarters average beat celgene earning estimate have inched past day stock have rally year date outperform industry aduro biotech loss share estimate narrow last day company deliver positive earning surprise trail quarters average today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3267,CELG,amgen inc amgn free report partner ucb sa announce fda have issue complete response letter crl biologic license application bla evenity romosozumab amgen be look get evenity approve treatment postmenopausal woman osteoporosis original bla include datum pivotal frame study however fda now require safety efficacy datum other pivotal phase iii study arch bridge be include application agency have ask resubmission bla be consider extension current review remind investor amgen have present datum arch fracture study romosozumab compare merck co inc mrk free report fosamax alendronate postmenopausal woman osteoporosis datum study show evenity romosozumab lead statistically significant superior fracture risk reduction fosamax alendronate be current standard care osteoporosis however cardiovascular side effect be observed study company then say safety datum arch datum now be consider regulatory review agree fda follow heart related safety issue emerge otherwise successful arch result amgen warn do not expect evenity be approve year crl thus do not come surprise so far year amgen share be better increase register zack categorize biom genetic industry frame study evaluate effectiveness evenity reduce risk new vertebral fracture month also compare effectiveness month evenity administration follow month xgeva placebo follow xgeva administration bridge study evaluate evenity older man osteoporosis history fragility fracture vertebral fracture study evaluate effectiveness evenity increase bone mineral density bmd lumbar spine effect bmd femoral neck total hip company be work fda be process re submit bla request datum separate press release amgen announce submission supplemental new drug application snda fda variation marketing application european medicine agency ema myeloma drug kyproli submission regulatory application be do expand drug label include overall survival os datum phase iii endeavor study remind investor kyproli twice weekly be already approve use combination dexamethasone celgene corporation celg free report revlimid lenalidomide dexamethasone base primary analysis progression free survival pfs datum aspire study submission include datum pivotal endeavor study compare kyproli velcade combination dexamethasone patient relapse refractory multiple myeloma datum demonstrated kyproli reduce risk death compare velcade increase median os month month vs month kyproli be first only therapy achieve superior os head head comparison current standard care velcade last week amgen announce os datum aspire study overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli revlimid dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd kyproli be also be evaluate couple other study potential label expansion amgen be evaluate weekly dose regimen kyproli phase iii study arrow relapse refractory multiple myeloma patient datum be expect be amgen inc price consensus amgen inc price consensus amgen inc quotezack rankamgen currently have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3268,CELG,second quarter earning season be expect be strong index anticipate see earning growth revenue growth latest earning trend stock market be also record level however ongoing turmoil washington geopolitical risk fed related uncertainty lofty valuation bring difficulty stock season read sector etfs stock tap earning growth zack sector be expect post double digit earning growth sector lag current earning estimate be project start second quarter such volatility investor focus etfs large allocation stock have high chance surprising upcoming release result winning bet earning season find etfs handpicking etfs portfolio stock be most likely beat earning be mean task however proprietary methodology find earning esp stock calculate percentage difference most accurate estimate zack consensus estimate be solid build block uncover best stock buy sell re report earning esp filter bet etfs winning combination stock have positive earning esp favorable zack rank strong buy buy hold lead profit investor portfolio be especially true earning beat definitely draw investor attention propel stock price related etfs higher let see etfs have be select combination stock first run zack stock screener find stock positive earning esp favorable zack rank then narrow list select group stock higher positive earning esp accordingly choose etfs contain few stock higher chance beating estimate particular industry see etf category here research show stock combination chance positive earning surprise be high result trio be excellent investor seek sure profit earning season powershare dynamic leisure entertainment fund pej free report fund track dynamic leisure entertainment intellidex index hold small basket stock be pretty well spread various security hold less total asset half stock portfolio be expect come earning beat suggest solid upside etf particular american airline aal free report delta air line dal free report mcdonald mcd time warner be top holding account share have earning esp respectively aal dal have zack rank other have zack rank industry look restaurant airline take largest share pej respectively follow hotel leisure facility casino gaming etf have amassed asset base trade light volume share day average expense ratio come pej have zack etf rank high risk outlook read lie ahead leisure travel etfs ishare dow jone transportation average fund iyt free report etf provide exposure broad transportation sector tracking dow jone transportation average index hold small basket stock half have higher chance beating estimate quarter air freight logistic take top spot share basket airline railroad round top railroad company norfolk southern nsc free report union pacific unp free report kansa city southern ksu free report have earning esp respectively meanwhile alaska air group alk free report landstar system lstr free report ryder system free report have earning esp respectively have zack rank hold top position iyt fund have accumulate nearly aum see good trading volume share day charge bps fee year investor fund currently have zack etf rank sell rating high risk outlook be expect get term boost earning growth read transport etf hit new week high vaneck vector biotech etf bbh free report fund offer exposure large biotechnology corporation tracking mvis list biotech index stock portfolio be expect beat earning quarter investor note celgene celg gilead science gild have zack rank account double digit exposure basket have earning esp respectively bbh have amassed asset base charge bps fee year volume be moderate exchange share daily average have zack etf rank high risk outlook read forget big tech biotech etfs be soar higher want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3269,CELG,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
3270,CELG,investor seek momentum spdr biotech etf xbi free report be probably radar now fund just hit week high be week low price share be more gain store etf let take quick look fund term outlook get better idea be head xbi fund offer exposure biotechnology select industry index represent biotechnology sub industry portion total market index bioverativ mimedx group juno therapeutic be top holding fund charge basis point annual fee see health care etfs here move buyout biotech space be spotlight currently celgene corporation celg free report buy juno therapeutic inc sanofi sa adr sny free report buy bioverativ inc recently be probably push space higher tax reform entail biotech company repatriate hundred billion dollar stack international economy extra cash be used buy back share pay dividend come day more gain ahead currently xbi have zack etf rank buy high risk outlook suggest outperformance continue month ahead want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3271,CELG,investor seek momentum virtus lifesci biotech clinical trial etf bbc free report be probably radar now fund just hit week high be nearly week low price share be more gain store etf let take quick look fund term outlook get better idea be head bbc fund have novel approach biotechnology investing exposure company be clinical trial stage have well diversify portfolio stock key holding hottest stock juno therapeutic currently market bbc charge bps fee year investor see healthcare etfs here move biotech segment broad equity market have be area watch lately give new tax legislation have entice company corner bring offshore cash back home lead wave merger acquisition additionally slower growth mature drug have compel prominent biotechs acquire smaller one promising pipeline latest catalyst be juno have agree be acquire celgene corporation celg free report share cash more gain ahead currently bbc have zack etf rank buy high risk outlook suggest outperformance continue month ahead further many segment make etf have strong zack industry rank so be definitely still promise want ride surge etf little longer want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
3272,CELG,acquisition once again remain focus week celgene celg free report rumore be talk juno regard possible deal recap week most important storiesjuno soar acquisition rumor juno share sky-rocket report celgene be interested acquire immuno oncology focuse company accord wall street journal report company be talk regard possible acquisition deal juno acquisition rumor turn be true be second acquisition announcement be make celgene year just last week company announce intention acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera celgene be lot pressure strengthen pipeline revenue stream company have tough issue pipeline setback well weak performance otezla weigh stock however remain be see much celgene be willing shell juno juno market cap jan be juno share have be upward trend follow gilead kite acquisition announcement last year august juno be focuse development innovative cellular immunotherapy treatment cancer company have long be consider potential acquisition target last year juno share be compare gain record industry belong juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma juno suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death company be now focuse liso cel next generation car cell product target cd juno expect file fda approval liso cel relapse refractory diffuse large cell lymphoma dlbcl second half immuno oncology space remain quite lucrative celgene have pay hefty premium finalize deal juno celgene already have collaboration deal place concert patent challenge update concert pharmaceutical cnce free report suffer major blow post grant review pgr petition challenge validity patent be reject patent trial appeal board ptab patent trademark office concert have file petition last year july challenge validity patent have be assign incyte pharmaceutical incy free report concern patent cover deuterate ruxolitinib analog concert ctp be deuterium modify version ruxolitinib incyte market ruxolitinib unite state name jakafi have patent cover ruxolitinib be unexpired concert seek marketing approval ctp setback concert say always challenge validity patent later federal court moreover company say decision do not affect plan develop ctp alopecia areata however company be now reassess plan develop ctp additional indication ctp be novel jak inhibitor currently phase ii development alopecia areata fda recently grant fast track status candidate indication read more concert pharmaceutical plunge patent petition setback vertex orkambi label expand eu vertex pharmaceutical vrtx free report gain eu approval use orkambi lumacaftor ivacaftor child cystic fibrosis cf year age group copy del mutation child europe category approval be line expectation consider company have get positive opinion european union committee medicinal product human use chmp indication november read more vertex cystic fibrosis drug pediatric use eu vertex be zack rank strong buy stock see complete list today zack rank stock here humira biosimilar bla accept fda fda have accept review biologic license application bla submit sandoz biosimilar version abbvie blockbuster drug humira adalimumab humira be approve wide range indication recent healthcare conference abbvie say global humira sale crossed approach company expect drug lose exclusivity international market fourth quarter believe sale erosion be manageable note sandoz be not first file biosimilar version humira fact company amgen amgn free report boehringer ingelheim have already gain approval humira biosimilar amgen enter global settlement license agreement abbvie expect launch humira biosimilar europe october unite state january meanwhile abbvie boehringer be engage patent litigation unite state eiger plunge pipeline setback eiger suffer major setback investigational treatment ubenimex pulmonary arterial hypertension pah fail meet primary endpoint mid stage study base disappointing update company have decide discontinue development ubenimex pah continue evaluate ubenimex lymphedema ubenimex be mid stage study indication datum expect second half year company share be news biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be slightly last trading session major biotech stock celgene decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here celgene acquire impact morgan healthcare conference focus next biotech world watch usual regulatory pipeline update synergy pharmaceutical get know approval status trulance use adult patient irritable bowel syndrome constipation ib jan more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3273,CELG,expect bristol myer squibb company bmy free report beat expectation report third quarter result oct market open year date bristol myer share have increase industry have record increase bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation average positive earning surprise last quarters be last report quarter bristol myer come positive surprise let see thing be shape quarter factor playbristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter drug be already approve multiple cancer indication quarter fda approve drug additional indication hepatocellular carcinoma metastatic colorectal cancer patient have receive prior treatment label expansion be not expect have much impact top line combine label expansion second quarter certainly boost sale second quarter see stability second line lung cancer set fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc increase competition impact sale unfavorably zack consensus estimate indicate drug sale increase year quarter july fda also approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma zack consensus estimate drug quarter be meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug drug register growth previous quarter be expect generate sale quarter zack consensus estimate other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter company be develop key drug opdivo monotherapy well combination therapy several tumor type multiple study label expansion application review unite state expect investor focus update related opdivo conference call likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer currently have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock warrant lookhere be biotech stock also want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be expect release result nov company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result oct company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3274,CELG,year have be better expect biotech sector nasdaq biotechnology index be drug pricing issue competition slowdown growth key drug be expect remain hangover well approval new drug strategic acquisition several big wig be likely boost investor sentiment thus needless say hold promise generate stellar return slowdown mature product compel bigwig gilead science gild free report undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab gilead currently carry zack rank hold see complete list today zack rank strong buy stock here recently celgene inc celg free report inked deal acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera celgene be look new deal acquisition give lacklustre have suffer few pipeline setback weakness otezla sale celgene currently carry zack rank acquisition merger keep investor focuse space addition new drug approval label expansion exist drug boost top line prominent biotech company amgen inc amgn free report look poise growth several blockbuster drug portfolio amgen new drug prolium xgeva vectibix nplate sensipar be perform well company recently win fda approval supplemental biologic license application sbla xvega expand drug label treatment multiple myeloma amgen carry zack rank exelixis inc exel free report be biotech look poise growth recent fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma be expect drive growth drug have perform impressively approval exelixis currently carry zack rank alexion pharmaceutical inc alxn free report blockbuster drug soliris continue perform well fda approval drug generalized myasthenia gravis further boost sale new product strensiq be gain momentum company redefine strategy kanuma alexion carry zack rank investor also keep eye key upcoming pdufa date regeneron pharmaceutical inc regn free report be look expand label newly approve drug dupixent drug be already approve treatment adult moderate severe atopic dermatitis company be also evaluate drug treat asthma adult liberty asthma quest study sbla same be expect be file shortly regeneron be work expand lead ophthalmology drug eylea label additional indication fda have accept review company sbla label expansion eylea injection company be seek approval week dose interval eylea injection patient wet age related macular degeneration wet amd base physician assessment action date set fda be aug regeneron carry zack rank big biotech vertex pharmaceutical incorporate vrtx free report be take measure strengthen already dominant position cystic fibrosis market cf vertex have cf drug kalydeco orkambi portfolio blockbuster potential company have develop cf corrector tezacaftor vx combination ivacaftor regulatory application be review unite state pdufa date feb eu potential approval further bolster demand vertex currently carry zack rank medical biomedical genetic industry yr return medical biomedical genetic industry yr threat biosimilar loom large key drug most company expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3275,CELG,amgen inc amgn free report announce fda have accept regulatory application unite state seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop fda be expect give decision next year prolium be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture supplemental biologic license application sbla be submit july year sbla be base phase iii study evaluate safety efficacy prolium compare risedronate patient receive glucocorticoid medication giop be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month begin treatment prolium approve treatment giop cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state international market first half drug generate sale year year amgen share have rally year so far better industry growth so far year currently amgen hold zack rank buy see complete list today zack rank strong buy stock here key pickssome other top rank biotech stock include vertex pharmaceutical incorporate vrtx free report pdl biopharma inc pdli free report celgene corporation celg free report vertex pdl biopharma sport zack rank strong buy celgene have same zack rank amgen vertex have witness zack consensus estimate current year earning climb past day company share have increase year so far pdl biopharma earning estimate have go share have rise year so far celgene earning estimate inched go past day stock have rally so far year outperform industry today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3276,CELG,israel base generic drug maker teva pharmaceutical industry limit teva free report see share decline last week company suffering fresh setback form fda approval generic version company top selling brand drug copaxone multiple sclerosis mylan nv myl free report gain fda approval generic version mg thrice weekly dosage well once daily mg formulation copaxone mylan be first applicant challenge mg patent company enjoy day exclusivity mylan have launch product mylan also gain approval mg dose eu fda approval generic copaxone be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug copaxone bring total sale first half end second quarter copaxone mg account more total copaxone prescription unite state entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva generic pricing erosion remain huge issue generic company teva sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor consolidation industry have increase ability negotiate lower price generic drug lead increase price erosion decrease volume moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track company have be work address issue recently announce appointment new ceo read more do teva pharmaceutical stock soar today teva have also make significant progress divestment core business however entry copaxone mg be major setback company well be teva be able get back track teva be zack rank sell stock company have see zack consensus estimate current year earning be revise downward last day zack consensus estimate have be revise downward last day teva have lose value year date versus decline industry teva deal challenge here be look drug company sport strong zack rank look well position celgene corporation celg free report celgene be focuse discovery development innovative therapy treatment cancer inflammatory disease company have several blockbuster product portfolio include revlimid pomalyst otezla celgene have rich promising pipeline well key datum readout line next year celgene zack rank buy stock have gain year date outperform rally industry belong company also have vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank strong buy stock here pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product first half year company paid dividend share buyback shareholder include accelerate share repurchase program pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score amgen amgn free report amgen most well know name biotech industry have presence oncology hematology inflammation nephrology bone health cardiovascular disease market key product include enbrel neulasta aranesp prolium xgeva epogen kyproli repatha blincyto other most product be blockbuster have blockbuster potential amgen have deep pipeline company work bring new product market combat impact potential biosimilar competition mature product franchise company have be return value shareholder form share buyback dividend amgen be also zack rank stock vgm score stock have gain year date outperform rally industry belong vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market company hold strong position market market product orkambi kalydeco vertex be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong ligand pharmaceutical incorporate lgnd free report ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen novartis other ligand also have licensing deal base omniab technology ligand recent decision acquire crystal bioscience leader avian genetic generation fully human therapeutic antibody be expect boost company revenue least earning least cent share ligand zack rank stock have gain year date substantially outperform rally industry belong look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3277,CELG,biotech stock have be move north late largely drive spate deal news such deal lend financial stability business maximize shareholder wealth further more deal be expect be sign biotech space now tax reform bill allow company repatriate cash pill overseas corporate taxe meantime be trim price gouge fear have ebb bode well biotech company banking such positive investing sound biotech stock seem judicious biotech etfs hit record high deal biotech sector scale record high jan follow couple multus dollar deal flurry merger sector be always encourage such merger give control market increase value reduce cost needless say also lead economy scale sharing resource reduce risk owing usage innovative technique well tax advantage spdr biotech etf xbi rise biggest day percentage gain june fund register gain so far year well rise quite time fund have remain popular investor have see inflow year date basis other hand fund have witness meager outflow same period factset similarly ishare nasdaq biotechnology etf ibb go highest september fund also post biggest day percentage gain last august rise follow sanofi sny free report acquisition bioverativ inc order establish authority specialty care space french company insist pay cash share purchase represent whopping premium bioverativ close price jan accord sanofi even sanofi share take beating company expect deal boost earning help achieve return invest capital just year share bioverativ meantime jump close fact company see share price hit intraday high read more sanofi acquire haemophilium focuse bioverativ stock dip biotech buyout hog limelight be juno therapeutic inc celgene corporation celg free report latter agree buy juno therapeutic cash deal help celgene access seattle base firm car cancer drug pipeline celgene add juno research capability strengthen company leadership hematology add new driver growth long run deal be expect add cent share celgene adjust earning year share celgene juno therapeutic be respectively read more juno hit week high celgene rumore buyout interest merger gain momentum tax plan boost profitscourtesy new tax overhaul policy biotech firm be able repatriate hundred billion dollar strand overseas pay only tax instead current extra cash be used merger acquisition activity biotech firm have cash invest merger acquisition jay rao medical doctor money manager balyasny asset management have say consolidation be inevitable biotech sector president trump business tax plan also benefit biotech company headline grab corporate tax rate be lower be implement year instead be delay lower tax burden be expect boost profit large biotech company read more gop pass landmark tax bill best worst stock best biotech stock buy biotech sector have come alive courtesy slew deal notably such deal further get boost new tax reform inventor have also lately start feel drug pricing issue win be damage fear earlier fear price control be put place have deter investor investing biotech give positive seem prudent invest solid biotech firm such stock essentially have strong fundamental thus be great investment option also company flaunt zack rank strong buy buy anthera pharmaceutical inc anth free report focus development medicine patient unmet medical need company have zack rank zack consensus estimate current year earning surge more last day company expect growth rate current year be higher zack medical biomedical genetic industry rally bio techne corporation tech free report together subsidiary develop manufacture sell biotechnology reagent instrument clinical diagnostic control company carry zack rank zack consensus estimate current year earning advanced last day company expect growth rate current year be higher industry rally exelixis inc exel free report zack rank company engage discovery development new medicine potential enhance care outcome cancer patient zack consensus estimate current year earning soar last day company expect growth rate current year be way higher industry rally see complete list today zack rank stock here paratek pharmaceutical inc prtk free report clinical stage company focus development therapeutic base tetracycline chemistry unite state company have zack rank zack consensus estimate current year earning climb more last day company expect growth rate current year be higher industry gain bioverativ focus research discovery development therapy treatment hemophilia other blood disorder company have zack rank zack consensus estimate current year earning increase last day company expect growth rate next quarter be solid wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3278,CELG,have complete just week biotech sector be already see significant pickup merger acquisition deal year start celgene corporation celg free report announce intention acquire impact biomedicine soon thereafter nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect last week celgene be once again news rumor be look acquire immuno oncology focuse juno therapeutic yesterday rumor be confirm company say be acquire juno approximately acquisition announcement be make yesterday french pharma giant sanofi sny free report say be buy biopharma company bioverativ celgene be look strengthen presence cancer space impact juno acquisition sanofi be look expand presence specialty care strengthen leadership rare disease bioverativ acquisition more deal follow announcement be make expectation be pretty high more such deal fact last week acorda therapeutic share be rumor biogen biib free report be interested acquire company factor grow biosimilar competition slowdown growth legacy product major pipeline setback loom patent expiry pricing challenge grow competition have force big player seek deal acquisition grow pipeline boost revenue stream tax reform expect lead increase cash repatriation seem set more announcement company pfizer amgen amgn free report biogen merck johnson johnson gilead be expect be lookout suitable deal year end third quarter gilead have acquire kite approximately have cash equivalent balance include overseas cash amgen cash balance be also sep be hold overseas meanwhile merck exit third quarter cash equivalent worth be hold overseas bristol myer squibb overseas cash holding be approximately end third quarter biogen overseas cash balance be approximately end third quarter cash be likely be used share buyback dividend payment company be also expect use fund acquisition deal most company be lookout asset technology be potentially address unmet need immuno oncology be currently very much demand company be also focuse rare disease orphan disease area valuation look high cancer focuse company especially one involved immuno oncology valuation appear be more reasonable specialty pharma company company be focuse central nervous system disease other such area many large cap player have expressed interest pursue deal have also point deal make sense financial perspective high valuation bidding war keep key player sideline company avexis bluebird biomarin puma biotechnology incyte exelixis exel free report be often consider acquisition target exelixis be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3279,CELG,be eventful year pharma biotech stock industry face challenge drug pricing scrutiny pricing pressure increase competition concern regard amazon interest enter healthcare arena fewer expect acquisition deal major pipeline setback be positive development well be significant surge fda approval investor appear more comfortable drug pricing controversy innovation win day fda grant approval gene therapy cancer well rare form blindness tax reform be also expect work sector favor merger acquisition expect pick come quarters keep mind here be look key takeaway presentation make major pharma biotech stock annual morgan healthcare conference largest most informative healthcare investment symposium industry pfizer inc pfe free report pharmaceutical giant pfizer expect be rich datum delivery year company focus be therapeutic area include oncology inflammation immunology vaccine rare disease internal medicine immuno oncology portfolio focus remain mainly drug combination bavencio variety pfizer target agent first half year company present late stage datum bavencio second line small cell lung cancer vyndaqel cardiomyopathy regulatory submission be expect xtandi metastatic castration resistant prostate cancer parp inhibitor talazoparib breast cancer second half year see company present phase iii datum rivipansel sickle cell tanezumab pain company also have couple pdufa date xeljanz ulcerative colitis first indication outside rheumatology lorlatinib second line small cell lung cancer pfizer be zack rank hold stock company share be last year compare gain record industry belong celgene corporation celg free report biotech company celgene announce preliminary result well outlook healthcare conference celgene also be present significant amount datum year include revlimid rituxan relapse refractory follicular lymphoma otezla scalp psoriasis several study initiation be also expect year moreover company expect submit supplemental new drug application snda fda revlimid combination bortezomib dexamethasone rvd patient newly diagnosed multiple myeloma ndmm new drug application nda fedratinib myelofibrosis snda otezla behçet disease meanwhile fda decision be expect year ozanimod relapse multiple sclerosis rm once daily formulation otezla company say continue invest business development celgene be zack rank stock company share be last year compare gain record industry belong bristol myer squibb company bmy free report bristol myer pipeline represent several opportunity long term growth company provide update blockbuster drug opdivo be expect drive mid term growth small cell lung cancer renal cell carcinoma rcc hepatocellular carcinoma gastric cancer be area represent commercial potential excess be disease area high prevalence high unmet medical need low survival rate bristol myer have several datum readout opdivo plan company immuno oncology portfolio have several early stage candidate late stage asset relatlimab lag bms bms ido company say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially bristol myer be zack rank hold stock company share be last year merck mrk free report merck too business development remain key priority company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need merck provide outlook february company say headwind remain form competitive pressure drug zostavax zepatier zetia vytorin still feel impact generic competition however keytruda represent significant growth opportunity drug be several study label expansion combination use moreover company pipeline oncology asset novel vaccine select hospital specialty product also provide scope long term growth merck be also zack rank stock see complete list today zack rank strong buy stock here company share be last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3280,CELG,share agio pharmaceutical inc agio free report have soar year time outperform industry increase let analyze factor lead rally fda approval agio only market drug idhifa enasidenib last year company rapid progress robust pipeline past year accompany study initiation positive readout have drive share price consistently august fda approve idhifa treat patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation approval offer huge boost company give immense commercial potential target market moreover idhifa provide first ever treatment alternative patient live aforementioned indication unite state notably idhifa also enjoy orphan drug status eu treatment aml agio progress pipeline have be quite impressive company have interesting candidate portfolio include idh mutant inhibitor ag ivosidenib pan idh mutant inhibitor ag june agio present positive datum dose escalation expansion cohort phase study evaluate single agent ivosidenib mutant positive asco ivosidenib be also be evaluate phase expansion cohort treatment patient idh aml datum study demonstrated durable response allow company submit new drug application nda fda ivosidenib late december same month company also announce positive result phase study assess ivosidenib combination standard induction chemotherapy celgene celg free report vidaza azacitadine treatment newly diagnosed aml patient not eligible intensive chemotherapy presently phase iii agile study examine ivosidenib combination vidaza be also underway give indication apart ivosidenib agio be conduct phase trial ag treatment patient advanced idh idh mutant positive solid tumor earlier october company announce positive datum study aacr nci eortc international conference molecular target cancer therapeutic notably company also plan initiate perioperative window study analyze ivosidenib ag low grade glioma investigate effect brain tumor tissue first half company have interesting candidate portfolio lead rare genetic disease candidate ag be evaluation phase ii study adult transfusion independent patient pyruvate kinase pk deficiency agio report positive datum program june fda grant fast track designation candidate give indication rgd market be still untapped newer therapy area hold huge potential successful development investigational candidate boost company top line go forward consider lucrative market be target agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote zack rank key picsagio carry zack rank hold better rank stock health care sector be exelixis inc exel free report sucampo pharmaceutical inc exelixis sport zack rank strong buy sucampo carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company deliver positive earning surprise trail quarters average beat share price company have soar year time sucampo earning share estimate have moved north last day company come positive earning surprise trail quarters average beat share price company have surge year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3281,CELG,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition share have gain past year outperform increase witness industry belong domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line pharma segment also continue benefit easier comp second half compare first continue share gain be likely drive sale imbruvica cancer indication stelara psoriasis strong adoption newer indication crohn disease be expect contribute stelara growth also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale multiple myeloma product darzalex positive offset loss sale drug invokana due higher manage care discounting also gain fda approval several line extension second third quarters lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other line extension expand eligible patient population drug drive sale fourth quarter new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report overall strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line quarter meanwhile higher investment product launch continue hurt profit have be case third quarter read more set pharma earning motion carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3282,CELG,share juno therapeutic inc hit new week high jan eventually close share company hit new high report company be be acquire celgene corp celg free report juno already have agreement celgene global development immunotherapy potential acquisition juno help celgene build diversify drug pipeline build future revenue stream share juno have gain past year industry register increase juno be develop car therapy same have remain investor focus courtesy immense potential car space be expect be revolutionary treatment cancer therefore company have be newsever car cancer therapy designer kite pharma be acquire biotech giant gilead science inc gild free report fact be rumor juno potential acquisition gilead even biggest partner celgene fda also approve novartis nvs free report kymriah first car therapy follow yet car approval kite pharma yescarta past year juno have be player market develop therapy juno most advanced pipeline candidate jcar jcar use car cell technology target cd jcar be presently undergo phase pivotal transcend study hodgkin lymphoma nhl include diffuse large cell lymphoma dlbcl follicular lymphoma grade mantle cell lymphoma mcl juno report promising additional datum pivotal study include patient dlbcl december company plan bring jcar market nhl end biologic license application bla expect be file second half same year third quarter conference call juno celgene also initiate phase ib platform study evaluate combination jcar astrazeneca imfinzi durvalumab treatment patient relapse refractory nhl juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rank juno have zack rank sell see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3283,CELG,interest car chimeric antigen receptor cell space continue build fda give nod second car therapy last week gilead science gild free report yescarta cell base gene therapy gain approval treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment make yescarta second gene therapy gain fda approval first be novartis ag nvs free report kymriah kymriah be approve late august certain pediatric young adult patient form acute lymphoblastic leukemia do car cell therapy work car fall ambit cellular immunotherapy involve used patient own immune cell attack get rid harmful disease cell body car approach involve collection patient cell genetic modification outside body incorporation specific receptor target cancer cell finally re infusion modify cell back patient be lot enthusiasm car study have show help achieve durable complete response leukemias lymphomas include patient have suffer multiple relapse however car come own set challenge include high level investment well safety issue serious immune toxicity crs neurotoxicity fact kymriah yescarta have box warning label crs neurologic toxicity treatment also not come cheap novartis have set price kymriah list price gilead yescarta be fda fda grant back back approval car treatment look regulatory environment well be encourage gene cell therapy candidate fact fda commissioner scott gottlieb say approval yescarta show continue momentum promising new area medicine agency intend release comprehensive policy plan support development cell base regenerative medicine car stock increase focus corner immuno oncology market huge commercial potential approve treatment market here be look company be work car cell treatment juno therapeutic inc company juno be focuse development innovative cellular immunotherapy treatment cancer juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar next generation car cell product target cd jcar be currently registrational study hodgkin lymphoma nhl company also have strong partner celgene corporation celg free report juno stock have gain year date substantially outperform rally industry belong bluebird bio inc blue free report bluebird be clinical stage company work develop gene therapy serious genetic disease cell base immunotherapy cancer company bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene bluebird stock have gain year date substantially outperform rally industry belong ziopharm oncology inc ziop free report biotech company ziopharm used innovative gene expression control cell technology provide safe effective scalable cell viral base therapy cancer graft versus host disease ziopharm immune oncology platform include car well other adoptive cell base approach announce second quarter result company have say car program be continue phase second generation study cd specific car lymphoid malignancy expect move third generation cd mbil early stage study evaluate point care plan be also commence phase study cd specific car relapse refractory acute myeloid leukemia aml year ziopharm share be so far juno bluebird ziopharm be zack rank hold stock see complete list today zack rank strong buy stock here addition company bellicum pharmaceutical inc blcm free report cellectis also have presence area however cellectis french company focuse develop immunotherapy base gene edit allogeneic car cell ucart have run roadblock fda place clinical hold couple early stage study be conduct ucart hold come place company report death study go forward expect investor focus remain corner immuno oncology market addition tracking performance kymriah yescarta believe more deal be announce cell therapy space make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3284,CELG,share juno therapeutic inc have soar year so far massively outperform industry gain here analyze factor lead rally car therapy space have remain investor focus courtesy immense potential juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma juno most advanced pipeline candidate jcar jcar use car cell technology target cd company share have see upward trend reason jcar be presently undergo phase pivotal transcend study hodgkin lymphoma nhl include diffuse large cell lymphoma dlbcl follicular lymphoma grade mantle cell lymphoma mcl juno report promising additional datum pivotal study include patient dlbcl company plan bring jcar market nhl end biologic license application bla expect be file second half same year recently juno celgene corporation celg free report also initiate phase ib platform study evaluate combination jcar astrazeneca azn free report imfinzi durvalumab treatment patient relapse refractory nhl additionally juno celgene announce fda have grant breakthrough therapy designation jcar treatment aggressive large cell nhl include diffuse large cell lymphoma dlbcl primary mediastinal cell lymphoma pmbcl further candidate be grant priority medicine prime eligibility dlbcl european medicine agency be positive juno year deal celgene global development immunotherapy collaboration see company leverage cell therapeutic strategy develop treatment patient cancer autoimmune disease initial focus be car cell receptor technology fact deal be major positive juno give strong partner form celgene juno be also look develop treatment target cancer associate protein other cd next year company collaborator intend advance several additional candidate clinical testing significant focus solid tumor be major cause cancer related death develop world solid tumor pipeline candidate different target include jcar be phase patient ror express cancer jcar phase ovarian cancer jcar phase patient refractory recurrent pediatric neuroblastoma jtcr phase ii patient high risk relapse aml mesothelioma chronic myeloid leukemia patient have receive allogeneic hsct be also phase advanced nsclc patient jcar phase cd positive nhl juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rank stock considerjuno have zack rank hold better rank health care stock be sucampo pharmaceutical carry zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have surge year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3285,CELG,share celgene corporation celg free report have decline industry gain celgene suffer series setback last few month company suffer setback last week late stage study lead cancer drug revlimid combination roche holding rhhby free report rituxan fail study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance previously untreated follicular lymphoma however treatment arm not achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week term progression free survival pfs observed pre plan analysis none arm prove superior co primary endpoint meanwhile additional analysis trial be underway celgene key growth engine be revlimid drug worldwide sale increase contribute almost total revenue revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing drug label expansion have boost sale potential company have expect lymphoma increase revlimid growth prospect company portfolio also include pomalyst imnovid abraxane otezla istodax vidaza thalomid thalidomide however abraxane sale be pressure due highly competitive market lung breast cancer therapy scenario dependence revlimid have inherent risk addition october company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis meanwhile deep yet persistently slow growth psoriatic arthritis psoriasis market especially entire third quarter have lead weak performance otezla consequently company also reduce annual guidance challenge market condition be drive increasingly restrictive pbm formulary control factor remain hangover company share well positive note august company obtain fda approval idhifa treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report expect celgene look strategic acquisition same note bigwig gilead science inc gild free report aid top line zack rankcelgene currently carry zack rank sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3286,CELG,share tesla inc tsla free report decline keybanc reduce fourth quarter delivery estimate electric car maker model lineboee co ba free report share gain royal air maroc have order dreamliner value billionshare celgene corporation celg free report fall follow company pipeline setback crash upside potentialshare energous corp watt free report soar company report have receive fcc certification air power distance wireless charge
3287,CELG,year have be quite impressive biotech sector evident gain register so far nasdaq biotechnology index be surely welcome news investor industry suffer decline last year drug pricing issue competition slowdown growth key drug dent sector performance new drug approval encourage outlook company boost investor sentiment immuno oncology continue remain spotlight fda approval car chimeric antigen cell receptor therapy kymriah gilead science gild free report yescarta leukemia lymphoma shift investor attention small biotechs company develop therapy investor also keep tab key candidate datum slowdown mature product force bigwig gilead undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab celgene corporation celg free report too be look acquisition bolster portfolio approval new drug dupixient kevzara idhifa tremfya other label expansion exist drug cabometyx boost respective company portfolio note see larger number drug approval fda threat biosimilar loom large sector expect further boost performance sector notably medical biom genetic sub industry carry zack industry rank place top zack industry smaller biotechs have perform impressively bigwig weren far expect momentum continue well here list few biotech company outperform market acadium pharmaceutical inc acad free report lead drug nuplazid be approve treatment hallucination delusion associate parkinson disease psychosis drug be approve fda notably be only drug approve unite state condition drug generate sale first month company be look expand drug label further be roller coaster ride acadium share company have moved year date compare industry gain believe zack rank buy company perform well boost nulpazid see complete list today zack rank strong buy stock here look best stock be first see top stock portfolio here sangamo therapeutic inc sgmo free report focus translate ground breaking science genomic therapy transform patient life used company industry lead platform technology genome editing gene therapy gene regulation cell therapy sangamo be conduct phase ii clinical trial hemophilia lysosomal storage disorder mps mps ii company have collaborate lead global company various pipeline candidate zack rank company have phenomenal run stock soar year date compare industry gain anaptysbio anab free report be clinical stage biotechnology company inflammatory pipeline include il antibody anb treatment moderate severe adult atopic dermatitis severe adult peanut allergy severe adult eosinophilic asthma il antibody anb treatment rare inflammatory disease include generalized pustular psoriasis palmo plantar pustular psoriasis company also have portfolio checkpoint receptor agonist antibody treatment certain autoimmune disease immune checkpoint receptor be insufficiently activate have demonstrated efficacy animal model graft versus host disease company be expect report top line datum go phase iia study anb severe adult peanut allergy severe adult eosinophilic asthma first second quarters respectively zack rank company have phenomenal run stock soar compare industry gain sino limit research develop manufacture market wide array chinese medicine chemical medicine major therapeutic category hepatitis cardio cerebral disease company also actively develop medicine treat tumor analgesia orthopedic disease infection parenteral nutrition respiratory system disease anorectal disease diabetes other disease meet increase demand market medical practitioner patient lead product include tianqingganmei injection runzhong dispersible tablet mingzheng capsule tianqingganp enteric capsule cardio cerebral medicine such yilunping tuotuo tablet company currently carry zack rank expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3288,CELG,agio pharmaceutical inc agio free report announce have submit new drug application nda fda investigational candidate ivosidenib ag treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation notably company have request regulatory agency priority review keep mind latter have complete process span month accept application agio share increase almost dec follow news release moreover stock have outperformed industry so far year have surge compare industry rally nda submission be base encourage datum dose expansion part ongoing phase study evaluate ivosidenib single agent patient advanced hematologic malignancy idh mutation phase trial be assess safety tolerability ivosidenib advanced solid tumor include glioma intrahepatic chondrosarcoma earlier month company present datum study annual meeting american society hematology atlanta ivosidenib be also be evaluate phase iii study examine ivosidenib front line aml patient idh mutant positive advanced remind investor agio announce agreement celgene corporation celg free report field metabolic immuno oncology company also agree amend certain right collaboration agio gain full global development right ivosidenib previously agio have only right ivosidenib agio be conduct phase ii program combination celgene vidaza treat newly diagnosed aml patient not eligible intensive chemotherapy fda grant orphan drug designation ivosidenib treatment aml patient same press release company also announce fda have accept investigational new drug application ag proceed phase dose escalation study evaluate candidate treatment multiple tumor type carry mtap deletion company expect initiate phase study first half agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quotezack rank key picksagio carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have be revise upward cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion have see zack consensus estimate loss share be narrow cent cent cent cent last day company come positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3289,CELG,amgen inc amgn free report announce strategic immuno oncology collaboration cytomx therapeutic inc ctmx free report jointly develop cell engage bispecific probody deal amgen make upfront payment cytomx investing california base biotech company stock markedly company develop cytomx probody cell engage bispecific program target egfr protein thereby offer significant potential treat various type cancer cytomx lead early development amgen take care late stage development however late stage development cost be share company apart upfront payment equity investment cytomx also be eligible receive milestone well opt right profit royalty outside sale product be commercialize deal amgen also receive global right develop commercialize undisclosed cytomx candidate amgen take target cytomx be eligible receive upfront payment milestone well royalty result product addition bispecific technology platform expand amgen immuno oncology capability give cytomx strong partner amgen ensure regular flow fund share cytomx be hour trading tuesday amgen share remain stable nonetheless amgen share have rally better industry growth so far year currently amgen hold zack rank buy seethe complete list today zack rank strong buy stock here key pickssome other top rank biotech stock sporting same bullish rank amgen include biogen inc biib free report celgene corporation celg free report biogen have witness zack consensus estimate current year earning climb past day company share have increase year celgene earning estimate have inched past day stock have rally year outperform industry hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
3290,CELG,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year medical biotech genetic industry have rise year so far outpace gain same time frame nasdaq biotechnology index be almost year date slide zack industry rank be zack industry medical biom genetic indicate bright outlook sector go forward biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor continue drive sector rest year probably next well challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last biotech stock tear here have picked biggest biotech company look well poise growth be add portfolioamgen inc amgn free report amgen be lead biotechnology company world several blockbuster drug portfolio amgen newer drug prolium xgeva vectibix nplate sensipar be perform well amgen be also progress pipeline include biosimilar drug last month receive fda approval mvasi biosimilar version roche cancer drug avastin mvasi be first biosimilar approve unite state treatment cancer other recent positive pipeline regulatory development amgen include eu approval pediatric formulation mimpara positive long term datum kyproli endeavor study regulatory filing label expansion prolium kyproli other support positive development amgen share have outperformed industry so far year share have rise compare favorably industry gain amgen carry zack rank buy see complete list today zack rank strong buy stock here earning estimate have rise have go past day celgene corporation celg free report celgene key growth driver multiple myeloma drug revlimid continue drive revenue company meanwhile celgene label expansion effort revlimid bode well further sale growth drug other key product pomalyst imnovid abraxane otezla be also perform well recent positive development celgene be fda approval idhifa treatment adult patient relapse refractory acute myeloid leukemia aml celgene also carry zack rank earning estimate have rise past day stock have go year outperform industry biogen inc biib free report biogen have strong position multiple sclerosis market backed wide range product biogen be try diversify be look strengthen alzheimer disease ad other disorder pipeline newly launch spinraza spinal muscular atrophy be also promising start spinraza have witness faster expect adoption unite state biogen be ramp launch effort internationally recent key positive pipeline regulatory development biogen include promising long term dataon alzheimer disease candidate aducanumab eu approval imraldi biogen biosimilar version abbvie top selling blockbuster drug humira biogen have make several new executive appointment bring management team back track several key executive depart past couple year include ceo george scango cfo paul clancy biogen also rank stock have see earning estimate rise past day share have rise year other biotech company smaller mentioned company be worth mention vertex pharmaceutical incorporate vrtx free report have see share price shoot year so far earning estimate rise stock be ride high success cystic fibrosis cf pipeline particularly triple combination cf regimen have potential treat cf patient regeneron pharmaceutical inc regn free report see launch key pipeline candidate dupixent atopic dermatitis kevzara rheumatoid arthritis unite state year drug be also approve eu meanwhile regeneron key growth driver eylea continue drive revenue market share gain company be expand drug label additional indication regeneron share have rise year earning estimate have go vertex regeneron have be sporting zack rank strong buy quite time soon join league big biotech stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
3291,CELG,share bluebird bio blue free report major player emerge gene therapy car research market slump more morning trading monday receive key analyst downgrade note client morgan stanley downgrade biotech firm equal weight underweight reiterate price target share call represent drop friday close morgan stanley matt harrison say expect share underperform cite headwind bluebird sickle cell business still analyst note bluebird bcma target car candidate do provide valuation support most biotech investor know now car therapy be emerge method treat cancer include make genetic change patient immune cell reinject body attack cancer cell bluebird currently have several active clinical pre clinical program car umbrella company lead car program bb be collaboration biotech giant celgene celg free report have produce encourage datum thus far phase study be busy year car industry several major milestone have be reach august novartis nvs free report receive approval innovative new lymphoblastic leukemia treatment make first approve car therapy world earlier same week biotech behemoth gilead science gild free report announce be acquire kite pharma competitor car market gilead pay staggering kite be expect receive approval own car therapy november more current state car market check friday finish line team exclusive interview brad loncar creator loncar cancer immunotherapy index want more stock market analysis author make sure follow ryan_mcqueeney twitter today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3292,CELG,amgen inc amgn free report announce fda have approve regulatory application include overall survival os datum head head endeavor study label multiple myeloma drug kyproli please note fda decision come much earlier expect be initially expect april amgen have submit supplemental new drug application snda fda july last year regulatory application eu seek approval include os datum endeavor study be also submit same month datum present endeavor study earlier have demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone second line multiple myeloma set kyproli dexamethasone arm reduce risk death increase os month compare combination velcade dexamethasone kyproli be already approve patient population overall survival datum help drive usage boost sale other ongoing study kyprolisinclude phase iii arrow study be evaluate weekly dose regimen kyproli relapse refractory multiple myeloma patient phase iii aspire study evaluate triple combination regimen kyproli celgene celg free report revlimid lenalidomide dexamethasone krd patient relapse multiple myeloma compare revlimid dexamethasone rd amgen have also form collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma kyproli generate sale third quarter record year year growth drive higher demand robust uptake outside market share amgen be more wednesday past year amgen share have return compare increase register industry amgen carry zack rank hold better rank biotech stock be vertex pharmaceutical incorporate vrtx free report zack rank strong buy see complete list today zack rank stock here vertex stock have return past year earning estimate have go almost past day zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3293,CELG,co tif free report share rise report global comparable sale advanced last month share csx corporation csx free report decrease post fourth quarter revenue miss zack consensus estimate millionjuno therapeutic inc share jump news celgene corporation celg free report be look acquire biotech companyshare fastenal company fast free report slump fourth quarter operate profit margin decline year year
3294,CELG,gilead science inc gild free report announce fda have approve chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl drug be add gilead portfolio follow recent acquisition kite pharma earlier month notably yescarta be first car therapy approve fda aforementioned indication candidate be also review eu tentative approval expect first half share gilead have outperformed industry so far year stock have rally broader industry decrease approval be support positive datum zuma phase ii study find study show single infusion axicabtagene ciloleucel demonstrated overall response rate orr include patient detectable trace cancer remain also patient achieve complete remission median follow month have not earlier reach estimate median duration response significantly cart therapy be manufacture kite pharma state art commercial manufacturing facility el segundo california zuma pivotal trial kite pharma achieve manufacturing success rate median manufacturing turnaround time day remind investor novartis nvs free report have also receive fda approval car therapy kymriah august treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later stage relapse additionally juno therapeutic be develop cell base cancer immunotherapy base car technology partnership celgene celg free report heal adult aggressive nhl include dlbcl hence gilead be expect face intense competition product long run company press release approximately patient unite state have run option fight disease be detected refractory dlbcl year only achieve complete remission treat current standard care hence give huge market opportunity open yescarta company widely address vast unmet need patient suffering disease approve therapy market such new treatment option bring table gilead science inc price gilead science inc price gilead science inc quotezack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3295,CELG,share celgene corporation celg free report decline company announce phase iii trial revolve cd pipeline candidate ged crohn disease extension trial sustain cd be discontinue celgene stock have moved year date compare industry gain decision discontinue trial come follow recommendation datum monitoring committee assessed overall benefit risk recent interim futility analysis consequently phase iii trial define cd crohn disease not be initiate meanwhile celgene be wait review full dataset phase ii trial ulcerative colitis determine next step news come disappointment candidate be late stage development celgene inflammatory bowel disease portfolio currently consist ozanimod phase iii otezla phase ii ongoing uc pending positive result phase iii trial be initiate otezla be approve patient suffering moderate severe plaque psoriasis be candidate phototherapy systemic therapy drug be also approve treatment adult patient active psoriatic arthritis celgene be currently work label expansion drug pomalyst imnovid abraxane otezla other meanwhile celgene revlimid continue outperform drive further market share increase newly diagnosed myeloma continue increase treatment duration recent approval idhifa unite state relapse refractory acute myeloid leukemia have further boost company portfolio however celgene be highly dependent revlimid foreign exchange headwind be expect continue abraxane sale be competitive pressure last month celgene aannounce fda put hold several trial fusion program partial clinical hold have be put trial full clinical hold trial trial be evaluate imfinzi pd antibody combination chemotherapy agent blood cancer such multiple myeloma chronic lymphocytic leukemia lymphoma celgene enter strategic collaboration astrazeneca plc azn free report medimmune april develop commercialize imfinzi hematologic malignancy combination revlimid pomalyst vidaza other fda have place hold trial due risk identify other trial pd antibody merck co mrk free report keytruda patient multiple myeloma combination agent zack rank key pick celgene currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report currently carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company have top estimate trail quarters average wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3296,CELG,biotech major amgen inc amgn free report report third quarter result oct market close amgen deliver positive earning surprise last quarter amgen share be so far year compare favorably increase register industry period amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be let see thing be shape company quarter factor playamgen newer product prolium xgeva kyproli blincyto continue perform well backed higher demand thus make lower sale mature brand enbrel epogen neulasta neupogen due competitive pressure neulasta demand be be hurt due competition pd other new cancer sale be also be hurt biosimilar competition unite state mainly zarxio sandoz biosimilar version neupogen be launch september neulasta neupogen sale be expect be hurt competitive dynamic third fourth quarters zack consensus estimate neulasta neupogen be respectively third quarter however management mentioned call new biosimilar competition be expect year suggest neulasta epogen not start face biosimilar competition year contrary previous expectation company mylan biocon novartis nvs free report coherus look launch generic version neulasta company look launch generic version epogen have receive complete response letter fda respective application delay launch bottom line continue be drive company overall cost cut effort share buyback company restructure plan likely make leaner more cost efficient investor focus remain performance company pcsk inhibitor repatha uptake repatha gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction however second quarter repatha revenue improve sequentially drive higher demand management say presentation outcome study datum fourier have positive impact repatha share trend remain be see positive trend continue third quarter earning whispersour proven model do not conclusively show amgen be likely beat earning quarter be stock need have positive earning zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report ourearning esp filter zack rank amgen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision amgen inc price ep surprise amgen inc price ep surprise amgen inc quotestock consider stock biom genetic sector have positive esp favorable zack rank be celgene corporation celg free report earning esp zack rank company be schedule release result oct also schedule release result oct alexion pharmaceutical inc alxn free report have earning esp zack rank see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3297,CELG,share therapeutic incorporate cort free report have soar so far year massively outperform growth register industry here analyze factor lead rally only market drug korlym mifepristone be approve treatment patient cush syndrome company be strive commercialize korlym successfully deploy medical liaison sale representative person be newly diagnosed cush syndrome year translate more new patient annually unite state increase awareness physician patient drug expand sale effort be likely bolster sale meanwhile be currently work develop drug additional indication be conduct phase ii safety efficacy study korlym combination eisai co ltd cancer drug halaven treatment triple negative breast cancer tnbc enrolment study be complete company announce encourage datum december anticipate successful label expansion korlym boost top line significantly disease represent huge potential many woman unite state be diagnosed year university chicago be conduct phase ii study korlym combination pfizer pfe free report xtandi treatment metastatic castration resistant prostate cancer institution also plan conduct phase ii study korlym combination celgene celg free report abraxane treatment patient tnbc importantly apart korlym be also evaluate cort cush syndrome range solid tumor early datum candidate cush syndrome have be quite promising company have begin dose patient phase ii study cort combination abraxane treatment range solid tumor cancer possible target indication include triple negative breast cancer ovarian cancer pancreatic cancer sarcoma company also have selective cortisol modulator cort phase study result be expect second quarter compound be very potent animal model fatty liver disease prevention reversal weight gain cause antipsychotic medication such zyprexa olanzapine company expect begin phase ii trial indication third quarter also third quarter earning release company raise revenue guidance company now project revenue be range higher prior expectation therapeutic incorporate price therapeutic incorporate price therapeutic incorporate quotezack rank other stock have zack rank buy top rank health care stock include sucampo pharmaceutical sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3298,CELG,key highlight week include announcement couple acquisition agreement well pipeline news biogen biib free report celgene celg free report announcement relate acquisition ignyta roche sucampo pharmaceutical mallinckrodt recap week most important storiescelgene revlimid combo datum celgene share be disappointing datum combination evaluate company blockbuster cancer drug revlimid treatment naïve follicular lymphoma patient late stage relevance study evaluate revlimid rituxan follow maintenance compare standard care rituxan chemotherapy chop bendamustine cvp follow rituxan maintenance treatment arm fail achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week progression free survival read more celgene discourage datum revlimid celgene share be year date compare gain record industry belong acquisition agreement announce couple acquisition deal be announce week first agreement see ignyta be acquire swiss pharma giant roche cash deal value share ignyta be focuse develop precisely target therapeutic guide diagnostic patient rare cancer acquisition slate close first half roche add entrectinib portfolio entrectinib be currently mid stage development second agreement see sucampo be acquire mallinckrodt share approximately acquisition mallinckrodt get source term net sale earning accretion amitiza boost rare disease pipeline vts cpp sulindac deal be expect close first quarter sucampo be zack rank strong buy stock see complete list today zack rank stock here biogen share alzheimer datum biogen share decline datum ongoing alzheimer disease study ban be be develop collaboration eisai independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study study fail show early positive result company say blind study be be conduct patient prodromal mild alzheimer disease collectively know early alzheimer disease continue comprehensive final analysis be conduct month result be expect be obtain second half study datum come disappointment positive datum have be major boost moreover result have raise concern candidate chance success give high rate failure experience other company bring alzheimer disease treatment market read more biogen alzheimer drug miss goal interim analysis biomarin pdufa date extend fda have extend prescription drug user fee act pdufa goal date biomarin pharmaceutical bmrn free report pegvaliase month biomarin be look get investigational therapy approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management extension be expect agency have ask company submit additional chemistry manufacturing control cmc information company say due memorial day weekend action goal date be read more biogen alzheimer drug miss goal interim analysis agio submit ivosidenib nda agio pharmaceutical agio free report have submit new drug application nda seek fda approval ivosidenib ag investigational oral treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company have ask priority review cut review period month agio also announce have receive permission fda move pipeline candidate ag clinical study company intend commence phase study first quarter biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex vrtx free report gain biogen decline last month biogen be regeneron lose see last biotech stock roundup here label expansion exelixis cabometyx fda nod spark gene therapy next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3299,CELG,share celgene corporation celg free report be company report disappointing datum phase iii study relevance revlimid combination roche holding rhhby free report rituxan treatment naïve follicular lymphoma study evaluate revlimid rituxan follow maintenance compare standard care feature rituxan chemotherapy chop bendamustine vn cvp follow rituxan maintenance patient previously untreated follicular lymphoma however treatment arm not achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week term progression free survival pfs observed pre plan analysis none arm prove superior co primary endpoint meanwhile additional analysis trial be underway revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma failure study be disappointing revlimid be celgene growth driver drug label expansion have boost sale potential company expect lymphoma majorly increase revlimid growth prospect augment combination rituxan relapse refractory follicular marginal zone lymphoma be also progress revlimid sale continue be impressive be concern company sole dependence product growth celgene stock have lose value last month industry loss stock be also hit earlier phase iii trial revolve cd candidate ged crohn disease extension trial sustain cd be discontinue deep yet persistently slow growth psoriatic arthritis psoriasis market especially entire third quarter have lead weak performance otezla consequently company also reduce annual guidance challenge market condition be drive increasingly restrictive pbm formulary control meanwhile august company obtain fda approval idhifa enasidenib treatment relapse refractory acute myeloid leukemia isocitrate dehydrogenase idh mutation drug be develop partnership agio pharmaceutical inc agio free report go forward expect approval new drug boost top line celgene be also encouragingly work label expansion drug pomalyst imnovid abraxane other instance pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be recently update unite state well eu include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function zack rank key pickcelgene be zack rank hold stock better rank stock same space be sucampo pharmaceutical carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have be moved cent last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3300,CELG,roche hold ag rhhby free report announce european commission ec have approve immunotherapy drug tecentriq monotherapy treatment patient locally advanced metastatic small cell lung cancer have be previously treat chemotherapy regardless pd status ec also grant marketing authorisation drug monotherapy treatment person locally advanced metastatic urothelial carcinoma have be previously treat platinum contain chemotherapy be consider ineligible cisplatin chemotherapy regardless pd status note drug be already approve unite state indication approval other geography further boost sale estimate patient die year due lung cancer earlier month fda have put partial clinical hold phase ib phase ii trial evaluate tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corporation celg free report revlimid pomalyst roche also announce ec have approve label expansion gazyvaro drug have be approve combination chemotherapy follow gazyvaro maintenance patient achieve response new treatment previously untreated advanced follicular lymphoma approval be base result phase iii gallium study show show superior progression free survival mabthera note drug be approve combination chlorambucil patient previously untreated chronic lymphocytic leukaemia comorbidity make unsuitable full dose fludarabine base therapy gazyvaro be also approve combination bendamustine follow gazyvaro maintenance patient follicular lymphoma do not respond progressed month treatment mabthera mabthera contain regimen addition ec approve actemra roactemra tocilizumab treatment giant cell arteritis gca make first therapy approve treatment gca europe roche drug be also approve unite state indication actemra be approve treatment adult patient moderate severe active rheumatoid arthritis roche stock have gain year date compare industry gain roche have strong presence oncology market company dominate breast cancer space due strong demand franchise drug herceptin perjeta kadcyla however sale avastin tarceva continue decline generic competition xeloda continue hurt sale competition biosimilar loom large roche key drug herceptin avastin rituxan fda have accept novartis ag nvs free report biologic license application propose biosimilar version rituxan hence approval new drug label expansion exist drug bode well roche zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
3301,CELG,juno therapeutic inc share drop more company announce have launch propose follow public offer share common stock share offer subject customary close condition be expect close sep underwriter have be grant option buy additional share day cover allotment completion actual size term offer be not make public company notably offer get complete juno plan private placement share subsidiary celgene corp celg free report share juno share have significantly outperformed industry so far year stock have soar industry have register rally company be expect generate net proceed public offer deduct underwriting discount commission however include underwriter option purchase additional share gross proceed be estimate be juno plan utilize net proceed offer general corporate purpose include work capital requirement remind investor company have year agreement celgene global development immunotherapy addition make upfront payment celgene buy share juno common stock share collaboration see company leverage cell therapeutic strategy develop treatment patient cancer autoimmune disease initial focus be car cell receptor technology deal be major positive juno give strong partner form celgene also juno agreement medimmune subsidiary astrazeneca azn free report give company much need experience combine car cell checkpoint inhibitor medimmune pdl antibody durvalumab juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quotezack rank stock consider key pickjuno currently carry zack rank sell better rank stock pharma sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
3302,CELG,novartis ag nvs free report supplemental biologic license application sbla kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct have be accept fda priority review moreover european medicine agency ema also grant accelerate assessment marketing authorization application maa kymriah treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct remind investor kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse novel immunocellular therapy time treatment kymriah used patient cell fight cancer car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment cell be draw patient blood cell be then reprogram manufacturing facility create genetically code cell express chimeric antigen receptor recognize fight cancer cell other cell express specific antigen drug be develop collaboration university pennsylvania approval be major boost novartis give potential car therapy space approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year old be most common childhood cancer unite state kymriah have be launch unite state respective designation fda ema expedite standard review time assume approval fda ema kymriah be first chimeric antigen receptor cell car therapy available distinct indication hodgkin lymphoma cell application be base datum sponsored global clinical trial program kymriah child young adult cell adult patient dlbcl demonstrate efficacy safety kymriah study result pivotal phase ii trial juliet serve basis sbla maa kymriah adult patient dlcbl result pivotal phase ii eliana study be submit part maa kymriah child young adult cell novartis plan additional regulatory submission kymriah pediatric young adult patient cell adult patient dlbcl unite state eu novartis stock have rally past year compare industry gain car therapy space be spotlight approval kymriah subsequently gilead science inc gild free report acquire kite pharma obtain fda approval yescarta axicabtagene ciloleucel latter chimeric car therapy candidate meanwhile rumour surface celgene corporation celg free report be advanced talk acquire juno therapeutic juno pipeline include cd cd direct car cell product candidate give immense potential therapy expect spotlight space zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3303,CELG,pharma biotech stock make impressive comeback nasdaq biotechnology index nyse arca pharmaceutical index gain respectively investor appear be more comfortable drug pricing scenario be major overhang moreover significantly higher number drug gain approval include path breaking gene cell therapy treatment cancer novartis nvs free report kymriah gilead gild free report yescarta tax reform be also expect work sector favor merger acquisition expect pick come quarters immuno oncology remain key focus area gilead acquire kite last year celgene celg free report currently rumore be interested acquire juno new product sale ramp success innovation continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum say headwind remain form drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback pick winnersanyone interested biotech pharma stock know be challenge pick winner high risk high return industry be constantly grow change company hit bull eye become overnight success story share double even triple positive news however negative outcome have equally strong effect share failure very well spell doom company such scenario let take look stock prefer analyst have deep knowledge understand industry company have zero stock help zack stock screener stock have be give strong buy buy rating more broker sport favorable zack rank strong buy buy vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market product orkambi kalydeco cf portfolio patient be eligible treatment company current cf portfolio number expect grow back eu reimbursement orkambi label expansion drug potential approval tezacaftor ivacaftor combination expect unite state february eu second half year vertex expect cf revenue range company have strong earning track record have surpass expectation last quarters average surprise go forward vertex expect start pivotal development triple regimen cf pipeline first half year company be also work expand pipeline cf disease sickle cell disease beta thalassemia alpha antitrypsin deficiency polycystic kidney disease vertex be zack rank stock strong buy buy broker rating see complete list today zack rank stock here vertex have gain last year substantially outperform rally industry belong collegium pharmaceutical inc coll free report specialty pharma company collegium be zack rank stock strong buy buy broker rating company be focuse develop portfolio product incorporate proprietary deterx technology platform treatment chronic pain other disease company first product xtampza be abuse deterrent extend release oral formulation oxycodone moreover collegium acquire license right commercialize nucynta franchise unite state deal close last week be expect be immediately accretive accelerate company path profitability last year collegium share be compare gain record industry belong syndax pharmaceutical inc sndx free report clinical stage biopharma company syndax be focuse development cancer therapy lead pipeline candidate entinostat be grant breakthrough therapy designation be currently late stage development combination treatment hr advanced breast cancer candidate be be evaluate combination other treatment include keytruda different kind cancer syndax second pipeline candidate sndx be early stage development potential be evaluate variety cancer syndax be zack rank stock strong buy buy broker rating company share be last year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
3304,CELG,gilead science inc gild free report announce long term follow datum phase ii study evaluate chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment patient refractory large cell lymphoma detailed result study be present annual meeting american society hematology ash atlanta notably drug be add gilead portfolio follow acquisition kite pharma early october subsequently receive fda approval later same month treat refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl drug be also review eu tentative approval expect first half share gilead have outperformed industry so far year stock have gain broader industry increase update datum zuma study show drug single infusion axicabtagene ciloleucel demonstrated overall response rate orr include patient achieve complete remission median follow month study be conduct total patient notably previously report datum study show overall response rate orr include patient achieve complete remission median follow month remind investor novartis nvs free report have also receive fda approval car therapy kymriah august treatment patient age year cell precursor acute lymphoblastic leukemia be refractory second later stage relapse additionally juno therapeutic be develop cell base cancer immunotherapy base car technology partnership celgene celg free report cure adult aggressive nhl include dlbcl hence gilead be expect face fierce competition product long run gilead science inc price gilead science inc price gilead science inc quotezack rankgilead carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3305,CELG,novartis ag nvs free report announce update result pivotal juliet study show sustain complete response month kymriah suspension intravenous infusion adult patient difficult treat cancer relapse refractory diffuse large cell lymphoma dlbcl kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve drug have be develop collaboration university pennsylvania novel immunocellular therapy time treatment used patient cell fight cancer car therapy be develop individual patient used own cell thereby make different typical small molecule biologic therapy so far year novartis share have gain compare industry growth juliet be first multus center global registration study kymriah adult patient dlbcl second global car cell therapy trial study month patient treat kymriah show complete response relapse free probability month first response be median overall survival be not achieve median time infusion datum cutoff be month patient dlbcl enrolled study have go multiple round chemotherapy many have unsuccessful stem cell transplant leave few option poor prognosis study show kymriah be able considerably increase chance achieve maintain sustain response stem cell transplant thus highlight benefit additionally study reveal cytokine release syndrome crs occur total patient treatment experience grade crs grade grade used penn grade scale also show patient experience grade neurologic event patient have grade neurologic adverse event be provide supportive care study patient be infuse outpatient set patient remain outpatient more day infusion patient discontinue infusiondue rapid progression disease deterioration clinical status accord study only enrolled patient not be infuse due inability manufacture adequate dose car cell novartis submit supplemental biologic license application sbla fda october kymriah suspension intravenous infusion applicationwa file treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct again november company submit application european medicine agency ema kymriah treatment adult patient dlbcl be ineligible asct child well young adult cell late gilead gild free report also receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy yescarta be first car therapy approve fda indication company bluebird bio inc blue free report bcma car therapy bb be be evaluate relapse refractory multiple myeloma bb well bb be be develop collaboration celgene celg free report novartis ag price novartis ag price novartis ag quotezack rank novartis carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
3306,CELG,immuno oncology space have be limelight car therapy space particular have be grab investor courtesy key approval fda approval novartis ag nvs free report breakthrough gene transfer treatment kymriah suspension treatment cell precursor acute lymphoblastic leukemia be refractory second later relapse patient year age be significant boost space kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve novel immunocellular therapy time treatment kymriah used patient cell fight cancer novartis also submit supplemental biologic license application fda kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible autologous stem cell transplant asct kymriah be give breakthrough therapy designation dlbcl approve be second indication kymriah long term impact treatment be yet be evaluate approval open new frontier cancer treatment start car used patient cell identify destroy cancer cell thereby make different other small molecule biologic therapy treatment cell be draw patient blood cell be then reprograme manufacturing facility create genetically code cell lead creation chimeric antigen receptor recognize fight cancer cell other cell express specific antigen gilead science inc gild free report acquire kite pharma foray space fda approval yescarta axicabtagene ciloleucel latter car therapy candidate provide significant boost fda approve therapy treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma therapy be also review europe approval be expect gilead also acquire therapy candidate clinical trial hematologic cancer solid tumor include kite car therapy candidate target cell maturation antigen expressed multiple myeloma give vast potential therapy biotech company be leave stone unturned develop pipeline candidate nevertheless stiff competition continue remain major concern juno therapeutic inc be develop cell base cancer immunotherapy base car high affinity tcr technology genetically engineer cell recognize cancer cell company be currently conduct phase trial jcar adult aggressive nhl include dlbcl company plan initiate phase ii trial jcar chronic lymphocyctic leukemia cll fourth quarter company expect fda approve rdlbcl cll share company have surge whopping year date company currently carry zack rank hold see complete list today zack rank strong buy stock here bluebird bio inc blue free report collaboration celgene corp celg free report be evaluate bb car cell product candidate treatment multiple myeloma phase study bb target cell maturation antigen bcma previously treat patient multiple myeloma be grant breakthrough therapy status fda company be also develop second bcma car program bb share company have increase year date company presently carry zack rank ziopharm oncology inc ziop free report be develop car cell therapy advanced lymphoid malignancy company be currently enrole patient investigator lead phase study used second generation cd specific car cell revise car structure patient advanced lymphoid malignancy company present carry zack rank buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
3307,CELG,pipeline regulatory update be focus week ultragenyx pharmaceutical rare free report gain fda approval first drug company cytokinetic cytk free report acorda therapeutic acor free report be hit pipeline setback recap week most important get fda approval rare genetic disease drug ultragenyx gain fda approval first drug mepsevii vestronidase alfa treatment child adult vii mps also know sly syndrome mepsevii be also first medicine be approve rare genetic disease be estimate affect patient develop world mepsevii be launch later month fda have ask post marketing study evaluate long term safety product mps be extraordinarily rare disease sale build gradually patient be identify place therapy meanwhile mepsevii be currently review eu opinion committee medicinal product human use chmp be available first half addition gain fda approval mepsevii ultragenyx also get rare pediatric disease priority review voucher be used gain priority review subsequent drug application be not eligible priority review company also sell voucher million dollar other company want fasten review process candidate biomarin unite therapeutic knight therapeutic be company sell priority review voucher million dollar read more ultragenyx rhgus get fda nod rare genetic disease cytokinetic phase iii setback cytokinetic share plunge negative datum company late stage study tirasemtiv patient amyotrophic lateral sclerosis al company say study fail meet primary endpoint well secondary endpoint cytokinetic have decide suspend development tirasemtiv focus now shift cytokinetic next generation fast skeletal muscle activator ck company believe be better tolerate potentially more effective tirasemtiv phase ii result ck be expect ck be also be evaluate spinal muscular atrophy chronic obstructive pulmonary disease al progressive disease afflict person unite state approximately new case be diagnosed year country be high unmet need new therapy average life expectancy al patient be year diagnosis only patient survive more year cytokinetic have previously say tirasemtiv generate sale more unite state alone cytokinetic share be year date compare gain record industry belong acorda scraps tozadenant program just few day announce safety issue associate late stage study investigational treatment parkinson disease acorda say be discontinue clinical development program tozadenant read more acorda stock phase iii trial tozadenant stop company say immediately discontinue dose participant currently enrolled tozadenant study decision discontinue development be base new information obtain phase iii program related previously disclose agranulocytosis absence white blood cell fight infection associate serious adverse event company say not be confident weekly white blood cell count screening be enough ensure patient safety last week acorda have announce have identify case agranulocytosis possibly drug related case associate sepsis death time company have say be higher frequency blood cell count monitoring phase iii program tozadenant read more acorda report death parkinson trial stock tozadenant oral adenosine receptor antagonist become part acorda pipeline follow acquisition biotie approximately last year acorda have say pipeline candidate inbrija cvt tozadenant parkinson plumiaz epilepsy represent potential peak net sale more however addition tozadenant setback acorda run trouble plumiaz discontinue program have also not be sailing inbrija company have file new drug application nda inbrija june fda issue refusal file rtf letter acorda intend resubmit nda year end pipeline setback weigh acorda start face generic competition flagship drug ampyra august month additional exclusivity uthr adcirca unite therapeutic uthr free report announce have gain pediatric exclusivity unite state pulmonary arterial hypertension pah treatment adcirca mean drug now enjoy exclusivity fda grant approval generic version read more unite therapeutic pah drug exclusivity period extend alnylam start roll nda patisiran alnylam have start submit roll nda unite state patisiran investigational rnai therapeutic target transthyretin ttr treatment hereditary attr hattr amyloidosis company expect finish submission year end alnylam be seek priority review nda grant review process be cut month meanwhile regulatory application eu also be submit end year alnylam have collaboration agreement sanofi patisiran once approve drug be market alnylam unite state canada western europe sanofi sell product rest world read more alnylam start roll nda submission rnai candidate tesaro ovarian cancer drug get eu nod tesaro tsro free report ovarian cancer drug zejula gain approval european commission ec use monotherapy maintenance treatment adult patient platinum sensitive relapse high grade serous epithelial ovarian fallopian tube primary peritoneal cancer be complete response cr partial response pr platinum base chemotherapy make zejula first parp inhibitor be approve europe regardless brca mutation biomarker status treatment initially be launch germany uk december eu approval be largely expect consider chmp have issue positive opinion zejula september zejula be already available unite state gain approval earlier year march read more tesaro ovarian cancer drug zejula get approval eu tesaro be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock celgene celg free report be vertex decline last month biogen biib free report be regeneron lose see last biotech stock roundup here dynavax vaccine get fda nod loxo inks deal bayer next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3308,CELG,agio pharmaceutical inc agio free report announce new datum dose expansion part phase study evaluate idh mutant inhibitor ivosidenib ag single agent treat low grade isocitrate dehydrogenase mutant idh glioma datum be present annual meeting society neuro oncology sno san francisco agio share have significantly outperformed industry so far year stock have surge compare industry rally new datum dose expansion part demonstrated durable stable disease reduction tumor growth rate patient low grade glioma median progression free survival be month median treatment duration be month treatment ivosidenib compare favorably pre treatment interval month notably phase study be assess safety tolerability ivosidenib advanced solid tumor include glioma intrahepatic chondrosarcoma harbor idh mutation press release company also present preclinical datum evaluate ivosidenib pan idh mutant inhibitor ag orthotopic mouse xenograft model human midh glioma poster datum study demonstrated ivosidenib ag result suppression hg level brain tumor mouse model notably earlier company have announce plan initiate perioperative window study evaluate ivosidenib ag low grade glioma investigate effect brain tumor tissue first half remind investor agio be conduct phase ii study combination celgene celg free report vidaza treatment newly diagnosed aml patient not eligible intensive chemotherapy fda grant orphan drug designation ivosidenib treatment aml patient company say be track submit new drug application nda fda ivosidenib year end ivosidenib be also be evaluate phase iii study evaluate ivosidenib front line aml patient idh mutant positive advanced agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quotezack rank key picksagio carry zack rank hold better rank stock health care sector include ligand pharmaceutical inc lgnd free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
3309,CELG,busy earning season almost come end impressive run be again focuse latest cancer update happen week week go see cancer drug receive fda approval new indication roche hold ag rhhby free report gazyva pfizer inc pfe free report sutent astrazeneca plc azn free report faslodex however interesting product development be cancer vaccine moderna therapeutic merck mrk free report be work merck have provide fund develop vaccine combination pd therapy keytruda return right half potential sale vaccine be personalize moderna have just develop first enrolled patient top line datum be expect september aveo pharmaceutical inc aveo free report also announce launch first drug fotivda be approve europe treat kidney cancer august recap week most important faslodex approve combination use fda approve new indication breast cancer drug faslodex nov label faslodex now be expand include combination use eli lilly lly new cdk inhibitor verzenio treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy read more astrazeneca faslodex get fda nod use verzenio astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotepfizer sutent approve adjuvant treatment kidney cancer fda approve label expansion cancer drug sutent sunitinib malate latest fda approval sutent label have be expand include adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc approval mark first only adjuvant treatment recurrent rcc sutent be presently market first line treatment advanced rcc have be standard care indication approval decade application use same patient population be also review eu pfizer inc price consensus pfizer inc price consensus pfizer inc quoteroche gazyva approve first line set blood cancer roche obtain fda approval gazyva combination chemotherapy previously untreated advanced follicular lymphoma stage ii bulky iii iv patient respond combination therapy continue be treat gazyva alone approval be base superior progression free survival achieve drug compare rituxan phase iii gallium study drug be already approve use combination chlorambucil treat chronic lymphocytic leukemia cll adult have not have previous cll treatment roche hold ag price consensus roche hold ag price consensus roche hold ag quoteaveo add first drug commercial portfolio aveo partner eusa pharma announce launch kidney cancer drug fotivda european union company expect initiate selling europe start germany drug receive approval august first line treatment advanced rcc adult patient drug be also approve patient be not treat vegfr mtor pathway inhibitor therapy follow disease progression cytokine base therapy approval launch be major milestone aveo fotivda be first only market drug company portfolio acceptance drug be yet be see cut aveo dependence fund collaboration extent aveo pharmaceutical inc price consensus aveo pharmaceutical inc price consensus aveo pharmaceutical inc quoteapart label expansion drug launch buzzword immuno oncology segment car therapy grab headline major boost celgene corporation celg free report bluebird bio inc blue free report fda grant breakthrough therapy designation car therapy candidate bb candidate also receive access priority medicine europe bb be be develop previously treat patient multiple myeloma regulatory designation development be expect expedite meanwhile bayer sign collaboration agreement small base company loxo oncology give access latter pipeline candidate loxo bayer get entry field cancer treatment drug attack cancer base genetic rather attack organ origin moreover celsion submit phase ii clinical study protocol fda evaluate dna base immunotherapy gen localize treatment ovarian cancer look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
